pyrroles has been researched along with atorvastatin in 4872 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 176 (3.61) | 18.2507 |
| 2000's | 2764 (56.73) | 29.6817 |
| 2010's | 1911 (39.22) | 24.3611 |
| 2020's | 21 (0.43) | 2.80 |
| Authors | Studies |
|---|---|
| Bak Mueller, S; Bocan, TM; Dehart, P; Ferguson, E; Krause, BR; McNally, W; Newton, RS; Roth, BD; Sliskovic, DR; Uhlendorf, PD | 1 |
| Ferguson, E; Krause, BR; Newton, RS; Roth, BD; Shaw, MK; Sliskovic, DR | 1 |
| Auerbach, BJ; Bisgaier, CL; Krause, BR; Newton, RS | 1 |
| Black, DM; Davidson, MH; Haber, HE; Jones, PH; Lupien, PJ; Nawrocki, JW; Schwartz, SL; Sprecher, DL; Weiss, SR | 1 |
| Anderson, JA; Dostal, LA; Schardein, JL | 1 |
| Ciaravino, V; Hovey, CA; Kropko, ML; Rothwell, CE; Theiss, JC | 1 |
| Crawford, LF; Kearney, AS; Mehta, SC; Radebaugh, GW | 1 |
| Bakker-Arkema, RG; Black, DM; Brown, WV; Davidson, MH; Davignon, J; Goldstein, RJ; Isaacsohn, JL; Keilson, LM; Miller, VT; Shurzinske, LJ; Weiss, SR | 1 |
| Cilla, DD; Posvar, EL; Radulovic, LL; Sedman, AJ; Whitfield, LR | 2 |
| Abe, Y; Ballantyne, CM; Dunn, K; Gotto, AM; Hackman, A; Insull, W; Pownall, H; Smith, L | 1 |
| Bron, NJ; Gibson, DM; Hounslow, NJ; Richens, A; Sedman, AJ; Whitfield, LR | 1 |
| Forgue, ST; Hounslow, NJ; Sedman, AJ; Yang, BB | 1 |
| Krause, BR; Newton, RS | 1 |
| Firth, JC; Marais, AD; Mountney, J; Naoumova, RP; Rendell, NB; Taylor, GW; Thompson, GR | 1 |
| Cilla, DD; Gibson, DM; Sedman, AJ; Whitfield, LR | 1 |
| Anderson, JA; Dostal, LA; Whitfield, LR | 1 |
| Conde, K; Fernandez, ML; Krause, BR; Newton, RS; Vergara-Jimenez, M | 1 |
| Cilla, DD; Gibson, DM; Posvar, EL; Sedman, AJ; Whitfield, LR | 1 |
| Abel, RB; Stern, RH | 1 |
| Bertolini, S; Bon, GB; Campbell, LM; Egros, F; Farnier, M; Fayyad, R; Langan, J; Mahla, G; Nawrocki, JW; Pauciullo, P; Sirtori, C | 1 |
| Lea, AP; McTavish, D | 1 |
| Bakker-Arkema, RG; Best, J; Black, DM; Fayyad, R; Heinonen, TM; Marais, AD; Nawrocki, JW | 1 |
| Bakker-Arkema, R; Black, D; Davidson, M; Fayyad, R; McKenney, J; Schrott, H; Stein, E | 1 |
| Best, J; Black, D; Bracs, P; d'Emden, M; Dart, A; Hamilton-Craig, I; Jerums, G; Nicholson, G; Sullivan, D; Tallis, G; West, M | 1 |
| Roberts, WC | 1 |
| Abu-Muhana, O; Dunn, S; Naoumova, RP; Neuwirth, C; Rallidis, L; Rendell, NB; Taylor, GW; Thompson, GR | 1 |
| Alaupovic, P; Black, DM; Heinonen, T; Shurzinske, L | 1 |
| Black, DM; Davidson, MH; Haber, HE; Jones, PH; Lupien, PJ; Nawrocki, JW; Schwartz, SL; Weiss, SR | 1 |
| Bateman, ME; Byrnes, P; Firth, JC; Marais, AD; Martens, C; Mountney, J | 1 |
| Alaupovic, P; Black, DM; Davignon, J; Heinonen, T; Leiter, L; Lupien, PJ; Ooi, TC; Shurzinske, L; Sniderman, AD; Sorisky, A; Tan, MH; Tremblay, G | 1 |
| Baetta, R; Calore, M; Comparato, C; Donetti, E; Fumagalli, R; Paoletti, R; Rossi, A; Soma, MR; Teruzzi, C | 1 |
| Black, DM; Brown, WV; McCormick, LS; Pitt, B; Waters, D | 1 |
| Firth, JC; Marais, AD; Naoumova, RP; Neuwirth, CK; Penny, C; Thompson, GR | 1 |
| Kupecz, D | 1 |
| Barrett, PH; Burnett, JR; Huff, MW; Kleinstiver, SJ; Newton, RS; Telford, DE; Wilcox, LJ | 2 |
| Sternon, J | 1 |
| Calder, RA | 1 |
| Robertson, DG; Rothwell, CE; Urda, ER; Walsh, KM | 1 |
| Connor, WE; Duell, PB; Illingworth, DR | 1 |
| Chambers, CM; Lopez, D; Ness, GC | 1 |
| Black, A; Chang, T; Huang, N; Sekerke, C; Shum, YY; Walter, G; Whitfield, LR | 1 |
| Crook, MA; Lumb, PJ; Semra, YK; Wierzbicki, AS | 2 |
| Abel, R; Besserer, J; Gibson, GL; Stern, R | 1 |
| Bergstrom, JD; Bostedor, RG; Chao, YS; Geissler, WM; Rew, DJ; Wright, SD | 1 |
| Black, D; Chaitman, BR; Ezekowitz, MD; Ganz, P; Kane, JP; Oliver, MF; Olsson, AG; Pressler, ML; Schwartz, GG; Texter, M; Waters, D | 1 |
| Hunninghake, D; Jones, P; Kafonek, S; Laurora, I | 1 |
| Anderson, JA; Black, A; Colgin, J; Craft, WR; Henck, JW | 1 |
| Bakker-Arkema, RG; Black, DM; Nawrocki, JW | 2 |
| Lane, M; Laskarzewski, P; Stein, EA | 1 |
| Black, DM; Kafonek, S; Koren, M; McCormick, LS; McKenney, JM; Weiss, S | 1 |
| Abel, RB; Horton, M; Moore, S; Olson, SC; Stern, RH; Yang, BB | 1 |
| Gibson, DM; Stern, RH; Whitfield, LR | 1 |
| Celermajer, DS; Simons, J; Simons, LA; Sullivan, D | 1 |
| Jagroop, IA; Mikhailidis, DP; Nair, DR; Papadakis, JA; Winder, AF | 1 |
| Black, DM | 2 |
| de Maat, MP; Haverkate, F; Koopman, J | 1 |
| Darko, DA; O'Shea, D | 1 |
| Adeli, K; Dulay, D; Macri, J; Mohammadi, A; Newton, R; Romain, T | 1 |
| Kazenoff, S; Pfeiffer, CM; Rothberg, HD | 1 |
| Davignon, J | 1 |
| Díaz, C; Hernández, G; Hernández-Perera, O; Lamas, S; Navarro-Antolín, J; Pérez-Sala, D; Sánchez-Pascuala, R | 1 |
| Tucker, G | 1 |
| Black, DM; Mahla, G; Muller, D; Pentrup, A; Wolffenbuttel, BH | 1 |
| Adzet, T; Alegret, M; Díaz, C; Hernández, G; Laguna, JC; Sánchez, RM; Verd, JC | 1 |
| Wehmeier, T; Ziajka, PE | 1 |
| Simons, LA | 1 |
| Aviram, M; Bisgaier, CL; Newton, RS; Rosenblat, M | 1 |
| Kantola, T; Kivistö, KT; Neuvonen, PJ | 1 |
| Black, AE; Hayes, RN; Sinz, MW; Woolf, TF | 1 |
| de Bont, N; Demacker, PN; Netea, MG; Rovers, C; Smilde, T; Stalenhoef, AF; van der Meer, JW | 1 |
| Pincus, J | 1 |
| Scheen, AJ | 7 |
| Olson, SC; Smithers, JA; Stern, RH | 1 |
| Ghali, JK | 1 |
| Alonso, C; Blanco-Colio, LM; Díaz, C; Egido, J; Guijarro, C; Hernández, G; Ortego, M; Ortiz, A; Plaza, JJ | 1 |
| Bakker-Arkema, RG; Black, DM; Brown, AS; Campbell, CF; Guthrie, R; Henley, RW; Koren, M; McLain, R; Woo, W; Yellen, L | 1 |
| Henry, K; Hermundson, J; Huebesch, J; Melroe, H; Simpson, J | 1 |
| Ballantyne, CM; Jacobson, TA; Schein, JR; Williamson, A | 1 |
| Conde, E; Duvós, E; González-Ponte, ML; González-Ruiz, M; Gutiérrez-Iñiguez, MA; Olalla, JI | 1 |
| Fong, NT; Yee, HS | 1 |
| Bachorik, PS | 1 |
| Assmann, G; Funke, H; Schulte, H; von Eckardstein, A | 1 |
| Olsson, AG | 1 |
| Malinowski, JM | 1 |
| Abdallah, P; Bakker-Arkema, RG; Black, DM; Drehobl, M; Early, JL; Hunninghake, D; McBride, S; Schrott, H; Wigand, JP | 1 |
| Barrett, PH; Burnett, JR; Huff, MW; Kleinstiver, SJ; Miller, DB; Telford, DE; Vicini, P | 1 |
| D'Agostino, RB; Ellison, RC; Hartz, SC; Huse, DM; Kraemer, DF; Miller, JD; Russell, MW | 1 |
| Bustos, C; Díaz, C; Egido, J; Hernández, G; Hernández-Presa, MA; Ortega, L; Ortego, M; Pérez, F; Tuñón, J | 1 |
| Bullen, WW; Hayes, RN; Miller, RA | 1 |
| Lee, TH | 4 |
| Liguori, E; Sarcinella, R | 1 |
| Strandberg, TE; Tikkanen, MJ; Vanhanen, H | 2 |
| Dietz, BL; Oberg, KC | 1 |
| Hoogerbrugge, N | 1 |
| Geiss, HC; Parhofer, KG; Schwandt, P | 1 |
| Bakker-Arkema, RG; Black, DM; Davidson, MH; Henley, RW; Hunninghake, DB; Koren, MJ; McKenney, JM; McLain, RW; Schrott, HG; Smith, DG; Tresh, P; Weiss, SR | 1 |
| Connelly, PW; Hegele, RA; Little, JA | 1 |
| Assang, C; Baillie, TA; Lin, JH; Lu, P; Ma, B; Meng, Y; Prueksaritanont, T; Reider, PJ; Tang, C | 1 |
| Bandinelli, S; Bertolotto, A; Lo Faro, A; Navalesi, R; Penno, G; Ruocco, L | 1 |
| Olson, SC; Siedlik, PH; Stern, RH; Yang, BB | 1 |
| Crouse, JR; Frohlich, J; Mercuri, M; Ose, L; Tobert, JA | 1 |
| Bataille, L; Hamoir, V; Horsmans, Y; Nakad, A; Sempoux, C | 1 |
| Bairaktari, ET; Elisaf, MS; Liberopoulos, EN; Miltiadous, GA; Tsimihodimos, VK; Tzallas, CS | 1 |
| Axelson, M; Dunn, S; Naoumova, RP; Neuwirth, CK; O'Neill, FH; Taylor, GW; Thompson, GR | 1 |
| Barrett, PH; Huff, MW; Wilcox, LJ | 1 |
| Alfon, J; Badimon, L; Pueyo Palazon, C; Royo, T | 1 |
| Chen, BC; Jemal, M; Ouyang, Z; Teitz, D | 1 |
| Cramb, R; Hartland, A; Hubscher, D; Kendall, MJ; Landray, MJ | 1 |
| Frane, AM; Gantner, SE; Joyce, DM; Kersten, ME; Murdock, AK; Murdock, DK; Murdock, RW; Olson, KJ | 1 |
| Ewy, GA | 1 |
| Brown, WV; Eisenberg, D; McCormick, LS; Pitt, B; Schwartz, L; Shurzinske, L; Title, LM; van Boven, AJ; Waters, D | 1 |
| Alfon, J; Badimon, L; Garcia-Moll, X; Royo, T | 1 |
| Klein, G; März, W; Neiss, A; Wehling, M; Wollschläger, H | 1 |
| Kostner, GM | 1 |
| Gänzer, H; Kirchmair, R; Patsch, JR; Sturm, W | 1 |
| Kostner, KM | 2 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
| Blanco-Colio, LM; Egido, J; Guijarro, C; Kasiske, BL; Keane, WF; Massy, ZA; O'Donnell, MP | 1 |
| Krane, V; März, W; Ritz, E; Ruf, G; Wanner, C | 1 |
| Frohlich, BH; Gregg, RE; Tesfamariam, B | 1 |
| Black, AE; Hayes, RN; Roth, BD; Woo, P; Woolf, TF | 1 |
| Dominiczak, MH; Murphy, MJ | 1 |
| Genest, J; Lavoie, MA | 1 |
| Martín, T; Murillas, J; Portero, JL; Ramos, A | 1 |
| Adzet, T; Alegret, M; Díaz, C; Hernández, G; Laguna, JC; Peris, C; Sánchez, RM; Vázquez, M; Verd, JC | 1 |
| Kivistö, KT; Lilja, JJ; Neuvonen, PJ | 1 |
| Jonkers, GH | 1 |
| Conde, K; Fernandez, ML; Newton, RS; Pineda, G | 1 |
| Hoogerbrugge, N; Jansen, H | 1 |
| Alfon, J; Badimon, L; Berrozpe, M; Guasch, JF | 1 |
| Rodrigues, M; Sinzinger, H | 1 |
| Crook, MA; Wierzbicki, AS | 1 |
| Eliot, LA; Jamali, F | 1 |
| Alvarez, ML; Ballester, B; Errasti, P; García, I; García, N; Gómez, G; Lavilla, FJ; Purroy, A | 1 |
| Branchi, A; Fiorenza, AM; Macor, S; Muzio, F; Rovellini, A; Sommariva, D; Torri, A | 1 |
| Ito, MK; Stolley, SN | 1 |
| Bustos, C; Díaz, C; Egido, J; Hernández, G; Hernández-Presa, MA; Ortego, M; Tuñón, J | 1 |
| Attanasio, E; Badia, X; Russo, P | 1 |
| Bäumer, AT; Böhm, M; Jockenhövel, F; Kebben, D; Nickenig, G; Temur, Y | 1 |
| Balog, DL; Cheigh, JS; Maltz, HC | 1 |
| Carpentier, Y; Ducobu, J; Sternon, J | 1 |
| Desager, JP; Descamps, O; Heller, F; Hondekijn, JC | 1 |
| Cheung, R; Mutus, B; Tannous, M; Vignini, A | 1 |
| Farnier, M | 1 |
| Baim, DS; Carrozza, JP; Cohen, DJ | 1 |
| Davidson, CJ; Ricciardi, MJ | 1 |
| Bloom, JM | 1 |
| Joffe, BI; Kotze, MJ; Pilcher, GJ; Raal, FJ; Veller, MG | 1 |
| Elkin, RG; Yan, Z | 1 |
| Eminton, Z; Fowler, G; Maton, S; Neil, HA; Patel, H | 1 |
| Fischer, JS | 1 |
| Furberg, CD; Rodrigues, M; Sinzinger, H | 1 |
| Mancini, M; Montefusco, S; Pauciullo, P; Piliego, T; Postiglione, A | 1 |
| Chik, G; Christ, ER; Crook, MA; Lumb, PJ; Semra, Y; Wierzbicki, AS | 1 |
| Hoshi, K; Ichihara, K; Satoh, K; Yamamoto, A | 1 |
| Boyd, RA; Randinitis, EJ; Reyner, EL; Stern, RH; Stewart, BH; Whitfield, L; Wu, X; Zegarac, EA | 1 |
| Hecker, M; Just, I; Köhler, T; Rückschloss, U; Wagner, AH | 1 |
| Chapman, MJ; Farnier, M; Guerin, M; Lassel, TS; Le Goff, W | 1 |
| Crook, MA; Mikhailidis, DP; Nair, DR; Wierzbicki, AS; Winder, AF | 1 |
| Crook, MA; Mikhailidis, DP; Wierzbicki, AS; Winder, AF | 1 |
| Conde, K; Fernandez, ML; Freake, HC; Newton, RS; Roy, S | 1 |
| Waters, DD | 2 |
| de Man, FH; Mohrschladt, MF; Smelt, AH; Stoeken, DJ; Sturk, A; Westendorp, RG; Weverling-Rijnsburger, AW | 1 |
| Baetta, R; Bellosta, S; Bernini, F; Corsini, A; Fumagalli, R; Paoletti, R | 1 |
| Ichihara, K; Satoh, K | 1 |
| Farnier, M; Maigret, P; Portal, JJ | 1 |
| Bakker-Arkema, R; Black, D; Brown, WV; Innis-Whitehouse, W; Le, NA; Li, X | 1 |
| Chik, G; Crook, MA; Lumb, PJ; Wierzbicki, AS | 3 |
| Jones, PH | 2 |
| Banyai, S; Derfler, K; Goldammer, A; Hörl, WH; Jansen, M; Rohac, M; Schmaldienst, S | 1 |
| Barter, PJ; O'Brien, RC | 1 |
| Blauw, GJ; de Man, FH; Jukema, JW; Smelt, AH; van der Laarse, A; Weverling-Rijnsburger, AW | 1 |
| Chan, M; Giannetti, N; Hayashi, S; Hunt, SA; Kato, T; Kobayashi, T; Morimoto, S; Namii, Y; Tokoro, T; Yokoyama, I | 1 |
| Kolsky, MP; Laureno, R; Negevesky, GJ; Yau, TH | 1 |
| Baker, JC; Emeson, EE; Hall, D; Jamal, S; Johnston, TP; Palmer, WK | 1 |
| Cooper, A; Kratzer, S; Pershad, A | 1 |
| Stewart, BH; Whitfield, LR; Wu, X | 1 |
| Currier, JS | 1 |
| Auch-Schwelk, W; Elsner, M; Mach, S; Schächinger, V; Walter, DH; Zeiher, AM | 1 |
| Waters, D | 2 |
| Arbustini, E; Cofrancesco, E; Cortellaro, M; Gabrielli, L; Tremoli, E | 1 |
| Barbagallo, M; Barbieri, M; Giordano, M; Paolisso, G; Petrella, G; Ragno, E; Varricchio, M | 1 |
| Cernigoi, AM; Merni, M; Tortul, C; Velussi, M | 1 |
| Hufnagel, G; Kossari, N; Michel, C; Mignon, F; Queffeulou, G; Vrtovsnik, F | 1 |
| Arikian, S | 1 |
| Belaïche, G; Ley, G; Slama, JL | 1 |
| Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; van den Berkmortel, FW; van Langen, H; Wollersheim, H | 1 |
| Böhmig, G; Demetriou, D; Hörl, WH; Schmaldienst, S; Shabpar, A; Watschinger, B | 1 |
| Black, DM; Firth, JC; Heinonen, TM; Illingworth, DR; Kotze, MJ; Marais, AD; Pappu, AS; Pilcher, GJ; Raal, FJ | 1 |
| Caslake, M; Packard, C; Shepherd, J | 1 |
| Arnaboldi, L; Bellosta, S; Bernini, F; Corsini, A; Ferri, N; Paoletti, R | 1 |
| Blair, SN; Capuzzi, DM; Cater, NB; Gottlieb, SO; Morgan, JM; Nguyen, T | 1 |
| Abel, RB; Hounslow, NJ; MacMahon, M; Olson, SC; Stern, RH; Yang, BB | 1 |
| Puri, S; Saucedo, J; Singh, BM; Talley, JD | 1 |
| Hiyoshi, H; Ito, M; Ohtsuka, I; Saeki, T; Tanaka, H; Yanagimachi, M; Yoshida, I | 1 |
| Choy, PC; Dembinski, T; Hatch, G; Kroeger, EA; McMaster, J; Mymin, D; Zhu, Q | 1 |
| Mikhailidis, DP; Wierzbicki, AS | 3 |
| Spielberg, T | 1 |
| Darioli, R; Keller, U; Mordasini, R; Noseda, G; Riesen, W; Schaffhauser, B; Shokry, A | 1 |
| O'Neill, BJ | 1 |
| Donner, MG; Geiss, HC; Otto, C; Parhofer, KG; Schwandt, P | 1 |
| Crouse, JR; Davidson, MH; Dujovne, CA; Frohlich, J; Habib, R; Hunninghake, DB; Isaacsohn, JL; Kastelein, JJ; Liu, M; Melino, MR; Mercuri, M; Mitchel, YB; O'Grady, L; Ose, L | 1 |
| Black, DM; Davidson, MH; Hunninghake, D; Isaacsohn, JL; McLain, R; Singer, R | 1 |
| Banyai, S; Derfler, K; Heinz, G; Hörl, WH; Jansen, M; Schmaldienst, S; Stulnig, TM | 1 |
| Black, D; Davila, M; Knapp, H; Schrott, HG; Shurzinske, L | 1 |
| Branzi, A; Carinci, V; Magelli, C; Magnani, G; Potena, L; Reggiani, LB | 1 |
| Deanfield, JE; Donald, AE; Mullen, MJ; Thomson, H; Thorne, S; Wright, D | 1 |
| Brophy, DF; Gehr, TW; Holdford, DA; Kennedy, DT; Wallace, JF | 1 |
| Otto, C; Schwandt, P | 1 |
| Dansette, PM; Jaoen, M; Pons, C | 1 |
| DiTusa, L; Luzier, AB | 1 |
| Calviño, J; Rodriguez, J; Romero, R; Sánchez-Guisande, D | 1 |
| Eisenberg, D | 1 |
| Blumenthal, RS; Cohn, G; Schulman, SP | 1 |
| El Menjawi, I; Fladerer, P; Krause, R; Pohanka, E; Wenisch, C | 1 |
| Huang, J; Kiener, PA; Knapp, AC; Starling, G | 1 |
| Bonardo, B; Juhan-Vague, I; Lopez, S; Nalbone, G; Peiretti, F | 1 |
| Aguilar-Salinas, CA; Alvarado Vega, A; Angélica Gómez-Díaz, R; Eduardo Romero-Nava, L; Gómez-Pérez, FJ; Guillén, LE; Gulías-Herrero, A; Meaney, E; Mendoza Pérez, E; Moguel, R; Novoa, G; Posadas-Romero, C; Salinas-Orozco, S; Vázquez-Chávez, C | 1 |
| Candigliota, M; Ceravolo, R; Chello, M; Cloro, C; Maio, R; Mastroroberto, P; Mattioli, PL; Mongiardo, A; Perticone, F; Scozzafava, A | 1 |
| Förstermann, U; Hausding, M; Kleinert, H; Rodriguez-Pascual, F; von Eichel-Streiber, C; Witteck, A | 1 |
| Acosta, S; Dobs, A; Recto, CS | 1 |
| Brown, WV | 1 |
| Böhm, M; Dirnagl, U; Endres, M; Gertz, K; Huang, P; Laufs, U; Nickenig, G | 1 |
| Benet, LZ; Christians, U; Jacobsen, W; Kirchner, G; Kollman, PA; Kuhn, B; Sewing, KF; Soldner, A | 1 |
| Adzet, T; Alegret, M; Cabrero, A; Laguna, JC; Sánchez, RM; Vázquez, M | 1 |
| Endo, M; Harada-Shiba, M; Hori, H; Imai, T; Ito, T; Kato, H; Kawaguchi, A; Kubo, H; Mikami, Y; Oi, K; Sakai, S; Sato, I; Suzuki, Y; Yamamoto, A | 1 |
| Agarwal, V; Lasseter, KC; Lettieri, J; Mazzu, AL; Shamblen, EC; Sundaresen, P | 1 |
| Lupattelli, G; Mannarino, E; Marchesi, S; Roscini, AR; Schillaci, G; Siepi, D; Sinzinger, H; Vaudo, G | 1 |
| Cromwell, WC; Ziajka, PE | 1 |
| Dotani, MI; Elnicki, DM; Gibson, CM; Jain, AC | 1 |
| Altman, R; Black, DM; Dujovne, CA; Harris, WS; Overhiser, RW | 1 |
| Armitage, J; Betteridge, DJ; Colhoun, H | 1 |
| Ose, L; Risberg, K; Svilaas, A; Thoresen, M | 1 |
| Barrett, PH; Parhofer, KG; Schwandt, P | 1 |
| Kwak, B; Mach, F; Mulhaupt, F; Myit, S | 1 |
| Grand-Perret, T; Issandou, M | 1 |
| Mitka, M | 1 |
| Stein, EA | 4 |
| Maron, DJ | 1 |
| Davidson, MH | 3 |
| Amore, C; Baccante, G; Cuccurullo, F; Di Castelnuovo, A; Di Febbo, C; Donati, MB; Iacoviello, L; Porreca, E | 1 |
| Balligand, JL; Desager, JP; Dessy, C; Feron, O | 1 |
| Frost, RJ; Geiss, HC; Otto, C; Parhofer, KG; Schwandt, P | 1 |
| Park, A | 1 |
| Mohrschladt, MF; Smelt, AH; Westendorp, RG | 1 |
| Aragoncillo, P; Cachofeiro, V; Díaz, C; Hernández, G; Lahera, V; Maeso, R; Navarro-Cid, J; Ruilope, LM; Vázquez-Pérez, S | 1 |
| Aspichueta, P; Díaz, C; Hernández, G; Hernández, ML; Isusi, E; Liza, M; Martínez, MJ; Ochoa, B | 1 |
| Dzurick, J; Hiller, D; Peralta, B; Rindone, JP | 1 |
| Bruckert, E; Chapman, MJ; Foglietti, MJ; Giral, P; Jacob, N; Turpin, G | 1 |
| Bäumer, AT; Böhm, M; Konkol, C; Laufs, U; Müller, K; Nickenig, G; Sauer, H; Wassmann, S | 1 |
| Elisaf, M; Miltiadous, G; Tsimihodimos, V | 1 |
| Atwal, AS; Davis, M; Hamilton, G; Jagroop, IA; Mikhailidis, DP; Nair, DR; Seifalian, AM | 1 |
| Campeau, L | 1 |
| Crouch, MA | 1 |
| Dorner, GT; Joukhadar, C; Klein, N; Prinz, M; Schmetterer, L; Schrolnberger, C; Vukovich, T; Wolzt, M | 1 |
| Marschall, HU | 1 |
| Burkhardt, K; Hauser, IA; Koch, C; Mayer-Kadner, I; Renders, L; Schärffe, S; Schmieder, RE; Veelken, R | 1 |
| Bairaktari, E; Elisaf, MS; Kiortisis, DN; Millionis, H | 1 |
| Harangi, M; Paragh, G | 1 |
| Celada Rodríguez, A; Cerdán Oliver, M; de Miguel Clavé, J; Ocaña López, JM; Solera Albero, J; Tárraga López, PJ | 1 |
| Jackson, G | 2 |
| Autin, JM; Bruniquel, F; Colpaert, FC; Degryse, AD; Delhon, A; Junquero, D; N'Guyen, X; Patoiseau, JF | 1 |
| Agrusta, M; Amodio, M; Corigliano, G; De Simone, G; Gaeta, I; Gentile, S; Guarino, G; Magliano, P; Oliviero, B; Salvatore, T; Sasso, CF; Torella, R; Turco, S | 1 |
| Dolfus, A; Faivre, M; Lipsker, D | 1 |
| Goldner, D; Insull, W; Kafonek, S; Zieve, F | 1 |
| Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; O'Malley, PG; Taylor, AJ | 1 |
| Arai, Y; Funatsu, T; Kakuta, H; Miyata, K; Suzuki, K; Tanaka, H | 1 |
| Puel, J | 1 |
| McBride, PE; Stein, JH | 1 |
| Bogman, K; Drewe, J; Küsters, E; Peyer, AK; Török, M | 1 |
| Rosenson, RS; Schaefer, EJ; Tangney, CC | 1 |
| Eickert, A; Hunzelmann, N; König, C; Krieg, T; Scharfetter-Kochanek, K | 1 |
| Bairaktari, ET; Chatzidimou, KG; Elisaf, MS; Goudevenos, JA; Mikhailidis, DP; Milionis, HJ | 1 |
| Chaitman, BR; Ezekowitz, MD; Ganz, P; Leslie, S; Oliver, MF; Olsson, AG; Schwartz, GG; Stern, T; Waters, D; Zeiher, A | 1 |
| Sacks, FM | 2 |
| Aragoncillo, P; Cachofeiro, V; Diaz, C; Hernández, G; Lahera, V; Maeso, R; Navarro-Cid, J; Ruilope, LM | 1 |
| Hartz, SC; Huse, DM; Kraemer, DF; Miller, JD; Russell, MW | 1 |
| Arístegui, R; Canudas, J; Cenarro, A; Civeira, F; Díaz, C; Garcí-Otín, AL; Hernández, G; Masramon, X; Pocoví, M; Sol, JM | 1 |
| Allen, SE; Attanasio, E; Russo, P | 1 |
| Dostal, LA; Juneau, P; Rothwell, CE | 1 |
| Berger, BL; Beuter, MJ; Callahan, AS; Devlin, TG | 1 |
| Aoki, T; Kitahara, M; Saito, Y; Sato, F; Suzuki, H; Tamaki, T; Yamazaki, H | 1 |
| Adams-Huet, B; Balis, D; Devaraj, S; Grundy, SM; Jialal, I; Stein, D | 1 |
| Hilleman, DE; Lenz, TL; Wurdeman, RL | 1 |
| Bachmann, GA; Callister, TQ; Davidson, M; Kafonek, S; Laskey, R; Pittman, D; Raggi, P; Scott, R; Welty, FK | 1 |
| Wierzbicki, AS | 3 |
| Mokuno, H | 1 |
| Kajinami, K; Takekoshi, N | 1 |
| Bourbon, M; Knight, BL; Naoumova, RP; Neuwirth, CK; O'Neill, FH; Patel, DD; Soutar, AK; Taylor, GW; Thompson, GR | 1 |
| Beinlich, CJ; Ichihara, K; Morgan, HE; Satoh, K; Shirota, F; Tsunajima, T | 1 |
| Brohet, C; De Backer, G; Heller, F; Muls, E | 1 |
| Dosch, R; Farber, SA; Halpern, ME; Hendrickson, EK; Hendrickson, HS; Ho, SY; Johnson, ID; Mullins, MC; Pack, M; Wagner, DS | 1 |
| Aragoncillo, P; Cachofeiro, V; Cediel, E; de Las Heras, N; Díaz, C; Hernández, G; Lahera, V; Navarro-Cid, J; Ruilope, LM; Sanz-Rosa, D; Vázquez-Pérez, S | 1 |
| Angus, C; Genest, J; McPherson, R; Murray, P | 1 |
| Bo, M; Fabris, F; Fiandra, U; Mercadante, G; Nicolello, MT; Piliego, T | 1 |
| Brox, J; Hansen, JB; Nordøy, A; Svensson, B | 1 |
| Angelin, B; Rudling, M | 1 |
| Cerottini, JP; Noël, B; Panizzon, RG | 1 |
| Lupattelli, G; Palumbo, B; Sinzinger, H | 1 |
| Bonardo, B; Deprez-Beauclair, P; Juhan-Vague, I; Laouenan, H; Lopez, S; Nalbone, G; Peiretti, F | 1 |
| Maclaine, GD; Patel, H | 1 |
| Ahlbory, K; Bäumer, AT; Böhm, M; Itter, G; Laufs, U; Linz, W; Müller, K; Nickenig, G; Rösen, R; Wassmann, S | 1 |
| Adler, K; Aicher, A; Dimmeler, S; Fichtlscherer, S; Martin, H; Vasa, M; Zeiher, AM | 1 |
| Arai, Y; Funatsu, T; Goto, M; Ida, M; Kakuta, H; Miyata, K; Nishijima, S; Suzuki, K; Tanaka, H; Yasuda, S | 1 |
| Mikhaildis, DP; Reynolds, TM; Wierzbicki, AS | 1 |
| Farnier, M; Mercuri, M; Stein, EA; Waldstreicher, J | 1 |
| Berra, C; Branchi, A; Colombo, E; Dalla Valle, E; Fiorenza, AM; Muzio, F; Rovellini, A; Sommariva, D; Torri, A | 2 |
| Dimitroulakos, J; Minden, MD; Penn, LZ; Tan, MM; Wong, WW; Xia, Z | 1 |
| Ito, MK | 1 |
| Fall, R; Jordan, A; Karl, T; Lindinger, W; Mayr, D; Prazeller, P; Rieder, J | 1 |
| Bairaktari, ET; Elisaf, MS; Liberopoulos, EN; Milionis, HJ | 1 |
| Crouse, JR; Davidson, MH; Escobar, ID; Hunninghake, DB; Illingworth, DR; Liu, M; Ma, PT; Melino, MR; Mercuri, M; Mitchel, YB; O'Grady, L; Paragh, G; Stalenhoef, AF | 1 |
| Breuer, HW | 1 |
| Beckmann, S; Bocksch, W; Gross, M; Hausmann, D; Karsch, KR; Koschyk, DH; Kreuzer, J; Schartl, M; Voelker, W | 1 |
| Mertens, A; Muls, E; Vansant, G | 1 |
| Black, DM; McCormick, LS; McKenney, JM; Schaefer, EJ; Watkins, ML | 1 |
| Athyros, VG; Bouloukos, VJ; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN | 1 |
| Geiss, HC; Otto, C; Parhofer, KG; Schwandt, P | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, E | 1 |
| Mikhaildis, DP; Reynolds, TR; Wierzbicki, AS | 1 |
| Chaitman, BR; Ezekowitz, MD; Ganz, P; Oliver, MF; Olsson, AG; Schwartz, GG; Waters, D; Zeiher, A | 1 |
| Anthony, M; Bleske, BE; Casselberry, N; Datwani, M; Secontine, SG; Shea, MJ; Uhley, VE; Willis, RA | 1 |
| Schwartz, JB | 2 |
| Hamakubo, T; Inoue, K; Kitahara, M; Kodama, T; Morikawa, S; Nakagawa, S; Saito, Y; Suganami, H; Umetani, M; Yamazaki, H | 1 |
| Breen, WJ; Johnson, K | 1 |
| Susekov, AV | 1 |
| Bakker-Arkema, RG; Black, DM; Corella, D; Ordovas, JM; Pedro-Botet, J; Schaefer, EJ; Stein, EM | 1 |
| Young, JH | 1 |
| Crook, MA; Mikhalidis, DP; Reynolds, TM; Wierzbicki, AS | 1 |
| Asberg, A; Fjeldså, E; Hartmann, A; Holdaas, H | 1 |
| McKellar, J; Mizan, J; Olsson, AG; Pears, J; Raza, A | 1 |
| Andrews, TC; Ballantyne, CM; Hsia, JA; Kramer, JH | 1 |
| Elisaf, M; Kakafika, A; Tsimihodimos, V | 1 |
| Durrington, PN | 1 |
| Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S; Wollersheim, H | 1 |
| Davidson, M; Hunninghake, D; Insull, W; Jones, P; Kafonek, S; Knopp, R; Lohrbauer, L | 1 |
| Lemmens, PJ; Oranje, WA; Rondas-Colbers, GJ; Sels, JP; Wolffenbuttel, BH | 1 |
| Basson, CT; Delanty, N; Vaughan, CJ | 1 |
| Auer, J; Eber, B | 1 |
| Arad, Y; Guerci, AD; Newstein, D; Roth, M | 1 |
| Akanuma, Y; Kawakami, M; Ohashi, Y; Saito, Y; Tanaka, A; Yamada, N | 1 |
| Burke, SK; Davidson, D; Donovan, JM; Hunninghake, D; Insull, W; Toth, P | 1 |
| Libby, P | 1 |
| Hsue, PY; Waters, DD | 2 |
| Deedwania, P | 1 |
| Grundy, SM | 1 |
| Raggi, P | 1 |
| Callahan, A | 1 |
| Erkelens, DW | 1 |
| Criqui, MH | 1 |
| Welty, FK | 1 |
| Bakker Schut, TC; Delsing, DJ; Havekes, LM; Jukema, JW; Princen, HM; Puppels, GJ; Römer, TJ; van De Poll, SW; van Der Laarse, A; Volger, OL | 1 |
| Conradie, MM; Gopal, R; Hough, S; Hulley, PA; Maritz, FJ | 1 |
| Igel, M; Sudhop, T; von Bergmann, K | 1 |
| Bagheri, H; Faixo, Y; Montastruc, JL; Sulem, P | 1 |
| Ichihara, K; Kaneta, S; Marumo, H; Satoh, K; Yamamoto, A | 1 |
| Keller, U; Mirsaidi, R; Miserez, AR | 1 |
| Ceska, R; Haas, T; Hradec, J; Malik, J; Melenovsky, V; Simek, J; Wichterle, D | 1 |
| Griffin, BP; Lauer, MS; Novaro, GM; Pearce, GL; Sprecher, DL; Tiong, IY | 1 |
| Ahotupa, M; Kantola, I; Nieminen, MS; Strandberg, T; Vanhanen, H; Vasankari, T; Viikari, J | 1 |
| Bazalo, GR | 1 |
| Alfón, J; Badimon, L; Berrozpe, M; Martínez-González, J | 1 |
| Dixon, JL; Hill, BJ; Sturek, M | 1 |
| Goa, KL; Malhotra, HS | 1 |
| Balligand, JL; Brouet, A; Dessy, C; Feron, O; Moniotte, S; Sonveaux, P | 1 |
| Ahsan, CH; Ezekowitz, M; Shah, A | 1 |
| Hsyu, PH; Kerr, BM; Lewis, RH; Lillibridge, JH; Schultz-Smith, MD | 1 |
| Fedtsov, A; Kolyada, AY; Madias, NE | 1 |
| Bernini, F; Paoletti, R; Poli, A | 1 |
| Kobayashi, J; Maruyama, T; Masuda, M; Shinomiya, M | 1 |
| Gavish, D; Hazanov, N; Leibovitz, E; Shargorodsky, M; Zimlichman, R | 1 |
| Harada-Shiba, M; Kawaguchi, A; Tsushima, M; Yamamoto, A | 1 |
| Böhm, M; Hilgers, S; Laufs, U; Nickenig, G; Ribaudo, N; Wassmann, S | 1 |
| Gierens, H; März, W; Nauck, M; Scharnagl, H; Schinker, R; Wieland, H | 1 |
| Hiyoshi, H; Ikuta, H; Ito, M; Kurusu, N; Okada, T; Saeki, T; Shinmyo, D; Tanaka, H; Tanaka, K; Yanagimachi, M; Yoshida, I | 1 |
| Alt, E; Banyai, M; Banyai, S; Derfler, K; Falger, J; Jansen, M; Koppensteiner, R | 1 |
| Bruegel, M; Stein, O; Stein, Y; Teupser, D; Thiery, J | 1 |
| Chen, HJ; Joseph, J; Li, DY; Mehta, JL; Romeo, F | 1 |
| Johnson, A; Zager, RA | 1 |
| Adams-Huet, B; Balis, D; Devaraj, S; Jialal, I; Stein, DT | 1 |
| Aparicio, C; Blanco-Colio, LM; Díaz, C; Egido, J; Gerique, JG; Gómez-Hernández, A; Hernández, G; Hernández-Presa, MA; Hernández-Vargas, P; Martín-Ventura, JL; Mas, S; Ortega, L; Ortego, M; Tuñón, J; Vivanco, F | 1 |
| Ellis, PM | 1 |
| Altamura, L; Chiariello, L; Crea, F; Gaspardone, A; Gioffrè, PA; Proietti, I; Tomai, F; Versaci, F | 1 |
| Crook, MA; Reynolds, TM; Wierzbicki, AS | 1 |
| Gussenhoven, EJ; Hagenaars, T; Poldermans, D; van der Lugt, A; van Urk, H | 1 |
| Chitra, R; Davidson, M; Gotto, AM; Hutchinson, H; Ma, P; Raza, A; Stein, EA | 1 |
| Berthier, S; Hartmann, S; Hubert, M; Kovarik, JM; Rordorf, C; Rosenkranz, B; Schneider, W | 1 |
| Aaronson, KD; Baliga, RR; Cody, RJ; Dyke, DB; Koelling, TM; Lake, KD; Pagani, FD; Patel, DN | 1 |
| Ahlbory, K; Bäumer, AT; Böhm, M; Konkol, C; Laufs, U; Linz, W; Müller, K; Nickenig, G; Wassmann, S | 1 |
| Bairaktari, E; Chapman, MJ; Elisaf, M; Goudevenos, JA; Karabina, SA; Tambaki, AP; Tselepis, AD; Tsimihodimos, V | 1 |
| Azuma, A; Harada, S; Kunitomo, K; Kuwahara, N; Nakagawa, M; Sasaki, S; Takeda, K; Yamada, T | 1 |
| Ai, VH; Chow, WS; Lam, CH; Lam, KS; Tam, SC; Tan, KC | 1 |
| Cooke, JP; Glassford, AJ; Heeschen, C; Weis, M | 1 |
| Castle, SS; Duncan, MC; Streetman, DS | 1 |
| Bastagi, L; Boni, P; Massarelli, G; Muscari, A; Poggiopollini, G; Puddu, P; Tomassetti, V | 1 |
| Aberg, JA; Alston, B; Aweeka, F; Blaschke, T; Fang, F; Fichtenbaum, CJ; Gerber, JG; Kosel, B; Rosenkranz, SL; Segal, Y | 1 |
| Funatsu, T; Goto, M; Ida, M; Kakuta, H; Miyata, K; Nishijima, S; Suzuki, M; Tanaka, H; Yasuda, S | 1 |
| Blanco-Colio, LM; Egido, J; Hernández-Presa, MA; Ortego, M; Pascual, A; Plaza, JJ; Villa, A | 1 |
| Allister, E; Mamo, JC; Pal, S; Thomson, A | 1 |
| Adeli, K; Cheung, RC; Parris, W; Pontrelli, L | 1 |
| Hidalgo, C; Jaimez, L; Jiménez-Alonso, J; Leon, L; Sabio, JM | 1 |
| Asch, SM; Escarce, JJ; Lewis, JH; Muñoz, JA; Rosen, MR; Schonlau, M; Yang, H | 1 |
| Karalis, DG; Ross, AM; Scott, R; Vacari, RM; Zarren, H | 1 |
| Baguet, JP; Cameron, JD; Dart, AM; Ferrier, KE; Jennings, GL; Kingwell, BA; Muhlmann, MH | 1 |
| Elisaf, M; Kakafika, A; Liamis, G; Mikhailidis, D | 1 |
| Anliker, MD; Wüthrich, B | 1 |
| Belder, R; Braunwald, E; Breen, J; Cannon, CP; McCabe, CH | 1 |
| Bradley, M; Chong, C; Kelly, S | 1 |
| Adeli, K; Cheung, RC; Mangaloglu, L; Pontrelli, L; Taghibiglou, C; Van Iderstine, SC | 1 |
| Celik, S; Erdöl, C; Kural, BV; Orem, A; Orem, C; Uydu, HA | 1 |
| Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Mackness, MI; Maton, SM; Neil, HA; Thomason, MJ | 1 |
| Chong, CC; Harris, KP; Wheeler, DC | 1 |
| Athyros, VG; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA | 1 |
| Böhm, M; Kilter, H; Konkol, C; Laufs, U; Nickenig, G; Wassmann, S | 1 |
| Grip, O; Janciauskiene, S; Lindgren, S | 2 |
| Ting, CT; Wang, KY | 1 |
| Dernbach, E; Dimmeler, S; Urbich, C; Zeiher, AM | 1 |
| Amsden, GW; Kuye, O; Wei, GC | 1 |
| Boquist, S; Danell-Toverud, K; Hamsten, A; Karpe, F | 1 |
| Arnesen, H; Hjermann, I; Seljeflot, I; Tonstad, S | 2 |
| Brödl, UC; Empen, K; Otto, C; Parhofer, KG | 1 |
| Baillie, TA; Fang, X; Lin, JH; Ma, B; Pearson, PG; Prueksaritanont, T; Qiu, Y; Subramanian, R | 1 |
| Hurt-Camejo, E; Mattsson-Hultén, L; Oscarsson, J; Wiklund, O | 1 |
| Castro, JG; Gutierrez, L | 1 |
| Piliero, PJ | 1 |
| Almenar Bonet, L; Arnau Vives, MA; Dicenta Gisbert, F; Martínez-Dolz, L; Osa Sáez, A; Palencia Pérez, M; Rueda Soriano, J | 1 |
| Barrett, PH; Chan, DC; James, AP; Mamo, JC; Martins, IJ; Mori, TA; Redgrave, TG; Watts, GF | 1 |
| Hecker, M; Schwabe, O; Wagner, AH | 1 |
| Iliff, RD | 1 |
| Jouanel, P; Malpuech, G; Meyer, M; Palcoux, JB; Vanlieferinghen, P | 1 |
| Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN | 1 |
| de la Iglesia Martínez, F; Diz-Lois Martínez, F; Nicolás Miguel, R; Pellicer Vázquez, C; Pita Fernández, S; Ramos Polledo, V | 1 |
| Baker, D; Hamilton, G; Jagroop, IA; Mikhailidis, DP; Myint, F; Seifalian, AM; Youssef, F | 1 |
| Barrett, PH; Beilin, LJ; Chan, DC; Mori, TA; Redgrave, TG; Watts, GF | 3 |
| Aristegui, R; Chaves, J; Civeira, F; da Silva, PM; Díaz, C; Gómez-Gerique, JA; Hernández, A; Hernández, G; Lima, J; Mostaza, JM; Oliván, J; Pintó, X; Rodriguez-Botaro, A; Ros, E; Sol, JM; Vilardell, M; Zambón, D | 1 |
| de Koning, EJ; Gaillard, CA; Honing, ML; Rabelink, TJ; Stroes, ES; van Etten, RW | 1 |
| Alexander, S; Bilodeau, T; Carlson, W; Clark, M; Johnstone, M; Karam, C; Kinlay, S; Lloyd-Jones, DM; Orav, J; Ridker, PM; Rifai, N; Rubenstein, J; Stone, PH; Timms, T | 1 |
| Kluft, C | 1 |
| Engler, H; Korte, W; Noseda, G; Riesen, WF; Risch, M | 1 |
| Moon, A; Smith, T | 1 |
| Delaval, D; Després, JP; Lemieux, I; Salomon, H | 1 |
| Barrett, PH; Beilin, LJ; Chan, DC; Mori, TA; Watts, GF | 1 |
| Chan, E; Charles, MA; Pan, J; Van, JT; Wasty, T; Wu, X | 1 |
| Abourjaily, HM; Alsheikh-Ali, AA; Karas, RH | 2 |
| Barsotti, A; Brunelli, C; Ghigliotti, G; Leslie, S; Olivotti, L; Rossettin, P; Spallarossa, P | 1 |
| Bruckert, E; Gagné, C; Gaudet, D | 1 |
| Caccese, D; Lauro, R; Lenti, L; Magnaterra, R; Martini, F; Pignatelli, P; Pulcinelli, FM; Sanguigni, V; Violi, F | 1 |
| Bonetta, L | 1 |
| Bellosta, S; Corsini, A; Paoletti, R | 1 |
| Bonow, RO; McConnell, JP; Niekrasz, M; Rajamannan, NM; Sebo, TC; Singh, RJ; Spelsberg, TC; Springett, M; Stone, NJ; Subramaniam, M | 1 |
| Athyros, VG; Kontopoulos, AG; Papageorgiou, AA | 1 |
| Chapman, MJ; Dupuis, R; Egger, P; Guerin, M; Le Goff, W; Soudant, C; van Tol, A | 1 |
| Auteri, A; Bova, G; Bruni, F; Cercignani, M; Console, E; Palazzuoli, A; Pasqui, AL; Puccetti, L | 1 |
| Hinman, J; Scanu, AM | 1 |
| Adzet, T; Alegret, M; Díaz, C; Hernández, G; Laguna, JC; Peris, C; Roglans, N; Sánchez, RM; Vázquez, M; Verd, JC | 1 |
| Aristegui, R; Civeira, F; Díaz, C; García-Otín, AL; Hernández, G; Masramon, X; Pocoví, M; Recalde, D; Sol, JM | 1 |
| Adzet, T; Alegret, M; Díaz, C; Hernández, G; Laguna, JC; Peris, C; Roglans, N; Sánchez, RM; Sanguino, E; Vázquez, M | 1 |
| Gavish, D; Harats, D; Leibovitz, E | 1 |
| Acevedo, M; Francis, G; Lauer, MS; Sprecher, DL | 1 |
| Mandó, OG; Ridruejo, E | 1 |
| Alber, HF; Dichtl, W; Dulak, J; Frick, M; Pachinger, O; Schwarzacher, SP; Weidinger, F | 1 |
| Athyros, VG; Athyrou, VV; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA | 1 |
| Banga, JD; Bots, ML; Huisman, MV; Stolk, RP; van de Ree, MA; van Venrooij, FV | 1 |
| Berk-Planken, I; de Konig, I; Hoogerbrugge, N; Jansen, H; Stolk, R | 1 |
| Achimastos, A; Bairaktari, E; Elisaf, M; Goudevenos, J; Kakafika, A; Liamis, G; Miltiadous, G; Tsimihodimos, V | 1 |
| Asberg, A; Bergan, S; Fjeldså, E; Hartmann, A; Holdaas, H | 1 |
| Braga, JC; Correia, LC; D'Oliveira, A; Esteves, JP; Lima, JC; Passos, LC; Rocha, MS; Spósito, AC | 1 |
| Chatlaong, B; Laothavorn, P; Nasawadi, C; Piamsomboon, C; Pongsiri, K; Saguanwong, S; Tanprasert, P | 1 |
| Delsing, DJ; Havekes, LM; Jukema, JW; Princen, HM; Puppels, GJ; van de Poll, SW; van der Laarse, A | 1 |
| Aviram, M; Fuhrman, B; Hayek, T; Keidar, S; Koren, L; Volkova, N | 1 |
| Ahmetov, S; Balci, M; Cefle, K; Kaymaz, AA; Onar, V; Ozturk, S; Palanduz, S; Salmayenli, N; Tamer, S | 1 |
| Velussi, M | 1 |
| Açil, T; Aksöyek, S; Atalar, E; Haznedaroglu, I; Kes, S; Ovünç, K; Ozer, N; Ozmen, F | 1 |
| Chen, H; Li, D; Mehta, JL; Romeo, F; Saldeen, T; Sawamura, T | 1 |
| Segal, AS | 1 |
| Brandes, RP; Vecchione, C | 1 |
| Blanco-Colio, LM; Bustos, C; Egido, J; Hernández, AG; Hernández-Presa, MA; Ortego, M; Tuñón, J | 1 |
| Bauersachs, J; Christ, M; Günther, A; Heck, M; Liebetrau, C; Wehling, M | 1 |
| Derfler, K; Goldammer, A; Heinz, G; Hörl, WH; Jansen, M; Stulnig, T; Wiltschnig, S | 1 |
| Edvinsson, L; Stenman, E; Xu, CB | 1 |
| Arbustini, E; Camera, M; Cofrancesco, E; Cortellaro, M; Gabrielli, L; Negri, A; Rossi, F; Tremoli, E | 1 |
| González, M; González-Santos, P; Márquez, M; Palacios, R; Ruiz, J; Santos, J; Valdivielso, P | 1 |
| Kawakami, A; Nakajima, K; Shimokado, K; Tanaka, A; Yoshida, M | 1 |
| Bey, L; Hamilton, MT; Laouenan, H; Maigret, P | 1 |
| Cayssials, A; Ferraris, JR; Krmar, RT; Legal, S; Ramirez, JA; Sorroche, P | 1 |
| de Beer, F; Havekes, LM; Kastelein, JJ; Lansberg, PJ; Prins, MH; Smelt, AH; Trip, MD; van Dam, M; Zwart, M | 1 |
| Athyros, VG; Athyrou, VV; Basayannis, EO; Demitriadis, DS; Kontopoulos, AG; Mercouris, BR; Papageorgiou, AA; Symeonidis, AN | 1 |
| Chapman, MJ; Doucet, C; Gonbert, S; Laouenan, H; Malinsky, S; Sposito, AC; Thillet, J | 1 |
| Asztalos, BF; Horvath, KV; McNamara, JR; Roheim, PS; Rubinstein, JJ; Schaefer, EJ | 2 |
| Alegret, M; Díaz, C; Hernández, G; Jové, M; Laguna, JC; Llaverías, G; Sánchez, RM; Vázquez-Carrera, M | 1 |
| Supanich, B | 1 |
| Hamakubo, T; Itoh, T; Izumi, A; Kanke, T; Kodama, T; Mataki, C; Morikawa, S; Saito, Y; Takabe, W; Wada, Y | 1 |
| Dick, JB; Patterson, D; Struthers, AD | 1 |
| Barrett, PH; Batal, R; Bernier, L; Cohn, JS; Davignon, J; Dubreuil, D; Jacques, H; Mamer, O; Rodriguez, C; Roy, M; Tremblay, M; Veilleux, L | 1 |
| Asakura, H; Ishino, C; Kanno, M; Matsuda, T; Minami, S; Morishita, E; Nakao, S; Uotani, C | 1 |
| Francis, PJ; Parmar, B; Ragge, NK | 1 |
| Lewin, JJ; Nappi, JM; Taylor, MH | 1 |
| Chaitman, BR; Ezekowitz, M; Ganz, P; Leslie, SJ; Oliver, MF; Olsson, AG; Schwartz, GG; Stern, T; Waters, DD; Zeiher, A | 1 |
| Cianciaruso, B; Pisani, A; Sabbatini, M; Somma, G; Torraca, S | 1 |
| Hin, AT; Lee, YT; Suyono, S; Sy, R; Tanphaichitr, V; Wu, CC | 1 |
| Bannykh, S; England, JD; Gray, NL; Haas, RH; Hathaway, S; Kimura, BJ; Phillips, PS; Vladutiu, GD | 1 |
| Jonasson, L; Linderfalk, C; Olsson, AG; Schwartz, GG | 1 |
| Daly, JA; Ferrari, A; Gleason, JA; McNamara, JR; Rubenstein, JJ; Schaefer, EJ; Seman, LJ; Tayler, T | 1 |
| Mercuro, G; Rosano, GM; Saiu, F; Sarais, C; Zoncu, S | 1 |
| Altamura, L; Chiariello, L; Gaspardone, A; Proietti, I; Skossyreva, O; Tomai, F; Versaci, F | 1 |
| Deedwania, PC; Matalka, MS; Ravnan, MC | 1 |
| Ceska, R; Malik, J; Melenovsky, V; Pisarikova, A; Poledne, R; Simek, J; Skrha, J; Stavek, P; Wichterle, D | 1 |
| Altavilla, D; Bonaiuto, M; Campo, S; Castaldo, M; Cinquegrani, M; Maesano, A; Nicocia, G; Saitta, A; Sardo, MA; Spadaro, M; Versace, A | 1 |
| Lisker-Melman, M; Shiels, P; Sreenarasimhaiah, J | 1 |
| Dixon, JL; Shen, S; Sturek, M; Sun, GY; Vuchetich, JP; Wysocka, E | 1 |
| Ammirati, F; Colivicchi, F; Guido, V; Montefoschi, N; Santini, M; Tubaro, M; Varveri, A | 1 |
| Shah, PK | 1 |
| Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; Taylor, AJ; Vernalis, MN | 1 |
| SoRelle, R | 2 |
| Lin, JH; Mu, L; Prueksaritanont, T; Qiu, Y; Subramanian, R; Tang, C | 1 |
| Ahmad, S; Ahmed, Z; Bhatia, V; Haskard, DO; Kinderlerer, A; Lidington, EA; Mankoff, R; Mason, JC; Randi, AM | 1 |
| Biswas, N; Brunzell, JD; Cohen, BR; Freed, MI; Kreider, MM; Marcovina, SM; Ratner, R | 1 |
| Nordøy, A | 1 |
| Chapman, MJ; Dupuis, R; Egger, P; Guerin, M; Le Goff, W; Soudant, C | 1 |
| Chmielewski, M; Rutkowski, B; Zdrojewski, Z | 1 |
| de Graaf, J; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S | 1 |
| Raison, J; Rudnichi, A; Safar, ME | 1 |
| Wekerle, H | 1 |
| Bravo, M; Hur, EM; Mitchell, DJ; Patarroyo, JC; Radosevich, JL; Ruiz, PJ; Sobel, RA; Steinman, L; Stüve, O; Youssef, S; Zamvil, SS | 1 |
| Gebauer, M; Güldenzoph, B; Hecker, M; Wagner, AH | 1 |
| Bernstein, D; Chin, C; Gamberg, P; Luikart, H; Miller, J | 1 |
| Carranza, DC; Chen, IY; Collisson, EA; Kolodney, MS | 1 |
| Funatsu, T; Kakuta, H; Miyata, K; Takasu, T | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Franiak, I; Klikczynska, K; Koter, M | 1 |
| Ashby, DT; Conditt, G; Dangas, G; Hirose, M | 1 |
| Bavendiek, U; Ganz, P; Gerdes, N; Horton, DB; Kinlay, S; Libby, P; Reynolds, RS; Robbie, L; Schönbeck, U; Varo, N | 1 |
| Barrett, PH; Lewis, GF; Rashid, S; Uffelman, KD | 1 |
| Hanson, SY; Johnson, AC; Zager, RA | 1 |
| Angelin, B; Björquist, A; Gälman, C; Ostlund-Lindqvist, AM; Rudling, M; Schreyer, S; Svensson, L | 1 |
| Huisman, MV; Kluft, C; Meinders, AE; Princen, HM; van de Ree, MA | 1 |
| Arisz, L; Kastelein, JJ; Koopman, MG; Ozsoy, RC | 2 |
| Ceska, R; Fialova, L; Malbohan, I; Stulc, T; Zima, T | 1 |
| Ceska, R; Kasalová, Z; Marinov, I; Stulc, T; Vrablík, M | 1 |
| Chasiotis, G; Elisaf, M; Miltiadous, G; Papakostas, J; Seferiadis, K | 1 |
| Clarke, TA; Waskell, LA | 1 |
| Istad, H; Luurila, O; Olsson, AG; Ose, L; Pears, J; Southworth, H; Stender, S; Tuomilehto, J; Wiklund, O; Wilpshaar, JW | 1 |
| Gaddam, V; Li, DY; Mehta, JL | 1 |
| Knight, BL; Naoumova, RP; O'Neill, FH; Patel, DD; Thompson, GR | 1 |
| Ostroumova, OD | 1 |
| At'kov, OIu; Balakhonova, TV; Kobylianskiĭ, AG; Kukharchuk, VV; Kuznetsova, TV; Masenko, VP; Pogorelova, OA; Susekov, AV; Titov, VN; Tvorogova, MG | 1 |
| Seeger, JD | 1 |
| Blaschke, F; Bokemeyer, J; Fleck, E; Goetze, S; Graf, K; Kappert, K; Kintscher, U; Schmidt, G; Stawowy, P | 1 |
| Frolkis, JP; Minor, S; Nambi, V; Pearce, GL; Sprecher, DL | 1 |
| Ballantyne, CM; Chitra, RR; Knopp, RH; McPherson, R; Schneck, DW; Simonson, SG | 1 |
| Harman, SM; Hecht, HS | 1 |
| Bates, ER; Carville, DG; Guyer, KE; Hopp, AS; Horowitz, K; Lau, WC; Neer, CJ; Tait, AR; Waskell, LA; Watkins, PB | 1 |
| Roth, BD | 1 |
| Abe, S; Hiyoshi, H; Ikuta, H; Ito, M; Kurusu, N; Okada, T; Saeki, T; Shinmyo, D; Tanaka, H; Tanaka, K; Yanagimachi, M; Yasuda, N; Yoshida, I | 1 |
| Beevers, DG; Lim, HS; Lip, GY; Nadar, S | 1 |
| Alber, HF; Ares, MP; Dichtl, W; Dulak, J; Frick, M; Nilsson, J; Pachinger, O; Schwarzacher, SP; Weidinger, F | 1 |
| Baghestanian, M; Bühring, HJ; Ghannadan, M; Hauswirth, AW; Majlesi, Y; Rezaie-Majd, A; Samorapoompichit, P; Schernthaner, GH; Sperr, WR; Valent, P; Valenta, R | 1 |
| Metcalfe, CD; Miao, XS | 1 |
| Sinzinger, H | 1 |
| Alvarez, E; Castaño, G; Fernández, L; Illnait, J; Lezcay, M; Mas, R; Mesa, M | 1 |
| Angori, P; Auteri, A; Bova, G; Bruni, F; Cercignani, M; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Puccetti, L | 1 |
| Amâncio, RF; Chapman, MJ; Maranhão, RC; Ramires, JA; Santos, RD; Sposito, AC | 1 |
| Aukrust, P; Frøland, SS; Gullestad, L; Kastelein, JJ; Pedersen, TR; Semb, AG; Smilde, T; Stalenhoef, AF; Tripp, MD; Ueland, T; van Wissen, S; Waehre, T | 1 |
| Baykan, M; Calapoğlu, M; Erdöl, C; Orem, A; Orem, C; Uydu, HA | 1 |
| Derhaschnig, U; Dorner, GT; Jilma, B; Joukhadar, C; Petternel, V; Rassoul, F; Richter, V; Wagner, OF; Wolzt, M | 1 |
| Berk-Planken, II; Bootsma, AH; Hoogerbrugge, N; Jansen, H; Stolk, RP | 1 |
| Benoliel, AM; Bernot, D; Bonardo, B; Bongrand, P; Juhan-Vague, I; Lopez, S; Nalbone, G; Peiretti, F | 1 |
| Anthopoulou, A; Elisaf, M; Miltiadous, G | 1 |
| Fuchs, D; Laich, A; Neurauter, G; Schennach, H; Weiss, G; Wirleitner, B | 1 |
| Barrett, PH; Burnett, JR; Edwards, JY; Huff, MW; Keller, BT; Krul, ES; Lipson, SM; Sutherland, B; Telford, DE | 1 |
| Backes, JM; Moriarty, PM | 1 |
| Athyros, VG; Athyrou, VV; Basayannis, EO; Demitriadis, DS; Kontopoulos, AG; Mercouris, BR; Mikhailidis, DP; Papageorgiou, AA; Symeonidis, AN | 1 |
| Hirooka, Y; Kishi, T; Mukai, Y; Shimokawa, H; Takeshita, A | 1 |
| Malik, P | 1 |
| Farmer, JA | 3 |
| Böhm, M; Dirnagl, U; Endres, M; Gertz, K; Laufs, U; Lindauer, U; Nickenig, G | 1 |
| Bell, RM; Yellon, DM | 1 |
| Laucevicius, A; Simaitis, A | 1 |
| Gylling, H; Lindbohm, N; Miettinen, TA; Miettinen, TE; Rajaratnam, RA; Relas, H | 1 |
| Coupal, L; Grover, SA; Ho, V; Lavoie, F; Pilote, L; Zowall, H | 1 |
| Chin-Dusting, JP; Kaye, DM; Parnell, MM; Starr, J | 1 |
| Silverstein, DM | 1 |
| Aitken, M; Argent, E; Kainer, G; Mackie, FE; Rosenberg, AR | 1 |
| Brady, TJ; Derfler, K; Haas, M; Hoffmann, U; Kostner, K; Stadler, A | 1 |
| Baldi, S; Blandizzi, C; Del Tacca, M; L'Abbate, A; Lubrano, V; Natali, A; Palombo, C; Vassalle, C | 1 |
| Bröcker, M; Grosse-Wilde, H; Kreuzfelder, E; Kröger, K; Lindemann, M; Santosa, F | 1 |
| Bruemmer, D; Fleck, E; Graf, K; Kiyono, T; Law, RE; Liu, J; Van Herle, A; Yin, F | 1 |
| Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; Taylor, AJ | 2 |
| Simons, J | 1 |
| Calzoni, F; Dalla Nora, E; Fellin, R; Passaro, A; Solini, A; Zamboni, PF | 1 |
| Barrett, PH; Chan, DC; Croft, KD; Ji, J; Johnson, AG; Loehrer, F; Serone, AP; Watts, GF | 1 |
| Krane, V; Wanner, C | 2 |
| Bianchi, S; Bigazzi, R; Caiazza, A; Campese, VM | 1 |
| Hutten, BA; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S | 1 |
| Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Larivière, M; Pirro, M | 1 |
| Ishii, T; Miyauchi, A; Nagakura, C; Sakurai, S; Tsujibayashi, T; Yoshitomi, Y | 1 |
| Delsing, DJ; Havekes, LM; Princen, HM; Puppels, GJ; van de Poll, SW; van der Laarse, A; Wouter Jukema, J | 1 |
| Aktas, O; Brocke, S; Dorr, J; Endres, M; Nitsch, R; Prozorovski, T; Sallach, S; Seeger, B; Smorodchenko, A; Waiczies, S; Zipp, F | 1 |
| Bays, HE; Crouse, JR; Dujovne, CA; Hutcheson, AG; Kashyap, ML; McGovern, ME; White, TE | 1 |
| Eriksson, M; Johnson, O; Kjellström, T; Lanke, J; Larsen, ML; Olsson, AG; Pedersen, T; Tikkanen, MJ; Wiklund, O | 1 |
| Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M | 1 |
| Baumgartner, RW; Georgiadis, D | 1 |
| Nissen, SE | 3 |
| Blasetto, JW; Brown, WV; Chitra, R; Raza, A; Stein, EA | 1 |
| Barter, P; Hunninghake, DB; Hutchinson, HG; McKenney, JM; Shepherd, J | 2 |
| Caplan, RJ; Davidson, MH; Pears, JS; Rader, DJ | 1 |
| Fuller, S; Gillen, D; Lacey, L; Marriott, J; Wilson, K | 1 |
| McBurney, CR; Smith, DG | 1 |
| Buller, N; Casciano, R; Doyle, J; Gillen, D; Wilson, K | 1 |
| Bolaman, Z; Kadikoylu, G; Yavasoglu, I; Yukselen, V | 1 |
| Clark, LT | 1 |
| Athyros, VG; Boudoulas, H; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA; Pehlivanidis, AN | 1 |
| Banga, JD; Dallinga-Thie, GM; Erkelens, DW; Sijmonsma, TP; Stolk, RP; van Tol, A; van Venrooij, FV | 1 |
| Dixon, JL; Katwa, LC; Lee, DL; Reddy, HK; Sturek, M; Voelker, DJ; Wamhoff, BR | 1 |
| Duffy, SJ; Gokce, N; Holbrook, M; Kahn, D; Keaney, JF; Palmisano, J; Thomas, S; Tomasian, D; Vita, JA | 1 |
| Hennekens, CH; Serebruany, VL; Steinhubl, SR | 1 |
| Barrett, PH; Laubach, E; Parhofer, KG | 1 |
| Aviles, RJ; Brennan, ML; Fu, X; Gokce, N; Goormastic, M; Hazen, SL; Keaney, JF; Pearce, GL; Penn, MS; Shishehbor, MH; Sprecher, DL; Vita, JA | 1 |
| Aicher, A; Assmus, B; Dimmeler, S; Haendeler, J; Hofmann, WK; Rössig, L; Spyridopoulos, I; Urbich, C; Zeiher, AM | 1 |
| Amano, Y; Imura, Y; Ishikawa, E; Nishimoto, T; Sugiyama, Y; Tozawa, Ri | 1 |
| Charbonnel, B; Krempf, M; Laouenan, H; Magot, T; Marchini, JS; Ouguerram, K; Zaïr, Y | 1 |
| Lindholm, LH; Samuelsson, O | 1 |
| Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H | 3 |
| Dratwa, M; Lameire, NH; Lins, RL; Matthys, KE; Peeters, PC; Stolear, JC; Verpooten, GA | 1 |
| Bendahan, D; Bernard, V; Cozzone, PJ; Figarella-Branger, D; Guis, S; Kozak-Ribbens, G; Lando, A; Mattei, JP; Pellissier, JF; Treffouret, S | 1 |
| Fujino, H; Kojima, J; Saito, T; Tsunenari, Y | 1 |
| Aoki, T; Kitahara, M; Saito, Y; Sato, F; Tamaki, T; Yamazaki, H | 1 |
| Khan, BV; Khan, QA; Lauten, WB; Lerakis, S; Parthasarathy, S; Rahman, ST; Rajagopalan, S | 1 |
| Ballantyne, CM; Houri, J; LeBeaut, AP; Lipka, LJ; Melani, L; Notarbartolo, A; Sager, PT; Sun, S; Suresh, R; Veltri, EP | 1 |
| Cassels, A; Cole, C; Hughes, MA; Lexchin, J; McCormack, JP; Mintzes, B | 1 |
| Fathi, R; Haluska, B; Marwick, TH; Short, L | 1 |
| Liebson, PR | 1 |
| Arnesen, KE; Aukrust, P; Damås, JK; Frøland, SS; Gullestad, L; Holm, AM; Pedersen, TR; Semb, AG; Torsvik, H; Waehre, T | 1 |
| Elkin, RG; Furumoto, EJ; Thomas, CR | 1 |
| Oguogho, A; Sinzinger, H | 1 |
| Belowski, D; Herman, ZS; Kalina, Z; Kowalski, J; Madej, A; Okopień, B; Zieliński, M | 1 |
| Funatsu, T; Kakuta, H; Miyata, K; Noguchi, M; Suzuki, M; Takasu, T | 1 |
| Erhart, KH; Graziadei, IW; Obermoser, GE; Sepp, NT; Vogel, W | 1 |
| Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL | 1 |
| Gilchrist, JM | 1 |
| Correia, LC; D'Oliveira, A; Esteves, JP; Magalhães, LP; Passos, LC; Rocha, MS; Santana, O; Spósito, AC | 1 |
| Bao, Y; Bernard, SA; Lazar, HL; Zhang, Y | 1 |
| Bokhart, GH; Jones, RJ; Sipe, BE | 1 |
| Chen, J; Chopp, M; Feldkamp, CS; Jiang, H; Katakowski, M; Li, Y; Lu, M; Wang, L; Wang, Y; Zhang, C; Zhang, ZG | 1 |
| Shechter, M | 1 |
| Berry, DA; Berry, SM; McKellar, J; Pearson, TA | 1 |
| Hirano, K; Hiraoka, H; Ishigami, M; Matsuzawa, Y; Nakamura, T; Sakai, N; Yamashita, S | 1 |
| Devroey, D; Ginst, LV | 1 |
| Ravnskov, U | 1 |
| Killestein, J | 1 |
| Trewby, P | 1 |
| Drummond, GA | 1 |
| Akbulut, H; Akbulut, M; Arslan, N; Ilkay, E; Karaca, I; Pekdemir, M; Yavuzkir, M | 1 |
| Ahmadi-Kashani, M; Balian, H; Bashir, M; Ebrahimi, R; Jafari, M | 1 |
| Beaudry, JA; Bhat, BG; Butteiger, DN; Hall, KA; Keller, BT; Luo, Y; Napawan, N; Null, CL; Rapp, SR | 1 |
| Böhm, M; Fries, R | 1 |
| Fan, YH; Tian, JW; Wang, SW; Xu, L; Yang, XD; Zhang, HT; Zhao, LY; Zheng, QS | 1 |
| Gill, MJ; Mah Ming, JB | 1 |
| Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Julier, K; Mackness, MI; Neil, HA; Soedamah-Muthu, SS; Thomason, MJ | 1 |
| Denman, R; Martin, PT | 1 |
| Hackam, DG | 1 |
| Barrett, PH; Chan, DC; O'Neill, FH; Thompson, GR; Watts, GF | 1 |
| Delsing, DJ; Emeis, JJ; Havekes, LM; Jukema, JW; Princen, HM; van de Wiel, MA; van der Laarse, A | 1 |
| Chang, G; DeNofrio, D; Goldberg, L; Kao, A; Kolansky, DM; Loh, E; Pickering, F; Sasseen, B; See, VY; Wilensky, RL | 1 |
| Bonet, R; Jorba, O; Ordóñez-Llanos, J; Pérez, A; Wägner, AM | 1 |
| Ashitkov, T; Ballinger, S; Birnbaum, Y; Motamedi, M; Uretsky, BF | 1 |
| Noda, K; Saku, K; Zhang, B | 3 |
| Sudhop, T; von Bergmann, K | 1 |
| Betz, W; Devroey, D; Duquet, W; Velkeniers, B | 1 |
| Aragoncillo, P; Cachofeiro, V; Cediel, E; de las Heras, N; Díaz, C; Hernández, G; Lahera, V; Oubiña, MP; Sanz-Rosa, D | 1 |
| Aoki, T; Kitahara, M; Maejima, T; Saito, Y; Sato, F; Yamazaki, H | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Davidson, MH; Jones, PH; McKenney, JM; Miller, E; Stein, EA | 1 |
| Huang, Q; Parker, RA; Tesfamariam, B | 1 |
| Ballantyne, CM; Gumbiner, B; Hunninghake, DB; Maccubbin, DL; Mitchel, YB; Shah, AK | 1 |
| de Boo, T; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S | 1 |
| Dechend, R; Dietz, R; Gieffers, J; Joerres, A; Luft, FC; Maass, M; Rupp, J | 1 |
| Aviles, RJ; Brennan, ML; Fu, X; Hazen, SL; Penn, MS; Shishehbor, MH; Sprecher, DL | 1 |
| Ceppa, P; Indiveri, F; Pelli, N; Setti, M; Toncini, C | 1 |
| Hansen, JB; Nordøy, A; Svensson, B | 1 |
| Hedner, T; Himmelman, A; Kjeldsen, SE | 1 |
| Bernier, L; Boulet, L; Castilho, LN; Chamberland, A; Cohn, JS; Davignon, J | 1 |
| Achimastos, A; Bairaktari, E; Elisaf, M; Karabina, SA; Tambaki, A; Tselepis, A; Tsimihodimos, V | 1 |
| Furberg, CD; Kritz, H; Sinzinger, H | 1 |
| Bednarz, B | 1 |
| Bossaller, C; Gitt, AK; Heer, T; Juenger, C; Limbourg, P; Meisenzahl, C; Schiele, R; Senges, J; Wienbergen, H | 1 |
| Correia, LC; D'Oliveira, A; Esteves, JP; Lima, JC; Magalhães, LP; Passos, LC; Rocha, MS; Spósito, AC | 1 |
| Ceska, R; Haas, T; Malik, J; Malik, M; Melenovsky, V; Simek, J; Wichterle, D | 1 |
| Lévesque, H | 1 |
| Khadipash, LA; Kiseleva, NV; Kosmatova, OV; Mamedov, MN; Oganov, RG; Perova, NV | 1 |
| Averkov, OV; Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Vaulin, NA | 1 |
| Averkov, OV; Deev, AD; Gratsianskiĭ, NA; Pokrovskaia, EV; Slavina, NN; Vaulin, NA | 1 |
| Czerny, K; Milewska, J; Zakrzewski, P | 1 |
| Celiński, K; Sekita-Krzak, J; Stepniewska, M; Visconti, J | 1 |
| Ceska, R; Kasalová, Z; Prázný, M; Skrha, J; Stulc, T; Vrablík, M | 1 |
| Harte, S; Mc Donnell, CG; O'Driscoll, J; O'Loughlin, C; Shorten, GD; Van Pelt, FD; Van Pelt, FN | 1 |
| De Maat, MP; Huisman, MV; Kluft, C; Meinders, AE; Princen, HM; Van De Ree, MA | 1 |
| Akhmedzhanov, NM; Metel'kaya, VA; Oganov, RG; Raszzivin, VA; Vasiutina, EI | 1 |
| Marais, AD; McCrindle, BW; Ose, L | 1 |
| Haloui, M; Jandrot-Perrus, M; Meilhac, O; Michel, JB | 1 |
| Annuar, R; Khalid, BA; Nawawi, H; Osman, NS; Yusoff, K | 1 |
| Castro Cabezas, M; Jansen, H; Meijssen, S; van Dijk, H; Verseyden, C | 1 |
| Alvarez, L; Casals, E; Casamitjana, R; Conget, I; Costa, A; Gomis, R; Hernández, G; Masramón, X; Morales, J | 1 |
| Berger, PB; Brennan, D; Kereiakes, DJ; Saw, J; Serebruany, VL; Steinhubl, SR; Topol, EJ | 1 |
| Empen, K; Geiss, HC; Lehrke, M; Otto, C; Parhofer, KG; Schwandt, P | 1 |
| Malkan, D; McDonnell, CG; Shorten, GD; Van Pelt, FD | 1 |
| Ishibashi, F; Mizuno, K; Okamatsu, K; Seimiya, K; Takano, M; Uemura, R; Yokoyama, S | 1 |
| Bax, JJ; Biagini, E; Boersma, E; Bountioukos, M; Kertai, MD; Krenning, BJ; Poldermans, D; Rizzello, V; Roelandt, JR; Schinkel, AF; Vourvouri, EC | 1 |
| Beniashvili, M; Freiman, A; Gavish, D; Leibovitz, E; Shargorodsky, M; Zimlichman, R | 1 |
| Abud-Mendoza, C; Baranda, L; Cruz-Rizo, J; Cuevas-Orta, E; de la Fuente, H; González-Amaro, R | 1 |
| Creager, MA; Hiatt, WR; Mohler, ER | 1 |
| Blanco-Colio, LM; Díaz, C; Egido, J; Hernández, G; Lorz, C; Martín-Ventura, JL; Muñoz-García, B | 1 |
| Khalid, BA; Nawawi, H; Osman, NS; Yusoff, K | 1 |
| Chasiotis, G; Elisaf, MS; Kakafika, A; Milionis, HJ; Papakostas, J; Seferiadis, K | 1 |
| Baumbach, A; Fitzke, M; Herdeg, C; Karsch, KR; Oberhoff, M; Schroeder, S | 1 |
| Fink, LM; Hauer-Jensen, M; Joseph, J; Li, D; Lin, P; Ling, W; Mehta, JL; Ponnappan, U; Shi, J; Wang, J; Zheng, H | 1 |
| Koh, CS | 1 |
| Jick, H; Jick, SS; Yang, CC | 1 |
| Belousov, IuB; Leonova, MV | 1 |
| Newman, CB; Palmer, G; Silbershatz, H; Szarek, M | 1 |
| Ganz, P; Kinlay, S; Leslie, SJ; Libby, P; Olsson, AG; Rifai, N; Sasiela, WJ; Schwartz, GG; Szarek, M | 1 |
| Berkenboom, G; Fontaine, D; Fontaine, J; Otto, A | 1 |
| Burger, F; Graber, P; Kwak, BR; Lüscher, TF; Mach, F; Matter, CM; Mulhaupt, F; Pelli, G; Veillard, NR | 1 |
| Zhang, DQ; Zhao, SP | 2 |
| Amsellem, S; Atassi, M; Benlian, P; Beucler, I; Bruckert, E; Gonbert, S; Khallouf, O; Sposito, AC; Turpin, G | 1 |
| Kerrigan, AT | 1 |
| Damkier, P | 1 |
| Bedynek, A; Bilz, S; Demant, T; Keller, U; Schmitz, M; Wagner, S | 1 |
| Lennernäs, H | 1 |
| CarloTonolo, G; Carrozza, C; Lulli, P; Musumeci, S; Santini, SA; Zuppi, C | 1 |
| Chan, D; Dane-Stewart, CA; Hung, J; Mamo, JC; Pal, S; Thompson, P; Watts, GF | 1 |
| Halsall, PJ; Hopkins, PM; Johi, RR; Mills, R | 1 |
| Després, JP; Lemieux, I; Salomon, H | 1 |
| Collisson, EA; De, A; Gambhir, SS; Kleer, C; Kolodney, MS; Merajver, SD; Wu, M | 1 |
| Nasu, M; Tamura, A; Watanabe, T | 1 |
| Fukuda, N; Nada, T; Sakabe, K; Shinohara, H; Tamura, Y; Wakayama, K | 3 |
| Arikian, S; Ganz, P; Schwartz, GG; Waters, D | 1 |
| Kajinami, K; Kanayama, S; Kanemitsu, S; Matsui, S; Okubo, S; Sato, R; Takekoshi, N; Yamashita, N | 1 |
| Jones, JK | 1 |
| Amarenco, P; Bogousslavsky, J; Callahan, AS; Goldstein, L; Hennerici, M; Sillsen, H; Welch, MA; Zivin, J | 1 |
| Aviram, M; Hayek, T; Hussein, K; Rosenblat, M | 1 |
| Aligisheeva, ZA; At'kov, OIu; Balakhonova, TV; Kukharchuk, VV; Pogorelova, OA; Susekov, AV; Titov, VN | 1 |
| Silverberg, C | 1 |
| Ballantyne, CM; Blazing, MA; Davidson, MH; DeLucca, P; Hunninghake, DB; Hustad, CM; Palmisano, J; Ramsey, KE; Yuan, Z | 1 |
| Karas, RH; Kimmelstiel, C; Pourati, I; Rand, W | 1 |
| Bays, HE; McGovern, ME | 2 |
| Arsenault, M; Auclair, L; Bogaty, P; Boyer, L; Dagenais, GR; Jobin, J; Pépin, G; Poirier, P | 1 |
| Kent, SM; Taylor, AJ | 1 |
| Alber, H; Cisowski, J; Dichtl, W; Dulak, J; Frick, M; Józkowicz, A; Pachinger, O; Schwarzacher, SP; Weidinger, F; Zwick, R | 1 |
| Gersh, BJ; Raco, DL; Rihal, CS; Yusuf, S | 1 |
| Brown, WV; Moussa, M | 1 |
| Gylling, H; Miettinen, TA | 1 |
| Diggle, PJ; Miller, E; Southworth, H; Stein, EA; Strutt, K | 1 |
| Li, QZ; Nie, S; Xu, ZM; Zhao, SP; Zhou, HN | 1 |
| Gross, B; Hättenschwiler, A; Schulthess, G; Widmer, Ch | 1 |
| Bertolami, MC; Cihon, F; Davidson, MH; Dujovne, CA; Escobar, ID; Frohlich, J; Maccubbin, DL; Mercuri, M; Ose, L; Scott, RS | 1 |
| Fattinger, K; Flury, R; Kohler, M; Meier, PJ; Pauli-Magnus, C; Perger, L | 1 |
| Heinonen, T; Klepack, E; Lovalvo, J; Marais, AD; McLain, R; Raal, FJ | 1 |
| Dierkes, J; Güttler, K; Luley, C; Westphal, S; Wiens, L | 1 |
| Ichihara, K; Kanda, M; Satoh, K | 1 |
| Ersoy, L; Ertürk, S; Fiçicioğlu, S; Sevinç Aktaş, E | 1 |
| Angelin, B; Berglund, L; Borgström, B; Eggertsen, G; Ericsson, S; Eriksson, M; Lind, S; Olivecrona, H; Rudling, M | 1 |
| Ceska, R; Fialová, L; Malbohan, I; Malík, J; Soukupová, J; Stulc, T | 1 |
| Böhm, M; Nickenig, G; Scheller, B; Schmitt, A | 1 |
| Isomustajärvi, M; Laakso, J; Laaksonen, R; Lakka, TA; Lehtimäki, T; Päivä, H; Ruokonen, I; Salonen, JT; Valkonen, VP | 1 |
| Gupta, S | 1 |
| Bolaman, Z; Kadikoylu, G | 1 |
| de Groot, E; Hutten, BA; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; van Wissen, S | 1 |
| Antonini-Canterin, F; Cervesato, E; Granata, G; Nicolosi, GL; Pavan, D; Piazza, R; Popescu, BA; Zuppiroli, A | 1 |
| Adim, SB; Dolar, E; Gulten, M; Gurel, S; Kiyici, M; Memik, F; Nak, SG; Savci, G; Yerci, O | 1 |
| Fujino, H; Hirano, M; Kojima, J; Shimada, S; Tsunenari, Y; Yamada, I | 1 |
| Alexy, T; Horvath, B; Kesmarky, G; Marton, Z; Szapary, L; Toth, K | 1 |
| Pandey, PS; Srinivasa Rao, T | 1 |
| Aicher, A; Badorff, C; Dimmeler, S; Fichtlscherer, S; Koyanagi, M; Rupp, S; Urbich, C; Zeiher, AM | 1 |
| Asai, T; Iguchi, A; Kanda, S; Koike, T; Kuzuya, M; Nakamura, A; Satake, S; Suzuki, Y; Umegaki, H | 1 |
| Adamczyk, MA; Blasetto, JW; Bryzinski, BS; Cain, VA; Jones, PH; McKenney, JM | 1 |
| García-Idoate, G; Mora, C; Muros, M; Navarro, JF | 1 |
| Harrell, TK; Jones, DW; King, DS; Lindley, BJ; Wilburn, AJ; Wofford, MR | 1 |
| Aleo, E; Dmitrieva, A; Littarru, GP; Passi, S; Stancato, A | 1 |
| Langsjoen, PH; Patil, H; Silver, MA; Szabo, S; Zelinger, A | 2 |
| Daly, JA; Ferrari, A; Gleason, JL; McNamara, JR; Rubenstein, JJ; Schaefer, EJ; Seman, LJ; Tayler, T | 1 |
| Böhm, M; Faul, A; Laufs, U; Nickenig, G; Ribaudo, N; Wassmann, S | 1 |
| Brousseau, ME; Kajinami, K; Ordovas, JM; Schaefer, EJ | 4 |
| Bugiardini, R; Fontana, F; Manfrini, O; Pizzi, C | 1 |
| Barshes, NR; Goodpastor, SE; Goss, JA | 1 |
| Brousseau, ME; Kajinami, K; Nartsupha, C; Ordovas, JM; Schaefer, EJ | 1 |
| Fyhrquist, F; Nyman, T; Saijonmaa, O; Stewen, P | 1 |
| Berger, T; Daniel, WG; Garlichs, CD; Ludwig, J; Raaz, D; Reiss, C; Steinkasserer, A; Stumpf, C; Tantawi, O; Weng, A; Yilmaz, A | 1 |
| Ayan, F; Curgunlu, A; Ertürk, N; Karter, Y; Mihmanli, I; Vehid, S | 1 |
| Fathi, R; Haluska, B; Isbel, N; Johnson, D; Marwick, TH; Short, L | 1 |
| Guyton, JR; Herrington, DM; McGowan, MP; Shear, C; Waters, DD; Wenger, NK | 1 |
| Gershovich, OE; Lyman, AE | 1 |
| Borensztajn, J; Catron, DM; Haldar, K; Jones, BD; Lange, Y; Sylvester, MD | 1 |
| Allen, J; Butler, M; Kubler, PA; Lynch, SV; Pillans, PI; Taylor, PJ | 1 |
| Kjeldsen, S; Midtbø, K; Svilaas, A; Syvertsen, JO; Westheim, A | 1 |
| Blasetto, J; Caplan, R; Dane, A; Hutchison, H; Strutt, K | 1 |
| Błaszczyk, J; Cegliński, T; Grycewicz, J; Irzmański, R; Kowalczyk, E; Kowalski, J; Pawlicki, L | 1 |
| Bernaud, C; Boutouyrie, P; Christin-Maitre, S; Gompel, A; Jaillon, P; Laurent, S; Simon, T; Thuillez, C; Zannad, F | 1 |
| Johnson, R; Manfredi, F; Ormiston, T; Reus, VI; Wolkowitz, OM | 1 |
| Davalos, A; Fisher, M | 1 |
| Caselli, A; Economides, PA; Horton, ES; Khaodhiar, L; Tiani, E; Veves, A | 1 |
| Gathof, BS; Gresser, U | 1 |
| Blanco-Colio, LM; Egido, J; Osende, JI; Ruiz-Ortega, M | 1 |
| Bernardi, A; Pegoraro, R | 1 |
| Alexy, T; Czopf, J; Habon, T; Horvath, B; Juricskay, I; Kesmarky, G; Koltai, K; Marton, Z; Szapary, L; Szots, M; Toth, K | 1 |
| Doitsidou, M; Farber, SA; Ho, SY; Raz, E; Thorpe, JL | 1 |
| Diehl, JF; Dimmeler, S; Haendeler, J; Hoffmann, J; Spyridopoulos, I; Vasa, M; Zeiher, AM | 1 |
| Ruef, J | 1 |
| März, W | 4 |
| Kröger, K; Wittlinger, T | 1 |
| Edwards, JE; Moore, RA | 1 |
| Einecke, D | 6 |
| de Maat, MM; de Rooij, BJ; Kleemann, R; Kooistra, T; Lindeman, J; Princen, HM; Szalai, AJ; Verschuren, L | 1 |
| Cannon, CP | 2 |
| Chimienti, S; Cristofano, C; Muscogiuri, P; Vernaglione, L | 1 |
| Chen, J; Chopp, M; Goussev, A; Li, Y; Lu, D; Mahmood, A; Pannu, P | 1 |
| Mach, F | 2 |
| Saw, J; Topol, EJ | 1 |
| Jukema, JW; van der Hoorn, JW | 1 |
| Brodie, B; Brown, BG; Cooper, CJ; Crowe, T; DeMaria, AN; Ganz, P; Grines, CL; Howard, G; Nissen, SE; Schoenhagen, P; Tuzcu, EM; Vogel, RA | 1 |
| Andrus, MR | 1 |
| Belder, R; Braunwald, E; Cannon, CP; Hill, KA; Joyal, SV; McCabe, CH; Pfeffer, MA; Rader, DJ; Rouleau, JL; Skene, AM | 1 |
| Topol, EJ | 1 |
| Corrales, MA; Gonzalez-Santos, P; Moliz, M; Sanchez-Chaparro, MA; Valdivielso, P; Valera, A | 1 |
| Kumagai, K; Nakashima, H; Saku, K | 1 |
| Blennow, K; Eikenberg, O; Höglund, K; Vanderstichele, H; Vanmechelen, E; Wiklund, O | 1 |
| Elisaf, M; Goudevenos, JA; Mitsios, JV; Papathanasiou, AI; Rodis, FI; Tselepis, AD | 1 |
| Fukazawa, I; Uchida, E; Uchida, N; Yasuhara, H | 1 |
| Bösel, J; Dirnagl, U; Endres, M; Megow, D; Schulz, JG; Stoeckel, M | 1 |
| Pelli, N; Setti, M | 1 |
| Horiuchi, S; Iida, KT; Matsuzaka, K; Nakagawa, Y; Nakakuki, M; Okazaki, H; Sakai, M; Sakamoto, Y; Shimano, H; Shu, M; Sone, H; Suzuki, H; Takahashi, A; Toyoshima, H; Yamada, N; Yokoo, T | 1 |
| Andreucci, M; Cianciaruso, B; Fuiano, G; Paternò, R; Pisani, A; Sabbatini, M; Serio, V; Serù, R; Uccello, F | 1 |
| Athyros, VG; Bouloukos, VI; Elisaf, M; Mikhailidis, DP; Milionis, HJ; Papageorgiou, AA; Pehlivanidis, AN; Symeonidis, AN | 1 |
| Li, J; Xu, Z; Ye, H; Zhao, S; Zhou, H | 1 |
| Fang, CH; Li, JJ | 2 |
| Aukrust, P; Damås, JK; Frøland, SS; Gullestad, L; Haug, T; Semb, AG; Smith, C; Tunheim, SH; Waehre, T; Yndestad, A | 1 |
| Bhansali, A; Gupta, A; Gupta, V; Thapar, S | 1 |
| Blanco-Colio, LM; Díaz, C; Egido, J; Hernández, G; Martín-Ventura, JL; Sol, JM | 1 |
| de Grooth, GJ; Fruchart, JC; Kastelein, JJ; Klerkx, AH; Kuivenhoven, JA; Smilde, TJ; Stalenhoef, AF; Van Wissen, S; Zwinderman, AH | 1 |
| Tellier, P | 1 |
| Blauw, GJ; Meinders, AE; Weverling-Rijnsburger, AW | 1 |
| Burk, MJ; Chen, P; Greenberg, WA; Hanson, SR; Huang, H; Varvak, A; Wong, K | 1 |
| Brewer, HB | 1 |
| Bloedon, LT; Brousseau, ME; Clark, RW; Digenio, AG; Mancuso, JP; Rader, DJ; Schaefer, EJ; Wolfe, ML | 1 |
| Cressman, MD; Harris, S; Hutchinson, HG; Pears, JS; Vidt, DG | 1 |
| Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C | 1 |
| Chalikias, GK; Chatseras, DI; Hatzinikolaou, EI; Karas, SM; Papadopoulos, ED; Papadopoulou, EG; Parissis, JT; Tentes, IK; Tripsiannis, GA; Tziakas, DN | 1 |
| Hennekens, CH; Novela, C | 1 |
| Alegret, M; Ciudad, CJ; Laguna, JC; Llaverias, G; Noé, V; Peñuelas, S; Sánchez, RM; Vázquez-Carrera, M | 1 |
| Caramelli, B; De Bernoche, C; Durazzo, AE; Ikeoka, DT; Machado, FS; Monachini, MC; Puech-Leão, P | 1 |
| Cording, SA; Newnham, HH; Rando, LP | 1 |
| Andreassen, AK; Aukrust, P; Gullestad, L; Hognestad, A; Holm, T; Kjekshus, JK; Semb, AG; Stokke, O; Wergeland, R | 1 |
| Carlson, W; Clark, ME; Creager, M; Frei, B; Johnstone, M; Kinlay, S; Lloyd-Jones, DM; Maccallum, G; Orav, J; Rubenstein, J; Selwyn, AP; Sopko, G; Stone, PH | 1 |
| Lawrence, JM; Reckless, JP; Reid, J; Stirling, C; Taylor, GJ | 1 |
| Kadioglu, M; Kalyoncu, NI; Kesim, M; Ulku, C; Yaris, E; Yaris, F | 1 |
| Clark, DS; Gerber, R; Ryan, JD | 1 |
| Daida, H; Miyauchi, K; Shimada, K | 1 |
| Kulbertus, H; Scheen, AJ | 1 |
| McKerracher, A | 1 |
| Baumstark, MW; Friedrich, I; Hauck, P; Hoffmann, MM; März, W; Nickell, HH; Schmitz, H; Weltzien, P; Wieland, H; Winkler, K | 1 |
| Hobbs, RA; Tafreshi, MJ | 1 |
| Mück, AO; Seeger, H; Wallwiener, D | 2 |
| Berk-Planken, II; Bootsma, AH; Dallinga-Thie, GM; Jansen, H | 1 |
| Fujisaki, K; Itoh, Y; Kubota, T; Oishi, R; Sendo, T; Yano, T | 1 |
| Alsheikh-Ali, AA; Karas, RH | 3 |
| Chu, K; Han, SY; Jeong, SW; Jung, KH; Kim, JY; Kim, M; Lee, ST; Roh, JK | 1 |
| Nash, DT | 1 |
| Athyros, VG; Bouloukos, VI; Elisaf, M; Mercouris, BR; Mikhailidis, DP; Papageorgiou, AA; Pehlivanidis, A; Symeonidis, AN | 1 |
| Salam, AM | 1 |
| Berry, DC; Knapp, P; Raynor, DK | 1 |
| Bernier, L; Chamberland, A; Davignon, J; Dubuc, G; Prat, A; Seidah, NG; Wassef, H | 1 |
| Beckman, JA; Chui, D; Creager, MA; Garrett, LA; Hurley, S; Liao, JK; Mitra, D | 1 |
| Mason, P | 1 |
| Alegret, M; Lacasa, D; Laguna, JC; Llaverias, G; Sánchez, RM; Vázquez-Carrera, M; Viñals, M | 1 |
| Ammann, P; Fehr, T; Fierz, W; Joller-Jemelka, HI; Kahlert, C; Rickli, H; Riesen, WF; Wüthrich, RP | 1 |
| Auteri, A; Bova, G; Bruni, F; Cercigani, M; Di Renzo, M; Leo, A; Pasqui, AL; Pastorelli, M; Puccetti, L | 1 |
| Ballantyne, CM; Blazing, MA; Brady, WE; King, TR; Palmisano, J | 1 |
| Desai, A; Gawde, A; Jain, MM; Jayaram, S; Naikawadi, AA | 1 |
| Azuma, N | 1 |
| Bocksch, W; Fateh-Moghadam, S; Schartl, M | 1 |
| Guay, AT; Jacobson, J; Saltzman, EA | 1 |
| Casciano, R; Olsson, A; Stern, L; Svangren, P | 1 |
| Economidou, O; Kalofoutis, A; Kalofoutis, C; Piperi, C; Skenderi, K | 1 |
| Baumeister, B; Berthold, HK; Degenhardt, R; Gouni-Berthold, I; Krone, W; Unverdorben, M; Unverdorben, S; Vetter, H; Zittermann, A | 1 |
| Hamsten, A; Klareskog, L | 1 |
| Capell, HA; Ford, I; Hampson, R; Madhok, R; McCarey, DW; McInnes, IB; Sattar, N; Scherbakov, O | 1 |
| Coates, K; DiMauro, S; Naini, A; Rundek, T; Sacco, R | 1 |
| Bredius, RG; Nibbering, PH; ten Cate, R | 1 |
| Düsing, R; Klose, G; Szucs, TD | 1 |
| Bolognese, MA; Caplan, R; Cressman, M; Hutchinson, H; Raza, A; Schwartz, GG; Tremblay, BP | 1 |
| Nissen, S | 1 |
| Bell, PR; Loftus, IM; Molloy, KJ; Naylor, AR; Schwalbe, EC; Thompson, MM | 1 |
| Athyros, VG; Bouloukos, VI; Elisaf, M; Mikhailidis, DP; Papageorgiou, AA; Pehlivanidis, AN; Symeonidis, AN | 1 |
| Bhatia, GS; Hughes, EA; Sosin, MD; Sutton, B | 1 |
| de Graaf, J; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; van Tits, LJ; van Wissen, S | 1 |
| Hayashi, A; Ogawa, Y; Sasamata, M; Sonoda, R; Suzuki, M | 1 |
| Hano, T; Imanishi, T; Nishio, I; Sawamura, T | 1 |
| Jacobs, MB | 1 |
| Jaimes, EA; Raij, L; Zhou, MS | 1 |
| Alver, A; Kural, BV; Orem, A; Orem, C; Uydu, HA | 1 |
| Chan, KH; Chau, E; Lai, KC; Wai-Hung Shek, T; Wong, WM | 1 |
| Gürel, CV; Güzelsoy, D; Kaya, A; Tekin, A; Tekin, G; Ulutin, T; Yiğit, Z | 1 |
| Akin, M; Aliyev, E; Altuglu, I; Ercan, E; Ercan, HE; Sekuri, C; Tengiz, I | 1 |
| Akiba, T; Nihei, H; Nitta, K | 1 |
| Bydon, A; Chen, J; Chopp, M; Han, Y; Lu, D; Seyfried, D | 1 |
| Carlier, M; Claeys, MJ; Cools, F; Cosyns, B; De Meester, A; Dewit, B; Gobin, E; Hoffer, E; Missault, L; Vermeersch, P | 1 |
| Ceyhan, C; Ercan, E; Onbasili, AO; Tekten, T; Turkoglu, C | 1 |
| Dugi, KA; Hamann, A; Nawroth, PP; Parhofer, KG; Schiekofer, S; Schneider, JG; Volkmer, JE; von Eynatten, M | 1 |
| De Leeuw, I; Manuel-Y-Keenoy, B; Van Gaal, L; Vertommen, J; Vinckx, M | 1 |
| Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Sasiela, WJ; Schwartz, GG; Szarek, M | 1 |
| Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Mackness, MI; Neil, HA; Thomason, MJ | 1 |
| Chen, YF; Hwang, YS; Lin, CC; Lu, YH; Tsai, WC | 1 |
| Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G; Pristipino, C; Richichi, G | 1 |
| Eichelbaum, M; Fromm, MF; Kivistö, KT; Niemi, M; Pitkälä, K; Schaeffeler, E; Schwab, M; Strandberg, T; Tilvis, R | 1 |
| Dorani, H; Eriksson, UG; Kalies, I; Ohlsson, L; Sarich, TC; Schützer, KM; Wall, U | 1 |
| Bogush, A; Buxbaum, JD; Diaz, N; Ehrlich, M; Gandy, S; Parvathy, S; Pedrini, S; Petanceska, S; Refolo, L | 1 |
| Dimmeler, S; Haendeler, J; Hoffmann, J; Zeiher, AM | 1 |
| Bates, ER; Carville, DG; Lau, WC | 1 |
| Ford, I; Hawksworth, G; Williams, D | 1 |
| van der Harst, P; van Veldhuisen, DJ; Voors, AA | 1 |
| Hegmann, T | 1 |
| LeLorier, J; Paradis, JM | 1 |
| Gotto, AM | 2 |
| Miller, M | 2 |
| Auer, J; Eber, B; Weber, T | 1 |
| Alizadeh, J; Ballantyne, CM; Lipka, LJ; Sager, PT; Strony, J; Suresh, R; Veltri, EP | 1 |
| Cao, LS; Feng, YB; Li, DZ; Ranjit, S; Tian, Y; Wang, X; Zeng, QT | 1 |
| Daniel, WG; Eskafi, S; Garlichs, CD; Kloos, H; Schmeisser, A; Soehnlein, O | 1 |
| Izdebska, M; Matusiewicz, J; Sekita-Krzak, J; Visconti, J; Zarebska, A | 1 |
| Fan, Q; Huang, K; Li, R; Liu, X; Tu, L; Yao, H | 1 |
| Asmus, HG; Krämer, W; Krane, V; Kühn, KW; Kütemeyer, H; Mann, JF; März, W; Olschewski, M; Ritz, E; Ruf, G; Wanner, C | 1 |
| Balogh, Z; Harangi, M; Illyés, L; Kovács, P; Paragh, G; Seres, I; Törocsik, D | 1 |
| Kinsella, BT; O'Meara, SJ | 1 |
| Daida, H; Kurata, T; Miyauchi, K; Okazaki, S; Sato, H; Shimada, K; Yokoyama, T | 1 |
| Elly, I; Frieman, A; Gavish, D; Hazanov, N; Leibovitz, E | 1 |
| Levy, Y | 2 |
| Neale, R; Reynolds, TM; Saweirs, W | 1 |
| Chu, CS; Lai, WT; Lee, KT; Sheu, SH; Tsai, LY; Voon, WC; Yen, HW | 2 |
| Adachi, M; Gushiken, N; Hirano, T; Hyodo, T; Ikejiri, A; Murayama, S; Taira, T; Yoshino, G | 1 |
| Bagg, W; Braatvedt, GD; Davidson, J; Gamble, G; Reid, IR | 1 |
| Bubnova, MG | 1 |
| Philips, JC; Radermecker, RP; Scheen, AJ | 1 |
| Horiuchi, N; Kawane, T; Kurahashi, I; Terashima, S; Yanagawa, T; Yoshida, H | 1 |
| Frishman, WH; Zuckerman, AL | 1 |
| Martus, P; Piorkowski, M; Rauch, U; Schultheiss, HP; Schwimmbeck, PL; Weikert, U | 1 |
| Miller, ER; Olsson, AG; Sasiela, WJ; Schwartz, GG; Szarek, M; Tsimikas, S; Witztum, JL | 1 |
| Madsen, S | 1 |
| Kalofoutis, A; Kalofoutis, C; Lagogianni, I; Piperi, C; Troupis, G | 1 |
| Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A | 1 |
| Bendhack, LM; Castro, MM; Nagassaki, S; Rascado, RR; Rizzi, E; Tanus-Santos, JE | 1 |
| Chan, WB; Chow, CC; Ko, GT; Ma, RC; Osaki, R; So, WY; Yeung, VT | 1 |
| März, W; Regourd, E; Ruf, G; Vetter, S | 1 |
| Lange, AP; Szucs, TD | 1 |
| Traut, V | 1 |
| Bendiksen, FS; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Palmer, G; Pedersen, TR; Tikkanen, MJ | 1 |
| Bae, JH; Bassenge, E; Kim, KY; Park, KR; Schwemmer, M; Synn, YC | 1 |
| Feng, C; Li, M; Liu, X; Ma, H; Ye, C | 1 |
| Athyros, VG; Bouloukos, VI; Daskalopoulou, SS; Kakafika, AI; Langer, A; Mikhailidis, DP; Papageorgiou, AA; Pehlivanidis, AN; Symeonidis, AN | 1 |
| Gallery, ED; McGinn, S; Pollock, CA; Poronnik, P | 1 |
| Lipka, L; Maccubbin, D; Mata, P; Melani, L; Ponsonnet, D; Sager, P; Stein, E; Stender, S; Suresh, R; Veltri, E | 1 |
| Jono, S; Kizu, A; Koyama, H; Nishizawa, Y; Okuno, Y; Shioi, A | 1 |
| Brain, RA; Hanson, ML; Johnson, DJ; Lam, MW; Mabury, SA; Richards, SM; Sanderson, H; Sibley, PK; Solomon, KR; Young, C | 1 |
| Economides, PA; Horton, ES; Mantzoros, CS; Shetty, GK; Veves, A | 1 |
| Diz-Lois, F | 1 |
| Athyros, VG; Bairaktari, ET; Elisaf, MS; Kakafika, AI; Milionis, HJ; Seferiadis, KI; Tsouli, SG | 1 |
| Bahlmann, FH; Drexler, H; Engberding, N; Fuchs, M; Haller, H; Heineke, A; Hilfiker-Kleiner, D; Hornig, B; Kotlarz, D; Landmesser, U; Mueller, M; Schaefer, A; Spiekermann, S; Templin, C; Wiencke, A | 1 |
| Egido, J; Tuñón, J | 1 |
| Barrios, V; Campuzano, R; Catalán, P; Megías, A; Moya, JL; Muriel, A; Recarte, MA; Ruiz, S; Tomás, JP | 1 |
| Asberg, A; Christensen, H; Hartmann, A; Hermann, M; Holdaas, H; Reubsaet, JL | 2 |
| Cabezas, MC; Meijssen, S; Verseyden, C | 1 |
| McGowan, MP | 1 |
| Berger, PB; Hennekens, CH; Lowry, DR; Malinin, AI; Midei, MG; O'Connor, CM; Oshrine, BR; Sane, DC; Serebruany, VL; Steinhubl, SR; Tanguay, JF | 1 |
| Hatta, T; Irie, H; Kameyama, H; Kusaba, T; Kuwahara, N; Matsubara, H; Narumiya, H; Sasaki, S; Takeda, K; Tamagaki, K | 1 |
| Abdalla, DS; Aldrighi, JM; Bertolami, MC; Faludi, AA; Nakamura, Y; Pereira, IR; Ramires, JA; Saleh, MH; Silva, RA; Sousa, JE | 1 |
| Ascer, E; Bertolami, MC; Buccheri, V; Nicolau, JC; Ramires, JA; Serrano, CV; Souza, J; Venturinelli, ML | 1 |
| Ding, QF; Fukatsu, A; Hayashi, T; Iguchi, A; Miyazaki, A; Nomura, T; Packiasamy, AR; Shiraishi, H | 1 |
| Emri, G; Harangi, M; Paragh, G; Remenyik, E; Seres, I; Szilvássy, Z; Varga, Z | 1 |
| Alpan, RS; Erenmemisoglu, A; Koytchev, R; Ozalp, Y; van der Meer, MJ | 1 |
| Hochman, JH; Lin, JH; Prueksaritanont, T; Pudvah, N; Qiu, J; Tang, C; Yamazaki, M | 1 |
| Manolopoulos, VG; Tavridou, A | 1 |
| Rajamannan, NM | 1 |
| Emeis, SJ; Kleemann, R; Kooistra, T; Offerman, EH; Princen, HM; Szalai, AJ; Verschuren, L | 1 |
| Hartmann, M; von Birgelen, C | 1 |
| Jacobson, TA | 1 |
| Hunninghake, DB; Koren, MJ | 1 |
| Bláha, V; Haas, T; Hyspler, R; Smahelová, A; Tichá, A; Zadák, Z | 1 |
| Brummendorf, TH; Dimmeler, S; Haendeler, J; Oh, H; Schneider, MD; Spyridopoulos, I; Urbich, C; Zeiher, AM | 1 |
| Das, V; Shrivastava, R; Singh, S | 1 |
| Gawaz, M; Gorchakova, O; Joost, A; Kastrati, A; Mocz, A; Schömig, A; von Beckerath, N | 1 |
| Billiouw, JM; Carpentier, YA; Dratwa, M; Ducobu, J; Dupont, P; Lameire, NH; Lins, RL; Maes, B; Matthys, KE; Peeters, PC; Stolear, JC; Tielemans, C; Verpooten, GA | 1 |
| Deac, R; Dobreanu, M; Gălăţeanu, C; Simionescu, A | 1 |
| Cannon, CP; Ray, KK | 3 |
| Klose, G | 1 |
| Blasetto, JW; Caplan, RJ; Ferdinand, KC; Gold, A; Hunninghake, DB; Jones, PH; Stein, EA | 1 |
| Bartuś, S; Chyrchel, M; Dubiel, JS; Dudek, D; Heba, G; Legutko, J | 1 |
| Alcaraz Tafalla, MS; Carrillo Alcaraz, A; Illán Gómez, F; Pascual Díaz, M | 1 |
| Dolan, JG; Nautiyal, A; Singh, S | 1 |
| Asano, T; Hayakawa, M; Kosaka, T; Miyajima, A; Mizuguchi, Y | 1 |
| Bhalodkar, NC; Brown, DL; Brown, EJ; Kaplan, RC; White, J | 1 |
| Captain, BK; Harris, WS; Jones, PG; O'Keefe, JH | 1 |
| Chopp, M; Goussev, A; Li, Y; Lu, D; Lu, M; Mahmood, A; Qu, C; Schallert, T; Zhang, ZG | 1 |
| Chopp, M; Goussev, A; Lu, D; Lu, M; Mahmood, A; Qu, C | 1 |
| Angelico, F; Arca, M; Burattin, M; Ceci, F; Del Ben, M; Violi, F | 1 |
| McColl, G; Van Doornum, S; Wicks, IP | 1 |
| Jorba, O; Ordóñez-Llanos, J; Pérez, A; Wägner, AM | 1 |
| Bern, VH | 1 |
| Laskowitz, DT; Lynch, JR; McGirt, MJ; Woodworth, GF | 1 |
| Castro Cabezas, M; Erkelens, DW; Jansen, H; Meijssen, S; Verseyden, C | 1 |
| Benz, R; Suter, PM | 1 |
| Couture, P; Lamarche, B; Mauger, JF; Paradis, ME | 1 |
| Cook, HT; Ehrenstein, MR; Jury, EC; Lawman, S; Mauri, C | 1 |
| Ibrahim, MM; Soliman, MF | 1 |
| Busso, N; Chobaz, V; Gabay, C; Palmer, G; So, A; Talabot-Ayer, D; Taylor, S | 1 |
| Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR | 1 |
| Herman, ZS; Krysiak, R; Okopien, B | 1 |
| Deng, Y; DeRose, RA; Farber, SA; Ho, SY; Santana, E; Thorpe, JL | 1 |
| Antoniades, C; Bosinakou, E; Kotsopoulou, M; Pitsavos, C; Stefanadis, C; Tentolouris, C; Tousoulis, D; Trikas, A; Tsioufis, C | 1 |
| Barbosa, E; Pannu, R; Singh, AK; Singh, I | 1 |
| Adams, GJ; Ballantyne, CM; Greene, J; Harrist, R; Insull, W; Karmonik, C; Kimball, KT; Morrisett, JD; Vick, GW | 1 |
| Abe, Y; Kushiya, F; Nakasaki, T; Nobori, T; Noda, M; Ooi, K; Sakaguchi, A; Sakurai, Y; Shiku, H; Tsukada, T; Wada, H | 1 |
| Berezovsky, A; Laszt, A; London, D; Magen, E; Mishal, J; Priluk, R; Viskoper, R; Yosefy, C | 1 |
| Croom, KF; Plosker, GL | 1 |
| Baghestanian, M; Bucek, RA; Minar, E; Pourazim, A; Reiter, M; Wirth, S | 1 |
| Campbell, SD; Chen, C; Lin, J; Mills, JB; Mireles, RJ; Smolarek, TA; Xu, JJ | 1 |
| Karch, AM | 1 |
| Bäcklund, T; Kahri, J; Kivistö, KT; Valkonen, M; Vuoristo, M | 1 |
| Hiramatsu, N; Mamo, JC; Pal, S; Takechi, R | 1 |
| Satish, B; Unnikrishnan, D | 1 |
| Deedwania, PC | 1 |
| Braunwald, E; Cannon, CP; McCabe, CH; Morrow, D; Pfeffer, MA; Ridker, PM; Rifai, N; Rose, LM | 1 |
| Crowe, T; Ganz, P; Magorien, RD; Nissen, SE; O'Shaughnessy, C; Orazem, J; Sasiela, WJ; Schoenhagen, P; Tsai, J; Tuzcu, EM | 1 |
| Hitsumoto, T; Iizuka, T; Nakamura, K; Noike, H; Ohsawa, H; Sakurai, T; Satoh, S; Shimizu, K; Shirai, K; Sugiyama, Y; Takahashi, M; Watanabe, H | 1 |
| Auteri, A; Bruni, F; Pasqui, AL; Pastorelli, M; Puccetti, L; Sawamura, T | 1 |
| Birnbaum, Y; Hu, ZY; Rosanio, S; Schwarz, ER; Tavackoli, S; Uretsky, BF; Ye, Y | 1 |
| Feely, J; Sigurdsson, EL; Strandberg, TE | 1 |
| Fukuhara, S; Ishibashi, T; Kamioka, M; Maruyama, Y; Matsuoka, I; Nagata, K; Ohkawara, H; Sakamoto, N; Sakamoto, T; Sugimoto, K; Sugimoto, N; Takuwa, Y; Yokoyama, K | 1 |
| Anderson, T; Boudreau, G; Buithieu, J; Chan, S; Charbonneau, F; Dorval, JF; Genest, J; Hutchison, S; Huynh, T; Jobin, J; Lonn, E; Poirier, P; Title, L; Tran, T; Walling, A | 1 |
| Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S | 1 |
| Endo, K; Ito, Y; Koide, N; Miyashita, Y; Otsuka, M; Oyama, T; Ozaki, H; Saiki, A; Shirai, K | 1 |
| Carter, TL; Ehrlich, ME; Gandy, S; Pedrini, S; Petanceska, S; Prendergast, G | 1 |
| Jacobs, PL; Johnson, BM; Nash, MS | 1 |
| Belowski, D; Herman, ZS; Huzarska, M; Kulach, A; Madej, A; Okopien, B; Stachura-Kulach, A; Zielinski, M | 1 |
| Baykan, M; Eminagaoglu, S; Gökçe, M; Orem, A; Orem, C; Uydu, HA; Yilmaz, R | 1 |
| Hasegawa, R; Hirata-Koizumi, M; Miyake, S; Saito, M; Urano, T | 1 |
| Downey, J; Jones, PH; Karalis, DG; McKenney, JM | 1 |
| Aznar, J; Gabriel, F; Guiral, V; Labiós, M; Martínez, E; Martínez, M | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH | 1 |
| Sawicki, PT; Weizel, A | 1 |
| Anlauf, M; Klose, G | 1 |
| Chen, J; Chopp, M; Jiang, H; Katakowski, M; Li, Y; Lu, M; Robin, A; Zhang, C; Zhang, L | 1 |
| Damkier, P; Korsholm, L; Kristensen, SR; Mickley, H; Poulsen, TS; Vinholt, P | 1 |
| Isley, WL | 1 |
| Chopp, M; Goussev, A; Lu, D; Mahmood, A; Qu, C; Zhang, ZG | 1 |
| Fitchett, DH; Goodman, S; Langer, A; Leiter, LA; Tardif, JC | 1 |
| Bellia, A; Carnevale, R; Ferro, D; Lauro, R; Lenti, L; Pignatelli, P; Sanguigni, V; Sorge, R; Tesauro, M; Violi, F | 1 |
| Arii, K; Hashimoto, K; Ikeda, Y; Kumon, Y; Osaki, F; Ota, K; Suehiro, T | 1 |
| Abe, K; Deguchi, K; Hayashi, T; Nagano, I; Nagotani, S; Sato, K; Shoji, M; Zhang, W | 1 |
| Ganda, OP | 1 |
| Brousseau, ME; Kajinami, K; Lamon-Fava, S; Ordovas, JM; Schaefer, EJ | 1 |
| Antoniades, C; Bosinakou, E; Kotsopoulou, M; Panagiotakos, D; Pitsavos, C; Stefanadis, C; Tousoulis, D; Vlachopoulos, C | 1 |
| Griebenow, R | 1 |
| Ilkay Alp, F; Kaleli, D; Ozdemir, O; Sönmez Uydeş-Doğan, B; Takir, S; Topal, G | 1 |
| Adamson, P; Baker, D; Calder, V; Gegg, M; Greenwood, J; Hankey, D; Harry, R; Pryce, G; Zambarakji, H | 1 |
| Hirsch, M; Jones, P; O'Donnell, JC | 1 |
| Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H | 2 |
| Casey, M; Healy, M; Martin, AJ; Walsh, JB | 1 |
| Owen, OG | 1 |
| Cheng, TO | 1 |
| Laguna, JC; Planavila, A; Vázquez-Carrera, M | 1 |
| Bonow, RH; Bonow, RO; Caira, F; Makkena, B; Rajamannan, NM; Salti, H; Spelsberg, TC; Subramaniam, M; Thennapan, S | 1 |
| Bigo, P; Brussino, L; Bucca, C; Marsico, A; Panaro, E | 1 |
| Casciano, R; Gómez-Gerique, JA; Rejas, J; Stern, L | 1 |
| Amin-Hanjani, S; Asahi, M; Huang, PL; Huang, Z; Liao, JK; Lo, EH; Mori, T; Moskowitz, MA; Qiu, J; Sumii, T; Thomas, S; Yoshimura, S | 1 |
| Chan, DC; Dogra, GK; Stanton, K; Watts, GF | 1 |
| Botma, GJ; Jansen, H; van Deursen, D; van Hoek, M; Verhoeven, AJ; Vieira, D | 1 |
| Florkowski, CM; Frampton, CM; George, PM; Molyneux, SL; Scott, RS; Strey, CH; Young, JM | 1 |
| Ahotupa, M; Nuotio, I; Strandberg, T; Tikkanen, MJ; Vanhanen, H; Vasankari, T; Viikari, J; Vuorenmaa, T | 1 |
| Albini, T; Evans, M; Giri, RK; Rao, NA; See, RF; Thomas, PB | 1 |
| Ishii, T; Kaneki, M; Miyauchi, A; Nagakura, C; Sakurai, S; Tsujibayashi, T; Yoshitomi, Y | 2 |
| Efthymiou, CA; Mocanu, MM; Yellon, DM | 1 |
| Hess, L; Krähenbühl, S; Krähenbühl-Melcher, A; Rätz Bravo, AE; Schlienger, RG; Tchambaz, L | 1 |
| Ayaori, M; Fayad, ZA; Higashi, K; Iwamoto, N; Kihara, T; Kusuhara, M; Momiyama, Y; Nagata, M; Nakamura, H; Ogura, M; Ohmori, R; Ohsuzu, F; Sawada, S; Tamai, S; Taniguchi, H; Yonemura, A | 1 |
| Bierhaus, A; Dugi, KA; Hadziselimovic, S; Hamann, A; Nawroth, PP; Schneider, JG; von Eynatten, M | 1 |
| Barraclough, D; Colman, PG; Reed, MD | 1 |
| Djanani, A; Feistritzer, C; Kaneider, NC; Mosheimer, BA; Patsch, JR; Sturn, DH; Wiedermann, CJ | 1 |
| Arimochi, H; Hagiwara, M; Kataoka, K; Kuwahara, T; Nakayama, H; Ohnishi, Y | 1 |
| Chan, JC; Cheng, CW; Tomlinson, B; Woo, KS; You, JH | 1 |
| Bösel, J; Dirnagl, U; Djoufack, PC; Endres, M; Fink, KB; Gandor, F; Harms, C; Harms, U; Hörtnagl, H; Megow, D; Synowitz, M | 1 |
| Pitt, B | 1 |
| Barter, P; Fruchart, JC; Gotto, AM; Greten, H; Grundy, SM; Kastelein, JJ; LaRosa, JC; Shear, C; Shepherd, J; Waters, DD; Wenger, NK | 1 |
| Chen, YT; Hsu, HY; Hu, HH; Sheng, WY; Sheu, WH; Wang, PY | 1 |
| Angelin, B; Asztalos, BF; Björkhem, I; Brousseau, ME; Diffenderfer, MR; Digenio, AG; Mancuso, JP; Millar, JS; Nartsupha, C; Rader, DJ; Rudling, M; Schaefer, EJ; Welty, FK; Wolfe, ML | 1 |
| Guillard, R; Issandou, M; Venteclef, N | 1 |
| Judge, HM; Peters, G; Smith, SM; Storey, RF | 1 |
| Ezekowitz, MD; Ganz, P; Oliver, MF; Olsson, AG; Sasiela, WJ; Schwartz, GG; Szarek, M; Waters, D; Zeiher, A | 1 |
| Ahotupa, M; Gylling, H; Miettinen, T; Nuotio, I; Strandberg, T; Tikkanen, MJ; Vanhanen, H; Vasankari, T; Viikari, J | 1 |
| Duman, S; Oreopoulos, DG; Sen, S; Sozmen, EY | 1 |
| Haberka, M; Herman, ZS; Krysiak, R; Okopien, B | 1 |
| Komaroff, AL | 1 |
| Fushimi, H | 1 |
| Carmina, E; Castello, F; Di Fede, G; Mansueto, P; Rini, GB; Rizzo, M | 1 |
| Stallard, N; Verzilli, CJ; Whittaker, JC | 1 |
| Arnaud, C; Burger, F; Mach, F; Nguyen, TH; Steffens, S; Trono, D; Veillard, NR | 1 |
| Bartok, A; Huber, K; Jetzl, A; Kopp, CW; Minar, E; Seidinger, D; Stefenelli, T; Steiner, S | 1 |
| Eisenbarth, GS | 1 |
| Ho, SS; Pal, S; Takechi, R | 1 |
| Cai, Y; Chen, P; Duan, S; Fang, X; Wu, S; Zhao, S | 1 |
| Andrews, TC; Carlson, W; Cole, H; Creager, MA; Frei, B; Johnstone, M; Kinlay, S; Lloyd-Jones, DM; Orav, J; Rubenstein, J; Selwyn, AP; Sopko, G; Stone, PH | 1 |
| Gibb, H; Scialli, AR | 1 |
| Lee, JD; Mikhailidis, DP; Morrissey, JR; Patel, V | 1 |
| Tsakok, AD | 1 |
| Argmann, CA; Edwards, JY; Hegele, RA; Huff, MW; O'Neil, CH; Pickering, JG; Sawyez, CG | 1 |
| Geiss, HC; Hund-Wissner, E; Otto, C; Parhofer, KG | 1 |
| Cheung, RC; Kallend, D; Morrell, JM; Schuster, H; Watkins, C | 1 |
| Brühl, T; de Vos, S; Dimmeler, S; Fichtlscherer, S; Hofmann, WK; Knau, A; Potente, M; Urbich, C; Walter, DH; Zeiher, AM | 1 |
| Cárcamo, CA; Celedón, C; Nygren, CE; Paulós, CP | 1 |
| Van Buuren, HR; Wolters, LM | 1 |
| Blanco, S; Egido, J; Gómez-Guerrero, C; López, D; Romero, R; Vaquero, M | 1 |
| Bilo, HJ; Diepeveen, SH; Dikkeschei, LD; Kolsters, G; Offerman, JJ; Stalenhoef, AF; Van Der Palen, J; Van Tits, LJ; Verhoeven, GW | 1 |
| Mensah, K; Mocanu, MM; Yellon, DM | 1 |
| Haskard, DO; Lunnon, MW; Mandryko, V; Naoumova, RP; Randi, AM; Wibaut-Berlaimont, V | 1 |
| Asztalos, BF; Daly, JA; Ferrari, A; Gleason, JL; McNamara, JR; Rubenstein, JJ; Schaefer, EJ; Seman, LJ; Tayler, T | 1 |
| Chin, H; Denu-Ciocca, CJ; Dornbrook-Lavender, KA; Hogan, SL; Joy, MS; Pieper, JA | 1 |
| Aktas, O; Hahner, A; Infante-Duarte, C; Prozorovski, T; Ullrich, O; Waiczies, S; Zipp, F | 1 |
| Higashikata, T; Inazu, A; Kawashiri, MA; Kobayashi, J; Koizumi, J; Mabuchi, H; Nohara, A | 1 |
| Abrahamowicz, M; Austin, PC; Eisenberg, MJ; Humphries, K; Pilote, L; Rahme, E; Tu, JV; Zhou, Z | 1 |
| Ahishali, B; Arican, N; Bilgic, B; Elmas, I; Kalayci, R; Kaya, M; Kucuk, M; Kudat, H; Uzun, H | 1 |
| Kim, JO; Kofler, S; Methe, H; Nabauer, M; Weis, M | 1 |
| Goez, P; Hagelgans, A; Hempel, U; Heyne, B; Jaross, W; Menschikowski, M; Neumeister, V; Siegert, G | 1 |
| Ascaso, JF; Carmena, R; Chaves, FJ; Civera, M; García-García, AB; González, C; González-Albert, V; Martín de Llano, JJ; Real, JT | 1 |
| Bairaktari, E; Cariolou, M; Elisaf, M; Ganotakis, M; Miltiadous, G; Xenophontos, S | 1 |
| Delles, C; Jacobi, J; John, S; Schmieder, RE; Schneider, MP | 1 |
| Schwartz, GG | 1 |
| Bhatt, DL; Karha, J | 1 |
| Badaracco, R; Brizuela, M; Cialzeta, JR; Doval, H; Farías, EF; Franciosi, V; Macin, SM; Medina, F; Perna, ER; Tajer, C | 1 |
| Barut, A; Sarikaya, S; Tanriverdi, HA | 1 |
| Assaloni, R; Ceriello, A; Da Ros, R; Esposito, K; Giugliano, D; Maier, A; Piconi, L; Quagliaro, L | 1 |
| Bates, ER; Lau, WC | 1 |
| Curtiss, FR | 1 |
| Bittolo Bon, G; Calabresi, L; Cattin, L; Fellin, R; Manzato, E; Montagnani, M; Pauciullo, P; Pisciotta, L; Sirtori, CR | 1 |
| Alacacioglu, A; Caliskan, S; Ceylan, C; Comlekci, A; Saklamaz, A; Temiz, A; Yesil, S | 1 |
| Almeida, EA; Carneiro, A; Jorge, M; Jorge, PA; Ozaki, MR | 1 |
| de Graaf, J; Stalenhoef, AF; van Tits, LJ | 1 |
| Browne, P; Connor, DJ; Johnson-Traver, S; Launer, LJ; Lochhead, J; Lopez, J; Sabbagh, MN; Sparks, DL; Wasser, D; Ziolwolski, C | 1 |
| Blank, R; LaSalle, J; Maroni, J; Reeves, R; Sun, F; Tarasenko, L | 1 |
| Battisti, WP; Brady, WE; Denke, MA; McBride, PE; Palmisano, J; Pearson, TA | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Ridker, PM; Rifai, N; Rose, LM | 1 |
| Ahn, JY; Choi, IS; Chung, WJ; Han, SH; Koh, KK; Quon, MJ; Seo, YH; Shin, EK | 1 |
| Bonow, RO; Ignatiev, KI; McConnell, JP; Rajamannan, NM; Singh, RJ; Spelsberg, TC; Springett, M; Stock, SR; Stone, NJ; Subramaniam, M | 1 |
| Berna, C; Calmy, A; Junod, AF; Peytremann-Bridevaux, I | 1 |
| Burmester, JK; Moore, JH; Wilke, RA | 1 |
| Jones, P; Miller, PS; Smith, DG | 1 |
| Bigazzi, F; Bionda, A; Chella, E; Dal Pino, B; Puntoni, MR; Rossi, G; Sampietro, T; Sbrana, F | 1 |
| Franken, AA; Vincent, HH; Wolffenbuttel, BH | 1 |
| Alegret, M; Laguna, JC; Roglans, N; Sánchez, RM; Sanguino, E; Vázquez-Carrera, M | 1 |
| Barada, KA; El-Hajj, II; Mourad, FH; Shabb, NS | 1 |
| Boyacioglu, S; Gur, G; Kanbay, M; Sekuk, H; Yilmaz, U | 1 |
| Cheng, X; Cheng, Y; Ge, H; Li, B; Liao, YH; Liu, Y; Lu, B; Wang, M; Yuan, J; Zhang, J | 1 |
| Adgey, J; Allen, C; Bedarida, GV; Cruz-Fernández, JM; Johnson-Levonas, AO; Massaad, R | 1 |
| Iwano, C; Matsuyama, K; Matzno, S; Nishikata, M; Yasuda, N | 1 |
| McFarlane, SI; Murad, O; Palmer, J; Sowers, J | 1 |
| Rosenberg, R | 1 |
| Christensen, H; Hermann, M; Reubsaet, JL | 1 |
| Cannon, CP; Reid, IR; Tonkin, A | 1 |
| Kakuta, H; Kihara, R; Shimano, H; Suzuki, M; Tada-Iida, K; Takahashi, A; Yamada, N; Yokoo, T | 1 |
| Higashikata, T; Inazu, A; Katsuda, S; Kawashiri, M; Kobayashi, J; Koizumi, J; Mabuchi, H; Mizuno, M; Nohara, A | 1 |
| Davies, R; Durrington, P; Gibson, M; Kaushal, K; Mackness, M; Mishra, M; Ray, DW; Siddals, KW | 1 |
| Bloomfield, P; Boon, NA; Cowell, SJ; Newby, DE; Northridge, DB; Prescott, RJ; Reid, J | 1 |
| Rosenhek, R | 1 |
| Barter, P; Kallend, D; Schuster, H; Stender, S; Watkins, C | 1 |
| Lavoie, S; Lipson, J; Zimmerman, D | 1 |
| Akcay, A; Bilgi, M; Bozbas, H; Kanbay, M; Muderrisoglu, H; Ozdemir, FN; Ulus, T; Yildirir, A | 1 |
| Kastelein, JJ; van Leuven, SI | 1 |
| Jarernsiripornkul, N; Kiatchusakul, S; Ojongpian, S; Srinakarin, J; Tantikosoom, W; Thinkhamrop, B | 1 |
| Cowie, MR | 1 |
| Fujita, H; Fujiwara, H; Ito, Y; Kawasaki, M; Minatoguchi, S; Murata, I; Okubo, M; Sano, K; Tsuchiya, K; Yokoyama, H; Zhou, X | 1 |
| Kummerow, FA; Mahfouz, MM | 1 |
| Bitto, A; Bonaiuto, A; Bonaiuto, M; Campo, S; Castaldo, M; Cinquegrani, M; Saitta, A; Saitta, C; Sardo, MA; Trimarchi, G | 1 |
| Barsante, MM; Castro, MS; Pinho, V; Roffê, E; Souza, DG; Tafuri, WL; Teixeira, MM; Yokoro, CM | 1 |
| Chiba, K; Hosokawa, M; Kameyama, Y; Kobayashi, K; Yamashita, K | 1 |
| Avorn, J | 1 |
| Cho, KH; Jung, WS; Kang, HS; Moon, SK; Park, SU | 1 |
| Browne, P; Connor, DJ; Johnson-Traver, S; Launer, LJ; Lochhead, J; Lopez, J; Petanceska, S; Sabbagh, MN; Sparks, DL; Wassar, D; Ziolkowski, C | 1 |
| Hinoi, T; Matsuo, S; Tadehara, F; Tsujiyama, S; Yamakido, M | 1 |
| Aberg, JA; Alston, BL; Brobst, SW; Fichtenbaum, CJ; Gerber, JG; Rosenkranz, SL; Segal, Y; Vega, JM; Yang, A | 1 |
| Blanco-Vaca, F; Calpe-Berdiel, L; Carrillo, J; Mauricio, D; Palomer, X; Pastor, X; Verdaguer, J | 1 |
| Moreno Sánchez, D | 1 |
| Karar, PK; Manavalan, R; Muthu, AK; Sethupathy, S | 1 |
| Arad, Y; Guerci, AD; Newstein, D; Roth, M; Spadaro, LA | 1 |
| Fantus, IG; Lewis, GF; Stavar, L; Szeto, L; Uffelman, K; Wang, CH; Wong, V | 1 |
| Auer, J; Eber, B; Lamm, G | 1 |
| Amasyali, B; Celik, T; Isik, E; Iyisoy, A; Kardesoglu, E; Kilic, S; Kose, S; Kursaklioglu, H | 1 |
| Antoniades, C; Bosinakou, E; Katsi, V; Kotsopoulou, M; Stefanadis, C; Tousoulis, D; Tsioufis, C | 1 |
| De Paepe, B; Laakso, J; Laaksonen, R; Lehtimäki, T; Lütjohann, D; Mattila, KM; Päivä, H; Smet, J; Thelen, KM; Van Coster, R; von Bergmann, K | 1 |
| Southern, W | 1 |
| Braunwald, E; Cannon, CP; Murphy, SA | 1 |
| Ravnskov, U; Rosch, PJ; Sutter, MC | 2 |
| de Graaf, J; Lemmers, HL; Stalenhoef, AF; van Himbergen, TM; van Tits, LJ | 1 |
| Hirose, T; Kawamori, R; Ohmura, C; Tanaka, Y; Watada, H | 1 |
| Elisaf, M; Goudevenos, JA; Mitsios, JV; Papathanasiou, AI; Tselepis, AD | 1 |
| Wu, ZH; Zhao, SP | 1 |
| Bach-Ngohou, K; Bard, JM; Frénais, R; Krempf, M; Maugère, P; Ouguerram, K; Ripolles-Piquer, B; Zaïr, Y | 1 |
| Chen, SN; Halder, T; Marian, AJ; Nagueh, SF; Roberts, R; Senthil, V; Tsybouleva, N; Willerson, JT | 1 |
| Blanco-Colio, LM; Egido, J; Gómez-Hernández, A; Hernández, G; Martín-Ventura, JL; Muñoz-García, B; Ortega, L; Serrano, J; Tuñón, J; Vega, M | 1 |
| Hamakubo, T; Izumi, A; Kodama, T; Morikawa, S; Murakami, T; Saito, Y; Yamazaki, H | 1 |
| Miyashita, Y; Murano, T; Oyama, T; Saiki, A; Shirai, K; Watanabe, F | 1 |
| Appel, K; Fiebich, BL; Hüll, M; Kauppinen, RA; Kettunen, M; Koistinaho, J; Yrjänheikki, J | 1 |
| Gao, YJ; Lee, RM; Yang, L | 1 |
| Bulut, D; Bulut-Streich, N; Graf, C; Hanefeld, C; Mügge, A; Spiecker, M | 2 |
| Dohi, Y; Ohashi, M; Sato, K; Sugiyama, M; Takase, H; Ueda, R | 1 |
| Mc Donnell, CG; Shorten, G; Van Pelt, FN | 1 |
| Burton, I; Koshman, SL; Lalonde, LD; Pearson, GJ; Tymchak, WJ | 1 |
| Krane, V; Mann, JF; März, W; Olschewski, M; Ritz, E; Ruf, G; Wanner, C | 1 |
| Fujioka, D; Ichigi, Y; Kawabata, K; Kitta, Y; Kodama, Y; Kugiyama, K; Mende, A; Nakamura, T; Obata, JE; Saito, Y; Takano, H; Umetani, K | 1 |
| Harman, SM; Naftolin, F | 1 |
| Abildstrom, SZ; Buch, P; Friberg, J; Gislason, GH; Gustafsson, I; Køber, L; Madsen, M; Rasmussen, JN; Rasmussen, S; Stender, S; Torp-Pedersen, C | 1 |
| Bell, DS; Vaughan, TB | 1 |
| Deng, P; Hong, SC; Wu, J; Wu, ZH; Zhao, SP | 1 |
| Antoniades, C; Pitsavos, C; Stefanadis, C; Tentolouris, C; Tousoulis, D; Toutouza, M; Trikas, A; Vassiliadou, C | 1 |
| Bergman, M; Bessler, H; Djaldetti, M; Salman, H; Straussberg, R | 1 |
| Climent, VE; de Teresa, L; García-Herola, A; Lorenzo, S; Marín, F; Roldán, V; Sogorb, F; Tello, A | 1 |
| Athyros, VG; Elisaf, M; Mikhailidis, DP | 1 |
| Akçay, G; Akçay, MN; Aydinli, B; Kiziltunç, A; Oztürk, G | 1 |
| Albertini, JP; Charniot, JC; Hantz, E; Le Moyec, L; Valensi, P | 1 |
| Ainsworth, CD; Beletsky, V; Blake, CC; Fenster, A; Spence, JD; Tamayo, A | 1 |
| Cardona-Muñoz, EG; Fonseca, FA; Fuenmayor, N; Marotti, M; Ruiz, A; Silva, JM | 1 |
| Elisaf, MS; Milionis, HJ | 1 |
| Backman, JT; Luurila, H; Neuvonen, M; Neuvonen, PJ | 1 |
| Courtney, BK; Fitzgerald, PJ; Koizumi, T; Komiyama, N; Komuro, I; Kuriyama, N; Nakayama, T; Nameki, M; Namikawa, S; Yokoyama, M | 1 |
| Corpataux, JM; London, NJ; Naik, J; Porter, KE | 1 |
| Athyros, VG; Didangelos, TP; Elisaf, M; Kakafika, AI; Karagiannis, A; Kleta, D; Mikhailidis, DP; Papageorgiou, AA; Peletidou, A; Tziomalos, K | 1 |
| Asberg, A; Hermann, M; Holdaas, H; Lemahieu, WP; Maes, BD; Vanrenterghem, Y; Verbeke, K | 1 |
| Cicero, AF; Gaddi, A | 1 |
| McKenney, JM | 2 |
| Boehlen, F; Daali, Y; de Moerloose, P; Fontana, P; Mach, F; Reber, G; Senouf, D; Sigwart, U | 1 |
| Banerjee, P; Johnson, KJ; Lira, ME; Lloyd, DB; Man, M; Milad, MA; Milos, PM; Myrand, SP; Paulauskis, J; Sasiela, WJ; Thompson, JF; Wood, LS | 1 |
| Toth, PP | 1 |
| Damkier, P; Hallas, J; Korsholm, L; Kristensen, SR; Mickley, H; Poulsen, TS; Vinholt, P | 1 |
| Ho, SS; Pal, S | 1 |
| Bley, S; Drexler, H; Grote, K; Grothusen, C; Luchtefeld, M; Schieffer, B; Selle, T; Tietge, UJ | 1 |
| Austin, PC; Mamdani, MM | 1 |
| Iwaniec, T; Potaczek, DP; Szczeklik, A; Undas, A | 1 |
| Crisby, M; Lindberg, C; Schultzberg, M; Winblad, B | 1 |
| Kintisch, E | 1 |
| Aso, Y; Inukai, T; Inukai, Y; Matsumoto, S; Matsutomo, R; Takebayashi, K; Wakabayashi, S | 1 |
| Dahlöf, B; Poulter, NR; Sever, PS; Wedel, H | 2 |
| Carbonell, T; Freire, E | 1 |
| Baller, D; Burchert, W; Gleichmann, U; Horstkotte, D; Pulawski, E; Wielepp, P | 1 |
| Smulders, YM | 1 |
| Liu, HX; Luo, Y; Xie, XM | 1 |
| Bertolami, MC; Faludi, AA; Hirata, MH; Hirata, RD; Rebecchi, IM; Rodrigues, AC | 1 |
| Laguna, JC; Merlos, M; Planavila, A; Sánchez, RM; Vázquez-Carrera, M | 1 |
| Bao, S; Barter, PJ; Cutri, B; Kee, P; Nicholls, SJ; Rye, KA; Worthley, SG | 1 |
| Emoto, M; Fujiwara, S; Fukumoto, S; Hatsuda, S; Kimoto, E; Koyama, H; Maeno, T; Nishizawa, Y; Shinohara, K; Shoji, T; Yokoyama, H | 1 |
| van der Harst, P; van Gilst, WH; van Veldhuisen, DJ; Voors, AA | 1 |
| Hamaad, A; Lip, GY; MacFadyen, RJ; Sosin, M | 1 |
| Ballantyne, CM; Murin, J; Rose, H; Sarti, C; Stalenhoef, AF; Tonstad, S; Wilpshaar, W | 1 |
| Basha, SJ; Mullangi, R; Muzeeb, S; Pasha, MK; Shashikumar, D; Srinivas, NR | 1 |
| Wu, SJ; Zhao, SP | 1 |
| Czerny, K; Jedrych, B; Lańcut, M; Lis-Sochocka, M | 1 |
| Czerny, K; Jedrych, B; Kifer-Wysocka, E; Lis-Sochocka, M; Matysiak, W; Romanowska-Sarlej, J | 1 |
| Czerny, K; Kifer-Wysocka, E; Masłyk, T; Matysiak, W; Romanowska, J | 1 |
| Foroutan, SM; Khoddam, A; Shafaati, A; Zarghi, A | 1 |
| Bahrami, G; Kiani, A; Mirzaeei, S; Mohammadi, B | 1 |
| Blais, L; Bouchard, MH; Collin, J; Dragomir, A; Lalonde, L; Laurier, C; Perreault, S | 1 |
| Blaschke, S; Emons, G; Frosch, KH; Gründker, C; Hofbauer, LC; Schoppet, M; Viereck, V | 1 |
| Chow, SC; Coward, W | 1 |
| Ceska, R; Malik, J; Stulc, T | 1 |
| Caira, F; Rajamannan, NM; Spelsberg, TC; Stock, SR; Subramaniam, M | 1 |
| Chiou, KR; Huang, WC; Lin, SL; Liu, CP; Shiang, JC; Wu, SC; Wu, TL | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Kostka, B; Marczyk, I; Michalska, M; Sikora, J | 1 |
| Hori, M; Kaneto, H; Katakami, N; Kosugi, K; Matsuhisa, M; Sakamoto, K; Waki, H; Yamasaki, Y | 1 |
| van Heyningen, C | 1 |
| Bailey, M; Denver, R; Krum, H; Martin, J | 1 |
| Chopp, M; Kapke, A; Liu, XS; Lu, M; Morris, DC; Zhang, L; Zhang, ZG | 1 |
| Adinaro, J; Beck, R; Doeppenschmidt, D; Henry, JS; Krasuski, RA; Smith, PB; Thompson, CM | 1 |
| Bays, H; Davidson, M; McKenney, J | 1 |
| Kalofoutis, A; Kalofoutis, C; Piperi, C; Skenderi, K; Zisaki, K | 1 |
| Field, KM | 1 |
| Hong, SC; Wu, J; Wu, ZH; Ye, HJ; Zhao, SP | 1 |
| Hirsch, M; O'donnell, J; Olsson, A | 1 |
| Baldassarre, S; Carpentier, YA; Deckelbaum, RJ; Ducobu, J; Dupont, IE; Scruel, O | 1 |
| Olsson, AG; Sasiela, WJ; Schwartz, GG; Szarek, M | 1 |
| Tseng, KH | 1 |
| Langmann, T; Schmitz, G | 1 |
| Burnett, JR | 1 |
| Aggarwal, D; Fernandez, ML; Shrestha, S; Vergara-Jimenez, M; West, KL; Zern, TL | 1 |
| Dieleman, JP; Dunselman, H; Straus, SM; Sturkenboom, MC; van Herpen, G; van Wijk, MA; van Wyk, JT | 1 |
| McGraw, KJ; Parker, RS | 1 |
| Forrest, K; Goebel, J; Logan, B; Mieczkowski, A; Roszman, TL; Wills-Karp, M | 1 |
| Shear, CL | 1 |
| Green, AM | 1 |
| Hirsch, RL | 1 |
| Bays, HE; Davidson, MH; McKenney, JM; Saponaro, J; Thompson, PD | 1 |
| Annovazzi, A; Arca, M; Bonanno, E; D'Alessandria, C; De Toma, G; Marcoccia, A; Scopinaro, F; Signore, A; Spagnoli, LG; Violi, F | 1 |
| Clarkson, PM; Hittel, D; Hoffman, EP; Thompson, PD; Urso, ML | 1 |
| Aukrust, P; Boullier, A; Damås, JK; Green, S; Quehenberger, O; Sandberg, WJ; Smith, C; Waehre, T | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Jackson, G; McCabe, CH; Ray, KK; Sacks, FM; Tonkin, AM | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Pfeffer, MA; Ray, KK; Wiviott, SD | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Gibson, CM; Kirtane, AJ; McCabe, CH; Morrow, DA; Ray, KK; Ridker, PM; Rifai, N; Skene, AM | 1 |
| Fujinami, A; Fukui, M; Hasegawa, G; Ichida, Y; Nakamura, N; Nakano, K; Obayashi, H; Ohta, K; Ohta, M; Yoshikawa, T | 1 |
| Baker, A; Cowell, R; Hampson, JP; Smith, D | 1 |
| Biccard, BM; Foëx, P; Sear, JW | 1 |
| Juszczyk, MA; Seip, RL; Thompson, PD | 1 |
| Davidson, M | 1 |
| Lundin, KE; Molberg, O; Ráki, M; Sollid, LM; Tollefsen, S | 1 |
| Ando, H; Fujimura, A; Kaneko, S; Miyata, M; Sugimoto, K; Takamura, T; Tsuruoka, S; Yamazoe, Y; Yanagihara, H | 1 |
| Błaszczyk, J; Ceglińiski, T; Grycewicz, J; Irzmańiski, R; Kowalczyk, E; Kowalski, J; Liban-Gałka, B; Pawlicki, L | 1 |
| de Graaf, J; Himbergen, TM; Roest, M; Stalenhoef, AF; van Tits, LJ; Voorbij, HA | 1 |
| Ferns, GA; Ghayour-Mobarhan, M; Lamb, DJ; Livingstone, C; Taylor, A; Vaidya, N; Wang, T | 1 |
| Gao, C; Li, WM; Liu, W; Sun, NL | 1 |
| Berne, C; Jørgensen, L; Sager, P; Siewert-Delle, A; Sorof, J | 1 |
| Langer, A | 1 |
| Robinson, JG | 1 |
| Jaber, BL; Madias, NE | 1 |
| Amarenco, P; Labreuche, J; Lavallée, PC; Touboul, PJ | 1 |
| Amyot, R; Arnold, M; Bonafede, N; Cannon, CP; Dupuis, J; Lonn, E; Ricci, J; Rouleau, JL; Roux, R; Tardif, JC; Title, LM; Woo, A | 1 |
| Pai, RG | 1 |
| Benet, LZ; Huang, Y; Lau, YY; Okochi, H | 2 |
| Juman, S; Matsuyama, K; Matzno, S; Nagareya-Ishida, N; Nakabayashi, T; Tazuya-Murayama, K; Yamamoto, Y; Yasuda, S | 1 |
| Phillips, PS | 1 |
| Chopp, M; Goussev, A; Lu, D; Mahmood, A; Qu, C; Schallert, T | 1 |
| Bergman, M; Bessler, H; Djaldetti, M; Salman, H | 3 |
| Ichihara, K; Kanda, M; Kasai, T; Keimatsu, N; Satoh, K; Sun, F; Takaguri, A | 1 |
| Candura, D; Chello, M; Covino, E; Di Sciascio, G; Goffredo, C; Mastrobuoni, S; Melfi, R; Patti, G | 1 |
| Boonstra, PW; Buikema, H; Morshuis, WJ; Nickenig, G; Plokker, HW; Six, AJ; van der Harst, P; van Gilst, WH; van Veldhuisen, DJ; Voors, AA; Wagenaar, LJ; Wassmann, S | 1 |
| Citkowitz, E | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G | 1 |
| Betteridge, DJ; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Neil, HA; Thomason, MJ | 1 |
| Fusegawa, Y; Handa, S; Homma, Y; Oguma, T; Ozawa, H; Shiina, Y; Tanabe, T | 1 |
| Auteri, A; Bruni, F; Ciani, F; Gioffrè, W; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Puccetti, L | 1 |
| Bendiksen, FS; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Szarek, M; Tikkanen, MJ; Tsai, J | 1 |
| Hobbs, FD | 2 |
| Amanavicius, N; Christensen, JH; Christoffersen, RP; Jensen, HS; Karmisholt, J; Niebuhr, U; Riahi, S; Schmidt, EB; Toft, E | 1 |
| Dernellis, J; Panaretou, M | 1 |
| Belmont, HM; Lydon, E | 1 |
| Brännström, M; Bucht, B; Crougneau, V; Dimeny, E; Ekspong, A; Granroth, B; Gröntoft, KC; Hadimeri, H; Holmberg, B; Ingman, B; Isaksson, B; Johansson, G; Lindberger, K; Lundberg, L; Mikaelsson, L; Olausson, E; Persson, B; Stegmayr, BG; Welin, D; Wikdahl, AM | 1 |
| Cohen, H; Plakogiannis, R; Taft, D | 1 |
| Fonarow, GC | 1 |
| Babita, K; Tiwary, AK | 1 |
| Briestensky, J; Jamborova, G; Jaynes, R; Kopecky, M; Nachtigal, P; Pospechova, K; Pospisilova, N; Santar, I; Semecky, V; Smahelova, A; Solichova, D; Zdansky, P | 1 |
| Buchetti, B; Lenti, L; Pignatelli, P; Sanguigni, V; Violi, F | 1 |
| Dunselman, PH; Jukema, JW; Liem, AH; Lok, DJ; van der Sloot, JA; Zwinderman, AH | 1 |
| Bertolami, MC; Cavalli, SA; Forestiero, FJ; Guzmán, EC; Hirata, MH; Hirata, RD; Salazar, LA; Sorkin, SC | 1 |
| Frick, B; Fuchs, D; Schroecksnadel, K; Weiss, G; Winkler, C; Wirleitner, B | 1 |
| Chard, M; DeGiovanni, C; Woollons, A | 1 |
| Bernard, D; De Backer, G; De Bacquer, D; De Buyzere, M; De Sutter, J; Jordaens, L; Langlois, M; Matthys, K; Tavernier, R; Van de Veire, NR | 1 |
| Hu, ZP; Jiang, B; Nie, S; Tan, LM; Wu, J; Xiao, ZJ; Zhao, SP; Zhou, HN | 1 |
| Araki, A; Miyao, M; Sasamoto, K; Yamada, S; Yamanouchi, T; Yanagawa, T | 1 |
| Antoniades, C; Bosinakou, E; Katsi, V; Kotsopoulou, M; Stefanadis, C; Tousoulis, D | 1 |
| Potaczek, DP; Szczeklik, A; Undas, A | 1 |
| Bauer, B; Böhler, S; da Silva, PM; Feldman, R; Genest, J; Gensini, G; Harvey, P; Hobbs, FD; Jenssen, TG; Mancini, GB; Manolis, AJ; Metcalfe, M | 1 |
| Arístegui, R; Artieda, M; Cenarro, A; Civeira, F; Díaz, C; Gañán, A; Gonzalvo, C; Meriño-Ibarra, E; Pocoví, M; Sol, JM | 1 |
| Atar, S; Birnbaum, Y; Freeberg, SY; Huang, MH; Lin, Y; Nishi, SP; Perez-Polo, JR; Rosanio, S; Uretsky, BF; Ye, Y | 1 |
| Belmans, A; de Klerk, E; Lesaffre, E; Matthys, K; Vrijens, B | 1 |
| Allen, C; Amabile, N; Barrios, V; Chen, JW; Johnson-Levonas, AO; Massaad, R; Paganelli, F; Vandormael, K | 1 |
| Bots, AF; Kastelein, JJ | 1 |
| Babkin, AA; Iliukhin, OV; Kalganova, EL; Lopatin, IuM | 1 |
| Nosaka, S; Ueki, M; Ushiroyama, T | 1 |
| Koren, MJ | 1 |
| Rouleau, J | 1 |
| Mason, RP | 3 |
| Avcu, F; Ural, AU | 1 |
| Crowe, T; Kapadia, S; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM | 1 |
| Lawler, RL; Letterer, RA; Levy, WC; McDonald, GB; Minami, E; Mozaffarian, D | 1 |
| Adamovich, E; Butler, WM; Galbreath, RW; Kurko, B; Merrick, GS; Moyad, MA; Wallner, KE | 1 |
| Kamat, AM; Nelkin, GM | 1 |
| Ferjan, M; Golicnik, A; Okrajsek, R; Radovancevic, B; Starc, V; Vrtovec, B | 1 |
| Esberg, D; Kowey, P | 1 |
| Banerjee, R; Basu, AK; Chatterjee, N; Guha, S; Pal, S; Pal, SK; Sarkar, G | 1 |
| Alber, HF; Dichtl, W; Doerler, J; Frick, M; Pachinger, O; Schirmer, M; Stocker, EM; Suessenbacher, A; Weidinger, F | 1 |
| Ahumada, M; Arcas, R; Arribas, JM; Gomez-Plana, J; Marín, F; Martínez, P; Oliver, C; Pascual, DA; Tornel, PL; Valdes, M | 1 |
| Kadzhaia, GV | 1 |
| Ballantyne, CM; Brady, WE; Davies, MJ; Feldman, TA; McKenney, J; Mitchel, YB; Palmisano, J; Shah, A | 1 |
| Graselli, U; Joukhadar, C; Kostner, K; Lackner, E; Thallinger, C; Urbauer, E; Wolzt, M | 1 |
| Beck, T; Burgstahler, C; Heuschmid, M; Kopp, AF; Kuettner, A; Reimann, A; Schroeder, S | 1 |
| Adler, C; Browne, P; Connor, D; Lochhead, J; Lopez, J; Petanceska, S; Sabbagh, M; Soares, H; Sparks, DL; Ziolkowski, C | 1 |
| Daskalopoulou, SS; Elisaf, M; Mikhailidis, DP; Tzovaras, V | 1 |
| Altinbas, A; Aslan, SM; Dede, O; Dogan, A; Ozaydin, M; Ozturk, M; Turker, Y; Varol, E | 1 |
| Gibson, E; Luo, D; Newman, C; Szarek, M; Tsai, J | 1 |
| Cairns, T; Cook, HT; Elliot, V | 1 |
| Kamezaki, F; Kubara, T; Miyamoto, M; Nakashima, Y; Tanaka, S; Tasaki, H; Tsutsui, M; Yamashita, K | 1 |
| Bayés, B; Bonet, J; Granada, ML; Lauzurica, R; Llopis, MA; Navarro, M; Pastor, MC; Romero, R | 1 |
| Aldama-López, G; Campo-Pérez, R; Castro-Beiras, A; Crespo-Leiro, MG; Llinares-García, D; Marzoa-Rivas, R; Muñiz-Garcia, J; Paniagua-Marin, MJ; Piñón-Esteban, P | 1 |
| Alegret, M; Laguna, JC; Llaverias, G; Pou, J; Rebollo, A; Sánchez, RM; Vázquez-Carrera, M | 1 |
| Brumeanu, TD; Casares, S; Goldstein, R | 1 |
| Fujino, H; Iwaki, K; Jin, JS; Kakumoto, M; Komoto, C; Nakamura, T; Nishiguchi, K; Okamura, N; Okumura, K; Sakaeda, T | 1 |
| Jadhav, SB; Jain, GK | 1 |
| Baz, A; Clofent, J; de Castro, ML; de Luaces, C; Hermo, JA; Pérez, R | 1 |
| Borges, JL | 1 |
| Ayalon, R; Chernichovski, T; Chernin, G; Levo, Y; Litvak, A; Reshef, R; Schwartz, D; Schwartz, IF; Weinstein, T | 1 |
| Khan, BV; Lerakis, S; Mir, MQ; Sola, S; Tandon, N | 1 |
| Donkin, SS; Elkin, RG; Hengstschläger-Ottnad, E; Schneider, WJ; Zhong, Y | 1 |
| Achenbach, S; Budde, T; Buziashvili, Y; Erbel, R; Förster, A; Friedrich, G; Henein, M; Kerkhoff, G; Knollmann, F; Kukharchuk, V; Lahiri, A; Leischik, R; Moshage, W; Schartl, M; Schmermund, A; Siffert, W; Sinitsyn, V; Steinhagen-Thiessen, E; Vogt, A; Wiedeking, B | 1 |
| Blanco-Colio, LM; Egido, J; Gómez-Hernández, A; Hernández, G; Martín-Ventura, JL; Ortega, L; Ortego, M; Sánchez-Galán, E; Serrano, J; Tunón, J; Vega, M; Vidal, C | 1 |
| de Maat, M; Emeis, J; Havekes, L; Jukema, W; Maas, A; Offerman, E; Princen, H; Szalai, A; Trion, A; van der Laarse, A | 1 |
| Błaszczyk, J; Cegliński, T; Grycewicz, J; Irzmański, R; Kowalczyk, E; Kowalski, J; Liban-Gałka, B; Pawlicki, L | 1 |
| Chen, MS; Crowe, T; Kapadia, S; Loyd, AB; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM | 1 |
| Crespo, MJ; Quidgley, JA | 1 |
| Kilkki, E; Kivistö, KT; Niemi, M; Soininen, K; Strandberg, T | 1 |
| Atar, S; Birnbaum, Y; Freeberg, SY; Huang, MH; Rahman, AM; Rosanio, S; Uretsky, BF; Ye, Y | 1 |
| Baghestanian, M; Ghannadan, M; Hauswirth, AW; Krauth, MT; Majlesi, Y; Müller, MR; Samorapoompichit, P; Schernthaner, GH; Sonneck, K; Sperr, WR; Valent, P; Worda, C | 1 |
| Barnes, BO; Brown, CD; Clark, LT; Cox, WR; Ferdinand, KC; Gold, A; Isaacsohn, J; Kong, BW; Neal, RC; Sager, PT; Watson, KE; Ycas, J; Zieve, FJ | 1 |
| Aronow, WS; Babu, S; Kakar, P; Sandhu, R; Sukhija, R | 1 |
| Pilote, L; Rahme, E; Zhou, Z | 1 |
| Shah, DI; Singh, M | 3 |
| Kuryata, OV; Yegorova, YV | 1 |
| Dai, HY; Deng, P; Guan, XS; Huang, HG; Zhao, SP | 1 |
| Boon, NA; Burton, J; Cowell, SJ; Houslay, ES; Newby, DE; Northridge, DB; Prescott, RJ; Reid, J | 1 |
| Li, ZD; Shen, HR; Zhong, MK | 2 |
| Broncel, M; Chojnowska-Jezierska, J; Franiak, I; Koter-Michalak, M | 1 |
| Clearfield, M | 3 |
| Musher, DM | 1 |
| Brantly, ML; Byars, JA; Kelly, KM; Lee, PY; Reeves, WH; Scumpia, PO; Segal, MS; Shuster, JS; Theriaque, DW; Zhuang, H | 1 |
| Day, CA; Jacob, RF; Mason, RP; Walter, MF | 1 |
| Eschenhagen, T; Mühlhäuser, U; Münzel, F; Rau, T; Wieland, T; Zolk, O | 1 |
| Blanco, J; Clotet, B; Moltó, J; Negredo, E; Pérez-Alvarez, N; Puig, J; Rey-Joly, C; Romeu, J; Ruiz, L | 1 |
| Auberger, P; Bouvet, S; Fromigué, O; Haÿ, E; Jacquel, A; Marie, PJ; Modrowski, D | 1 |
| Anjaneyulu, Y; Boosi, R; Kandikere, VN; Maurya, S; Mudigonda, K; Nirogi, RV; Shukla, M | 1 |
| Albertsson, P; Grip, L; Karlsson, T; Levin, M; Solem, J; Wiklund, O | 1 |
| Dunn, SE; Goldstein, MJ; Prod'homme, T; Steinman, L; Weber, MS; Youssef, S; Zamvil, SS | 1 |
| Emoto, M; Fukumoto, S; Koyama, H; Maemura, K; Motoyama, K; Nishizawa, Y; Shimano, H | 1 |
| Qi, SS; Shen, XQ; Zeng, GF; Zhou, HN; Zhou, SH; Zhou, T | 1 |
| Dulak, J; Jazwa, A; Jozkowicz, A; Loboda, A; Molema, G | 1 |
| Fukazawa, M; Ishikawa, M; Kubota, T; Moroi, M; Namiki, A; Sugi, K; Yajima, S | 1 |
| de Bont, N; Demacker, PN; Hijmans, A; Netea, MG; Rovers, C; Smilde, T; Stalenhoef, AF; van der Meer, JW | 1 |
| Baheti, NN; Kulkarni, PM; Panchal, NV; Parale, GP | 1 |
| Bradbury, D; Herrmann, HC; Kimmel, SE; Levine, LA; Macaluso, J; Mohler, ER; Schwartz, S; Walsh, M | 1 |
| Chu, CS; Lai, WT; Lee, KT; Lee, MY; Sheu, SH; Su, HM; Voon, WC | 2 |
| Braun, SL; Guha-Ray, DK; Penn, R; Rains, KT; Sawyers, WG; Williams, RX | 1 |
| Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V | 1 |
| Kivistö, KT | 1 |
| Biggi, A; Chauvie, S; Feola, M; La Scala, E; Papaleo, A; Rolfo, F; Uslenghi, E | 1 |
| Arant, CB; Chegini, N; Debella, AE; Luo, X; Schofield, RS; Welder, GJ; Wessel, TR; Zineh, I | 1 |
| Rosenson, RS | 2 |
| Ebisuno, M; Endo, K; Koide, N; Miyashita, Y; Ohira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Takeyoshi, M | 1 |
| Agrò, F; Candura, D; Carassiti, M; Chello, M; Covino, E; Di Sciascio, G; Mastrobuoni, S; Patti, G | 1 |
| Cai, YC; Fang, Y; Li, JQ; Li, P; Li, QZ; Wu, LR; Zhao, SP | 2 |
| Gao, C; Li, WM; Liu, W; Zhou, BG | 1 |
| Haghfelt, TH | 1 |
| Dincer, I; Erol, C; Ertas, F; Ongun, A; Ozdol, C; Turhan, S | 1 |
| Badziński, A; Dyrbuś, K; Mercik, G; Nowak, J; Nowalany-Kozielska, E; Poloński, L; Rozek, MM; Szyguła-Jurkiewicz, B; Wilczek, K; Wodniecki, J; Wojnicz, R; Zembala, M | 1 |
| Mishra, PK | 1 |
| Bax, JJ; Boersma, E; Dunkelgrün, M; Feringa, HH; Koning, J; Poldermans, D; Schouten, O; van Laanen, JH; van Urk, H; Vidakovic, R | 1 |
| Abruzzese, G; Avellone, G; Campisi, D; De Simone, R; Di Garbo, V; Licata, G; Raneli, G | 1 |
| Lynch, T | 1 |
| Blazing, M; Braunwald, E; Califf, R; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Kukreja, RC | 1 |
| Gupta, R; Lakshmy, R; Maulik, SK; Naik, N; Narang, D; Thomas, MK | 1 |
| Braunwald, E; Cannon, CP; McCabe, CH; Morrow, DA; Murphy, SA; O'Donoghue, M; Sabatine, MS | 1 |
| Demyanets, S; Hohensinner, PJ; Huber, K; Kaun, C; Maurer, G; Pammer, J; Pfaffenberger, S; Rega, G; Wojta, J | 1 |
| Zareba, G | 1 |
| Hemmer, B; Nessler, S; Prod'homme, T; Sobel, RA; Steinman, L; Stüve, O; von Büdingen, HC; Weber, MS; Youssef, S; Zamvil, SS | 1 |
| Antoniades, C; Stefanadis, C; Tousoulis, D | 1 |
| Brown, BG | 1 |
| Foody, JM; Galusha, D; Havranek, EP; Krumholz, HM; Masoudi, FA; Radford, MJ; Rathore, SS | 1 |
| Bailey, SR; Chandrasekar, B; Greene, WC; Imam, SZ; Mahimainathan, L; Mummidi, S; Patel, DN; Valente, AJ | 1 |
| Akishita, M; Eto, M; Iijima, K; Kojima, T; Kozaki, K; Maemura, K; Nakano, T; Ota, H; Ouchi, Y; Senda, Y; Son, BK | 1 |
| Castilla-Guerra, L; Espino-Montoro, A; Fernandez Moreno, Mdel C; Jimérnez, MD; López-Chozas, JM | 1 |
| Deng, P; Hong, SC; Nie, S; Wu, J; Wu, ZH; Zhao, SP; Zhou, HN | 1 |
| He, JC; Li, WX; Liu, YM; Liu, YY; Ma, XW; Qiao, CD; Shang, DY; Wang, JY; Yan, X; Yang, JG; Zhao, L | 1 |
| Liu, YX; Sheng, L; Ye, P | 1 |
| Borucki, K; Luley, C; Makarova, R; Schmidt-Lucke, C; Taneva, E; Westphal, S; Wiens, L | 1 |
| Barone, F; Lozanoska-Ochser, B; Peakman, M; Pitzalis, C | 1 |
| Balaraman, R; Bothara, SB; Majithiya, JB; Trivedi, CJ | 1 |
| Collins, L; Fabre, JW; Geissler, I; Schofield, R | 1 |
| Barrett, PH; Brousseau, ME; Diffenderfer, MR; Digenio, AG; Dolnikowski, GG; Faruqi, A; Mancuso, JP; Millar, JS; Nartsupha, C; Rader, DJ; Schaefer, EJ; Welty, FK; Wolfe, ML | 1 |
| Boerma, M; Burton, GR; Fink, LM; Hauer-Jensen, M; McGehee, RE; Wang, J | 1 |
| Lesaffre, E; Rizopoulos, D; Tsonaka, R | 1 |
| Hetta, MH; Yassin, NZ | 1 |
| Atar, S; Birnbaum, Y; Huang, MH; Lin, Y; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Agewall, S; Hernberg, A | 1 |
| Matsui, T; Nakamura, K; Yamagishi, S | 1 |
| Khor, TO; Kong, AN; Kopelovich, L; Rao, CV; Reddy, BS; Steele, VE; Wang, CX; Zheng, X | 1 |
| Briand, F; Krempf, M; Magot, T; Nguyen, P; Ouguerram, K | 1 |
| Huang, TG; Mondo, CK; Su, JZ; Yang, WS | 2 |
| Balla, J; Dorosz, J; Dulak, J; Jazwa, A; Jozkowicz, A; Loboda, A; Molema, G | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Otsuka, Y | 1 |
| Chow, SC; Coward, WR; Marei, A; Vasa-Nicotera, MM; Yang, A | 1 |
| Li, ML; Qiu, L; Wang, GL; Xiao, CS; Zeng, QT; Zhao, WY | 1 |
| Chopp, M; Ding, G; Ewing, JR; Jiang, Q; Li, L; Panda, S; Zhang, L; Zhang, ZG | 1 |
| Gregoor, PJ | 1 |
| Blank, R | 1 |
| Charlton-Menys, V; Durrington, P | 1 |
| Busseuil, D; Collin, B; Cottin, Y; Duvillard, L; Korandji, C; Pitois-Merli, I; Rioufol, G; Rochette, L; Zeller, M | 1 |
| Jellinek, SP; Mahboobi, SK; Rose, M; Shohat, EZ | 1 |
| Bradbury, J | 1 |
| Ajith, TA; Soja, M | 1 |
| de Teresa, E; Farsang, C; Gaw, A; Gensini, GF; Langer, A; Leiter, LA; Martineau, P | 1 |
| Galin, ID; Smith, DA | 1 |
| Ballantyne, CM; Bertolami, M; Cain, VA; Hernandez Garcia, HR; Nul, D; Raichlen, JS; Stein, EA; Theroux, P; Weiss, R | 1 |
| Dallinga-Thie, GM; Hattori, H; Rensen, PC; Sijbrands, EJ; van Tol, A | 1 |
| Cabrera, F; de Teresa, E; Espinosa, S; García-Pinilla, JM; Gómez-Doblas, JJ; Jiménez-Navarro, MF; Robledo, J; Rodríguez-Bailón, I | 1 |
| Badimon, L; Martínez-González, J | 1 |
| Chetty, N; Munster, M; Naran, NH | 1 |
| Bruckert, E; Carreau, V; Chauvenet, M; Faltaos, DW; Giral, P; Hulot, JS; Lechat, P; Urien, S | 1 |
| Altinbas, A; Aslan, SM; Dogan, A; Kucuktepe, Z; Ozaydin, M; Ozturk, M; Varol, E | 1 |
| Ishibashi, S; Kusaka, I; Matsuoka, H; Nagasaka, S; Nakata, M; Yada, T | 1 |
| Mongini, T; Musumeci, O; Olivero, N; Palmucci, L; Rodolico, C; Vercelli, L | 1 |
| Celinska-Löwenhoff, M; Löwenhoff, T; Szczeklik, A; Undas, A | 1 |
| Gehr, BT; Porzsolt, F; Weiss, C | 1 |
| García-Buey, L; Gisbert, JP; Gómez-Domínguez, E; Moreno-Monteagudo, JA; Moreno-Otero, R | 1 |
| Hirade, K; Ishisaki, A; Kozawa, O; Matsuno, H; Nakajima, K; Suga, H | 1 |
| Fujita, T; Hirata, Y; Matsumoto, A; Matsumura, T; Nagai, R; Ohno, M; Ohta, M; Suzuki, E; Suzuki, S; Takenaka, K | 1 |
| Athyros, VG; Burroughs, AK; Didangelos, TP; Elisaf, MS; Giouleme, OI; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Tziomalos, K | 1 |
| Frampton, CM; Lainchbury, JH; Nicholls, MG; Richards, AM; Scott, RS; Strey, CH; Young, JM | 1 |
| Hazen, SL; Nicholls, SJ; Nissen, SE; Ntanios, F; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wun, CC | 1 |
| Ikeda, Y; Kaburaki, J; Kawakami, Y; Kuwana, M; Okazaki, Y; Yasuoka, H | 1 |
| Clancy, RM | 1 |
| Chen, J; Chopp, M; Ding, J; Kapke, A; Li, A; Lu, M; Roberts, C; Zacharek, A; Zhang, C | 1 |
| Barter, P; Breazna, A; Carmena, R; Deedwania, P; Fruchart, JC; Grundy, S; Haffner, S; Hsia, J; LaRosa, J; Shepherd, J; Waters, D | 1 |
| Kimura, M; Okamura, A; Takahashi, M; Takano, T; Yamakawa, T | 1 |
| Barsotti, G; Carpi, A; Consani, C; Manca-Rizza, G; Mantuano, E; Marchetti, V; Panichi, V; Paoletti, S; Sbragia, G; Taccola, D | 1 |
| Hayashi, T; Ka, Y; Kitamura, A; Matsumura, Y; Mori, T; Ohkita, M; Sugii, M; Takaoka, M | 1 |
| Bennett, MR; Davenport, AP; Kuc, RE; Maguire, JJ; Stoneman, VE; Wiley, KE | 1 |
| Chu, CH; Chuang, MJ; Keng, HM; Lam, HC; Lee, JK; Lu, CC; Sun, CC; Tai, MH; Wang, MC; Wei, MC | 1 |
| Braunwald, E; Cannon, CP; Jarolim, P; McCabe, CH; Morrow, DA; Ray, KK; Sabatine, MS; Scirica, BM; Shui, A | 1 |
| Ali, SA; Arayne, MS; Haroon, U; Qureshi, F; Sultana, N | 1 |
| Dallinga-Thie, GM; Hattori, H; Jansen, H; Sijbrands, EJ; van Tol, A; van Vark-van der Zee, LC | 1 |
| Dörge, H; Grabedünkel, J; Liakopoulos, OJ; Nagorsnik, U; Schmitto, JD; Schoendube, FA | 1 |
| Cheah, JS; Ong, HT | 1 |
| Cayley, WE | 1 |
| Mann, SJ | 1 |
| Asberg, A; Bogsrud, MP; Hermann, M; Mohebi, BU; Molden, E; Ose, L; Retterstøl, K | 1 |
| Chen, AF; Hong, H; Kaufman, DI; Kreulen, DL; Zeng, JS | 1 |
| Apperson-Hansen, C; Churchill, T; Crowe, T; Lin, S; Loyd, A; Magyar, WA; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wang, C; Wolski, K | 1 |
| Briand, F; Krempf, M; Magot, T; Nguyen, P; Ouguerram, K; Serisier, S; Siliart, B | 1 |
| Burns, MP; Duff, K; Igbavboa, U; Wang, L; Wood, WG | 1 |
| Berneis, K; Rizzo, M | 1 |
| Chen, HZ; Chen, KQ; Dong, SH; Huang, ZX; Jiang, X; Li, YF; Liang, XJ; Liu, HD; Luo, LJ; Wen, JM | 1 |
| Clarke, AT; Mills, PR | 1 |
| Plans-Rubió, P | 1 |
| Ho, L; Levidiotis, V; Lim, AK | 1 |
| Geiss, HC; Huptas, S; Otto, C; Parhofer, KG | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Mega, JL; Morrow, DA; Murphy, S; Ridker, PM | 1 |
| Glennon, JD; Guihen, E; Scully, NM; Sisk, GD | 1 |
| Di Sciascio, G; Pasceri, V; Patti, G | 1 |
| Buerke, M; Hennen, R; Keller, A; Müller-Werdan, U; Russ, M; Schmidt, H; Werdan, K | 1 |
| Belazi, D; Dickson, M; Meissner, B; Reeder, CE; Senevirante, V; Shinogle, J | 1 |
| Bucek, RA; Minar, E; Pourazim, A; Reiter, M; Wirth, S | 1 |
| Corado Ramírez, J; Eblen-Zajjurz, A; Oria de Suárez, C; Ponce Hernández, L; Suárez Rodríguez, S; Tovar Mendoza, R | 1 |
| Becx, MC; Kuypers, KC; Seldenrijk, CA; Stolk, MF | 1 |
| Ritsch, A; Tancevski, I | 1 |
| Allemann, C; Babiychuk, EB; Draeger, A; Hoppeler, H; Mohaupt, M; Monastyrskaya, K; Savolainen, H | 1 |
| Delliaux, S; Jammes, Y; Lesavre, N; Oliver, C; Paganelli, F; Steinberg, JG | 1 |
| Asai, K; Ito, T; Kosaka, T; Kuhara, Y; Kuroda, Y; Ozaki, Y; Shinjo, H; Takashima, H; Wakita, Y; Waseda, K; Yasukawa, T | 1 |
| d'Emden, M; Knopp, RH; Pocock, SJ; Smilde, JG | 1 |
| Abdallah, MH; Dakik, HA; Karrowni, W | 1 |
| Arteaga Ll, A; Maiz G, A; Rigotti R, A | 1 |
| Arishima, H; Katafuchi, R; Matsunaga, A; Rye, KA; Saku, K; Zhang, B | 1 |
| Busser, E; de Kleijn, DP; de Vries, JP; Koekkoek, JA; Moll, FL; Pasterkamp, G; Schoneveld, A; van der Wal, AC; Velema, E; Verheijen, JH; Verhoeven, BA; Virmani, R | 1 |
| Blanco-Colio, LM; Egido, J; Hernández, G; Martín-Ventura, JL; Martínez, E; Muñoz-García, B; Ortega, L; Ortiz, A; Sánchez, S | 1 |
| Laaksonen, R; Lehtimäki, T; Lütjohann, D; Päivä, H; Thelen, KM | 1 |
| Kalina, A | 2 |
| Fujioka, D; Kawabata, K; Kitta, Y; Kobayashi, T; Kodama, Y; Kugiyama, K; Mende, A; Nakamura, T; Obata, JE; Saito, Y; Takano, H; Umetani, K | 2 |
| Alonso Troncoso, I; Fernández de Bobadilla, J; López de Sa, E; Moreno Gómez, R; Rubio-Terrés, C; Soto Alvarez, J | 1 |
| Boudoulas, H; Stefanadi, E; Stefanadis, C; Toutouzas, K; Tsiamis, E; Tsioufis, C; Vavuranakis, M | 1 |
| Bianchi, C; Boodhwani, M; Feng, J; Laham, R; Li, J; Mieno, S; Nakai, Y; Ramlawi, B; Sellke, FW; Voisine, P | 1 |
| Amrani, M; Chester, AH; Latif, N; Osman, L; Yacoub, MH | 1 |
| Amrani, M; Chester, AH; Osman, L; Smolenski, RT; Yacoub, MH | 1 |
| Lachaine, J; Merikle, EP; Rinfret, S; Tarride, JE | 1 |
| Barrett, PH; Chan, DC; Nguyen, MN; Watts, GF | 1 |
| Hatipoglu, SE; Iltimur, K; Tacar, O; Tuncer, CM | 1 |
| Iwashita, M; Kono, S; Sasaki, J | 1 |
| Raghubir, N | 1 |
| Arcas, I; Ayala, I; Castells, MT; Corral, J; García-Pérez, B; Hernández-Espinosa, D; Martín-Castillo, A; Miñano, A; Vicente, V | 1 |
| Plummer, CJ | 1 |
| Hirase, T; Inoue, T; Node, K; Wang, D | 1 |
| Braunwald, E; Giugliano, RP | 1 |
| Elisaf, MS; Filippatos, TD; Ganotakis, ES; Gazi, IF; Goudevenos, J; Kostapanos, M; Mikhailidis, DP; Milionis, HJ; Rizos, E | 1 |
| Binbrek, AS; Fonseca, FA; Middleton, A; Strandberg, TE; Watkins, C; Wilpshaar, W | 1 |
| Kopelovich, L; Patlolla, JM; Rao, CV; Reddy, BS; Steele, VE; Swamy, MV | 1 |
| Ayaori, M; Kusuhara, M; Momiyama, Y; Nakamura, H; Ogura, M; Ohmori, R; Ohsuzu, F; Sawada, S; Tanaka, N; Yonemura, A | 1 |
| Harten, SK; Haskard, DO; Johns, M; Kinderlerer, AR; Lidington, EA; Mason, JC; Maxwell, PH; Steinberg, R | 1 |
| Hey-Hadavi, JH; Kuntze, E; Lepetri, B; Luo, D; Pittman, D; Silverman, P | 1 |
| Masunyane, L | 1 |
| Robb-Nicholson, C | 1 |
| Edwards, RF; Hammons, KB; Rice, WY | 1 |
| Cunha, FQ; Cunha, TM; Ferreira, SH; Parada, CA; Poole, S; Santodomingo-Garzón, T; Valério, DA; Verri, WA | 1 |
| Browne, P; Connor, DJ; Lopez, J; Petersen, RB; Sabbagh, MN; Sparks, DL | 1 |
| Akers, WS; Steinhubl, SR | 1 |
| Babapulle, MN; Brophy, JM; Costa, V; Rinfret, S | 1 |
| Erbel, R; Schmermund, A | 1 |
| Chu, G; Ding, G; Jia, R; Tian, S | 1 |
| Clark, AL; Cleland, JG; Coletta, AP; Loh, PH; Tin, L | 1 |
| Brack, J; Harriss, L; Krum, H; Ninnio, D; Skiba, M; Szramka, M; Windebank, E | 1 |
| Cipriano, P; Di Marino, L; Gentile, A; Iovine, C; Lilli, S; Patti, L; Riccardi, G; Rivellese, AA | 1 |
| Bakris, GL; Ferrera, D; Flack, JM; Houston, MC; Lee, E; Messerli, FH; Neutel, JM; Petrella, RJ; Sun, W | 1 |
| Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A | 1 |
| Alemao, E; Attard, C; Bourgault, C; Cook, J; Huse, D; Kohli, M; Lam, A; Marentette, M; Yin, D | 1 |
| Amarenco, P; Bogousslavsky, J; Callahan, A; Goldstein, LB; Hennerici, M; Rudolph, AE; Sillesen, H; Simunovic, L; Szarek, M; Welch, KM; Zivin, JA | 1 |
| Kent, DM | 1 |
| Demova, H; Kluckova, H; Komers, R; Lecian, D; Lodererova, A; Teplan, V; Voska, L; Zdychova, J | 1 |
| Armani, A; Toth, PP | 2 |
| Poli, A; Pujia, A | 1 |
| Johnson, G; Macreadie, IG; Macreadie, PI; Schlosser, T | 1 |
| Brummel-Ziedins, KE; Bryniarski, L; Mann, KG; Potaczek, DP; Stobierska-Dzierzek, B; Szczeklik, A; Undas, A | 1 |
| Birnbaum, Y; Freeberg, SY; Huang, MH; Lin, Y; Martinez, JD; Nishi, SP; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Aizawa, Y; Fukaya, H; Imaki, R; Izumi, T; Kubo, T; Ohtaki, K; Ozaki, K; Ozaki, S; Shinagawa, H | 1 |
| Antoniades, C; Charakida, M; Koniari, K; Kourtellaris, P; Marinou, K; Ntarladimas, I; Siasos, G; Stefanadis, C; Tousoulis, D; Vasiliadou, C | 1 |
| Bolaman, Z; Kadikoylu, G; Ozgel, N; Yenisey, C | 1 |
| Davidson, MH; Robinson, JG | 1 |
| Clarke, RM; Lynch, MA; Lyons, A; O'Connell, F | 1 |
| Bramson, C; Calcagni, A; Chung, M; Glue, P | 2 |
| Gong, K; Song, G; Zhang, Z | 1 |
| Bayle, P; Bazex, J; Chouini-Lalanne, N; D'Incan, M; Drugeon, C; Gadroy, A; Journe, F; Marguery, MC | 1 |
| Barrett, B; Borek-Dohalský, V; Huclová, J; Jelínek, I; Nemec, B; Ulc, I | 1 |
| Pogacnik, T; Pretnar-Oblak, J; Sabovic, M; Sebestjen, M; Zaletel, M | 1 |
| Carod-Artal, FJ | 1 |
| Knopp, RH; Paramsothy, P | 1 |
| Beddhu, S; Cheung, AK; Kronenberg, F; Kwan, BC | 1 |
| Kiberd, BA | 1 |
| Hiasa, Y; Hosokawa, S; Kishi, K; Miyajima, H; Ogata, T; Ogura, R; Ohara, Y; Ohtani, R; Suzuki, N; Takahashi, T; Tomokane, T; Yuba, K | 1 |
| Gerlach, RF; Lopes, LF; Rego, EM; Sandrim, VC; Souza-Costa, DC; Tanus-Santos, JE | 1 |
| Adamovich, E; Allen, ZA; Butler, EG; Butler, WM; Galbreath, RW; Merrick, GS; Moyad, MA; Wallner, KE | 1 |
| Abraham, J; Alla, V; Bonkovsky, HL; Chalasani, NP; Raina, D; Siddiqui, J; Wu, GY | 1 |
| Deig, E; Guelar, A; Guil, J; Pedrol, E; Rodríguez-Martín, M; Soler, A | 1 |
| Palacios Muñoz, R; Santos González, J | 1 |
| Shen, H; Zhong, M | 1 |
| Sparks, DL; Stankovic, G | 1 |
| López Serrano, R; Otero Uribe, JL | 1 |
| Haffner, S; Lloret, R; Stein, M; Ycas, J | 1 |
| Arikan, O; Dokmetas, S; Yilmaz, A | 1 |
| Bestari, K; Brain, RA; Lissemore, LI; Reitsma, TS; Sibley, PK; Solomon, KR | 1 |
| Beugels, I; de Winther, MP; Gijbels, MJ; Mensink, RP; Plat, J | 1 |
| Guthrie, RM | 1 |
| Fitchett, DH; Goodman, SG; Langer, A; Leiter, LA | 1 |
| Jamborova, G; Nachtigal, P; Pospechova, K; Pospisilova, N; Semecky, V; Solichova, D; Zdansky, P | 1 |
| Chen, YH; Chua, S; Hang, CL; Hung, WC; Wu, CJ; Yeh, KH; Yip, HK; Youssef, AA | 1 |
| Barter, P; Carmena, R; Deedwania, P; Fruchart, JC; Grundy, SM; Haffner, S; Kastelein, JJ; LaRosa, JC; Schachner, H; Shepherd, J; Waters, DD | 1 |
| Dezfulian, C; Gladwin, MT; Raat, NJ | 1 |
| Bem, AF; Metzger, IF; Nagassaki, S; Rocha, JB; Sertório, JT; Tanus-Santos, JE | 1 |
| Edwards, C; Gladding, PA; Kerr, A | 1 |
| Alberti, A; Bergamasco, L; Brscic, E; Celeste, A; De Bernardi, A; Formato, L; Fuster, V; Moretti, C; Pucci, A; Sheiban, I; Trevi, G | 1 |
| Erkiliç, K; Koç, A; Mistik, S; Ozkiris, A | 1 |
| Bahl, A; Chongtham, DS | 1 |
| Miserez, AR; Romanens, MJ | 1 |
| Dushkin, MI; Khoshchenko, OM; Kudinova, EN; Schwartz, YSh | 1 |
| Lloyd, K | 2 |
| Bernik, MM; Bertolami, MC; Britto, LR; Curi, R; Dorea, EL; Hirata, MH; Hirata, RD; Rebbechi, IM; Rodrigues, AC | 1 |
| Cheong, SS; Han, KH; Hong, MK; Jang, JS; Kim, JJ; Kim, YH; Lee, CW; Lee, SW; Park, CB; Park, DW; Park, SJ; Park, SW | 1 |
| Abdelnoor, AM; El-Haibi, C; Khauli, RB; Rahal, E | 1 |
| Athyros, VG; Elisaf, M; Ganotakis, ES; Kakafika, AI; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Papageorgiou, AA; Tziomalos, K | 1 |
| März, P; Miserez, AR; Otten, U | 1 |
| Audikovszky, M; Illyés, L; Kalmár, T; Kassai, A; Mirdamadi, HZ; Paragh, G; Seres, I | 1 |
| Candura, D; Chello, M; Covino, E; D'Ambrosio, A; Di Sciascio, G; Pasceri, V; Patti, G | 1 |
| Agarwal, S; Coakely, M; Coakley, M; Mallett, S; Reddy, K; Riddell, A | 1 |
| Abramowicz, D; Berkenboom, G; Broeders, N; Carpentier, Y; Ghisdal, L; Unger, P; Wissing, KM | 1 |
| Morais, MG; Pedrosa, R; Sena, A | 1 |
| Healy, H; Morgan, C; Saltissi, D; Westhuyzen, J | 1 |
| Ansari Dogaheh, M; Ghorbani Bidkorbeh, F; Hashem, M; Mohammadi, A; Rezanour, N; Walker, RB | 1 |
| Andrýs, C; Bláha, M; Bláha, V; Hyspler, R; Knízek, J; Smahelová, A; Solichová, D; Zadák, Z | 1 |
| Laaksonen, R; Lehtimäki, T; Luomala, M; Lütjohann, D; Päivä, H; Peltonen, N; Thelen, K | 1 |
| Gennimata, V; Ikonomidis, I; Kotsis, V; Lekakis, J; Pitiriga, V; Protogerou, A; Zakopoulos, N | 1 |
| Brecht, K; Kaufmann, P; Krähenbühl, S; Török, M; Waldhauser, KM; Zahno, A | 1 |
| Emritte, N; Hajdúch, M; Mendoza, L; Platílová, V; Plausinaitis, R; Svoboda, M | 1 |
| Chiesa, G; Cippone, V; Conte Camerino, D; De Luca, A; De Vito, D; Didonna, MP; Frigeri, A; Nicchia, GP; Pierno, S; Pisoni, M; Rizzo, C; Scanziani, E; Sirtori, C; Svelto, M | 1 |
| Huang, TG; Mondo, CK; Yang, WS; Zhang, N | 1 |
| Jansen, TL | 1 |
| Chello, M; Colonna, D; Covino, E; D'Ambrosio, A; Di Sciascio, G; Miglionico, M; Nusca, A; Pasceri, V; Patti, G | 1 |
| Balakhonova, TV; Kukharchuk, VV; Masenko, VP; Pogorelova, OA; Susekov, AV; Tripoten', MI; Zubareva, Mi | 1 |
| Auteri, A; Bruni, F; Ciani, F; Ghezzi, A; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Pontani, A; Puccetti, L | 1 |
| Blanco-Colio, LM; de Teresa, E; Egido, J; Farsang, C; Gaw, A; Gensini, G; Hérnandez, G; Langer, A; Leiter, LA; Martín-Ventura, JL; Martineau, P | 1 |
| Hayashi, T; Kimura, S; Kitaura, Y; Kurumazuka, D; Matsumoto, N; Matsumura, Y; Mori, T; Nakano, D; Shirakawa, H | 1 |
| García-Fernández, A; Mainar, L; Marín, F; Martínez, JG; Roldán, V | 1 |
| Cariolou, M; Christidis, DS; Elisaf, MS; Ganotakis, ES; Kakafika, AI; Liberopoulos, EN; Mikhailidis, DP; Miltiadous, GA | 1 |
| Boyd, IW; O'Shea, JM; Ronaldson, KJ | 1 |
| Arant, CB; DeBella, AE; Schofield, RS; Welder, GJ; Wessel, TR; Zineh, I | 1 |
| Amrani, M; Isley, C; Osman, L; Smolenski, RT; Yacoub, MH | 1 |
| Betteridge, DJ; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Luo, D; Neil, HA | 1 |
| Gazi, IF; Mikhailidis, DP | 1 |
| Cubeddu, LX; Cubeddu, RJ; Heimowitz, T; Lamas, GA; Restrepo, B; Weinberg, GB | 1 |
| McHugh, A | 1 |
| Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM | 1 |
| Kurbanov, RD; Shek, AB; Tashkenbaeva, NF | 1 |
| Hirano, H; Morishita, T; Nakashima, Y; Nakata, S; Ozumi, K; Sabanai, K; Sasaguri, Y; Shimokawa, H; Suda, O; Tanimoto, A; Tasaki, H; Tsutsui, M; Yamashita, T; Yanagihara, N | 1 |
| Ehrenstein, MR; Isenberg, DA; Jury, EC; Mauri, C | 1 |
| Alemao, E; Jousilahti, P; Salomaa, V; Sintonen, H; Yin, D | 1 |
| Davidson, MH; McKenney, JM; Revkin, JH; Shear, CL | 1 |
| Barter, P; Breazna, A; Carter, R; Fruchart, JC; Gotto, AM; Grundy, SM; Kastelein, JJ; LaRosa, JC; Waters, DD | 1 |
| Nachtigal, P; Ouda, L; Semecký, V; Solichová, D; Syka, J | 1 |
| Antipova, V; Bansemer, S; Böttcher, T; Dazert, E; Gierl, L; Gimsa, U; Glass, A; Hoffrogge, R; Ibrahim, SM; Karopka, T; Koczan, D; Kundt, G; Lemcke, S; Mazón-Peláez, I; Mix, E; Müller, J; Pahnke, J; Rolfs, A; Scheel, T; Strauss, U; Warzok, R; Wree, A; Zschiesche, M | 1 |
| Banach, M; Barylski, M; Grycewicz, J; Irzmański, R; Kowalski, J; Pawlicki, L | 1 |
| Bartosová, L; Cermáková, E; Cibicek, N; Cibicková, L; Jun, D; Micuda, S; Palicka, V | 1 |
| Braun, C; Brinkkoetter, PT; Gottmann, U; Schulte, J; van der Woude, FJ; Yard, BA | 1 |
| Bardou, M; Dumas, M; Goirand, F; Guerard, P; Lirussi, F; Rakotoniaina, Z; Rochette, L | 2 |
| Fox, KM; Gandhi, SK; McKenney, JM; Ohsfeldt, RL; Stacy, TA | 1 |
| Barron, TI; Bennett, K; Feely, J | 1 |
| Mascitelli, L; Pezzetta, F | 3 |
| Gu, C; Lee, TS; Shyy, JY; Sun, W; Wang, Y; Zhu, M; Zhu, Y | 1 |
| Császár, A | 2 |
| Mistafa, O; Roudier, E; Stenius, U | 1 |
| Leighton, JA; Luckritz, TC; Patel, BM; Rady, MY; Wells, CD; Zornik, JM | 1 |
| Cannon, CP; Ganz, P; Ray, KK | 1 |
| Daida, H; Hiro, T; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Yamagishi, M | 1 |
| Blanco-Colio, LM; Duran, MC; Egido, J; Martín-Ventura, JL; Tuñon, J; Vivanco, F | 1 |
| Abad, S; Cachofeiro, V; de Vinuesa, SG; Goicoechea, M; Gómez-Campderá, F; Lahera, V; Luño, J; Vega, A | 1 |
| Alves-Filho, JC; Cunha, FQ; Figueiredo-Lopes, L; Gerlach, RF; Semprini, MC; Souza-Costa, DC; Tanus-Santos, JE | 1 |
| Andrade, RJ; Barriocanal, A; Borraz, Y; Costa, J; Durán, JA; Fernández, MC; García-Cortés, M; García-Muņoz, B; Guarner, C; Hidalgo, R; Kaplowitz, N; Lucena, MI; Muņoz-Yagüe, T; Pachkoria, K; Pelaez, G; Planas, R; Rodrigo, L; Romero-Gomez, M; Salmerón, J | 1 |
| Ho, W; Huo, Y; Liu, ZP; Meng, L | 1 |
| Cohen, JS | 1 |
| Kaupper, T; Walter, M; Ziegler, AG | 1 |
| Khan, NA | 1 |
| Elkind, MS | 1 |
| East, JE | 1 |
| Goudevenos, JA; Lourida, ES; Papathanasiou, AI; Tselepis, AD; Tsironis, LD | 1 |
| Boodhwani, M; Feng, J; Li, J; Mieno, S; Sellke, FW; Sodha, N; Voisine, P | 1 |
| Ferrer-García, JC; Herrera-Ballester, A; Martínez-Mir, I; Pérez-Silvestre, J | 1 |
| Agustín Herrero, J; Cámara Hijón, C; Costo Campoamor, A; Crespo Rincón, L; Fernández Pereira, L; Pereira Navarro, G; Sánchez Muñoz-Torrero, JF; Torres Pérez, F | 1 |
| Checa, JC; Fernández de Bobadilla, J; Navarro Artieda, R; Sicras Mainar, A | 1 |
| Evans, M; Golomb, B | 1 |
| Alhan, CC; Avkaroğullari, M; Cayli, M; Demir, M; Demirtaş, M; Dönmez, Y; Inal, T; Kanadaşi, M; Koç, M; San, M; Usal, A | 1 |
| Duan, J; Li, XP; Tan, MY; Xu, ZM; Zhang, DQ; Zhao, SP | 1 |
| Li, M; Ren, H; Zhang, Y; Zhu, X | 1 |
| Burggraaf, J; Cohen, AF; Dirsch, V; Espirito Santo, SM; Gebhardt, R; Haffner, T; Kamerling, IM; Meijer, P; Princen, HM; Schoemaker, RC; van Doorn, MB; Vollmar, A | 1 |
| Fyhrquist, F; Nyman, T; Saijonmaa, O | 1 |
| Moriguchi, H; Sato, C; Uemura, T | 1 |
| Edwards, P; Goldberg, RB; Guyton, JR; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS | 1 |
| Aukrust, P; Boullier, A; Breland, U; Damås, JK; Fevang, B; Frøland, SS; Gullestad, L; Halvorsen, B; Hansson, GK; Kjekshus, J; Ovchinnikova, O; Quehenberger, O; Robertson, AK; Sandberg, WJ; Smith, C; Taskén, K; Waehre, T; Yndestad, A; Øie, E | 1 |
| Fukunami, M; Kioka, H; Masuda, M; Mine, T; Morita, T; Node, K; Okuda, K; Tamaki, S; Tsukamoto, Y; Yamada, T | 2 |
| Böhm, M; Draber, K; Eckel, L; Felix, SB; Grube, M; Jedlitschky, G; Köck, K; Kroemer, HK; Meissner, K; Oswald, S; Siegmund, W; Vogelgesang, S; Warzok, R | 1 |
| de Vegvar, HE; Digennaro, C; Higgins, JP; Ho, PP; Kidd, BA; Lee, LY; Robinson, WH; Steinman, L; Tomooka, B | 1 |
| Junni, P; Katajamaa, M; Laaksonen, R; Lehtimäki, T; Lütjohann, D; Oresic, M; Päivä, H; Saarinen, L; Seppänen-Laakso, T; Smet, J; Soini, J; Sysi-Aho, M; Van Coster, R | 1 |
| Buĭdina, TA; Khokhlov, AL; Zhilina, AN | 1 |
| Bohrer, A; Dietzen, DJ; Page, KL; Tetzloff, TA; Turk, J | 1 |
| Fukao, A; Komatsu, Y; Majima, T; Matsumura, T; Nakao, K; Ninomiya, K | 1 |
| Chen, Y; Kohno, M; Kosaka, H; Mizukawa, M; Ohmori, K; Shinomiya, K; Yoshida, J; Zeng, Y; Zhang, L | 1 |
| Imaizumi, T; Ishida, S; Jinnouchi, J; Jinnouchi, Y; Takeuchi, M; Yamagishi, S | 1 |
| Bramlage, P; Brosnihan, KB; Ferrario, CM; Kirch, W; Koch, R; Maywald, U; Oertel, R; Schindler, C | 1 |
| Inoue, N; Ishikawa, M; Kato, T; Motomura, K; Oikawa, S; Okajima, F; Shimano, H; Takahashi, A; Yamada, N | 1 |
| Benet, LZ; Frassetto, L; Huang, Y; Lau, YY | 1 |
| Almog, Y; Avnon, LS | 1 |
| Hiatt, WH; Linnebur, SA | 1 |
| Wadman, M | 1 |
| Chyrchel, M; Dubiel, JS; Dudek, D; Dziewierz, A; Legutko, J; Rakowski, T; Rzeszutko, L | 1 |
| Liu, Y; Sheng, L; Ye, P; Zhang, C | 1 |
| Andrys, C; Jamborova, G; Nachtigal, P; Pospechova, K; Pospisilova, N; Semecky, V; Solichova, D; Zdansky, P | 2 |
| Kitahara, K; Kohno, H; Okano, K; Saito, S; Sakai, T | 1 |
| Goldstein, MR | 2 |
| Bernardi, M; Caputo, F | 1 |
| Butler, R; Wainwright, J | 1 |
| Baskurt, OK; Meiselman, HJ; Uyuklu, M | 1 |
| Deshpande, S; Lokhandwala, Y | 1 |
| Chen, F; Chen, FP; Ma, QL; Mo, L; Pu, XQ; Wu, SB; Xie, W; Yang, TL; Zeng, XL | 1 |
| Benndorf, R; Böger, RH; Kom, GD; Maas, R; Schneider, L; Schwedhelm, E | 1 |
| Barbosa, E; Christie, DK; Pannu, R; Singh, AK; Singh, I | 1 |
| Chen, L; Huang, J; Qian, H; Shen, D; Tang, Q; Wang, H; Wang, T; Wu, H; Xiong, R | 1 |
| Moulik, N; Patil, N; Rajadhyaksha, G; Save, V | 1 |
| Hashimoto, T; Igarashi, J; Kosaka, H; Kubota, Y; Miyoshi, M | 1 |
| Chou, SY; Gulmi, FA; Kim, H; Michli, E; Mooppan, UM | 1 |
| Bajo, MA; del Peso, G; Díez, JJ; Estrada, PN; Fernández-Reyes, MJ; Grande, C; Iglesias, P; Sánchez Hernández, R; Selgas, R | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, JA | 1 |
| Leiter, LA; Miller, P; Palmer, M; Reckless, JP; Rosenson, RS; Schleman, M; Schulte, KL; Sosef, F; Stein, E | 1 |
| Tall, AR; Wang, N; Yvan-Charvet, L | 1 |
| Bayraktar, N; Eroglu, D; Esinler, I; Haberal, N; Oktem, M; Zeyneloglu, HB | 1 |
| Cía, M; Martínez, M; Otermin, I; Pereda, A; Rivero, M | 1 |
| Nesto, RW; Singh, PP | 1 |
| Bays, HE; Jones, PH; Kashyap, ML; Knopp, RH; McGovern, ME; McKenney, JM; Ruoff, GE | 1 |
| Fabian, V; Knezevic, W; Mastaglia, FL; Needham, M; Panegyres, P; Zilko, P | 1 |
| Borok, GM; Bullano, MF; Gandhi, SK; Kamat, S; McDonough, KL; Wertz, DA; Willey, VJ | 1 |
| Balcells, S; Blanch, J; Carreras, R; Díez-Perez, A; Enjuanes, A; Grinberg, D; Mellibovsky, L; Monllau, JC; Nogues, X; Pedro-Botet, J; Ruiz-Gaspa, S | 1 |
| Coombes, JS; Fassett, RG; Oliver, KR; Summers, MJ | 1 |
| Birnbaum, Y; Freeberg, SY; Huang, MH; Lin, Y; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Billinger, M; Cook, S; Haeberli, A; Hess, OM; Meier, B; Togni, M; Wenaweser, P; Windecker, S | 1 |
| Bittner, V; Deedwania, PC; Kastelein, JJ; Khush, KK; Lewis, SJ; Waters, DD; Wenger, NK | 1 |
| Betteridge, DJ; Charlton-Menys, V; Colhoun, HM; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; McGuire, A; Neil, HA; Raikou, M | 1 |
| Chaudhari, BG; Patel, NM; Shah, PB | 1 |
| Honey, K | 1 |
| Birnbaum, Y; Huang, MH; Lin, Y; Lui, CY; Martinez, JD; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Aretini, A; Gentile, MT; Landolfi, A; Lembo, G; Maffei, A; Marino, G; Passarelli, F; Poulet, R; Vasta, A; Vecchione, C | 1 |
| Bairey Merz, CN; Cosin-Aguilar, J; Deedwania, P; Koylan, N; Luo, D; Ouyang, P; Piotrowicz, R; Schenck-Gustafsson, K; Sellier, P; Stein, JH; Stone, PH; Thompson, PL; Tzivoni, D | 1 |
| Hu, SJ; Kang, L | 2 |
| Antonini, R; Antonini, TM; Arca, M; Di Angelantonio, E; Diczfalusy, U; Iuliano, L; Micheletta, F; Montali, A; Natoli, S; Riggi, S | 1 |
| Camerino, DC; Camerino, GM; Cippone, V; Giannuzzi, V; Liantonio, A; Pierno, S | 1 |
| Hosoya, T; Kawamoto, S; Kawamura, T; Miyazaki, Y | 1 |
| Arima, J; Iguro, Y; Kariyazono, H; Masuda, H; Nakamura, K; Sakata, R; Yamada, K | 1 |
| Galgóczy, L; Leiter, E; Lukács, G; Papp, T; Pócsi, I; Vágvölgyi, C | 1 |
| Molden, E; Westergren, T | 1 |
| Messerli, FH | 1 |
| Cangemi, R; Carnevale, R; Loffredo, L; Pignatelli, P; Violi, F | 1 |
| Gupta, S; Hughes, EA; Lie, F; Patel, JV | 1 |
| Jamieson, MJ; Luo, D; Olsson, AG; Schwartz, GG; Szarek, M | 1 |
| Asztalos, BF; Dallal, GE; Horvath, KV; Jones, PH; Le Maulf, F; McTaggart, F; Schaefer, EJ; Stein, E | 1 |
| Ching, C; Chung, LM; Davis, SC; Fox, RJ; Gavrilovic, V; Grate, J; Gruber, J; Huisman, GW; Ma, SK; Muley, S; Mundorff, EC; Newman, LM; Sheldon, RA; Tam, S; Whitman, JC | 1 |
| Janíková, L; Stanková, B; Stopka, P; Tvrzická, E; Vareka, T; Vecka, M; Zahin, M; Zák, A; Zeman, M | 1 |
| Chopp, M; Goussev, A; Lu, D; Mahmood, A; Qu, C | 1 |
| Chang, KS; Choi, DH; Choi, JS; Hong, SP | 1 |
| Inoue, H; Matsui, T; Nakamura, K; Yamagishi, S | 1 |
| Côté, HC; Frohlich, JJ; Humphries, KH; Laaksonen, R; Lehtimäki, T; Päivä, H; Schick, BA | 1 |
| Andriolo, A; Borges, DR; Ito, DT; Molina, HM | 1 |
| Cetin, A; Igdem, AA; Ozacmak, ID; Ozacmak, VH; Sayan, H | 1 |
| Barderas, MG; Blanco-Colio, LM; Durán, MC; Egido, J; Jensen, ON; Martín-Ventura, JL; Mas, S; Mohammed, S; Moral, V; Ortega, L; Tuñón, J; Vivanco, F | 1 |
| Alber, HF; Dichtl, W; Dörler, J; Frick, M; Pachinger, O; Stocker, EM; Süssenbacher, A; Weidinger, F | 1 |
| Gans, RO; May, JF; Mulder, DJ; Smit, AJ; Tervaert, JW; van Doormaal, JJ; van Haelst, PL; Wobbes, MH; Zijlstra, F | 1 |
| Crossland, A; Mills, IW; Patel, A; Ramonas, H | 1 |
| Chan, IH; Chan, W; Cheng, KK; Fung, JW; Kong, SL; Lam, CW; Lam, L; Lee, SW; Lin, H; Sanderson, JE; Yu, CM; Zhang, Q | 1 |
| Choudhry, NK; Levin, R; Winkelmayer, WC | 1 |
| Arisz, L; Kastelein, JJ; Koopman, MG; Ozsoy, RC; van der Steeg, WA | 1 |
| Awada, M; Bautista, A; Gardner, JL; Hellerstein, MK; Lindwall, G; Turner, SM | 1 |
| Fischer, S; Jaster, M; Martus, P; Morguet, AJ; Piorkowski, M; Rauch, U; Schultheiss, HP; Stellbaum, C | 1 |
| Nidorf, M; Thompson, PL | 1 |
| Delgado, O; Kaczmarek, I; Meiser, B; Reichart, B; Sadoni, S; Schmöckel, M | 1 |
| Betteridge, DJ; Gibson, JM | 1 |
| Berg, RL; Brown-Switzer, C; Ghebranious, N; McCarty, CA; Peissig, P; Sirohi, E; Wilke, RA | 1 |
| Graff, J; Jönsson, B; Lindgren, P; Olsson, AG; Pedersen, TJ | 1 |
| Chen, S; Li, XP; Li, YG; Liu, QM; Xu, DM; Xu, YG; Zheng, CH; Zhou, SH | 1 |
| Heering, NJ | 1 |
| Bao, XF; Cai, HW; Cheng, G; Wang, HH; Xu, G | 1 |
| Fasshauer, M; Klein, J; Mäuser, W; Meier, B; Perwitz, N | 1 |
| Jose, J; Saravu, K; Shastry, BA | 1 |
| Huang, YC; Khan, S; Kim, MK; Li, P; Nguyen, T; Sanchez, J; Song, JC; Wang, CC | 1 |
| Gomez, EV; Howey, DC; McErlean, E; Nicholls, SJ; Nissen, SE; Russo, JM; Wang, MD; Wolski, K | 1 |
| Bachinsky, WB; Duggan, WT; Lasala, GP; Nicholls, SJ; Nissen, SE; Revkin, JH; Ruzyllo, W; Shear, CL; Tardif, JC; Tuzcu, EM | 1 |
| Tall, AR | 1 |
| Barter, PJ; Bots, ML; Burgess, L; Duggan, WT; Evans, GW; Grobbee, DE; Kastelein, JJ; Kuivenhoven, JA; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI | 1 |
| Bal, BS; Kant, R; Mahajan, M; Sharma, R; Singh, B | 1 |
| Carnevale, R; Lenti, L; Loffredo, L; Pignatelli, P; Sanguigni, V; Sorge, R; Violi, F | 1 |
| Itaya, M; Ogura, Y; Sakurai, E; Yamada, K; Yamasaki, S | 1 |
| Bank, AJ; Billups, KL; Crawford, WW; Kaiser, DR; Kelly, AS; Schow, DA; Waxman, B | 1 |
| Boissel, JP | 1 |
| Couderc, R; Cynober, L; Martin, C; Moinard, C; Rasmusen, C; Tricottet, V | 1 |
| Hammervold, T; Howe, PR; Meyer, BJ; Rustan, AC | 1 |
| Chan, JL; Chung, RT; McMahon, CM; O'Leary, JG | 1 |
| Colonna, G; Di Sciascio, G; Fischetti, D; Miglionico, M; Montinaro, A; Pasceri, V; Patti, G; Sardella, G | 1 |
| Abad, L; Chaves, J; Dueñas, A; Hernandez, G; Pérez-Castrillón, JL; Sanz, A; Vega, G | 1 |
| Fukuda, N; Fukuda, Y; Morishita, S; Nada, T; Sakabe, K; Shinohara, H; Tamura, Y; Wakayama, K | 2 |
| Zhou, MS | 1 |
| Blagden, MD; Chipperfield, R | 1 |
| Bots, ML; Evans, GW; Kastelein, JJ; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI | 1 |
| Prigent, B | 1 |
| Georgescu, EF; Georgescu, M | 1 |
| Birnbaum, Y; Huang, MH; Hughes, MG; Lin, Y; Manickavasagam, S; McAdoo, DJ; Perez-Polo, R; Uretsky, BF; Ye, Y | 1 |
| McMahon, DE | 1 |
| Rajshree, M; Vipul, K | 1 |
| Gorbas', IM; Iakimishina, LI; Kaĭdashev, IP; Petrushov, AV; Rasin, AM; Rasin, MS; Smirnova, IP; Vasil'ev, VN | 1 |
| Hatta, T; Hushiki, S; Irie, H; Kobara, M; Kuwahara, N; Matsubara, H; Nakata, T; Narumiya, H; Sasaki, S; Takeda, K; Tatsumi, T | 1 |
| Hawkins, NM; MacDonald, MR; Padfield, GJ | 1 |
| Orlandi, QG; Shroff, GR | 1 |
| Furu, K; Karlstad, Ø; Rønning, M; Sakshaug, S; Skurtveit, S | 1 |
| Buttmann, M; Lorenz, A; Rieckmann, P; Weishaupt, A | 1 |
| Allen, C; Chung, N; Constance, C; Johnson-Levonas, AO; Lund, M; Massaad, R; McCrary Sisk, C; Westphal, S | 1 |
| Kaplan, SA | 1 |
| Blanco-Colio, LM; de Teresa, E; Egido, J; Farsang, C; Gaw, A; Gensini, G; Langer, A; Leiter, LA; Martín-Ventura, JL; Martineau, P | 2 |
| Fu, LC; Gao, X; Hu, YJ | 1 |
| Abe, M; Hirose, T; Kawamori, R; Mita, T; Nakayama, S; Ogihara, T; Shimizu, T; Uchino, H; Watada, H | 1 |
| Ceska, R; Kasalová, Z; Marinov, I; Stulc, T; Svobodová, H; Vrablík, M | 1 |
| Caballero, R; Delpón, E; Gómez, R; Núñez, L; Tamargo, J; Vaquero, M | 1 |
| Bauman, JN; Davis, JA; Goosen, TC; Hurst, SI; Loi, CM; Williams, JA; Yu, C | 1 |
| Clarke, PJ; Grobler, MP; Levison, DB; Liew, D; Magliano, DJ; Rogers, SL; Webb, K | 1 |
| Chen, SH; Chu, CS; Kou, HS; Lai, WT; Lee, CJ; Lee, KT; Sheu, SH; Voon, WC | 1 |
| Fredrikson, H; Neuvonen, PJ; Niemi, M; Pasanen, MK | 1 |
| Bechis, G; Delliaux, S; Jammes, Y; Lesavre, N; Oliver, C; Paganelli, F; Steinberg, JG | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Koter-Michalak, M | 1 |
| Altman, JK; Antico, G; Katsoulidis, E; Minucci, S; Platanias, LC; Redig, AJ; Sassano, A; Tallman, MS | 1 |
| Chadarevian, R; Danchin, N; Gayet, JL; Licour, M; Valensi, P | 1 |
| Duplessis, CA; Fothergill, D; Gertner, J; Hughes, L; Schwaller, D | 1 |
| Erl, W | 1 |
| Vos, E | 1 |
| von Eckardstein, A | 2 |
| Hartung, HP; Neuhaus, O | 1 |
| Lavie, CJ; Milani, RV; O'Keefe, JH | 1 |
| Gandhi, SK; Ghali, JK; Hassman, DR; Insull, W; Miller, E; Y As, JW | 1 |
| Ezhov, MV; Kukharchuk, VV; Naumov, VG; Samoĭlenko, EIu; Sergienko, IV; Tvorogova, MG | 1 |
| Balakhonova, TV; Kukharchuk, VV; Kulev, BD; Masenko, VP; Pogorelova, OA; Rogozova, AN; Rozhkova, TA; Susekov, AV; Tripoten', MI; Zubareva, MIu | 1 |
| Baret, E; Briolant, S; Fontaine, A; Fusai, T; Henry, M; Mosnier, J; Pradines, B; Rogier, C; Torrentino-Madamet, M | 1 |
| Batt, AM; Bertrand-Thiebault, C; Masson, C; Siest, G; Visvikis-Siest, S | 1 |
| Badyal, DK; Calton, R; Chatley, P; Khosla, PP | 1 |
| Guyton, JR; Laskowitz, DT; Lynch, JR; Mace, B; Song, P; Wang, H; Warner, DS; Yang, HJ; Yates, RB | 1 |
| Fuchs, D; Schroecksnadel, K; Stanger, O; Teerlink, T; Weiss, G | 1 |
| Chu, CS; Lai, WT; Lee, KT; Lee, ST; Lin, TH; Lu, YH; Sheu, SH; Voon, WC | 1 |
| Asztalos, BF; Barrett, PH; Buchsbaum, A; Diffenderfer, MR; Dolnikowski, GG; Horvath, K; Lamon-Fava, S; Lichtenstein, AH; Matthan, NR; Schaefer, EJ; Zago, V | 1 |
| Canis, M; Hempel, JM; Mazurek, B; Olzowy, B; Suckfüll, M | 1 |
| Frost, RJ; Otto, B; Otto, C; Parhofer, KG; Pfeiffer, AF; Spranger, J; Vogeser, M | 1 |
| Dichgans, M; Freilinger, T; Opherk, C; Peters, N; Pfefferkorn, T | 1 |
| Deedwania, PC; Gold, A; Gupta, M; Stein, M; Ycas, J | 1 |
| Altug, T; Aslan, M; Balci, H; Bolayirli, IM; Hacibekiroglu, M; Seven, A | 1 |
| Czepluch, FS; Waltenberger, J | 1 |
| Chan, D; Dogra, G; Irish, A; Watts, G | 1 |
| Ge, CJ; Hu, SJ; Kang, L | 1 |
| Botteman, MF; Damen, J; Koren, MJ; Kuntze, CE; Liu, LZ; Mamdani, M; Straka, RJ | 1 |
| Guazzi, M; Guazzi, MD; Reina, G; Tumminello, G; Vicenzi, M | 1 |
| Hashemi, MJ; Hekmat, M; Kouhi, A; Mojtahedzadeh, S; Naderi, N; Nobahar, R; Rafeiyian, S | 1 |
| Dutt, P; Fanburg, BL; Li, M; Liu, Y; Toksoz, D | 1 |
| Burger, F; Mach, F; Packard, RR; Perneger, T; Schlegel, S; Senouf, D; Siegrist, CA; Sigaud, P | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Shui, A | 1 |
| Grimmsmann, T; Himmel, W; Schwabe, U | 1 |
| Ansell, BJ; Charles-Schoeman, C; Fogelman, AM; Furst, DE; Gong, T; Khanna, D; McMahon, M; Park, GS; Paulus, HE; Reddy, ST | 1 |
| Kaul, P | 1 |
| Brass, EP; Chung, J; Hiatt, WR; Ulrich, RG | 1 |
| Frial, T; Miller, PS; Tran, YB | 1 |
| Ballantyne, C; Maccubbin, D; Pearson, T; Shah, A; Sisk, C; Veltri, E | 1 |
| Bennett, MT; Bondy, GP; Johns, KW | 1 |
| Kulbertus, H | 1 |
| Byun, SS; Han, BK; Hong, SK; Jeong, SJ; Lee, SE | 1 |
| Christians, U; Kaisers, U; Laudi, S; McMurtry, IF; Mutlak, H; Schmitz, V; Steudel, W; Trump, S; Weimann, J; West, J | 1 |
| Kawamura, A; Mitsutake, R; Miura, S; Niimura, H; Okamura, K; Saku, K | 1 |
| Lachaine, J; Merikle, E; Montpetit, M; Rinfret, S; Tarride, JE | 1 |
| Gao, RL | 1 |
| Braunwald, E | 2 |
| Dhayat, N; Dhayat, S; Du, J; Hilfiker-Kleiner, D; Laufs, U; Noutsias, M; Riad, A; Schultheiss, HP; Spillmann, F; Tschöpe, C; Van Linthout, S; Westermann, D | 1 |
| Gruber, HJ; Landl, EM; März, W; Mayer, C; Pailer, S; Scharnagl, H; Truschnig-Wilders, M | 1 |
| Hess, G; Hill, J; Liu, LZ; Sanders, KN | 1 |
| Biecker, E; Heller, J; Hennenberg, M; Laleman, W; Nevens, F; Sauerbruch, T; Schepke, M; Shelest, N; Trebicka, J | 1 |
| Aznaouridis, K; Dagre, A; Masoura, C; Pitsavos, C; Skoumas, J; Stefanadi, E; Stefanadis, C; Vasiliadou, C; Vlachopoulos, C | 1 |
| Dande, A; Holford, TR; Kocherla, M; Ruaño, G; Seip, RL; Smith, A; Sorokin, A; Thompson, PD; Windemuth, A; Wu, AH | 1 |
| Parle, M; Singh, N | 1 |
| Rosenberg, L; Uretsky, S | 1 |
| Bittner, V; Herrington, DM; Lewis, SJ; Welty, FK; Wenger, NK | 2 |
| Claeys, M; Commers, K; Deforce, J; Ducobu, J; Nachtergaele, H; Van Mieghem, W; Vandenbroucke, M | 1 |
| Chen, J; Chopp, M; Goussev, A; Jiang, H; Li, Y; Lu, C; Lu, D; Mahmood, A; Qu, C; Schallert, T | 1 |
| Fang, Q; Hu, SJ; Kang, L | 1 |
| Birnbaum, Y; Huang, MH; Lin, Y; Manickavasagam, S; Merla, R; Perez-Polo, RJ; Uretsky, BF; Ye, Y | 1 |
| Birnbaum, Y; Huang, MH; Hughes, MG; Lin, Y; Lui, CY; Manickavasagam, S; McAdoo, DJ; Perez-Polo, RJ; Uretsky, BF; Ye, Y | 1 |
| Buranakitjaroen, P; Deerochanawong, C; Kosachunhanun, N; Nitiyanant, W; Piamsomboon, C; Sukonthasarn, A; Suwantamee, J; Suwanwela, NC; Vongthavaravat, V | 1 |
| Chang, M; Chen, J; Elchuri, S; Fan, AC; Felsher, DW; Goldstein, MJ; Mitchell, DJ; Nolan, GP; Perez, OD; Shachaf, CM; Sharpe, O; Shirer, AE; Steinman, L; Youssef, S | 1 |
| Athyros, V; Farsang, C; Gaw, A | 1 |
| Gu, M; Liu, M; Wu, Y; Yin, C; Zhang, W; Zhu, P | 1 |
| Mazzone, T | 1 |
| Bots, ML; Duggan, WT; Evans, GW; Grobbee, DE; Kastelein, JJ; Revkin, JH; Riley, WA; Shear, CL; Tegeler, CH; Vicari, RM; Visseren, FL | 1 |
| Bax, JJ; Davignon, J; Dunkelgrun, M; Feringa, HH; Hoeks, SE; Kastelein, JJ; Poldermans, D; Schouten, O; van Domburg, RT; Vidakovic, R; Welten, GM | 1 |
| Caracchini, R; Gresele, P; Guglielmini, G; Guzzetta, M; Impagnatiello, F; Momi, S; Monopoli, A; Olivieri, R | 1 |
| Cizek, L; Horakova, D; Janout, V; Janoutova, G; Karpisek, M; Kollar, P; Kotolova, H; Lichnovska, R; Ochmanova, R; Stejskal, D; Yahia, RB | 1 |
| Kazis, LE; Lee, A; Lee, TA; Li, NC; Wang, SW; Wolozin, B | 1 |
| Chen, C; Lin, J; Smolarek, T; Tremaine, L | 1 |
| Bray, F; Chu, B; Dodge, JT; Hatsukami, TS; Lee, CD; Moore, AB; Phan, BA; Polissar, NL; Yuan, C; Zhao, XQ | 1 |
| Birnbaum, Y; Huang, MH; Lin, Y; Manickavasagam, S; Nishi, SP; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Hill, JS; Qiu, G | 2 |
| Iwano, C; Matsuyama, K; Matzno, S; Tomiyama, N; Yasuda, N | 1 |
| McClendon, KS; Riche, DM | 1 |
| Erdogan, O; Ordulu, E | 1 |
| Bhatt, DL; Brennan, DM; Fox, K; Mak, KH; Saw, J; Steinhubl, SR; Topol, EJ | 1 |
| Ishisaka, DY; Karalis, DG; Luo, D; Ntanios, F; Wun, CC | 1 |
| Fauler, G; Gurakuqi, G; März, W; Putz-Bankuti, C; Scharnagl, H; Stadlbauer, V; Stauber, RE; Stojakovic, T; Trauner, M; Wagner, M | 1 |
| Adams, V; Doehner, W; Du, J; Mohr, Z; Pauschinger, M; Riad, A; Schultheiss, HP; Sobirey, M; Stiehl, S; Tschöpe, C; Westermann, D | 1 |
| Anderson, TJ; Buithieu, J; Chan, S; Charbonneau, F; Genest, J; Hutchison, S; Huyhn, T; Jobin, J; Lonn, E; Poirier, P; Title, L; Tran, T; Walling, A | 1 |
| Asher, J; Houston, M | 1 |
| Archer, SL; Bonnet, S; Haromy, A; McMurtry, MS; Michelakis, ED | 1 |
| Coleman, CI; Dale, KM; Henyan, NN; Kluger, J; White, CM | 1 |
| Das, S; Gidding, SS; Mitchell, D; Zhang, S | 1 |
| Inazu, A; Katsuda, S; Kawashiri, MA; Kobayashi, J; Koizumi, J; Mabuchi, H; Nohara, A | 1 |
| Amado Señaris, JA; García Unzueta, MT; Otero Martínez, M; Piedra León, M | 1 |
| Bergheanu, SC; Dallinga-Thie, GM; Dunselman, PH; Jukema, JW; Liem, A; Van der Bom, JG; Van Tol, A | 1 |
| Andrade, LE; Ferreira, GA; Navarro, TP; Sato, EI; Telles, RW | 1 |
| Lindberg, MB; Ohman, KP; Ose, L; Retterstøl, K; Svensson, M; Tonstad, S | 1 |
| Antel, J; Arnold, DL; Bar-Or, A; Bodner, CA; Campagnolo, D; Garren, H; Gianettoni, J; Jalili, F; Kachuck, N; Lapierre, Y; Niino, M; Oger, J; Price, M; Rhodes, S; Robinson, WH; Shi, FD; Steinman, L; Utz, PJ; Valone, F; Vollmer, T; Weiner, L | 1 |
| Frudakis, TN; Gabriel, R; Ginjupalli, SN; Gomez, HJ; Handelin, B; Thomas, MJ | 1 |
| Andreasson, A; Andrén, L; Eggertsen, R | 2 |
| deGoma, EM; Fonarow, GC; Rockson, SG | 1 |
| Katayama, Y; Katsumata, T; Nishiyama, Y; Otori, T; Tanaka, N | 1 |
| Guan, X; Sun, ZS; Zhou, SH | 1 |
| Funabashi, N; Komuro, I; Mikami, Y; Nakamura, K; Shiina, Y; Uehara, M | 1 |
| Athyros, VG; Kakafika, AI; Karagiannis, A; Mikhailidis, DP; Pagourelias, E; Papageorgiou, AA; Pirpasopoulou, A; Skaperdas, A; Tziomalos, K | 1 |
| Chopp, M; Hozeska-Solgot, A; Liu, XS; Zhang, L; Zhang, ZG | 1 |
| Hu, SJ; Sun, J; Zhang, ZJ | 1 |
| Lee, R | 1 |
| Greten, H; Grundy, SM; Kastelein, JJ; Kostis, JB; LaRosa, JC | 1 |
| Akima, T; Birnbaum, Y; Goland, S; Iida, K; Luo, H; Siegel, RJ | 1 |
| Chiu, B; Egger, M; Fenster, A; Parraga, G; Spence, JD | 1 |
| Blanco, M; Castellanos, M; Castillo, J; Dávalos, A; García-Gil, M; Leira, R; Lizasoain, I; Moro, MA; Nombela, F; Rodriguez-Yáñez, M; Serena, J; Vivancos, J | 1 |
| Bolognese, MA; Bone, HG; Kiel, DP; Leary, ET; Lewiecki, EM; Lindsay, RS; Lowe, W; McClung, MR | 1 |
| Blasetto, J; Marais, AD; Palmer, M; Raal, FJ; Rader, DJ; Stein, EA; Wilpshaar, W | 1 |
| Deeg, MA; Johnson, C; Raikwar, NS; Williams, CD | 1 |
| Bassi, A; Caltagirone, C; Colivicchi, F; Santini, M | 1 |
| Blank, N; Busse, F; Ho, AD; Kalden, JR; Krienke, S; Lorenz, HM; Schätz, B; Schiller, M | 1 |
| Epstein, M; Laskey, R; Leary, E; Lowe, W; Reed, D; Zuckerman, A | 1 |
| Mocanu, MM; Shakkottai, P; Yellon, DM | 1 |
| Caliskan, M; Ciftci, O; Erdogan, D; Gullu, H; Muderrisoglu, H; Topcu, S; Yildirir, A | 1 |
| Azzellino, A; Balestri, G; Cazzaniga, M; Cerrito, MG; Cusa, EN; DeCarlini, C; Ferrari, AU; Garducci, S; Guerra, L; Lavitrano, ML; Loardi, C; Mancia, G; Menicanti, L; Paolini, G; Radaelli, A; Santo, D | 1 |
| Baxi, H; Chag, M; Chandarana, A; Goyal, R; Mehta, A; Naik, A; Parikh, K; Shah, K; Shah, U | 1 |
| Jayaram, S; Langade, DG; Mane, PR; Prasad, HB; Sovani, VB | 1 |
| George, J; Keren, G; Luboshits, G; Mausner-Fainberg, K; Maysel-Auslender, S; Mor, A; Rubinstein, A | 1 |
| Baker, J; Kambham, N; Negrin, RS; Steinman, L; Youssef, S; Zeiser, R | 1 |
| Wong, V | 1 |
| Cuccurullo, F; Di Febbo, C; Di Nisio, M; Guglielmi, MD; Moretta, V; Porreca, E; Stuppia, L | 1 |
| Frøbert, O; Holmager, P; Jensen, KM; Schmidt, EB; Simonsen, U | 1 |
| Benatar, JR; Stewart, RA | 1 |
| Dallinga-Thie, GM; de Haan, W; Havekes, LM; Hoekstra, M; Jukema, JW; Princen, HM; Rensen, PC; Romijn, JA; van der Hoogt, CC; Westerterp, M | 1 |
| Avila, GE; Conney, AH; Cui, XX; Huang, MT; Kong, AN; Lin, Y; Liu, Y; Patel, J; Paulino, R; Rabson, AB; Reddy, BS; Shih, WJ; Zheng, X | 1 |
| Che, D; Sun, Y; Zhang, D; Zhao, S | 1 |
| Blazing, MA; Braunwald, E; Califf, RM; Cannon, CP; de Lemos, JA; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Calderaro, D; Caramelli, B; Gualandro, D; Yu, PC | 1 |
| Jankl, S; Kofler, S; Nickel, T; Schlichting, C; Weis, M | 1 |
| Bayés, B; Blanco, S; Bonet, J; Lauzurica, R; Navarro-Muñoz, M; Romero, R | 1 |
| Amato, M; Arquati, M; Baldassarre, D; Brusoni, B; Camera, M; Cortellaro, M; Fiorentini, C; Montorsi, P; Porta, B; Romano, S; Tremoli, E | 1 |
| Abdellah, AT; Clark, AL; Cleland, JG; Coletta, AP; Khaleva, O | 1 |
| Emanuele, E; Geroldi, D | 1 |
| Averna, MR; Bucciarelli, L; Cefalù, AB; Ciabattoni, G; Davì, G; Davì, V; Ferrante, E; Noto, D; Pettinella, C; Santilli, F | 1 |
| Braun, C; Brinkkoetter, PT; Coutinho, ZM; Gottmann, U; Gutermann, K; Hoeger, S; Hui, S; Liu, Z; Ruf, T; Schnuelle, P; van der Woude, FJ; Yard, BA | 1 |
| Méndez-Sánchez, N; Uribe, M; Zamora-Valdés, D | 1 |
| Betteridge, DJ; Colhoun, H; Durrington, PN; Fuller, J; Hitman, GA; Livingstone, S; Neil, HA; Newman, C; Szarek, M | 1 |
| Barter, P; Bittner, V; Fruchart, JC; Gotto, AM; Grundy, SM; Kastelein, JJ; LaRosa, JC; Maroni, J; Szarek, M | 1 |
| Hsu, M; Morioka, I; Muchova, L; Schröder, H; Stevenson, DK; Vitek, L; Wong, RJ; Zelenka, J | 1 |
| Bax, WH; Jukema, JW; Schutte-Bart, C; Trion, A; van der Laarse, A | 1 |
| Poli, A | 1 |
| Rubba, P | 1 |
| Arca, M; Gaspardone, A | 2 |
| Arca, M | 2 |
| Nisanci, Y; Oflaz, H; Pamukcu, B; Tirnaksiz, E | 1 |
| Betteridge, DJ; Gibson, JM; Sager, PT | 1 |
| Ali, F; Boyle, JJ; Hamdulay, SS; Haskard, DO; Kinderlerer, AR; Lidington, EA; Mason, JC; Randi, AM; Soares, MP; Yamaguchi, T | 1 |
| Michałek, A | 1 |
| Chang, KS; Choi, DH; Choi, JS; Han, HK; Hong, SP | 1 |
| Cieslik, G; Fedak, D; Galicka-Latala, D; Konduracka, E; Naskalski, J; Piwowarska, W; Rostoff, P; Sieradzki, J | 1 |
| Bittner, V; Breazna, A; Deedwania, P; Dobson, S; Kastelein, JJ; Shepherd, J; Wenger, NK; Wilson, DJ; Zuckerman, A | 2 |
| Campese, VM; Park, J | 1 |
| Fanburg, BL; Finlay, GA; Kwiatkowski, DJ; Liu, Y; Malhowski, AJ; Toksoz, D | 1 |
| Antonini, R; Antonini, TM; Arca, M; Fraioli, A; Letizia, C; Luigi, P; Maddaloni, M; Mastrantoni, M; Montali, A; Pigna, G | 1 |
| Chapman, MJ; Duchene, E; Guerin, M; Julia, Z; Le Goff, W; Nguyen, T; Shear, CL; Thuren, T | 1 |
| Amarenco, P | 1 |
| Inazu, A; Katsuda, S; Kawashiri, MA; Kobayashi, J; Koizumi, J; Mabuchi, H; Mori, M; Nohara, A; Tada, H; Tsuchida, M; Yamagishi, M | 1 |
| Arnaboldi, L; Corsini, A; Guzzetta, M; Paoletti, R; Pazzucconi, F; Radaelli, G; Sirtori, CR | 1 |
| Li, RT; Liu, TB; Shang, DY; Zhang, Y; Zhu, GY; Zhu, XL | 1 |
| Bhasin, B; Malhotra, S; Pandhi, P; Pattanaik, S; Shafiq, N; Singh, M; Venkateshan, SP | 1 |
| Hostalek, U; Kassner, U; Steinhagen-Thiessen, E; Vogt, A | 1 |
| Cox, ER; Henderson, R; Kulkarni, A | 1 |
| Hanson, ML; Kelly, SE; Richards, SM | 1 |
| Angermann, CE; Bauersachs, J; Ertl, G; Fidler, F; Frantz, S; Hoyer, C; Kung, M; Störk, S; Waller, C; Weidemann, F | 1 |
| Chu, K; Han, Z; Hong, NH; Im, WS; Jung, KH; Kang, L; Kim, M; Kim, MW; Lee, ST; Park, JE | 1 |
| Date, AA; Nagarsenker, MS | 1 |
| Dogan-Topal, B; Ozkan, SA; Uslu, B | 1 |
| Högberg, J; Mistafa, O; Stenius, U | 1 |
| Anyakoha, NG; Barry, CE; Clarke, RM; Deighan, BF; Lynch, MA; Lyons, A; Nicolaou, A; O'Connell, F | 1 |
| Barter, PJ; Brewer, B; Buhr, KA; Caulfield, M; Eriksson, M; Fisher, MR; Grundy, SM; Kastelein, JJ; Komajda, M; Lopez-Sendon, J; Mosca, L; Revkin, JH; Shear, CL; Tall, AR; Tardif, JC; Waters, DD | 1 |
| Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Schwartz, GG; Szarek, M; Waters, DD | 1 |
| Blasetto, J; Gandhi, S; Harley, CR; Heien, H; Nelson, SP; Sasane, R | 1 |
| Chin, H; Denu-Ciocca, C; Dornbrook-Lavender, KA; Hogan, SL; Joy, MS | 1 |
| Horwich, TB; MacLellan, WR | 1 |
| di Sciascio, G | 1 |
| Hu, ZJ; Liu, DL; Wang, MP; Wu, G; Wu, J; Xu, GY | 1 |
| Argenti, A; Berkowitz, JD; Burnham, BS; Dalglish, GA; Evans, MA; Getzel, A; Glersaye, J; Gupton, JT; Holub, JM; Krumpe, K; Lam, KS; Lukens, JR; McCranor, BJ; Miller, RB; Miott, U; O'Toole-Colin, K; Rifat, S; Smith, DC; Taylor, BM; Wilson, DL | 1 |
| Manavalan, R; Muralidharan, C; Sivakumar, T; Valliappan, K | 1 |
| Macreadie, IG; Westermeyer, C; Wikhe, K | 1 |
| Barrett, PH; Chan, DC; Hegele, RA; van Bockxmeer, FM; Wang, J; Watts, GF | 1 |
| Alborn, WE; Cao, G; Careskey, HE; Davis, RA; Konrad, RJ; Troutt, JS | 1 |
| Barrett, PH; Brousseau, ME; Cohn, JS; Diffenderfer, MR; Digenio, AG; Dolnikowski, GG; Mancuso, JP; Millar, JS; Nartsupha, C; Rader, DJ; Schaefer, EJ; Schaefer, PM; Welty, FK; Wilson, A; Wolfe, ML | 1 |
| Azuma, A; Matsubara, H; Sasaki, S; Sawada, T; Yamada, T | 1 |
| Hirata, MH; Hirata, RD; Rodrigues, AC | 1 |
| Cannon, CP; Kumar, A | 1 |
| Brunetti, ND; Casavecchia, GP; De Gennaro, L; Di Biase, M; Distaso, C; Maulucci, G; Pellegrino, PL | 1 |
| Lyseng-Williamson, KA; Plosker, GL | 1 |
| Dykstra, G; Gillen, D; Harvey, P; Herfert, O; Jukema, JW; Preston, RA; Sun, F | 1 |
| Hassan, MK; Heeba, G; Khalifa, M; Malinski, T | 1 |
| Midgley, L; O'Regan, DJ; Porter, KE; Turner, NA | 1 |
| Eggen, AE; Engeland, A; Furu, K; Hartz, I; Njølstad, I; Sakshaug, S; Skurtveit, S | 1 |
| Hu, Y; Hu, Z; Li, D; Yang, K | 1 |
| Bauersachs, J; Brandt, M; Closs, E; Daiber, A; Ertl, G; Förstermann, U; Münzel, T; Oelze, M; Thum, T; Wenzel, P; Xu, J; Zou, MH | 1 |
| Bielinska, A; Gluszko, P | 1 |
| Chen, J; Chopp, M; Cui, X; Li, A; Lu, M; Roberts, C; Zacharek, A | 1 |
| Cangemi, R; Carnevale, R; Loffredo, L; Patrizi, MP; Perri, L; Pignatelli, P; Sanguigni, V; Violi, F | 1 |
| Bech, JN; Holm, C; Paulsen, L; Pedersen, EB; Starklint, J | 1 |
| Ghattas, AE; Pimenta, J | 1 |
| Paraskevas, KI | 1 |
| Chen, HJ; Chen, JZ; Chen, TG; Wang, LH; Yao, L; Yu, M | 1 |
| Taldone, T; Talele, TT; Zito, SW | 1 |
| Han, YL; Kang, J; Li, CY; Li, Y; Yan, CH | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, M; Sillesen, H; Szarek, M; Welch, KM; Zivin, JA | 1 |
| Budoff, MJ; Gao, YL; Kessler, P; Mao, SS; Moustafa, M; Qunibi, W | 1 |
| Braunwald, E; Buros, J; Cannon, CP; Croce, K; Gao, H; Healy, AM; Libby, P; McCabe, CH; Morrow, DA; Pradhan, AD; Sabatine, MS; Sakuma, M; Simon, DI; Wang, Y | 1 |
| Favre, G; Leveque, K; Sarrabayrouse, G; Synaeve, C; Tilkin-Mariamé, AF | 1 |
| Day, CA; Funovics, P; Heeba, G; Jacob, RF; Kubant, R; Malinski, T; Mason, RP; Medlin, YS | 1 |
| Kohno, K; Murata, Y; Sasaguri, Y; Tanimoto, A; Tsutsui, M; Wang, KY | 1 |
| Chen, M; Liu, B; Ou, ST; Peng, HX; Zhang, C | 1 |
| Davidson, MH; Fox, KM; Gandhi, SK; Ohsfeldt, RL | 1 |
| Askew, V; Auerbach, B; Dillon, L; Hanselman, JC; Kennedy, RM; Kowala, MC; Larsen, SD; Lin, Z; Lu, GH; Miller, S; Park, WK; Robertson, A; Roth, BD; Sekerke, C; Song, Y; Steinbaugh, BA; Sun, K; Tait, BD; Trivedi, BK | 1 |
| Conover, CA; Harrington, SC; Henry, TD; MacDonald, H; Miedema, MD; Oberg, D; Schwartz, RS; Wilson, D | 1 |
| Ahn, TH; Cha, KS; Choi, SW; Chung, N; Han, SW; Ho Yun, K; Hyon, MS; Kim, CJ; Kim, DI; Kim, HS; Kim, WH; Kwan, J; Lee, SH; Park, SH; Seo, HS; Shim, WJ; Shin, DG; Shin, YW; Yoon, MH | 1 |
| Amrani, M; Ilsley, C; Osman, L; Smolenski, RT; Yacoub, MH | 1 |
| Chen, MH; D'Amico, AV; Kantoff, PW | 1 |
| Brännström, M; Bucht, S; Crougneau, V; Dimeny, E; Ekspong, A; Eriksson, M; Granroth, B; Gröntoft, KC; Hadimeri, H; Holmberg, B; Ingman, B; Isaksson, B; Johansson, G; Lindberger, K; Lundberg, L; Mikaelsson, L; Olausson, E; Persson, B; Stegmayr, BG; Stenlund, H; Wikdahl, AM | 1 |
| Gajski, G; Garaj-Vrhovac, V | 1 |
| Baskurt, M; Cakar, MA; Coskun, U; Guzelsoy, D; Okcun, B; Yildiz, A | 1 |
| Auteri, A; Capati, E; Puccetti, L | 1 |
| Li, ZM; Ma, JF; Wang, LN | 1 |
| Lin, Y; Reddy, BS; Xiao, H; Yang, CS; Zhang, Q | 1 |
| Acampa, M; Auteri, A; Bruni, F; Ciani, F; Palazzuoli, A; Pasqui, AL; Pastorelli, M; Puccetti, L | 1 |
| Bruschi, P; Ferdinand, KC; Flack, JM; Jamieson, MJ; Saunders, E; Shi, H; Tarasenko, L; Victor, R; Watson, K | 1 |
| Bright, J | 1 |
| Dal Pan, G; McAdams, M; Staffa, J | 1 |
| Bała, A; Broncel, M; Chojnowska-Jezierska, J; Duchnowicz, P; Koter-Michalak, M; Wojsznis, W | 1 |
| Beevers, G; Caulfield, M; Collins, R; Dahlof, B; Kjeldsen, SE; Kristinsson, A; McInnes, G; Mehlsen, J; Nieminen, MS; O'Brien, ET; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Boodhwani, M; Clements, RT; Feng, J; Mieno, S; Sellke, FW; Sodha, NR; Xu, SH | 1 |
| Antoniades, C; Bosinakou, E; Katsi, V; Latsios, G; Marinou, K; Papageorgiou, N; Stefanadi, E; Stefanadis, C; Tousoulis, D; Triantafyllou, G; Tsioufis, C; Vavuranakis, E | 1 |
| Bergeron, J; Couture, P; Deshaies, Y; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ | 1 |
| Choi, DH; Choi, JS; Shin, WG | 1 |
| Ankola, DD; Chandraiah, G; Kumar, MN; Meena, AK; Rao, PR; Ratnam, DV | 1 |
| Lee, YT; Ro, YM; Sim, KH; Sriratanasathavorn, C; Tomlinson, B; Zhu, JR | 1 |
| Shaley, FM | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, J | 1 |
| Adamidou, A; Giannopoulos, S; Hatzitolios, AI; Kosmidou, MS; Milionis, HJ; Parharidis, G; Raikos, N | 1 |
| Kanagarajan, N; Murthy, S; Nam, JH; Noah, ZA | 1 |
| Kaminnyi, AI; Kapel'ko, VI; Konovalova, GG; Lakomkin, VL; Lankin, VZ | 1 |
| Hirooka, Y; Kishi, T; Shimokawa, H; Sunagawa, K; Takeshita, A | 1 |
| Garner, J; Gould, KL; McLain, R; Sdringola, S; Zamarka, LG | 1 |
| Blazing, M; Cannon, CP; Gersh, B; McLean, DS; Ravid, S; Shui, A | 1 |
| Behlouli, H; Eisenberg, MJ; Humphries, K; Pilote, L; Rinfret, S; Tu, JV | 1 |
| Bestehorn, HP; Büttner, HJ; Frundi, D; Hochholzer, W; Neumann, FJ; Stratz, C; Trenk, D; Valina, CM | 1 |
| Amann-Vesti, B; Brockes, C; Koppensteiner, R; Kovacevic, T; Rousson, V; Simon, R; Spring, S; van der Loo, B | 1 |
| Caulin-Glaser, T; Falko, JM; Meis, SB; Moser, RJ | 1 |
| Braunwald, E; Cannon, CP; Catanese, JJ; Devlin, JJ; Iakoubova, OA; Kirchgessner, TG; Ranade, K; Rowland, CM; Sabatine, MS; Simonsen, KL; Tong, CH | 1 |
| Hashimoto, T; Inayama, Y; Iwatsubo, K; Kihara, M; Kokuho, T; Kuji, T; Oshikawa, J; Tamura, K; Tanaka, K; Toya, Y; Umemura, S; Yabana, M; Yanagi, M; Yoshida, S | 1 |
| Dallinga-Thie, GM; Dunselman, PH; Jukema, JW; Liem, AH; Roeters van Lennep, HW; Zwinderman, AH | 1 |
| Kotyla, PJ | 2 |
| Barbata, V; Benesch-Lee, F; Crawford, G; Reid, J; Shansky, J; Thorrez, L; Valentini, R; Vandenburgh, H | 1 |
| Chello, M; D'Ambrosio, A; Di Sciascio, G; Nusca, A; Pasceri, V; Patti, G; Vetrovec, GW | 1 |
| Ai, M; Asztalos, BF; Jones, PH; Nakajima, K; Otokozawa, S; Schaefer, EJ; Stein, E | 1 |
| Cappelleri, JC; Dubois, RW; Messerli, FH; Pinto, L; Sichrovsky, T; Tang, SS; Thakker, KM | 1 |
| Kumar, V; Shah, RP; Singh, S | 2 |
| Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ | 1 |
| Fromigué, O; Hamidouche, Z; Marie, PJ | 2 |
| Ameliushkina, VA; Kaminnyĭ, AI; Korotaeva, AA; Kucharchuk, VV; Naumov, VG; Pirkova, AA; Prokazova, NV; Samoĭlova, EV; Titov, VN | 1 |
| Kazantseva, MO; Logacheva, IV | 1 |
| Kaminnĭ, AI; Kukharchuk, VV | 1 |
| Dupliakov, DV | 1 |
| Bilbie, CL; Clarkson, PM; Gadarla, M; Kearns, AK; O'Fallon, KS; Sewright, KA; Thompson, PD; White, CM | 1 |
| De Angelis, S; De Lorenzo, A; Di Daniele, N; Di Renzo, L; Miani, N; Noce, A; Tozzo, C | 1 |
| Aikawa, E; Chen, JW; Figueiredo, JL; Libby, P; Nahrendorf, M; Panizzi, P; Sosnovik, D; Swirski, FK; Weissleder, R | 1 |
| Chen, MH; Liu, JH; Zhou, Y | 1 |
| Braunwald, E; Cannon, CP; Miller, M; Murphy, SA; Qin, J; Ray, KK | 1 |
| Chen, X; Estey, C; Moon, TW | 1 |
| Mascitelli, L; Vos, E | 1 |
| Alter, RA | 1 |
| Birnbaum, Y; Lin, Y; Merla, R; Perez-Polo, JR; Uretsky, BF; Ye, Y | 1 |
| Andrys, C; Jamborova, G; Micuda, S; Nachtigal, P; Pospechova, K; Pospisilova, N; Semecky, V; Solichova, D; Zdansky, P | 1 |
| Lewis, LS | 1 |
| Asberg, A; Gedde-Dahl, A; Hejazifar, S; Hoel, K; Skottheim, IB | 1 |
| Jesmin, S; Kato, N; Liang, YQ; Ochiai, Y | 1 |
| Chu, CH; Chuang, MJ; Lam, HC; Lee, JK; Lu, CC; Sun, CC; Wang, MC; Wei, MC | 1 |
| Gao, Y; Ge, GY; Jia, YJ; Jiang, MN; Song, LX | 1 |
| McKeage, K; Siddiqui, MA | 1 |
| Jukema, JW; Liem, AH; van de Woestijne, AP; Visseren, FL; Zwinderman, AH | 1 |
| Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, H; Mikhailidis, DP; Tziomalos, K | 1 |
| Ferjan, M; Golicnik, A; Okrajsek, R; Radovancevic, B; Schlegel, TT; Starc, V; Vrtovec, B | 1 |
| Bezerra, DG; Lacerda Andrade, LM; Mandarim-de-Lacerda, CA; Pinto da Cruz, FO | 1 |
| Tanne, JH | 1 |
| Karam, JG; Loney-Hutchinson, L; McFarlane, SI | 1 |
| Abu Said, GH; Birnbaum, Y; Hughes, MG; Lin, Y; Manickavasagam, S; McAdoo, DJ; Perez-Polo, RJ; Ye, Y | 1 |
| Fidani, L; Giannopoulos, S; Goulas, A; Hatzitolios, AI; Kosmidou, M; Mirtsou, V; Molyva, D | 1 |
| He, J; McCarter, RJ; Moudgil, A; Sgambat, K | 1 |
| Badimon, JJ; Chew, DP; Corti, R; Fallon, JT; Fayad, ZA; Fuster, V; Helft, G; Worthley, MI; Worthley, SG; Zaman, AG | 1 |
| Bacarea, A; Dobreanu, D; Dobreanu, M; Fodor, A | 1 |
| Aprigliano, I; Dudas, J; Ramadori, G; Saile, B | 1 |
| Aukrust, P; Breland, UM; Damås, JK; Fevang, B; Frøland, SS; Gullestad, L; Halvorsen, B; Oie, E; Otterdal, K; Sandberg, WJ; Smith, C; Waehre, T; Yndestad, A | 1 |
| Angelin, B; Davis, MA; Einarsson, C; Eriksson, M; Gustafsson, U; Larsson, L; Omura, S; Parini, P; Rudel, LL; Rudling, M; Sahlin, S; Tomoda, H; Wilson, M | 1 |
| Findling, O; Grandgirard, D; Greeve, I; Leib, SL; Mattle, HP; Sellner, J | 1 |
| Benner, JS; Foody, JM; Joyce, AT; Liu, LZ; Rudolph, AE | 2 |
| Gandhi, SK; Harley, CR; Heien, H; McDonough, K; Nelson, SP | 1 |
| Ballerini, C; Bellucci, A; Biagioli, T; Biamonte, F; Casamenti, F; Grossi, C; Luccarini, I; Massacesi, L; Rosi, MC | 1 |
| Balakrishnan, VK; Dussault, EB; Sibley, PK; Solomon, KR; Sverko, E | 1 |
| Arsova, V; Jurukovska-Nospal, M; Levchanska, J; Sidovska-Ivanovska, B | 1 |
| Bybee, KA; Lee, JH; O'Keefe, JH | 1 |
| Hwang, SJ; Jin, SJ; Kim, JS; Kim, MS; Neubert, RH; Park, HJ; Song, HS | 1 |
| Asakura, M; Asanuma, H; Kato, H; Kim, J; Kitakaze, M; Liao, Y; Minamino, T; Ogai, A; Takashima, S; Zhao, H | 1 |
| Caputi, AP; Catania, MA; Giustini, SE; Oteri, A; Polimeni, G; Russo, A; Travaglini, R | 1 |
| Ball, MJ; Coombes, JS; Fassett, RG; Geraghty, DP; Robertson, IK | 3 |
| Clarke, LD; Johnson, SJ; Liu, LZ; Ramsey, SD; Roberts, CS; Sullivan, SD | 1 |
| Kontoyannis, CG; Skorda, D | 1 |
| Blanco-Colio, LM; de Teresa, E; Egido, J; Farsang, C; Gaw, A; Gensini, G; Gómez-Guerrero, C; Langer, A; Leiter, LA; Martín-Ventura, JL; Masramon, X | 1 |
| Alcaino, H; Bustos, C; Castro, PF; Chiong, M; Gabrielli, LA; Garcia, L; Godoy, I; Greig, D; Lavandero, S; Mellado, R; Miranda, R; Verdejo, HE; Vukasovic, JL | 1 |
| Bolewski, A; Burchardt, P; Lipiecki, J; Plewa, R; Siminiak, T | 1 |
| Doggrell, SA | 2 |
| Brown, AP; Corot, C; Gillard, JH; Graves, MJ; Lancelot, E; Müller, K; Patterson, AJ; Skepper, JN; Tang, TY; Thompson, PW | 1 |
| Abe, Y; Furukado, S; Hori, M; Hoshi, T; Hougaku, H; Kitagawa, K; Sakaguchi, M; Yamagami, H | 1 |
| Başar, MM; Batislam, E; Doğru, MT; Ebinç, H; Güneri, M; Simşek, A; Yuvanç, E | 1 |
| de Kaste, D; de Peinder, P; Visser, T; Vredenbregt, MJ | 1 |
| Brenner, H; Hahmann, H; Hoffmann, MM; Rothenbacher, D; Vossen, CY; Wüsten, B | 1 |
| Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF | 1 |
| Andalib, S; Garjani, A; Maleki-Dizaji, N; Ziaee, M | 1 |
| Allina, J; Bach, N; Bodenheimer, H; Bodian, C; Odin, JA; Stanca, CM | 1 |
| Avisar, I; Brook, JG; Wolfovitz, E | 1 |
| Bandios, S; Fotiadis, G; Gerasimidis, T; Kadoglou, NP; Kapelouzou, A; Karayannacos, PE; Katinios, A; Kougias, P; Liapis, CD; Moumtzouoglou, A; Sailer, N; Vitta, I; Voliotis, K | 1 |
| Garwood, CL; Lepczyk, M; Peters, JT | 1 |
| Aktas, O; Bellmann-Strobl, J; Dörr, J; Haertle, M; Paul, F; Volk, HD; Waiczies, H; Waiczies, S; Wernecke, KD; Wuerfel, J; Zipp, F | 1 |
| Gawaz, M; Geisler, T; Paterok, M; Zürn, CS | 1 |
| Loscalzo, J; Pitt, B; Raichlen, JS; Ycas, J | 1 |
| Ranki, A | 1 |
| Alonso, R; Fernández de Bobadilla, J; Lázaro, P; Mata, N; Mata, P; Méndez, I | 1 |
| Hausenloy, DJ; Riksen, NP; Yellon, DM | 1 |
| Farmer, JA; Jones, PH | 1 |
| Liew, TV; Ray, KK | 1 |
| Budoff, M; Diaz-Buxo, JA; He, DY; Kessler, PD; Moustafa, M; Muenz, LR; Qunibi, W | 1 |
| Gardiner, P; Paine, SW; Parker, AJ; Riley, RJ; Webborn, PJ | 1 |
| Ando, H; Fujimura, A; Kaneko, S; Saito, T; Sugimoto, K; Takamura, T; Tsuruoka, S; Yanagihara, H | 1 |
| Anagnostis, P; Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, C; Mikhailidis, DP; Pagourelias, E; Papageorgiou, AA; Paraskevas, KI; Tziomalos, K | 1 |
| Florkowski, CM; Frampton, CM; George, PM; Scott, RS; Sies, CW; Strey, CH; Young, JM | 1 |
| Asmar, R; Duffield, E; Faergeman, O; Hill, L; Sosef, F; Wiklund, O; Windler, E | 1 |
| Arazi, SS; Bernik, M; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Willrich, MA | 1 |
| Ballantyne, CM; Davidson, MH; Hanefeld, M; Johnson, JL; Mohler, ER; Ruilope, LM; Zalewski, A | 1 |
| Koenig, W | 1 |
| Burke, A; FitzGerald, GA; Ky, B; Rader, DJ; Szapary, PO; Tadesse, MG; Tsimikas, S; Witztum, JL; Wolfe, ML | 1 |
| Cohn, LJ | 1 |
| Cannon, CP; Giugliano, GR; Lotfi, A; Murphy, SA; Schweiger, MJ | 1 |
| Fang, ZF; Li, XP; Liu, QM; Qiu, SF; Shen, XQ; Zhang, M; Zhao, SP; Zhou, SH | 1 |
| Camm, J; De Souza, A; Jahangiri, M; Kourliouros, A; Marciniak, A; Roberts, N; Tsiouris, A; Valencia, O | 1 |
| Goldstein, MR; Mascitelli, L; Pezzetta, F | 5 |
| Feldmann, J; Jurcsik, A; Kopcsányi, H; Péch, Z | 1 |
| Pretnar-Oblak, J; Sabovic, M; Sebestjen, M | 1 |
| Ebdrup, L; Granfeldt, A; Hokland, M; Krog, J; Larsen, PØ; Tønnesen, E; Vestergaard, C | 1 |
| Breazna, A; Deedwania, PC; Kostis, JB; LaRosa, JC | 1 |
| Bonnaire, B; Bugnicourt, JM; Garcia, PY; Godefroy, O; Lefranc, M; Lepage, L | 1 |
| Dou, KF; Gao, RL; Geng, YJ; He, ZX; Huang, J; Li, JJ; Lu, MJ; Qian, HY; Shen, R; Yang, GS; Yang, YJ; Zhao, SH | 1 |
| Gratsianskii, NA; Vaulin, NA | 1 |
| de Haan, W; de Vries-van der Weij, J; Gautier, T; Havekes, LM; Jukema, JW; Princen, HM; Rensen, PC; Romijn, JA; van der Hoogt, CC; van der Hoorn, JW; Westerterp, M | 1 |
| Arnold, M; Daniel, WG; Garlichs, CD; Petzi, S; Raaz, D; Seybold, K; Stumpf, C; Wasmeier, G; Yilmaz, A | 1 |
| Gaughan, JP; Klibanov, OM; Tedaldi, EM; van den Berg-Wolf, M | 1 |
| Jaimes, EA; Raij, L; Schuman, IH; Zhou, MS | 1 |
| Mawhinney, DB; Rosario-Ortiz, FL; Snyder, SA; Vanderford, BJ | 1 |
| Bernstein, D; Chin, C; Lukito, SS; Perry, SB; Shek, J | 1 |
| Faerber, GJ; Martinez-Suarez, HJ; Wang, R | 1 |
| Birnbaum, Y; Lin, Y; Martinez, JD; Perez-Polo, RJ; Uretsky, BF; Ye, Y | 1 |
| Ichihara, K; Itagaki, M; Satoh, K; Takaguri, A; Tokumitsu, Y | 1 |
| Bujo, H; Hanaoka, H; Kodama, T; Mikami, K; Miyashita, Y; Nishikawa, T; Saito, Y; Shinomiya, M; Tada, N; Yokote, K | 1 |
| Grime, K; Riley, RJ; Webborn, PJ | 1 |
| Greeve, I; Leib, SL; Mattle, HP; Sellner, J | 1 |
| Dimitri, E; Landry, P; Légaré, N; Tessier, S | 1 |
| Barter, P; Breazna, A; DeMicco, DA; Kastelein, JJ; LaRosa, JC; Shah, SJ; Shepherd, J; Waters, DD; Wenger, NK | 1 |
| Aoki, M; Miyake, T; Morishita, R; Nishimura, M; Ogihara, T; Ohgi, S; Shiraya, S; Yoshikazu, F | 1 |
| Kruger, PS | 1 |
| Hallinen, T; Martikainen, J; Niskanen, L; Peura, P; Soini, E | 1 |
| Gajski, G; Garaj-Vrhovac, V; Orescanin, V | 1 |
| Fox, KM; Gandhi, SK; McKenney, JM; Ohsfeldt, RL | 1 |
| Kapoor, S | 1 |
| Derdak, Z; Harangi, M; Mirdamadi, HZ; Paragh, G; Seres, I; Sztanek, F | 1 |
| Cachofeiro, V; Lahera, V | 1 |
| Hwang, SJ; Jin, SJ; Kim, JS; Kim, MS; Lee, S; Park, HJ | 1 |
| Fildes, JE; Leonard, CT; Mitsidou, A; Rogacev, K; Shaw, SM; Williams, SG; Yonan, N | 1 |
| Gao, CY; Li, MW; Liang, ZT; Liao, YH; Wang, XP; Zeng, QT | 1 |
| Akalin, A; Akcar, N; Sensoy, B; Temiz, G | 1 |
| Laffan, M; Sohal, M | 1 |
| Elmendorf, JS; Horvath, EM; Tackett, L | 1 |
| Yamagishi, S | 1 |
| Brener, SJ; Hu, T; Ivanc, TB | 1 |
| Akcay, B; Doven, O; Erol, T; Gen, R; Kocum, TH; Ozcan, TI; Tekin, A | 1 |
| Engelhardt, B; Findling, O; Grandgirard, D; Greeve, I; Kamm, CP; Leib, SL; Mattle, HP; Minten, C; Sellner, J | 1 |
| Altafullah, I; Birnbaum, G; Cree, B; Reder, AT; Zinser, M | 1 |
| Fu, Q; Gao, Y; Zhang, LR | 1 |
| Duda, M; Maczewska, J; Maczewski, M | 1 |
| Fehér, G; Horváth, B; Komoly, S; Márton, Z; Szapáry, L; Tóth, K | 1 |
| Baxter, LC; Connor, DJ; Haut, MW; Johnson, SC; Lemieux, SK; Lopez, JE; Sabbagh, MH; Sampath, H; Sparks, DL; Sparks, LM | 1 |
| Kevelaitiene, S; Slapikas, R | 1 |
| Chan, KC; Chou, HH; Chou, MC; Huang, CN | 1 |
| Jia, CW; Jing, HM; Pan, M; Qin, XT; Shen, AG | 1 |
| Chaplin, A; Chrétien, M; Cousins, M; Dewpura, T; Lahaye, SA; Lahey, KA; Mayne, J; Mbikay, M; Ooi, TC; Raymond, A | 1 |
| Xiao, H; Yang, CS | 1 |
| Chaikin, P; Dvorchik, B; Mori, A; Rao, N; Sussman, N; Uchimura, T; Wang, H; Yamamoto, K | 1 |
| Braathen, P; Molden, E; Skovlund, E | 1 |
| Barrett, PH; Chan, DC; Ji, J; Johnson, AG; Ooi, EM; Watts, GF | 1 |
| Blanco-Colio, LM; Egido, J; Gómez-Hernández, A; Jiménez-Nacher, JJ; López-Bescos, L; Martín-Ventura, JL; Ortego, M; Sánchez-Galán, E; Tarín-Vicente, N; Tuñón, J | 1 |
| Greeve, I; Mattle, HP; Sellner, J | 1 |
| Graham, KL; Higgins, JP; Ho, PP; Lee, LY; Steinman, L; Utz, PJ | 1 |
| Caselli, S; Celotto, A; Cohen, A; De Castro, S; Di Angelantonio, E; Fiorelli, M; Marcantonio, A; Pandian, N; Papetti, F; Passaseo, I | 1 |
| Adánez, G; Ayala, I; Castells, MT; García Pérez, B; Martín Castillo, A; Montes, A; Sánchez-Polo, MT | 1 |
| Chae, A; Choi, SH; DeMaria, AN; Messig, M; Miller, E; Nissen, SE; Ntanios, F; Tsimikas, S; Witztum, JL | 1 |
| Lee, JK; Singh, AK; Singh, I; Won, JS | 1 |
| Kadav, AA; Vora, DN | 1 |
| Chiang, FT; Hwang, JJ; Lai, LP; Lin, JL; Tsai, CT; Wang, YC | 1 |
| Chandra, N; Mateen, AA; Naidu, MU; Raju, YS; Usharani, P | 1 |
| Chan, MY; Heng, CK; Zhao, Y; Zhou, S | 1 |
| Deedwania, P; Singh, V | 2 |
| Berbée, M; Boerma, M; Fink, LM; Fu, Q; Hauer-Jensen, M; Qiu, X; Wang, J | 1 |
| Hirano, T; Ito, Y; Michishita, I; Nozue, T | 1 |
| Kasyanova, O; Shpektor, A; Vasilieva, E | 1 |
| Lóopez-Marure, R; Massó, FA; Montaño, LF; Páez, A; Rodríguez, E; Sánchez, CA; Varela, E; Zapata, E | 1 |
| Gokkaya, SC; Guzel, O; Hakan Koyuncu, H; Levent Ozdal, O; Memis, A; Ozden, C | 1 |
| Nambi, V; Polsani, VR; Virani, SS | 1 |
| George, M; Joseph, L; Rao B, VR | 1 |
| Amarenco, P; Callahan, A; Gilbert, S; Goldstein, LB; Hennerici, M; Lamonte, M; Messig, M; Sillesen, H; Welch, KM | 1 |
| Acar, G; Nacar, AB; Sökmen, G; Tuncer, C | 1 |
| Derdemezis, C; Elisaf, M; Filippatos, T; Mikhailidis, D; Tselepis, A | 1 |
| Dhaliwal, S; Galloway, S; Jian, L; Johnsen, R; Mamo, JC; Pallebage-Gamarallage, MM | 1 |
| Breazna, A; Doody, R; Feldman, H; Hey-Hadavi, J; Jones, RW; Kivipelto, M; Ramos, H; Schindler, RJ; Sparks, L; Waters, DD | 1 |
| Sabbagh, MN | 1 |
| Carvajal-González, G; Egido, J; Mezzano, S; Ortiz, A; Rodrigues Díez, R; Rodrigues-Díez, R; Rodríguez-Vita, J; Ruiz-Ortega, M; Sánchez-López, E; Selgas, R | 1 |
| Albalat-Galera, R; Berzosa-Sanchez, M; Ferrer-García, JC; Herrera-Ballester, A; Sanchez-Ballester, E | 1 |
| Badyal, DK; Chopra, S; Gupta, A; Jaison, TM; Khosla, PP; Uppal, B | 1 |
| Devaraj, S; Jialal, I; Siegel, D; Singh, U | 1 |
| Ageta, M; Biro, S; Ikeda, Y; Kajiwara, K; Kobori, S; Kono, S; Kuribayashi, T; Otonari, T; Saikawa, T; Sasaki, J; Yamamoto, K | 1 |
| Agnew-Blais, J; Cassels, A; Maclure, M; Marshall, B; Patrick, AR; Polinski, JM; Schneeweiss, S | 1 |
| Al-Khayatt, MS; Brull, DJ; Campbell, VL; O'Mahony, C | 1 |
| Ikeda, S; Koga, S; Kohno, S; Miyahara, Y; Oka, H | 1 |
| Bergheanu, SC; Bobeldijk, I; Hankemeier, T; Jukema, JW; Liem, AH; Ramaker, R; Reijmers, T; van der Greef, J; Zwinderman, AH | 1 |
| Colin, X; Lafuma, A; Solesse, A | 1 |
| Ford, JS; Tayek, JA | 1 |
| Kim, JH; Kim, JS; Kim, WS; Lee, SH; Lee, YT; On, YK; Shin, DH; Song, YB; Sung, J | 1 |
| Srinivas, NR | 3 |
| Bellesi, S; Biasucci, LM; Brugaletta, S; Crea, F; Galiuto, L; Garramone, B; Giannico, MB; Leone, AM; Leone, G; Liuzzo, G; Niccoli, G; Perfetti, M; Porto, I; Rebuzzi, AG; Rutella, S; Zaccone, V | 1 |
| Todd, DJ | 1 |
| Abe, M; Fujita, M; Hasegawa, K; Kawamura, T; Kita, T; Morimoto, T; Ono, K; Satoh, N; Shimatsu, A; Takaya, T; Wada, H | 1 |
| Bybee, KA; Lavie, CJ; O'Keefe, JH | 1 |
| Bittner, VA; Breazna, A; Carmena, R; Deedwania, PC; Dobson, S; Kastelein, JP; Shepherd, J; Wenger, NK; Wilson, DJ; Zuckerman, AL | 1 |
| Jin, H; Lin, Y; Lu, G; Snagaski, B; Xiao, H; Yang, CS; You, H | 1 |
| Alegret, M; Cofán, M; Laguna, JC; Llaverias, G; Pou, J; Ros, E; Sánchez, A; Sánchez, RM; Vázquez-Carrera, M; Zambón, D | 1 |
| Acharjee, S; Welty, FK | 1 |
| Bucci, A; Di Giacomo, S; Fraone, N; Mazza, F; Mazzarella, B; Stefanutti, C; Vivenzio, A | 1 |
| Jaggi, AS; Koladiya, RU; Sharma, BK; Singh, N | 1 |
| Beamer, B; Costa-Scharplatz, M; Frial, T; Gandhi, S; Ramanathan, K | 1 |
| Chen, XM; Field, MJ; Kelly, DJ; Mangiafico, S; Mather, A; McGinn, S; Pollock, CA; Sumual, S; Zhang, Y | 1 |
| Berker, B; Cengiz, SD; Cesur, M; Demirtaş, S; Erdoğan, G; Kaya, C | 1 |
| Lindsley, CW | 2 |
| Critchfield, J; Deeks, SG; Lee, E; Lollo, N; Price, RW; Probasco, JC; Spudich, SS | 1 |
| Czechowska, M; Goracy, J; Kaliszczak, R; Kaźmierczak, J; Kornacewicz-Jach, Z; Lewandowski, M; Millo, B; Naruszewicz, M; Płońska, E; Zielonka, J | 1 |
| Ballantyne, CM; Cain, VA; Raichlen, JS | 1 |
| Martin, J | 1 |
| Abou-Raya, A; Abou-Raya, S; Helmii, M | 1 |
| Birnbaum, Y; Lin, Y; Perez-Polo, JR; Tieu, BC; Uretsky, BF; Ye, Y; Ye, Z | 1 |
| Cawley, PJ; Otto, CM | 1 |
| Bae, SK; Kim, KB; Liu, KH; Moon, BS; Park, JE; Shin, JG | 1 |
| Banerjee, S; Blazing, MA; Braunwald, E; Brilakis, ES; Califf, RM; Cannon, CP; de Lemos, JA; Morrow, DA; Murphy, SA; Sabatine, MS; Wiviott, SD | 1 |
| Climent, VE; Lip, GY; López-Cuenca, A; Marín, F; Roldán, V; Valdés, M | 1 |
| Feng, M; Li, L; Meng, X; Qie, L; Wang, Y; Zhong, M | 1 |
| Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W | 1 |
| Elsais, A; Kerty, E; Lund, C | 1 |
| Arazi, SS; Bernik, MM; Bertolami, MC; Dorea, EL; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Rebecchi, IM; Rodrigues, AC; Willrich, MA | 1 |
| Fujii, N; Igarashi, N; Inoue, H; Matsuki, A; Nozawa, T; Sobajima, M; Suzuki, T | 1 |
| Bérard, A; Blais, L; Dragomir, A; Lalonde, L; Perreault, S; White, M | 1 |
| Gutiérrez, C; López, P; Suárez, A | 1 |
| Chaudhuri, R; Donnelly, I; Hothersall, EJ; Lafferty, J; McInnes, I; McMahon, AD; McSharry, C; Meiklejohn, J; Sattar, N; Thomson, NC; Weir, CJ; Wood, S | 1 |
| Vogel, RA; Willke, RJ; Zhou, S | 1 |
| Mehlsen, J | 1 |
| Kumar, S; Liang, SL; Liu, H; Liu, W; Weyman, CM; Zhou, A | 1 |
| Kim, YH; Kim, YJ; Lee, SH; Yoon, BW | 1 |
| Amarenco, P; Breazna, A; Callahan, A; Chaturvedi, S; Goldstein, LB; Hennerici, M; Rudolph, A; Sillesen, H; Welch, MA; Zivin, J | 1 |
| Beitelshees, AL; Chegini, N; Cresci, S; Hou, W; Province, MA; Spertus, JA; Welder, GJ; Wu, J; Zineh, I | 1 |
| Avello L, M; Bravo D, M; Calvo M, C; Mennickent C, S | 1 |
| Buss, S; Filusch, A; Hansen, A; Hardt, S; Katus, HA; Kuecherer, HF | 1 |
| Braunwald, E; Cannon, CP; Giraldez, RR; Giugliano, RP; McCabe, CH; Mohanavelu, S; Murphy, SA | 1 |
| Alber, HF; Bartel, T; Dichtl, W; Feuchtner, GM; Grander, W; Hintringer, F; Müller, S; Pachinger, O; Reinthaler, M; Süssenbacher, A; Ulmer, H | 1 |
| Benner, JS; Foody, JM; Jeffers, BW; Joyce, AT; Liu, LZ | 1 |
| Auster, S; Betteridge, DJ; Colhoun, HM; Demicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Neil, HA; Newman, CB; Szarek, M | 1 |
| Baumann, M; Bierhaus, A; Bluemm, A; Dugi, KA; Heemann, U; Humpert, PM; Liu, D; Lutz, J; Nawroth, PP; Schuster, T; von Eynatten, M | 1 |
| Bienvenu, AL; Picot, S | 1 |
| Bays, HE; Buttler, SM; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Bizot, MN; Camenisch, G; Dieterich, HA; Dole, WP; Howard, D; Reynolds, C; Schuetz, H; Vaidyanathan, S; Yeh, CM | 1 |
| Beskonakl i, E; Bodur, E; Eroglu, H; Gurcan, O; Okutan, O; Oner, L; Sargon, MF; Turkoglu, OF | 1 |
| Fitchett, DH; Goodman, SG; Langer, A | 1 |
| Benjanuwatra, T; Boonbaichaiyapruck, S; Buakhamsri, A; Cheepudomwit, S; Moleelerkpoom, W; Panjavenin, P; Sukanandachai, B; Suthichaiyakul, T | 1 |
| Bothwell, AL; Colangelo, CM; Cuchara, LA; Lorber, MI; Pober, JS; Rao, DA; Tang, PC; Tellides, G; Wang, Y; Yi, T | 1 |
| Ayares, D; Cooper, DK; Ezzelarab, M; Hara, H; Long, C; Torres, C; Welchons, D; Yeh, P | 1 |
| Akgullu, C; Aydinlar, A; Kazazoglu, AR; Ozdemir, B; Yilmaz, Y | 1 |
| Daubresse, JC; Herregods, MC; Lamotte, M; Michel, G; Vandenhoven, G; Vissers, E | 1 |
| Bari, AU; Hashim, R; Hussain, M; Rahman, SB | 1 |
| Ginsberg, HN; Ramakrishnan, R | 1 |
| Aguilar-Salinas, CA; Chaves, H; Chopra, P; Erdine, S; Guindy, R; Howes, LG; Moller, RA; Ro, YM; Schou, IM; Tse, HF | 1 |
| Carmena, R; Chu, P; Drummond, M; Graff, J; Greten, H; Pandya, A; Shepherd, J; Taylor, DC; Thompson, D; Weinstein, MC; Wenger, N | 1 |
| Momohara, C; Nonomura, N; Okuyama, A; Tsujihata, M; Tsujimura, A; Yoshioka, I | 1 |
| Kékes, E | 1 |
| Bredberg, A; Grip, O; Janciauskiene, S | 1 |
| Gamie, Z; Graham, S; Linder, T; Tang, QO; Tran, GT; Tsialogiannis, E; Tsiridis, E | 1 |
| Boccara, F; Hatem, S | 1 |
| Alonso, J; Crean, P; Danchin, N; Farah, M; Farnier, M; Lablanche, JM; Leone, A; Licour, M; Morais, J; Santini, M; Tardif, JC; Tedgui, A; Vicaut, E | 1 |
| Chen, GP; Hu, SJ; Li, L; Lu, X; Yao, L | 1 |
| Chen, XJ; Dong, J; Sun, YB; Wang, GJ; Wang, L; Yu, X | 1 |
| Alena, T; Brcakova, E; Cibicek, N; Cibickova, L; Daniel, J; Eva, B; Helena, Z; Hyspler, R; Jun, D; Micuda, S; Norbert, C; Palicka, V; Radomir, H; Stanislav, M; Ticha, A; Vladimir, P; Zivna, H | 1 |
| Drechsler, C; Krane, V; Lilienthal, J; März, W; Wanner, C; Winkler, K | 2 |
| Godwinkumar, S; Muralidharan, S; Nagarajan, M; Nirmal, J; Peddanna, C; Saisivam, S | 1 |
| Barrios, V; Echarri, R; Escobar, C | 1 |
| Foody, JM; Honda, D; Leslie, RS; Nichol, MB; Patel, BV; Solomon, H; Tang, SS; Thiebaud, P | 1 |
| Bartolozzi, A; Boerma, M; Ellis, JL; Fink, LM; Fu, Q; Hauer-Jensen, M; Loose, DS; McGonigle, S; Paradise, E; Sweetnam, P; Vozenin-Brotons, MC; Wang, J | 1 |
| Berg, RL; Krauss, RM; Linneman, JG; McCarty, CA; Wilke, RA; Zhao, C | 1 |
| Chen, GP; Hu, SJ; Lu, X; Mou, Y; Yao, L; Zheng, LR | 1 |
| Agarwal, S; Baruch, L; Eng, C; Gupta, B; Lieberman-Blum, SS | 1 |
| Devlin, J; Haroon, M | 1 |
| Burke, JP; Dhonnchu, TN; Maher, BM; Soo, A; Watson, RW; Wood, AE | 1 |
| de Teresa, E; Farsang, C; Gaw, A; Gensini, G; Langer, A; Leiter, LA; Martineau, P | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; Messig, M; Sillesen, H; Welch, KM; Zivin, J | 1 |
| Chen, X; Liu, C; Peng, W; Qi, B; Wan, J; Yang, Q | 1 |
| Ando, H; Araki, N; Enosawa, S; Fujimura, A; Hasegawa, G; Nagai, H; Omasa, T; Tsuruoka, S; Wang, N; Yanagihara, H | 1 |
| Alon, US; Haney, CJ; Srivastava, T | 1 |
| Campistol Plana, JM | 1 |
| Arazi, SS; Avanzo, JL; Bernik, MM; Bertolami, MC; Dagli, ML; Dorea, EL; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Rebecchi, IM; Rodrigues, AC; Soares, SA; Willrich, MA | 1 |
| Assmann, G; Breithardt, G; Nofer, JR; Schubert, A; Schulte, H; Stypmann, J; Welp, H | 1 |
| Coimbra, SR; Crisostomo, LM; Favarato, D; Luz, PL; Mendes, CM; Souza, CA | 1 |
| Anstrom, KJ; Cowper, PA; Davidson-Ray, L; Knight, JD; Mark, DB | 1 |
| Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Moedas, AR; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R | 1 |
| Mullangi, R; Srinivas, NR | 1 |
| Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T | 2 |
| Dobson, R | 1 |
| Bartoletti, R; Cai, T; Mazzoli, S; Mondaini, N | 1 |
| Freedland, SJ; Goldberg, KC; Hamilton, RJ; Platz, EA | 1 |
| Forst, T; Fuchs, W; Hanefeld, M; Konrad, T; Lehmann, U; Müller, J; Pfützner, A; Schaper, F; Weber, M; Wilhelm, B | 1 |
| Atkin, SL; Kilpatrick, ES; Sathyapalan, T | 4 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; O'Neill, BJ; Rudolph, AE; Sillesen, H; Simunovic, L; Welch, KM; Zivin, JA | 1 |
| Martinez, DG | 1 |
| Acimovic, J; Bernhardt, R; Kóbori, L; Kocjan, D; Köhalmy, K; Kuzman, D; Monostory, K; Pascussi, JM; Rozman, D; Szabó, P; Temesvári, M; Wilzewski, B | 1 |
| Betteridge, DJ; Charlton-Menys, V; Colhoun, H; DeMicco, DA; Durrington, PN; France, M; Fuller, J; Hitman, GA; Livingstone, SJ; Neil, HA; Newman, CB; Szarek, M | 2 |
| von Haehling, S | 1 |
| Chiang, CK; Hsu, SP; Huang, JW; Hung, KY; Pai, MF; Peng, YS; Wu, KD; Yang, SY | 1 |
| de Barros e Silva, MJ; de Paiva, TF; Fanelli, MF; Gimenes, DL; Rinck, JA | 1 |
| Balasubramanian, R; Baliga, VP; Bolmall, C; Kathale, A; Nagraj, LM; Nayak, UP; Periyandavar, I; Sharma, A; Varadharajan, S | 1 |
| Kadonosono, K; Takano, T; Tanaka, S; Terauchi, Y; Yamakawa, T | 1 |
| Calvo, L; Cenarro, A; Civeira, F; García-Otín, AL; Gómez-Coronado, D; Martín-Fuentes, P | 1 |
| Iesce, MI; Lhiaubet-Vallet, V; Miranda, MA; Montanaro, S; Previtera, L | 1 |
| Calza, L; Chiodo, F; Colangeli, V; Manfredi, R; Pavoni, M; Pocaterra, D | 1 |
| Kukhrchuk, VV; Nasonov, EL; Novikova, DS; Popkova, TV; Tutunov, VS | 1 |
| Zuber, M | 1 |
| Bittner, V; Breazna, A; DeMicco, DA; Greten, H; Grundy, SM; Johnson, C; LaRosa, JC; Waters, DD | 1 |
| Alrasadi, K; Alwaili, K; Awan, Z; Genest, J; Hafiane, A; Krimbou, L; Ruel, I | 1 |
| Abad, L; de Luis, D; Duenas-Laita, A; Gonzalez Sagredo, M; Pérez-Castrillón, JL; Sanz-Cantalapiedra, A; Vega, G | 1 |
| Basart, DC; Defesche, JC; Heeringa, J; Kastelein, JJ; Lansberg, PJ; Liem, AH; Oosterveer, DM; Sijbrands, EJ; Versmissen, J; Witteman, JC; Yazdanpanah, M | 1 |
| Farmer, A; Holman, RR; Neil, HA; Paul, S; Stratton, IM; Tucker, L | 1 |
| Di Spirito, M; Doyle, RT; Johnson, J; McKenney, J; Morelli, G | 1 |
| Castro-Beiras, A; Crespo-Leiro, MG; Flores, X; Franco, R; Grille, Z; Marzoa, R; Mosquera, V; Naya, C; Paniagua, MJ; Rodriguez, JA | 1 |
| Arihiro, K; Chayama, K; Hyogo, H; Inoue, M; Ishitobi, T; Iwamoto, K; Nabeshima, Y; Nonaka, M; Tazuma, S | 1 |
| Arora, P; Devereaux, PJ; Mills, EJ; Perri, D; Rachlis, B; Wu, P | 1 |
| Abad, L; De Luis, D; Duenas-Laita, A; Pérez-Castrillón, JL; Sagredo, MG; Sanz-Cantalapiedra, A; Vega, G | 1 |
| Annapurna, A; Reddy, YN; Srinivas, M | 1 |
| Korber, KE | 1 |
| Goodsaid, FM | 1 |
| Brandt, JT; Ernest, CS; Farid, NA; Jakubowski, JA; Konkoy, CS; Li, YG; Payne, CD; Salazar, DE; Small, DS; Winters, KJ | 1 |
| Bays, HE; Bird, SR; Conard, SE; Leiter, LA; Lowe, RS; Rubino, J; Tershakovec, AM; Tomassini, JE | 1 |
| Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Rubino, J; Tershakovec, AM; Tomassini, JE | 1 |
| Pedersen, TR | 1 |
| Brennan, DM; Nicholls, SJ; Nissen, SE; Tardif, JC; Tuzcu, EM | 1 |
| Basart, DC; Bots, ML; Evans, GW; Grobbee, DE; Kastelein, JJ; Sijbrands, EJ; Stalenhoef, AF; Stroes, ES; van Leuven, SI; Vergeer, M; Visseren, FL | 1 |
| Blanco-Colio, LM; Egido, J; Madrigal-Matute, J; Martín-Conejero, A; Martín-Ventura, JL; Muñoz-Garcia, B; Ortega, L; Serrano, J; Vega, M | 1 |
| Freir, NM; Jones, M; Kruger, PS; Roberts, MS; Robertson, TA; Venkatesh, B | 1 |
| Amudha, K; Choy, AM; Lang, CC; Mustafa, MR | 1 |
| Catalano, G; Chapman, MJ; Fournier, N; Frisdal, E; Guerin, M; Julia, Z; Le Goff, W; Vedie, B | 1 |
| Cui, W; Liu, F; Lu, JC; Pei, WN; Xie, RQ; Yang, C | 1 |
| Ai, M; Jones, PH; Matthan, NR; Otokozawa, S; Resteghini, NA; Schaefer, EJ; Stein, EA; van Himbergen, TM | 1 |
| Saegusa, Y; Shiragami, M; Takahashi, T; Takimoto, Y | 1 |
| Cziraky, M; Grochulski, D; Hoy, T; Jacobson, TA; Kuznik, A; Wertz, DA | 1 |
| Cheng, CC; Cheng, SM; Ho, LJ; Lai, JH; Liou, JT; Tsao, TP; Yang, SP | 1 |
| Bech, JN; Holst, LM; Paulsen, L; Pedersen, EB; Starklint, J | 1 |
| Bantly, A; Hamamdzic, D; Mohler, ER; Moore, J; Parmacek, M; Putt, M; Rader, DJ; Shi, Y; Wilensky, RL; Yoder, M; Zhang, L | 1 |
| Barroso, E; Coll, T; Laguna, JC; Merlos, M; Palomer, X; Rodríguez-Calvo, R; Sánchez, RM; Serrano, L; Vázquez-Carrera, M | 1 |
| Abraldes, JG; Arroyo, V; Bataller, R; Colmenero, J; Dominguez, M; Egido, J; Ginès, P; Moreno, M; Ramalho, F; Ramalho, LN; Ruiz-Ortega, M; Sancho-Bru, P | 1 |
| Cohn, JN; Grimm, R; Houston, M; Neutel, J; Smith, DH; Sun, W; Weinberger, MH; Wilson, DJ | 1 |
| Fukumoto, Y; Rashid, M; Seto, M; Shimokawa, H; Tawara, S; Yano, K | 1 |
| Kurabayashi, M; Yamazaki, T | 1 |
| Mazurek, S; Szostak, R | 1 |
| Smith, M; Sullivan, D; Wlodarczyk, J | 1 |
| Chiong, M; Lavandero, S; Llancaqueo, M; Noriega, V; Pennanen, C; Prieto, JC; Sánchez, MP | 1 |
| Cermakova, E; Cibicek, N; Cibickova, L; Hyspler, R; Palicka, V; Ticha, A; Zadak, Z | 1 |
| Argyropoulou, MI; Elisaf, M; Kiortsis, DN; Tselepis, AD; Tsouli, SG; Xydis, V | 1 |
| Fujii, T; Kunita, E; Maeda, K; Sekiguchi, Y; Tasaki, N; Tsujiyama, S; Urabe, Y | 1 |
| González-Gallego, J; Mauriz, JL; Tuñón, MJ | 1 |
| Barbik-Zhagar, B; Belenkov, IuN; Mareev, VIu; Oganov, RG | 1 |
| Caínzos Romero, T; Fernández Fernández, FJ; Pía Iglesias, G; Sesma, P | 1 |
| Hoffmann, M; Nowosielski, M | 1 |
| Jiang, GH; Qu, HY; Wang, ZY; Xiao, YW; Zhang, M; Zhang, Y | 1 |
| Blanco-Colio, LM; Egido, J; Ortiz, A; Rodrigues-Díez, R; Rodríguez-Vita, J; Ruiz-Ortega, M; Sánchez-Galán, E; Sánchez-López, E; Santamaría, B | 1 |
| Itoh, T; Minami, Y; Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y | 3 |
| Hopkins, LN; Levy, EI; Samuelson, RM; Siddiqui, AH | 1 |
| Simon, HB | 1 |
| Fu, SY; Li, WM; Li, ZQ; Tang, Q; Wang, LF | 1 |
| Shen, J; Zhang, Q; Zhang, RY | 1 |
| Akar Bayram, N; Aydoğdu, S; Canbay, A; Diker, E; Durmaz, T; Kayhan, T; Keleş, T; Ozdemir, O; Sahin, D | 1 |
| Collier, D; Cruickshank, JK; Hughes, AD; Lacy, PS; Stanton, A; Thom, S; Thurston, H; Williams, B | 1 |
| Aliabadi, AZ; Dunkler, D; Grimm, M; Grömmer, M; Mahr, S; Wolner, E; Zimpfer, D; Zuckermann, AO | 1 |
| Graeff, CF; Herculano, RD; Nagassaki, S; Tanus-Santos, JE | 1 |
| Hanhart, J; Koskas, P; Le Mer, Y; Obadia, M; Paques, M; Sahel, JA | 1 |
| Cheng, S; Ge, S; Liu, D; Liu, X; Xu, G; Xu, J; Zhou, G | 1 |
| Dushkin, MI; Komarova, NI; Kuznetsova, IS; Schwartz, YSh; Vorontsova, EV | 1 |
| Channer, KS; Jones, TH; Kapoor, D; Stanworth, RD | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Morrow, DA; Ray, KK; Ridker, PM | 1 |
| Bestermann, WH; Dyess, EM; Graff, A; Kursun, A; Neutel, JM; Sutradhar, S; Yunis, C | 1 |
| Hoeger, KM | 1 |
| Habon, T; Horvath, B; Szapary, L; Toth, K | 1 |
| Chen, Z; DeFea, K; Fu, Y; Hsu, PH; Pan, S; Peng, IC; Shyy, JY; Su, MI; Sun, W; Tsai, MD; Zhu, Y | 1 |
| Alt, M; Andrès, E | 1 |
| Ehmke, H; El-Armouche, A; Eschenhagen, T; Grimm, M; Höppner, G; Schmechel, A; Schwoerer, AP | 1 |
| Sniderman, A; Solhpour, A | 1 |
| Böger, R; Eggeling, S; Meinertz, T; Munzel, T; Ostad, MA; Schwedhelm, E; Tschentscher, P; Warnholtz, A; Wenzel, P | 1 |
| Glueck, CJ; Goldenberg, N; Khan, NA; Rawal, B; Wang, P; Yeramaneni, S | 1 |
| Angermann, C; Bauersachs, J; Frantz, S; Heinrich, F; Krane, V; Lilienthal, J; Meesmann, M; Olschewski, M; Störk, S; Wanner, C | 1 |
| Cheng, G; Shi-Guang, Z; Wei, L; Xiang-Zhen, L; Zhi-Dan, S | 1 |
| Li, Y; Wang, M; Wu, Q; Xia, ZE | 1 |
| Cater, NB; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ | 1 |
| Beghi, C; Bosio, S; Corradi, D; Curulli, A; De Cicco, G; Gelsomino, S; Gerometta, P; Lorusso, R; Maestri, R; Moreo, A; Rosano, G; Russo, C; Volterrani, M | 1 |
| Bonnet, J; Davignon, J; Martineau, P; McPherson, R; Nozza, A; Simoneau, D; Tedgui, A | 1 |
| Akioka, H; Anan, F; Hara, M; Iwao, T; Nakagawa, M; Saikawa, T; Takahashi, N; Teshima, Y; Yonemochi, H; Yufu, K | 1 |
| Creager, MA; Ganz, P; Liao, JK; Liu, PY; Nohria, A; Okamoto, R; Prsic, A; Selwyn, A | 1 |
| Chavalmane, AK; Fibbi, B; Filippi, S; Forti, G; Maggi, M; Morelli, A; Sarchielli, E; Silvestrini, E; Vannelli, GB; Vignozzi, L; Zhang, XH | 1 |
| Dubertret, L; Gressier, L; Pruvost-Balland, C; Viguier, M | 1 |
| Amato, M; Arquati, M; Baldassarre, D; Brusoni, B; Camera, M; Cortellaro, M; Fiorentini, C; Montorsi, P; Porta, B; Romano, S; Tremoli, E; Veglia, F | 1 |
| Collins, RT; Hanna, B; Shaddy, RE | 1 |
| Körnicke, T; Rathgen, K; Reseski, K; Roth, W; Stähle, H; Stangier, J | 1 |
| Abel, T; Fehér, J | 1 |
| Lüscher, TF | 1 |
| Cable, EE; Chi, B; Erion, MD; Fujitaki, JM; Ito, BR; Linemeyer, DL; MacKenna, DA; Song, X; van Poelje, PD; Wilker, CE; Zhang, BH | 1 |
| Bloomfield, D; Carlson, GL; Littlejohn, TW; McKenney, JM; Mitchel, Y; Pasternak, RC; Sapre, A; Sisk, CM; Tribble, D | 1 |
| Asztalos, BF; Brousseau, ME; Diffenderfer, MR; Digenio, AG; Mancuso, JP; Millar, JS; Nartsupha, C; Rader, DJ; Schaefer, EJ; Wolfe, ML | 1 |
| Agnew-Blais, J; Choudhry, NK; Parker, RM; Shekelle, P; Shrank, WH; Wolf, MS | 1 |
| Creager, MA; Donnelly, J; Ganz, P; Liao, JK; Liu, PY; Nohria, A; Rawlings, R; Selwyn, A | 1 |
| Ballantyne, CM; Bays, HE; Buttler, SM; Goldberg, AC; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Boring, D; Grubbs, CJ; Juliana, MM; Lubet, RA; Ruppert, JM; Steele, VE | 1 |
| Ai, M; Asztalos, BF; Jones, PH; Otokozawa, S; Schaefer, EJ; Stein, EA; Tanaka, A; Van Himbergen, T | 1 |
| Bahl, A; Dhawan, V; Mahajan, N | 1 |
| Almroth, H; Boman, K; Englund, A; Höglund, N; Jensen, S; Kjellman, B; Rosenqvist, M; Tornvall, P | 1 |
| Hart, RG | 1 |
| Satoh, A; Satoh, M | 1 |
| Byrne, CD; Chipperfield, AJ; Clough, GF; Gamble, J; Krentz, AJ; Turzyniecka, M; Walter, L; Wild, SH | 1 |
| Dallinga-Thie, GM; Jansen, H; Kastelein, JJ; Sijbrands, EJ; van Hoek, M; van Tol, A; van Vark-van der Zee, LC | 1 |
| Holmberg, B; Stegmayr, BG | 1 |
| Aguilar, EM; Casariego, CV; García, FA; González, AF; Miralles, Jde H; Moreno, SB | 1 |
| Davidson, MH; Fayyad, RS; Koren, MJ; Reed, DP; Wilson, DJ; Zuckerman, A | 1 |
| Blanco-Colio, LM; de Teresa, E; Dilaghi, B; Egido, J; Farsang, C; Gaw, A; Gensini, GF; Gori, AM; Langer, A; Leiter, LA; Martineau, P; Nozza, A; Rostagno, C | 1 |
| Bianco, G; Camerino, GM; Cippone, V; Conte Camerino, D; De Luca, A; Desaphy, JF; George, AL; Kunic, JD; Liantonio, A; Pierno, S; Rolland, JF | 1 |
| Anthony, FW; Curzen, NP; Hanson, MA; Hopkins, LA; Kelsall, CJ; Torrens, C | 1 |
| Hirayama, A; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O | 2 |
| Abramsky, O; Boimel, M; Grigoriadis, N; Lourbopoulos, A; Rosenmann, D; Rosenmann, H; Touloumi, O | 1 |
| Gryglewski, R; Hassan, M; Heeba, G; Khalifa, M; Malinski, T; Moselhy, ME | 1 |
| Ajith, TA; Anu, V; Riji, T | 1 |
| Glinkina, IV; Il'in, AV; Mel'nichenko, GA; Roĭtman, AP; Zilov, AV | 1 |
| Kapoor, AS; Majumdar, SR; McAlister, FA; Mohamed, R; Norris, CM; Pretorius, V; Ross, DB | 1 |
| Amarenco, P; Benavente, O; Callahan, A; Gilbert, S; Goldstein, LB; Hennerici, MG; Rudolph, AE; Sillesen, H; Simunovic, L; Welch, KM; Zivin, JA | 1 |
| Cater, NB; Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Szarek, M; Tikkanen, MJ | 3 |
| Corson, MA | 1 |
| Chang, CL; Dahlof, B; Mastorantonakis, S; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Bien, S; Greinacher, A; Grube, M; Jedlitschky, G; Kamiie, J; Kawakami, H; Kroemer, HK; Niessen, J; Ohtsuki, S; Oswald, S; Rosskopf, D; Schwertz, H; Siegmund, W; Starke, K; Strobel, U; Terasaki, T | 1 |
| Coull, BM; Johnston, SC | 1 |
| Keskitalo, JE; Kurkinen, KJ; Neuvoneni, PJ; Niemi, M | 1 |
| Backman, JT; Kalliokoski, A; Kurkinen, KJ; Neuvonen, PJ; Niemi, M | 1 |
| Antico, G; Calogero, RA; Jordan, A; Lo Iacono, M; Platanias, LC; Sassano, A; Uddin, S | 1 |
| Ayaori, M; Fayad, ZA; Kihara, T; Kusuhara, M; Momiyama, Y; Nagata, M; Nakamura, H; Nakaya, K; Ogura, M; Ohmori, R; Ohsuzu, F; Tamai, S; Tanaka, N; Taniguchi, H; Yonemura, A | 1 |
| Beach, RA; McQueen, M; Wismer, J | 1 |
| Akbay, E; Corapcioglu, D; Emral, R; Gen, R; Sezer, K | 1 |
| Blaschke, S; Guerluek, S; Klinger, HM; Müller, GA; Schwarz, G; Viereck, V | 1 |
| Chen, Y; Cheng, X; Ding, Y; Liao, M; Liao, YH; Tang, T; Wang, M; Xia, C; Xie, J; Yao, R; Yu, X | 1 |
| Davis, TM; Wong, RP | 1 |
| Erem, C; Ersoz, HO; Hacihasanoglu, AB; Karti, SS; Ukinc, K | 1 |
| Ikewaki, K; Inoue, Y; Nakada, Y; Ozasa, H; Terao, Y; Tohyama, J; Yoshimura, M | 1 |
| Clementi, F; Di Luozzo, M; Luciani, G; Mango, R; Martuscelli, E; Mehta, JL; Pizzuto, F; Romeo, F; Trivisonno, A | 1 |
| Hsia, J; Otvos, JD; Rosenson, RS | 1 |
| Horna, A; Kulichová, B; Lopéz, SA; Nováková, L; Satínský, D; Solich, P; Solichová, D | 1 |
| Chen, P; Gan, Y; Wu, S; Xing, X; Zhao, S | 1 |
| Chen, TY; Kuo, YL; Lin, WC; Tan, TY | 1 |
| Daferera, N; Goulas, A; Hatzitolios, AI; Kokkas, V; Kosmidou, M; Molyva, D; Raikos, N; Savopoulos, C | 1 |
| Li, J; Li, X; Li, ZQ; Liu, YY; Pan, W; Sun, YM; Tian, Y; Wang, LF | 1 |
| Alonso, J; Cardier, JE; Ledezma, E; Wittig, O | 1 |
| Koren, MJ; Kuznik, A; Mullins, CD; Rattinger, GB | 1 |
| Amarenco, P; Brenner, D; Gongora-Rivera, F; Jaramillo, A; Klein, IF; Labreuche, J; Lavallée, PC; Touboul, PJ; Vicaut, E | 1 |
| Hirata, K; Inoue, N; Kawashima, S; Masano, T; Nakajima, K; Nishimura, K; Sasaki, N; Satomi-Kobayashi, S; Shinohara, M; Sugiyama, D; Takaya, T; Takeda, M; Tawa, H; Toh, R; Yamashita, T; Yokoyama, M | 1 |
| Barderas, MG; Dardé, VM; De la Cuesta, F; Egido, J; Jiménez-Nácher, JJ; López-Bescós, L; Tarín, N; Tuñón, J; Vivanco, F | 1 |
| Chen, IJ; Hsieh, SL; Kwan, AL; Lin, HL; Shen, KP; Wu, BN | 1 |
| Aksakal, O; Gungor, T; Kelekci, S; Mollamahmutoglu, L; Sirvan, L; Soysal, S; Sut, N; Yilmaz, B | 1 |
| Dallinga-Thie, GM; Dullaart, RP; van Tol, A | 1 |
| Derdák, Z; Harangi, M; Illyés, L; Kassai, A; Mirdamadi, HZ; Molnár, M; Paragh, G; Seres, I; Sztanek, F | 1 |
| Li, JJ; Li, XY; Li, Y; Qin, L; Yang, P | 1 |
| Almeras, L; Amalvict, R; Baret, E; Briolant, S; Fusaï, T; Henry, M; Parquet, V; Pradines, B; Rogier, C; Torrentino-Madamet, M | 1 |
| Alonso, S; Alvarez, Y; Fernández, N; Municio, C; San Román, JA; Sánchez Crespo, M | 1 |
| Komiyama, N | 1 |
| Giraudeaux, V; Guillausseau, PJ; Kévorkian, JP; Laloi-Michelin, M; Meas, T; Peynet, J; Virally, M | 1 |
| Fildes, JE; Khan, U; Najam, O; Shaw, SM; Williams, SG; Yonan, N | 1 |
| Kromer, A; Moosmann, B | 1 |
| Barbieri, M; Bertolini, S; Canonica, GW; Descalzi, D; Folli, C; Gamalero, C; Passalacqua, G; Riccio, AM; Scordamaglia, F | 1 |
| Haller, MJ; Pepine, C; Samyn, MM; Shuster, JJ; Silverstein, JH; Stein, JM; Theriaque, D | 1 |
| Bernstein, SJ; Bruhnsen, KD; Choe, HM; Kennedy, DM; Parsons, DM; Standiford, CJ; Stevenson, JG; Sy, FZ | 1 |
| Jani, AJ; Mehta, AA; Rathnam, S | 1 |
| Caruthers, SD; Lanza, GM; Wickline, SA; Williams, TA; Winter, PM; Zhang, H | 1 |
| Arbustini, E; Gambarin, FI | 1 |
| Cannon, CP; Gibson, CM; McCabe, CH; Murphy, SA; Tung, P; Wiviott, SD | 1 |
| Kanic, V; Naji, F; Sabovic, M; Suran, D; Vokac, D | 1 |
| Chowdhury, S; Mukherjee, S; Mukhopadhyay, P; Pandit, K | 1 |
| Dabora, SL; Lee, N; Messina, MP; Nobil, AM; Rauktys, AE; Woodrum, CL | 1 |
| Itoh, T; Maesawa, C; Minami, Y; Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y | 1 |
| Ahn, CM; Hong, SJ; Kim, KA; Kim, YH; Lim, DS; Park, JS; Park, JY; Park, SM; Shim, WJ | 1 |
| Chen, BL; Chen, Y; Guo, D; He, YJ; Kirchheiner, J; Li, Z; Tan, ZR; Tu, JH; Xu, LY; Yu, BN; Zhang, W; Zhou, G; Zhou, HH | 1 |
| Byun, J; Jacob, RF; Mason, RP; Mizuno, Y; Self-Medlin, Y | 1 |
| Antonioli, L; Blandizzi, C; Colucci, R; Daghini, E; Del Tacca, M; Duranti, E; Fornai, M; Ghisu, N; Giannarelli, C; Taddei, S; Versari, D; Virdis, A | 1 |
| Baytur, Y; Demir, BC; Gumuser, G; Inceboz, U; Ozbilgin, K; Uyar, Y | 1 |
| Curi, R; Hirata, MH; Hirata, RD; Rodrigues, AC | 1 |
| Bao, W; Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Schwartz, GG | 1 |
| Boyle, A; Connelly, KA; Gilbert, RE; Kelly, D; Kompa, A; Krum, H; Martin, JH; Zhang, Y | 1 |
| Ghante, MH; Ghule, BV; Saoji, AN; Yeole, PG | 1 |
| Braga, MF; Gupta, M; Teoh, H; Tsigoulis, M; Verma, S | 1 |
| Inui, N; Kagawa, Y; Kokudai, M; Sakaeda, T; Takeuchi, K; Watanabe, H | 1 |
| Tokgözoğlu, L | 1 |
| Kültürsay, H | 1 |
| Karadağ, B; Ongen, Z; Yilmaz, Y | 1 |
| Amano, A; Daida, H; Kajimoto, K; Kasai, T; Kojima, Y; Miyauchi, K; Niinami, H; Shimada, A; Shimada, K | 1 |
| Alcudia, JF; Badimon, L; Guadall, A; Martínez-González, J; Raposo, B; Rodríguez, C; Sánchez-Gómez, S | 1 |
| Bauer, B; da Silva, PM; Feldman, RD; Genest, J; Gensini, G; Harvey, P; Jenssen, TG; John Mancini, GB; Manolis, AJ; Richard Hobbs, FD | 1 |
| Cui, W; Du, J; Han, M; Liu, DM; Liu, F; Lu, JC; Yin, HN; Zhang, HL; Zhang, K | 1 |
| Aarts, JC; Bax, L; Beek, FJ; Beutler, JJ; Braam, B; Buskens, E; de Haan, MW; Doorenbos, CJ; Huysmans, FT; Kouwenberg, HJ; Kroon, AA; Mali, WP; Pattynama, PM; Plouin, PF; Postma, CT; Rabelink, TJ; Raynaud, A; Reekers, JA; Rutten, MJ; Schultze Kool, LJ; van de Ven, PJ; van den Meiracker, AH; van Montfrans, GA; Vroegindeweij, D; Woittiez, AJ | 1 |
| Chen, JF; Lu, YF; Wang, JX; Yun, J; Zhang, HX; Zhao, H | 1 |
| Falagas, ME; Kopterides, P | 1 |
| Antoine, JC; Estour, B; Germain, N; Khalfallah, Y; Leca, V; Vergely, N | 1 |
| Grip, O; Janciauskiene, S | 1 |
| Dounousi, E; Ioannou, K; Kelesidis, A; Kotzadamis, N; Papakonstantinou, S; Tsakiris, D; Tsouchnikas, I; Xanthopoulou, K | 1 |
| Faergeman, O; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Strandberg, TE; Tikkanen, MJ | 1 |
| Beaumont, E; Benderdour, M; Déry, MA; Rousseau, G | 1 |
| Altug, T; Aydin, S; Sozer, V; Uzun, H | 1 |
| Guo, Z; Zhao, H | 1 |
| Frosch, DL; Grande, D; Kahn, BE; Perkins, AW | 1 |
| Chen, JF; Le, Y; Shen, ZG; Wang, JX; Zhang, HX; Zhang, ZB | 1 |
| Alonso, MJ; Briones, AM; Egido, J; García-Redondo, AB; Hernanz, R; Rodrigues-Díez, RR; Rodríguez-Criado, N; Ruiz-Ortega, M; Salaices, M | 1 |
| Feldman, T; Koren, MJ; Mendes, RA | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; Messig, M; O'Neill, BJ; Sillesen, H; Welch, KM; Zivin, JA | 1 |
| Ageev, FT; Kulev, BD | 1 |
| Boyce, RW; Dalmas, DA; Frazier, KS; Scicchitano, MS; Thomas, HC | 1 |
| Halava, H; Helin-Salmivaara, A; Huupponen, R; Junnila, J | 1 |
| Chua, SK; Kuan, P; Shyu, KG; Wang, BW | 1 |
| Fromm, MF; Keskitalo, JE; Kurkinen, KJ; Neuvonen, PJ; Niemi, M; Zolk, O | 1 |
| Bangalore, S; Devabhaktuni, M | 1 |
| Boyle, JR; Brown, AP; Gaunt, ME; Gillard, JH; Graves, MJ; Hayes, PD; Howarth, SP; Kirkpatrick, PJ; Li, ZY; Miller, SR; Patterson, AJ; Tang, TY; U-King-Im, JM; Varty, K; Walsh, SR; Warburton, EA; Zalewski, A | 1 |
| Briley-Saebo, KC; Fayad, ZA; Mani, V; Razzouk, L | 1 |
| Kishi, T; Okamatsu, S; Sunagawa, K; Yamada, A | 1 |
| El-Remessy, AB; Elewa, HF; Ergul, A; Fagan, SC; Frye, RF; Johnson, MH; Kozak, A | 1 |
| Baker, SP; Caselli, R; Evans, BA; Evans, JE; Hinerfeld, D; Kane, K; Moonis, M; Pollen, DA; Rogaeva, E; St George-Hyslop, P; Swearer, J | 1 |
| Gottmann, U; Quintes, S; Ruf, TF; Sternik, P | 1 |
| Hoskova, L; Kautzner, J; Kubanek, M; Malek, I; Podzimkova, M; Skalicka, B; Vymetalova, Y | 1 |
| Jewells, V; Markovic-Plese, S; Speer, D | 1 |
| Caro, JJ; Kongnakorn, T; O'Brien, JA; Proskorovsky, I; Roberts, CS; Ward, A | 1 |
| Asberg, A; Christensen, H; Hjelmesaeth, J; Jakobsen, GS; Jenssen, T; Reubsaet, JL; Sandbu, R; Skottheim, IB; Stormark, K | 1 |
| Fraley, AE; Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Schwartz, GG; Szarek, M; Tsimikas, S; Witztum, JL | 1 |
| Welch, KM | 1 |
| Jeon, TI; Osborne, TF; Seo, YK; Zhu, B | 1 |
| Banga, JD; Dallinga-Thie, GM; Dullaart, RP; Huisman, MV; Kappelle, PJ; Sluiter, WJ; Zwang, L | 1 |
| Akiyoshi, T; Anami, S; Matsuyama, K; Matzno, S; Nakabayashi, T; Nishiguchi, T | 1 |
| Brunet, M; Cofán, F; Cofán, M; Guillén, D; Millán, O; Rimola, A; Ros, E | 1 |
| Goldberg, RB; Guyton, JR; Jensen, E; Mazzone, T; Polis, A; Tershakovec, AM; Tomassini, JE; Weinstock, RS | 1 |
| Boeck, CR; Carqueja, CL; Dal'agnolo, D; de Araújo Herculano, B; Martins, WC; Piermartiri, TC; Stroeh, E; Tasca, CI; Vandresen-Filho, S | 1 |
| Chu, P; Goetghebeur, M; Merikle, E; Pandya, A; Taylor, DC; Wagner, M | 1 |
| Adewale, AJ; Ballantyne, CM; Grundy, SM; Hsueh, WA; Parving, HH; Polis, AB; Robinson, JG; Rosen, JB; Tershakovec, AM; Tomassini, JE | 1 |
| Bláha, M; Bláha, V; Nováková, L; Sadílek, P; Satínský, D; Solich, P; Solichová, D; Vlcková, H | 1 |
| Betteridge, DJ; Charlton-Menys, V; Colhoun, HM; DeMicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Livingstone, SJ; Neil, HA | 1 |
| Mistafa, O; Stenius, U | 1 |
| Curi, R; Genvigir, FD; Hirata, MH; Hirata, RD; Rodrigues, AC | 1 |
| Coplan, N; Gintautas, J; Gupta, MP; Labana, SS; Polena, S; Shaikh, H; Soffer, D; Zazzali, K | 1 |
| Chaiyaroj, SC; Chansrichavala, P; Chantharaksri, U; Sritara, P | 1 |
| Hjemdahl, P; Jørgensen, L; Malmström, RE; Ostergren, J | 1 |
| Choi, BC; Choi, MK; Chung, SJ; Cui, FD; Kim, DD; Kim, JS; Shim, CK; Yin, YM | 1 |
| Brcakova, E; Micuda, S; Nachtigal, P; Pospechova, K; Pospisilova, N; Semecky, V; Vecerova, L | 1 |
| Saito, Y; Yokote, K | 1 |
| An, SG; Sohn, YT | 1 |
| Hohenegger, M; Minichsdorfer, C | 1 |
| Cho, L; Jacob, M | 1 |
| Chen, YX; Fu, Y; Kong, MY; Nie, RQ; Wang, JF; Wang, XQ; Yao, YJ | 1 |
| Schwartz, JB; Verotta, D | 1 |
| Fu, YG; Guo, YD; Tan, ZF; Wang, TG; Xu, AD; Yang, WY | 1 |
| Knopp, RH; Krieger, EV | 1 |
| Das, R; Jaydip, R; Mohan, V; Sudhakaran, C; Unnikrishnan, R | 1 |
| Finlay, GA; Kwiatkowski, DJ; Malhowski, AJ; Malinowska-Kolodziej, I; Polizzi, K | 1 |
| Brocheriou, I; Capron, F; Dupuis, M; Haloui, M; Louedec, L; Michel, JB; Nadaud, S; Soubrier, F | 1 |
| Bregar, U; Jug, B; Poredos, P; Sabovic, M; Sebestjen, M | 1 |
| Longyhore, DS; Stockton, CM; Thomas, MR | 1 |
| Tsuda, K | 1 |
| Myint, PK; Niruban, A; Potter, JF | 1 |
| Kaburaki, J; Kuwana, M; Okazaki, Y | 1 |
| Jin, D; Kim, DH; Kim, SK; Lee, KJ; Li, JH; Qi, XF; Teng, YC; Yoon, YS | 1 |
| Daida, H; Hiro, T; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Saito, S; Yamagishi, M; Yamaguchi, T | 2 |
| Chen, YH; Chen, YL; Chien, HF; Hsieh, FY; Kuan, II; Lin, CC; Lin, FY; Lin, SJ; Wang, SH; Wu, CC | 1 |
| Bastarda, A; Grahek, R; Kocijan, A; Kocjan, D; Kracun, M; Plavec, J | 1 |
| Boroumand, MA; Djalali, M; Eshragian, MR; Khatami, MR; Shojaei, MH; Siassi, F | 1 |
| Abramczyk, P; Bidiuk, J; Ciarka, A; Dobosiewicz, A; Gaciong, Z; Lewandowski, J; Siński, M | 1 |
| Castilla-Guerra, L; Chaturvedi, S; Fernandez-Moreno, Mdel C; Jimenez-Hernandez, MD | 1 |
| Chaturvedi, S; Goldstein, MR; Mascitelli, L; Pezzetta, F | 1 |
| Malizos, KN; Poultsides, L; Simopoulou, T; Tsezou, A | 1 |
| Kitas, GD; Melas, N; Saratzis, A; Saratzis, N | 1 |
| Jin, H; Koo, PT; Tsang, DJ; Xiao, H; Yang, CS; Yang, Z | 1 |
| Jin, H; Li, ZG; Xu, ZY; Yao, F | 1 |
| Antonini, R; Arca, M; Baroni, MG; Cambuli, VM; Campagna, F; Filippi, E; Montali, A; Quagliarini, F; Romeo, S; Sentinelli, F | 1 |
| Aizawa, K; Ikeda, U; Izawa, A; Kasai, H; Kashima, Y; Koshikawa, M; Koyama, J; Kumazaki, S; Tomita, T; Tsutsui, H | 1 |
| Jin, R; Liu, M; Wang, F; Wang, Y | 1 |
| Chopp, M; Cui, Y; Jia, L; Lu, M; Zhang, L; Zhang, ZG | 1 |
| Akdemir, R; Karakurt, O | 1 |
| Colonna, G; Di Sciascio, G; Gaspardone, A; Montinaro, A; Pasceri, V; Patti, G | 1 |
| Anker, SD; Földes, G; von Haehling, S | 1 |
| Chopp, M; Han, Y; Karki, K; Knight, RA; Ledbetter, KA; Seyfried, DM; Yang, D; Zhang, J | 1 |
| Chiu, B; Fenster, A; Krasinski, A; Parraga, G; Spence, JD | 2 |
| Chen, P; Gan, Y; Li, G; Wu, S; Xing, X; Zhang, J; Zhang, Y; Zhao, S | 1 |
| Han, SH; Kim, SJ; Koh, KK; Koh, Y; Lee, Y; Park, JB; Quon, MJ; Shin, EK | 1 |
| Barrett, PH; Chan, DC; Ji, J; Johnson, AG; Ooi, EM; Rye, KA; Watts, GF | 1 |
| Briguori, C; Castelli, A; Chieffo, A; Colombo, A; Focaccio, A; Golia, B; Montorfano, M; Mussardo, M; Ricciardelli, B; Visconti, G | 1 |
| Brown, A; Cannon, CP; Mega, JL; Morrow, DA; Sabatine, MS | 1 |
| Barditch-Crovo, P; Cameron, DW; Elgadi, MM; Flexner, C; Fuchs, E; la Porte, CJ; Lee, LS; Pham, PA; Piliero, PJ; Sabo, JP; van Heeswijk, R | 1 |
| Cole, RP | 1 |
| Cayc, MK; Erbilen, E; Gulcan, E; Olgun, EG; Ozay, Y; Toker, S | 1 |
| Fukuda, N; Kobayashi, N; Matsumoto, T; Matsumura, M; Negishi, N; Takasaka, A; Ueno, T; Umezawa, H; Yao, EH | 1 |
| Ge, ZM; Geng, J; Kang, WQ; Wang, W; Zhang, Y; Zhao, Z | 1 |
| Geng, J; Kang, W; Wang, W; Zhang, Y; Zhao, Z; Zhiming, GE | 1 |
| Davy, KP; Dengo, AL; Orr, JS; Rivero, JM | 1 |
| Chou, SY; Fitzgerald, JP; Franco, I; Gulmi, FA; Kim, H; Mooppan, UM; Saini, R | 1 |
| Bai, L; Hu, M; Huang, XS; Zhang, Q; Zhao, SP; Zhao, W | 2 |
| Parker, T | 1 |
| Adlová, R; Hájek, P; Malý, M; Martinkovicová, L; Tesar, D; Veselka, J; Zemánek, D | 1 |
| Boari, B; Manfredini, F; Manfredini, R; Salmi, R | 1 |
| Ak, K; Arsan, S; Eksioglu-Demiralp, E; Iqbal, O; Isbir, S; Tetik, S; Yardimci, T | 1 |
| Asano, T; Enomoto, Y; Iwama, T; Kawasaki, M; Minatoguchi, S; Yamada, K; Yoshimura, S | 1 |
| Chen, SY; Li, YG; Li, YH; Sang, ZC; Wang, F; Wang, HP; Zhou, Q | 1 |
| Abad, L; Andres Domingo, M; de Luis, D; Duenas-Laita, A; Gonzalez Sagredo, M; Pérez Castrillón, JL; San Miguel, A; Vega, G | 1 |
| Hughes, AD; Manisty, C; Mayet, J; McG Thom, SA; Poulter, N; Sever, PS; Tapp, RJ | 1 |
| Fang, Y; Li, X; Lin, J; Ren, L; Wang, X; Yin, Z; Zhang, A | 1 |
| Betteridge, DJ; Chow, WS; Shiu, SW; Tam, HL; Tan, KC; Wong, Y | 1 |
| Bertrand, OF; Cossette, M; Grégoire, J; Guertin, MC; Ibrahim, R; L'allier, PL; Larose, E; Rodés-Cabau, J; Tardif, JC | 1 |
| Landau, W | 1 |
| Devine, A; Hamilton, PK; Hughes, SM; Johnston, D; Leahey, W; Lyons, KS; McVeigh, GE; Plumb, RD | 1 |
| Bate, A; Edwards, IR; Hägg, S; Strandell, J | 1 |
| Strupp, M | 1 |
| Chen, BY; Deng, CQ; Li, H; Tang, YH; Wu, L; Zhang, GM; Zhang, W | 1 |
| Zdebik, AA | 1 |
| Chakrabarti, D; Saikia, PK | 1 |
| Blann, AD; Goon, PK; Jaumdally, RJ; Lip, GY; Varma, C | 1 |
| Kathirvel, K; Kuntamallappanavar, G; Leo, MD; Mishra, SK; Subramani, J; Uttam Singh, T | 1 |
| Castelli, P; Castiglioni, L; Consuelo Maio, R; Cosentino, M; De Leo, A; Guasti, L; Lecchini, S; Legnaro, M; Marino, F; Maroni, L; Piffaretti, G; Rasini, E; Schembri, L; Tozzi, M; Venco, A | 1 |
| Bao, XM; Lu, GP; Wu, CF | 3 |
| Davignon, J; Dubuc, G | 1 |
| Nikitina, NM; Rebrov, AP | 1 |
| Wu, S; Zhang, A; Zhang, H | 1 |
| Chen, GL; Su, JZ | 1 |
| Jin, YZ; Min, R; Wang, Q; Zhang, XY; Zhou, X | 1 |
| Liang, W; Lu, GP; Wu, CF; Yang, H; Yu, Q; Zhang, DD | 1 |
| Huo, Y; Peng, DQ; Yu, BL; Zhao, SP | 2 |
| Barceló, D; Jelić, A; Petrović, M | 1 |
| Claudel, T; Fauler, G; März, W; Putz-Bankuti, C; Scharnagl, H; Sourij, H; Stauber, RE; Stojakovic, T; Trauner, M; Wagner, M; Wascher, TC; Winkler, K | 1 |
| Altuntas, Y; Arinc, H; Bolayirli, M; Celebi, H; Dirican, A; Kanat, M; Karagoz, Y; Oguz, A; Sahin, S; Serin, E; Tunckale, A; Yildiz, O | 1 |
| Aigbirhio, FI; Bird, JL; Davenport, AP; Davies, JR; Figg, N; Fryer, TD; Izquierdo-Garcia, D; Richards, HK; Rudd, JH; Warburton, EA; Weissberg, PL | 1 |
| Altafullah, I; Birnbaum, G; Cree, B; Morra, VB; Orefice, G; Reder, A; Salvatore, E | 1 |
| Bi, S; Li, J; Li, YB; Liu, GD; Liu, XM; Su, Y; Sun, YM; Xu, Y | 1 |
| Hofmann, U; Keskitalo, JE; Klein, K; Neuvonen, PJ; Niemi, M; Riedmaier, S; Schwab, M; Zanger, UM | 1 |
| Holdsworth, SR; Jones, LK; Kitching, AR; Phoon, RK | 1 |
| Favaro, RR; Furuya, DT; Machado, UF; Martins, JO; Poletto, AC; Zorn, TM | 1 |
| Dallinga-Thie, GM; Dullaart, RP; Kappelle, PJ | 1 |
| Becker, ML; Hofman, A; Stricker, BH; Uitterlinden, AG; van Schaik, RH; Visser, LE | 1 |
| Deng, JT; Hu, XY; Li, L; Liu, XL; Shang, YY; Wang, ZH; Zhang, LP; Zhang, W; Zhang, Y; Zhong, M | 1 |
| He, CC; He, WK; Liang, LY; Luo, BH; Su, CJ; Zeng, ZH; Zhang, ZH | 1 |
| Andrade, SP; Araújo, FA; Mendes, JB; Rocha, MA | 1 |
| Ferdinand, KC; Flack, JM; Jamieson, MJ; Kursun, A; Saunders, E; Shi, H; Victor, R; Watson, K | 1 |
| Cai, J; Chi, L; Feng, J; Ji, Q; Mei, Y; Sun, Y; Wang, X; Xie, S | 1 |
| Bonkovsky, HL; Russo, MW; Scobey, M | 1 |
| Ali, S; Ginsburg, GS; Reed, CR; Salisbury, BA; Shah, SH; Spasojevic, I; Voora, D | 1 |
| Aikawa, E; Figueiredo, JL; Hembrador, S; Keliher, E; Kelly, K; Libby, P; Nahrendorf, M; Panizzi, P; Weissleder, R; Zhang, H | 1 |
| Alfano, G; Casacalenda, A; Chello, M; Covino, E; Genovese, J; Pollari, F; Spadaccio, C | 1 |
| Kuriyama, G; Mori, Y; Tajima, N; Tanaka, T | 1 |
| Beheshti, A; Dinarvand, R; Farahani, H; Ganjali, MR; Norouzi, P; Sobhi, HR | 1 |
| Gerasimidis, T; Kadoglou, NP; Kapelouzou, A; Liapis, CD; Moumtzouoglou, A; Sailer, N | 1 |
| Anton, M; Bengel, FM; Dumler, K; Higuchi, T; Nekolla, SG; Pelisek, J; Saraste, A; Schwaiger, M | 1 |
| Cekmen, M; Ilbey, YO; Ozbek, E; Polat, EC; Simsek, A; Somay, A | 1 |
| Ege, E; Kurban, S; Mehmetoglu, I | 1 |
| Terland, O | 1 |
| Raczak, G | 1 |
| Backus, S; Lee, HB; Peart, TE; Svoboda, ML | 1 |
| Kirilmaz, A; Uzun, M; Yiğiner, O | 1 |
| Bahcivan, M; Erenler, BH; Gol, MK; Keceligil, HT; Kolbakir, F; Yucel, S | 1 |
| Cui, W; Ibi, M; Ikami, K; Iwata, K; Kakehi, T; Katsuyama, M; Matsuno, K; Sasaki, M; Yabe-Nishimura, C; Zhu, K | 1 |
| Bailey, KM; Balmforth, AJ; Hall, AS; Romaine, SP | 1 |
| Goetghebeur, M; Jönsson, B; Lindgren, P; Merikle, E; Wagner, M | 1 |
| Andrushko, N; Andrushko, V; Börner, A; König, G; Korostylev, A; Tararov, V | 1 |
| Frisbee, JC; Frisbee, SJ; Goodwill, AG; James, ME; Stapleton, PA | 1 |
| Adar, I; Golzman, G; Minha, S; Rapoport, M | 1 |
| Ko, SK; Liew, D; Park, HJ | 1 |
| Abate, N; Ballantyne, CM; Catapano, AL; Davidson, MH; Polis, AB; Smugar, SS; Tershakovec, AM | 1 |
| Alha, P; Knuuttila, M; Saxlin, T; Suominen-Taipale, L; Ylöstalo, P | 1 |
| Mamotte, CD; Pocathikorn, A; Taylor, RR | 1 |
| Hillyer, J; Kwon, BK; Lee, JH; Mann, CM; Stammers, AM; Tetzlaff, W | 1 |
| Kumar, VL; Wahane, VD | 1 |
| Adánez, G; Ayala, I; Castells, MT; Martín-Castillo, A; Pérez, BG; Polo, MT | 1 |
| Abraham, C; Chalifour, LE; Dostanic, S; Mitmaker, B; Obrand, D; Schweitzer, M; Sheiner, N | 1 |
| Gui, Y; Yin, H; Zheng, XL | 1 |
| Kim, RB; Knauer, MJ; Leake, BF; Lemke, CJ; Meyer zu Schwabedissen, HE; Schwarz, UI; Tirona, RG; Urquhart, BL | 1 |
| Dhaliwal, LK; Dhawan, V; Mahajan, N; Saha, SC; Sharma, I | 1 |
| Carluccio, MA; De Caterina, R; Distante, A; Massaro, M; Scoditti, E; Storelli, C; Zampolli, A | 1 |
| Banach, M; Bielecka-Dabrowa, A; Goch, JH; Maciejewski, M; Mikhailidis, DP; Rysz, J | 1 |
| Amalvict, R; Baret, E; Briolant, S; Pradines, B; Rogier, C; Savini, H; Souraud, JB | 1 |
| Geng, L; Li, ZX; Meng, XP; Wang, SX; Yin, CY; Zhang, JC | 1 |
| Culler, SD; Weintraub, WS | 1 |
| Birnbaum, H; Connolly, C; Ivanova, J; Kidolezi, Y; Kuznik, A; Signorovitch, J; Simpson, RJ | 1 |
| Chung, RT; Moriguchi, H; Sato, C | 1 |
| Cannon, CP; Gibson, CM; Hochberg, CP; Pride, YB; Sabatine, MS; Sloan, S | 1 |
| Fuset, MP; Moscardó, A; Ruano, M; Santos, MT; Valles, J | 1 |
| Basili, S; Cangemi, R; Carnevale, R; Loffredo, L; Pignatelli, P; Sanguigni, V; Stefanutti, C; Violi, F | 1 |
| Kelly, MT; Kipnes, MS; Lele, A; Rhyne, JM; Roth, EM; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Alikhan, R; Keeling, D | 1 |
| Cheng, S; Ge, S; Liu, D; Liu, X; Liu, Z; Xu, G; Zhang, R; Zhou, G; Zhu, W | 1 |
| Faoagali, J; Kruger, P; Welsh, AM | 1 |
| Hirooka, Y; Kishi, T; Konno, S; Sunagawa, K | 2 |
| Andrews, S; Callegari, S; de Barros Lopes, MA; McKinnon, RA | 1 |
| Derksen, C; Khan, K; Saqqur, M; Sebastian, J | 1 |
| Kamm, CP; Mattle, HP | 1 |
| Li, L; Meng, X; Qie, L; Wang, Y; Zhong, M | 1 |
| Avgerinos, ED; Gerasimidis, T; Kadoglou, NP; Kakisis, JD; Kapelouzou, A; Karayannacos, PE; Liapis, CD; Moumtzouoglou, A | 1 |
| Eller, K; Eller, P; Mayer, G; Patsch, JR; Reinstadler, SJ; Rosenkranz, AR; Tagwerker, A; Wolf, AM | 1 |
| Day, A; Kumar, SS; LaHaye, SA; Lahey, KA | 1 |
| Bangit, JR; Batsell, RR; John, S; Molinella, R; Reddy, KJ; Singh, M; Varghese, S; Zaheer, MS | 1 |
| Huan, Y; Huang, H; Shen, ZF; Song, GM; Sun, SJ; Zhang, N | 1 |
| Bernátová, I; Dlugosová, K; Okruhlicová, L; Slezák, J; Sotníková, R; Weismann, P | 1 |
| Crosslin, DR; Ginsburg, GS; Messer, C; Reed, CR; Salisbury, BA; Shah, SH; Voora, D; Zhai, J | 1 |
| Cox, DR; Hinds, DA; Hovingh, GK; Hyde, CL; Kastelein, JJ; Paciga, SA; Thompson, JF; Wood, LS | 1 |
| Ball, MJ; Coombes, JS; Fassett, RG; Geraghty, DP; Robertson, IK; Sharman, JE | 1 |
| Antoniades, C; Charakida, M; Kamboli, AM; Koniari, K; Marinou, K; Miliou, A; Nikolopoulou, A; Noutsou, M; Papageorgiou, N; Siasos, G; Stefanadi, E; Stefanadis, C; Tousoulis, D | 1 |
| Abraham, C; Chalifour, LE; Dostanic, S; Meilleur, M; Mitmaker, B; Obrand, D; Schweitzer, M; Sheiner, N; Sugahara, T | 1 |
| Daida, H; Dohi, T; Kojima, T; Kurata, T; Miyauchi, K; Okazaki, S; Tamura, H; Yanagisawa, N; Yokoyama, K; Yokoyama, T | 2 |
| Chung, JY; Jang, SB; Lee, MG; Lee, YJ; Lim, LA | 1 |
| Celermajer, DS; Harmer, JA; Kainer, G; Mackie, FE; Rosenberg, AR | 1 |
| Conney, AH; Cui, XX; Gao, Z; Huang, MT; Lin, Y; Liu, Y; Rabson, A; Reddy, B; Shih, WJ; Yang, CS; Zhao, Y; Zheng, X | 1 |
| Bech, JN; Matthesen, SK; Paulsen, L; Pedersen, EB; Starklint, J | 1 |
| Leekha, S; Lena, YL; Ong, LM; Punithavathi, N | 1 |
| Arazi, SS; Bernik, MM; Bertolami, MC; Cerda, A; Dorea, EL; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD | 1 |
| Whayne, TF | 1 |
| Arishiro, K; Hanafusa, T; Hoshiga, M; Ishihara, T; Kohbayashi, E; Miyazaki, N; Nakakoji, T; Negoro, N; Okabe, T | 1 |
| Annemans, L; Marbaix, S; Scheen, A; Van Gaal, L; Webb, K | 1 |
| Agroyannis, I; Kakavas, I; Papadakis, IT; Petras, D; Stamatelou, K; Stavroulopoulos, A; Stefanadis, C; Vyssoulis, G | 1 |
| Kaminski, K; Knapp, M; Kozieradzka, A; Kuklinska, AM; Mroczko, B; Musial, WJ; Sawicki, R; Szmitkowski, M; Usowicz-Szarynska, M | 1 |
| Chang, SA; Kim, DH; Kim, HK; Kim, YJ; Oh, BH; Park, YB; Sohn, DW | 1 |
| Maciocia, PM | 1 |
| Guo, YL; He, JG; Li, J; Li, JJ; Nan, JL; Xiong, CM | 1 |
| Cater, NB; Faergeman, O; Fayyad, R; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Szarek, M; Tikkanen, MJ | 1 |
| Braunwald, E; Cannon, CP; McCabe, CH; Murphy, SA; Wiviott, SD | 1 |
| Gattani, SG; Kadu, PJ; Kushare, SS; Thacker, DD | 1 |
| Dhawan, V; Mahajan, N | 2 |
| Han, YL; Jing, QM; Li, Y; Wang, DM; Wang, SL; Wang, ZL; Zhang, ZL | 1 |
| Cui, L; Li, M; Liu, L; Wang, L; Yang, R; Zhang, X | 1 |
| Barter, PJ; Brandrup-Wognsen, G; Nicholls, SJ; Palmer, M | 1 |
| Breazna, A; Deedwania, PC; DeMicco, DA; Greten, H; LaRosa, JC; Shepherd, J; Wenger, NK | 1 |
| Amato, M; Bellandi, F; Gallopin, M; Leoncini, M; Maioli, M; Manzone, C; Micheletti, C; Tedeschi, D; Toso, A | 1 |
| Beckert, M; Davidson, MH; Drucker, J; Eugene Griffin, H; Oosman, S; Rooney, MW | 1 |
| Kelesidis, I; Kelesidis, T | 1 |
| Amarenco, P; Benavente, O; Callahan, A; Goldstein, LB; Hennerici, MG; Sillesen, H; Welch, KM; Zivin, JA; Zweifler, RM | 1 |
| Arihiro, K; Chayama, K; Hyogo, H; Ishitobi, T; Kimura, Y; Nabeshima, Y; Takeuchi, M; Yamagishi, S | 1 |
| Chung, BC; Jung, BH; Kumar, BS; Lee, YJ; Yi, HJ | 1 |
| Aksakal, O; Aksoy, Y; Gungor, T; Kilic, S; Lordlar, N; Ozat, M; Sut, N; Yilmaz, B | 1 |
| Kaneda, H; Ma, J; Morita, T | 1 |
| Bays, HE; Carter, RN; Doyle, RT; Maki, KC; McKenney, J; Stein, E | 1 |
| Faergeman, O; Hyde, CL; Lira, M; Macinnes, A; Mazzarella, RA; Paciga, SA; Sanders, FA; Thompson, JF; van Wijk, DF; Wood, L | 1 |
| Buchetti, B; Carnovale, A; Fallarino, M; Filetti, S; Gatti, A; Lenti, L; Lococo, E; Mandosi, E; Morano, S; Rossetti, M | 1 |
| Childress, C; Deitrick, K; Lin, Q; Parikh, A; Rukstalis, D; Yang, W | 1 |
| Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K | 1 |
| Liu, L; Zhao, SP; Zheng, XY | 1 |
| Cai, JZ; Feng, J; Ji, Q; Mei, YQ; Sun, YF; Wang, XS; Xie, SL; Zhou, YX | 1 |
| Faergeman, O; Fayyad, R; Holdaas, H; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ | 1 |
| Cengiz, SD; Dünder, I; Kaya, C; Pabuccu, R | 1 |
| Gratsianskiĭ, NA; Kuznetsova, MA; Masenko, VP; Vaulin, NA | 1 |
| Choi, D; Chung, N; Her, AY; Jang, Y; Kang, SM; Kim, JY; Lee, SH; Manabe, I | 1 |
| Goldberg, RB; Guyton, JR; Mazzone, T; Polis, AB; Tershakovec, AM; Tipping, D; Tomassini, JE; Weinstock, RS | 1 |
| Brescia Morra, V; Brunetti, A; Carotenuto, B; Lanzillo, R; Lus, G; Orefice, G; Prinster, A; Quarantelli, M; Rinaldi, C; Salvatore, E; Spitaleri, D; Tedeschi, G; Vacca, G; Ventrella, G | 1 |
| Calciu, CD; Langer, A; Leiter, LA; Rabkin, SW; Ur, E | 1 |
| Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Lin, J; Shah, A; Tershakovec, AM | 1 |
| Alvaro, D; Attili, AF; Bragazzi, MC; Callea, F; Giubilo, F; Merli, M | 1 |
| Edholm, B | 1 |
| Chen, WJ; Hung, CR; Kuan, P; Shyu, KG; Wang, BW | 1 |
| Buerke, M; Chen, L; Frister, A; Hofmann, B; Lautenschläger, M; Loppnow, H; Luther, T; Müller-Werdan, U; Rose-John, S; Schlitt, A; Silber, RE; Song, N; Werdan, K; Zhang, L | 1 |
| Anderson, M; Blann, A; Herrick, AL; Moore, TL; Murray, A; Sadik, HY; Vail, A | 1 |
| Cui, L; Du, W; Li, M; Liu, L; Wang, L; Yang, R; Zhang, X | 1 |
| Abdul-Salam, VB; Boyle, JJ; Davies, AH; Edwards, RJ; Gillard, JH; Krishnan, U; Owen, DR; Ramrakha, P; Shalhoub, J; Tang, TY; Wilkins, MR | 1 |
| Näntö-Salonen, K; Niinikoski, H; Simell, O; Tanner, LM | 1 |
| Aronow, WS; Banach, M; Bielecka-Dabrowa, A; Desai, R; Goch, JH; Maciejewski, M; Rysz, J | 1 |
| Gunnarsson, I; Jacobson, SH; Lundahl, J; Lundberg, S | 1 |
| Dhumma-Upakorn, R; Putwai, P; Sansanayudh, N; Wongwiwatthananukit, S | 1 |
| Barrett, PH; Chan, DC; Nguyen, MN; Ooi, EM; Watts, GF | 1 |
| Acharjee, S; Cannon, CP; McCabe, C; Murphy, SA; Qin, J | 1 |
| Ben-Yehuda, O; Bird, S; Constance, C; Hanson, ME; Jones-Burton, C; Lee, R; Tershakovec, AM; Wenger, NK; Zieve, F | 1 |
| Berger, M; Krane, V; Lilienthal, J; Schambeck, C; Wanner, C; Winkler, K | 1 |
| Carpentino, JE; Eaton, K; Higgins, PD; Huang, EH; Hynes, MJ; Johnson, LA | 1 |
| Chen, C; Huang, QY; Liu, L; Shu, J; Wasti, B; Xu, DY; Zhao, SP | 1 |
| Knap, N; Larczynski, W; Neuwelt, A; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Wozniak, M | 1 |
| Chae, JK; Choi, JY; Hong, TJ; Jeong, MH; Kim, DS; Kim, KY; Kim, YJ; Kim, YN; Oh, SK; Park, JS; Seong, IW | 1 |
| Arvanitakis, Z; Knopman, DS | 1 |
| Breazna, A; DeMicco, DA; Doody, RS; Feldman, HH; Hey-Hadavi, J; Jones, RW; Kivipelto, M; Schindler, R; Schwam, E; Sparks, DL; Waters, DD | 1 |
| Shimano, H; Teramoto, T; Urashima, M; Yokote, K | 1 |
| Al Khadra, A; Erdine, S; Kim, JH; Lopez, AP; Sutradhar, S; Westergaard, M; Yunis, C; Zamorano, J | 1 |
| Burke, JP; Rublee, DA | 1 |
| Lacchini, R; Silva, PS; Tanus-Santos, JE | 1 |
| King, S; Superko, HR | 1 |
| Liang, Y; Shen, F; Wang, A; Wang, J | 1 |
| Ciralik, H; Gümüşalan, Y; Kilinc, M; Ozbag, D; Toru, H; Yasim, A | 1 |
| de Vries, JP; Hoefer, IE; Hurks, R; Kerver, M; Moll, FL; Pasterkamp, G; Schoneveld, A; Tangelder, MJ; Vink, A | 1 |
| Chang, LL; Chen, HW; Cheng, WL; Kuo, CL; Lii, CK; Liu, CS; Su, SL; Tsai, CW | 1 |
| Beals, TC; Jensen, A; Swallow, NC | 1 |
| Chen, J; Ge, S; Liu, D; Liu, X; Xu, G; Yin, Q; Zhang, R; Zhou, G; Zhu, W | 1 |
| Han, SH; Kim, SJ; Koh, KK; Lee, Y; Quon, MJ; Shin, EK | 1 |
| King, S; Momary, K; Superko, HR | 1 |
| Cho, DK; Cho, JR; Cho, YH; Choi, D; Hong, MK; Jang, Y; Jeon, DW; Kim, BK; Kim, J; Kim, JS; Ko, YG; Lee, CJ; Lee, NH; Lee, SH; Oh, SJ; Yang, JY | 1 |
| Lavie, CJ; Milani, RV | 1 |
| Tasci, I | 1 |
| Armaganidis, A; Glynos, C; Kopterides, P; Magkou, C; Maniatis, NA; Roussos, C; Siempos, II | 1 |
| DU, H; Gu, P; Jiang, WM; Shao, JQ; Wang, J; Zhang, K | 1 |
| Chan, KE; Hakim, RM; Lazarus, JM; Thadhani, R | 1 |
| Barber, MJ; Chasman, DI; Chatterjee, A; Hyde, CL; Krauss, RM; Li, X; Mangravite, LM; McCarty, CA; Nickerson, DA; Ridker, PM; Rieder, MJ; Rotter, JI; Smith, JD; Stephens, M; Wilke, RA; Williams, PT | 1 |
| Cadirci, E; Coskun, K; Halici, Z; Kilic, C; Nuri Keles, O; Odabasoglu, F; Oral, A; Suleyman, H; Unal, B | 1 |
| Arai, H; Ito, F; Miyagi, N; Someya, T; Tamura, K; Ushiyama, T | 1 |
| Ge, J; Jang, YS; Kim, YJ; Lam, W; Marschner, IC; Zhu, J | 1 |
| Feng, L; Jiang, J; Li, M; Ren, H; Zhang, Y; Zhu, X | 1 |
| Bansal, AK; Kumar, L; Puri, V; Shete, G | 1 |
| Cairns, R; Cannon, CP; Michael Gibson, C; Nazer, B; Ray, KK | 1 |
| Chen, L; Ding, G; Jia, R; Tu, Y | 1 |
| Hoenig, MR; Sellke, FW | 1 |
| Bijjem, KV; Goyal, S; Kumar, S; Singh, M | 1 |
| Tuttle, KR | 1 |
| Colivicchi, F; Genovesi Ebert, A; Melina, G; Mocini, D; Santini, M; Strano, S; Tubaro, M; Uguccioni, M | 1 |
| Chou, SY; Gulmi, FA; Kamdar, C; Kim, H; Mooppan, UM | 1 |
| Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K; Wierzbicki, AS | 1 |
| Ahn, TH; Ahn, YK; Bae, JH; Baek, SH; Choi, DJ; Choi, YJ; Hong, SJ; Hong, TJ; Hur, SH; Ihm, SH; Jang, YS; Kim, BS; Kim, DI; Kim, HS; Kim, YJ; Lee, CW; Lee, SH; Lee, SU; Park, DG; Ryu, KH; Seung, KB | 1 |
| Yilmaz, Y | 1 |
| Benner, JS; Chapman, RH; Foody, JM; Hussein, MA; Joyce, A; Solomon, HA; Tang, SS | 1 |
| Arany, EJ; Hill, DJ; Marchand, KC | 1 |
| Cao, HY; Li, J; Li, ZQ; Pan, W; Sun, YM; Wang, LF | 1 |
| Alemdar, R; Aydin, M; Basar, C; Caglar, O; Erden, I; Ordu, S; Ozhan, H; Yalcin, S | 1 |
| Huang, MQ; Li, XX; Liu, DY; Lu, WM; Wang, SM; Yu, JX; Zhu, YF | 1 |
| Chen, YH; Yang, S; Zhou, JZ | 1 |
| Cherkanova, MS; Korolenko, EC; Korolenko, TA | 1 |
| Fan, Y; Gan, RT; Han, W; Hao, JH; Huang, YL; Li, WM; Wang, Z; Yang, SS; Yu, JB | 1 |
| Fan, YH; Hu, T; Jia, G; Li, H; Tao, HR; Wang, HC; Zhang, RQ | 1 |
| Huisa, BN; Stemer, AB; Zivin, JA | 1 |
| Ferreira, GA; Sato, EI; Teixeira, AL | 1 |
| Dong, X; Gong, F; Wang, L; Zeng, Q; Zhou, W | 1 |
| Aykaç, Y; Fentoğlu, O; Gürgan, CA; Kale, B; Kirzioğlu, FY; Oz, SG; Sönmez, Y; Sözen, T; Tonguç, MO | 1 |
| López-Cuenca, A; Marín, F; Roldán, V | 1 |
| Abel, R; Alvey, C; Bullen, W; Hartman, D; Porcari, AR; Whitfield, LR | 1 |
| Cipollone, F; Faggin, E; Ganassin, L; Grego, F; Mezzetti, A; Pauletto, P; Plebani, M; Puato, M; Rattazzi, M; Zambon, A | 1 |
| Abuladze, GV; Dundua, GI; Dzhindzholiia, NR; Nebieridze, MI | 1 |
| Alonso, J; Demil, N; Eha, J; Lablanche, JM; Leone, A; Licour, M; Merkely, B; Morais, J; Santini, M; Tardif, JC | 1 |
| Bagshaw, SM; Bellomo, R; Cruz, DN; Gibney, N; Haase, M; Honore, PM; Joannes-Boyau, O; McAlister, FA; Palevsky, PM; Prowle, J; Ronco, C | 1 |
| Chang, CZ; Howng, SL; Hwang, SL; Kwan, AL; Lin, CL; Wu, SC | 1 |
| Borggrefe, M; Dempfle, CE; Hoffmeister, HM; Lang, S; Suselbeck, T; Swoboda, S; Szabo, S; Walter, T | 1 |
| Awad, J; Fenster, A; Krasinski, A; Parraga, G | 1 |
| Eckel, RH | 1 |
| Asberg, A; Christensen, H; Hjelmesaeth, J; Jakobsen, GS; Jenssen, T; Sandbu, R; Skottheim, IB; Stormark, K | 1 |
| Ahn, CM; Choi, SC; Hong, SJ; Kim, JS; Kim, YH; Lim, DS; Park, JH; Park, SM; Shim, WJ | 1 |
| Coban, AY; Durupinar, B; Güney, AK; Tekeli, HO | 1 |
| Perlamutrov, IuN; Shkol'nik, EL; Shkol'nik, MN; Vasiuk, IuA | 1 |
| Foody, JM; Liu, LZ; Mendys, PM; Simpson, RJ | 1 |
| Harinarayan, CV; Kumar, R; Pola, P; Rajagopal, G; Reddy, AP; Sachan, A; Suchitra, MM; Suresh, V | 1 |
| Chaiyaroj, SC; Chansrichavala, P; Chantharaksri, U; Ngaosuwankul, N; Sritara, P | 1 |
| Allgar, V; Chipperfield, R; Gaunt, R; Harvey, P; McCormack, T; Robinson, P | 1 |
| Fan, Y; Lu, JP; Ren, JH; Zhang, XS | 1 |
| Amez, JM; Gallego, VA; Molinero, ÁV; Torres, MS; Valle, MB | 1 |
| Beckerman, B; Buch, J; Bultas, J; Deanfield, JE; Sellier, P; Shi, H; Thaulow, E; Yunis, C | 1 |
| Watson, KE | 1 |
| Amalvict, R; Baret, E; Briolant, S; Dormoi, J; Gil, M; Henry, M; Parquet, V; Pradines, B; Rogier, C; Wurtz, N | 1 |
| Joo, IW; Oh, HJ; Ryu, JH | 1 |
| Buxton, M; Dahlöf, B; Eriksson, J; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Almeras, L; Amalvict, R; Baret, E; Briolant, S; Gil, M; Henry, M; Parquet, V; Pradines, B; Rogier, C; Wurtz, N | 1 |
| Boaz, M; Gilad, R; Lampl, Y; Lorberboym, M; Sadeh, M; Tikozky, A; Vysberg, I | 1 |
| Adámek, T; Alusik, S; Lejsková, M; Paluch, Z | 1 |
| Amundsen, R; Asberg, A; Christensen, H; Zabihyan, B | 1 |
| Hu, XJ; Jia, M; Li, YP; Zhang, LR | 1 |
| Di Sciascio, G; Melfi, R; Nusca, A; Patti, G | 2 |
| Cao, G; Konrad, RJ; Pacanowski, MA; Troutt, JS; Welder, G; Zineh, I | 1 |
| Kamran, KA; Khan, M | 1 |
| Derosa, G; Maffioli, P | 1 |
| Ahire, YS; Dandawate, PR; Gandhi, SP; Ghaisas, MM; Zawar, SA | 1 |
| Dougu, N; Nukui, T; Taguchi, Y; Takashima, S; Tanaka, K; Toyoda, S | 1 |
| Frank, PG; Lanza-Jacoby, S; Laury-Kleintop, L; Raval, M; Yan, G | 1 |
| Chen, CJ; Cheng, FC; Ho, SP; Ou, YC; Pan, HC; Yang, DY | 1 |
| Ando, D; Hirawa, N; Umemura, S; Yasuda, G | 1 |
| Fujimori, S; Kaneko, K; Ogata, N; Oka, Y | 1 |
| Borlu, M; Dogan, A; Duran, M; Gunebakmaz, O; Heyit, T; Inanc, MT; Kalay, N; Kasapkara, HA; Kaya, MG; Oguzhan, A; Ozdogru, I; Yarlıoglues, M | 1 |
| Archimandritis, A; Frenzilli, G; Peluso, C; Rocco, L; Stingo, V; Zito, G | 1 |
| Strandberg, TE | 1 |
| Athyros, VG; Karagiannis, A; Mikhailidis, DP; Tziomalos, K | 1 |
| Cooper, DK; Dorling, A; Ezzelarab, M; Hara, H; Lin, CC; Lin, CW; Long, C | 1 |
| Fang, W; Li, H; Liang, Y; Mu, Y; Su, L; Zhou, L | 1 |
| Chapman, RH; Roberts, CS; Yeaw, J | 1 |
| Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM | 1 |
| Arrospide, A; Caro, J; Mar, J; Rejas-Gutiérrez, J; Vivancos-Mora, J | 1 |
| Abd-Elghany, MI; Heeba, GH | 1 |
| Bahl, A; Khullar, M; Poduri, A; Sehrawat, BS; Sharma, Y; Talwar, KK | 1 |
| Geleedst-De Vooght, M; Jansen, P; Maitland-van der Zee, AH; Mantel-Teeuwisse, A; Schalekamp, T | 1 |
| Bachowski, R; Gdula-Dymek, A; Krysiak, R; Okopien, B | 1 |
| Chen, L; Eaddy, M; Jackson, JH; Kean, AJ; Lunacsek, OE; Neutel, JM; Roberts, C | 1 |
| Garg, N; Mittal, B; Srivastava, A; Srivastava, K | 1 |
| Achkouty, G; Aydanian, H; Azar, M; Azar, RR; Badaoui, G; Harb, S; Kassab, R; Sarkis, A | 1 |
| Asberg, A; Ellesat, KS; Hylland, K; Thomas, KV; Tollefsen, KE | 1 |
| Holford, TR; Kane, JP; Kocherla, M; Pullinger, CR; Ruaño, G; Seip, RL; Thompson, PD; Windemuth, A; Wu, AH | 1 |
| Ghalali, A; Högberg, J; Kadekar, S; Mistafa, O; Stenius, U | 1 |
| Agnew-Blais, J; Brookhart, MA; Choudhry, NK; Federman, AD; Fischer, MA; Kesselheim, AS; Liberman, JN; Liu, J; Shrank, WH | 1 |
| Bonassin, F; Schneemann, M; Wyss, C | 1 |
| Alfano, G; Chello, M; Covino, E; Di Sciascio, G; Gatto, L; Miglionico, M; Patti, G | 1 |
| Brown, SL; Jenrow, KA; Kim, JH; Kolozsvary, A; Lapanowski, K; Liu, J | 1 |
| Cariou, B; Costet, P; Guyomarc'h Delasalle, B; Hoffmann, MM; Konrad, T; Winkler, K | 1 |
| Camm, J; Hosseini, MT; Jahangiri, M; Kourliouros, A; Mayr, M; Sarsam, M; Valencia, O | 1 |
| Beadle, K; Gurnsey, C; Hoenig, MR; Johnson, L; Walker, PJ | 1 |
| Clarkson, PM; Grimaldi, AS; Haller, RG; Hoffman, EP; Levine, BD; Parker, BA; Pescatello, LS; Thompson, PD; White, CM | 1 |
| Inamadugu, JK; Karra, VK; Mullangi, R; Pilli, NR; Rao, JV; Vaidya, JR | 1 |
| Lombardi, R; Marian, AJ; Nagueh, SF; Tan, Y; Wang, J; Willerson, JT | 1 |
| Kruger, A; Ostadal, P; Vondrakova, D | 1 |
| Funder, JW | 1 |
| Dienes, HP; Granzow, M; Heller, J; Hennenberg, M; Klein, S; Lammert, F; Odenthal, M; Reichen, J; Sauerbruch, T; Shir, K; Trebicka, J; Vogt, A | 1 |
| Asteriou, C; Ballas, KD; Kontoulis, T; Lalountas, MA; Pissas, D; Sakantamis, AK; Skouras, C; Triantafyllou, A | 1 |
| Adamson, U; Antovic, A; Henriksson, P; Jörneskog, G; Lins, PE; Mobarrez, F; Santesson, P; Tehrani, S; Wallén, NH | 1 |
| Bots, ML; Dogan, S; Duivenvoorden, R; Evans, GW; Grobbee, DE; Kastelein, JJ; Shear, CL; Visseren, FL | 1 |
| Huang, QY; Liu, L; Shu, J; Xu, DY; Zhao, SP | 1 |
| Aslani, A; Cheng, KK; Gharravi, M; Khoshnia, M; Larijani, B; Malekzadeh, F; Malekzadeh, R; Marshall, T; Nateghi, A; Pourshams, A; Rastegarpanah, M; Salahi, R; Semnani, S; Thomas, GN | 1 |
| Lopatin, IuM | 1 |
| Abeysinghe, N; Aston, J; Polouse, S | 1 |
| Alencar, NM; Barboza, DR; Brito, GA; Gomes, AS; Leitão, RF; Macedo, RN; Medeiros, CA; Nogueira, NA; Ribeiro, RA | 1 |
| Barut, T; Ekerbiçer, N; Gürpınar, T; Harzadın, NU; Tarakçı, F; Tuglu, MI | 1 |
| Abrecht, L; Eshtehardi, P; Haeberli, A; Hess, OM; Meier, B; Schmidlin, K; Wenaweser, P; Windecker, S; Zwahlen, M | 1 |
| Ducharme, A; Dupuis, J; Jiang, BH; Martin, JG; Sauvageau, S; Shi, Y; Tardif, JC | 1 |
| Rao, N | 1 |
| Dermitzakis, I; Drakoulis, C; Gialernios, K; Gialernios, T; Gika, E; Iliopoulos, N; Katsadorou, E; Kougialis, S; Kroustalis, A; Mpilinis, H; Nikolaou, S; Polydorou, A; Polydorou, V; Skopelitis, E; Zervou, A | 1 |
| Colivicchi, F; Santini, M; Tubaro, M | 1 |
| Wheelan, KR; Winter, FD | 1 |
| Arai, H; Daida, H; Hiro, T; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Saito, S; Yamagishi, M; Yamaguchi, T | 1 |
| Jia, JY; Li, GX; Liu, GY; Liu, YM; Lu, C; Pu, HH; Wang, W; Weng, LP; Xu, RJ; Yu, C; Zhang, MQ | 1 |
| Daida, H; Hiro, T; Ichimiya, S; Ishii, H; Kanashiro, M; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Murohara, T; Nakagawa, Y; Ohashi, T; Ozaki, Y; Shibata, R; Yamagishi, M | 1 |
| Bullock, R; Craig, D; Malouf, R; McGuinness, B; O'Hare, J; Passmore, P | 1 |
| Berk, M; Henry, MJ; Jacka, FN; Kotowicz, MA; Nicholson, GC; Pasco, JA; Williams, LJ | 1 |
| He, XZ; Wan, XH; Wang, HY; Xue, JF; Zhong, QH; Zhou, SH | 2 |
| Cannon, CP; Khera, AV; Qin, J; Rader, DJ; Wolfe, ML | 1 |
| Kalonia, H; Kumar, A; Kumar, P | 1 |
| Aki, K; Arai, T; Fujita, E; Fukuda, Y; Iino, Y; Katayama, Y; Kuwahara, N; Masuda, Y; Mii, A; Nagasaka, S; Natori, Y; Shimizu, A | 1 |
| Mehta, JL | 1 |
| Akishita, M; Eto, M; Iijima, K; Kahyo, T; Kano, MR; Ogawa, S; Ota, H; Ouchi, Y; Setou, M | 1 |
| Enlund, H; Helin-Salmivaara, A; Korhonen, MJ; Martikainen, JE; Saastamoinen, LK | 1 |
| Dereli, Y; Ege, E; Kurban, S; Sarigül, A | 1 |
| Kino, T; Matsuzawa, Y; Nishikawa, T; Omura, M; Saito, J; Suematsu, S | 1 |
| Abdel-Aziz, NA; Abo-Elmatty, DM; Ghattas, MH; Tawfik, MK | 1 |
| Ding, J; Huang, C; Jiang, H; Yang, J | 1 |
| Baer, A; Ky, B; Millar, JS; Pruscino, L; Rader, DJ; Wolfe, ML | 1 |
| Aydin, C; Baysal, A; Bugra, O; Buyukbayrak, F; Caliskan, A; Erdem, H; Fedekar, A; Sasmazel, A; Sunar, H | 1 |
| Araújo, LF; Duarte, AJ; Jabot, B; Nicolau, JC; Orii, NM; Rached, F; Ramires, JA; Serrano Júnior, CV; Soeiro, Ade M | 1 |
| Chopp, M; Ding, C; Han, Y; Karki, K; Knight, RA; Seyfried, DM; Yang, D; Zhang, J | 1 |
| Cao, PY; Ito, D; Ito, O; Kanazawa, M; Kohzuki, M; Mori, N; Muroya, Y; Takashima, K | 1 |
| Dong, W; Guan, J; Liang, Y; Sun, X; Wang, G; Zhang, L; Zhu, J | 1 |
| Ozturk, EI; Uma, S | 1 |
| El-Shenawy, SM; ElRokh, el-SM; Ibrahim, BM; Yassin, NA | 1 |
| Bergheanu, SC; Dallinga-Thie, GM; Hattori, H; Karalis, IK; Liem, AH; van Tol, A; Wolterbeek, R; Wouter Jukema, J | 1 |
| Bodmer, M; Brecht, K; Bur, D; Krähenbühl, S; Tsakiris, DA; Zahno, A | 1 |
| Abt, M; Derks, M; Meneses-Lorente, G; Parr, G; Phelan, M; Young, AM | 1 |
| Ben Abdelmelek, S; Cooper, WJ; O'Shea, KE; Razavi, B; Song, W | 1 |
| Mombelli, G; Sirtori, CR | 1 |
| Acharjee, S; Cannon, CP | 1 |
| Birnbaum, H; Ivanova, J; Kuznik, A; Ramakrishnan, K; Signorovitch, J; Simpson, RJ | 1 |
| Ak, K; Arsan, S; Gulsoy, O; Isbir, S; Sahin, Y; Tetik, S; Yardimci, T | 1 |
| Aydin, NE; Elmali, N; Esenkaya, I; Sakarya, B; Unay, K | 1 |
| Barary, MA; El-Kimary, EI; Hassan, EM; Maher, HM; Youssef, RM | 1 |
| Bezerra, SC; de Bem, AF; Duarte, FS; Figueiredo, CP; Mancini, G; Piermartiri, TC; Prediger, RD; Rial, D; Tasca, CI | 1 |
| Arnett, C; Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T; Shepherd, J | 1 |
| Fan, ZX; Gao, YF; Jing, ZC; Li, J; Li, L; Ma, D; Shi, DM; Wang, YW; Wu, BX; Zhu, XD | 1 |
| Akhlaghi, F; Asberg, A; Hermann, M; Narwal, R; Rosenbaum, SE | 1 |
| Li, X; Lu, F; Suo, AQ; Zhang, JW | 1 |
| Alarcón, E; Ebensperger, R; González-Béjar, M; Gorelsky, S; Lopez-Alarcón, C; Netto-Ferreira, JC; Scaiano, JC | 1 |
| Beskonakli, E; Bodur, E; Eroglu, H; Nacar, O; Nemutlu, E; Oner, L; Sargon, MF; Turkoglu, OF | 1 |
| Holman, JR; Jamieson, B; Lin, V | 1 |
| Espinosa-Chávez, EJ; Fajardo, ME; Rocha, ML; Sánchez-Marin, FJ | 1 |
| Alessi, MC; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Moro, PJ; Poyet, R; Quilici, J | 1 |
| Abrashkina, ED; Nazarova, OA; Pakhrova, OA; Shaalali, N; Shutemova, EA | 1 |
| Bartimoccia, S; Basili, S; Carnevale, R; Di Santo, S; Napoleone, L; Pignatelli, P; Sanguigni, V; Tanzilli, G; Violi, F | 1 |
| Dong, Q; Qian, H; Song, L; Xu, Z; Yang, Y | 1 |
| Bays, HE; Bird, SR; Conard, SE; Leiter, LA; Lowe, RS; Tershakovec, AM | 1 |
| Antoniades, C; Antonopoulos, AS; Bakogiannis, C; Casadei, B; Channon, KM; Demosthenous, M; Economopoulos, G; Marinou, K; Miliou, A; Paschalis, A; Psarros, C; Reilly, S; Sfyras, N; Stefanadis, C; Tousoulis, D; Zhang, MH | 1 |
| Boulanger, L; Chen, SY; Mardekian, J; Rao, P; Rublee, DA; Wu, N | 1 |
| Ahmadi, N; Budoff, MJ; Foster, T; Gordon, C; Guerci, AD; Saab, S | 1 |
| Bangalore, S; DeMicco, D; Kostis, JB; LaRosa, JC; Messerli, FH; Wun, CC; Zuckerman, AL | 1 |
| Aohara, F; Fujimura, Y; Harakawa, N; Hasegawa, R; Katori, N; Kim, SR; Maekawa, K; Naito, M; Niwa, T; Okuda, H; Sai, K; Saito, Y; Sawada, J; Tohkin, M; Yoshimura, T | 1 |
| Astarita, G; Barrett, E; Beckett, TL; Dowling, AL; Head, E; Kryscio, RJ; Levine, H; Lin, Y; Morales, J; Murphy, MP; Piomelli, D; Studzinski, CM; Wang, X; Weidner, A | 1 |
| Bentz, K; Eick, C; Kettering, K; Laszlo, R; Menzel, KA; Schreieck, J; Schreiner, B | 1 |
| Arazi, SS; Bernik, MM; Cerda, A; Curi, R; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Oliveira, R; Rodrigues, AC; Willrich, MA | 1 |
| Akar, H; Kolatan, E; Meteoglu, I; Sarioglu, S; Uzelce, O; Yeniçerioglu, Y; Yenisey, C; Yilmaz, O | 1 |
| Elliott, M; Goulder, M; Hislop, C; Rosenson, RS; Stasiv, Y; Waters, D | 1 |
| Chung, BC; Jung, BH; Kumar, BS; Lee, BH; Lee, YJ; Yi, HJ | 1 |
| Chen, CC; Lin, YC; Liu, YL; Shun, CT; Wu, MS; Yang, PM | 1 |
| Holme, I; Kvien, TK; Pedersen, TR; Semb, AG | 1 |
| Amark, P; Angelin, B; Cao, G; Dahlin, M; Eriksson, M; Gälman, C; Hafström, I; Konrad, RJ; Lind, S; Persson, L; Rudling, M; Sjöberg, BG; Ståhle, L; Troutt, JS; Wallén, H | 1 |
| Clarkson, MR; Conlon, PJ; Leavey, SF; Magee, CN; Medani, SA | 1 |
| Akgün-Dar, K; Aksu, U; Uzüm, G | 1 |
| Sun, RP; Yang, L; Yin, P; Zhou, HY | 1 |
| Chetter, IC; Khan, JA; Mazari, FA; McCollum, PT; Mockford, K; Rahman, MN | 1 |
| Famularo, G; Gasbarrone, L; Minisola, G | 1 |
| Cirkovic, MV; Djukanovic, BP; Gradinac, SDj; Jovic, MDj; Maravic-Stojkovic, VR; Milojevic, PS; Peric, MS; Vukovic, PM | 1 |
| Takagi, H; Umemoto, T | 11 |
| Liu, DQ; Ran, X; Ran, XZ; Su, YP; Xiang, GM; Zheng, HE; Zong, ZW | 1 |
| Aukrust, P; Birkeland, KI; Gullestad, L; Johansen, OE; Jørgensen, AP; Orvik, E; Sørgård, B; Torjussen, BR; Ueland, T | 1 |
| Aksoy, N; Bas, M; Buyukhatıpoglu, H; Celik, H; Demirbag, R; Guntekin, U; Polat, M; Sezen, Y; Taskin, A; Yildiz, A | 1 |
| Melfi, R; Nusca, A; Patti, G; Sciascio, GD | 1 |
| Goldberg, AC; Jones, PH; Kelly, MT; Knapp, HR; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Cardona-Gómez, GP; Céspedes-Rubio, A; Jurado, FW | 1 |
| Choi, MK; Choi, YL; Deng, JW; Shin, HJ; Shin, JG; Song, IS | 1 |
| Bloom, HL; Dudley, SC; Jones, DP; Negi, S; Shukrullah, I; Veledar, E | 1 |
| Bays, H; Conard, S; Hanson, ME; Leiter, LA; Lin, J; Shah, A; Tershakovec, AM | 1 |
| Biswas, D; Biswas, T; Sarkar, A; Sen, G | 1 |
| Ahn, CW; Cha, BS; Kang, ES; Kang, SB; Lee, BW; Lee, HC; Moon, JH; Park, JS | 1 |
| Gomes, ME; Lenders, JW; Smits, P; Tack, CJ; Verheugt, FW | 1 |
| Chen, YC; Hsieh, CH; Hsieh, MW; Jeng, JC; Jeng, SF; Lu, TH; Rau, CS | 1 |
| Anetseder, M; Hager, M; Metterlein, T; Roewer, N; Schuster, F; Tadda, L | 1 |
| Harward, ML; Jones, MA; Joyce, CJ; Kostner, KM; Kruger, PS; Roberts, MS; Venkatesh, B | 1 |
| Haron, MM; Houssen, ME; Ibrahim, TM; Metwally, SS | 1 |
| Bruggisser, M; Haschke, M; Rätz Bravo, A; Terraciano, L | 1 |
| Acikel, S; Aydinalp, A; Bal, U; Bayraktar, N; Muderrisoglu, H; Ozin, B; Sade, E; Yildirir, A | 1 |
| Bonbled, F; Hantson, P; Huberlant, V; Montiel, V; Vincent, MF | 1 |
| Atanasova, P; Bełtowski, J; Chaldakov, GN; Chylińska-Kula, B; Jamroz-Wiśniewska, A; Wójcicka, G | 1 |
| Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kawai, H; Liu, N; Liu, W; Matsuura, T; Ohta, Y; Shang, J; Tian, F; Yamashita, T; Zhang, X | 1 |
| Fung, GL; Gandelman, K; Laskey, R; Messig, M | 1 |
| Schunn, H | 1 |
| Abdel-Salam, Z; Adel, A; Nammas, W | 1 |
| Adewale, AJ; Brown, WV; Flaim, D; Foody, JM; Jones-Burton, C; Lowe, RS; Tershakovec, AM; Zieve, F | 1 |
| Lakhin, DI; Vasil'eva, LV | 1 |
| Ceglarek, U; Farmer, A; Holman, RR; Neil, HA; Paul, S; Thiery, J | 1 |
| Belgamwar, V; Maurya, D; Tekade, A | 1 |
| El-Barbary, AM; Hamouda, HE; Hussein, MS; Ismail, RG; Rageh, EM; Wagih, AA | 1 |
| Chen, P; Duan, S; Gan, Y; Jiang, LZ; Li, GY; Wu, SJ; Zhang, J; Zhang, Y; Zhao, SP | 1 |
| Alitalo, K; Gjini, E; Hekking, LH; Küchler, A; Post, JA; Saharinen, P; Schulte-Merker, S; Wienholds, E | 1 |
| Amato, M; Bellandi, F; Gallopin, M; Leoncini, M; Maioli, M; Tedeschi, D; Toso, A | 1 |
| Brunet, M; Cofán, F; Cofán, M; Guillén, D; Millán, O; Ros, E | 1 |
| Auteri, A; Ciabattoni, G; Ciani, F; Davì, G; Ferrante, E; Ghezzi, A; Lattanzio, S; Liani, R; Pasqui, AL; Puccetti, L; Santilli, F; Scarpini, F | 1 |
| Aboosaeedi, HR; Eskandari, M; Eskandary, H; Karamouzian, S; Malekpoor-Afshar, R; Reihani-Kermani, H; Saeed, A; Safizade, H | 1 |
| Bangalore, S; Cannon, CP; Murphy, SA; Qin, J; Sloan, S | 1 |
| Gaur, V; Kumar, A | 1 |
| Ay, ZY; Fentoğlu, Ö; Hiçyılmaz, H; Kırzıoğlu, FY; Köroğlu, BK; Orhan, H; Özdem, M; Öztürk Tonguç, M; Sert, T; Sütçü, R; Tamer, MN | 1 |
| Dong, FY; Gu, XL; He, BX; Hong, CJ; Li, R; Qiu, J; Shi, L; Tao, L; Yang, L; Zeng, XH; Zhao, SJ | 1 |
| Sharma, PL; Sharma, S; Singh, M | 1 |
| Guruprasad, B; Kumar, VL; Wahane, VD | 1 |
| Aicher, A; Dimmeler, S; Fichtlscherer, S; Schmidt-Lucke, C; Schultheiss, HP; Tschöpe, C; Zeiher, AM | 1 |
| Arranz Martínez, E; Gordillo López, FJ; Hermosa Hernán, JC; Ruiz García, A | 1 |
| Bláha, M; Bláha, V; Lánská, M; Malý, J; Nováková, L; Solich, P; Solichová, D; Vlcková, H | 1 |
| Gao, Y; Pang, X; Qi, G; Sun, Y; Zhang, H; Zhang, Z; Zhao, W | 1 |
| Frey, P; Waters, DD | 1 |
| Bastien, NR; Francis, GA; Genest, JJ; Goodman, SG; Langer, A; Leiter, LA; McPherson, R | 1 |
| Li, L; Sun, TW; Wang, LX; Zhang, JY | 1 |
| Aleksandrowicz, E; Larczyński, W; Lysiak-Szydłowska, W; Neuwelt, A; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Ziętkiewicz, M | 1 |
| Abe, A; Katayama, Y; Katsura, K; Nagayama, H; Nishiyama, Y; Otsuka, T; Ueda, M | 1 |
| Bajaj, N; Fan, J; Hughes, NC; Wong, EY | 1 |
| Acheampong, A; Ellis, R; Ni, J; Ouyang, H; Rowe, J; Sakuma, T; Seto, C; Szekely-Klepser, G; Welty, D | 1 |
| Eriksson, M; Gustafsson, U; Parini, P; Pramfalk, C; Sahlin, S | 1 |
| Cheng, KA; Cheng, Z; Ding, L; Fang, F; Fang, Q; Liu, Y; Shi, GP | 1 |
| Hirooka, Y; Kishi, T | 1 |
| Lin, P; Xie, H; Xie, L; Xu, C | 1 |
| Kuo, CD | 1 |
| Belli, S; Colakoglu, T; Ezer, A; Haberal, M; Karakayali, H; Kayaselcuk, F; Nursal, TZ; Parlakgumus, A | 1 |
| Cho, YS; Hong, SJ; Hyon, MS; Kim, DW; Kim, HS; Kim, SH; Lee, MY; Moon, GW; Park, K; Sung, JD; Yoon, MH | 1 |
| Kukes, IV; Paukov, SV; Ruvinov, IuV; Sivkov, AS | 1 |
| Abe, K; Ikeda, Y; Kozuki, M; Kurata, T; Matsuura, T; Miyazaki, K; Morimoto, N; Nagai, M; Ohta, Y; Panin, VL | 1 |
| Foley-Comer, AJ; Jordan, P; Russell-Yarde, F; Young, AM | 1 |
| Bailey, C; Capps, N; Ramachandran, S; Saraf, S; Shetty, C | 1 |
| Mareev, VIu | 1 |
| Bays, H; Bird, S; Conard, S; Hanson, ME; Jensen, E; Leiter, LA; Shah, A; Tershakovec, AM | 1 |
| Alegret, M; Ađalsteisson, GS; Laguna, JC; Merlos, M; Rebollo, A; Roglans, N; Vilà, L | 1 |
| Benjannet, S; Couture, P; Davis, HR; Hoos, L; Lamarche, B; Lemelin, V; Seidah, NG; Tremblay, AJ | 1 |
| Bando, YK; Monji, A; Morimoto, Y; Murohara, T; Shigeta, T | 1 |
| Almond, A; Donaldson, K; Isles, C; Robertson, S; Teckchandani, S | 1 |
| Sasaki, J | 1 |
| Hu, XJ; Wei, KK; Zhang, LR; Zhang, Y | 1 |
| Benowitz, NL; Breazna, A; DeMicco, DA; Frey, P; Pipe, A; Samuels, L; Waters, DD; Wun, CC | 1 |
| Koh, KK; Quon, MJ; Sakuma, I | 1 |
| Biessen, EA; Bot, I; Jukema, JW; Lankhuizen, IM; van Berkel, TJ | 1 |
| Blanco-Vaca, F; Chacón, P; Ciudin, A; Francisco, G; Hernández, C; Llaverias, G; Montoro, B; Simó, R | 1 |
| Doi, M; Fukushima, H; Hamada, M; Matsui, H; Mizuno, T; Nishio, K; Shida, Y; Shima, M; Sugimoto, M; Yoshioka, A | 1 |
| Demers, LM; Hogeman, CS; Kunselman, AR; Legro, RS; Raja-Khan, N; Stetter, CM | 1 |
| Cámara, C; Costo, A; Crespo, L; Fernández Pereira, L; Pereira, G; Sánchez Muñoz-Torrero, JF | 1 |
| Alcaino, H; Castro, PF; Chiong, M; Gabrielli, LA; Garcia, L; Godoy, I; Greig, D; Lavandero, S; López, R; Mellado, R; Navarro, M; Nogerol, C; Tapia, F; Verdejo, HE | 1 |
| Caballero, F; Elena, M; Fernández, A; Fernández-Checa, JC; García-Ruiz, C; Llacuna, L; Martínez, L; Matías, N; Montfort, CV; Morales, A; Rimola, A | 1 |
| Wilke, RA | 1 |
| Calisto, KL; Camacho, AC; Carvalheira, JB; Carvalho, Bde M; Guadagnini, D; Mittestainer, FC; Ropelle, ER; Saad, MJ | 1 |
| Civantos, E; Egido, J; Lavoz, C; Mezzano, S; Ortiz, A; Rayego-Mateos, S; Rodrigues Díez, R; Rodrigues-Díez, R; Rodríguez-Vita, J; Ruiz-Ortega, M | 1 |
| Ghilencea, L; Mario, CD; Moreno-Ambroj, C; Tyczyński, P; Witkowska, AB | 1 |
| Luo, H; Luo, M; Wang, J; Xiao, Y; Zhang, X | 1 |
| Ahmed, K; Ahn, Y; Cho, JG; Cho, SH; Choi, YH; Hachinohe, D; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Ko, JS; Lee, MG; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS | 1 |
| Chaiyakunapruk, N; Cheewasithirungrueng, N; Dilokthornsakul, P; Jeanpeerapong, N; Nimpitakpong, P; Srisupha-olarn, W; Thanarungroj, A | 1 |
| Miao, HF; Qian, LB; Ru, XC; Wang, HP; Xu, HC; Ye, ZG | 1 |
| Charlton-Menys, V; Cruickshank, JK; Davies, RR; Dean, J; Durrington, PN; France, M; Gibson, JM; Gittins, M; Jinadev, P; Kalra, PA; Moorhouse, A; Prais, HR; Roberts, C; Rutter, MK; Wiles, PG | 1 |
| Byrne, CD; Chipperfield, AJ; Clough, GF; Gamble, J; Krentz, AJ; L'Esperance, V; Turzyniecka, M; Walter, L | 1 |
| Chen, WQ; Ge, ZM; Geng, J; Ji, XP; Ren, SD; Wu, TT; Yu, XL; Zhang, HJ; Zhong, L | 1 |
| Chen, YL; Li, L; Liu, GQ; Liu, RY; Yang, PL; Zhang, JY; Zhao, XY | 1 |
| Christopher-Stine, L; Kiani, AN; Magder, LS; Petri, MA; Post, W | 1 |
| Gade, J; Neerati, P | 1 |
| Arsenault, BJ; Bao, W; Barter, P; Deedwania, P; DeMicco, DA; Greten, H; Grundy, SM; Kastelein, JJ; LaRosa, JC; Preston, GM; Shepherd, J; Waters, DD; Wenger, NK | 1 |
| Di Stolfo, G; Gori, T; Liuni, A; Luca, MC; Mariani, JA; Parker, JD; Uxa, A | 1 |
| Crane, HM; Crane, PK; Harrington, RD; Kitahata, MM; Knopp, RH; Kosel, BW; Mugavero, MJ; Saag, MS; Singh, S; Willig, JH | 1 |
| Insull, W; Jiang, P; Krause, S; Padley, RJ; Parreno, RA; Superko, HR; Thakkar, RB; Toth, PP | 1 |
| Butterfield, DA | 1 |
| Barone, E; Butterfield, DA; Cenini, G; Di Domenico, F; Head, E; Mancuso, C; Martin, S; Murphy, MP; Sultana, R | 1 |
| Betteridge, J | 1 |
| Antoniades, C; Koniari, K; Marinou, K; Miliou, A; Nikolopoulou, A; Noutsou, M; Papageorgiou, N; Stefanadi, E; Stefanadis, C; Tousoulis, D | 1 |
| Kandic, I; Kutryk, MJ; Zhang, Q | 1 |
| Goes, P; Lima, AP; Lima, V; Melo, IM; Rêgo, RO | 1 |
| Benya, R; Chiorean, M; Della'Zanna, G; Gostout, C; Heigh, R; Lawson, MJ; Levine, J; Limburg, PJ; Mahoney, MR; Mandrekar, SJ; Richmond, E; Rodriguez, L; Schoen, RE; Smyrk, TC; Sontag, SJ; Stoffel, E; Weinberg, DS; Ziegler, KL | 1 |
| Allard, JP; Arendt, BM | 1 |
| Mikhailidis, DP; Paraskevas, KI; Veith, FJ | 1 |
| Chang, H; Jin, X; Qi, Z; Wang, Y; Zou, J | 1 |
| Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R | 1 |
| Agrogiannis, G; Iliopoulos, DG; Karatzas, G; Mikhailidis, DP; Pantopoulou, A; Paraskevas, KI; Perrea, DN; Tzivras, D; Vlachos, IS | 1 |
| Bacova, B; Barancik, M; Knezl, V; Kolenova, L; Mitasikova, M; Navarova, J; Radosinska, J; Tribulova, N; Weismann, P | 1 |
| Meek, CL; Pathmanathan, H; Ramsbottom, T; Reston, JD; Viljoen, A | 1 |
| Almroth, H; Andersson, J; Boman, K; Englund, A; Höglund, N; Jensen, S; Rosenqvist, M; Tornvall, P | 1 |
| Ashour, S; Bahbouh, M; Khateeb, M | 1 |
| Brunham, LR; Carleton, BC; Carter, C; Hayden, MR; Hovingh, GK; Jukema, JW; Kastelein, JJ; Lansberg, PJ; Miao, F; Ross, CJ; Stalenhoef, AF; Visscher, H; Zhang, L | 1 |
| Higa, M; Masuzaki, H; Shimabukuro, M; Shimabukuro, T; Tanaka, H; Yamakawa, K | 1 |
| Cho, EJ; Kim, CJ; Kim, JE; Kwon, JE; Min, YJ; Oh, MS | 1 |
| Al-Malaq, HA; Al-Obaid, AR; Darwish, IA | 1 |
| Ai, M; Asztalos, BF; Himbergen, TV; Jones, PH; Nakajima, K; Otokozawa, S; Schaefer, EJ; Stein, E; Thongtang, N | 1 |
| Chen, Z; Jia, F; Lu, G; Wu, C | 2 |
| Gandelman, K; Glue, P; Jones, J; LaBadie, R; Laskey, R; Ose, L | 1 |
| Gillard, JH; Graves, MJ; Müller, KH; Patterson, AJ; Tang, TY | 1 |
| Arzeno, J; Bellovin, DI; Cao, Z; Fan-Minogue, H; Felsher, DW; Gambhir, SS; Yang, Q; Yevtodiyenko, A | 1 |
| Ji, G; Jiang, Z; Leng, L; Liu, P; Zhao, X | 1 |
| Hagita, S; Osaka, M; Shimokado, K; Yoshida, M | 1 |
| Hirata, Y; Sata, M | 1 |
| Crook, MA | 1 |
| Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Kawai, H; Kurata, T; Matsuura, T; Ohta, Y; Omote, Y; Yamashita, T | 1 |
| Bhonde, R; Govindasamy, V; Mamidi, MK; Pal, R; Zakaria, Z | 1 |
| Ho, RH; Kim, RB; Leake, BF; Meyer zu Schwabedissen, HE; Mizuguchi, K; Mokrab, Y; Schwarz, UI; Suzuki, A; Tirona, RG | 1 |
| Furusawa, T; Inazu, T; Kawahara, T; Nishikawa, M; Suzuki, G | 1 |
| Chen, YX; Filion, L; Hibbert, B; Ma, X; O'Brien, ER; Pourdjabbar, A; Rayner, K; Simard, T; Sun, J | 1 |
| Guan, Y; Li, N; Su, G; Wang, L; Wang, S; Xie, W; Zhang, D; Zhao, P | 1 |
| Buch, J; Caulfield, MJ; Collier, DJ; Dahlöf, B; Poulter, NR; Sever, PS; Wedel, H | 1 |
| Choi, D; Chung, N; Jang, Y; Kang, SM; Lee, SH; Park, S | 2 |
| Charles, J; Miller, G; Pan, Y | 1 |
| Al-Khadra, A; Erdine, S; Kim, JH; Pavia, A; Sutradhar, S; Westergaard, M; Yunis, C; Zamorano, J | 1 |
| Bouwels, L; de Leeuw, FE; Enajat, M; Pop, G; Pop-Purceleanu, M; Tendolkar, I; van Kuilenburg, J; van Wingen, G; Zwiers, MP | 1 |
| Chakraborty, BS; Gaur, S; Ghosh, C; Jain, I; Patel, N; Upadhyay, A | 1 |
| Gassman, J; Gipson, D; Greene, T; Joy, M; Pinsk, M; Savin, V; Somers, M; Trachtman, H; Vento, S; Wickman, L | 1 |
| Dai, L; Wu, S | 1 |
| Barbry, P; Fromigue, O; Hamidouche, Z; Lecanda, F; Mari, B; Marie, PJ; Patino, A; Vaudin, P | 1 |
| Ding, SF; Li, L; Liu, FQ; Meng, X; Sun, T; Wang, XP; Wang, Y; Wang, YY; Yang, JM; Yu, GS; Zhang, C; Zhang, MX; Zhang, Y | 1 |
| Dong, Y; Li, ZH; Wei, LQ | 1 |
| Cai, J; Chi, L; Feng, J; Ji, Q; Mei, Y; Sun, Y; Wang, X | 1 |
| Ahmad, L; Iqbal, Z; Khan, A; Khan, MI; Nasir, F; Nazir, S; Shah, Y | 1 |
| Bavaro, M; Brandt, C; Crum-Cianflone, N; Decker, CF; Follmann, D; Ganesan, A; Higgins, J; Maldarelli, F; Metcalf, J; Qin, J; Rehm, C; Sklar, P; Tasker, S; Vita, J | 1 |
| Babaoglu, MO; Bozkurt, A; Kilicarslan, A; Sain-Guven, G; Yardimci, Y; Yasar, U | 1 |
| Campo, N; Campo-Bustillo, I; Forteza, A; Gutierrez, J; Haussen, DC; Koch, S; Romano, JG | 1 |
| Bláha, M; Nováková, L; Solich, P; Solichová, D; Vlčková, H | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Nazer, B; Ray, KK; Scirica, B; Sloan, S | 1 |
| Bergman, AJ; Dockendorf, MF; Dykstra, K; Green, M; Krishna, R; Wagner, JA | 1 |
| Adlová, R; Hájek, P; Malý, M; Martinkovičová, L; Tesař, D; Tomašov, P; Veselka, J; Zemánek, D | 1 |
| Kadonosono, K; Kaneko, T; Kawaguchi, J; Morita, S; Shigematu, E; Terauchi, Y; Yamakawa, T | 1 |
| Boutros, PC; Clendening, JW; Goard, CA; Martirosyan, A; Mather, RG; Penn, LZ; Sharom, FJ; Vinepal, B | 1 |
| Amano, T; Aoyama, T; Hayashi, M; Ishii, H; Matsubara, T; Murohara, T; Nishio, M; Takahashi, H; Tamaki, T; Tanaka, M; Toriyama, T; Yoshikawa, D | 1 |
| Dehpour, AR; Fakhraei, N; Javadi-Paydar, M; Mirazi, N; Norouzi, A; Rayatnia, F; Zakeri, M | 1 |
| Inazu, A; Kawashiri, MA; Kobayashi, J; Mabuchi, H; Nakanishi, C; Noguchi, T; Nohara, A; Tada, H; Yamagishi, M | 1 |
| Alonso, DF; Farina, HG; Gomez, DE; Hermo, GA | 1 |
| Arrouss, I; Assi, S; Mazier, D; N'dilimabaka, N; Pino, P; Rebollo, A; Soubrier, F; Taoufiq, Z | 1 |
| Brus, J; Brusova, H; Sedenkova, I; Urbanova, M | 1 |
| Jiang, R; Kan, H; Song, W; Xie, Y; Zhao, J | 1 |
| Akhlaghi, F; Dostalek, M; Ionita, IA; Macwan, JS | 1 |
| Blankier, S; Ito, S; McCrindle, BW; Yeung, RS | 1 |
| Bruggisser, M; Franz, CC; Krähenbühl, S; Rätz Bravo, AE | 1 |
| Cheng, X; Ding, YJ; Du, R; Jevallee, H; Liao, MY; Liao, YH; Shi, GP; Song, Y; Tang, TT; Xiao, H; Yao, R; Yu, X; Yuan, J; Zhou, ZH | 1 |
| Djalali, M; Eshraghian, M; Khatami, M; Shojaei, M; Siassi, F | 1 |
| Boncler, M; Czyz, M; Luzak, B; Rysz, J; Rywaniak, J; Stanczyk, L; Watala, C; Wilk, R | 1 |
| Andersson, KE; Eussen, SR; Garssen, J; Hellstrand, P; Klungel, OH; Oste, R; Rompelberg, CJ; van Kranen, H | 1 |
| Bayés, B; Egido, J; Lauzurica, R; Martínez-Cáceres, E; Mas, S; Navarro-Muñoz, M; Pastor, MC; Pérez, V; Romero, R | 1 |
| Asuphol, O; Chaiyakunapruk, N; Dhippayom, T; Jeanpeerapong, N; Poowaruttanawiwit, P | 1 |
| Chen, G; Deng, CQ; Wu, L | 1 |
| Hasegawa, Y; Isahaya, K; Kato, B; Sakurai, K; Shimizu, K; Shimomura, K; Takaishi, S; Tokuyama, Y | 1 |
| Ballarín, J; Bestard, O; Carrera, M; Cruzado, JM; Díaz, M; Fulladosa, X; Grinyó, JM; Ibernón, M; Navarro, I; Poveda, R; Romero, R; Torras, J | 1 |
| Akhtar, S; Al-Sagair, OA; Arif, JM; Salman Khan, M | 1 |
| Puszczewicz, M; Ruchala, M; Sosnowski, P; Sowinski, J; Szczepanek, E | 1 |
| Nonomura, N; Okuyama, A; Tsujihata, M; Tsujimura, A; Yoshioka, I | 1 |
| Abolhasani, E; Araghi, ZM; Beiraghdar, F; Panahi, Y; Pishgoo, B; Sahebkar, A | 1 |
| Dimitrow, PP; Gackowski, A; Jawień, M | 1 |
| Alanen, T; Helin-Salmivaara, A; Huupponen, R; Korhonen, MJ | 1 |
| Ahanger, AA; Choudhury, S; Kandasamy, K; Mishra, SK; More, AS; Parida, S; Prawez, S; Singh, TU | 1 |
| Heinemann, L; Heise, T; Herder, C; Koenig, W; Kolb, H; Martin, S; Schloot, NC | 1 |
| Allolio, B; Blouin, K; Drechsler, C; Fenske, W; Krane, V; Lilienthal, J; Wanner, C | 1 |
| Ballantyne, CM; Jones, PH; Kelly, MT; Lele, A; Setze, CM; Stolzenbach, JC; Thakker, KM | 1 |
| Caretta, G; Dei Cas, L; Della Pina, P; Gorga, E; Madureri, A; Raddino, R | 1 |
| Cerda, A; Curi, R; Genvigir, FD; Hirata, MH; Hirata, RD; Rodrigues, AC | 1 |
| Abe, K; Ikeda, Y; Kozuki, M; Kurata, T; Miyazaki, K; Morimoto, N; Ohta, Y | 3 |
| Abdel Rahman, MN; Abdelmotelb, AA | 1 |
| Cho, SK; Chung, JY; Jang, SB; Lee, DH; Lee, YJ; Lim, LA; Oh, ES; Park, K; Park, MS | 1 |
| Bhandari, U; Khanna, N; Kumar, V; Pathan, RA | 1 |
| Aktunc, E; Arasli, M; Barut, F; Gun, BD; Kayhan, B | 1 |
| Ascaso, JF; Lorente, R; Martínez-Hervás, S; Molina, M; Navarro-Hidalgo, MI; Priego, A; Real, JT | 1 |
| Kelly, MT; Mohiuddin, SM; Setze, CM; Thakker, KM | 1 |
| Azar, M; Azar, RR; Badaoui, G; Kassab, R; Sarkis, A; Valentin, E | 1 |
| Andrys, C; Brcakova, E; Micuda, S; Mullerova, Z; Nachtigal, P; Rathouska, J; Slanarova, M; Strasky, Z; Vecerova, L | 1 |
| Bancells, C; Benítez, S; Ordóñez-Llanos, J; Pérez, A; Sánchez-Quesada, JL; Wägner, AM | 1 |
| Góralska, M; Piotrowska, J; Somogyi, E; Wiliński, B; Wiliński, J | 1 |
| Ballantyne, C; Barter, P; Borgman, M; Chapman, MJ; Erbel, R; Libby, P; Nicholls, SJ; Nissen, SE; Raichlen, JS | 1 |
| Handal, J; Kwok, SC; Samuel, SP | 1 |
| Belo, VA; Gerlach, RF; Guimaraes, DA; Izidoro-Toledo, TC; Tanus-Santos, JE | 1 |
| Faergeman, O; Fayyad, R; Holme, I; Kastelein, JJ; Larsen, ML; Lindahl, C; Olsson, AG; Pedersen, TR; Tikkanen, MJ | 1 |
| Patti, G | 1 |
| Clarke, R; Lynch, MA; Lyons, A; Murphy, KJ | 1 |
| Arsenault, BJ; Barter, P; Breazna, A; Colhoun, H; DeMicco, DA; Ho, JE; Kastelein, JJ; Waters, DD; Wun, CC | 1 |
| Bartos, J; Fischbein, MP; Itoh, S; Kimura, N; Palmer, O; Robbins, RC; Schrepfer, S; Stein, W; Velotta, J; Wang, X | 1 |
| Iwasaki, Y; Jinnouchi, H; Matsui, K; Ogawa, H; Oka, H; Sugiyama, S; Sumida, H; Tanaka, T; Tayama, S; Toyama, K | 1 |
| Ara, R; Durrington, PN; Pandor, A; Rafia, R; Rees, A; Reynolds, TM; Stevens, J; Stevenson, M; Ward, SE; Wierzbicki, AS | 1 |
| Dean, IN; Rawal, SY; Stein, SH; Tipton, DA | 1 |
| Blann, AD; Jaumdally, RJ; Lip, GY; Varma, C | 1 |
| Braganza, G; Chaudhuri, R; Donnelly, I; Jolly, L; Lafferty, J; Lloyd, SM; Mair, F; McSharry, C; Spears, M; Thomson, NC; Weir, CJ | 1 |
| Djoussé, L; Gaziano, JM; Rahilly-Tierney, C; Sesso, HD | 1 |
| Achimastos, A; Alexandrides, T; Athyros, VG; Bilianou, E; Elisaf, MS; Ganotakis, E; Kakafika, A; Karagiannis, A; Kolovou, GD; Liberopoulos, EN; Mikhailidis, DP; Nicolaou, V; Paletas, K; Petridis, D; Tziomalos, K | 1 |
| Bi, H; Chen, WA; Daugherty, A; Hong, B; Luo, Y; Wang, JA; Wang, Y; Xie, X; Zhang, S | 1 |
| Gillard, JH; Jiang, F; Li, ZY; Tang, TY; Zhang, Y | 1 |
| Berkowitz, DE; Holowatz, LA; Kenney, WL; Santhanam, L; Webb, A | 1 |
| Armani, A; Cannon, CP; McCabe, CH; Murphy, SA; Truong, QA | 1 |
| Drechsler, C; Genser, B; Grammer, TB; Holdaas, H; Holme, I; Krane, V; März, W; Ritz, E; Scharnagl, H; Stojakovic, T; Wanner, C; Winkler, K | 1 |
| Chen, H; Chu, B; Dong, L; Hatsukami, TS; Kerwin, WS; Neradilek, MB; Underhill, HR; Yuan, C; Zhao, XQ | 1 |
| Fujii, N; Inoue, H; Kameyama, T; Matsuki, A; Nozawa, T; Ohori, T; Shida, T; Sobajima, M; Suzuki, T | 1 |
| DeFilippis, A; Eberlein, M; Girgis, RE; Iacono, A; Jones, S; Lechtzin, N; Reed, RM | 1 |
| D'Avolio, LW; Farwell, WR; Gaziano, JM; Lawler, EV; Scranton, RE | 1 |
| John, H; Kitas, GD; Toms, TE | 1 |
| Browne, K; Derendorf, H; Ellington, D; Greenblatt, DJ; Harmatz, JS; Parent, SJ; Reddy, P; Zdrojewski, I; Zhu, Y | 1 |
| Dong, X; Mao, Y; Wang, L; Zeng, Q; Zhou, W | 1 |
| Abela, GS; Durga, S; Huang, R; Janoudi, A; Tamhane, U; Vedre, A | 1 |
| Clumeck, N; De Wit, S; Delforge, M; Necsoi, CV | 1 |
| Arazi, SS; Bernik, MM; Cerda, Á; Dorea, EL; Genvigir, FD; Hirata, MH; Hirata, RD; Oliveira, Rd; Rodrigues, AC; Willrich, MA | 1 |
| Al Nuaimi, H; Al-Ani, B; Savage, C | 1 |
| Colonna, G; D'Ambrosio, A; Di Sciascio, G; Montinaro, A; Nusca, A; Pasceri, V; Patti, G; Ricottini, E | 1 |
| Ayaori, M; Ikewaki, K | 1 |
| Barone, E; Butterfield, DA; Mancuso, C | 1 |
| Sadat, U | 1 |
| Abe, K; Deguchi, K; Deguchi, S; Ikeda, Y; Liu, N; Liu, W; Matsuura, T; Ohta, Y; Shang, J; Tian, F; Yamashita, T; Zhang, X | 1 |
| Bonner Freeman, A; Brouwers, MC; Konrad, RJ; Lu, A; Schaper, NC; Stehouwer, CD; Troutt, JS; van Greevenbroek, MM | 1 |
| Cremonezzi, D; Fiore, MC; García, NH; Jimenez, PM; Juncos, LI | 1 |
| Ball, MJ; Cardinal, JW; Coombes, JS; Fassett, RG; Geraghty, DP; Robertson, IK | 1 |
| Chen, G; Keyes, KT; Long, B; Qian, J; Ye, Y | 1 |
| Anzivino, C; Baldelli, E; Bertolotti, M; Carulli, L; Carulli, N; Corna, F; Del Puppo, M; Gabbi, C; Galli Kienle, M; Loria, P | 1 |
| Bucher, J; Marcus, K; Nüssler, AK; Reuss, M; Riedmaier, S; Schnabel, A; Thasler, WE; Vacun, G; Weiss, TS; Zanger, UM | 1 |
| Reinke, T | 1 |
| Chisaki, I; Gouda, K; Iseki, K; Itagaki, S; Kobayashi, M; Ochiai, M | 1 |
| Dai, R; Li, L; Lu, Y; Su, B; Su, Q; Wang, Y; Zhao, Y | 1 |
| Harris, KP; Haylor, JL; Huang, Q; Nicholson, ML; Waller, HL; Yang, B | 1 |
| Eeg-Olofsson, K; Eliasson, B; Gudbjörnsdóttir, S; Jonasson, JM; Miftaraj, M; Sundell, KA; Svensson, AM | 1 |
| Cheng, QL; Ye, P; Zhao, JH | 1 |
| Jialal, I; Kaur, J | 1 |
| Anagnostis, P; Athyros, VG; Karagiannis, A; Kita, M; Mikhailidis, DP; Panagiotidou, A; Panagiotou, A; Polyzos, SA; Selalmatzidou, D; Slavakis, A | 1 |
| Chaitman, BR; Goldberger, JJ; Messig, M; Schwartz, GG | 1 |
| Eren, MA; Koksal, M; Sabuncu, T; Turan, MN | 1 |
| Andalib, S; Biabani, S; Doustar, Y; Garjani, A; Maleki-Dizaji, N; Soraya, H | 1 |
| Cherkanova, MS; Johnston, TP; Kaledin, VI; Korolenko, TA; Loginova, VM; Tuzikov, FV; Tuzikova, NA | 1 |
| An, LM; Chang, WT; Chen, IJ; Lin, HL; Shen, KP; Wu, BN | 1 |
| Kongsuwan, S; Niyomrat, P; Poolsup, N; Rungkanchananon, B; Suksomboon, N; Wongyaowarat, K | 1 |
| Acuña-Castroviejo, D; Dayoub, JC; Del Pino-Zumaquero, A; Escames, G; López, LC; Ortiz, F; Roda, O; Sánchez-Montesinos, I; Venegas, C | 1 |
| Ferreira-Sae, MC; Franchini, KG; Geloneze, B; Grespan-Magossi, AM; Nadruz, W; Pio-Magalhães, JA; Schreiber, R; Souza, FA; Velloso, LA | 1 |
| Kasner, SE; Taylor, RA; Weigele, JB | 1 |
| Shi, J; Xue, Z | 1 |
| Sillence, D; Tchan, M | 1 |
| Blanco-Colio, LM; de Teresa, E; Després, JP; Egido, J; Farsang, C; Gaw, A; Gensini, GF; Gupta, M; Langer, A; Leiter, LA; Martineau, P; Tran, T | 1 |
| Antovic, A; Antovic, J; Bröijersen, A; Egberg, N; He, S; Jörneskog, G; Mobarrez, F; Wallén, H; Wiklund, B | 1 |
| Lip, GY; Montoro-García, S; Shantsila, E | 1 |
| Kruger, P; Phillips, LK; Prins, J; Robinson, K; Venkatesh, B | 1 |
| Allami, N; Dehpour, AR; Javadi-Paydar, M; Norouzi, A; Rastegar, H; Rayatnia, F; Zakeri, M | 1 |
| Kiiakbaev, GK; Kobalava, ZhD; Moiseev, VS; Ozova, EM | 1 |
| Chang, BC; Chen, LM; Fang, PH; Ren, HZ; Shan, CY; Wang, Y; Yang, JH; Zheng, MY | 1 |
| Daida, H; Dohi, T | 1 |
| Harrison, C | 1 |
| Chedgy, F; Howlett, DC; Inglis, C | 1 |
| Alexander, S; Bullman, J; Fleck, R; Messenheimer, J; Miller, J; Nicholls, A; Van Landingham, K; Vuong, A | 1 |
| Anagnostis, P; Athyros, VG; Karagiannis, A; Mikhailidis, DP | 1 |
| Kadoglou, NP; Kapelouzou, A; Kostakis, A; Lampropoulos, S; Liapis, CD; Sailer, N; Vrabas, IS | 1 |
| Cannon, CP; De Lemos, JA; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Wilson, SR; Wiviott, SD; Zhou, S | 1 |
| Nakamura, M; Satoh, M; Tabuchi, T; Takahashi, Y | 1 |
| Afanas'eva, MI; Afanas'eva, OI; Ezhov, MV; Liakishev, AA; Pokrovskiĭ, SN; Safarova, MS; Tripoten', MI; Trukhacheva, EP | 1 |
| Feng, B; Hu, JF; Liu, F; Wang, H; Xu, L; Xue, J; Yan, X | 1 |
| Koppensteiner, R; Spring, S; van der Loo, B | 1 |
| Boerner, JL; Bohin, N; Ge, Y; Irwin, ME; Mueller, KL | 1 |
| Alonso, R; Badimón, L; Barba, A; Díaz, JL; Fuentes, F; Guallar, E; Irigoyen, L; López-Miranda, J; Mata, N; Mata, P; Muñiz, O; Ordovas, JM; Padró, T; Perez-Jiménez, F; Piedecausa, M; Sanchez, JF; Vidal, JI | 1 |
| Altafullah, I; Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, M; Ledbetter, LY; MacLeod, MJ; Messig, M; Samsa, GP; Scott, R; Sillesen, H; Welch, KM; Zivin, JA | 1 |
| Bramanti, P; Calabrò, RS; Gervasi, G; Pezzini, A; Pollicino, P | 1 |
| Barthwal, MK; Dikshit, M; Jain, M; Jyoti, A; Keshari, RS; Khanna, V; Prakash, P; Singh, V | 1 |
| Fujita, K; Hasuike, T; Horimatsu, T; Maruyama, T; Masuda, S; Miki, K; Nishibori, Y; Takada, M | 1 |
| Hassanian, MA; Samy, W | 1 |
| Chayama, K; Inoue, M; Ishigaki, T; Ishii, Y; Itsuki, H; Kamigaki, M; Kobayashi, K; Kosaka, K; Minami, T; Okazaki, A; Sasaki, T; Serikawa, M; Yukutake, M | 1 |
| Ahmed, D; Pillai, KK; Sharma, M | 1 |
| Aubin, MC; Carrier, M; Forcillo, J; Maltais, S; Perrault, LP; Shi, YF; Tardif, JC | 1 |
| Al-Khateeb, A; Ibrahim, S; Imran, K; Mohamed, MS; Yusof, Z; Zilfalill, BA | 1 |
| Chupka, J; Duignan, DB; El-Kattan, AF; Feng, B; Goosen, TC; Litchfield, J; Rotter, CJ; Varma, MV; Whalen, KM | 1 |
| Nemati, MH | 1 |
| Eban, K | 1 |
| Alexandrides, T; Athyros, VG; Bacharoudis, G; Ganotakis, ES; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Nicolaou, V; Paletas, K; Tziomalos, K | 1 |
| Eick, C; Laszlo, R; Menzel, KA; Schreieck, J; Schreiner, B; Schwiebert, M | 1 |
| Holowatz, LA; Kenney, WL | 2 |
| Elisaf, M; Katsiki, N | 1 |
| Fagan, SC; Guan, W; Kozak, A | 1 |
| Ananthi, S; Chandronitha, C; Gayathri, V; Sangeetha, MK; Vasanthi, HR | 1 |
| Aronica, E; Gorter, JA; Holtman, L; Schmitz, LJ; van Vliet, EA; Wadman, WJ | 1 |
| Antoniades, C; Antonopoulos, AS; Bakogiannis, C; Bendall, J; Casadei, B; Channon, KM; Demosthenous, M; Guzik, TJ; Hale, A; Leeson, P; Marinou, K; Paschalis, A; Psarros, C; Stefanadis, C; Tousoulis, D; Triantafyllou, C; Zhang, MH | 1 |
| Nart, D; Onat, T; Sezer, ED; Sozmen, EY | 1 |
| Fujii, M; Horie, M; Ibe, K; Kawahara, C; Nakae, I; Sakai, H; Tsutamoto, T; Yamaji, M; Yamamoto, T | 1 |
| Catapano, AL; Norata, GD; Pirillo, A | 1 |
| Boh, M; Ceska, R; Jezovnik, M; Opolski, G; Poredos, P | 1 |
| Choi, Y; Kim, DE; Lee, DK; Park, JE; Schellingerhout, D; Shon, SM | 1 |
| Kadoglou, NP; Kapelouzou, A; Kostakis, A; Lampropoulos, S; Liapis, CD; Sailer, N; Vitta, I | 1 |
| Caulfield, M; Chang, CL; Chapman, N; Dahlöf, B; Feder, G; Poulter, NR; Sever, PS | 1 |
| Chen, ZY; Lei, L; Li, LY; Liu, Q; Liu, SN; Shen, ZF; Zhang, N | 1 |
| Bays, HE; Choi, YJ; Karpf, DB; Kerzner, B; Krauss, RM; Littlejohn, T; Naim, S; Roberts, BK; Schwartz, S; Wang, X | 1 |
| Bonin, M; Burk, O; Dräger, A; Schröder, A; Thasler, WE; Thomas, M; Wollnik, J; Wrzodek, C; Zanger, UM; Zell, A | 1 |
| Akilli, H; Alihanoglu, Y; Altunkeser, BB; Aribas, A; Ayhan, S; Can, I; Demir, K; Koc, F; Vatankulu, MA | 1 |
| Benit, E; Channon, KM; de Winter, RJ; den Dekker, WK; den Heijer, P; Duckers, HJ; Grisold, M; Hill, J; Houtgraaf, JH; Ligtenberg, E; Onuma, Y; Rensing, BJ; Rowland, SM; Serruys, PW; Silber, S; Teiger, E; Verheye, S; Wiemer, M; Wijns, W | 1 |
| Barone, E; Butterfield, DA; Cenini, G; Dowling, AL; Head, E; Mancuso, C; Martin, SB; Murphy, MP | 1 |
| DeCastro, A; Janakiram, NB; Lee, HJ; Paul, S; Rao, CV; Reddy, BS; Simi, B; Smolarek, AK; So, JY; Steele, V; Suh, N; Wang, CX | 1 |
| Cho, JY; Jang, IJ; Kim, SE; Kim, TE; Lee, MG; Shin, KH; Shin, SG; Song, IS; Yoon, SH; Yu, KS | 1 |
| Barone, E; Butterfield, DA; Cenini, G; Di Domenico, F; Head, E; Mancuso, C; Murphy, MP; Sultana, R | 1 |
| Broccolini, A; Della Marca, G; Di Lazzaro, V; Pilato, F; Profice, P; Santoliquido, A | 1 |
| Childress, C; Parikh, A; Rukstalis, D; Toepfer, N; Yang, W | 1 |
| Dziedzic, H; Gryga, K; Konieczynska, M; Musial, J; Plazak, W; Podolec, P; Tomkiewicz-Pajak, L | 1 |
| Auwerx, J; Bouitbir, J; Charles, AL; Daussin, F; Echaniz-Laguna, A; Geny, B; Kindo, M; Piquard, F; Zoll, J | 1 |
| Cortopassi, WA; França, TC; Krettli, AU; Oliveira, AA; Penna-Coutinho, J | 1 |
| Alekperov, RT; Aleksandrova, EN; Anan'eva, LP; Korzeneva, EG; Novikov, AA | 1 |
| Chen, QJ; Lu, L; Peng, WH; Shen, WF; Wang, LJ; Wang, W | 1 |
| Chang, CL; Hingorani, A; Hughes, AD; Poulter, NR; Sattar, N; Sever, PS; Thom, SA; Welsh, P | 1 |
| Barbosa, CP; Bersani-Amado, CA; Bracht, A; Bracht, L; Caparroz-Assef, SM; Cuman, RK; Ishii-Iwamoto, EL | 1 |
| Belisario, DC; Bolli, E; Bosia, A; Calogero, RA; Cavallo, F; Pinto, H; Riganti, C | 1 |
| Barter, PJ; Boekholdt, SM; Breazna, A; Kastelein, JJ; Rye, KA; Tardif, JC; Waters, DD | 1 |
| Chen, SC; Cheng, WP; Hung, HF; Shyu, KG; Wang, BW | 1 |
| Crabbe, A; Delkhah, Y; Jones, J; Leonard, D; Nesbitt, S; Oliver, S | 1 |
| Chang, B; Chen, L; Fang, P; Li, H; Lu, S; Yang, J | 1 |
| Budinski, D; Gosho, M; Gumprecht, J; Hounslow, N | 1 |
| Åsberg, A; Bogsrud, MP; Hermann, M; Retterstøl, K; Skottheim, IB | 1 |
| Endo, T; Fukui, K; Himeno, H; Iwahashi, N; Iwasawa, Y; Kimura, K; Kobayashi, S; Mochida, Y; Morita, Y; Okada, K; Sawada, R; Shigemasa, T; Shimizu, M; Shimizu, T; Uchino, K; Umemura, S; Wada, A | 2 |
| Alves, K; Garg, V; Lee, JE; Smith, F; van Heeswijk, R | 1 |
| Che, WJ; Ou-Yang, PK; Tan, XH; Wei, P; Zhang, ZJ; Zou, QG | 1 |
| Azuma, Y; Fujita, T; Haruyama, Y; Ikeda, Y; Kumagai, Y; Maeda, K; Sugiyama, Y; Yamane, N; Yoshida, K | 1 |
| Babu, G; Bognolo, G; Boston-Griffiths, E; Hasleton, J; Hausenloy, DJ; Hayward, M; Kolvekar, S; Lawrence, D; Ludman, AJ; Rees, P; Venugopal, V; Yap, J; Yellon, DM | 1 |
| Ageno, W; Dentali, F; Romualdi, E; Squizzato, A | 1 |
| Aguilar, C; Rodríguez-Delfín, L; Ventura, F | 1 |
| Ren, Y; Sun, X; Wei, D; Zhang, M; Zhou, J | 1 |
| Chopp, M; Ding, C; Jiang, F; Jiang, J; Lu, Y; Yang, H; Zhang, L; Zhao, D; Zheng, X | 1 |
| Furman, A; Lopez, JR; Malmstrom, RA; Meier, JL; Schaefer, S | 1 |
| Acar, Z; Ağaç, MT; Demir, S; Demircan, S; Durna, K; Kale, A; Meriç, M; Turgut, M | 1 |
| Bouitbir, J; Charles, AL; Dufour, S; Geny, B; Piquard, F; Rasseneur, L; Zoll, J | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Karlgren, M; Palm, J; Svensson, R | 1 |
| Ahmad, FJ; Akhter, S; Anwar, M; Gahoi, S; Jain, GK; Khar, RK; Mallick, N; Talegaonkar, S; Warsi, MH | 1 |
| Hafner, M; Juvan, P; Monostory, K; Pascussi, JM; Rezen, T; Rozman, D | 1 |
| Bergh, JJ; Mienie, LJ; Terre'Blanche, G; van der Walt, MM | 1 |
| Drechsler, C; Genser, B; Hoffmann, MM; März, W; Wanner, C | 1 |
| Garcia, GG; Miranda, HF; Noriega, V; Olavarría, L; Prieto, JC; Sierralta, F; Zepeda, RJ | 1 |
| Abu-Fadel, MS; Pappy, R | 1 |
| De Backer, GG | 1 |
| Chang, CL; Gupta, AK; Poulter, NR; Sever, PS; Whitehouse, A | 1 |
| Kiani, AN; Magder, LS; Petri, M; Post, WS | 1 |
| Aref, A; Ehsanpour, A; Ghorbani, A; Shahbazian, H | 1 |
| Dehghan, MH; Khan, FN | 1 |
| Georgianos, PI; Kanaki, AI; Kanavos, K; Lasaridis, AN; Sarafidis, PA; Stafylas, PC; Tziolas, IM | 1 |
| Bronckers, I; Hopman, MT; Rongen, GA; Smits, P; Thijssen, DH; Wever, KE; Wouters, CW | 1 |
| Cao, LL; Dou, YC; Duan, RS; Li, XL; Liu, Y; Shi, CW; Zhang, XQ; Zhu, J | 1 |
| Atanassova, P; Bełtowski, J; Chaldakov, GN; Jamroz-Wiśniewska, A; Kula, W; Rusek, M | 1 |
| Björnsson, E; Jacobsen, EI; Kalaitzakis, E | 1 |
| Blankestijn, PJ; Joles, JA; Oey, PL; Siddiqi, L | 1 |
| Daida, H; Hibi, K; Hiro, T; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Saito, S; Yamagishi, M; Yamaguchi, T | 1 |
| Gradosova, I; Palicka, V; Svejkovska, K; Tichy, A; Zivna, H; Zivny, P | 1 |
| Della-Morte, D; DeRosa, JT; Elkind, MS; Gutierrez, J; Lorenzo, D; McClendon, MS; Ratchford, EV; Rundek, T; Sacco, RL | 1 |
| de Mello, CF; de Oliveira, CV; Ferreira, J; Funck, VR; Furian, AF; Guerra, GP; Mallmann, CA; Oliveira, MS; Pereira, LM; Rambo, LM; Ribeiro, LR; Royes, LF | 1 |
| Bansal, AK; Kaushal, AM; Kohli, G; Kumar, L; Puri, V; Sonje, VM | 1 |
| Darwish, HW; El-Zeiny, BA; Hassan, SA; Salem, MY | 1 |
| Abraham, G; Gnanaraj, A; Sankardas, MA; Victor, SM | 1 |
| Burk, O; Ghebreghiorghis, L; Hoffart, E; Nussler, AK; Schwab, M; Thasler, WE; Weiss, TS | 1 |
| Inamdar, MN; Kumar, VR; Viswanatha, GL | 1 |
| Arora, R; Dey, S; Kandhwal, K; Monif, T; Nazarudheen, S; Rao, S; Reyar, S; Singh, MK; Thudi, NR | 1 |
| Chu, B; Dong, L; Hatsukami, T; Lane, T; Lee, C; Monick, D; Moore, A; Neradilek, MB; Phan, BA; Polissar, N; Underhill, H; Yuan, C; Zhao, XQ | 1 |
| Fayad, ZA; Kramer, CM; Mani, V | 1 |
| Asirvatham, SJ; Bradley, D; Brady, PA; Cha, YM; Friedman, PA; Herges, R; Hodge, D; Koestler, C; Lerman, A; Lopez-Jimenez, F; Munger, TM; Packer, DL; Suleiman, M | 1 |
| Shinohara, Y | 1 |
| Wang, KF; Xie, LD; Xu, CS; Xu, SH | 1 |
| Aout, M; Clarençon, F; Colonne, C; Fonfrede, M; Jean, B; Le Jean, L; Nouet, A; Puybasset, L; Sanchez-Peña, P; Vicaut, E | 1 |
| Chacra, AP; Gagliardi, AC; Krieger, JE; Miname, MH; Pereira, AC; Santos, PC; Santos, RD | 1 |
| Awasthi, S; Nagaprashantha, L; Singhal, J; Singhal, SS; Vatsyayan, R | 1 |
| Azizova, OA; Baranova, OA; Blagodatskikh, KA; Koroleva, OS; Nosikov, VV; Pushkov, AA; Reznichenko, NE; Zateĭshchikov, DA | 1 |
| Sankar, AS; Venkappaya, D; Vetrichelvan, T | 1 |
| Czaikoski, PG; Dias-Junior, CA; Neto-Neves, EM; Pereira, RP; Spiller, F; Tanus-Santos, JE; Uzuelli, JA | 1 |
| Bang, OY; Huh, W; Kim, HG; Kim, JW; Kim, SR; Ko, JW; Lee, SC; Lee, SY; McLeod, HL; O'Connell, TM; Won, HH | 1 |
| Frye, RF; Johnson, JA; Langaee, T; Pacanowski, MA; Pauly, DF; Shin, J | 1 |
| Gabriel, CL; Kastelein, JJ; Major, AS; Mendez-Fernandez, YV; Stroes, ES; Tak, PP; van Leuven, SI; Wade, NS; Wilhelm, AJ | 1 |
| Abdulhalim, AM; Grabner, M; Johnson, W; Kuznik, A; Mullins, CD | 1 |
| He, B; Hu, LH; Jing, Q; Pu, J; Shao, Q; Shen, LH | 1 |
| Haygood, TM; Jonasch, E; Manoukian, GE; Qiao, W; Tannir, NM; Tu, SM | 1 |
| Korkor, MT; Liu, B; Liu, JY; Song, XJ; Wei, Q; Yang, CY; Yang, P | 1 |
| Ellesat, KS; Holth, TF; Hylland, K; Yazdani, M | 1 |
| Bajramovic, JJ; Kondova, I; Kuipers, HF; Van Den Elsen, PJ; Van Der Putten, C; Van Straalen, L; Zuiderwijk-Sick, EA | 1 |
| Chuang, WL; Chuang, YH; Huang, CH; Huang, SP; Liu, CK | 1 |
| Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T; Smith, KA | 1 |
| Hart, RJ; Hunter, T; Raval, AD; Stuckey, B | 1 |
| Liao, JK | 1 |
| Bi, Q; Bolli, R; Dawn, B; Hunt, G; Peng, Y; Sanganalmath, SK; Sato, H; Shirk, G; Tang, XL; Vincent, RJ | 1 |
| Cai, A; Dai, G; Dong, Y; Huang, Y; Jiang, Z; Kuang, J; Liao, X; Mai, W; Qiu, R; Rao, S; Song, Y; Zheng, D | 1 |
| Brunetti, ND; Correale, M; De Gennaro, L; Di Biase, M; Ieva, R; Montrone, D; Ruggiero, A | 1 |
| Tanaka, M | 1 |
| Chang, CW; Chang, YC; Hsieh, MC; Kao, YH; Lai, YH; Wu, HJ; Wu, KY; Wu, MH; Wu, WC | 1 |
| Grassi, G; Seravalle, G; Zoccali, C | 1 |
| Fraser, H; Goulder, MA; Hislop, C; Rosenson, RS | 1 |
| Binning, MJ; Darkhabani, Z; Levy, EI; Mokin, M; Siddiqui, AH | 1 |
| Högberg, J; Miraglia, E; Stenius, U | 1 |
| Dlugošová, K; Javorková, V; Mézešová, L; Mitašíková, M; Okruhlicová, L; Tribulová, N; Vlkovičová, J; Vrbjar, N | 1 |
| Ali, OF; Butrous, GS; Growcott, EJ; Wharton, J | 1 |
| Daemen, MJ; Gabriels, K; Gijbels, MJ; Heeneman, S; Hoving, S; Pol, JF; Russell, NS; Stewart, FA; te Poele, JA | 1 |
| Goette, A | 1 |
| Barone, E; Butterfield, DA; Di Domenico, F; Head, E; Mancuso, C; Murphy, MP; Sultana, R | 1 |
| Cui, JJ; Gao, F; Li, YR; Wang, D | 1 |
| Charlton-Menys, V; Dissanayake, S; Durrington, PN; France, MW; Kwok, S; Soran, H; Younis, NN | 1 |
| Achimastos, A; Alexandrides, T; Athyros, VG; Bilianou, E; Elisaf, MS; Ganotakis, E; Karagiannis, A; Liberopoulos, EN; Mikhailidis, DP; Tziomalos, K | 1 |
| Hydzik, P; Szpak, D | 1 |
| Tuğlu, MI; Vural, K | 1 |
| Fullerton, DA; Meng, X; Reece, TB; Reppert, AE; Sadaria, MR; Weyant, MJ; Yu, JA | 1 |
| Arazi, SS; Bernik, MM; Bertolami, MC; Carracedo, A; Dorea, EL; Faludi, AA; Fondevila, M; Freire, A; Genvigir, FD; Hirata, MH; Hirata, RD; Lareu, MV; Luchessi, AD; Perin, PM; Phillips, C; Porras-Hurtado, L; Purim, SG; Rodrigues, AC; Salas, A; Santos, C; Silbiger, VN; Willrich, MA | 1 |
| Schneider, A; Simons, M | 1 |
| Eussen, SR; Klungel, OH; Rompelberg, CJ; van Eijkeren, JC | 1 |
| Augeri, AL; Capizzi, JA; Grimaldi, AS; Michael White, C; Parker, BA; Thompson, PD | 1 |
| Buikema, A; Kulakodlu, M; Kuznik, A; Potash, J; Swindle, JP | 1 |
| Anderson, L; Bhattacharya, S; Bose, N; Fraser, E; Graham, K; Lumsden, G; McClue, L; Robertson, L; Tho, LM; Yosef, H | 1 |
| Bhome, R; Penn, H | 1 |
| Ehsani, AH; Faghihi, T; Mehrabian, Z; Radfar, M; Rezaei Hemami, M | 1 |
| Ravelli, A | 1 |
| Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Imundo, LF; Jung, L; Kimura, Y; Klein-Gitelman, M; McCurdy, D; Mieszkalski, KL; Provenzale, J; Punaro, M; Reed, AM; Sandborg, C; Schanberg, LE; Sherry, DD; Silver, R; Silverman, E; Singer, NG; Soep, JB; Thompson, SD; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E | 1 |
| Bi, YA; El-Kattan, AF; Fenner, KS; Iseki, K; Kimoto, E; Lai, Y; Linder, C; Walsky, R; Whalen, KM; Xiao, Y; Yang, YS; Zhang, H | 1 |
| Antovic, J; Bröijersen, A; Egberg, N; Jörneskog, G; Mobarrez, F; Wallén, H | 1 |
| Fonarow, GC; Horwich, TB; Maclellan, WR; Middlekauff, HR | 1 |
| Beer, C; Blacker, D; Bynevelt, M; Hankey, GJ; Puddey, IB | 1 |
| Czuczwar, SJ; Luszczki, JJ; Stepien, KM; Tomaszewski, M | 1 |
| Chu, Q; Dunlop, D; Hao, D; Jacobs, CD; Leighl, N; Lopez-Anaya, A; Middleton, G; Ramlau, R; Rodon, J; Rowinsky, EK; Takimoto, CH; Wakelee, HA; Zatloukal, P | 1 |
| Corcione, N; Di Pace, AL; Ferraro, P; Giordano, A; Monaco, M; Nappo, G; Polimeno, M; Romano, MF; Romano, S; Sorrentino, A | 1 |
| Arazi, SS; Bernik, MM; Bertolami, MC; Cerda, A; Dorea, EL; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Willrich, MA | 1 |
| Ghalali, A; Högberg, J; Stenius, U; Ye, ZW | 1 |
| Antoniades, C; Antonopoulos, AS; Bakogiannis, C; Brili, S; Hatzis, G; Papageorgiou, N; Stefanadis, C; Tousoulis, D | 1 |
| Aschermann, M; Downe, RW; Horak, J; Kovarnik, T; Kral, A; Linhart, A; Martasek, P; Mintz, GS; Mrazek, V; Skalicka, H; Skulec, R; Sonka, M; Uhrova, J; Wahle, A | 1 |
| Akar, AR; Arslan, Ö; Baran, Ç; Dalva, K; Dogan, A; Durdu, S; Gürman, G; Ocakoglu, G; Zaim, Ç | 1 |
| Iyer, D; Patil, UK; Sharma, BK | 1 |
| Della-Morte, D; Elkind, MS; Moussa, I; Rundek, T; Sacco, RL | 1 |
| Ballantyne, CM; Barter, PJ; Borgman, M; Chapman, MJ; Erbel, RM; Libby, P; Nicholls, SJ; Nissen, SE; Raichlen, JS; Uno, K; Wolski, K | 1 |
| Bandivadeka, MM; Choudhari, A; Kaul-Ghanekar, R; Koppikar, S; Pancholi, SS | 1 |
| Liu, JL; Luo, YT; Peng, L | 1 |
| Akçalı, Z; Borlu, F; Namal, E; Oztekin, E; Sener, N; Ulaş, T | 1 |
| Brewer, HB; Hu, B; Kastelein, JJ; Krueger, KA; McErlean, E; Nicholls, SJ; Nissen, SE; Shao, M; Wang, MD | 1 |
| Bertolami, MC; Cavalli, SA; Cerda, A; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Issa, MH | 1 |
| Ishii, H; Koyasu, M; Matsubara, T; Murohara, T; Shibata, R; Takemoto, K; Uemura, Y; Watarai, M; Yoshikawa, D | 1 |
| Brcakova, E; Micuda, S; Nachtigal, P; Rathouska, J; Slanarova, M; Strasky, Z; Vecerova, L | 1 |
| Bouma, BJ; de Groot, E; Groenink, M; Luijendijk, P; Mulder, BJ; Pieper, PG; Sieswerda, GT; van Dijk, AP; Veen, G; Vliegen, HW; Vriend, JW; Zwinderman, AH | 1 |
| Bash, D; Cavender, MA; Hislop, C; Kastelein, JJ; Nicholls, SJ; Rosenson, RS; Schwartz, G; Waters, DD | 1 |
| Chen, MF; Chi, YC; Huang, CL; Huang, PJ; Kao, HL; Lin, HJ; Lin, LY; Lin, YH; Tzen, KY; Wang, YC; Wu, YW; Yang, WS; Yen, RF | 1 |
| Braunwald, E; Cannon, CP; Grandin, EW; Jarolim, P; Morrow, DA; Murphy, SA; Ritterova, L | 1 |
| Leekha, S; Lena, YL; Mahanim, O; Ong, LM; Punithavathi, N | 1 |
| Bagshaw, SM; Bellomo, R; Calzavacca, P; Devarajan, P; Echeverri, JE; Haase, M; Haase-Fielitz, A; Licari, E; Ligabo, EV; Prowle, JR | 1 |
| Alvear, M; Cuevas, A; Rosales, A; Saavedra, N; Salazar, LA; Zambrano, T | 1 |
| Kawaguchi, R | 1 |
| Chiu, CZ; Shyu, KG; Wang, BW | 1 |
| Ledford, H | 1 |
| Burzynska, B; Gora, M; Hoser, G; Iwanicka-Nowicka, R; Kiliszek, M; Koblowska, M; Kotlinski, M; Leszczynska, A; Plochocka, D; Rawa, K; Szkopinska, A | 1 |
| Havekes, LM; Jukema, JW; Kühnast, S; Liau, G; Princen, HM; van den Hoek, AM; van der Hoorn, JW | 1 |
| Arsenault, BJ; Barter, P; Boekholdt, SM; Chatterjee, A; Deedwania, P; DeMicco, DA; Hovingh, GK; Hyde, CL; Kastelein, JJ; LaRosa, JC; Pedersen, TR; Waters, DD | 1 |
| Ahn, KJ; Choi, JH; Choi, SH; Choi, YJ; Gwon, HC; Hahn, JY; Jo, SH; Kim, HJ; Lee, KH; Lee, S; Lee, SH; Song, YB | 1 |
| Ghafourifar, P; Parihar, A; Parihar, MS; Zenebe, WJ | 1 |
| Boerman, OC; Frederix, GW; Janssen, CI; Meijer, P; Oyen, WJ; Rongen, GA; Smits, P; Wouters, CW | 1 |
| Chou, MM; Jackevicius, CA; Krumholz, HM; Ross, JS; Shah, ND | 1 |
| Schalkwijk, CG; Simsek, S; Wolffenbuttel, BH | 1 |
| Fentoğlu, O; Kirzioğlu, FY; Koçak, H; Ozdem, M; Sert, T; Sütçü, R | 1 |
| Saito, Y | 1 |
| Chapman, MJ | 1 |
| Teramoto, T | 1 |
| An, Y; Chen, J; Li, X; Liu, B; Pan, Y; Tie, L; Yang, J; Yuan, J; Zhang, J | 1 |
| Abulhul, E; Baugh, J; Hennessy, M; Ledwidge, M; Martos, R; McDonald, K; O'Loughlin, C; Phelan, D; Spiers, JP; Watson, C | 1 |
| Hadoke, PW | 1 |
| Hayashi, K; Ikewaki, K; Inazu, A; Kawashiri, MA; Kobayashi, J; Konno, T; Mabuchi, H; Miwa, K; Nakanishi, C; Noguchi, T; Nohara, A; Tada, H; Takata, M; Terao, Y; Tsuchida, M; Yamagishi, M | 1 |
| MacMillan, DW; Nagib, DA | 1 |
| Gao, Y; Li, Y; Zeng, D | 1 |
| Luo, H; Luo, M; Wang, J; Xiao, Y | 1 |
| Casto, BC; Knobloch, TJ; Lubet, RA; Pereira, MA; Steele, VE; Warner, BM; Weghorst, CM | 1 |
| Braitman, LE; Goldstein, DT; Handal, JA; John, TK; Khurana, JS; Saing, M; Samuel, SP | 1 |
| Feig, JE; Fernandez-Hernando, C; Fisher, EA; Garabedian, MJ; Rotllan, N; Shamir, R; Shang, Y; Torra, IP; Vengrenyuk, Y; Wu, C | 1 |
| Buianova, SV; Korobov, GD; Osochuk, SS | 1 |
| DeGorter, MK; Gradhand, U; Kim, RB; Tirona, RG; Urquhart, BL | 1 |
| Choi, YJ; Geaney, JC; Karpf, DB; Krauss, RM; Naim, S; Roberts, BK; Wang, X; Wojnoonski, K | 1 |
| Allahkhah, AA; Enshaei, A; Falahatkar, S; Farhat, B; Heidari Bateni, Z; Khosropanah, D; Khosropanah, I | 1 |
| Alsop, DC; Asthana, S; Barnet, JH; Blazel, HM; Carlsson, CM; Chappell, RJ; Fain, SB; Johnson, SC; Rowley, HA; Sager, MA; Stein, JH; Wen, Z; Xu, G | 1 |
| Bertocchi, C; Dörler, J; Dunzendorfer, S; Hasslacher, J; Joannidis, M; Traunwieser, M | 1 |
| Bielecka, A; Bułdak, Ł; Duława-Bułdak, A; Krysiak, R; Madej, A; Okopień, B; Łabuzek, K | 1 |
| Bada, V; Bozek, P; Gvozdjakova, A; Kucharska, J; Ulicna, O; Vancova, O; Waczulikova, I | 1 |
| Becker, ML; Elens, LL; Hofman, A; Stricker, BH; Uitterlinden, AG; van Schaik, RH; Visser, LE | 1 |
| Komatsu, T; Kunugita, F; Nakamura, M; Ozawa, M; Sato, Y; Tachibana, H | 1 |
| Hacker, M | 1 |
| Antoniades, C; Antonopoulos, A; Bakogiannis, C; Casadei, B; Channon, KM; Demosthenous, M; Jayaram, R; Koumallos, N; Margaritis, M; Marinou, K; Miliou, A; Nahar, K; Psarros, C; Reilly, S; Sayeed, R; Stefanadis, C; Tousoulis, D; Triantafyllou, C; Zhang, MH | 1 |
| Adam, O; Laufs, U | 1 |
| Abd El-Halim, MS; Abdin, AA; El-Saadany, AA; Hedeya, SE | 1 |
| Drechsler, C; Hoffmann, MM; Krane, V; Wanner, C; Winkler, K | 1 |
| Chan, WC; Hopkins, R; Jackson, G; Lawes, CM; Marshall, R; Thornley, S; Young, R | 1 |
| Krasznai, Z; Toth, P | 1 |
| Adamczak, M; Chudek, J; Czerwienska, B; Szotowska, M; Wiecek, A | 1 |
| Reddy, PJ; Sekhar, MC | 1 |
| Bao, W; Benessiano, J; Mallat, Z; Olsson, AG; Ryu, SK; Schwartz, GG; Tedgui, A; Tsimikas, S | 1 |
| Amalvict, R; Baret, E; Briolant, S; Dormoi, J; Mosnier, J; Pradines, B; Rogier, C; Savini, H; Soulard, R; Souraud, JB | 1 |
| Du, Y; Ji, H; Li, L; Li, S; Liu, H; Zhang, X | 1 |
| Bakhai, A; Emmas, C; Hollis, S; Rigney, U | 1 |
| Foulet-Rogé, A; Gagnadoux, F; Goupil, F; Kernaonet, E; Lebas, FX; Molinier, O; Paris, A | 1 |
| Asteriou, C; Ballas, KD; Giakoustidis, DE; Lalountas, M; Michalakis, A; Nikolaidou, C; Pavlidis, TE; Psarras, K; Sakantamis, AK; Venizelos, I | 1 |
| Bhardwaj, A | 1 |
| Gokce, Mİ; Güleç, S; Gülpınar, Ö; Öztürk, E; Yaman, Ö | 1 |
| Schaefer, JR | 1 |
| Bellanger, N; Chapman, MJ; Duchene, E; El Khoury, P; Fournier, N; Guerin, M; Julia, Z; Le Goff, W; Villard, EF | 1 |
| Chayama, K; Hyogo, H; Ishitobi, T; Kimura, Y; Maeda, S; Yamagishi, S | 1 |
| Cheng, Y; Feng, Y; Gao, J; Huang, B; Lin, G; Wu, Y; Xie, Q; Xu, D | 1 |
| Bennie, M; Bishop, I; Campbell, S; Godman, B | 1 |
| Nammas, W; Rifaie, O; Zahran, A | 1 |
| Mantri, SK; Murthy, KV; Pashikanti, S | 1 |
| Schreinemacher, MH | 1 |
| Janakiram, NB; Lightfoot, S; Mohammed, A; Qian, L; Rao, CV; Steele, VE | 1 |
| de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ | 1 |
| Deli, CK; Fatouros, IG; Fotopoulou, N; Jamurtas, AZ; Koutedakis, Y; Nikolaidis, MG; Panayiotou, G; Paschalis, V; Sampanis, M; Theodorou, AA | 1 |
| Cao, HM; Feng, J; Li, GY; Li, J; Liu, B; Liu, M; Wang, Q | 1 |
| Bada, V; Božek, P; Kucharská, J; Šikurová, L; Uličná, O; Vančová, O; Waczulíková, I | 1 |
| Civeira, F; Dan, AG; De Tilleghem, Cle B; Hanson, ME; Hing Ling, PK; Massaad, R; Milardo, C; Triscari, J | 1 |
| El-Bassossy, HM; El-Nagar, M; Mahmoud, MF | 1 |
| Borggrefe, M; Elmas, E; Fischer, J; Kälsch, T; Lang, S; Nguyen, XD; Stach, K; Weiss, C | 1 |
| Sidorenko, BA; Zateĭshchikova, AA | 1 |
| Blomqvist, P; Chen, E; Chen, F; Davidson, M; Maccubbin, D; McKenney, JM; Sirah, W; Sisk, CM; Yan, L | 1 |
| An, Y; Chen, J; Hou, J; Lan, T; Li, X; Liu, J; Pan, Y; Tie, L; Zhang, J | 1 |
| Gradosova, I; Hubena, S; Palicka, V; Svejkovska, K; Zivna, H; Zivny, P | 1 |
| Munhoz, RP; Teive, HA; Werneck, LC | 1 |
| Avila Castellanos, R; Lucena Soto, JM; Ortega-Camarero, M; Piñero Saavedra, MC; Prados Castaño, M; Sánchez, B | 1 |
| Bandgar, TR; Faruqui, AA | 1 |
| Cherkanova, MS; Filjushina, EE; Johnston, TP; Kaledin, VI; Korolenko, TA; Loginova, VM; Tuzikov, FV; Tuzikova, NA | 1 |
| Cai, WQ; Chai, DJ; Chen, GL; Chen, XP; Huang, QY; Su, JZ; Wang, FB; Xue, Y; Zhang, DS | 1 |
| Jiang, P; Padley, RJ; Thakker, KM; Toth, PP | 1 |
| Dong, QT; Meng, XM; Qian, HY; Song, L; Tang, Y; Xu, H; Yang, YJ | 1 |
| Hirayama, A; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Okada, K; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O | 1 |
| Han, C; Han, L; Li, M; Liu, Y; Ye, P | 1 |
| Gao, F; Liang, Y; Liu, D; Luo, Z; Ni, Y; Wang, J; Xu, X; Yan, Z; Zhu, S; Zhu, Z | 1 |
| Pearson, M | 1 |
| Altman, JK; Gordon, LI; Platanias, LC; Sassano, A | 1 |
| Dong, QT; Qian, HY; Wang, H; Wang, TJ; Xu, H; Yang, YJ; Zhang, Q | 1 |
| Bai, S; Dybowski, C; Gao, X; Strohmeier, M; Wang, W; Wang, WD | 1 |
| Loscalzo, J; Miller, E; Monyak, J; Pitt, B; Raichlen, J | 1 |
| Alberti, PF; Conti, V; Corazzi, T; Falcinelli, E; Gresele, P; Miglietta, D; Minuz, P; Momi, S; Monopoli, A; Ongini, E | 1 |
| Cheng, XS; Gu, Q; He, JG; Liu, ZH; Ni, XH; Shan, GL; Wilkins, MR; Xiong, CM; Xue, F; Zeng, WJ; Zhao, L; Zhao, ZH | 1 |
| Itoh, T; Nakamura, M; Satoh, M; Tabuchi, T | 2 |
| Betteridge, DJ; Calle, RA; Caulfield, M; Charlton-Menys, V; Chatterjee, A; Colhoun, HM; DeMicco, DA; Deshmukh, HA; Durrington, PN; Ford, I; Fuller, JH; Hitman, GA; Hyde, C; Johnson, T; Jukema, JW; Livingstone, S; McKeigue, PM; Neil, A; Postmus, I; Poulter, N; Sever, P; Shields, DC; Stanton, AV; Trompet, S | 1 |
| Ciesla-Dul, M; Undas, A; Zolcinski, M | 1 |
| Guo, CX; Li, Q; Liu, ZQ; Meng, XG; Ouyang, DS; Pei, Q; Peng, XD; Wang, G; Wu, LX; Yin, JY; Zhang, W; Zhao, YC; Zhou, BT; Zhou, HH | 1 |
| Cai, A; Dai, G; Huang, Y; Kuang, J; Mai, W; Qiu, R; Song, Y | 1 |
| An, C; An, F; Dong, Z; Liu, H; Wang, Y; Wu, Y; Zhang, M; Zhang, Y | 1 |
| Hohendorff, B; Mühldorfer-Fodor, M; Prommersberger, KJ; Schmitt, R; Wagner, M | 1 |
| Lee, T | 1 |
| Amalvict, R; Baret, E; Briolant, S; Charras, S; Dormoi, J; Feraud, M; Huyghues des Etages, E; Pascual, A; Pradines, B | 1 |
| Alafris, A; Cohen, H; Liu, M; Longo, AJ | 1 |
| Lv, HX; Waddad, AY; Zhang, ZH; Zhou, JP | 1 |
| Balk, B; Bujok, K; Fromm, MF; Glaeser, H; Mandery, K; Schmidt, I | 1 |
| Asai, K; Hata, N; Kobayashi, N; Matsushita, M; Mizuno, K; Shinada, T; Shirakabe, A; Tomita, K; Tsurumi, M; Yokoyama, S | 1 |
| Dehpour, AR; Fakhrzad, A; Hassanipour, M; Hassanpour, S; Moezi, L; Shafaroodi, H | 1 |
| Luzak, B; Rywaniak, J; Stanczyk, L; Watala, C | 1 |
| Gajula, R; Inamadugu, JK; Mullangi, R; Pilli, NR; Ponneri, V; Ravi, VB | 1 |
| Choudhury, RP; Iacob, AO | 1 |
| Doevendans, PA; Eefting, FD; Goumans, MJ; Post, MC; Post, S; Rensing, BJ; Stella, PR; van den Branden, BJ; van Es, HW; Wildbergh, TX | 1 |
| Guerci, AD; Kastelein, JJ; Mulders, TA; Pinto-Sietsma, SJ; Sivapalaratnam, S; Stroes, ES | 1 |
| Villines, TC | 1 |
| Brus, J; Kobera, L; Policianova, O; Sedenkova, I; Urbanova, M | 1 |
| Ding, YZ; Fu, Y; Gu, MX; Li, CH; Pan, S; Pang, W; Sun, XL; Zhu, Y | 1 |
| Emamzadeh-Fard, S; Moazzami, K; Shabani, M | 1 |
| Bidhendi, LM; Bina, P; Fathollahi, MS; Karimi, A; Molai, M; Rezvanfard, M; Sadeghian, S; Yousefi, A; Zare, E | 1 |
| Ajamieh, H; Chen, J; Chu, E; Farrell, G; Teoh, N; Wong, HJ; Yu, J | 1 |
| Du, Y; Gasparino, E; Gutierrez, M; Kranz, T; Lisbon, E; Logan, D; Mellis, S; Smith, WB; Stahl, N; Stein, EA; Swergold, GD; Webb, C; Wu, R; Yancopoulos, GD | 1 |
| Araki, A; Iimuro, S; Ito, H; Matsuyama, Y; Ohashi, Y; Sakurai, T; Shinozaki, T; Umegaki, H | 1 |
| Ahn, JM; Kang, SJ; Kim, WJ; Kim, YH; Lee, CW; Lee, JY; Lee, SW; Park, DW; Park, SJ; Park, SW; Song, HG | 1 |
| Borda, E; Passafaro, D; Reina, S; Sterin-Borda, L | 1 |
| Gambassi, G; Lapane, KL; Motzkus-Feagans, CA; Pakyz, A; Polk, R | 1 |
| Vareka, T; Vecka, M; Vítková, D; Zák, A; Zeman, M | 1 |
| Ai, J; Ban, X; Niu, H; Sun, L; Wang, N; Xu, Y; Yang, B; Yu, Y; Zhang, R; Zhao, R | 1 |
| Wang, H; Ye, P; Zhang, JY | 1 |
| Bonaca, MP; Bui, AH; Cannon, CP; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS | 1 |
| Heinemann, L; Heise, T; Herder, C; Koenig, W; Kolb, H; Martin, S; Roden, M; Schloot, NC; Simon, MC; Strom, A | 1 |
| Nishigaki, K | 1 |
| Daida, H; Hasegawa, Y; Hirayama, A; Hiro, T; Kadota, K; Kimura, K; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ozaki, Y; Uchiyama, S; Yamagishi, M | 1 |
| Guo, Y; Wang, J; Xu, D; Xu, J; Yang, Z; Zhang, Y; Zhou, C | 1 |
| Breazna, A; Deedwania, PC; Demicco, DA; Ho, JE; Kean, A; Khush, KK; Waters, DD; Wilson, DJ; Wun, CC | 1 |
| Bar-Or, A; Calabresi, PA; Cohen, JA; Cross, A; Ding, L; Goodman, A; Iklé, D; Kachuck, N; Kita, M; Kopetskie, H; Mass, M; Miller, A; Mokhtarani, M; Murphy, S; Pelletier, D; Preiningerova, J; Racke, M; Rosenberg, E; Schwid, S; Spencer, C; Stüve, O; Vollmer, T; Waubant, E; Weinstock-Guttman, B; Zamvil, SS | 1 |
| Nachtigal, P; Rathouska, J; Strasky, Z; Zemankova Vecerova, L | 1 |
| Arsenault, BJ; Boekholdt, SM; Breazna, A; Deedwania, P; Demicco, DA; Kastelein, JJ; Mora, S; Waters, DD; Wenger, NK | 1 |
| Stone, NJ | 1 |
| Ferrand, AC; Hanotin, C; Kereiakes, DJ; Koren, MJ; McKenney, JM; Stein, EA | 1 |
| Vogel, RA | 1 |
| Hwang, SJ; Kim, MS; Park, HJ; Song, HS | 1 |
| Buhre, WF; van Klei, WA | 1 |
| Beattie, WS; Fleisher, LA | 1 |
| Davies, GR | 1 |
| Narula, SC; Sangwan, A; Sharma, RK; Singh, H; Tewari, S | 1 |
| Bragagnolo, JC; Catalano, H; Comignani, PD; Cornejo Pucci, E; Herrera, L; Igarzabal, C; Laffaye, N; Macchia, A; Mariani, JA; Nicolucci, A; Scazziota, AS; Tognoni, G | 1 |
| Chang, XR; Fu, L; He, XQ; Liu, M; Shang, LC; Yu, BS; Yuan, JL; Yue, ZH; Zhang, L | 1 |
| Lonardo, A; Loria, P | 1 |
| Böhm, M; Laufs, U; Schirmer, SH; Werner, CM | 1 |
| Andrade, L; Danilovic, A; Dénes, FT; Lopes, RI; Oshiro, FM; Sanches, TR; Seguro, AC; Shimizu, MH | 1 |
| Butany, J; Fefer, P; Fujii, H; Leong-Poi, H; Nili, N; Osherov, AB; Qiang, B; Samuel, M; Sparkes, JD; Strauss, BH; Toma, J | 1 |
| Chen, Y; Duan, Y; Hajjar, DP; Han, J; He, GW; Hu, W; Jiang, M; Li, X; Yao, Z; Yin, Z; Zhou, X; Zhu, Y | 1 |
| Fenech, ME; Mackay, JW; Myint, KS | 1 |
| Hitman, GA | 1 |
| Ahn, JH; Bliden, KP; Gho, EH; Gurbel, PA; Hwang, JY; Hwang, SJ; Jeong, YH; Kim, S; Kwak, CH; Kwon, TJ; Park, JR; Park, Y; Tantry, US | 1 |
| An, Y; Chen, J; Hou, J; Li, X; Liu, J; Yue, L; Zhang, J; Zhang, X | 1 |
| He, Z; Mangala, LS; Rohde, LH; Theriot, CA; Wu, H; Zhang, Y | 1 |
| Klein, K; Niemi, M; Nussler, AK; Schwab, M; Thomas, M; Winter, S; Zanger, UM | 1 |
| Hong, T; Huo, Y; Jia, J; Jiang, J; Li, J; Liu, P; Yu, R; Zhang, Y | 1 |
| Endo, K; Miyashita, Y; Murano, T; Ohira, M; Saiki, A; Shirai, K; Tatsuno, I; Terai, K; Watanabe, F | 1 |
| Alaminos, M; Esteban, M; Garrido, JM; Roda, O; Sánchez-Montesinos, I | 1 |
| Breitkreitz, MC; Polla, G; Poppi, RJ; Sabin, GP | 1 |
| Boersma, E; Daemen, J; de Jaegere, PP; Eindhoven, JA; Oemrawsingh, RM; Onuma, Y; Serruys, PW; van Domburg, RT; van Nierop, JW | 1 |
| Bryson, GL; Neilipovitz, DT; Taljaard, M | 1 |
| Aebi, JD; Chapuis-Bernasconi, C; Dehmlow, H; Fischer, H; Juillerat-Jeanneret, L; Staedler, D | 1 |
| Colosi, LM; Ottmar, KJ; Smith, JA | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Hajheydari, Z; Mahmoudi, M; Moosa-Kazemi, SH; Nikookar, SH; Shahmohammadi, S | 1 |
| Chung, YT; Li, H; Liao, J; Yan, L; Yang, AL; Yang, GY; Zhang, M; Zhang, W | 1 |
| Covelli, D; Crisanti, F; De Vuono, S; Lupattelli, G; Mannarino, E; Pirro, M; Roscini, AR; Siepi, D | 1 |
| Cho, SK; Chung, JY; Oh, ES; Park, K; Park, MS | 1 |
| Ellesat, KS; Holth, TF; Hylland, K; Wojewodzic, MW | 1 |
| Goto, SN; Iwata, K; Takagi, H; Umemoto, T; Yamamoto, H | 2 |
| Al-Azzam, S; Alnasser, Z; Alzoubi, K; Masadeh, M; Mhaidat, N | 1 |
| Malhotra, S; Pandhi, P; Pattanaik, S; Sharma, YP | 1 |
| Burren, Y; Donati, F; El-Koussy, M; Findling, O; Goebels, N; Humpert, S; Kamm, CP; Kappos, L; Mattle, HP; Müller, F; Müller, M; Naegelin, Y; Schött, D; Schwegler, G; Slotboom, J; Tettenborn, B; von Bredow, F | 1 |
| Arsenault, BJ; Bao, W; Barter, PJ; Boekholdt, SM; Davaine, JM; DeMicco, DA; Huijgen, R; Kastelein, JJ; Lambert, G; Petrides, F; Rye, KA; Tabet, F | 1 |
| Betteridge, J; DeMicco, DA; Fayyad, R; Holme, I; Kvien, TK; LaRosa, JC; Pedersen, TR; Semb, AG; Wun, CC | 1 |
| Gugliucci, A; Ishibashi, S; Kotani, K; Miyamoto, M; Taniguchi, N; Yamada, T | 1 |
| Angelica Merlini, P; Antonietta Demola, M; Ardissino, D; Francesca Notarangelo, M; Guidorossi, A; Marziliano, N; Pigazzani, F | 1 |
| Boussoula, E; Boutsikou, M; Giannakopoulou, V; Katsiki, N; Kollia, A; Kolovou, G; Kolovou, V; Mavrogeni, S; Mihas, C; Vasiliadis, I | 1 |
| Sweet, M | 1 |
| Filippatos, TD | 1 |
| Cao, H; Cui, W; Du, B; Lin, S; Liu, Y; Qin, L; Xu, G | 1 |
| Drevenšek, G; Janić, M; Jerin, A; Lunder, M; Sabovič, M; Skitek, M; Ziberna, L | 1 |
| Cao, J; Fan, L; Gao, Y; Liu, XF; Lu, XC; Ma, C | 1 |
| Gui, Y; Jiang, J; Li, D; Li, H; Li, J; Tian, R; Walsh, MP; Wang, L; Wang, Y; Wang, Z; Yin, H; Zheng, XL | 1 |
| Bartimoccia, S; Basili, S; Cangemi, R; Carnevale, R; Napoleone, L; Nocella, C; Pastori, D; Pignatelli, P; Violi, F | 1 |
| Bandivadekar, M; Choudhari, A; Kaul-Ghanekar, R; Koppikar, S; Pancholi, S | 1 |
| Ike, A; Iwata, A; Kawamura, A; Miura, S; Nishikawa, H; Saku, K; Sugihara, M; Tanaka, T | 1 |
| Ballantyne, CM; Carlson, DM; Davidson, M; Maki, KC; Nicholls, SJ; Rosenson, RS; Setze, C; Stolzenbach, J | 1 |
| Choi, H; Lee, H; Lee, J; Lee, MK | 1 |
| Musella, F; Paneni, F; Perrone-Filardi, P; Savarese, G; Volpe, M | 1 |
| Blanco, M; Castillo, J; Pérez-Mato, M; Rodríguez-Yáñez, M; Sobrino, T | 1 |
| Awad, GA; Kamel, AO; Mekhail, GM; Mortada, ND | 1 |
| Itoh, H; Mitsuishi, M; Miyashita, K; Muraki, A; Tamaki, M; Tanaka, K | 1 |
| Chen, J; Jiang, R; Li, Z; Sun, L; Tian, Y; Wang, B; Wang, D; Wei, H; Yang, Z; Zhang, J | 1 |
| Finn, AV; Nakano, M; Otsuka, F; Virmani, R; Yazdani, SK | 1 |
| Chen, Z; Dixon, RA; Ganjehei, L; Haidari, M; Mortazavi, A; Vanderslice, P; Warier, N; Zhang, W | 1 |
| Bożentowicz-Wikarek, M; Chudek, J; Kocełak, P; Olszanecka-Glinianowicz, M; Smertka, M | 1 |
| Kishi, T; Sunagawa, K | 1 |
| Chen, L; Guo, L; Li, R; Li, Z; Liu, J; Niu, X; Ping, M; Xie, X | 1 |
| Araújo, AC; Jorge, VC; Noronha, C; Panarra, A; Riso, N; Vaz Riscado, M | 1 |
| Cunha, MP; Dal-Cim, T; Ludka, FK; Rodrigues, AL; Tasca, CI; Zeni, AL; Zomkowski, AD | 1 |
| Fisher, EA; Fisher, R; Peters, MR | 1 |
| Alavi, KH; Assadi, AR; Damavandi, M; Shafiee, K; Zangiabadi, N | 1 |
| Dinarvand, B; Dinarvand, P; Farhadian, S; Jalali, A; Sanaei-Rad, P; Seyedjafari, E; Shafiee, A; Soleimani, M | 1 |
| Baigorria, ST; Eynard, AR; Fiore, MC; García, NH; Juncos, LA; Juncos, LI; Martín, FL; Pasqualini, ME | 1 |
| Claycombe, KJ; Nair, MG; Zhou, Z | 1 |
| Almroth, H; Andersson, J; Boman, K; Englund, A; Höglund, N; Jensen, SM; Rosenqvist, M; Tornvall, P | 1 |
| Barter, PJ; Karlson, BW; Lundman, P; Nicholls, SJ; Palmer, MK | 3 |
| Ding, Q; Dong, Y; Jin, Y; Jin, YX; Qu, WH; Sui, HJ; Yu, SX | 1 |
| Alver, A; Calapoglu, M; Kural, B; Orem, A; Orem, C; Uydu, HA; Yıldırmış, S | 1 |
| Chen, ZC; Lou, M; Shi, ZH; Sun, JZ | 1 |
| Dandri, M; Kah, J; Keller, AD; Montalbano, R; Ocker, M; Sass, G; Sirma, H; Tiegs, G; Volz, T; Wüstenberg, A | 1 |
| Gill, L; Keehn, J; Peter, DL; Santa, J | 1 |
| El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A | 1 |
| Alperin, P; Gandhi, S; Hsia, J; Peskin, B; Schuetz, CA; van Herick, A | 1 |
| Guan, F; Ju, J; Li, G; Liu, AB; Sun, Y; Yang, CS; Yang, Z | 1 |
| Andrews, S; Bellon, J; Callegari, S; de Barros Lopes, MA; Gregory, PA; McKinnon, RA; Sykes, MJ | 1 |
| Miyauchi, K | 1 |
| Hasebe, N; Ota, H; Takeuchi, T | 1 |
| Elis, A; Lishner, M | 1 |
| Budhiraja, RD; Sharma, S; Tyagi, S | 1 |
| Eroğlu, H; Kurum, B; Simşek, S; Ulubayram, K | 1 |
| Creswell, LL | 1 |
| Bruckert, E; Dallongeville, J; Rosenbaum, D; Sabouret, P | 1 |
| Kilpatrick, ES; Narayanan, D | 1 |
| Heintjes, EM; Herings, RM; Meerding, WJ; Penning-van Beest, FJ; Plat, AW; Sturkenboom, MC; Webb, K | 1 |
| Banaszewska, A; Dudziak, J; Piechota, M; Plewa, R; Slomczynski, M | 1 |
| Cao, J; Fan, L; Gao, Y; Liu, XF; Lu, XC; Yang, HY | 1 |
| Bereal-Williams, C; Cannon, RO; Chi, A; Dalby, CK; Hauser, KP; Hunter, CJ; Hunter, L; Kato, GJ; Machado, RF; McGowan, V; Tailor, A | 1 |
| Akhlaghi, F; Dostalek, M; Gohh, RY; Macwan, JS; Paryani, KR; Sam, WJ | 1 |
| Bech, JN; Larsen, T; Mose, FH; Pedersen, EB | 1 |
| Gupta, A; Kalonia, H; Kumar, A; Mishra, J; Sharma, N | 1 |
| Abe, K; Ikeda, Y; Kawai, H; Kozuki, M; Kurata, T; Miyazaki, K; Morimoto, N; Ohta, Y | 1 |
| Hennessey, MJ; Murphy, SM; Ryan, D | 1 |
| Lazareva, NV; Oshchepkova, EV | 1 |
| Ghosh, AK; Kumar, KK; Kumar, KV; Prusty, P | 1 |
| Chen, XY; Guo, LX; Shen, Y; Zhang, YF; Zhong, DF | 1 |
| Andalib, S; Asadpoor, M; Doustar, Y; Garjani, A; Garjani, M; Khorrami, A; Maleki-Dizaji, N; Rezazadeh, H; Soraya, H; Ziaee, M | 1 |
| Munshi, A | 1 |
| Jin, J; Kim, BY; Kim, DE; Kim, EK; Kim, JS; Lee, DK; Lee, H; Park, EJ; Shin, IJ | 1 |
| Aukrust, P; Breland, UM; Hagelsteen, K; Halvorsen, B; Haraldsen, G; Hol, J; Kasprzycka, M; Otterdal, K; Pedersen, TM; Ranheim, T; Stang, E | 1 |
| Gracia-Sancho, J | 1 |
| Christensen, NP; Cornett, C; Rantanen, J; Taylor, LS | 1 |
| Chang, K; Gwon, HC; Jeon, DS; Kim, HS; Kim, MJ; Kim, SJ; Tahk, SJ | 1 |
| Iwasaki, Y; Jinnouchi, H; Ogawa, H; Oka, H; Sugiyama, S; Sumida, H; Tanaka, T; Tayama, S; Toyama, K | 2 |
| Gogolashvili, NG | 1 |
| Ban, MR; Hegele, RA; Rahalkar, AR | 1 |
| Gupta, LK | 1 |
| Cetinkaya Demir, B; Köse, C; Ozbilgin, K; Uyar, Y | 1 |
| Fan, W; Fu, X; Geng, W; Gu, X; Hao, G; Jiang, Y; Li, S; Li, W; Li, X; Wang, X; Wang, Y; Wu, W; Yang, Z | 1 |
| Waeber, C; Wang, QM; Wei, Y; Zheng, Y | 1 |
| Cheng, WP; Shyu, KG; Wang, BW; Wu, GJ | 1 |
| Chan, CW; Chan, KK; Chan, PH; Chan, RH; Hau, WK; Kong, SL; Lam, SC; Lam, YM; Lee, SW; Tam, FC; Tse, HF; Wong, MK | 1 |
| Ali, J; Baboota, S; Goel, A; Gupta, A; Gupta, RS; Sahni, JK; Semwal, VP; Srinivas, KS | 1 |
| Jin, C; Mintz, GS; Tang, Y; Tian, Y; Wang, TJ; Xu, B; Yang, YJ; Zhang, Q | 1 |
| Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T; Shepherd, J | 1 |
| Chen, P; Chen, XD; Jiang, XY; Li, SY; Lu, M; Wang, GC; Wang, HB; Zhang, NN; Zhang, Q; Zhuang, MQ | 1 |
| Chen, X; Feng, LX; Ge, CJ; Huo, Y; Lü, SZ; Meng, K; Song, XT; Yuan, F | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP | 2 |
| Ding, X; Huang, S; Li, W; Lu, X; Sun, B; Wang, B; Zhang, Y | 1 |
| Li, J; Tan, W; Wang, J; Yan, W; Yang, K; Zhou, Y | 1 |
| Chen, D; Chen, F; Dong, L; Ge, J; Guan, L; Qian, J; Zhou, D | 1 |
| Fürst, DO; Granzow, M; Huss, S; Klein, S; Klösel, J; Körner, C; Lammert, F; Mazar, IG; Nattermann, J; Pieper-Fürst, U; Sauerbruch, T; Schierwagen, R; Trebicka, J; van den Ven, PF; Weber, S | 1 |
| He, B; Hu, LH; Jin, SX; Li, DD; Nie, P; Shao, Q; Shen, LH; Yi, J; Zhang, T | 1 |
| Ballantyne, CM; Belmont, JW; Brautbar, A; Keinan, A; Ma, L | 1 |
| Brown, K; Bucerius, J; Calcagno, C; Dickson, SD; Fayad, ZA; Fisher, EA; Fuster, V; Hayashi, K; Kotsuma, M; Lin, J; Moon, MJ; Moshier, E; Mounessa, JS; Nicolay, K; Ramachandran, S; Roytman, M; Rudd, JH; Tanimoto, T; Tsimikas, S; Vucic, E | 1 |
| Hirayama, A; Nagao, K; Tani, S | 1 |
| Choi, J; Kim, JY; Lee, EB; Lee, EY; Lee, YJ; Song, YW; Yoo, HJ | 1 |
| Bouitbir, J; Charles, AL; Daussin, F; Dufour, S; Geny, B; Piquard, F; Rasseneur, L; Richard, R; Zoll, J | 1 |
| Dehpour, AR; Fakhrzad, A; Hassanipour, M; Moezi, L; Rezayat, M; Shafaroodi, H | 1 |
| Erkoseoglu, I; Kadioglu, M; Kalyoncu, NI; Kesim, M; Muci, E; Okuyan, M; Yaris, E | 1 |
| Doğru, MT; Ebinç, H; Sahin, O; Simşek, V; Tireli, E; Tulmac, M; Yildirim, N | 1 |
| Butler, KA; Mitchell, PD; Teng, R | 1 |
| Degnan, AJ; Gillard, JH; Howarth, SP; Patterson, AJ; Tang, TY | 1 |
| Cannon, CS | 1 |
| Li, L; Nouraldeen, A; Wilson, AG | 1 |
| Barrett, PH; Chan, DC; Ng, TW; Ooi, EM; Watts, GF | 2 |
| Drevenšek, G; Janić, M; Lunder, M; Šabovič, M; Žiberna, L | 1 |
| Arla, R; Rajak, S; Varanasi, KV; Vats, R; Veeraraghvan, S | 1 |
| Dimbil, M; Golomb, BA; Hoffman, KB; Kraus, C | 1 |
| Barter, PJ; Beltangady, MS; Boekholdt, SM; DeMicco, DA; Duggan, WT; Kastelein, JJ; Ports, WC; Rye, KA; Shear, CL | 1 |
| Figueiredo, A; Mota, A; Neto, P; Parada, B; Pinto, Â; Reis, F; Rocha-Pereira, P; Sereno, J; Teixeira, F; Xavier-Cunha, M | 1 |
| Buldak, L; Dulawa-Buldak, A; Labuzek, K; Okopien, B | 1 |
| Li, SJ; Wu, WZ; Xu, ZR; Yang, YM; Yao, HP | 1 |
| Gong, FY; Lu, YS; Qu, RB | 1 |
| Bahrami, A; Farid Hosseini, R; Jabbari, F; Pezeshkpoor, F; Rafatpanah, H; Sadri, H; Shakerian, B; Yousefzadeh, H; Zamani, MA; Zandkarimi, MR | 1 |
| Babazono, T; Fujimoto, A; Imamoto, M; Kasahara, M; Kimura, G; Koya, D; Nakao, K; Sato, T; Tanaka, S; Ueshima, K; Yasuno, S | 1 |
| Alvarez Sanz, C; Barrios, V; Brosa, M; Capel, M; Lobos, JM; Serrano, A | 1 |
| Cao, Y; Fan, Y; Huang, Y; Yang, S | 1 |
| Ali, S; Iyer, RS; Krishnan, M; Kumar, S | 1 |
| Kalil Filho, R; Kowatsch, I; Lario, FC; Mathias, W; Miname, MH; Ramires, JA; Santos, RD; Sbano, JC; Tsutsui, JM | 1 |
| Amano, T; Asai, K; Daida, H; Hiro, T; Kimura, T; Kosaka, T; Kuhara, Y; Kurita, A; Kuroda, Y; Maeda, K; Matsuzaki, M; Miyauchi, K; Mizuno, T; Morimoto, T; Nakagawa, Y; Ozaki, Y; Takashima, H; Yamagishi, M | 1 |
| Gillard, JH; Graves, MJ; Howarth, SP; Sadat, U; Tang, TY; Taviani, V; Usman, A | 1 |
| Clark, K; Galloway, S; Lam, V; Mamo, J; Pallebage-Gamarallage, M; Takechi, R | 1 |
| Bittner, V; DeMicco, DA; LaRosa, JC; Messig, M; Waters, DD; Wenger, NK | 1 |
| Chung, JY; Lee, SH; Oh, ES; Park, K; Park, MS | 1 |
| Doevendans, PA; Goumans, MJ; Pasterkamp, G; Post, S; Rensing, BJ; van den Broek, AJ | 1 |
| Grube, M; Keiser, M; Köck, K; Koenen, A; Kroemer, HK; Siegmund, W | 1 |
| Li, W; Liu, K; Ma, A; Shao, L; Wang, J; Wang, Z; Wu, D; Zhang, P; Zhang, Y | 1 |
| Berg, JP; Grimholt, RM; Kringen, MK; Piehler, AP; Stormo, C | 1 |
| Farah, R; Jubran, F; Khamisy-Farah, R | 1 |
| Bosch, J; García-Cardeña, G; García-Pagán, JC; Gracia-Sancho, J; Hide, D; Marrone, G; Rosado, E; Russo, L | 1 |
| Oĭnotkinova, OSh | 1 |
| Gross, PL; Ni, R; Peleg, T | 1 |
| Chu, LM; Elmadhun, NY; Feng, J; Lassaletta, AD; Liu, Y; Sellke, FW | 1 |
| Medvedev, IN; Skoriatina, IA | 1 |
| Cho, HJ; Kim, HS; Kim, SJ; Kwon, YW; Lee, HY; Lee, SW; Oh, BH; Park, YB; Youn, SW | 1 |
| Bang, CN; Gislason, GH; Greve, AM; Køber, L; Torp-Pedersen, C; Wachtell, K | 1 |
| Andersen, K; Björnsdóttir, LR; Einarsdóttir, R; Gizurarson, S; Halldórsson, M | 1 |
| Kumari, M; Martande, SS; Naik, SB; Pradeep, AR; Rao, NS | 1 |
| Gerasimidis, T; Kadoglou, NP; Kapelouzou, A; Kostakis, A; Liapis, CD; Moumtzouoglou, A; Sailer, N | 1 |
| Bottinelli, R; D'Antona, G; Mascaro, A; Miglietta, D; Monopoli, A; Ongini, E | 1 |
| Binongo, JN; Corban, MT; Dhawan, SS; Eshtehardi, P; Golub, L; Krishnan, SK; McDaniel, MC; Quyyumi, AA; Raggi, P; Samady, H | 1 |
| Arla, R; Murthy, AN; Rajak, S; Varanasi, KV; Vats, R; Veeraraghavan, S | 1 |
| Jackevicius, CA; Krumholz, HM; Tu, JV | 1 |
| Christensen, JH; Lundbye-Christensen, S; Lysgaard, C; Nielsen, MS; Riahi, S; Schmidt, EB | 1 |
| Breborowicz, A; Kawka, E; Korybalska, K; Witowski, J | 1 |
| Berger, E; Biro, A; Boaz, M; Briliant, A; Fux, A; Katzir, Z; Leibovitch, E; Matas, Z; Schreiber, L; Vaknin, H | 1 |
| Bacic-Vrca, V; Bozina, N; Horvatic, I; Lisicic, A; Marusic, S | 1 |
| Bansal, SS; Ferrari, M; Ferrati, S; Filipini, S; Filippini, S; Fine, D; Grattoni, A; Nicolov, E; Palapattu, G; Raghuwansi, K; Sih, J; Zabre, E | 1 |
| Chaogang, T; Ewen, T; Guanghong, X; Jun, W; Liming, T; Qiuting, L; Tao, T | 1 |
| Černe, D; Drevenšek, G; Janić, M; Lunder, M; Marc, J; Šabovič, M | 1 |
| Cali, G; Corcione, N; Ferraro, P; Giordano, A; Messina, S; Monaco, M; Nappo, G; Polimeno, M; Romano, MF; Romano, S; Zambrano, N | 1 |
| Fuhrmeister, J; Kromer, A; Moosmann, B; Tews, M | 1 |
| Puri, R; Tuzcu, EM | 1 |
| Adámková, V; Ceška, R; Dlouhá, D; Hubáček, JA; Lánská, V; Prusíková, M; Rynekrová, J; Vrablík, M; Zlatohlávek, L | 1 |
| Ban, X; Cheng, W; Han, X; Hu, S; Jang, IK; Sun, Y; Tian, J; Yu, B; Yu, H; Zhang, S | 1 |
| Desplaces, N; Gabignon, C; Le Guyader, N; Lidove, O; Zeller, V; Ziza, JM | 1 |
| Fang, W; Li, R; Qu, X; Quan, Z; Yang, SS | 1 |
| Cao, Y; Fan, Y; Huang, Y; Yang, S; Zhang, X | 1 |
| Asset, G; Hanotin, C; McKenney, JM; Roth, EM; Stein, EA | 1 |
| Fujii, K; Masuyama, T | 1 |
| Fromm, MF; Klatt, S; König, J | 1 |
| Futagami, K; Kataoka, Y; Nakashima, A; Nishioku, T; Watanabe, T; Yamauchi, A; Yasutaka, Y | 1 |
| Dohnal, J; Grunwaldova, V; Jampilek, J; Kral, V; Vaculikova, E | 1 |
| Bird, J; Courtney, P; Fihn, BM; Grime, K; Palmgren, AP | 1 |
| Bond, AD; Christensen, NP; Cornett, C; Kwok, K; Rades, T; Rantanen, J; Taylor, LS; Van Eerdenbrugh, B | 1 |
| Gibbs, S; Niessen, FB; Scheper, RJ; van den Broek, LJ | 1 |
| Gong, P; Lin, J; Liu, S; Lu, J; Lu, X; Qiu, J; Wang, H; Zhang, X | 1 |
| Delgado-Montero, A; Zamorano, JL | 1 |
| Enache, I; Garrouste, C; Heng, AE; Kaysi, S; Philipponnet, C; Tiple, A | 1 |
| Bianco, A; Briguori, C; Colombo, A; Condorelli, G; De Micco, F; Donnarumma, E; Fiore, D; Focaccio, A; Golia, B; Quintavalle, C; Ricciardelli, B; Troncone, G; Visconti, G; Zabatta, MA | 1 |
| Baxa, J; Eberlová, L; Houdek, K; Kobr, J; Křížková, V; Moláček, J; Tonar, Z; Třeška, V | 1 |
| Yeboah, J | 1 |
| Daida, H; Hiro, T; Kimura, T; Matsuzaki, M; Miyauchi, K; Morimoto, T; Nakagawa, Y; Ogita, M; Ozaki, Y; Yamagishi, M | 1 |
| Cai, A; Dong, Y; Feng, Y; Huang, Y; Mai, W; Qiu, R; Rao, S; Yu, D; Zheng, D; Zhou, Y | 1 |
| Loughrey, BV; McCance, DR; McGinty, A; Powell, LA; Young, IS | 1 |
| Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL | 1 |
| Anderson, TJ; Hillard, D; Hubacek, J; Philpott, AC; Sun, YC | 1 |
| Furutani, N; Ikewaki, K; Ito, K; Kurata, H; Shoda, T; Tada, N; Tsimikas, S; Witztum, JL; Yanai, H; Yoshida, H | 1 |
| Cao, S; Cui, K; Hou, Y; Wang, P; Zhang, L | 1 |
| Deng, SB; Du, JL; Li, Q; She, Q; Xia, S | 1 |
| Arya, A; Christensen, JH; Hjortshøj, S; Kabir, S; Lundbye-Christensen, S; Riahi, S; Schmidt, EB | 1 |
| Adámkova, V; Ceska, R; Dlouha, D; Hubacek, JA; Lanska, V; Vrablik, M | 1 |
| Capizzi, JA; Chipkin, S; Clarkson, PM; Cole, SM; Grimaldi, AS; Keadle, J; Parker, BA; Pescatello, LS; Simpson, K; Thompson, PD; White, CM | 1 |
| Chen, P; Deng, X; Xia, K; Yang, T; Zhao, Z | 1 |
| Foroughipour, M; Nikbin, Z; Pezeshki Rad, M; Sahebari, M; Shoeibi, A | 1 |
| Davutoglu, V; Ercan, S; Sari, I | 1 |
| Frank, J; Grebenstein, N; Hofmann, U; Podszun, MC | 1 |
| Grabowski, T; Jaroszewski, JJ; Sasinowska-Motyl, M | 1 |
| Becka, M; Kubitza, D; Mueck, W; Roth, A | 1 |
| Eisa-Beygi, S; Ekker, M; Hatch, G; Moon, TW; Noble, S | 1 |
| Davies, E | 1 |
| Allolio, B; Bidlingmaier, M; Blouin, K; Drechsler, C; Fassnacht, M; Hammer, F; Krane, V; März, W; Pilz, S; Ritz, E; Schönfeld, S; Tomaschitz, A; Wanner, C | 1 |
| Cannon, CP; Gibson, CM; Murphy, SA; Nazer, B; Ray, KK | 1 |
| Ali, KA; Bandyopadhyay, AK; Mukherjee, B | 1 |
| Asztalos, BF; Diffenderfer, MR; Dolnikowski, GG; Lamon-Fava, S; Ooi, EM; Schaefer, EJ; Thongtang, N | 1 |
| Boekholdt, SM; Breazna, A; DeMicco, DA; Ho, JE; Kastelein, JJ; Messig, M; Pedersen, TR; Waters, DD | 1 |
| Barnett, AH; Cooke, MW; Gao, F; Hawkey, P; Hong, T; Jones, A; Linhartova, L; Melody, T; Patel, JM; Perkins, GD; Snaith, C; Thickett, DR | 1 |
| Adams, SP; Tsang, M; Wright, JM | 2 |
| Cai, K; Hu, Y; Luo, Z; Xie, D | 1 |
| Simoens, S; Sinnaeve, PR | 1 |
| Rosenberg, JL | 1 |
| Huang, CF; Lo, WT; Peng, HJ; Shih, YL; Wu, CC; Wu, TC | 1 |
| Arazi, SS; Bernik, MM; Bertolami, M; Brion, MJ; Carracedo, A; Dorea, EL; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Rodrigues, AC; Sobrino, B; Willrich, MA | 1 |
| Asberg, A; Christensen, H; Hjelmesæth, J; Jakobsen, GS; Røislien, J; Sandbu, R; Skottheim, IB | 1 |
| Alexandre, F; Danelon, MR; Faria, EC; Panzoldo, NB; Parra, ES; Quintão, EC; Santos, JE; Silva, RM; Virgínio, VW; Zago, VH | 1 |
| Larijani, B; Mottaghi, S; Sharifi, AM | 1 |
| Armitage, J; Chen, F; Chen, YP; Chen, ZM; Feng, F; Gao, Y; Hopewell, JC; Hundei, WB; Jiang, LX; Landray, M; Li, J; Li, X; Liu, JM; Valdes-Marquez, E; Zhang, D; Zhang, HB | 1 |
| Bush, M; Collins, D; Generaux, G; Hussey, E; McMullen, S; Nunez, DJ; Polli, JW; Smith, G; Turner, N | 1 |
| Biro, S; Ikeda, Y; Kono, S; Otonari, T; Sasaki, J; Uchida, Y | 1 |
| Ishikawa, T; Kinoshita, M; Mashimo, Y; Numakura, M; Teramoto, T | 1 |
| Fu, Q; Gao, Y; Jia, M; Li, YP; Lu, PQ; Yang, SH; Zhang, LR | 1 |
| Ahmed, W; Ali, IS; Ali, SH; Azam, M; Niazi, AK; Niazi, SH; Qamar, R; Riaz, M; Sadeque, A; Younas, A | 1 |
| Darwish, HW; El-Zeany, BA; Hassan, SA; Salem, MY | 1 |
| Wang, H; Ye, P; Zhang, J | 1 |
| Araki, W; Hosaka, A; Oda, A; Tamaoka, A; Tomidokoro, Y | 1 |
| Choi, DH; Hong, TJ; Kim, HS; Kim, SH; Seo, MK; Yoon, MH | 1 |
| Dubas, K; Kersnik, J; Kijowska, V; Seifert, B; Tomasik, T; Windak, A | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J | 1 |
| Artamoshina, NE; Belaya, OL; Bondar, KY; Kuropteva, ZV; Lazutina, OM; Raider, LM; Yakovleva, TV | 1 |
| Gropp, C | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; McPeters, G; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Ciudad, CJ; Izquierdo-Pulido, M; Noé, V; Oleaga, C | 1 |
| Arnal, JF; Lucanus, E; Nickenig, G; Pelster, B; Steinmetz, M; Werner, N | 1 |
| Arnesen, KE; Bogsrud, MP; Langslet, G; Malt, UF; Ose, L; Retterstøl, K; Sm Stuen, MC; Woldseth, B | 1 |
| Fujimoto, M; He, P; Ishibashi, R; Ishikawa, T; Kawamura, H; Kobayashi, K; Okabe, E; Onishi, S; Takemoto, M; Yokote, K | 1 |
| Kitzmiller, JP; Phelps, MA; Sadee, W; Sullivan, DM; Wang, D | 1 |
| Davies, RR; Durrington, P; Gibson, JM; Gittins, M; Hudson, JE; Narayanan, RP; Oliver, RL; Rutter, MK; Siddals, KW; White, A | 1 |
| Dingemanse, J; Hoch, M; Hoever, P; Theodor, R | 1 |
| Kim, MS | 1 |
| Abe, K; Ikeda, Y; Kawai, H; Kurata, T; Miyazaki, K; Morimoto, N; Ohta, Y | 1 |
| Abe, K; Deguchi, K; Deguchi, S; Kawai, H; Kono, S; Kurata, T; Ohta, Y; Omote, Y; Yamashita, T | 1 |
| Berbée, JF; Havekes, LM; Hiemstra, PS; Khedoe, PP; Mol, IM; Princen, HM; Rensen, PC; Romijn, JA; Tsikas, D; van der Hoorn, JW; van Klinken, JB; Wang, Y; Wong, MC | 1 |
| García-Estévez, DA; Navarro, C; San Millán, B; Sogo, T | 1 |
| Aeed, H; Bruck, R; Gavish, D; Sharvit, E; Shirin, H | 1 |
| Bailey, M; Bellomo, R; Cooper, DJ; Harward, M; Higgins, A; Howe, B; Jones, D; Joyce, C; Kostner, K; Kruger, P; McNeil, J; Nichol, A; Roberts, MS; Syres, G; Venkatesh, B | 1 |
| Belinelo, VJ; Oliveira, MA; Valotto, RS; Yoshida, MI | 1 |
| Latorre, A; Madrid, I; Moscardó, A; Santos, MT; Vallés, J | 1 |
| Atkin, SL; Kilpatrick, ES; Sathyapalan, T; Shepherd, J | 1 |
| Adamova, IY; Afanasieva, OI; Atanesyan, RV; Ezhov, MV; Konovalov, GA; Matchin, YG; Pokrovsky, SN; Safarova, MS; Utkina, EA | 1 |
| Adamova, IY; Afanasieva, OI; Akchurin, RS; Atanesyan, RV; Ezhov, MV; Il'ina, LN; Konovalov, GA; Pokrovsky, SN; Safarova, MS | 1 |
| Hayashi, M; Hayashida, R; Ishii, H; Jinno, Y; Murohara, T; Okada, K; Okumura, S; Sakakibara, M; Tanaka, A | 1 |
| Andersson, TB; Asberg, A; Bremer, S; Christensen, H; Hjelmesæth, J; Jakobsen, GS; Molden, E; Sandbu, R; Skottheim, IB; Ulvestad, M | 1 |
| Liu, XG; Miao, N; Mu, SH; Sui, MS; Xie, RJ; Zhao, SL | 1 |
| Bird, J; Grime, K; Nordell, P; Svanberg, P | 1 |
| Bi, XY; He, X; Yu, XJ; Zang, WJ; Zhao, M | 1 |
| Alawi, M; Arafat, T; Awwad, AA; Yacoub, M | 1 |
| Buckley, DB; Funk, RS; Hensley, T; Kazmi, F; Loewen, GJ; Parkinson, A; Pope, C | 1 |
| Davidson, SM; Elliot, PM; Harding, SE; Hausenloy, DJ; McGregor, C; Rees, PS; Yellon, DM | 1 |
| El-Tahtawy, A; Gandelman, K; Gastonguay, MR; Jen, F; Knebel, W; Malhotra, B | 1 |
| Jena, GB; Kushwaha, S; Ramanjaneyulu, SV; Trivedi, PP; Vikram, A | 1 |
| Fan, YC; Li, XH; Wang, D; Wang, M; Zhang, YY | 1 |
| Gębska, A; Korbut, R; Madej, J; Olszanecki, R; Stachowicz, A; Suski, M; Uracz, D | 1 |
| DiNicolantonio, JJ; Lavie, CJ; O'Keefe, JH; Serebruany, VL | 1 |
| Bassik, MC; Chen, S; Hein, MY; Horlbeck, MA; Hyman, AA; Kampmann, M; Lebbink, RJ; Leproust, EM; Mann, M; McManus, MT; Poser, I; Wang, S; Weibezahn, J; Weissman, JS | 1 |
| Guo, R; Heng, X; Liang, X; Shi, Y; Yang, L; Zhou, X | 1 |
| Arnaboldi, L; Baetta, R; Bellosta, S; Bonomo, A; Corsini, A; Ferri, N; Granata, A; Miglietta, D; Oliva, F; Ongini, E | 1 |
| Spence, JD | 1 |
| Baldazza, M; Cachot, S; Faury, G; Fhayli, W; Joyeux-Faure, M; Korichneva, I; Lévy, P; Pépin, JL; Ribuot, C; Totoson, P | 1 |
| Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y | 1 |
| Kalonia, H; Kumar, A; Kumar, P; Mishra, J; Vashist, A | 1 |
| Aquilante, CL; Kosmiski, LA; Predhomme, JA; Sidhom, MS; Wempe, MF | 1 |
| Chang, FC; Chen, JB; Chen, JH; Chen, JW; Chen, YL; Chen, YM; Huang, PH; Huang, TM; Ko, WJ; Kuo, YS; Liang, CJ; Lo, SC; Sun, CY; Wang, KC; Wu, KD; Wu, VC; Young, GH | 1 |
| Jing, LM; Li, H; Liu, HL; Luo, JP; Shen, ZQ; Yang, SL; Yang, Y | 1 |
| Cardona-Gomez, GP; Eckert, GP; Posada-Duque, RA; Velasquez-Carvajal, D | 1 |
| Hanouz, JL; Legallois, D; Lemoine, S; Manrique, A; Massetti, M; Zhu, L | 1 |
| Abbate, R; Angiolillo, DJ; Bellandi, F; Giusti, B; Leoncini, M; Maioli, M; Marcucci, R; Toso, A | 2 |
| Bonello, L; Laine, M; Paganelli, F | 1 |
| de Oliveira, CV; Funck, VR; Furian, AF; Grigoletto, J; Oliveira, MS; Pereira, LM; Rambo, LM; Ribeiro, LR; Royes, LF | 1 |
| Cui, W; Hu, HJ; Liu, DM; Liu, J; Wang, Q; Zhang, HL; Zhang, YN | 1 |
| Chrysohoou, C; Dilaveris, P; Kioufis, S; Maniatis, K; Michalea, S; Miliou, A; Oikonomou, E; Papavassiliou, AG; Siasos, G; Stefanadis, C; Tousoulis, D; Zaromitidou, M | 1 |
| Abbar, JC; Nandibewoor, ST | 1 |
| Chaudhary, S; Kawato, Y; Kumagai, N; Shibasaki, M | 1 |
| Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Imundo, LF; Jung, L; Kimura, Y; Klein-Gitelman, M; Levy, D; McCurdy, DK; Mieszkalski, KL; Punaro, L; Reed, AM; Sandborg, CI; Schanberg, LE; Sherry, DD; Silver, RM; Silverman, E; Singer, NG; Soep, JB; Thompson, SD; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E | 1 |
| Brborić, J; Crevar-Sakač, M; Kuntić, V; Uskoković-Marković, S; Vujić, Z | 1 |
| Borowiak, A; Błoński, JZ; Cebula-Obrzut, B; Hikisz, P; Kiliańska, ZM; Robak, T; Smolewski, P; Żołnierczyk, JD | 1 |
| Drechsler, M; Soehnlein, O; Weber, C | 1 |
| Dhull, P; Kumar, KV; Patnaik, SK; Upreti, V | 1 |
| Al-Dabbagh, B; Albawardi, A; Alfazari, AS; Almarzooqi, S; Souid, AK | 1 |
| Cai, DQ; Kim, CS; Kim, DH; Kim, SK; Lee, KJ; Qi, XF; Qin, JW; Wu, Z; Yu, YH; Zheng, L | 1 |
| Georgianos, PI; Kanaki, AI; Kanavos, K; Lasaridis, AN; Sarafidis, PA; Tziolas, IM; Zebekakis, PE | 1 |
| Feng, B; Li, X; Wang, H; Xu, L | 1 |
| Borrego, L; Hernández, N; Peñate, Y | 1 |
| Endo, J; Sano, M | 1 |
| Akin, F; Akin, MN; Ayça, B; Canbek, TD; Güngör, O; Köse, N; Sahin, I | 1 |
| Gupta, YK; Padhy, BM; Yadav, R | 1 |
| Lee, CW; Park, SJ | 1 |
| Hradec, J; Sutradhar, S; Zamorano, J | 1 |
| Bendahl, PO; Bjarnadottir, O; Borgquist, S; Grabau, D; Jirström, K; Johannesson, H; Loman, N; Romero, Q; Rose, C; Rydén, L; Uhlén, M | 1 |
| Ensafi, AA; Khoddami, E; Rezaei, B | 1 |
| Hirayama, A; Hiro, T; Honye, J; Kodama, K; Komatsu, S; Li, Y; Nanto, S; Saito, S; Takayama, T; Takazawa, K; Ueda, Y; Yajima, J; Yamaguchi, O | 1 |
| Bradley, JD; Brosnan, MJ; Connell, CA; Kim, HY; Lee, SH; Luo, Z; Mandel, D; McInnes, IB; Song, YW; Zuckerman, A; Zwillich, SH | 1 |
| Knap, N; Lizakowski, S; Renke, M; Rutkowski, B; Rutkowski, P; Tylicki, L; Woźniak, M | 1 |
| Aurigemma, C; D'Ambrosio, A; Di Sciascio, G; Giardina, A; Leporace, M; Macrì, M; Melfi, R; Patti, G; Ricottini, E; Sedati, P; Tomai, F | 1 |
| Correa, D; Landau, M | 1 |
| Farrell, GC; Gan, LT; Haigh, WG; Ioannou, G; Larter, CZ; Teoh, NC; Van Rooyen, DM; Yeh, MM | 1 |
| Alexopoulos, N; Arepalli, CD; Chen, Z; Hartlage, GR; Kim, S; Melek, BH; Raggi, P; Stillman, AE | 1 |
| Bertoldo, DB; de Bem, AF; Herculano, BA; Mancini, G; Martins, WC; Tasca, CI; Vandresen-Filho, S | 1 |
| Arazi, SS; Baudhuin, LM; Bernik, MM; Bertolami, MC; Bryant, SC; Cerda, A; Dorea, EL; Faludi, A; Genvigir, FD; Hirata, MH; Hirata, RD; Largura, A; Rodrigues, AC; Willrich, MA | 1 |
| Aguirre, AC; Amaral, JB; Barbosa, SP; Bianco, HT; Fonseca, FA; França, CN; Izar, MC; Lins, LC; Matos, LN; Santana, JM | 1 |
| Cui, L; Lai, Y; Li, J; Li, Y; Liu, X; Pang, X; Wang, J; Yao, Y; Zhang, Y | 1 |
| Dormuth, CR; Ernst, P; Garg, AX; Hemmelgarn, BR; James, MT; Lafrance, JP; Levy, A; Paterson, JM; Raymond, CB; Teare, GF | 1 |
| Hu, JR; Lv, GH; Yin, BL | 1 |
| Delgado, G; Naves, M | 1 |
| Ghannouchi, MM; Hamdi, W; Kaffel, D; Kchir, MM | 1 |
| Battula, R; Betha, MR; Cheerla, R; Gadiko, C; Khan, SM; Nakkawar, M; Thota, S; Tippabhotla, SK; Vobalaboina, V; Yergude, S | 1 |
| Butterton, JR; Feng, HP; Gupta, S; Hulskotte, EG; O'Mara, E; van Zutven, MG; Wagner, JA; Xuan, F | 1 |
| Ding, M; He, W; Jin, J; Wu, H; Xu, M; Yang, X; Yuchi, M | 1 |
| McAuley, DF; O'Kane, CM; Perkins, GD | 1 |
| Chen, JX; Chiu, CW; Shih, PK | 1 |
| Cao, LL; Dou, YC; Duan, RS; Li, H; Li, XH; Li, XL; Liu, Y; Wang, S; Yue, LT; Zhang, M | 1 |
| Eshraghian, A; Kamyab, AA | 1 |
| Castro, AA; Lapa, FR; Matheus, FC; Prediger, RD; Santos, AR; Tasca, CI; Viola, GG; Wiemes, BP | 1 |
| Hou, T; Lee, SM; Li, P; Li, S; Li, Y; Pan, P; Shen, M; Yu, H; Zhang, L; Zhou, S | 1 |
| Ping, D; Qin, X; Xiao, H; Zuo, K | 1 |
| Bremer, C; Demmer, P; Frenzel, T; Hahnenkamp, A; Immenschuh, S; Larmann, J; Schmitz, M; Theilmeier, G; Tietge, UJ | 1 |
| Chello, M; Coccia, R; Covino, E; De Marco, F; Di Domenico, F; Di Sciascio, G; Lusini, M; Patti, G; Pettinari, M; Pollari, F; Spadaccio, C; Zanzonico, R | 1 |
| Cheng, C; de Boer, SP; de Jong, R; de Winter, RJ; den Dekker, WK; den Heijer, P; Duckers, HJ; Houtgraaf, JH; Ligtenberg, E; Rowland, SM; Serruys, PW; Zijlstra, F | 1 |
| Kalonia, H; Kumar, A; Mishra, J; Sharma, N | 1 |
| Banach, M; Bielecka-Dabrowa, A; Mikhailidis, DP; Rizzo, M; Rysz, J; von Haehling, S | 1 |
| Cho, W; Hwang, SJ; Kim, JS; Kim, MS; Park, HJ | 1 |
| Das, DK; Das, N; Dey, S; Kesh, SB; Khan, A; Manna, K; Sikder, K | 1 |
| Jacob, RF; Mason, RP; Self-Medlin, Y; Walter, MF | 1 |
| Filipiak, KJ; Mamcarz, A; Naruszewicz, M; Siebert, J; Sliż, D | 1 |
| Åsberg, A; Bogsrud, MP; Hermann, M; Kringen, MK; Piehler, AP; Retterstøl, K; Stormo, C | 1 |
| Flores, RM; Kanth, R; Shah, MS | 1 |
| Ballet, S; Bini, J; Corot, C; Dickson, SD; Fayad, ZA; Izquierdo-Garcia, D; Klink, A; Lancelot, E; Mateo de Castro, J; Millon, A; Robert, P | 1 |
| Bare, LA; Devlin, JJ; Iakoubova, OA; Leahy, KJ; O'Sullivan, AK; Parthan, A; Weinstein, MC | 1 |
| Briolant, S; Desgrouas, C; Dormoi, J; Pradines, B | 1 |
| O'Reilly, E; Turner, NJ | 1 |
| Branny, M; Hájek, P; Malý, M; Martinkovičová, L; Tesař, D; Tomašov, P; Veselka, J; Zemánek, D | 1 |
| Berberich, R; Dieplinger, B; Dieplinger, H; Ikewaki, K; Koenig, P; Kronenberg, F; Nakada, Y; Neyer, U; Salmhofer, H; Schwaiger, JP; Zitt, E | 1 |
| Hashimoto, Y; Matsue, Y; Matsumura, A; Suzuki, M; Yoshida, M | 1 |
| Campbell, SM; Godman, B; Gustafsson, LL; Pichetti, S; Sermet, C | 1 |
| Asada, K; Chisaki, I; Gouda, K; Iseki, K; Kobayashi, M; Konishi, T; Koshida, Y; Ogura, J; Sasaki, S; Takahashi, N; Yamaguchi, H | 1 |
| Guo, RW; Heng, XH; Qi, F; Si, YK; Yang, LX; Zhou, XB | 1 |
| Gierman, LM; Huizinga, TW; Kloppenburg, M; Koudijs, A; Kühnast, S; Pieterman, EJ; Princen, HM; Stojanovic-Susulic, V; van Osch, GJ; Zuurmond, AM | 1 |
| Anderson, L; Bond, V; Liu, M; Patrickson, J; Pitts, S; Solomon, W; Stiles, JK; Wilson, NO | 1 |
| Chen, D; Feng, B; Francone, OL; Frederick, KS; Goosen, TC; Gosset, JR; Kalgutkar, AS; Rotter, CJ; Scialis, RJ; Terra, SG; Varma, MV; Walsky, RL; West, MA | 1 |
| Brewer, M; Janakiram, NB; Mohammed, A; Rao, CV; Steele, VE; Vedala, K | 1 |
| Fukumoto, Y; Kudo, S; Liao, JK; Minami, T; Nochioka, K; Shiba, N; Shimokawa, H; Takai, Y; Tanaka, S; Williams, CL | 1 |
| Balu, S; Montouchet, C; Ruff, L | 1 |
| Hu, M; Ko, GT; Lui, SS; Tomlinson, B | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; St John, J; Uno, K; Wolski, K | 1 |
| Goto, SN; Mizuno, Y; Niwa, M; Takagi, H; Umemoto, T; Yamamoto, H | 1 |
| Ayas, B; Balli, U; Cetinkaya, BO; Erdogan, D; Keles, GC; Mercan, U | 1 |
| Cziraky, M; Jacobson, TA; Kuznik, A; Wertz, DA | 1 |
| Islam, M; Kumar, B; Sharma, S; Teknos, TN | 1 |
| Brodowski, K; Jaworski, K; Kosior, DA; Krzykwa, A; Opolski, G; Zylińska, E | 1 |
| Inazu, T; Kawahara, C; Kawahara, T; Nishikawa, M; Sakai, K; Suzuki, G | 1 |
| Epstein, L; Gurevich, A; Stein, GY | 1 |
| Hou, XL; Liang, P; Zhang, Y; Zhang, YM | 1 |
| Hattori, N; Oji, Y; Sekiguchi, K; Tanaka, R; Tanaka, Y; Tomizawa, Y; Yamashiro, K | 1 |
| Abdel-Rahman, MN; El Rashidy, MA; El-Sisi, Ael-D; Ezzat, NM; Haleem, MS; Kabel, AM | 1 |
| D'Ettorre, A; Macchia, A; Mariani, J; Romero, M; Tognoni, G | 1 |
| Biwa, T; Kurogi, K; Matsui, K; Nakamura, S; Ogawa, H; Sakamoto, K; Sugiyama, S; Tayama, S | 1 |
| Gao, J; Gao, X; Pan, S | 1 |
| Bakhoum, SW; Issac, MS; Mishriki, AA; Shabana, MF | 1 |
| Buszman, P; Cybulski, W; Dworowy, S; Jadczyk, T; Kawecki, D; Król, M; Milewski, K; Ochała, A; Pawłowski, T; Pyrlik, A; Rudnik, A; Smolka, G; Tendera, M; Wojakowski, W; Wyderka, R | 1 |
| Govindan, R; Kavitha, M; Narasimhan, S; Varalakshmi, PR | 1 |
| Bolaman, Z; Kadikoylu, G; Karul, A; Sargin, G; Yavasoglu, I | 1 |
| Cao, S; Fang, W; He, Y; Li, R; Li, Y; Wang, J; Xi, S; Zhang, B | 1 |
| Bordet, R; Darteil, R; Duriez, P; Gautier, S; Hanf, R; Laprais, M; Ouk, T; Potey, C; Staels, B | 1 |
| Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR | 1 |
| Lei, C; Shuyun, H; Xiangrong, C; Yiquan, K; Yongjun, Y; Zhilin, Y | 1 |
| Ozaydin, M; Varol, E | 1 |
| Fan, Y; He, X; Jia, M; Li, H; Li, J; Li, W; Liu, M; Xiong, Z; Zhou, Y | 1 |
| Baxa, J; Boudová, L; Eberlová, L; Houdek, K; Kobr, J; Kočová, J; Křížková, V; Liška, V; Moláček, J; Nedorost, L; Tolinger, P; Tonar, Z; Třeška, V; Witter, K | 1 |
| Chen, C; Liu, T; Shen, DZ; Xin, SL | 1 |
| Chen, M; Li, H; Wang, Y | 1 |
| Chai, W; Peng, L; Tan, DJ; Wu, XL; Yang, DY; Yao, HC | 1 |
| Dadjou, Y; Panahi, Y; Pishgoo, B; Rakhshankhah, AS; Sahebkar, A; Taghipour, HR | 1 |
| Wu, du C | 1 |
| Abdelbaky, A; Alon, A; Beals, CR; Dansky, H; Farkouh, ME; Fayad, ZA; Klimas, MT; Mogg, R; Nunes, IO; Rudd, JH; Shankar, SS; Subramanian, SS; Tawakol, A | 1 |
| Gerber, BL | 1 |
| Kang, HJ; Kim, HS; Lee, JH; Oh, BH; Park, YB; Sohn, DW | 1 |
| Dong, QT; Gao, RL; Geng, YJ; Gersh, BJ; He, ZX; Lu, MJ; Qian, HY; Qiao, SB; Shen, R; Song, L; Yang, YJ; Zhao, SH | 1 |
| Alencar, NM; Benevides, NM; Goes, P; Lima, V; Melo, IM; Ribeiro, RA; Silva, LM | 1 |
| Gitirana, LB; Machado, MN; Magalhães, CB; Melo, AC; Porto, LC; Ribeiro, ML; Santos, JC; Valença, SS; Zin, WA | 1 |
| Amini, R; Jahanbakhsh, Z; Mohammadi, MT; Shekarforoush, S | 1 |
| Bergström, H; Björkhem-Bergman, L; Ekström, L; Eriksson, M; Johansson, M; Parini, P; Rane, A | 1 |
| Chang, HJ; Cho, IJ; Chung, N; Ha, JW; Hong, GR; Hong, SJ; Kang, DR; Park, S; Shim, CY; Shin, S | 1 |
| Abdoli, N; Azarmi, Y; Eghbal, MA; Heidari, R | 1 |
| An, Z; Dong, N; Ge, LL; He, YQ; Li, SM; Yang, G; Zhang, WQ | 1 |
| Heikkilä, P; Huupponen, R; Laine, K; Tirkkonen, T; Vahlberg, T | 1 |
| Steurer, J | 1 |
| Cieśla-Dul, M; Potaczek, DP; Undas, A; Żółciński, M | 1 |
| Artenjak, A; Cerne, D; Lakota, K; Marc, J; Mirjanic-Azaric, B; Rizzo, M; Sodin-Semrl, S; Sormaz, L; Stojanovic, D; Uletilovic, S | 1 |
| Abaci, O; Coskun, U; Kilickesmez, KO; Kocas, C; Oktay, V; Yigit, Z; Yildiz, A; Yildiz, CE | 1 |
| Chou, DW; Guo, H; Li, Q; Uitto, J | 1 |
| Lappegård, KT; Pop, G; Pop-Purceleanu, M; Sexton, J; Tendolkar, I; van Heerde, W | 1 |
| Medvedeva, EA; Seleznev, EI; Shchukin, IuV | 1 |
| Adamson, U; Jörneskog, G; Lins, PE; Mobarrez, F; Tehrani, S; Wallén, HN | 1 |
| Alderson, P; Lewis, SR; Nicholson, A; Sanders, RD; Smith, AF | 1 |
| Chen, L; Song, W; Wang, W; Wang, Y; Yan, X | 1 |
| Arbeiter, D; Begunk, R; Grabow, N; Hussner, J; Kroemer, HK; Meyer zu Schwabedissen, HE; Petersen, S; Reske, T; Schmitz, KP; Senz, V; Sternberg, K | 1 |
| Beaumont, E; Beaumont, PH; Cloutier, FC; Hébert-Davies, J; Rouleau, DM | 1 |
| Biondi-Zoccai, G; Calcagno, S; Canali, E; Conti, G; Fedele, F; Lucisano, L; Mancone, M; Pennacchi, M; Sardella, G; Stio, RE | 1 |
| Bu, L; Cheng, Z; Dong, D; Huang, T; Shen, B; Tu, Y; Wan, L; Zhao, D | 1 |
| Chagovets, V; Holčapek, M; Jirásko, R; Mikysek, T; Vokřál, I | 1 |
| Chahal, N; Manlhiot, C; McCrindle, BW; Niedra, E; Yeung, RS | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Balaganur, V; Kant, V; Kumar, D; Lingaraju, MC; More, AS; Pathak, NN; Tandan, SK | 1 |
| Hobbenaghi, R; Malekinejad, H; Moshtaghion, SM; Shafie-Irannejad, V; Tabatabaie, SH | 1 |
| Choi, YH; DeGorter, MK; Dresser, GK; Hegele, RA; Iwuchukwu, O; Kim, RB; Myers, K; Schwarz, UI; Suskin, N; Tirona, RG; Wei, WQ; Wilke, RA; Zou, G | 1 |
| Ichinomiya, S; Iwata, H; Sato, H; Siddig, S; Suwa, E; Tuerdi, G; Ueno, K; Yano, T | 1 |
| El-Bagary, RI; El-Sherif, ZA; Elkady, EF; Kadry, AM | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K | 4 |
| Gillon, JT; Lowden, MR; Smith, SE | 1 |
| Brown, E; Crane, HM; Delaney, JA; Eron, JJ; Hunt, PW; Kahn, JO; Kitahata, MM; Liu, W; Mathews, WC; Mugavero, MJ; Muñoz, MA; Napravnik, S; Saag, MS; Willig, JH | 1 |
| Engelke, DR; Good, PD; Haeusler, RA; Hopper, AK; McLeod, IX; Miller, EL; Pai, DA; Pratt-Hyatt, M; Wozniak, GG; Yates, JR | 1 |
| Andersson, O; Bergh, N; Grote, L; Hrafnkelsdóttir, TJ; Saluveer, O; Widgren, BR | 1 |
| Groenewoud, H; van der Wilt, GJ; Vermeulen, B; Woertman, W | 1 |
| Kang, S; Liu, XB; Liu, Y | 1 |
| Kopelovich, L; Li, W; McCormick, DL; Mehta, RG; Peng, X; Yuan, L | 1 |
| Beigmohammadi, MT; Farboud, ES; Farsaei, S; Karimzadeh, I; Khalili, H | 1 |
| Farkas, Z; Gácser, A; Grózer, Z; Márki-Zay, J; Nagy, K; Pfeiffer, I; Szenzenstein, J; Vágvölgyi, C | 1 |
| Atochina-Vasserman, EN; Goncharov, DA; James, ML; Krymskaya, VP; Milavec, M; Volgina, AV | 1 |
| Chang, CL; Hughes, AD; Poulter, NR; Sattar, N; Sever, PS; Thom, SA; Welsh, P | 1 |
| Blumenthal, RS; Martin, SS; Ndumele, CE | 1 |
| Chen, CH; Chu, CS; Dixon, RA; Huang, RY; Lai, WT; Lu, J; Lu, LS; Sawamura, T; Walton, B; Wang, YC; Yilmaz, HR | 1 |
| Abdollahi, A; Meysamie, A; Nafasi, L; Rahmani, R; Salari, A; Shafiee, A | 1 |
| Kikuchi, M; McCrary Sisk, C; Nakagomi, M; Numaguchi, H; Shirakawa, M; Surks, HK; Tamura, S; Teramoto, T | 1 |
| Ballard, KD; Capizzi, JA; Chipkin, S; Clarkson, PM; Cole, SM; Grimaldi, AS; Keadle, J; Parker, BA; Pescatello, LS; Simpson, K; Thompson, PD; White, CM | 1 |
| Dai, XP; Li, XR; Wang, JQ; Wang, Z; Wu, GR | 1 |
| Li, Y; Liu, J; Liu, X; Lv, Q; Ma, C; Qi, Y; Sun, J; Wang, M; Wang, W; Zhao, D | 1 |
| de Graaf, MA; Jukema, JW | 1 |
| Do e, Z; Fukumoto, Y; Kanazawa, M; Matsumoto, Y; Sato, A; Satoh, K; Shimizu, T; Shimokawa, H; Takahashi, K | 1 |
| Delibas, N; Gocmen, AY; Gumuslu, S; Ocak, GA; Ozbilim, G | 1 |
| Reiner, Ž; Tedeschi-Reiner, E | 1 |
| Briolant, S; Desgrouas, C; Dormoi, J; Pascual, A; Pradines, B; Travaillé, C | 1 |
| Jiang, X; Qu, Z; Tian, Y; Xu, H | 1 |
| Bangalore, S; Deedwania, P; DeMicco, D; Fayyad, R; Kostis, JB; Laskey, R; Messerli, FH | 1 |
| Faergeman, O; Fayyad, R; Holme, I; Kastelein, JJ; Laskey, R; Olsson, AG; Pedersen, TR; Tikkanen, MJ; Wun, CC | 1 |
| Bertolami, MC; Cavalli, SA; Cerda, A; Faludi, AA; Genvigir, FD; Hirata, MH; Hirata, RD; Issa, MH; Rohde, CB | 1 |
| Guay, J; Ochroch, EA | 1 |
| Gong, HR; Huang, WY; Huang, XS; Li, XP; Zhao, SP | 1 |
| Arican, N; Gelisgen, R; Kalayci, R; Kaya, M; Konukoglu, D; Sozer, V; Tabak, O; Uzun, H | 1 |
| Luft, FC | 1 |
| Groenemeijer, M; Nanayakkara, PW; Scheffer, PG; Schindhelm, RK; Simsek, S; Smulders, YM; van Verschuer, VM | 1 |
| Marrion, NV; Robertson, JD; Robinson, ES; Stuart, SA | 1 |
| Benet, LZ; Estudante, M; Maya, M; Morais, JG; Soveral, G | 1 |
| Brown, MM | 1 |
| Dabrowski, M; Wiliński, J | 1 |
| Abtahi Froushani, SM; Delirezh, N; Hobbenaghi, R; Mosayebi, G | 1 |
| Averna, M; Bays, HE; Brudi, P; De Pellegrin, A; Farnier, M; Giezek, H; Lee, R; Lowe, RS; Majul, C; Muller-Wieland, D; Triscari, J | 1 |
| Guo, F; Han, W; Li, JX; Li, YD; Tang, BP; Tang, Q; Zhang, YY | 1 |
| Blaha, MJ; Martin, SS | 1 |
| Ahn, BC; Kim, DE; Kim, JY; Kim, K; Kwon, IC; Lee, DK; Lee, HW; Lee, SK; Park, JY; Schellingerhout, D; Shin, IJ; Shon, SM | 1 |
| Alon, A; Emami, H; Farkouh, M; Fayad, ZA; Fifer, KM; Rudd, JHF; Shankar, SS; Singh, P; Subramanian, S; Tawakol, A; Van Dyke, TE; Vijayakumar, J; Vucic, E | 1 |
| Bi, H; Chen, J; Hou, J; Liu, B; Liu, D; Liu, J; Shi, H; Wen, X; Yuan, J; Yue, L; Zhang, C; Zhang, X | 1 |
| Alonso, F; Corpataux, JM; Déglise, S; Delie, F; Dubuis, C; Haefliger, JA; Jordan, O; Luca, L; May, L; Meda, P; Mylonaki, I; Saucy, F | 1 |
| Tremoulet, AH | 1 |
| Catapano, AL; Corrao, G; Ibrahim, B; Mancia, G; Merlino, L; Nicotra, F; Pasini, TS; Zambon, A | 1 |
| Laaksonen, R | 1 |
| Chen, Q; Cong, HL; Cui, R; Gao, J; Liu, T; Liu, Y; Mao, YM; Zhang, N | 1 |
| Berg, RL; Davis, RL; Denny, JC; Feng, Q; Iwuchukwu, OF; Jiang, L; Jiang, M; Krauss, RM; McCarty, CA; Nickerson, DA; Peissig, PL; Roden, DM; Rotter, JI; Waitara, MS; Wei, WQ; Wilke, RA; Xu, H | 1 |
| Chen, JW; Chen, JY; Chien, KL; Hsia, CH; Hung, YR; Lin, HJ; Lin, LY; Liu, PY; Wu, TC; Yeh, HI | 1 |
| Guo, YL; Jiang, LX; Li, JJ; Liu, J; Wu, NQ; Xu, RX; Zhu, CG | 1 |
| Calabria, P; Limbruno, U; Micheli, A; Picchi, A | 1 |
| Manlhiot, C; McCrindle, BW | 1 |
| Butte, AJ; De Vusser, K; Fischbein, MP; Gong, Y; Khatri, P; Kimura, N; Morgan, AA; Naesens, M; Robbins, RC; Roedder, S; Sarwal, MM | 1 |
| Burzynska, B; Danikiewicz, W; Gora, M; Kaminska, J; Leszczynska, A; Maciejak, A; Odolczyk, N; Plochocka, D; Siedlecka, J; Sojka, M; Swiezewska, E; Sygitowicz, G; Szkopinska, A; Tulacz, D; Warchol, I; Wysocka-Kapcinska, M | 1 |
| Alves, Mdo S; de Araújo Júnior, RF; de Araújo, AA; de Moura, LM; de Souza, LB; Rocha, HO; Souza, TO; Torres, KP | 1 |
| Bhansali, A; Jani, RH; Jariwala, G; Jha, P; Joshi, S; Mukhopadhyay, S; Pai, V | 1 |
| Bae, JH; Bae, JW; Cha, MJ; Chae, IH; Cho, MC; Kim, HS; Kwon, TG; Lee, SP; Rha, SW; Suh, JW | 1 |
| Li, ZH; Moreno, SN; Ramakrishnan, S; Striepen, B | 1 |
| Ammineni, P; Kondreddy, Vk; Mallikarjuna, S; Peraman, R | 1 |
| Bloigu, R; Morin-Papunen, L; Piltonen, T; Puukka, K; Puurunen, J; Ruokonen, A; Savolainen, MJ; Tapanainen, JS | 1 |
| Eleftheriadou, I; Grigoropoulou, P; Katsilambros, N; Makrilakis, K; Margeli, A; Papassotiriou, I; Perrea, D; Tentolouris, N; Zoupas, C | 1 |
| Andalib, S; Garjani, A; Khorrami, A; Maleki-Dijazi, N; Shayanfar, A | 1 |
| Chen, S; Tang, R; Zhang, HY | 1 |
| Fromigué, O; Girault, I; Habel, N; Hamidouche, Z; Lecanda, F; Marie, PJ; Patiño-García, A | 1 |
| Khoramjouy, M; Malekinejad, H; Mehrabi, M; Rezaei-Golmisheh, A | 1 |
| Banach, M; Celecova, Z; Gaspar, L; Hirnerova, E; Huckova, N; Kucera, M; Oravec, S | 1 |
| Akturk, E; Altas, Y; Atas, H; Balta, S; Can, C; Demirkol, S; Erdem, K; Korkmaz, H; Kurtoglu, E; Sincer, I; Yilmaz, M | 1 |
| Li, T; Liu, J; Sai, X; Sun, Y; Wang, D; Yang, B; Zhou, R | 1 |
| Bickel, JP; de Ferranti, SD; Mendelson, MM; Zachariah, JP | 1 |
| Al-Mansoub, MA; Asmawi, MZ; Murugaiyah, V | 1 |
| Brundage, KM; Bunner, P; Craig, MD; Cumpston, A; Gibson, LF; Hamadani, M; Petros, W; Remick, SC; Tse, W; Vos, JA; Wen, S | 1 |
| Chen, Q; Cong, HL; Cui, RZ; Gao, J; Liu, T; Liu, Y; Mao, YM; Zhang, N | 1 |
| Cui, Y; Ju, SH; Li, KC; Lu, T; Teng, GJ; Wen, S | 1 |
| Chintala, M; Chintala, R; Guda, M; Komarraju, AL; Mangamoori, LN; Rentala, S | 1 |
| Fan, J; Keyamura, Y; Kohashi, M; Koyama, T; Niimi, M; Nozako, M; Yasufuku, R; Yoshikawa, T | 1 |
| Bao, JQ; Fallon, JK; Higgins, JW; Ke, AB; Manro, JR; Smith, PC; Zamek-Gliszczynski, MJ | 1 |
| Belagali, Y; Bhagwath, V; Maskeri, R; Ramya, K; Shoeb, A; Ullal, SD | 1 |
| Aksoy, Y; Senen, K; Sivri, N; Tekin, G; Yalta, K; Yetkin, E | 1 |
| Ishimitsu, T; Nagase, A; Nakano, N; Ohira, T; Ohno, E; Onoda, S; Satonaka, H; Ueno, Y | 1 |
| Atkinson, PH; Bellows, DS; Bircham, PW; Maass, DR; Yibmantasiri, P | 1 |
| Ghavimi, H; Hamishekar, H; Jouyban, A; Shayanfar, A | 1 |
| Bangalore, S; Deedwania, P; Demicco, DA; Fayyad, R; Kostis, JB; Laskey, R; Messerli, FH | 1 |
| He, BX; Qiu, J; Shi, L; Zeng, XH; Zhao, SJ | 1 |
| Ge, J; Jang, Y; Ji, C; Kim, YJ; Lam, W; Zhu, J | 1 |
| Chakrabarti, A; Dhamija, P; Hota, D; Kochhar, R; Sachdev, A | 1 |
| Ma, X; Wang, F; Wang, M; Wang, Y; Zhao, C; Zhao, M | 1 |
| Almeida, S; Bruxel, EM; Ferreira, ME; Fiegenbaum, M; Hutz, MH; Lima, LO; Pires, RC; Van der Sand, CR; Van der Sand, LC | 1 |
| Chen, Y; Huang, A; Ku, H; Li, LC; Li, Q; Moorhead, JF; Powis, SH; Ruan, XZ; Varghese, Z; Wheeler, DC; Zhao, L | 1 |
| Aukrust, P; Holven, KB; Nenseter, MS; Ose, L | 1 |
| Dinesh, N; Kaur, PK; Kishore Babu, N; Pallerla, DS; Singh, S | 1 |
| Bash, D; Brennan, DM; Cavender, MA; Jukema, JW; Kastelein, JJ; Koenig, W; Lincoff, AM; Menon, V; Nambi, V; Nicholls, SJ; Nissen, SE; Rosenson, RS; Schwartz, GG; Wright, RS | 1 |
| Bech, JN; Hansen, AB; Jensen, JM; Larsen, T; Mose, FH; Pedersen, EB | 2 |
| Carnevale, R; Pastori, D; Pignatelli, P; Violi, F | 1 |
| Becker, ML; de Keyser, CE; Hofman, A; Klungel, OH; Maitland-van der Zee, AH; Peters, BJ; Stricker, BH; Uitterlinden, AG; Verstuyft, C; Visser, LE | 1 |
| Lloyd, DG; Ma, D; O'Dea, KP; Pac-Soo, C; Penn, JW; Takata, M; Vizcaychipi, MP; Wan, Y; Watts, HR | 1 |
| Lange, AD; Machado, JC; Todeschini, V; Volpato, NM | 1 |
| Foody, JM; Hu, H; Neff, D; Ramey, DR; Sajjan, S; Tershakovec, AM; Tomassini, JE; Toth, PP; Tunceli, K | 1 |
| Abdallah, FR; Aldohmy, S; Elseweidy, MM; Kassem, HM; Younis, NN | 1 |
| El-Moselhy, MA; El-Sheikh, AA | 1 |
| Chen, J; Dong, J; Jiang, R; Jin, C; Li, T; Quan, W; Tian, Y; Wang, D; Wang, J; Wang, S; Wei, H; Zhang, J | 1 |
| Abreu, GR; Andrade, TU; Bissoli, NS; Caliman, IF; Dalpiaz, PL; Figueiredo, SG; Gusmão, LN; Lamas, AZ; Medeiros, AR | 1 |
| Aksakal, E; Ekinci, M; Işik, T; Kaya, A; Kaya, Y; Kurt, M; Sevimli, S; Tanboğa, IH; Topçu, S | 1 |
| Ahn, CW; Cha, BS; Cho, Y; Choe, EY; Huh, KH; Kang, ES; Kim, MS; Kim, YS; Kwon, O; Lee, HC; Wang, HJ | 1 |
| Ashton, JC; Maggo, S | 1 |
| Cheng, X; Conney, AH; Cui, XX; Ding, N; Dipaola, RS; Du, Z; Goodin, S; Huang, MT; Liu, Y; Van Doren, J; Wang, H; Zheng, X | 1 |
| Abad, L; Dueñas-Laita, A; Gonzalez-Sagredo, M; Pérez-Castrillón, JL; Riancho, JA; Ruiz-Mambrilla, M; Vega, G; Zarrabeitia, MT | 1 |
| Cai, A; Dong, Y; Huang, Y; Li, L; Mai, W; Qiu, R; Rao, S; Yu, D; Zheng, D; Zhou, Y | 1 |
| Ivanova, MV; Ragino, YI; Safronova, OG; Shintyapina, AB; Stakhneva, EM; Vavilin, VA | 1 |
| Davoodpour, P; Larsson, L; Malm, J; Mörk, LM; Norata, GD; Parini, P; Rehnmark, S; Witt, MR | 1 |
| Awoniyi, O; Gosmanov, AR | 1 |
| Inaba, T; Kamiya, F; Katayama, Y; Katsura, K; Muraga, K; Nito, C; Saito, T; Ueda, M | 1 |
| Chen, X; Fei, X; He, F; Hu, Y; Lou, Y; Wang, S; Yang, R; Ye, H | 1 |
| Alizadeh-Fanalou, S; Amniattalab, A; Hassani-Dizaj, S; Malekinejad, H; Rezabakhsh, A; Rokhsartalab-Azar, S | 1 |
| Dang, XM; Ma, AQ; Yang, L; Zhu, B | 1 |
| Ceron, CS; Gerlach, RF; Guimarães, DA; Pinheiro, LC; Rizzi, E; Tanus-Santos, JE | 1 |
| Boulanger, L; Chen, SY; Kuznik, A; Lee, YC; Mardekian, J; Shah, SN | 1 |
| Droog, S; Havekes, LM; Maas, AC; Offerman, EH; Pieterman, EJ; Princen, HM; van den Hoek, AM; van den Hoogen, RM; van der Hoorn, JW; van Nieuwkoop, A | 1 |
| Aramin, H; Eslami, L; Malekzadeh, R; Merat, S; Nasseri-Moghaddam, S | 1 |
| Han, L; Li, MG; Ye, P | 1 |
| Franzoni, F; Gaudio, C; Greco, C; Marazzi, G; Pelliccia, F; Polacco, M; Rosano, G; Speziale, G; Spoletini, I; Vitale, C | 2 |
| Geddawy, A; Imamura, T; Iwasaki, H; Masada, M; Okamura, T; Shimosato, T; Shinozaki, K; Shintaku, H; Tawa, M; Yoshida, Y | 1 |
| Duleba, AJ; Ortega, I; Sokalska, A; Stanley, SD; Villanueva, JA | 1 |
| Louro, T; Matafome, P; Nunes, E; Seiça, RM; Sena, CM | 1 |
| Kasahara, M; Kuwabara, T; Mori, K; Mukoyama, M; Nakagawa, T; Ueshima, K; Yasuno, S; Yokoi, H | 1 |
| Ben-Yehuda, O; Constance, C; Hanson, ME; Lin, J; Lowe, RS; Tershakovec, AM; Wenger, NK; Zieve, F | 1 |
| Jaimes, EA; Raij, L; Tian, R; Zhou, MS | 1 |
| Andy Schuetz, C; Folse, H; Gandhi, S; Rengarajan, B; Sternhufvud, C | 1 |
| Lei, W; Li, H; Tian, J; Wu, K | 1 |
| Boobalan, R; Choudhury, S; Kandasamy, K; Mishra, SK; Parida, S; Reddy, N; Singh, TU; Singh, V; Sukumarn, SV; Thangamalai, R | 1 |
| Elens, L; Elisaf, M; Kolovou, G; Kolovou, V; Manolopoulos, VG; Ragia, G; Tavridou, A; Tselepis, AD; Van Schaik, RH | 1 |
| Danesh-Meyer, HV; Gale, J | 1 |
| Li, L; Liu, Y; Su, Q; Sun, Y; Wang, J; Zhou, Y | 1 |
| Cai, W; Cao, Y; Chen, X; Li, S; Ma, W; Su, J; Wang, F; Zou, W | 1 |
| Mintz, GS | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Tuzcu, EM; Uno, K; Wolski, K | 1 |
| Ghalali, A; Högberg, J; Stenius, U; Wiklund, F; Zheng, H | 1 |
| Du, Y; Gao, J; Hu, R; Lu, M; Wang, Y; Wei, W; Zhang, S; Zhou, Q; Zhu, H; Zuo, L | 1 |
| Davis, MW; Wason, S | 1 |
| Izuhara, M; Matsuda, M; Mitsuoka, H; Shioji, K; Uegaito, T | 1 |
| Bermúdez-Ocaña, DY; Díaz-Zagoya, JC; Espinosa-García, MT; Jiménez-Santos, MA; Juárez-Oropeza, MA; Juárez-Rojop, IE; Ramón-Frías, T; Tovilla-Zárate, CA | 1 |
| Fu, G; Gong, X; Ma, Y; Ruan, Y; Wu, S | 1 |
| Fotiadis, G; Kadoglou, NP; Kapelouzou, A; Liapis, CD; Sailer, N | 1 |
| Albers, GW; Tai, WA | 1 |
| Amato, AA; Puig, A; Scripko, PD | 1 |
| Barkate, H; Dalal, J; Dani, S; Hiremath, MS; Jindal, C; Kahali, D; Kaul, U; Ramchandran, P; Rane, R; Varma, J | 1 |
| Laracuente, ML; Ronaldson, PT; Sanchez-Covarrubias, L; Slosky, LM; Thompson, BJ; Zhang, Y | 1 |
| Fang, D; Jia, H; Qu, Z; Quan, W; Quan, Z; Yang, S | 1 |
| An, T; Hayashi, H; Kikkawa, A; Kose, E; Matsumoto, Y | 1 |
| Gutkin, SW; Jameson, K; Marrett, E; Ramey, DR; Tershakovec, AM; Zhang, Q; Zhao, C | 1 |
| Burren, Y; Donati, F; El-Koussy, M; Findling, O; Humpert, S; Kamm, CP; Kappos, L; Mattle, HP; Müller, F; Müller, M; Naegelin, Y; Schwegler, G; Slotboom, J | 1 |
| Anjali, CH; George, PD; Rajith, B; Ravindran, A; Sripriyalakshmi, S | 1 |
| Dunn, SE; Prod'homme, T; Steinman, L; Weber, MS; Youssef, S; Zamvil, SS | 1 |
| Ben-Eltriki, M; Brocks, DR; Chaudhary, HR; El-Kadi, AO; Elsherbiny, ME | 1 |
| Coombes, JS; Fassett, RG; Geraghty, DP | 1 |
| Aka Bolat, F; Bulgan Kilicdag, E; Parlakgumus, A; Parlakgumus, HA; Simsek, E | 1 |
| Balaganur, V; Kant, V; Kumar, D; Latief, N; Lingaraju, MC; More, AS; Pathak, NN; Tandan, SK | 1 |
| David, DC; Haribalaji, N; Harivenkatesh, N; Sudhakar, MK | 1 |
| Augustin, S; Esteban, R; Ezkurdia, N; Genescà, J; Martell, M; Raurell, I; Rodríguez, S | 1 |
| Kapoor, A; Kumar, S; Rai, H; Sinha, N; Tewari, S | 1 |
| Gong, HR; Huang, WY; Li, XP; Zhao, SP | 1 |
| Chattopadhyay, S; Dey, S; Mazumder, B | 1 |
| Baretton, GB; Bauer, T; Benad-Mehner, P; Bornhäuser, M; Ebert, R; Göbel, A; Hadji, P; Hofbauer, LC; Jakob, F; Muders, MH; Rachner, TD; Rauner, M; Schem, C; Thiele, S | 1 |
| Jannes, CE; Krieger, JE; Morgan, AC; Pereira, AC; Santos, PC; Santos, RD; Turolla, L | 1 |
| Beckx, K; Dhar, M; Eyskens, F; Luyckx, E; Simons, A; Van West, D | 1 |
| Aslam, M; Bhattacharya, SK; Galav, V; Jafri, AA; Madhu, SV | 1 |
| Kamalzadeh, Z; Shahrokhian, S | 1 |
| Campese, VM | 1 |
| Alexandre, F; D'Alexandri, FL; de Faria, EC; de Souza Zago, VH; Gardin Danelon, MR; Panzoldo, NB; Parra, ES; Rocha Quintão, EC; Tanus-Santos, JE; Vieira, IC | 1 |
| He, GX; Liu, XL; Xu, HP; Zhao, XJ | 1 |
| Casiano, H; Crespo, MJ; Cruz, N; Hernandez, C; Quidgley, J; Rivera, K; Torres, H | 1 |
| Cunnane, G; Durcan, L; Gleeson, N; McKiernan, S | 1 |
| Kakuda, H; Matoba, M; Nagao, S; Nakatoh, H; Takekoshi, N | 1 |
| Duan, RS; Li, H; Li, XL; Wang, CC; Wang, S; Xu, H; Yue, LT; Zhang, M | 1 |
| Marques-Vidal, P; Preisig, M; Vaucher, J; Vollenweider, P; Waeber, G | 1 |
| Chen, P; Dai, L; Wu, S; Zhang, Y; Zhao, S | 1 |
| Chen, F; Chen, W; Chen, X; He, Q; Xiong, F | 1 |
| Amarenco, P; Callahan, A; Goldstein, LB; Hennerici, MG; Messig, M; Ovbiagele, B; Sillesen, H; Welch, KM; Zivin, J | 1 |
| Amarenco, P; Arsenault, BJ; Bao, W; Barter, P; Boekholdt, SM; DeMicco, DA; Mora, S; Pedersen, T; Tardif, JC; Waters, DD | 1 |
| Deng, Y; Guo, X; Liu, H; Shang, J; Yuan, X; Zhu, D | 1 |
| Crocker, L; Liu, Y; Ma, W; Shen, J; Wang, C; Zhang, L | 1 |
| Bilal Waqar, A; Fan, J; Kang, D; Koike, T; Li, S; Liang, J; Niimi, M; Shiomi, M; Wang, Y | 1 |
| Abdelbary, A; Hamza, M; Unis, A | 1 |
| Chang, CY; Chang, KC; Chang, RW; Chen, YS; Ko, WJ; Ko, YH; Tsai, PR; Wang, CH; Wang, SS; Young, TH | 1 |
| Corrigan, B; Hooker, AC; Ito, K; Karlsson, MO; Plan, EL; Ueckert, S | 1 |
| Barroso, MV; Benjamim, CF; de Brito-Gitirana, L; Ferreira, TS; Lanzetti, M; Porto, LC; Rueff-Barroso, CR; Valença, SS | 1 |
| Lagos, J; Rosales, A; Salazar, LA; Zambrano, T | 1 |
| Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A | 1 |
| Gao, R; Jin, C; Li, N; Qian, H; Yang, Y; Zhang, Q | 1 |
| Catharino, RR; de Oliveira, DN; Ferreira, MS; Rodrigues, LR | 1 |
| Chang, WT; Huang, SK; Liau, I; Yang, YC | 1 |
| Conney, AH; Cui, XX; Ding, N; Du, Z; Gao, Z; Hu, C; Huang, H; Lin, Y; Rabson, AB; Shih, WJ; Wei, X; Zheng, X | 1 |
| Bauer, I; Bertolotto, M; Dallegri, F; Fabre, M; Galan, K; Lenglet, S; Mach, F; Montecucco, F; Nencioni, A; Palombo, D; Pane, B; Pelli, G; Pende, A; Python, M; Quercioli, A; Spinella, G; Vuilleumier, N | 1 |
| Avihingsanon, Y; Chancharoenthana, W; Praditpornsilpa, K; Somparn, P; Townamchai, N; Vadcharavivad, S; Wanitchanont, A | 1 |
| Cui, W; Drummond, JC; Godoy, JC; Head, BP; Niesman, IR; Patel, HH; Patel, PM; Risbrough, VB; Roth, DM; Schilling, JM; Zemljic-Harpf, AE | 1 |
| Barter, PJ; DeMicco, DA; Messig, M; Ong, KL; Rye, KA; Waters, DD | 1 |
| Elisaf, M; Giannakopoulou, E; Kolovou, G; Kolovou, V; Manolopoulos, VG; Ragia, G; Tavridou, A; Tselepis, AD | 1 |
| Al-Rashed, F; Boyle, JJ; Calay, D; Cole, J; Dryden, N; Dumont, O; Hamdulay, SS; Haskard, DO; Holla, VR; Hoong, C; Kiprianos, AP; Liu, Z; Mason, JC; Randi, AM; Shamsi, A; Thornton, CC; Wang, B | 1 |
| Chang, JH; Cheong, J; Ly, J; Messick, K; Plise, E; Wright, M; Zhang, X | 1 |
| Cong, H; Fu, N; Jin, D; Li, H; Li, X; Ma, H; Wang, Y | 1 |
| Ballantyne, CM; Blom, DJ; Bolognese, M; Burgess, L; Ceska, R; Hala, T; Kim, JB; Koren, MJ; Lillestol, MJ; Monsalvo, ML; Roth, E; Scott, R; Stein, EA; Toth, PD; Tsirtsonis, K; Wasserman, SM | 1 |
| Adewale, A; Behm, MO; Kerbusch, T; Mandema, J; Vargo, R | 1 |
| Hegazy, ND; Issa, MM; Nejem, RM; Shanab, AA; Stefan-van Staden, RI | 1 |
| Chaudagar, KK; Mehta, AA | 1 |
| Dehpour, AR; Honarmand, AR; Javadi-Paydar, M; Pourtabatabaei, N; Rahimi, N | 1 |
| Krossnes, BK; Ljøstad, U; Mygland, Å | 1 |
| Cho, DY; Hong, JH; Hyeon, SH; Kim, CJ; Kim, EY; Kim, H; Kim, SW; Kim, TH; Kwon, JE; Lee, WS; Mintz, GS; Senguttuvan, NB; Seo, JS; Seok, JW; Weissman, NJ | 1 |
| Feldman, C | 1 |
| Chalmers, JD; Davidson, DJ; Doherty, C; Govan, JW; Graham, C; Harley, C; Hill, AT; Mandal, P; Rossi, AG; Sethi, T; Sidhu, MK | 1 |
| Chen, L; Chen, M; Zhou, W | 1 |
| Bao, W; Betteridge, DJ; Buchan, AP; Colhoun, H; DeMicco, DA; Durrington, PN; Fuller, JH; Hawa, MI; Hitman, GA; Leslie, RD; Neil, HA; Ola, T; Wun, CC | 1 |
| Kawahara, T; Suzuki, G | 1 |
| Bergheim, I; Frank, J; Grebenstein, N; Kremoser, C; Podszun, MC; Schlueter, T; Spruss, A | 1 |
| Hayashi, T; Hirayama, A; Hiro, T; Ishihara, M; Kodama, K; Komatsu, S; Matsuoka, H; Saito, S; Takayama, T; Ueda, Y | 1 |
| Aguirre, B; Alvarez-Gago, T; Bratos, MA; Cenizo Revuelta, N; Gonzalez-Fajardo, JA; Vaquero, C | 1 |
| Armstrong, ZB; Boughner, DR; Carruthers, CP; Drangova, M; Rogers, KA | 1 |
| Alarcón-Galván, G; Cámara-Lemarroy, CR; Cordero-Pérez, P; Fernández-Garza, NE; Guzmán-de la Garza, FJ; Muñoz-Espinosa, L; Torres-González, L | 1 |
| Cerne, D; Djeric, M; Jelic-Ivanovic, Z; Kos, J; Marc, J; Milivojac, T; Mirjanic-Azaric, B; Pecar Fonovic, U; Vekic, J; Zeljkovic, A | 1 |
| Dingemanse, J; Nicolas, LB; van Bortel, L | 1 |
| Cao, Z; Feng, Y; Gao, P; Lu, Z; Wang, P; Wang, S; Zhang, G; Zhou, P | 1 |
| Hegele, RA; Joy, TR; Mahon, JL; McDonald, CG; Monjed, A; Zou, GY | 1 |
| Deng, B; Li, J; Lv, LX; Xie, NZ; Zhang, L; Zheng, LQ | 1 |
| Du, S; Han, YG; Li, L; Luo, P; Wang, GG; Wang, LX; Wu, SL; Zhu, HH | 1 |
| Guo, YL; Li, JJ; Li, S; Li, XL; Xu, RX | 1 |
| Cen, C; Ding, X; Huang, C; Wang, C; Zhan, H | 1 |
| Belcaro, G; Cornelli, U; Finco, A | 1 |
| Bigot, N; Galera, P; Gruchy, N; Jeanne Pasquier, C; Leporrier, N; Odent, S; Read, MH | 1 |
| Ballantyne, CM; Camp, HS; Carlson, DM; Davidson, MH; Kelly, MT; Lele, A; Maki, KC; Mazzone, T; Nicholls, SJ; Rosenson, RS; Stolzenbach, JC; Williams, LA | 1 |
| Corat, EJ; Fatibello-Filho, O; Silva, TA; Vicentini, FC; Zanin, H | 1 |
| Simonyi, G | 1 |
| Chi, L; Hu, X; Pan, N; Peng, L; Zhang, Y | 2 |
| Akahori, H; Eguchi, A; Hirotani, S; Iwasaku, T; Masuyama, T; Matsumoto, M; Naito, Y; Sasaki, N; Sawada, H; Tsujino, T | 1 |
| Bellandi, F; Colonna, G; Di Sciascio, G; Grieco, D; Leoncini, M; Maioli, M; Patti, G; Toso, A | 1 |
| Binder, LB; Constantino, LC; Cunha, MP; Dal-Cim, T; Kuminek, G; Ludka, FK; Rodrigues, AL; Tasca, CI; Zomkowski, AD | 1 |
| Chen, L; Fan, Y; Jiang, J; Wan, J; Zhou, J | 1 |
| Chen, J; Cui, W; Jiang, R; Li, T; Quan, W; Tian, Y; Wang, D; Wang, Y; Yu, H; Zhang, J; Zhou, L | 1 |
| Bijl, M; de Leeuw, K; Kallenberg, CG; Limburg, PC; Souza, AW; Stegeman, CA; van Timmeren, MM; Westra, J | 1 |
| Anticoli, S; Gambardella, L; Malorni, W; Maselli, A; Matarrese, P; Panusa, A; Ruggieri, A; Vona, R | 1 |
| Aguirre, AC; Barbosa, SP; Bianco, HT; do Amaral, JB; Fonseca, FA; França, CN; Izar, MC; Lins, LC; Matos, LN | 1 |
| Cai, JQ; Cao, XZ; Luo, ZR; Zhang, HM | 1 |
| Cannon, CP; de Lemos, J; Guo, J; Lewis, EF; Mega, JL; O'Donoghue, ML; Rouleau, JL; Sabatine, MS; Sarma, A | 1 |
| Krueger, KA; Morisaki, Y; Ruotolo, G; Takeuchi, M; Teramoto, T | 1 |
| Jin, Y; Liang, B; Qu, WH; Sui, HJ; Wang, HM; Yu, SX; Zhang, LL | 1 |
| Bangalore, S; DeMicco, DA; Fayyad, R; Hovingh, GK; Laskey, R; Vogt, L; Waters, DD | 1 |
| Brown, I; Gallivan, C | 1 |
| Artursson, P; Karlgren, M; Lai, Y; Norén, A; Svedberg, EK; Vildhede, A; Wisniewski, JR | 1 |
| Adachi, R; Amano, Y; Ishikawa, E; Miura, S; Shimada, M; Shinozawa, E; Tozawa, R | 1 |
| Azushima, K; Dejima, T; Kanaoka, T; Kobayashi, R; Maeda, A; Ohsawa, M; Tamura, K; Toya, Y; Umemura, S; Uneda, K; Wakui, H | 1 |
| Imaizumi, A; Itabe, H; Keyamura, Y; Kohashi, M; Koyama, T; Nagano, C; Niimi, M; Nozako, M; Yasufuku, R; Yoshikawa, T | 1 |
| Chen, J; Chen, S; Huang, H; Huang, Y; Liu, P; Liu, Z; Shen, X; Xu, S | 1 |
| Jeong, CW; Kang, M; Kim, HH; Ku, JH; Kwak, C | 1 |
| Cai, Z; He, B; Hu, L; Jin, S; Li, D; Nie, P; Shao, Q; Shen, J; Shen, L; Xiao, H; Yi, J; Yu, Y | 1 |
| Farajzadegan, Z; Fatemi, A; Kazemi, M; Moosavi, M; Sayedbonakdar, Z; Smiley, A | 1 |
| Panchangam, V | 1 |
| Fialkow, J; Legg, JC; Nedergaard, BS; Nelson, P; Neutel, JM; Ramstad, D; Robinson, JG; Rogers, WJ; Scott, R; Somaratne, R; Wasserman, SM; Weiss, R | 1 |
| Abdel Hakiem, AF; Ali, HR; El-Kommos, ME; Mohamed, NA | 1 |
| Lozzi, A | 1 |
| Chabouk, M; Ejlali, M; Panahi, HA | 1 |
| Holčapek, M; Jirásko, R; Kuneš, M; Svatoš, A | 1 |
| Belen, AD; Cetinalp, NE; Daglioglu, E; Eroglu, H; Menekse, G; Nacar, OA; Turkoglu, OF; Uckun, OM; Yildirim, AE | 1 |
| Baruch, A; Chilton, J; Erwin, R; Forrest, AS; Gelzleichter, TR; Halpern, W; Leabman, M; Peng, K; Satterwhite, CM; Stevens, D | 1 |
| Marrett, E; Neff, DR; Ramey, DR; Tershakovec, AM; Tomassini, JE; Zhang, NJ; Zhang, Q; Zhao, C | 1 |
| Doad, GJ; Kabange, W | 1 |
| Cai, J; Ding, X; Fang, Y; Liu, S; Liu, T; Yu, X; Zhang, B; Zhang, H | 1 |
| Dicker, D; Elis, A; Gevrielov-Yusim, N; Goldenberg, I; Klempfner, R; Kopel, E; Matetzky, S; Pereg, D | 1 |
| Chang, YH; Lee, YJ; Lin, KD; Shin, SJ | 1 |
| Baek, IH; Cho, W; Ha, ES; Hwang, SJ; Kim, MS | 1 |
| Ismail, S; Küchler, P; Murarka, S; Nussbaumer, P; Schultz-Fademrecht, C; Triola, G; Waldmann, H; Wittinghofer, A; Zimmermann, G | 1 |
| Amalvict, R; Baret, E; Dormoi, J; Pradines, B; Savini, H | 1 |
| Evdakimova, AA; Iakovenko, EI; Mamedov, MN; Sharvadze, GG; Toguzova, ZA | 1 |
| Chen, Y; Li, Q; Moorhead, JF; Powis, SH; Ruan, XZ; Varghese, Z; Wheeler, DC; Zhao, L | 1 |
| Abdelbaset, M; Agha, AM; Mahmoud, SS; Negm, SA; Safar, MM | 1 |
| Chen, X; Li, Y; Meng, Q; Sun, H; Xu, P; Yin, Q; Yu, H; Zhang, Z | 1 |
| Liu, X; Qu, Y; Shen, H; Xia, J | 1 |
| Dorecka, M; Francuz, T; Garczorz, W; Romaniuk, W; Siemianowicz, K | 1 |
| Bátai-Konczos, A; Jemnitz, K; Kékesi, O; Kis, E; Szabó, K; Szabó, M; Veres, Z | 1 |
| Gul, M; Ozerol, E; Ozerol, IH; Parlakpinar, H; Simsek, Y; Yilmaz, E | 1 |
| Caporale, R; Clemente, AM; Filippelli, A; Gelli, AM; Guasti, D; Musilli, C; Paccosi, S; Parenti, A; Romagnoli, P; Torcia, MG | 1 |
| Goyal, A; Gupta, N; Gupta, YK; Singh, S; Tandon, N | 1 |
| Cai, Y; Fan, Z; Feng, J; Jiang, F; Li, J; Liu, X; Ma, D; Zha, K; Zheng, S | 1 |
| Cardona-Gómez, GP; Garcia-Segura, LM; Gutierrez-Vargas, JA; Muñoz-Manco, JI | 1 |
| Angus, PW; Ekinci, EI; Gow, PJ; Jones, RM; O'Brien, RC; Page, MM | 1 |
| Chen, ZY; Gao, LH; Lei, L; Li, CN; Liu, Q; Liu, SN; Shen, ZF; Sun, SJ | 1 |
| Cao, YJ; Du, HP; Hu, LF; Li, J; Liu, CF; Liu, H; Wang, F; Wang, YL; Xu, R; Xu, Y; You, SJ | 1 |
| Huang, XH; Hui, RT; Liu, G; Lu, J; Xu, YL; Zheng, XX | 1 |
| Al-Azzam, SI; Alzayadeen, RN; Alzoubi, KH; Khabour, OF | 1 |
| Cheng, X; He, Y; Li, X; Liu, X; Song, L; Zhang, H | 1 |
| Guo, YQ; Li, YF; Shi, ST; Wang, ZH | 1 |
| Chen, S; Conney, AH; Cui, XX; Dipaola, RS; Goodin, S; He, Y; Huang, H; Li, D; Liu, Y; Van Doren, J; Wang, H; Zheng, X | 1 |
| Akdemir, A; Aktug, H; Erbas, O; Ergenoglu, M; Taskiran, D; Yavasoglu, A; Yildirim, N; Zeybek, B | 1 |
| Bai, J; Cai, W; Feng, X; Han, Y; Liu, T; Tao, J; Tian, X; Yan, C; Zhang, X | 1 |
| Devkar, TB; Divase, GT; Rodde, MS; Tekade, AR | 1 |
| Chen, W; Gao, DC; Ye, PX; Ye, PZ; Zhu, JH | 1 |
| Liu, XH; Qu, Y; Shen, H; Song, DG; Xia, JG; Xu, FF | 1 |
| Bullock, R; Craig, D; Malouf, R; McGuinness, B; Passmore, P | 1 |
| Horoshko, OM; Zamors'kyĭ, II; Zeleniuk, VH | 1 |
| Deng, T; Li, H; Li, Y; Tian, L; Zhao, P; Zhou, S | 1 |
| Adamson, J; Baracaia, S; Belatri, R; Cassell, J; Delaney, B; Dyson, L; Fox, R; Goldacre, B; Gulliford, M; Hunter, T; Mahmood, S; McCann, G; Padmanabhan, S; Pirmohamed, M; Ronaldson, S; Round, T; Smeeth, L; Taweel, A; Torgerson, D; van Staa, TP | 1 |
| Bendix, I; Herz, J; Infante-Duarte, C; Leuenberger, T; Luenstedt, S; Luessi, F; Paterka, M; Pfueller, CF; Prozorovski, T; Siffrin, V; Treue, D; Waiczies, S; Zipp, F | 1 |
| Brugnon, F; Drevet, J; Gouby, G; Gremeau, AS; Grizard, G; Janny, L; Maqdasy, S; Marceau, G; Pereira, B; Pons-Rejraji, H; Sion, B; Tauveron, I | 1 |
| Mokhtari-Dizaji, M; Rahmani-Cherati, T; Rostami, A; Vajhi, A | 1 |
| Cai, M; Cheng, L; Kai, Z; Liu, Z; Wang, Z; Wu, F | 1 |
| Chang, TT; Chen, JS; Chen, JW; Huang, CC; Huang, PH; Leu, HB; Lin, LY; Lin, SJ; Wu, TC | 1 |
| Ceng, C; Han, W; Huang, C; Liu, Y; Zhan, H; Zheng, D | 1 |
| de Ceuninck, M; Trenson, S | 1 |
| Chang, CH; Chang, YC; Chuang, LM; Lee, YC; Lin, JW; Liu, YC | 1 |
| Grzegorzewska, AE; Jagodziński, PP; Janków, M; Niepolski, L; Sikora, J; Sowińska, A | 1 |
| da Silva, MG; do Nascimento, DC; Duarte, RS; Ferreira, Jda S; Hacker, MA; Lara, FA; Lobato, LS; Monteiro, CP; Moraes, MO; Neumann, Ada S; Oliveira, DS; Pedrini, SC; Pereira, GM; Pessolani, MC; Ribeiro-Alves, M; Rosa, PS; Soares, CT | 1 |
| Budoff, M; Folse, HJ; Goswami, D; Kahn, R; Rengarajan, B | 1 |
| Hyder, SM; Liang, Y; Mafuvadze, B | 1 |
| Carlson, J | 1 |
| Gupta, P; Kannan, K; Kesavan, M; Kurade, NP; Mishra, SK; Sankar, P; Sarath, TS; Sarkar, SN; Suresh, S; Vijayakaran, K | 1 |
| Du, Y; Ferrand, AC; Gaudet, D; Ginsberg, HN; Gipe, D; Hanotin, C; Kereiakes, DJ; McKenney, JM; Roth, EM; Stein, EA | 1 |
| Luo, YQ; Xu, Y; Yang, Y | 1 |
| Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Wang, Y; Zhao, S; Zhu, N | 1 |
| Deng, J; He, J; Hu, Z; Lei, Q; Liu, J; Lu, W; Song, T; Tao, X; Zhang, J; Zheng, L | 1 |
| Alfonso, H; Lake, RA; Musk, AW; Nowak, AK; Olsen, N; Robinson, BW; Robinson, C; Walsh, A; Woo, S | 1 |
| Arévalo, M; Docherty, NG; Eleno, N; Fuentes-Calvo, I; Grande, MT; López-Novoa, JM; Pérez-Barriocanal, F; Rodríguez-Peña, AB | 1 |
| Kartashova, EA; Romantsov, MG; Sarvilina, IV | 1 |
| Kuwano, T; Miura, S; Saku, K; Shimizu, T; Tanigawa, H; Uehara, Y; Zhang, B | 1 |
| Drechsler, C; Kalousová, M; Krane, V; März, W; Tesař, V; Wanner, C; Zima, T | 1 |
| Berlot, CH; Childress, C; Lin, Q; Mi, W; Robishaw, J; Shabahang, M; Sudol, M; Yang, W | 1 |
| Chen, Z; Ge, J; Ma, Y; Zou, Y | 1 |
| O'Brien, E | 1 |
| Fang, Z; Huang, D; Li, X; Liu, Q; Xu, Y; Zheng, C; Zhou, S | 1 |
| Li, Y; Qi, X; Yang, Q | 1 |
| Almeida, S; Ferreira, ME; Fiegenbaum, M; Hutz, MH; Lima, LO; Pires, RC; Smiderle, L; Van der Sand, CR; Van der Sand, LC | 1 |
| Al Zhrany, N; Atwill, M; Bennaceur, K; Breault, D; Hoffmann, J; Keavney, B; Richardson, G; Saretzki, G; Spyridopoulos, I; von Zglinicki, T | 1 |
| Chen, T; Liang, L; Shen, Y; Yan, Y; Yuan, Y; Zhong, C | 1 |
| Ahmadpanah, M; Bajoghli, H; Brand, S; Haghighi, M; Holsboer-Trachsler, E; Jahangard, L; Khodakarami, S | 1 |
| Chen, Y; Chen, Z; Gu, M; Lin, Y; Luo, N; Wang, J; Wang, X | 1 |
| Hu, SD; Qu, Y; Xia, JG; Xu, D; Xu, J; Yin, CL | 1 |
| Coldewey, SM; Thiemermann, C | 1 |
| Dong, QT; Jin, C; Li, N; Qian, HY; Wang, H; Wang, TJ; Wang, XM; Yang, YJ; Zhang, Q | 1 |
| Havekes, LM; Jukema, JW; Kühnast, S; Landmesser, U; Lüscher, TF; Pieterman, E; Princen, HM; Rensen, PC; Simic, B; van der Hoorn, JW; van der Tuin, SJ; van Klinken, JB; Willems van Dijk, K | 1 |
| Amarenco, P; Callahan, A; Campese, VM; Goldstein, LB; Hennerici, MG; Messig, M; Sillesen, H; Welch, KM; Wilson, DJ; Zivin, JA | 1 |
| Choudhary, PR; Sharma, MS | 1 |
| Doerfer, J; Grulich-Henn, J; Grünert, SC; Holder, M; Krebs, A; Lichte, K; Schmidt-Trucksäss, A; Schwab, KO; Stier, B; Winkler, K; Wöhrl, J | 1 |
| Berg, JP; Kringen, MK; Lyle, R; Olstad, OK; Piehler, AP; Sachse, D; Stormo, C | 1 |
| Ahmadi, M; Bacot, S; Barone-Rochette, G; Broisat, A; Devoogdt, N; Dumas, LS; Fagret, D; Ghezzi, C; Lahoutte, T; Perret, P; Riou, LM; Slimani, L; Soubies, A; Toczek, J | 1 |
| Blumenthal, RS; Greenland, P; Polonsky, TS | 1 |
| Aslani, P; Ayoub, R; Gelissen, IC; Moles, R; Nguyen, HL; Tiao, DK | 1 |
| Choi, D; Hong, N; Kang, SM; Lee, SH; Oh, J; Park, S; Youn, JC | 1 |
| Jannes, CE; Krieger, JE; Morgan, AC; Pereira, AC; Santos, PC; Santos, RD | 1 |
| Al Batran, R; Al-Bayaty, F; Al-Obaidi, MM; Ashrafi, A | 1 |
| Bińczak-Kuleta, A; Clark, JS; Hornowska, I; Kaczmarczyk, M; Safranow, K; Sałacka, A | 1 |
| Chi, J; Guo, L; Jiang, L; Li, H; Li, M; Pan, Q; Sun, M; Wang, X; Wang, Y; Xian, T; Yu, D | 1 |
| Amniattalab, A; Hobbenaghi, R; Khoramjouy, M; Malekinejad, H | 1 |
| Lin, Z; Tong, B; Xie, L; Xu, C | 1 |
| Chngrian, GV; Mysyshin, MB; Semegen-Bodak, KV; Slaba, NA; Solomenchuk, TN | 1 |
| Brosh, T; Chechik, O; Dolkart, O; Gabet, Y; Liron, T; Maman, E; Somjen, D | 1 |
| Jinnouchi, H; Masuda, I; Matsui, K; Mori, H; Ogawa, H; Saito, Y; Sugawara, M; Sugiyama, S; Waki, M; Watada, H; Yoshiyama, M | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Cho, L; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Stegman, B; Uno, K | 1 |
| Asrar Ul Haq, M; Mutha, V; Rudd, N; Subiakto, I; Van Gaal, WJ | 1 |
| Chang, YP; Mitchell, BD; Montasser, ME; O'Hare, EA; Wang, X; Zaghloul, NA | 1 |
| Almlöf, M; Johansen, HT; Nilsen, H; Smith, R; Solberg, R; Tewolde, E | 1 |
| Al Batran, R; Al-Bayaty, F; Al-Obaidi, MM; Hussain, SF; Mulok, TZ | 1 |
| Choudhury, S; Gupta, P; Harikumar, SK; Kannan, K; Mishra, SK; Pillai, AH; Sarath, TS; Sarkar, SN; Waghe, P | 1 |
| Baguet, JP; Dias-Domingos, S; Gagnadoux, F; Janssens, JP; Joyeux-Faure, M; Launois, SH; Leftheriotis, G; Lévy, PA; Pepin, JL; Perrig, S; Stanke-Labesque, F; Tamisier, R; Trzepizur, W | 1 |
| Belló-Klein, A; Lehnen, AM; Lehnen, TE; Machado, UF; Markoski, MM; Schaan, B; Tavares, AM | 1 |
| Akiyama, E; Kimura, K; Kosuge, M | 1 |
| Ebensperger, R; Hidalgo, P; Massardo, T; Mezzano, D; Panes, O; Pereira, J; Pereira-Flores, K; Sáez, CG | 1 |
| Bianchi, C; Chu, LM; Elmadhun, NY; Sabe, AA; Sadek, AA; Sellke, FW | 1 |
| Cozzi, R; Lo Schiavo, A; Puca, RV; Romano, F | 1 |
| Černe, D; Drevenšek, G; Janić, M; Lunder, M; Marc, J; Šabovič, M; Zupan, J | 1 |
| Chitose, T; Hokamaki, J; Ogawa, H; Sakamoto, K; Shimomura, H; Shiraishi, S; Sugiyama, S; Tsunoda, R; Yamashita, T; Yamashita, Y | 1 |
| Chen, C; Li, P; Song, J; Zeng, J; Zhang, L; Zhang, Y | 1 |
| Kadoglou, NP; Kapelouzou, A; Karayannacos, PE; Katsimpoulas, M; Kostakis, A; Kostomitsopoulos, N; Liapis, CD; Moustardas, P | 1 |
| Chngrian, GV; Mysyshin, MB; Salomenchuk, TN; Semegen-Bodak, KV; Slaba, nA; Slabyĭ, OM | 1 |
| Bays, HE; Colhoun, HM; Donahue, S; Du, Y; Hanotin, C; Jones, PH; Robinson, JG | 1 |
| Cui, JY; Fu, ZD; Klaassen, CD | 1 |
| Chen, L; Fang, Q; Li, L; Wang, Y; Xu, Y; Yan, X | 1 |
| Kanwar, AJ; Kaul, D; Parsad, D; Soodgupta, D | 1 |
| Li, WS; Li, YX; Lin, CQ; Shi, DY; Zeng, SY | 1 |
| Fang, M; Han, H; Li, D; Wang, H; Wu, H | 1 |
| Blaschke, F; Chemitz, J; Draube, A; Hallek, M; Holtick, U; Kochanek, M; Liebig, TM; Pallasch, C; Scheid, C; Shimabukuro-Vornhagen, A; Theurich, S; von Bergwelt-Baildon, MS; Wennhold, K; Zoghi, S | 1 |
| Ahn, CW; Cha, BS; Cho, Y; Choe, E; Choi, Y; Kang, ES; Lee, HC; Lee, YH; Seo, JW; Wang, HJ; Yun, Y | 1 |
| Braeuning, A; Bucher, P; Buchmann, A; Hofmann, U; Schwarz, M | 1 |
| Ai, R; Chen, F; Li, G; Lu, WH; Tang, ZZ; Wu, XW | 1 |
| Cohen Tervaert, JW; de Jong, HJ; Helle, MJ; Klungel, OH; Meyboom, RH; Niskanen, L | 1 |
| Guan, XH; Guo, WS; He, YB; Pan, AQ; Wang, JX; Xie, Y; Zhang, J; Zhang, SX | 1 |
| Chen, YX; Gu, MN; Lin, YQ; Luo, NS; Salah, ZQ; Wang, XQ | 1 |
| Krysiak, R; Okopien, B | 1 |
| Hunter, ML; Mahvan, TD; Mlodinow, SG; Onysko, MK; Vandiver, JW | 1 |
| Chen, JY; Chen, PY; Duan, CY; Li, HL; Li, LW; Liu, Y; Liu, YH; Luo, JF; Tan, N; Zhou, YL | 1 |
| Antunes, TT; Bruder-Nascimento, T; Callera, GE; He, Y; Montezano, AC; Nguyen Dinh Cat, A; Tostes, RC; Touyz, RM | 1 |
| Sun, B; Yan, WJ; Zhang, WL; Zou, ZP | 1 |
| Abdulghani, HM; Al-Drees, A; Khalil, MS; Khamis, N | 1 |
| Bahrami, G; Fattahi, N; Jalali, F; Taheri, S | 1 |
| Bento, CF; Fernandes, R; Matafome, P; Pereira, P; Seiça, RM; Sena, CM | 1 |
| Duncan, BB; Polanczyk, CA; Restelatto, LM; Ribeiro, RA; Stella, SF; Vieira, JL; Ziegelmann, PK | 1 |
| Canas, JA; Caulfield, MP; Damaso, LC; Gidding, SS; Hossain, J; Mauras, N; Ross, JL; Sikes, KM; Taboada, MV | 1 |
| Drechsler, C; Genser, B; Hengstschläger, M; Kaltenecker, CC; Kopecky, C; Krane, V; März, W; Säemann, MD; Wanner, C; Weichhart, T | 1 |
| Giacomini, P; Izzo, C; Manuppella, F; Marchione, P; Maugeri, A; Morreale, M; Romeo, T; Vento, C | 1 |
| Berdan, LG; Bessac, L; Bhatt, DL; Bittner, V; Diaz, R; Goodman, SG; Hanotin, C; Harrington, RA; Jukema, JW; Mahaffey, KW; Moryusef, A; Pordy, R; Roe, MT; Rorick, T; Sasiela, WJ; Schwartz, GG; Shirodaria, C; Steg, PG; Szarek, M; Tamby, JF; Tricoci, P; White, H; Zeiher, A | 1 |
| Bayigga, L; Elliott, A; Joloba, M; Kaleebu, P; Kambugu, AD; Kamya, MR; Kiragga, A; Mayanja-Kizza, H; Nabatanzi, R; Nakanjako, D; Sekaly, R; Ssinabulya, I | 1 |
| Dehpour, A; Jahanabadi, S; Javadi, S; Khoshnoodi, M; Mehr, SE; Shafaroodi, H; Shahsavarian, A; Shamsaee, J | 1 |
| Jiang, H; Li, XL; Wang, MX; Yan, X; Yu, CM; Zhang, B; Zhang, WJ; Zhang, ZC | 1 |
| Jacob, RF; Mason, RP | 1 |
| Akagi, H; Akasaka, T; Imanishi, T; Ino, Y; Kitabata, H; Komukai, K; Kubo, T; Kumiko, H; Matsuo, Y; Okumoto, Y; Orii, M; Ozaki, Y; Shimamura, K; Shiono, Y; Takarada, S; Tanaka, A; Tanimoto, T; Ueno, S; Yamaguchi, T; Yamano, T | 1 |
| Moreno, PR | 1 |
| Chung, YM; Han, S; Kim, BH; Lee, H; Lee, HG; Park, CH; Shin, K; Ye, SK | 1 |
| Dostal, E; Gaspar, L; Goliasch, G; Hofbauer, SL; Huber, K; Kastl, SP; Katsaros, KM; Krychtiuk, KA; Maurer, G; Oravec, S; Pfaffenberger, S; Pongratz, T; Speidl, WS; Wojta, J; Wonnerth, A | 1 |
| Han, SH; Jang, Y; Koh, KK; Oh, PC; Park, YM | 1 |
| Bespalova, ID; Kaliuzhin, VV; Mediantsev, IuA; Murashev, BIu; Osikhov, IA; Riazantseva, NV | 2 |
| Chan, LW; Gu, XY; Li, J; Liu, L; Luo, XP; Ni, HC; Qiao, J; Shi, HM; Wen, ZC | 1 |
| Berk, M; Li, X; Redlich, C; Sundquist, J; Sundquist, K; Williams, LJ | 1 |
| Braeckman, RA; Soni, PN; Stirtan, WG | 1 |
| Buttari, B; Profumo, E; Rigano, R; Saso, L | 1 |
| Karpe, PA; Kumar, S; Malek, V; Patel, G; Sanghavi, M; Srinivasan, K; Tikoo, K | 1 |
| Basile, G; Catalano, A; Cucinotta, D; Lasco, A; Morabito, N | 1 |
| Baldane, S; Ipekçi, SH; Kebapçılar, L; Sözen, M | 1 |
| Huang, C; Li, Z; Liu, H; Song, X; Wang, X | 1 |
| Agarwal, NB; Raisuddin, S; Sehar, N; Vohora, D | 1 |
| Bianchi, C; Chu, LM; Dalal, RS; Elmadhun, NY; Sabe, AA; Sadek, AA; Sellke, FW | 1 |
| Basso, RG; Cerda, A; Fajardo, CM; Hirata, MH; Hirata, RD | 1 |
| Farrell, GC; Haigh, WG; Ioannou, GN; Savard, C; Teoh, NC; Van Rooyen, DM; Yeh, MM | 1 |
| Drogari, E; Elens, L; Manolopoulos, VG; Mollaki, V; Ragia, G; Van Schaik, RH | 1 |
| Guan, Y; Guo, HY; Shan, ZL; Wang, YT; Yuan, HT; Zhang, Y | 1 |
| Athanasiou, D; Chrysohoou, C; Hatzis, G; Mazaris, S; Mourouzis, K; Oikonomou, E; Papavassiliou, AG; Siasos, G; Stefanadis, C; Tourikis, P; Tousoulis, D; Zaromitidou, M; Zisimos, K | 1 |
| Deng, JG; Liu, J; Song, T; Tao, X | 1 |
| Dubrovins'ka, TV; Skrypnyk, IM | 1 |
| Luo, YH; Wang, YY; Xie, YM; Yang, W; You, L; Zhuang, Y | 1 |
| Eguchi, Y; Fujita, K; Honda, Y; Hyogo, H; Imajo, K; Kessoku, T; Kirikoshi, H; Mawatari, H; Nakajima, A; Nozaki, Y; Ogawa, Y; Ono, M; Saito, S; Sumida, Y; Taguri, M; Tomeno, W; Wada, K; Yoneda, M | 1 |
| Gu, GL; Xu, XL; Yang, QY; Zeng, RL | 1 |
| Bansal, A; Burkholder, G; Goepfert, PA; Kahan, SM; Overton, ET; Sterrett, S; Westfall, AO; Zajac, AJ | 1 |
| Assassi, AL; Auzerie, J; Gaudin, K; Hamon, T; Perovitch, P; Roy, CE | 1 |
| Ye, YC; Zhang, SY; Zhao, XL | 1 |
| Chan, KA; Chou, HW; Lai, CL; Lai, MS | 1 |
| Boekholdt, SM; Fayyad, R; Hovingh, GK; Laskey, R; Pedersen, TR; Stoekenbroek, RM; Tikkanen, MJ | 1 |
| Dawani, ML; Mahboob, T; Yasmeen, G | 1 |
| Desfontaine, V; Desmet, G; Guillarme, D; Tyteca, E | 1 |
| Kitzmiller, JP; Luzum, JA; Phelps, MA; Wang, J | 1 |
| Chen, M; Huang, BT | 1 |
| Nicholls, SJ; Puri, R; Shao, M; Stegman, B | 1 |
| Chen, Y; Fan, Y; Jiang, C; Liu, F; Liu, M | 1 |
| Amar, D; Fleisher, M; Park, B; Rusch, VW; Shi, W; Thaler, HT; Zhang, H | 1 |
| Betteridge, J; Bittner, VA; Fayyad, R; Hsue, PY; Laskey, R; Waters, DD; Wenger, NK | 1 |
| Shi, M; Tang, XY; Yang, HB; Zhao, YZ | 1 |
| Stimac, D; Vojvodić, Z | 1 |
| Anzalone, DA; Cain, VA; Cressman, MD; de Zeeuw, D; Heerspink, HJ; Molitoris, BA; Monyak, JT; Parving, HH; Remuzzi, G; Sowers, JR; Vidt, DG | 1 |
| Chotenimitkhun, R; D'Agostino, R; Hamilton, CA; Herrington, DM; Hundley, WG; Jordan, JH; Lash, TL; Lawrence, JA; Vasu, S; Yeboah, J | 1 |
| Alpay, MF; Cakir, O; Colak, N; Nazli, Y; Uysal, S; Uzunlar, AK | 1 |
| Hui, L; Xiao-Ping, G; Yi, R | 1 |
| Guo, X; Huang, X; Wang, Q | 1 |
| Ding, Y; Feng, GK; Jiang, XJ; Li, XY; Wang, CQ; Wang, ZX | 1 |
| Abdel-Rahman, I; Murphy, C | 1 |
| Lewicki, M; Ng, I; Schneider, AG | 1 |
| Bochar, OM | 1 |
| Chen, J; Hu, YJ; Peng, DF; Tang, SY | 1 |
| Arsenault, BJ; Bao, W; Byun, YS; DeMicco, D; Laskey, R; Lee, JH; Tsimikas, S; Witztum, JL; Yang, X | 1 |
| Kritharides, L; Nicholls, SJ | 1 |
| Phongtuntakul, B; Tungsubutra, W | 1 |
| Song, J; Sun, YZ | 1 |
| Carr, AJ; Cornell, HR; Hulley, PA; Kuzma-Kuzniarska, M; Moneke, MC | 1 |
| Haysom, L; Samaras, K; Stapylton, C; Wines, J | 1 |
| Bangalore, S; Breazna, A; DeMicco, DA; Messerli, FH; Wun, CC | 1 |
| Bonaca, MP; Creager, MA | 1 |
| Abdelbaky, A; Ballantyne, CM; Du, S; Ehlgen, A; Emami, H; Farkouh, ME; Farmer, M; Fayad, ZA; Hayes, W; Kim, J; Langenickel, TH; Li, L; Mohler, ER; Roth, E; Subramanian, S; Tawakol, A; Velasquez, L; Vucic, E | 1 |
| Hao, L; Huang, ZW; Liu, YS; Lu, QH; Wang, X; Xu, DL | 1 |
| Cheng, WP; Lo, HM; Shyu, KG; Wang, BW | 1 |
| Blonk, M; Burger, D; Colbers, A; Schouwenberg, B; van Beek, M | 1 |
| Baer, AL; deGoma, EM; Donovan, DS; Dunbar, RL; Ginsberg, HN; Gutstein, DE; Holleran, S; Johnson-Levonas, AO; Jumes, P; Karmally, W; Lassman, ME; Liu, Y; Millar, JS; Obunike, J; Pollan, L; Rader, DJ; Rafeek, H; Ramakrishnan, R; Reyes-Soffer, G; Tohyama, J; Wagner, JA | 1 |
| Bredie, SJ; Kramers, C; Lobo, CM; van der Vlugt, MJ; Willemsen, AE | 1 |
| Sommer, M; Stoevesandt, J; Trautmann, A | 1 |
| Carreño-Rojo, A; Chica-Marchal, A; Huertas, AJ; Mérida-Fernández, C; Ramírez-Hernández, M | 1 |
| Hanlin, S; Kexuan, T; Ming, Y; Yuliang, W; Zejian, W | 1 |
| Bašić-Jukić, N; Ivandić, E | 1 |
| Baumgartner, I; Drechsler, C; Fauler, G; Genser, B; Grammer, TB; Krane, V; März, W; Ritz, E; Scharnagl, H; Silbernagel, G; Wanner, C | 1 |
| Bays, H; Donahue, S; Gaudet, D; Gouni-Berthold, I; Hanotin, C; Robinson, J; Ruiz, JL; Watts, GF; Weiss, R; Zhao, J | 1 |
| Barter, PJ; Brewer, HB; Ford, J; Hovingh, GK; Kastelein, JJ; Rader, DJ; Round, P; Saleheen, D; van Deventer, SJ | 1 |
| Fabiny, A | 1 |
| Bruthans, J; Mayer, O | 1 |
| Akalin Çiftçi, G; Akalin, A; Alataş, İÖ; Ertorun, İ; Musmul, A | 1 |
| Biswal, PK; Dixit, PK; Pani, NR | 1 |
| Nater, H; Perger, L; Suter, PM | 1 |
| Cannon, CP; Khera, AV; Murphy, SA; Qamar, A; Rader, DJ; Sabatine, MS | 1 |
| Gu, HY; Jiang, L; Shi, MY; Teng, SC; Xue, FH; Yin, F; Zhu, J | 1 |
| Gao, X; Gu, G; Hu, W; Jin, S; Li, J; Li, Y; Wu, PH; Zhan, C; Zhang, L | 1 |
| Komai, E; Takemoto, M; Yokote, K | 1 |
| Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Karpov, RS; Konko, TIu; Koshel'skaia, OA; Kravchenko, ES; Suslova, TE; Vinnitskaia, IV | 1 |
| Faunce, T | 1 |
| Hou, T; Lee, SM; Li, C; Li, D; Li, Y; Pan, P; Shen, M; Sun, H; Tian, S; Zhou, H | 1 |
| Ballocca, F; Barbero, U; Biondi-Zoccai, G; Bonora, S; Calcagno, A; Cannillo, M; Cerrato, E; D'Ascenzo, F; DiNicolantonio, JJ; Gaita, F; Gasparini, M; Gili, S; Grosso Marra, W; Lavie, CJ; Lonni, E; Mancone, M; Montefusco, A; Moretti, C; Omedè, P; Pianelli, M | 1 |
| Ferenci, T; Simonyi, G | 1 |
| Bastos, MM; Boechat, N; Carvalho, RC; Kaiser, CR; Krettli, AU; Martins, WA; Pinheiro, LC; Silva, TP | 1 |
| Komaroff, A | 1 |
| Wang, M; Zeng, R; Zhang, L | 1 |
| El-Zeany, SB; Elzanfaly, ES; Hassan, SA; Salem, MY | 1 |
| Gromnaky, NI; Mikhin, VP; Zhilyaeva, YA | 1 |
| Fleige, M; Glorius, F | 1 |
| Gong, Y; Saren, G; Yi, X | 1 |
| Abate, N; Chandalia, M; Jialal, I; Sallam, HS; Tuvdendorj, DR | 1 |
| Bortolotto, LA; de Oliveira, DS; Dos Santos, AM; Hong, VAC; Misse, RG; Pires Borges, IB; Shinjo, SK | 1 |
| Chiba, T; Fujioka, T; Hara, F; Iwasaki, Y; Moroi, M; Nagayama, D; Nishizawa, K; Saiki, A; Sato, N; Shiba, T; Shimizu, K; Shirai, K; Sugi, K; Sugimoto, H; Takahashi, M; Tatsuno, I; Usui, S; Yamamura, S; Yamasaki, J | 1 |
| Baba, Y; Hirota, T; Kawada, Y; Kitaoka, H; Kubo, T; Tanioka, K; Yamasaki, N | 1 |
| Arefieva, TI; Filatova, AY; Masenko, VP; Noeva, EA; Osokina, AK; Potekhina, AV; Provatorov, SI; Romasov, IV; Samko, AN; Shchinova, AM; Shlevkova, GV; Zharova, EA | 1 |
| Kang, HT; Kim, HS; Kim, J; Lee, JW; Yang, W | 1 |
| Dymkowska, D; Wrzosek, A; Zabłocki, K | 1 |
| Abrahamsson, B; Agrawal, R; Bergenholm, L; Björkbom, A; Bright, J; Cavallin, A; Gopaul, VS; Hammarberg, M; Hawthorne, G; Hurt-Camejo, E; Jansson-Löfmark, R; Jarke, A; Johansson, MJ; Li, X; Lundborg, E; Pieterman, EJ; Princen, HMG; Svensson, L | 1 |
| Kobayashi, J | 1 |
| Cha, DH; Cho, EJ; Chung, WJ; Hong, SJ; Hong, TJ; Jeon, DS; Jeon, DW; Jeong, JC; Jeong, JO; Jeong, MH; Kim, CJ; Kim, KS; Kim, MH; Kim, SK; Kwan, J; Lee, HY; Lee, JH; Lee, JW; Park, CG; Shin, J; Woo, JS; Youn, HJ | 1 |
| Baye, J; Hajek, C; Larson, EA; McDermaid, A; Narayana Gowda, S; Nicole Myrmoe, A; Voora, D; Wilke, RA | 1 |
| El Medany, AMH; Ghazala, RA; Hammadi, SHM; Khalifa, HM; Zakaria Mohammed, HS | 1 |
| Tang, X; Wang, L | 1 |
| Cauthon, KAB; Hanson, K; Mattes, RG | 1 |
| Bagga, A; Hari, P; Khandelwal, P; Lakshmy, R; Ramesh, PL; Sinha, A | 1 |
| Cai, SY; Gu, X; Jiang, JJ; Jiang, YN; Li, RS; Liu, PJ; Wang, JA; Yao, W; Yin, YH; Yu, B; Yuan, ZY; Zhao, SP | 1 |
| Farooq Ur Rehman, RM; Khokhar, SA; Masood, S | 1 |
| Araujo-Lima, CF; Bastos, MM; Boechat, N; Carvalho, RCC; Castelo-Branco, FS; Felzenszwalb, I; Fiuza, LFA; Galvão, BVD; Peres, RB; Soeiro, MNC | 1 |
| Mancinelli, M; Mazzanti, A; Pecorari, D | 1 |
| Bergan, S; Gjertsen, E; Gullestad, L; Husebye, E; Kristiansen, O; Munkhaugen, J; Peersen, K; Sverre, E; Vethe, NT; Weedon-Fekjaer, H | 1 |
| Dautović, E; Halilčević, D; Hatkić, A; Husejnović, MŠ; Rustemović-Čorbić, M; Smajlović, A; Softić, A; Srabović, N | 1 |
| Cho, JM; Choi, JY; Chun, SW; Chung, JW; Hong, SJ; Hong, YJ; Kim, BJ; Kim, CS; Kim, DH; Kim, HS; Kim, KS; Kim, SH; Kim, TN; Lee, CW; Lee, SA; Lee, SH; Lee, SR; Park, HC; Sung, JH; Yoon, SB | 1 |
324 review(s) available for pyrroles and atorvastatin
| Article | Year |
|---|---|
Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias.
Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Drug Interactions; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrroles | 1997 |
A brief review paper of the efficacy and safety of atorvastatin in early clinical trials.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrroles | 1997 |
[Post myocardial infarction management].
Topics: Aftercare; Anticholesteremic Agents; Antioxidants; Atorvastatin; Chromans; Clopidogrel; Diet, Fat-Restricted; Heptanoic Acids; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Risk Factors; Thiazoles; Thiazolidinediones; Ticlopidine; Troglitazone | 1997 |
Comparison of statins in hypertriglyceridemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 1998 |
Statins revisited.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Naphthalenes; Pyrroles | 1998 |
Advances in drug treatment of dyslipidemia: focus on atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Pyrroles; Triglycerides | 1998 |
Peripheral neuropathy and lipid-lowering therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Naphthalenes; Niacin; Peripheral Nervous System Diseases; Pravastatin; Pyrroles; Simvastatin | 1998 |
Maximizing the cost-effectiveness of lipid-lowering therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Cerebrovascular Disorders; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1998 |
Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles; Treatment Outcome | 1998 |
Addressing the challenge.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Pyrroles | 1998 |
Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Pyrroles | 1998 |
[Pharmacology of HMG CoA reductase inhibitors (statins)].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin | 1999 |
[Statins in diabetic hyperlipidemia].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrroles; Risk Factors; Triglycerides | 1999 |
[Aggressive therapy and combination therapy in severe hyperlipidemia].
Topics: Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin | 1999 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
[Atorvastatin (Lipitor)].
Topics: Anticholesteremic Agents; Atorvastatin; Belgium; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Primary Prevention; Pyrroles | 1999 |
[The hyperlipidemias. Role of various statins].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
New insights into the pharmacodynamic and pharmacokinetic properties of statins.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cell Division; Cytochrome P-450 Enzyme System; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Mevalonic Acid; Pyridines; Pyrroles; Simvastatin | 1999 |
Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Simvastatin; Treatment Outcome | 2000 |
Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the atorvastatin versus revascularization (AVERT) trial.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Heptanoic Acids; Humans; Myocardial Revascularization; Pyrroles | 2000 |
The role of small, dense low density lipoprotein (LDL): a new look.
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Pyrroles | 2000 |
HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Pyrroles; Simvastatin | 2000 |
Clinical data: AVERT and QUO VADIS.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Coronary Angiography; Coronary Disease; Decision Making; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoquinolines; Myocardial Revascularization; Pyrroles; Quinapril; Randomized Controlled Trials as Topic; Tetrahydroisoquinolines; Treatment Outcome | 2000 |
Implications of the atorvastatin versus revascularization treatment (AVERT) study for the clinician.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Artery Disease; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrroles; Treatment Outcome | 2000 |
Medical therapy versus coronary angioplasty in stable coronary artery disease: a critical review of the literature.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Myocardial Ischemia; Myocardial Revascularization; Pyrroles; Randomized Controlled Trials as Topic | 2000 |
Cholesterol lowering in atherosclerosis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Simvastatin | 2000 |
Percutaneous coronary intervention versus medical therapy for coronary heart disease.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Nitrates; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2000 |
Statin trials in progress: unanswered questions.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
New statins and new doses of older statins.
Topics: Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2001 |
Statins in children: what do we know and what do we need to do?
Topics: Atorvastatin; Bezafibrate; Child; Child Welfare; Cost-Benefit Analysis; Drug Approval; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Lipid lowering and coronary bypass graft surgery.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Postoperative Period; Pyrroles; Randomized Controlled Trials as Topic | 2000 |
Effective use of statins to prevent coronary heart disease.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin | 2001 |
[The role of HDL in the prevention of cardiovascular events].
Topics: Anticholesteremic Agents; Arteriosclerosis; Aryldialkylphosphatase; Atorvastatin; Cholesterol, HDL; Esterases; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipid Peroxidation; Lovastatin; Phosphatidylcholine-Sterol O-Acyltransferase; Pyrroles; Simvastatin | 2001 |
[Atorvastatin (Lipitor): a review of its pharmacological and clinical profile].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Lipoproteins, VLDL; Liver; Pyrroles; Receptors, LDL; Triglycerides | 2001 |
[Statins and unstable angina: MIRACL].
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pyrroles | 2001 |
Statin therapy--what now?
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Patient Selection; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2001 |
Atorvastatin.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2001 |
[AVERT [The Atorvastatin versus Revascularization Treatment]].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic | 2001 |
[Atorvastatin].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic | 2001 |
Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Topics: Atorvastatin; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Niacin; Pyridines; Pyrroles; Risk Factors; Triglycerides | 2001 |
Synthetic statins: more data on newer lipid-lowering agents.
Topics: Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipids; Pyridines; Pyrroles; Simvastatin | 2001 |
Lipid-lowering medications: what the new guidelines and data mean to women.
Topics: Age Factors; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Practice Guidelines as Topic; Pyrroles; Triglycerides | 2001 |
[Substantiation of increasing doses of statins in clinical practice].
Topics: Adult; Aged; Angiography; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Colestipol; Coronary Disease; Dogs; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Primates; Prospective Studies; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors | 2001 |
Statin therapy and stroke prevention.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Encephalitis; Endothelium, Vascular; Fibrinolytic Agents; Heptanoic Acids; Humans; Lovastatin; Nitric Oxide Synthase; Pyrroles; Stroke | 2001 |
A clinical focus on statins.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Down-Regulation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Multicenter Studies as Topic; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Simvastatin | 2001 |
What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes?
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Pyrroles; Treatment Outcome | 2001 |
United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, Dietary; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Practice Guidelines as Topic; Pyrroles | 2001 |
Cerebrovascular disease and statins: a potential addition to the therapeutic armamentarium for stroke prevention.
Topics: Anticholesteremic Agents; Atorvastatin; Cerebral Infarction; Cholesterol; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Intracranial Arteriosclerosis; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic | 2001 |
Systemic atherosclerosis risk and the mandate for intervention in atherosclerotic peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Arterial Occlusive Diseases; Arteriosclerosis; Atorvastatin; Cholesterol; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Survival Rate | 2001 |
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
Topics: Atorvastatin; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Pyrroles | 2001 |
Safety of HMG-CoA reductase inhibitors: focus on atorvastatin.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2001 |
Apheresis technology for prevention and regression of atherosclerosis.
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Plasmapheresis; Pyrroles; Treatment Outcome | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
Pharmacological interactions of statins.
Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Tolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Muscular Diseases; Pyrroles; Rhabdomyolysis | 2002 |
Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diet; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Exercise; Fatty Acids, Omega-3; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2002 |
Benefits and menaces related to the use of statins in patients after renal transplantation.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Transplantation; Lovastatin; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin | 2002 |
The discovery and development of atorvastatin, a potent novel hypolipidemic agent.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Structure-Activity Relationship | 2002 |
Non-high-density lipoprotein cholesterol: a target of lipid-lowering in dialysis patients.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Renal Dialysis; Simvastatin | 2003 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome | 2003 |
[Secondary prevention after ischemic stroke].
Topics: Administration, Oral; Angioplasty, Balloon; Anticholesteremic Agents; Anticoagulants; Aspirin; Atorvastatin; Carotid Stenosis; Endarterectomy, Carotid; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Placebos; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Smoking Prevention; Stents; Stroke; Vertebral Artery Dissection | 2003 |
Pathobiology, not angiography, should guide management in acute coronary syndrome/non-ST-segment elevation myocardial infarction: the non-interventionist's perspective.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Outcome Assessment, Health Care; Pyrroles; Randomized Controlled Trials as Topic | 2003 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Treating dyslipidemia with statins: the risk-benefit profile.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States | 2003 |
Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Bayes Theorem; Cholesterol, LDL; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2003 |
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Topics: Abciximab; Acute Disease; Adrenergic beta-Antagonists; Angina, Unstable; Antibodies, Monoclonal; Anticholesteremic Agents; Arrhythmias, Cardiac; Aspirin; Atorvastatin; Clopidogrel; Defibrillators, Implantable; Double-Blind Method; Fibrinolytic Agents; Heart Failure; Heart Septal Defects, Atrial; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Myocardial Infarction; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Regeneration; Risk Factors; Syndrome; Ticlopidine; Time Factors; Tirofiban; Tyrosine | 2003 |
Effect of atorvastatin on the concentration, relative distribution, and chemical composition of lipoprotein subfractions in patients with dyslipidemias of type IIA and IIB.
Topics: Adolescent; Adult; Aged; Atorvastatin; Child; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Tissue Distribution | 2003 |
[Effects of statins on coronary artery disease. Review of the recent publications].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic | 2003 |
[Effects of atorvastatin in multiple sclerosis].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Encephalomyelitis, Autoimmune, Experimental; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multiple Sclerosis; Pyrroles | 2003 |
[Efficacy of atorvastatin in long-term treatment of patients with ischemic heart disease].
Topics: Atorvastatin; Drug Administration Schedule; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pyrroles; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2003 |
Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients.
Topics: Adolescent; Adult; Aged; Atorvastatin; Child; Child, Preschool; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles | 2003 |
Clinical pharmacokinetics of atorvastatin.
Topics: Administration, Oral; Anticholesteremic Agents; Atorvastatin; Biological Availability; Clinical Trials as Topic; Drug Interactions; Food-Drug Interactions; Gastrointestinal Tract; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Pyrroles | 2003 |
Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: review of the evidence and methodological considerations.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; Chronic Disease; Coronary Artery Bypass; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Survival Rate | 2003 |
Perspectives from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial--Lipid Lowering Trial and the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2003 |
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin | 2003 |
More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Evaluation; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Pyrimidines; Pyrroles; Racial Groups; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2004 |
Emerging therapies for cerebrovascular disorders.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cerebrovascular Circulation; Cerebrovascular Disorders; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Intracranial Aneurysm; Pyrroles; Randomized Controlled Trials as Topic; Risk; Simvastatin; Therapeutics; Tissue Plasminogen Activator; Treatment Outcome | 2004 |
Atorvastatin: gold standard for prophylaxis of myocardial ischemia and stroke - comparison of the clinical benefit of statins on the basis of randomized controlled endpoint studies.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Myocardial Ischemia; Pyrroles; Randomized Controlled Trials as Topic; Stroke | 2004 |
Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study.
Topics: Atorvastatin; Clinical Trials Data Monitoring Committees; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic | 2004 |
[Interactions of statins with antithrombotic drugs].
Topics: Animals; Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Clopidogrel; Controlled Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Follow-Up Studies; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pravastatin; Primary Prevention; Pyrroles; Rats; Ticlopidine; Time Factors | 2004 |
[LDL cholesterol in normal range. The lower the better? Implications of the GREACE study].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Placebos; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2003 |
[Role of lipid lowering therapy in patients with peripheral arterial occlusive disease].
Topics: Anticholesteremic Agents; Arterial Occlusive Diseases; Atorvastatin; Disease Progression; Exercise Test; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Jejunoileal Bypass; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2004 |
Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2003 |
The next step in cardiovascular protection.
Topics: Angina, Unstable; Anti-Bacterial Agents; Anticholesteremic Agents; Atorvastatin; Chlamydia Infections; Chlamydophila pneumoniae; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention | 2003 |
Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy.
Topics: Amlodipine; Animals; Arteriosclerosis; Atorvastatin; Calcium Channel Blockers; Combined Modality Therapy; Heptanoic Acids; Humans; Hypertension; Hypolipidemic Agents; Pyrroles | 2004 |
Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature.
Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Atorvastatin; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; International Normalized Ratio; Male; Patient Compliance; Pyrroles; Simvastatin; Venous Thrombosis; Warfarin | 2004 |
[Ezetimibe: from pharmacology to clinical trials].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Depression, Chemical; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Intestinal Absorption; Liver; Lovastatin; Pravastatin; Pyrroles; Safety; Simvastatin; Treatment Outcome | 2003 |
Rosuvastatin-induced arrest in progression of renal disease.
Topics: Aged; Atorvastatin; Controlled Clinical Trials as Topic; Creatine; Disease Progression; Drug Administration Schedule; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Hypothesis: atorvastatin has pleiotropic effects that translate into early clinical benefits on cardiovascular disease.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Heptanoic Acids; Humans; Lipid Peroxidation; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Ticlopidine | 2004 |
Intensive lipid-lowering therapy in coronary artery disease: implications of the REVERSAL and PROVE-IT trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
[LDL adsorption for therapy of hyperlipidemia].
Topics: Adsorption; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Hemoperfusion; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pyrroles | 2004 |
Statin precipitated lactic acidosis?
Topics: Acidosis, Lactic; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Diet; Female; Heptanoic Acids; Humans; Pyrroles; Thiamine Deficiency; Ubiquinone | 2004 |
Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease.
Topics: Amlodipine; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2004 |
The use of atorvastatin treatment in usual care environments: pooled analysis of six prospective, observational studies in 90,535 patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Drug Administration Schedule; Drug Utilization Review; Germany; Heptanoic Acids; Humans; Lipids; Prospective Studies; Pyrroles | 2004 |
[The role of intestinal absorption blockade in hypercholesterolemia treatment].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Intestinal Obstruction; Pyrroles | 2004 |
Intravascular ultrasound assessment of coronary atherosclerosis and percutaneous interventions.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Coronary Restenosis; Heptanoic Acids; Humans; Pyrroles; Stents; Treatment Outcome; Ultrasonography, Interventional | 2004 |
Intensive statin therapy in acute coronary syndromes: clinical benefits and vascular biology.
Topics: Acute Disease; Animals; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; T-Lymphocytes | 2004 |
[Low HDL-cholesterol, high triglycerides--well known but often ignored].
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Clofibric Acid; Combined Modality Therapy; Exercise; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Metabolic Syndrome; Niacin; Pyrroles; Risk Factors; Smoking Cessation; Triglycerides; Weight Loss; World Health Organization | 2004 |
Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Pyrroles | 2005 |
Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence.
Topics: Atorvastatin; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Multicenter Studies as Topic; Prodrugs; Pyrroles; Ticlopidine | 2005 |
Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?
Topics: Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Maximum Tolerated Dose; Practice Guidelines as Topic; Pravastatin; Prognosis; Pyrroles; Quebec; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome | 2005 |
The role of lipid management in diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus; Diabetic Angiopathies; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, HDL; Pyrroles; Simvastatin; Triglycerides | 2005 |
[Treatment of cerebral infarction patients with IGT].
Topics: Antidepressive Agents; Antipyrine; Atorvastatin; Cerebral Infarction; Edaravone; Free Radical Scavengers; Glucose Intolerance; Heptanoic Acids; Humans; Hyperglycemia; Hypertension; Hypertriglyceridemia; Insulin Resistance; Pyrroles; Secondary Prevention; Thrombolytic Therapy | 2005 |
Statins and osteoporosis: myth or reality?
Topics: Anticholesteremic Agents; Atorvastatin; Bone Development; Female; Fractures, Bone; Heptanoic Acids; Humans; Osteoporosis; Pyrroles; Simvastatin | 2004 |
Statins and CVD prevention in the diabetic population: implications of the CARDS trial.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Survival Analysis | 2005 |
["Treating to New Targets": plea for a LDL cholesterol target of or below 75 mg/dl in any patient with coronary heart disease].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Atorvastatin and cardiovascular protection: a review and comparison of recent clinical trials.
Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles | 2005 |
Atorvastatin.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Coronary Artery Disease; Drug Interactions; Endothelium, Vascular; Forecasting; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes; Pravastatin; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Pyrroles; Risk Factors; Treatment Outcome | 2005 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscular Diseases; Niacin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
New insights in the treatment of dyslipidemia: a focus on cardiovascular event reduction and the anti-atherosclerotic effects of atorvastatin.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol; Dyslipidemias; Heptanoic Acids; Humans; Pyrroles; Risk Factors | 2005 |
Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2005 |
Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2005 |
Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Safety of high-dose atorvastatin therapy.
Topics: Atorvastatin; Drug Administration Schedule; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2005 |
[Statins: for the time being, do not as a rule prescribe the maximum dose].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Pyrroles | 2005 |
Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis a
Topics: Animals; Atorvastatin; Chromatography, High Pressure Liquid; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pharmaceutical Preparations; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Torcetrapib/atorvastatin combination therapy.
Topics: Animals; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines | 2005 |
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Topics: Animals; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2005 |
High-density lipoproteins and ATP-binding cassette transporters as targets for cardiovascular drug therapy.
Topics: Animals; Atorvastatin; ATP-Binding Cassette Transporters; Cardiovascular Diseases; DNA-Binding Proteins; Hepatocytes; Heptanoic Acids; Homeostasis; Humans; Intestinal Mucosa; Kidney; Lipid Metabolism; Lipoproteins, HDL; Liver X Receptors; Macrophages; Niacin; Orphan Nuclear Receptors; Pyrroles; Receptors, Cytoplasmic and Nuclear | 2005 |
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Stroke prevention, blood cholesterol and statins.
Topics: Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk Factors; Stroke | 2005 |
Statins and aortic stenosis progression: are biologic targets still an option?
Topics: Aortic Valve Stenosis; Atorvastatin; Disease Progression; Echocardiography, Doppler; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2005 |
[Prevention of periprocedural myocardial damage in patients undergoing percutaneous coronary intervention].
Topics: Actuarial Analysis; Adenosine; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers; Clopidogrel; Creatine Kinase, MB Form; Electrocardiography; Embolism; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardium; Necrosis; Placebos; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stents; Ticlopidine; Time Factors; Vasodilator Agents | 2005 |
Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Models, Biological; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Triglycerides | 2006 |
Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrroles; Risk Factors | 2005 |
In-hospital initiation of statin therapy in acute coronary syndromes: maximizing the early and long-term benefits.
Topics: Angina, Unstable; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myocardial Ischemia; Pravastatin; Pyrroles; Syndrome; Treatment Outcome | 2005 |
Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Fenofibrate; Heptanoic Acids; Humans; Losartan; Pyrroles; Uric Acid | 2005 |
Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Albuminuria; Aspartate Aminotransferases; Atorvastatin; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Utilization; Female; Hematuria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pain; Pyrroles; Retrospective Studies | 2006 |
Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors.
Topics: Animals; Antigen-Presenting Cells; Atorvastatin; Autoimmune Diseases; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Down-Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; T-Lymphocytes | 2006 |
Statins and osteoporosis: new role for old drugs.
Topics: Animals; Atorvastatin; Bone and Bones; Clinical Trials as Topic; Drug Delivery Systems; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fractures, Bone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Osteogenesis; Osteoporosis; Pharmacokinetics; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutic Equivalency; Treatment Outcome | 2006 |
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2006 |
Atorvastatin and diabetic vascular complications.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pyrroles | 2006 |
A single-pill combination of amlodipine besylate and atorvastatin calcium.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Clinical Trials as Topic; Drug Combinations; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Pyrroles; Tablets | 2006 |
Apolipoproteins AI and B as therapeutic targets.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Lipoproteins; Lipoproteins, LDL; Postprandial Period; Pyrroles | 2006 |
The fading of reported effectiveness. A meta-analysis of randomised controlled trials.
Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Drug Evaluation; Heptanoic Acids; Humans; Intraocular Pressure; Latanoprost; Pravastatin; Prostaglandins F, Synthetic; Publication Bias; Pyrroles; Randomized Controlled Trials as Topic; Sample Size; Selection Bias; Time Factors; Timolol; Treatment Outcome | 2006 |
Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study.
Topics: Acute Disease; Atorvastatin; Cardiac Output, Low; Coronary Disease; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Natriuretic Peptide, Brain; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Syndrome | 2006 |
The clinical relevance of low-density-lipoproteins size modulation by statins.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Particle Size; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Atorvastatin associated liver disease.
Topics: Aged; Atorvastatin; Chemical and Drug Induced Liver Injury; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Male; Middle Aged; Pyrroles | 2006 |
[Intensive cholesterol lowering therapy to reduce cardiovascular risk].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clofibric Acid; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2006 |
[Thoughts about the results of the "IDEAL" study].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Follow-Up Studies; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2006 |
Statins: beneficial or adverse for glucose metabolism.
Topics: Atorvastatin; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles | 2006 |
Concurrent use of clopidogrel (Plavix) and atorvastatin (Lipitor) is contraindicated.
Topics: Atorvastatin; Biotransformation; Clopidogrel; Contraindications; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Antagonism; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2006 |
What's in the CARDS?
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Risk Assessment; Smoking | 2006 |
The year in non-ST-segment elevation acute coronary syndromes.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Clopidogrel; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multivariate Analysis; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Prognosis; Pyrroles; Risk Assessment; Stents; Syndrome; Thrombolytic Therapy; Ticlopidine | 2006 |
Tolerability of atorvastatin in a population aged > or =65 years: a retrospective pooled analysis of results from fifty randomized clinical trials.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Diseases; Male; Musculoskeletal Diseases; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies | 2006 |
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Lipoproteins, LDL; Phytosterols; Pravastatin; Pyrroles; Simvastatin | 2006 |
How safe is aggressive statin therapy?
Topics: Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients.
Topics: Atorvastatin; Canada; Cholesterol, LDL; Death, Sudden, Cardiac; Dyslipidemias; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Stroke | 2006 |
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States | 2006 |
[Vascular pleiosynergism--a new concept?].
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Carrier Proteins; Cell Movement; Cell Proliferation; Cytokines; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Myocytes, Smooth Muscle; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Reactive Oxygen Species; Vascular Diseases | 2006 |
Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2006 |
Molecular basis of differences among statins and a comparison with antioxidant vitamins.
Topics: Antioxidants; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyridines; Pyrroles; Vitamins | 2006 |
Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients.
Topics: Amlodipine; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Calcium Channel Blockers; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2006 |
[Immunointervention in newly diagnosed type 1 diabetes].
Topics: Antibodies, Monoclonal; Atorvastatin; Autoimmune Diseases; Diabetes Mellitus, Type 1; Heptanoic Acids; Humans; Immunosuppressive Agents; Insulin-Secreting Cells; Prediabetic State; Pyrroles | 2006 |
The pressure is rising.
Topics: Animals; Atorvastatin; Critical Care; Disease Models, Animal; Drug Evaluation, Preclinical; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Pulmonary Embolism; Pyrroles; Rats | 2007 |
[Interaction risk with statin switch].
Topics: Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Diltiazem; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Hemorrhages; Muscular Diseases; Pyrroles; Risk Factors; Simvastatin; Warfarin | 2007 |
[Selection of statin considering the HDL cholesterol level].
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; PPAR alpha; Pyrroles; Simvastatin | 2006 |
A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2007 |
Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis.
Topics: Atorvastatin; Drug Evaluation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multiple Sclerosis; Pyrroles; Simvastatin | 2007 |
Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2007 |
Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles; Randomized Controlled Trials as Topic | 2007 |
Statins and C-reactive protein levels.
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Pyrroles; Risk Factors | 2007 |
Impact of statin dosing intensity on transaminase and creatine kinase.
Topics: Atorvastatin; Creatine Kinase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Transaminases | 2007 |
Reinforcing a continuum of care: in-hospital initiation of long-term secondary prevention following acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiology; Clinical Trials as Topic; Continuity of Patient Care; Disease Management; Guideline Adherence; Heptanoic Acids; Hospital Mortality; Hospitalization; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Preventive Medicine; Pyrroles | 2007 |
The power of drug co-administration: smaller doses better outcomes.
Topics: Animals; Atorvastatin; Cardiovascular Diseases; Cilostazol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heptanoic Acids; Humans; Pyrroles; Tetrazoles; Treatment Outcome | 2007 |
Is it time to stop treating dyslipidaemia with fibrates?
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Cardiovascular Diseases; Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic | 2007 |
Atorvastatin: pharmacological characteristics and lipid-lowering effects.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2007 |
Effects of atorvastatin on the different phases of atherogenesis.
Topics: Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2007 |
Atorvastatin efficacy in the primary and secondary prevention of cardiovascular events.
Topics: Angioplasty, Balloon; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; Myocardial Ischemia; Pyrroles | 2007 |
Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Stroke | 2007 |
Atorvastatin: its clinical role in cerebrovascular prevention.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Stroke | 2007 |
Atorvastatin: a safety and tolerability profile.
Topics: Aged; Aging; Alanine Transaminase; Aspartate Aminotransferases; Atorvastatin; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Pyrroles | 2007 |
Atorvastatin in prevention of stroke and transient ischaemic attack.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Randomized Controlled Trials as Topic; Stroke | 2007 |
A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 2007 |
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.
Topics: Atorvastatin; Azetidines; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2007 |
Atorvastatin and statins in the treatment of heart failure.
Topics: Animals; Atorvastatin; Cardiovascular Agents; Drug Interactions; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Pyrroles; Treatment Outcome | 2007 |
The ARMYDA trials (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) at Campus Bio-Medico University: rationale, results and future horizons.
Topics: Angina Pectoris; Angioplasty; Atorvastatin; Cardiomyopathies; Forecasting; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
Biological consequences of statins in Candida species and possible implications for human health.
Topics: Antifungal Agents; Atorvastatin; Candida glabrata; DNA, Mitochondrial; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Pyrroles; Simvastatin | 2007 |
The genetic determinants of atorvastatin response.
Topics: Animals; Atorvastatin; Cardiovascular Diseases; Cholesterol; Genetic Variation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Muscular Diseases; Pyrroles; Risk Factors | 2007 |
Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ultrasonography, Interventional | 2007 |
Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors | 2007 |
[Statins--are they potentially useful in rheumatology?].
Topics: Arthritis, Rheumatoid; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Osteoporosis; Pyrroles; Rheumatic Diseases; Simvastatin; Treatment Outcome | 2007 |
Statin therapy in peritoneal dialysis patients: effects beyond lipid lowering.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Chronic Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Kidney Diseases; Lipids; Peritoneal Dialysis; Pyrroles; Risk Assessment; Risk Factors; Survival Rate; Treatment Outcome | 2008 |
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin.
Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Drug Therapy, Combination; Guidelines as Topic; Heptanoic Acids; Humans; Pyrroles; Risk Factors | 2007 |
Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
Topics: Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Medical Records Systems, Computerized; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Cardiovascular disease risk of type 2 diabetes mellitus and metabolic syndrome: focus on aggressive management of dyslipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Heptanoic Acids; Humans; Metabolic Syndrome; Niacin; Pyrroles; Triglycerides; United States | 2005 |
Impact of systemic hypertension on the cardiovascular benefits of statin therapy--a meta-analysis.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Therapeutics | 2008 |
[Clopidogrel and statins or once more on the danger of direct transfer of results of experimental studies in clinical practice].
Topics: Atorvastatin; Clopidogrel; Coronary Thrombosis; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hypercholesterolemia; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2008 |
Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2008 |
Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Heptanoic Acids; Humans; Kidney Failure, Chronic; Pyrroles; Risk Factors; Stroke | 2008 |
Adjunctive interventions in myocardial infarction: the role of statin therapy.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Circulation; Coronary Occlusion; Dyslipidemias; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Plasminogen Activator Inhibitor 1; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2008 |
Intensive statin therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Atorvastatin; Blood Platelets; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin | 2008 |
Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management.
Topics: Amlodipine; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Drug Combinations; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors | 2008 |
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Clinical Trials as Topic; Clofibric Acid; Ezetimibe; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Indoles; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
[A new approach to the treatment of dyslipidemia].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Middle Aged; Practice Guidelines as Topic; Prognosis; Pyrroles; Risk Factors | 2008 |
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Celecoxib; Colorectal Neoplasms; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Evidence-Based Medicine; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Meta-Analysis as Topic; Neoplasms; Pravastatin; Pyrazoles; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Sulfonamides; Sulindac | 2008 |
Expanding roles for atorvastatin.
Topics: Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Metabolic Syndrome; Pyrroles; Renal Insufficiency; Stroke | 2008 |
Atorvastatin and cardiovascular risk in the elderly--patient considerations.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic | 2008 |
Statins and congestive heart failure.
Topics: Animals; Atorvastatin; Cardiovascular Diseases; Endothelium, Vascular; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Outcome | 2008 |
Prevention of calcific aortic valve stenosis-fact or fiction?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aortic Valve Stenosis; Atherosclerosis; Atorvastatin; Calcinosis; Cardiomyopathies; Disease Progression; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Renin-Angiotensin System | 2009 |
[Important aim of statin therapy: ischemic cardiovascular event (stroke)].
Topics: Acute Disease; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Myocardial Ischemia; Pyrroles; Recurrence; Stroke | 2008 |
[Pleiotropic effects of statins].
Topics: Anticholesteremic Agents; Antioxidants; Atherosclerosis; Atorvastatin; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors | 2008 |
Statins: under investigation for increasing bone mineral density and augmenting fracture healing.
Topics: Animals; Atorvastatin; Bone Density; Bone Morphogenetic Protein 2; Clinical Trials as Topic; Fracture Healing; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 9; Osteoclasts; Pravastatin; Pyrroles; Simvastatin; Vascular Endothelial Growth Factor A | 2008 |
Relative safety profiles of high dose statin regimens.
Topics: Acute Coronary Syndrome; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Muscle, Skeletal; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin | 2008 |
[Chronic transplant nephropathy].
Topics: Animals; Atorvastatin; Atrophy; Biopsy; Chronic Disease; Complement C4b; Heptanoic Acids; Humans; Kidney Transplantation; Kidney Tubules; Nephritis, Interstitial; Peptide Fragments; Postoperative Complications; Pyridoxamine; Pyrroles; Rats; Risk Factors; Terminology as Topic; Transplants | 2008 |
Clopidogrel: review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies.
Topics: Atorvastatin; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Indoles; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Ticlopidine | 2009 |
Statins for heart failure: still caught in no man's land?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Evidence-Based Medicine; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Pyrroles | 2009 |
Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Confidence Intervals; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk | 2008 |
Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
Topics: Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2008 |
Apoptotic signaling pathways as a target for the treatment of liver diseases.
Topics: Animals; Apoptosis; Atorvastatin; Gliotoxin; Heptanoic Acids; Humans; Liver Diseases; Molecular Conformation; Pyrroles; Signal Transduction; Ursodeoxycholic Acid | 2008 |
What's new in stroke? The top 10 studies of 2006-2008. Part II.
Topics: Anticoagulants; Atorvastatin; Drug Therapy, Combination; Enoxaparin; Evidence-Based Medicine; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Heparin, Low-Molecular-Weight; Heptanoic Acids; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Stroke | 2008 |
[Dyslipidemia, atherosclerosis, and vulnerable plaques: the effect of atorvastatin on atherosclerosis and plaque structure].
Topics: Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors | 2009 |
[Atorvastatin in primary prevention].
Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrroles | 2009 |
[Atorvastatin in secondary prevention].
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pyrroles; Secondary Prevention; Stroke | 2009 |
Statins for sepsis: a critical and updated review.
Topics: Anticholesteremic Agents; Atorvastatin; Bacterial Infections; Heptanoic Acids; Humans; Pyrroles; Sepsis; Simvastatin; Treatment Outcome | 2009 |
Medicinal chemistry strategies in follow-on drug discovery.
Topics: Animals; Atorvastatin; Bendamustine Hydrochloride; Benzazepines; Chemistry, Pharmaceutical; Clinical Trials as Topic; Drug Delivery Systems; Drug Discovery; gamma-Aminobutyric Acid; Heptanoic Acids; Humans; Lapatinib; Nitrogen Mustard Compounds; Pregabalin; Pyrimidines; Pyrroles; Quinazolines; Sulfonamides | 2009 |
Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Medication Adherence; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Quality of Life; Treatment Outcome | 2009 |
Review of the SPARCL trial and its subanalyses.
Topics: Age Factors; Atorvastatin; Cholesterol; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Pyrroles; Risk Factors; Sex Factors; Stroke | 2009 |
Reducing morbidity and mortality in high risk patients with statins.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Kidney Failure, Chronic; Metabolic Diseases; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2009 |
Lipid reduction in acute coronary syndrome: how much, when, and how?
Topics: Acute Coronary Syndrome; Atorvastatin; Heptanoic Acids; Humans; Hypolipidemic Agents; Meta-Analysis as Topic; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin | 2009 |
Can statins suppress the development of abdominal aortic aneurysms? A review of the current evidence.
Topics: Animals; Aortic Aneurysm, Abdominal; Atorvastatin; Blood Vessels; Cardiovascular Agents; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Matrix Metalloproteinases; Models, Animal; Pyrroles; Risk Assessment; Simvastatin | 2010 |
Drug-induced liver injury associated with statins.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Autoimmunity; Biomarkers; Biopsy; Chemical and Drug Induced Liver Injury; Chronic Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Liver; Liver Diseases; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Risk Assessment; Treatment Outcome; Young Adult | 2009 |
The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.
Topics: Anticholesteremic Agents; Asian People; Atorvastatin; Fluorobenzenes; Gene Frequency; Haplotypes; HeLa Cells; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Highly stereoselective hydrogenations--as key-steps in the total synthesis of statins.
Topics: Atorvastatin; Fluorobenzenes; Heptanoic Acids; Hydrogenation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stereoisomerism; Sulfonamides | 2010 |
Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
New evidence on pitavastatin: efficacy and safety in clinical studies.
Topics: Animals; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Practice Guidelines as Topic; Pyrroles; Quinolines | 2010 |
A pharmacogenetics-based approach to reduce cardiovascular mortality with the prophylactic use of statins.
Topics: Atorvastatin; Cardiovascular Diseases; Cardiovascular System; Genetic Markers; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide; Nitric Oxide Synthase Type III; Polymorphism, Genetic; Pyrroles; Up-Regulation | 2010 |
Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?
Topics: Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intracranial Hemorrhages; Primary Prevention; Pyrroles; Risk Factors; Secondary Prevention; Stroke | 2010 |
Statin loading for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cytokines; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Oxidative Stress; Preoperative Care; Pyrroles; Time Factors | 2010 |
Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Pyrroles | 2010 |
Lipid-lowering drugs and heart failure: where do we go after the statin trials?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pravastatin; Primary Prevention; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Triglycerides | 2010 |
Atorvastatin: safety and tolerability.
Topics: Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Meta-Analysis as Topic; Product Surveillance, Postmarketing; Pyrroles; Randomized Controlled Trials as Topic | 2010 |
Aldosterone, hypertension and heart failure: insights from clinical trials.
Topics: Aldosterone; Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Dihydrotestosterone; Drug Therapy, Combination; Enzyme Inhibitors; Female; Heart Failure; Heptanoic Acids; Humans; Hydrocortisone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Mice; Mineralocorticoid Receptor Antagonists; Ouabain; Pyrroles; Quinolines; Rats; Spironolactone | 2010 |
Statins for the treatment of dementia.
Topics: Alzheimer Disease; Atorvastatin; Dementia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2010 |
Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Obesity; Office Visits; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Risk Assessment; Smoking; United States | 2010 |
Clinical Inquiries: Which drugs should post-MI patients routinely receive?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Clopidogrel; Eplerenone; Heptanoic Acids; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Spironolactone; Ticlopidine | 2010 |
Statin loading before percutaneous coronary intervention: proposed mechanisms and applications.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers, Pharmacological; Confidence Intervals; Endothelium, Vascular; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Inflammation; Kidney Diseases; Multivariate Analysis; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2010 |
Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides | 2010 |
Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies.
Topics: Adult; Area Under Curve; Asian People; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; White People; Young Adult | 2012 |
Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Dyslipidemias; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
Differential metabolic effects of distinct statins.
Topics: Adiponectin; Animals; Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Databases, Nucleic Acid; Dose-Response Relationship, Drug; Dyslipidemias; Electronic Health Records; Genetic Association Studies; Genetic Markers; Heptanoic Acids; Humans; Obesity; Pravastatin; Pyrroles; Risk Assessment; Simvastatin; Treatment Outcome | 2011 |
Statins for multiple sclerosis.
Topics: Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-beta; Multiple Sclerosis; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention | 2010 |
Atorvastatin and Aβ(1-40): not as simple as cholesterol reduction in brain and relevance to Alzheimer disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Atorvastatin; Brain; Cholesterol; Heptanoic Acids; Humans; Peptide Fragments; Pyrroles | 2011 |
Pitavastatin - results from phase III & IV.
Topics: Atorvastatin; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Simvastatin | 2010 |
Optimal statin type and dosage for vascular patients.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Drug Tolerance; Endovascular Procedures; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Selection; Pyrimidines; Pyrroles; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Vascular Diseases; Vascular Surgical Procedures | 2011 |
[Indications for statin therapy in patients with acute coronary syndrome of ischemic origin].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol; Electrocardiography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Practice Guidelines as Topic; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Secondary Prevention | 2010 |
Rheumatoid arthritis: is it a coronary heart disease equivalent?
Topics: Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Coronary Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hyperlipidemias; Pyrroles; Risk Factors | 2011 |
Contrast-induced nephropathy: do statins offer protection?
Topics: Amidohydrolases; Atorvastatin; Contrast Media; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic | 2011 |
Meta-analysis of the comparative efficacy and safety of pitavastatin and atorvastatin in patients with dyslipidaemia.
Topics: Anticholesteremic Agents; Atorvastatin; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Current management of symptomatic intracranial stenosis.
Topics: Angioplasty; Anticoagulants; Atorvastatin; Brain; Brain Ischemia; Cilostazol; Constriction, Pathologic; Endovascular Procedures; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Phosphodiesterase 3 Inhibitors; Platelet Aggregation Inhibitors; Pyrroles; Stents; Stroke; Tetrazoles | 2011 |
A meta-analysis of randomized trials for effects of atorvastatin on renal function in chronic kidney disease.
Topics: Atorvastatin; Chronic Disease; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic | 2011 |
Statins for acute ischemic stroke.
Topics: Atorvastatin; Cause of Death; Clopidogrel; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Neuroprotective Agents; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Stroke; Ticlopidine | 2011 |
[Japanese Guidelines for the Management of Stroke 2009 : important revised points necessary for the neurologist].
Topics: Aspirin; Atorvastatin; Cilostazol; Diabetes Complications; Dyslipidemias; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Japan; Neurology; Physicians; Pioglitazone; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pyrroles; Secondary Prevention; Stroke; Tetrazoles; Thiazolidinediones; Tissue Plasminogen Activator | 2010 |
A meta-analysis of randomized trials for effects of periprocedural atorvastatin on contrast-induced nephropathy.
Topics: Atorvastatin; Contrast Media; Heptanoic Acids; Humans; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Statins for women with polycystic ovary syndrome not actively trying to conceive.
Topics: Adult; Atorvastatin; Female; Heptanoic Acids; Hirsutism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperandrogenism; Hypoglycemic Agents; Menstruation Disturbances; Metformin; Polycystic Ovary Syndrome; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Young Adult | 2011 |
Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Heart Diseases; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein(a); Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
A meta-analysis of randomized head-to-head trials of atorvastatin versus rosuvastatin for reductions in C-reactive protein.
Topics: Atorvastatin; C-Reactive Protein; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2012 |
Pitavastatin: an overview.
Topics: Antioxidants; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Endothelium, Vascular; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Japan; Metabolic Syndrome; Molecular Structure; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Receptors, LDL | 2011 |
Pitavastatin: novel effects on lipid parameters.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Coronary Artery Disease; Double-Blind Method; Dyslipidemias; Europe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Russia; Simvastatin; Triglycerides | 2011 |
Pitavastatin: clinical effects from the LIVES Study.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Diseases; Multicenter Studies as Topic; Muscular Diseases; Prospective Studies; Pyrroles; Quinolines; Risk; Simvastatin; Treatment Outcome; Triglycerides | 2011 |
Statins for multiple sclerosis.
Topics: Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-beta; Multiple Sclerosis; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin | 2011 |
Atorvastatin, not rosuvastatin, improves cardiac function in heart failure: a meta-analysis of randomized trials.
Topics: Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Stroke Volume; Sulfonamides | 2012 |
[HDL level or HDL function as the primary target in preventive cardiology].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Membrane Transport Proteins; Myocardial Infarction; Niacin; Pyrimidines; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reference Values; Rosuvastatin Calcium; Scavenger Receptors, Class B; Sulfonamides; Survival Rate; Up-Regulation | 2012 |
Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
Topics: Atorvastatin; Coronary Disease; Drug Therapy, Combination; Dyslipidemias; Flushing; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Medication Adherence; Niacin; Pyrroles | 2012 |
Atorvastatin reduces coronary plaque volume in dependence on reductions in low-density lipoprotein: a meta-analysis and meta-regression of randomized controlled trials.
Topics: Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Lipoproteins, LDL; Plaque, Atherosclerotic; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis | 2012 |
Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Heptanoic Acids; Humans; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Uric Acid | 2012 |
Effects of rosuvastatin and atorvastatin on renal function: meta-analysis.
Topics: Atorvastatin; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Proteinuria; PubMed; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2012 |
Irreversible atorvastatin-associated hearing loss.
Topics: Adult; Atorvastatin; Hearing Loss; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles | 2012 |
Targeting HDL-cholesterol to reduce residual cardiovascular risk.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2012 |
The role of endoglin in atherosclerosis.
Topics: Animals; Antigens, CD; Atherosclerosis; Atorvastatin; Endoglin; Endothelium, Vascular; Heptanoic Acids; Humans; Hypercholesterolemia; Mice; Nitric Oxide Synthase Type III; Plaque, Atherosclerotic; Proteoglycans; Pyrroles; Receptors, Cell Surface; Receptors, Transforming Growth Factor beta; Swine | 2012 |
Low-density lipoprotein-independent improvement of flow-mediated dilatation with atorvastatin: a meta-analysis and meta-regression of randomized controlled trials.
Topics: Atorvastatin; Coronary Artery Disease; Coronary Circulation; Heptanoic Acids; Humans; Lipoproteins, LDL; Pyrroles; Randomized Controlled Trials as Topic; Regional Blood Flow; Vasodilation | 2012 |
Effects of atorvastatin on carotid intima media thickness: a meta-analysis of randomized controlled trials.
Topics: Atherosclerosis; Atorvastatin; Carotid Intima-Media Thickness; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.
Topics: Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrazines; Pyrroles; Risk Assessment; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.
Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Effects of atorvastatin and rosuvastatin on renal function: a meta-analysis.
Topics: Atorvastatin; Cardiovascular Diseases; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: results from VOYAGER.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Databases, Factual; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult | 2012 |
[Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study].
Topics: Acute Coronary Syndrome; Atorvastatin; Endosonography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrroles | 2011 |
[Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-aCS) study].
Topics: Acute Coronary Syndrome; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2011 |
Non-every day statin administration--a literature review.
Topics: Atorvastatin; Cardiovascular Diseases; Drug Administration Schedule; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
[Atorvastatin or rosuvastatin? Select from the perspective of evidence-based medicine].
Topics: Atorvastatin; Biological Availability; Cardiovascular Diseases; Dose-Response Relationship, Drug; Evidence-Based Medicine; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides; Therapeutic Equivalency | 2012 |
Atorvastatin calcium plus amlodipine for the treatment of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Drug Combinations; Dyslipidemias; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
Lipid lowering efficacy of atorvastatin.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides | 2012 |
Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Belgium; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Heptanoic Acids; Humans; Hypercholesterolemia; Marketing of Health Services; Pyrroles | 2013 |
Statin wars: the heavyweight match--atorvastatin versus rosuvastatin for the treatment of atherosclerosis, heart failure, and chronic kidney disease.
Topics: Atherosclerosis; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2013 |
Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥ 50% reduction in high-risk patients: results from VOYAGER.
Topics: Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Risk Reduction Behavior; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2013 |
Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases.
Topics: Acute Kidney Injury; Adult; Aged; Atorvastatin; British Columbia; Cohort Studies; Confidence Intervals; Databases, Factual; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Logistic Models; Male; Middle Aged; Odds Ratio; Patient Safety; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United Kingdom; United States | 2013 |
Effects of rosuvastatin versus atorvastatin on small dense low-density lipoprotein: a meta-analysis of randomized trials.
Topics: Atorvastatin; Biomarkers; Chi-Square Distribution; Down-Regulation; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Particle Size; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Liptruzet: a combination of ezetimibe and atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Combinations; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery.
Topics: Adult; Angioplasty; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Cause of Death; Cholestyramine Resin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Perioperative Care; Postoperative Complications; Pyrroles; Randomized Controlled Trials as Topic; Sitosterols; Vascular Surgical Procedures | 2013 |
Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Registries; Saphenous Vein; Simvastatin; Treatment Outcome; Young Adult | 2013 |
Long-term clinical outcomes of statin use for chronic heart failure: a meta-analysis of 15 prospective studies.
Topics: Atorvastatin; Chronic Disease; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; MEDLINE; Prospective Studies; Pyrroles | 2014 |
Effects of adding statins before surgery on mortality and major morbidity: a meta-analysis.
Topics: Adult; Atorvastatin; Cardiac Surgical Procedures; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Length of Stay; Myocardial Infarction; Odds Ratio; Preoperative Care; Publication Bias; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome | 2014 |
Aggressive medical therapy alone is not adequate in certain patients with severe symptomatic carotid stenosis.
Topics: Aspirin; Atorvastatin; Carotid Artery Diseases; Clopidogrel; Constriction, Pathologic; Endovascular Procedures; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2013 |
A low-density lipoprotein-dependent effect of atorvastatin upon the systolic blood pressure reduction: meta-regression analyses of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Pressure; Heptanoic Acids; Humans; Hypertension; Lipoproteins, LDL; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Treatment Outcome | 2013 |
A meta-analysis of randomized head-to-head trials for effects of rosuvastatin versus atorvastatin on apolipoprotein profiles.
Topics: Apolipoproteins; Atorvastatin; Coronary Artery Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Antioxidant and antiplatelet effects of atorvastatin by Nox2 inhibition.
Topics: Animals; Antioxidants; Atorvastatin; Blood Platelets; Dose-Response Relationship, Drug; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Glycoproteins; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Reactive Oxygen Species; Thrombosis | 2014 |
The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study.
Topics: Aged; Aging; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cytosine; Databases, Factual; Dose-Response Relationship, Drug; Female; Genetic Association Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Single Nucleotide; Prospective Studies; Pyrroles; Risk Factors; Sex Characteristics; Simvastatin; Thymine | 2014 |
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Topics: Alanine Transaminase; Atorvastatin; Fatty Liver; Fenofibrate; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Non-alcoholic Fatty Liver Disease; Pyrroles; Simvastatin | 2013 |
Do statins play a role in renoprotection?
Topics: Adult; Aged; Albuminuria; Animals; Atorvastatin; Cardiovascular Diseases; Diet, High-Fat; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Renal Insufficiency, Chronic | 2014 |
Statins can induce myasthenia gravis.
Topics: Aged; Atorvastatin; Autoimmunity; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myasthenia Gravis; Pyrroles | 2014 |
Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.
Topics: Acute Kidney Injury; Atorvastatin; Disease Progression; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials.
Topics: Acute Kidney Injury; Aged; Atorvastatin; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Reference Values; Risk Assessment; Survival Analysis | 2014 |
Changes in high-density-lipoprotein cholesterol upon statin treatment in type 2 diabetic patients: a meta-analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin; Triglycerides | 2014 |
Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies.
Topics: Adult; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Consanguinity; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Heart Valve Diseases; Heart Valve Prosthesis Implantation; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins, LDL; Liver Transplantation; Male; Pyrroles; Receptors, LDL | 2014 |
Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials.
Topics: Atorvastatin; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Stroke Volume; Ventricular Dysfunction, Left | 2014 |
Statins for the treatment of dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Atorvastatin; Dementia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2014 |
The preventive effect of atorvastatin on atrial fibrillation: a meta-analysis of randomized controlled trials.
Topics: Anti-Arrhythmia Agents; Atorvastatin; Atrial Fibrillation; Chi-Square Distribution; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Odds Ratio; Primary Prevention; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Secondary Prevention; Treatment Outcome | 2014 |
Meta-analysis of short-term high versus low doses of atorvastatin preventing contrast-induced acute kidney injury in patients undergoing coronary angiography/percutaneous coronary intervention.
Topics: Acute Kidney Injury; Aged; Atorvastatin; Contrast Media; Coronary Angiography; Creatinine; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Pyrroles; Randomized Controlled Trials as Topic | 2015 |
Pleiotropic effects of statins in atherosclerotic disease: focus on the antioxidant activity of atorvastatin.
Topics: Antioxidants; Atherosclerosis; Atorvastatin; Heptanoic Acids; Humans; Pyrroles | 2014 |
Use of atorvastatin in lipid disorders and cardiovascular disease in Chinese patients.
Topics: Atorvastatin; Cardiovascular Diseases; China; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2015 |
HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass.
Topics: Acute Kidney Injury; Adult; Atorvastatin; Cardiac Surgical Procedures; Cardiopulmonary Bypass; Coronary Artery Bypass; Creatinine; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Length of Stay; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Replacement Therapy; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
Lipid-lowering efficacy of atorvastatin.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Controlled Before-After Studies; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Pyrroles; Randomized Controlled Trials as Topic; Sex Factors; Triglycerides | 2015 |
Pharmacological treatment and current management of peripheral artery disease.
Topics: Atorvastatin; Exercise; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyrroles; Simvastatin; Smoking Cessation; Treatment Outcome | 2015 |
[Choosing wisely when prescribing statins].
Topics: Atorvastatin; Cardiovascular Diseases; Fluorobenzenes; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Quality of Health Care; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
[Help me--I do not tolerate my statin].
Topics: Aged; Aged, 80 and over; Atorvastatin; Diagnosis, Differential; Drug Substitution; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myalgia; Patient Education as Topic; Pyrroles; Quinolines; Risk Factors; Ubiquinone | 2015 |
Effect of Atorvastatin on Serum Levels of Total Cholesterol and High-Sensitivity C-reactive Protein in High-Risk Patients with Atrial Fibrillation in Asia.
Topics: Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Outcome | 2015 |
Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Primary Prevention; Pyrroles; Rosuvastatin Calcium; Simvastatin | 2016 |
1577 trial(s) available for pyrroles and atorvastatin
| Article | Year |
|---|---|
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
Topics: Adolescent; Adult; Aged; Apolipoproteins; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Middle Aged; Pyrroles | 1995 |
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Linear Models; Lipoproteins; Male; Middle Aged; Pyrroles; Triglycerides | 1996 |
Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor.
Topics: Administration, Oral; Adult; Atorvastatin; Biological Availability; Cross-Over Studies; Dietary Fats; Enzyme Inhibitors; Fasting; Female; Food-Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 1995 |
Effect of age and gender on pharmacokinetics of atorvastatin in humans.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Female; Half-Life; Headache; Heptanoic Acids; Humans; Male; Pyrroles; Sex Factors | 1996 |
Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening.
Topics: Adult; Analysis of Variance; Atorvastatin; Cross-Over Studies; Drug Administration Schedule; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Pyrroles | 1996 |
Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects.
Topics: Adult; Area Under Curve; Atorvastatin; Double-Blind Method; Drug Tolerance; Enzyme Inhibitors; Female; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Clearance Rate; Middle Aged; Pyrroles | 1996 |
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects.
Topics: Acyl Coenzyme A; Adult; Anticholesteremic Agents; Area Under Curve; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Half-Life; Heptanoic Acids; Humans; Least-Squares Analysis; Linear Models; Male; Middle Aged; Pyrroles; Reference Values | 1996 |
Rate of low-density lipoprotein cholesterol and apolipoprotein B changes on initiation and discontinuation of atorvastatin treatment.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Cross-Over Studies; Heptanoic Acids; Humans; Pyrroles | 1997 |
Atorvastatin--a new lipid-lowering drug.
Topics: Anti-Bacterial Agents; Anticholesteremic Agents; Antifungal Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Interactions; Erythromycin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Ketoconazole; Pyrroles | 1997 |
Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Double-Blind Method; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Triglycerides | 1997 |
Efficacy of atorvastatin in primary hypercholesterolemia. Japan Cholesterol Lowering Atorvastatin Study (J-CLAS) Group.
Topics: Aged; Apolipoproteins; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Triglycerides | 1997 |
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.
Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pyrroles; Treatment Outcome | 1997 |
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Arthralgia; Atorvastatin; Cholesterol; Cholesterol, Dietary; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperhidrosis; Hyperlipidemias; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pyrroles; Simvastatin; Triglycerides | 1997 |
Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Creatinine; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Mevalonic Acid; Middle Aged; Pyrroles | 1997 |
Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
Topics: Adolescent; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles | 1997 |
Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome | 1997 |
Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Uric Acid | 1997 |
Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Diet; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Safety | 1997 |
Rationale, design, and baseline characteristics of a trial comparing aggressive lipid lowering with Atorvastatin Versus Revascularization Treatments (AVERT).
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Revascularization; Pyrroles; Research Design; Stents | 1997 |
Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Enzyme Inhibitors; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Kinetics; Lipids; Lipoproteins, LDL; Male; Mevalonic Acid; Pyrroles | 1997 |
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome | 1998 |
An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor.
Topics: Acyl Coenzyme A; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Creatine Kinase; Female; Heptanoic Acids; Humans; Liver; Male; Middle Aged; Muscles; Pyrroles; Transaminases | 1998 |
A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Male; Middle Aged; Niacin; Pyrroles; Treatment Outcome; Triglycerides; United States | 1998 |
Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cholesterol, LDL; Cimetidine; Cross-Over Studies; Drug Interactions; Female; Heptanoic Acids; Histamine H2 Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Reference Values | 1998 |
Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Arthralgia; Atorvastatin; Brachial Artery; Cholestyramine Resin; Drug Therapy, Combination; Endothelium, Vascular; Exanthema; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Ultrasonography | 1998 |
Efficacy and safety of a new cholesterol synthesis inhibitor, atorvastatin, in comparison with simvastatin and pravastatin, in subjects with hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Drug Administration Schedule; Drug Combinations; Fenofibrate; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 1998 |
Comparison of atorvastatin alone versus simvastatin +/- cholestyramine in the management of severe primary hypercholesterolaemia (the six cities study).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
Effect of itraconazole on the pharmacokinetics of atorvastatin.
Topics: Adult; Anticholesteremic Agents; Antifungal Agents; Area Under Curve; Atorvastatin; Cross-Over Studies; Double-Blind Method; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Itraconazole; Male; Pyrroles; Smoking | 1998 |
LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; CD11 Antigens; Cohort Studies; Cytokines; Double-Blind Method; Heptanoic Acids; Heterozygote; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipopolysaccharide Receptors; Lipopolysaccharides; Mice; Monocytes; Pyrroles; Simvastatin | 1998 |
Atorvastatin does not produce a clinically significant effect on the pharmacokinetics of terfenadine.
Topics: Adolescent; Adult; Aged; Atorvastatin; Drug Interactions; Female; Heart Rate; Heptanoic Acids; Histamine H1 Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Terfenadine | 1998 |
Rationale and design of the Myocardial Ischemia Reduction With Aggressive Cholesterol lowering (MIRACL) Study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Pyrroles; Research Design | 1998 |
Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Colestipol; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lovastatin; Male; Pyrroles; Simvastatin; Treatment Outcome | 1998 |
Treating to meet NCEP-recommended LDL cholesterol concentrations with atorvastatin, fluvastatin, lovastatin, or simvastatin in patients with risk factors for coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyrroles; Risk Factors | 1998 |
Effect of statins on C-reactive protein in patients with coronary artery disease.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 1999 |
Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1998 |
Atorvastatin compared with simvastatin in patients with severe LDL hypercholesterolaemia treated by regular LDL apheresis.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Pyrroles; Simvastatin; Treatment Outcome | 1999 |
The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Female; Fluvastatin; Health Policy; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pyrroles; Simvastatin; United States | 1998 |
[Fluvastatin in a comparative study. Are there substance-specific differences between various CSE-inhibitors?].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Indoles; Pyrroles | 1999 |
More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Treatment Outcome | 1999 |
[AVERT study (Atorvastatin Versus Revascularization Treatment). Clinical advantage of aggressive lipid lowering].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 1999 |
Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin; Triglycerides | 1999 |
Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.
Topics: Adolescent; Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoprotein(a); Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 1999 |
Effect of inhibiting HMG-CoA reductase on 7 alpha-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway.
Topics: Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Biomarkers; Cholestenones; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Jejunoileal Bypass; Lipids; Lipoproteins; Male; Mevalonic Acid; Middle Aged; Pyrroles; Up-Regulation | 1999 |
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Quality of Life; Risk; Treatment Outcome | 1999 |
Safety of low-density lipoprotein cholestrol reduction with atorvastatin versus simvastatin in a coronary heart disease population (the TARGET TANGIBLE trial).
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Diet, Fat-Restricted; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Safety; Simvastatin; Time Factors | 1999 |
Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Beverages; Citrus; Cross-Over Studies; Female; Gas Chromatography-Mass Spectrometry; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Reference Values; Volunteers | 1999 |
Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Sex Distribution; Treatment Outcome | 1999 |
Effect of atorvastatin of the treatment of hypercholesterolemia after renal transplantation.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Pyrroles; Time Factors; Triglycerides | 1999 |
Lowering effects of four different statins on serum triglyceride level.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 1999 |
A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin | 1999 |
Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Blood Proteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Enzyme Induction; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Male; Middle Aged; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidation-Reduction; Pyrroles; Treatment Outcome; Triglycerides; Tyrosine; Vasodilation | 1999 |
An assessment of the efficacy of atorvastatin in achieving LDL cholesterol target levels in patients with coronary heart disease: a general practice study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Family Practice; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Patient Compliance; Pyrroles; Treatment Outcome | 1999 |
Dosing of atorvastatin and increases in fibrinogen level.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Reference Values; Treatment Outcome | 1999 |
Effects of atorvastatin in patients with homozygous familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Pyrroles; Treatment Outcome | 1999 |
Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Digoxin; Dose-Response Relationship, Drug; Drug Interactions; Female; Heptanoic Acids; Humans; Intestinal Mucosa; Male; Middle Aged; Pyrroles; Time Factors; Verapamil | 2000 |
Medical therapy versus revascularization: the atorvastatin versus revascularization treatment AVERT trial.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Artery Bypass; Coronary Disease; Decision Making; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Revascularization; Pyrroles; Safety; Survival Rate; Treatment Outcome | 2000 |
Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Cross-Over Studies; Cytokines; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperlipoproteinemias; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Reference Values | 2000 |
Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Single-Blind Method | 2000 |
Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
Topics: Anticholesteremic Agents; Apolipoproteins; Apolipoproteins B; Apolipoproteins E; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, VLDL; Chromatography, High Pressure Liquid; Double-Blind Method; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipids; Lipoproteins, HDL; Particle Size; Pyrroles; Triglycerides | 2000 |
Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia.
Topics: Adult; Aged; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin | 1999 |
Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholestyramine Resin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Family Practice; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Linear Models; Logistic Models; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2000 |
Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvastatin.
Topics: Acetylcholine; Acute Disease; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Chronic Disease; Endothelium, Vascular; Free Radical Scavengers; Heptanoic Acids; Humans; Hypertriglyceridemia; Injections, Intravenous; Male; Middle Aged; Nitroprusside; Pyrroles; Serotonin; Triglycerides; Vasodilation; Vasodilator Agents | 2000 |
Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.
Topics: Adolescent; Adult; Atorvastatin; Cholesterol; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Graft Rejection; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lovastatin; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.
Topics: Aged; Atorvastatin; Calorimetry, Indirect; Carbon Dioxide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Oxygen Consumption; Pyrroles; Simvastatin; Single-Blind Method; Triglycerides | 2000 |
Atorvastatin for the management of Type 2 diabetic patients with dyslipidaemia. A mid-term (9 months) treatment experience.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Male; Middle Aged; Pyrroles; Triglycerides | 1999 |
Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Peritoneal Dialysis; Prospective Studies; Pyrroles; Triglycerides; Uremia | 2000 |
The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Blood Pressure; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Elasticity; Family Health; Female; Femoral Artery; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides; Tunica Intima | 2000 |
Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Cyclosporine; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Failure, Chronic; Kidney Function Tests; Kidney Transplantation; Liver Function Tests; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2000 |
Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Biomarkers; Child; Child, Preschool; Cholesterol; Cholesterol, LDL; DNA; DNA Mutational Analysis; Female; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Mevalonic Acid; Mutation; Polymorphism, Single-Stranded Conformational; Prognosis; Pyrroles; Receptors, LDL | 2000 |
Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Margarine; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Sitosterols; Treatment Outcome; Triglycerides | 2000 |
Influence of atorvastatin versus simvastatin on fibrinogen and other hemorheological parameters in patients with severe hypercholesterolemia treated with regular low-density lipoprotein immunoadsorption apheresis.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Blood Viscosity; Combined Modality Therapy; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Fibrinogen; Hemorheology; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Immunosorbent Techniques; Lipoproteins, LDL; Male; Middle Aged; Plasma Volume; Pyrroles; Simvastatin | 2000 |
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Pyrroles; Simvastatin | 2000 |
Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia.
Topics: Adsorption; Adult; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cross-Over Studies; Dextran Sulfate; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Immunosorbent Techniques; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Pyrroles | 2000 |
Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2000 |
Role of statins in the management of dyslipidemia after cardiac transplant: randomized controlled trial comparing the efficacy and the safety of atorvastatin with pravastatin.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, LDL; Creatine Kinase; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Pyrroles; Treatment Outcome; Triglycerides | 2000 |
Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study.
Topics: Adolescent; Adult; Arginine; Atorvastatin; Diabetes Mellitus, Type 1; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Vasodilation | 2000 |
Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles | 2000 |
Effects of atorvastatin and vitamin C on endothelial function of hypercholesterolemic patients.
Topics: Acetylcholine; Adult; Anticholesteremic Agents; Antioxidants; Ascorbic Acid; Atorvastatin; Blood Flow Velocity; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Infusions, Intra-Arterial; Male; Middle Aged; Nitroprusside; omega-N-Methylarginine; Plethysmography; Pyrroles; Vasodilation; Vasodilator Agents | 2000 |
High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Regression Analysis; Simvastatin; Triglycerides | 2000 |
Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Statistics, Nonparametric | 2000 |
Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Topics: Adult; Anticholesteremic Agents; Antifungal Agents; Area Under Curve; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Male; Pravastatin; Pyridines; Pyrroles; Reference Values; Time Factors | 2000 |
Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women.
Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Middle Aged; Postmenopause; Pyrroles; Vasodilation | 2000 |
Effect of lipid-lowering treatment on factor VII profile in hyperlipidemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diet; Factor VII; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles | 2000 |
Associations between change in C-reactive protein and serum lipids during statin treatment.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Time Factors | 2000 |
Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Hemorheology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Prospective Studies; Pyrroles; Statistics, Nonparametric | 2001 |
Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin | 2001 |
Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia.
Topics: Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Chromatography, High Pressure Liquid; Cysteine; Dipeptides; Female; Fenofibrate; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides | 2001 |
The effect of short-term lipid lowering with atorvastatin on carotid artery intima media thickness in patients with peripheral vascular disease: a pilot study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Cholesterol; Exercise Test; Female; Fibrinogen; Heptanoic Acids; Homocysteine; Humans; Male; Middle Aged; Peripheral Vascular Diseases; Pilot Projects; Pyrroles; Statistics, Nonparametric; Tunica Intima; Tunica Media; Ultrasonography | 2000 |
Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Therapeutic Equivalency; Thrombophilia; Treatment Outcome | 2001 |
Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cyclosporine; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Pyridines; Pyrroles; Safety | 2001 |
Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cholesterol; Drug Combinations; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides | 2000 |
[Cost-effectiveness of atorvastatin against simvastatin as hypolipemic treatment in hypercholesterolemic patients in primary care].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Triglycerides | 2001 |
Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2001 |
Design and rationale of the ARBITER trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)--a randomized trial comparing the effects of atorvastatin and pravastatin on carotid artery intima-media thickness.
Topics: Atorvastatin; Carotid Artery, Common; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Tunica Intima; Tunica Media | 2001 |
Comparative study of HMG-CoA reductase inhibitors on fibrinogen.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Cross-Over Studies; Fatty Acids, Monounsaturated; Female; Fibrinogen; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 2001 |
The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia--a pilot study involving serial sampling.
Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Drug Monitoring; Fasting; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type V; Lipids; Lipoprotein(a); Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrroles; Treatment Outcome | 2001 |
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Recurrence; Survival Analysis | 2001 |
Chitotriosidase genotype and serum activity in subjects with combined hyperlipidemia: effect of the lipid-lowering agents, atorvastatin and bezafibrate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Bezafibrate; DNA; Double-Blind Method; Exons; Female; Genotype; Heptanoic Acids; Hexosaminidases; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Middle Aged; Polymorphism, Genetic; Pyrroles | 2001 |
Cost-minimization analysis of simvastatin versus atorvastatin for maintenance therapy in patients with coronary or peripheral vascular disease.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost Control; Drug Costs; Europe; Heptanoic Acids; Humans; Hypercholesterolemia; Peripheral Vascular Diseases; Pyrroles; Simvastatin | 2001 |
Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Interleukin-6; Male; Middle Aged; Pravastatin; Pyrroles; Receptors, Interleukin-6; Simvastatin; Treatment Outcome; Triglycerides | 2001 |
Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
Topics: Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Cost-Benefit Analysis; Cross-Over Studies; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Treatment Outcome | 2001 |
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Postmenopause; Pravastatin; Prognosis; Prospective Studies; Pyrroles; Reproducibility of Results; Safety; Tomography, X-Ray Computed | 2001 |
Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestenones; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipoproteinemia Type II; Male; Mevalonic Acid; Middle Aged; Mutation; Pyrroles; Receptors, LDL; RNA, Messenger | 2001 |
The efficacy of atorvastatin in treating patients with hypercholesterolaemia to target LDL-cholesterol goals: the LIPI-GOAL trial.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2001 |
Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholest
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Canada; Cardiovascular Diseases; Cholesterol, LDL; Female; Health Education; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Practice Guidelines as Topic; Pyrroles; Risk Factors; Women's Health | 2001 |
Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fibrinogen; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Time Factors; Treatment Outcome; Triglycerides | 2001 |
Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Pressure; Cholesterol, LDL; Double-Blind Method; Drug Synergism; Fatty Acids, Omega-3; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Postprandial Period; Pyrroles; Triglycerides | 2001 |
Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease.
Topics: Adult; Anticholesteremic Agents; Antigens, CD; Atorvastatin; Blood Cells; Cell Count; Coronary Disease; Endothelium, Vascular; Female; Hematopoietic Stem Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Stem Cells | 2001 |
Effects of statins on biomarkers of bone metabolism: a randomised trial.
Topics: Adult; Aged; Alkaline Phosphatase; Anticholesteremic Agents; Atorvastatin; Biomarkers; Bone and Bones; Bone Development; Bone Resorption; Collagen; Collagen Type I; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Peptides; Pyrroles; Simvastatin | 2001 |
Effects of low doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol levels in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin | 2001 |
The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Serine Proteinase Inhibitors; Simvastatin | 2001 |
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; United States | 2001 |
Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease.
Topics: Anticholesteremic Agents; Arteriosclerosis; Arthralgia; Atorvastatin; Butyrates; Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Coronary Disease; Creatinine; Exanthema; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Dropouts; Pyrroles; Treatment Outcome; Triglycerides; Ultrasonography, Interventional; Venous Thrombosis | 2001 |
The effect of atorvastatin on postprandial lipaemia in overweight or obese women homozygous for apo E3.
Topics: Adult; Apolipoprotein E3; Apolipoproteins E; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL; Double-Blind Method; Energy Intake; Female; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Obesity; Polymerase Chain Reaction; Postprandial Period; Pyrroles; Triglycerides | 2001 |
Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Niacin; Pyrroles | 2001 |
The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diabetic Retinopathy; Dose-Response Relationship, Drug; Double-Blind Method; Fatty Acids, Nonesterified; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein Lipase; Lipoproteins; Male; Middle Aged; Placebos; Pyrroles; Time Factors; Triglycerides | 2001 |
The effect of pravastatin and atorvastatin on coenzyme Q10.
Topics: Adult; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromatography, High Pressure Liquid; Coenzymes; Coronary Disease; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Reference Values; Triglycerides; Ubiquinone | 2001 |
Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner.
Topics: Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Double-Blind Method; Female; Genotype; Heptanoic Acids; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Pyrroles; Sex Factors | 2001 |
Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Reference Values; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2001 |
Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pravastatin; Pyrroles; Risk; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; United States | 2001 |
Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Middle Aged; Pyrroles; Simvastatin; Tunica Intima | 2001 |
Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyridines; Pyrroles; Treatment Outcome; Triglycerides; United States | 2001 |
Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients.
Topics: Aged; Anticholesteremic Agents; Antioxidants; Atorvastatin; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Oxidation-Reduction; Pyrroles; Ubiquinone; Vitamin E | 2001 |
A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Glucose; Cholesterol; Deoxyglucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fructosamine; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2001 |
Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively.
Topics: Adult; Aged; Allylamine; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Colesevelam Hydrochloride; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Triglycerides | 2001 |
Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).
Topics: Adult; Arm; Atorvastatin; C-Reactive Protein; Case-Control Studies; Cholesterol, HDL; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Image Processing, Computer-Assisted; Male; Middle Aged; Muscle, Smooth, Vascular; Pyrroles; Regional Blood Flow; Regression Analysis; Triglycerides; Ultrasonography, Doppler, Duplex | 2001 |
Acute statin treatment in reducing risk after acute coronary syndrome: the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Trial.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Health Behavior; Heart Conduction System; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Primary Prevention; Prospective Studies; Pyrroles; Treatment Outcome | 2001 |
Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Atorvastatin; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Nelfinavir; Pyrroles; Simvastatin | 2001 |
Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects.
Topics: Aged; Apolipoproteins B; Apolipoproteins E; Atorvastatin; Blood Glucose; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoprotein Lipase; Male; Middle Aged; Pyrroles; Triglycerides | 2001 |
Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2001 |
Is aggressive lipid-lowering therapy preferable to angioplasty in stable coronary artery disease?
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2001 |
Rationale and design for the SARIS trial; effect of statin on atherosclerosis and vascular remodeling assessed with intravascular sonography. Effect of Statin on Atherosclerosis and vascular Remodeling assessed with Intravascular Sonography.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol; Coronary Circulation; Echocardiography, Stress; Female; Heptanoic Acids; Humans; Hyperplasia; Male; Multicenter Studies as Topic; Prospective Studies; Pyrroles; Sensitivity and Specificity; Tunica Intima | 2001 |
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Canada; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diet; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides; United States | 2002 |
Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.
Topics: Adult; Area Under Curve; Atorvastatin; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Interactions; Everolimus; Female; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Male; Mass Spectrometry; Middle Aged; Pravastatin; Pyrroles; Sirolimus | 2002 |
Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Anticholesteremic Agents; Apolipoproteins B; Apolipoproteins E; Aryldialkylphosphatase; Atorvastatin; Cholesterol, LDL; Esterases; Heptanoic Acids; Humans; Hyperlipidemias; Lipoproteins, LDL; Macrophages; Phospholipases A; Pyrroles | 2002 |
Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Reference Values; Triglycerides; Ultrasonography; Vasodilation | 2002 |
Short term effect of atorvastatin and vitamin E on serum levels of C3, a sensitive marker of the risk of myocardial infarction in men.
Topics: Anticholesteremic Agents; Antioxidants; Atorvastatin; Biomarkers; Cholesterol, HDL; Complement C3c; Double-Blind Method; Drug Therapy, Combination; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Vitamin E | 2001 |
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Drug Interactions; Heptanoic Acids; HIV Protease Inhibitors; HIV Seronegativity; Human Experimentation; Humans; Pravastatin; Pyrroles; Ritonavir; Saquinavir; Simvastatin | 2002 |
Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
Topics: Apolipoproteins B; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin Resistance; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Peptide Fragments; Pyrroles | 2002 |
Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Patient Compliance; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2002 |
Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension.
Topics: Aged; Alanine Transaminase; Arteries; Aspartate Aminotransferases; Atorvastatin; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Hemodynamics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Patient Compliance; Pyrroles; Systole; Triglycerides; Victoria | 2002 |
Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Lipids; Lipoproteins; Middle Aged; Patient Selection; Placebos; Pyrroles; Research Design | 2002 |
A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Placebos; Pyrroles; Treatment Outcome | 2002 |
A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Triglycerides | 2001 |
A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Atorvastatin; Azithromycin; Clarithromycin; Confidence Intervals; Drug Interactions; Female; Healthy Volunteers; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2002 |
Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia.
Topics: Adult; Analysis of Variance; Atorvastatin; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chylomicron Remnants; Chylomicrons; Cross-Over Studies; Double-Blind Method; Drug Evaluation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Lipids; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Patient Compliance; Postprandial Period; Pyrroles; Sweden; Time Factors; Treatment Outcome; Triglycerides | 2002 |
Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Evaluation; E-Selectin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Male; Norway; P-Selectin; Pyrroles; Simvastatin; Statistics as Topic; Thrombomodulin; Tissue Plasminogen Activator; Treatment Outcome; Triglycerides; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 2002 |
The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1.
Topics: Adsorption; Adult; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Blood Component Removal; Cell Adhesion; Chelating Agents; Chemical Precipitation; Combined Modality Therapy; Coronary Disease; Dextran Sulfate; E-Selectin; Edetic Acid; Female; Hematocrit; Heparin; Heptanoic Acids; Humans; Hyperlipoproteinemias; Intercellular Adhesion Molecule-1; Lipids; Lipoproteins, LDL; Male; Pyrroles; Vascular Cell Adhesion Molecule-1 | 2002 |
Effects of simvastatin and atorvastatin on inflammation markers in plasma.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Middle Aged; Pyrroles; Simvastatin | 2002 |
Lipid-lowering effect of atorvastatin in heart transplantation.
Topics: Adult; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Follow-Up Studies; Heart Transplantation; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Postoperative Complications; Pyrroles; Time Factors | 2002 |
Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test.
Topics: Anticholesteremic Agents; Atorvastatin; Body Mass Index; Breath Tests; Carbon Dioxide; Carbon Isotopes; Cholesterol; Chylomicron Remnants; Chylomicrons; Double-Blind Method; Heptanoic Acids; Humans; Hyperlipidemias; Lipoproteins; Obesity; Placebos; Pyrroles; Time Factors; Triglycerides; Viscera | 2002 |
Weekly versus daily dosing of atorvastatin.
Topics: Adult; Aged; Analysis of Variance; Atorvastatin; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pilot Projects; Pyrroles; United States | 2002 |
Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
Topics: Adult; Aged; Atorvastatin; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2002 |
[Significance of the follow-up of patients with ischemic cardiopathy in the treatment with atorvastatin as secondary prevention. Pilot study].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Ischemia; Pilot Projects; Prospective Studies; Pyrroles | 2002 |
Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Obesity; Pyrroles; Viscera | 2002 |
Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia.
Topics: Adult; Atorvastatin; Bezafibrate; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides | 2002 |
Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angina Pectoris; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Lovastatin; Middle Aged; Myocardial Ischemia; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2002 |
Short-term effects of atorvastatin on C-reactive protein.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Pyrroles; Sensitivity and Specificity; Switzerland; Time Factors; Triglycerides | 2002 |
A preliminary evaluation of neural network analysis for pharmacodynamic modeling of the dosing of the hydroxymethylglutaryl coenzyme A-reductase inhibitors simvastatin and atorvastatin.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Models, Biological; Neural Networks, Computer; Pyrroles; Simvastatin | 2002 |
Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial.
Topics: Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2002 |
Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Colorimetry; Cross-Sectional Studies; Enzyme Inhibitors; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Immunoassay; Interleukin-6; Male; Middle Aged; Obesity; Pyrroles; Tumor Necrosis Factor-alpha | 2002 |
Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease.
Topics: Atorvastatin; Blood Coagulation; Coronary Disease; Double-Blind Method; Female; Fibrinolysis; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Pyrroles; Simvastatin; Time Factors | 2002 |
High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Platelet Aggregation; Pyrroles; Thromboplastin; Thrombosis | 2002 |
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Azetidines; Blood Component Removal; Child; Cholesterol, LDL; Creatine Kinase; Diet Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Liver Function Tests; Male; Pyrroles; Simvastatin; Treatment Outcome | 2002 |
Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Topics: Adult; Aged; Apolipoprotein B-100; Apolipoproteins B; Arteriosclerosis; Atorvastatin; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Female; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, HDL; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Male; Membrane Proteins; Middle Aged; Phospholipid Transfer Proteins; Pyrroles | 2002 |
Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Simvastatin; Thrombin; Treatment Outcome | 2001 |
Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2002 |
Allelic polymorphism -491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Bezafibrate; Cholesterol; DNA; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Male; Middle Aged; Polymorphism, Genetic; Promoter Regions, Genetic; Pyrroles; Triglycerides | 2002 |
Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity.
Topics: Atorvastatin; Diet; Double-Blind Method; Drug Synergism; Exercise; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Obesity; Placebos; Pyrroles; Risk Factors | 2002 |
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein(a); Lipoproteins, HDL; Male; Middle Aged; Pyrroles; Triglycerides | 2002 |
Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Lipids; Male; Middle Aged; Placebos; Pyrroles; Smoking; Vasodilation | 2002 |
Atorvastatin, diabetic dyslipidemia, and cognitive functioning.
Topics: Aged; Atorvastatin; Cholesterol; Cognition; Diabetes Complications; Diabetes Mellitus; Fasting; Heptanoic Acids; Humans; Hyperlipidemias; Middle Aged; Pyrroles; Time Factors; Triglycerides | 2002 |
Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Clofibric Acid; Drug Administration Schedule; Drug Therapy, Combination; Female; Fenofibrate; Fibric Acids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Lipids; Liver; Male; Middle Aged; Pyrroles; Treatment Outcome | 2002 |
Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients.
Topics: Adult; Aged; Antibodies, Monoclonal; Area Under Curve; Atorvastatin; Basiliximab; Cyclosporine; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Prednisolone; Pyrroles; Recombinant Fusion Proteins | 2001 |
Short-term effect of atorvastatin (80 mg) on plasma lipids of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Myocardial Infarction; Pyrroles; Treatment Outcome; Triglycerides | 2002 |
Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.
Topics: Adult; Anticholesteremic Agents; Apoptosis; Atorvastatin; Cholesterol; Coronary Artery Disease; Fatty Acids; Female; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; L-Selectin; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2002 |
Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
Topics: Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Fasting; Fatty Acids, Nonesterified; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin; Insulin Resistance; Kinetics; Male; Middle Aged; Obesity; Placebos; Pyrroles | 2002 |
Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Carotid Artery Diseases; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipoproteins; Macrophages; Male; Middle Aged; Prospective Studies; Pyrroles; Thromboplastin; Thrombosis | 2002 |
Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients.
Topics: Adolescent; Atorvastatin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Child; Child, Preschool; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension, Renal; Kidney Transplantation; Male; Prospective Studies; Pyrroles; Treatment Outcome | 2002 |
Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coronary Disease; Cost-Benefit Analysis; Female; Greece; Heptanoic Acids; Humans; Male; Middle Aged; National Health Programs; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides | 2002 |
Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk.
Topics: Adult; Aged; Apolipoproteins A; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Logistic Models; Male; Middle Aged; Probability; Pyrroles; Reference Values; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Simvastatin; Statistics, Nonparametric; Treatment Outcome | 2002 |
Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients.
Topics: Adult; Aged; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Maximum Tolerated Dose; Middle Aged; Pravastatin; Probability; Pyrroles; Reference Values; Severity of Illness Index; Simvastatin; Single-Blind Method; Treatment Outcome | 2002 |
Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia.
Topics: Adult; Apolipoproteins E; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Kinetics; Lipoproteins, VLDL; Male; Middle Aged; Pyrroles; Time Factors | 2002 |
Atorvastatin reduces plasma levels of factor VII activity and factor VII antigen in patients with hyperlipidemia.
Topics: Aged; Anticholesteremic Agents; Antigens; Atorvastatin; Blood Glucose; Factor VII; Female; Fibrinogen; Hemostasis; Heptanoic Acids; Humans; Hyperlipidemias; Isoantigens; Male; Middle Aged; Pyrroles; Risk Factors; Thrombosis; Triglycerides | 2002 |
Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
Topics: Acute Disease; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Incidence; Lipids; Male; Myocardial Infarction; Myocardial Ischemia; Proportional Hazards Models; Pyrroles; Risk; Risk Assessment; Secondary Prevention; Stroke; Treatment Outcome | 2002 |
Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin | 2002 |
Statin-associated myopathy with normal creatine kinase levels.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biopsy; Creatine Kinase; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscular Diseases; Pain; Pyrroles; Simvastatin | 2002 |
Are early clinical effects of cholesterol lowering mediated through effects on inflammation?
Topics: Angina Pectoris; Anticholesteremic Agents; Atorvastatin; Cholesterol; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Simvastatin; T-Lymphocytes | 2002 |
Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dietary Fats; Dose-Response Relationship, Drug; Fasting; Female; Heptanoic Acids; Humans; Lipoprotein(a); Lipoproteins; Male; Middle Aged; Postprandial Period; Pyrroles; Treatment Outcome; Triglycerides | 2002 |
Effect of atorvastatin on endothelium-dependent vasodilation in postmenopausal women with average serum cholesterol levels.
Topics: Acetylcholine; Anticholesteremic Agents; Arginine; Atorvastatin; Brachial Artery; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Nitroprusside; omega-N-Methylarginine; Postmenopause; Pyrroles; Reference Values; Regional Blood Flow; Treatment Outcome; Vasodilation; Vasodilator Agents | 2002 |
Effect of atorvastatin (80 mg) initiated at the time of coronary artery stent implantation on C-reactive protein and six-month clinical events.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Incidence; Italy; Male; Middle Aged; Postoperative Care; Preoperative Care; Prospective Studies; Pyrroles; Stents; Survival Analysis; Time Factors; Treatment Outcome; Triglycerides | 2002 |
Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS).
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pilot Projects; Pyrroles | 2002 |
Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia.
Topics: Apolipoproteins B; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides | 2002 |
Effects of atorvastatin treatment on sICAM-1 and plasma nitric oxide levels in hypercholesterolemic subjects.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Male; Middle Aged; Nitric Oxide; Placebos; Pyrroles; Time Factors | 2002 |
Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Coronary Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins, HDL; Male; Middle Aged; Pyrroles | 2002 |
Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pyrroles; Recurrence; Survival Rate | 2002 |
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.
Topics: Adult; Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol; Cholesterol, LDL; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Tunica Intima; Ultrasonography | 2002 |
Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; North America; Pyrroles; Rosiglitazone; Safety; Thiazoles; Thiazolidinediones; Time Factors; Treatment Outcome | 2002 |
Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy.
Topics: Adult; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2002 |
Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolaemia: a preliminary study.
Topics: Adult; Aged; Anticholesteremic Agents; Aorta; Atorvastatin; Blood Pressure; Double-Blind Method; Elasticity; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pulse; Pyrroles; Statistics, Nonparametric; Treatment Outcome | 2002 |
Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells.
Topics: Animals; Atorvastatin; Blood Coagulation; CD40 Antigens; CD40 Ligand; Cells, Cultured; Cohort Studies; Coronary Stenosis; Cytokines; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Lipoproteins, LDL; Male; Mice; Middle Aged; Muscle, Smooth, Vascular; Phagocytes; Pyridines; Pyrroles; RNA, Messenger; Simvastatin | 2002 |
Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Body Mass Index; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Middle Aged; Pyrroles; Treatment Outcome | 2003 |
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2002 |
Treatment with atorvastatin alters the ratio of interleukin-12/interleukin-10 gene expression [corrected].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Interleukin-10; Interleukin-12; Interleukin-12 Subunit p35; Leukocytes, Mononuclear; Lipids; Male; Mevalonic Acid; Middle Aged; Protein Subunits; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Single-Blind Method | 2003 |
[Effect of atorvastatin on endothelial function in patients with familial hypercholesterolemia].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2002 |
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Linear Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2003 |
Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.
Topics: Adolescent; Adult; Atorvastatin; Breath Tests; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erythromycin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Ticlopidine | 2003 |
Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fatty Alcohols; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Pyrroles; Single-Blind Method; Treatment Outcome | 2003 |
Time-dependent effect of statins on platelet function in hypercholesterolaemia.
Topics: Adult; Analysis of Variance; Antiporters; Atorvastatin; Blood Platelets; Case-Control Studies; Cholesterol; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase; P-Selectin; Platelet Activation; Pravastatin; Pyrroles; Simvastatin; Time Factors | 2002 |
Atorvastatin enhances the plasma clearance of chylomicron-like emulsions in subjects with atherogenic dyslipidemia: relevance to the in vivo metabolism of triglyceride-rich lipoproteins.
Topics: Adult; Aged; Analysis of Variance; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Chylomicrons; Dose-Response Relationship, Drug; Drug Administration Schedule; Fat Emulsions, Intravenous; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Particle Size; Probability; Pyrroles; Triglycerides | 2003 |
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.
Topics: Atorvastatin; CD40 Ligand; Coronary Artery Disease; Double-Blind Method; Down-Regulation; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2003 |
Levels of adhesion molecules do not decrease after 3 months of statin therapy in moderate hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cell Adhesion Molecules; Cholesterol; Cross-Sectional Studies; Double-Blind Method; E-Selectin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2003 |
Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant.
Topics: Aged; Alleles; Atorvastatin; Black People; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Female; Genetic Variation; Heptanoic Acids; Heterozygote; Humans; Hyperlipidemias; Lipase; Liver; Male; Middle Aged; Polymorphism, Genetic; Promoter Regions, Genetic; Pyrroles; Sex Characteristics; White People | 2003 |
Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestanol; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Phytosterols; Pyrroles; Simvastatin; Sitosterols; Squalene; Sterols | 2003 |
Low-dose atorvastatin therapy does not augment endothelial function in active hypercholesterolaemic males.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2003 |
Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Child; Child, Preschool; Cholesterol; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Transplantation; Prospective Studies; Pyrroles; Risk Factors | 2003 |
Effects of combined low-density lipoprotein apheresis and aggressive statin therapy on coronary calcified plaque as measured by computed tomography.
Topics: Administration, Oral; Aged; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Calcinosis; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease; Drug Monitoring; Female; Follow-Up Studies; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Severity of Illness Index; Simvastatin; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Effect of atorvastatin and pravastatin on serum C-reactive protein.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Carotid Arteries; Cholesterol, LDL; Female; Fibrinogen; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Tunica Intima | 2003 |
Atorvastatin improves metabolic control and endothelial function in type 2 diabetic patients: a placebo-controlled study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cadherins; Cholesterol, LDL; Diabetes Mellitus, Type 2; E-Selectin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Placebos; Pyrroles; Vascular Cell Adhesion Molecule-1 | 2003 |
Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diet; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Insulin; Kinetics; Lipoproteins; Lipoproteins, HDL; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Metabolic Syndrome; Middle Aged; Obesity; Placebos; Pyrroles; Triglycerides | 2003 |
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.
Topics: Anticholesteremic Agents; Atorvastatin; Chronic Disease; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Kidney Glomerulus; Male; Middle Aged; Prospective Studies; Proteinuria; Pyrroles | 2003 |
Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia.
Topics: Administration, Oral; Adult; Atorvastatin; Biomarkers; Carotid Arteries; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Probability; Pyrroles; Reference Values; Severity of Illness Index; Simvastatin; Treatment Outcome; Tunica Media | 2003 |
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Time Factors | 2003 |
A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2003 |
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Multicenter Studies as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2003 |
An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2003 |
A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cohort Studies; Cost-Benefit Analysis; Double-Blind Method; Endpoint Determination; Health Care Costs; Heptanoic Acids; Hospitalization; Humans; Hypercholesterolemia; Myocardial Ischemia; Pyrroles; Treatment Outcome; United Kingdom | 2003 |
Hemostatic effects of atorvastatin versus simvastatin.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemostasis; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin | 2003 |
Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Aortic Valve; Atorvastatin; Cardiovascular Diseases; Echocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Pyrroles; Time; United States | 2003 |
Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes.
Topics: Aged; Atorvastatin; Base Sequence; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Diabetes Mellitus, Type 2; DNA Primers; Double-Blind Method; Female; Genotype; Glycated Hemoglobin; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Placebos; Polymorphism, Genetic; Pyrroles; Restriction Mapping; Triglycerides | 2003 |
Effect of atorvastatin on endothelium-dependent vasodilation in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Blood Flow Velocity; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Muscle, Smooth, Vascular; Nitroglycerin; Pyrroles; Syndrome; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents | 2003 |
Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Flow Velocity; Cholesterol; Diterpenes; Heptanoic Acids; Humans; Hypertriglyceridemia; Lipoproteins; Postprandial Period; Pyrroles; Retinyl Esters; Triglycerides; Vitamin A | 2003 |
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Risk Factors; Stroke | 2003 |
Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Drug Tolerance; Female; Half-Life; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Renal Dialysis | 2003 |
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Digestive System; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Musculoskeletal Diseases; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides | 2003 |
A randomized trial of aggressive lipid reduction for improvement of myocardial ischemia, symptom status, and vascular function in patients with coronary artery disease not amenable to intervention.
Topics: Angina Pectoris; Anticholesteremic Agents; Atorvastatin; Brachial Artery; Carotid Arteries; Cholesterol, LDL; Coronary Artery Disease; Coronary Stenosis; Echocardiography, Stress; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Surveys and Questionnaires; Vascular Resistance | 2003 |
LIFE and ARBITER.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pravastatin; Pyrroles; Treatment Outcome | 2003 |
Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease.
Topics: Adult; Aged; Atorvastatin; Chemokines; Coronary Artery Disease; Dose-Response Relationship, Drug; Down-Regulation; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Male; Middle Aged; Pyrroles; Receptors, Chemokine; RNA, Messenger; Simvastatin; Time Factors | 2003 |
Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.
Topics: Atorvastatin; Cells, Cultured; Chemokine CCL2; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Monocytes; Pyrroles; Simvastatin | 2003 |
Effect of atorvastatin (80 mg) on recurrent ischemia in unstable angina pectoris or non-ST-elevation acute myocardial infarction.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography, Ambulatory; Female; Heptanoic Acids; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Recurrence; Treatment Outcome | 2003 |
Atorvastatin affects C-reactive protein levels in patients with coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2003 |
Efficacy of alternate-day dosing versus daily dosing of atorvastatin.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Function Tests; Middle Aged; Prospective Studies; Pyrroles; Triglycerides | 2003 |
The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
Topics: Aged; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Magnetic Resonance Spectroscopy; Male; Middle Aged; Myocardial Ischemia; Patient Compliance; Probability; Pyrroles; Reference Values; Risk Assessment; Treatment Outcome | 2003 |
Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, VLDL; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Phytosterols; Pyrroles | 2003 |
Effect of atorvastatin on postcardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Disease Progression; Endothelium, Vascular; Female; Heart Transplantation; Heptanoic Acids; Humans; Hyperplasia; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Postoperative Period; Pyrroles; Tunica Intima | 2003 |
Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Gemfibrozil; Heptanoic Acids; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Treatment Outcome | 2003 |
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2003 |
Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Time Factors; Triglycerides | 2003 |
Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia.
Topics: Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoprotein(a); Male; Middle Aged; Pyrroles; Simvastatin | 2003 |
Statins promote potent systemic antioxidant effects through specific inflammatory pathways.
Topics: Antioxidants; Arteriosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipoproteins; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Pyrroles; Reactive Oxygen Species; Signal Transduction; Statistics, Nonparametric; Tyrosine | 2003 |
Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Factor VIIa; Fasting; Fatty Acids, Omega-3; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Kinetics; Male; Middle Aged; Peptide Fragments; Postprandial Period; Prothrombin; Pyrroles; Thrombophilia; Triglycerides | 2003 |
Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction.
Topics: Aged; Angina, Unstable; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Syndrome; Treatment Outcome | 2003 |
Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia.
Topics: Adult; Atorvastatin; Autonomic Nervous System; Baroreflex; Cross-Over Studies; Fenofibrate; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrroles | 2003 |
[Markers of inflammation and platelet aggregation in patients with non ST elevation acute coronary syndrome treated with atorvastatin or pravastatin].
Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Disease; Drug Administration Schedule; Electrocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; Platelet Aggregation; Pravastatin; Pyrroles; Time Factors | 2003 |
[Non ST elevation acute coronary syndrome: early use of pravastatin or atorvastatin is associated with divergent changes of parameters of hemostasis].
Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Electrocardiography; Female; Heptanoic Acids; Homeostasis; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Syndrome; Time Factors | 2003 |
Decrease of hemostatic cardiovascular risk factors by aggressive vs. conventional atorvastatin treatment in patients with Type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Factor VIIIa; Female; Fibrinogen; Hemostatics; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Placebos; Pyrroles; Risk Factors; Time Factors; Tissue Plasminogen Activator; von Willebrand Factor | 2003 |
Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Apolipoproteins B; Atorvastatin; Child; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrroles; Severity of Illness Index; Triglycerides | 2003 |
Soluble intercellular adhesion molecule-1 and interleukin-6 levels reflect endothelial dysfunction in patients with primary hypercholesterolaemia treated with atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; E-Selectin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Pyrroles; Vascular Cell Adhesion Molecule-1; Vasodilation | 2003 |
Effects of atorvastatin on fasting and postprandial complement component 3 response in familial combined hyperlipidemia.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Chylomicrons; Complement C3; Fasting; Fatty Acids, Nonesterified; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Postprandial Period; Pyrroles; Triglycerides | 2003 |
Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; C-Reactive Protein; Double-Blind Method; Fasting; Female; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Homeostasis; Humans; Male; Middle Aged; Postprandial Period; Pyrroles; Triglycerides | 2003 |
Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Therapy, Combination; Female; Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Stroke; Ticlopidine; Treatment Outcome | 2003 |
Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin.
Topics: Adult; Aged; Alfentanil; Analgesics, Opioid; Anticholesteremic Agents; Area Under Curve; Atorvastatin; Chromatography, Gas; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Infusions, Intravenous; Male; Middle Aged; Pyrroles; Time Factors | 2003 |
Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy.
Topics: Aged; Angioscopy; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Color; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles | 2003 |
Effect of atorvastatin on myocardial contractile reserve assessed by tissue Doppler imaging in moderately hypercholesterolemic patients without heart disease.
Topics: Aged; Atorvastatin; Blood Flow Velocity; Blood Pressure; Cardiotonic Agents; Cholesterol, HDL; Cholesterol, LDL; Diastole; Diet, Fat-Restricted; Dobutamine; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Contraction; Pyrroles; Stroke Volume; Systole; Treatment Outcome; Triglycerides | 2003 |
Therapy with statins in patients with refractory rheumatic diseases: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Atorvastatin; Biomarkers; Blood Sedimentation; C-Reactive Protein; Child; Chloroquine; Dose-Response Relationship, Drug; Granulomatosis with Polyangiitis; Heptanoic Acids; HLA-DR Antigens; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Lupus Erythematosus, Systemic; Middle Aged; Proteinuria; Pyrroles; Rheumatic Diseases; Rheumatic Fever; Simvastatin; Treatment Outcome | 2003 |
Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intermittent Claudication; Male; Peripheral Vascular Diseases; Prospective Studies; Pyrroles; Quality of Life; Treatment Outcome; Walking | 2003 |
Reduction in serum levels of adhesion molecules, interleukin-6 and C-reactive protein following short-term low-dose atorvastatin treatment in patients with non-familial hypercholesterolemia.
Topics: Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; E-Selectin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Male; Middle Aged; Multivariate Analysis; Pyrroles; Vascular Cell Adhesion Molecule-1 | 2003 |
Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
Topics: Analysis of Variance; Atorvastatin; Blood Glucose; Female; Fenofibrate; Heptanoic Acids; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Simvastatin; Uric Acid | 2003 |
High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
Topics: Acute Disease; Aged; Angina, Unstable; Apolipoproteins; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Pyrroles; Serum Amyloid A Protein; Syndrome; Troponin | 2003 |
Magnitude of HDL cholesterol variation after high-dose atorvastatin is genetically determined at the LDL receptor locus in patients with homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Atorvastatin; Blood Component Removal; Child; Cholesterol, HDL; Female; Heptanoic Acids; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Male; Mutation; Phenotype; Pyrroles; Receptors, LDL | 2003 |
Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Kinetics; Leucine; Lipids; Male; Middle Aged; Pyrroles | 2004 |
Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia.
Topics: Adrenal Cortex Hormones; Adrenal Glands; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Female; Gonadal Steroid Hormones; Gonads; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Severity of Illness Index | 2003 |
Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein B-48; Apolipoproteins B; Area Under Curve; Atorvastatin; Chylomicrons; Coronary Disease; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Postprandial Period; Pyrroles; Receptors, LDL; Treatment Outcome; Triglycerides | 2003 |
Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein C-III; Apolipoproteins C; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoprotein Lipase; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2003 |
Effects of atorvastatin and pravastatin on malondialdehyde-modified LDL in hypercholesterolemic patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Oxidation-Reduction; Pravastatin; Pyrroles | 2003 |
Effects of atorvastatin therapy on the low-density lipoprotein subfraction, remnant-like particles cholesterol, and oxidized low-density lipoprotein within 2 weeks in hypercholesterolemic patients.
Topics: Aged; Atorvastatin; Biomarkers; Cholesterol; Female; Fibrinolysis; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Thiobarbituric Acid Reactive Substances; Time Factors | 2003 |
Effect of pretreatment vitamin D levels on in vivo effects of atorvastatin on bone metabolism in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Bone and Bones; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Osteogenesis; Pyrroles; Vitamin D | 2003 |
Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Double-Blind Method; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Patient Selection; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Secondary Prevention; Stroke | 2003 |
[Atorvastatin in the treatment of patients with hereditary hypercholesterolemia].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Male; Middle Aged; Pyrroles; Treatment Outcome | 2003 |
Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).
Topics: Adult; Aged; Alkaline Phosphatase; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Diarrhea; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Musculoskeletal Diseases; Nausea; Pyrroles; Simvastatin | 2003 |
Effect of atorvastatin on exercise-induced myocardial ischemia in patients with stable angina pectoris.
Topics: Aged; Angina, Unstable; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myocardial Ischemia; Pyrroles | 2003 |
Usefulness of lowering low-density lipoprotein cholesterol to <70 mg/dl and usefulness of C-reactive protein in patient selection.
Topics: Aged; Atorvastatin; C-Reactive Protein; Carotid Arteries; Carotid Artery Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Pravastatin; Pyrroles; Tunica Intima; Tunica Media | 2003 |
Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Analysis of Variance; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Least-Squares Analysis; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Statistics, Nonparametric; Sulfonamides; Treatment Outcome | 2003 |
Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome.
Topics: Atorvastatin; Cells, Cultured; Chemokine CCL2; Coronary Disease; Culture Media, Conditioned; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Monocytes; Pyrroles; RNA, Messenger | 2003 |
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin | 2003 |
Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia.
Topics: Acetamides; Acetates; Administration, Oral; Adolescent; Adult; Age Factors; Atorvastatin; Child; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Probability; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Sex Factors; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sulfonamides; Sulfonic Acids; Treatment Outcome | 2003 |
Chylomicron remnants of various sizes are lowered more effectively by fenofibrate than by atorvastatin in patients with combined hyperlipidemia.
Topics: Administration, Oral; Adult; Atorvastatin; Chylomicron Remnants; Chylomicrons; Cross-Over Studies; Drug Administration Schedule; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Particle Size; Postprandial Period; Probability; Prospective Studies; Pyrroles; Risk Assessment; Statistics, Nonparametric; Treatment Outcome | 2003 |
Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels?
Topics: Acute Disease; Adult; Aged; Arginine; Atorvastatin; Biomarkers; Blood Glucose; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Female; Finland; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Statistics as Topic; Triglycerides | 2003 |
The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Double-Blind Method; Female; Femoral Artery; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Tunica Intima; Tunica Media | 2003 |
Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Fatty Liver; Female; Hepatitis; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Ursodeoxycholic Acid | 2003 |
Statin therapy in patients with coronary artery disease improves the impaired endothelial progenitor cell differentiation into cardiomyogenic cells.
Topics: Adult; Animals; Anticholesteremic Agents; Atorvastatin; Cell Differentiation; Cells, Cultured; Coronary Artery Disease; Endothelial Cells; Female; Heptanoic Acids; Humans; Lovastatin; Male; Myocytes, Cardiac; Pyrroles; Rats; Simvastatin | 2004 |
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North America; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2003 |
Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lipoproteins; Lovastatin; Male; Middle Aged; Postprandial Period; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2004 |
Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels <130 mg/dl.
Topics: Administration, Oral; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Brachial Artery; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperemia; Male; Middle Aged; Nitroglycerin; Pulsatile Flow; Pyrroles; Treatment Outcome; Triglycerides; Vasodilation | 2004 |
Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Brachial Artery; Drug Therapy, Combination; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microvascular Angina; Middle Aged; Oxidative Stress; Pyrroles; Ramipril; Sickness Impact Profile; Superoxide Dismutase; Vasodilation | 2004 |
Effects of low and high doses of atorvastatin on arterial compliance.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Artery, Common; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Compliance; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Triglycerides; Ultrasonography, Doppler, Color; Ultrasonography, Interventional | 2003 |
The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Brachial Artery; Carotid Artery, Common; Coronary Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tunica Intima; Tunica Media; Ultrasonography | 2004 |
Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke; Time Factors | 2004 |
Effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients.
Topics: Adult; Aged; Area Under Curve; Atorvastatin; Cholesterol; Cyclosporine; Drug Interactions; Female; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrroles; Treatment Outcome | 2004 |
[Statin therapy for hypertensive patients].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles | 2004 |
Marked low-density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosis.
Topics: Arteriosclerosis; Atorvastatin; C-Reactive Protein; Carotid Artery Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrroles; Tunica Intima; Ultrasonography | 2004 |
Plasma antioxidative activity during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention.
Topics: Adult; Antioxidants; Atorvastatin; Cholesterol; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pyrroles | 2004 |
Rationale, design and methods of the CASHMERE study.
Topics: Aged; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Carotid Arteries; Double-Blind Method; Drug Therapy, Combination; Echocardiography; Endpoint Determination; Estrogen Replacement Therapy; Female; Femoral Artery; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Prospective Studies; Pyrroles; Research Design; Treatment Outcome | 2004 |
Hormonal changes with cholesterol reduction: a double-blind pilot study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Double-Blind Method; Female; Heptanoic Acids; Hormones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Pyrroles | 2004 |
The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes.
Topics: Adult; Atorvastatin; Biomarkers; Brachial Artery; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Microcirculation; Middle Aged; Nitroglycerin; Pyrroles; Regional Blood Flow; Risk Factors; Skin; Vasodilation; Vasodilator Agents | 2004 |
Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis?
Topics: Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Renal Dialysis | 2004 |
Time course differences for statin-induced pleiotropic effects in hypercholesterolemic patients.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Mutation; Phenotype; Pyridines; Pyrroles; Time Factors | 2004 |
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Male; Middle Aged; Observer Variation; Pravastatin; Pyrroles; Ultrasonography, Interventional | 2004 |
[Atorvastatin for primary prevention of cardiovascular events. ASCOT-LLA Study].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cause of Death; Cholesterol; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles | 2004 |
Atorvastatin in dyslipidaemia of the nephrotic syndrome.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Nephrotic Syndrome; Prospective Studies; Pyrroles | 2003 |
Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins.
Topics: Adult; Aged; Amyloid beta-Peptides; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Peptide Fragments; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2004 |
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; CD40 Ligand; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inactivation, Metabolic; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Stents; Ticlopidine; Treatment Outcome | 2004 |
Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Beverages; Citrus; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Heptanoic Acids; Humans; Male; Pravastatin; Pyrroles | 2004 |
Atorvastatin lowers plasma matrix metalloproteinase-9 in patients with acute coronary syndrome.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Middle Aged; Myocardial Infarction; Pyrroles | 2004 |
Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors.
Topics: Angina Pectoris; Angina, Unstable; Atorvastatin; Coronary Artery Disease; Cross-Sectional Studies; Down-Regulation; Female; Gene Expression Profiling; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1; Leukocytes, Mononuclear; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Pyrroles; Simvastatin; Tumor Necrosis Factor-alpha | 2004 |
Lipid-lowering drug atorvastatin as an adjunct in the management of diabetic macular edema.
Topics: Administration, Oral; Atorvastatin; Chemotherapy, Adjuvant; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Exudates and Transudates; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Laser Coagulation; Lipoproteins, LDL; Macular Edema; Male; Middle Aged; Prospective Studies; Pyrroles; Triglycerides; Visual Acuity | 2004 |
Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin.
Topics: Adult; Antineoplastic Agents; Atorvastatin; Bezafibrate; Biomarkers; Carotid Artery Diseases; Carotid Artery, Common; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Endothelial Cells; Fas Ligand Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Male; Membrane Glycoproteins; Mevalonic Acid; Middle Aged; Pyrroles; Terpenes; Time Factors; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha | 2004 |
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia.
Topics: Administration, Oral; Analysis of Variance; Arteriosclerosis; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Glycoproteins; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Linear Models; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Probability; Prognosis; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Simvastatin; Treatment Outcome; Tunica Media | 2004 |
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Single-Blind Method; Triglycerides | 2004 |
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2004 |
Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cytokines; Female; Heptanoic Acids; Humans; Male; Matrix Metalloproteinases; Middle Aged; Myocardial Infarction; Pyrroles; Tissue Inhibitor of Metalloproteinases | 2004 |
Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Patient Compliance; Postoperative Complications; Prospective Studies; Pyrroles; Risk Factors; Time Factors; Vascular Surgical Procedures | 2004 |
Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation.
Topics: Arteriosclerosis; Atorvastatin; C-Reactive Protein; Chronic Disease; Coronary Artery Disease; E-Selectin; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Nitric Oxide; Pyrroles; Simvastatin; Treatment Outcome | 2004 |
Vascular basis for the treatment of myocardial ischemia study: trial design and baseline characteristics.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antioxidants; Ascorbic Acid; Atorvastatin; Brachial Artery; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Regional Blood Flow; Ultrasonography; Vasodilation; Vitamin E | 2004 |
The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Apolipoproteins B; Atorvastatin; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lipid Metabolism; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Obesity; Pyrroles; Reference Values; Treatment Outcome | 2004 |
[Clinical study of the month. REVERAL and PROVE-IT: confirmation of the concept " the lower, the better" for cholesterol therapy in patients with coronary heart disease].
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2004 |
Treating to hypertension targets.
Topics: Adrenergic beta-Antagonists; Ambulatory Care; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Blood Pressure; Blood Pressure Determination; Coronary Disease; Female; Heptanoic Acids; Humans; Hypertension; Male; Pyrroles | 2004 |
Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.
Topics: Adult; Aged; Atorvastatin; Drug Therapy, Combination; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Liver Function Tests; Male; Middle Aged; Pyrroles; Time Factors | 2004 |
Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.
Topics: Angiotensin-Converting Enzyme Inhibitors; Apolipoprotein C-III; Apolipoproteins B; Apolipoproteins C; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypertriglyceridemia; Lipoproteins, HDL; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Greece; Heptanoic Acids; Humans; Male; Middle Aged; National Health Programs; Proportional Hazards Models; Pyrroles; Treatment Outcome | 2004 |
Comparison of two methods of presenting risk information to patients about the side effects of medicines.
Topics: Adult; Aged; Atorvastatin; Cardiac Surgical Procedures; Communication; Comprehension; Constipation; Drug Information Services; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Likelihood Functions; Male; Middle Aged; Myocardial Infarction; Pancreatitis; Patient Education as Topic; Physician-Patient Relations; Pyrroles; Risk Assessment; Simvastatin; Terminology as Topic | 2004 |
Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein.
Topics: Adult; Atorvastatin; Brachial Artery; Cholesterol; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Oxidative Stress; Pyrroles; RNA, Messenger; Skin; Smoking; Tyrosine; Ultrasonography; Vasodilation | 2004 |
Statin-induced immunomodulatory effects on human T cells in vivo.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Adult; Antigens, CD; Atorvastatin; Cytokines; Down-Regulation; Enterotoxins; Female; Flow Cytometry; Heptanoic Acids; HLA-DR Antigens; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interferon-gamma; Lipids; Lymphocyte Activation; Major Histocompatibility Complex; Male; Membrane Glycoproteins; Pyrroles; Simvastatin; Superantigens; T-Lymphocytes | 2004 |
Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects.
Topics: Adult; Analysis of Variance; Atorvastatin; Female; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Statistics, Nonparametric | 2004 |
Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia.
Topics: Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Azetidines; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2004 |
Comparative evaluation of the efficacy, safety, and tolerability of rosuvastatin 10 mg with atorvastatin 10 mg in adult patients with hypercholesterolaemia: the first Indian study.
Topics: Apolipoproteins B; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2004 |
Effects of lipid-lowering therapy on coronary artery remodeling.
Topics: Aged; Atorvastatin; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Longitudinal Studies; Male; Middle Aged; Pyrroles; Statistics as Topic; Treatment Outcome; Ultrasonography, Interventional | 2004 |
Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Postmenopause; Pyrroles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome; Triglycerides | 2004 |
Age-dependent effects of atorvastatin on biochemical bone turnover markers: a randomized controlled trial in postmenopausal women.
Topics: Aged; Aging; Atorvastatin; Biomarkers; Bone and Bones; Bone Density; Cardiovascular Diseases; Collagen; Collagen Type I; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Multivariate Analysis; Osteocalcin; Peptides; Postmenopause; Prospective Studies; Pyrroles; Risk Factors | 2004 |
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Biomarkers; Blood Sedimentation; Blood Viscosity; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Methotrexate; Middle Aged; Pyrroles; Risk Factors; von Willebrand Factor | 2004 |
Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Logistic Models; Male; Middle Aged; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2004 |
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol, HDL; Coronary Disease; Creatinine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles | 2004 |
Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemi
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Simvastatin; Tunica Media; Ultrasonography | 2004 |
The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Antioxidants; Aryldialkylphosphatase; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Treatment Outcome | 2004 |
Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Matrix Metalloproteinase 9; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2004 |
Short-term effect of atorvastatin on ischaemic threshold in hypercholesterolaemic patients with stable ischaemic heart disease.
Topics: Aged; Angina Pectoris; Atorvastatin; Cholesterol, LDL; Disease Progression; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myocardial Ischemia; Pyrroles; Time Factors | 2004 |
Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo.
Topics: Aged; Atorvastatin; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Lipoprotein Lipase; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
Impact of Vitamin E supplementation on lipoprotein peroxidation and composition in Type 1 diabetic patients treated with Atorvastatin.
Topics: Adult; Aged; alpha-Tocopherol; Antioxidants; Atorvastatin; Diabetes Mellitus, Type 1; Dietary Supplements; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lipoproteins; Male; Middle Aged; Pyrroles | 2004 |
Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
Topics: Aged; Angina Pectoris; Angina, Unstable; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Biomarkers; CD40 Ligand; Double-Blind Method; Female; Heart Arrest; Heptanoic Acids; Humans; Inflammation Mediators; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pyrroles; Recurrence; Risk; Solubility; Treatment Outcome | 2004 |
Baseline characteristics in the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticoagulants; Atorvastatin; Biomarkers; Coronary Stenosis; Creatine Kinase; Creatine Kinase, MB Form; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoenzymes; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Myoglobin; Premedication; Prospective Studies; Pyrroles; Stents; Treatment Outcome; Troponin I | 2004 |
No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran.
Topics: Administration, Oral; Adult; Anticholesteremic Agents; Anticoagulants; Area Under Curve; Atorvastatin; Azetidines; Benzylamines; Cross-Over Studies; Drug Combinations; Drug Interactions; Female; Glycine; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Partial Thromboplastin Time; Prodrugs; Pyrroles | 2004 |
Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Treatment Outcome | 2004 |
Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Renal; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Renal Dialysis | 2004 |
Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinaemia.
Topics: Adult; Aged; Aryldialkylphosphatase; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipid Metabolism; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin | 2004 |
Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atorvastatin; Cardiovascular Agents; Cholesterol, LDL; Cilostazol; Combined Modality Therapy; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Tetrazoles; Ticlopidine; Treatment Outcome; Ultrasonography, Interventional | 2004 |
The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes.
Topics: Atorvastatin; Biomarkers; Bone Remodeling; Confidence Intervals; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Osteocalcin; Pyrroles | 2004 |
ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin.
Topics: Adenosine Diphosphate; Adolescent; Adult; Atorvastatin; Cell Degranulation; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Fibrinogen; Heptanoic Acids; Humans; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Pyrroles; Ticlopidine | 2004 |
High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
Topics: Aged; Angina, Unstable; Antigen-Antibody Complex; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Autoantibodies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin G; Immunoglobulin M; Lipoprotein(a); Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Oxidation-Reduction; Phospholipids; Pyrroles | 2004 |
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Drug Therapy, Combination; Female; Fibrinolysis; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Insulin Resistance; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Tissue Plasminogen Activator | 2004 |
A comparative study of atorvastatin and simvastatin as monotherapy for mixed hyperlipidaemia in Type 2 diabetic patients.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2004 |
Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Research Design; Simvastatin; Treatment Outcome | 2004 |
Effects of low-dose atorvastatin on vascular responses in patients undergoing percutaneous coronary intervention with stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Carotid Arteries; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Stents; Ultrasonography | 2004 |
Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Practice Guidelines as Topic; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Survival Rate | 2004 |
Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides | 2004 |
Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes.
Topics: Adiponectin; Adult; Age Distribution; Aged; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Hormones, Ectopic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Inflammation Mediators; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Prediabetic State; Predictive Value of Tests; Probability; Prognosis; Pyrroles; Reference Values; Resistin; Risk Assessment; Sex Distribution; Vascular Resistance | 2004 |
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.
Topics: Atorvastatin; Female; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Logistic Models; Male; Middle Aged; Pyrroles; Simvastatin; Uric Acid | 2004 |
Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients.
Topics: Adult; Anticholesteremic Agents; Area Under Curve; Atorvastatin; Chromatography, High Pressure Liquid; Cyclosporine; Drug Interactions; Female; Heptanoic Acids; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Mass Spectrometry; Middle Aged; Pyrroles | 2004 |
Effects of atorvastatin on fasting plasma and marginated apolipoproteins B48 and B100 in large, triglyceride-rich lipoproteins in familial combined hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Atorvastatin; Cholesterol; Fasting; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
There is no evidence for an increase in acute coronary syndromes after short-term abrupt discontinuation of statins in stable cardiac patients.
Topics: Acute Disease; Atorvastatin; Coronary Disease; Disease-Free Survival; Double-Blind Method; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Life Tables; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Stroke; Substance Withdrawal Syndrome; Syndrome; Withholding Treatment | 2004 |
Progesterone abolishes estrogen and/or atorvastatin endothelium dependent vasodilatory effects.
Topics: Aged; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Estradiol; Estrogen Antagonists; Estrogens; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Middle Aged; Norethindrone; Progesterone; Pyrroles; Vasodilation | 2004 |
Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage.
Topics: Adult; Aged; Aryldialkylphosphatase; Atorvastatin; Cholesterol; Comet Assay; DNA Damage; Female; Heptanoic Acids; Humans; Hydrogen Peroxide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Neutrophils; Oxidative Stress; Pyrroles; Thiobarbituric Acid Reactive Substances | 2004 |
Bioequivalence study of atorvastatin tablets.
Topics: Adolescent; Adult; Area Under Curve; Atorvastatin; Chromatography, High Pressure Liquid; Cross-Over Studies; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mass Spectrometry; Middle Aged; Pyrroles; Tablets; Therapeutic Equivalency | 2004 |
Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Topics: Adolescent; Adult; Anticholesteremic Agents; Antiprotozoal Agents; Area Under Curve; Atorvastatin; Biomarkers; Calcium Channel Blockers; Clarithromycin; Creatine Kinase; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Male; Mibefradil; Middle Aged; Pravastatin; Protein Synthesis Inhibitors; Pyrroles; Simvastatin; Verapamil | 2004 |
Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.
Topics: Adult; Aged; Ambulatory Care Facilities; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Disease Management; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Managed Care Programs; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Triglycerides; United States | 2004 |
Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study.
Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Renal Dialysis; Time Factors; Treatment Outcome | 2004 |
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2004 |
High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina.
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Coronary Angiography; Cyclooxygenase Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Middle Aged; Pyrroles; Sulfones; Treatment Outcome | 2004 |
Atorvastatin reduces remnant lipoproteins and small, dense low-density lipoproteins regardless of the baseline lipid pattern.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides | 2004 |
Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction.
Topics: Aged; Anticholesteremic Agents; Antioxidants; Atorvastatin; Coenzymes; Echocardiography, Doppler; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Ubiquinone; Ventricular Function, Left | 2004 |
Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
Effects of atorvastatin on the clearance of triglyceride-rich lipoproteins in familial combined hyperlipidemia.
Topics: Administration, Oral; Adult; Apolipoproteins B; Atorvastatin; Cholesterol; Fat Emulsions, Intravenous; Fats; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Lipoproteins; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kinetics; Lipids; Male; Middle Aged; Pyrroles; Simvastatin | 2005 |
Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure.
Topics: Aged; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Blood Coagulation; Blood Coagulation Factors; Endothelium, Vascular; Fibrinolysis; Forearm; Heart Failure; Heptanoic Acids; Humans; Hyperemia; Lipids; Middle Aged; Pyrroles; Regional Blood Flow; Vasodilation | 2005 |
Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging.
Topics: Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Observer Variation; Pilot Projects; Pravastatin; Pyrroles; Reproducibility of Results; Simvastatin | 2004 |
Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis.
Topics: Adult; Aged; Anion Exchange Resins; Atorvastatin; Electrophoresis, Agar Gel; Epichlorohydrin; Female; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Imidazoles; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Resins, Synthetic | 2005 |
Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Ascorbic Acid; Atorvastatin; Blood Pressure; Brachial Artery; Cross-Sectional Studies; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Pyrroles | 2004 |
Statin therapy has no significant effect on skin tissue cholesterol: results from a prospective randomized trial.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Skin | 2005 |
C-reactive protein levels and outcomes after statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Risk Factors; Secondary Prevention | 2005 |
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Regression Analysis; Risk Factors; Secondary Prevention; Ultrasonography, Interventional | 2005 |
Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2004 |
Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Canada; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2005 |
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein Lipase; Middle Aged; Pravastatin; Pyrroles | 2004 |
Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Triglycerides | 2005 |
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients.
Topics: Adenosine Diphosphate; Atorvastatin; Biomarkers; Blood Coagulation; Blood Platelets; CD40 Ligand; Collagen; Coronary Disease; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Monocytes; Multifactorial Inheritance; Peptide Fragments; Prothrombin; Pyrroles; Solubility; Thrombin; Thromboplastin; Treatment Outcome | 2005 |
Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Double-Blind Method; Estrogen Receptor alpha; Female; Haplotypes; Heptanoic Acids; Humans; Lovastatin; Middle Aged; Pharmacogenetics; Placebos; Polymorphism, Genetic; Pyrroles; Sex Factors; Treatment Outcome | 2005 |
Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cytokines; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Female; Forearm; Heart Failure; Heptanoic Acids; Humans; Hyperemia; Inflammation; Male; Middle Aged; Pyrroles; Regional Blood Flow; Vascular Cell Adhesion Molecule-1 | 2005 |
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutical; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Topics: Atorvastatin; Coronary Artery Disease; Cost-Benefit Analysis; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Placebos; Pyrroles; Stroke; Treatment Outcome | 2005 |
The collaborative atorvastatin diabetes study: preliminary results.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Prospective Studies; Pyrroles | 2005 |
Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients.
Topics: Anticholesteremic Agents; Area Under Curve; Atorvastatin; Cyclosporine; Drug Interactions; Half-Life; Heptanoic Acids; Humans; Immunosuppressive Agents; Kidney Transplantation; Linear Models; Pyrroles | 2005 |
Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuria.
Topics: Adolescent; Adult; Aged; Albuminuria; Apolipoproteins B; Atorvastatin; Brachial Artery; Cholesterol, LDL; Cross-Over Studies; Cyclic GMP; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Nitroglycerin; Pyrroles; Regional Blood Flow; Statistics, Nonparametric; Vasodilation; Vasodilator Agents | 2005 |
Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure.
Topics: Atorvastatin; Chronic Disease; Coenzymes; Cross-Over Studies; Endothelium, Vascular; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Ubiquinone; Vascular Resistance; Vasodilation | 2005 |
Effects of statin therapy on circulating conjugated dienes, a measure of LDL oxidation.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Simvastatin | 2005 |
Relationship between insulin resistance and effect of atorvastatin in non-diabetic subjects.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin Resistance; Male; Middle Aged; Pyrroles | 2005 |
Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging.
Topics: Aged; Anticholesteremic Agents; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Image Enhancement; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Treatment Outcome | 2005 |
Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes.
Topics: Adiponectin; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Hormones, Ectopic; Humans; Intercellular Signaling Peptides and Proteins; Leptin; Male; Placebos; Pyrroles; Resistin | 2005 |
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
Topics: Adult; Aged; Alanine Transaminase; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Prospective Studies; Pyrroles; Risk; Triglycerides | 2005 |
Changes in flow-mediated dilatation, cytokines and carotid arterial stenosis during aggressive atorvastatin treatment in normocholesterolemic patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Carotid Artery, Internal; Carotid Stenosis; Cell Adhesion Molecules; Cholesterol; Cholesterol, LDL; Cytokines; Dilatation, Pathologic; Endothelins; Female; Heptanoic Acids; Humans; Interleukin-1; Interleukin-6; Male; Middle Aged; Pyrroles; Radiography; Treatment Outcome; Tumor Necrosis Factor-alpha; Ultrasonography; Vascular Cell Adhesion Molecule-1 | 2005 |
Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Bile Acids and Salts; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cohort Studies; Drug Therapy, Combination; Dyslipidemias; Feces; Glycoproteins; Heptanoic Acids; Humans; Pyrroles; Quinolines; Sterols | 2005 |
High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Lipoproteins, HDL; Male; Myocardial Infarction; Myocardial Ischemia; Prognosis; Proportional Hazards Models; Pyrroles; Recurrence | 2005 |
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomis
Topics: Adult; Aged; Atorvastatin; Cholesterol; Coronary Disease; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Scandinavian and Nordic Countries; Stroke; Treatment Outcome; United Kingdom | 2004 |
Effect of 12-month statin therapy on antioxidant potential of LDL and serum antioxidant vitamin concentrations.
Topics: alpha-Tocopherol; Atorvastatin; beta Carotene; Cholesterol, LDL; Chromatography, High Pressure Liquid; Female; gamma-Tocopherol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Simvastatin | 2004 |
Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia.
Topics: Adult; Analysis of Variance; Atorvastatin; Chemokine CCL2; Double-Blind Method; Drug Administration Schedule; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Statistics, Nonparametric | 2005 |
Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Atorvastatin; Cohort Studies; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lipids; Lipoproteins; Male; Middle Aged; Prothrombin; Pyrroles; Thrombin; Thromboplastin; Treatment Outcome | 2005 |
Statin treatment of patients with diabetes.
Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2005 |
Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for the Treatment of Myocardial Ischemia Study.
Topics: Angina Pectoris; Antioxidants; Ascorbic Acid; Atorvastatin; Coronary Artery Disease; Diet Therapy; Dose-Response Relationship, Drug; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lipoproteins, LDL; Male; Myocardial Ischemia; Pyrroles; Vasomotor System; Vitamin E | 2005 |
Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Combined Modality Therapy; Cross-Over Studies; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2005 |
Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
Topics: Analysis of Variance; Apolipoproteins; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia.
Topics: Aged; Atorvastatin; Chile; Community Pharmacy Services; Drug-Related Side Effects and Adverse Reactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Patient Compliance; Patient Education as Topic; Patient Satisfaction; Pyrroles; Quality of Life | 2005 |
Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial.
Topics: Adult; alpha-Tocopherol; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Peritoneal Dialysis; Pyrroles; Renal Dialysis; Statistics, Nonparametric; Triglycerides | 2005 |
Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Chronic Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Male; Middle Aged; Particle Size; Phenotype; Pilot Projects; Pyrroles; Renal Dialysis; Risk Factors; Triglycerides | 2005 |
Efficacy of colestimide coadministered with atorvastatin in japanese patients with heterozygous familial hypercholesterolemia (FH).
Topics: Anion Exchange Resins; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Therapy, Combination; Epichlorohydrin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Imidazoles; Japan; Male; Middle Aged; Pyrroles; Resins, Synthetic | 2005 |
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke | 2005 |
Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Atorvastatin; B7-1 Antigen; Bacterial Proteins; Bacterial Toxins; Cells, Cultured; Cytokines; Drug Interactions; Female; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1 Receptor-Associated Kinases; Lipopolysaccharide Receptors; Lipopolysaccharides; Male; Middle Aged; Monocytes; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Protein Prenylation; Pyrroles; RNA, Messenger; Signal Transduction; Toll-Like Receptor 4 | 2005 |
Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients.
Topics: Acetylcholine; Adult; Aged; Ascorbic Acid; Atorvastatin; Biological Availability; C-Reactive Protein; Dose-Response Relationship, Drug; Double-Blind Method; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Male; Middle Aged; Nitric Oxide; Nitroprusside; omega-N-Methylarginine; Pyridines; Pyrroles; Regional Blood Flow; Vasodilation | 2005 |
Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.
Topics: Acute Disease; Acute-Phase Proteins; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Double-Blind Method; Drug Administration Schedule; Female; Guidelines as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Secondary Prevention; Syndrome | 2005 |
Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women.
Topics: Atorvastatin; Bone Density; Bone Diseases, Metabolic; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Pelvic Bones; Postmenopause; Pyrroles; Risedronic Acid | 2005 |
Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Biphenyl Compounds; Case-Control Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperglycemia; Hypertriglyceridemia; Inflammation; Irbesartan; Male; Middle Aged; Oxidative Stress; Postprandial Period; Pyrroles; Tetrazoles; Treatment Outcome | 2005 |
Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Particle Size; Pravastatin; Pyrroles; Treatment Outcome; Triglycerides | 2005 |
The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Erythrocyte Deformability; Female; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Triglycerides | 2005 |
Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Cholesterol; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Mental Status Schedule; Neuropsychological Tests; Placebos; Pyrroles; Treatment Outcome | 2005 |
Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study).
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atorvastatin; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome | 2005 |
A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Middle Aged; Nephelometry and Turbidimetry; Practice Guidelines as Topic; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2005 |
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
Topics: Administration, Oral; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Cohort Studies; Coronary Restenosis; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention; Statistics as Topic; Survival Rate; Treatment Outcome | 2005 |
Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia.
Topics: Arteriosclerosis; Atorvastatin; Brachial Artery; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Treatment Outcome; Ultrasonography | 2005 |
Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
Topics: Adolescent; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2005 |
A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Bile Acids and Salts; Cholesterol 7-alpha-Hydroxylase; Cholesterol, LDL; Double-Blind Method; Female; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Placebos; Polymorphism, Genetic; Promoter Regions, Genetic; Pyrroles; Sex Factors; Treatment Outcome | 2005 |
Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Safety | 2005 |
Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients.
Topics: Aged; Atorvastatin; Biomarkers; Cholesterol; Coenzymes; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrroles; Risk Factors; Treatment Outcome; Ubiquinone | 2005 |
The effect of atorvastatin on serum lipoproteins in acromegaly.
Topics: Acromegaly; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol; Cross-Over Studies; Double-Blind Method; Female; Growth Hormone; Heptanoic Acids; Humans; Insulin-Like Growth Factor I; Lipoproteins; Male; Middle Aged; Pyrroles; Statistics, Nonparametric; Triglycerides | 2005 |
A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis.
Topics: Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Atorvastatin; Blood Flow Velocity; Calcinosis; Cholesterol, LDL; Disease Progression; Double-Blind Method; Echocardiography, Doppler; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Failure | 2005 |
Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients.
Topics: Antihypertensive Agents; Atorvastatin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Outpatients; Pyrroles; Treatment Outcome; Triglycerides | 2005 |
Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level.
Topics: Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Outpatients; Pyrroles; Vascular Diseases | 2005 |
Volumetric quantitative analysis of tissue characteristics of coronary plaques after statin therapy using three-dimensional integrated backscatter intravascular ultrasound.
Topics: Aged; Atorvastatin; Coronary Stenosis; Drug Administration Schedule; Echocardiography, Three-Dimensional; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pravastatin; Pyrroles; Reproducibility of Results; Ultrasonography, Interventional | 2005 |
Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
Topics: Anticholesteremic Agents; Aryldialkylphosphatase; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Oxidation-Reduction; Placebos; Polymorphism, Genetic; Promoter Regions, Genetic; Pyrroles; Vitamin E | 2005 |
Efficacy and safety of chunghyul-dan (qingwie-dan) in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Drugs, Chinese Herbal; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome | 2005 |
Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cognition; Depression; Disease Progression; Double-Blind Method; Female; Free Radicals; Heptanoic Acids; Humans; Male; Mental Status Schedule; Pilot Projects; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome | 2005 |
Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Circulation; Echocardiography, Doppler; Female; Heptanoic Acids; Humans; Male; Middle Aged; Placebos; Pyrroles; Regional Blood Flow | 2005 |
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atorvastatin; Benzoxazines; Cholesterol, LDL; Cyclopropanes; Drug Interactions; Female; Heptanoic Acids; HIV Infections; HIV Seronegativity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Oxazines; Pravastatin; Pyrroles; Simvastatin | 2005 |
Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial.
Topics: Aged; alpha-Tocopherol; Antioxidants; Ascorbic Acid; Aspirin; Atorvastatin; Calcinosis; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Tomography, X-Ray Computed | 2005 |
The impact of early administration of low-dose atorvastatin treatment on inflammatory process, in patients with unstable angina and low cholesterol level.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Chemokine CCL2; Cholesterol; Female; Heptanoic Acids; Humans; Inflammation; Interleukin-6; Male; Middle Aged; Prospective Studies; Pyrroles; Time Factors; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2006 |
High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
Topics: Adult; Age Factors; Aged; Atorvastatin; Biopsy; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Citrate (si)-Synthase; Dose-Response Relationship, Drug; Double-Blind Method; Electron Transport; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscles; Patient Selection; Phytosterols; Pyrroles; Sex Factors; Simvastatin; Sitosterols; Succinate Cytochrome c Oxidoreductase; Time Factors; Ubiquinone | 2005 |
Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month.
Topics: Aged; Anti-Inflammatory Agents; Atherosclerosis; Atorvastatin; Blotting, Southern; Blotting, Western; Carotid Arteries; Chemokine CCL2; Cyclooxygenase 2; Dinoprostone; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Immunohistochemistry; Inflammation; Leukocytes, Mononuclear; Lipids; Male; Middle Aged; NF-kappa B; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
Topics: Aged; Atorvastatin; Cerebrovascular Disorders; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Renal Dialysis; Stroke | 2005 |
Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Biomarkers; Cholesterol; Coronary Artery Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Triglycerides; Vasodilation | 2005 |
Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure.
Topics: Aged; Antioxidants; Atorvastatin; Biomarkers; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Pyrroles; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; Vasodilation; Vitamin E | 2005 |
Inflammatory markers and the metabolic syndrome.
Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hypolipidemic Agents; Inflammation; Lactones; Leukocyte Count; Metabolic Syndrome; Metformin; Orlistat; Prospective Studies; Pyrroles; Treatment Outcome | 2005 |
The effect of short-term treatment with atorvastatin on E-selectin levels in severely burned patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Burns; E-Selectin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2005 |
Serum 1H-nuclear magnetic spectroscopy followed by principal component analysis and hierarchical cluster analysis to demonstrate effects of statins on hyperlipidemic patients.
Topics: Aged; Atorvastatin; Cholesterol; Cluster Analysis; Coronary Disease; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Nuclear Magnetic Resonance, Biomolecular; Principal Component Analysis; Pyrroles; Reproducibility of Results; Simvastatin | 2005 |
3D ultrasound measurement of change in carotid plaque volume: a tool for rapid evaluation of new therapies.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Carotid Stenosis; Cohort Studies; Double-Blind Method; Evaluation Studies as Topic; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Placebos; Pyrroles; Regression Analysis; Research Design; Risk Factors; Time Factors; Ultrasonography | 2005 |
The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Program Evaluation; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
Topics: Adult; Area Under Curve; Atorvastatin; Cross-Over Studies; Drug Interactions; Female; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pyrroles; Rifampin | 2005 |
Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiovascular Agents; Cholesterol, LDL; Comorbidity; Coronary Artery Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Radio Waves; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional | 2005 |
Targeting vascular risk in patients with metabolic syndrome but without diabetes.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Diabetes Mellitus; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Obesity; Prevalence; Prospective Studies; Pyrroles; Risk Factors; Risk Reduction Behavior | 2005 |
Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
Topics: Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcineurin Inhibitors; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lactones; Liver; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pravastatin; Pyrroles; Simvastatin; Tacrolimus; Time Factors | 2005 |
An association study of 43 SNPs in 16 candidate genes with atorvastatin response.
Topics: Aged; Apolipoprotein E2; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Female; Gene Frequency; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Triglycerides; White People | 2005 |
Effects of 4 weeks of atorvastatin administration on the antiinflammatory cytokine interleukin-10 in patients with unstable angina.
Topics: Angina, Unstable; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-10; Pyrroles | 2005 |
The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Diabetes Mellitus, Type 2; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles | 2005 |
Beneficial effects of atorvastatin on myocardial regions with initially low vasodilatory capacity at various stages of coronary artery disease.
Topics: Aged; Atorvastatin; Blood Flow Velocity; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Disease Progression; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Radionuclide Imaging; Treatment Outcome; Vasodilation; Ventricular Dysfunction, Left | 2005 |
[Effect of atorvastatin on the nuclear factor-kappaB and soluble inter-cellular adhesion molecules-1 in patients with acute coronary syndrome].
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Intercellular Adhesion Molecule-1; Male; Middle Aged; Myocardial Infarction; NF-kappa B; Pyrroles | 2004 |
Short-term adjuvant atorvastatin improves frequency domain indices of heart rate variability in stable systolic heart failure.
Topics: Adult; Aged; Atorvastatin; Autonomic Nervous System; Female; Heart Failure; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Single-Blind Method; Systole | 2005 |
A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2005 |
Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Pyrroles; Simvastatin; Statistics, Nonparametric; Treatment Outcome | 2005 |
[The comparison of simvastatin and atorvastatin effects on hemostatic parameters in patients with hyperlipidemia type II].
Topics: Aged; Antithrombin III; Atorvastatin; Factor X; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2005 |
Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2005 |
Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial.
Topics: Acute Disease; Aged; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Metabolic Syndrome; Middle Aged; Myocardial Ischemia; Predictive Value of Tests; Prognosis; Pyrroles; Recurrence; Risk Factors; Treatment Outcome | 2005 |
Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors | 2005 |
Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins.
Topics: Adolescent; Adult; Atorvastatin; Exercise; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscle, Skeletal; Muscular Diseases; Oligonucleotide Array Sequence Analysis; Proteasome Endopeptidase Complex; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Ubiquitin | 2005 |
Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy.
Topics: Angina, Unstable; Atorvastatin; Cell Adhesion; Cells, Cultured; Chemokine CX3CL1; Chemokines, CX3C; Chemotaxis; Cholesterol, LDL; Coronary Artery Disease; CX3C Chemokine Receptor 1; Endothelium, Vascular; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-8; Leukocytes, Mononuclear; Membrane Proteins; Myocardial Infarction; Pyrroles; Receptors, Chemokine; Simvastatin; Umbilical Veins | 2005 |
Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome; Time Factors | 2005 |
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
Topics: Acute Disease; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Pravastatin; Pyrroles; Risk Factors; Syndrome | 2005 |
Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Atorvastatin; Cells, Cultured; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Male; Mice; Middle Aged; Monocytes; Pyrroles; Resistin; RNA, Messenger | 2006 |
Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin.
Topics: Adult; Anticholesteremic Agents; Area Under Curve; Atorvastatin; Beverages; Citrus paradisi; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Food-Drug Interactions; Heptanoic Acids; Humans; Male; Pyrroles; Quinolines | 2005 |
[Estimation of antioxidative effect of atorvastatin and fluvastatin used in primary prevention of coronary heart disease--effect on antioxidative enzymatic activity].
Topics: Adult; Antioxidants; Atorvastatin; Coronary Artery Disease; Erythrocytes; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Primary Prevention; Pyrroles; Treatment Outcome | 2005 |
The effect of statin therapy on plasma high-density lipoprotein cholesterol levels is modified by paraoxonase-1 in patients with familial hypercholesterolaemia.
Topics: Anticholesteremic Agents; Aryldialkylphosphatase; Atorvastatin; Carboxylic Ester Hydrolases; Cholesterol, HDL; Double-Blind Method; Female; Genotype; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Simvastatin; Treatment Outcome | 2005 |
Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients.
Topics: Aged; Albuminuria; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Function Tests; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2006 |
Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial).
Topics: Acute Disease; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Brachial Artery; Cholesterol, LDL; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Syndrome; Ultrasonography; Vasodilation | 2005 |
Effects of atorvastatin on arterial endothelial function in coronary bypass surgery.
Topics: Adult; Aged; Analysis of Variance; Atorvastatin; Brachial Artery; Cholesterol; Coronary Artery Bypass; Double-Blind Method; Endothelium, Vascular; Female; Hemodynamics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperemia; Male; Middle Aged; Nitroglycerin; Postoperative Period; Pyrroles; Statistics, Nonparametric; Vasodilation; Vasodilator Agents | 2005 |
Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease.
Topics: Aged; Angiotensin II; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; In Vitro Techniques; Male; Mammary Arteries; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome; Vasodilation | 2005 |
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Proportional Hazards Models; Pyrroles; Risk Factors; Time Factors; Treatment Outcome | 2005 |
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Pyrroles; Risk; Simvastatin | 2005 |
The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery.
Topics: Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Artery Bypass; Coronary Disease; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrroles; Triglycerides | 2006 |
Effect of C-reactive protein reduction on paroxysmal atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles | 2005 |
Avascular necrosis prevention with lipitor in lupus erythematosus.
Topics: Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Osteonecrosis; Pyrroles | 2005 |
Safety and efficacy of atorvastatin in patients with severe renal dysfunction.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Prospective Studies; Pyrroles; Severity of Illness Index; Treatment Outcome; Triglycerides | 2005 |
Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia.
Topics: Atorvastatin; Cholesterol; Chronotherapy; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Triglycerides | 2005 |
LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2005 |
Coronary risk factors and inflammation in patients with coronary artery disease and internal cardioverter defibrillator implants.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Belgium; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Defibrillators, Implantable; Double-Blind Method; Female; Follow-Up Studies; Glycated Hemoglobin; Greece; Heptanoic Acids; Humans; Inflammation; Inflammation Mediators; Lipids; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prevalence; Pyrroles; Research Design; Risk Factors; Tachycardia, Ventricular; Treatment Outcome; Ventricular Fibrillation | 2006 |
[Effects of atorvastatin on plasma hypersensitive C-reactive protein and interleukin-6 in patients with acute cerebral infarction].
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; C-Reactive Protein; Cerebral Infarction; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Middle Aged; Pyrroles | 2005 |
Atorvastatin lowers plasma low-density lipoprotein cholesterol and C-reactive protein in Japanese type 2 diabetic patients.
Topics: Adult; Atorvastatin; Biomarkers; Blood Pressure; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Japan; Liver; Liver Function Tests; Male; Middle Aged; Pyrroles | 2006 |
Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina.
Topics: Angina, Unstable; Atorvastatin; Biomarkers; Blood Coagulation; Blood Coagulation Factors; Blood Proteins; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles | 2006 |
Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
Topics: Adult; Aged; Atorvastatin; Bezafibrate; Cytosine; Female; Genetic Variation; Genotype; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipase; Lipids; Lipoproteins; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Pyrroles; Reference Values; Thymine | 2005 |
Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin.
Topics: Atorvastatin; Belgium; Community Pharmacy Services; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medical Records Systems, Computerized; Middle Aged; Patient Compliance; Patient Education as Topic; Pharmacists; Professional-Patient Relations; Pyrroles; Time Factors | 2006 |
Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Taiwan; Treatment Outcome | 2005 |
Achieving lipid goals in real life: the Dutch DISCOVERY study.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Netherlands; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
[Changes of elastic properties of magistral arteries in patients with ischemic heart disease during treatment with atorvastatin and simvastatin].
Topics: Anticholesteremic Agents; Arteries; Atorvastatin; Carotid Arteries; Cholesterol; Data Interpretation, Statistical; Elasticity; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperemia; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Myocardial Ischemia; Pyrroles; Radial Artery; Simvastatin; Time Factors; Triglycerides | 2005 |
Short-term effects of low-dose atorvastatin on inflammatory status and lipid profiles in perimenopausal hypercholesterolemic, hypertriglyceridemic women.
Topics: Adult; Atorvastatin; Blood Coagulation; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Female; Fibrinolysis; Gonadal Steroid Hormones; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Inflammation; Lipids; Lipoproteins; Malondialdehyde; Middle Aged; Plasminogen Activator Inhibitor 1; Postmenopause; Premenopause; Prospective Studies; Pyrroles; Time Factors; Tissue Plasminogen Activator; Triglycerides | 2006 |
The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
Topics: Adult; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cross-Over Studies; Double-Blind Method; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Pyrroles; Receptors, Tumor Necrosis Factor, Type I; Treatment Outcome | 2005 |
Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atorvastatin; Electrocardiography; Female; Heart Failure; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prospective Studies; Pyrroles; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2005 |
Effect of chitosan on lipid levels when administered concurrently with atorvastatin--a placebo controlled study.
Topics: Anticholesteremic Agents; Atorvastatin; Chitosan; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pyrroles | 2005 |
Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study.
Topics: Atorvastatin; CD40 Ligand; Coronary Artery Disease; Cytokines; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; T-Lymphocyte Subsets | 2006 |
Preoperative statin therapy and troponin T predict early complications of coronary artery surgery.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Comorbidity; Coronary Artery Bypass; Creatine Kinase, MB Form; Female; Heptanoic Acids; Hospital Mortality; Hospitals, University; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Incidence; Interleukin-6; Lipids; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Premedication; Preoperative Care; Prospective Studies; Pyrroles; Risk Assessment; Simvastatin; Systemic Inflammatory Response Syndrome; Troponin T | 2006 |
LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHD.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin | 2005 |
The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Pyrroles; Simvastatin; Thiobarbituric Acid Reactive Substances | 2005 |
Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT).
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Atorvastatin; Ceruloplasmin; Cholesterol; Cholinergic Antagonists; Cognition Disorders; Copper; Cross-Sectional Studies; Heptanoic Acids; Humans; Longitudinal Studies; Middle Aged; Peptide Fragments; Pyrroles; Verbal Learning | 2005 |
Effects of morning versus evening intake of atorvastatin on major cardiac event and restenosis rates in patients undergoing first elective percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Chronotherapy; Coronary Restenosis; Coronary Stenosis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Treatment Outcome | 2006 |
Cross-over trial of intensive monotherapy with atorvastatin and combined therapy with atorvastatin and colestimide for Japanese familial hypercholesterolemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cross-Over Studies; Drug Therapy, Combination; Epichlorohydrin; Female; Genetic Carrier Screening; Heptanoic Acids; Humans; Hyperlipoproteinemia Type I; Imidazoles; Male; Middle Aged; Patient Dropouts; Pyrroles; Resins, Synthetic; Triglycerides | 2006 |
Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.
Topics: Adiponectin; Adult; Atorvastatin; Biomarkers; Blood Glucose; C-Reactive Protein; Dyslipidemias; Female; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Kidney Transplantation; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Tumor Necrosis Factor-alpha | 2005 |
Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure.
Topics: Atorvastatin; C-Reactive Protein; Double-Blind Method; Erythrocytes; Female; Heart Failure; Heart Ventricles; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-6; Male; Middle Aged; Pilot Projects; Pyrroles; Receptors, Tumor Necrosis Factor, Type II; Stroke Volume; Superoxide Dismutase; Systole; Ultrasonography; Ventricular Function, Left | 2006 |
Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Calcinosis; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome | 2006 |
[Estimation of antioxidative effect of atorvastatin and fluvastatin used in primary prevention of coronary heart disease--effect on lipid peroxidation].
Topics: Adult; Anticholesteremic Agents; Antioxidants; Atorvastatin; Coronary Artery Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Free Radical Scavengers; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipid Peroxidation; Male; Malondialdehyde; Middle Aged; Primary Prevention; Pyrroles; Treatment Outcome | 2005 |
Paradoxical increase in lumen size during progression of coronary atherosclerosis: observations from the REVERSAL trial.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Severity of Illness Index; Treatment Outcome; Ultrasonography, Interventional | 2006 |
Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial.
Topics: Adult; Aged; Atorvastatin; Black or African American; C-Reactive Protein; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2006 |
Atorvastatin reduces the expression of COX-2 mRNA in peripheral blood monocytes from patients with acute myocardial infarction and modulates the early inflammatory response.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Cyclooxygenase 2; Female; Heptanoic Acids; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Myocardial Infarction; Protein C; Pyrroles; RNA, Messenger; Treatment Outcome | 2006 |
Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial.
Topics: Adult; Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Coronary Artery Disease; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Tomography, Spiral Computed; Treatment Failure | 2006 |
[Erythrocyte fluidity in patients with hyperlipidemia during statins therapy].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Erythrocyte Membrane; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Peroxidation; Male; Membrane Fluidity; Membrane Lipids; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Statistics, Nonparametric; Triglycerides | 2005 |
Short-term atorvastatin treatment enhances specific antibody production following tetanus toxoid vaccination in healthy volunteers.
Topics: Acute-Phase Proteins; Adult; Antibodies, Bacterial; Antibody Specificity; Atorvastatin; Clostridium tetani; Cytokines; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin G; Immunologic Factors; Kinetics; Male; Pyrroles; Tetanus Toxoid | 2006 |
The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy.
Topics: Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Heptanoic Acids; HIV Infections; HIV-1; Humans; Pilot Projects; Pyrroles; RNA, Viral; Virus Replication | 2006 |
Composition of coronary plaques obtained by directional atherectomy in stable angina: its relation to serum lipids and statin treatment.
Topics: Adult; Aged; Angina Pectoris; Apolipoprotein A-I; Atherectomy, Coronary; Atorvastatin; Biomarkers; Collagen; Combined Modality Therapy; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Immunity, Cellular; Inflammation Mediators; Lipids; Lymphocyte Count; Male; Middle Aged; Pyrroles; T-Lymphocytes | 2006 |
The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome.
Topics: Acute Disease; Atorvastatin; C-Reactive Protein; Coronary Disease; Female; Heptanoic Acids; Humans; Lipid Metabolism; Middle Aged; Peroxidase; Pyrroles; Syndrome | 2006 |
Effects of atorvastatin on higher functions.
Topics: Atorvastatin; Cardiovascular Diseases; Cognition; Female; Heptanoic Acids; Humans; Intelligence Tests; Male; Mental Processes; Middle Aged; Pyrroles; Treatment Outcome | 2006 |
Can atorvastatin improve the response to sildenafil in men with erectile dysfunction not initially responsive to sildenafil? Hypothesis and pilot trial results.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Erectile Dysfunction; Heptanoic Acids; Humans; Male; Middle Aged; Penile Erection; Pilot Projects; Piperazines; Purines; Pyrroles; Sildenafil Citrate; Sulfones; Treatment Outcome | 2006 |
Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Adiponectin; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; CD40 Ligand; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Matrix Metalloproteinase 9; Middle Aged; Pyrroles; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Triglycerides; Vasodilator Agents | 2006 |
An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Atorvastatin; Cross-Over Studies; Delayed-Action Preparations; Drug Carriers; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pyrroles; Reference Values; Simvastatin; Treatment Outcome | 2006 |
[The IDEAL study comparing simvastatin 20-40 mg versus atorvastatin 80 mg for secondary prevention after myocardial infarction: between two ideas of the ideal].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Single-Blind Method; Treatment Outcome | 2006 |
Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Anticholesteremic Agents; Antioxidants; Atorvastatin; Biomarkers; Deoxyguanosine; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Oxidative Stress; Probucol; Pyrroles; Treatment Outcome | 2006 |
Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery.
Topics: Aged; Analysis of Variance; Atorvastatin; Coronary Artery Bypass; Cytokines; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neutrophil Activation; Postoperative Complications; Pyrroles; Systemic Inflammatory Response Syndrome | 2006 |
Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels.
Topics: Adult; Atorvastatin; Cardiomyopathy, Dilated; Cholesterol, LDL; Drug Therapy, Combination; Endpoint Determination; Evaluation Studies as Topic; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Male; Myocardium; Pyrroles; Quality of Life; Treatment Outcome; Ventricular Function, Left | 2006 |
Correlation between inflammation and oxidative stress in normocholesterolemic coronary artery disease patients 'on' and 'off' atorvastatin for short time intervals.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Artery Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Oxidative Stress; Pyrroles; Thiobarbituric Acid Reactive Substances | 2006 |
Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction)
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Disease; Atorvastatin; Coronary Disease; Double-Blind Method; Enzymes; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Phospholipases A; Phospholipases A2; Pravastatin; Pyrroles; Survival Analysis; Syndrome; Thrombolytic Therapy; Treatment Outcome | 2006 |
[Atorvastatin reduces the expression of COX-2 mRNA in peripheral blood monocytes in patients with acute myocardial infarction and modulates the early inflammatory response].
Topics: Aged; Atorvastatin; Cyclooxygenase 2; Female; Heptanoic Acids; Humans; Inflammation; Interleukin-6; Leukocytes, Mononuclear; Male; Middle Aged; Myocardial Infarction; Pyrroles; RNA, Messenger | 2005 |
Early effects on endothelial function of atorvastatin 40 mg twice daily and its withdrawal.
Topics: Adult; Aged; Atorvastatin; Brachial Artery; Double-Blind Method; Drug Administration Schedule; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Time Factors; Vasodilation; Withholding Treatment | 2006 |
Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
Topics: Adult; Aged; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cross-Over Studies; Drug Synergism; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipids; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Middle Aged; Pyrroles; Quinolines; Single-Blind Method | 2006 |
Atorvastatin normalizes endothelial function in healthy smokers.
Topics: Adult; Atorvastatin; Brachial Artery; Cholesterol, LDL; Cross-Over Studies; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Pyrroles; Smoking; Ultrasonography; Vasodilation | 2006 |
Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome | 2007 |
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2006 |
Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein E?
Topics: Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins E; Atorvastatin; Cholesterol; Diabetes Mellitus, Type 2; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Phospholipid Transfer Proteins; Placebos; Pyrroles | 2006 |
[Effect of statin treatment begun early after acute myocardial infarction on endothelial function in patients with normal levels of cholesterol. VAATOPE Study (VAlue of ATOrvastatin in Postinfarction Endothelium)].
Topics: Aged; Atorvastatin; Brachial Artery; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Pyrroles; Ultrasonography | 2006 |
Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion.
Topics: Aged; Anti-Arrhythmia Agents; Atorvastatin; Atrial Fibrillation; Body Mass Index; C-Reactive Protein; Electric Countershock; Female; Heptanoic Acids; Humans; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; Recurrence; Risk Factors; Treatment Outcome | 2006 |
Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Fenofibrate; Fibrinolysis; Genotype; Heptanoic Acids; Humans; Male; Permeability; Pyrroles; Quinapril; Simvastatin; Tetrahydroisoquinolines; Thrombin; Thrombosis | 2006 |
Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.
Topics: Anti-Obesity Agents; Atorvastatin; Diet, Fat-Restricted; Drug Therapy, Combination; Dyslipidemias; Fatty Liver; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Lactones; Male; Metabolic Syndrome; Middle Aged; Orlistat; Prevalence; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome; Ultrasonography; Weight Loss | 2006 |
Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure.
Topics: Atorvastatin; Biomarkers; Cholesterol; Cross-Over Studies; Double-Blind Method; Echocardiography; Endothelium, Vascular; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Natriuretic Peptides; Pyrroles; Vascular Resistance; Vasodilation | 2006 |
Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Coronary Disease; Coronary Vessels; Disease Progression; Endosonography; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Obesity; Pravastatin; Pyrroles; Risk Factors | 2006 |
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
Topics: Aged; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Triglycerides | 2006 |
Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study.
Topics: Aged; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Quinolines; Safety; Triglycerides | 2006 |
The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyslipidemias; Endothelin-1; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 2006 |
Plasma apolipoprotein A5 and triglycerides in type 2 diabetes.
Topics: Aged; Apolipoprotein A-V; Apolipoprotein C-III; Apolipoproteins A; Apolipoproteins E; Atorvastatin; Diabetes Complications; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Genetic Variation; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Placebos; Pyrroles; Triglycerides | 2006 |
Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial.
Topics: Adaptation, Physiological; Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiac Catheterization; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Models, Cardiovascular; Pravastatin; Prospective Studies; Pyrroles; Risk Factors; Single-Blind Method; Triglycerides; Ultrasonography, Interventional; Vasculitis | 2006 |
[The effects of 40 mg atorvastatin on serum lipids, inflammatory markers and clinical events in ACS patients post PCI].
Topics: Acute Coronary Syndrome; Alanine Transaminase; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Heptanoic Acids; Humans; Hypolipidemic Agents; Matrix Metalloproteinase 9; Prospective Studies; Pyrroles | 2006 |
Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome.
Topics: Adult; Atorvastatin; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Pyrroles; Treatment Outcome | 2006 |
Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Epidemiologic Methods; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Stroke | 2006 |
Prevention of myocardial damage during coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Cardiovascular Agents; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Treatment Outcome | 2006 |
Effect of long-term atorvastatin treatment on the electrophysiological and mechanical functions of muscle.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Dyslipidemias; Electromyography; Exercise; Female; Heptanoic Acids; Humans; Male; Middle Aged; Muscle Contraction; Muscle Fatigue; Muscle, Skeletal; Pyrroles; Triglycerides | 2006 |
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk Assessment; Treatment Outcome | 2006 |
Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction.
Topics: Atorvastatin; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Growth Substances; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Male; Middle Aged; Myocardial Infarction; Placenta Growth Factor; Pregnancy Proteins; Pyrroles; Stroke Volume; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Ventricular Function, Left | 2006 |
Relation between local temperature and C-reactive protein levels in patients with coronary artery disease: effects of atorvastatin treatment.
Topics: Aged; Atorvastatin; Body Temperature; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Inflammation; Male; Middle Aged; Pyrroles; Thermography | 2007 |
Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity.
Topics: Abdominal Fat; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Atorvastatin; Dietary Supplements; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Omega-3; Fish Oils; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hyperlipidemias; Insulin Resistance; Kinetics; Lipoproteins, HDL; Male; Middle Aged; Obesity; Placebos; Pyrroles; Treatment Outcome | 2006 |
Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study).
Topics: Atorvastatin; Blood Proteins; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2006 |
Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Europe; Female; Fluorobenzenes; Guidelines as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Male; Meta-Analysis as Topic; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Social Change; Sulfonamides | 2006 |
Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Atorvastatin; Cholesterol; Cognition Disorders; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neuropsychological Tests; Pyrroles; Severity of Illness Index; Treatment Outcome | 2006 |
Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia.
Topics: Adiponectin; Aged; Anticholesteremic Agents; Atorvastatin; CD40 Ligand; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Resistin; Substance Withdrawal Syndrome; Triglycerides | 2006 |
The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Autonomic Nervous System; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrroles | 2007 |
Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
Topics: Anticholesteremic Agents; Area Under Curve; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, VLDL; Male; Middle Aged; Postprandial Period; Pyrroles; Treatment Outcome; Triglycerides | 2006 |
Lessons learnt from the 4D trial.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Placebos; Pyrroles; Renal Dialysis | 2006 |
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.
Topics: Adolescent; Adult; Aged; Amlodipine; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome | 2006 |
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Biomarkers; Blood Glucose; Body Mass Index; Calcium Channel Blockers; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation; Insulin Resistance; Interleukin-6; Male; Middle Aged; Obesity; Pyrroles; Tablets; Tumor Necrosis Factor-alpha | 2006 |
High-dose atorvastatin after stroke or transient ischemic attack.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Proportional Hazards Models; Pyrroles; Risk; Secondary Prevention; Stroke | 2006 |
The CARDS trial: diabetic patients dealt a winning hand.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome | 2006 |
Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atorvastatin; Blood Coagulation; Blood Coagulation Factors; Coronary Artery Disease; Double-Blind Method; Evaluation Studies as Topic; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Quinapril; Risk Factors; Stroke; Tetrahydroisoquinolines; Time Factors | 2006 |
Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus.
Topics: Anti-Inflammatory Agents; Antioxidants; Arginine; Ascorbic Acid; Atorvastatin; Cytokines; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hyperemia; Male; Middle Aged; Pyrroles; Regional Blood Flow; Single-Blind Method; Vitamins | 2007 |
Bioavailability of amlodipine besylate/atorvastatin calcium combination tablet.
Topics: Adolescent; Adult; Amlodipine; Atorvastatin; Biological Availability; Cross-Over Studies; Drug Combinations; Female; Health; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Tablets | 2006 |
Treatment of hypercholesterolemia in patients with metabolic syndrome: how do different statins compare?
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Metabolic Syndrome; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
The effects of atorvastatin on coronary endothelial function in patients with recent myocardial infarction.
Topics: Acetylcholine; Analysis of Variance; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Angiography; Coronary Vessels; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Pyrroles; Regression Analysis; Time Factors | 2006 |
Anti-inflammatory effects of atorvastatin: modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Biomarkers; Heptanoic Acids; Humans; Male; Middle Aged; Nitric Oxide Synthase Type III; Polymorphism, Genetic; Proteins; Pyrroles; Single-Blind Method | 2007 |
[Effectiveness and tolerance of atorvastatin for antiretroviral therapy-secondary dyslipemia].
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atorvastatin; Female; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles | 2006 |
Change in circulating C-reactive protein is not associated with atorvastatin treatment in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cognition; Coronary Artery Disease; Heptanoic Acids; Humans; Middle Aged; Neuropsychological Tests; Placebos; Prognosis; Pyrroles; Vasculitis | 2006 |
Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Hispanic or Latino; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2006 |
Effects of statins on bone mineral density.
Topics: Anticholesteremic Agents; Atorvastatin; Bone Density; Calcium; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lumbar Vertebrae; Male; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Prospective Studies; Pyrroles; Turkey | 2006 |
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors | 2006 |
eNOS gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite.
Topics: Adolescent; Adult; Amino Acid Substitution; Atorvastatin; Cyclic GMP; Heptanoic Acids; Humans; Male; Malondialdehyde; Middle Aged; Nitric Oxide Synthase Type III; Nitrites; Polymorphism, Genetic; Pyrroles; Thiobarbiturates | 2006 |
In vivo coronary plaque histology in patients with stable and acute coronary syndromes: relationships with hyperlipidemic status and statin treatment.
Topics: Acute Disease; Aged; Angina, Unstable; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherectomy, Coronary; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Glycophorins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunohistochemistry; Male; Middle Aged; Pravastatin; Pyrroles | 2007 |
Effect of atorvastatin on ocular blood flow velocities in patients with diabetic retinopathy.
Topics: Atorvastatin; Blood Flow Velocity; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Double-Blind Method; Eye; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Ophthalmic Artery; Pyrroles; Retinal Artery; Triglycerides | 2007 |
Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet.
Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Area Under Curve; Atorvastatin; Biological Availability; Cross-Over Studies; Dietary Fats; Disorders of Excessive Somnolence; Dose-Response Relationship, Drug; Drug Combinations; Female; Food-Drug Interactions; Half-Life; Headache; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Tablets; Therapeutic Equivalency | 2006 |
Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia.
Topics: Adiponectin; Aged; Atorvastatin; Bezafibrate; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2007 |
The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase.
Topics: Adult; Aged; Anticholesteremic Agents; Antioxidants; Apolipoproteins; Aryldialkylphosphatase; Atorvastatin; Cholesterol Ester Transfer Proteins; Female; Heptanoic Acids; Humans; Lipoproteins, HDL; Male; Middle Aged; Phosphatidylcholine-Sterol O-Acyltransferase; Pyrroles | 2007 |
Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study.
Topics: Aged; Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Cardiac Surgical Procedures; Cerebrovascular Disorders; Female; Heart Diseases; Heptanoic Acids; Humans; Length of Stay; Male; Middle Aged; Postoperative Complications; Pyrroles | 2006 |
Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission platelet aggregometry.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atorvastatin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Light; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Pyrroles; Surgical Procedures, Operative; Thrombelastography; Ticlopidine | 2006 |
Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation.
Topics: Adult; Apolipoproteins; Atorvastatin; Body Mass Index; Creatinine; Cross-Over Studies; Drug Therapy, Combination; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunosuppressive Agents; Kidney Transplantation; Lipids; Male; Middle Aged; Pyrroles; Tacrolimus; Triglycerides | 2006 |
Beneficial effect of statins in multiple sclerosis: is it dose-dependent?
Topics: Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Lovastatin; Multiple Sclerosis; Pyrroles; Simvastatin; Treatment Outcome | 2007 |
Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Prospective Studies; Pyrroles; Renal Dialysis; Triglycerides | 2006 |
Plasma-soluble CD40 is related to cholesterol metabolism in patients with moderate hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; CD40 Antigens; Cholesterol; Cholesterol, Dietary; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles; Severity of Illness Index; Simvastatin; Solubility | 2006 |
Pharmacokinetic and bioequivalence testing of atorvastatin formulations in healthy male volunteers.
Topics: Adolescent; Adult; Area Under Curve; Atorvastatin; Biotransformation; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Cross-Over Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mass Spectrometry; Middle Aged; Pyrroles; Therapeutic Equivalency | 2006 |
Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-C
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiotonic Agents; Cell Adhesion Molecules; Coronary Disease; E-Selectin; Heart Injuries; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Intercellular Adhesion Molecule-1; Multicenter Studies as Topic; Pyrroles; Vascular Cell Adhesion Molecule-1 | 2006 |
[Randomized FARVATER Study. Part 1. Effect of 10 and 20 mg/day atorvastatin on levels of lipids, C-reactive protein, and fibrinogen in patients with ischemic heart disease and hyperlipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Male; Mass Screening; Middle Aged; Pyrroles | 2006 |
Increased soluble Fas plasma levels in subjects at high cardiovascular risk: Atorvastatin on Inflammatory Markers (AIM) study, a substudy of ACTFAST.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus; Dose-Response Relationship, Drug; Fas Ligand Protein; fas Receptor; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Factors | 2007 |
Atorvastatin effect on circulating and leukocyte-produced CD40 ligand concentrations in people with normal cholesterol levels: a pilot study.
Topics: Adult; Atorvastatin; CD40 Ligand; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes; Male; Pyrroles; Triglycerides | 2006 |
Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Age Distribution; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Risk Reduction Behavior; Stroke | 2006 |
Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fatty Alcohols; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2006 |
[Effects of atorvastatin and acipimox on the lipid spectrum of blood plasma, endothelial function and a clinical course of unstable angina pectoris].
Topics: Angina, Unstable; Atorvastatin; Brachial Artery; Cholesterol, LDL; Drug Therapy, Combination; Endothelium, Vascular; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pyrazines; Pyrroles; Treatment Outcome; Vasodilation | 2006 |
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
Topics: Adult; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Quinolines | 2006 |
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.
Topics: Aged; Atorvastatin; Cerebrovascular Disorders; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Drug Delivery Systems; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles | 2006 |
Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention.
Topics: Adult; Atorvastatin; Coronary Disease; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins, LDL; Male; Middle Aged; Neutrophils; Primary Prevention; Pyrroles; Superoxides; Zymosan | 2006 |
Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Myocardial Ischemia; Pyrroles; Quinolines; Research Design; Syndrome | 2006 |
Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Chronic Disease; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fibrinogen; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Kidney Diseases; Lipid Metabolism; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Tissue Plasminogen Activator | 2006 |
Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Coronary Syndrome; Aged; Atorvastatin; Autoantibodies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin G; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 2008 |
Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Administration Schedule; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Spain | 2006 |
[Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Delayed-Action Preparations; Drug Therapy, Combination; Female; Headache; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Niacin; Pyrroles; Treatment Outcome; Triglycerides | 2006 |
Effect of garlic powder on C-reactive protein and plasma lipids in overweight and smoking subjects.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Endothelium; Female; Garlic; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Overweight; Plant Extracts; Powders; Pyrroles; Smoking; Triglycerides | 2006 |
Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin | 2006 |
A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle.
Topics: Atorvastatin; Biomarkers; Computational Biology; Gene Expression; Gene Expression Profiling; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Muscle, Skeletal; Muscular Diseases; Pyrroles; Simvastatin; Systems Biology | 2006 |
[Atorvastatin in correction of metabolic syndrome: clinico-economical assessment of efficacy].
Topics: Atorvastatin; Costs and Cost Analysis; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Treatment Outcome | 2006 |
Short-term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia.
Topics: Aged; Alkaline Phosphatase; Anticholesteremic Agents; Atorvastatin; Biomarkers; Bone Remodeling; Collagen Type I; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Peptides; Pyrroles; Time Factors | 2007 |
Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Female; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Matched-Pair Analysis; Pyrroles | 2006 |
Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects.
Topics: Adult; Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Biphenyl Compounds; Compliance; Cross-Over Studies; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irbesartan; Male; Peptide Fragments; Pyrroles; Renin-Angiotensin System; Tetrazoles; Vasoconstriction; Veins | 2007 |
effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Atorvastatin; Bile; Binding, Competitive; Biological Transport; Cell Line; Cross-Over Studies; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infusions, Intravenous; Liver; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Pyrroles; Rifampin; Substrate Specificity; Tablets; Transfection | 2007 |
[Effect of different doses of atorvastatin on adhesion molecules of the patients undergoing percutaneous coronary intervention].
Topics: Aged; Atorvastatin; Female; Heptanoic Acids; Humans; Intercellular Adhesion Molecule-1; Male; Middle Aged; Percutaneous Coronary Intervention; Pyrroles | 2006 |
Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; F2-Isoprostanes; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2007 |
Effect of atorvastatin on type 2 diabetic dyslipidemia.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein B-100; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glutathione; Glutathione Peroxidase; Glutathione Transferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Pyrroles; Superoxide Dismutase; Time Factors; Treatment Outcome; Triglycerides | 2006 |
Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
Topics: Adult; Atorvastatin; Cholesterol, LDL; Delayed-Action Preparations; Drug Combinations; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Niacin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cognition; Double-Blind Method; Female; Heptanoic Acids; Humans; Kidney Diseases; Lipids; Male; Middle Aged; Neuropsychological Tests; Placebos; Predictive Value of Tests; Pyrroles; Regression Analysis | 2007 |
Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis.
Topics: Aged; Aspirin; Atorvastatin; Clopidogrel; Coronary Restenosis; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Prosthesis Failure; Pyrroles; Stents; Ticlopidine; Treatment Outcome | 2007 |
Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study.
Topics: Aged; Atorvastatin; Drug Delivery Systems; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Male; Middle Aged; Pyrroles | 2007 |
Drug designed to raise HDL levels falls down.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Drug Industry; Heart Diseases; Heptanoic Acids; Humans; Lipoproteins, HDL; Pyrroles; Quinolines | 2007 |
Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pravastatin; Pyrroles; Sex Characteristics | 2007 |
Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy.
Topics: Adult; alpha-Tocopherol; Atorvastatin; Biomarkers; Drug Combinations; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxycholesterols; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Ketocholesterols; Lipids; Lipoproteins; Male; Middle Aged; Models, Biological; Oxidative Stress; Pyrroles | 2007 |
Effects of atorvastatin and aspirin combined therapy on inflammatory responses in patients undergoing coronary artery bypass grafting.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antithrombins; Aspirin; Atorvastatin; Blood Platelets; Cholesterol; Coronary Artery Bypass; Cytokines; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Inflammation; Male; Middle Aged; P-Selectin; Pyrroles; Receptors, Cytokine; Thrombin; Thromboxane B2; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2006 |
Efficacy and safety of atorvastatin in South Asian patients with dyslipidemia: an open label noncomparative pilot study.
Topics: Asia; Asian People; Atorvastatin; Clinical Trials as Topic; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Patient Selection; Pilot Projects; Pyrroles; Treatment Outcome; United Kingdom | 2005 |
Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study).
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Retrospective Studies; Syndrome; Treatment Outcome | 2007 |
Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high-density lipoproteins.
Topics: Adult; Aged; Apolipoprotein A-I; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, HDL; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2007 |
[Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia].
Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Omega-3; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin | 2006 |
Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin.
Topics: Adult; Aged; Atorvastatin; DNA, Mitochondrial; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Mitochondria, Muscle; Pyrroles; Retrospective Studies; Simvastatin; Ubiquinone | 2007 |
Effect of atorvastatin on peripheral endothelial function and systemic inflammatory markers in patients with stable coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Brachial Artery; C-Reactive Protein; Coronary Disease; Double-Blind Method; E-Selectin; Endothelium, Vascular; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Middle Aged; Pyrroles; Vasodilation | 2007 |
The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress.
Topics: Adult; Aged; Antibodies; Atorvastatin; Biomarkers; C-Reactive Protein; Cell Adhesion Molecules; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipoproteins, LDL; Male; Middle Aged; Neopterin; Oxidative Stress; Pyrroles; Simvastatin; von Willebrand Factor | 2007 |
Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement.
Topics: Aged; Analysis of Variance; Atorvastatin; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Pyrroles; Quality of Life; Treatment Outcome; Urination Disorders | 2007 |
Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease.
Topics: Aged; Atorvastatin; C-Reactive Protein; Carotid Arteries; Carotid Artery Diseases; Coronary Disease; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-18; Interleukin-6; Interleukin-8; Lipids; Male; Middle Aged; Pyrroles; Tumor Necrosis Factor-alpha; Tunica Intima; Tunica Media | 2007 |
Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
Topics: Atorvastatin; Azetidines; Blood Chemical Analysis; Blood Platelets; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Probability; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome | 2007 |
Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease.
Topics: Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Colchicine; Coronary Angiography; Coronary Artery Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Pyrroles; Treatment Outcome | 2007 |
Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
Topics: Atorvastatin; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; PPAR alpha; Propionates; Pyrroles; Triazoles | 2007 |
Effect of torcetrapib on the progression of coronary atherosclerosis.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Ultrasonography, Interventional | 2007 |
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines | 2007 |
Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
Topics: Adult; Apolipoproteins B; Atorvastatin; Biomarkers; Coronary Disease; Drug Administration Schedule; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Nephelometry and Turbidimetry; Pyrroles; Simvastatin; Treatment Outcome | 2006 |
Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin.
Topics: Atorvastatin; Autoantibodies; Blood Platelets; Case-Control Studies; CD40 Ligand; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; In Vitro Techniques; Male; Middle Aged; NADPH Oxidases; Oxidative Stress; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Superoxides; Up-Regulation | 2007 |
The effects of quinapril and atorvastatin on the responsiveness to sildenafil in men with erectile dysfunction.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Impotence, Vasculogenic; Male; Middle Aged; Phosphodiesterase Inhibitors; Piperazines; Purines; Pyrroles; Quinapril; Sildenafil Citrate; Sulfones; Surveys and Questionnaires; Tetrahydroisoquinolines; Time Factors; Treatment Failure; Treatment Outcome | 2006 |
Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects.
Topics: Animals; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Dietary Fats; Dietary Fats, Unsaturated; Dietary Supplements; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fish Oils; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lipid Metabolism; Lipids; Lipoproteins, IDL; Lipoproteins, VLDL; Male; Middle Aged; Pyridines; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2007 |
Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial.
Topics: Adult; Aged; Atorvastatin; Female; Hepacivirus; Hepatitis C, Chronic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Pyrroles; Virus Replication | 2007 |
Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
Topics: Acute Disease; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Syndrome; Time Factors; Treatment Outcome | 2007 |
Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Endothelium, Vascular; Female; Fibrinolysis; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Time Factors; Vasodilation | 2008 |
Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome | 2007 |
Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.
Topics: Adolescent; Adult; Aged; Algorithms; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Models, Biological; Pyrroles; Quinolines; Research Design; Tunica Intima; Ultrasonography | 2007 |
Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholagogues and Choleretics; Fatty Liver; Female; Hematologic Agents; Hepatitis; Heptanoic Acids; Humans; Losartan; Male; Middle Aged; Pentoxifylline; Pyrroles; Treatment Outcome; Ursodeoxycholic Acid | 2007 |
Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Body Mass Index; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2007 |
Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Chemokine CCL2; Cholesterol; Diabetes Complications; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Inflammation; Intercellular Adhesion Molecule-1; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2007 |
Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia.
Topics: Atorvastatin; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Humans; Hypercholesterolemia; Insulin-Secreting Cells; Japan; Patient Compliance; Pravastatin; Pyrroles | 2007 |
Leukocyte and endothelial adhesion molecules in patients with hypercholesterolemia: the effect of atorvastatin treatment.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cell Adhesion Molecules; E-Selectin; Endothelial Cells; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Integrins; Intercellular Adhesion Molecule-1; L-Selectin; Leukocytes; Male; Matched-Pair Analysis; Middle Aged; Pyrroles; Reference Values; Statistics, Nonparametric; von Willebrand Factor | 2008 |
Statins alter oxidant-antioxidant status and lower exercise-induced oxidative stress.
Topics: Anticholesteremic Agents; Antioxidants; Ascorbic Acid; Atorvastatin; Exercise; Female; Heptanoic Acids; Humans; Hyperlipidemias; Isometric Contraction; Longitudinal Studies; Male; Middle Aged; Muscle Fibers, Skeletal; Oxidative Stress; Oxygen Consumption; Pyrroles; Reactive Oxygen Species; Thiobarbituric Acid Reactive Substances | 2007 |
[The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia].
Topics: Adult; Aged; Antioxidants; Atorvastatin; Catalase; Dyslipidemias; Erythrocyte Membrane; Female; Glutathione Peroxidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Superoxide Dismutase; Treatment Outcome | 2006 |
[Compared with atorvastatin at the dose of 10 mg per day rosuvastatin was more effective to reach an LDL goal of < 1.00 g/l in high cardiovascular risk patients (ARIANE study)].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
Prophylactic statins as a possible method to decrease bubble formation in diving.
Topics: Adult; Atorvastatin; Chemoprevention; Decompression Sickness; Diving; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nitric Oxide; Pyrroles; Surface-Active Agents | 2007 |
Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Disease; Creatinine; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Managed Care Programs; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2007 |
[Effect of therapy with atorvastatin on parameters of postprandial lipemia and factors of inflammation in patients with ischemic heart disease].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemias; Inflammation; Lipids; Male; Myocardial Ischemia; Postprandial Period; Pyrroles; Treatment Outcome | 2007 |
[Randomized FARVATER study. Part 2. Effect of atorvastatin on endothelial function, distensibility and stiffness of vascular wall].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Vessels; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Myocardial Ischemia; Pyrroles | 2007 |
Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Atorvastatin; Cholesterol; Creatine Kinase; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides | 2007 |
Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoprotein B-48; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Kinetics; Male; Middle Aged; Pyrroles; Time Factors; Triglycerides | 2007 |
Effect of atorvastatin on progression of sensorineural hearing loss and tinnitus in the elderly: results of a prospective, randomized, double-blind clinical trial.
Topics: Aged; Atorvastatin; Audiometry; Auditory Threshold; Cholesterol; Cholesterol, LDL; Disease Progression; Double-Blind Method; Female; Hearing Loss, Sensorineural; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Presbycusis; Prospective Studies; Pyrroles; Speech Perception; Tinnitus; Treatment Outcome | 2007 |
Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia.
Topics: Adiponectin; Aged; Atorvastatin; Body Mass Index; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fenofibrate; Ghrelin; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Peptide Hormones; Pyrroles; Resistin | 2007 |
Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Apolipoprotein A-I; Asian People; Atorvastatin; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States | 2007 |
A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD.
Topics: Adult; Aged; Atorvastatin; Brachial Artery; Double-Blind Method; Elasticity; Endothelium, Vascular; Female; Gemfibrozil; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Insulin Resistance; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Treatment Outcome | 2007 |
Atorvastatin therapy improves exercise oxygen uptake kinetics in post-myocardial infarction patients.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Echocardiography; Exercise Test; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Oxygen Consumption; Pyrroles | 2007 |
Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study.
Topics: Aged; Atorvastatin; Atrial Natriuretic Factor; Disease-Free Survival; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyrroles; Stroke Volume; Ventricular Dysfunction, Left | 2007 |
Atorvastatin treatment and vaccination efficacy.
Topics: Adult; Antibody Formation; Anticholesteremic Agents; Atorvastatin; Cholesterol; Double-Blind Method; Drug Interactions; Female; Hepatitis A Antibodies; Hepatitis A Vaccines; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles | 2007 |
Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome.
Topics: Acute Disease; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Biomarkers; Coronary Artery Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Monocytes; Neopterin; Pravastatin; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Survival Analysis | 2007 |
Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Lipoproteins, HDL; Male; Middle Aged; Pilot Projects; Pyrroles | 2007 |
Effect of atorvastatin on energy expenditure and skeletal muscle oxidative metabolism at rest and during exercise.
Topics: Adult; Anaerobic Threshold; Atorvastatin; Cholesterol, LDL; Creatine Kinase; Double-Blind Method; Energy Metabolism; Exercise; Fatty Acids; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Middle Aged; Muscle, Skeletal; Oxidation-Reduction; Oxidative Phosphorylation; Oxygen Consumption; Pulmonary Gas Exchange; Pulmonary Ventilation; Pyrroles; Reference Values; Time Factors | 2008 |
Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
Topics: Adult; Atorvastatin; Canada; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance, Pharmaceutical Services; Male; Models, Economic; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Effect of statin therapy on early return of potency after nerve sparing radical retropubic prostatectomy.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Aged; Atorvastatin; Cyclic Nucleotide Phosphodiesterases, Type 5; Denervation; Drug Therapy, Combination; Erectile Dysfunction; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microsurgery; Middle Aged; Penile Erection; Peripheral Nerves; Piperazines; Postoperative Complications; Prospective Studies; Prostate; Prostatectomy; Prostatic Neoplasms; Purines; Pyrroles; Sildenafil Citrate; Sulfones; Vasodilator Agents | 2007 |
[The efficacy and safety of rosuvastatin on treating patients with hypercholesterolemia in Chinese: a randomized, double-blind, multi-center clinical trial].
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Asian People; Atorvastatin; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Young Adult | 2007 |
Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects.
Topics: Adult; Atorvastatin; Brachial Artery; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Oxidative Stress; Pyrroles; Salmonella typhi; Salmonella Vaccines; Systemic Inflammatory Response Syndrome; Vascular Diseases; Vasodilation | 2007 |
Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease.
Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Pyrroles; Treatment Outcome; Triglycerides | 2007 |
Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome | 2007 |
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Pressure; Carotid Arteries; Cholesterol; Double-Blind Method; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Quinolines; Tunica Intima | 2007 |
Testing the hypothesis of atherosclerotic plaque lipid depletion during lipid therapy by magnetic resonance imaging: study design of Carotid Plaque Composition Study.
Topics: Allylamine; Atherosclerosis; Atorvastatin; Carotid Stenosis; Colesevelam Hydrochloride; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipid Metabolism; Magnetic Resonance Imaging; Male; Middle Aged; Niacin; Prospective Studies; Pyrroles | 2007 |
Early effects of low versus high dose atorvastatin treatment on coagulation and inflammation parameters in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Atorvastatin; Blood Coagulation; C-Reactive Protein; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Pyrroles | 2008 |
Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial.
Topics: Atorvastatin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine | 2007 |
Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipids; Male; Middle Aged; Pyrroles; Triglycerides | 2007 |
Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX).
Topics: Adult; Aged; Amlodipine; Apolipoproteins B; Atorvastatin; Biomarkers; Blood Pressure; Brachial Artery; Calcium Channel Blockers; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Triglycerides; Ultrasonography; Vasodilation | 2008 |
Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Function Tests; Male; Middle Aged; Muscles; Myoglobin; Pyrroles; Ubiquinone; Vitamins | 2007 |
Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol.
Topics: Adult; Aged; Aged, 80 and over; Aryldialkylphosphatase; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Dose-Response Relationship, Drug; Double-Blind Method; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial.
Topics: Adult; Atorvastatin; Brachial Artery; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Pyrroles; Risk Factors; Severity of Illness Index; Ultrasonography; Vasodilation | 2007 |
The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
Topics: Adult; Alkanesulfonates; Anticholesteremic Agents; Atorvastatin; Chemotherapy, Adjuvant; Cross-Over Studies; Drug Combinations; Drug Synergism; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Phenylpropionates; Pioglitazone; Placebos; PPAR alpha; PPAR gamma; Pyrroles; Thiazolidinediones | 2007 |
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial.
Topics: Adult; Atorvastatin; Disability Evaluation; Double-Blind Method; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immune Tolerance; Immunization; Injections, Intramuscular; Lymphocyte Count; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Myelin Basic Protein; Oligonucleotide Array Sequence Analysis; Plasmids; Pyrroles; Recurrence; T-Lymphocytes; Vaccines, DNA | 2007 |
Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia.
Topics: Aged; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Enzyme Induction; Female; Heptanoic Acids; Herb-Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypericum; Intestinal Mucosa; Intestines; Liver; Male; Middle Aged; Plant Preparations; Pyrroles; Time Factors; Treatment Outcome; Triglycerides; Up-Regulation | 2007 |
Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
Topics: Age Factors; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Cohort Studies; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Assessment; Safety; Sex Factors; Stroke; Time Factors; Treatment Outcome | 2007 |
Mapping spatial and temporal changes in carotid atherosclerosis from three-dimensional ultrasound images.
Topics: Aged; Atherosclerosis; Atorvastatin; Carotid Artery, Common; Carotid Stenosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Pyrroles; Treatment Outcome; Ultrasonography | 2008 |
Statin treatment withdrawal in ischemic stroke: a controlled randomized study.
Topics: Acute Disease; Aged; Atorvastatin; Brain Ischemia; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neuroprotective Agents; Odds Ratio; Pyrroles; Risk Factors; Stroke; Survival Analysis; Time Factors; Treatment Outcome; Withholding Treatment | 2007 |
Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial.
Topics: Absorptiometry, Photon; Adult; Aged; Atorvastatin; Biomarkers; Bone and Bones; Bone Density; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Middle Aged; Postmenopause; Pyrroles; Spine | 2007 |
A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia.
Topics: Adolescent; Adult; Atorvastatin; Child; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2008 |
Statin therapy reduces serum levels of glycosylphosphatidylinositol-specific phospholipase D.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cell Line, Tumor; Cells, Cultured; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Liver; Male; Middle Aged; Phospholipase D; Pyrroles; Simvastatin; Triglycerides | 2007 |
Atorvastatin does not induce glomerular or tubular dysfunction even at high doses.
Topics: Acetylglucosaminidase; Adult; Aged; Atorvastatin; beta 2-Microglobulin; Creatinine; Cystatin C; Cystatins; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Function Tests; Kidney Tubules; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Pyrroles | 2007 |
Effects of atorvastatin on coronary flow reserve in patients with slow coronary flow.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Echocardiography, Doppler; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Triglycerides | 2007 |
Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Atorvastatin; Coronary Artery Bypass; Coronary Artery Disease; Coronary Circulation; Creatine Kinase; Dose-Response Relationship, Drug; E-Selectin; Enalapril; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Interleukin-6; Leukocyte Count; Male; Middle Aged; Platelet Count; Pyrroles; Ramipril; Simvastatin; Stroke Volume; Time Factors; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 2007 |
Effect of pioglitazone and its combination with statins in coronary artery disease patients with hyperinsulinemia.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol, HDL; Coronary Artery Disease; Diabetes Complications; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Antagonists; Male; Middle Aged; Pioglitazone; Pyrroles; Thiazolidinediones; Treatment Outcome | 2007 |
Randomised study to compare the efficacy and safety of isapgol plus atorvastatin versus atorvastatin alone in subjects with hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Psyllium; Pyrroles; Treatment Outcome | 2007 |
Effect of acute changes in oxygen tension on flow-mediated dilation. Relation to cardivascular risk.
Topics: Administration, Inhalation; Adult; Atorvastatin; Brachial Artery; Cardiovascular Diseases; Cholesterol; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hyperoxia; Hypoxia; Lipoproteins; Male; Middle Aged; Nitroglycerin; Oxygen; Pyrroles; Regional Blood Flow; Research Design; Risk Factors; Treatment Outcome; Triglycerides; Ultrasonography; Vasoconstriction; Vasodilation; Vasodilator Agents | 2008 |
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Tirofiban; Treatment Outcome; Tyrosine | 2007 |
Atorvastatin treatment in the short term: does it induce renoprotection or vasculoprotection in renal transplantation?
Topics: Adult; Aged; Atorvastatin; Blood Pressure; Cohort Studies; Dyslipidemias; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Proteinuria; Pyrroles; Transforming Growth Factor beta | 2007 |
Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins.
Topics: Anticholesteremic Agents; Arginine; Atherosclerosis; Atorvastatin; Cross-Sectional Studies; Dinoprost; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic | 2007 |
Stroke prediction and stroke prevention with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Pyrroles; Risk Factors; Stroke | 2007 |
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Multivariate Analysis; Pyrroles; Risk | 2007 |
Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Collagen; Coronary Disease; Diabetes Complications; Drug Resistance; Epinephrine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Pyrroles; Smoking | 2009 |
Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study).
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; England; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North Carolina; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2007 |
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Topics: Adult; Atorvastatin; Brachial Artery; Coronary Artery Disease; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Vasodilation; von Willebrand Factor | 2008 |
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Male; Middle Aged; Pyrroles | 2007 |
Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Endothelin-1; Endothelium, Vascular; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2007 |
Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Chylomicrons; Dietary Fats; Dietary Proteins; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, VLDL; Male; Middle Aged; Postprandial Period; Pyrroles; Quinolines | 2008 |
Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia: results from a crossover study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Coenzymes; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Quinolines; Triglycerides; Ubiquinone | 2008 |
Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation.
Topics: Adult; Aged; Atorvastatin; Cell Line; Cell Proliferation; Cholesterol; Cross-Over Studies; Double-Blind Method; Female; Femoral Artery; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocytes, Smooth Muscle; Pyrroles; Serum; Simvastatin | 2007 |
HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
Topics: Adult; Atorvastatin; C-Reactive Protein; Cardiomyopathy, Hypertrophic; Cholesterol, LDL; Double-Blind Method; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Ventricles; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Middle Aged; Pilot Projects; Pyrroles; Ventricular Dysfunction, Left | 2007 |
Effects of torcetrapib in patients at high risk for coronary events.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Mortality; Pyrroles; Quinolines | 2007 |
Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Pyrroles; Risk Factors; ROC Curve; Serum Amyloid A Protein; Stroke | 2008 |
Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Fibrinogen; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoprotein(a); Lipoproteins; Male; Middle Aged; Pyrroles; Renal Dialysis; Serum Albumin | 2008 |
[Effect of atorvastatin on carotid intima-medial of thickness of primary hypertension patients of Han nationality in China].
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzazepines; Carotid Arteries; China; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media | 2007 |
SPARCL: the glimmer of statins for stroke risk reduction.
Topics: Atorvastatin; Coronary Disease; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Stroke | 2007 |
Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men.
Topics: Adult; Anti-Obesity Agents; Apolipoprotein B-100; Atorvastatin; Cholesterol, VLDL; Drug Resistance; Genetic Variation; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Obesity; Pyrroles; Treatment Outcome | 2008 |
Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism.
Topics: Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Cholesterol Ester Transfer Proteins; Drug Therapy, Combination; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Kinetics; Lipoproteins, VLDL; Male; Pyrroles; Quinolines; Single-Blind Method | 2008 |
Randomized evaluation of atorvastatin in patients with coronary heart disease: a serial intravascular ultrasound study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Ultrasonography, Interventional | 2007 |
Improvement in endothelium dysfunction in diabetics treated with statins: a randomized comparison of atorvastatin 20 mg versus rosuvastatin 10 mg.
Topics: Aged; Atorvastatin; C-Reactive Protein; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Regional Blood Flow; Rosuvastatin Calcium; Sulfonamides; Vasodilation | 2007 |
A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial.
Topics: Alanine Transaminase; Alkaline Phosphatase; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Aspartate Aminotransferases; Atorvastatin; Blood Pressure; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Hypertension; Male; Pyrroles; Treatment Outcome | 2007 |
Changes of CD4+CD25+ regulatory T cells in patients with acute coronary syndrome and the effects of atorvastatin.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Cytokines; Female; Flow Cytometry; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; T-Lymphocytes, Regulatory | 2007 |
Early decrease of oxidative stress by atorvastatin in hypercholesterolaemic patients: effect on circulating vitamin E.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Platelets; Cholesterol, LDL; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Isoprostanes; Male; Middle Aged; NADPH Oxidases; Oxidative Stress; Pyrroles; Superoxides; Vitamin E | 2008 |
Effects of statins on renal sodium and water handling: acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans.
Topics: Adult; Angiotensin II; Arginine Vasopressin; Atorvastatin; Atrial Natriuretic Factor; Blood Pressure; Cross-Over Studies; Diuresis; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Tubules; Male; Natriuresis; Natriuretic Peptide, Brain; Pyrroles; Renal Plasma Flow | 2008 |
Efficacy of atorvastatin when not administered daily.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides | 2007 |
[The antiplatelet effect of clopidogrel is not attenuated by statin treatment in patients with acute coronary syndromes undergone coronary stenting].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine | 2007 |
Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrroles; Sex Factors; Survival Analysis; Treatment Outcome; United States | 2008 |
Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cerebral Infarction; Cholesterol, LDL; Comorbidity; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Pyrroles; Risk Assessment; Secondary Prevention; Sex Factors | 2008 |
The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)-2 study.
Topics: Acetates; Atorvastatin; Calcinosis; Calcium Compounds; Chelating Agents; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Polyamines; Prospective Studies; Pyrroles; Reproducibility of Results; Sevelamer; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial
Topics: Acute Coronary Syndrome; Aged; Anti-Infective Agents; Atorvastatin; Biomarkers; Calgranulin A; Calgranulin B; Case-Control Studies; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pravastatin; Probability; Pyrroles; Reference Values; Risk Assessment; Survival Rate; Thrombolytic Therapy; Treatment Outcome | 2008 |
Pregnancy-associated plasma protein-A elevation in patients with acute coronary syndrome and subsequent atorvastatin therapy.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; C-Reactive Protein; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pregnancy-Associated Plasma Protein-A; Pyrroles | 2008 |
Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Middle Aged; Pyrroles; Quinolines; Triglycerides | 2007 |
Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiovascular Diseases; Coronary Artery Bypass; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Myocardial Infarction; Prospective Studies; Pyrroles | 2005 |
Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase; Polymorphism, Genetic; Pyrroles; Scavenger Receptors, Class E | 2008 |
Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black or African American; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome | 2008 |
Physicochemical modifications induced by statins therapy on human erythrocytes membranes.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Erythrocyte Membrane; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Peroxidation; Male; Membrane Fluidity; Membrane Lipids; Middle Aged; Pyrroles; Simvastatin; Sodium-Potassium-Exchanging ATPase; Triglycerides | 2007 |
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Epidemiologic Methods; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke | 2008 |
Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation.
Topics: Atorvastatin; Biomarkers; Electrocardiography; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Plasminogen Activator Inhibitor 1; Pyrroles; Time Factors; Tissue Plasminogen Activator; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 2009 |
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoprotein B-48; Atorvastatin; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hypertriglyceridemia; Kinetics; Leucine; Male; Middle Aged; Pyrroles; Triglycerides | 2008 |
Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil.
Topics: Adult; Anticholesteremic Agents; Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Calcium Channel Blockers; Cytochrome P-450 CYP3A; Drug Interactions; Heptanoic Acids; Humans; Male; Pyrroles; Verapamil | 2008 |
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study).
Topics: Anticholesteremic Agents; Asia; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2007 |
Effects of atorvastatin on red-blood cell Na(+)/Li(+) countertransport in hyperlipidemic patients with and without hypertension.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Biological Transport; Blood Pressure; Cholesterol; Dose-Response Relationship, Drug; Erythrocytes; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Insulin Resistance; Linear Models; Lithium; Male; Middle Aged; Pyrroles; Sodium; Triglycerides | 2008 |
A 6 month randomized, double blind, placebo controlled, multi-center trial of high dose atorvastatin on myocardial perfusion abnormalities by positron emission tomography in coronary artery disease.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Double-Blind Method; Heart; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Ischemia; Positron-Emission Tomography; Prospective Studies; Pyrroles | 2008 |
Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) and Aggrastat to Zocor (A to Z) trials.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents; Atorvastatin; Atrial Fibrillation; Dose-Response Relationship, Drug; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Pravastatin; Pyrroles; Thrombolytic Therapy; Tirofiban; Tyrosine | 2008 |
Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement.
Topics: Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Coronary Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Pyrroles; Simvastatin; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2008 |
High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial.
Topics: Aged; Ankle; Atorvastatin; Blood Pressure; Brachial Artery; Cardiovascular Diseases; Carotid Arteries; Disease Progression; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Peripheral Vascular Diseases; Pilot Projects; Prospective Studies; Pyrroles; Research Design; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography; Vasodilation | 2008 |
Polymorphism in KIF6 gene and benefit from statins after acute coronary syndromes: results from the PROVE IT-TIMI 22 study.
Topics: Atorvastatin; Cohort Studies; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Middle Aged; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Treatment Outcome | 2008 |
The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels.
Topics: Aged; Atorvastatin; Cell Count; Cholesterol, LDL; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Biomarkers; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Inflammation; Lipids; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pyrroles | 2008 |
[Effect of atorvastatin therapy on the level of secretory phospholipase A2 group IIA and on the modification of low density lipoproteins in patients with ischemic heart disease].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Group II Phospholipases A2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lecithins; Lipoproteins, LDL; Lysophosphatidylcholines; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Treatment Outcome; Triglycerides | 2007 |
[Immunoinflammatory factors in unstable angina. Possibility of influence of atorvastatin].
Topics: Angina, Unstable; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Inflammation; Interleukin-4; Male; Middle Aged; Pyrroles; T-Lymphocytes; Treatment Outcome; Tumor Necrosis Factor-alpha | 2007 |
The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Creatine Kinase; Dose-Response Relationship, Drug; Exercise; Exercise Test; Heptanoic Acids; Humans; Male; Middle Aged; Muscle, Skeletal; Pain; Pyrroles | 2008 |
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Triglycerides | 2008 |
Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes.
Topics: Adiponectin; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hyperlipidemias; Insulin Resistance; Leptin; Male; Middle Aged; Pyrroles | 2008 |
Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Creatinine; Diabetes Mellitus; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Peripheral Vascular Diseases; Prospective Studies; Pyrroles; Stroke | 2008 |
Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure.
Topics: Atorvastatin; Death, Sudden, Cardiac; Disease Progression; Female; Health Status Indicators; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyrroles; Risk Factors; Stroke Volume | 2008 |
Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2.
Topics: Apolipoproteins E; Atorvastatin; Biopsy; Cholesterol; Cholesterol, VLDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Male; Middle Aged; Pyrroles; Receptors, LDL; RNA, Messenger; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2 | 2008 |
Atorvastatin does not alter serum levels of sCD95 and sCD95L in multiple sclerosis.
Topics: Adolescent; Adult; Atorvastatin; Drug Therapy, Combination; Fas Ligand Protein; fas Receptor; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon beta-1b; Interferon-beta; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Pyrroles; Solubility; Treatment Outcome | 2008 |
Flexible initial dosing of atorvastatin based upon initial low-density lipoprotein cholesterol levels in type 2 diabetic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Brachial Artery; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Regional Blood Flow; Time Factors; Treatment Outcome | 2008 |
The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Probability; Pyrroles; Reference Values; Severity of Illness Index; Treatment Outcome | 2008 |
Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk.
Topics: Adiponectin; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Risk; Triglycerides | 2008 |
Statin therapy increases carotid plaque echogenicity in hypercholesterolemic patients.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Stenosis; Cholesterol; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-18; Interleukin-6; Male; Middle Aged; Pravastatin; Probability; Prospective Studies; Pyrroles; Simvastatin; Triglycerides; Tunica Intima; Ultrasonography | 2008 |
Effects of statin treatment on serum sex steroids levels and autonomic and erectile function.
Topics: Adult; Atorvastatin; Autonomic Nervous System; Follow-Up Studies; Gonadal Steroid Hormones; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Libido; Lipids; Male; Middle Aged; Penile Erection; Pyrroles | 2008 |
Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Drug Synergism; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypertrophy, Left Ventricular; Lipids; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Uric Acid; Ventricular Remodeling | 2008 |
Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
Topics: Aged; Atorvastatin; Bezafibrate; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Treatment Outcome; Triglycerides | 2008 |
Intensive lipid-lowering therapy ameliorates novel calcification markers and GSM score in patients with carotid stenosis.
Topics: Aged; Atorvastatin; Biomarkers; Blood Pressure; C-Reactive Protein; Calcinosis; Carotid Stenosis; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocyte Count; Male; Middle Aged; Osteopontin; Osteoprotegerin; Prospective Studies; Pyrroles; Severity of Illness Index; Treatment Outcome; Ultrasonography | 2008 |
Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis.
Topics: Adjuvants, Immunologic; Administration, Oral; Atorvastatin; Gadolinium; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-beta; Interleukins; Magnetic Resonance Imaging; Models, Biological; Multiple Sclerosis, Relapsing-Remitting; Multivariate Analysis; Pyrroles; Recurrence; Treatment Outcome | 2008 |
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Pyrroles; Risk; Triglycerides | 2008 |
A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study.
Topics: Acetates; Anticholesteremic Agents; Atorvastatin; Calcinosis; Calcium Compounds; Chelating Agents; Coronary Artery Disease; Disease Progression; Female; Heptanoic Acids; Humans; Male; Middle Aged; Polyamines; Prospective Studies; Pyrroles; Renal Dialysis; Sevelamer; Time Factors | 2008 |
Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.
Topics: Adipokines; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blood Glucose; Cross-Over Studies; Female; Glucose Intolerance; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Male; Middle Aged; Pravastatin; Pyrroles | 2008 |
Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Outcome Assessment, Health Care; Pyrroles; Sex Factors | 2008 |
Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure.
Topics: Arginine; Atorvastatin; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Ventricular Dysfunction, Left | 2008 |
Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study.
Topics: Aged; Atorvastatin; Canada; Cholesterol, LDL; Coronary Disease; European Union; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2008 |
The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-bl
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Benzaldehydes; Biomarkers; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukins; Male; Middle Aged; Oximes; Prognosis; Pyrroles; Recurrence; Risk Factors | 2008 |
The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Autoantibodies; Biomarkers; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Male; Middle Aged; Oxidative Stress; Phospholipids; Pravastatin; Pyrroles; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2008 |
High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) a
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Clopidogrel; Cytochrome P-450 Enzyme System; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Treatment Outcome | 2008 |
The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Systole; Time Factors; Treatment Outcome | 2008 |
Use of lipid-modulating drugs in complicated course of coronary heart disease.
Topics: Antithrombin III; Atorvastatin; Cholesterol, LDL; Coronary Disease; Echocardiography; Female; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Peptide Hydrolases; Pravastatin; Prothrombin; Pyrroles; Simvastatin; von Willebrand Factor | 2007 |
Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis preventi
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Body Mass Index; Body Weight; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrroles; Quinolines; Waist Circumference | 2008 |
Atorvastatin does not alter interferon Beta-induced changes of serum matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in patients with multiple sclerosis.
Topics: Adjuvants, Immunologic; Adult; Atorvastatin; Biomarkers; Central Nervous System; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Interferon beta-1b; Interferon-beta; Matrix Metalloproteinase 9; Multiple Sclerosis, Relapsing-Remitting; Pyrroles; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2008 |
Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Bypass; Coronary Artery Disease; Coronary Restenosis; Female; Graft Occlusion, Vascular; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2008 |
HMG-CoA reductase inhibitors deplete circulating classical and non-classical monocytes following human heart transplantation.
Topics: Adult; Aged; Atorvastatin; Cross-Sectional Studies; Down-Regulation; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrin alpha4; Leukocyte Count; Male; Middle Aged; Monocytes; Pravastatin; Pyrroles; Receptors, IgG; Up-Regulation | 2008 |
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Topics: Adult; Analysis of Variance; Atorvastatin; Chi-Square Distribution; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neurologic Examination; Pyrroles; Survival Analysis | 2008 |
Atorvastatin administration after percutaneous coronary intervention in patients with coronary artery disease and normal lipid profiles: impact on plasma adiponectin level.
Topics: Adiponectin; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Radioimmunoassay; Treatment Outcome | 2008 |
Plasma PCSK9 levels are significantly modified by statins and fibrates in humans.
Topics: Atorvastatin; Clofibric Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Receptors, LDL; Serine Endopeptidases | 2008 |
A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin.
Topics: Administration, Oral; Antiparkinson Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Purines; Pyrroles | 2008 |
Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.
Topics: Adult; Apolipoprotein C-III; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol; Cross-Over Studies; Double-Blind Method; Down-Regulation; Dyslipidemias; Fenofibrate; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Lipoproteins, VLDL; Male; Metabolic Syndrome; Middle Aged; Models, Biological; Pyrroles; Treatment Outcome; Triglycerides | 2008 |
Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Atorvastatin; Dinoprostone; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukotriene B4; Male; Matrix Metalloproteinase 9; Middle Aged; NF-kappa B; Pyrroles; Treatment Outcome | 2008 |
Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Atorvastatin; Biomarkers; C-Reactive Protein; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon beta-1b; Interferon-beta; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Pyrroles | 2008 |
Atorvastatin prevents atrial fibrillation in patients with bradyarrhythmias and implantation of an atrial-based or dual-chamber pacemaker: a prospective randomized trial.
Topics: Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; Bradycardia; Cardiac Pacing, Artificial; Combined Modality Therapy; Confidence Intervals; Echocardiography, Doppler; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Pacemaker, Artificial; Probability; Proportional Hazards Models; Prospective Studies; Pyrroles; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study.
Topics: Adrenergic beta-Agonists; Adult; Albuterol; Atorvastatin; Biomarkers; Blood Glucose; Cholesterol; Curcumin; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Oxidative Stress; Pyrroles; Triglycerides | 2008 |
Effects of statin on small dense low-density lipoprotein cholesterol and remnant-like particle cholesterol in heterozygous familial hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Models, Biological; Pyrroles; Quinolines; Regression Analysis; Triglycerides | 2008 |
The antiplatelet effect of atorvastatin in patients with acute coronary syndrome depends on the hs-CRP level.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atorvastatin; C-Reactive Protein; Clopidogrel; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2008 |
Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
Topics: Apolipoprotein A-I; Atorvastatin; Blood Pressure; Cholesterol; Data Interpretation, Statistical; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Male; Middle Aged; Pyrroles; Reproducibility of Results; Sex Characteristics; Sex Factors; Stroke; Treatment Outcome; Triglycerides | 2008 |
Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Pilot Projects; Pyrroles | 2008 |
The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Indans; Lipids; Male; Middle Aged; Piperidines; Pyrroles | 2008 |
Efficacy of atorvastatin for achieving cholesterol targets after LDL-cholesterol based dose selection in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Feasibility Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2008 |
Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Dose-Response Relationship, Drug; F2-Isoprostanes; Female; Heptanoic Acids; Humans; Inflammation; Male; Matrix Metalloproteinase 9; Metabolic Syndrome; Middle Aged; Monocytes; NF-kappa B; Oxidative Stress; Polyethylene; Pyrroles; Superoxides; Tyrosine | 2008 |
A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density li
Topics: Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Enzyme Inhibitors; Female; Follow-Up Studies; Glucose Intolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrroles; Quinolines; Time Factors; Treatment Outcome | 2008 |
Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases.
Topics: Aged; Atorvastatin; Blood Platelets; Cholesterol; Combined Modality Therapy; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; P-Selectin; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2008 |
Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins.
Topics: Atorvastatin; Chromatography, Liquid; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Mass Spectrometry; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery.
Topics: Aged; Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Coronary Artery Bypass, Off-Pump; Elective Surgical Procedures; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Natriuretic Peptide, Brain; Peptide Fragments; Postoperative Complications; Premedication; Prospective Studies; Pyrroles | 2008 |
Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Cell Count; Combined Modality Therapy; Endothelial Cells; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2008 |
Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Risk; Treatment Outcome; United States | 2008 |
Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2008 |
Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Homocysteine; Humans; Hyperhomocysteinemia; Metabolic Clearance Rate; Polycystic Ovary Syndrome; Pyrroles; Retrospective Studies; Simvastatin; Treatment Outcome | 2009 |
Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study.
Topics: Adult; Anti-HIV Agents; Atorvastatin; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Heptanoic Acids; HIV Infections; HIV-1; Humans; Male; Neopterin; Pilot Projects; Pyrroles; Viral Load | 2008 |
The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Coronary Angiography; Coronary Restenosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Inflammation Mediators; Interleukin-6; Male; Middle Aged; Probability; Pyrroles; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome; Tumor Necrosis Factor-alpha | 2008 |
Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvas
Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Topics: Atorvastatin; Double-Blind Method; Female; Fingers; Health Status; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pain; Pain Measurement; Pyrroles; Raynaud Disease; Scleroderma, Systemic; Severity of Illness Index; Skin Ulcer; Surveys and Questionnaires; Treatment Outcome | 2008 |
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials).
Topics: Atorvastatin; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Care; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Syndrome; Thrombolytic Therapy; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2008 |
Effects of atorvastatin 80 mg daily on indices of matrix remodelling in 'high-risk' patients with ischemic heart disease.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 1; Myocardial Ischemia; Pyrroles; Risk Factors; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2010 |
Effects of atorvastatin added to inhaled corticosteroids on lung function and sputum cell counts in atopic asthma.
Topics: Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adult; Anti-Asthmatic Agents; Asthma; Atorvastatin; Biomarkers; Chronic Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Forced Expiratory Volume; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Sputum; Vital Capacity | 2008 |
Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Pravastatin; Pyrroles; Treatment Outcome | 2008 |
Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg).
Topics: Aged; Aortic Valve; Aortic Valve Stenosis; Atorvastatin; C-Reactive Protein; Calcinosis; Cholesterol; Disease Progression; Female; Heart Valve Prosthesis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Prospective Studies; Pyrroles; Risk Factors; Tomography, X-Ray Computed | 2008 |
The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastrointestinal Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ireland; Male; Middle Aged; Muscular Diseases; Practice Guidelines as Topic; Pyrroles; Time Factors; Treatment Outcome; United Kingdom | 2008 |
Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes.
Topics: Adiponectin; Adult; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Protein Multimerization; Pyrroles | 2009 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Prospective Studies; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome | 2008 |
Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
Topics: Adult; Amides; Animals; Antifungal Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Line; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Female; Fumarates; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ketoconazole; Male; Organic Anion Transporters; Pyrroles; Renin; Tissue Distribution; Young Adult | 2008 |
Effect of atorvastatin on LDL & hs-CRP in a selected Thai population.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Thailand; Treatment Outcome | 2008 |
Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease.
Topics: Atorvastatin; Coronary Artery Disease; Coronary Vessels; Disease Progression; Elasticity; Female; Health Status Indicators; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyrroles; Risk Factors; Vascular Resistance | 2008 |
Discovery Belux: comparison of rosuvastatin with atorvastatin in hypercholesterolaemia.
Topics: Atorvastatin; Belgium; Cholesterol, LDL; Female; Fluorobenzenes; Health Status Indicators; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Logistic Models; Male; Markov Chains; Middle Aged; Models, Statistical; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyrroles; Treatment Outcome | 2009 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Incidence; Lisinopril; Male; Metabolic Syndrome; Middle Aged; Prevalence; Pyrroles; Risk Factors | 2008 |
Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease.
Topics: Adult; Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Chemokine CCL8; Crohn Disease; CX3C Chemokine Receptor 1; Female; Follow-Up Studies; Gene Expression Regulation; Heptanoic Acids; Humans; Leukocyte L1 Antigen Complex; Lipopolysaccharide Receptors; Male; Monocytes; Pyrroles; Receptors, CCR2; Receptors, Chemokine; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Tumor Necrosis Factor-alpha; Young Adult | 2008 |
Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Double-Blind Method; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cause of Death; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Inflammation; Middle Aged; Placebos; Predictive Value of Tests; Pyrroles; Renal Dialysis; Survival Rate; Treatment Outcome; Young Adult | 2008 |
Ezetimibe 5 and 10 mg for lowering LDL-C: potential billion-dollar savings with improved tolerability.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Dose-Response Relationship, Drug; Ezetimibe; Female; Heptanoic Acids; Hospitals, Veterans; Humans; Hypercholesterolemia; Male; Pyrroles | 2008 |
How to reach LDL targets quickly in patients with diabetes or metabolic syndrome.
Topics: Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome | 2008 |
Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion.
Topics: Acetaminophen; Acute-Phase Reaction; Anticholesteremic Agents; Atorvastatin; Bone Density Conservation Agents; C-Reactive Protein; Child; Diphosphonates; Female; Heptanoic Acids; Humans; Infusions, Intravenous; Male; Oxycodone; Pain; Placebos; Pyrroles | 2009 |
Atorvastatin therapy is associated with reduced levels of N-terminal prohormone brain natriuretic peptide and improved cardiac function in patients with heart failure.
Topics: Atorvastatin; Echocardiography; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoassay; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Protein Precursors; Pyrroles; Retrospective Studies; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2008 |
Vascular and metabolic response to statin in the mildly hypertensive hypercholesterolemic elderly.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Pyrroles; Regional Blood Flow; Severity of Illness Index; Vasodilation | 2008 |
Long-term economic outcomes associated with intensive versus moderate lipid-lowering therapy in coronary artery disease: results from the Treating to New Targets (TNT) Trial.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Hospital Costs; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medicare; Middle Aged; Myocardial Revascularization; Outcome Assessment, Health Care; Prospective Studies; Pyrroles; United States | 2008 |
The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study.
Topics: Adult; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Polycystic Ovary Syndrome; Pyrroles; Testosterone | 2009 |
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk.
Topics: Aged; Atherosclerosis; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Carotid Artery, Common; Double-Blind Method; Drug Therapy, Combination; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Microcirculation; Middle Aged; Pioglitazone; Prospective Studies; Pyrroles; Radial Artery; Risk Assessment; Skin; Thiazolidinediones; Treatment Outcome; Ultrasonography | 2008 |
Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Aged; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Risk Assessment; Risk Factors; Secondary Prevention; Stroke; Time Factors; Treatment Outcome; Triglycerides | 2009 |
Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Triglycerides | 2009 |
Atorvastatin increases erythropoietin-stimulating agent hyporesponsiveness in maintenance hemodialysis patients: role of anti-inflammation effects.
Topics: Aged; Anemia; Atorvastatin; Drug Synergism; Erythropoietin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Recombinant Proteins; Renal Dialysis; Tumor Necrosis Factor-alpha | 2009 |
Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Glycemic Index; Heptanoic Acids; Humans; Hypoglycemic Agents; India; Male; Metformin; Middle Aged; Pyrroles | 2008 |
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Viral Load | 2008 |
[Comparative assessment of antiinflammatory action of atorvastatin in ischemic heart disease and rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Prospective Studies; Pyrroles; Treatment Outcome | 2008 |
Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study)
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Artery Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Reoperation | 2008 |
Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Body Size; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Placebos; Pyrroles | 2009 |
Effect of omega-3-acid ethyl esters on steady-state plasma pharmacokinetics of atorvastatin in healthy adults.
Topics: Adult; Atorvastatin; Fatty Acids, Omega-3; Female; Health; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles | 2008 |
Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia.
Topics: Adipokines; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Combined Modality Therapy; Diet, Carbohydrate-Restricted; Diet, Fat-Restricted; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Lipids; Liver; Male; Middle Aged; Pyrroles; Treatment Outcome | 2008 |
Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.
Topics: Adolescent; Adult; Anticholesteremic Agents; Area Under Curve; Atorvastatin; Chromatography, Liquid; Clopidogrel; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Interactions; Epistaxis; Heptanoic Acids; Humans; Liver; Male; Metabolic Clearance Rate; Middle Aged; Molecular Structure; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrroles; Tandem Mass Spectrometry; Thiophenes; Ticlopidine; United Kingdom; Young Adult | 2008 |
Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pyrroles; Risk Assessment; Risk Factors; Treatment Outcome | 2008 |
Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Assessment; Treatment Outcome | 2008 |
Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosi
Topics: Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Disease Progression; Female; Heptanoic Acids; Humans; Lipoproteins, HDL; Male; Middle Aged; Potassium; Pyrroles; Quinolines; Sodium; Ultrasonography | 2008 |
Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Cholesterol Ester Transfer Proteins; Female; Heptanoic Acids; Humans; Male; Middle Aged; Mineralocorticoids; Pyrroles; Quinolines | 2008 |
Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; CD40 Ligand; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Inflammation; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Triglycerides | 2008 |
Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Carotid Artery Diseases; Carotid Stenosis; Chemokine CCL2; Cholesterol, LDL; Drug Synergism; Female; Heptanoic Acids; Humans; Hypertension; Macrophages; Male; Middle Aged; NF-kappa B; Pyrroles; RNA, Messenger | 2008 |
Short-term effect of atorvastatin on endothelial function in healthy offspring of parents with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Atorvastatin; Blood Flow Velocity; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Male; Pyrroles; Vasodilation; Young Adult | 2008 |
Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway.
Topics: Adult; Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, HDL2; Lipoproteins, HDL3; Liver; Male; Mice; Mice, Inbred C57BL; Middle Aged; Pyrroles; Quinolines; Scavenger Receptors, Class B; Time Factors; Treatment Outcome | 2009 |
Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure.
Topics: Atorvastatin; Chronic Disease; Electrocardiography; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Long QT Syndrome; Pyrroles; Treatment Outcome; Ventricular Function, Left | 2010 |
Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers.
Topics: Absorption; Adult; Aged; Atorvastatin; Biomarkers; Cholesterol; Diabetes Complications; Female; Fluorobenzenes; Glycated Serum Albumin; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Phytosterols; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serum Albumin; Sterols; Sulfonamides | 2009 |
Glomerular filtration rate and blood pressure are unchanged by increased sodium intake in atorvastatin-treated healthy men.
Topics: Adult; Aldosterone; Angiotensin II; Aquaporin 2; Atorvastatin; Atrial Natriuretic Factor; Blood Pressure; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney Function Tests; Lithium; Male; Natriuretic Peptide, Brain; Pyrroles; Renin; Sodium; Vasopressins | 2009 |
Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia.
Topics: Adult; Aged; Amlodipine; Arteries; Atorvastatin; Compliance; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Placebos; Pyrroles | 2009 |
Importance of Rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Angiotensin II; Animals; Atorvastatin; Cells, Cultured; Cross-Over Studies; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Leukocytes; Male; Pravastatin; Pyrroles; Quinolines; rac1 GTP-Binding Protein; ras Proteins; Rats; Rats, Inbred WKY; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction | 2009 |
Superior benefit of aggressive lipid-lowering therapy for high- risk patients using statins: the SUBARU study--more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
(TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients.
Topics: Aged; Alleles; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Pyrroles; Triglycerides; Trinucleotide Repeats | 2009 |
[Atorvastatin in treatment of patients with coronary heart disease and dislipidemiya and high general risk: efficiency and safety estimation. Design and main results of ATLANTIKA].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Research Design; Risk Factors; Safety; Time Factors; Treatment Outcome; Triglycerides | 2008 |
Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia.
Topics: Adiponectin; Adult; Aged; Atorvastatin; Biomarkers; Brachial Artery; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation Mediators; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents | 2009 |
Effect of intensive lipid-lowering therapy on telomere erosion in endothelial progenitor cells obtained from patients with coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Cell Count; Cells, Cultured; Cholesterol; Coronary Artery Disease; Endothelial Cells; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Single-Blind Method; Stem Cells; Telomere | 2009 |
[Impact of statins on clopidogrel platelet inhibition in patients with acute coronary syndrome or stable angina].
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angina Pectoris; Atorvastatin; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Pravastatin; Prospective Studies; Pyrroles; Ticlopidine | 2008 |
The comparison of the effects of standard 20 mg atorvastatin daily and 20 mg atorvastatin every other day on serum LDL-cholesterol and high sensitive C-reactive protein levels.
Topics: Analysis of Variance; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Drug Administration Schedule; Female; Health Care Costs; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Statistics, Nonparametric; Treatment Outcome | 2008 |
Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) Study.
Topics: Aorta; Atorvastatin; Blood Pressure; Brachial Artery; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Placebos; Pulsatile Flow; Pyrroles; Radial Artery; Treatment Outcome | 2009 |
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Recurrence; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study.
Topics: Amlodipine; Analysis of Variance; Atorvastatin; Calcium Channel Blockers; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Life Style; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome | 2009 |
Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2009 |
Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome | 2009 |
Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?
Topics: Atorvastatin; Cholesterol, LDL; Creatine Kinase; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis.
Topics: Aged; Arrhythmias, Cardiac; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Kaplan-Meier Estimate; Male; Middle Aged; Practice Guidelines as Topic; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2009 |
Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the Incremental Decrease In End-points Through Aggressive Lipid-lowering Trial (IDEAL).
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Predictive Value of Tests; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Canada; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Female; Heptanoic Acids; Humans; Male; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2008 |
Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Atrial Natriuretic Factor; Cholesterol; Echocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Natriuretic Peptide, Brain; Prospective Studies; Pyrroles; Stroke Volume; Triglycerides; Ventricular Remodeling | 2009 |
Statins inhibit Rho kinase activity in patients with atherosclerosis.
Topics: Aged; Atherosclerosis; Atorvastatin; C-Reactive Protein; Cholesterol; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Placebos; Pyrroles; rho-Associated Kinases; Signal Transduction; Time Factors | 2009 |
Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment.
Topics: Aged; Atherosclerosis; Atorvastatin; Biomarkers; Blood Coagulation; Carotid Artery Diseases; Coronary Disease; Cross-Sectional Studies; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Myocardial Infarction; Plasma; Pyrroles; Sample Size; Thrombosis; Ultrasonography | 2009 |
Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics.
Topics: Administration, Oral; Adult; Anticoagulants; Area Under Curve; Atorvastatin; Benzimidazoles; Cross-Over Studies; Dabigatran; Dose-Response Relationship, Drug; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyridines; Pyrroles; Sex Factors; Thrombin | 2009 |
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Middle Aged; Oxazolidinones; Pyrroles; Treatment Outcome | 2009 |
Effects of cholesteryl ester transfer protein inhibition on apolipoprotein A-II-containing HDL subspecies and apolipoprotein A-II metabolism.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Heptanoic Acids; Humans; Placebos; Pyrroles; Quinolines | 2009 |
Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event.
Topics: Aged; Atherosclerosis; Atorvastatin; Brachial Artery; Cholesterol, LDL; Double-Blind Method; Endothelium, Vascular; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Regional Blood Flow; rho-Associated Kinases; Rosuvastatin Calcium; Sulfonamides; White People | 2009 |
Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2009 |
Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study.
Topics: Aged; Anti-Arrhythmia Agents; Atorvastatin; Atrial Fibrillation; Double-Blind Method; Electric Countershock; Female; Heptanoic Acids; Humans; Male; Prospective Studies; Pyrroles; Secondary Prevention; Sweden; Treatment Outcome | 2009 |
Muscle microvascular dysfunction in central obesity is related to muscle insulin insensitivity but is not reversed by high-dose statin treatment.
Topics: Adolescent; Adult; Aged; Atorvastatin; Biological Transport; Blood Pressure; Double-Blind Method; Energy Metabolism; Exercise Test; Female; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Lipids; Male; Microcirculation; Middle Aged; Muscle, Skeletal; Obesity; Pyrroles | 2009 |
Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes.
Topics: Adiponectin; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Placebos; Pyrroles | 2009 |
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Dyslipidemias; Female; Follow-Up Studies; Glomerular Filtration Rate; Health Maintenance Organizations; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome | 2009 |
Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Factors | 2010 |
Qualitative and quantitative changes in coronary plaque associated with atorvastatin therapy.
Topics: Aged; Angioscopy; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Time Factors; Ultrasonography, Interventional | 2009 |
[Comparison of the effects of carbohydrate metabolism compensation and atorvastatin treatment on lipid metabolism and C-reactive protein in type 2 diabetes mellitus].
Topics: Atorvastatin; C-Reactive Protein; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Male; Middle Aged; Pyrroles | 2008 |
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes.
Topics: Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cerebral Hemorrhage; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Placebos; Proportional Hazards Models; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2009 |
Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Myocardial Infarction; Pyrroles; Simvastatin | 2009 |
Coronary heart disease benefits from blood pressure and lipid-lowering.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Coronary Disease; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Risk Factors; Risk Reduction Behavior; Sodium Chloride Symporter Inhibitors | 2009 |
Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
Topics: Administration, Oral; Adult; Area Under Curve; Atorvastatin; Blood Glucose; Carbamates; Cross-Over Studies; Drug Interactions; Female; Gemfibrozil; Genotype; Half-Life; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Piperidines; Polymorphism, Genetic; Pyrroles | 2008 |
Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques: a 2-year follow-up by noninvasive MRI.
Topics: Aged; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Aortography; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Angiography; Male; Middle Aged; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome | 2009 |
Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients.
Topics: Acute-Phase Proteins; Adult; Anticholesteremic Agents; Atorvastatin; Blood Glucose; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Ferritins; Fibrinogen; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Time Factors | 2009 |
Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Placebos; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides; White People | 2009 |
Placebo-controlled trial of high-dose atorvastatin in patients with severe cerebral small vessel disease.
Topics: Aged; Atorvastatin; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Databases, Factual; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Risk Factors; Stroke; Treatment Outcome; Vasodilation | 2009 |
Plasma tetrahydrobiopterin/dihydrobiopterin ratio: a possible marker of endothelial dysfunction.
Topics: Aged; Atorvastatin; Biomarkers; Biopterins; Brachial Artery; Cardiovascular Diseases; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Risk Assessment; Risk Factors; Ultrasonography; Vasodilation | 2009 |
Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Chi-Square Distribution; Dose-Response Relationship, Drug; Electrophoresis, Gel, Two-Dimensional; Female; Gene Expression; Gene Expression Profiling; Heat-Shock Proteins; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Monocytes; Pyrroles; Statistics, Nonparametric; Tandem Mass Spectrometry; Thrombosis | 2009 |
Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein.
Topics: Atorvastatin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Heptanoic Acids; High-Density Lipoproteins, Pre-beta; Humans; Male; Middle Aged; Phospholipid Transfer Proteins; Pyrroles; Triglycerides | 2009 |
Adherence-adjusted efficacy with intensive versus standard statin therapy in patients with acute myocardial infarction in the IDEAL study.
Topics: Aged; Atorvastatin; Confounding Factors, Epidemiologic; Drug Prescriptions; Europe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Odds Ratio; Proportional Hazards Models; Prospective Studies; Pyrroles; Research Design; Risk Assessment; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2009 |
Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Triglycerides | 2009 |
Pediatric Atorvastatin in Diabetes Trial (PADIT): a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Child; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Patient Compliance; Peripheral Vascular Diseases; Pilot Projects; Placebos; Pyrroles; Radial Artery; Vascular Resistance; Young Adult | 2009 |
Phenotyping of cytochrome P450 3A enzyme in Gujarat population.
Topics: Adult; Atorvastatin; Cytochrome P-450 CYP3A; Female; Gene Frequency; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Isoenzymes; Male; Phenotype; Polymorphism, Genetic; Pyrroles; Young Adult | 2008 |
Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE
Topics: Acute Coronary Syndrome; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Seasons | 2009 |
Atorvastatin improves arterial stiffness in normotensive normolipidaemic persons with type 2 diabetes.
Topics: Adult; Aged; Ankle; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Blood Flow Velocity; Blood Pressure; Body Mass Index; Brachial Artery; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pulsatile Flow; Pyrroles; Treatment Outcome | 2008 |
Effect of atorvastatin on microRNA 221 / 222 expression in endothelial progenitor cells obtained from patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Endothelial Cells; Female; Heptanoic Acids; Humans; Male; MicroRNAs; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Single-Blind Method; Statistics as Topic; Stem Cells | 2009 |
Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Heptanoic Acids; Humans; Korea; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Single-Blind Method; Sirolimus; Ticlopidine; Time Factors | 2009 |
Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Female; Fibrin Fibrinogen Degradation Products; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Recurrence; Risk; Tissue Plasminogen Activator | 2009 |
Effects of statins on the pharmacokinetics of midazolam in healthy volunteers.
Topics: Adult; Area Under Curve; Atorvastatin; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypnotics and Sedatives; Japan; Male; Midazolam; Pyrroles; Quinolines; Simvastatin | 2009 |
Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall.
Topics: Aged; Aged, 80 and over; Aortic Aneurysm, Abdominal; Atorvastatin; Cell Proliferation; Dendritic Cells; Female; Heptanoic Acids; Humans; Inflammation; JNK Mitogen-Activated Protein Kinases; Male; Matrix Metalloproteinases; Middle Aged; Muscle, Smooth, Vascular; Pyrroles; Tissue Inhibitor of Metalloproteinase-1 | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Canada; Cardiovascular Diseases; Drug Combinations; Dyslipidemias; Europe; Female; Heptanoic Acids; Humans; Hypertension; Lipid Metabolism; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Tablets; Treatment Outcome | 2009 |
Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial.
Topics: Aged; Antihypertensive Agents; Aspirin; Atherosclerosis; Atorvastatin; Combined Modality Therapy; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Pyrroles; Renal Artery; Renal Artery Obstruction; Stents | 2009 |
Comparative effect of atorvastatin (80 mg) versus simvastatin (20 to 40 mg) in preventing hospitalizations for heart failure in patients with previous myocardial infarction.
Topics: Atorvastatin; Female; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2009 |
Effect of exposure to small pharmaceutical promotional items on treatment preferences.
Topics: Adult; Atorvastatin; Attitude of Health Personnel; Clinical Competence; Drug Industry; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Marketing of Health Services; Organizational Policy; Pyrroles; Simvastatin; Students, Medical; Young Adult | 2009 |
Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years.
Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Confidence Intervals; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Pyrroles; Risk | 2009 |
Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Risk Factors; Secondary Prevention; Stroke; Treatment Outcome; Triglycerides; Young Adult | 2009 |
[Effect of various approaches to therapy with statins in high risk patients from the point of view of vascular endothelium].
Topics: Aged; Atorvastatin; Brachial Artery; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Risk Factors; Treatment Outcome; Ultrasonography; Vasodilation | 2009 |
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.
Topics: Adult; Anticholesteremic Agents; Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cross-Over Studies; Drug Resistance, Multiple; Female; Finland; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Linear Models; Male; Neoplasm Proteins; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Reference Values; Rosuvastatin Calcium; Sulfonamides; White People | 2009 |
The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Carotid Arteries; Carotid Stenosis; Contrast Media; Dextrans; Double-Blind Method; Female; Ferrosoferric Oxide; Heptanoic Acids; Humans; Inflammation; Iron; Macrophages; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Middle Aged; Nanoparticles; Oxides; Pyrroles | 2009 |
Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients.
Topics: Acids; Adult; Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cytochrome P-450 CYP3A; DNA; Female; Gastric Bypass; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Middle Aged; Obesity, Morbid; Prospective Studies; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardia
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Autoantibodies; Biomarkers; Cholesterol, LDL; Cohort Studies; Female; Heptanoic Acids; Humans; Immunoglobulin G; Immunoglobulin M; Inflammation; Lipoprotein(a); Male; Middle Aged; Oxidation-Reduction; Phospholipids; Pyrroles; Reactive Oxygen Species; Risk Factors; Thromboembolism | 2009 |
Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Young Adult | 2009 |
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study).
Topics: Adolescent; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome; Young Adult | 2009 |
Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Aged; Albuminuria; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2009 |
Platelet aggregation inhibition in patients receiving statins either fully or partially metabolized by CYP3A4.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Cytochrome P-450 CYP3A; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Simvastatin; Thrombosis; Ticlopidine | 2008 |
Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Double-Blind Method; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ticlopidine | 2009 |
Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study).
Topics: Atherosclerosis; Atorvastatin; Diabetes Mellitus, Type 2; Glucose Intolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Quinolines; Treatment Outcome | 2009 |
Population analyses of atorvastatin clearance in patients living in the community and in nursing homes.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Cross-Sectional Studies; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nursing Homes; Pyrroles; Residence Characteristics; Sex Factors | 2009 |
[The statin dosage for achieving goal of cholesterol-lowering based on risk stratification in patients with ischemic cerebrovascular diseases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cystatins; Cysteine Proteinase Inhibitors; Heptanoic Acids; Humans; Ischemic Attack, Transient; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome; Young Adult | 2009 |
The influence of atorvastatin on walking performance in peripheral arterial disease.
Topics: Aged; Anticholesteremic Agents; Arterial Occlusive Diseases; Atorvastatin; Cholesterol, LDL; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Double-Blind Method; Exercise Test; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Intermittent Claudication; Male; Middle Aged; Pyrroles; Statistics, Nonparametric; Walking | 2009 |
Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2009 |
Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Baroreflex; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Pressoreceptors; Pyrroles | 2009 |
Rationale and design of assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction (the ALPS-AMI) study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Prospective Studies; Pyrroles; Research Design | 2009 |
Atorvastatin improves endothelial function and cardiac performance in patients with dilated cardiomyopathy: the role of inflammation.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Cardiomyopathy, Dilated; Cholesterol; Double-Blind Method; Endothelium, Vascular; Exercise; Exercise Test; Female; Heart Function Tests; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Intercellular Adhesion Molecule-1; Male; Middle Aged; Myocardial Contraction; Prospective Studies; Pyrroles; Vasodilation; Ventricular Function, Left; Young Adult | 2009 |
Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Combined Modality Therapy; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Treatment Outcome | 2009 |
Three-dimensional ultrasound quantification of intensive statin treatment of carotid atherosclerosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Carotid Artery, Common; Carotid Stenosis; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Interpretation, Computer-Assisted; Male; Middle Aged; Pyrroles; Tunica Intima; Tunica Media; Ultrasonography | 2009 |
Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Cross-Over Studies; Drug Synergism; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Prospective Studies; Pyrroles; Severity of Illness Index; Single-Blind Method | 2011 |
Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome.
Topics: Atorvastatin; Cross-Over Studies; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Lipoprotein(a); Lipoproteins, HDL; Male; Metabolic Syndrome; Nephelometry and Turbidimetry; Placebos; Pyrroles | 2009 |
Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Dose-Response Relationship, Drug; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Pyrroles; Treatment Outcome | 2009 |
Identification of genetic variants associated with response to statin therapy.
Topics: Acute Coronary Syndrome; Apolipoproteins E; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Cholesterol, LDL; Haplotypes; Heptanoic Acids; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Phenotype; Polymorphism, Genetic; Practice Guidelines as Topic; Pravastatin; Pyrroles; Treatment Outcome | 2009 |
Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Atorvastatin; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyridines; Pyrimidines; Pyrones; Pyrroles; Ritonavir; Rosuvastatin Calcium; Sulfonamides; Young Adult | 2009 |
Efficacy and safety of atorvastatin during early hospitalization in elderly patients with unstable angina.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Heptanoic Acids; Hospitalization; Humans; Inflammation Mediators; Length of Stay; Lipids; Male; Middle Aged; Pyrroles; Treatment Outcome | 2009 |
Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS).
Topics: Adult; Atorvastatin; C-Reactive Protein; Drug Synergism; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Pyrroles; Testosterone | 2010 |
Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults.
Topics: Adult; Aged; Aging; Atorvastatin; Blood Flow Velocity; C-Reactive Protein; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Double-Blind Method; Elasticity; Female; Femoral Artery; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Obesity; Overweight; Pyrroles; Regional Blood Flow; Risk Factors | 2009 |
Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Prospective Studies; Pyrroles; Troponin I | 2009 |
Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study.
Topics: Adenosine Diphosphate; Aged; Aspirin; Atorvastatin; Clopidogrel; Comorbidity; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, LDL; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Complications; Prospective Studies; Pyrroles; Ticlopidine | 2010 |
Effects of atorvastatin on carotid atherosclerotic plaques: a randomized trial for quantitative tissue characterization of carotid atherosclerotic plaques with integrated backscatter ultrasound.
Topics: Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Carotid Stenosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diffusion Magnetic Resonance Imaging; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Magnetic Resonance Angiography; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pyrroles; Rupture; Severity of Illness Index; Time Factors; Treatment Outcome; Triglycerides; Ultrasonography | 2009 |
Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins A; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Lipid Metabolism; Male; Middle Aged; Niacin; Pyrroles | 2009 |
Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT).
Topics: Aged; Amlodipine; Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure Determination; Carotid Arteries; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Probability; Prospective Studies; Pulsatile Flow; Pyrroles; Reproducibility of Results; Scandinavian and Nordic Countries; Severity of Illness Index; United Kingdom; Vasodilator Agents | 2009 |
Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Ultrasonography, Interventional | 2009 |
Statins have beneficial effects on platelet free radical activity and intracellular distribution of GTPases in hyperlipidaemia.
Topics: Adult; Aged; Atorvastatin; Blood Platelets; Double-Blind Method; Free Radicals; GTP Phosphohydrolases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Nitric Oxide; Pyrroles; rac GTP-Binding Proteins; rho GTP-Binding Proteins; Superoxides | 2010 |
[The use of atorvastatin in patients with rheumatoid arthritis with hyperlipidemia].
Topics: Administration, Oral; Adult; Aged; Arthritis, Rheumatoid; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Treatment Outcome; Vascular Resistance | 2009 |
[Atorvastatin attenuated contrast induced renal function damage].
Topics: Acute Kidney Injury; Aged; Atorvastatin; Contrast Media; Coronary Angiography; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles | 2009 |
[Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography].
Topics: Aged; Atorvastatin; Contrast Media; Coronary Angiography; Female; Heptanoic Acids; Humans; Kidney Diseases; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles | 2009 |
[Effects of different statin regimens on lipid profile and serum metalloproteinases in patients with coronary heart disease].
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Metalloproteases; Middle Aged; Pyrroles; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome; Young Adult | 2009 |
Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; China; Cholesterol, LDL; Dose-Response Relationship, Drug; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Prospective Studies; Pyrroles; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2009 |
Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Inflammation; Male; Prospective Studies; Pyrroles; Renal Dialysis | 2009 |
Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment.
Topics: Atorvastatin; Blood Vessels; Cardiovascular Diseases; Cholestasis; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver Cirrhosis, Biliary; Male; Middle Aged; Prospective Studies; Pyrroles | 2010 |
A multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study).
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Cross-Over Studies; Dehydroepiandrosterone; Diabetes Mellitus, Type 2; Drug Administration Schedule; Estradiol; Ezetimibe; Female; Heptanoic Acids; Humans; Hydrocortisone; Luminescent Measurements; Male; Middle Aged; Prospective Studies; Pyrroles; Statistics, Nonparametric; Testosterone; Treatment Outcome | 2009 |
Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Pyrroles; Triglycerides | 2010 |
Pleiotropic effects of atorvastatin on monocytes in atherosclerotic patients.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Administration, Oral; Anticholesteremic Agents; Apoptosis; Atherosclerosis; Atorvastatin; CD13 Antigens; Coronary Disease; Cysteine Endopeptidases; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Gene Expression; Heptanoic Acids; Humans; Lipid Metabolism; Male; Matrix Metalloproteinase 1; Middle Aged; Monocytes; Prolyl Oligopeptidases; Pyrroles; Receptors, Leptin; Reverse Transcriptase Polymerase Chain Reaction; Serine Endopeptidases; Time Factors; Treatment Outcome | 2010 |
Effect of preoperative atorvastatin therapy on atrial fibrillation following off-pump coronary artery bypass grafting.
Topics: Administration, Oral; Aged; Atorvastatin; Atrial Fibrillation; Biomarkers; C-Reactive Protein; Coronary Artery Bypass, Off-Pump; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Odds Ratio; Preoperative Care; Pyrroles; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2009 |
The SLCO1B1*5 genetic variant is associated with statin-induced side effects.
Topics: Aged; Atorvastatin; Creatine Kinase; Female; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Simvastatin | 2009 |
Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized control study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiopulmonary Bypass; Cholesterol; Cross-Over Studies; Cytokines; Double-Blind Method; Endothelial Cells; Female; Flow Cytometry; Hematopoietic Stem Cells; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Time Factors | 2010 |
Usefulness of aggressive lipid-lowering therapy with rosuvastatin in hypercholesterolemic patients with concomitant type 2 diabetes.
Topics: Aged; Atorvastatin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Stenosis; Cerebrovascular Disorders; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Osteopontin; Osteoprotegerin; Prospective Studies; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Doppler | 2010 |
Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Atorvastatin; Canada; Cardiovascular Diseases; Confidence Intervals; Cost of Illness; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Health Care Costs; Heptanoic Acids; Hospitalization; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Markov Chains; Middle Aged; Myocardial Infarction; Probability; Pyrroles; Risk Assessment; Simvastatin; Survival Rate; Treatment Outcome | 2009 |
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Dual effect of statin medication on the periodontium.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Dental Plaque; Female; Gingivitis; Heptanoic Acids; Humans; Immunomodulation; Male; Middle Aged; Periodontal Index; Periodontal Pocket; Periodontium; Pyrroles; Regression Analysis; Risk Factors; Simvastatin | 2009 |
The influence of atorvastatin on parameters of inflammation and function of the left ventricle in patients with dilated cardiomyopathy.
Topics: Aged; Atorvastatin; Cardiomyopathy, Dilated; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-10; Interleukin-6; Lipids; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Pyrroles; Time Factors; Tumor Necrosis Factor-alpha; Ventricular Function, Left | 2009 |
[Effects of probucol, aspirin and atorvastatin combination therapy upon atherosclerosis].
Topics: Aged; Aspirin; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Male; Matrix Metalloproteinase 9; Middle Aged; Probucol; Pyrroles | 2009 |
Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis I
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Pyrroles | 2009 |
Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atorvastatin; Blood Platelets; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Thromboxane A2; Treatment Outcome | 2009 |
Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia.
Topics: Antioxidants; Atorvastatin; Biomarkers; Blood Platelets; Blotting, Western; Case-Control Studies; Cholesterol; Combined Modality Therapy; Cross-Sectional Studies; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunoprecipitation; Isoprostanes; Leukocytes, Mononuclear; Male; Membrane Glycoproteins; Middle Aged; NADPH Oxidase 2; NADPH Oxidases; Pyrroles; Time Factors; Treatment Outcome | 2010 |
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
SWiss Atorvastatin and interferon Beta-1b trial In Multiple Sclerosis (SWABIMS)--rationale, design and methodology.
Topics: Adjuvants, Immunologic; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Interferon beta-1b; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Pyrroles; Secondary Prevention; Switzerland | 2009 |
Assessment of arterial stiffness affected by atorvastatin in coronary artery disease using pulse wave velocity.
Topics: Aged; Anticholesteremic Agents; Arteries; Atorvastatin; Compliance; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles | 2009 |
Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Demography; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Time Factors; Treatment Outcome; Young Adult | 2009 |
Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
Topics: Adolescent; Adult; Aged; Alleles; Anticholesteremic Agents; Apolipoprotein E3; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Regression Analysis; Simvastatin | 2008 |
Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort.
Topics: Adult; Aged; Apolipoproteins E; Atorvastatin; Cohort Studies; Coronary Disease; Female; Genome-Wide Association Study; Genotype; Heptanoic Acids; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases | 2009 |
Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial.
Topics: Adult; Aged; Arteries; Atorvastatin; Blood Pressure; Creatinine; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Placebos; Pyrroles; Regression Analysis | 2010 |
Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Pyrroles; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Disease-Free Survival; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome | 2010 |
Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects.
Topics: Adult; Alleles; Area Under Curve; Asian People; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Female; Genotype; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Korea; Lactones; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pyrroles; Young Adult | 2010 |
HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)--a pilot study.
Topics: Adolescent; Atorvastatin; Blood Pressure; Child; Child, Preschool; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Failure, Chronic; Lipids; Pilot Projects; Prospective Studies; Pyrroles; Treatment Outcome | 2010 |
Acute effects of atorvastatin on glomerular filtration rate, tubular function, blood pressure, and vasoactive hormones in patients with type 2 diabetes.
Topics: Adult; Aged; Atorvastatin; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules; Male; Middle Aged; Peptide Hormones; Pyrroles; Sodium | 2010 |
A multicenter study in Malaysia to determine the efficacy and safety of a generic atorvastatin.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Drugs, Generic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2009 |
Influence of atorvastatin on blood pressure control in treated hypertensive, normolipemic patients - An open, pilot study.
Topics: Adult; Antihypertensive Agents; Atorvastatin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cholesterol; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypertension; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Pilot Projects; Pyrroles; Triglycerides | 2010 |
Persistent regional diastolic dysfunction after myocardial ischemia and the effect of statin treatment: assessment with two-dimensional radial strain rate.
Topics: Angina Pectoris, Variant; Atorvastatin; Diastole; Exercise Test; Female; Fluorobenzenes; Heart; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Pyrimidines; Pyrroles; Reference Standards; Rosuvastatin Calcium; Sulfonamides; Ultrasonography; Ventricular Dysfunction, Left | 2010 |
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial.
Topics: Angina, Unstable; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Revascularization; Proportional Hazards Models; Pyrroles | 2009 |
Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection T
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Regression Analysis; Secondary Prevention; Stroke | 2009 |
[Comparison on long-term effects of atorvastatin or pravastatin combined with clopidogrel for patients undergoing coronary stenting: a randomized controlled trial].
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Ticlopidine; Time; Treatment Outcome; Young Adult | 2009 |
Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Coronary Restenosis; Diabetes Complications; Double-Blind Method; Drug Administration Schedule; Heart Diseases; Heart Failure; Heptanoic Acids; Humans; Metabolic Syndrome; Pyrroles; Risk Factors; Treatment Outcome | 2010 |
Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers; Contrast Media; Coronary Angiography; Creatinine; Female; Fluid Therapy; Heptanoic Acids; Humans; Male; Prospective Studies; Pyrroles; Renal Insufficiency, Chronic; Risk Factors | 2010 |
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation Mediators; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tablets; Time Factors; Treatment Outcome; Triglycerides; United States | 2009 |
Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Atorvastatin; Cholesterol; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Pyrroles; Stroke | 2010 |
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Biopsy; Body Mass Index; Dyslipidemias; Fatty Liver; Female; Follow-Up Studies; Glucose Tolerance Test; Glycation End Products, Advanced; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Reactive Oxygen Species; Tomography, X-Ray Computed; Young Adult | 2010 |
Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin.
Topics: Analysis of Variance; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Prescriptions; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Male; Middle Aged; Pyrroles; Treatment Outcome; United States | 2010 |
Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Chromosomes, Human, Pair 3; Female; Gene Deletion; Gene Frequency; Genotype; Heptanoic Acids; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Receptors, CCR; Receptors, CCR5; Retrospective Studies; Risk Factors; Simvastatin; Triglycerides | 2010 |
[Effects of atorvastatin, alone and in combination with probucol on endothelial function in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Middle Aged; Probucol; Pyrroles | 2009 |
[Effect of atorvastatin on postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting].
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Coronary Artery Bypass; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pyrroles; Risk Factors | 2009 |
Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cardiovascular Diseases; Female; Glomerular Filtration Rate; Heart Arrest; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipoproteins; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Pyrroles; Regression Analysis; Simvastatin | 2010 |
Comparison of the effects of atorvastatin and simvastatin in women with polycystic ovary syndrome: A prospective, randomized study.
Topics: Adult; Atorvastatin; C-Reactive Protein; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperandrogenism; Inflammation; Insulin; Insulin Resistance; Luteinizing Hormone; Oxidative Stress; Polycystic Ovary Syndrome; Prospective Studies; Pyrroles; Simvastatin; Testosterone; Young Adult | 2010 |
[Non-ST-elevation acute coronary syndrome. Comparison of effects of atorvastatin and rosuvastatin on blood levels of lipids and markers of inflammation].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Data Interpretation, Statistical; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Lipids; Lipoproteins; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Statistics, Nonparametric; Sulfonamides; Tumor Necrosis Factor-alpha | 2010 |
Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, LDL; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Glucose; Glycated Hemoglobin; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Black People; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Hispanic or Latino; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2010 |
Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
Topics: Adult; Anti-Inflammatory Agents; Atorvastatin; Chi-Square Distribution; Contrast Media; Disability Evaluation; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Interferon beta-1a; Interferon-beta; Longitudinal Studies; Magnetic Resonance Imaging; Male; Multiple Sclerosis, Relapsing-Remitting; Predictive Value of Tests; Pyrroles; Severity of Illness Index; Statistics, Nonparametric; Time Factors; Treatment Outcome | 2010 |
Achieving cholesterol targets by individualizing starting doses of statin according to baseline low-density lipoprotein cholesterol and coronary artery disease risk category: the CANadians Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titr
Topics: Adult; Aged; Atorvastatin; Canada; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome | 2010 |
Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Canada; Coronary Artery Disease; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; United States; Young Adult | 2010 |
Statins potently reduce the cytokine-mediated IL-6 release in SMC/MNC cocultures.
Topics: Aspirin; Atorvastatin; Cell Separation; Coculture Techniques; Dose-Response Relationship, Drug; Drug Synergism; Heptanoic Acids; HMGB1 Protein; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indomethacin; Interleukin-1; Interleukin-6; Leukocytes, Mononuclear; Lipopolysaccharides; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Pyrroles; Recombinant Proteins; Simvastatin; STAT3 Transcription Factor; Time Factors; Tumor Necrosis Factor-alpha | 2011 |
Lack of effect of 8 weeks atorvastatin on microvascular endothelial function in patients with systemic sclerosis.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cholesterol; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Scleroderma, Systemic; Time Factors; Vasodilation; Young Adult | 2010 |
Influence of co-existing atrial fibrillation on the efficacy of atorvastatin treatment in patients with dilated cardiomyopathy: a pilot study.
Topics: Adult; Aged; Atorvastatin; Atrial Fibrillation; Body Mass Index; Cardiomyopathy, Dilated; Echocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-10; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pilot Projects; Prospective Studies; Pyrroles; Tumor Necrosis Factor-alpha | 2010 |
Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Cholesterol, LDL; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Treatment Outcome | 2010 |
Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein C-III; Atorvastatin; Cholesterol, VLDL; Dietary Supplements; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Omega-3; Heptanoic Acids; Humans; Male; Middle Aged; Obesity, Abdominal; Pyrroles; Triglycerides | 2010 |
Distribution of traditional and novel risk factors and their relation to subsequent cardiovascular events in patients with acute coronary syndromes (from the PROVE IT-TIMI 22 trial).
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol; Cohort Studies; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2010 |
Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study).
Topics: Age Factors; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2010 |
Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes.
Topics: Aged; Antibodies; Aspirin; Atorvastatin; Cause of Death; Chi-Square Distribution; Death, Sudden; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Kidney Diseases; Logistic Models; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Factor 4; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2010 |
Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine.
Topics: Aged; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Drugs, Chinese Herbal; Female; Heptanoic Acids; Humans; Hyperlipidemias; Intercellular Adhesion Molecule-1; Male; Matrix Metalloproteinase 9; Medicine, Chinese Traditional; Middle Aged; P-Selectin; Pyrroles; Triglycerides | 2010 |
Atorvastatin attenuates oxidative stress in patients with chronic kidney disease.
Topics: Adult; Atorvastatin; Dinoprost; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoprostanes; Kidney Failure, Chronic; Male; Oxidative Stress; Placebos; Pyrroles | 2010 |
Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.
Topics: Atorvastatin; Blood Glucose; Cholesterol, LDL; Female; Fluorobenzenes; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperglycemia; Insulin; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2010 |
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Atorvastatin; Cholesterol, LDL; Cholinergic Antagonists; Double-Blind Method; Female; Heptanoic Acids; Hippocampus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Middle Aged; Organ Size; Pyrroles | 2010 |
Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cluster Analysis; Drug Combinations; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Internationality; Male; Middle Aged; Primary Prevention; Prospective Studies; Pyrroles; Research Design; Risk Assessment; Risk Factors; Surveys and Questionnaires | 2010 |
Atorvastatin increases blood ratios of vitamin E/low-density lipoprotein cholesterol and coenzyme Q10/low-density lipoprotein cholesterol in hypercholesterolemic patients.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Deoxyguanosine; Erythrocytes; Female; Glutathione; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Oxidative Stress; Pyrroles; Ubiquinone; Vitamin E | 2010 |
Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients.
Topics: Adult; Aged; Atorvastatin; Blood Glucose; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Insulin Resistance; Male; Middle Aged; Pyrroles; Treatment Outcome | 2010 |
Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Chi-Square Distribution; Clopidogrel; Coronary Angiography; Coronary Circulation; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Korea; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Recurrence; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
[Effects of atorfastatin on the cognitive function of patients with vascular cognitive impairment and different apolipoprotein E genotypes].
Topics: Aged; Apolipoproteins E; Atorvastatin; Cognition Disorders; Dementia, Vascular; Female; Genotype; Heptanoic Acids; Humans; Male; Middle Aged; Neuroprotective Agents; Pyrroles | 2010 |
Genome-wide association of lipid-lowering response to statins in combined study populations.
Topics: Adult; Aged; Atorvastatin; Bayes Theorem; Cholesterol; Female; Genome-Wide Association Study; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Simvastatin | 2010 |
Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers; China; Drug Tolerance; Electrocardiography; Heptanoic Acids; Humans; Korea; Premedication; Prospective Studies; Pyrroles; Treatment Outcome | 2010 |
Association between percutaneous coronary intervention and long-term C-reactive protein levels in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Atorvastatin; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Observation; Pravastatin; Pyrroles; Treatment Outcome | 2010 |
Full-dose atorvastatin versus conventional medical therapy after non-ST-elevation acute myocardial infarction in patients with advanced non-revascularisable coronary artery disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Italy; Male; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Recurrence; Treatment Outcome | 2010 |
A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of Korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg.
Topics: Adult; Aged; Algorithms; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Chemokine CCL2; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Epidemiologic Research Design; Female; Heptanoic Acids; Humans; Interleukin-6; Korea; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha; Young Adult | 2010 |
Comparison of effects of simvastatin versus atorvastatin on oxidative stress in patients with coronary heart disease.
Topics: Aged; Analysis of Variance; Atorvastatin; Biomarkers; Chi-Square Distribution; Coronary Disease; Diet, Fat-Restricted; Female; Glutathione; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Simvastatin; Superoxide Dismutase; Treatment Outcome | 2010 |
Efficacy of short-term high-dose atorvastatin for prevention of contrast-induced nephropathy in patients undergoing coronary angiography.
Topics: Acetylcysteine; Acute Kidney Injury; Adult; Atorvastatin; Contrast Media; Coronary Angiography; Creatinine; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2010 |
[Atorvastatin use and coronary flow reserve in patients with coronary slow flow].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Female; Fractional Flow Reserve, Myocardial; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles | 2010 |
Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus.
Topics: Adult; Atorvastatin; Chemokine CXCL9; Chemokines; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferons; Lupus Erythematosus, Systemic; Pyrroles; Severity of Illness Index | 2010 |
Hypouricemic effect of statins: another pleiotropic benefit?
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Coronary Artery Bypass; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperuricemia; Lipids; Pyrroles; Time Factors; Treatment Outcome; Uric Acid | 2010 |
Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.
Topics: Adult; Atorvastatin; Biotransformation; Cross-Over Studies; Drug Interactions; Enzyme Inhibitors; Female; Fenofibrate; Gemfibrozil; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lactones; Male; Middle Aged; Pyrroles | 2011 |
Atorvastatin reduces macrophage accumulation in atherosclerotic plaques: a comparison of a nonstatin-based regimen in patients undergoing carotid endarterectomy.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Cholestyramine Resin; Endarterectomy, Carotid; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lymphocyte Count; Macrophages; Male; Pyrroles; Sitosterols | 2010 |
Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2010 |
Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch.
Topics: Adult; Aged; Area Under Curve; Atorvastatin; Biliopancreatic Diversion; Biological Availability; Dose-Response Relationship, Drug; Duodenum; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestine, Small; Male; Middle Aged; Obesity, Morbid; Prospective Studies; Pyrroles | 2010 |
Low-dose versus moderate-dose atorvastatin after acute myocardial infarction: 8-month effects on coronary flow reserve and angiogenic cell mobilisation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Atorvastatin; Biomarkers; Cholesterol, LDL; Coronary Circulation; Cytokines; Dose-Response Relationship, Drug; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Middle Aged; Myocardial Infarction; Neovascularization, Physiologic; Pyrroles; Receptors, CXCR4; Stents; Young Adult | 2010 |
[Possibilities of atorvastatin in complex management of extensive psoriasis in patients with arterial hypertension].
Topics: Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Psoriasis; Pyrroles; Quality of Life; Severity of Illness Index; Skin; Treatment Outcome | 2010 |
Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin in Acut
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Coronary Artery Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2010 |
Efficacy of low dose atorvastatin in diabetic dyslipidaemia.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome | 2009 |
Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; General Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Treatment Outcome | 2010 |
Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?
Topics: Aged, 80 and over; Amlodipine; Angina, Stable; Antihypertensive Agents; Atorvastatin; Chronic Disease; Double-Blind Method; Drug Combinations; Electrocardiography, Ambulatory; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Young Adult | 2010 |
The economic consequences of non-adherence to lipid-lowering therapy: results from the Anglo-Scandinavian-Cardiac Outcomes Trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Cost-Benefit Analysis; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Markov Chains; Medication Adherence; Middle Aged; Pyrroles; Quality-Adjusted Life Years; Risk Factors | 2010 |
CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women.
Topics: Alleles; Asian People; Atorvastatin; China; Cytochrome P-450 CYP3A; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Prospective Studies; Pyrroles; Sex Factors; Simvastatin | 2011 |
Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Benzimidazoles; Benzoates; Cells, Cultured; Coronary Artery Disease; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; MicroRNAs; Middle Aged; Pyrroles; Renin-Angiotensin System; Signal Transduction; Single-Blind Method; Telmisartan; Toll-Like Receptor 4 | 2010 |
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol.
Topics: Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Triglycerides | 2010 |
Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Diseases; Lipoproteins, LDL; Male; Middle Aged; Particle Size; Probucol; Prospective Studies; Pyrroles; Young Adult | 2010 |
Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Uric Acid | 2010 |
Effects of atorvastatin and lisinopril on endothelial dysfunction in patients with Behçet's disease.
Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Behcet Syndrome; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Lisinopril; Male; Placebo Effect; Pyrroles; Treatment Outcome; Ultrasonography; Ventricular Dysfunction, Left | 2010 |
Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cytokines; Factor VII; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Metabolic Syndrome; Plasminogen Activator Inhibitor 1; Prediabetic State; Pyrroles | 2010 |
Effect of ezetimibe/atorvastatin combination on oxidized low density lipoprotein cholesterol in patients with coronary artery disease or coronary artery disease equivalent.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Treatment Outcome | 2010 |
Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplas
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antigens, CD; Atorvastatin; Cadherins; Cell Adhesion Molecules; Chi-Square Distribution; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Intercellular Adhesion Molecule-1; Italy; Male; Middle Aged; Myocardial Infarction; Myocardium; Placebo Effect; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome; Vascular Cell Adhesion Molecule-1 | 2010 |
Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; France; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Time Factors; Treatment Outcome; Triglycerides; Up-Regulation | 2010 |
Preoperative high-dose atorvastatin for prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Chi-Square Distribution; Coronary Artery Bypass; Drug Administration Schedule; Female; Heart Valve Prosthesis Implantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; London; Male; Middle Aged; Preoperative Care; Prospective Studies; Pyrroles; Regression Analysis; Risk Assessment; Risk Factors; Single-Blind Method; Time Factors; Treatment Outcome | 2011 |
Markers of cholesterol absorption and synthesis predict the low-density lipoprotein cholesterol response to atorvastatin.
Topics: Absorption; Aged; Atorvastatin; Biomarkers; Cholestanol; Cholesterol; Cholesterol, LDL; Desmosterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Prognosis; Prospective Studies; Pyrroles | 2010 |
A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Creatine Kinase; Decision Trees; Double-Blind Method; Exercise Test; Female; Health Status Indicators; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Isometric Contraction; Male; Motor Activity; Muscle Strength; Muscle Strength Dynamometer; Muscle Weakness; Muscle, Skeletal; Physical Endurance; Pyrroles; Research Design; Surveys and Questionnaires | 2010 |
Immediate effect of intensive atorvastatin therapy on lipid parameters in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Triglycerides | 2010 |
Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Platelets; C-Reactive Protein; Cell-Derived Microparticles; Cross-Over Studies; Diabetes Mellitus, Type 1; Double-Blind Method; Dyslipidemias; Fibrin; Fibrinolytic Agents; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrin beta3; Middle Aged; P-Selectin; Plasminogen Activator Inhibitor 1; Pyrroles; Sweden; Thrombin; Thromboplastin; Thrombosis; Time Factors; Treatment Outcome | 2010 |
Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40 mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial)
Topics: Aged; Atorvastatin; Denmark; Female; Finland; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Netherlands; Norway; Proportional Hazards Models; Prospective Studies; Pyrroles; Secondary Prevention; Simvastatin; Sweden; Treatment Outcome | 2010 |
Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Artery, Internal; Disease Progression; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reproducibility of Results; Tunica Intima; Ultrasonography | 2010 |
[A comparative study of the efficacy and safety Zhibitai and atorvastatin].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Drugs, Chinese Herbal; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles | 2010 |
A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Chronic Disease; Double-Blind Method; Drug Combinations; Enalapril; Female; Heptanoic Acids; Humans; Hydrochlorothiazide; Male; Middle Aged; Pilot Projects; Platelet Aggregation Inhibitors; Pyrroles; Risk Factors; Tablets | 2010 |
A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atorvastatin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Drug-Eluting Stents; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Prosthesis Design; Pyrroles; Switzerland; Ticlopidine; Time Factors; Treatment Outcome | 2010 |
More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome--sub-analysis of JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Treatment Outcome; Ultrasonography, Interventional | 2010 |
Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males.
Topics: Administration, Oral; Adult; Area Under Curve; Asian People; Atorvastatin; China; Cross-Over Studies; Drugs, Generic; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Tablets; Therapeutic Equivalency; Young Adult | 2010 |
Correlation between circulating adiponectin levels and coronary plaque regression during aggressive lipid-lowering therapy in patients with acute coronary syndrome: subgroup analysis of JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Adiponectin; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Logistic Models; Male; Middle Aged; Odds Ratio; Prospective Studies; Pyrroles; Quinolines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Triglycerides; Ultrasonography, Interventional; Up-Regulation | 2010 |
The effect of early and intensive statin therapy on ventricular premature beat or non-sustained ventricular tachycardia in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Chi-Square Distribution; China; Double-Blind Method; Drug Administration Schedule; Electrocardiography, Ambulatory; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Risk Assessment; Risk Factors; Tachycardia, Ventricular; Time Factors; Treatment Outcome; Ventricular Premature Complexes | 2010 |
On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study).
Topics: Acute Coronary Syndrome; Atorvastatin; C-Reactive Protein; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Risk Factors; Triglycerides | 2010 |
Short-term treatment with high-dose atorvastatin reduces LDL cholesterol but shows no anti-inflammatory effects in normolipidemic subjects with normal CRP levels.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Leukocytes; Male; Middle Aged; Pyrroles; Young Adult | 2010 |
The effect of statin therapy on stimulation of endothelium-derived nitric oxide before and after coronary artery bypass surgery.
Topics: Aged; Atorvastatin; Cardiopulmonary Bypass; Coronary Artery Bypass; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperemia; Intraoperative Period; Male; Middle Aged; Nitric Oxide; Nitroglycerin; Postoperative Care; Preoperative Care; Pyrroles; Vasodilator Agents | 2010 |
Lack of clopidogrel-statin interaction in patients undergoing coronary stent implantation.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Simvastatin; Ticlopidine | 2010 |
Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Carrier Proteins; Dose-Response Relationship, Drug; Enzymes; Female; Fluorobenzenes; Heptanoic Acids; Humans; Inflammation; Lipid Metabolism; Lipoproteins; Male; Maximum Tolerated Dose; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2010 |
No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin.
Topics: Adult; Amides; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Esters; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrroles; Sulfhydryl Compounds; Young Adult | 2010 |
Postoperative statin therapy attenuates the intensity of systemic inflammation and increases fibrinolysis after coronary artery bypass grafting.
Topics: Aged; Atorvastatin; Coronary Artery Bypass; Cytokines; Female; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Postoperative Complications; Pyrroles; Systemic Inflammatory Response Syndrome; Tissue Plasminogen Activator | 2011 |
Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Pyrroles; Simvastatin | 2010 |
Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome | 2010 |
Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome.
Topics: Adult; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Polycystic Ovary Syndrome; Pyrroles; Vitamin D | 2010 |
Effect of atorvastatin on chronic periodontitis: a randomized pilot study.
Topics: Adult; Alveolar Bone Loss; Anticholesteremic Agents; Atorvastatin; Chronic Periodontitis; Dental Plaque; Dental Scaling; Double-Blind Method; Female; Gingival Recession; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Pilot Projects; Pyrroles; Radiography, Dental, Digital; Statistics, Nonparametric; Tooth Mobility | 2010 |
Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: the prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronar
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Combined Modality Therapy; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stents; Sulfonamides; Ticlopidine | 2010 |
Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients.
Topics: Adiponectin; Aged; Antioxidants; Atorvastatin; Blood Platelets; Case-Control Studies; Cross-Sectional Studies; Female; Free Radicals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Membrane Glycoproteins; Middle Aged; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Pyrroles | 2010 |
Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease.
Topics: Adolescent; Adult; Age Factors; Aged; Atorvastatin; Azetidines; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Racial Groups; Risk Factors; Sex Factors; Treatment Outcome; Young Adult | 2011 |
Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity.
Topics: Aged; Atherosclerosis; Atorvastatin; Coronary Artery Bypass; Double-Blind Method; Enzyme Activation; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; NADPH Oxidases; Organ Culture Techniques; Oxidation-Reduction; Preoperative Care; Pyrroles; rac1 GTP-Binding Protein; Saphenous Vein; Superoxides | 2010 |
Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Antioxidants; Ascorbic Acid; Atorvastatin; California; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Pyrroles; Risk Assessment; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Vitamin D | 2011 |
J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial.
Topics: Adult; Aged; Antihypertensive Agents; Atorvastatin; Blood Pressure; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Arrest; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2010 |
Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
Topics: Acetates; Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Indoles; Keto Acids; Logistic Models; Male; Middle Aged; Phospholipases A2, Secretory; Prospective Studies; Pyrroles; Reference Values; Treatment Outcome | 2010 |
Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Circadian Rhythm; Cross-Over Studies; Diet, Ketogenic; Down-Regulation; Energy Intake; Fasting; Female; Heptanoic Acids; Human Growth Hormone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Receptors, LDL; Serine Endopeptidases; Sweden | 2010 |
A randomized placebo controlled trial of the effect of preoperative statin use on matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in areas of low and peak wall stress in patients undergoing elective open repair of abdominal ao
Topics: Aged; Aged, 80 and over; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Atorvastatin; Chi-Square Distribution; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; England; Female; Finite Element Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 8; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Middle Aged; Placebo Effect; Preoperative Care; Pyrroles; Stress, Mechanical; Time Factors; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinases; Treatment Outcome; Vascular Surgical Procedures | 2011 |
Steroids and statins: an old and a new anti-inflammatory strategy compared.
Topics: Anti-Inflammatory Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Methylprednisolone; Middle Aged; Pyrroles; Treatment Outcome; Ventricular Dysfunction, Left | 2011 |
Diabetic foot ulcer burden may be modified by high-dose atorvastatin: A 6-month randomized controlled pilot trial.
Topics: Aged; Ankle Brachial Index; Atorvastatin; Blood Pressure; C-Reactive Protein; Cost of Illness; Diabetic Foot; Dose-Response Relationship, Drug; Endpoint Determination; Female; Foot; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocyte Count; Lipids; Liver Function Tests; Male; Middle Aged; Pilot Projects; Pyrroles; Secondary Prevention; Wound Healing | 2009 |
Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome; Young Adult | 2010 |
Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial).
Topics: Aged; Atorvastatin; Atrial Fibrillation; Biomarkers; Double-Blind Method; Electric Countershock; Female; Follow-Up Studies; Heptanoic Acids; Humans; Inflammation Mediators; Male; Middle Aged; Oxidative Stress; Pyrroles; Treatment Outcome | 2011 |
Sympathoinhibition by atorvastatin in hypertensive patients.
Topics: Adolescent; Adult; Aged; Animals; Atorvastatin; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Norepinephrine; Prospective Studies; Pyrroles; Sympathetic Nervous System; Time Factors | 2010 |
Continuation of statin therapy in patients with presumed infection: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cholesterol; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Prospective Studies; Pyrroles; Sepsis; Severity of Illness Index; Treatment Outcome | 2011 |
Prevention of contrast-induced impairment of renal function by short-term or long-term statin therapy in patients undergoing elective coronary angiography.
Topics: Atorvastatin; Contrast Media; Coronary Angiography; Creatinine; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Pyrroles | 2010 |
Higher baseline LDL-C levels amplify the short-term benefit of early intensive statin treatment in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, LDL; Cohort Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Pyrroles; Treatment Outcome | 2011 |
Low-dose statin therapy improves endothelial function in type 2 diabetic patients with normal serum total cholesterol: a randomized placebo-controlled study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Brachial Artery; Cholesterol; Diabetes Mellitus, Type 2; Endothelium, Vascular; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Placebos; Pyrroles; Statistics, Nonparametric; Time Factors | 2010 |
Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Logistic Models; Male; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2010 |
[Effect of atorvastatin (liptonorm) on indicators of the lipid spectrum of blood in patients with the metabolic syndrome].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2010 |
Impact of atorvastatin and omega-3 ethyl esters 90 on plasma plant sterol concentrations and cholesterol synthesis in type 2 diabetes: a randomised placebo controlled factorial trial.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Docosahexaenoic Acids; Double-Blind Method; Drug Combinations; Eicosapentaenoic Acid; Heptanoic Acids; Humans; Lanosterol; Phytosterols; Pyrroles; Triglycerides | 2010 |
Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis.
Topics: Adiponectin; Adult; Aged; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Drug Therapy, Combination; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Methotrexate; Middle Aged; Prednisone; Pyrroles; Regional Blood Flow; Resistin; Risk Factors; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2011 |
Biomarker assessment of the immunomodulator effect of atorvastatin in stable renal transplant recipients and hypercholesterolemic patients.
Topics: Adenosine Triphosphate; Adult; Aged; Atorvastatin; Biomarkers; Cell Proliferation; Culture Media, Conditioned; Cytokines; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hypercholesterolemia; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Tacrolimus; Transplantation | 2010 |
Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia.
Topics: 3' Untranslated Regions; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Oxidative Stress; Platelet Activation; Polymorphism, Genetic; Prospective Studies; Prostaglandins A; Pyrimidines; Pyrroles; Regression Analysis; Rosuvastatin Calcium; Sulfonamides; Thromboxane B2 | 2011 |
What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TI
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Prognosis; Proportional Hazards Models; Pyrroles; Risk Factors; Thrombolytic Therapy; Treatment Outcome | 2010 |
Effect of different loading doses of atorvastatin on percutaneous coronary intervention for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Alanine Transaminase; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; C-Reactive Protein; Creatine Kinase, MB Form; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardium; Preoperative Care; Pyrroles; Treatment Outcome; Troponin I | 2010 |
Atorvastatin improves tubular status in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
Topics: Adult; Atorvastatin; Cross-Over Studies; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules; Male; Pyrroles; Renal Insufficiency, Chronic | 2010 |
Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients.
Topics: Aged; Aged, 80 and over; Arginine; Atherosclerosis; Atorvastatin; Brain Ischemia; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Linear Models; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Quinolines; Stroke | 2011 |
Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism.
Topics: Adult; Aged; Atorvastatin; Blood Glucose; C-Peptide; Carbohydrates; Drug Administration Schedule; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Lipids; Liver; Male; Middle Aged; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Triglycerides | 2011 |
Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drugs, Generic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Therapeutic Equivalency; Treatment Outcome; Young Adult | 2010 |
Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin.
Topics: Adolescent; Adult; Aged; Area Under Curve; Atorvastatin; Cross-Over Studies; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Thiophenes; Young Adult | 2011 |
[Atorvastatin in the treatment of high risk patients with ischemic heart disease and dyslipidemia. Safety assessment in the Russian Multicenter Study ATLANTIKA].
Topics: Acute Coronary Syndrome; Aged; Aspartate Aminotransferases; Atorvastatin; Comparative Effectiveness Research; Drug Dosage Calculations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Metabolic Networks and Pathways; Middle Aged; Monitoring, Physiologic; Pyrroles; Risk Assessment; Russia; Secondary Prevention; Treatment Outcome | 2010 |
Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles | 2010 |
Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men.
Topics: Adult; Atorvastatin; Cholesterol; Drug Administration Schedule; Duodenum; Gene Expression Regulation; Heptanoic Acids; Humans; Hyperlipidemias; Intestinal Mucosa; Intestines; Male; Membrane Proteins; Membrane Transport Proteins; Pyrroles; RNA, Messenger | 2011 |
Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heart Rate; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Smoking; Survival Rate; Treatment Outcome; United States | 2011 |
Effect of atorvastatin on lipoprotein (a) and interleukin-10: a randomized placebo-controlled trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Interleukin-10; Lipoprotein(a); Male; Middle Aged; Placebos; Pyrroles | 2011 |
Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Androgens; Anticholesteremic Agents; Atorvastatin; Blood Vessels; Double-Blind Method; Female; Heptanoic Acids; Humans; Inflammation; Placebos; Polycystic Ovary Syndrome; Pregnancy; Pyrroles; Young Adult | 2011 |
Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters.
Topics: Allopurinol; Atorvastatin; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidative Stress; Pyrroles; Regional Blood Flow; Treatment Outcome; Xanthine Oxidase | 2011 |
Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).
Topics: Albuminuria; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Drug Administration Schedule; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Kidney; Kidney Failure, Chronic; Male; Middle Aged; Placebos; Pyrroles; Treatment Outcome; United Kingdom | 2011 |
Functional dilator capacity is independently associated with insulin sensitivity and age in central obesity and is not improved by high dose statin treatment.
Topics: Acute Disease; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Female; Heptanoic Acids; Humans; Hyperemia; Hyperinsulinism; Insulin Resistance; Male; Microcirculation; Middle Aged; Obesity, Abdominal; Pyrroles; Risk Factors; Vasodilation | 2011 |
Effects of loading dose of atorvastatin before percutaneous coronary intervention on periprocedural myocardial injury.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; C-Reactive Protein; Chi-Square Distribution; China; Creatine Kinase, MB Form; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Secondary Prevention; Time Factors; Treatment Outcome; Troponin I | 2011 |
After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
Topics: Acetates; Acute Coronary Syndrome; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Keto Acids; Logistic Models; Male; Middle Aged; Phospholipases A2, Secretory; Pyrroles | 2011 |
Lupus Atherosclerosis Prevention Study (LAPS).
Topics: Adolescent; Adult; Aged; Atherosclerosis; Atorvastatin; Carotid Artery Diseases; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Middle Aged; Pyrroles; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography; Young Adult | 2011 |
Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers.
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Retrospective Studies; Stroke; Time Factors | 2011 |
Coadministration of atorvastatin prevents nitroglycerin-induced endothelial dysfunction and nitrate tolerance in healthy humans.
Topics: Adolescent; Adult; Atorvastatin; Blood Pressure; Brachial Artery; Double-Blind Method; Drug Administration Routes; Drug Tolerance; Endothelium, Vascular; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitroglycerin; Oxidative Stress; Pyrroles; Reference Values; Vasodilation; Vasodilator Agents; Young Adult | 2011 |
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; United States | 2010 |
Impact of 6 weeks of treatment with low-dose metformin and atorvastatin on glucose-induced changes of endothelial function in adults with newly diagnosed type 2 diabetes mellitus: A single-blind study.
Topics: Atherosclerosis; Atorvastatin; Blood Flow Velocity; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Female; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Plethysmography; Pyrroles; Single-Blind Method; Treatment Outcome; Vasodilation | 2010 |
Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention.
Topics: Aberrant Crypt Foci; Aged; Antineoplastic Agents; Atorvastatin; Colorectal Neoplasms; Dietary Fiber; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Mucosa; Male; Middle Aged; Pyrroles; Sulindac; Survival Rate; Treatment Outcome | 2011 |
Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required?
Topics: Antioxidants; Ascorbic Acid; Atorvastatin; Confidence Intervals; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Non-alcoholic Fatty Liver Disease; Odds Ratio; Pyrroles; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Vitamin A | 2011 |
Markers of fibrinolysis as predictors for maintenance of sinus rhythm after electrical cardioversion.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Electric Countershock; Female; Fibrinolysis; Heptanoic Acids; Humans; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Recurrence; Tissue Plasminogen Activator | 2011 |
Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome | 2011 |
Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation.
Topics: Adiponectin; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus; Female; Fluorobenzenes; Glucose; Glycated Serum Albumin; Glycation End Products, Advanced; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serum Albumin; Sulfonamides; Triglycerides | 2011 |
An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia.
Topics: Adolescent; Atorvastatin; Child; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Tolerance; Female; Follow-Up Studies; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Pyrroles; Retrospective Studies; Treatment Outcome | 2011 |
The effect of early and intensive statin therapy on ventricular premature beat or nonsustained ventricular tachycardia in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Anti-Arrhythmia Agents; Atorvastatin; Chi-Square Distribution; China; Double-Blind Method; Drug Administration Schedule; Electrocardiography, Ambulatory; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Risk Assessment; Risk Factors; Tachycardia, Ventricular; Time Factors; Treatment Outcome; Ventricular Premature Complexes | 2011 |
Pre-procedural atorvastatin mobilizes endothelial progenitor cells: clues to the salutary effects of statins on healing of stented human arteries.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Arteries; Atorvastatin; Cell Adhesion; Endothelial Cells; Hematopoietic Stem Cell Mobilization; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Regeneration; Stem Cells; Stents; Treatment Outcome; Young Adult | 2011 |
Effect of oral atorvastatin on CD4+CD25+ regulatory T cells, FoxP3 expression, and prognosis in patients with ST-segment elevated myocardial infarction before primary percutaneous coronary intervention.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; CD4 Antigens; Coronary Vessels; Electrocardiography; Female; Flow Cytometry; Forkhead Transcription Factors; Heptanoic Acids; Humans; Immunologic Factors; Interferon-gamma; Interleukin-2 Receptor alpha Subunit; Lymphocyte Count; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Treatment Outcome | 2011 |
Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm.
Topics: Adult; Age Factors; Aged; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipids; Male; Middle Aged; Pyrroles | 2011 |
The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A₂.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers, Pharmacological; Chemokine CCL2; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Male; Middle Aged; Pyrroles; Treatment Outcome; Young Adult | 2011 |
Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Preventive Health Services; Pyrroles; Risk Factors; Standard of Care | 2011 |
One-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: evidence from a parallel group randomized trial.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Atrial Fibrillation; Atrophy; Azetidines; Biomarkers; Cholesterol; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Memory; Memory Disorders; Neuropsychological Tests; Pyrroles; Temporal Lobe | 2012 |
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
Topics: Adalimumab; Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combination; Follow-Up Studies; Galactose; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Humans; Infant; Lisinopril; Losartan; Middle Aged; Pyrroles; Treatment Outcome; Young Adult | 2011 |
Role of preoperative atorvastatin administration in protection against postoperative atrial fibrillation following conventional coronary artery bypass grafting.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Biomarkers; C-Reactive Protein; Coronary Artery Bypass; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Postoperative Period; Preoperative Period; Pyrroles; Treatment Outcome | 2011 |
High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial.
Topics: Adult; Atorvastatin; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Over Studies; Double-Blind Method; Heptanoic Acids; HIV Infections; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Placebos; Pyrroles; RNA, Viral | 2011 |
High-dose atorvastatin enhances impaired cerebral vasomotor reactivity.
Topics: Aged; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Flow Velocity; Blood Pressure; Brain Infarction; Cerebrovascular Circulation; Chi-Square Distribution; Cholesterol, LDL; Female; Florida; Hemodynamics; Heptanoic Acids; Hispanic or Latino; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Middle Cerebral Artery; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Transcranial | 2012 |
Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Male; Middle Aged; Neopterin; Pravastatin; Proportional Hazards Models; Pyrroles; Sensitivity and Specificity; Treatment Outcome | 2011 |
Effect of two-day atorvastatin pretreatment on long-term outcome of patients with stable angina pectoris undergoing elective percutaneous coronary intervention.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome | 2011 |
Comparison of atorvastatin 5 and 20 mg/d for reducing F-18 fluorodeoxyglucose uptake in atherosclerotic plaques on positron emission tomography/computed tomography: a randomized, investigator-blinded, open-label, 6-month study in Japanese adults scheduled
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Dose-Response Relationship, Drug; Dyslipidemias; Female; Femoral Artery; Fluorodeoxyglucose F18; Heptanoic Acids; Humans; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Pyrroles; Treatment Outcome | 2010 |
Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.
Topics: Aged; Apolipoprotein E2; Apolipoprotein E3; Atorvastatin; Bezafibrate; Chromatography, High Pressure Liquid; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Phenotype; Pyrroles | 2011 |
Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis.
Topics: Adult; Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Signal Transduction; T-Lymphocytes, Regulatory | 2011 |
Effects of carnitine and coenzyme Q10 on lipid profile and serum levels of lipoprotein(a) in maintenance hemodialysis patients on statin therapy.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Carnitine; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoprotein(a); Lovastatin; Male; Middle Aged; Pyrroles; Renal Dialysis; Ubiquinone; Young Adult | 2011 |
The effect of a platelet cholesterol modulation on the acetylsalicylic acid-mediated blood platelet inhibition in hypercholesterolemic patients.
Topics: Acetylation; Aspirin; Atorvastatin; Blood Platelets; Blood Proteins; Cholesterol; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 2011 |
Proteomic approach to the study of statin pleiotropy in kidney transplant patients.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Immunoenzyme Techniques; Kidney Function Tests; Kidney Transplantation; Lipids; Male; Middle Aged; Molecular Weight; Peptide Fragments; Prospective Studies; Proteomics; Pyrroles; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia.
Topics: Adult; Aged; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Fasting; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Postprandial Period; Pyrroles; Treatment Outcome; Triglycerides; Young Adult | 2012 |
Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Blood Pressure; Case-Control Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Female; Follow-Up Studies; Glomerular Filtration Rate; Glomerulonephritis, IGA; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Glomerulus; Male; Middle Aged; Pilot Projects; Prognosis; Prospective Studies; Pyrroles; Sirolimus; Young Adult | 2011 |
Results of a randomized,open-label,clinical trial investigating the effects of supplementation with Heracleumpersicum extract as an adjunctive therapy for dyslipidemia.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Body Mass Index; Cholesterol; Dietary Supplements; Dyslipidemias; Female; Heptanoic Acids; Heracleum; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plant Extracts; Pyrroles | 2011 |
The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Biomarkers; Calcinosis; Down-Regulation; Drug Administration Schedule; Echocardiography, Doppler; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Osteopontin; Osteoprotegerin; Poland; Pyrroles; RANK Ligand; Sclerosis; Severity of Illness Index; Time Factors; Treatment Outcome | 2011 |
Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial.
Topics: Adult; Atorvastatin; C-Peptide; Diabetes Mellitus, Type 1; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Insulin-Secreting Cells; Lipids; Male; Pyrroles; Treatment Outcome | 2011 |
Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Biomarkers; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glycopeptides; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Outcome Assessment, Health Care; Predictive Value of Tests; Pyrroles; Regression Analysis; Risk Factors; Stroke; Treatment Outcome | 2011 |
Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2011 |
Effect of HMGCR variant alleles on low-density lipoprotein cholesterol-lowering response to atorvastatin in healthy Korean subjects.
Topics: Adult; Asian People; Atorvastatin; Cholesterol, LDL; Female; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hypolipidemic Agents; Male; Polymorphism, Genetic; Pyrroles; Young Adult | 2012 |
Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis.
Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2011 |
Comparison of the effects of combination atorvastatin (40 mg) + ezetimibe (10 mg) versus atorvastatin (40 mg) alone on secretory phospholipase A2 activity in patients with stable coronary artery disease or coronary artery disease equivalent.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Phospholipases A2, Secretory; Pyrroles; Treatment Outcome | 2011 |
Effect of statin and fibrate treatment on inflammation in type 2 diabetes. A randomized, cross-over study.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Atorvastatin; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Fibric Acids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Phospholipases A2; Phospholipases A2, Secretory; Pyrroles | 2011 |
Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN).
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography | 2011 |
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Biomarkers; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Secondary Prevention; Simvastatin; Treatment Outcome | 2011 |
Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials.
Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Female; Forecasting; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Pyrroles; Risk Factors | 2011 |
Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Coronary Artery Disease; Echocardiography; Exercise; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Smoking; Sulfonamides; Ubiquinone | 2011 |
Effects of short-term treatment with atorvastatin in smokers with asthma--a randomized controlled trial.
Topics: Adult; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Asthma; Atorvastatin; Beclomethasone; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Forced Expiratory Volume; Heptanoic Acids; Humans; Male; Peak Expiratory Flow Rate; Pyrroles; Quality of Life; Smoking; Surveys and Questionnaires; Treatment Outcome | 2011 |
Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Sex Factors | 2011 |
Reduction in arterial wall strain with aggressive lipid-lowering therapy in patients with carotid artery disease.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents; Atorvastatin; Biomechanical Phenomena; Carotid Stenosis; China; Contrast Media; Dextrans; Double-Blind Method; Female; Hemodynamics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Magnetic Resonance Angiography; Magnetite Nanoparticles; Male; Middle Aged; Prospective Studies; Pyrroles; Severity of Illness Index; Stress, Mechanical; Time Factors; Treatment Outcome | 2011 |
Oral atorvastatin therapy restores cutaneous microvascular function by decreasing arginase activity in hypercholesterolaemic humans.
Topics: Administration, Oral; Adult; Analysis of Variance; Arginase; Arginine; Atorvastatin; Biomarkers; Biopsy; Blood Flow Velocity; Cholesterol; Down-Regulation; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Microcirculation; Microdialysis; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type III; Pennsylvania; Pyrroles; Regional Blood Flow; Skin; Time Factors; Treatment Outcome; Triglycerides | 2011 |
Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Sex Characteristics; Stroke; Treatment Outcome | 2011 |
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
Topics: Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Dyslipidemias; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2011 |
Carotid artery atherosclerosis: effect of intensive lipid therapy on the vasa vasorum--evaluation by using dynamic contrast-enhanced MR imaging.
Topics: Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Artery Diseases; Contrast Media; Female; Gadolinium DTPA; Heptanoic Acids; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Prognosis; Pyrroles; Treatment Outcome; Vasa Vasorum | 2011 |
Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial.
Topics: Aged; Analysis of Variance; Atorvastatin; Biomarkers; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Middle Aged; Patient Selection; Prospective Studies; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2011 |
Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during an
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Coronary Angiography; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Kidney Function Tests; Male; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome | 2011 |
Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial.
Topics: Acute-Phase Proteins; Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cystatin C; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipocalin-2; Lipocalins; Male; Middle Aged; Prognosis; Proto-Oncogene Proteins; Pyrroles; Young Adult | 2012 |
Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study.
Topics: Adipokines; Aged; Atorvastatin; Blood Glucose; Cholesterol; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2011 |
High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Atorvastatin; Atrial Fibrillation; Cholesterol; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Retrospective Studies; Stroke; Survival Rate; Time Factors; Treatment Outcome | 2011 |
The effects of atorvastatin and rosuvastatin on oxidative stress in diabetic patients.
Topics: Adolescent; Adult; Aged; Antioxidants; Atorvastatin; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Oxidative Stress; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Young Adult | 2011 |
Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: insights from the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACT
Topics: Aged; Asian People; Atherosclerosis; Atorvastatin; Body Mass Index; C-Reactive Protein; Case-Control Studies; Cholesterol, LDL; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Monitoring; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Life Style; Male; Middle Aged; Pyrroles; Risk; White People | 2012 |
Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease.
Topics: Aged; Atorvastatin; Blood Platelets; Cell-Derived Microparticles; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Integrin beta3; Male; Middle Aged; P-Selectin; Peripheral Arterial Disease; Pyrroles; Thrombin; Thromboplastin | 2011 |
[Effect of carvedilol and metoprolol R administered with or without atorvastatin on elastic properties of vascular wall and parameters of inflammation in patients with chronic heart failure of ischemic origin].
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Aged; Anticholesteremic Agents; Arterioles; Atorvastatin; Blood Pressure; C-Reactive Protein; Carbazoles; Carvedilol; Chronic Disease; Drug Therapy, Combination; Elasticity; Female; Heart Failure; Heptanoic Acids; Humans; Interleukin-6; Male; Metoprolol; Middle Aged; Myocardial Ischemia; Propanolamines; Pyrroles; Stroke Volume; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Resistance | 2011 |
[Series: Clinical study from Japan and its reflections: introduction and summary of results: the ESTABLISH study].
Topics: Acute Coronary Syndrome; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Ultrasonography, Interventional | 2011 |
Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers.
Topics: Adolescent; Adult; Anticonvulsants; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lamotrigine; Male; Middle Aged; Phenytoin; Pyrroles; Triazines | 2011 |
Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Cytokines; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Prospective Studies; Pyrroles; Regression Analysis; Risk Factors; Risk Reduction Behavior; Serpins | 2011 |
Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PR
Topics: Acute Coronary Syndrome; Adiponectin; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Recurrence; Risk Assessment | 2011 |
Prospective, randomized, single-blind comparison of effects of 6 months' treatment with atorvastatin versus pravastatin on leptin and angiogenic factors in patients with coronary artery disease.
Topics: Aged; Analysis of Variance; Angiogenic Proteins; Angiopoietin-2; Atorvastatin; Biomarkers; Coronary Artery Disease; Down-Regulation; Female; Hepatocyte Growth Factor; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Leptin; Lipids; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Single-Blind Method; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
[Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Atherosclerosis; Atorvastatin; Carotid Arteries; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Lipid Metabolism; Lipoprotein(a); Male; Middle Aged; Niacin; Plasminogen Activator Inhibitor 1; Pyrroles; Treatment Outcome; Tunica Intima | 2011 |
High-dose atorvastatin treatment in patients with peripheral arterial disease: effects on platelet aggregation, blood rheology and plasma homocysteine.
Topics: Aged; Atorvastatin; Female; Hemorheology; Heptanoic Acids; Homocysteine; Humans; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation; Prospective Studies; Pyrroles | 2011 |
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Physiological Phenomena; Cholesterol; Confidence Intervals; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Stroke; Triglycerides; Young Adult | 2011 |
Comparison of preventive effect on cardiovascular events with different statins. -The CIRCLE study-.
Topics: Aged; Aged, 80 and over; Angioplasty; Asian People; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Postoperative Complications; Pyrroles; Quinolines; Retrospective Studies; Risk Factors | 2011 |
Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
Topics: Adult; Alanine Transaminase; Anticholesteremic Agents; Aryldialkylphosphatase; Aspartate Aminotransferases; Atorvastatin; Cholesterol; Cross-Sectional Studies; Disease Progression; Fatty Liver; Female; Glutathione Peroxidase; Hepatitis; Heptanoic Acids; Humans; Lipid Peroxidation; Lipoproteins, HDL; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Pyrroles; Risk Factors; Triglycerides | 2011 |
Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Disease-Free Survival; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Uric Acid | 2011 |
Oral atorvastatin therapy increases nitric oxide-dependent cutaneous vasodilation in humans by decreasing ascorbate-sensitive oxidants.
Topics: Administration, Oral; Adult; Analysis of Variance; Antioxidants; Arginase; Ascorbic Acid; Atorvastatin; Enzyme Inhibitors; Female; Heating; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Microdialysis; Microvessels; Middle Aged; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Pennsylvania; Pyrroles; Skin; Time Factors; Treatment Outcome; Vasodilation; Vasodilator Agents | 2011 |
Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling.
Topics: Aged; Atorvastatin; Biological Availability; Biopterins; Coronary Artery Bypass; Coronary Artery Disease; Coronary Vessels; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidation-Reduction; Oxidative Coupling; Oxygen; Pyrroles; Superoxides | 2011 |
Effect of atorvastatin vs. rosuvastatin on cardiac sympathetic nerve activity in non-diabetic patients with dilated cardiomyopathy.
Topics: Aged; Atorvastatin; Cardiomyopathy, Dilated; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pyrimidines; Pyrroles; Radionuclide Imaging; Rosuvastatin Calcium; Stroke Volume; Sulfonamides; Sympathetic Nervous System; Time Factors | 2011 |
Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk.
Topics: Atorvastatin; Biomarkers; Blood Pressure; Chi-Square Distribution; Cholesterol, LDL; Coronary Disease; Czech Republic; Double-Blind Method; Drugs, Generic; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Poland; Pyrroles; Therapeutic Equivalency; Time Factors; Treatment Outcome | 2011 |
Ethnic variations in lipid-lowering in response to a statin (EVIREST): a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Topics: Aged; Atorvastatin; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Ireland; Male; Middle Aged; Pyrroles; Racial Groups; Treatment Outcome; United Kingdom | 2011 |
MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Liver; Male; Middle Aged; Overweight; PPAR delta; Pyrroles; Treatment Outcome | 2011 |
Atorvastatin given prior to electrical cardioversion does not affect the recurrence of atrial fibrillation in patients with persistent atrial fibrillation who are on antiarrhythmic therapy.
Topics: Analysis of Variance; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Chronic Disease; Electric Countershock; Female; Fibrinogen; Health Status Indicators; Heptanoic Acids; Humans; Leukocyte Count; Male; Middle Aged; Pyrroles; Secondary Prevention; Time Factors; Warfarin | 2011 |
Final results of the HEALING IIB trial to evaluate a bio-engineered CD34 antibody coated stent (Genous™Stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients.
Topics: Adult; Aged; Antigens, CD34; Atorvastatin; Cell Movement; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Restenosis; Disease-Free Survival; Drug-Eluting Stents; Endothelial Cells; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Stem Cells; Stents; Treatment Outcome | 2011 |
The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Area Under Curve; Atorvastatin; Biphenyl Compounds; Cross-Over Studies; Drug Interactions; Estrone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pyrimidines; Pyrroles; RNA, Complementary; Tetrazoles; Young Adult | 2011 |
Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study.
Topics: Adult; Aged; Atorvastatin; Calcinosis; Coronary Artery Disease; Coronary Vessels; Double-Blind Method; Female; Heart; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Middle Aged; Multimodal Imaging; Myocardial Perfusion Imaging; Myocardium; Positron-Emission Tomography; Prospective Studies; Pyrroles; Tomography, X-Ray Computed; Young Adult | 2011 |
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Risk Assessment; Stroke; Treatment Outcome | 2012 |
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Homeostasis; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines | 2011 |
Improving adherence with amlodipine/atorvastatin therapy: IMPACT study.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black or African American; Blood Pressure; Cholesterol; Comorbidity; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypertension; Lipoproteins, LDL; Male; Middle Aged; Patient Compliance; Pyrroles; Treatment Outcome | 2011 |
Acute localized administration of tetrahydrobiopterin and chronic systemic atorvastatin treatment restore cutaneous microvascular function in hypercholesterolaemic humans.
Topics: Anticholesteremic Agents; Arginase; Arginine; Atorvastatin; Biopterins; Cholesterol; Female; Heating; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Microcirculation; Microdialysis; Middle Aged; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Regional Blood Flow; Skin; Vasodilation | 2011 |
Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines; Treatment Outcome; Young Adult | 2011 |
Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pyrroles; Rhabdomyolysis; Sensitivity and Specificity | 2011 |
Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. - From the viewpoint of cholesterol metabolism.-.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2011 |
Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin.
Topics: Adult; Amlodipine; Antiviral Agents; Atorvastatin; Biological Availability; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Female; Hepacivirus; Heptanoic Acids; Humans; Male; Middle Aged; Oligopeptides; Peptide Hydrolases; Protease Inhibitors; Pyrroles | 2011 |
Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study.
Topics: Adult; Atorvastatin; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Liver; Male; Metabolic Clearance Rate; Midazolam; Organic Anion Transporters; Pravastatin; Pyrroles; Time Factors; Young Adult | 2011 |
Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial.
Topics: Area Under Curve; Atorvastatin; Coronary Artery Bypass; Creatine Kinase; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Postoperative Complications; Pyrroles; Single-Blind Method; Troponin T | 2011 |
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: the 4D study.
Topics: Aged; Analysis of Variance; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Female; Genetic Predisposition to Disease; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Logistic Models; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Risk Factors; Treatment Outcome | 2011 |
The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the U.K.
Topics: Adult; Aged; Atorvastatin; Cause of Death; Coronary Disease; Double-Blind Method; Early Termination of Clinical Trials; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2011 |
Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Calcium; Carotid Artery Diseases; Carotid Intima-Media Thickness; Comorbidity; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Male; Maryland; Pyrroles | 2011 |
Alteration of panel-reactive antibodies following treatment with either atorvastatin or low-dose mycophenolate mofetil in sensitized hemodialysis patients.
Topics: Adult; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Failure, Chronic; Male; Mycophenolic Acid; Pyrroles; Renal Dialysis | 2011 |
Low-dose atorvastatin reduces ambulatory blood pressure in patients with mild hypertension and hypercholesterolaemia: a double-blind, randomized, placebo-controlled study.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome | 2012 |
Short-term statin treatment does not prevent ischemia and reperfusion-induced endothelial dysfunction in humans.
Topics: 5'-Nucleotidase; Adolescent; Adult; Atorvastatin; Blood Pressure; Brachial Artery; Dose-Response Relationship, Drug; Double-Blind Method; Endothelium, Vascular; Female; Fluorobenzenes; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides; Time Factors; Vasodilation; Young Adult | 2012 |
Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in ac
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Atherosclerosis; Atorvastatin; Chi-Square Distribution; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prospective Studies; Pyrroles; Quinolines; Regression Analysis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2011 |
Expression of let-7i is associated with Toll-like receptor 4 signal in coronary artery disease: effect of statins on let-7i and Toll-like receptor 4 signal.
Topics: Aged; Atorvastatin; Cell Line; Coronary Artery Disease; Down-Regulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; RNA, Messenger; Rosuvastatin Calcium; Sulfonamides; Toll-Like Receptor 4 | 2012 |
Short-term effect of atorvastatin on carotid artery elasticity: a pilot study.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Carotid Arteries; Elasticity; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Pyrroles; Treatment Outcome; Ultrasonography | 2011 |
Pharmacokinetics of a fixed-dose combination of atorvastatin and metformin extended release versus concurrent administration of individual formulations: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivale
Topics: Adult; Asian People; Atorvastatin; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Combinations; Electrocardiography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrroles; Therapeutic Equivalency; Vital Signs; Young Adult | 2011 |
MR imaging of carotid plaque composition during lipid-lowering therapy a prospective assessment of effect and time course.
Topics: Apolipoproteins B; Atorvastatin; Biomarkers; Calcium; Carotid Arteries; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Fibrosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Idaho; Lipid Metabolism; Magnetic Resonance Angiography; Male; Middle Aged; Necrosis; Predictive Value of Tests; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome; Washington | 2011 |
Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: a double-blind, placebo-controlled, randomized trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Catheter Ablation; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Postoperative Complications; Pulmonary Veins; Pyrroles; Quality of Life; Secondary Prevention; Treatment Outcome | 2012 |
Effect of cytochrome P450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin.
Topics: Adult; Alleles; Atorvastatin; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prospective Studies; Pyrroles; Young Adult | 2011 |
Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Biomarkers, Tumor; Bone Neoplasms; Bone Remodeling; Carcinoma, Renal Cell; Diphosphonates; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Imidazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Pilot Projects; Pyrroles; Zoledronic Acid | 2011 |
Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study.
Topics: Adrenal Glands; Adult; Androstenedione; Atorvastatin; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperandrogenism; Insulin; Metformin; Ovary; Placebos; Polycystic Ovary Syndrome; Pyrroles; Testosterone; Treatment Outcome; United Kingdom | 2012 |
Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome.
Topics: Acetates; Acute Coronary Syndrome; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Group II Phospholipases A2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-6; Keto Acids; Male; Middle Aged; Pyrroles; Treatment Outcome | 2011 |
Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis.
Topics: Aged; Atorvastatin; Biomarkers; Cardiovascular Diseases; Chi-Square Distribution; Diabetes Mellitus; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Risk Reduction Behavior; Time Factors; Treatment Outcome | 2012 |
Atorvastatin increases exercise leg blood flow in healthy adults.
Topics: Adult; Aged; Analysis of Variance; Atorvastatin; Blood Flow Velocity; Connecticut; Double-Blind Method; Drug Administration Schedule; Exercise; Female; Femoral Artery; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperemia; Lipids; Lower Extremity; Male; Middle Aged; Muscle Contraction; Placebos; Pyrroles; Regional Blood Flow; Time Factors; Ultrasonography, Doppler; Vasodilation | 2011 |
Atorvastatin for the treatment of plaque-type psoriasis.
Topics: Administration, Oral; Adolescent; Adult; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Male; Middle Aged; Prospective Studies; Psoriasis; Pyrroles; Severity of Illness Index; Treatment Outcome; Young Adult | 2011 |
Use of atorvastatin in systemic lupus erythematosus in children and adolescents.
Topics: Adolescent; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Intima-Media Thickness; Child; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Lipids; Lupus Erythematosus, Systemic; Male; Pyrroles; Treatment Outcome; Young Adult | 2012 |
Release of endothelial microparticles in vivo during atorvastatin treatment; a randomized double-blind placebo-controlled study.
Topics: Aged; Antigens, CD; Atorvastatin; Biomarkers; Cadherins; Cell-Derived Microparticles; Cross-Over Studies; Double-Blind Method; Endothelial Cells; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Peripheral Arterial Disease; Placebos; Pyrroles; Sweden; Thromboplastin; Time Factors; Treatment Outcome | 2012 |
Statins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trial.
Topics: Anticholesteremic Agents; Atorvastatin; Double-Blind Method; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Peroneal Nerve; Pyrroles; Stroke Volume; Surveys and Questionnaires; Sympathetic Nervous System; Time Factors; Ventricular Function, Left | 2011 |
A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Biphenyl Compounds; Brain Ischemia; Cerebral Infarction; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irbesartan; Male; Middle Aged; Monitoring, Physiologic; Pyrroles; Sample Size; Stroke; Tetrazoles; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Atorvastatin; Bexarotene; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Pyrroles; Tetrahydronaphthalenes; Treatment Outcome | 2012 |
Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta.
Topics: Adult; Aortic Coarctation; Atorvastatin; Biomarkers; Cell Adhesion Molecules; Cytokines; Disease Progression; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Postoperative Period; Prognosis; Prospective Studies; Pyrroles; Time Factors; Vascular Surgical Procedures | 2012 |
Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cell Adhesion Molecules; Cholesterol; Coronary Artery Disease; Coronary Vessels; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Effects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: a randomized, controlled trial.
Topics: Aged; Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Coronary Artery Bypass; Coronary Artery Disease; Endothelium; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Preoperative Period; Pyrroles; Stem Cell Transplantation; Treatment Outcome; Troponin I | 2012 |
The short-term effect of atorvastatin on carotid plaque morphology assessed by computer-assisted gray-scale densitometry: a pilot study.
Topics: Aged; Atorvastatin; Carotid Stenosis; Cholesterol, LDL; Densitometry; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Interpretation, Computer-Assisted; Male; Pilot Projects; Pyrroles; Ultrasonography | 2011 |
Effect of two intensive statin regimens on progression of coronary disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2011 |
[Effects of different statins, ezetimibe/simvastatin combination on hsCRP levels in unstable angina pectoris and non-ST elevation myocardial infarction patients: a randomized trial].
Topics: Angina, Unstable; Atorvastatin; Azetidines; C-Reactive Protein; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Single-Blind Method; Sulfonamides; Treatment Outcome | 2011 |
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Topics: Aged; Atorvastatin; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Atorvastatin and hormone therapy effects on APOE mRNA expression in hypercholesterolemic postmenopausal women.
Topics: Aged; Amplified Fragment Length Polymorphism Analysis; Apolipoproteins; Apolipoproteins E; Atorvastatin; Brazil; Cholesterol, LDL; Down-Regulation; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Liver X Receptors; Middle Aged; Orphan Nuclear Receptors; Polymorphism, Single Nucleotide; Postmenopause; Pyrroles; RNA, Messenger | 2012 |
Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Glucose Intolerance; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Malondialdehyde; Oxidation-Reduction; Prospective Studies; Pyrroles | 2012 |
Rationale and design of a trial on the effect of high dose statins on cardiovascular risk in adults after successful coarctation repair.
Topics: Adult; Aortic Coarctation; Atherosclerosis; Atorvastatin; Cardiac Surgical Procedures; Carotid Arteries; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; History, Ancient; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Postoperative Care; Prospective Studies; Pyrroles; Treatment Outcome; Ultrasonography | 2012 |
Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial.
Topics: Acetates; Acute Coronary Syndrome; Atorvastatin; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Inflammation; Keto Acids; Phospholipases A2, Secretory; Pyrroles | 2012 |
The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers.
Topics: Abdominal Fat; Adult; Aged; Anti-Inflammatory Agents; Arteritis; Atherosclerosis; Atorvastatin; Biomarkers; Calcium; Female; Fluorodeoxyglucose F18; Heptanoic Acids; Humans; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Pyrroles; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vascular Calcification | 2012 |
Long-term efficacy and safety of a generic atorvastatin in usual clinical care setting.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Drug Administration Schedule; Drugs, Generic; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2011 |
Pilot double-blind, randomized controlled trial of short-term atorvastatin for prevention of acute kidney injury after cardiac surgery.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Aged; Atorvastatin; Cardiac Surgical Procedures; Creatinine; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipocalin-2; Lipocalins; Male; Middle Aged; Multivariate Analysis; Pilot Projects; Postoperative Complications; Proto-Oncogene Proteins; Pyrroles | 2012 |
The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies.
Topics: Aged; Alleles; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Female; Follow-Up Studies; Genotype; Heptanoic Acids; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2012 |
Effects of atorvastatin pretreatment on infarct size in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Chemoprevention; Drug Administration Schedule; Electrocardiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2011 |
Atorvastatin does not affect ischaemia-induced phosphatidylserine exposition in humans in-vivo.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Double-Blind Method; Exercise; Forearm; Heptanoic Acids; Humans; Ischemia; Ischemic Preconditioning; Male; Middle Aged; Phosphatidylserines; Pyrroles; Reperfusion Injury; Young Adult | 2012 |
Effects of rosuvastatin and atorvastatin on glycaemic control in Type 2 diabetes---the CORALL study.
Topics: Atorvastatin; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Fasting; Female; Fluorobenzenes; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Netherlands; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2012 |
Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Atorvastatin; Biomarkers; Chi-Square Distribution; Cholesterol; Collagen; Collagen Type I; Down-Regulation; Female; Heart Failure, Systolic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Ireland; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Peptides; Procollagen; Prospective Studies; Pyrroles; Recovery of Function; Stroke Volume; Time Factors; Treatment Outcome; Up-Regulation; Ventricular Function, Left | 2012 |
Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects.
Topics: Adult; Animals; Area Under Curve; Atorvastatin; Cross-Over Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver-Specific Organic Anion Transporter 1; Male; Mice; Mice, Knockout; Middle Aged; Organic Anion Transporters, Sodium-Independent; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Young Adult | 2012 |
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia.
Topics: Acetates; Analysis of Variance; Atherosclerosis; Atorvastatin; Biomarkers; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Obesity; Overweight; Particle Size; PPAR gamma; Pyrroles; Time Factors; Treatment Outcome; Triazoles | 2012 |
Assessment of atorvastatin effectiveness on serum PSA level in hypercholesterolemic males.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Pyrroles; Triglycerides | 2011 |
Effects of atorvastatin on cerebral blood flow in middle-aged adults at risk for Alzheimer's disease: a pilot study.
Topics: Adult; Aged; Alzheimer Disease; Atorvastatin; Cerebrovascular Circulation; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Pyrroles; Risk Factors | 2012 |
Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery effects of short-term pre-operative statin treatment.
Topics: Aged; Atorvastatin; Cardiac Surgical Procedures; Confidence Intervals; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Lipid Peroxidation; Male; Middle Aged; Myocardium; Oxidation-Reduction; Postoperative Complications; Predictive Value of Tests; Preoperative Care; Proportional Hazards Models; Prospective Studies; Pyrroles; Survival Analysis; Treatment Outcome | 2012 |
Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Area Under Curve; Atorvastatin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Renal Dialysis; Risk Factors | 2012 |
Effect of atorvastatin on erectile functions in comparison with regular tadalafil use. A prospective single-blind study.
Topics: Adult; Aged; Atorvastatin; Carbolines; Erectile Dysfunction; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Penile Erection; Phosphodiesterase 5 Inhibitors; Pyrroles; Single-Blind Method; Tadalafil | 2012 |
Effect of 40 mg versus 10 mg of atorvastatin on oxidized low-density lipoprotein, high-sensitivity C-reactive protein, circulating endothelial-derived microparticles, and endothelial progenitor cells in patients with ischemic cardiomyopathy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiomyopathies; Cell-Derived Microparticles; Echocardiography; Endothelial Cells; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Stem Cells | 2012 |
Alternate-day versus daily atorvastatin in coronary artery disease: a randomized study.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Single-Blind Method; Treatment Outcome | 2012 |
Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
Topics: Adenine; Androstenes; Anti-HIV Agents; Atazanavir Sulfate; Atorvastatin; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Interactions; Emtricitabine; Ethinyl Estradiol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Least-Squares Analysis; Linear Models; Lopinavir; Male; Oligopeptides; Organophosphonates; Patient Safety; Phosphinic Acids; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tenofovir | 2012 |
Effects of rosuvastatin versus atorvastatin on rho-associated coiled-coil containing protein kinase activity and endothelial function in patients with atherosclerosis.
Topics: Atherosclerosis; Atorvastatin; C-Reactive Protein; Endothelium, Vascular; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Phosphorylation; Protein Subunits; Pyrimidines; Pyrroles; rho-Associated Kinases; Rosuvastatin Calcium; Sulfonamides; Vasodilation | 2011 |
Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2012 |
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome | 2013 |
[Association between high sensitivity C-reactive protein and contrast induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention: impact of atorvastatin].
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Contrast Media; Female; Heptanoic Acids; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pyrroles | 2011 |
Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy.
Topics: Atorvastatin; Biomarkers; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Particle Size; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome; United States | 2012 |
[Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): -- the PATROL trial].
Topics: Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Influence of achieved low-density lipoprotein cholesterol level with atorvastatin therapy on stabilization of coronary plaques: sub-analysis of the TWINS study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Ultrasonography, Interventional | 2012 |
Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study).
Topics: Acute Coronary Syndrome; Adult; Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Survival Rate; Treatment Outcome; United States; Young Adult | 2012 |
Atorvastatin in pulmonary arterial hypertension (APATH) study.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Hemodynamics; Heptanoic Acids; Humans; Hypertension, Pulmonary; Lung; Male; Middle Aged; Pyrroles; Treatment Outcome; Walking; Young Adult | 2012 |
MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression.
Topics: Aged; Atorvastatin; Cell Count; Cell Movement; Cells, Cultured; Coronary Artery Disease; Endothelial Cells; Female; Fluorobenzenes; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Longevity; Male; MicroRNAs; Oxidative Stress; Pyrimidines; Pyrroles; RNA, Messenger; Rosuvastatin Calcium; Sirtuin 1; Sulfonamides; Transfection | 2012 |
Effects of Ginkgo biloba extracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices.
Topics: Administration, Oral; Adult; Atorvastatin; Cholesterol; Ginkgo biloba; Heptanoic Acids; Herb-Drug Interactions; Humans; Male; Plant Extracts; Pyrroles; Treatment Outcome | 2012 |
Immediate administration of atorvastatin decreased the serum MMP-2 level and improved the prognosis for acute heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Matrix Metalloproteinase 2; Prognosis; Pyrroles; Survival Rate; Time Factors; Treatment Outcome | 2012 |
Early statin treatment prior to primary PCI for acute myocardial infarction: REPERATOR, a randomized placebo-controlled pilot trial.
Topics: Aged; Atorvastatin; Biomarkers; Chi-Square Distribution; Coronary Circulation; Drug Administration Schedule; Female; Hemodynamics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Microcirculation; Middle Aged; Myocardial Infarction; Myocardium; Netherlands; No-Reflow Phenomenon; Percutaneous Coronary Intervention; Pilot Projects; Predictive Value of Tests; Pyrroles; Time Factors; Treatment Outcome; Ventricular Function, Left; Ventricular Remodeling | 2012 |
Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study.
Topics: Age of Onset; Aged; Asymptomatic Diseases; Atorvastatin; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; New York; Patient Selection; Pedigree; Primary Prevention; Proportional Hazards Models; Pyrroles; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; Vascular Calcification | 2012 |
Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Injections, Intravenous; Injections, Subcutaneous; Least-Squares Analysis; Lipoproteins; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Receptors, LDL; Serine Endopeptidases | 2012 |
Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).
Topics: Atorvastatin; Coronary Angiography; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Republic of Korea; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2012 |
Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Placenta Growth Factor; Pravastatin; Pregnancy Proteins; Pyrroles; Risk Factors | 2012 |
Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial).
Topics: Adolescent; Adult; Age of Onset; Atorvastatin; C-Peptide; C-Reactive Protein; Diabetes Mellitus, Type 1; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin-Secreting Cells; Male; Pyrroles; Young Adult | 2012 |
Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study).
Topics: Adult; Aged; Atorvastatin; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Retrospective Studies | 2012 |
Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Brain; Canada; Confounding Factors, Epidemiologic; Contrast Media; Double-Blind Method; Female; Gadolinium; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Male; Middle Aged; Odds Ratio; Pyrroles; Research Design; Syndrome; Treatment Outcome; United States | 2012 |
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Cardiopulmonary Resuscitation; Cholesterol, LDL; Death, Sudden, Cardiac; Female; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk; Sex Factors; Stroke | 2012 |
Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Synergism; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Time Factors; Treatment Outcome | 2012 |
Statins but not aspirin reduce thrombotic risk assessed by thrombin generation in diabetic patients without cardiovascular events: the RATIONAL trial.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Thrombin | 2012 |
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
Topics: Adenosine Diphosphate; Aspirin; Atorvastatin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP3A; Drug Substitution; Drug Therapy, Combination; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ticlopidine | 2012 |
Intensive statin therapy for Chinese patients with coronary artery disease undergoing percutaneous coronary intervention (ISCAP study): rationale and design.
Topics: Angioplasty, Balloon, Coronary; Asian People; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; China; Coronary Artery Disease; Creatine; Creatine Kinase, MB Form; Drug Administration Schedule; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Research Design; Time Factors; Treatment Outcome; Troponin I | 2012 |
STAR VaS--Short Term Atorvastatin Regime for Vasculopathic Subjects: a randomized placebo-controlled trial evaluating perioperative atorvastatin therapy in noncardiac surgery.
Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Perioperative Care; Postoperative Complications; Pyrroles; Risk Factors; Surgical Procedures, Operative | 2012 |
Comparison of topical triamcinolone and oral atorvastatin in treatment of paederus dermatitis Northern Iran.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Animals; Atorvastatin; Child; Coleoptera; Dermatitis, Atopic; Double-Blind Method; Female; Heptanoic Acids; Humans; Iran; Middle Aged; Placebos; Pyrroles; Treatment Outcome; Triamcinolone; Young Adult | 2012 |
Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Lipids; Male; Middle Aged; Phytosterols; Pyrroles; Simvastatin; Sitosterols | 2012 |
Comparison of alternate-day atorvastatin treatment to daily treatment in maintaining LDL-cholesterol targets in patients with variable coronary risk profile.
Topics: Adult; Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Risk; Time Factors; Treatment Outcome; Triglycerides | 2012 |
Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial.
Topics: Adolescent; Adult; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Interferon beta-1b; Interferon-beta; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Pyrroles; Single-Blind Method; Treatment Outcome; Young Adult | 2012 |
Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study.
Topics: Aged; Atorvastatin; Biomarkers; Case-Control Studies; Coronary Disease; Double-Blind Method; Drug Delivery Systems; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Treatment Outcome | 2012 |
Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease.
Topics: Adult; Aged; Anticholesteremic Agents; Arthritis; Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2012 |
Influence of atorvastatin on serum amyloid A-low density lipoprotein complex in hypercholesterolemic patients.
Topics: Antioxidants; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Pyrroles; Serum Amyloid A Protein | 2012 |
Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2.
Topics: Aged; Aged, 80 and over; Antioxidants; Atorvastatin; Combined Modality Therapy; Diet, Mediterranean; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Membrane Glycoproteins; Middle Aged; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Platelet Activation; Pyrroles; Treatment Outcome | 2012 |
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides | 2012 |
Increased levels of circulating endothelial progenitor cells in patients with ischaemic stroke treated with statins during acute phase.
Topics: Aged; Atorvastatin; Chromatography, High Pressure Liquid; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Nitric Oxide; Pyrroles; Stem Cells; Stroke; Vascular Endothelial Growth Factor A | 2012 |
Atorvastatin treatment improves diabetic polyneuropathy electrophysiological changes in non-insulin dependent diabetic patients: a double blind, randomized clinical trial.
Topics: Animals; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Electrophysiology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neural Conduction; Pyrroles; Rats; Tibial Nerve | 2012 |
The predictive value of C-reactive protein on recurrence of atrial fibrillation after cardioversion with or without treatment with atorvastatin.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Biomarkers; C-Reactive Protein; Double-Blind Method; Electric Countershock; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pyrroles; Recurrence; Treatment Outcome | 2013 |
[Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study].
Topics: Acute Coronary Syndrome; Atorvastatin; Endosonography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrroles | 2011 |
[Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-aCS) study].
Topics: Acute Coronary Syndrome; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2011 |
Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia.
Topics: Adult; Anemia, Sickle Cell; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cohort Studies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2012 |
Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.
Topics: Adult; Atorvastatin; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Transplantation; Male; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged; Models, Biological; Pyrroles | 2012 |
Effects of atorvastatin on systemic and renal nitric oxide in healthy man.
Topics: Adolescent; Adult; Aquaporin 2; Arginine; Atorvastatin; Blood Flow Velocity; Blood Pressure; Cross-Over Studies; Female; Glomerular Filtration Rate; Heart Rate; Heptanoic Acids; Hormones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Nitric Oxide; Nitric Oxide Synthase; Placebos; Potassium; Pulsatile Flow; Pyrroles; Renin-Angiotensin System; Sodium Chloride; Vascular Stiffness; Young Adult | 2013 |
[Pharmacokinetics and bioequivalence of atorvastatin calcium tablets in healthy male Chinese volunteers].
Topics: Adult; Area Under Curve; Asian People; Atorvastatin; Cross-Over Studies; Half-Life; Heptanoic Acids; Humans; Male; Pyrroles; Tablets; Therapeutic Equivalency; Young Adult | 2012 |
Combination treatment of rosuvastatin or atorvastatin, with regular exercise improves arterial wall stiffness in patients with coronary artery disease.
Topics: Atorvastatin; Coronary Artery Disease; Exercise; Fluorobenzenes; Heptanoic Acids; Humans; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Vascular Stiffness | 2012 |
Beneficial effects of high-dose atorvastatin pretreatment on renal function in patients with acute ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Creatinine; Cystatin C; Emergency Treatment; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Kidney Function Tests; Male; Myocardial Infarction; Pyrroles | 2012 |
Virtual histology findings and effects of varying doses of atorvastatin on coronary plaque volume and composition in statin-naive patients: the VENUS study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Time Factors | 2012 |
Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome.
Topics: Adult; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Malondialdehyde; Metformin; Oxidative Stress; Polycystic Ovary Syndrome; Pyrroles; Treatment Outcome | 2012 |
Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Glomerular Filtration Rate; Greece; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Incidence; Male; Prognosis; Pyrroles; Reference Values; Survival Rate; Treatment Outcome | 2012 |
Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Phytosterols; Proprotein Convertase 9; Proprotein Convertases; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angiopoietins; Apolipoproteins; Apolipoproteins B; Atorvastatin; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Association of cholesteryl ester transfer protein mass with peripheral leukocyte count following statin therapy: a pilot study.
Topics: Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocyte Count; Lipids; Male; Middle Aged; Multivariate Analysis; Pilot Projects; Pravastatin; Pyrroles; Regression Analysis; Risk Factors | 2012 |
Single high dose atorvastatin does not ameliorate endothelial function and large arterial stiffness in dyslipidemic patients without atherosclerosis.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Dyslipidemias; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Vascular Stiffness; Vasodilation | 2012 |
Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers.
Topics: Adenosine; Adult; Area Under Curve; Atorvastatin; Biotransformation; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Least-Squares Analysis; Linear Models; Male; Metabolic Clearance Rate; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyrroles; Simvastatin; Ticagrelor | 2013 |
Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome.
Topics: Adult; Apolipoproteins B; Apolipoproteins E; Atorvastatin; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, VLDL; Male; Metabolic Syndrome; Middle Aged; Pyrroles | 2012 |
Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
Topics: Adipokines; Adiponectin; Adult; Aged; Analysis of Variance; Atorvastatin; Biomarkers; Blood Glucose; Cytokines; Drug Therapy, Combination; Female; Fenofibrate; Glucose Metabolism Disorders; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type V; Hypolipidemic Agents; Inflammation Mediators; Insulin; Insulin Resistance; Interleukin-6; Leptin; Lipids; Male; Middle Aged; Poland; Pyrroles; Resistin; Risk Reduction Behavior; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Efficacy of atorvastatin and antihistamines in comparison with antihistamines plus placebo in the treatment of chronic idiopathic urticaria: a controlled clinical trial.
Topics: Adolescent; Adult; Atorvastatin; Biomarkers; Chronic Disease; Cytokines; Drug Therapy, Combination; Female; Heptanoic Acids; Histamine Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Iran; Male; Middle Aged; Pyrroles; Severity of Illness Index; Single-Blind Method; Time Factors; Treatment Outcome; Urticaria; Young Adult | 2012 |
Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Data Interpretation, Statistical; Disease Progression; Dyslipidemias; Endpoint Determination; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Pyrroles; Renal Insufficiency, Chronic; Research Design; Treatment Outcome | 2013 |
Atorvastatin treatment improves myocardial and peripheral blood flow in familial hypercholesterolemia subjects without evidence of coronary atherosclerosis.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Flow Velocity; Coronary Artery Disease; Coronary Circulation; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Myocardial Perfusion Imaging; Pyrroles; Treatment Outcome | 2013 |
Clustering of metabolic syndrome components attenuates coronary plaque regression during intensive statin therapy in patients with acute coronary syndrome: the JAPAN-ACS subanalysis study.
Topics: Acute Coronary Syndrome; Aged; Analysis of Variance; Atorvastatin; Biomarkers; Body Mass Index; Chi-Square Distribution; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Linear Models; Male; Metabolic Syndrome; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Quinolines; Time Factors; Treatment Outcome; Triglycerides; Ultrasonography, Interventional | 2012 |
Effect of low-and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaging -a post-hoc sub group analysis of ATHEROMA (Atorvastatin Therapy: Effects On Reduction Of Macrophage Activity) Study.
Topics: Aged; Atorvastatin; Carotid Arteries; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Magnetic Resonance Imaging; Male; Manometry; Middle Aged; Pyrroles | 2013 |
Vitamin D levels do not predict cardiovascular events in statin-treated patients with stable coronary disease.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Risk Factors; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2012 |
Modeling of the LDL cholesterol-lowering effect of atorvastatin in Korean dyslipidemic patients and non-patient volunteers.
Topics: Adult; Asian People; Atorvastatin; Biomarkers; Cholesterol, LDL; Computer Simulation; Decision Support Techniques; Down-Regulation; Drug Administration Schedule; Drug Dosage Calculations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Biological; Pyrroles; Republic of Korea; Treatment Outcome; Young Adult | 2012 |
Clinical efficacy of subgingivally delivered 1.2% atorvastatin in chronic periodontitis: a randomized controlled clinical trial.
Topics: Administration, Topical; Adult; Alveolar Bone Loss; Atorvastatin; Chronic Periodontitis; Combined Modality Therapy; Dental Plaque Index; Dental Scaling; Female; Follow-Up Studies; Gels; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Osteogenesis; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Placebos; Pyrroles; Root Planing; Treatment Outcome | 2013 |
Effect of intensive atorvastatin therapy on coronary atherosclerosis progression, composition, arterial remodeling, and microvascular function.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Artery Disease; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Microvessels; Middle Aged; Phenotype; Pilot Projects; Pyrroles; Regional Blood Flow; Retrospective Studies; Treatment Outcome; Ultrasonography, Interventional; Vascular Resistance | 2012 |
No changes of cholesterol levels with a commercially available glucosamine product in patients treated with lipid lowering drugs: a controlled, randomised, open cross-over trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cross-Over Studies; Drug Interactions; Female; Glucosamine; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2012 |
No effect of high-dose atorvastatin on leukotriene B₄ formation from neutrophils in patients treated with coronary bypass surgery: a randomized placebo-controlled double-blinded trial with a crossover design.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Calcimycin; Calcium Ionophores; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Bypass; Coronary Disease; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukotriene B4; Male; Middle Aged; Neutrophil Activation; Neutrophils; Pyrroles | 2012 |
Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atorvastatin; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Least-Squares Analysis; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Treatment Outcome | 2012 |
Intensive-dose atorvastatin regimen halts progression of atherosclerotic plaques in new-onset unstable angina with borderline vulnerable plaque lesions.
Topics: Aged; Angina, Unstable; Atorvastatin; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles | 2013 |
Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury.
Topics: Acetylcysteine; Acute Kidney Injury; Aged; Animals; Atorvastatin; Cells, Cultured; Contrast Media; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; JNK Mitogen-Activated Protein Kinases; Male; Middle Aged; Pyrroles; Tumor Suppressor Protein p53 | 2012 |
Increased circulating CC chemokine levels in the metabolic syndrome are reduced by low-dose atorvastatin treatment: evidence from a randomized controlled trial.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Chemokine CCL11; Chemokine CCL2; Chemokine CCL4; Chemokines, CC; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-6; Male; Metabolic Syndrome; Middle Aged; Monocytes; Pyrroles; Receptors, CCR5; RNA, Messenger | 2013 |
Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoalphalipoproteinemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Pyrroles | 2013 |
Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia.
Topics: Atorvastatin; Biomarkers; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Pyrroles; Quinolines | 2013 |
[Atorvastatin prevents contrast agent-induced renal injury in patients undergoing coronary angiography by inhibiting oxidative stress].
Topics: Aged; Atorvastatin; Contrast Media; Coronary Angiography; Female; Heptanoic Acids; Humans; Kidney Diseases; Male; Middle Aged; Oxidative Stress; Pyrroles | 2012 |
Impact of intensive statin use on the level of inflammation and platelet activation in stable angina after percutaneous coronary intervention: a clinical study.
Topics: Aged; Angina Pectoris; Animals; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Premedication; Prospective Studies; Pyrroles; Reoperation; Single-Blind Method; Stents | 2013 |
High dose atorvastatin therapy and QTc interval in patients treated with coronary bypass surgery.
Topics: Aged; Atorvastatin; Coronary Artery Bypass; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2013 |
Effect of statins on skeletal muscle function.
Topics: Adult; Atorvastatin; Creatine Kinase; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscle Strength; Muscle, Skeletal; Musculoskeletal Pain; Placebos; Pyrroles; Young Adult | 2013 |
Absence of clinically relevant interactions between rivaroxaban--an oral, direct Factor Xa inhibitor--and digoxin or atorvastatin in healthy subjects.
Topics: Adult; Anti-Arrhythmia Agents; Atorvastatin; Cross-Over Studies; Digoxin; Drug Interactions; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Headache; Heptanoic Acids; Humans; Male; Middle Aged; Morpholines; Pyrroles; Rivaroxaban; Self Administration; Thiophenes; Young Adult | 2012 |
Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy.
Topics: Acute Coronary Syndrome; Aged; Albuminuria; Anticholesteremic Agents; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pravastatin; Pyrroles; Risk Factors | 2013 |
Effects of atorvastatin on human C-reactive protein metabolism.
Topics: Atorvastatin; C-Reactive Protein; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kinetics; Male; Middle Aged; Pyrroles | 2013 |
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Stroke | 2013 |
Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial).
Topics: Anti-Inflammatory Agents; Atorvastatin; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Length of Stay; Male; Middle Aged; Patient Readmission; Pyrroles; Sepsis; Severity of Illness Index; Treatment Outcome | 2012 |
Long-term effects of gastric bypass and duodenal switch on systemic exposure of atorvastatin.
Topics: Adult; Atorvastatin; Biliopancreatic Diversion; Biological Availability; Female; Gastric Bypass; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Obesity, Morbid; Prospective Studies; Pyrroles | 2013 |
Effects of atorvastatin and T-786C polymorphism of eNOS gene on plasma metabolic lipid parameters.
Topics: Adolescent; Adult; Analysis of Variance; Atorvastatin; C-Reactive Protein; Cholesterol Ester Transfer Proteins; Heptanoic Acids; Humans; Lipid Metabolism; Lipids; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type III; Polymorphism, Genetic; Pyrroles; Single-Blind Method; Statistics, Nonparametric; Treatment Outcome; Young Adult | 2013 |
Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.
Topics: Adolescent; Adult; Aged; Animals; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Demography; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Madin Darby Canine Kidney Cells; Male; Mesylates; Middle Aged; Oxadiazoles; Piperidines; Pyrimidines; Pyrroles; Reference Standards; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Troleandomycin; Young Adult | 2013 |
Effects of pravastatin and atorvastatin on HDL cholesterol and glucose metabolism in patients with dyslipidemia and glucose intolerance: the PRAT study.
Topics: Adult; Atorvastatin; Blood Glucose; Cholesterol, HDL; Dyslipidemias; Female; Glucose; Glucose Intolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Postmenopause; Pravastatin; Pyrroles; Young Adult | 2013 |
Assessment of the efficacy and tolerability of 2 formulations of atorvastatin in Korean adults with hypercholesterolemia: a multicenter, prospective, open-label, randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Apolipoproteins B; Asian People; Atorvastatin; Biomarkers; C-Reactive Protein; Chemistry, Pharmaceutical; Cholesterol, HDL; Cholesterol, LDL; Drugs, Generic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Republic of Korea; Therapeutic Equivalency; Time Factors; Treatment Outcome; Triglycerides; Young Adult | 2013 |
The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Fasting; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Complications; Diabetic Angiopathies; Double-Blind Method; Drug Combinations; Drug Monitoring; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Severity of Illness Index; Simvastatin; Sulfonamides | 2013 |
No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy.
Topics: Adult; Aged; Antioxidants; Atorvastatin; Dietary Supplements; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Prospective Studies; Pyrroles; Selenium; Surveys and Questionnaires; Treatment Outcome; Ubiquinone; Vitamins | 2013 |
Atorvastatin administration is associated with dose-related changes in IGF bioavailability.
Topics: Aged; Atorvastatin; Biological Availability; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Male; Middle Aged; Pyrroles | 2013 |
Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
Topics: Acetamides; Administration, Oral; Adult; Area Under Curve; Atorvastatin; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Germany; Half-Life; Heptanoic Acids; Humans; Hydroxylation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypnotics and Sedatives; Intestines; Isoquinolines; Liver; Male; Metabolic Clearance Rate; Pyrroles; Simvastatin; Young Adult | 2013 |
A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis.
Topics: Aged; Atorvastatin; C-Reactive Protein; Critical Illness; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intensive Care Units; Interleukin-6; Length of Stay; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Sepsis | 2013 |
Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography.
Topics: Adult; Atorvastatin; Biomarkers; Blood Component Removal; Chi-Square Distribution; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pyrroles; Russia; Time Factors; Treatment Outcome | 2013 |
Cascade plasma filtration during the first year after CABG in patients with hyperlipidemia refractory to statins.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Component Removal; Chi-Square Distribution; Cholesterol, LDL; Combined Modality Therapy; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Drug Resistance; Graft Occlusion, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Russia; Time Factors; Treatment Outcome; Vascular Patency | 2013 |
Simultaneous determination of amlodipine and atorvastatin with its metabolites; ortho and para hydroxy atorvastatin; in human plasma by LC-MS/MS.
Topics: Administration, Oral; Amlodipine; Atorvastatin; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Combinations; Drug Stability; Heptanoic Acids; Humans; Isomerism; Linear Models; Pravastatin; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Therapeutic Equivalency | 2013 |
Population pharmacokinetics of atorvastatin and its active metabolites in children and adolescents with heterozygous familial hypercholesterolemia: selective use of informative prior distributions from adults.
Topics: Adolescent; Adult; Atorvastatin; Child; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Models, Biological; Pyrroles | 2013 |
Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers.
Topics: Adult; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biotransformation; Cohort Studies; Colorado; Cross-Over Studies; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Genetic Association Studies; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Clearance Rate; Middle Aged; Polymorphism, Single Nucleotide; Pyrazines; Pyrroles; Sitagliptin Phosphate; Triazoles; Young Adult | 2013 |
Administration of a loading dose of atorvastatin before percutaneous coronary intervention prevents inflammation and reduces myocardial injury in STEMI patients: a randomized clinical study.
Topics: Aged; Atorvastatin; C-Reactive Protein; Combined Modality Therapy; Echocardiography; Female; Heptanoic Acids; Humans; Inflammation; Male; Matrix Metalloproteinase 9; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Percutaneous Coronary Intervention; Prospective Studies; Pyrroles; Ventricular Function, Left | 2013 |
High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study.
Topics: Age Factors; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Pyrroles; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure.
Topics: Aged; Arteries; Atorvastatin; Cholesterol, LDL; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Male; Matrix Metalloproteinase 9; Middle Aged; Myocardial Ischemia; Natriuretic Peptide, Brain; Pyrroles; Regression Analysis; Ventricular Remodeling | 2013 |
Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein.
Topics: Adolescent; Age Factors; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol, LDL; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Prospective Studies; Puberty; Pyrroles; Treatment Outcome | 2014 |
Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Aorta; Atorvastatin; Blood Pressure; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemodynamics; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Pulse Wave Analysis; Pyrroles; Treatment Outcome; Vascular Stiffness | 2013 |
Hypolipidaemic and anti-inflammatory effects of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; India; Intercellular Adhesion Molecule-1; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Treatment Outcome | 2013 |
Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Coronary Disease; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Risk Factors | 2013 |
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Atorvastatin; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Combined Modality Therapy; Female; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ki-67 Antigen; Middle Aged; Pyrroles; Treatment Outcome | 2013 |
Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.
Topics: Administration, Oral; Adult; Arthritis, Rheumatoid; Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Piperidines; Placebos; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2014 |
[Isoprostanes - important marker of the oxidative stress estimation in patients with chronic kidney disease].
Topics: Adolescent; Adult; Aged; Atorvastatin; Biomarkers; Female; Heptanoic Acids; Humans; Isoprostanes; Male; Middle Aged; Oxidative Stress; Protective Agents; Pyrroles; Renal Insufficiency, Chronic; Renin-Angiotensin System; Young Adult | 2013 |
Strategies of clopidogrel load and atorvastatin reload to prevent ischemic cerebral events in patients undergoing protected carotid stenting. Results of the randomized ARMYDA-9 CAROTID (Clopidogrel and Atorvastatin Treatment During Carotid Artery Stenting
Topics: Aged; Angioplasty, Balloon; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Carotid Artery Diseases; Carotid Stenosis; Clopidogrel; Diffusion Magnetic Resonance Imaging; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Platelet Aggregation Inhibitors; Pyrroles; Research Design; Stents; Ticlopidine; Treatment Outcome | 2013 |
Effect of intensive versus moderate lipid-lowering therapy on epicardial adipose tissue in hyperlipidemic post-menopausal women: a substudy of the BELLES trial (Beyond Endorsed Lipid Lowering with EBT Scanning).
Topics: Adipose Tissue; Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Postmenopause; Pravastatin; Pyrroles; Vascular Calcification | 2013 |
Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Desmosterol; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Phytosterols; Prospective Studies; Pyrroles; Risk Factors; Sitosterols; Statistics, Nonparametric | 2013 |
Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects.
Topics: Adult; Area Under Curve; Aspirin; Atorvastatin; Capsules; Cross-Over Studies; Drug Combinations; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Therapeutic Equivalency | 2013 |
Efficiency of statin treatment on EPC recruitment depends on baseline EPC titer and does not improve angiographic outcome in coronary artery disease patients treated with the Genous stent.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Demography; Endothelial Progenitor Cells; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Multivariate Analysis; Pyrroles; Regression Analysis; Stents; Treatment Outcome | 2014 |
The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy--5-year follow-up.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Cardiomyopathy, Dilated; Cytokines; Female; Follow-Up Studies; Heptanoic Acids; Hospitalization; Humans; Inflammation; Male; Middle Aged; Pyrroles; Uric Acid; Ventricular Function, Left | 2013 |
Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Atorvastatin; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; Genetic Testing; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinesins; Male; Markov Chains; Middle Aged; Molecular Targeted Therapy; Pravastatin; Pyrroles; Quality-Adjusted Life Years | 2013 |
Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study.
Topics: Aged; Atorvastatin; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Postoperative Complications; Pyrroles; Time Factors | 2013 |
Differences in action of atorvastatin and ezetimibe in lowering low-density lipoprotein cholesterol and effect on endothelial function: randomized controlled trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Endothelium, Vascular; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Triglycerides | 2013 |
Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Animals; Atorvastatin; Biomarkers; Cardiomegaly; Cells, Cultured; Cholesterol; Cholesterol, LDL; Coronary Vessels; Cross-Over Studies; Cytoskeletal Proteins; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Guanine Nucleotide Exchange Factors; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Mice; Mice, Knockout; Neuropeptides; Oxidative Stress; Phosphatidylinositol 3-Kinase; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; rac GTP-Binding Proteins; rac1 GTP-Binding Protein; RNA Interference; Signal Transduction; Transfection | 2013 |
Factors underlying regression of coronary atheroma with potent statin therapy.
Topics: Analysis of Variance; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Endosonography; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Atorvastatin; Bone Density; Calcinosis; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Angiography; Male; Middle Aged; Organ Specificity; Plaque, Atherosclerotic; Prospective Studies; Pyrroles | 2013 |
Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Coronary Artery Disease; Endpoint Determination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Quinolines; Young Adult | 2013 |
Circulating endothelial progenitor cells are inversely correlated with in-stent restenosis in patients with non-ST-segment elevation acute coronary syndromes treated with EPC-capture stents (JACK-EPC trial).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Coated Materials, Biocompatible; Coronary Restenosis; Drug-Eluting Stents; Endothelial Cells; Female; Follow-Up Studies; Heart Conduction System; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Radiography; Risk Factors; Stem Cells; Stents; Treatment Outcome | 2013 |
Protection by atorvastatin pretreatment in patients undergoing primary percutaneous coronary intervention is associated with the lower levels of oxygen free radicals.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiotonic Agents; China; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Reperfusion Injury; Percutaneous Coronary Intervention; Premedication; Pyrroles; Reactive Oxygen Species; Severity of Illness Index | 2013 |
Atorvastatin therapy is not associated with slowing the progression of aortic stenosis: findings of a randomized controlled trial.
Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Disease Progression; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrroles | 2013 |
Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study.
Topics: Adult; Aged; Aged, 80 and over; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Carotid Arteries; Double-Blind Method; Feasibility Studies; Female; Fluorodeoxyglucose F18; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Multimodal Imaging; Plaque, Atherosclerotic; Positron-Emission Tomography; Pyrroles; Treatment Outcome | 2013 |
Effects of ezetimibe/simvastatin 10/20 mg vs. atorvastatin 20 mg on apolipoprotein B/apolipoprotein A1 in Korean patients with type 2 diabetes mellitus: results of a randomized controlled trial.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Asian People; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidemias; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Pyrroles; Republic of Korea; Simvastatin; Treatment Outcome | 2013 |
Atorvastatin treatment induces uptake and efflux transporters in human liver.
Topics: Adult; Aged; Atorvastatin; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Male; Membrane Transport Proteins; Middle Aged; Pyrroles; RNA, Messenger; Young Adult | 2013 |
Impact of atorvastatin treatment in first-degree relatives of patients with premature coronary artery disease with endothelial dysfunction: a double-blind, randomized, placebo-controlled crossover trial.
Topics: Age of Onset; Atorvastatin; Biomarkers; Coronary Artery Disease; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Pedigree; Phenotype; Primary Prevention; Prospective Studies; Pyrroles; Republic of Korea; Time Factors; Treatment Outcome | 2013 |
[Prevention of cardiovascular complications in patients undergoing aortic-iliac reconstructions by correction of inflammation and endotoxemia].
Topics: Aorta, Abdominal; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Endotoxemia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Inflammation; Middle Aged; Postoperative Complications; Pyrroles; Treatment Outcome; Vascular Surgical Procedures | 2013 |
Impaired endothelium-dependent skin microvascular function during high-dose atorvastatin treatment in patients with type 1 diabetes.
Topics: Administration, Cutaneous; Adult; Atorvastatin; Biomarkers; Cell-Derived Microparticles; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Double-Blind Method; Dyslipidemias; Endothelium, Vascular; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iontophoresis; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Pyrroles; Risk Factors; Skin; Sweden; Time Factors; Treatment Outcome; Vasodilator Agents | 2013 |
Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial.
Topics: Aged; Angina, Stable; Atorvastatin; Elective Surgical Procedures; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Necrosis; Percutaneous Coronary Intervention; Postoperative Complications; Preoperative Care; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Pharmacodynamic effects of adjunctive high dose atorvastatin on double dose clopidogrel in patients with high on-treatment platelet reactivity depending on diabetes mellitus status.
Topics: Aged; Atorvastatin; Clopidogrel; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Thrombosis; Ticlopidine | 2014 |
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Obesity; Peptide Fragments; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cholesterol; Cohort Studies; Cytochrome P-450 CYP3A; Databases, Factual; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Linear Models; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Neoplasm Proteins; Organic Anion Transporters; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2013 |
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
Topics: Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2013 |
Efficacy of topical atorvastatin for the treatment of pressure ulcers: a randomized clinical trial.
Topics: Administration, Topical; Aged; Atorvastatin; Chemistry, Pharmaceutical; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Male; Middle Aged; Pressure Ulcer; Pyrroles; Treatment Outcome | 2014 |
NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin.
Topics: Aged; Atorvastatin; Carrier Proteins; Case-Control Studies; Cell Line, Tumor; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammasomes; Interleukin-18; Interleukin-1beta; Lipids; Male; Middle Aged; NLR Family, Pyrin Domain-Containing 3 Protein; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Treatment Outcome | 2013 |
Can a high reloading dose of atorvastatin prior to percutaneous coronary intervention reduce periprocedural myocardial infarction?
Topics: Aged; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Placebos; Premedication; Pyrroles | 2014 |
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Dyslipidemias; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Japan; Male; Middle Aged; Oxazolidinones; Patient Safety; Pyrroles; Time Factors; Treatment Outcome; Young Adult | 2013 |
Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance.
Topics: Adult; Atorvastatin; Creatine Kinase; Double-Blind Method; Exercise; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscle Strength; Muscle, Skeletal; Muscles; Myalgia; Pyrroles; Treatment Outcome | 2013 |
Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease.
Topics: Absorption; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk | 2013 |
Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2014 |
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.
Topics: Aged; Alanine Transaminase; Anticholesteremic Agents; Atorvastatin; Biomarkers; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Single-Blind Method; Treatment Outcome | 2013 |
Atorvastatin and hormone therapy influence expression of ABCA1, APOA1 and SCARB1 in mononuclear cells from hypercholesterolemic postmenopausal women.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; ATP Binding Cassette Transporter 1; Cells, Cultured; Estradiol; Female; Heptanoic Acids; Heterocyclic Compounds; Humans; Hypercholesterolemia; Leukocytes, Mononuclear; Middle Aged; Postmenopause; Pyrroles; Scavenger Receptors, Class B; Transcriptome | 2013 |
The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Apolipoprotein A-V; Apolipoproteins A; Atorvastatin; Bezafibrate; Cholesterol, HDL; Drug Synergism; Drug Therapy, Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2013 |
No effect of atorvastatin and simvastatin on oxidative stress in patients at high risk for cardiovascular disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Deoxyguanosine; F2-Isoprostanes; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Peroxidase; Pyrroles; Simvastatin; Ubiquinone | 2013 |
C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
Topics: Aged; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Aggressive medical therapy alone is not adequate in certain patients with severe symptomatic carotid stenosis.
Topics: Aspirin; Atorvastatin; Carotid Artery Diseases; Clopidogrel; Constriction, Pathologic; Endovascular Procedures; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2013 |
Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
High-dose atorvastatin reduces periodontal inflammation: a novel pleiotropic effect of statins.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Periodontal Diseases; Pyrroles; Treatment Outcome | 2013 |
Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lipoproteins; Male; Middle Aged; Pyrroles; Quinolines; Risk Factors; Treatment Outcome; Triglycerides | 2013 |
Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9.
Topics: Adult; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases | 2013 |
A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRES
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Patient Safety; Phenylpropionates; Prospective Studies; Pyrroles; Risk Reduction Behavior; Treatment Failure; Treatment Outcome; Triglycerides | 2014 |
Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; Clopidogrel; Combined Modality Therapy; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prognosis; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ticlopidine | 2014 |
Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adult; Androgen Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Body Mass Index; Double-Blind Method; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperandrogenism; Hyperinsulinism; Hyperlipidemias; Insulin Resistance; Insulin-Secreting Cells; Middle Aged; Overweight; Polycystic Ovary Syndrome; Pyrroles | 2013 |
Effect of atorvastatin on baroreflex sensitivity in subjects with type 2 diabetes and dyslipidaemia.
Topics: Aged; Atorvastatin; Baroreflex; Body Mass Index; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Diet, Fat-Restricted; Dyslipidemias; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myalgia; Obesity; Patient Dropouts; Prospective Studies; Pyrroles; Risk Factors | 2014 |
Comparision of effects of rosuvastatin versus atorvastatin treatment on plasma levels of asymmetric dimethylarginine in patients with hyperlipidemia having coronary artery disease.
Topics: Arginine; Atorvastatin; Biomarkers; Coronary Angiography; Coronary Stenosis; Down-Regulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Severity of Illness Index; Sulfonamides; Time Factors; Treatment Outcome; Turkey | 2014 |
Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease.
Topics: Administration, Oral; Adult; Aged; Atorvastatin; Bacterial Infections; Cytokines; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Siblings; Survival Analysis; Tissue Donors; Transplantation Immunology; Transplantation, Homologous; Treatment Outcome; Virus Diseases; Young Adult | 2013 |
Effects of atorvastatin and ezetimibe on endothelial function in dyslipidemic patients with chronic kidney disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cross-Over Studies; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Oxidative Stress; Pyrroles; Renal Insufficiency, Chronic | 2014 |
Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Coronary Disease; Diuretics; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Prevalence; Pyrroles; Risk Factors; Treatment Outcome | 2014 |
The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease.
Topics: Alleles; Asian People; Atorvastatin; Coronary Disease; Cytochrome P-450 CYP3A; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2014 |
Preloading with atorvastatin before percutaneous coronary intervention in statin-naïve Asian patients with non-ST elevation acute coronary syndromes: A randomized study.
Topics: Acute Coronary Syndrome; Aged; Asian People; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Percutaneous Coronary Intervention; Postoperative Care; Postoperative Complications; Preoperative Care; Pyrroles; Time Factors; Ultrasonography | 2014 |
Randomized clinical trial: atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis.
Topics: Acute Disease; Adult; Atorvastatin; Colitis, Ulcerative; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intention to Treat Analysis; Male; Middle Aged; Placebo Effect; Prednisolone; Pyrroles; Severity of Illness Index | 2014 |
Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
Topics: Acetates; Acute Coronary Syndrome; Aged; Angina, Unstable; Atherosclerosis; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Heptanoic Acids; Humans; Indoles; Keto Acids; Male; Middle Aged; Myocardial Infarction; Phospholipases A; Phospholipases A2, Secretory; Pyrroles; Risk; Stroke; Survival Analysis; Treatment Outcome | 2014 |
Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes.
Topics: Aged; Arginine Vasopressin; Atorvastatin; Atrial Natriuretic Factor; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules; Male; Middle Aged; Natriuretic Peptide, Brain; Nitric Oxide; omega-N-Methylarginine; Pulse Wave Analysis; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome; Vascular Stiffness; Vasopressins | 2014 |
Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).
Topics: Atorvastatin; Contrast Media; Coronary Angiography; Dose-Response Relationship, Drug; Electrocardiography; Female; Fluorobenzenes; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Turkey | 2013 |
Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Docosahexaenoic Acids; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Eicosapentaenoic Acid; Heptanoic Acids; Humans; Insulin Resistance; Lipoproteins, VLDL; Male; Middle Aged; Obesity; Pyrroles; Treatment Outcome; Triglycerides | 2014 |
Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease.
Topics: Adult; Aged; Anti-Inflammatory Agents; Atorvastatin; Biomarkers; Creatinine; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Linear Models; Logistic Models; Male; Middle Aged; Pyrroles; Renal Insufficiency, Chronic; Tasmania; Time Factors; Treatment Outcome | 2014 |
High-dose atorvastatin reloading before percutaneous coronary intervention increased circulating endothelial progenitor cells and reduced inflammatory cytokine expression during the perioperative period.
Topics: Aged; Angina Pectoris; Antigens, CD; Atorvastatin; C-Reactive Protein; Cytokines; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelial Progenitor Cells; Female; Heptanoic Acids; Humans; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Period; Pyrroles; Troponin I | 2014 |
Pharmacodynamic comparison of pitavastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease treated with dual antiplatelet therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Atorvastatin; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Cytochrome P-450 CYP3A; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Quinolines; Ticlopidine | 2014 |
Atorvastatin 10 mg plus ezetimibe versus titration to atorvastatin 40 mg: attainment of European and Canadian guideline lipid targets in high-risk subjects ≥65 years.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Canada; Cholesterol, LDL; Double-Blind Method; Europe; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Treatment Outcome | 2014 |
Effect of intensive atorvastatin therapy on periprocedural PDCD4 expression in CD4+ T lymphocytes of patients with unstable angina undergoing percutaneous coronary intervention.
Topics: Aged; Angina, Unstable; Apoptosis Regulatory Proteins; Atorvastatin; C-Reactive Protein; CD4-Positive T-Lymphocytes; Creatine Kinase, MB Form; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-10; Male; Percutaneous Coronary Intervention; Pyrroles; RNA-Binding Proteins; RNA, Messenger; Troponin I; Tumor Necrosis Factor-alpha | 2014 |
Pharmacodynamic effects of atorvastatin versus rosuvastatin in coronary artery disease patients with normal platelet reactivity while on dual antiplatelet therapy--the PEARL randomized cross-over study.
Topics: Atorvastatin; Blood Platelets; Cholesterol, LDL; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP3A; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Research Design; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Tunica Intima; Ultrasonography, Interventional | 2014 |
Effect of steady-state atorvastatin on the pharmacokinetics of a single dose of colchicine in healthy adults under fasted conditions.
Topics: Adult; Anticholesteremic Agents; Area Under Curve; Atorvastatin; Colchicine; Drug Interactions; Fasting; Female; Gout Suppressants; Healthy Volunteers; Heptanoic Acids; Humans; Male; Pyrroles; Young Adult | 2014 |
Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
Topics: Aged; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol, LDL; Coronary Artery Disease; Drug Substitution; Dyslipidemias; Female; Fluorobenzenes; Guideline Adherence; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Societies, Medical; Sulfonamides; Time Factors; Treatment Outcome | 2014 |
The impact of type 2 diabetes and atorvastatin treatment on serum levels of MMP-7 and MMP-8.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Matrix Metalloproteinase 7; Matrix Metalloproteinase 8; Middle Aged; Pyrroles | 2014 |
Post-marketing study of clinical experience of atorvastatin 80 mg vs 40 mg in Indian patients with acute coronary syndrome- a randomized, multi-centre study (CURE-ACS).
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; India; Male; Middle Aged; Pyrroles; Secondary Prevention; Treatment Outcome | 2013 |
Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial.
Topics: Adjuvants, Immunologic; Adult; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Interferon beta-1b; Interferon-beta; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Pyrroles; Single-Blind Method; Treatment Outcome; Young Adult | 2014 |
Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
Topics: Adult; Atorvastatin; Cholesterol; Cost-Benefit Analysis; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Triglycerides | 2014 |
Pharmacological measures to increase HDL-C among high risk isolated low HDL cases: a randomized study amongst north Indians.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Fenofibrate; Heptanoic Acids; Humans; India; Lipids; Male; Middle Aged; Niacin; Pyrroles; Risk Factors | 2013 |
[The lipid-regulating effect and safety of combined statin and bezafibrate therapy in acute coronary syndrome patients complicating with dyslipidemia].
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Bezafibrate; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles; Treatment Outcome | 2013 |
Chemical modification of high density lipoprotein subfractions - HDL2 and HDL3 - after use of atorvastatin.
Topics: Adult; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL2; Lipoproteins, HDL3; Male; Pyrroles | 2014 |
Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling.
Topics: Aged; Aged, 80 and over; Apolipoprotein A-I; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Male; Middle Aged; Pyrimidines; Pyrroles; Quinolines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Middle Aged; Prognosis; Pyrroles; Risk Assessment; Stroke; Treatment Outcome; Vascular Diseases | 2014 |
Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL).
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve Stenosis; Atorvastatin; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Global Health; Heptanoic Acids; Humans; Incidence; Male; Middle Aged; Prognosis; Pyrroles; Risk Factors; Time Factors | 2014 |
The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Agents; China; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2014 |
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Oxidative Stress; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Uric Acid | 2014 |
Effects of atorvastatin on the pharmacokinetics of everolimus among kidney transplant recipients.
Topics: Adult; Area Under Curve; Atorvastatin; Cross-Over Studies; Everolimus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Transplantation; Middle Aged; Prospective Studies; Pyrroles; Sirolimus | 2014 |
Effect of change in body weight on incident diabetes mellitus in patients with stable coronary artery disease treated with atorvastatin (from the treating to new targets study).
Topics: Atorvastatin; Body Weight; Coronary Artery Disease; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Global Health; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Life Style; Male; Middle Aged; Pyrroles; Risk Factors; Time Factors; Weight Loss | 2014 |
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atorvastatin; Azetidines; Cholesterol, LDL; Combined Modality Therapy; Double-Blind Method; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Least-Squares Analysis; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases | 2014 |
Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Blood Pressure; Cross-Over Studies; Double-Blind Method; Epithelial Sodium Channels; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Pyrroles; Renal Insufficiency, Chronic; Vascular Stiffness | 2014 |
Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial.
Topics: Adolescent; Adult; Aged; Atorvastatin; Bronchiectasis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Forced Expiratory Volume; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quality of Life; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
LADA and CARDS: a prospective study of clinical outcome in established adult-onset autoimmune diabetes.
Topics: Adult; Age of Onset; Aged; Anticholesteremic Agents; Atorvastatin; Autoantibodies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Germany; Glucose Intolerance; Glutamate Decarboxylase; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Middle Aged; Phenotype; Prevalence; Prospective Studies; Pyrroles; Risk Factors | 2014 |
[Series: Clinical study from Japan and its reflections; atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial].
Topics: Adult; Aged; Aged, 80 and over; Aorta; Atorvastatin; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Japan; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Risk | 2014 |
Rationale and design of a randomized clinical study to investigate the effect of ezetimibe, a cholesterol absorption inhibitor, on the regression of intracoronary plaque evaluated by non-obstructive angioscopy and ultrasound: The ZIPANGU study.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Pyrroles; Research Design; Treatment Outcome; Ultrasonography, Interventional | 2014 |
Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882.
Topics: Adolescent; Adult; Atorvastatin; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyridines; Pyrroles; Simvastatin; Substrate Specificity; Young Adult | 2014 |
Efficacy and safety of intensive statin therapy in Chinese patients with atherosclerotic intracranial arterial stenosis: a single-center, randomized, single-blind, parallel-group study with one-year follow-up.
Topics: Aged; Atorvastatin; China; Clinical Protocols; Constriction, Pathologic; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Ischemic Attack, Transient; Male; Middle Aged; Middle Cerebral Artery; Pyrroles; Single-Blind Method; Stroke; Vertebrobasilar Insufficiency | 2014 |
N-of-1 (single-patient) trials for statin-related myalgia.
Topics: Aged; Aged, 80 and over; Atorvastatin; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myalgia; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Sulfonamides | 2014 |
Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 2014 |
Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
Topics: Atorvastatin; Carotid Intima-Media Thickness; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Triglycerides | 2014 |
Effects of ezetimibe on endothelial progenitor cells and microparticles in high-risk patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Blood Platelets; C-Reactive Protein; Cardiovascular Diseases; Cell-Derived Microparticles; Cholesterol, LDL; Drug Interactions; Endothelial Progenitor Cells; Ezetimibe; Heptanoic Acids; Humans; Middle Aged; Pyrroles; Risk | 2014 |
Effect of atorvastatin on vascular endothelial function in moderately nicotine-dependent smokers.
Topics: Adult; Atorvastatin; Cholesterol, LDL; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Lipids; Lipoproteins, HDL; Male; Middle Aged; Nicotine; Pyrroles; Tobacco Use Disorder; Triglycerides; Vasodilation | 2014 |
The incidence of kidney injury for patients treated with a high-potency versus moderate-potency statin regimen after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Atorvastatin; Creatinine; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Pravastatin; Pyrroles | 2014 |
Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Benzodiazepines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Reference Values; Risk Assessment; Treatment Outcome | 2014 |
Atorvastatin effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial.
Topics: Adult; Antirheumatic Agents; Atorvastatin; Blood Sedimentation; C-Reactive Protein; Double-Blind Method; Female; Heptanoic Acids; Humans; Lipids; Lupus Erythematosus, Systemic; Male; Middle Aged; Pyrroles; Severity of Illness Index; Treatment Outcome | 2014 |
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2014 |
[Optimization of long-term hypolipidemia treatment of patients with myocardial infarction in combination with non-alcoholic steatohepatitis].
Topics: Atorvastatin; Bilirubin; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipids; Liver; Middle Aged; Myocardial Infarction; Non-alcoholic Fatty Liver Disease; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Transaminases; Triglycerides; Ursodeoxycholic Acid | 2014 |
[Dose-dependent effect of atorvastatin on erectile function and androgen status in men with high cardiovascular risk].
Topics: Adult; Androgens; Atorvastatin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Erectile Dysfunction; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Penile Erection; Pyrroles; Risk Factors | 2014 |
Patients with stable coronary artery disease receiving chronic statin treatment who are undergoing noncardiac emergency surgery benefit from acute atorvastatin reload.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Coronary Artery Disease; Death, Sudden, Cardiac; Disease-Free Survival; Double-Blind Method; Emergency Treatment; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Length of Stay; Myocardial Infarction; Postoperative Complications; Preoperative Care; Prospective Studies; Pyrroles; Treatment Outcome | 2014 |
Effect of atorvastatin on pancreatic Beta-cell function and insulin resistance in type 2 diabetes mellitus patients: a randomized pilot study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heptanoic Acids; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Lipids; Male; Middle Aged; Pilot Projects; Pyrroles; Quality of Life | 2014 |
[Effect of atorvastatin on exercise tolerance in patients with diastolic dysfunction and exercise-induced hypertension].
Topics: Aged; Atorvastatin; C-Reactive Protein; Double-Blind Method; Endothelins; Exercise Tolerance; Female; Heart Failure; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyrroles | 2014 |
Evaluation of atorvastatin efficacy and toxicity on spermatozoa, accessory glands and gonadal hormones of healthy men: a pilot prospective clinical trial.
Topics: Acrosome Reaction; Adult; Antispermatogenic Agents; Asthenozoospermia; Atorvastatin; Biomarkers; Cholesterol; Down-Regulation; Epididymis; Gonadal Hormones; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pilot Projects; Prostate; Pyrroles; Semen; Spermatogenesis; Spermatozoa; Testis; Young Adult | 2014 |
Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study.
Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelial Progenitor Cells; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrroles; Quinolines; Risk Factors; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atorvastatin; Cholic Acids; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Middle Aged; Nephelometry and Turbidimetry; Pyrroles; Steroid Metabolism, Inborn Errors; Subtilisin; Time Factors; Treatment Outcome | 2014 |
[The influence of citoflavin on molecular mechanisms of hypertensive encephalopathy development in patients with systolic arterial hypertension].
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Atorvastatin; Blood Pressure; Blood Proteins; Drug Combinations; Drug Therapy, Combination; Echocardiography; Female; Flavin Mononucleotide; Hemodynamics; Heptanoic Acids; Humans; Hypertension; Hypertensive Encephalopathy; Inosine Diphosphate; Male; Neuroprotective Agents; Niacinamide; Pyrroles; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Succinates; Systole; Tetrazoles; Valine; Valsartan | 2014 |
Pregnancy-associated plasma protein A associates with cardiovascular events in diabetic hemodialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cause of Death; Comorbidity; Death, Sudden, Cardiac; Diabetes Complications; Diabetic Nephropathies; Female; Follow-Up Studies; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Mortality; Myocardial Infarction; Pregnancy-Associated Plasma Protein-A; Prognosis; Proportional Hazards Models; Prospective Studies; Pyrroles; Renal Dialysis; Risk Assessment; Smoking; Stroke; Young Adult | 2014 |
Influence of carotid artery stenting on cognition of elderly patients with severe stenosis of the internal carotid artery.
Topics: Aged; Analysis of Variance; Angioplasty; Aspirin; Atorvastatin; Carotid Stenosis; China; Clopidogrel; Cognition; Female; Heptanoic Acids; Humans; Male; Pyrroles; Quality of Life; Regional Blood Flow; Stents; Ticlopidine; Treatment Outcome; Ultrasonography, Doppler, Transcranial | 2014 |
In a randomized, double-blind clinical trial, adjuvant atorvastatin improved symptoms of depression and blood lipid values in patients suffering from severe major depressive disorder.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Chi-Square Distribution; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lipids; Male; Psychiatric Status Rating Scales; Pyrroles; Treatment Outcome; Young Adult | 2014 |
[Cardioprotective effect and mechanism of intensive lipid modulation on patients with coronary artery disease undergoing noncardiac surgery].
Topics: Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Brugada Syndrome; Cardiac Conduction System Disease; Coronary Artery Disease; Elective Surgical Procedures; Heart Conduction System; Heptanoic Acids; Humans; Lipids; Myocardial Infarction; Perioperative Period; Pyrroles | 2014 |
Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
Topics: Aged; Atorvastatin; Double-Blind Method; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Kidney; Male; Middle Aged; Pyrroles; Stroke | 2014 |
Decreased levels of homoarginine and asymmetric dimethylarginine in children with type 1 diabetes: associations with cardiovascular risk factors but no effect by atorvastin.
Topics: Adolescent; Anticholesteremic Agents; Arginine; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Female; Follow-Up Studies; Glycated Hemoglobin; Heptanoic Acids; Homoarginine; Humans; Lipids; Male; Pilot Projects; Pyrroles; Risk Factors; Treatment Outcome | 2015 |
Effect of high-dose statin loading on biomarkers related to inflammation and renal injury in patients hospitalized with acute heart failure. Randomized, controlled, open-label, prospective pilot study.
Topics: Acute Kidney Injury; Administration, Oral; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Female; Heart Failure; Heptanoic Acids; Hospital Mortality; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pilot Projects; Prospective Studies; Pyrroles | 2014 |
Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabete
Topics: Asian People; Atorvastatin; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Japan; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2014 |
Use of ivabradine and atorvastatin in emergent orthopedic lower limb surgery and computed tomography coronary plaque imaging and novel biomarkers of cardiovascular stress and lipid metabolism for the study and prevention of perioperative myocardial infarc
Topics: Anti-Arrhythmia Agents; Atorvastatin; Benzazepines; Biomarkers; Clinical Protocols; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Emergencies; Femoral Neck Fractures; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ivabradine; Middle Aged; Myocardial Infarction; Orthopedic Procedures; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Pyrroles; Research Design; Risk Factors; Severity of Illness Index; Tachycardia, Ventricular; Tomography, X-Ray Computed; Treatment Outcome; Victoria | 2014 |
Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Incidence; Longitudinal Studies; Male; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography | 2014 |
Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Blood Pressure; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Sleep Apnea, Obstructive | 2014 |
Effect of a hydrophilic and a hydrophobic statin on cardiac salvage after ST-elevated acute myocardial infarction - a pilot study.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Echocardiography; Fatty Acids; Female; Fluorobenzenes; Heart; Heptanoic Acids; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iodobenzenes; Male; Middle Aged; Myocardial Infarction; Myocardium; Natriuretic Peptide, Brain; Pilot Projects; Prospective Studies; Pyrimidines; Pyrroles; Radionuclide Imaging; Rosuvastatin Calcium; Sulfonamides; Thallium; Tomography, Emission-Computed, Single-Photon; Ubiquinone | 2014 |
The complementary effects of atorvastatin and exercise treatment on the composition and stability of the atherosclerotic plaques in ApoE knockout mice.
Topics: Animals; Apolipoproteins E; Atorvastatin; Blood Glucose; Cholesterol; Collagen; Diet, High-Fat; Elastin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 3; Matrix Metalloproteinase 8; Matrix Metalloproteinase 9; Mice; Mice, Knockout; Myocytes, Smooth Muscle; Physical Conditioning, Animal; Plaque, Atherosclerotic; Pyrroles; Random Allocation; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinase-3; Triglycerides | 2014 |
[Antiatherogenic and nephroprotective efficacy of atorvastatin in patients with chronic renal disease of non-diabetic origin].
Topics: Anticholesteremic Agents; Atorvastatin; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Kidney Function Tests; Lipid Metabolism; Male; Middle Aged; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome | 2014 |
Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS Studies
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
[Treatment of combined hyperlipidemia patients by jiangzhi tongluo soft capsule combined atorvastatin calcium tablet: a clinical study].
Topics: Adult; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2014 |
Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention.
Topics: Aged; Atorvastatin; Contrast Media; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides | 2014 |
A randomized, double blind, placebo-controlled pilot trial of the safety and efficacy of atorvastatin in children with elevated low-density lipoprotein cholesterol (LDL-C) and type 1 diabetes.
Topics: Adolescent; Atorvastatin; Child; Cholesterol, LDL; Combined Modality Therapy; Diabetes Mellitus, Type 1; Diet, Diabetic; Diet, Fat-Restricted; Double-Blind Method; Drug Monitoring; Exercise; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Pilot Projects; Pyrroles | 2015 |
Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis.
Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Germany; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoproteins, HDL; Male; Middle Aged; Proportional Hazards Models; Pulmonary Surfactant-Associated Protein B; Pyrroles; Renal Dialysis; Risk Factors; Serum Amyloid A Protein; Time Factors; Treatment Outcome | 2015 |
Atorvastatin treatment and carotid plaque morphology in first-ever atherosclerotic transient ischemic attack/stroke: a case-control study.
Topics: Aged; Atorvastatin; Carotid Artery Diseases; Case-Control Studies; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Ischemic Attack, Transient; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Stroke; Ultrasonography | 2015 |
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Topics: Acute Coronary Syndrome; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Stroke; Sulfonamides; Treatment Outcome | 2014 |
Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial.
Topics: Adult; Anti-HIV Agents; Atorvastatin; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocyte Activation; Lymphocyte Depletion; Male; Middle Aged; Pyrroles; Uganda; Viral Load | 2015 |
Atorvastatin calcium in combination with methylprednisolone for the treatment of multiple sclerosis relapse.
Topics: Administration, Oral; Adult; Atorvastatin; Brain; Cytokines; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Pyrroles; Spinal Cord; Treatment Outcome | 2014 |
Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study.
Topics: Aged; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Macrophages; Male; Malondialdehyde; Matrix Metalloproteinase 9; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Tomography, Optical Coherence | 2014 |
Calcifediol improves lipid profile in osteopenicatorvastatin-treated postmenopausal women.
Topics: Administration, Oral; Atorvastatin; Bone Diseases, Metabolic; Calcifediol; Cholecalciferol; Dietary Supplements; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Middle Aged; Postmenopause; Pyrroles; Vitamin D; Vitamin D Deficiency; Vitamins | 2015 |
Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients.
Topics: AC133 Antigen; Aged; Aged, 80 and over; Antigens, CD; Antigens, CD34; Atorvastatin; Biomarkers; Brachial Artery; Cell Movement; Cross-Over Studies; Double-Blind Method; Endothelial Progenitor Cells; Endothelium, Vascular; Female; Glycoproteins; Greece; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Male; Middle Aged; Myocardial Ischemia; Peptides; Pyrroles; Recovery of Function; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor Receptor-2; Vasodilation | 2015 |
LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.
Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Cross-Sectional Studies; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrroles; Risk Factors | 2014 |
High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Netherlands; Peripheral Arterial Disease; Prospective Studies; Pyrroles; Scandinavian and Nordic Countries; Simvastatin | 2015 |
Association of high-density lipoprotein cholesterol with improvement of endothelial dysfunction recovery in renovascular disease.
Topics: Adult; Atorvastatin; Biomarkers; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Kidney Diseases; Male; Middle Aged; Niacin; Nitrates; Pakistan; Pyrroles; Recovery of Function; Renal Artery; Time Factors; Treatment Outcome; Ultrasonography, Doppler | 2015 |
[IMPROVE-IT Study proves effectiveness of ezetimib. The Higgs particle of lipidologists].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Simvastatin | 2014 |
[Efficacy and safety comparison of different statins in elderly patients].
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
Beneficial effects of perioperative statins for major pulmonary resection.
Topics: Aged; Atorvastatin; Biomarkers; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Male; Middle Aged; New York City; Perioperative Care; Pneumonectomy; Postoperative Complications; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome | 2015 |
Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trials.
Topics: Atorvastatin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Follow-Up Studies; Global Health; Heptanoic Acids; Humans; Incidence; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Sex Factors | 2015 |
Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.
Topics: Adult; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Creatinine; Diabetes Complications; Diabetic Nephropathies; Dose-Response Relationship, Drug; Double-Blind Method; Europe; Fluorobenzenes; Heptanoic Acids; Humans; Kidney; Lipids; North America; Proteinuria; Pyrimidines; Pyrroles; Rosuvastatin Calcium; South America; Sulfonamides | 2015 |
Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Neoplasms; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Function, Left | 2015 |
[Pleiotropic effects of atorvastatin and dynamics of quality of life characteristics in patients with hypertensive disease and metabolic syndrome].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypertension; Metabolic Syndrome; Middle Aged; Pyrroles; Quality of Life; Treatment Outcome | 2013 |
[Effect of intensive pretreatment with atorvastatin calcium on outcomes of percutaneous coronary intervention in elderly patients with coronary heart disease].
Topics: Aged, 80 and over; Atorvastatin; Biomarkers; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrroles | 2015 |
Changes of naturally occurring CD4(+)CD25(+) FOXP3(+) regulatory T cells in patients with acute coronary syndrome and the beneficial effects of atorvastatin treatment.
Topics: Acute Coronary Syndrome; Adult; Aged; Atorvastatin; CD4 Antigens; Cytokines; Female; Forkhead Transcription Factors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-2 Receptor alpha Subunit; Male; Middle Aged; Pyrroles; RNA, Messenger; T-Lymphocytes, Regulatory | 2015 |
Combined effect of appointment telmisartan and atorvastatin on hemodynamic indicators and the indicators of lipid profile in patients with arterial hypertension combined with obesity and steatohepatitis.
Topics: Acetamides; Adipokines; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Benzoates; Breath Tests; Cholesterol, LDL; Drug Therapy, Combination; Fatty Liver; Female; Hemodynamics; Heptanoic Acids; Humans; Hypertension; Lipids; Male; Middle Aged; Obesity; Pyrroles; Telmisartan; Triglycerides | 2014 |
Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial.
Topics: Aged; Apolipoprotein B-100; Atorvastatin; Biomarkers; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidation-Reduction; Phospholipids; Pyrroles; Risk Factors | 2015 |
[Clinical trials for treatment of primary hyperlipidemia by using acupuncture in combination with Lipitor].
Topics: Acupuncture Therapy; Adult; Aged; Atorvastatin; Cholesterol, LDL; Combined Modality Therapy; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Triglycerides | 2015 |
Visit-to-visit low-density lipoprotein cholesterol variability and risk of cardiovascular outcomes: insights from the TNT trial.
Topics: Adult; Aged; Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Follow-Up Studies; Heart Arrest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pyrroles; Stroke | 2015 |
The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial.
Topics: Aged; Anti-Inflammatory Agents; Aortic Diseases; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Double-Blind Method; Female; Fluorodeoxyglucose F18; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Middle Aged; Multimodal Imaging; p38 Mitogen-Activated Protein Kinases; Plaque, Atherosclerotic; Positron-Emission Tomography; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrroles; Radiopharmaceuticals; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Triazines; United States | 2015 |
Pharmacokinetic Drug-Drug Interaction Study Between Raltegravir and Atorvastatin 20 mg in Healthy Volunteers.
Topics: Adolescent; Adult; Anti-HIV Agents; Anticholesteremic Agents; Area Under Curve; Atorvastatin; Cross-Over Studies; Drug Interactions; Female; Healthy Volunteers; Heptanoic Acids; Humans; Lipids; Male; Plasma; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Time Factors; Young Adult | 2015 |
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Oxazolidinones; Pyrroles; Time Factors; Triglycerides | 2015 |
Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patients.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholestanol; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Renal Dialysis | 2015 |
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.
Topics: Aged; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome | 2015 |
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Denmark; Double-Blind Method; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Netherlands; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Young Adult | 2015 |
[In what extend we can reach the current LDL-cholesterol treatment goals in secondary prevention].
Topics: Acute Coronary Syndrome; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Goals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Retrospective Studies; Secondary Prevention; Treatment Outcome | 2015 |
On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study).
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Leptin; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pravastatin; Pyrroles; Recurrence; Resistin; Retrospective Studies; Risk Factors; Survival Rate; Thrombolytic Therapy; United States | 2015 |
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Drug Monitoring; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heptanoic Acids; Humans; Japan; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles; Treatment Outcome; Ultrasonography, Interventional | 2015 |
[Comparative Randomized Study of the Effects of Long-Term Therapy With Rosuvastatin and Combination of Atorvastatin and Ezetimibe on Carbohydrate Metabolism and Adipokines Levels in Patients With Coronary Artery Disease and Diabetes Mellitus].
Topics: Adipokines; Anticholesteremic Agents; Atorvastatin; Azetidines; Blood Glucose; Carbohydrate Metabolism; Coronary Artery Disease; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2015 |
Therapeutic lifestyle change intervention improved metabolic syndrome criteria and is complementary to amlodipine/atorvastatin.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Behavior Therapy; Biomarkers; Blood Pressure; Cardiometabolic Risk Factors; Combined Modality Therapy; Drug Combinations; Female; Heptanoic Acids; Humans; Life Style; Lipids; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Oxidative Stress; Placebos; Pyrroles; Risk Reduction Behavior | 2020 |
Safety of Atorvastatin in Patients With Stable Systemic Autoimmune Myopathies: A Pilot Longitudinal Study.
Topics: Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Middle Aged; Muscular Diseases; Pyrroles | 2021 |
Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pyrroles; Quinolines; Treatment Outcome | 2020 |
Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ω-3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Random
Topics: Aged; Atorvastatin; Double-Blind Method; Fatty Acids, Omega-3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Pyrroles; Treatment Outcome; Triglycerides | 2021 |
[Efficacy and safety of various doses of hybutimibe monotherapy or in combination with atorvastatin for primary hypercholesterolemia: a multicenter, randomized, double-blind, double-dummy, parallel-controlled phase Ⅲ clinical trial].
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2023 |
Comparison of efficiency between Rosuvastatin and Atorvastatin in reducing low-density lipoprotein (LDL-C) in patients with diabetes mellitus.
Topics: Atorvastatin; Cholesterol, LDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2022 |
Plasma concentration of atorvastatin metabolites correlates with low-density lipoprotein cholesterol reduction in patients with coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Triglycerides | 2023 |
Effectiveness of low-intensity atorvastatin 5 mg and ezetimibe 10 mg combination therapy compared with moderate-intensity atorvastatin 10 mg monotherapy: A randomized, double-blinded, multi-center, phase III study.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Treatment Outcome | 2023 |
2979 other study(ies) available for pyrroles and atorvastatin
| Article | Year |
|---|---|
Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Fatty Acids, Unsaturated; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Lovastatin; Male; Pravastatin; Pyrroles; Rats; Rats, Inbred Strains; Sterols; Tetrazoles; Tissue Distribution | 1992 |
Hep-G2 cells and primary rat hepatocytes differ in their response to inhibitors of HMG-CoA reductase.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Fibroblasts; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver Neoplasms; Lovastatin; Male; Naphthalenes; Pravastatin; Pyrroles; Rats; Rats, Inbred Strains; Sterols; Tetrazoles; Tumor Cells, Cultured | 1990 |
Comparative effects of HMG-CoA reductase inhibitors on apo B production in the casein-fed rabbit: atorvastatin versus lovastatin.
Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Caseins; Cholesterol; Diet; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iodine Radioisotopes; Lipoproteins, LDL; Lovastatin; Male; Pyrroles; Rabbits; Random Allocation | 1995 |
Developmental toxicity of the HMG-CoA reductase inhibitor, atorvastatin, in rats and rabbits.
Topics: Abnormalities, Drug-Induced; Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; Dose-Response Relationship, Drug; Embryonic and Fetal Development; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pregnancy; Pyrroles; Rabbits; Rats; Rats, Sprague-Dawley; Toxicity Tests | 1994 |
The genotoxicity profile of atorvastatin, a new drug in the treatment of hypercholesterolemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cricetinae; Cricetulus; Escherichia coli; Female; Fibroblasts; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoxanthine Phosphoribosyltransferase; Lung; Male; Mice; Micronucleus Tests; Mutagenicity Tests; Pyrroles; Salmonella typhimurium | 1995 |
The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981.
Topics: Atorvastatin; Buffers; Chromatography, High Pressure Liquid; Drug Stability; Heptanoic Acids; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lactones; Pyrroles; Solubility; Temperature | 1993 |
Levels of soluble cell adhesion molecules in patients with dyslipidemia.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cell Adhesion Molecules; Colestipol; Drug Therapy, Combination; E-Selectin; Endothelium, Vascular; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lovastatin; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Solubility; Vascular Cell Adhesion Molecule-1 | 1996 |
Effects of atorvastatin, an HMG-CoA reductase inhibitor, on hepatic oxidative metabolism of antipyrine.
Topics: Administration, Oral; Adult; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Atorvastatin; Drug Interactions; Drug Therapy, Combination; Enzyme Inhibitors; Heptanoic Acids; Humans; Male; Pyrroles | 1996 |
Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Guinea Pigs; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Liver; Lovastatin; Male; Pyrroles; Rabbits; Rats; Rats, Sprague-Dawley; Triglycerides | 1995 |
Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1996 |
Fertility and general reproduction studies in rats with the HMG-CoA reductase inhibitor, atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Enzyme Inhibitors; Female; Fertility; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Reproduction | 1996 |
Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea pig.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Guinea Pigs; Heptanoic Acids; Lipids; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Male; Microsomes, Liver; Pyrroles; Receptors, Lipoprotein; Triglycerides | 1996 |
[Lowering cholesterol. New concepts with atorvastatin].
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipids; Pyrroles; Treatment Outcome | 1997 |
The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.
Topics: Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 1997 |
Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells.
Topics: Animals; Apoptosis; Atorvastatin; Carotid Stenosis; Cell Division; Cells, Cultured; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Muscle, Smooth, Vascular; Pravastatin; Pyrroles; Rabbits; Simvastatin | 1997 |
[What is new? Therapy with lipid lowering agents].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles | 1997 |
Atorvastatin: a new agent for hyperlipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pyrroles | 1997 |
[Effective cholesterol and triglyceride lowering with atorvastatin].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertriglyceridemia; Pyrroles | 1996 |
Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol; Depression, Chemical; Dietary Fats; Female; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestine, Small; Kinetics; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Male; Models, Biological; Pyrroles; Receptors, LDL; RNA, Messenger; Swine; Swine, Miniature; Triglycerides | 1997 |
Atorvastatin versus simvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin | 1997 |
Atorvastatin is not cataractogenic in beagle dogs.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cataract; Cholesterol; Dogs; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lens, Crystalline; Male; Pyrroles; Time Factors | 1997 |
Rhabdomyolysis after taking atorvastatin with gemfibrozil.
Topics: Adult; Atorvastatin; Drug Interactions; Drug Therapy, Combination; Female; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hypertriglyceridemia; Hypolipidemic Agents; Pyrroles; Rhabdomyolysis | 1998 |
Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity.
Topics: Animals; Atorvastatin; Cholesterol; Gene Expression; Half-Life; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Microsomes, Liver; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, LDL; RNA, Messenger; Therapeutic Irrigation; Up-Regulation | 1998 |
Development, validation, and interlaboratory comparison of an HMG-CoA reductase inhibition assay for quantitation of atorvastatin in plasma matrices.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Biological Assay; Cholesterol, LDL; Dogs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Laboratories; Linear Models; Mice; Pyrroles; Rats | 1998 |
Effect of atorvastatin on plasma fibrinogen.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles | 1998 |
Atorvastatin does not alter the anticoagulant activity of warfarin.
Topics: Adult; Aged; Anticoagulants; Atorvastatin; Blood Coagulation; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prothrombin; Prothrombin Time; Pyrroles; Warfarin | 1997 |
Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Carcinoma, Hepatocellular; Cholesterol; Enzyme Induction; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Liver; Liver Neoplasms; Male; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Simvastatin; Transcription, Genetic; Tumor Cells, Cultured | 1998 |
Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Research Design; Treatment Outcome | 1998 |
Pre- and postnatal toxicity of the HMG-CoA reductase inhibitor atorvastatin in rats.
Topics: Animals; Area Under Curve; Atorvastatin; Behavior, Animal; Body Weight; Eating; Female; Fertility; Gastric Mucosa; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactation; Male; Postural Balance; Pregnancy; Pregnancy, Animal; Prenatal Exposure Delayed Effects; Pyrroles; Rats; Rats, Sprague-Dawley; Reflex, Startle; Survival Rate; Tissue Distribution | 1998 |
Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Renal Insufficiency | 1997 |
Statins and fibrinogen.
Topics: Anticholesteremic Agents; Atorvastatin; Fibrinogen; Heptanoic Acids; Humans; Lipoprotein(a); Pyrroles | 1998 |
Statins and fibrinogen.
Topics: Anticholesteremic Agents; Atorvastatin; Fibrinogen; Heptanoic Acids; Humans; Pyrroles | 1998 |
Statins and fibrinogen.
Topics: Anticholesteremic Agents; Atorvastatin; Fibrinogen; Heptanoic Acids; Humans; Pyrroles | 1998 |
Statins and fibrinogen.
Topics: Anticholesteremic Agents; Atorvastatin; Fibrinogen; Heptanoic Acids; Humans; Pyrroles | 1998 |
Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells.
Topics: Albumins; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cell Membrane Permeability; Cholesterol; Cholesterol Esters; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Fluid; Leupeptins; Multienzyme Complexes; Oleic Acid; Proteasome Endopeptidase Complex; Pyrroles; Tumor Cells, Cultured | 1998 |
Toxic epidermal necrolysis from atorvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Stevens-Johnson Syndrome | 1998 |
[Prevention of cardiovascular diseases: Value of CSE inhibitors in the management of lipid metabolism disorders].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Pyrroles | 1998 |
Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.
Topics: Animals; Atorvastatin; Cattle; Cells, Cultured; Endothelin-1; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyrroles; RNA, Messenger; Simvastatin | 1998 |
Atorvastatin (Lipitor).
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic | 1998 |
Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits.
Topics: Acyltransferases; Animals; Atorvastatin; Bezafibrate; Cholesterol; Diacylglycerol O-Acyltransferase; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hypolipidemic Agents; Lipids; Liver; Male; Phospholipids; Pyrroles; Rabbits; Simvastatin; Triglycerides | 1998 |
Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation.
Topics: Antioxidants; Atorvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hypolipidemic Agents; In Vitro Techniques; Lipid Peroxidation; Lipoproteins, LDL; Pyrroles | 1998 |
Metabolism and excretion studies in mouse after single and multiple oral doses of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Carbon Radioisotopes; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Enzyme Induction; Feces; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Mice; Mice, Inbred Strains; Pyrroles | 1998 |
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 1998 |
[Drug clinics. Drug of the month. Atorvastatin (Lipitor)].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diet, Fat-Restricted; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Liver; Pyrroles; Receptors, LDL; Tablets; Triglycerides | 1998 |
3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture.
Topics: Animals; Apoptosis; Atorvastatin; Cell Survival; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Mevalonic Acid; Muscle, Smooth, Vascular; Polyisoprenyl Phosphates; Protein Prenylation; Pyrroles; Rats; Rats, Sprague-Dawley; Sesquiterpenes; Solubility | 1998 |
Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Protease Inhibitors; Pyrroles; Ritonavir; Saquinavir | 1998 |
Atorvastatin-induced severe thrombocytopenia.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Thrombocytopenia | 1998 |
Therapy and clinical trials.
Topics: Antioxidants; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Vitamin A; Vitamin E | 1998 |
The emergence of triglycerides as a significant independent risk factor in coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Triglycerides | 1998 |
The HMG-CoA reductase inhibitor atorvastatin increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs.
Topics: Animals; Atorvastatin; Chylomicrons; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Lipoproteins, VLDL; Metabolic Clearance Rate; Postprandial Period; Pyrroles; Receptors, LDL; Swine; Swine, Miniature; Triglycerides | 1998 |
Cost-effectiveness of statins.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Markov Chains; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1998 |
HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.
Topics: Animals; Atorvastatin; Chemokine CCL2; Coronary Artery Disease; Disease Models, Animal; Evaluation Studies as Topic; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; NF-kappa B; Pyrroles; Rabbits; Random Allocation; Tunica Intima | 1998 |
Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho-hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Chromatography, High Pressure Liquid; Dogs; Heptanoic Acids; Humans; Mass Spectrometry; Pyrroles; Quality Control; Rats; Solutions; Species Specificity | 1999 |
After I had a heart attack and two bypass operations, I was put on Lipitor to lower my cholesterol. My cholesterol was never high--about 170-180 mg/dL. But my HDL was always low and triglycerides were somewhat high. Now my total cholesterol is 124 and my
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hypertriglyceridemia; Pyrroles | 1999 |
[Evaluation of the efficacy of statin therapy in dyslipidemic diseases such as combined hypercholesterolemia IIA and hyperlipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Male; Middle Aged; Pyrroles; Time Factors | 1998 |
Judicious evaluation of adverse drug reactions: inaccurate assessment of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced muscle injury.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Atorvastatin; Diagnostic Errors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pyrroles; Rhabdomyolysis; Simvastatin | 1999 |
Atorvastatin in the management of an index patient with complete hepatic lipase deficiency.
Topics: Anticholesteremic Agents; Atorvastatin; Follow-Up Studies; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipase; Lipids; Liver; Male; Pyrroles | 1999 |
Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Benzimidazoles; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Ketoconazole; Kinetics; Lovastatin; Mibefradil; Microsomes, Liver; Oxidoreductases, N-Demethylating; Pyridines; Pyrroles; Simvastatin; Tetrahydronaphthalenes | 1999 |
Erythromycin coadministration increases plasma atorvastatin concentrations.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Area Under Curve; Atorvastatin; Drug Interactions; Erythromycin; Female; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 1999 |
Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Interactions; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin | 1999 |
Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin.
Topics: Apolipoproteins B; Atorvastatin; Carrier Proteins; Cell Line; Cholesterol Esters; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lipoproteins; Liver; Pyrroles; Receptors, LDL; RNA, Messenger; Simvastatin | 1999 |
Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model.
Topics: Animals; Aorta; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Male; Platelet Adhesiveness; Platelet Aggregation; Pyrroles; Rabbits; Simvastatin; Thrombosis | 1999 |
Quantitation of the acid and lactone forms of atorvastatin and its biotransformation products in human serum by high-performance liquid chromatography with electrospray tandem mass spectrometry.
Topics: Acids; Anticholesteremic Agents; Atorvastatin; Biotransformation; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Indicators and Reagents; Lactones; Mass Spectrometry; Pyrroles; Quality Control | 1999 |
Effect of atorvastatin on low-density lipoprotein subfraction profile.
Topics: Adult; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 1999 |
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 1999 |
Antioxidant therapy for coronary artery disease: don't paint the walls without treating the termites!
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Antioxidants; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Lung Neoplasms; Oxidation-Reduction; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Risk; Survival Analysis; Treatment Outcome; Vitamin A; Vitamin E | 1999 |
Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Lipids; Platelet Aggregation; Pyrroles; Swine; von Willebrand Factor | 1999 |
Lipophilic statins induce apoptosis of human vascular smooth muscle cells.
Topics: Animals; Anticholesteremic Agents; Apoptosis; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth, Vascular; Pravastatin; Protein Prenylation; Pyrroles; Rats; Simvastatin | 1999 |
Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Proportional Hazards Models; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Research Design; Treatment Outcome | 1999 |
Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity.
Topics: Animals; Anticholesteremic Agents; Aorta; Atorvastatin; Calcium; Cells, Cultured; Chelating Agents; Dose-Response Relationship, Drug; Drug Interactions; Fura-2; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Mevalonic Acid; Muscle Contraction; Muscle, Smooth, Vascular; Phenylephrine; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Vasoconstrictor Agents | 1999 |
Metabolism and excretion of atorvastatin in rats and dogs.
Topics: Animals; Atorvastatin; Bile; Biotransformation; Chromatography, High Pressure Liquid; Dogs; Female; Glucuronidase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Rats; Species Specificity; Spectrometry, Mass, Fast Atom Bombardment | 1999 |
Efficacy of statin therapy: possible effect of phenytoin.
Topics: Anticholesteremic Agents; Atorvastatin; Cytochrome P-450 Enzyme System; Drug Interactions; Epilepsy; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Middle Aged; Phenytoin; Pyrroles; Simvastatin | 1999 |
Images in clinical medicine. Homozygous familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Elbow; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Male; Pyrroles | 1999 |
Atorvastatin for protease inhibitor-related hyperlipidaemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Male; Pyrroles; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 1999 |
Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits.
Topics: Acyl Coenzyme A; Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, Dietary; Choline-Phosphate Cytidylyltransferase; Enzymes; Heptanoic Acids; Lipids; Lipoprotein Lipase; Lipoproteins, VLDL; Liver; Male; Phospholipids; Pyrroles; Rabbits; Simvastatin; Sterol O-Acyltransferase; Triglycerides | 1999 |
You recently wrote that cholesterol-lowering drugs should be taken in the evening--except for Lipitor. If that's the case, when should I take Lipitor?
Topics: Anticholesteremic Agents; Atorvastatin; Drug Administration Schedule; Heptanoic Acids; Humans; Pyrroles | 1999 |
Tamoxifen and hypertriglyceridemia.
Topics: Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Atorvastatin; Breast Neoplasms; Clofibrate; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Middle Aged; Pyrroles; Simvastatin; Tamoxifen; Treatment Outcome | 1999 |
Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Guinea Pigs; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Lipoproteins, LDL; Liver; Male; Pyrroles; Simvastatin | 1999 |
Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors.
Topics: Animals; Arteriosclerosis; Atorvastatin; Chemokine CCL2; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; DNA; Down-Regulation; Fibrinogen; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Polymerase Chain Reaction; Pyrroles; Rabbits; Simvastatin; Tunica Intima | 1999 |
Atorvastatin and fibrinogen--a small subgroup shows extreme response.
Topics: Adult; Aged; Atorvastatin; Coronary Artery Disease; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Treatment Outcome | 1999 |
Cholestatic liver dysfunction.
Topics: Anticholesteremic Agents; Atorvastatin; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Diagnosis, Differential; Heptanoic Acids; Humans; Liver Function Tests; Male; Middle Aged; Pyrroles | 1999 |
Pharmacokinetics and pharmacodynamics of nifedipine in untreated and atorvastatin-treated hyperlipidemic rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholesterol; Dose-Response Relationship, Drug; Drug Interactions; Heptanoic Acids; Hyperlipidemias; Male; Nifedipine; Pyrroles; Rats; Rats, Sprague-Dawley | 1999 |
The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
Topics: Animals; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol, LDL; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Microsomes, Liver; Pyrroles; Simvastatin; Swine; Swine, Miniature; Triglycerides | 1999 |
Lipophilic nature of atorvastatin.
Topics: Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pyrroles; Solubility | 1999 |
Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells.
Topics: Animals; Atorvastatin; Base Sequence; Blotting, Western; Cells, Cultured; Chemokines; Coronary Artery Disease; Coronary Vessels; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Molecular Sequence Data; Monocytes; Muscle, Smooth, Vascular; NF-kappa B; Polymerase Chain Reaction; Pyrroles; Rats; Reproducibility of Results; Sensitivity and Specificity | 1999 |
Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men.
Topics: Adult; Angiotensin Receptor Antagonists; Atorvastatin; Blood Pressure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Reactive Oxygen Species; Receptors, Angiotensin; Simvastatin | 1999 |
Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine.
Topics: Anticholesteremic Agents; Atorvastatin; Cadaver; Clinical Enzyme Tests; Cyclosporine; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Transplantation; Middle Aged; Pyrroles; Rhabdomyolysis | 1999 |
Atorvastatin and low-density lipoprotein subfractions profile in mixed hyperlipidaemia: a contributory effect of reduced hepatic lipase activity?
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipase; Lipoproteins, LDL; Liver; Male; Middle Aged; Pyrroles | 1999 |
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Ischemia; Pyrroles; Recurrence | 1999 |
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Stents | 1999 |
Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Platelet Aggregation Inhibitors; Pyrroles | 1999 |
Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; DNA; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Male; Mutation; Pyrroles; Receptors, LDL; Simvastatin; Treatment Outcome; Triglycerides; Tunica Intima; Vitamin E | 1999 |
Relationship between inhibition of mevalonate biosynthesis and reduced fertility in laying hens.
Topics: Animals; Atorvastatin; Chickens; Enzyme Inhibitors; Female; Fertility; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insemination, Artificial; Lovastatin; Mevalonic Acid; Oviposition; Pyrroles; Simvastatin | 1999 |
The right pill for growth. The high cost of developing blockbuster drugs forces big makers into bigger mergers.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Costs; Drug Industry; Heptanoic Acids; Humans; Organizational Affiliation; Pyrroles; Research Support as Topic; United States | 1999 |
Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Prospective Studies; Pyrroles; Rhabdomyolysis; Simvastatin; Triglycerides | 1999 |
[Are all HMG-CoA reductase inhibitors protective against ischemic heart disease?].
Topics: Adenosine Triphosphate; Animals; Atorvastatin; Dogs; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myocardial Contraction; Myocardial Ischemia; Myocardial Stunning; Myocardium; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation.
Topics: Animals; Aorta, Thoracic; Atorvastatin; Base Sequence; Botulinum Toxins; DNA Primers; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Mevalonic Acid; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phorbol 12,13-Dibutyrate; Pravastatin; Protein Kinase C; Pyridines; Pyrroles; Rats; Rats, Wistar; Superoxide Dismutase; Superoxides; Vasodilation | 2000 |
Action of atorvastatin in combined hyperlipidemia : preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles.
Topics: Apolipoproteins B; Atorvastatin; Biological Transport, Active; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Lipoproteins, HDL; Lipoproteins, VLDL; Pyrroles | 2000 |
More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolaemia.
Topics: Anticholesteremic Agents; Atorvastatin; Fibrinogen; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles | 2000 |
Natural statins and stroke.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fibrinogen; Heptanoic Acids; Humans; Pyrroles; Risk Factors; Stroke | 2000 |
Atorvastatin and simvastatin have distinct effects on hydroxy methylglutaryl-CoA reductase activity and mRNA abundance in the guinea pig.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Enzyme Inhibitors; Fasting; Gene Expression Regulation, Enzymologic; Guinea Pigs; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Lipids; Male; Microsomes, Liver; Pyrroles; RNA, Messenger; Simvastatin | 1999 |
Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs.
Topics: Adenosine Triphosphate; Animals; Atorvastatin; Cholesterol; Dogs; Fatty Acids, Monounsaturated; Female; Fluvastatin; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Myocardial Reperfusion Injury; Myocardial Stunning; Perfusion; Pyridines; Pyrroles; Random Allocation; Simvastatin; Solubility; Time Factors | 2000 |
The nature of the statins.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2000 |
Direct adsorption of lipoproteins (DALI) from whole blood: first long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Equipment Design; Evaluation Studies as Topic; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipoprotein(a); Lipoproteins, LDL; Long-Term Care; Male; Middle Aged; Plasmapheresis; Pyrroles; Treatment Outcome | 2000 |
Reversible atorvastatin-associated external ophthalmoplegia, anti-acetylcholine receptor antibodies, and ataxia.
Topics: Ataxia; Atorvastatin; Autoantibodies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Ophthalmoplegia; Pyrroles; Receptors, Cholinergic; Visual Acuity | 2000 |
Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin.
Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, Dietary; Cholesterol, LDL; Culture Techniques; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Heptanoic Acids; Injections, Intraperitoneal; Liver; Mice; Mice, Inbred C57BL; Poloxamer; Pyrroles; Reference Values; Remission Induction; Triglycerides | 2000 |
Coronary revascularization and aggressive lipid lowering.
Topics: Aspirin; Atorvastatin; Coronary Stenosis; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Metoprolol; Middle Aged; Myocardial Revascularization; Plasminogen Activators; Pyrroles; Risk Factors | 1999 |
Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Topics: Acetic Acid; Anion Transport Proteins; Antineoplastic Agents, Phytogenic; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoic Acid; Biological Transport; Caco-2 Cells; Calcium Channel Blockers; Carbon Radioisotopes; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; Carboxylic Acids; Carrier Proteins; Cell Polarity; Cyclosporine; Drug Interactions; Heptanoic Acids; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indicators and Reagents; Ionophores; Niacin; Protons; Pyrroles; Verapamil; Vinblastine | 2000 |
How to manage metabolic complications of HIV therapy: what to do while we wait for answers.
Topics: Anabolic Agents; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; Exercise Therapy; Gemfibrozil; Growth Hormone; Guidelines as Topic; Heptanoic Acids; HIV Infections; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipodystrophy; Metabolic Diseases; Metformin; Nucleosides; Protease Inhibitors; Pyrroles; Reverse Transcriptase Inhibitors; Risk Factors; Thiazoles; Thiazolidinediones | 2000 |
Effect of statin therapy on restenosis after coronary stent implantation.
Topics: Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Coronary Angiography; Coronary Disease; Disease-Free Survival; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hyperplasia; Indoles; Lovastatin; Male; Middle Aged; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Stents; Time Factors; Tunica Intima | 2000 |
[Will heart catheters besides hospitalization also become superfluous?. Interview by Dr. med. Ulrike Wepner].
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Hospitalization; Humans; Pyrroles; Treatment Outcome | 1999 |
Systemic cause of unstable atherosclerotic plaques. Atorvastatin and Thrombogenicity of Carotid Atherosclerotic Plaque (ATROCAP) study group.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Stenosis; Cause of Death; Heptanoic Acids; Humans; Pyrroles; Risk Factors | 2000 |
A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study.
Topics: Anticholesteremic Agents; Atorvastatin; Costs and Cost Analysis; Heptanoic Acids; Humans; Pyrroles; Simvastatin | 2000 |
[Acute pancreatitis associated with atorvastatine therapy].
Topics: Acute Disease; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Male; Middle Aged; Pancreatitis; Pyrroles | 2000 |
Pleiotropic effects of statins in atherosclerosis and diabetes.
Topics: Animals; Arteriosclerosis; Atorvastatin; Cell Division; Cell Movement; Cells, Cultured; Cholesterol; Cholesterol Esters; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endocytosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins; Lovastatin; Macrophages; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Muscle, Smooth; Pyridines; Pyrroles; Simvastatin | 2000 |
Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrroles | 2000 |
Atorvastatin versus revascularization treatment (AVERT): fact or fancy?
Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Myocardial Revascularization; Patient Selection; Pyrroles; Sensitivity and Specificity; Treatment Outcome | 2000 |
By the way, doctor... My hair has been thinning out for the past decade or so, but since my doctor started me on Lipitor (atorvastatin) a few months ago for high cholesterol, I swear it's been falling out much faster. My doctor discounts the possibility,
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypotrichosis; Pyrroles | 2000 |
Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-coa reductase inhibitors.
Topics: Alanine Transaminase; Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Diphosphonates; Dose-Response Relationship, Drug; Farnesyl-Diphosphate Farnesyltransferase; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Macaca mulatta; Male; Microsomes, Liver; Prodrugs; Pyrroles; Rats; Rats, Sprague-Dawley | 2000 |
Effects of atorvastatin treatment on the oxidatively modified low density lipoprotein in hyperlipidemic patients.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Combined Modality Therapy; Diet Therapy; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lysophosphatidylcholines; Muscle, Smooth, Vascular; Oxidation-Reduction; Phospholipids; Pyrroles | 2000 |
Elevated lipoprotein(a) with statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein(a); Pyrroles | 2000 |
[Evaluating the efficacy and tolerance of atorvastatin in hyperlipidemia in general practice (SWITCH Study)].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Switzerland; Treatment Outcome | 2000 |
Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic | 2000 |
Cost-effectiveness of sevelamer versus calcium carbonate plus atorvastatin to reduce LDL in patients with chronic renal insufficiency with dyslipidemia and hyperphosphatemia.
Topics: Atorvastatin; Calcium Carbonate; Cost-Benefit Analysis; Decision Support Techniques; Epoxy Compounds; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Lipoproteins, LDL; Phosphates; Polyamines; Polyethylenes; Pyrroles; Sevelamer | 2000 |
More on atorvastatin and fibrinogen.
Topics: Anticholesteremic Agents; Atorvastatin; Fibrinogen; Heptanoic Acids; Humans; Pyrroles | 2000 |
HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
Topics: Animals; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Microsomes, Liver; Pravastatin; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Species Specificity | 2000 |
Potential interaction between troglitazone and atorvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Chromans; Diabetes Mellitus; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypoglycemic Agents; Male; Middle Aged; Pyrroles; Retrospective Studies; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 2000 |
Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Resistance; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Transplantation; Male; Middle Aged; Pyrroles; Retreatment; Time Factors; Treatment Outcome; Triglycerides | 2000 |
Acute rhabdomyolysis after atorvastatin and fusidic acid therapy.
Topics: Acute Disease; Aged; Angioplasty, Balloon; Anti-Bacterial Agents; Arterial Occlusive Diseases; Atorvastatin; Drug Therapy, Combination; Fusidic Acid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Pyrroles; Rhabdomyolysis; Risk Factors; Surgical Wound Infection; Tibial Arteries | 2000 |
Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death.
Topics: Apoptosis; Atorvastatin; Cell Survival; Cells, Cultured; Coronary Vessels; Cytokines; Dose-Response Relationship, Drug; Endothelium, Vascular; Fas Ligand Protein; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Glycoproteins; Muscle, Smooth, Vascular; Pravastatin; Pyrroles; Reference Values; Sensitivity and Specificity; Simvastatin | 2000 |
Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type-1 in cultured human endothelial cells.
Topics: Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-1; Plasminogen Activator Inhibitor 1; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Tissue Plasminogen Activator; Tumor Necrosis Factor-alpha | 2000 |
Inhibition of small G proteins of the rho family by statins or clostridium difficile toxin B enhances cytokine-mediated induction of NO synthase II.
Topics: 3T3 Cells; Animals; Atorvastatin; Bacterial Proteins; Bacterial Toxins; Cytokines; Drug Interactions; Enzyme Induction; Gene Expression Regulation, Enzymologic; GTP-Binding Proteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mevalonic Acid; Mice; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Polyisoprenyl Phosphates; Promoter Regions, Genetic; Pyrroles; rho GTP-Binding Proteins; Tumor Cells, Cultured | 2000 |
Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice.
Topics: Animals; Aorta; Atorvastatin; beta-Thromboglobulin; Blood Coagulation; Blood Platelets; Brain Ischemia; Cholesterol; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Mice; Mice, Knockout; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Platelet Activation; Platelet Factor 4; Pyrroles; Reperfusion Injury; Reverse Transcriptase Polymerase Chain Reaction; rho GTP-Binding Proteins; RNA, Messenger; Up-Regulation | 2000 |
Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.
Topics: Atorvastatin; DNA, Complementary; Heptanoic Acids; Humans; Hydroxylation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Microsomes, Liver; Pyrroles | 2000 |
Down-regulation of uncoupling protein-3 and -2 by thiazolidinediones in C2C12 myotubes.
Topics: Acyl-CoA Dehydrogenase; Animals; Atorvastatin; Bezafibrate; Carnitine O-Palmitoyltransferase; Carrier Proteins; Cell Line; Cholesterol; Chromans; Down-Regulation; Fatty Acid Desaturases; Heptanoic Acids; Hypoglycemic Agents; Ion Channels; Ligands; Membrane Transport Proteins; Mice; Mitochondrial Proteins; Muscles; Oleic Acid; Peroxisome Proliferators; Proteins; Pyrimidines; Pyrroles; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Thiazoles; Thiazolidinediones; Transcription Factors; Triazenes; Troglitazone; Uncoupling Protein 2; Uncoupling Protein 3 | 2000 |
The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy.
Topics: Adolescent; Adult; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Blood Component Removal; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoprotein(a); Lipoproteins; Lipoproteins, LDL; Lymphocytes; Male; Mevalonic Acid; Middle Aged; Pyrroles; Receptors, LDL | 2000 |
Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.
Topics: Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Least-Squares Analysis; Linear Models; Lovastatin; Nonlinear Dynamics; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Tachyphylaxis; Time Factors | 2000 |
Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting.
Topics: Aged; Anticholesteremic Agents; Arrhythmias, Cardiac; Atorvastatin; Cause of Death; Coronary Artery Bypass; Coronary Disease; Female; Heart Failure; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Lovastatin; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Preoperative Care; Pyrroles; Recurrence; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2000 |
Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Cholesterol, LDL; Cholesterol, VLDL; Fibrinogen; Heptanoic Acids; Humans; Hyperlipoproteinemias; Male; Middle Aged; Pilot Projects; Plasminogen Activator Inhibitor 1; Pyrroles; Single-Blind Method; Treatment Outcome; Triglycerides | 2000 |
Status report of lipid-lowering trials in diabetes.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Pyrroles; Risk Factors | 2000 |
Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipids; Male; Middle Aged; Norway; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Simvastatin; Surveys and Questionnaires | 2000 |
Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects.
Topics: Adult; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chylomicrons; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Lipoproteins, VLDL; Male; Postprandial Period; Pyrroles; Reference Values; Time Factors; Triglycerides | 2000 |
Statins as a newly recognized type of immunomodulator.
Topics: Adjuvants, Immunologic; Anticholesteremic Agents; Atorvastatin; Endothelium, Vascular; Genes, MHC Class II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Lovastatin; Lymphocyte Activation; Macrophages; Monocytes; Nuclear Proteins; Pravastatin; Pyrroles; Saphenous Vein; T-Lymphocytes; Trans-Activators | 2000 |
Multidrug resistance P-glycoprotein is not involved in cholesterol esterification.
Topics: Acridines; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cholesterol; Cholesterol Esters; DNA-Binding Proteins; Fluoresceins; Fluorescent Dyes; Heptanoic Acids; Humans; Isoquinolines; Kinetics; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Probenecid; Progesterone; Pyrroles; Sterol O-Acyltransferase; Tetrahydroisoquinolines; Tumor Cells, Cultured; Verapamil | 2000 |
Fast, aggressive treatment for myocardial infarction urged.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Artery Bypass; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Stents; Tirofiban; Tyrosine | 2000 |
Lipid modulation and atherosclerotic events: extending the clinical spectrum with fibrates and statins.
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Evidence-Based Medicine; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Middle Aged; Myocardial Revascularization; Preventive Medicine; Pyrroles | 2000 |
Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance.
Topics: Animals; Atorvastatin; Cattle; Caveolin 1; Caveolins; CCAAT-Enhancer-Binding Proteins; Cells, Cultured; Cholesterol; Cholesterol, LDL; Cysteine Proteinase Inhibitors; DNA-Binding Proteins; Dose-Response Relationship, Drug; Endothelium, Vascular; Heptanoic Acids; HSP90 Heat-Shock Proteins; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leupeptins; Lipoproteins, LDL; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyrroles; Sterol Regulatory Element Binding Protein 1; Transcription Factors; Up-Regulation | 2001 |
The state of the heart. If you thought cholesterol was all you had to worry about, better think again.
Topics: American Heart Association; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Folic Acid; Heptanoic Acids; Humans; Inflammation; Pyrroles; United States | 2000 |
Endotoxin-lipoprotein hypothesis.
Topics: Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Interleukin-10; Lipopolysaccharides; Pyrroles; Tumor Necrosis Factor-alpha | 2000 |
The protective role of atorvastatin on function, structure and ultrastructure in the aorta of dyslipidemic rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Microscopy, Electron; Pyrroles; Rabbits | 2000 |
Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Cholesterol Esters; Female; Heptanoic Acids; Lipoproteins, VLDL; Liver; Lovastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin | 2000 |
Effect of atorvastatin 15 mg/week on serum lipids in patients with hypercholesterolemia.
Topics: Aged; Atorvastatin; Cholesterol; Coronary Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles | 2001 |
Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase.
Topics: Angiotensin II; Animals; Atorvastatin; Cells, Cultured; Down-Regulation; Free Radicals; Gene Expression; GTP Phosphohydrolases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscle, Smooth, Vascular; Protein Prenylation; Pyrroles; rac1 GTP-Binding Protein; Radioligand Assay; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA Stability; RNA, Messenger | 2001 |
ICAAC: nelfinavir interacts with statins and an antiseizure drug.
Topics: Anticholesteremic Agents; Anticonvulsants; Atorvastatin; Drug Interactions; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nelfinavir; Phenytoin; Pyrroles; Simvastatin | 2000 |
Therapy with statins is effective in some patients with homozygous familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Pyrroles; Simvastatin | 2000 |
[Meeting report. "MIRACL" study of "Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering"].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Ischemia; Patient Selection; Pyrroles; Treatment Outcome | 2000 |
[Disturbances in cholesterol metabolism].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Triglycerides | 2001 |
Statins early in acute coronary syndromes.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Treatment Outcome | 2000 |
F 12511, a novel ACAT inhibitor, and atorvastatin regulate endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet.
Topics: Adrenal Glands; Anilides; Animals; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Caseins; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Male; Pyrroles; Rabbits; Sterol O-Acyltransferase | 2001 |
[Lymphocyte infiltration in superficial dermis].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Eruptions; Heptanoic Acids; Humans; Lymphocytes; Male; Pyrroles | 2001 |
Tachyphylaxis and statin drugs.
Topics: Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors; Tachyphylaxis | 2001 |
HMG-CoA reductase inhibitors and P-glycoprotein modulation.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dose-Response Relationship, Drug; Drug Interactions; Fluorometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microscopy, Confocal; Pyrroles; Reproducibility of Results; Tumor Cells, Cultured | 2001 |
Linear IgA bullous dermatosis induced by atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Eruptions; Heptanoic Acids; Humans; Immunoglobulin A; Male; Middle Aged; Pyrroles; Skin Diseases, Vesiculobullous | 2001 |
Lipid-lowering therapy in acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Myocardial Infarction; Pyrroles | 2001 |
Effect of atorvastatin on endothelium-dependent constrictor factors in dyslipidemic rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atorvastatin; Drug Interactions; Endothelins; Endothelium, Vascular; Enzyme Inhibitors; Heptanoic Acids; Hyperlipidemias; Male; NG-Nitroarginine Methyl Ester; Pyrroles; Rabbits; Receptor, Endothelin A; Receptors, Endothelin; Receptors, Prostaglandin; Receptors, Thromboxane A2, Prostaglandin H2; Vasoconstriction | 2000 |
Cost effectiveness of HMG-CoA reductase inhibition in Canada.
Topics: Aged; Atorvastatin; Canada; Coronary Disease; Cost-Benefit Analysis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Sensitivity and Specificity | 2001 |
Repeated analysis of semen parameters in beagle dogs during a 2-year study with the HMG-CoA reductase inhibitor, atorvastatin.
Topics: Acyl Coenzyme A; Animals; Atorvastatin; Cholesterol; Dogs; Ejaculation; Epididymis; Heptanoic Acids; Male; Organ Size; Prostate; Pyrroles; Semen; Sperm Count; Sperm Motility; Spermatozoa; Testis; Time Factors | 2001 |
Possible short-term amelioration of basilar plaque by high-dose atorvastatin: use of reductase inhibitors for intracranial plaque stabilization.
Topics: Aged; Angioplasty, Balloon; Anticholesteremic Agents; Atorvastatin; Cerebral Angiography; Combined Modality Therapy; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Male; Neurologic Examination; Pyrroles; Vertebrobasilar Insufficiency | 2001 |
Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Diet; Guinea Pigs; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Lauric Acids; Lipids; Lipoproteins, LDL; Liver; Male; Pyrroles; Quinolines; Triglycerides | 2001 |
Tachyphylaxis in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Tachyphylaxis | 2001 |
[Decreasing blood lipids for prevention of coronary heart disease--discussion of the "permissive LDL level". Diagnostic imaging facilitates therapeutic decision].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Diagnostic Imaging; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Treatment Outcome | 2001 |
[Prevention in coronary heart disease. Can a CSE inhibitor arrest calcium deposits?].
Topics: Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Myocardial Infarction; Pyrroles; Risk Factors; Survival Rate | 2001 |
Limitation of heart growth in neonatal piglets by simvastatin and atorvastatin: comparison with pravastatin.
Topics: Administration, Oral; Animals; Animals, Newborn; Atorvastatin; Blood Pressure; Body Weight; DNA; Heart; Heart Rate; Heart Ventricles; Heptanoic Acids; Mitogen-Activated Protein Kinases; Myocardium; Organ Size; Pravastatin; Proteins; Pyrroles; RNA; Simvastatin; Swine; Water | 2001 |
Genetic analysis of digestive physiology using fluorescent phospholipid reporters.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Boron Compounds; Cholesterol; Digestive System; Digestive System Physiological Phenomena; Fluorescent Dyes; Gallbladder; Heptanoic Acids; Larva; Lipase; Mice; Microscopy, Fluorescence; Microscopy, Video; Mutation; Phospholipids; Pyrroles; Signal Transduction; Zebrafish | 2001 |
Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits.
Topics: Acetylcholine; Animals; Anticholesteremic Agents; Atorvastatin; Bridged Bicyclo Compounds, Heterocyclic; Cholesterol, Dietary; Disease Models, Animal; Endothelium, Vascular; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Hypercholesterolemia; Kidney; Male; Nitroprusside; Oxazoles; Phenylephrine; Platelet Aggregation Inhibitors; Pyrroles; Rabbits; Renal Circulation; Vasodilation | 2001 |
Growth hormone reduces plasma cholesterol in LDL receptor-deficient mice.
Topics: Animals; Atorvastatin; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cholestyramine Resin; Growth Hormone; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Male; Mice; Mice, Knockout; Pyrroles; Receptors, LDL; Triglycerides | 2001 |
Atorvastatin-induced dermatomyositis.
Topics: Adult; Antibodies, Antinuclear; Apoptosis; Atorvastatin; Creatine Kinase; Dermatomyositis; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Keratinocytes; Male; Pyrroles | 2001 |
Statin induced myopathy does not show up in MIBI scintigraphy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi | 2001 |
Effect of atorvastatin on plasminogen activator inhibitor type-1 synthesis in human monocytes/macrophages.
Topics: Atorvastatin; Heptanoic Acids; HL-60 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Monocytes; Plasminogen Activator Inhibitor 1; Pyrroles; Tetradecanoylphorbol Acetate; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2001 |
A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Models, Economic; Pravastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.
Topics: Angiotensin Receptor Antagonists; Animals; Anticholesteremic Agents; Aorta; Atorvastatin; Blood Pressure; Culture Techniques; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipids; Male; NADPH Oxidases; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyrroles; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger; Vasoconstriction; Vasodilation | 2001 |
Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Cell Line; Cholesterol; Down-Regulation; Heptanoic Acids; Humans; Liver; Pyrroles; Time Factors; Triglycerides | 2001 |
Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the atorvastatin versus revascularization (AVERT) trial.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Myocardial Revascularization; Pyrroles | 2001 |
Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin.
Topics: Acute Disease; Apoptosis; Atorvastatin; Cell Division; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Leukemia, Myeloid; Lovastatin; Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Pyrroles; Sensitivity and Specificity; Tumor Cells, Cultured | 2001 |
Human breath isoprene and its relation to blood cholesterol levels: new measurements and modeling.
Topics: Anticholesteremic Agents; Atorvastatin; Breath Tests; Butadienes; Cholesterol; Exercise; Heart Rate; Hemiterpenes; Heptanoic Acids; Humans; Lipoproteins, LDL; Mass Spectrometry; Models, Biological; Monitoring, Physiologic; Pentanes; Physical Exertion; Posture; Pyrroles; Respiratory Mechanics; Sleep; Time Factors | 2001 |
Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Fenofibrate; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Pyrroles | 2001 |
Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Coronary Disease; Exercise Test; Female; Heart Rate; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Time Factors | 2001 |
Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects.
Topics: Atorvastatin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 2001 |
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
Topics: 3T3 Cells; Adenosine Triphosphate; Animals; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Pravastatin; Pyrroles; Simvastatin | 2001 |
Atorvastatin for acute coronary syndromes.
Topics: Acute Disease; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2001 |
Atorvastatin for acute coronary syndromes.
Topics: Acute Disease; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2001 |
Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
Topics: Atorvastatin; Cell Line; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lovastatin; Pravastatin; Pyrroles; Quinolines; Receptors, LDL; RNA, Messenger; Simvastatin | 2000 |
Can early treatment with atorvastatin (Lipitor) improve the outcome of patients with acute coronary syndromes?
Topics: Adult; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Controlled Clinical Trials as Topic; Double-Blind Method; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Time Factors | 2001 |
Measurement of atherosclerosis progression.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Pyrroles; Simvastatin | 2001 |
Measurement of atherosclerosis progression.
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Pyrroles; Simvastatin | 2001 |
Atorvastatin improves endothelial function in renal-transplant recipients.
Topics: Adult; Aged; Atorvastatin; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Transplantation; Lipids; Male; Microcirculation; Middle Aged; Nitric Oxide; Pilot Projects; Pyrroles; Skin | 2001 |
By the way, doctor... My brother takes Mevacor and has been told to take the drug at bedtime. But when I started on Lipitor, my doctor said to take the medication at any time of the day. Why the difference?
Topics: Anticholesteremic Agents; Atorvastatin; Drug Administration Schedule; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Pyrroles | 2001 |
Effect of atorvastatin on serum uric acid levels.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrroles; Uric Acid | 2001 |
Rigorous detection and vigorous treatment of familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Tunica Intima; Ultrasonography | 2001 |
Rationale and design of the St. Francis Heart Study: a randomized clinical trial of atorvastatin plus antioxidants in asymptomatic persons with elevated coronary calcification.
Topics: Aged; Antioxidants; Atorvastatin; Calcinosis; Coronary Disease; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Pyrroles; Randomized Controlled Trials as Topic; Research Design | 2001 |
What have we learned about the biology of atherosclerosis? The role of inflammation.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, Dietary; Coronary Artery Disease; Coronary Stenosis; Heptanoic Acids; Humans; Inflammation Mediators; Pyrroles; Rabbits | 2001 |
Global risk assessment in the presymptomatic patient.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Critical Pathways; Family Practice; Heptanoic Acids; Humans; Hypercholesterolemia; Life Style; Mass Screening; Pyrroles; Risk Assessment | 2001 |
The use of electron-beam computed tomography as a tool for primary prevention.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Male; Mass Screening; Middle Aged; Myocardial Infarction; Pyrroles; Tomography, X-Ray Computed | 2001 |
Insulin resistance syndrome and type 2 diabetes mellitus.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Metabolic Syndrome; Pyrroles; Risk Factors; Survival Rate | 2001 |
Women and cardiovascular risk.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Sex Factors; Survival Rate | 2001 |
Raman spectroscopic evaluation of the effects of diet and lipid-lowering therapy on atherosclerotic plaque development in mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Calcinosis; Cholesterol; Diet, Atherogenic; Disease Progression; Female; Heptanoic Acids; Male; Mice; Mice, Transgenic; Pyrroles; Reproducibility of Results; Spectrum Analysis, Raman; Treatment Outcome | 2001 |
Effect of statins on bone mineral density and bone histomorphometry in rodents.
Topics: Animals; Atorvastatin; Bone Density; Bone Development; Bone Resorption; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ovariectomy; Pravastatin; Pyrroles; Radiography; Rats; Rats, Sprague-Dawley; Simvastatin | 2001 |
Atorvastatin-induced diaphragmatic muscle impairment.
Topics: Asthenia; Atorvastatin; Diaphragm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscles; Pain; Pyrroles | 2001 |
Simvastatin and atorvastatin enhance hypotensive effect of diltiazem in rats.
Topics: Animals; Antihypertensive Agents; Atorvastatin; Blood Pressure; Diltiazem; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley | 2001 |
Development of tachyphylaxis on statin treatment.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pyrroles; Research Design; Simvastatin; Tachyphylaxis | 2001 |
Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.
Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Echocardiography; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Multivariate Analysis; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; Vascular Patency | 2001 |
Effects of atorvastatin (and blood pressure lowering comparing amlodipide-based therapy with beta-blocker-based therapy) on serum variables of cholesterol synthesis and absorption, thrombogenicity and on low-density lipoprotein oxidation in vivo.
Topics: Adrenergic beta-Antagonists; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol; Coronary Disease; Heptanoic Acids; Humans; Lipoproteins, LDL; Oxidation-Reduction; Pyrroles; Sympatholytics; Thrombosis; Triglycerides | 2001 |
Managed care trends in statin usage.
Topics: Anticholesteremic Agents; Atorvastatin; Databases, Factual; Drug Costs; Drug Utilization Review; Fatty Acids, Monounsaturated; Fluvastatin; Health Care Sector; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Managed Care Programs; Pravastatin; Pyridines; Pyrroles; Simvastatin; United States | 2001 |
HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels.
Topics: Animals; Aorta; Arteries; Arteriosclerosis; Atorvastatin; Carotid Arteries; Chemokine CCL2; Cholesterol; Coronary Vessels; Down-Regulation; Femoral Artery; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iliac Artery; Immunohistochemistry; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pravastatin; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Swine | 2001 |
Effect of atorvastatin on intracellular calcium uptake in coronary smooth muscle cells from diabetic pigs fed an atherogenic diet.
Topics: Animals; Atorvastatin; Caffeine; Calcium; Coronary Vessels; Cytoplasm; Diabetes Mellitus, Experimental; Diet, Atherogenic; Fluorescent Dyes; Fura-2; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Vitro Techniques; Ionomycin; Ionophores; Male; Microscopy, Fluorescence; Muscle, Smooth, Vascular; Pyrroles; Sarcoplasmic Reticulum; Sodium; Swine; Swine, Miniature; Thapsigargin | 2001 |
Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins.
Topics: Animals; Atorvastatin; Benzoquinones; Biological Assay; Cattle; Caveolin 1; Caveolins; Cells, Cultured; Endothelium, Vascular; Enzyme Inhibitors; Gene Expression; Heptanoic Acids; HSP90 Heat-Shock Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Lactams, Macrocyclic; Mice; Models, Cardiovascular; Neovascularization, Physiologic; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Phosphorylation; Protein Binding; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrroles; Quinones; Rats; Transfection | 2001 |
. . . from the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Topics: Anti-HIV Agents; Anti-Infective Agents; Antineoplastic Agents; Atorvastatin; Drug Administration Schedule; Drug Interactions; Drug Resistance, Microbial; Heptanoic Acids; HIV Infections; Humans; Pyrroles; Rhabdomyolysis | 2000 |
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells.
Topics: Animals; Atorvastatin; Cells, Cultured; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscle, Smooth, Vascular; NF-kappa B; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Promoter Regions, Genetic; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Transcriptional Activation; Up-Regulation | 2001 |
Low-density-lipoprotein cholesterol goals for patients with coronary disease: treating between the lines.
Topics: Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Artery Bypass; Coronary Disease; Follow-Up Studies; Heptanoic Acids; Humans; Japan; Male; Practice Guidelines as Topic; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; United States | 2001 |
Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Arteries; Atorvastatin; Compliance; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Severity of Illness Index; Treatment Outcome | 2001 |
Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men.
Topics: Adult; Atorvastatin; Blood Flow Velocity; C-Reactive Protein; Cholesterol; Endothelium, Vascular; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitroglycerin; Plethysmography; Pyrroles; Reference Values; Vasodilation | 2001 |
Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells.
Topics: Anticholesteremic Agents; Atorvastatin; CCAAT-Enhancer-Binding Proteins; Cholesterol; DNA-Binding Proteins; fas Receptor; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lovastatin; Pyrroles; Receptors, LDL; Simvastatin; Sterol Regulatory Element Binding Protein 1; Transcription Factors; Triglycerides; Tumor Cells, Cultured | 2001 |
Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism.
Topics: Animals; Atorvastatin; Bezafibrate; Cholesterol; Diphosphonates; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Hepatocytes; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Lipids; Macaca mulatta; Molecular Structure; Pyrroles; Rabbits; Receptors, LDL; Triglycerides | 2001 |
Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Combined Modality Therapy; Erythrocyte Aggregation; Female; Fibrinogen; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Plasmapheresis; Probability; Prospective Studies; Pyrroles; Rheology; Sensitivity and Specificity; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2001 |
[60% of patients with coronary disease receive antilipemic drugs. Nevertheless cholesterol often is too high].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2001 |
HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells.
Topics: Anticholesteremic Agents; Atorvastatin; Cell Adhesion; Cells, Cultured; Endothelium, Vascular; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lipopolysaccharide Receptors; Monocytes; NF-kappa B; Pyridines; Pyrroles; Receptors, LDL; RNA, Messenger; Simvastatin; Tetradecanoylphorbol Acetate; U937 Cells; Vascular Cell Adhesion Molecule-1 | 2001 |
Inhibition of LOX-1 by statins may relate to upregulation of eNOS.
Topics: Atorvastatin; Cells, Cultured; Coronary Vessels; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Mitogen-Activated Protein Kinases; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyrroles; Receptors, LDL; Receptors, Oxidized LDL; RNA, Messenger; Scavenger Receptors, Class E; Simvastatin; Up-Regulation | 2001 |
Renal cortical cholesterol accumulation is an integral component of the systemic stress response.
Topics: Acute Kidney Injury; Animals; Atorvastatin; Blotting, Western; Cell Line; Cholesterol; Cholesterol Esters; Escherichia coli Infections; Glycerol; Heptanoic Acids; Hot Temperature; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Cortex; Male; Mice; Mice, Inbred Strains; Pyrroles; Shock; Stress, Physiological | 2001 |
Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells.
Topics: Animals; Arteriosclerosis; Atorvastatin; Cells, Cultured; Cyclooxygenase 1; Cyclooxygenase 2; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-8; Isoenzymes; Lipids; Macrophages; Male; Matrix Metalloproteinases; Muscle, Smooth, Vascular; NF-kappa B; Prostaglandin-Endoperoxide Synthases; Protein Isoforms; Pyrroles; Rabbits; Random Allocation; Randomized Controlled Trials as Topic; Time Factors | 2002 |
The use over time of statins in coronary patients in an Italian tertiary referral center.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Utilization Review; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Italy; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin | 2001 |
Usefulness of Orlistat in the treatment of severe hypertriglyceridemia.
Topics: Adult; Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Dietary Fiber; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Heptanoic Acids; Humans; Hypertriglyceridemia; Lactones; Male; Middle Aged; Niacin; Orlistat; Pyrroles; Statistics, Nonparametric; Treatment Outcome | 2002 |
Safety and efficacy of atorvastatin in heart transplant recipients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Glucocorticoids; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pravastatin; Prednisone; Pyrroles; Retrospective Studies; Treatment Outcome | 2002 |
Cellular antioxidant effects of atorvastatin in vitro and in vivo.
Topics: Animals; Antioxidants; Atorvastatin; Catalase; Cattle; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Muscle, Smooth, Vascular; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; NADPH Oxidases; Pyrroles; Rats; Rats, Inbred SHR; Reactive Oxygen Species; RNA, Messenger; Up-Regulation | 2002 |
Effects of atorvastatin on oxidized low-density lipoprotein, low-density lipoprotein subfraction distribution, and remnant lipoprotein in patients with mixed hyperlipoproteinemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Electrophoresis, Polyacrylamide Gel; Heptanoic Acids; Homocysteine; Humans; Hyperlipoproteinemias; Lipoprotein(a); Middle Aged; Pyrroles; Triglycerides | 2002 |
Statins have biphasic effects on angiogenesis.
Topics: Animals; Apolipoproteins E; Apoptosis; Atorvastatin; Carcinoma, Lewis Lung; Cell Differentiation; Cell Division; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Growth Factors; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lymphokines; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Neovascularization, Physiologic; Polyisoprenyl Phosphates; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Effect of tablet splitting on serum cholesterol concentrations.
Topics: Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Drug Costs; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Retrospective Studies; Simvastatin; Tablets; West Virginia | 2002 |
Reduction in hepatic non-esterified fatty acid concentration after long-term treatment with atorvastatin lowers hepatic triglyceride synthesis and its secretion in sucrose-fed rats.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Coenzyme A Ligases; Dietary Sucrose; Disease Models, Animal; Down-Regulation; Fatty Acids, Nonesterified; Heptanoic Acids; Hypertriglyceridemia; Lipase; Lipoproteins, VLDL; Liver; Male; Oleic Acid; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Triglycerides; Tritium | 2002 |
3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation.
Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Atorvastatin; Caspase Inhibitors; Caspases; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Flow Cytometry; Fluorescent Antibody Technique, Indirect; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Muscle, Smooth, Vascular; Polyisoprenyl Phosphates; Protein Prenylation; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Rabbits; Rats; rhoA GTP-Binding Protein; Sesquiterpenes; Simvastatin; Time Factors | 2002 |
Cholesterol esters regulate apoB48 secretion in CaCo2 cells.
Topics: Apolipoprotein B-48; Apolipoproteins B; Atorvastatin; Caco-2 Cells; Cholesterol; Cholesterol Esters; Culture Media; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Methionine; Phenylurea Compounds; Pyrroles; Sterol O-Acyltransferase | 2002 |
Atorvastatin-induced reversible positive antinuclear antibodies.
Topics: Adult; Antibodies, Antinuclear; Atorvastatin; Autoimmune Diseases; Heptanoic Acids; Histones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Pyrroles | 2002 |
Compliance among pharmacies in California with a prescription-drug discount program for Medicare beneficiaries.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antidepressive Agents; Atorvastatin; California; Cost Savings; Drug Costs; Drug Prescriptions; Health Expenditures; Heptanoic Acids; Humans; Insurance Coverage; Insurance, Pharmaceutical Services; Lactones; Medicare; Prescription Fees; Pyrroles; Sertraline; Sulfones; United States | 2002 |
Effect of atorvastatin on serum creatinine levels.
Topics: Anticholesteremic Agents; Atorvastatin; Creatinine; Heptanoic Acids; Humans; Pyrroles; Retrospective Studies; Uric Acid | 2001 |
Chronic urticaria to atorvastatin.
Topics: Atorvastatin; Chronic Disease; Drug Hypersensitivity; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Urticaria | 2002 |
Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial.
Topics: Angina, Unstable; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Chlamydophila Infections; Chlamydophila pneumoniae; Cholesterol, LDL; Double-Blind Method; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Myocardial Infarction; Pneumonia, Bacterial; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design | 2002 |
Effectiveness of low doses of simvastatin versus atorvastatin: resolving conflicting evidence.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Evidence-Based Medicine; Heptanoic Acids; Humans; Pyrroles; Simvastatin | 2002 |
Treatment with atorvastatin ameliorates hepatic very-low-density lipoprotein overproduction in an animal model of insulin resistance, the fructose-fed Syrian golden hamster: evidence that reduced hypertriglyceridemia is accompanied by improved hepatic ins
Topics: Animals; Apolipoproteins B; Atorvastatin; Blood Glucose; Cells, Cultured; Cholesterol; Cricetinae; Disease Models, Animal; Fructose; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Insulin Resistance; Kinetics; Lipoproteins, VLDL; Liver; Luminescent Measurements; Mesocricetus; Phosphorylation; Pyrroles; Receptor, Insulin; Triglycerides | 2002 |
The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status.
Topics: Adult; Aged; Antioxidants; Apolipoproteins; Arteriosclerosis; Atorvastatin; Autoantibodies; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Immunoassay; Lipids; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pyrroles | 2002 |
Atorvastatin plus pravastatin for the treatment of heterozygous familial hypercholesterolaemia--a pilot study.
Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Treatment Outcome | 2001 |
Impact of HMG CoA reductase inhibition on small GTPases in the heart.
Topics: Angiotensin II; Animals; Atorvastatin; Atrial Natriuretic Factor; Cardiac Myosins; Cardiomegaly; Cell Membrane; Cells, Cultured; Gene Expression Regulation; GTP Phosphohydrolases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; Myocardium; Myosin Light Chains; Pyrroles; rac1 GTP-Binding Protein; Rats; Rats, Sprague-Dawley; rhoA GTP-Binding Protein; RNA, Messenger; Simvastatin | 2002 |
Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes.
Topics: Anticholesteremic Agents; Atorvastatin; Cell Death; Cells, Cultured; Chemokine CCL2; Heptanoic Acids; Humans; Inflammation; Matrix Metalloproteinase 9; Monocytes; Oxygen Consumption; Pyrroles; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Tumor Necrosis Factor-alpha | 2002 |
Double-edged role of statins in angiogenesis signaling.
Topics: Apoptosis; Atorvastatin; Bacterial Proteins; Cell Movement; Cells, Cultured; Coculture Techniques; Dose-Response Relationship, Drug; Endothelium, Vascular; Enterotoxins; Fibroblasts; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Monocytes; Neovascularization, Physiologic; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinases; Pyrroles; Signal Transduction | 2002 |
Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization.
Topics: Animals; Atorvastatin; Bile; Dogs; Glucuronides; Glucuronosyltransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Magnetic Resonance Spectroscopy; Microsomes, Liver; Protein Isoforms; Pyridines; Pyrroles; Rats; Recombinant Proteins; Simvastatin; Uridine Diphosphate Glucuronic Acid | 2002 |
Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine.
Topics: Acute Kidney Injury; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Delavirdine; Drug Interactions; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Mixed Function Oxygenases; Pyrroles; Rhabdomyolysis | 2002 |
Interaction between ritonavir and statins.
Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Drug Interactions; Heptanoic Acids; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Ritonavir; Simvastatin | 2002 |
Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ.
Topics: Animals; Aorta, Thoracic; Atorvastatin; Cells, Cultured; Cytokines; DNA-Binding Proteins; Electrophoretic Mobility Shift Assay; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; In Vitro Techniques; Interferon-gamma; Male; Muscle, Smooth, Vascular; NF-kappa B; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Oligonucleotides; Pyrroles; Rats; Rats, Wistar; STAT1 Transcription Factor; Trans-Activators; Tumor Necrosis Factor-alpha | 2002 |
Comparison of different treatment regimens in a case of homozygous familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Pyrroles | 2002 |
The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT).
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Carotid Artery, Common; Female; Femoral Artery; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Tunica Intima | 2002 |
Intensive lipid lowering by statin therapy does not improve vasoreactivity in patients with type 2 diabetes.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Drug Administration Schedule; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Microcirculation; Middle Aged; Nitric Oxide; Nitroprusside; Plethysmography; Prospective Studies; Pyrroles; Serotonin; Vasodilation | 2002 |
Is C-reactive protein an additional, surrogate end-point for statin treatment?
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Pyrroles; Sensitivity and Specificity; Triglycerides | 2002 |
Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus.
Topics: Atorvastatin; Cholesterol; Delayed-Action Preparations; Diabetes Mellitus; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrroles; Retrospective Studies; Triglycerides | 2002 |
Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose).
Topics: Acarbose; Adverse Drug Reaction Reporting Systems; Anticholesteremic Agents; Atorvastatin; Chromans; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrroles; Simvastatin; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Increased superoxide anion production by platelets in hypercholesterolemic patients.
Topics: Anticholesteremic Agents; Arachidonic Acid; Atorvastatin; Blood Platelets; Cholesterol; Cholesterol, LDL; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Superoxides; Triglycerides | 2002 |
Potential neurological value of statins increases.
Topics: Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Costs and Cost Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Nervous System Diseases; Pyrroles; United States | 2002 |
Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve.
Topics: Alkaline Phosphatase; Animals; Anticholesteremic Agents; Aortic Valve; Atorvastatin; Biomarkers; C-Reactive Protein; Calcinosis; Cell Division; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Heart Valve Diseases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Macrophages; Male; Microscopy, Immunoelectron; Osteoblasts; Osteopontin; Proliferating Cell Nuclear Antigen; Pyrroles; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sialoglycoproteins | 2002 |
Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia.
Topics: Adolescent; Atorvastatin; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Long-Term Care; Male; Prognosis; Prospective Studies; Pyrroles; Treatment Outcome | 2002 |
High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
Topics: Acetyl-CoA Carboxylase; Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cricetinae; DNA-Binding Proteins; Enzyme Activation; Fatty Acid Synthases; Fatty Acids; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, VLDL; Liver; Male; Mesocricetus; Phospholipids; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Simvastatin; Sterol Regulatory Element Binding Protein 2; Transcription Factors; Triglycerides | 2002 |
Atorvastatin treatment induced peroxisome proliferator-activated receptor alpha expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats.
Topics: Adipose Tissue; Animals; Apolipoproteins B; Atorvastatin; Cholesterol, VLDL; Fatty Acids, Nonesterified; Fructose; Glucose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Lipid Metabolism; Liver; Male; Oxidation-Reduction; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors; Triglycerides | 2002 |
Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the Treat to Target (TTT-Israel) Study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Chi-Square Distribution; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Israel; Male; Middle Aged; Primary Prevention; Prospective Studies; Pyrroles; Risk Factors; Treatment Outcome | 2002 |
Routine statin treatment after acute coronary syndromes?
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Myocardial Infarction; Patient Discharge; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Syndrome; Thrombolytic Therapy; Treatment Outcome | 2002 |
Acute cholestatic hepatitis after reinitiating treatment with atorvastatin.
Topics: Acute Disease; Aged; Atorvastatin; Cholestasis; Hepatitis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles | 2002 |
Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Disease; Endothelial Growth Factors; Heptanoic Acids; Humans; Lymphokines; Male; Middle Aged; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Clinical Trials as Topic; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2002 |
Efficacy and safety of atorvastatin 10 mg every other day in hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2002 |
Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Cholesterol; Disease Models, Animal; Drug Synergism; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Transgenic; Pyrroles; Spectrum Analysis, Raman | 2002 |
Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes.
Topics: Adult; Atorvastatin; CD36 Antigens; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Macrophages; Male; Middle Aged; Monocytes; Oxidation-Reduction; Pyrroles; Receptors, Immunologic; Receptors, Scavenger; RNA | 2002 |
The effect of atorvastatin on hemorheological parameters in rabbits fed on a normal diet.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Erythrocyte Deformability; gamma-Globulins; Hemorheology; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pyrroles; Rabbits | 2002 |
Atorvastatin increases HDL cholesterol in hypercholesterolemic patients. Evidence of a relationship with baseline HDL cholesterol.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Regression Analysis; Triglycerides | 2002 |
Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Longitudinal Studies; Male; Middle Aged; Pyrroles; Risk Factors; Treatment Outcome; Triglycerides | 2002 |
Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1.
Topics: Atorvastatin; Cell Adhesion; Cell Adhesion Molecules; Coronary Vessels; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; NF-kappa B; Pyrroles; Receptors, LDL; Receptors, Oxidized LDL; Scavenger Receptors, Class E; Simvastatin | 2002 |
Alopecia associated with atorvastatin.
Topics: Adult; Alopecia; Atorvastatin; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Risk Assessment | 2002 |
Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice.
Topics: Acridines; Animals; Aorta; Atorvastatin; Cell Membrane; Cells, Cultured; Endothelium, Vascular; Fluoresceins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Knockout; NADP; NADPH Oxidase 2; NADPH Oxidases; Organ Culture Techniques; Oxidative Stress; Protein Transport; Pyridines; Pyrroles; rac1 GTP-Binding Protein; Superoxides; Vasodilation | 2002 |
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase the binding activity and nuclear level of Oct-1 in mononuclear cells.
Topics: Atorvastatin; Cell Line; Cell Nucleus; DNA-Binding Proteins; Dose-Response Relationship, Drug; Heptanoic Acids; Host Cell Factor C1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Monocytes; Octamer Transcription Factor-1; Protein Binding; Pyrroles; Simvastatin; Transcription Factors; Up-Regulation | 2002 |
Glucose increases endothelial-dependent superoxide formation in coronary arteries by NAD(P)H oxidase activation: attenuation by the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor atorvastatin.
Topics: Animals; Atorvastatin; Coronary Vessels; Endothelium, Vascular; Enzyme Activation; Glucose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Mevalonic Acid; NADH, NADPH Oxidoreductases; NADPH Oxidases; Pyrroles; Superoxides; Swine | 2002 |
Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Cost-Benefit Analysis; Female; Fibrinogen; Heptanoic Acids; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Triglycerides | 2002 |
Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin.
Topics: Animals; Anticholesteremic Agents; Aorta; Atorvastatin; Cell Division; Cerebral Arteries; Drug Interactions; Endothelin Receptor Antagonists; Fibroblast Growth Factor 2; Heptanoic Acids; Lovastatin; Male; Muscle, Smooth; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2002 |
Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy.
Topics: Adult; Aged; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Female; Heptanoic Acids; HIV Infections; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2002 |
[Absolutely essential in cardiovascular high risk patients. Statins--more than only anticholesteremic drugs].
Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Germany; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Risk; Survival Rate | 2002 |
Atorvastatin attenuates remnant lipoprotein-induced monocyte adhesion to vascular endothelium under flow conditions.
Topics: Actin Cytoskeleton; Atorvastatin; Cell Adhesion; Cell Line; Cells, Cultured; Cholesterol; Endothelium, Vascular; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrins; Lipids; Lipoproteins; Monocytes; Protein Kinase C; Protein-Tyrosine Kinases; Pyrroles; rhoA GTP-Binding Protein; Triglycerides; U937 Cells | 2002 |
Induction of lipoprotein lipase gene expression in 3T3-L1 preadipocytes by atorvastatin, a cholesterol- and triglyceride-lowering drug.
Topics: 3T3 Cells; Adipocytes; Animals; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Gene Expression; Heptanoic Acids; Hypolipidemic Agents; Lipoprotein Lipase; Mice; Pyrroles; RNA, Messenger; Time Factors | 2002 |
Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia.
Topics: Adult; Aged; Apolipoproteins B; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperlipoproteinemia Type III; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2002 |
The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coronary Disease; Female; Greece; Heptanoic Acids; Humans; Male; Middle Aged; National Health Programs; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Triglycerides | 2002 |
Avasimibe and atorvastatin synergistically reduce cholesteryl ester content in THP-1 macrophages.
Topics: Acetamides; Acetates; Atorvastatin; Cells, Cultured; Cholesterol Esters; Drug Synergism; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Pyrroles; Sulfonamides; Sulfonic Acids | 2002 |
Aggressive lipid-lowering in stable patients with coronary artery disease.
Topics: Angioplasty; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hyperlipidemias; Male; Multicenter Studies as Topic; Myocardial Ischemia; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic | 1999 |
The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells.
Topics: Atorvastatin; Blood Coagulation; Cells, Cultured; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Oligonucleotide Array Sequence Analysis; Pyrroles; Quinolines; Receptors, LDL; RNA, Messenger; Vasoconstriction | 2002 |
Intensive statin treatment improves baroreflex sensitivity: another cardioprotective mechanism for statins?
Topics: Anticholesteremic Agents; Atorvastatin; Baroreflex; Blood Pressure; Cholestyramine Resin; Heart Rate; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Norepinephrine; Pyrroles; Sympathomimetics | 2002 |
Statins, fibrates, and ocular myasthenia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Myasthenia Gravis; Pyrroles | 2002 |
Rhabdomyolysis with concurrent atorvastatin and diltiazem.
Topics: Acute Disease; Acute Kidney Injury; Atorvastatin; Cardiovascular Agents; Chemical and Drug Induced Liver Injury; Diltiazem; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Rhabdomyolysis | 2002 |
The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Muscular Diseases; Myositis; Pravastatin; Pyrroles; Rhabdomyolysis; Simvastatin | 2002 |
Effects of atorvastatin on renal function in patients with chronic renal failure.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Failure, Chronic; Pyrroles | 2002 |
Summaries for patients. Muscle abnormalities in four patients taking statins to treat unfavorable cholesterol levels.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biopsy; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscular Diseases; Pain; Pyrroles; Simvastatin | 2002 |
Multiorgan failure induced by atorvastatin.
Topics: Aged; Atorvastatin; Chemical and Drug Induced Liver Injury, Chronic; Diagnosis, Differential; Fatal Outcome; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Multiple Organ Failure; Pyrroles | 2002 |
Increased atherosclerosis in diabetic dyslipidemic swine: protection by atorvastatin involves decreased VLDL triglycerides but minimal effects on the lipoprotein profile.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Blood Glucose; Cholesterol; Collagen; Diabetes Mellitus, Experimental; Diet, Atherogenic; Fasting; Heptanoic Acids; Hyperlipidemias; Insulin; Lipoproteins, VLDL; Liver; Male; Pyrroles; Swine; Swine, Miniature; Triglycerides; Vitamin A; Vitamin E | 2002 |
Low-density lipoprotein lowering and atherosclerosis progression: does more mean less?
Topics: Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol; Cholesterol, LDL; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Pravastatin; Pyrroles; Ultrasonography | 2002 |
The lower the LDL, the better.
Topics: Academies and Institutes; Atorvastatin; Heptanoic Acids; Human Experimentation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insurance Coverage; Insurance, Health; Lipoproteins, LDL; Pravastatin; Pyrroles | 2002 |
[Maintaining the full benefit of statins. Therapy start 10 years earlier?].
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention | 2002 |
Effects of fibrates on metabolism of statins in human hepatocytes.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cytochrome P-450 CYP2C8; Fenofibrate; Fluorobenzenes; Gemfibrozil; Glucuronosyltransferase; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; In Vitro Techniques; Microsomes, Liver; Oxidation-Reduction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2002 |
Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury.
Topics: Atorvastatin; CD55 Antigens; Cell Line; Cells, Cultured; Complement Activation; Complement C3; Cytoprotection; Diterpenes; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Nitric Oxide; Phosphatidylinositol 3-Kinases; Polyisoprenyl Phosphates; Protein Kinase C; Pyrroles; rho GTP-Binding Proteins; RNA, Messenger; Simvastatin; Up-Regulation | 2002 |
Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Chylomicrons; Fasting; Food; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Pyrroles; Triglycerides | 2002 |
Tackling multiple sclerosis.
Topics: Animals; Antigen Presentation; Atorvastatin; Central Nervous System Diseases; Encephalomyelitis, Autoimmune, Experimental; Heptanoic Acids; Histocompatibility Antigens Class II; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Multiple Sclerosis; Pyrroles; T-Lymphocytes | 2002 |
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
Topics: Adoptive Transfer; Amino Acid Sequence; Animals; Antigen-Presenting Cells; Atorvastatin; Cell Division; Central Nervous System Diseases; Cytokines; DNA-Binding Proteins; Encephalomyelitis, Autoimmune, Experimental; Female; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice; Microglia; Molecular Sequence Data; Multiple Sclerosis; Nuclear Proteins; Paralysis; Phosphorylation; Pyrroles; RNA, Messenger; STAT4 Transcription Factor; STAT6 Transcription Factor; Th2 Cells; Trans-Activators | 2002 |
[Stable angina pectoris. PTCA improves symptoms, but not prognosis].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; Combined Modality Therapy; Heptanoic Acids; Humans; Hypercholesterolemia; Prognosis; Pyrroles; Recurrence; Risk Factors; Stents; Treatment Outcome | 2002 |
3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells.
Topics: Atorvastatin; CD40 Antigens; CD40 Ligand; Cell Communication; Cell Line; Cells, Cultured; Cytokines; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-12; Interleukin-12 Subunit p40; Jurkat Cells; Leukocytes; Mevalonic Acid; Monocytes; Protein Subunits; Pyrroles; Transcriptional Activation; Tumor Cells, Cultured; Umbilical Veins; Vascular Cell Adhesion Molecule-1 | 2002 |
Efficacy and safety of atorvastatin after pediatric heart transplantation.
Topics: Adolescent; Atorvastatin; Child; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Postoperative Period; Pyrroles; Retrospective Studies; Rhabdomyolysis | 2002 |
Zeroing in on how low cholesterol should go.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Risk Factors | 2002 |
Isoprenylation is necessary for the full invasive potential of RhoA overexpression in human melanoma cells.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Biocompatible Materials; Cell Movement; Collagen; Drug Combinations; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Humans; Laminin; Melanoma; Neoplasm Invasiveness; Neoplasm Metastasis; Protein Prenylation; Protein Processing, Post-Translational; Proteoglycans; Pyrroles; rhoA GTP-Binding Protein; Signal Transduction; Skin Neoplasms; Transcription, Genetic; Tumor Cells, Cultured | 2002 |
Atorvastatin increases hepatic fatty acid beta-oxidation in sucrose-fed rats: comparison with an MTP inhibitor.
Topics: Animals; Apolipoproteins B; Atorvastatin; Benzimidazoles; Carrier Proteins; Cholesterol; Fatty Acids; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipoproteins, VLDL; Liver; Male; Oxidation-Reduction; Pyrroles; Rats; Rats, Sprague-Dawley; Sucrose; Triglycerides | 2002 |
The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Erythrocyte Membrane; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipid Peroxidation; Lipids; Male; Membrane Fluidity; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2002 |
Coronary artery spasm associated with a moderately severe atherosclerotic stenosis in the proximal LAD.
Topics: Adult; Aspirin; Atorvastatin; Cardiac Catheterization; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vasospasm; Diltiazem; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Isosorbide; Pyrroles; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome; Ultrasonography, Interventional | 2002 |
Effect of atorvastatin on high-density lipoprotein apolipoprotein A-I production and clearance in the New Zealand white rabbit.
Topics: Animals; Apolipoprotein A-I; Atorvastatin; Cholesterol; Cholesterol Esters; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iodine Radioisotopes; Lipoproteins, HDL; Male; Metabolic Clearance Rate; Models, Animal; Phospholipids; Pyrroles; Rabbits; Radioactive Tracers; Triglycerides | 2002 |
Sepsis syndrome stimulates proximal tubule cholesterol synthesis and suppresses the SR-B1 cholesterol transporter.
Topics: Animals; Atorvastatin; Blood Proteins; CD36 Antigens; Cholesterol; Escherichia coli; Female; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Cortex; Kidney Tubules, Proximal; Male; Membrane Proteins; Mice; Mice, Inbred Strains; Mice, Knockout; Pyrroles; Receptors, Immunologic; Receptors, LDL; Receptors, Lipoprotein; Receptors, Scavenger; RNA, Messenger; Scavenger Receptors, Class B; Systemic Inflammatory Response Syndrome | 2003 |
Pharmacological interference with intestinal bile acid transport reduces plasma cholesterol in LDL receptor/apoE deficiency.
Topics: Animals; Apolipoproteins E; Atorvastatin; Carrier Proteins; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Mice; Mice, Knockout; Organic Anion Transporters, Sodium-Dependent; Pyrroles; Receptors, Lipoprotein; RNA, Messenger; Symporters; Thiazepines | 2003 |
Atorvastatin and the dyslipidemia of early renal failure.
Topics: Adolescent; Adult; Aged; Atorvastatin; Body Mass Index; Cholesterol, LDL; Combined Modality Therapy; Creatinine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Linear Models; Male; Middle Aged; Pyrroles; Renal Insufficiency; Risk Factors; Treatment Outcome | 2003 |
PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP.
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Coronary Disease; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Pregnancy-Associated Plasma Protein-A; Pyrroles | 2003 |
Atorvastatin reduces expression of leukocyte adhesion molecules in patients with hypercholesterolemia.
Topics: Atorvastatin; Cell Adhesion Molecules; Cholesterol, LDL; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2003 |
Statins and homocysteine.
Topics: Atorvastatin; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperhomocysteinemia; Pyrroles; Risk Factors; Simvastatin | 2003 |
The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Catalysis; Clopidogrel; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Isoenzymes; Male; Microsomes, Liver; Oxidation-Reduction; Oxidoreductases, N-Demethylating; Pyrroles; Rats; Rats, Inbred F344; Spodoptera; Ticlopidine | 2003 |
Anti-thrombotic effects of atorvastatin--an effect unrelated to lipid lowering.
Topics: Animals; Aorta, Abdominal; Atorvastatin; Fibrinolytic Agents; Heptanoic Acids; Lipids; Male; Nitric Oxide Synthase; Oxidative Stress; Pyrroles; Rats; Rats, Sprague-Dawley; Thrombosis | 2002 |
[Some new data concerning effectiveness of amlodipine, atorvastatine and quinaprile for heart diseases].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Heptanoic Acids; Humans; Hypercholesterolemia; Isoquinolines; Pyrroles; Quinapril; Tetrahydroisoquinolines | 2002 |
Causal structures for evaluating statin class effects.
Topics: Atorvastatin; Biomarkers; Cholesterol, LDL; Drug Costs; Drug Prescriptions; Formularies as Topic; Health Maintenance Organizations; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Risk | 2002 |
Statins regulate alpha2beta1-integrin expression and collagen I-dependent functions in human vascular smooth muscle cells.
Topics: Animals; Atorvastatin; Cell Adhesion; Cells, Cultured; Chemotaxis; Collagen Type I; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrin alpha2beta1; Muscle, Smooth, Vascular; Pravastatin; Pyrroles; Rats; Reverse Transcriptase Polymerase Chain Reaction | 2003 |
Statins do not meet expectations for lowering low-density lipoprotein cholesterol levels when used in clinical practice.
Topics: Aged; Atorvastatin; Cardiology; Cholesterol, LDL; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Observer Variation; Patient Compliance; Pravastatin; Probability; Prospective Studies; Pyrroles; Reference Values; Simvastatin; Treatment Failure; Treatment Outcome | 2002 |
Comparison of the effects of atorvastatin versus simvastatin on subclinical atherosclerosis in primary preventionas determined by electronbeam tomography.
Topics: Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Chi-Square Distribution; Disease Progression; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Niacin; Primary Prevention; Pyrroles; Risk Factors; Simvastatin; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes.
Topics: Animals; Atorvastatin; Benzylamines; Cells, Cultured; Cholesterol; Enzyme Inhibitors; Farnesol; Farnesyl-Diphosphate Farnesyltransferase; Hepatocytes; Heptanoic Acids; Lipid Metabolism; Male; Oxidation-Reduction; Pyrroles; Rats; Rats, Sprague-Dawley; Thiophenes; Triglycerides | 2003 |
Lipid lowering in hypertension and heart protection: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholesterol; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells.
Topics: Atorvastatin; Cell Line; Cell Survival; Down-Regulation; Endothelial Growth Factors; Endothelium, Vascular; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia-Inducible Factor 1, alpha Subunit; I-kappa B Proteins; Inflammation; Lovastatin; Muscle, Smooth, Vascular; NF-kappa B; NF-KappaB Inhibitor alpha; Plasminogen Activator Inhibitor 1; Protein Binding; Proto-Oncogene Proteins c-jun; Pyrroles; RNA, Messenger; Simvastatin; Transcription Factor AP-1; Transcription Factors; Vascular Endothelial Growth Factor A | 2003 |
Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3.
Topics: Antigens, CD; Atorvastatin; Basophils; Cell Differentiation; Cell Division; Dose-Response Relationship, Drug; Down-Regulation; Heptanoic Acids; Histamine Release; Humans; Immunoglobulin E; Interleukin-3; Phosphoric Diester Hydrolases; Pyridines; Pyrophosphatases; Pyrroles | 2003 |
Determination of pharmaceuticals in aqueous samples using positive and negative voltage switching microbore liquid chromatography/electrospray ionization tandem mass spectrometry.
Topics: Atorvastatin; Chromatography, Liquid; Heptanoic Acids; Molecular Structure; Novobiocin; Pharmaceutical Preparations; Pyrroles; Reference Standards; Roxithromycin; Sensitivity and Specificity; Solutions; Spectrometry, Mass, Electrospray Ionization; Water; Water Pollutants, Chemical | 2003 |
Statin-induced myositis migrans.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Myositis; Pravastatin; Pyrroles; Simvastatin; Time Factors | 2002 |
[Ezetimib plus statin combination. A strong duo].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Risk Factors; Simvastatin | 2002 |
Plasma fibronectin level and its relationships with lipids, lipoproteins and C-reactive protein in patients with dyslipidaemia during lipid-lowering therapy.
Topics: Adult; Aged; Apolipoproteins A; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Female; Fibronectins; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Probability; Prospective Studies; Pyrroles; Sensitivity and Specificity; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2002 |
Effect of atorvastatin on adhesive phenotype of human endothelial cells activated by tumor necrosis factor alpha.
Topics: Atorvastatin; Cell Line; Endothelium, Vascular; Heptanoic Acids; HL-60 Cells; Humans; Intercellular Adhesion Molecule-1; Phenotype; Pyrroles; Tumor Necrosis Factor-alpha; Umbilical Veins; Vascular Cell Adhesion Molecule-1 | 2003 |
Acute pancreatitis possibly associated with combined salicylate and atorvastatin therapy.
Topics: Acute Disease; Anticholesteremic Agents; Atorvastatin; Drug Combinations; Heptanoic Acids; Humans; Male; Middle Aged; Pancreatitis; Pyrroles; Salicylates; Treatment Outcome | 2003 |
Atorvastatin suppresses interferon-gamma -induced neopterin formation and tryptophan degradation in human peripheral blood mononuclear cells and in monocytic cell lines.
Topics: Atorvastatin; Cell Line; Cells, Cultured; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Leukocytes, Mononuclear; Monocytes; Neopterin; Pyrroles; Tryptophan | 2003 |
Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB.
Topics: Animals; Apolipoproteins B; Atorvastatin; Carrier Proteins; Cholesterol, LDL; Cyclic N-Oxides; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins; Lipoproteins, LDL; Male; Organic Anion Transporters, Sodium-Dependent; Pyrroles; Receptors, LDL; RNA, Messenger; Swine, Miniature; Symporters; Time Factors; Tropanes | 2003 |
Re: Gómez-Gerique, et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 2002;162:245-51.
Topics: Atorvastatin; Bezafibrate; C-Reactive Protein; Drug Interactions; Estrogen Replacement Therapy; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Pyrroles | 2003 |
Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Europe; Guideline Adherence; Heptanoic Acids; Humans; Myocardial Infarction; Practice Guidelines as Topic; Preventive Health Services; Pyrroles; Societies; Stroke; United Kingdom | 2002 |
Atorvastatin causes depressor and sympatho-inhibitory effects with upregulation of nitric oxide synthases in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Aorta; Atorvastatin; Blood Pressure; Brain; Genetic Predisposition to Disease; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Isoenzymes; Lipids; Male; Myocardium; Neural Inhibition; Nitric Oxide Synthase; Norepinephrine; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Sympathetic Nervous System; Up-Regulation | 2003 |
Drug interactions: gasoline and matches.
Topics: Atorvastatin; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Databases, Factual; Drug Interactions; Heptanoic Acids; Pyrroles; Ticlopidine | 2003 |
Benefits of atorvastatin in cholesterol lowering.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Triglycerides | 2003 |
Withdrawal of statin treatment abrogates stroke protection in mice.
Topics: Animals; Aorta; Atorvastatin; Bleeding Time; Blood Coagulation; Brain; Brain Ischemia; Disease Models, Animal; Drug Administration Schedule; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligation; Mice; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Platelet Activation; Pyrroles; rhoA GTP-Binding Protein; RNA, Messenger; Stroke; Substance Withdrawal Syndrome; Vena Cava, Inferior; Venous Thrombosis | 2003 |
Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway.
Topics: Animals; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardial Ischemia; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Pyrroles; Reperfusion; Signal Transduction; Time Factors; Up-Regulation | 2003 |
[Effect of high doses of atorvastatin on the endothelial function of the coronary arteries].
Topics: Acetylcholine; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Data Interpretation, Statistical; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Pyrroles; Regression Analysis; Time Factors; Triglycerides | 2003 |
The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Canada; Cardiovascular Diseases; Cost of Illness; Cost-Benefit Analysis; Direct Service Costs; Efficiency; Female; Health Care Costs; Health Expenditures; Heptanoic Acids; Humans; Hypolipidemic Agents; Life Expectancy; Male; Middle Aged; Primary Prevention; Pyrroles; Sensitivity and Specificity | 2003 |
Indications and outcome of treatment of hyperlipidemia in pediatric allograft recipients.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Child; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Transplantation; Pyrroles | 2003 |
The effect of lipoproteins on endothelial nitric oxide synthase is modulated by lipoperoxides.
Topics: Adult; Anticholesteremic Agents; Ascorbic Acid; Atorvastatin; Cells, Cultured; Cholesterol, LDL; Cross-Sectional Studies; Dose-Response Relationship, Drug; Drug Synergism; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipid Peroxidation; Lipid Peroxides; Lipids; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Nitrates; Nitric Oxide Synthase; Nitrites; Pyrroles | 2003 |
Effect of atorvastatin and clopidogrel on cellular immune function.
Topics: Adult; Atorvastatin; Clopidogrel; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Immunosuppressive Agents; In Vitro Techniques; Leukocyte Count; Lymphocyte Activation; Lymphocyte Subsets; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2003 |
Atorvastatin inhibits expression of minichromosome maintenance proteins in vascular smooth muscle cells.
Topics: Adenovirus E2 Proteins; Animals; Atorvastatin; Cell Cycle Proteins; Cells, Cultured; DNA-Binding Proteins; Dose-Response Relationship, Drug; Gene Expression Regulation; Genetic Vectors; Heptanoic Acids; Immunoblotting; Luciferases; Muscle, Smooth, Vascular; Nuclear Proteins; Phosphorylation; Promoter Regions, Genetic; Pyrroles; Rats; Rats, Sprague-Dawley; Recombinant Fusion Proteins; Retinoblastoma Protein; RNA, Messenger; Transcription, Genetic; Transfection | 2003 |
The $10 billion pill.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Design; Drug Industry; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; United States | 2003 |
Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia.
Topics: Adult; Analysis of Variance; Atorvastatin; Cholesterol, LDL; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrophoresis, Polyacrylamide Gel; Female; Follow-Up Studies; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Linear Models; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Particle Size; Probability; Prospective Studies; Pyrroles; Treatment Outcome | 2003 |
Related factors of meeting National Cholesterol Education Program-recommended goals with atorvastatin.
Topics: Aged; Atorvastatin; Body Mass Index; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; National Health Programs; Pyrroles; Risk Factors; Safety | 2003 |
Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Aorta; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Calcium Channel Blockers; Cholesterol; Heptanoic Acids; Humans; Mice; Mice, Transgenic; Pyrroles; Triglycerides | 2003 |
Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin.
Topics: Animals; Apoptosis; Atorvastatin; CD4-Positive T-Lymphocytes; Cell Cycle; Cell Division; Cell Line; Encephalomyelitis, Autoimmune, Experimental; Female; Genes, MHC Class II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Mice; Mice, Inbred Strains; Myelin Proteolipid Protein; Paralysis; Peptide Fragments; Pyrroles; Recurrence; Spinal Cord; Th1 Cells | 2003 |
Introduction: rosuvastatin--an efficacy assessment based on pooled trial data.
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Meta-Analysis as Topic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2003 |
A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Topics: Atorvastatin; Cholesterol; Clinical Trials as Topic; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Models, Economic; Pravastatin; Pyrroles; Simvastatin; United Kingdom | 2003 |
Increased endothelin-induced Ca2+ signaling, tyrosine phosphorylation, and coronary artery disease in diabetic dyslipidemic Swine are prevented by atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Calcium; Calcium Signaling; Coronary Artery Disease; Diabetes Complications; Diet; Disease Models, Animal; Endothelin-1; Endothelins; Heptanoic Acids; Hyperlipidemias; Male; Phosphorylation; Pyrroles; Receptor, Endothelin A; Receptors, Endothelin; Swine; Tyrosine | 2003 |
Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested.
Topics: Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pyrroles; Research; Ticlopidine | 2003 |
Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tyrosine | 2003 |
HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes.
Topics: Atorvastatin; Cell Cycle Proteins; Cell Division; Cells, Cultured; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Endothelium, Vascular; Gene Expression Profiling; Gene Expression Regulation; Genes, cdc; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Lovastatin; Oligonucleotide Array Sequence Analysis; Pyrroles; Signal Transduction; Stem Cells; Telomerase; Tumor Suppressor Proteins | 2003 |
Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia.
Topics: Administration, Oral; Animals; Atorvastatin; Cholesterol, HDL; Disease Models, Animal; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Mice; Mice, Knockout; Oxazepines; Piperidines; Pyrroles; Rabbits; Receptors, LDL; Simvastatin; Species Specificity; Time Factors; Triglycerides | 2003 |
Effect of atorvastatin on apolipoprotein B100 containing lipoprotein metabolism in type-2 diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Kinetics; Lipid Metabolism; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Pyrroles | 2003 |
What are the odds at ASCOT today?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic | 2003 |
Comparison of the frequency of adverse events in patients treated with atorvastatin or simvastatin.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscles; Pyrroles; Simvastatin | 2003 |
Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility.
Topics: Atorvastatin; Cholinesterase Inhibitors; Disease Susceptibility; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Malignant Hyperthermia; Middle Aged; Pain; Pyrroles; Rhabdomyolysis | 2003 |
Interaction between several medicines and statins.
Topics: Acids; Anticholesteremic Agents; Atorvastatin; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Indicators and Reagents; Lactones; Microsomes, Liver; Pyrroles; Quinolines | 2003 |
Triglyceride-lowering effect of pitavastatin in a guinea pig model of postprandial lipemia.
Topics: Animals; Anticoagulants; Atorvastatin; Carrier Proteins; Guinea Pigs; Heparin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Intestinal Mucosa; Lipids; Lipoproteins; Male; Postprandial Period; Pyrroles; Quinolines; Simvastatin; Triglycerides | 2003 |
Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Aspirin; Atorvastatin; Biphenyl Compounds; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Interleukin-6; Irbesartan; Isoquinolines; Male; Middle Aged; Monocytes; Platelet Aggregation Inhibitors; Pyrroles; Quinapril; Tetrahydroisoquinolines; Tetrazoles | 2003 |
Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs.
Topics: Acetamides; Advertising; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antiviral Agents; Atorvastatin; Bibliometrics; Canada; Celecoxib; Cholinesterase Inhibitors; Consumer Product Safety; Disclosure; Donepezil; Drug Industry; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Estrogen Antagonists; Heptanoic Acids; Humans; Indans; Newspapers as Topic; Oseltamivir; Patient Education as Topic; Piperidines; Pyrazoles; Pyrroles; Raloxifene Hydrochloride; Sulfonamides | 2003 |
Assessment of egg nutrient compositional changes and residue in eggs, tissues, and excreta following oral administration of atorvastatin to laying hens.
Topics: Amino Acids; Animals; Anticholesteremic Agents; Atorvastatin; Carbon Radioisotopes; Chickens; Cholesterol; Diet; Drug Residues; Egg White; Eggs; Fatty Acids; Feces; Female; Heptanoic Acids; Ovalbumin; Oviposition; Pyrroles | 2003 |
Variable influence of statins on isoprostanes in hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Dinoprost; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Isoprostanes; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Smoking | 2003 |
New lipid-lowering combo proves successful.
Topics: Atorvastatin; Attitude to Health; Azetidines; Drug Synergism; Drug Therapy, Combination; Europe; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Stroke; Treatment Outcome | 2003 |
Experimental model of postprandial hypertriglyceridemia in sucrose-fed rats and the effectiveness of atorvastatin in the model.
Topics: Animals; Area Under Curve; Atorvastatin; Dietary Fats; Emulsions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipoproteins; Lipoproteins, VLDL; Male; Olive Oil; Plant Oils; Postprandial Period; Pyrroles; Rats; Rats, Sprague-Dawley; Sucrose; Triglycerides | 2003 |
Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis.
Topics: Anticholesteremic Agents; Atorvastatin; Female; Hepatitis, Autoimmune; Heptanoic Acids; Humans; Immunosuppressive Agents; Liver; Liver Failure; Lupus Erythematosus, Systemic; Middle Aged; Pyrroles | 2003 |
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States | 2003 |
Time course of serum CK immediately before and after a single muscle cramp.
Topics: Amyotrophic Lateral Sclerosis; Atorvastatin; Creatine Kinase; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Muscle Cramp; Muscle, Skeletal; Pyrroles; Time Factors; Up-Regulation | 2003 |
Pretreatment with statins enhances myocardial protection during coronary revascularization.
Topics: Animals; Atorvastatin; Cardiopulmonary Bypass; Disease Models, Animal; Electric Countershock; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Myocardial Ischemia; Myocardial Revascularization; Premedication; Pyrroles; Random Allocation; Swine | 2003 |
Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction.
Topics: Atorvastatin; Clarithromycin; Drug Interactions; Esomeprazole; Female; Heart Block; Heptanoic Acids; Humans; Middle Aged; Pyrroles; Rhabdomyolysis | 2003 |
By the way, doctor. I'm 84, 5-foot-9, and weigh 160. I do an hour's exercise every day. I take a diuretic, potassium, and calcium-channel blocker. Should I also take Lipitor to avoid a heart attack?
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Diuretics; Exercise; Heptanoic Acids; Humans; Potassium; Pyrroles | 2003 |
Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke.
Topics: Animals; Antibodies; Atorvastatin; Brain; Enzyme Inhibitors; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Mitogen-Activated Protein Kinases; Neovascularization, Physiologic; Neuronal Plasticity; Neurons; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Wistar; Signal Transduction; Stroke; Synapses; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Atorvastatin and the ability of clopidogrel to inhibit platelet aggregation.
Topics: Atorvastatin; Clopidogrel; Dose-Response Relationship, Drug; Graft Occlusion, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Activation; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2003 |
Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins; Apolipoproteins B; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hyperlipoproteinemia Type III; Lipids; Lipoproteins; Male; Middle Aged; Osmolar Concentration; Pyrroles; Triglycerides | 2003 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Complications; Female; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles; Sex Factors | 2003 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Neoplasms; Pyrroles | 2003 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Heptanoic Acids; Humans; Hypertension; Pyrroles; Research Design | 2003 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Pyrroles; Risk | 2003 |
ASCOT-LLA: questions about the benefits of atorvastatin.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black People; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles; Risk Factors | 2003 |
Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE-/- mice by SC-435.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Bile Acids and Salts; Biological Transport; Cells, Cultured; Cricetinae; Cyclic N-Oxides; Enzyme Inhibitors; Gene Deletion; Heptanoic Acids; Humans; Ileum; Male; Mice; Mice, Knockout; Organic Anion Transporters, Sodium-Dependent; Pyrroles; Symporters; Tropanes | 2003 |
[Effects of atorvastatin on the proliferation and collagen synthesis of rat cardiac fibroblasts].
Topics: Animals; Animals, Newborn; Atorvastatin; Cell Division; Cells, Cultured; Collagen; Fibroblasts; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley; Ventricular Remodeling | 2003 |
Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV.
Topics: Adult; Anti-Bacterial Agents; Atorvastatin; Clarithromycin; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lopinavir; Male; Pyrimidinones; Pyrroles; Rhabdomyolysis; Ritonavir | 2003 |
Atorvastatin-clopidogrel interaction.
Topics: Aspirin; Atorvastatin; Clinical Trials as Topic; Clopidogrel; Confounding Factors, Epidemiologic; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2003 |
Do hypertensive patients with average cholesterol levels benefit from atorvastatin therapy?
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2003 |
Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice.
Topics: Amlodipine; Animals; Aorta, Thoracic; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholesterol; Cholesterol, Dietary; Drug Therapy, Combination; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Transgenic; Pyrroles | 2003 |
Statins benefit people with high blood pressure.
Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2003 |
Reduction of infarct size by short-term pretreatment with atorvastatin.
Topics: Animals; Atorvastatin; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; NG-Nitroarginine Methyl Ester; Pyrroles; Rats; Rats, Sprague-Dawley | 2003 |
Effect of atorvastatin on total lipid profiles assessed by analytical capillary isotachophoresis.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Protein Electrophoresis; Electrophoresis, Capillary; Follow-Up Studies; Heptanoic Acids; Humans; Lipoproteins; Lipoproteins, LDL; Male; Myocardial Infarction; Pyrroles | 2003 |
[Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Meta-Analysis as Topic; Placebos; Pravastatin; Primary Prevention; Pyrroles; Simvastatin; Time Factors | 2003 |
Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Male; Microfilament Proteins; Middle Aged; Muscle Proteins; Pravastatin; Pyrroles; Retrospective Studies | 2003 |
Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits.
Topics: Acyl Coenzyme A; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Thoracic; Arteriosclerosis; Atorvastatin; Blood Pressure; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fibrinolysis; Heptanoic Acids; Hypercholesterolemia; In Vitro Techniques; Inflammation Mediators; Male; Pyrroles; Quinapril; Rabbits; Tetrahydroisoquinolines; Tunica Intima; Vasodilation | 2003 |
Effect of pitavastatin on sterol and bile acid excretion in guinea pigs.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol 7-alpha-Hydroxylase; Cholesterol, HDL; Feces; Guinea Pigs; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Quinolines; RNA, Messenger; Simvastatin; Sterols | 2003 |
Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature.
Topics: Animals; Aorta; Atorvastatin; Bradykinin; Calcimycin; Cells, Cultured; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; In Vitro Techniques; Lipids; Microscopy, Fluorescence; NAD; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Oxidation-Reduction; Oxygen; Pyrroles; Rats; Rats, Sprague-Dawley; Rhodamines; Simvastatin; Subcellular Fractions; Superoxide Dismutase; Up-Regulation; Vasodilation | 2003 |
Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation.
Topics: Animals; Arteriosclerosis; Atorvastatin; Cell Communication; Cell Membrane; Cells, Cultured; Chemokines; Chlamydophila Infections; Chlamydophila pneumoniae; Coculture Techniques; Dose-Response Relationship, Drug; Enzyme Activation; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice; Mice, Knockout; Muscle, Smooth, Vascular; NF-kappa B; Protein Prenylation; Pyridines; Pyrroles; rac1 GTP-Binding Protein; Reactive Oxygen Species; rhoA GTP-Binding Protein; RNA, Messenger; Signal Transduction | 2003 |
Autoimmune hepatitis revealed by atorvastatin.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Atorvastatin; Autoimmune Diseases; Bilirubin; Chemical and Drug Induced Liver Injury; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Function Tests; Pyrroles | 2003 |
In light of ALLHAT and ASCOT: are there benefits of statins as add-on treatment in hypertensives?
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2003 |
Effect of atorvastatin on ApoE and ApoC-I synthesis and secretion by THP-1 macrophages.
Topics: Apolipoprotein C-I; Apolipoproteins C; Apolipoproteins E; Atorvastatin; Cells, Cultured; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Pyrroles | 2003 |
Atorvastatin reduces microalbuminuria in patients with familial hypercholesterolemia and normal glucose tolerance.
Topics: Adult; Albuminuria; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Case-Control Studies; Cholesterol, LDL; Creatinine; Female; Heptanoic Acids; Homeostasis; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles | 2003 |
Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies.
Topics: Acute Disease; Aged; Atorvastatin; Clopidogrel; Comorbidity; Coronary Disease; Drug Interactions; Drug Utilization; Female; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Registries; Stroke; Survival Analysis; Syndrome; Ticlopidine; Treatment Outcome | 2003 |
[Atorvastatin and clopidogrel. A possible drug interaction with clinical consequences still unknown].
Topics: Anticholesteremic Agents; Atorvastatin; Clopidogrel; Drug Interactions; Heptanoic Acids; Humans; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2003 |
[Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome].
Topics: Adult; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Indapamide; Male; Metabolic Syndrome; Middle Aged; Perindopril; Pyrroles; Simvastatin; Treatment Outcome | 2003 |
The eye lens evaluation of the atorvastatin-treated white rat.
Topics: Administration, Oral; Animals; Atorvastatin; Cataract; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lens, Crystalline; Pyrroles; Rats; Rats, Wistar | 2002 |
The influence of Atorvastatin on ultrastructure of rat pancreatic exocrine cells in the course of experimental intoxication with ethanol.
Topics: Alcoholic Intoxication; Animals; Anticholesteremic Agents; Atorvastatin; Drug Interactions; Drug Synergism; Ethanol; Heptanoic Acids; Male; Pancreas; Pancreatitis, Alcoholic; Pyrroles; Rats; Rats, Wistar | 2002 |
Microvascular reactivity in patients with hypercholesterolemia: effect of lipid lowering treatment.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperemia; Laser-Doppler Flowmetry; Male; Microcirculation; Middle Aged; Pilot Projects; Pyrroles; Skin | 2003 |
The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam.
Topics: Aged; Anesthesia, General; Anesthetics, Intravenous; Anticholesteremic Agents; Atorvastatin; Drug Interactions; Female; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matched-Pair Analysis; Midazolam; Middle Aged; Pyrroles | 2003 |
[Comparative study of lipid lowering effect and influence on platelet aggregation of atorvastatin and simvastatin in patients ischemic heart disease with type II diabetes and combined hyperlipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation; Pyrroles; Simvastatin | 2003 |
Atorvastatin limits the pro-inflammatory response of rat aortic smooth muscle cells to thrombin.
Topics: Animals; Aorta, Thoracic; Atorvastatin; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Inflammation; Male; Mice; Muscle, Smooth, Vascular; Pyrroles; Rats; Rats, Wistar; Thrombin | 2003 |
Effect of atorvastatin on lipid parameters, LDL subtype distribution, hemorrheological parameters and adhesion molecule concentrations in patients with hypertriglyceridemia.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Cholesterol, HDL; Cholesterol, LDL; Female; Hemorheology; Heptanoic Acids; Humans; Hypertriglyceridemia; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Triglycerides | 2003 |
Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Arteries; Atorvastatin; Biomarkers; Blood Pressure; Calcium Channel Blockers; Cholesterol, LDL; Diastole; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Pyrroles; Stroke Volume; Systole; Treatment Outcome; Vascular Resistance | 2003 |
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes.
Topics: ADP Ribose Transferases; Animals; Atorvastatin; Botulinum Toxins; Cells, Cultured; Cytotoxicity Tests, Immunologic; Enzyme Inhibitors; Fas Ligand Protein; Genes, Dominant; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ionophores; Jurkat Cells; Leukocytes, Mononuclear; Lymphocyte Activation; Membrane Glycoproteins; Mevalonic Acid; Mice; Phorbol Esters; Protein Prenylation; Pyrroles; rhoA GTP-Binding Protein; Simvastatin; T-Lymphocytes; Transfection | 2003 |
Effects of atorvastatin on in-stent stenosis in normo- and hypercholesterolemic rabbits.
Topics: Animals; Atorvastatin; Cholinergic Antagonists; Constriction, Pathologic; Femoral Artery; Heptanoic Acids; Hypercholesterolemia; Muscle, Smooth, Vascular; Pyrroles; Rabbits; Stents | 2003 |
[Statin soon to become standard addition to antihypertensive therapy? Better prevention of coronary heart disease for hypertensive patients].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Treatment Outcome | 2003 |
Statins increase thrombomodulin expression and function in human endothelial cells by a nitric oxide-dependent mechanism and counteract tumor necrosis factor alpha-induced thrombomodulin downregulation.
Topics: Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Nitric Oxide; Polyisoprenyl Phosphates; Pyrroles; Simvastatin; Thrombomodulin; Tumor Necrosis Factor-alpha | 2003 |
Lipid-lowering drugs and the risk of depression and suicidal behavior.
Topics: Adult; Aged; Atorvastatin; Case-Control Studies; Depression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Multivariate Analysis; Pyrroles; Regression Analysis; Risk Factors; Suicide | 2003 |
Prevention of nitrate tolerance by long-term treatment with statins.
Topics: Administration, Oral; Animals; Aorta, Thoracic; Atorvastatin; Down-Regulation; Drug Administration Schedule; Drug Tolerance; Guanylate Cyclase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Injections, Subcutaneous; Luminescent Measurements; Male; NADH, NADPH Oxidoreductases; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Nitroglycerin; Pravastatin; Pyrroles; Rats; Rats, Wistar; Superoxides; Vasodilator Agents | 2003 |
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
Topics: Animals; Arteriosclerosis; Atorvastatin; Blotting, Western; CD40 Antigens; Cells, Cultured; Depression, Chemical; Dose-Response Relationship, Drug; Endothelial Cells; Fibroblasts; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interferon-gamma; Lovastatin; Macrophages; Mevalonic Acid; Mice; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Simvastatin; Transcription Factors | 2003 |
Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits.
Topics: Adipocytes; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Cholesterol, Dietary; Gene Expression; Heptanoic Acids; Hypercholesterolemia; Interleukin-6; Male; Pyrroles; Rabbits; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors | 2003 |
No absolutes.
Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Risk; Sample Size | 2003 |
Atorvastatin and clopidogrel.
Topics: Atorvastatin; Clopidogrel; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2003 |
Anaesthetic management of coronary artery bypass grafting in a patient with central core disease and susceptibility to malignant hyperthermia on statin therapy.
Topics: Adult; Anesthesia, Intravenous; Anticholesteremic Agents; Aprotinin; Atorvastatin; Coronary Artery Bypass; Female; Heptanoic Acids; Humans; Malignant Hyperthermia; Myopathy, Central Core; Pyrroles | 2003 |
Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells.
Topics: Animals; Atorvastatin; Cell Movement; Green Fluorescent Proteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunoblotting; Immunohistochemistry; Luciferases; Luminescent Proteins; Melanoma; Mice; Mice, SCID; Microscopy, Fluorescence; Neoplasm Invasiveness; Neoplasm Metastasis; Plasmids; Protein Processing, Post-Translational; Pyrroles; ras Proteins; rho GTP-Binding Proteins; rhoC GTP-Binding Protein; Serum Response Factor; Subcellular Fractions; Time Factors; Tumor Cells, Cultured | 2003 |
Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Cost-Benefit Analysis; Economics, Pharmaceutical; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardial Ischemia; Pyrroles; Secondary Prevention; Syndrome | 2003 |
Spontaneous reports cannot serve as a basis for comparison of two drugs.
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin; United States; United States Food and Drug Administration | 2003 |
Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy.
Topics: Adult; Aryldialkylphosphatase; Atorvastatin; Cholesterol; Enzyme Induction; Foam Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Macrophages; Male; Middle Aged; Oxidative Stress; Pyrroles | 2004 |
Atorvastatin-induced polyneuropathy.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Male; Middle Aged; Polyneuropathies; Pyrroles | 2003 |
Statin use is associated with enhanced collateralization of severely diseased coronary arteries.
Topics: Aged; Aspirin; Atorvastatin; Calcium Channels; Collateral Circulation; Coronary Angiography; Coronary Disease; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Neovascularization, Pathologic; Pyrroles; Retrospective Studies | 2003 |
Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Niacin; Particle Size; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2003 |
[Following the ASCOT Study. A statin for every hypertensive patient?].
Topics: Anticholesteremic Agents; Atorvastatin; Cerebral Infarction; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Treatment Outcome | 2003 |
Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells.
Topics: Atorvastatin; Cells, Cultured; Coronary Vessels; Dose-Response Relationship, Drug; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscle, Smooth, Vascular; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Simvastatin; Umbilical Veins; Vascular Endothelial Growth Factor A | 2003 |
[Clinical study of the month. Premature interruption of ASCOT and CARDS clinical trials of cardiovascular prevention with atorvastatin in patients with arterial hypertension or diabetes mellitus: compromise between ethics and statistics in evidence-based
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Diabetes Complications; Ethics, Research; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Ireland; Pyrroles; Risk Factors; Scandinavian and Nordic Countries; United Kingdom | 2003 |
Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Feces; Heptanoic Acids; Humans; Hypercholesterolemia; Intestinal Absorption; Lipids; Lipoproteins; Liver; Male; Middle Aged; Phytosterols; Pyrroles; Squalene | 2003 |
["Gout tophi" and heart disease in the family].
Topics: Adult; Arcus Senilis; Atorvastatin; Cholesterol; Cholesterol, HDL; Diagnosis, Differential; Female; Follow-Up Studies; Foot Dermatoses; Hand Dermatoses; Heart Diseases; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Time Factors; Xanthomatosis | 2003 |
Fatal liver failure with atorvastatin.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Fatal Outcome; Heptanoic Acids; Humans; Liver Failure, Acute; Male; Pyrroles | 2003 |
Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin.
Topics: Administration, Oral; Animals; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Glucose; Glucose Tolerance Test; Heptanoic Acids; Injections, Intravenous; Insulin; Insulin Secretion; Male; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Streptozocin; Time Factors | 2003 |
An HPLC method for the determination of atorvastatin and its impurities in bulk drug and tablets.
Topics: Atorvastatin; Chromatography, High Pressure Liquid; Drug Contamination; Heptanoic Acids; Pyrroles; Tablets | 2003 |
Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans.
Topics: Adult; Atorvastatin; Bile Acids and Salts; Child; Cholesterol, LDL; Colestipol; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Heterozygote; Human Growth Hormone; Humans; Hyperlipoproteinemia Type II; Hypopituitarism; Lipoproteins, LDL; Male; Middle Aged; Pyrroles | 2004 |
Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; Case-Control Studies; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pregnancy-Associated Plasma Protein-A; Pyrroles | 2003 |
Atorvastatin stent coating does not reduce neointimal proliferation after coronary stenting.
Topics: Administration, Topical; Angioplasty, Balloon, Coronary; Animals; Anticholesteremic Agents; Atorvastatin; Cell Division; Cell Movement; Coated Materials, Biocompatible; Coronary Restenosis; Coronary Vessels; Heptanoic Acids; Muscle, Smooth, Vascular; Pyrroles; Stents; Swine | 2003 |
Statin face-off. Surprises from the first head-to-head comparison.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Treatment Outcome; United States | 2003 |
Effects of simvastatin and atorvastatin in hypercholesterolemic patients.
Topics: Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin; Triglycerides | 2003 |
Effect of statins on the progression of bioprosthetic aortic valve degeneration.
Topics: Aged; Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Atorvastatin; Bioprosthesis; Coronary Artery Bypass; Coronary Artery Disease; Female; Heart Valve Prosthesis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pravastatin; Prosthesis Failure; Pyrroles; Retrospective Studies; Simvastatin; Treatment Outcome; Ultrasonography | 2003 |
Interaction between fibrates and statins--metabolic interactions with gemfibrozil.
Topics: Atorvastatin; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microsomes, Liver; Pyridines; Pyrroles; Quinolines | 2003 |
Short-term effects of atorvastatin on haemorheologic parameters, platelet aggregation and endothelium dysfunction in patients with hypercholesterolaemia.
Topics: Anticholesteremic Agents; Antigens; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Platelet Aggregation; Pyrroles; von Willebrand Factor | 2004 |
An efficient synthesis of N3,4-diphenyl-5-(4-fluorophenyl)-2-isopropyl-1H-3-pyrrolecarboxamide, a key intermediate for atorvastatin synthesis.
Topics: Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2004 |
Atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces bone resorption in the elderly.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Atorvastatin; Biomarkers; Bone Density; Bone Resorption; Case-Control Studies; Collagen; Collagen Type I; Creatinine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Peptides; Prospective Studies; Pyrroles; Treatment Outcome | 2003 |
Atorvastatin enhances cellular uptake of oxidized LDL in adipocytes from hypercholesterolemic rabbits.
Topics: Adipocytes; Animals; Anticholesteremic Agents; Atorvastatin; CD36 Antigens; Heptanoic Acids; Hypercholesterolemia; Iodine Radioisotopes; Lipoproteins, LDL; Pyrroles; Rabbits; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors | 2004 |
Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Homocysteine; Humans; Hypercholesterolemia; Kidney Failure, Chronic; Lipid Metabolism; Lipids; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Renal Dialysis; Risk Factors | 2003 |
Cognitive impairment associated with atorvastatin and simvastatin.
Topics: Aged; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Memory Disorders; Pyrroles; Simvastatin | 2003 |
Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA.
Topics: Antioxidants; Atorvastatin; Catalase; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Erythrocytes; Fatty Acids, Unsaturated; Glutathione; Glutathione Peroxidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lymphocytes; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Superoxide Dismutase; Ubiquinone; Vitamin E | 2003 |
Statin cardiomyopathy? A potential role for Co-Enzyme Q10 therapy for statin-induced changes in diastolic LV performance: description of a clinical protocol.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Protocols; Clinical Trials as Topic; Coenzymes; Diastole; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Ubiquinone; Ventricular Dysfunction, Left | 2003 |
CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genetic Variation; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient.
Topics: Adult; Atorvastatin; Diabetes Mellitus, Type 1; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Islets of Langerhans Transplantation; Pyrroles; Sirolimus | 2003 |
ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; ATP-Binding Cassette Transporters; Drug Resistance; Female; Gene Frequency; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Linkage Disequilibrium; Lipoproteins; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles | 2004 |
Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells.
Topics: Amides; Atorvastatin; Cell Division; Cells, Cultured; Drug Interactions; Endothelium, Vascular; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Signaling Peptides and Proteins; Mevalonic Acid; Peptidyl-Dipeptidase A; Phosphorylation; Polyisoprenyl Phosphates; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; rho-Associated Kinases; RNA, Messenger; Sesquiterpenes; Umbilical Veins; Up-Regulation; Vascular Endothelial Growth Factor A | 2004 |
HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis.
Topics: Adjuvants, Immunologic; Antigens, CD; Arteriosclerosis; Atorvastatin; B7-2 Antigen; Bone Marrow Cells; CD83 Antigen; Cell Survival; Cells, Cultured; Dendritic Cells; Flow Cytometry; Heptanoic Acids; HLA-DR Antigens; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulins; Lymphocyte Culture Test, Mixed; Membrane Glycoproteins; Pyrroles; Receptors, CCR7; Receptors, Chemokine; Simvastatin; Time Factors; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2004 |
Liver function test abnormalities and pruritus in a patient treated with atorvastatin: case report and review of the literature.
Topics: Administration, Oral; Aged; Alanine Transaminase; Atorvastatin; Drug Monitoring; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Liver; Liver Function Tests; Pruritus; Pyrroles | 2004 |
Salmonella enterica serovar Typhimurium requires nonsterol precursors of the cholesterol biosynthetic pathway for intracellular proliferation.
Topics: Animals; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Lovastatin; Macrophages; Mice; Mice, Inbred BALB C; Pyrroles; Salmonella typhimurium | 2004 |
Aggressive lipid-lowering regimen halts CHD progression.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2004 |
Italian drug policy: ethical aims of essential assistance levels.
Topics: Anticholesteremic Agents; Atorvastatin; Carbamates; Cholinesterase Inhibitors; Drug Costs; Drugs, Essential; Formularies as Topic; Health Care Costs; Health Care Rationing; Health Policy; Heptanoic Acids; Humans; Insurance, Health, Reimbursement; Italy; Medical Assistance; National Health Programs; Phenylcarbamates; Pyrroles; Rivastigmine | 2003 |
Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia.
Topics: Aged; Atorvastatin; Cerebral Hemorrhage; Cerebrovascular Disorders; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Platelet Aggregation; Pyrroles; Time Factors | 2004 |
Germ cell migration in zebrafish is dependent on HMGCoA reductase activity and prenylation.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cell Movement; Chemokine CXCL12; Chemokines, CXC; Diterpenes; Dose-Response Relationship, Drug; Drug Interactions; Embryo, Nonmammalian; Enzyme Inhibitors; Farnesol; gamma-Glutamyltransferase; Germ Cells; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Mevalonic Acid; Microinjections; Morpholines; Protein Prenylation; Pyrroles; RNA-Binding Proteins; RNA, Messenger; Somites; Time Factors; Zebrafish; Zebrafish Proteins | 2004 |
Antioxidants inhibit nuclear export of telomerase reverse transcriptase and delay replicative senescence of endothelial cells.
Topics: Acetylcysteine; Antioxidants; Atorvastatin; Cell Nucleus; Cells, Cultured; Cellular Senescence; Depression, Chemical; DNA Replication; DNA-Binding Proteins; DNA, Mitochondrial; Endothelial Cells; Endothelium, Vascular; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydrogen Peroxide; Oxidation-Reduction; Oxidative Stress; Protein Transport; Pyrimidines; Pyrroles; Reactive Oxygen Species; src-Family Kinases; Telomerase | 2004 |
[First comparison of 2 statins shows: only radical LDL lowering stops coronary atherosclerosis].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Time Factors; Ultrasonography, Interventional | 2003 |
Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro.
Topics: Animals; Atorvastatin; C-Reactive Protein; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Cholesterol; Down-Regulation; Gene Expression; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; I-kappa B Proteins; In Vitro Techniques; Interleukin-1; Male; Mice; Mice, Transgenic; NF-kappa B; NF-kappa B p50 Subunit; NF-KappaB Inhibitor alpha; Pyrroles; Receptors, Cytoplasmic and Nuclear; Simvastatin; Transcription Factors; Up-Regulation | 2004 |
Clash of the statins? A trial pitting two popular statins against each other helps answer a far more important question: how low should cholesterol go?
Topics: Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke | 2004 |
Is there a "best" statin drug?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury.
Topics: Administration, Oral; Animals; Atorvastatin; Brain; Brain Injuries; Cell Survival; Disease Models, Animal; Heptanoic Acids; Immunohistochemistry; Male; Neovascularization, Physiologic; Neurons; Neuroprotective Agents; Pyrroles; Rats; Rats, Wistar; Synapses; Synaptophysin | 2004 |
Toward a role for statins in immunomodulation.
Topics: Adjuvants, Immunologic; Animals; Atorvastatin; Autoimmune Diseases; Cytokines; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Genes, MHC Class II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Lovastatin; Mice; Pravastatin; Pyrroles; Simvastatin | 2002 |
Lack of adverse clopidogrel-atorvastatin clinical interaction.
Topics: Atorvastatin; Clopidogrel; Coronary Disease; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pyrroles; Research Design; Ticlopidine | 2004 |
High-intensity statin treatment for coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Dropouts; Pravastatin; Pyrroles; Risk Factors; Ultrasonography, Interventional | 2004 |
Is Lipitor better than Pravachol?
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Pravastatin; Pyrroles | 2004 |
Intensive statin therapy--a sea change in cardiovascular prevention.
Topics: Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model.
Topics: Animals; Arrhythmias, Cardiac; Atorvastatin; C-Reactive Protein; Dogs; Female; Heart Atria; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Models, Animal; Pericarditis; Pyrroles; Random Allocation | 2004 |
HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis.
Topics: Animals; Atorvastatin; Cell Death; Cell Survival; Cholesterol; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Neurites; Neurons; Polyisoprenyl Phosphates; Pyrroles; Rats; Sesquiterpenes; Squalene | 2004 |
Atorvastatin as a trigger of autoimmune hepatitis.
Topics: Antibodies, Antinuclear; Anticholesteremic Agents; Atorvastatin; Autoantibodies; Female; Hepatitis, Autoimmune; Heptanoic Acids; Humans; Liver Failure, Acute; Male; Muscle, Smooth; Pyrroles | 2004 |
Statins downregulate ATP-binding-cassette transporter A1 gene expression in macrophages.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Biological Transport; Blotting, Northern; Cell Line; Cholesterol; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Luciferases; Macrophages; Mice; Oxygen; Promoter Regions, Genetic; Pyrroles; RNA, Messenger; Simvastatin; Swiss 3T3 Cells; Time Factors; Transcription, Genetic | 2004 |
Atorvastatin improves the course of ischemic acute renal failure in aging rats.
Topics: Acute Kidney Injury; Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Kidney; Male; Pyrroles; Rats; Rats, Sprague-Dawley | 2004 |
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study.
Topics: Aged; Atorvastatin; Coronary Disease; Creatinine; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Uric Acid | 2004 |
C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
Topics: Acute-Phase Reaction; Aspirin; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Incidence; Inflammation; Interleukin-6; Lovastatin; Pravastatin; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin | 2004 |
Effect of atorvastatin on impaired vascular function in healthy old men.
Topics: Acetylcholine; Adult; Aged; Aged, 80 and over; Aging; Anticholesteremic Agents; Atorvastatin; Brachial Artery; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Endothelium, Vascular; Forearm; Heptanoic Acids; Humans; Male; Nitroprusside; Plethysmography; Pyrroles; Reference Values; Regional Blood Flow; Serotonin; Triglycerides; Vasodilation; Vasodilator Agents | 2004 |
Development of an efficient, scalable, aldolase-catalyzed process for enantioselective synthesis of statin intermediates.
Topics: Amino Acid Sequence; Atorvastatin; Catalysis; Fluorobenzenes; Fructose-Bisphosphate Aldolase; Heptanoic Acids; Molecular Sequence Data; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stereoisomerism; Sulfonamides | 2004 |
Increasing HDL Cholesterol Levels.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Biological Transport; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines; Triglycerides | 2004 |
Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Female; Genes, MDR; Heptanoic Acids; Humans; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Sex Factors | 2004 |
What to do about cholesterol now. Here's the take-home message from startling new research findings.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Biomedical Research; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Pravastatin; Pyrroles | 2004 |
Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apolipoproteins E; Atorvastatin; Autoradiography; Blotting, Western; Carrier Proteins; Cell Line; Databases, Protein; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Gene Expression; Gene Expression Profiling; Heptanoic Acids; Humans; LDL-Receptor Related Protein-Associated Protein; Lipoproteins, LDL; Macrophages; Metalloendopeptidases; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Suppressor Proteins | 2004 |
Successful reintroduction of statin therapy after myositis: was there another cause?
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypothyroidism; Male; Myositis; Pyrroles; Simvastatin | 2004 |
Lipitor bests Pravachol at certain doses.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention | 2004 |
Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman.
Topics: Adult; Anxiety Disorders; Apgar Score; Atorvastatin; Chronic Disease; Diabetes Complications; Epilepsy; Female; Gliclazide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Infant, Newborn; Obesity, Morbid; Pregnancy; Pregnancy Complications, Cardiovascular; Pregnancy Outcome; Pyrroles; Rosiglitazone; Thiazolidinediones | 2004 |
Cell-based screen of HMG-CoA reductase inhibitors and expression regulators using LC-MS.
Topics: Atorvastatin; Biological Assay; Calibration; Cell Line; Chromatography, Liquid; Enzyme Induction; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mass Spectrometry; Mevalonic Acid; Pyrroles; Simvastatin | 2004 |
Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench.
Topics: Acute Disease; Angina Pectoris; Angina, Unstable; Anion Exchange Resins; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Atorvastatin; CD4 Lymphocyte Count; Coronary Disease; Epichlorohydrin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Imidazoles; Immunophenotyping; Male; Prospective Studies; Pyrroles; Resins, Synthetic; Th1 Cells; Th2 Cells | 2004 |
Cholesterol: low is good. Lower is better. PROVE IT has doctors rethinking how to treat high cholesterol and what's a good target.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values | 2004 |
Cholesterol limbo: How low should the bar go. Ratcheting down LDL to extra-low levels with high-dose statins seems to work wonders.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Reference Values | 2004 |
Clopidogrel-atorvastatin interaction.
Topics: Atorvastatin; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Heptanoic Acids; Humans; Platelet Aggregation Inhibitors; Pravastatin; Prodrugs; Pyrroles; Ticlopidine | 2004 |
Class-specific pro-apoptotic effect of statins on human vascular endothelial cells.
Topics: Apoptosis; Atorvastatin; Cell Division; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Fas Ligand Protein; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Membrane Glycoproteins; Metabolic Clearance Rate; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Simvastatin; Umbilical Veins | 2004 |
Believe-it then PROVE-IT.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Evidence-Based Medicine; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Reference Values | 2004 |
Apoptotic injury in cultured human hepatocytes induced by HMG-CoA reductase inhibitors.
Topics: Adult; Annexin A5; Apoptosis; Atorvastatin; Caspase 3; Caspases; Cholesterol; Enzyme Inhibitors; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Pravastatin; Proto-Oncogene Proteins c-bcl-2; Pyrroles; RNA, Messenger; Simvastatin | 2004 |
Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Atorvastatin; Databases, Factual; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrroles; Rosiglitazone; Simvastatin; Thiazolidinediones; United States; United States Food and Drug Administration | 2004 |
HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Atrophy; Brain; Cell Death; Cerebral Hemorrhage; Hematoma; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Models, Animal; Neuroprotective Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Psychomotor Performance; Pyrroles; Rats; Rats, Sprague-Dawley | 2004 |
A statin for a patient with hyperlipidemia and hepatitis C?
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholestyramine Resin; Diet; Exercise; Ezetimibe; Hepatitis C, Chronic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Risk Factors | 2004 |
Statins as immunomodulatory agents.
Topics: Atorvastatin; Cells, Cultured; Endothelium, Vascular; Heptanoic Acids; Histocompatibility Antigens Class II; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interferon-gamma; Lymphocyte Activation; Pyrroles; T-Lymphocytes | 2004 |
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.
Topics: Alitretinoin; Animals; Atorvastatin; Base Sequence; Cell Line; Cholesterol; Consensus Sequence; DNA-Binding Proteins; Gene Expression Regulation; Hepatocytes; Heptanoic Acids; Homeostasis; Humans; Hydroxycholesterols; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver X Receptors; Lovastatin; Mevalonic Acid; Mice; Orphan Nuclear Receptors; Promoter Regions, Genetic; Proprotein Convertase 9; Proprotein Convertases; Pyridines; Pyrroles; Quinolines; Rats; Receptors, Cytoplasmic and Nuclear; Regulatory Sequences, Nucleic Acid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Alignment; Sequence Homology, Nucleic Acid; Serine Endopeptidases; Simvastatin; Sp1 Transcription Factor; Species Specificity; Sterol Regulatory Element Binding Protein 2; Transcription Factors; Tretinoin | 2004 |
Update on statins.
Topics: Atorvastatin; Coronary Disease; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Biological Transport; CD36 Antigens; Cells, Cultured; Cholesterol; Gene Expression; Heptanoic Acids; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Macrophages; Pyrroles; Receptors, Immunologic; Receptors, Lipoprotein; Receptors, Scavenger; Rosiglitazone; Scavenger Receptors, Class B; Thiazolidinediones | 2004 |
"Major surprise" in a new study means likely changes in treatment.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values | 2004 |
Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels: a clinical observation.
Topics: Adult; Atorvastatin; Comorbidity; Erectile Dysfunction; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Penile Erection; Pyrroles | 2004 |
A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Health Care Costs; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Retrospective Studies; Sweden; Syndrome; Time Factors; Treatment Outcome | 2004 |
Statins in rheumatoid arthritis--two birds with one stone?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors | 2004 |
Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke.
Topics: Aged; Analysis of Variance; Atorvastatin; Cardiovascular Diseases; Coenzymes; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Stroke; Ubiquinone | 2004 |
Therapy-refractory systemic juvenile idiopathic arthritis successfully treated with statins.
Topics: Anticholesteremic Agents; Arthritis, Juvenile; Atorvastatin; Child, Preschool; Heptanoic Acids; Humans; Male; Pyrroles | 2004 |
[Cost-effectiveness of atorvastatin for the prevention of coronary disease. An analysis of the ASCOT study].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Cost-Benefit Analysis; Female; Germany; Health Care Costs; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2004 |
[Lower, lower, lower. The LDL goal value of 200 mg/dl is still much too high].
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Artery Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Risk; Survival Analysis; Survival Rate | 2004 |
[Results of randomized study: intensive lipid lowering treatment stops coronary atherosclerosis].
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Ultrasonography, Interventional | 2004 |
[Regarding LDL cholesterol: the lower, the better (interview by Dr. Dirk Einecke)].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively.
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Carotid Artery Diseases; Endarterectomy, Carotid; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukins; Male; Matrix Metalloproteinases; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Tissue Inhibitor of Metalloproteinases; Tumor Necrosis Factor-alpha; Ultrasonography | 2004 |
Managing hyperlipidaemia: a real headache.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Headache Disorders; Heptanoic Acids; Humans; Hyperlipidemias; Male; Pyrroles | 2004 |
New LDL goals: even lower?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Secondary Prevention | 2004 |
Post-stroke atorvastatin treatment reduces neurological deficits and mortality rate in the stroke-prone spontaneously hypertensive rat.
Topics: Animals; Atorvastatin; Blood Pressure; Cholesterol; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitric Oxide; Pyrroles; Rats; Rats, Inbred SHR; Stroke | 2004 |
Oxidized low-density lipoprotein induces endothelial progenitor cell senescence, leading to cellular dysfunction.
Topics: Atorvastatin; beta-Galactosidase; Cell Division; Cell Survival; Cells, Cultured; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Mitogens; Oxidation-Reduction; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA; Stem Cells; Vascular Endothelial Growth Factor A | 2004 |
Amlodipine/atorvastatin (Caduet).
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Pyrroles | 2004 |
Atorvastatin-induced polyneuropathy.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Polyneuropathies; Pyrroles | 2004 |
Atorvastatin prevents end-organ injury in salt-sensitive hypertension: role of eNOS and oxidant stress.
Topics: Animals; Aorta; Atorvastatin; Down-Regulation; Endothelium, Vascular; Heart Ventricles; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; In Vitro Techniques; Male; Myocardial Reperfusion Injury; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Organ Size; Oxidative Stress; Pyrroles; Rats; Rats, Sprague-Dawley; Sodium, Dietary | 2004 |
Rhabdomyolysis triggered by cytomegalovirus infection in a heart transplant patient on concomitant cyclosporine and atorvastatin therapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Colon; Colonoscopy; Cyclosporine; Cytomegalovirus Infections; Drug Interactions; Heart Transplantation; Heptanoic Acids; Humans; Immunosuppressive Agents; Male; Postoperative Complications; Pyrroles; Rhabdomyolysis; Treatment Outcome | 2004 |
Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Comorbidity; Coronary Angiography; Coronary Disease; Endothelium, Vascular; Female; Hemostasis; Heptanoic Acids; Humans; Hyperlipidemias; Lipoprotein(a); Male; Middle Aged; Peptide Fragments; Prospective Studies; Prothrombin; Pyrroles; Tissue Plasminogen Activator | 2004 |
Colestimide co-administered with atorvastatin attenuates the progression of vascular calcification in haemodialysis patients.
Topics: Anion Exchange Resins; Anticholesteremic Agents; Atorvastatin; Blood Vessels; Calcinosis; Disease Progression; Drug Therapy, Combination; Epichlorohydrin; Heptanoic Acids; Humans; Imidazoles; Prospective Studies; Pyrroles; Renal Dialysis; Resins, Synthetic | 2004 |
Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats.
Topics: Animals; Atorvastatin; Brain; Cerebral Hemorrhage; Disease Models, Animal; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nervous System; Pyrroles; Rats; Rats, Wistar; Recovery of Function; Severity of Illness Index; Treatment Outcome | 2004 |
The effect of atorvastatin on platelet function in patients with coronary artery disease.
Topics: Atorvastatin; Blood Platelets; Case-Control Studies; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Platelet Aggregation; Prospective Studies; Pyrroles | 2004 |
Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin.
Topics: Aged; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Cholesterol 7-alpha-Hydroxylase; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
Effect of atorvastatin on the expression of CD40 ligand and P-selectin on platelets in patients with hypercholesterolemia.
Topics: Adult; Atorvastatin; Biomarkers; Case-Control Studies; CD40 Ligand; Cohort Studies; Dose-Response Relationship, Drug; Down-Regulation; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; P-Selectin; Probability; Prognosis; Pyrroles; Reference Values; Sensitivity and Specificity; Severity of Illness Index | 2004 |
Lipid-lowering response to statins is affected by CYP3A5 polymorphism.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genotype; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Polymorphism, Genetic; Pyrroles; Simvastatin | 2004 |
Atorvastatin-induced activation of Alzheimer's alpha secretase is resistant to standard inhibitors of protein phosphorylation-regulated ectodomain shedding.
Topics: Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Atorvastatin; Cell Line, Tumor; Dose-Response Relationship, Drug; Endopeptidases; Enzyme Activation; Enzyme Activators; Enzyme Inhibitors; Genes, Dominant; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mitogen-Activated Protein Kinases; Mutation; Neuroblastoma; Phosphorylation; Protein Kinase C; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Structure, Tertiary; Pyrroles | 2004 |
Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins.
Topics: Amino Acid Substitution; Antioxidants; Atorvastatin; Cells, Cultured; Cysteine; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mutagenesis, Site-Directed; Nitric Oxide; Oxidation-Reduction; Oxidative Stress; Protein Processing, Post-Translational; Pyrroles; Reactive Oxygen Species; Recombinant Fusion Proteins; S-Nitrosothiols; Simvastatin; Thioredoxins; Transfection; Umbilical Veins | 2004 |
Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin.
Topics: Adolescent; Adult; Atorvastatin; Biomarkers; Case-Control Studies; Chemokine CCL2; Crohn Disease; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Macrophage Migration-Inhibitory Factors; Male; Middle Aged; Monocytes; Pyrroles; Tumor Necrosis Factor-alpha | 2004 |
Clinical significance of the atorvastatin-clopidogrel drug-drug interaction.
Topics: Atorvastatin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Sample Size; Ticlopidine | 2004 |
Potential statin-clopidogrel interaction requires more study.
Topics: Atorvastatin; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
Battle of the statins, or how the news media can change patient care.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mass Media; Practice Patterns, Physicians'; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Patient Dropouts; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Triglycerides | 2004 |
Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles | 2004 |
[Effects of atorvastatin on the function of dendritic cells in patients with unstable angina pectoris].
Topics: Adult; Aged; Angina, Unstable; Antigens, CD; Atorvastatin; B7-2 Antigen; Cells, Cultured; Cytokines; Dendritic Cells; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocyte Culture Test, Mixed; Male; Membrane Glycoproteins; Middle Aged; Pyrroles | 2004 |
Atorvastatin induces tissue transglutaminase in human endothelial cells.
Topics: Apoptosis; Atorvastatin; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Gene Expression Regulation, Enzymologic; GTP-Binding Proteins; Heptanoic Acids; Humans; Protein Glutamine gamma Glutamyltransferase 2; Pyrroles; Transglutaminases; Tumor Necrosis Factor-alpha | 2004 |
Histological and morphometrical examinations of suprarenal glands in rats after experimental administration of atorvastatin and ethanol.
Topics: Adrenal Glands; Animals; Anticholesteremic Agents; Atorvastatin; Ethanol; Heptanoic Acids; Male; Pyrroles; Rats; Rats, Wistar; Time Factors | 2003 |
The lipid-regulating effects of atorvastatin on type 2 elder diabetes patients with hyperlipidemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Triglycerides | 2004 |
Lipid-altering changes and pleiotropic effects of atorvastatin in patients with hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Basilar Artery; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Endothelium, Vascular; Female; Fibrinolysis; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Long-Term Care; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prospective Studies; Pyrroles; Thiobarbituric Acid Reactive Substances; Treatment Outcome; Triglycerides; Vasodilation | 2004 |
Effect of the statin atorvastatin on intracellular signalling by the prostacyclin receptor in vitro and in vivo.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenylyl Cyclases; Animals; Atorvastatin; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Calcium; Cell Line; Cell Line, Tumor; Cholesterol; Clinical Trials as Topic; Cyclic AMP; Drug Evaluation, Preclinical; Fatty Acids, Unsaturated; Female; Heptanoic Acids; Humans; Hydantoins; Hydrazines; Iloprost; Ireland; Lipids; Male; Mice; Middle Aged; Propanolamines; Protein Prenylation; Pyrroles; Radioligand Assay; Receptor Cross-Talk; Receptors, Epoprostenol; Receptors, Immunologic; Receptors, Prostaglandin; Signal Transduction; Tritium | 2004 |
Atorvastatin reduces fibrinogen levels in patients with severe hypercholesterolemia: additional evidence to support the anti-inflammatory effects of statins.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Fibrinogen; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Severity of Illness Index | 2004 |
Beyond cholesterol lowering: effect of statins on markers of cardiovascular disease.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; C-Reactive Protein; Fibrinogen; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Risk Factors | 2004 |
Effect of withdrawal of statin on C-reactive protein.
Topics: Aged; Atorvastatin; C-Reactive Protein; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Risk Factors; Substance Withdrawal Syndrome | 2004 |
Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients.
Topics: Alanine Transaminase; Apolipoproteins B; Aspartate Aminotransferases; Atorvastatin; C-Reactive Protein; Cholesterol; Creatine Kinase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Particle Size; Pyrroles; Renal Dialysis; Triglycerides; Vasculitis | 2004 |
[Atorvastatin: lipid lowering activity, pleiotropic properties and efficacy in prevention of atherosclerosis and coronary heart disease].
Topics: Atherosclerosis; Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2004 |
[Optimizing the managment of patients with diabetes mellitus: selected clinical trials from the 2004 Congress of the American Diabetes Association].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Exenatide; Glucagon; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Islets of Langerhans Transplantation; Peptide Fragments; Peptides; Protein Precursors; Pyrroles; Venoms | 2004 |
Atorvastatin enhances bone density in ovariectomized rats given 17beta-estradiol or human parathyroid hormone(1-34).
Topics: Animals; Atorvastatin; Bone Density; Calcium; Estradiol; Female; Femur; Heptanoic Acids; Humans; Injections, Subcutaneous; Lumbar Vertebrae; Ovariectomy; Parathyroid Hormone; Peptide Fragments; Phosphorus; Pyrroles; Rats; Rats, Sprague-Dawley | 2004 |
Avoid angioplasty by lowering cholesterol?
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Pyrroles; Randomized Controlled Trials as Topic | 1999 |
[Statins and hypertension].
Topics: Anticholesteremic Agents; Atorvastatin; Drug Costs; Heptanoic Acids; Humans; Hypertension; Pyrroles; Stroke | 2004 |
Comparison of raloxifene and atorvastatin effects on serum lipids composition of healthy post-menopausal women.
Topics: Adult; Aged; Atorvastatin; Female; Heptanoic Acids; Humans; Lipid Metabolism; Lipids; Middle Aged; Postmenopause; Pyrroles; Raloxifene Hydrochloride | 2004 |
Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms.
Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Aorta, Thoracic; Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; Enzyme Inhibitors; Heptanoic Acids; In Vitro Techniques; Male; NG-Nitroarginine Methyl Ester; Nitrates; Nitric Acid; Nitric Oxide Synthase; Nitrites; Piperazines; Purines; Pyrroles; Rats; Rats, Wistar; Sildenafil Citrate; Sulfones; Vasodilation; Vasodilator Agents | 2004 |
[Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study].
Topics: Acute Disease; Adolescent; Adult; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cost Savings; Cost-Benefit Analysis; Costs and Cost Analysis; Diagnosis-Related Groups; Double-Blind Method; Germany; Heptanoic Acids; Humans; Middle Aged; Myocardial Infarction; Patient Compliance; Placebos; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Syndrome; Time Factors | 2004 |
[Cost effectiveness of atorvastatin for prevention of coronary disease--an analysis of the ASCOT study. Re: the article from DMW 25/26 2004].
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Heptanoic Acids; Humans; Pyrroles; Treatment Outcome | 2004 |
Beta4 integrin is involved in statin-induced endothelial cell death.
Topics: Apoptosis; Atorvastatin; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Integrin beta4; Neovascularization, Physiologic; Pyrroles | 2004 |
The effects of high glucose and atorvastatin on endothelial cell matrix production.
Topics: Atorvastatin; Blotting, Western; Cells, Cultured; Collagen Type IV; Dose-Response Relationship, Drug; Endothelial Cells; Extracellular Matrix; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 2; Pyrroles; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Umbilical Veins | 2004 |
Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators.
Topics: Alkaline Phosphatase; Atorvastatin; Calcinosis; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mevalonic Acid; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Polyisoprenyl Phosphates; Pyridines; Pyrroles; Sesquiterpenes | 2004 |
Microcosm evaluation of the effects of an eight pharmaceutical mixture to the aquatic macrophytes Lemna gibba and Myriophyllum sibiricum.
Topics: Acetaminophen; Analysis of Variance; Atorvastatin; Biological Assay; Biomass; Caffeine; Carbamazepine; Complex Mixtures; Dose-Response Relationship, Drug; Heptanoic Acids; Heterocyclic Compounds; Levofloxacin; Magnoliopsida; Ofloxacin; Pharmaceutical Solutions; Pyrroles; Sertraline; Sulfamethoxazole; Toxicity Tests; Trimethoprim; Water Pollutants, Chemical | 2004 |
Recent changes to FDA-approved labeling.
Topics: Acetamides; Aminoquinolines; Atazanavir Sulfate; Atorvastatin; Botulinum Toxins, Type A; Dosage Forms; Drug Labeling; Epoetin Alfa; Erythropoietin; Heptanoic Acids; Humans; Imiquimod; Insulin; Insulin Lispro; Mandelic Acids; Oligopeptides; Oseltamivir; Pyridines; Pyrroles; Recombinant Proteins; United States; United States Food and Drug Administration | 2004 |
Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase.
Topics: Animals; Atorvastatin; Biological Availability; Capillaries; Cells, Cultured; Collateral Circulation; Drug Resistance; Endothelial Cells; Fibrosis; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrroles; Random Allocation; Ultrasonography; Vasodilation; Ventricular Function, Left; Ventricular Remodeling | 2004 |
[Endothelial dysfunction, inflammation and statins: new evidences].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Circulation; Endothelium, Vascular; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Interleukin-6; Pravastatin; Pyrroles; Rabbits; Time Factors | 2004 |
[Noninvasive assessment of the effect of atorvastatin on coronary microvasculature and endothelial function in patients with dyslipidemia].
Topics: Aged; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Circulation; Data Interpretation, Statistical; Echocardiography; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Microcirculation; Middle Aged; Models, Theoretical; Pyrroles; Time Factors; Triglycerides; Vasodilation | 2004 |
Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Blood Vessel Prosthesis Implantation; Clopidogrel; Coronary Stenosis; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Pyrroles; Stents; Ticlopidine | 2004 |
HMG-CoA reductase inhibitors up-regulate anti-aging klotho mRNA via RhoA inactivation in IMCD3 cells.
Topics: Amides; Analysis of Variance; Angiotensin II; Atorvastatin; Cell Line; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation; Glucuronidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubules; Klotho Proteins; Membrane Proteins; Pyridines; Pyrroles; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; rhoA GTP-Binding Protein; RNA, Messenger | 2004 |
Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients.
Topics: Adolescent; Adult; Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intercellular Adhesion Molecule-1; Interleukin-1; Interleukin-6; Male; Middle Aged; Pyrroles; Tumor Necrosis Factor-alpha | 2004 |
The effect of high glucose on NO and O2- through endothelial GTPCH1 and NADPH oxidase.
Topics: Animals; Atorvastatin; Biopterins; Blotting, Western; Cattle; Endothelial Cells; Flow Cytometry; Gene Expression Regulation, Enzymologic; Glucose; GTP Cyclohydrolase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Oxygen; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Statistics, Nonparametric | 2004 |
Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Cell Line; Drug Interactions; Heptanoic Acids; Humans; Hypolipidemic Agents; Pyrroles; Ritonavir; Simvastatin; Time Factors | 2004 |
Atorvastatin and simvastatin decrease the uptake of acetylated low-density lipoprotein by human monocytes.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Calcium Channel Blockers; Dose-Response Relationship, Drug; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Monocytes; Pyrroles; Simvastatin; U937 Cells | 2005 |
Is it time for medical therapy for aortic valve disease?
Topics: Aged; Aged, 80 and over; Animals; Aortic Valve Stenosis; Atorvastatin; Biopsy, Needle; Calcinosis; Controlled Clinical Trials as Topic; Disease Models, Animal; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Immunohistochemistry; Male; Middle Aged; Practice Guidelines as Topic; Prognosis; Pyrroles; Risk Assessment; Severity of Illness Index; Survival Rate; Treatment Outcome | 2004 |
Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Diet; Diet, Atherogenic; Drug Administration Schedule; Female; Heptanoic Acids; Inflammation; Male; Mice; Mice, Transgenic; Pyrroles; Serum Amyloid A Protein | 2005 |
Effect of atorvastatin on non-cholesterol sterols in patients with type 2 diabetes mellitus and cardiovascular disease.
Topics: Aged; Analysis of Variance; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Statistics, Nonparametric; Sterols | 2005 |
Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells.
Topics: Adenoviridae; Amino Acid Sequence; Atorvastatin; Cell Movement; Cells, Cultured; Cellular Senescence; Checkpoint Kinase 2; Endothelial Cells; Endothelium, Vascular; Enzyme Induction; Flow Cytometry; Genetic Vectors; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Hybridization, Fluorescence; Interleukin-4; Lovastatin; Macrophage Colony-Stimulating Factor; Molecular Sequence Data; Protein Serine-Threonine Kinases; Pyrroles; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Telomere; Telomeric Repeat Binding Protein 2; Vascular Endothelial Growth Factor A | 2004 |
Formulary conversion programs: the need for patient-specific risk assessment.
Topics: Aged; Atorvastatin; Cyclosporine; Drug Interactions; Female; Formularies as Topic; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Postoperative Care; Pyrroles; Rhabdomyolysis; Risk Assessment; Simvastatin | 2004 |
Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting.
Topics: Aged; Atorvastatin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation Inhibitors; Preoperative Care; Prospective Studies; Pyrroles; Simvastatin; Stents; Ticlopidine | 2004 |
Effects of Atorvastatin on some inflammatory parameters in severe primary hypercholesterolemia.
Topics: Adult; Atorvastatin; Biomarkers; Coronary Stenosis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2002 |
[Decreasing LDL level moderately or drastically. Is differential therapy with statins available? (interview by Dirk Einecke)].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Drug Approval; Drugs, Generic; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles | 2004 |
[Sequelae of the CARDS Study. LDL of 110 mg/dl still too high?].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Long-Term Care; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2004 |
Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003.
Topics: Atorvastatin; Coronary Disease; Fluorobenzenes; Goals; Heptanoic Acids; History, 20th Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2004 |
[Atorvastatin lowers C-reactive protein in dislipemic patients with type 2 diabetes mellitus].
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2004 |
Recurrent acute pancreatitis possibly induced by atorvastatin and rosuvastatin. Is statin induced pancreatitis a class effect?
Topics: Acute Disease; Aged; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatitis; Pyrimidines; Pyrroles; Recurrence; Rosuvastatin Calcium; Sulfonamides | 2004 |
Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction.
Topics: Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Pyrroles; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta; Ureteral Obstruction | 2004 |
Race, ethnicity, and sociocultural characteristics predict noncompliance with lipid-lowering medications.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Female; Health Status; Heptanoic Acids; Humans; Interviews as Topic; Male; Middle Aged; Multivariate Analysis; Patient Compliance; Pyrroles; Simvastatin; Socioeconomic Factors; Surveys and Questionnaires; Time Factors; Treatment Outcome; Urban Population | 2004 |
[Lowering of cholesterol. What role is played by the choice of statins?].
Topics: Adult; Age Factors; Anticholesteremic Agents; Atorvastatin; Child; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Meta-Analysis as Topic; Pravastatin; Pyrroles; Risk Factors; Time Factors | 2004 |
Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury.
Topics: Animals; Atorvastatin; Brain Injuries; Cerebral Cortex; Cerebrovascular Circulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Memory; Microcirculation; Pyrroles; Rats; Rats, Wistar; Thrombin; Vascular Patency | 2004 |
Atorvastatin reduction of intracranial hematoma volume in rats subjected to controlled cortical impact.
Topics: Animals; Atorvastatin; Brain Injuries; Cerebral Cortex; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Hemorrhage, Traumatic; Male; Pyrroles; Rats; Rats, Wistar | 2004 |
Treatment of severe hypercholesterolemia with atorvastatin in congenital analbuminemia.
Topics: Adult; Albumins; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Hypoproteinemia; Male; Pyrroles | 2004 |
Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arteries; Arthritis, Rheumatoid; Atorvastatin; Drug Evaluation; Elasticity; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Middle Aged; Pulsatile Flow; Pyrroles; Radial Artery | 2004 |
Rheumatoid arthritis treatment progressing.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Cyclophosphamide; Drug Therapy, Combination; Heptanoic Acids; Humans; Methotrexate; Pyrroles; Rituximab | 2004 |
[CARDS confirms usefulness of LDL lowering in type 2 diabetics].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Placebos; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Time Factors | 2004 |
[Target values are more often attainable. Almost doubly so many patients with values under 100mg/dl].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic; Reference Values; Simvastatin; Time Factors | 2004 |
Synthes Award for Resident Research in Spinal Cord & Spinal Column Injury: Statins for the treatment of neurological injury: a role beyond cholesterol lowering.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Awards and Prizes; Brain Injuries; Heptanoic Acids; Hypercholesterolemia; Immunoblotting; Interleukin-6; Internship and Residency; Mice; Pyrroles; Research; RNA, Messenger; Simvastatin; Spinal Cord Injuries; Subarachnoid Hemorrhage | 2004 |
How low should your cholesterol go? Even lower may be better. For those at highest risk, very low cholesterol levels may help prevent a second heart attack or stroke.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke | 2004 |
Atorvastatin inhibits autoreactive B cell activation and delays lupus development in New Zealand black/white F1 mice.
Topics: Animals; Atorvastatin; B-Lymphocyte Subsets; Cell Proliferation; Cholesterol; Crosses, Genetic; Down-Regulation; Female; Growth Inhibitors; Heptanoic Acids; Histocompatibility Antigens Class II; Hypolipidemic Agents; Immunosuppressive Agents; Kidney; Lupus Nephritis; Lymphocyte Activation; Mice; Mice, Inbred NZB; Pyrroles; Spleen; T-Lymphocytes; Time Factors | 2004 |
Antischistosomal action of atorvastatin alone and concurrently with medroxyprogesterone acetate on Schistosoma haematobium harboured in hamster: surface ultrastructure and parasitological study.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Contraceptive Agents; Cricetinae; Drug Therapy, Combination; Female; Heptanoic Acids; Liver; Male; Medroxyprogesterone; Mesocricetus; Microscopy, Electron, Scanning; Parasite Egg Count; Pyrroles; Random Allocation; Schistosoma haematobium; Schistosomiasis haematobia | 2005 |
Assessment of the efficacy of different statins in murine collagen-induced arthritis.
Topics: Animals; Arthritis, Experimental; Atorvastatin; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lymph Nodes; Male; Mice; Mice, Inbred DBA; Nuclear Proteins; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Trans-Activators; Treatment Outcome | 2004 |
Statin-associated exacerbation of myasthenia gravis.
Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone | 2004 |
I've taken Lipitor since my first heart attack two years ago, and my LDL has dropped steadily to 140. Given the new LDL guidelines, though, just how am I supposed to go about slashing it to a level of 70?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Pyrroles; Reference Values | 2004 |
Effect of monthly atorvastatin treatment on hemostasis.
Topics: Adult; Aged; Atorvastatin; Blood Coagulation Factors; Case-Control Studies; Female; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors | 2004 |
Lipid metabolism in zebrafish.
Topics: 4-Chloro-7-nitrobenzofurazan; Alkyl and Aryl Transferases; Animals; Annexin A2; Atorvastatin; Azetidines; Boron Compounds; Caveolin 1; Caveolins; Cell Movement; Cholesterol; Diterpenes; DNA; Embryo, Nonmammalian; Ethylnitrosourea; Ezetimibe; Farnesol; Farnesyltranstransferase; Geranyltranstransferase; Germ Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Lovastatin; Mevalonic Acid; Microscopy, Fluorescence; Mutagenesis, Site-Directed; Mutation; Phosphatidylethanolamines; Protein Binding; Protein Prenylation; Pyrroles; Simvastatin; Zebrafish | 2004 |
Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Disease Models, Animal; Female; Gliosis; Heptanoic Acids; Interleukin-1; Motor Activity; Myelitis; Necrosis; Nerve Degeneration; Neurons; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Oligodendroglia; Oxidative Stress; Pyrroles; Rats; Rats, Sprague-Dawley; Recovery of Function; Spinal Cord; Spinal Cord Injuries; Treatment Outcome; Tumor Necrosis Factor-alpha | 2005 |
Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.
Topics: Adenosine Triphosphate; Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Dogs; Estradiol; Fluoresceins; Heptanoic Acids; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Permeability; Pyrroles; Simvastatin; Structure-Activity Relationship | 2005 |
The grapefruit challenge: the juice inhibits a crucial enzyme, with possibly fatal consequences.
Topics: Anticholesteremic Agents; Atorvastatin; Beverages; Citrus paradisi; Food-Drug Interactions; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Rhabdomyolysis | 2004 |
Inhibitory effect of statins on the proliferation of human breast cancer cells.
Topics: Anticholesteremic Agents; Apoptosis; Atorvastatin; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Antagonism; Estradiol; Estrogens; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Neoplasms, Hormone-Dependent; Pyrroles | 2004 |
Rhabdomyolysis in a patient receiving atorvastatin and fluconazole.
Topics: Antifungal Agents; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Synergism; Fatal Outcome; Fluconazole; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Mycoses; Pyrroles; Rhabdomyolysis | 2005 |
Red wine polyphenolics suppress the secretion and the synthesis of Apo B48 from human intestinal CaCo-2 cells.
Topics: Apolipoprotein B-48; Apolipoproteins B; Atorvastatin; Cell Line, Tumor; Colonic Neoplasms; Flavonoids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Phenols; Polyphenols; Pyrroles; Wine | 2004 |
High-dose statins in acute coronary syndromes.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Myocardial Ischemia; Pyrroles; Risk; Simvastatin | 2005 |
Exertion-induced rhabdomyolysis in a patient on statin therapy.
Topics: Acute Kidney Injury; Atorvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Long-Term Care; Male; Middle Aged; Physical Exertion; Pyrroles; Rhabdomyolysis; Risk Assessment; Severity of Illness Index | 2005 |
Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; Pravastatin; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Research Design | 2004 |
[A relationship between insulin resistance and reduction in oxidative stress in vivo by atorvastatin].
Topics: Aged; Atorvastatin; Dinoprost; Female; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Lipids; Male; Middle Aged; Oxidative Stress; Pyrroles | 2004 |
Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Blood Platelets; CD36 Antigens; Citrulline; Female; Flow Cytometry; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Nitric Oxide Synthase; P-Selectin; Platelet Activation; Pyrroles; Receptors, LDL; Receptors, Oxidized LDL; Scavenger Receptors, Class E | 2005 |
Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury.
Topics: Animals; Atorvastatin; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Cytochrome P-450 Enzyme System; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Intramolecular Oxidoreductases; Isoxazoles; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Phospholipases A; Phospholipases A2; Phosphorylation; Prostaglandin-E Synthases; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sulfonamides | 2005 |
Thrombin-induced rapid geranylgeranylation of RhoA as an essential process for RhoA activation in endothelial cells.
Topics: Actins; Aorta; Atorvastatin; Blotting, Western; Cells, Cultured; Cytoskeleton; Densitometry; Detergents; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Guanosine Diphosphate; Guanosine Triphosphate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leucine; Lipid Metabolism; Octoxynol; Polyethylene Glycols; Protein Prenylation; Pyrroles; rhoA GTP-Binding Protein; Signal Transduction; Thrombin; Time Factors | 2005 |
Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Triglycerides | 2005 |
Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK.
Topics: Alzheimer Disease; Amino Acid Sequence; Amyloid beta-Protein Precursor; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Signaling Peptides and Proteins; Molecular Sequence Data; Neuroblastoma; Phosphorylation; Protein Serine-Threonine Kinases; Pyrroles; rho-Associated Kinases; Simvastatin; Tumor Cells, Cultured | 2005 |
Combined hyperlipidemia in a single subject with tetraplegia: ineffective risk reduction after atorvastatin monotherapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cervical Vertebrae; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Male; Odds Ratio; Pyrroles; Spinal Cord Injuries; Treatment Failure; Triglycerides; Wounds, Gunshot | 2004 |
Hypolipidemic drugs affect monocyte IL-1beta gene expression and release in patients with IIa and IIb dyslipidemia.
Topics: Atorvastatin; Cells, Cultured; Clofibric Acid; Cytokines; Fenofibrate; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Interleukin-1; Lipids; Monocytes; Plasminogen Activator Inhibitor 1; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Diet, Fat-Restricted; Drug Administration Schedule; Female; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Obesity; Plasminogen Activator Inhibitor 1; Pyrroles; Risk Factors; Smoking; Tissue Plasminogen Activator; Triglycerides | 2004 |
A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Topics: Area Under Curve; Atorvastatin; Biomedical Research; Databases, Bibliographic; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Japan; Pharmacology, Clinical; Pravastatin; Product Labeling; Pyrroles; Quinolines; Simvastatin; United States; United States Food and Drug Administration | 2005 |
Effect of atorvastatin upon platelet activation in hypercholesterolemia, evaluated by flow cytometry.
Topics: Adenosine Diphosphate; Adult; Aged; Atorvastatin; Blood Platelets; Case-Control Studies; Cholesterol; Cholesterol, LDL; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; In Vitro Techniques; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Risk Factors; Thrombin; Thrombosis | 2005 |
[Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Artery Disease; Cost Control; Drug Costs; Ezetimibe; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance Coverage; Male; Middle Aged; National Health Programs; Pyrroles; Simvastatin | 2004 |
[Lean years for patients].
Topics: Anticholesteremic Agents; Atorvastatin; Cost Control; Drug Costs; Drug Industry; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; National Health Programs; Pyrroles | 2004 |
Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice.
Topics: Animals; Atorvastatin; Brain-Derived Neurotrophic Factor; Cell Movement; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Mice; Neovascularization, Physiologic; Neuronal Plasticity; Pyrroles; Rats; Recovery of Function; Stem Cells; Stroke; Vascular Endothelial Growth Factor A | 2005 |
What did PROVE-IT prove?
Topics: Anticholesteremic Agents; Atorvastatin; Diabetic Angiopathies; Heptanoic Acids; Humans; Myocardial Infarction; Pravastatin; Pyrroles; Reproducibility of Results; Thrombolytic Therapy | 2004 |
Delayed thrombosis after traumatic brain injury in rats.
Topics: Animals; Atorvastatin; Blood Coagulation Factors; Brain; Brain Injuries; Disease Models, Animal; Fibrin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Thrombosis; Male; Pyrroles; Rats; Rats, Wistar; Time Factors | 2004 |
Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene.
Topics: Alkyl and Aryl Transferases; Aryldialkylphosphatase; Atorvastatin; Cell Line; Cell Nucleus; DNA; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Farnesyltranstransferase; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Luciferases; Mevalonic Acid; Plasmids; Polyisoprenyl Phosphates; Pyrroles; Quinolines; Sesquiterpenes; Sp1 Transcription Factor; Time Factors; Transcriptional Activation; Transfection | 2005 |
Reduction of cerebral infarction in stroke-prone spontaneously hypertensive rats by statins associated with amelioration of oxidative stress.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldehydes; Animals; Atorvastatin; Blood Pressure; Body Weight; Deoxyguanosine; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Infarction, Middle Cerebral Artery; Lipids; Lysine; Oxidative Stress; Pyrroles; Quinolines; Rats; Rats, Inbred SHR; Simvastatin; Survival Analysis | 2005 |
[The CARDS Study: cardiovascular primary prevention in diabetes patients using Atorvastin].
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome | 2005 |
Relaxant effects of pravastatin, atorvastatin and cerivastatin on isolated rat aortic rings.
Topics: Animals; Aorta, Thoracic; Atorvastatin; Endothelium, Vascular; Glyburide; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Nitroarginine; Ouabain; Pravastatin; Pyridines; Pyrroles; Rats; Rats, Wistar; Vasodilation | 2005 |
Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction.
Topics: Administration, Oral; Animals; Atorvastatin; Autoimmune Diseases; Cell Line; Cell Migration Inhibition; Cell Proliferation; Cytokines; Female; Growth Inhibitors; Heptanoic Acids; Humans; Immunosuppressive Agents; Injections, Intraperitoneal; Lovastatin; Male; Mice; Mice, Inbred C57BL; Pyrroles; Rats; Rats, Inbred Lew; Retinitis; Th2 Cells; Uveitis | 2005 |
Effect of atorvastatin on markers of bone turnover.
Topics: Atorvastatin; Biomarkers; Bone Density; Bone Remodeling; Female; Heptanoic Acids; Humans; Postmenopause; Pyrroles; Research Design | 2005 |
PROVE IT then believe it.
Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Pravastatin; Pyrroles | 2005 |
Influence of withdrawal of statin treatment on proinflammatory response and fibrinolytic activity in humans: an effect independent on cholesterol elevation.
Topics: Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Tissue Plasminogen Activator; Vascular Cell Adhesion Molecule-1 | 2005 |
Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation.
Topics: Animals; Atorvastatin; Cardiomegaly; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; NF-kappa B; Peroxisome Proliferator-Activated Receptors; Pressure; Protein Isoforms; Protein Subunits; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Signal Transduction | 2005 |
Atorvastatin decreases cellular proliferation and bone matrix expression in the hypercholesterolemic mitral valve.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Matrix; Calcinosis; Cell Division; Heart Valve Diseases; Heptanoic Acids; Hypercholesterolemia; Male; Mitral Valve; Pyrroles; Rabbits | 2005 |
Statins and nasal polyps.
Topics: Atorvastatin; Chemotaxis; Eosinophils; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Nasal Polyps; Pyrroles | 2005 |
A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Coronary Artery Bypass; Cost Savings; Cost-Benefit Analysis; Diagnosis-Related Groups; Double-Blind Method; Economics, Pharmaceutical; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Infarction; Placebos; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Spain; Syndrome; Time Factors; Treatment Outcome | 2004 |
Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia.
Topics: Animals; Atorvastatin; Brain Ischemia; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Embolism; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Neuroprotective Agents; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrroles; Simvastatin; Stroke; Tissue Plasminogen Activator | 2005 |
Sterol-regulatory-element binding protein inhibits upstream stimulatory factor-stimulated hepatic lipase gene expression.
Topics: Anticholesteremic Agents; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholesterol; DNA-Binding Proteins; Fatty Acids, Unsaturated; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Homeostasis; Humans; Lipase; Liver Neoplasms; Oleic Acid; Promoter Regions, Genetic; Pyrroles; Sterol Regulatory Element Binding Protein 2; Transcription Factors | 2005 |
The effects of atorvastatin in experimental autoimmune uveitis.
Topics: Animals; Atorvastatin; Autoimmune Diseases; Blotting, Western; DNA-Binding Proteins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1; Interleukin-2; Mice; Mice, Inbred Strains; Models, Animal; Pyrroles; STAT4 Transcription Factor; STAT6 Transcription Factor; Th1 Cells; Th2 Cells; Trans-Activators; Tumor Necrosis Factor-alpha; Uveitis | 2005 |
Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling.
Topics: Animals; Atorvastatin; Blotting, Western; Cell Survival; Densitometry; Heat-Shock Proteins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 1; Myocardial Reperfusion Injury; Myocardium; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction | 2005 |
Intensive versus moderate lipid lowering with statins in acute coronary syndromes.
Topics: Adolescent; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hyperlipidemias; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Treatment Outcome | 2005 |
Reversal of atherosclerosis with aggressive lipid lowering.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hyperlipidemias; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Topics: Aged; Ambulatory Care; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Comorbidity; Cross-Sectional Studies; Cyclosporine; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Male; Niacin; Oxidoreductases, N-Demethylating; Physicians; Pravastatin; Prevalence; Product Surveillance, Postmarketing; Pyrroles; Simvastatin; Time Factors | 2005 |
Cyclical Cushing's disease causing recurrent oedema and knee effusions.
Topics: Adult; Antihypertensive Agents; Atorvastatin; Diuretics; Drug Therapy, Combination; Edema; Enalapril; Follow-Up Studies; Heptanoic Acids; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Knee; Male; Pituitary ACTH Hypersecretion; Pyrroles; Sodium Chloride Symporter Inhibitors | 2005 |
CD40-ligand-dependent induction of COX-2 gene expression in endothelial cells by activated platelets: inhibitory effects of atorvastatin.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Blood Platelets; CD40 Antigens; CD40 Ligand; Cells, Cultured; Cyclooxygenase 2; Endothelial Cells; Gene Expression Regulation; Heptanoic Acids; Humans; Membrane Proteins; Platelet Activation; Prostaglandin-Endoperoxide Synthases; Pyrroles | 2005 |
Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal antiinflammatory drug.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ileal Diseases; Ileum; Indoles; Male; Pravastatin; Pyrroles; Rats; Rats, Wistar; Ulcer | 2005 |
Assessing adherence to statin therapy using patient report, pill count, and an electronic monitoring device.
Topics: Atorvastatin; Cohort Studies; Data Collection; Electronics, Medical; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Compliance; Prospective Studies; Pyrroles; Research Design; Simvastatin | 2005 |
Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones.
Topics: Acyl Coenzyme A; Animals; Apoptosis; Atorvastatin; Calcium Signaling; Cells, Cultured; Cerebral Cortex; Glucose; Glutamic Acid; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoxia-Ischemia, Brain; Mitochondria; Neurons; Neuroprotective Agents; Neurotoxins; Pyrroles; Rats; Receptors, Glutamate | 2005 |
Low-density lipoprotein cholesterol in patients with stable coronary heart disease--is it time to shift our goals?
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk | 2005 |
The imidazoline-like drug S23515 affects lipid metabolism in hepatocyte by inhibiting the oxidosqualene: lanosterol cyclase activity.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Primers; Enzyme Inhibitors; Hepatocytes; Heptanoic Acids; Intramolecular Transferases; Kinetics; Lipid Metabolism; Liver Neoplasms; Oxazoles; Polymerase Chain Reaction; Pyrroles; Rats | 2005 |
Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Ticlopidine | 2004 |
Atorvastatin improves peritoneal sclerosis induced by hypertonic PD solution in rats.
Topics: Animals; Atorvastatin; Cholesterol; Glucose; Glucose Solution, Hypertonic; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microscopy; Peritoneum; Pyrroles; Rats; Rats, Wistar; Sclerosis; Transforming Growth Factor beta; Transforming Growth Factor beta1; Ultrafiltration; Urea; Vascular Endothelial Growth Factor A | 2005 |
By the way, doctor. I recently started taking Lipitor for high cholesterol. The label says: "Do not eat grapefruit or drink grapefruit juice at any time while taking this medication." My doctor didn't warn me about grapefruit. Several medically trained fr
Topics: Anticholesteremic Agents; Atorvastatin; Beverages; Citrus paradisi; Food-Drug Interactions; Heptanoic Acids; Humans; Pyrroles | 2005 |
Bayesian modelling of multivariate quantitative traits using seemingly unrelated regressions.
Topics: Algorithms; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Bayes Theorem; Cholesterol; Cholesterol, LDL; Computer Simulation; Genotype; Heptanoic Acids; Humans; Models, Genetic; Models, Statistical; Multivariate Analysis; Phenotype; Polymorphism, Single Nucleotide; Pyrroles; Quantitative Trait Loci; Regression Analysis; Sample Size; Triglycerides | 2005 |
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.
Topics: Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Liver Neoplasms; Phosphorylation; Pravastatin; Protein Prenylation; Pyrroles; RNA, Messenger; Simvastatin; STAT3 Transcription Factor | 2005 |
Red wine polyphenolics suppress the secretion of ApoB48 from human intestinal CaCo-2 cells.
Topics: Anticholesteremic Agents; Apolipoprotein B-48; Apolipoproteins B; Atorvastatin; Caco-2 Cells; Cholesterol; Flavonoids; Heptanoic Acids; Humans; Intestinal Mucosa; Intestines; Phenols; Polyphenols; Pyrroles; Wine | 2005 |
Atorvastatin reduces lipopolysaccharide-induced expression of cyclooxygenase-2 in human pulmonary epithelial cells.
Topics: Atorvastatin; Cell Line; Cyclooxygenase 2; Dinoprostone; Dose-Response Relationship, Drug; Epithelial Cells; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Membrane Proteins; Metabolic Clearance Rate; Pyrroles; Respiratory Mucosa | 2005 |
Statin drugs and congenital anomalies.
Topics: Abnormalities, Drug-Induced; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant, Newborn; Lovastatin; Pregnancy; Pregnancy Outcome; Pyrroles; Simvastatin | 2005 |
CARDS on the table: should everybody with type 2 diabetes take a statin?
Topics: Atorvastatin; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors; Vascular Diseases | 2005 |
Beneficial effects of raloxifene and atorvastatin on serum lipids.
Topics: Anticholesteremic Agents; Atorvastatin; Confounding Factors, Epidemiologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Pyrroles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators | 2005 |
Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux.
Topics: Animals; Apolipoprotein A-I; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cell Line; Cholesterol; Diterpenes; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gene Expression; Gene Expression Regulation; Genes, Dominant; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipoproteins; Macrophages; Mevalonic Acid; Mice; Models, Biological; Phosphorylation; Polyisoprenyl Phosphates; PPAR gamma; Pyrroles; rhoA GTP-Binding Protein; RNA, Messenger; Sesquiterpenes; Transfection; Up-Regulation | 2005 |
FOXO-dependent expression of the proapoptotic protein Bim: pivotal role for apoptosis signaling in endothelial progenitor cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Atorvastatin; Bcl-2-Like Protein 11; Cell Cycle Proteins; Cell Line; Cell Survival; Cells, Cultured; Endothelial Cells; Flow Cytometry; Forkhead Transcription Factors; Gene Expression; Heptanoic Acids; Humans; Hydrogen Peroxide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Membrane Proteins; Oxidative Stress; Phosphatidylinositol 3-Kinases; Phosphorylation; Promoter Regions, Genetic; Proto-Oncogene Proteins; Pyrroles; Stem Cells; Transcription Factors; Transfection; Umbilical Veins | 2005 |
Rosuvastatin-associated hepatitis with autoimmune features.
Topics: Anticholesteremic Agents; Atorvastatin; Autoimmune Diseases; Chemical and Drug Induced Liver Injury; Female; Heptanoic Acids; Humans; Middle Aged; Pyrroles | 2005 |
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Kidney; Kidney Glomerulus; Linear Models; Microscopy, Electron; Obesity; Pyrroles; Quinapril; Rats; Rats, Zucker; Staining and Labeling; Tetrahydroisoquinolines | 2005 |
[Coronary disease patient has already LDL of 100 mg/dl. Why lipid lowering is still worthwhile].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Placebos; Pyrroles; Risk Factors; Time Factors | 2005 |
Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?
Topics: Animals; Atorvastatin; Blotting, Western; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Phosphatidylinositol 3-Kinases; Phosphoric Monoester Hydrolases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Tumor Suppressor Proteins | 2005 |
Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis.
Topics: Adult; Anticholesteremic Agents; Apoptosis; Atorvastatin; Cholesterol; Cluster Analysis; Gene Expression Regulation; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Leukocytes; Leukocytes, Mononuclear; Lipid Metabolism; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Pyrroles; Receptors, LDL; Reverse Transcriptase Polymerase Chain Reaction; RNA; Time Factors | 2005 |
Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Case-Control Studies; Coronary Artery Disease; Fasting; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Male; Middle Aged; Phospholipases A; Phospholipases A2; Placebos; Postprandial Period; Pyrroles | 2005 |
Atorvastatin induces T cell anergy via phosphorylation of ERK1.
Topics: Adjuvants, Immunologic; Atorvastatin; Butadienes; Cell Line; Clonal Anergy; Heptanoic Acids; Humans; Interleukin-10; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Pyrroles; T-Lymphocytes; Time Factors | 2005 |
The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritis.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol; Chronic Disease; Creatinine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glomerulonephritis; Heptanoic Acids; Humans; Insulin; Insulin, Long-Acting; Insulin, Regular, Human; Lipoproteins; Male; Middle Aged; Proteinuria; Pyrroles; Retrospective Studies; Serum Albumin; Serum Albumin, Human; Time Factors; Treatment Outcome | 2005 |
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Topics: Aged; Atorvastatin; Cohort Studies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Mortality; Myocardial Infarction; Patient Compliance; Pravastatin; Proportional Hazards Models; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Survival Analysis | 2005 |
Effects of atorvastatin on blood-brain barrier permeability during L-NAME hypertension followed by angiotensin-II in rats.
Topics: Angiotensin II; Animals; Atorvastatin; Blood-Brain Barrier; Heptanoic Acids; Hypertension; Male; NG-Nitroarginine Methyl Ester; Permeability; Pyrroles; Rats; Rats, Wistar | 2005 |
Adverse events with concomitant amiodarone and statin therapy.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Amiodarone; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Simvastatin; United States; United States Food and Drug Administration | 2005 |
Statins potentiate the IFN-gamma-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells.
Topics: Amides; Aorta; Atorvastatin; Bacterial Proteins; Bacterial Toxins; Butadienes; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Drug Synergism; Flavonoids; Group II Phospholipases A2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Janus Kinase 2; Lovastatin; Myocytes, Smooth Muscle; NF-kappa B; Nitriles; Phospholipases A; Phospholipases A2; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyridines; Pyrroles; RNA Stability; Up-Regulation | 2005 |
Influence of microsomal triglyceride transfer protein promoter polymorphism -493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia.
Topics: Alleles; Apolipoproteins E; Atorvastatin; Body Mass Index; Carrier Proteins; Cholesterol; Cholesterol, LDL; DNA; Fasting; Female; Genetic Variation; Genotype; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipid Metabolism; Lipoproteins; Lipoproteins, LDL; Male; Mutation; Pharmacogenetics; Phenotype; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Single-Stranded Conformational; Promoter Regions, Genetic; Pyrroles; Sex Factors; Triglycerides | 2005 |
Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia.
Topics: Apolipoproteins E; Atorvastatin; Body Mass Index; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Female; Genotype; Glycoproteins; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipid Metabolism; Lipoproteins, LDL; Male; Multivariate Analysis; Mutation; Pharmacogenetics; Polymorphism, Genetic; Promoter Regions, Genetic; Pyrroles; Receptors, LDL | 2005 |
Statins in acute coronary syndromes: the sooner, the better?
Topics: Acute Disease; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Guidelines as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Secondary Prevention; Syndrome | 2005 |
Plaque regression--a new target for antiatherosclerotic therapy.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Premedication; Pyrroles; Radiography; Remission Induction; Risk Reduction Behavior; Simvastatin; Ultrasonography | 2005 |
Controversies in antiplatelet therapy for patients with cardiovascular disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Cardiovascular Diseases; Cyclooxygenase Inhibitors; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Heptanoic Acids; Humans; Platelet Aggregation Inhibitors; Pyrroles | 2005 |
Value for money in disease management of acute coronary syndrome--the price of aspirin to reduce the costs of ACS.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles | 2005 |
[Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits].
Topics: Animals; Anticholesteremic Agents; Aortic Diseases; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hypercholesterolemia; Indoles; Lipid Peroxidation; Male; Malondialdehyde; Pravastatin; Pyrroles; Rabbits; Simvastatin | 2005 |
Letter regarding article by Tsimikas et al, "high-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial".
Topics: Acute Disease; Antigen-Antibody Complex; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Lipoproteins, LDL; Phospholipids; Pyrroles; Reagent Kits, Diagnostic; Reproducibility of Results | 2005 |
Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve.
Topics: Animals; Anticholesteremic Agents; Aortic Valve; Atorvastatin; Blotting, Western; C-Reactive Protein; Calcinosis; Cholesterol; Heart Valve Diseases; Heptanoic Acids; Hypercholesterolemia; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Nitrites; Pyrroles; Rabbits; Tomography, X-Ray Computed | 2005 |
[The PROVE IT-TIMI-22 study or the biter being bit].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles | 2005 |
Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Base Sequence; Case-Control Studies; Creatine Kinase; DNA Primers; Genotype; Heptanoic Acids; Humans; Muscular Diseases; Pyrroles; Risk Factors | 2005 |
Upregulation of the immune system in primary hypercholesterolaemia: effect of atorvastatin therapy.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Complement C3; Complement C4; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Immunity, Cellular; Intercellular Adhesion Molecule-1; Lipids; Male; Middle Aged; Pyrroles; Up-Regulation | 2005 |
Atorvastatin reverses age-related reduction in rat hepatic PPARalpha and HNF-4.
Topics: Aging; Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol Esters; Diet; DNA-Binding Proteins; Fatty Acids, Nonesterified; Female; Gene Expression Regulation; Heptanoic Acids; Lipid Metabolism; Liver; Liver X Receptors; Male; Orphan Nuclear Receptors; PPAR alpha; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Sex Factors; Triglycerides | 2005 |
Atorvastatin-induced severe gastric ulceration: a case report.
Topics: Abdominal Pain; Adult; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Male; Pyrroles; Stomach Ulcer | 2005 |
Acute pancreatitis associated with combined lisinopril and atorvastatin therapy.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Drug Interactions; Heptanoic Acids; Humans; Lisinopril; Male; Pancreatitis; Pyrroles | 2005 |
Effects of Atorvastatin on Th polarization in patients with acute myocardial infarction.
Topics: Atorvastatin; Cells, Cultured; Disease Progression; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lymphocyte Activation; Male; Middle Aged; Myocardial Infarction; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes, Helper-Inducer | 2005 |
Evaluation of apoptosis and necrosis induced by statins using fluorescence-enhanced flow cytometry.
Topics: Apoptosis; Atorvastatin; Avidin; Biotin; Cell Line; Cell Separation; Cells, Cultured; Drug Industry; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Flow Cytometry; Fluorescein-5-isothiocyanate; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Leukemia; Microscopy, Fluorescence; Necrosis; Pharmaceutical Preparations; Pravastatin; Propidium; Pyridines; Pyrroles; Simvastatin; Time Factors | 2005 |
Images in clinical medicine. A medical mystery--bradycardia.
Topics: Atorvastatin; Bradycardia; Electrocardiography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2005 |
Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS.
Topics: Atorvastatin; Biotransformation; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Molecular Structure; Pyrroles; Reference Standards; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry | 2005 |
Comparison of the effects of pravastatin and atorvastatin on fracture incidence in the PROVE IT-TIMI 22 trial--secondary analysis of a randomized controlled trial.
Topics: Atorvastatin; Fractures, Bone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice.
Topics: Animals; Arteriosclerosis; Atorvastatin; Biomarkers; Blood Glucose; Blotting, Northern; CCAAT-Enhancer-Binding Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Gene Expression Regulation, Enzymologic; Glucose Tolerance Test; Glucose-6-Phosphatase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipids; Male; Mice; Mice, Inbred Strains; Pyrroles; RNA, Messenger; Sterol Regulatory Element Binding Protein 1; Transcription Factors | 2005 |
Statins for aortic stenosis.
Topics: Aortic Valve Stenosis; Atorvastatin; Calcinosis; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2005 |
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Gabapentin-induced myopathy in 2 patients on short daily hemodialysis.
Topics: Adult; Amines; Anticonvulsants; Atorvastatin; Calcium Channels; Comorbidity; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Glomerulonephritis; Glomerulonephritis, Membranoproliferative; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Neuromuscular Diseases; Peritoneal Dialysis; Physical Exertion; Postoperative Complications; Pyrroles; Recurrence; Renal Dialysis; Restless Legs Syndrome | 2005 |
Atorvastatin reduces the plasma lipids and oxidative stress but did not reverse the inhibition of prostacyclin generation by aortas in streptozotocin diabetic rats.
Topics: Animals; Aorta; Atorvastatin; Diabetes Mellitus, Experimental; Epoprostenol; Heptanoic Acids; Lipids; Male; Oxidative Stress; Pyrroles; Rats; Rats, Sprague-Dawley; Streptozocin | 2005 |
Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Atorvastatin; Chemokine CCL2; Chemokine CCL5; Chemokines, CC; Dose-Response Relationship, Drug; Edema; Female; Heptanoic Acids; Hindlimb; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperalgesia; Interleukin-1; Interleukin-10; Interleukin-6; Leukocytes; Neutrophils; Peroxidase; Pyrroles; Rats; Tarsal Joints; Time Factors; Tumor Necrosis Factor-alpha | 2005 |
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.
Topics: Alleles; Atorvastatin; Biological Transport; Cells, Cultured; Genetic Variation; HeLa Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Liver-Specific Organic Anion Transporter 1; Mutagenesis, Site-Directed; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pravastatin; Pyridines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Substrate Specificity; Transfection | 2005 |
Torcetrapib and atorvastatin--should marketing drive the research agenda?
Topics: Anticholesteremic Agents; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Clinical Trials as Topic; Coronary Artery Disease; Drug Approval; Drug Combinations; Drug Industry; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Marketing; Molecular Structure; Pyrroles; Quinolines; Research Design; United States; United States Food and Drug Administration | 2005 |
Atorvastatin does not decrease or delay diabetes onset in two different mouse models of type 1 diabetes.
Topics: Animals; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 1; Female; Food-Drug Interactions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Pyrroles | 2005 |
Hypolipidemic effect of methanolic extract of Dolichos biflorus Linn. in high fat diet fed rats.
Topics: Animals; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diet, Atherogenic; Dietary Fats; Dolichos; Fatty Acids; Heptanoic Acids; Lipid Metabolism; Lipids; Lipoproteins; Male; Methanol; Phospholipids; Plant Extracts; Pyrroles; Rats; Rats, Wistar; Triglycerides | 2005 |
Atorvastatin induces insulin sensitization in Zucker lean and fatty rats.
Topics: Adipose Tissue; Animals; Atorvastatin; Blotting, Western; Body Weight; Diabetes Mellitus, Type 2; Follow-Up Studies; Glucose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Muscle, Skeletal; Phosphorylation; Pyrroles; Rats; Rats, Zucker | 2006 |
Intensive lipid lowering with atorvastatin in coronary disease.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk | 2005 |
The effects of prior use of atorvastatin on coronary blood flow after primary percutaneous coronary intervention in patients presenting with acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Coronary Circulation; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Retrospective Studies; Stroke Volume; Treatment Outcome | 2005 |
Intensive lipid lowering with atorvastatin in coronary disease.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk | 2005 |
Intensive lipid lowering with atorvastatin in coronary disease.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mortality; Pyrroles; Simvastatin | 2005 |
Intensive lipid lowering with atorvastatin in coronary disease.
Topics: Atorvastatin; Cardiovascular Diseases; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mortality; Pyrroles; Rhabdomyolysis | 2005 |
Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; C-Reactive Protein; Carotid Arteries; Cholesterol, LDL; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pyrroles; Simvastatin; Tunica Intima; Tunica Media | 2006 |
Acute onset and worsening of diabetes concurrent with administration of statins.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles | 2005 |
The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Blood Platelets; CD40 Ligand; Cholesterol; Cholesterol, LDL; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Interactions; Female; Flow Cytometry; Heptanoic Acids; Humans; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Triglycerides | 2005 |
Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits.
Topics: Adipocytes; Adipose Tissue; Animals; Atorvastatin; Cholesterol; Drug Evaluation, Preclinical; Heptanoic Acids; Hypercholesterolemia; Leptin; Pyrroles; Rabbits; RNA, Messenger | 2005 |
Influence of atorvastatin on apolipoprotein E and AI kinetics in patients with type 2 diabetes.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins E; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins, HDL; Lipoproteins, VLDL; Male; Middle Aged; Pyrroles | 2005 |
Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy.
Topics: Animals; Animals, Genetically Modified; Apoptosis; Atorvastatin; Cardiomyopathy, Hypertrophic; Cholesterol; Disease Models, Animal; DNA, Mitochondrial; Extracellular Signal-Regulated MAP Kinases; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; Myosin Heavy Chains; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Pyrroles; Rabbits; Ventricular Function, Left | 2005 |
Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins.
Topics: Animals; Atorvastatin; Cell Culture Techniques; Cholesterol; Gene Expression Profiling; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Fibers, Skeletal; Myoblasts, Skeletal; Pyridines; Pyrroles; Quinolines; Rats; RNA, Messenger | 2005 |
Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes.
Topics: 3T3-L1 Cells; Animals; Atorvastatin; Cell Culture Techniques; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Mevalonic Acid; Mice; Pioglitazone; PPAR gamma; Pravastatin; Pyrroles; Quinolines; RNA, Messenger; Simvastatin; Thiazolidinediones | 2005 |
Long-term protective effect of atorvastatin in permanent focal cerebral ischemia.
Topics: Animals; Atorvastatin; Behavior, Animal; Blood Circulation; Brain Infarction; Brain Ischemia; Dizocilpine Maleate; Heptanoic Acids; Infarction, Middle Cerebral Artery; Magnetic Resonance Imaging; Male; Motor Activity; Neuroprotective Agents; Psychomotor Performance; Pyrroles; Rats; Rats, Long-Evans; Recovery of Function; Staining and Labeling; Time; Time Factors | 2005 |
The effects of quinapril and atorvastatin on artery structure and function in adult spontaneously hypertensive rats.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Apoptosis; Arteries; Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; Electric Stimulation; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; In Situ Nick-End Labeling; In Vitro Techniques; Male; Mesenteric Arteries; Microscopy, Confocal; Nitroprusside; Norepinephrine; Pyrroles; Quinapril; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrahydroisoquinolines; Time Factors; Vasoconstriction; Vasoconstrictor Agents; Vasodilator Agents | 2005 |
Comparison of endothelial function in patients with metabolic syndrome on bezafibrate or atorvastatin therapy.
Topics: Aged; Atorvastatin; Bezafibrate; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Coronary Circulation; Endothelium, Vascular; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Regional Blood Flow; Treatment Outcome; Vasodilation | 2005 |
Effects of atorvastatin on inflammation and oxidative stress.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Insulin Resistance; Isoprostanes; Middle Aged; Oxidative Stress; Pyrroles; Tunica Intima | 2005 |
Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro.
Topics: Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypnotics and Sedatives; In Vitro Techniques; Indoles; Microsomes, Liver; Midazolam; Pyrroles | 2005 |
Supratherapeutic response to ezetimibe administered with cyclosporine.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cyclosporine; Drug Interactions; Ezetimibe; Heart Transplantation; Heptanoic Acids; Humans; Hyperlipidemias; Immunosuppressive Agents; Male; Middle Aged; Postoperative Complications; Pyrroles | 2005 |
Progesterone abolishes estrogen and/or atorvastatin endothelial dependent vasodilatory effects.
Topics: Anticholesteremic Agents; Atorvastatin; Contraceptives, Oral, Synthetic; Drug Interactions; Estradiol; Heptanoic Acids; Humans; Norethindrone; Progesterone; Pyrroles; Terminology as Topic; Vasodilation | 2005 |
Statin use after acute myocardial infarction: a nationwide study in Denmark.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Ambulatory Care; Atorvastatin; Denmark; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Population Surveillance; Pravastatin; Pyrroles; Registries; Sex Distribution; Simvastatin | 2005 |
Statin neuropathy masquerading as diabetic autoimmune polyneuropathy.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Autoimmunity; Diabetes Mellitus, Type 1; Diabetic Neuropathies; Female; Heptanoic Acids; Humans; Pyrroles; Restless Legs Syndrome | 2005 |
Effect of atorvastatin on tumor necrosis factor alpha serum concentration and mRNA expression of adipose in hypercholesterolemic rabbits.
Topics: Adipose Tissue; Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; Cholesterol; Cholesterol, LDL; Disease Models, Animal; Heptanoic Acids; Hypercholesterolemia; Male; Pyrroles; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha | 2005 |
In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells.
Topics: Atorvastatin; Cell Proliferation; Cytokines; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Leukocytes, Mononuclear; Lovastatin; Mitogens; Pravastatin; Pyrroles; Simvastatin | 2005 |
[Effect of maximum dose of atorvastatin on inflammation, thrombogenesis and fibrinolysis in high-risk patients with ischemic heart disease].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Disease; Data Interpretation, Statistical; Enzyme-Linked Immunosorbent Assay; Female; Fibrinolysis; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunochemistry; Lipids; Male; Middle Aged; Prothrombin; Pyrroles; Risk Factors; Time Factors | 2005 |
Reply to Al-Shaer, is atorvastatin more appropriate to use in combination with niacin than simvastatin in patients with the metabolic syndrome? (Am Heart J 2005;149:e17.).
Topics: Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Pyrroles; Simvastatin | 2005 |
The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells.
Topics: Atorvastatin; Cell Division; Cell Movement; Chemotaxis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Myocytes, Smooth Muscle; Pravastatin; Pyridines; Pyrroles; Saphenous Vein; Simvastatin | 2005 |
REVERSAL and PROVE-IT: are clinically oriented trials really better than "pure" scientific studies?
Topics: Atorvastatin; Coronary Artery Disease; Data Interpretation, Statistical; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Outcome Assessment, Health Care; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Not all statins interfere with clopidogrel during antiplatelet therapy.
Topics: Adult; Atorvastatin; Chromatography, High Pressure Liquid; Clopidogrel; Drug Interactions; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ticlopidine | 2005 |
The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease.
Topics: Aged; Atorvastatin; Blood Platelets; Cholesterol, LDL; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Ticlopidine; Time Factors; Wound Healing | 2005 |
Margarine phytosterols decrease the secretion of atherogenic lipoproteins from HepG2 liver and Caco2 intestinal cells.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Atherosclerosis; Atorvastatin; Caco-2 Cells; Carcinoma, Hepatocellular; Cholesterol; Drug Synergism; Enterocytes; Hepatocytes; Heptanoic Acids; Humans; Liver Neoplasms; Margarine; Phytosterols; Pyrroles; Sitosterols; Stigmasterol | 2005 |
Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Benzimidazoles; Benzoates; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interleukin-10; Interleukin-6; Macrophages; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Monocytes; Pyrroles; Ramipril; Renin-Angiotensin System; Telmisartan | 2005 |
Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Drug Utilization; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infections; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Thrombolytic Therapy | 2005 |
The angiotensin-converting enzyme gene insertion/deletion polymorphism and effects of quinapril and atorvastatin on haemostatic parameters in patients with coronary artery disease.
Topics: Alleles; Angiography; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Blood Pressure; Coronary Artery Disease; Fibrin Fibrinogen Degradation Products; Genotype; Hemostasis; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Pyrroles; Quinapril; Risk; Tetrahydroisoquinolines; Time Factors | 2005 |
Effects of statins on microglia.
Topics: Amyloid beta-Peptides; Animals; Atorvastatin; Cell Death; Cell Line; Cell Survival; Cytokines; Dose-Response Relationship, Drug; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; L-Lactate Dehydrogenase; Lipopolysaccharides; Microglia; Peptide Fragments; Pyrroles; Rats; Simvastatin; Statistics, Nonparametric; Tetrazolium Salts; Thiazoles | 2005 |
Dan Ravicher profile. A 'Robin Hood' declares war on lucrative U.S. patents.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Industry; Drugs, Generic; Foundations; Heptanoic Acids; History, 20th Century; History, 21st Century; Patents as Topic; Pyrroles; Software; Transformation, Genetic; United States | 2005 |
Binding thermodynamics of statins to HMG-CoA reductase.
Topics: Atorvastatin; Binding Sites; Calorimetry; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Protein Binding; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Thermodynamics | 2005 |
High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brazil; Cholesterol, LDL; Female; Gene Frequency; Genes, MDR; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrroles; White People | 2005 |
Ready, aim, treat to hit new cholesterol targets.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Pyrroles; Reference Values | 2005 |
[Intensive LDL lowering to under 80 mg/dl: hypercholesteremia patients with stable coronary disease and diabetes profit especially significantly].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Expectancy; Pravastatin; Pyrroles; Risk; Risk Factors; Time Factors | 2005 |
[To lessen the cardiovascular risk of the diabetic patient. Atorvastatin of use for diabetic patients without coronary disease, too].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Placebos; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Triglycerides | 2005 |
Atorvastatin prevents peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) downregulation in lipopolysaccharide-stimulated H9c2 cells.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cell Line; Chemokine CCL2; Down-Regulation; Fatty Acids; Heptanoic Acids; Lipopolysaccharides; Muscle Cells; NF-kappa B; PPAR gamma; PPAR-beta; Protein Binding; Protein Kinases; Pyrroles; Rats; Sesquiterpenes; Transcription Factors; Transcriptional Activation | 2005 |
Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits.
Topics: Animals; Aortic Diseases; Atherosclerosis; Atorvastatin; Cholesterol, Dietary; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Male; Pyrroles; Rabbits | 2005 |
Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus.
Topics: Aged; Arteries; Atorvastatin; Blood Flow Velocity; Blood Pressure; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leg; Male; Middle Aged; Prospective Studies; Pyrroles | 2005 |
Statins and autonomic function in chronic heart failure.
Topics: Atorvastatin; Autonomic Nervous System; Chronic Disease; Heart Failure; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2005 |
[Effects of atorvastatin on LPS-induced PGE2 and IL-6 secretions in human pulmonary epithelial cells].
Topics: Anticholesteremic Agents; Atorvastatin; Cell Line; Dinoprostone; Epithelial Cells; Heptanoic Acids; Humans; Interleukin-6; Lipopolysaccharides; Lung; Pyrroles | 2004 |
Histological and ultrastructural changes in cross-striation muscle cells, under the influence of atorvastatin-reductase HMG-CoA inhibitor.
Topics: Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microscopy, Electron; Muscle Cells; Muscle, Skeletal; Pyrroles; Rats; Rats, Wistar | 2004 |
Histological picture of intestinal mucosa of rats after simultaneous administration of atorvastatin and ethyl alcohol.
Topics: Animals; Atorvastatin; Ethanol; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Mucosa; Pyrroles; Rats | 2004 |
High doses of atorvastatin (Sortis) modify the secretory process in the exocrine portion of the pancreas.
Topics: Animals; Atorvastatin; Calcium; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreas, Exocrine; Pyrroles; Rats; Rats, Wistar | 2004 |
A simple and rapid HPLC method for the determination of atorvastatin in human plasma with UV detection and its application to pharmacokinetic studies.
Topics: Adult; Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indicators and Reagents; Male; Pyrroles; Reference Standards; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2005 |
Determination of atorvastatin in human serum by reversed-phase high-performance liquid chromatography with UV detection.
Topics: Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2005 |
Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease.
Topics: Atorvastatin; Cardiovascular Diseases; Drug Prescriptions; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pyrroles; Regression Analysis; Time Factors | 2005 |
Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts.
Topics: Adult; Atorvastatin; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Female; Glucocorticoids; Glycoproteins; Heptanoic Acids; Humans; Male; Mevalonic Acid; Models, Biological; Osteoblasts; Osteoprotegerin; Pyrroles; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2005 |
Effect of atorvastatin on TH1 and TH2 cytokine secreting cells during T cell activation and differentiation.
Topics: Anticholesteremic Agents; Atorvastatin; Cell Death; Cell Differentiation; Cells, Cultured; Cytokines; Heptanoic Acids; Humans; Immunophenotyping; Immunosuppressive Agents; Lymphocyte Activation; Pyrroles; Th1 Cells; Th2 Cells | 2006 |
Endothelial function in the forearm circulation of patients with the metabolic syndrome--effect of different lipid-lowering regimens.
Topics: Acetylcholine; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Regional Blood Flow; Treatment Outcome; Vasodilation | 2005 |
Matrix metalloproteinases in isolated hypercholesterolemia.
Topics: Atherosclerosis; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Matrix Metalloproteinases; Middle Aged; Pyrroles; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinases | 2005 |
Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway.
Topics: Animals; Animals, Inbred Strains; Aortic Valve Stenosis; Atorvastatin; beta Catenin; Calcinosis; Cell Division; Cells, Cultured; Cholesterol, Dietary; Diet, Atherogenic; Fibroblasts; Gene Expression Regulation; Heptanoic Acids; Hypercholesterolemia; LDL-Receptor Related Proteins; Lipoproteins, LDL; Low Density Lipoprotein Receptor-Related Protein-5; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocytes, Cardiac; Ossification, Heterotopic; Osteopontin; Pyrroles; Rabbits; Sialoglycoproteins; Sus scrofa | 2005 |
Lipid-lowering with atorvastatin improves tissue characteristics of carotid plaque.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Common; Carotid Artery, Internal; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Pyrroles; Treatment Outcome; Ultrasonography | 2005 |
Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Hepatitis, Autoimmune; Heptanoic Acids; Humans; Hypercholesterolemia; Liver Function Tests; Middle Aged; Pyrroles | 2005 |
In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling.
Topics: Angiotensin II; Animals; Atorvastatin; Cells, Cultured; Collagen; Connective Tissue Growth Factor; Dose-Response Relationship, Drug; Extracellular Matrix; Fibroblasts; Heart; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Myocardium; Procollagen; Pyrroles; Rats; Transforming Growth Factor beta; Transforming Growth Factor beta1; Ventricular Remodeling | 2005 |
Atorvastatin downregulates tissue plasminogen activator-aggravated genes mediating coagulation and vascular permeability in single cerebral endothelial cells captured by laser microdissection.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Coagulation; Brain; Brain Ischemia; Capillary Permeability; Down-Regulation; Endothelial Cells; Gene Expression; Heptanoic Acids; Humans; Lasers; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Microdissection; Pyrroles; Rats; Rats, Wistar; Receptor, PAR-1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thromboplastin; Tissue Plasminogen Activator | 2006 |
Conversion to atorvastatin in patients intolerant or refractory to simvastatin therapy: the CAPISH study.
Topics: Aged; Atorvastatin; Cholesterol; Cohort Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Retrospective Studies; Simvastatin; Treatment Failure; Triglycerides | 2005 |
Cholesterol drug may help treat Alzheimer's.
Topics: Alzheimer Disease; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2005 |
[Considerable LDL lowering is advantageous].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Controlled Clinical Trials as Topic; Diabetes Mellitus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Placebos; Pyrroles; Risk; Risk Factors; Triglycerides | 2005 |
Evidence of improved serum fatty acid profile of postmenopausal women receiving atorvastatin and raloxifene.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Drug Therapy, Combination; Fatty Acids; Female; Heptanoic Acids; Humans; Middle Aged; Postmenopause; Pyrroles; Raloxifene Hydrochloride; Risk; Treatment Outcome | 2005 |
Effect of atorvastatin on SR-BI expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits.
Topics: Adipocytes; Animals; Anticholesteremic Agents; Atorvastatin; Biological Transport; CD36 Antigens; Cholesterol; DNA Primers; Heptanoic Acids; In Vitro Techniques; Lipoproteins, HDL; Male; Pyrroles; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2006 |
Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Double-Blind Method; Europe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; North America; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): response to Server et al.
Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Torcetrapib + atorvastatin (Pfizer).
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Combinations; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines | 2005 |
JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs.
Topics: Animals; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, Dietary; Cholesterol, LDL; Dose-Response Relationship, Drug; Guinea Pigs; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Models, Animal; Particle Size; Pyrroles; Triglycerides | 2005 |
New light on statin side effects. What recent research on the cholesterol drugs means to you.
Topics: Atorvastatin; Biomedical Research; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyridines; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
Differences between statins on clinical endpoints: a population-based cohort study.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Endpoint Determination; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Netherlands; Pravastatin; Pyridines; Pyrroles; Simvastatin; Treatment Outcome | 2005 |
A novel lipoprotein-mediated mechanism controlling sexual attractiveness in a colorful songbird.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Beak; Carotenoids; Carrier Proteins; Cholesterol; Heptanoic Acids; Male; Pigmentation; Pyrroles; Sex Factors; Sexual Behavior, Animal; Songbirds | 2006 |
Atorvastatin affects interleukin-2 signaling by altering the lipid raft enrichment of the interleukin-2 receptor beta chain.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Immunologic Factors; In Vitro Techniques; Interleukin-2; Interleukin-2 Receptor beta Subunit; Membrane Microdomains; Pyrroles; Receptors, Interleukin; Signal Transduction | 2005 |
Torcetrapib and atorvastatin.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Combinations; Drug Industry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines | 2005 |
Torcetrapib and atorvastatin.
Topics: Atorvastatin; Drug Combinations; Drugs, Generic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Legislation, Drug; Patents as Topic; Pyrroles; Quinolines; United States | 2005 |
Torcetrapib and atorvastatin.
Topics: Atorvastatin; Drug Costs; Drug Industry; Heptanoic Acids; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines; Ritonavir | 2005 |
Statins don't stop aortic valve narrowing...or memory loss (yet).
Topics: Aortic Valve Stenosis; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Memory Disorders; Pyrroles; Treatment Failure | 2005 |
99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Diet, Atherogenic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-2; Male; Middle Aged; Pyrroles; Radionuclide Imaging; Technetium | 2006 |
Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy.
Topics: Acute Disease; Angina, Unstable; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Syndrome | 2005 |
Hypotension and eosinophilia with atorvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Hypersensitivity; Eosinophilia; Heptanoic Acids; Humans; Hypotension; Male; Pyrroles | 2005 |
The pharmaco-economics of peri-operative statin therapy.
Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Costs; Drug Monitoring; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Perioperative Care; Prospective Studies; Pyrroles; State Medicine; United Kingdom; Vascular Surgical Procedures | 2005 |
Decreasing LDL cholesterol and medication cost with every-other-day statin therapy.
Topics: Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2005 |
Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Niacin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2005 |
The effects of atorvastatin on gluten-induced intestinal T cell responses in coeliac disease.
Topics: Adult; Aged; Anticholesteremic Agents; Antigens, CD; Apoptosis; Atorvastatin; CD83 Antigen; Celiac Disease; Cells, Cultured; Cytokines; Dendritic Cells; Dose-Response Relationship, Immunologic; Glutens; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Immunity, Mucosal; Immunoglobulins; Intestinal Mucosa; Lymphocyte Activation; Membrane Glycoproteins; Middle Aged; Organ Culture Techniques; Pyrroles; T-Lymphocytes; Up-Regulation | 2005 |
Effect of statin therapy on serum trace element status in dyslipidaemic subjects.
Topics: Adult; Antioxidants; Atorvastatin; Blood Chemical Analysis; Ceruloplasmin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Trace Elements | 2005 |
Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats.
Topics: Animals; Atorvastatin; Autoimmune Diseases; Cholesterol; Cytokines; Genetic Predisposition to Disease; Heart Function Tests; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocarditis; Myocardium; Pyrroles; Rats; Rats, Inbred Lew; Th1 Cells; Th2 Cells | 2005 |
[ASCOT-BPLA Study raises new questions regarding: which is the best initial antihypertensive drug?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Doxazosin; Drug Therapy, Combination; Follow-Up Studies; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Sodium Chloride Symporter Inhibitors; Treatment Outcome | 2005 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Treatment Failure | 2005 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis.
Topics: Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Treatment Failure | 2005 |
Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis.
Topics: Atorvastatin; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis; Risk Factors; Stroke | 2005 |
Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems.
Topics: Animals; Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Cell Line; Dose-Response Relationship, Drug; Heptanoic Acids; Liver; Male; Microsomes, Liver; Organic Anion Transporters; Pyrroles; Rats; Rats, Sprague-Dawley; Rifampin; Tissue Distribution | 2006 |
Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein.
Topics: Animals; Apoptosis; Atorvastatin; Caspase 8; Cell Line; Fatty Acids, Monounsaturated; Flow Cytometry; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Membrane Lipids; Microscopy, Fluorescence; Myoblasts, Skeletal; Protein Prenylation; Pyridines; Pyrroles; ras Proteins; Rats; rho GTP-Binding Proteins; Signal Transduction | 2005 |
How common is rhabdomyolysis in patients receiving lipid-lowering therapy?
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Creatine Kinase; Drug Therapy, Combination; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Incidence; Middle Aged; Pravastatin; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States | 2005 |
Effect of atorvastatin on spatial memory, neuronal survival, and vascular density in female rats after traumatic brain injury.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Brain Injuries; Cell Survival; Female; Heptanoic Acids; Immunohistochemistry; Memory; Neovascularization, Physiologic; Neurons; Pyrroles; Rats; Rats, Wistar; Reproducibility of Results; Sex Factors | 2005 |
Effect of pravastatin, simvastatin and atorvastatin on the phagocytic activity of mouse peritoneal macrophages.
Topics: Animals; Atorvastatin; Cell Proliferation; Concanavalin A; Heptanoic Acids; Lectins; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Microspheres; Mitogens; Phagocytosis; Pravastatin; Pyrroles; Simvastatin; Spleen | 2006 |
HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Male; Pravastatin; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2005 |
Statin comparisons in controlled clinical trials.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Controlled Clinical Trials as Topic; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Phospholipases A; Postprandial Period; Pyrroles | 2005 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
A case of familial hypercholesterolemia; secession from LDL-apheresis by the drug treatment with potent statin and resin.
Topics: Achilles Tendon; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Component Removal; Coronary Vessels; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Middle Aged; Pedigree; Pyrroles; Radiography; Xanthomatosis | 2005 |
3'UTR/T polymorphism of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is associated with modified anti-platelet activity of atorvastatin in hypercholesterolemic subjects.
Topics: Adult; Alleles; Anticholesteremic Agents; Atorvastatin; Blood Platelets; Chromatography, High Pressure Liquid; Citrulline; DNA; Female; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Intracellular Fluid; Male; Middle Aged; Nitric Oxide Synthase; P-Selectin; Platelet Activation; Polymerase Chain Reaction; Polymorphism, Genetic; Pyrroles; Scavenger Receptors, Class E | 2005 |
The IDEAL cholesterol: lower is better.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin | 2005 |
Skin lipid synthesis inhibition: a possible means for enhancing percutaneous delivery of levodopa.
Topics: Administration, Cutaneous; Animals; Anticholesteremic Agents; Antiparkinson Agents; Atorvastatin; beta-Alanine; Calcium Channel Blockers; Calcium Chloride; Cholesterol; Dose-Response Relationship, Drug; Ethanol; Female; Heptanoic Acids; In Vitro Techniques; Levodopa; Male; Pyrroles; Rats; Rats, Wistar; Serine C-Palmitoyltransferase; Skin; Sphingosine; Time Factors; Verapamil | 2004 |
MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cellulose, Oxidized; Diet; Disease Models, Animal; Endothelium, Vascular; Heptanoic Acids; Hyperlipidemias; Intercellular Adhesion Molecule-1; Lipoproteins; Male; Mice; Mice, Knockout; Pyrroles; Simvastatin; Triglycerides; Vascular Cell Adhesion Molecule-1 | 2006 |
Early anticoagulant effect of atorvastatin.
Topics: Anticholesteremic Agents; Anticoagulants; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles | 2005 |
APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Genetic Variation; Genomics; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Polymorphism, Genetic; Pyrroles; Sex Factors; Treatment Outcome; Triglycerides | 2005 |
Atorvastatin suppresses homocysteine formation in stimulated human peripheral blood mononuclear cells.
Topics: Anti-Inflammatory Agents; Atorvastatin; Cardiovascular Diseases; Concanavalin A; Dose-Response Relationship, Drug; Heptanoic Acids; Homocystine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Neopterin; Oxidative Stress; Phytohemagglutinins; Pyrroles | 2005 |
Eosinophilic fasciitis secondary to treatment with atorvastatin.
Topics: Aged; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Eosinophilia; Fasciitis; Female; Heptanoic Acids; Humans; Pyrroles; Treatment Outcome | 2006 |
[How can lipid therapy be improved? Cardiologists insist on dual cholesterol inhibition].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Factors | 2005 |
[Cholesterol goals are now easier to reach. Half LDL cholesterol with only one tablet daily].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Controlled Clinical Trials as Topic; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin; Time Factors | 2005 |
Interleukin-6 (IL-6)-174 G/C polymorphism--lack of association with inflammatory and haemostatic variables in patients with coronary heart disease treated with atorvastatin and quinapril.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Biomarkers; Coronary Disease; Cytosine; Drug Therapy, Combination; Genotype; Guanine; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-6; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Quinapril; Tetrahydroisoquinolines; Treatment Outcome | 2006 |
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorv
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Drug Combinations; Dyslipidemias; Heptanoic Acids; Humans; Hypertension; Lipid Metabolism; Multicenter Studies as Topic; Pyrroles; Surveys and Questionnaires; Tablets | 2006 |
Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2.
Topics: Animals; Atorvastatin; Cardiotonic Agents; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Heart; Heptanoic Acids; Ischemic Preconditioning; Male; Myocardial Infarction; Myocardium; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2006 |
Statin use in a "real-world" clinical setting: aggressive lipid lowering compared with usual care in the Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) trial.
Topics: Adolescent; Adult; Aged; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic | 2005 |
Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
Topics: Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Infections; Male; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
A rationale for combination therapy in risk factor management: a mechanistic perspective.
Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Disease Management; Drug Therapy, Combination; Endothelium, Vascular; Heptanoic Acids; Humans; Nitric Oxide; Pyrroles; Risk Factors | 2005 |
HMG-CoA reductase inhibitors may affect thrombin generation by reducing factor VII activity in hyperlipidemic patients.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Atorvastatin; Cohort Studies; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Prothrombin; Pyrroles; Thrombin; Thromboplastin; Treatment Outcome | 2006 |
Effect of atorvastatin (80 mg/day) versus pravastatin (40 mg/day) on arterial remodeling at coronary branch points (from the REVERSAL study).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Treatment Outcome; Ultrasonography, Interventional | 2005 |
Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer.
Topics: Aged; Atorvastatin; Brachytherapy; Disease Progression; Disease-Free Survival; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prostatic Neoplasms; Pyrroles | 2005 |
Atorvastatin: a potential chemopreventive agent in bladder cancer.
Topics: Atorvastatin; Carcinoma, Transitional Cell; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Urinary Bladder Neoplasms | 2005 |
Does "anti-lipid" also mean "anti-arrhythmic"?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atorvastatin; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2005 |
[Fluctuation of C-reactive protein levels in acute coronary syndrome].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles | 2005 |
Statins for high-risk patients without heart disease or high cholesterol.
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pravastatin; Pyrroles; Simvastatin; Stroke | 2006 |
Imaging of a regressive coronary soft plaque under lipid lowering therapy by multi-slice computed tomography.
Topics: Aspirin; Atorvastatin; Carotid Stenosis; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Radiography | 2006 |
Evolution of lesions over 10 years in a patient with SLE: flowchart approach to the new International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification of lupus nephritis.
Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Biopsy, Needle; Disease Progression; Follow-Up Studies; Hematuria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunoglobulin A; Immunoglobulin M; Immunosuppressive Agents; Kidney Glomerulus; Lupus Erythematosus, Systemic; Lupus Nephritis; Male; Organelles; Plasma Exchange; Pyrroles; Sclerosis; Severity of Illness Index; Software Design | 2006 |
Safety of statins when response is carefully monitored: a study of 336 heart recipients.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Graft Rejection; Heart Transplantation; Heptanoic Acids; Humans; Middle Aged; Overweight; Pravastatin; Pyrroles; Retrospective Studies; Safety | 2005 |
Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes.
Topics: Atorvastatin; Base Sequence; Blotting, Western; Cell Differentiation; Cell Line; Cholesterol; DNA Primers; Gene Expression; Heptanoic Acids; Homeostasis; Humans; Monocytes; Polymerase Chain Reaction; Pyrroles; RNA, Messenger; Rosiglitazone; Scavenger Receptors, Class B; Thiazolidinediones | 2006 |
Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microsomes, Liver; Molecular Structure; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Swine; Transfection | 2006 |
[Acute cholestatic hepatitis after atorvastatin reintroduction].
Topics: Acute Disease; Aged; Atorvastatin; Chemical and Drug Induced Liver Injury; Cholestasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles | 2006 |
[Drug combinations: statins and niacin].
Topics: Age Distribution; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Niacin; Pyrroles; Sex Factors; Simvastatin | 2005 |
Arginine uptake is attenuated through modulation of cationic amino-acid transporter-1, in uremic rats.
Topics: Animals; Aorta; Arginine; Atorvastatin; Biological Transport; Cationic Amino Acid Transporter 1; Cationic Amino Acid Transporter 2; Creatinine; Gene Expression Regulation; Heptanoic Acids; In Vitro Techniques; Kidney Failure, Chronic; Kidney Glomerulus; Male; Nitric Oxide; Pyrroles; Rats; Rats, Wistar; Uremia | 2006 |
Effects of atorvastatin on lipid metabolism in normolipidemic and hereditary hyperlipidemic, non-laying hens.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; Chickens; Cholesterol; Down-Regulation; Female; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Liver; Organ Size; Point Mutation; Pyrroles; Receptors, LDL; RNA, Messenger; Triglycerides | 2006 |
Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization.
Topics: Aged; Atherosclerosis; Atorvastatin; Carotid Artery Diseases; Cells, Cultured; Cyclooxygenase 2; Dinoprostone; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Signaling Peptides and Proteins; Intramolecular Oxidoreductases; Male; Matrix Metalloproteinase 1; Mevalonic Acid; Middle Aged; Monocytes; Prostaglandin-E Synthases; Protein Serine-Threonine Kinases; Pyrroles; Receptors, Prostaglandin E; rho GTP-Binding Proteins; rho-Associated Kinases | 2006 |
Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice.
Topics: Amlodipine; Animals; Apolipoprotein E3; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blood Pressure; C-Reactive Protein; Cholesterol; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Mice; Mice, Transgenic; Pyrroles; Serum Amyloid A Protein; von Willebrand Factor | 2006 |
Statins decrease serotonin-induced contractions in coronary arteries of swine in vitro.
Topics: Animals; Atorvastatin; Coronary Vessels; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lovastatin; Male; Pravastatin; Pyrroles; Serotonin; Simvastatin; Swine; Time Factors; Vasoconstriction | 2006 |
Muscle symptoms associated with statins: a series of twenty patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pravastatin; Pyrroles; Simvastatin | 2006 |
Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin.
Topics: Amidines; Animals; Atorvastatin; Benzylamines; Cardiotonic Agents; Drug Synergism; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Phosphodiesterase Inhibitors; Phosphorylation; Piperazines; Purines; Pyrroles; Rats; Rats, Sprague-Dawley; Sildenafil Citrate; Sulfones; Up-Regulation | 2006 |
Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells.
Topics: Apoptosis; Atorvastatin; Cell Differentiation; Cell Division; Cell Proliferation; Cells, Cultured; Cytokines; Heptanoic Acids; Histamine Release; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin E; Lovastatin; Mast Cells; Probability; Pyridines; Pyrroles; Sensitivity and Specificity | 2006 |
Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins.
Topics: Aged; Aortic Aneurysm, Abdominal; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2006 |
Involvement of Rho-kinase in experimental vascular endothelial dysfunction.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetylcholine; Animals; Antibiotics, Antineoplastic; Aorta, Thoracic; Atorvastatin; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Experimental; Endothelium, Vascular; Heptanoic Acids; Homocysteine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperhomocysteinemia; Intracellular Signaling Peptides and Proteins; Male; Nitrates; Nitrites; Oxidative Stress; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrroles; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Streptozocin; Thiobarbituric Acid Reactive Substances; Vasodilation | 2006 |
The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Stenosis; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles | 2006 |
I'm taking Zocor to help lower my cholesterol. The directions say to take it at night. My friend takes Lipitor, but doesn't have to take it at night. Why the difference?
Topics: Anticholesteremic Agents; Atorvastatin; Chronotherapy; Heptanoic Acids; Humans; Pyrroles; Simvastatin | 2005 |
HPLC assay and pharmacokinetic study of atorvastatin in beagle dogs after oral administration of atorvastatin self-microemulsifying drug delivery system.
Topics: Animals; Atorvastatin; Chromatography, High Pressure Liquid; Dogs; Drug Delivery Systems; Emulsions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indicators and Reagents; Male; Pyrroles; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2006 |
Aggressive low-density lipoprotein cholesterol lowering in secondary prevention of coronary heart disease.
Topics: Alanine Transaminase; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Risk; Triglycerides | 2006 |
C-reactive protein levels and outcomes after statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors | 2006 |
Reduction in cardiovascular events with atorvastatin in type 2 diabetes.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2006 |
Undisclosed conflicts of interest.
Topics: Anticholesteremic Agents; Atorvastatin; Conflict of Interest; Heptanoic Acids; Pyrroles | 2006 |
Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism.
Topics: Antioxidants; Apoptosis; Atherosclerosis; Atorvastatin; Cell Membrane; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Lipid Peroxidation; Membrane Lipids; Models, Biological; Oxidative Stress; Pyrroles; X-Ray Diffraction | 2006 |
Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits.
Topics: Animals; Atorvastatin; Cells, Cultured; Cyclic AMP; Gene Expression Regulation; GTP-Binding Protein gamma Subunits; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocytes, Cardiac; Protein Prenylation; Protein Subunits; Pyrroles; Rats; Rats, Wistar; Receptors, Adrenergic, beta; RNA, Messenger; Signal Transduction | 2006 |
RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation.
Topics: Anticholesteremic Agents; Apoptosis; Atorvastatin; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Caspases; Cell Differentiation; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Humans; Osteosarcoma; Phenotype; Phosphorylation; Polyisoprenyl Phosphates; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrroles; rhoA GTP-Binding Protein; RNA, Messenger; Signal Transduction; Simvastatin; Transforming Growth Factor beta | 2006 |
Simultaneous quantification of atorvastatin and active metabolites in human plasma by liquid chromatography-tandem mass spectrometry using rosuvastatin as internal standard.
Topics: Atorvastatin; Biological Availability; Calibration; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mass Spectrometry; Pyrroles; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Therapeutic Equivalency | 2006 |
Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin.
Topics: Animals; Atorvastatin; Cell Differentiation; Cell Membrane; Cell Proliferation; Cells, Cultured; Cholesterol; Encephalomyelitis, Autoimmune, Experimental; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred Strains; Mice, Transgenic; Protein Prenylation; Pyrroles; ras Proteins; rhoA GTP-Binding Protein; Terpenes; Th1 Cells; Th2 Cells | 2006 |
SREBP inhibits VEGF expression in human smooth muscle cells.
Topics: Animals; Atorvastatin; Cells, Cultured; Gene Expression Regulation; Heptanoic Acids; Humans; Myocytes, Smooth Muscle; Promoter Regions, Genetic; Pyrroles; Rats; Sterol Regulatory Element Binding Protein 1; Umbilical Arteries; Vascular Endothelial Growth Factor A | 2006 |
Angiogenic transcriptome of human microvascular endothelial cells: Effect of hypoxia, modulation by atorvastatin.
Topics: Atorvastatin; Cell Hypoxia; Cell Line; Dose-Response Relationship, Drug; Endothelial Cells; Gene Expression Profiling; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-8; Oligonucleotide Array Sequence Analysis; Placenta Growth Factor; Pregnancy Proteins; Promoter Regions, Genetic; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thrombospondin 1; Transcription, Genetic; Vascular Endothelial Growth Factor A | 2006 |
Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Carbohydrate Metabolism; Diabetes Mellitus; Female; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Metabolism; Male; Pravastatin; Pyrroles; Retrospective Studies; Treatment Outcome | 2006 |
LPS-induced release of IL-1 beta, IL-1Ra, IL-6, and TNF-alpha in whole blood from patients with familial hypercholesterolemia: no effect of cholesterol-lowering treatment.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Female; Genetic Carrier Screening; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Male; Middle Aged; Pyrroles; Simvastatin; Tumor Necrosis Factor-alpha | 2006 |
Comments on "Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: Application of in vitro and ex situ systems".
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Cytochrome P-450 CYP3A; Drug Interactions; Heptanoic Acids; Liver; Organic Anion Transporters; Pyrroles; Rats; Rifampin | 2006 |
Atorvastatin improves myocardial perfusion in a patient with hypercholesterolemia and single-vessel coronary disease.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Circulation; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Organophosphorus Compounds; Organotechnetium Compounds; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Treatment Outcome | 2006 |
[Preparation and evaluation of self-microemulsifying drug delivery systems containing atorvastatin].
Topics: Administration, Oral; Animals; Area Under Curve; Atorvastatin; Biological Availability; Dogs; Drug Delivery Systems; Emulsions; Glycerol; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Particle Size; Polyethylene Glycols; Pyrroles; Solubility | 2005 |
Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors.
Topics: Atorvastatin; Cells, Cultured; Chemokine CCL2; Chemokine CXCL5; Chemokines, CXC; Endothelial Cells; Fibroblast Growth Factors; Granulocyte Colony-Stimulating Factor; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Interleukin-6; Interleukin-8; Mevalonic Acid; Pyrroles | 2006 |
Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Particle Size; Polymorphism, Genetic; Pravastatin; Pyrroles; Risk Factors; Simvastatin | 2006 |
Atorvastatin reduces plasminogen activator inhibitor-1 expression in adipose tissue of atherosclerotic rabbits.
Topics: Adipose Tissue; Animal Feed; Animals; Atherosclerosis; Atorvastatin; Cholesterol; Gene Expression Regulation; Heptanoic Acids; Male; Mevalonic Acid; Plasminogen Activator Inhibitor 1; Pyrroles; Rabbits; RNA, Messenger; Triglycerides | 2006 |
Immunoregulatory effects of atorvastatin on experimental autoimmune myocarditis in Lewis rats.
Topics: Adoptive Transfer; Animals; Atorvastatin; Autoimmune Diseases; Disease Models, Animal; Echocardiography; Enzyme-Linked Immunosorbent Assay; Genes, MHC Class II; Heptanoic Acids; Histocompatibility Antigens Class II; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocarditis; Myocardium; Myocytes, Cardiac; Nuclear Proteins; Polymerase Chain Reaction; Pyrroles; Rats; Rats, Inbred Lew; RNA, Messenger; T-Lymphocytes; Th2 Cells; Trans-Activators | 2006 |
[Treatment of hypercholesterolemia--lower is better].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Evidence-Based Medicine; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin | 2006 |
Effect of statin treatment on coronary collateral development in patients with diabetes mellitus.
Topics: Angina Pectoris; Atorvastatin; Cholesterol, LDL; Collateral Circulation; Coronary Angiography; Coronary Disease; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
Stress on pleiotropic effects of statins.
Topics: Age Factors; Atorvastatin; Coronary Artery Bypass; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2006 |
Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth.
Topics: Aged; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Atorvastatin; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Netherlands; Population Surveillance; Pyrroles; Retrospective Studies; Simvastatin; Time Factors; Ultrasonography | 2006 |
One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood Platelets; C-Reactive Protein; Carotid Artery Diseases; Carotid Artery, Common; Cholesterol, HDL; Cholesterol, LDL; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Patient Compliance; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2006 |
Medication costs as a primary cause of nonadherence in the elderly.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Prescriptions; Drugs, Generic; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Metformin; Metoprolol; Patient Compliance; Pharmacists; Pyrroles; Self Administration | 2006 |
A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Case Management; Chemical and Drug Induced Liver Injury; Comorbidity; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Tables; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Risk Factors; Simvastatin; Stroke; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Synergistic effects of atorvastatin and sildenafil in cardioprotection--role of NO.
Topics: Animals; Atorvastatin; Cardiotonic Agents; Drug Synergism; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Reperfusion Injury; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Pyrroles; Sildenafil Citrate; Sulfones | 2006 |
Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro.
Topics: Adult; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Cells, Cultured; DNA Fragmentation; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Histones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Myeloid Cell Leukemia Sequence 1 Protein; Myocytes, Cardiac; Neoplasm Proteins; Pravastatin; Proto-Oncogene Proteins c-bcl-2; Pyrroles; RNA, Messenger; Simvastatin | 2006 |
Torcetrapib and atorvastatin: a novel combination therapy for dyslipidemia.
Topics: Animals; Atorvastatin; Cholesterol, HDL; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Pyrroles; Quinolines | 2006 |
Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.
Topics: Animals; Atorvastatin; Cells, Cultured; Cytokines; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Female; Glatiramer Acetate; Heptanoic Acids; Immunologic Factors; Mice; Mice, Inbred Strains; Monocytes; Multiple Sclerosis; Peptides; Pyrroles; T-Lymphocytes, Regulatory; Th1 Cells | 2006 |
Statins and antioxidant vitamins: should co-administration be avoided?
Topics: Antioxidants; Ascorbic Acid; Atorvastatin; Calcinosis; Cardiovascular Diseases; Coronary Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Vitamin E | 2006 |
Direct comparison of the A to Z and PROVE IT trials: a second chance to gain a first impression.
Topics: Africa; Angioplasty, Balloon, Coronary; Asia; Atorvastatin; Australia; Canada; Case Management; Cholesterol, LDL; Confounding Factors, Epidemiologic; Dose-Response Relationship, Drug; Endpoint Determination; Europe; Heptanoic Acids; Humans; Multicenter Studies as Topic; Myocardial Ischemia; New Zealand; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk; Simvastatin; South America; Stents; Tirofiban; Treatment Outcome; Tyrosine; United States | 2006 |
Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction.
Topics: Age Factors; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Drug Prescriptions; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Myocardial Infarction; Odds Ratio; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Survival Rate; Treatment Outcome | 2006 |
Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin.
Topics: Atherosclerosis; Atorvastatin; Base Sequence; Cell Movement; Cell Proliferation; Cells, Cultured; Coronary Vessels; DNA, Complementary; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-18; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Muscle, Smooth, Vascular; NF-kappa B; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Pyrroles; Recombinant Proteins; RNA, Messenger; Transcription Factor AP-1 | 2006 |
Statins protect human aortic smooth muscle cells from inorganic phosphate-induced calcification by restoring Gas6-Axl survival pathway.
Topics: Aorta; Apoptosis; Atorvastatin; Axl Receptor Tyrosine Kinase; Calcinosis; DNA Primers; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Signaling Peptides and Proteins; Muscle, Smooth, Vascular; Oncogene Proteins; Phosphates; Proto-Oncogene Proteins; Pyrroles; Receptor Protein-Tyrosine Kinases; RNA, Messenger; RNA, Small Interfering; Signal Transduction | 2006 |
Statins and stroke: current clinical practice.
Topics: Age Factors; Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Pyrroles; Secondary Prevention; Simvastatin; Stroke | 2006 |
[The effect of atorvastatin on the expression of CD55, CD59 in patients with hyperlipidemia].
Topics: Aged; Atorvastatin; Case-Control Studies; CD55 Antigens; CD59 Antigens; Complement Activation; Gene Expression Regulation; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2005 |
[Atorvastatin upregulates the expression of PPAR alpha/gamma and inhibits the hypertrophy of cardiac myocytes in vitro].
Topics: Angiotensin II; Animals; Atorvastatin; Cardiomegaly; Cells, Cultured; Gene Expression Regulation; Heptanoic Acids; Myocytes, Cardiac; PPAR alpha; PPAR-beta; Pyrroles; Rats; Rats, Wistar; Up-Regulation | 2005 |
Atorvastatin fails to prevent the development of autoimmune diabetes despite inhibition of pathogenic beta-cell-specific CD8 T-cells.
Topics: Animals; Atorvastatin; CD8-Positive T-Lymphocytes; Diabetes Mellitus, Type 1; Female; Heptanoic Acids; Histocompatibility Antigens Class II; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Interleukin-10; Interleukin-4; Mice; Mice, Inbred NOD; Pyrroles | 2006 |
Effect of atorvastatin treatment on isoproterenol-induced myocardial infarction in rats.
Topics: Adenosine Triphosphatases; Animals; Atorvastatin; Body Weight; Catalase; Glutathione; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoproterenol; Lipid Peroxidation; Male; Myocardial Infarction; Myocardium; Necrosis; Organ Size; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxide Dismutase | 2006 |
In vivo suppression of major histocompatibility complex class II expression on porcine vascular endothelial cells by an HMG-CoA reductase inhibitor.
Topics: Animals; Atorvastatin; Endothelial Cells; Fluorescent Antibody Technique; Heptanoic Acids; Histocompatibility Antigens Class II; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoenzyme Techniques; Male; Pyrroles; Swine | 2006 |
Comparative expression profiling in primary and immortalized endothelial cells: changes in gene expression in response to hydroxy methylglutaryl-coenzyme A reductase inhibition.
Topics: Apoptosis; Atorvastatin; Cell Cycle; Cell Line, Transformed; Cells, Cultured; Endothelial Cells; Gene Expression Profiling; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Oligonucleotide Array Sequence Analysis; Pyrroles; Simvastatin | 2006 |
The logistic transform for bounded outcome scores.
Topics: Anticholesteremic Agents; Atorvastatin; Computer Simulation; Coronary Disease; Data Interpretation, Statistical; Female; Fibrinolytic Agents; Heptanoic Acids; Humans; Male; Middle Aged; Models, Statistical; Patient Compliance; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Stroke; Tissue Plasminogen Activator | 2007 |
Comparative studies on hypocholesterolemic effect of different fractions of Hyphaene thebaica (Doum) in experimental animals.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Diet; Female; Fruit; Heptanoic Acids; Lipoproteins; Plant Extracts; Plants; Pyrroles; Rats; Rats, Sprague-Dawley; Triglycerides | 2006 |
Myocardial protection by pioglitazone, atorvastatin, and their combination: mechanisms and possible interactions.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Synergism; Drug Therapy, Combination; Gene Expression Regulation; Heptanoic Acids; Hypoglycemic Agents; Inositol Polyphosphate 5-Phosphatases; Male; Myocardial Infarction; Nitric Oxide Synthase Type III; Oncogene Protein v-akt; Phospholipases A; Phospholipases A2; Phosphoric Monoester Hydrolases; Phosphorylation; Pioglitazone; PTEN Phosphohydrolase; Pyrazoles; Pyrroles; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Thiazolidinediones | 2006 |
Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Aspirin; Atorvastatin; Azoxymethane; Carcinogens; Celecoxib; Cell Growth Processes; Colonic Neoplasms; Dose-Response Relationship, Drug; Heptanoic Acids; Male; Pyrazoles; Pyrroles; Rats; Rats, Inbred F344; Sulfonamides | 2006 |
Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Chromatography, Liquid; Dogs; Female; Heptanoic Acids; Immunoblotting; Lipase; Liver; Ovariectomy; Phospholipid Transfer Proteins; Phospholipids; Pyrroles; Scavenger Receptors, Class B; Triglycerides | 2006 |
Atorvastatin prevented and partially reversed adrenocorticotropic hormone-induced hypertension in the rat.
Topics: Adrenocorticotropic Hormone; Animals; Atorvastatin; Blood Pressure; Body Weight; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Nitric Oxide; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides | 2006 |
Atorvastatin prevents hypoxia-induced inhibition of endothelial nitric oxide synthase expression but does not affect heme oxygenase-1 in human microvascular endothelial cells.
Topics: Atherosclerosis; Atorvastatin; Blotting, Western; Cells, Cultured; Endothelium, Vascular; Gene Expression Regulation, Enzymologic; Heme Oxygenase-1; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoxia; Microcirculation; Nitric Oxide Synthase Type III; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Inhibitory effects of statins on human monocarboxylate transporter 4.
Topics: Animals; Atorvastatin; Basigin; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lactic Acid; LLC-PK1 Cells; Lovastatin; Monocarboxylic Acid Transporters; Muscle Proteins; Pyridines; Pyrroles; Simvastatin; Swine; Transfection | 2006 |
Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes.
Topics: Amino Acid Chloromethyl Ketones; Antibodies; Atorvastatin; Caspase 1; CD28 Antigens; CD3 Complex; Cells, Cultured; Enzyme Activation; Heptanoic Acids; Humans; Inflammation; Interferon-gamma; Interleukin-1; Interleukin-12; Interleukin-18; Mevalonic Acid; Mitosis; Monocytes; Pyrroles; Simvastatin; Solubility; T-Lymphocytes | 2006 |
Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism.
Topics: Administration, Oral; Animals; Antibiotics, Antitubercular; Atorvastatin; Biological Availability; Drug Interactions; Heptanoic Acids; Hydroxylation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intravenous; Intestinal Mucosa; Intestines; Liver; Male; Microsomes; Organic Anion Transporters; Pyrroles; Rats; Rats, Sprague-Dawley; Rifampin | 2006 |
[Time course of G-CSF, estrogen and various doses of atorvastatin on endothelial progenitor cells mobilization].
Topics: Animals; Atorvastatin; Endothelial Cells; Estrogens; Granulocyte Colony-Stimulating Factor; Heptanoic Acids; Hypolipidemic Agents; Lipids; Male; Nitric Oxide; Pyrroles; Rabbits; Recombinant Proteins; Stem Cells | 2006 |
MRI of combination treatment of embolic stroke in rat with rtPA and atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cerebrovascular Circulation; Data Interpretation, Statistical; Heptanoic Acids; Intracranial Embolism; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Male; Microcirculation; Microscopy, Fluorescence; Plasminogen Activators; Pyrroles; Rats; Rats, Wistar; Recombinant Proteins; Stroke | 2006 |
Atorvastatin may cause nightmares.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Night Terrors; Pyrroles | 2006 |
Short-term atorvastatin treatment does not modify neointimal morphology but reduces MMP-2 expression in normocholesterolemic rabbit stented arteries.
Topics: Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iliac Artery; Immunohistochemistry; Male; Matrix Metalloproteinase 2; Muscle, Smooth, Vascular; Pyrroles; Rabbits; Stents; Tissue Inhibitor of Metalloproteinase-2; Tunica Intima | 2006 |
Systemic infections can decrease the threshold of statin-induced muscle injury.
Topics: Acute Kidney Injury; Aged, 80 and over; Atorvastatin; Bacteremia; Enterococcus faecalis; Escherichia coli; Heart Valve Prosthesis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscular Diseases; Pyrroles | 2006 |
Atorvastatin and glatiramer acetate: new hope in MS?
Topics: Adjuvants, Immunologic; Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Disease Models, Animal; Drug Therapy, Combination; Glatiramer Acetate; Heptanoic Acids; Humans; Immunotherapy; Inflammation; Multiple Sclerosis; Peptides; Pyrroles | 2006 |
A comparative study on the antimutagenicity of atorvastatin and lovastatin against directly acting mutagens.
Topics: Anticarcinogenic Agents; Antimutagenic Agents; Atorvastatin; Carcinoma; Cell Line, Tumor; DNA Damage; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Lovastatin; Mutagenesis; Mutagenicity Tests; Mutagens; Mutation; Pyrroles; Salmonella; Salmonella typhimurium | 2006 |
Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Dose-Response Relationship, Drug; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Simvastatin | 2006 |
[Early effect of statins after myocardial infarction. A statin-induced pleiotropic effect?].
Topics: Atorvastatin; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Myocardial Infarction; Pyrroles | 2006 |
Concurrent use of clopidogrel (Plavix) and atorvasatin (Lipitor) is contraindicated.
Topics: Atorvastatin; Clopidogrel; Contraindications; Coronary Disease; Drug Incompatibility; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2006 |
Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients.
Topics: Adolescent; Adult; Aged; Atorvastatin; Child; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Male; Middle Aged; Models, Biological; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control.
Topics: 3T3 Cells; Adipocytes; Animals; Atorvastatin; Biological Transport; Blood Glucose; Cell Differentiation; Cellular Senescence; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Glucose Transporter Type 4; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Middle Aged; Obesity; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Chinese red rice depletes muscle coenzyme Q10 and maintains muscle damage after discontinuation of statin treatment.
Topics: Aged; Ascomycota; Atorvastatin; Biological Products; Coenzymes; Creatine Kinase; Dietary Supplements; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscle Weakness; Muscle, Skeletal; Pyrroles; Ubiquinone | 2006 |
A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Drug Evaluation; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Prospective Studies; Pyrroles; Treatment Outcome | 2006 |
Differential roles of MAP kinases in atorvastatin-induced VEGF release in cardiac myocytes.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blotting, Western; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flavonoids; Heptanoic Acids; Imidazoles; Mice; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Myocytes, Cardiac; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Pyrroles; Vascular Endothelial Growth Factor A | 2006 |
A case of cholesterol embolism confirmed by skin biopsy and successfully treated with statins and steroids.
Topics: Aged; Atorvastatin; Biopsy; Blue Toe Syndrome; Diagnosis, Differential; Embolism, Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prednisolone; Pyrroles; Simvastatin; Skin; Skin Diseases, Vascular; Steroids | 2006 |
Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis.
Topics: Adult; Aged; Atorvastatin; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Prospective Studies; Pyrroles; Scleroderma, Systemic | 2006 |
Preventing and repairing vascular damage in scleroderma: should we focus beyond vasodilatation to recruitment of endothelial precursor cells?
Topics: Arteries; Atorvastatin; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Scleroderma, Systemic; Vasodilation | 2006 |
Vascular endothelial growth factor mediates atorvastatin-induced mammalian achaete-scute homologue-1 gene expression and neuronal differentiation after stroke in retired breeder rats.
Topics: Analysis of Variance; Animals; Antibodies; Atorvastatin; Basic Helix-Loop-Helix Transcription Factors; Cell Differentiation; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Infarction, Middle Cerebral Artery; Male; Motor Activity; Neurons; Pyrroles; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tubulin; Vascular Endothelial Growth Factor A | 2006 |
Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucose Tolerance Test; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Retrospective Studies | 2006 |
Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cyclosporine; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Function Tests; Kidney Transplantation; Lipids; Male; Middle Aged; Pilot Projects; Pyrroles; Triglycerides | 2006 |
Differential effects of different statins on endothelin-1 gene expression and endothelial NOS phosphorylation in porcine aortic endothelial cells.
Topics: Animals; Aorta; Atorvastatin; Cells, Cultured; Endothelial Cells; Endothelin-1; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide Synthase Type III; Phosphorylation; Pravastatin; Pyridines; Pyrroles; Quinolines; RNA, Messenger; Swine | 2006 |
Endothelin-mediated vasoconstriction in early atherosclerosis is markedly increased in ApoE-/- mouse but prevented by atorvastatin.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Endothelins; Female; Heptanoic Acids; Homozygote; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrroles; Time Factors; Vasoconstriction | 2006 |
In vitro availability of atorvastatin in presence of losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Drug Interactions; Heptanoic Acids; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Models, Chemical; Pyrroles; Solubility; Spectrophotometry, Ultraviolet; Temperature; Time Factors | 2006 |
Effects of preoperative statin therapy on cytokines after cardiac surgery.
Topics: Aged; Anti-Inflammatory Agents; Atorvastatin; Cardiopulmonary Bypass; Coronary Artery Bypass; Female; Heart Arrest, Induced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-10; Interleukin-6; Male; Postoperative Complications; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors | 2006 |
High-dose statins and the IDEAL study.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2006 |
High-dose statins and the IDEAL study.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2006 |
High-dose statins and the IDEAL study.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2006 |
High-dose statins and the IDEAL study.
Topics: Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Simvastatin | 2006 |
Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Case-Control Studies; Creatine Kinase; Creatinine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genotype; Heptanoic Acids; Humans; Lactones; Liver; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Pyrroles | 2006 |
Atorvastatin protects against cerebral infarction via inhibition of NADPH oxidase-derived superoxide in ischemic stroke.
Topics: Animals; Atorvastatin; Cerebral Infarction; Disease Models, Animal; Heptanoic Acids; Male; NADPH Oxidases; Neuroprotective Agents; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides; Time Factors | 2006 |
Atorvastatin increases intestinal cholesterol absorption in dogs.
Topics: Animals; Atorvastatin; Carrier Proteins; Cholesterol; Dogs; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Pyrroles | 2006 |
Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anticholesteremic Agents; Atorvastatin; Cell Membrane; Central Nervous System; Cholesterol; Ergosterol; Heptanoic Acids; Lovastatin; Male; Mice; Peptide Fragments; Pyrroles; Simvastatin; Synaptosomes | 2006 |
Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Meta-Analysis as Topic; Pravastatin; Pyrroles; Risk Factors; Simvastatin; Spain | 2006 |
Quinine-induced renal failure as a result of rhabdomyolysis, haemolytic uraemic syndrome and disseminated intravascular coagulation.
Topics: Acute Kidney Injury; Anticholesteremic Agents; Atorvastatin; Disseminated Intravascular Coagulation; Drug Synergism; Female; Hemolytic-Uremic Syndrome; Heptanoic Acids; Humans; Middle Aged; Muscle Relaxants, Central; Pyrroles; Quinine; Rhabdomyolysis; Sleep-Wake Transition Disorders | 2006 |
Rapid analysis of atorvastatin calcium using capillary electrophoresis and microchip electrophoresis.
Topics: Atorvastatin; Electrophoresis, Capillary; Electrophoresis, Microchip; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Tablets | 2006 |
Association of statin therapy and increased survival in patients with multiple organ dysfunction syndrome.
Topics: Atorvastatin; Cohort Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multiple Organ Failure; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin; Survival Rate | 2006 |
Drug and medical cost effects of a drug formulary change with therapeutic interchange for statin drugs in a multistate managed Medicaid organization.
Topics: Acyl Coenzyme A; Atorvastatin; Drug Costs; Dyslipidemias; Female; Formularies as Topic; Health Expenditures; Heptanoic Acids; Humans; Insurance Claim Review; Male; Managed Care Programs; Medicaid; Middle Aged; Pyrroles; Retrospective Studies; Therapeutic Equivalency | 2006 |
Influence of HMG-CoA-reductase inhibitors on the body fat status.
Topics: Adipose Tissue; Aged; Arterial Occlusive Diseases; Atorvastatin; Body Composition; Body Mass Index; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Simvastatin | 2006 |
[Effect of atorvastatin on Fas (CD95/Apo-1) expression in normal or ischemic brain].
Topics: Animals; Apoptosis; Atorvastatin; Brain Ischemia; fas Receptor; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neuroprotective Agents; Pyrroles; Rats; Rats, Sprague-Dawley | 2006 |
Severe hepatic side effects of ezetimibe.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Liver Diseases; Male; Middle Aged; Pyrroles; Transaminases | 2006 |
Comment on 'Effect of atorvastatin on SR-BI expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits' by Zhao et al. (Clin Chim Acta 2006; 365: 119-24).
Topics: Adipocytes; Animals; Anticholesteremic Agents; Atorvastatin; CD36 Antigens; Cholesterol; Gene Expression Regulation; Heptanoic Acids; Hypercholesterolemia; Lipoproteins, HDL; Pyrroles; Rabbits; RNA, Messenger | 2006 |
Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia.
Topics: Adult; Aged; Aged, 80 and over; Animals; Annexins; Anticholesteremic Agents; Atorvastatin; Biomarkers; Calcium Channels, L-Type; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Microscopy, Electron; Middle Aged; Muscle Fibers, Skeletal; Muscle, Skeletal; Pravastatin; Pyrroles; Receptors, LDL; Simvastatin | 2006 |
[Regression of a large lipid-rich pool in the coronary artery during treatment with statin detected by intravascular ultrasound: a case report].
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Disease; Coronary Vessels; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pyrroles; Stents; Ultrasonography, Interventional | 2006 |
Profound regression of coronary atherosclerosis with statins.
Topics: Atorvastatin; Cholesterol; Coronary Angiography; Coronary Artery Disease; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2006 |
Effects of atorvastatin and apoA-I/phosphatidylcholine discs on triglyceride-rich lipoprotein subfractions as characterized by capillary isotachophoresis.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein E2; Atorvastatin; Electrophoresis, Capillary; Heptanoic Acids; Humans; Hyperlipoproteinemia Type III; Lipoproteins; Macromolecular Substances; Male; Phenotype; Phosphatidylcholines; Pyrroles; Sensitivity and Specificity; Time Factors; Triglycerides | 2006 |
Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cytokines; Dose-Response Relationship, Drug; Endarterectomy, Carotid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Macrophages; Peptide Hydrolases; Phenotype; Pravastatin; Pyrroles; Retrospective Studies; Simvastatin | 2006 |
Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin.
Topics: Aged; Aorta; Atorvastatin; Carotid Artery Diseases; Cells, Cultured; Chemokine CCL2; Cytokine TWEAK; Cytokines; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Intracranial Arteriosclerosis; Male; Mevalonic Acid; Middle Aged; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Polyisoprenyl Phosphates; Pyrroles; Receptors, Tumor Necrosis Factor; Recombinant Proteins; rho GTP-Binding Proteins; Tumor Necrosis Factors; TWEAK Receptor; Up-Regulation | 2006 |
High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Brain; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2006 |
[Cost-effectiveness analysis of the use of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic model of the CARDS study].
Topics: Adult; Aged; Atorvastatin; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrroles; Retrospective Studies | 2006 |
Atorvastatin reduces tissue factor expression in adipose tissue of atherosclerotic rabbits.
Topics: Animals; Atherosclerosis; Atorvastatin; Heptanoic Acids; Male; Pyrroles; Rabbits; Subcutaneous Fat; Thromboplastin | 2007 |
Atorvastatin prevented and reversed dexamethasone-induced hypertension in the rat.
Topics: Analysis of Variance; Animals; Atorvastatin; Biomarkers; Blood Pressure; Body Weight; Dexamethasone; Disease Models, Animal; Down-Regulation; Glucocorticoids; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Nitrates; Nitric Oxide Synthase Type III; Nitrites; Organ Size; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides; Thymus Gland | 2006 |
High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adenosine Diphosphate; Angiostatins; Animals; Apoptosis; Apoptosis Inducing Factor; Arterioles; Atorvastatin; Caspase 3; Caspases; Cholesterol; Coronary Circulation; Coronary Vessels; Drug Evaluation, Preclinical; Endostatins; Endothelium, Vascular; Female; Fibroblast Growth Factor 2; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Matrix Metalloproteinase 9; Myocardial Ischemia; Neovascularization, Physiologic; Nitric Oxide; Nitric Oxide Synthase Type III; Nitroprusside; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Receptor, TIE-2; Swine; Swine, Miniature; Vascular Endothelial Growth Factor A; Vasodilation | 2006 |
Role of human valve interstitial cells in valve calcification and their response to atorvastatin.
Topics: Aged; Alkaline Phosphatase; Aortic Valve; Aortic Valve Stenosis; Atorvastatin; Bone Morphogenetic Protein 2; Bone Morphogenetic Protein 4; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Calcinosis; Cell Differentiation; Cells, Cultured; Connective Tissue Cells; Culture Media; Fibrosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Osteoblasts; Osteocalcin; Pyrroles; Transforming Growth Factor beta; Transforming Growth Factor beta1; Transforming Growth Factor beta3 | 2006 |
A novel role of extracellular nucleotides in valve calcification: a potential target for atorvastatin.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Triphosphatases; Adenosine Triphosphate; Aged; Alkaline Phosphatase; Aortic Valve; Aortic Valve Stenosis; Apyrase; Atorvastatin; Biomarkers; Calcinosis; Cell Differentiation; Cells, Cultured; Drug Evaluation, Preclinical; Heptanoic Acids; Humans; Middle Aged; Osteoblasts; Pyrroles; Receptors, Purinergic P2; Second Messenger Systems | 2006 |
Persistence and adherence to cholesterol lowering agents: evidence from Régie de l'Assurance Maladie du Québec data.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Pyrroles; Quebec; Registries; Retrospective Studies; Simvastatin | 2006 |
Single coronary artery with retroaortic course. An unusual origin of right Valsalva sinus.
Topics: Adult; Aspirin; Atorvastatin; Chest Pain; Coronary Vessel Anomalies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pyrroles; Radiography; Sinus of Valsalva; Vasodilator Agents; Verapamil | 2006 |
Intracellular retention of hepatic serpins caused by severe hyperlipidemia.
Topics: Animals; Antithrombins; Atorvastatin; Chickens; Dietary Fats; Disease Models, Animal; Factor Xa Inhibitors; Fatty Liver; Heparin Cofactor II; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Intracellular Fluid; Lipid Metabolism; Lipids; Liver; Male; Pyrroles; Serpins | 2006 |
Atorvastatin inhibits angiotensin II-induced T-type Ca2+ channel expression in endothelial cells.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Calcium Channels, T-Type; Cells, Cultured; Endothelial Cells; Flavonoids; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Microscopy, Fluorescence; Pyrroles; ras Proteins; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tetrazoles; Vasoconstrictor Agents | 2006 |
Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Topics: Adenomatous Polyposis Coli; Animals; Anticarcinogenic Agents; Apoptosis; Atorvastatin; Caspase 3; Caspases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Poly(ADP-ribose) Polymerases; Pyrazoles; Pyrroles; Sulfonamides | 2006 |
[High lowering of lipids can melt coronary plaques -- is coronary disease reversible?].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Coronary Vessels; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Placebos; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2006 |
[For coronary disease patients is certain: the lower the LDL the better].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Controlled Clinical Trials as Topic; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Odds Ratio; Pravastatin; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 2006 |
[After TIA and stroke: a statin for secondary prevention?].
Topics: Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Placebos; Pyrroles; Recurrence; Stroke; Time Factors | 2006 |
Effect of atorvastatin on plasma osteopontin levels in patients with hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Osteopontin; Pyrroles; Sialoglycoproteins | 2006 |
Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Atorvastatin; CD55 Antigens; CD59 Antigens; Cells, Cultured; Cobalt; Cytoprotection; Deferoxamine; Diterpenes; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia; Iron Chelating Agents; Mevalonic Acid; Pyrroles; RNA, Messenger; Up-Regulation | 2006 |
Concurrent use of clopidogrel (Plavix) and atorvastatin (Lipitor) is contraindicated.
Topics: Atorvastatin; Clopidogrel; Contraindications; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Antagonism; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2006 |
By the way, doctor. Pomegranate juice is supposed to be a health food, but I've heard that it can interfere with some medications, the way grapefruit juice can. I take Lipitor and wonder if I should be concerned.
Topics: Anticholesteremic Agents; Atorvastatin; Beverages; Cytochrome P-450 CYP3A Inhibitors; Female; Food-Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lythraceae; Pyrroles | 2006 |
Golf-inhibiting gynecomastia associated with atorvastatin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Golf; Gynecomastia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leisure Activities; Male; Middle Aged; Pyrroles | 2006 |
Atorvastatin inhibits inflammatory hypernociception.
Topics: Animals; Atorvastatin; Bradykinin; Cholesterol; Cytokines; Dinoprostone; Enzyme Inhibitors; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperalgesia; Inflammation; Interleukin-1; Lipopolysaccharides; Male; Mice; Nitric Oxide Synthase; Pain Measurement; Pyrroles; Skin | 2006 |
Clopidogrel-statin interaction: a mountain or a mole hill?
Topics: Atorvastatin; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Ticlopidine | 2006 |
A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Heptanoic Acids; Humans; Logistic Models; Male; Middle Aged; Pharmacoepidemiology; Platelet Aggregation Inhibitors; Pyrroles; Quebec; Retrospective Studies; Stents; Ticlopidine | 2006 |
Letter by Schmermund and Erbel regarding article, "Coronary artery calcium: should we rely on this surrogate marker?".
Topics: Anticholesteremic Agents; Atorvastatin; Calcinosis; Calcium; Coronary Artery Disease; Coronary Vessels; Disease Progression; Heptanoic Acids; Humans; Predictive Value of Tests; Prognosis; Pyrroles; Risk Factors | 2006 |
Tubulointerstitial macrophage accumulation is regulated by sequentially expressed osteopontin and macrophage colony-stimulating factor: implication for the role of atorvastatin.
Topics: Animals; Atorvastatin; Cell Proliferation; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Kidney Tubules; Lipids; Macrophage Colony-Stimulating Factor; Macrophages; Osteopontin; Pyrroles; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902.
Topics: Anemia; Atorvastatin; Cardiology; Clinical Trials as Topic; Congresses as Topic; Darbepoetin alfa; Diuretics; Erythropoietin; Europe; Exercise Tolerance; Ferric Compounds; Ferric Oxide, Saccharated; Glucaric Acid; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Societies, Medical; Xanthines | 2006 |
Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2006 |
Stroke--an equal opportunity for the initiation of statin therapy.
Topics: Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Secondary Prevention; Stroke | 2006 |
Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis.
Topics: Albuminuria; Analysis of Variance; Animals; Atorvastatin; Blood Pressure; Caveolin 1; Glomerular Filtration Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Diseases; Kidney Glomerulus; Male; Models, Animal; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pyrroles; Rats; Rats, Wistar; rhoA GTP-Binding Protein; Vascular Endothelial Growth Factor A | 2006 |
Pleiotropic effects of statins and early benefit in the PROVE IT-TIMI-22 study.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Endpoint Determination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrroles; Reproducibility of Results | 2006 |
Growth inhibition of Candida species and Aspergillus fumigatus by statins.
Topics: Antifungal Agents; Aspergillus fumigatus; Atorvastatin; Candida; Cholesterol; Ergosterol; Growth Inhibitors; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Pyrroles; Simvastatin | 2006 |
Augmentation of myocardial production of 15-epi-lipoxin-a4 by pioglitazone and atorvastatin in the rat.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Heart; Heptanoic Acids; Lipoxins; Models, Animal; Myocardium; Pioglitazone; Pyrroles; Rats; Thiazolidinediones | 2006 |
The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipids; Male; Middle Aged; Pyrroles; Time Factors; Tunica Intima; Tunica Media | 2006 |
Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Blood Coagulation; Coronary Disease; Female; Fibrinogen; Follow-Up Studies; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2006 |
High-dose statins for diabetes.
Topics: Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2006 |
The HMG-CoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-beta1-42 in the rat hippocampus in vivo.
Topics: Amyloid beta-Peptides; Analysis of Variance; Animals; Atorvastatin; B7-2 Antigen; Cytokines; Drug Administration Schedule; Drug Interactions; Gene Expression Regulation; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Interleukin-4; Long-Term Potentiation; Male; Peptide Fragments; Pyrroles; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2007 |
Statin therapy for patients with chronic heart failure.
Topics: Atorvastatin; Cholesterol; Diastole; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Outcome; Ventricular Function, Left | 2006 |
UV-B phototoxic effects induced by atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Dermatitis, Phototoxic; Diagnosis, Differential; Female; Heptanoic Acids; Humans; Middle Aged; Pyrroles; Sezary Syndrome; Skin Neoplasms; Skin Tests; Ultraviolet Rays | 2006 |
Validated HPLC-MS-MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma-pharmacokinetic study.
Topics: Anticholesteremic Agents; Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2006 |
Influence of atorvastatin treatment on L-arginine cerebrovascular reactivity and flow-mediated dilatation in patients with lacunar infarctions.
Topics: Aged; Anticholesteremic Agents; Arginine; Atorvastatin; Blood Pressure; Carbon Dioxide; Cerebral Infarction; Cerebrovascular Circulation; Comorbidity; Endothelium, Vascular; Female; Follow-Up Studies; Heart Rate; Hemorheology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Single-Blind Method; Ultrasonography, Doppler, Transcranial; Vasodilation; Vasodilator Agents | 2006 |
Statins and cerebral vasomotor reactivity: implications for a new therapy?
Topics: Adult; Animals; Arginine; Atorvastatin; Brain Ischemia; Cerebrovascular Circulation; Clinical Trials, Phase II as Topic; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Intracranial Aneurysm; Mice; Middle Cerebral Artery; Nitric Oxide; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Simvastatin; Stroke; Subarachnoid Hemorrhage; Ultrasonography, Doppler, Transcranial; Vasodilation; Vasomotor System; Vasospasm, Intracranial | 2006 |
Does statin therapy improve cardiovascular outcomes in patients with type 2 diabetes receiving hemodialysis?
Topics: Atorvastatin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Dialysis | 2006 |
Atorvastatin has no beneficial effect on cardiovascular outcomes in patients with advanced chronic kidney disease.
Topics: Atorvastatin; Cardiovascular Diseases; Chronic Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Pyrroles; Randomized Controlled Trials as Topic; Treatment Failure | 2006 |
Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer.
Topics: Aged; Atorvastatin; Biopsy; Brachytherapy; Cause of Death; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; Fatty Acids, Monounsaturated; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Neoplasm Staging; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Retrospective Studies; Simvastatin; Survival Analysis | 2006 |
Autoimmune hepatitis triggered by statins.
Topics: Atorvastatin; Female; Hepatitis, Autoimmune; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Simvastatin | 2006 |
[HIV infection: from Pneumocystis to statins].
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pneumocystis Infections; Pyrroles; Risk Factors | 2006 |
Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin.
Topics: Administration, Oral; Animals; Atorvastatin; Biological Availability; Chemistry, Pharmaceutical; Dogs; Drug Delivery Systems; Drug Stability; Emulsions; Excipients; Glycerides; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microscopy, Electron, Transmission; Normal Distribution; Particle Size; Phase Transition; Polyethylene Glycols; Propylene Glycol; Pyrroles; Solubility; Surface-Active Agents; Tablets | 2006 |
[Do statins have benefit on migraine].
Topics: Adult; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Migraine Disorders; Pyrroles | 2006 |
Herbicidal effects of statin pharmaceuticals in Lemna gibba.
Topics: Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Herbicides; Hydroxymethylglutaryl CoA Reductases; Lovastatin; Mevalonic Acid; Models, Chemical; Pharmaceutical Preparations; Plants; Plastoquinone; Pyrroles; Risk Assessment; Sitosterols; Sterols; Ubiquinone; Ultraviolet Rays | 2006 |
Plant sterol or stanol esters retard lesion formation in LDL receptor-deficient mice independent of changes in serum plant sterols.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Artery Disease; Female; Heptanoic Acids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Phytosterols; Pyrroles; Receptors, LDL; Sitosterols | 2006 |
Atorvastatin has distinct effects on endothelial markers in different mouse models of atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Biomarkers; Diet, Atherogenic; Endothelium, Vascular; Heptanoic Acids; Intercellular Adhesion Molecule-1; Lipid Metabolism; Lipoproteins; Male; Mice; Mice, Inbred C57BL; Pyrroles; Vascular Cell Adhesion Molecule-1 | 2006 |
Re-elevation of high-sensitivity C-reactive protein but not the von Willebrand Factor after withdrawing atorvastatin therapy in patients with unstable angina undergoing coronary artery stenting.
Topics: Angina, Unstable; Atorvastatin; Biomarkers; C-Reactive Protein; Coronary Angiography; Coronary Artery Bypass; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoenzyme Techniques; Male; Middle Aged; Nephelometry and Turbidimetry; Prognosis; Pyrroles; Retrospective Studies; Severity of Illness Index; Stents; Time Factors; von Willebrand Factor | 2006 |
Does the metabolic syndrome help to select patients requiring high statin dose?
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Diabetes Complications; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Incidence; Metabolic Syndrome; Patient Selection; Pyrroles; Risk Assessment; Risk Factors | 2006 |
A pharmacogenomic study of atorvastatin effects on eNOS activity: do "statins" modulate blood nitrite levels and intravascular oxidant stress in susceptible individuals?
Topics: Animals; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide Synthase Type III; Nitrites; Oxidative Stress; Pyrroles | 2006 |
Media report of rare rhabdomyolysis cases seems to have triggered reluctance among some New Zealanders to use statins.
Topics: Anticholesteremic Agents; Atorvastatin; Health Education; Health Knowledge, Attitudes, Practice; Heptanoic Acids; Humans; Hypercholesterolemia; Mass Media; New Zealand; Pyrroles; Rhabdomyolysis; Simvastatin | 2006 |
Atorvastatin for stroke prevention.
Topics: Atorvastatin; Cerebral Hemorrhage, Traumatic; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Muscular Diseases; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides; Time Factors | 2006 |
Atorvastatin in nonischemic left ventricular systolic dysfunction.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Systole; Ventricular Dysfunction, Left | 2006 |
Letter by Romanens and Miserez regarding article, "Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial".
Topics: Anticholesteremic Agents; Atorvastatin; Calcinosis; Coronary Artery Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sample Size | 2006 |
Effects of hydroxysterols and atorvastatin on lipopolysaccharide-induced secretion of tumor necrosis factor and interleukin-10 by mouse macrophages.
Topics: Animals; Atorvastatin; Cholesterol; Heptanoic Acids; In Vitro Techniques; Inflammation Mediators; Interleukin-10; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; Pyrroles; Sterols; Tumor Necrosis Factor-alpha | 2006 |
More on switching statins: comments from Pfizer.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Simvastatin | 2006 |
Down-regulation of ABCB1 transporter by atorvastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Primers; Down-Regulation; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Monocytes; Organic Anion Transporters; Pyrroles; Rhodamine 123; RNA, Messenger | 2006 |
Usefulness of follow-up low-density lipoprotein cholesterol level as an independent predictor of changes of coronary atherosclerotic plaque size as determined by intravascular ultrasound analysis after statin (atorvastatin or simvastatin) therapy.
Topics: Atorvastatin; Cholesterol; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Databases as Topic; Elastic Tissue; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Pyrroles; Simvastatin; Tunica Media; Ultrasonography, Interventional | 2006 |
Effect of atorvastatin on antibody, interleukin-4 and gamma-interferon production in mice immunized with egg albumin.
Topics: Albumins; Animals; Antibody Formation; Atorvastatin; Dose-Response Relationship, Drug; Egg White; Electrophoresis, Agar Gel; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization Schedule; Interferon-gamma; Interleukin-4; Mice; Mice, Inbred BALB C; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic | 2006 |
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluati
Topics: Aged; Atorvastatin; Coronary Disease; Cost-Benefit Analysis; Creatinine; Female; Glomerular Filtration Rate; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Uric Acid | 2007 |
Statins induce differentiation and cell death in neurons and astroglia.
Topics: Animals; Animals, Newborn; Apoptosis; Astrocytes; Atorvastatin; Cell Communication; Cell Differentiation; Cell Shape; Cell Survival; Cells, Cultured; Central Nervous System; Cholesterol; Coculture Techniques; Diterpenes; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Neurons; Polyisoprenyl Phosphates; Pyrroles; Rats; Rats, Wistar; Receptors, LDL; Simvastatin; Up-Regulation | 2007 |
A stability-indicating high performance liquid chromatographic (HPLC) assay for the simultaneous determination of atorvastatin and amlodipine in commercial tablets.
Topics: Amlodipine; Atorvastatin; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tablets | 2007 |
Effect of atorvastatin on soluble CD14, CD40 Ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: relationship to cholesterol turnover.
Topics: Atorvastatin; CD40 Antigens; Chemokine CCL2; Cholesterol; Diabetes Mellitus, Type 2; E-Selectin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligands; Lipid Metabolism; Lipopolysaccharide Receptors; Male; Middle Aged; P-Selectin; Pyrroles | 2006 |
Arterial stiffness and Chlamydia pneumoniae infection in coronary artery disease. Is there a link?
Topics: Adult; Aged; Arteries; Atorvastatin; Chlamydia Infections; Chlamydophila pneumoniae; Constriction, Pathologic; Coronary Artery Disease; Diabetes Mellitus; Double-Blind Method; Female; Heptanoic Acids; Humans; Immunoglobulin A; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Smoking; Vascular Resistance | 2006 |
Toxicity of statins on rat skeletal muscle mitochondria.
Topics: Animals; Apoptosis; Atorvastatin; Cytochromes c; DNA Fragmentation; Fatty Acids; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Membrane Potentials; Mitochondria, Muscle; Mitochondrial Membranes; Muscle, Skeletal; Oxygen; Pravastatin; Pyridines; Pyrroles; Rats; Simvastatin | 2006 |
Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study.
Topics: Action Potentials; Animals; Aquaporin 4; Atorvastatin; Body Weight; Chloride Channels; Dose-Response Relationship, Drug; Eating; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Diseases; Lipids; Male; Membrane Potentials; Muscle Contraction; Muscle Fibers, Fast-Twitch; Muscle, Skeletal; Muscular Diseases; Myosin Heavy Chains; Organ Size; Pyrroles; Rats; Rats, Wistar; Rhabdomyolysis; Time Factors | 2006 |
Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.
Topics: Animals; Antioxidants; Aorta; Atorvastatin; Dexamethasone; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Hypertension; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; RNA, Messenger; Vasoconstriction; Vasodilation | 2006 |
Atorvastatine for chronic synovitis due to massive intra-articular cholesterol monohydrate deposition in long-standing rheumatoid arthritis.
Topics: Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Cholesterol; Crystallization; Female; Heptanoic Acids; Humans; Middle Aged; Pyrroles; Synovitis | 2006 |
Lectin-like oxidized-LDL receptor-1 (LOX-1) polymorphisms influence cardiovascular events rate during statin treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Drug Resistance; Female; Heptanoic Acids; Heterozygote; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Retrospective Studies; Risk Factors; Scavenger Receptors, Class E; Simvastatin; Thrombosis | 2007 |
Gender difference of atorvastatin's vasoprotective effect in balloon-injured rat carotid arteries.
Topics: Animals; Atorvastatin; Carotid Artery Injuries; Catheterization; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; NADPH Oxidases; Orchiectomy; Ovariectomy; Pyrroles; Rats; Rats, Sprague-Dawley; Sex Characteristics; Superoxides | 2006 |
Effect of statins on preventing recurrence of atrial fibrillation after electrical cardioversion.
Topics: Anti-Arrhythmia Agents; Atorvastatin; Atrial Fibrillation; Combined Modality Therapy; Electric Countershock; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Secondary Prevention | 2006 |
The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Topics: Adult; Aged; Analysis of Variance; Apolipoprotein A-I; Apolipoproteins B; Apolipoproteins E; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Fenofibrate; Gene Frequency; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Treatment Outcome; Triglycerides | 2006 |
Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
Topics: Atorvastatin; Australia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Rhabdomyolysis; Risk Factors; Simvastatin | 2006 |
Stimulatory effects of atorvastatin on extracellular nucleotide degradation in human endothelial cells.
Topics: 5'-Nucleotidase; Adenosine; Adenosine Triphosphate; Atorvastatin; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nucleotides; Pyrroles | 2006 |
Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN): response to
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Pyrroles | 2006 |
Fake drugs: a problem for all.
Topics: Atorvastatin; Drug Industry; Drug-Related Side Effects and Adverse Reactions; Fraud; Heptanoic Acids; Humans; Pyrroles | 2006 |
Statin treatment upregulates vascular neuronal nitric oxide synthase through Akt/NF-kappaB pathway.
Topics: Angiotensin II; Animals; Atorvastatin; Cells, Cultured; Endothelin-1; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mevalonic Acid; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oncogene Protein v-akt; Pyrroles; Rats; Rats, Sprague-Dawley; Up-Regulation | 2007 |
Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Enzyme Activation; Female; G(M1) Ganglioside; Heptanoic Acids; Humans; Intracellular Fluid; Kinetics; Lupus Erythematosus, Systemic; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Male; Membrane Microdomains; Middle Aged; Protein Prenylation; Pyrroles; Receptors, Antigen, T-Cell; Signal Transduction; T-Lymphocyte Subsets | 2006 |
Evaluation of lipid-lowering therapy and cholesterol goal attainment in Finland: the National FINRISK Study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cohort Studies; Coronary Disease; Female; Finland; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Surveys and Questionnaires; Treatment Outcome | 2006 |
Atorvastatin slows down the deterioration of inner ear function with age in mice.
Topics: Acoustic Stimulation; Aging; Animals; Apolipoproteins E; Atorvastatin; Auditory Threshold; Dose-Response Relationship, Radiation; Ear, Inner; Food, Formulated; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Mice; Mice, Inbred C57BL; Mice, Knockout; Otoacoustic Emissions, Spontaneous; Presbycusis; Pyrroles; Receptors, Vasopressin; Time Factors | 2007 |
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE.
Topics: Animals; Atorvastatin; Encephalomyelitis, Autoimmune, Experimental; Flow Cytometry; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes; Lymph Nodes; Male; Mice; Multiple Sclerosis; Myelin Proteolipid Protein; Oligonucleotide Array Sequence Analysis; Peptide Fragments; Pyrroles; Spinal Cord | 2006 |
Differential effects of statins and alendronate on cholinesterases in serum and brain of rats.
Topics: Alendronate; Animals; Atorvastatin; Bone Density Conservation Agents; Brain; Butyrylcholinesterase; Cholinesterases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2007 |
Atorvastatin interferes with activation of human CD4(+) T cells via inhibition of small guanosine triphosphatase (GTPase) activity and caspase-independent apoptosis.
Topics: Apoptosis; Atorvastatin; Blotting, Western; Caspases; CD4-Positive T-Lymphocytes; Cell Cycle; Cell Proliferation; Cytokines; Dose-Response Relationship, Immunologic; Enzyme Activation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-2 Receptor alpha Subunit; Lymphocyte Activation; Monomeric GTP-Binding Proteins; Pyrroles | 2006 |
The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.
Topics: Acetylcholine; Animals; Apoptosis; Atorvastatin; Caspase 3; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Nitric Oxide Synthase Type III; Nitroprusside; Pravastatin; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar; Ventricular Pressure | 2006 |
Possible role of exogenous cAMP to improve vascular endothelial dysfunction in hypertensive rats.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Aorta; Atorvastatin; Blood Pressure; Cyclic AMP; Drug Administration Schedule; Endothelium, Vascular; Heptanoic Acids; Hypertension; Male; NADPH Oxidases; Nitrates; Nitric Oxide Synthase Type III; Nitrites; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides; Thiobarbituric Acid Reactive Substances; Vasodilation | 2006 |
Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cost-Benefit Analysis; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Patterns, Physicians'; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2006 |
Impact of high dose statin trials on hospital prescribers.
Topics: Aged; Atorvastatin; Cohort Studies; Coronary Disease; Databases, Factual; Drug Prescriptions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ireland; Patient Discharge; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic | 2007 |
Statin treatment, reduced T-cell content of atherosclerotic plaques and cancer.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Heptanoic Acids; Humans; Immunity, Cellular; Neoplasms; Pyrroles; T-Lymphocytes | 2006 |
Statins activate AMP-activated protein kinase in vitro and in vivo.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Atorvastatin; Cells, Cultured; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multienzyme Complexes; Neovascularization, Physiologic; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Protein Serine-Threonine Kinases; Pyrroles | 2006 |
Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Carcinoma, Hepatocellular; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; Etoposide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Morpholines; Phosphorylation; Pravastatin; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2006 |
Bezoar formation requiring endoscopic removal after intentional overdose of extended-release nifedipine.
Topics: Anticholesteremic Agents; Antidepressive Agents; Atorvastatin; Bezoars; Calcium Channel Blockers; Cyclohexanols; Delayed-Action Preparations; Drug Overdose; Endoscopy, Digestive System; Fatal Outcome; Female; Heptanoic Acids; Humans; Middle Aged; Nifedipine; Pyrroles; Radiography; Sertraline; Stomach; Venlafaxine Hydrochloride | 2006 |
Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9.
Topics: Acute Disease; Analysis of Variance; Animals; Atorvastatin; Disease Models, Animal; Drug Evaluation, Preclinical; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Injections, Intravenous; Luminescence; Lung; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Microspheres; Nitrates; Nitrites; Proportional Hazards Models; Pulmonary Embolism; Pulmonary Wedge Pressure; Pyrroles; Random Allocation; Rats; Rats, Wistar; Survival Rate | 2007 |
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Atorvastatin; Azepines; Captopril; Cardiovascular Agents; Central Nervous System Agents; Chemical and Drug Induced Liver Injury; Chronic Disease; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Heptanoic Acids; Humans; Liver; Liver Diseases; Male; Middle Aged; Pyrroles; Registries; Spain | 2006 |
Clinical characteristics and outcomes of Chinese patients with cholesterol crystal embolism after coronary intervention.
Topics: Acute Kidney Injury; Aged; Angioplasty, Balloon, Coronary; Arteriosclerosis; Atorvastatin; China; Coronary Angiography; Embolism, Cholesterol; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Prognosis; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Treatment Outcome | 2006 |
Statin therapy after stroke or transient ischemic attack.
Topics: Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors; Stroke; Transaminases | 2006 |
Statin therapy after stroke or transient ischemic attack.
Topics: Atorvastatin; Conflict of Interest; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Research Design; Risk; Secondary Prevention; Stroke | 2006 |
Statin therapy after stroke or transient ischemic attack.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Secondary Prevention; Severity of Illness Index; Stroke | 2006 |
Statin therapy after stroke or transient ischemic attack.
Topics: Atorvastatin; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk; Secondary Prevention; Stroke | 2006 |
Statin therapy after stroke or transient ischemic attack.
Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mortality; Pyrroles; Stroke; Survival Analysis | 2006 |
High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Coronary Vessels; Female; Heptanoic Acids; Hypercholesterolemia; Male; Neovascularization, Physiologic; Pyrroles; Swine; Swine, Miniature; Vascular Endothelial Growth Factor A | 2006 |
[Effects of atorvastatin in N-terminal pro-brain natriuretic peptide plasma levels in hypercholesterolemic patients with or without hypertension].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Pyrroles | 2006 |
[Effectiveness of atorvastatin compared to other statins of usual clinical practice in primary care].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Primary Health Care; Pyrroles; Retrospective Studies; Treatment Outcome | 2006 |
Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Rhabdomyolysis; Risk Factors; Simvastatin | 2006 |
The effect of early statin treatment on inflammation and cardiac events in acute coronary syndrome patients with low-density lipoprotein cholesterol.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Inflammation; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrroles; Serum Amyloid A Protein; Statistics as Topic; Syndrome; Treatment Outcome; Triglycerides | 2006 |
Effect of clopidogrel on the inflammatory progression of early atherosclerosis in rabbits model.
Topics: Animals; Aspirin; Atherosclerosis; Atorvastatin; Chemokine CCL2; Clopidogrel; Diet, Atherogenic; Disease Models, Animal; Femoral Artery; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Intercellular Adhesion Molecule-1; Male; P-Selectin; Platelet Aggregation Inhibitors; Pyrroles; Rabbits; Ticlopidine; Vascular Cell Adhesion Molecule-1 | 2007 |
Atorvastatin inhibits angiotensin-converting enzyme induction in differentiating human macrophages.
Topics: Adolescent; Adult; Aged; Atorvastatin; Cell Differentiation; Enzyme Induction; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Macrophages; Mevalonic Acid; Middle Aged; Peptidyl-Dipeptidase A; Phosphorylation; Polyisoprenyl Phosphates; Protein Kinase C; Pyrroles; RNA, Messenger; Sesquiterpenes; Terpenes; Up-Regulation | 2007 |
Cholesterol: the good, the bad, and the stopped trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Clinical Trials, Phase III as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Quinolines; Treatment Failure | 2006 |
The MEGA study.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2006 |
Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization.
Topics: Angioplasty, Balloon, Coronary; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Biopsy, Needle; Cells, Cultured; Chemokine CCL19; Chemokine CCL21; Chemokines, CC; Coronary Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Gene Expression Regulation; Heptanoic Acids; Humans; Immunohistochemistry; In Vitro Techniques; Leukocytes, Mononuclear; Mice; Mice, Transgenic; Prognosis; Pyrroles; Receptors, CCR7; Receptors, Chemokine; Reference Values; Risk Factors; RNA, Messenger; Sensitivity and Specificity; Simvastatin; Treatment Outcome | 2007 |
Atorvastatin therapy associated with improvement in left ventricular remodeling in a case of idiopathic dilated cardiomyopathy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cardiomyopathy, Dilated; Cardiovascular Agents; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles; Ventricular Remodeling | 2006 |
Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart.
Topics: Aged; Animals; Anticholesteremic Agents; Atorvastatin; Biological Transport; Dogs; Estrone; Female; Heart; Heptanoic Acids; Humans; Liver; Male; Myocardium; Organic Anion Transporters; Pyrroles; RNA, Ribosomal; Transfection | 2006 |
Tolerizing DNA vaccines for autoimmune arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Atorvastatin; Autoantibodies; Collagen; Cytokines; Heptanoic Acids; Hindlimb; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-4; Joints; Male; Mice; Mice, Inbred DBA; Protein Array Analysis; Pyrroles; Systems Biology; Vaccines, DNA | 2006 |
Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase blunts factor VIIa/tissue factor and prothrombinase activities via effects on membrane phosphatidylserine.
Topics: Animals; Atorvastatin; Blotting, Western; Cattle; Cells, Cultured; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Factor VIIa; Fibroblasts; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Phosphatidylserines; Pyrroles; Sensitivity and Specificity; Thromboplastin | 2007 |
Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes.
Topics: Adiponectin; Adipose Tissue; Animals; Anticholesteremic Agents; Atorvastatin; Chemokine CCL2; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Glucose; Heptanoic Acids; Hypertriglyceridemia; Insulin Resistance; Leptin; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin; Pyrroles; Rats; Rats, Long-Evans; Rats, Mutant Strains; RNA, Messenger; Transforming Growth Factor beta1; Ventricular Dysfunction, Left | 2007 |
Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Secretion; Insulin-Secreting Cells; Mice; Mice, Inbred C57BL; Pravastatin; Pyrroles; Simvastatin; Sterol Regulatory Element Binding Protein 1 | 2006 |
Probable statin-induced testicular pain.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pain; Pyrroles; Simvastatin; Testis | 2007 |
When the party's over.
Topics: Atorvastatin; Clinical Trials as Topic; Drug Industry; Heptanoic Acids; Humans; Pyrroles; Quinolines; Treatment Failure | 2007 |
Effects of high-dose statin administered prior to coronary angioplasty on the incidence of cardiac events in patients with acute coronary syndrome.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Artery Bypass; Coronary Disease; Coronary Restenosis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Premedication; Pyrroles; Retrospective Studies; Syndrome; Treatment Outcome | 2006 |
Atorvastatin attenuating down-regulation of peroxisome proliferator-activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo.
Topics: Animals; Atorvastatin; Cells, Cultured; Down-Regulation; Heptanoic Acids; Hypertrophy, Left Ventricular; Male; PPAR gamma; Pyrroles; Rats; Rats, Sprague-Dawley | 2006 |
Endoglin expression in hyper-cholesterolemia and after atorvastatin treatment in apoE-deficient mice.
Topics: Animals; Apolipoproteins E; Atorvastatin; Diet, Atherogenic; Endoglin; Gene Expression Regulation; Heptanoic Acids; Hypercholesterolemia; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrroles | 2006 |
Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin.
Topics: Administration, Oral; Animals; Arrestin; Atorvastatin; Autoimmune Diseases; Cattle; Cell Proliferation; Cytokines; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypersensitivity, Delayed; Immunohistochemistry; Injections, Intraperitoneal; Lovastatin; Lymph Nodes; Macrophages; Models, Animal; Pyrroles; Rats; Rats, Inbred Lew; Retina; Retinitis; T-Lymphocytes; Uvea; Uveitis | 2007 |
Cholesterol lowering in patients with CHD and metabolic syndrome.
Topics: Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Metabolic Syndrome; Pyrroles; Randomized Controlled Trials as Topic | 2007 |
Cholesterol lowering in patients with CHD and metabolic syndrome.
Topics: Aged; Atorvastatin; Coronary Disease; Diet, Mediterranean; Female; Heptanoic Acids; Humans; Life Style; Metabolic Syndrome; Pyrroles | 2007 |
Cholesterol lowering in patients with CHD and metabolic syndrome.
Topics: Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Ethanol; Heptanoic Acids; Humans; Metabolic Syndrome; Pyrroles | 2007 |
Cholesterol lowering in patients with CHD and metabolic syndrome.
Topics: Aged; Atorvastatin; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Male; Medical Audit; Middle Aged; Patient Readmission; Pyrroles; Simvastatin; United Kingdom | 2007 |
Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties.
Topics: Alanine Transaminase; Animals; Anticholesteremic Agents; Aspartate Aminotransferases; Atorvastatin; Cholesterol; Erythrocyte Deformability; Erythrocyte Indices; Erythrocyte Membrane; Guinea Pigs; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Membrane Lipids; Phospholipids; Pyrroles; Sodium-Potassium-Exchanging ATPase | 2007 |
API expert consensus document on management of ischemic heart disease.
Topics: Angioplasty; Atorvastatin; Clinical Trials as Topic; Coronary Angiography; Drug Costs; Dyslipidemias; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Myocardial Infarction; Pyrroles; Streptokinase; Thrombolytic Therapy | 2006 |
Post-trauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury.
Topics: Animals; Atorvastatin; Blood-Brain Barrier; Chemotaxis, Leukocyte; Cytokines; Down-Regulation; Endothelial Cells; Female; Gait Disorders, Neurologic; Heptanoic Acids; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Neuroprotective Agents; Paralysis; Pyrroles; Rats; Rats, Sprague-Dawley; Recovery of Function; Regional Blood Flow; rhoA GTP-Binding Protein; Spinal Cord; Spinal Cord Injuries; Terpenes; Treatment Outcome | 2007 |
Antiarrhythmic effect of atorvastatin on autoimmune myocarditis is mediated by improving myocardial repolarization.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Atorvastatin; Autoimmune Diseases; Disease Models, Animal; Heart; Heart Ventricles; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Mice; Mice, Inbred BALB C; Myocarditis; Myocardium; Myocytes, Cardiac; Patch-Clamp Techniques; Potassium Channels; Pyrroles; Tumor Necrosis Factor-alpha; Ventricular Function | 2007 |
Statins induce S1P1 receptors and enhance endothelial nitric oxide production in response to high-density lipoproteins.
Topics: Alkyl and Aryl Transferases; Animals; Atorvastatin; Blotting, Western; Cattle; Dose-Response Relationship, Drug; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Lysophospholipids; Mevalonic Acid; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Pyrroles; Quinolines; Receptors, Lysosphingolipid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sphingosine; Stimulation, Chemical | 2007 |
Atorvastatin preserves renal function in chronic complete unilateral ureteral obstruction.
Topics: Animals; Atorvastatin; Chronic Disease; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Function Tests; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Ureteral Obstruction | 2007 |
Statin effective in preventing recurrent stroke.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Pyrroles; Stroke | 2006 |
[Hypoadiponectinemia: a cardiovascular risk factor in uremia. A view from the evidence].
Topics: Adiponectin; Animals; Atorvastatin; Cardiovascular Diseases; Coronary Restenosis; Disease Models, Animal; Heptanoic Acids; Humans; Insulin Resistance; Kidney Failure, Chronic; Peritoneal Dialysis; PPAR gamma; Prospective Studies; Pyrroles; Rats; Renal Dialysis; Risk Factors; Thiazolidinediones; Uremia | 2006 |
Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Family Practice; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Losartan; Male; Middle Aged; Patient Satisfaction; Pyrroles; Simvastatin; Tetrazoles; Treatment Outcome | 2007 |
The failure of torcetrapib: was it the molecule or the mechanism?
Topics: Angina Pectoris; Animals; Anticholesteremic Agents; Atorvastatin; Cardiac Output, Low; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Mice; Myocardial Revascularization; Pyrroles; Quinolines; Rabbits; Treatment Failure | 2007 |
High-dose atorvastatin causes regression of endometriotic implants: a rat model.
Topics: Animals; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Endometriosis; Endometrium; Female; Heptanoic Acids; Leuprolide; Pyrroles; Rats; Rats, Wistar; Vascular Endothelial Growth Factor A | 2007 |
[Musculoskeletal adverse effects of levofloxacin].
Topics: Anti-Bacterial Agents; Arthralgia; Arthritis; Arthritis, Infectious; Arthroplasty, Replacement, Knee; Atorvastatin; Combined Modality Therapy; Debridement; Diagnosis, Differential; Doxycycline; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Levofloxacin; Middle Aged; Ofloxacin; Postoperative Complications; Prosthesis-Related Infections; Pyrroles; Recurrence; Reoperation; Rifampin; Thyroiditis, Autoimmune; Thyroxine; Trimethoprim, Sulfamethoxazole Drug Combination | 2006 |
Diabetes and residual risk of coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Heptanoic Acids; Humans; Insulin Resistance; Obesity; Pyrroles; Risk Factors; Simvastatin | 2007 |
Effect of demethylasterriquinone b1 in hypertension associated vascular endothelial dysfunction.
Topics: Animals; Aorta, Thoracic; Atorvastatin; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Male; Microscopy, Electron; Muscle Relaxation; Muscle, Smooth, Vascular; NADPH Oxidases; Nitrates; Nitric Oxide Synthase Type III; Nitrites; Oxidative Stress; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Superoxides; Thiobarbituric Acid Reactive Substances | 2007 |
Progressive myopathy with up-regulation of MHC-I associated with statin therapy.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Atorvastatin; Creatine Kinase; Female; Folic Acid Antagonists; Genes, MHC Class I; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Methotrexate; Middle Aged; Mitochondria, Muscle; Muscle Weakness; Muscular Diseases; Prednisolone; Pyrroles; Sarcolemma; Simvastatin; Up-Regulation | 2007 |
Effectiveness of rosuvastatin versus atorvastatin in reducing lipid levels and achieving low-density-lipoprotein cholesterol goals in a usual care setting.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Cohort Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medical Audit; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; United States | 2007 |
Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures.
Topics: Aged; Atorvastatin; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Collagen Type I; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Osteoblasts; Osteocalcin; Osteosarcoma; Pyrroles; Simvastatin; Transforming Growth Factor beta | 2007 |
Aspirin augments 15-epi-lipoxin A4 production by lipopolysaccharide, but blocks the pioglitazone and atorvastatin induction of 15-epi-lipoxin A4 in the rat heart.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atorvastatin; Biotin; Cyclooxygenase 2; Enzyme Induction; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lipopolysaccharides; Lipoxins; Male; Myocardium; Nitroso Compounds; Pioglitazone; Pyrroles; Rats; Rats, Sprague-Dawley; Thiazolidinediones | 2007 |
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2007 |
Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Models, Economic; Primary Prevention; Pyrroles; Quality-Adjusted Life Years | 2007 |
Stability indicating RP-HPLC method for simultaneous determination of atorvastatin and amlodipine from their combination drug products.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Stability; Heptanoic Acids; Hydrolysis; Oxidative Stress; Photolysis; Pyrroles; Quality Control; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Temperature; Time Factors | 2007 |
Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Atorvastatin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Membrane Proteins; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley | 2007 |
A novel mechanism of action for statins against diabetes-induced oxidative stress.
Topics: Animals; Antioxidants; Aorta; Atorvastatin; Diabetes Complications; Diabetes Mellitus; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Mice; Mice, Inbred C57BL; Oxidative Stress; Polyisoprenyl Phosphates; Pyrroles; rac GTP-Binding Proteins | 2007 |
[Effect of atorvastatin on left ventricular remodeling in spontaneously hypertensive rats].
Topics: Animals; Anticholesteremic Agents; Apoptosis; Atorvastatin; Blood Pressure; Heptanoic Acids; Hydroxyproline; Hypertension; Lipids; Male; Myocardium; Proliferating Cell Nuclear Antigen; Pyrroles; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Up-Regulation; Ventricular Remodeling | 2007 |
Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system.
Topics: Animals; Atorvastatin; Caffeine; Calcium; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Homeostasis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Manganese; Mitochondria; Muscle Fibers, Skeletal; Muscle Strength; Muscle, Skeletal; Pyrroles; Rats; Rats, Wistar; Sarcolemma; Sarcoplasmic Reticulum | 2007 |
Statin therapy and the elderly: SAGE advice?
Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Ischemia; Pravastatin; Pyrroles | 2007 |
[Effects of atorvastatin on hyperlipidemia in kidney disease patients].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Disease Progression; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hyperlipidemias; Kidney Diseases; Male; Middle Aged; Pyrroles; Renal Dialysis | 2007 |
Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes.
Topics: Antifungal Agents; Atorvastatin; Dose-Response Relationship, Drug; Drug Synergism; Fluorobenzenes; Fungi; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Microbial Sensitivity Tests; Penicillium chrysogenum; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spores, Fungal; Sulfonamides | 2007 |
Amlodipine/atorvastatin for preventing heart disease.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Drug Combinations; Heart Diseases; Heptanoic Acids; Humans; Pyrroles | 2007 |
Statins enhance circulating vitamin E.
Topics: Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Oxidative Stress; Pyrroles; Retrospective Studies; Simvastatin; Vitamin E | 2008 |
Improving catalytic function by ProSAR-driven enzyme evolution.
Topics: Algorithms; Anticholesteremic Agents; Atorvastatin; Bacteria; Catalysis; Directed Molecular Evolution; Heptanoic Acids; Hydrolases; Kinetics; Molecular Sequence Data; Proteins; Pyrroles; Quantitative Structure-Activity Relationship | 2007 |
Treatment of traumatic brain injury with a combination therapy of marrow stromal cells and atorvastatin in rats.
Topics: Animals; Atorvastatin; Bone Marrow Transplantation; Brain Injuries; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Rats; Rats, Wistar; Stromal Cells; Treatment Outcome | 2007 |
Effect of atorvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats.
Topics: Administration, Oral; Animals; Area Under Curve; Atorvastatin; Biological Availability; Biotransformation; Calcium Channel Blockers; Diltiazem; Dose-Response Relationship, Drug; Drug Interactions; Half-Life; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intravenous; Male; Metabolic Clearance Rate; Pyrroles; Rats; Rats, Sprague-Dawley | 2007 |
A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.
Topics: Atorvastatin; Diabetic Angiopathies; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2007 |
The combination of atorvastatin and ethanol is not more hepatotoxic to rats than the administration of each drug alone.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Atorvastatin; Biomarkers; Drug Synergism; Ethanol; Heptanoic Acids; L-Lactate Dehydrogenase; Liver; Liver Function Tests; Male; Oxygen Consumption; Perfusion; Pyrroles; Rats; Rats, Wistar; Sulfobromophthalein | 2007 |
Attenuation of contractile dysfunction by atorvastatin after intestinal ischemia reperfusion injury in rats.
Topics: Administration, Oral; Animals; Atorvastatin; Carbachol; Cholinergic Agonists; Dose-Response Relationship, Drug; Glutathione; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ileum; In Vitro Techniques; Intestines; Male; Malondialdehyde; Muscle Contraction; Neurotransmitter Agents; Peroxidase; Potassium Chloride; Pyrroles; Rats; Rats, Wistar; Reperfusion Injury; Substance P | 2007 |
Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques.
Topics: Atorvastatin; Blotting, Western; Carotid Arteries; Carotid Artery Diseases; Cathepsin D; Cluster Analysis; Electrophoresis, Gel, Two-Dimensional; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Proteins; Proteomics; Pyrroles; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2007 |
Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice.
Topics: Aged; Atorvastatin; Chi-Square Distribution; Coronary Disease; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Pravastatin; Proportional Hazards Models; Pyrroles; Recurrence; Retrospective Studies; Simvastatin; Treatment Outcome | 2007 |
Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cohort Studies; Disease Progression; Dyslipidemias; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pyrroles | 2007 |
Measurement of liver collagen synthesis by heavy water labeling: effects of profibrotic toxicants and antifibrotic interventions.
Topics: Administration, Oral; Alanine; Animals; Atorvastatin; Carbon Tetrachloride; Collagen; Deuterium Oxide; Drug Evaluation, Preclinical; Enalapril; Gas Chromatography-Mass Spectrometry; Griseofulvin; Heptanoic Acids; Hydroxyproline; Interferon-gamma; Liver; Liver Cirrhosis, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pyrroles; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Rosiglitazone; Species Specificity; Thiazolidinediones; Time Factors | 2007 |
Fluvastatin as co-medication in heart transplant recipients with elevated creatine-kinase.
Topics: Adult; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 2007 |
Construction of atorvastatin dose-response relationships using data from a large population-based DNA biobank.
Topics: Aged, 80 and over; Algorithms; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cohort Studies; Databases, Nucleic Acid; Dose-Response Relationship, Drug; Drug Utilization Review; Female; Heptanoic Acids; Humans; Male; Pyrroles; Reproducibility of Results; Simvastatin; Treatment Outcome; Wisconsin | 2007 |
Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drugs, Generic; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quality of Life; Simvastatin; Survival Rate; Time Factors | 2007 |
The mechanism underlying vascular smooth muscle cell apoptosis induced by atorvastatin may be mainly associated with down-regulation of survivin expression.
Topics: Animals; Apoptosis; Atorvastatin; Blotting, Western; Cell Nucleus; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Fas Ligand Protein; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microtubule-Associated Proteins; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oligonucleotides, Antisense; Pyrroles; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survivin; Time Factors; Transfection; Vascular Endothelial Growth Factor A | 2007 |
[Secondary prevention of recurrent stroke by lowering cholesterol levels and blood pressure].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Heptanoic Acids; Humans; Ischemic Attack, Transient; Pyrroles; Recurrence; Risk Factors; Stroke | 2007 |
Effect of atorvastatin on non-ischemic heart failure and matrix metalloproteinase-2 and 9 in rats.
Topics: Animals; Arteriovenous Fistula; Atorvastatin; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Ultrasonography | 2007 |
Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function, and inhibition of glucose uptake.
Topics: Adipocytes, Brown; Adipocytes, White; Animals; Apoptosis; Atorvastatin; CCAAT-Enhancer-Binding Protein-beta; Cell Differentiation; Cell Proliferation; Cell Survival; Cells, Cultured; Endocrine System; Gene Expression Regulation; Glucose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Inflammation Mediators; Insulin Resistance; Ion Channels; Mice; Mitochondrial Proteins; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Uncoupling Protein 1 | 2007 |
Atorvastatin-induced early-onset rhabdomyolysis in a patient with nephrotic syndrome.
Topics: Adolescent; Atorvastatin; Early Diagnosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Male; Nephrotic Syndrome; Pyrroles; Rhabdomyolysis | 2007 |
Use of maximum-dose simvastatin or atorvastatin in an ethnically diverse population.
Topics: Aged; Atorvastatin; California; Drug Interactions; Ethnicity; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Retrospective Studies; Simvastatin | 2007 |
CETP inhibitors to increase HDL cholesterol levels.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Pyrroles; Quinolines | 2007 |
Inhibition of laser-induced choroidal neovascularization by atorvastatin by downregulation of monocyte chemotactic protein-1 synthesis in mice.
Topics: Administration, Oral; Animals; Atorvastatin; Cell Movement; Chemokine CCL2; Choroidal Neovascularization; Disease Models, Animal; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Laser Coagulation; Macrophages; Male; Mice; Mice, Inbred C57BL; Pyrroles; Vascular Endothelial Growth Factor A | 2007 |
How to deal with multiple treatment or dose groups in randomized clinical trials? Another approach.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Clinical Protocols; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Models, Statistical; Pyrroles; Randomized Controlled Trials as Topic; Research Design | 2007 |
L-arginine plus atorvastatin for prevention of atheroma formation in genetically hypercholesterolaemic rabbits.
Topics: Animals; Arginine; Atherosclerosis; Atorvastatin; Cholesterol; Combined Modality Therapy; Dietary Supplements; Eating; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Nitric Oxide; Pyrroles; Rabbits | 2007 |
Effects of Atorvastatin on vitamin D levels in patients with acute ischemic heart disease.
Topics: Aged; Angina, Unstable; Atorvastatin; Calcifediol; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; Chromatography, High Pressure Liquid; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Networks and Pathways; Middle Aged; Myocardial Infarction; Pyrroles; Treatment Outcome; Triglycerides; Vitamin D; Vitamin D Deficiency | 2007 |
Gender differences in short-term effects of atorvastatin on lipid profile, fibrinolytic parameters, and endothelial function.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Peroxidation; Lipids; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Pyrroles; Regional Blood Flow; Sex Factors; Thiobarbituric Acid Reactive Substances; Treatment Outcome | 2008 |
Upregulation of nitric oxide, inhibition of oxidative stress, and antihypertensive effects of statins.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Nitric Oxide; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Dahl; Reactive Oxygen Species; Up-Regulation; Vasoconstriction | 2007 |
Statin wars following coronary revascularization - evidence-based clinical practice?
Topics: Atorvastatin; Canada; Drug Industry; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Myocardial Revascularization; Pyrroles | 2007 |
Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination.
Topics: Adenosine; Administration, Oral; Animals; Atorvastatin; Cardiotonic Agents; Dipyridamole; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Heptanoic Acids; Male; Myocardial Reperfusion Injury; Pyrroles; Rats; Rats, Sprague-Dawley; Treatment Outcome | 2007 |
Did a flawed study design affect the results of the VYTAL study?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Multicenter Studies as Topic; Pyrroles; Random Allocation; Research Design; Simvastatin | 2007 |
Simultaneous quantitative resolution of atorvastatin calcium and fenofibrate in pharmaceutical preparation by using derivative ratio spectrophotometry and chemometric calibrations.
Topics: Anticholesteremic Agents; Atorvastatin; Calibration; Fenofibrate; Heptanoic Acids; Pharmaceutical Preparations; Pyrroles; Spectrophotometry, Ultraviolet | 2007 |
[Metabolic syndrome in men of 35-65 years old from rural district of Poltava region and possibility of the prophylactic therapy with atorvastatine].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Body Weight; Cardiovascular Diseases; Heptanoic Acids; Humans; Incidence; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Rural Health; Rural Population; Ukraine | 2006 |
HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Glucuronidase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Klotho Proteins; Male; Nitric Oxide Synthase; Pyrroles; Quinolines; Rats; Rats, Wistar | 2008 |
Letter by Padfield et al regarding article, "Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After Ca
Topics: Atorvastatin; Atrial Fibrillation; Cardiac Surgical Procedures; Confounding Factors, Epidemiologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Postoperative Complications; Pyrroles; Randomized Controlled Trials as Topic; Research Design | 2007 |
Letter by Shroff and Orlandi regarding article, "Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia Afte
Topics: Atorvastatin; Atrial Fibrillation; Cardiac Surgical Procedures; Confounding Factors, Epidemiologic; Coronary Artery Bypass; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Postoperative Complications; Pyrroles; Randomized Controlled Trials as Topic; Research Design | 2007 |
Switching statins in Norway after new reimbursement policy: a nationwide prescription study.
Topics: Atorvastatin; Drug Costs; Drug Utilization; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Norway; Pyrroles; Reimbursement Mechanisms; Simvastatin | 2007 |
Atorvastatin partially prevents an inflammatory barrier breakdown of cultured human brain endothelial cells at a pharmacologically relevant concentration.
Topics: Atorvastatin; Brain; Cell Survival; Cells, Cultured; Chemokines; Claudin-3; Dose-Response Relationship, Drug; Drug Interactions; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Interleukin-1beta; Membrane Proteins; Pyrroles; Tumor Necrosis Factor-alpha | 2007 |
Metabolic dysfunction and male pelvic health.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Prostatic Hyperplasia; Pyrroles; Urination Disorders | 2007 |
[Blood lipid-regulation of stilbene glycoside from polygonum multiflorum].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Glucosides; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Male; Plant Tubers; Plants, Medicinal; Polygonum; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, LDL; RNA, Messenger; Stilbenes; Triglycerides | 2007 |
Effects of atorvastatin and simvastatin on atrial plateau currents.
Topics: Action Potentials; Animals; Atorvastatin; Cell Separation; CHO Cells; Cricetinae; Cricetulus; Heart Ventricles; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kv1.5 Potassium Channel; Male; Membrane Potentials; Mice; Myocytes, Cardiac; Pyrroles; Shal Potassium Channels; Simvastatin | 2007 |
Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid.
Topics: Anticholesteremic Agents; Area Under Curve; Atorvastatin; Catalysis; Drug Interactions; Fenofibrate; Gemfibrozil; Glucuronic Acid; Glucuronides; Glucuronosyltransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lactones; Microsomes, Liver; Models, Biological; Molecular Structure; Pyrroles; Recombinant Proteins; Tandem Mass Spectrometry; Uridine Diphosphate Glucuronic Acid | 2007 |
Effect of atorvastatin withdrawal on circulating coenzyme Q10 concentration in patients with hypercholesterolemia.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Substance Withdrawal Syndrome; Triglycerides; Ubiquinone | 2006 |
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.
Topics: Administration, Oral; Adult; Area Under Curve; Atorvastatin; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Polymorphism, Genetic; Prospective Studies; Pyrimidines; Pyrroles; Reference Values; Rosuvastatin Calcium; Sulfonamides; White People | 2007 |
Suppressive effects of statins on acute promyelocytic leukemia cells.
Topics: Atorvastatin; cdc42 GTP-Binding Protein; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Drug Synergism; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; JNK Mitogen-Activated Protein Kinases; Leukemia, Promyelocytic, Acute; Pyrroles; rac1 GTP-Binding Protein; Tretinoin | 2007 |
Atorvastatin-induced downregulation of survivin and vascular smooth muscle cell apoptosis: a causal relationship in restenosis?
Topics: Animals; Apoptosis; Atorvastatin; Coronary Restenosis; Down-Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Muscle, Smooth, Vascular; Neoplasm Proteins; Pyrroles; Survivin | 2007 |
Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients.
Topics: Atorvastatin; Canada; Cholesterol, LDL; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2007 |
[CME-Lab 2/Solution. Hypercholesteremia and therapy control].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Interactions; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypericum; Male; Middle Aged; Patient Compliance; Pyrroles; Triglycerides | 2007 |
Study highlights need for considered clinical approach to statin switching.
Topics: Atorvastatin; Cost Savings; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Practice Patterns, Physicians'; Pyrroles; Simvastatin | 2007 |
Statin wars: emphasis on potency vs event reduction and safety?
Topics: Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum.
Topics: Animals; Antimalarials; Atorvastatin; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Inhibitory Concentration 50; Malaria, Falciparum; Microbial Sensitivity Tests; Plasmodium falciparum; Pyrroles; Structure-Activity Relationship | 2007 |
[Hypercholesterolemia and control with therapy].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diagnosis, Differential; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Predictive Value of Tests; Pyrroles; Treatment Refusal; Triglycerides | 2007 |
Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line.
Topics: Analysis of Variance; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Blotting, Western; Cell Line; Cell Proliferation; Cell Survival; Constitutive Androstane Receptor; Cytochrome P-450 CYP2C9; Cytochrome P-450 Enzyme System; Endothelial Cells; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pregnane X Receptor; Pyrroles; Receptors, Cytoplasmic and Nuclear; Receptors, Glucocorticoid; Receptors, Steroid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Saphenous Vein; Transcription Factors; Up-Regulation | 2007 |
Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Brain Edema; Brain Injuries; Brain Ischemia; Cerebrovascular Circulation; Chemotaxis, Leukocyte; Cognition Disorders; Cytokines; Disease Models, Animal; Encephalitis; Endothelial Cells; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurons; Pyrroles; Recovery of Function; RNA, Messenger; Simvastatin; Treatment Outcome | 2007 |
Increased asymmetric dimethylarginine concentrations in stimulated peripheral blood mononuclear cells.
Topics: Arginine; Atorvastatin; Cells, Cultured; Concanavalin A; Enzyme Inhibitors; Heptanoic Acids; Humans; Leukocytes, Mononuclear; Mitogens; Nitric Oxide; Nitric Oxide Synthase; Phytohemagglutinins; Pyrroles; Salicylic Acid | 2007 |
Effects of atorvastatin on ventricular late potentials and repolarization dispersion in patients with hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Electrocardiography; Female; Heart Ventricles; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles | 2007 |
Effects of short term atorvastatin treatment on cerebral hemodynamics in CADASIL.
Topics: Adult; Arginine; Atorvastatin; CADASIL; Carbon Dioxide; Cerebral Arteries; Cerebrovascular Circulation; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercapnia; Hypoxia-Ischemia, Brain; Male; Middle Aged; Middle Cerebral Artery; Nitric Oxide; Pyrroles; Treatment Outcome; Ultrasonography, Doppler, Transcranial; Vasodilation | 2007 |
Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine.
Topics: Animals; Arginine; Aryldialkylphosphatase; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diet; Heptanoic Acids; Homocysteine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Male; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Pyrroles; Rabbits; Thiobarbituric Acid Reactive Substances; Triglycerides | 2007 |
High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine: relevance to the human situation?
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Coronary Vessels; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Neovascularization, Physiologic; Pyrroles; Swine; Swine, Miniature; Vascular Endothelial Growth Factor A | 2007 |
Beneficial effect of atorvastatin on left ventricular remodeling in spontaneously hypertensive rats.
Topics: Animals; Apoptosis; Atorvastatin; Blood Pressure; Cardiomegaly; Collagen; Cyclin-Dependent Kinase Inhibitor p27; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Myocardium; Pyrroles; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Ventricular Remodeling | 2007 |
Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective.
Topics: Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Costs and Cost Analysis; Diabetes Mellitus; Drug Costs; Female; Heptanoic Acids; Humans; Male; Models, Theoretical; Pyrroles; Simvastatin; United States | 2007 |
Supravalvular and valvular aortic stenosis in heterozygous familial hypercholesterolemia.
Topics: Adolescent; Aortic Stenosis, Supravalvular; Aortic Valve Stenosis; Atorvastatin; Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Niacin; Pyrroles | 2007 |
Inhibition of serotonin-induced mitogenesis, migration, and ERK MAPK nuclear translocation in vascular smooth muscle cells by atorvastatin.
Topics: Animals; Atorvastatin; Cattle; Cell Division; Cell Movement; Cell Nucleus; Cells, Cultured; DNA; Drug Interactions; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Signaling Peptides and Proteins; Kidney; Mevalonic Acid; Muscle, Smooth, Vascular; Polyisoprenyl Phosphates; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pulmonary Artery; Pyrroles; rho-Associated Kinases; rhoA GTP-Binding Protein; Serotonin; Serotonin Agents; Serum Response Factor | 2007 |
The influence of hospitalisation on drug prescription in primary care--a large-scale follow-up study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Atorvastatin; Continuity of Patient Care; Databases, Factual; Drug Prescriptions; Drug Utilization Review; Follow-Up Studies; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Outpatients; Pantoprazole; Proton Pump Inhibitors; Pyrroles | 2007 |
Cost-effectiveness of high-dose atorvastatin compared with usual-dose simvastatin: less than IDEAL?
Topics: Atorvastatin; Coronary Artery Disease; Cost-Benefit Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin; Treatment Outcome | 2007 |
Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.
Topics: Adult; Aged; Anti-Retroviral Agents; Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Protease Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2007 |
[The 2006 American Heart Association selection of the "top ten advances in heart disease and stroke research"].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; American Heart Association; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Brain Ischemia; Child; Coronary Disease; Heart Diseases; Heart Valve Prosthesis; Heart-Assist Devices; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Obesity; Peptidyl-Dipeptidase A; Process Assessment, Health Care; Pyrroles; Stroke; Tissue Engineering; United States | 2007 |
Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin.
Topics: Actins; Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Blotting, Western; Dose-Response Relationship, Drug; Echocardiography; Gene Expression Regulation; Heart Ventricles; Heptanoic Acids; Hypertension, Pulmonary; Immunohistochemistry; Male; Muscle, Smooth; Organ Size; Polymerase Chain Reaction; Pulmonary Artery; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Serotonin Plasma Membrane Transport Proteins; Systole | 2007 |
Successful intensive lipid-lowering therapy using atorvastatin stabilizes coronary artery plaque as assessed by multi-detector row computed tomography.
Topics: Adult; Angina Pectoris; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Stenosis; Follow-Up Studies; Heptanoic Acids; Humans; Male; Pyrroles; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets.
Topics: Atorvastatin; Canada; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Economic; Pyrroles; Simvastatin | 2007 |
Reducing myocardial injury by minimizing imbalance between oxygen supply and demand.
Topics: Anesthesiology; Animals; Atorvastatin; Blood Pressure; Cardiovascular Agents; Coronary Disease; Dogs; Heart Diseases; Heart Rate; Heptanoic Acids; History, 20th Century; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Myocardial Revascularization; Necrosis; Oxygen; Pyrroles | 2007 |
Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Collagen; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Heart; Heptanoic Acids; Inflammation; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley; Ventricular Dysfunction, Left; Ventricular Function, Left | 2007 |
Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion.
Topics: Atorvastatin; C-Reactive Protein; CCAAT-Enhancer-Binding Proteins; Cells, Cultured; Fluorobenzenes; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoassay; Interleukin-6; Mevalonic Acid; Pyrimidines; Pyrroles; RNA, Messenger; Rosuvastatin Calcium; STAT3 Transcription Factor; Sulfonamides; Transcription Factors | 2007 |
Therapeutic dose assessment of patient switching from atorvastatin to simvastatin.
Topics: Atorvastatin; Drugs, Generic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quality of Health Care; Retrospective Studies; Simvastatin; Therapeutic Equivalency; United States | 2007 |
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase.
Topics: Animals; Atorvastatin; Blood Pressure; Enzyme Activation; Heptanoic Acids; Hydroxyproline; Intracellular Signaling Peptides and Proteins; Liver Cirrhosis; Male; Nitric Oxide Synthase Type III; Portal System; Protein Serine-Threonine Kinases; Pyrroles; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; rho-Associated Kinases; rhoA GTP-Binding Protein | 2007 |
Physiogenomic association of statin-related myalgia to serotonin receptors.
Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Genomics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; Pain; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Receptors, Serotonin; Simvastatin | 2007 |
Reversal of memory deficits by Atorvastatin and Simvastatin in rats.
Topics: Alprazolam; Amnesia; Animals; Atorvastatin; Body Weight; Cholesterol; Dietary Fats; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Maze Learning; Memory; Pyrroles; Rats; Rats, Wistar; Reaction Time; Scopolamine; Simvastatin; Stimulation, Chemical | 2007 |
Letter by Rosenberg and Uretsky regarding article, "Risks associated with statin therapy: a systematic overview of randomized clinical trials".
Topics: Atorvastatin; Biomarkers; Creatine Kinase, MM Form; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Pain; Pyrroles; Randomized Controlled Trials as Topic; Rhabdomyolysis | 2007 |
Summaries for patients. High- or low-dose atorvastatin in elderly patients with stable coronary artery disease.
Topics: Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Pyrroles; Treatment Outcome; Triglycerides | 2007 |
Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury.
Topics: Animals; Atorvastatin; Brain Injuries; Cell Proliferation; Dentate Gyrus; Dose-Response Relationship, Drug; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Maze Learning; Memory Disorders; Neovascularization, Physiologic; Nerve Degeneration; Nerve Regeneration; Neuronal Plasticity; Neurons; Neuroprotective Agents; Pyrroles; Rats; Rats, Wistar; Recovery of Function; Simvastatin; Stem Cells; Treatment Outcome | 2007 |
Regulation of phospholamban and sarcoplasmic reticulum Ca2+-ATPase by atorvastatin: implication for cardiac hypertrophy.
Topics: Animals; Atorvastatin; Calcium-Binding Proteins; Cardiomegaly; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Systole | 2007 |
The central role of adenosine in statin-induced ERK1/2, Akt, and eNOS phosphorylation.
Topics: 5'-Nucleotidase; Adenosine; Animals; Atorvastatin; Butadienes; Enzyme Inhibitors; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 3; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Nitriles; Phosphodiesterase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Receptors, Purinergic P1; Theophylline | 2007 |
The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation.
Topics: Adenosine; Administration, Oral; Animals; Atorvastatin; Body Weight; Cilostazol; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Heptanoic Acids; Immunoblotting; Male; Myocardium; Nitric Oxide Synthase Type III; Organ Culture Techniques; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Risk Factors; Tetrazoles; Treatment Outcome | 2007 |
The Atorvastatin Goal Achievement Across Risk Levels: (ATGOAL) study in Thailand.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Risk Assessment; Treatment Outcome | 2007 |
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.
Topics: Animals; Atorvastatin; Cell Survival; Cell Transformation, Neoplastic; Cells, Cultured; Flow Cytometry; Gene Expression Profiling; Glycine; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphoma; Mice; Mice, Transgenic; Mutation; Oncogene Protein p55(v-myc); Phosphoproteins; Phosphorylation; Precancerous Conditions; Pyrroles; ras Proteins; Signal Transduction; Survival Rate | 2007 |
A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) s
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles | 2007 |
Protective effects of atorvastatin on chronic allograft nephropathy in rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Chemokines; Chronic Disease; Cyclosporine; Cytokines; Drug Therapy, Combination; Extracellular Matrix Proteins; Fibrosis; Gene Expression; Graft Rejection; Heptanoic Acids; Immunosuppressive Agents; Kidney Transplantation; Male; Monocytes; Proteinuria; Pyrroles; Rats; Rats, Inbred F344; Rats, Inbred Lew; T-Lymphocytes; Transplantation, Homologous | 2007 |
HDL cholesterol and atherosclerosis.
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Heptanoic Acids; Humans; Pyrroles; Quinolines; Tunica Intima | 2007 |
Effect of statin withdrawal on frequency of cardiac events after vascular surgery.
Topics: Aged; Atorvastatin; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Pravastatin; Pyrroles; Simvastatin; Substance Withdrawal Syndrome; Troponin T; Vascular Surgical Procedures | 2007 |
NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Aorta, Thoracic; Atorvastatin; Blood Pressure; Cell Line; Cholesterol; Cyclic GMP; Fibrinolytic Agents; Heptanoic Acids; Hyperlipidemias; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Knockout; Myocytes, Smooth Muscle; Nitric Oxide Donors; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Nitrites; PC12 Cells; Pulmonary Embolism; Pyrroles; Rabbits; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; Vasodilator Agents | 2007 |
Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia.
Topics: Adipocytes; Aged; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Cholesterol; Fatty Acid-Binding Proteins; Female; Heptanoic Acids; Humans; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrroles | 2007 |
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease.
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Databases as Topic; Dementia; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lovastatin; Male; Parkinson Disease; Proportional Hazards Models; Pyrroles; Simvastatin; United States; Veterans | 2007 |
P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Brain; Heptanoic Acids; Lactones; Liver; Lovastatin; Male; Mice; Mice, Inbred Strains; Mice, Knockout; Pravastatin; Pyrroles; Simvastatin | 2007 |
Activation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) by atorvastatin is mediated by 15-deoxy-delta-12,14-PGJ2.
Topics: Animals; Atorvastatin; CD36 Antigens; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Models, Biological; Models, Chemical; Myocardium; Pioglitazone; PPAR gamma; Prostaglandin D2; Pyrroles; Rats; Thiazolidinediones; Transcription Factors | 2007 |
Atorvastatin decreases lipoprotein lipase and endothelial lipase expression in human THP-1 macrophages.
Topics: Animals; Atorvastatin; Cell Line; DNA-Binding Proteins; Dose-Response Relationship, Drug; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipase; Lipoprotein Lipase; Liver X Receptors; Macrophages; NF-kappa B; Orphan Nuclear Receptors; Polyisoprenyl Phosphates; Pyrroles; Receptors, Cytoplasmic and Nuclear; Sesquiterpenes; Simvastatin | 2007 |
Flow cytometric evaluation of synergistic pro-apoptotic effects of statins and clofibrates in IM-9 human lymphoblasts.
Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; Caspase 3; Cell Line; Clofibrate; DNA Fragmentation; Drug Synergism; Enzyme Activation; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocytes; Pravastatin; Pyridines; Pyrroles | 2007 |
On the factors modulating the effect of statins on malignant cell proliferation.
Topics: Annexin A5; Atorvastatin; Cell Division; Cell Line, Tumor; DNA Fragmentation; DNA, Neoplasm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; K562 Cells; Kinetics; Lovastatin; Pravastatin; Pyrroles; Simvastatin | 2007 |
Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholagogues and Choleretics; Cholestasis; Cholesterol; Female; Heptanoic Acids; Humans; Lipoproteins, LDL; Liver Cirrhosis, Biliary; Male; Middle Aged; Prospective Studies; Pyrroles; Single-Blind Method; Transaminases; Ursodeoxycholic Acid | 2007 |
Low-dose treatment with atorvastatin leads to anti-oxidative and anti-inflammatory effects in diabetes mellitus.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Atorvastatin; Diabetes Mellitus, Experimental; Endothelium, Vascular; Gene Expression; Heptanoic Acids; Inflammation; Inflammation Mediators; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; NADPH Oxidases; Oxidative Stress; Phosphorylation; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Streptozocin; Transcription Factor RelA; Vasodilation | 2007 |
Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study.
Topics: Animals; Atorvastatin; Blood Pressure; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Echocardiography; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Monocrotaline; Phosphorylation; Pulmonary Artery; Pyrroles; Rats; Rats, Sprague-Dawley; Ribosomal Protein S6 Kinases, 70-kDa; Simvastatin; Sirolimus | 2007 |
Metabolic syndrome with early aortic atherosclerosis in a child.
Topics: Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Obesity; Pyrroles; Treatment Outcome; Triglycerides | 2006 |
[Rhabdomyolysis associated to combined ezetimibe-statin treatment].
Topics: Adult; Alcohol Drinking; Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Rhabdomyolysis; Risk Factors; Time Factors | 2007 |
CYP2D6*4 polymorphism is associated with statin-induced muscle effects.
Topics: Alleles; Atorvastatin; Case-Control Studies; Cytochrome P-450 CYP2D6; Gene Frequency; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscles; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin | 2007 |
Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats.
Topics: Animals; Arginine; Atorvastatin; Brain; Cerebral Arteries; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipid Metabolism; Male; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase; Pyrroles; Rats; Rats, Inbred SHR; Stroke; Survival Rate; Time; Time Factors; Treatment Outcome | 2007 |
Impact of blood circulation on reendothelialization, restenosis and atrovastatin's restenosis prevention effects.
Topics: Angioplasty, Balloon, Coronary; Animals; Atorvastatin; Carotid Arteries; Coronary Circulation; Coronary Restenosis; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Rats | 2008 |
Quantitative effect of atorvastatin on size and content of non-calcified plaques of coronary arteries 1 year after atorvastatin treatment by multislice computed tomography.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Risk Factors; Time Factors; Tomography, Spiral Computed | 2008 |
Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Fasting; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Regression Analysis; Risk Factors; Triglycerides | 2007 |
The PI3K/Akt pathway mediates the neuroprotective effect of atorvastatin in extending thrombolytic therapy after embolic stroke in the rat.
Topics: Animals; Atorvastatin; Biosynthetic Pathways; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Early Growth Response Protein 1; Fibrinolytic Agents; Heptanoic Acids; Infarction, Middle Cerebral Artery; Male; Neuroprotective Agents; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Wistar; Tissue Plasminogen Activator; Vascular Endothelial Growth Factor A | 2007 |
[Effects of atorvastatin on endothelium protection in spontaneously hypertensive rats].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Endothelium, Vascular; Heptanoic Acids; Hypertension; Lipids; Male; Nitric Oxide; Pyrroles; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; von Willebrand Factor | 2007 |
Ask the doctor. Are Lipitor and Crestor equally good for me?
Topics: Atorvastatin; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Insurance, Pharmaceutical Services; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Therapeutic Equivalency | 2007 |
Effect of a single 20-mg tablet of Atorvastatin on brachial artery blood flow in normolipidemic male smokers versus nonsmokers.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Brachial Artery; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperemia; Male; Middle Aged; Prospective Studies; Pyrroles; Regional Blood Flow; Smoking; Time Factors; Ultrasonography, Doppler; Vascular Resistance; Vasodilation | 2007 |
Discontinuation of statin therapy and clinical outcome after ischemic stroke.
Topics: Aged; Atorvastatin; Brain Ischemia; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Pyrroles; Simvastatin; Stroke; Substance Withdrawal Syndrome | 2007 |
Hydrophobic but not hydrophilic statins enhance phagocytosis and decrease apoptosis of human peripheral blood cells in vitro.
Topics: Adult; Apoptosis; Atorvastatin; Dose-Response Relationship, Drug; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Leukocytes; Lovastatin; Male; Middle Aged; Phagocytes; Phagocytosis; Pravastatin; Pyrroles; Simvastatin | 2008 |
Atorvastatin inhibits T cell activation through 3-hydroxy-3-methylglutaryl coenzyme A reductase without decreasing cholesterol synthesis.
Topics: Antigen-Presenting Cells; Atorvastatin; Biomarkers; Calcium Signaling; Cell Membrane; Cell Proliferation; Cells, Cultured; Cholesterol; Extracellular Signal-Regulated MAP Kinases; G(M1) Ganglioside; Growth Inhibitors; Heptanoic Acids; HLA-DR Antigens; Humans; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Immunosuppressive Agents; Interferon-gamma; Jurkat Cells; Lymphocyte Activation; Phosphorylation; Protein Prenylation; Pyrroles; T-Lymphocytes | 2007 |
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells.
Topics: Adult; Animals; Atorvastatin; Forkhead Transcription Factors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Mice; Mice, Inbred C57BL; Pravastatin; Pyrroles; T-Lymphocytes, Regulatory; Up-Regulation | 2008 |
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity.
Topics: Adoptive Transfer; Animals; Antigen Presentation; Atorvastatin; Chemoprevention; Cytokines; Graft vs Host Disease; Graft vs Leukemia Effect; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Mice; Mice, Knockout; Premedication; Pyrroles; Signal Transduction; STAT6 Transcription Factor; T-Lymphocytes; Th2 Cells | 2007 |
Medication use as a confounding factor in the use of the cerebrospinal fluid tau/beta-amyloid42 ratio.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Biomarkers; Cyclooxygenase Inhibitors; Estrogens; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Peptide Fragments; Pyrroles; tau Proteins | 2007 |
Effects of toll-like receptor-4 gene polymorphisms on soluble P-selectin and von Willebrand factor levels in hypercholesterolemic patients.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Case-Control Studies; Cohort Studies; Cross-Sectional Studies; Female; Gene Frequency; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; P-Selectin; Phenotype; Polymorphism, Genetic; Pyrroles; Risk Factors; Toll-Like Receptor 4; Treatment Outcome; von Willebrand Factor | 2007 |
Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.
Topics: Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, VLDL; Dose-Response Relationship, Drug; Female; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pyrroles; RNA, Messenger | 2008 |
Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice.
Topics: Animals; Apoptosis; Atorvastatin; Celecoxib; Cell Proliferation; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intraperitoneal; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays | 2007 |
Effects of atorvastatin on C-reactive protein secretions by adipocytes in hypercholesterolemic rabbits.
Topics: Adipocytes; Animals; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Heptanoic Acids; Hypercholesterolemia; Male; Nephelometry and Turbidimetry; PPAR gamma; Pyrroles; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Up-Regulation | 2007 |
Preoperative lipid-lowering therapy on postoperative outcome.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Bypass; Coronary Artery Disease; Heptanoic Acids; Humans; Postoperative Complications; Preoperative Care; Pyrroles; Survival Analysis; Treatment Outcome | 2007 |
Dual mode of HMG-CoA reductase inhibition on dendritic cell invasion.
Topics: Antibodies; Atherosclerosis; Atorvastatin; Cell Adhesion; Cell Line; Cell Movement; Cholesterol; Dendritic Cells; Dose-Response Relationship, Drug; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prenylation; Pyrroles; Vasculitis | 2008 |
E-selectin and TFPI are associated with carotid intima-media thickness in stable IHD patients: the baseline findings of the MIAMI study.
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Cholesterol; E-Selectin; Endothelium, Vascular; Female; Fibrinogen; Heptanoic Acids; Humans; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Interleukin-8; Lipoproteins; Male; Middle Aged; Prospective Studies; Pyrroles; Thromboplastin; Triglycerides; Tumor Necrosis Factor-alpha; Tunica Intima; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 2008 |
Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure.
Topics: Acute Disease; Amides; Atorvastatin; Cardiac Pacing, Artificial; Clinical Trials as Topic; Fumarates; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pulmonary Edema; Pyrroles; Renin; Respiration, Artificial | 2007 |
A novel mechanism of action of atorvastatin against cardiovascular risk: a commentary on "decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins".
Topics: Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic | 2007 |
Atorvastatin donor pretreatment prevents ischemia/reperfusion injury in renal transplantation in rats: possible role for aldose-reductase inhibition.
Topics: Aldehyde Reductase; Animals; Atorvastatin; Gene Expression Profiling; Graft Survival; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Transplantation; Male; Pyrroles; Rats; Rats, Inbred Strains; Reperfusion Injury | 2007 |
Atorvastatin and portal pressure.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cholesterol; Disease Models, Animal; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Liver Cirrhosis; Pyrroles; Rats | 2007 |
Endothelial expression of endoglin in normocholesterolemic and hypercholesterolemic C57BL/6J mice before and after atorvastatin treatment.
Topics: Animals; Atorvastatin; Endoglin; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Nitric Oxide; Platelet Endothelial Cell Adhesion Molecule-1; Pyrroles; Transforming Growth Factor beta | 2007 |
Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection.
Topics: Animals; Antioxidants; Atorvastatin; Bilirubin; Carbon Monoxide; Carboxyhemoglobin; Fluorobenzenes; Heme Oxygenase (Decyclizing); Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Liver Function Tests; Mice; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2007 |
Modulation of calcification of vascular smooth muscle cells in culture by calcium antagonists, statins, and their combination.
Topics: Amlodipine; Animals; Animals, Newborn; Aorta; Apoptosis; Ascorbic Acid; Atorvastatin; Calcinosis; Calcium; Cell Proliferation; Cell Separation; Cells, Cultured; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Space; Heptanoic Acids; Muscle, Smooth, Vascular; Phosphates; Pyrroles; Rats; Rats, Wistar | 2008 |
Statin-mediated cytoprotection of human vascular endothelial cells: a role for Kruppel-like factor 2-dependent induction of heme oxygenase-1.
Topics: Antioxidants; Atorvastatin; Bilirubin; Biliverdine; Cell Survival; Cells, Cultured; Cytoprotection; Dose-Response Relationship, Drug; Endothelial Cells; Enzyme Induction; Enzyme Inhibitors; Ferritins; Heme Oxygenase-1; Heptanoic Acids; Humans; Hydrogen Peroxide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iron Chelating Agents; Kruppel-Like Transcription Factors; Mevalonic Acid; Oxidants; Oxidative Stress; Prenylation; Promoter Regions, Genetic; Protoporphyrins; Pyrroles; Reactive Oxygen Species; RNA Interference; RNA, Messenger; RNA, Small Interfering; Terpenes | 2007 |
[Results of ARMYDA-ACS trial show good outcome of 80 mg atorvastatin pretreatment in patients with acute coronary syndromes undergoing early percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Pyrroles; Treatment Outcome | 2007 |
Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Area Under Curve; Atorvastatin; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Interactions; Half-Life; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intravenous; Male; Metabolic Clearance Rate; Pyrroles; Rats; Rats, Sprague-Dawley; Verapamil | 2008 |
HMG-CoA reductase inhibitors and renal function.
Topics: Anticholesteremic Agents; Atorvastatin; Chronic Disease; Coronary Disease; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Lipoproteins, LDL; Pyrroles | 2007 |
Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.
Topics: Animals; Atorvastatin; Cell Growth Processes; Drug Interactions; Female; Heptanoic Acids; Male; Mice; Monomeric GTP-Binding Proteins; Neuropeptides; Phosphorylation; Polyisoprenyl Phosphates; Prenylation; Protein Kinases; Pyrroles; Ras Homolog Enriched in Brain Protein; Rats; rho GTP-Binding Proteins; Ribosomal Protein S6 Kinases; Sesquiterpenes; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2007 |
[Atorvastatin inhibits scavenger receptor A and monocyte chemoattractant protein-1 expressions in foam cell].
Topics: Atorvastatin; Cell Differentiation; Cell Line; Chemokine CCL2; Foam Cells; Heptanoic Acids; Humans; Monocytes; Pyrroles; Scavenger Receptors, Class A | 2007 |
Impact of patient and plan design factors on switching to preferred statin therapy.
Topics: Atorvastatin; Drugs, Generic; Female; Formularies as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance, Pharmaceutical Services; Male; Middle Aged; Patient Education as Topic; Prescription Fees; Pyrroles | 2007 |
Zooplankton chitobiase activity as an endpoint of pharmaceutical effect.
Topics: Acetylglucosaminidase; Animals; Atorvastatin; Biological Assay; Daphnia; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Environmental Monitoring; Fluoxetine; Heptanoic Acids; Lethal Dose 50; Lovastatin; Pyrroles; Sertraline; Water Pollutants, Chemical; Xenobiotics; Zooplankton | 2008 |
Atorvastatin attenuates mitochondrial toxin-induced striatal degeneration, with decreasing iNOS/c-Jun levels and activating ERK/Akt pathways.
Topics: Animals; Atorvastatin; Corpus Striatum; Disease Models, Animal; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Signaling System; Mitochondria; Nerve Degeneration; Neurotoxins; Nitric Oxide Synthase Type II; Nitro Compounds; Propionates; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley | 2008 |
Novel delivery systems of atorvastatin should be evaluated for pharmacodynamics instead of pharmacokinetics.
Topics: Administration, Oral; Animals; Atorvastatin; Disease Models, Animal; Drug Delivery Systems; Emulsions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Pyrroles; Tissue Distribution | 2007 |
Investigation of electrochemical behavior of lipid lowering agent atorvastatin calcium in aqueous media and its determination from pharmaceutical dosage forms and biological fluids using boron-doped diamond and glassy carbon electrodes.
Topics: Atorvastatin; Boron; Carbon; Diamond; Electrochemistry; Electrodes; Heptanoic Acids; Humans; Hydrogen-Ion Concentration; Hypolipidemic Agents; Molecular Conformation; Oxidation-Reduction; Pharmaceutical Preparations; Pyrroles; Reference Values; Reproducibility of Results; Sensitivity and Specificity; Solutions; Tablets; Water | 2007 |
Statins and ATP regulate nuclear pAkt via the P2X7 purinergic receptor in epithelial cells.
Topics: Adenosine Triphosphate; Animals; Atorvastatin; Cell Line, Tumor; Cell Nucleus; Epithelial Cells; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2X7; RNA, Small Interfering; Signal Transduction | 2008 |
A pivotal role for interleukin-4 in atorvastatin-associated neuroprotection in rat brain.
Topics: Animals; Atorvastatin; Brain Chemistry; Cholesterol; Gene Expression Regulation; Heptanoic Acids; Hippocampus; Histocompatibility Antigens Class II; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interferon-gamma; Interleukin-1beta; Interleukin-4; Lipopolysaccharides; Male; Mice; Mice, Knockout; Microglia; Neuroprotective Agents; Pyrroles; Rats; Rats, Wistar | 2008 |
Higher dose of statin medication may be better for older adults.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrroles; Stroke | 2007 |
Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Databases, Factual; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Male; Managed Care Programs; Odds Ratio; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2007 |
Lipid-lowering effects of ethyl 2-phenacyl-3-aryl-1H-pyrrole- 4-carboxylates in rodents.
Topics: Acetophenones; Animals; Atorvastatin; Carboxylic Acids; Cholesterol, HDL; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Mice; Pyrroles; Rats; Rats, Sprague-Dawley | 2004 |
An improved HPLC method with the aid of a chemometric protocol: simultaneous analysis of amlodipine and atorvastatin in pharmaceutical formulations.
Topics: Amlodipine; Atorvastatin; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Heptanoic Acids; Models, Chemical; Molecular Structure; Pyrroles; Reproducibility of Results; Sensitivity and Specificity | 2007 |
Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.
Topics: Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Humans; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Subtilisin | 2008 |
Adverse balance of nitric oxide/peroxynitrite in the dysfunctional endothelium can be reversed by statins.
Topics: Acetophenones; Atorvastatin; Calcimycin; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type III; Peroxynitrous Acid; Pyrroles; Simvastatin | 2007 |
Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.
Topics: Atorvastatin; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pravastatin; Pyrroles; Saphenous Vein; Simvastatin | 2007 |
Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption - an individual-level prescription database study.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Databases, Factual; Drug Administration Schedule; Drug Prescriptions; Drug Utilization; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Norway; Patient Selection; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Sex Factors; Simvastatin; Tablets | 2007 |
Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus.
Topics: Animals; Atorvastatin; Biopterins; Body Weight; Cell Adhesion Molecules; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Disease Models, Animal; Endothelium, Vascular; Enzyme Activation; GTP Cyclohydrolase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intramolecular Oxidoreductases; Male; Microfilament Proteins; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphoproteins; Pyrroles; Rats; Rats, Wistar; Stem Cells; Tetrahydrofolate Dehydrogenase; Vasodilation | 2008 |
Atorvastatin promotes presenilin-1 expression and Notch1 activity and increases neural progenitor cell proliferation after stroke.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Basic Helix-Loop-Helix Transcription Factors; Cell Proliferation; Disease Models, Animal; Heptanoic Acids; Homeodomain Proteins; Male; Middle Cerebral Artery; Neurons; Presenilin-1; Pyrroles; Rats; Rats, Wistar; Receptor, Notch1; Signal Transduction; Stem Cells; Stroke; Transcription Factor HES-1 | 2008 |
Atorvastatin prevents connexin43 remodeling in hypertrophied left ventricular myocardium of spontaneously hypertensive rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Blotting, Western; Connexin 43; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Immunohistochemistry; Lipid Metabolism; Lipids; Male; Microscopy, Electron, Transmission; Myocardium; Natriuretic Peptide, Brain; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 2007 |
Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin.
Topics: Atorvastatin; Catalytic Domain; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Heptanoic Acids; Hydrogen Bonding; Hydrolysis; Models, Molecular; Protease Inhibitors; Pyrroles | 2008 |
Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; ADP Ribose Transferases; Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Atorvastatin; Benzamides; Botulinum Toxins; Cell Line, Tumor; Fas Ligand Protein; fas Receptor; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocytes; Lymphoma; Melanoma, Experimental; Membrane Proteins; Methionine; Mevalonic Acid; Mice; Pyrroles; Recombinant Fusion Proteins; rho GTP-Binding Proteins; rho-Associated Kinases; rhoA GTP-Binding Protein; RNA, Small Interfering | 2007 |
Synergistic effect of amlodipine and atorvastatin in reversing LDL-induced endothelial dysfunction.
Topics: Amlodipine; Atorvastatin; Blotting, Western; Calcium Channel Blockers; Cells, Cultured; Drug Synergism; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Bilayers; Lipoproteins, LDL; Membrane Lipids; Nitric Oxide; Nitric Oxide Synthase Type III; Peroxynitrous Acid; Pyrroles; Vascular Diseases; X-Ray Diffraction | 2008 |
Monocyte chemoattractant protein-1 expression is enhanced by granulocyte-macrophage colony-stimulating factor via Jak2-Stat5 signaling and inhibited by atorvastatin in human monocytic U937 cells.
Topics: Atorvastatin; Chemokine CCL2; Down-Regulation; Granulocyte-Macrophage Colony-Stimulating Factor; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Janus Kinase 2; Monocytes; Pyrroles; Response Elements; RNA Stability; RNA, Messenger; Signal Transduction; STAT5 Transcription Factor; Transcription, Genetic; U937 Cells; Up-Regulation | 2008 |
[Effects of atorvastatin on expression of peroxisome proliferation activated receptor gamma in unilateral ureteral obstruction in rats].
Topics: Animals; Atorvastatin; Disease Models, Animal; Female; Heptanoic Acids; Kidney Tubules; Nephrosclerosis; PPAR gamma; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Ureteral Obstruction | 2007 |
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
Topics: Animals; Atorvastatin; Combinatorial Chemistry Techniques; Disease Models, Animal; Fluorobenzenes; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Molecular Structure; Muscle Cells; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Atorvastatin accelerates extracellular nucleotide degradation in human endothelial cells.
Topics: 5'-Nucleotidase; Adenosine Monophosphate; Adenosine Triphosphate; Atorvastatin; Cell Extracts; Cells, Cultured; Endothelial Cells; Extracellular Space; Heptanoic Acids; Humans; L-Lactate Dehydrogenase; Mevalonic Acid; Polyisoprenyl Phosphates; Pyrroles; Umbilical Veins | 2008 |
Aspirin and hormone therapy for prostate cancer.
Topics: Androgen Antagonists; Aspirin; Atorvastatin; Drug Therapy, Combination; Flutamide; Gonadotropin-Releasing Hormone; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Function Tests; Logistic Models; Male; Prostatic Neoplasms; Pyrroles | 2007 |
Application of cytogenetic endpoints and comet assay on human lymphocytes treated with atorvastatin in vitro.
Topics: Adult; Atorvastatin; Cells, Cultured; Chromosome Aberrations; Comet Assay; DNA Damage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocytes; Pyrroles; Sister Chromatid Exchange | 2008 |
The effects of atorvastatin therapy on endothelial function in patients with coronary artery disease.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Angiography; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome; Ultrasonography | 2007 |
Genetic modulation of anti-inflammatory effects of atorvastatin; probably a multi-gene condition.
Topics: Anti-Inflammatory Agents; Atorvastatin; Heptanoic Acids; Humans; Nitric Oxide Synthase Type III; Oxidative Stress; Pyrroles; Vasculitis | 2008 |
[Influence of atorvastatin on the expression of monocyte chemoattractant protein-1 in peritoneal mesothelial cells by high glucose].
Topics: Animals; Atorvastatin; Blotting, Western; Cells, Cultured; Chemokine CCL2; Dose-Response Relationship, Drug; Epithelial Cells; Gene Expression; Glucose; Heptanoic Acids; I-kappa B Proteins; Male; NF-KappaB Inhibitor alpha; Peritoneum; Pyrroles; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Transcription Factor RelA | 2007 |
Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells.
Topics: Apoptosis; Atorvastatin; Celecoxib; Cell Cycle; Cell Survival; Colonic Neoplasms; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; G1 Phase; GTP-Binding Proteins; HCT116 Cells; Heptanoic Acids; HT29 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; MAP Kinase Kinase 4; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrroles; Resting Phase, Cell Cycle; Signal Transduction; Sulfonamides; Time Factors | 2008 |
American Heart Association--Scientific Sessions 2007. Part 1.
Topics: Atorvastatin; Cardiovascular Diseases; Drug Therapy, Combination; Drugs, Investigational; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Molecular Structure; Pyrroles | 2008 |
Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Atorvastatin; Child; Child, Preschool; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Infant; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Rhabdomyolysis; Simvastatin; United States; United States Food and Drug Administration | 2008 |
Atorvastatin impairs the myocardial angiogenic response to chronic ischemia in normocholesterolemic swine.
Topics: Animals; Atorvastatin; Cholesterol; Collateral Circulation; Coronary Circulation; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Microcirculation; Myocardial Ischemia; Neovascularization, Physiologic; Pyrroles; Swine | 2008 |
High-density lipoprotein mass, cholesteryl ester transport protein, and macrophage reverse cholesterol transport: from the bedside back to the bench.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Pyrroles; Quinolines; Treatment Outcome | 2008 |
Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lactic Acid; Lipids; Male; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrroles; Rats; Rats, Sprague-Dawley | 2008 |
Lowering LDL-C for optimal protection in high-risk patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Guideline Adherence; Heptanoic Acids; Humans; Hypercholesterolemia; Practice Guidelines as Topic; Pravastatin; Pyrroles; Risk Assessment | 2008 |
Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cholesterol; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Losartan; Male; Pyrroles; Retrospective Studies; Simvastatin; Tetrazoles; Therapeutic Equivalency; Treatment Outcome | 2008 |
Disease modifying effect of statins in dextran sulfate sodium model of mouse colitis.
Topics: Animals; Apolipoprotein A-I; Atorvastatin; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Mice; Occult Blood; Pyrroles; Simvastatin; Tumor Necrosis Factor-alpha | 2008 |
Effect of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor atorvastatin on contractility of the isolated rat heart under normal conditions and during oxidative stress.
Topics: Animals; Atorvastatin; Heart; Heptanoic Acids; Hydrogen Peroxide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Myocardial Contraction; Oxidative Stress; Pyrroles; Rats; Rats, Wistar | 2007 |
Atorvastatin reduces oxidative stress in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
Topics: Animals; Atorvastatin; Blood Pressure; Brain; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medulla Oblongata; Nitric Oxide; Norepinephrine; Oxidative Stress; Pyrroles; Rats; Rats, Inbred SHR; Sympathetic Nervous System; Thiobarbituric Acid Reactive Substances | 2008 |
Class effects of statins in elderly patients with congestive heart failure: a population-based analysis.
Topics: Aged; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Pravastatin; Pyrroles; Simvastatin; Survival Analysis; Treatment Outcome | 2008 |
Behçet's disease complicated by IgA nephropathy with nephrotic syndrome.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Behcet Syndrome; Benzimidazoles; Biphenyl Compounds; Dilazep; Drug Therapy, Combination; Female; Glomerulonephritis, IGA; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nephrotic Syndrome; Pyrroles; Tetrazoles; Vasodilator Agents | 2008 |
Comment on: Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 week controlled trial.
Topics: Atorvastatin; Controlled Clinical Trials as Topic; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Male; Pyrroles; Treatment Outcome; Vasodilation | 2008 |
Drug-screening platform based on the contractility of tissue-engineered muscle.
Topics: Animals; Atorvastatin; Biological Assay; Cells, Cultured; Drug Evaluation, Preclinical; Electric Stimulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin-Like Growth Factor I; Male; Mice; Mice, Inbred C3H; Muscle Contraction; Muscular Atrophy; Myoblasts; Pyrroles; Tissue Engineering | 2008 |
Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Contrast Media; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Length of Stay; Male; Middle Aged; Multivariate Analysis; Pravastatin; Preoperative Care; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Liquid chromatography/mass spectrometric studies on atorvastatin and its stress degradation products.
Topics: Anticholesteremic Agents; Atmosphere; Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Light; Molecular Structure; Oxidation-Reduction; Photochemistry; Photolysis; Pyrroles; Spectrometry, Mass, Electrospray Ionization | 2008 |
Statin-induced inhibition of 3-hydroxy-3-methyl glutaryl coenzyme a reductase sensitizes human osteosarcoma cells to anticancer drugs.
Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; Cell Line, Tumor; Cell Movement; Cell Survival; Cisplatin; Doxorubicin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 2; Osteosarcoma; Pyrroles | 2008 |
[Assessment of hypolipidemic efficacy and safety of various doses of atorvastatin].
Topics: Administration, Oral; Adult; Aged; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol, HDL; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2007 |
Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvastatin; Body Fat Distribution; Body Mass Index; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Inflammation; Kidney Failure, Chronic; Lipid Metabolism; Male; Middle Aged; Nutrition Assessment; Obesity; Prealbumin; Pyrroles; Renal Dialysis; Serum Albumin; Syndrome | 2008 |
Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Gadolinium; Heptanoic Acids; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Peroxidase; Pyrroles | 2008 |
[Cardioprotective effects of atorvastatin preconditioning via iNOS upregulation in a rabbit ischemia/reperfusion model].
Topics: Animals; Atorvastatin; Disease Models, Animal; Heptanoic Acids; Ischemic Preconditioning, Myocardial; Male; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type II; Potassium Channels; Pyrroles; Rabbits; Up-Regulation | 2007 |
3-Hydroxy-3-methylglutaryl coenzyme A reductase in rainbow trout: effects of fasting and statin drugs on activities and mRNA transcripts.
Topics: Amino Acid Sequence; Animals; Atorvastatin; Brain; Cholesterol; Dose-Response Relationship, Drug; Fasting; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoenzymes; Liver; Molecular Sequence Data; Oncorhynchus mykiss; Phosphorylation; Pyridines; Pyrroles; RNA, Messenger; Time Factors; Water Pollutants, Chemical | 2008 |
Analyzing the results of the treating to new targets study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Mortality; Pyrroles | 2008 |
Analyzing the results of the treating to new targets study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Pyrroles; Research Design | 2008 |
Analyzing the results of the treating to new targets study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Neoplasms; Pyrroles | 2008 |
Pretreatment with high-dose statin, but not low-dose statin, ezetimibe, or the combination of low-dose statin and ezetimibe, limits infarct size in the rat.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Up-Regulation | 2008 |
Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Blotting, Western; Chemokine CCL2; Diet, Atherogenic; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lipids; Mice; Mice, Knockout; Myocardium; Pyrroles; Receptors, LDL | 2008 |
Strategies for statins: The CASE for fire and forget.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2008 |
Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro.
Topics: Acids; Atorvastatin; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Stability; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Indoles; Lactones; Microscopy, Fluorescence; Molecular Structure; Muscle Fibers, Skeletal; Muscle, Skeletal; Pravastatin; Pyrroles; Satellite Cells, Skeletal Muscle; Simvastatin; Structure-Activity Relationship | 2008 |
Systemic evaluation of gene expression changes in major target organs induced by atorvastatin.
Topics: Animals; Atorvastatin; Blood Pressure; Brain; Disease Models, Animal; Gene Expression Profiling; Gene Expression Regulation; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney; Lipids; Male; Myocardium; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reproducibility of Results; RNA, Messenger; Time Factors | 2008 |
Effects of traditional chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis.
Topics: Acute-Phase Proteins; Alanine Transaminase; Animals; Atorvastatin; Carrier Proteins; Dietary Fats; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drugs, Chinese Herbal; Endotoxins; Fatty Liver; Hepatitis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interleukin-1beta; Lipids; Lipopolysaccharide Receptors; Liver; Lymphocyte Antigen 96; Male; Membrane Glycoproteins; NF-kappa B; Nitric Oxide Synthase Type II; Polymerase Chain Reaction; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Immunologic; RNA, Messenger; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2008 |
Determinants of CRP level in statin-treated patients.
Topics: Atorvastatin; Blood Pressure; C-Reactive Protein; Enzyme Inhibitors; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Logistic Models; Male; Metabolic Syndrome; Middle Aged; Pilot Projects; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; Sulfonamides | 2008 |
Atorvastatin attenuates cardiomyocyte loss in adult rats from protein-restricted dams.
Topics: Animals; Atorvastatin; Blood Pressure; Body Mass Index; Cardiomegaly; Diet, Protein-Restricted; Fibrosis; Heptanoic Acids; Hypertrophy, Left Ventricular; Male; Myocardial Reperfusion; Myocytes, Cardiac; Perfusion; Pyrroles; Rats; Rats, Wistar | 2008 |
Pfizer ends advertisements featuring inventor of artificial heart.
Topics: Advertising; Anticholesteremic Agents; Artificial Organs; Atorvastatin; Drug Industry; Heart Transplantation; Heptanoic Acids; Humans; Pyrroles | 2008 |
High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cholesterol, LDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk; Stroke | 2008 |
Caffeinated coffee blunts the myocardial protective effects of statins against ischemia-reperfusion injury in the rat.
Topics: Administration, Oral; Animals; Atorvastatin; Blood Pressure; Caffeine; Coffee; Disease Models, Animal; Food-Drug Interactions; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1 | 2008 |
Glutathione S-transferase null and cholesteryl ester transfer protein TaqI B polymorphisms and lipid response to atorvastatin in Greek dyslipidaemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol Ester Transfer Proteins; Female; Gene Silencing; Genetic Predisposition to Disease; Genotype; Glutathione Transferase; Greece; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Reference Values | 2008 |
Lipoprotein profile changes in children after renal transplantation in the modern immunosuppression era.
Topics: Adolescent; Adult; Atorvastatin; Child; Child, Preschool; Female; Heptanoic Acids; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Diseases; Kidney Transplantation; Lipoproteins; Male; Prednisolone; Prevalence; Pyrroles | 2008 |
Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
Topics: Acetamides; Acetates; Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Catheterization; Cholesterol; Disease Progression; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Magnetic Resonance Imaging; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Pyrroles; Rabbits; Random Allocation; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2007 |
Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin.
Topics: Adult; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cohort Studies; Coronary Artery Disease; Female; Flow Cytometry; Heptanoic Acids; Humans; Hypercholesterolemia; Integrin alpha Chains; Lymphocyte Activation; Male; Middle Aged; Monocytes; Pyrroles; T-Lymphocytes | 2007 |
Atorvastatin induces apoptosis by a caspase-9-dependent pathway: an in vitro study on activated rat hepatic stellate cells.
Topics: Analysis of Variance; Animals; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Blotting, Western; Caspase 9; Cells, Cultured; Disease Models, Animal; Fas Ligand Protein; Female; Flow Cytometry; Hepatocytes; Heptanoic Acids; JNK Mitogen-Activated Protein Kinases; Male; Microscopy, Confocal; NF-kappa B; Probability; Pyrroles; Rats; Rats, Wistar; Sensitivity and Specificity | 2008 |
High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins.
Topics: Aged; Atorvastatin; Case-Control Studies; Cells, Cultured; Chemokine CCL2; Chemokine CXCL16; Chemokines, CXC; Coronary Artery Disease; Down-Regulation; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-8; Leukocytes, Mononuclear; Male; Middle Aged; Muscle, Smooth, Vascular; Pyrroles; Receptors, Scavenger; Simvastatin | 2008 |
LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases. Part 1. Separation of active components and classification of their interaction/degradation products.
Topics: Aspirin; Atenolol; Atorvastatin; Cardiovascular Agents; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Drug Stability; Heptanoic Acids; Hydrochlorothiazide; Lisinopril; Pravastatin; Pyrroles; Simvastatin; Spectrometry, Mass, Electrospray Ionization | 2008 |
Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Topics: Atorvastatin; Cardiovascular Diseases; Databases, Factual; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Managed Care Programs; Middle Aged; Myocardial Revascularization; Outcome Assessment, Health Care; Primary Prevention; Proportional Hazards Models; Pyrroles; Simvastatin; United States | 2008 |
Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Diabetes Complications; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Managed Care Programs; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2008 |
Combined treatment with atorvastatin and minocycline suppresses severity of EAE.
Topics: Animals; Anti-Bacterial Agents; Atorvastatin; Body Weight; Cell Proliferation; Cytokines; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Enzyme-Linked Immunosorbent Assay; Female; Glial Fibrillary Acidic Protein; Glycoproteins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Minocycline; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; Neurologic Examination; Peptide Fragments; Pyrroles; Stereotaxic Techniques; T-Lymphocytes; Time Factors | 2008 |
Toxicity of human pharmaceuticals and personal care products to benthic invertebrates.
Topics: Animals; Anti-Infective Agents, Local; Anticholesteremic Agents; Anticonvulsants; Atorvastatin; Biological Assay; Carbamazepine; Dose-Response Relationship, Drug; Ecosystem; Environmental Monitoring; Estradiol; Estrogens; Heptanoic Acids; Humans; Invertebrates; Pyrroles; Triclosan | 2008 |
Effects of statins (atorvastatin) on serum lipoprotein levels in patients with primary hyperlipidemia and coronary heart disease.
Topics: Adult; Atorvastatin; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Pyrroles | 2007 |
Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.
Topics: Animals; Area Under Curve; Atorvastatin; Chromatography, Gas; Chromatography, Supercritical Fluid; Drug Compounding; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Spectroscopy; Male; Microscopy, Electron, Scanning; Nanoparticles; Pyrroles; Rats; Rats, Sprague-Dawley; Solubility; Solvents; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; X-Ray Diffraction | 2008 |
Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation.
Topics: Animals; Atorvastatin; Cardiomegaly; Disease Progression; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Heart Failure; Heparin-binding EGF-like Growth Factor; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Natriuretic Peptide, Brain; Phosphorylation; Pyrroles; Ventricular Function, Left | 2008 |
Gynecomastia possibly induced by rosuvastatin.
Topics: Atorvastatin; Fluorobenzenes; Gynecomastia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Probability; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Steroids; Sulfonamides | 2008 |
An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.
Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Economic; Pyrroles; Quality-Adjusted Life Years | 2008 |
Identification and quantitative determination of atorvastatin calcium polymorph in tablets using FT-Raman spectroscopy.
Topics: Atorvastatin; Calibration; Fourier Analysis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Spectrophotometry, Infrared; Spectrum Analysis, Raman; Tablets; X-Ray Diffraction | 2008 |
Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity.
Topics: Aged; Atorvastatin; Biomarkers; Brachial Artery; Chronic Disease; Endothelium, Vascular; Exercise Tolerance; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Time Factors; Vasodilation; Walking | 2008 |
The effect of atorvastatin treatment on lipid profile and adhesion molecule levels in hypercholesterolemic patients: relation to low-density lipoprotein receptor gene polymorphism.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; E-Selectin; Female; Follow-Up Studies; Gene Expression Regulation; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Middle Aged; Polymorphism, Genetic; Probability; Prospective Studies; Pyrroles; Receptors, LDL; Reference Values; Severity of Illness Index; Treatment Outcome | 2008 |
The failure of torcetrapib: is there a case for independent preclinical and clinical testing?
Topics: Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Drug Evaluation, Preclinical; Heptanoic Acids; Humans; Pyrroles; Quinolines; Research Design | 2008 |
Atorvastatin and uptake of ultrasmall superparamagnetic iron oxide nanoparticles (Ferumoxtran-10) in human monocyte-macrophages: implications for magnetic resonance imaging.
Topics: Atorvastatin; Cells, Cultured; Contrast Media; Dextrans; Dose-Response Relationship, Drug; Ferrosoferric Oxide; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Iron; Macrophages; Magnetic Resonance Imaging; Magnetite Nanoparticles; Nanoparticles; Oxides; Particle Size; Pyrroles; Tetradecanoylphorbol Acetate | 2008 |
Detection of Lipitor counterfeits: a comparison of NIR and Raman spectroscopy in combination with chemometrics.
Topics: Anticholesteremic Agents; Atorvastatin; Dosage Forms; Drug Storage; Excipients; Heptanoic Acids; Least-Squares Analysis; Molecular Structure; Principal Component Analysis; Pyrroles; Spectroscopy, Near-Infrared; Spectrum Analysis, Raman; Tablets; Technology, Pharmaceutical | 2008 |
Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program.
Topics: Adult; Aged; Alleles; Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Decision Making; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Inpatients; Linear Models; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Predictive Value of Tests; Pyridines; Pyrroles; Simvastatin; Triglycerides | 2008 |
Biphasic effects of atorvastatin on inflammation.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Carrageenan; Edema; Heptanoic Acids; Hindlimb; Inflammation; Male; Mevalonic Acid; Mice; Pyrroles; Rats; Rats, Wistar | 2008 |
Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipids; Liver Cirrhosis, Biliary; Liver Function Tests; Male; Middle Aged; Pyrroles; Quality of Life; Retrospective Studies; Treatment Outcome | 2008 |
Behavioral changes with paranoia in an elderly woman taking atorvastatin.
Topics: Aged; Atorvastatin; Cognition; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Paranoid Disorders; Pyrroles; Serotonin Plasma Membrane Transport Proteins | 2008 |
[Influence of statins on the antiplatelet effect of clopidogrel and on cardiovascular outcome in patients after coronary intervention].
Topics: Atorvastatin; Clopidogrel; Coronary Disease; Coronary Stenosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Simvastatin; Stents; Ticlopidine | 2008 |
Lipid levels after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heart Conduction System; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prognosis; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Time Factors; Triglycerides | 2008 |
Lipid levels in the post-acute coronary syndrome setting: destabilizing another myth?
Topics: Acute Coronary Syndrome; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Prognosis; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2008 |
Bexarotene combination therapy for patients with Sézary syndrome.
Topics: Antineoplastic Agents; Atorvastatin; Bexarotene; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Sezary Syndrome; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine | 2008 |
[Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Cost-Benefit Analysis; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Middle Aged; Models, Economic; Pyrroles | 2008 |
Wake up and smell the coffee: yet another no go for cardiac patients? : editorial to "caffeinated coffee blunts the myocardial protective effects of statins against ischemia-reperfusion injury in the rat" by Ye et al.
Topics: Administration, Oral; Animals; Atorvastatin; Caffeine; Coffee; Food-Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Pyrroles; Rats | 2008 |
Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes.
Topics: Animals; Atorvastatin; Hepatocytes; Heptanoic Acids; Indomethacin; Male; Models, Biological; Pyridines; Pyrroles; Rats; Rats, Sprague-Dawley | 2008 |
Atorvastatin inhibits ABCA1 expression and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway.
Topics: Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cell Line; Cholesterol; DNA-Binding Proteins; Dose-Response Relationship, Drug; Foam Cells; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Liver X Receptors; Macrophage Activation; Macrophages; Orphan Nuclear Receptors; Pyrroles; Receptors, Cytoplasmic and Nuclear; rhoA GTP-Binding Protein; RNA, Messenger; Tetradecanoylphorbol Acetate | 2008 |
Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Base Sequence; DNA Primers; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hypercholesterolemia; Intracellular Signaling Peptides and Proteins; Lipids; Male; Membrane Proteins; Middle Aged; Polymerase Chain Reaction; Pyrroles; Sterol Regulatory Element Binding Protein 1 | 2008 |
Treating residual cardiovascular risk: will lipoprotein-associated phospholipase A2 inhibition live up to its promise?
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Inflammation; Pyrroles | 2008 |
Torcetrapib and coronary events.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Pyrroles; Quinolines; Treatment Failure | 2008 |
Atorvastatin downregulates BMP-2 expression induced by oxidized low-density lipoprotein in human umbilical vein endothelial cells.
Topics: Antioxidants; Atorvastatin; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Cell Nucleus; Cells, Cultured; Cytoplasm; Down-Regulation; Drug Interactions; Endothelial Cells; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Malondialdehyde; Proline; Pyrroles; RNA, Messenger; Superoxide Dismutase; Thiocarbamates; Transcription Factor RelA; Transforming Growth Factor beta; Umbilical Veins | 2008 |
Dose-related effect of statins on atrial fibrillation after cardiac surgery.
Topics: Aged; Aged, 80 and over; Aortic Valve; Atorvastatin; Atrial Fibrillation; Cohort Studies; Coronary Artery Bypass; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Heart Valve Prosthesis Implantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Postoperative Complications; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome | 2008 |
Statins, leptin and regulatory T cells.
Topics: Animals; Atorvastatin; Heptanoic Acids; Humans; Leptin; Lymphocyte Activation; Neoplasms; Obesity; Pyrroles; Risk Factors; T-Lymphocytes, Regulatory; Thinness | 2008 |
[Difficulties in detecting the causative agent of an adverse drug reaction in a complicated case].
Topics: Administration, Cutaneous; Administration, Oral; Anticonvulsants; Antidepressive Agents; Atorvastatin; Azabicyclo Compounds; Drug Eruptions; Female; Heptanoic Acids; Humans; Lamotrigine; Middle Aged; Piperazines; Pyrroles; Risperidone; Sertraline; Skin Tests; Triazines | 2008 |
Statin treatment improves cerebral more than systemic endothelial dysfunction in patients with arterial hypertension.
Topics: Arginine; Atorvastatin; Blood Circulation; Cerebrovascular Circulation; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Ultrasonography, Doppler, Transcranial | 2008 |
Leukocyte, plasma, and organ-associated cytokine profiles in an animal model of acute inflammation.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Cytokines; Disease Models, Animal; Down-Regulation; Endotoxemia; Female; Heart; Heptanoic Acids; Inflammation Mediators; Kidney; Leukocytes; Lipopolysaccharides; Myocardium; Organ Specificity; Pyrroles; Random Allocation; Swine; Up-Regulation | 2008 |
[Stroke due to spontaneous calcified cerebral embolus as presenting feature of calcified aortic stenosis].
Topics: Aged, 80 and over; Anterior Cerebral Artery; Aortic Valve; Aortic Valve Stenosis; Aspirin; Atorvastatin; Calcinosis; Heptanoic Acids; Humans; Intracranial Embolism; Male; Pyrroles; Stroke; Tomography, X-Ray Computed | 2008 |
Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts.
Topics: Animals; Apoptosis; Atorvastatin; Biomarkers; Cell Differentiation; Combined Modality Therapy; Cytokines; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Angiography; Mesenchymal Stem Cell Transplantation; Myocardial Infarction; Oxidative Stress; Pyrroles; Survival Rate; Swine; Swine, Miniature; Tomography, Emission-Computed, Single-Photon | 2008 |
Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Drug Synergism; Heptanoic Acids; Inflammation; Mice; Mice, Inbred Strains; Pyrroles; Quinolines | 2008 |
Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction.
Topics: Animals; Atorvastatin; Cytokines; Disease Models, Animal; Drug Evaluation, Preclinical; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-10; Macrophages; Male; Myocardial Infarction; Pyrroles; Rats; Rats, Sprague-Dawley; Ventricular Dysfunction, Left; Ventricular Function, Left | 2009 |
Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients.
Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Azetidines; Cholesterol, LDL; Drug Administration Schedule; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Lopinavir; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Ritonavir; Treatment Outcome | 2008 |
Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-beta, and fibronectin with concomitant increase in nitric oxide bioavailability.
Topics: Animals; Atorvastatin; Biological Availability; Blood Pressure; Chemokine CCL2; Fibronectins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Failure, Chronic; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Proteinuria; Pyrroles; Rats; Rats, Inbred Dahl; RNA, Messenger; Scavenger Receptors, Class E; Transforming Growth Factor beta | 2008 |
Real-time detection and identification of aqueous chlorine transformation products using QTOF MS.
Topics: Atorvastatin; Chlorine; Halogenation; Heptanoic Acids; Mass Spectrometry; Methanol; Pharmaceutical Preparations; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Time Factors; Triclosan; Water; Water Pollutants, Chemical | 2008 |
Prevention of pediatric graft coronary artery disease: atorvastatin.
Topics: Angiography; Atorvastatin; Case-Control Studies; Child; Coronary Artery Disease; Female; Follow-Up Studies; Graft Survival; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Pyrroles; Time Factors; Treatment Outcome | 2008 |
Atorvastatin-induced hemorrhagic cystitis: a case report.
Topics: Aged; Atorvastatin; Cystitis; Female; Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2009 |
The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Atorvastatin; Cyclooxygenase 2; Disease Models, Animal; Electrophoretic Mobility Shift Assay; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Janus Kinases; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; NF-kappa B; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Peptides; Phosphorylation; Protein Kinase Inhibitors; Pyrroles; Time Factors; Tyrphostins; Up-Regulation | 2008 |
Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes.
Topics: 3T3-L1 Cells; Adaptor Proteins, Signal Transducing; Adipocytes; ADP Ribose Transferases; Amides; Animals; Atorvastatin; Botulinum Toxins; Dose-Response Relationship, Drug; Glucose; Glucose Transporter Type 4; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Receptor Substrate Proteins; Mice; Phosphorylation; Polyisoprenyl Phosphates; Pravastatin; Protein Kinase Inhibitors; Protein Prenylation; Protein Transport; Proto-Oncogene Proteins c-akt; Pyridines; Pyrroles; rab4 GTP-Binding Proteins; Receptor, Insulin; rho GTP-Binding Proteins; rho-Associated Kinases; rhoA GTP-Binding Protein; RNA, Messenger; Signal Transduction | 2008 |
Functional consequences of active hepatic uptake on cytochrome P450 inhibition in rat and human hepatocytes.
Topics: Animals; Atorvastatin; Cells, Cultured; Culture Media; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diclofenac; Enzyme Inhibitors; Estrone; Hepatocytes; Heptanoic Acids; Humans; Hydroxylation; Liver; Midazolam; Pyrroles; Quinolines; Rats; Recombinant Proteins; Tritium | 2008 |
Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Atorvastatin; Cholesterol; Clozapine; Female; Fenofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Psychotic Disorders; Pyrroles; Retrospective Studies; Schizophrenia; Treatment Outcome; Triglycerides | 2008 |
Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration.
Topics: Animals; Anticholesteremic Agents; Aortic Aneurysm, Abdominal; Atorvastatin; Cell Movement; Collagen; Disease Models, Animal; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Pancreatic Elastase; Pyrroles; Rats; Rats, Wistar; Treatment Outcome | 2009 |
Re: Statins and sepsis.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sepsis | 2008 |
Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
Topics: Atorvastatin; Cohort Studies; Coronary Disease; Cost-Benefit Analysis; Finland; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Expectancy; Male; Markov Chains; Middle Aged; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Cytogenetic status and oxidative DNA-damage induced by atorvastatin in human peripheral blood lymphocytes: standard and Fpg-modified comet assay.
Topics: Adult; Atorvastatin; Cell Survival; Comet Assay; Cytogenetics; DNA Damage; DNA-Formamidopyrimidine Glycosylase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lymphocytes; Male; Micronucleus Tests; Mutagenicity Tests; Oxidation-Reduction; Oxidative Stress; Pyrroles | 2008 |
Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Drugs, Generic; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Atorvastatin and celecoxib: a future role in cancer chemoprevention.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antineoplastic Agents; Atorvastatin; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Pyrazoles; Pyrroles; Sulfonamides | 2008 |
The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters.
Topics: Aryldialkylphosphatase; Atorvastatin; Cholesterol, LDL; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lipids; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Pyrroles; Simvastatin | 2008 |
Specific amelioration of cerebral endothelial dysfunction in hypertensive patients treated with atorvastatin.
Topics: Animals; Atorvastatin; Cerebrovascular Circulation; Cerebrovascular Disorders; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pyrroles | 2008 |
Physicochemical properties and oral bioavailability of amorphous atorvastatin hemi-calcium using spray-drying and SAS process.
Topics: Acetone; Administration, Oral; Animals; Area Under Curve; Atorvastatin; Biological Availability; Crystallization; Furans; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Particle Size; Pyrroles; Rats; Rats, Sprague-Dawley; Solubility; Solvents | 2008 |
[Changes of blood lipids in colorectal cancer patients with coronary heart disease and value of lipid-lowering therapy with statins].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Colorectal Neoplasms; Coronary Disease; Female; Heptanoic Acids; Humans; Lipoprotein(a); Male; Middle Aged; Pyrroles; Treatment Outcome; Triglycerides | 2008 |
Short term effects of atorvastatin on endothelial functions and oxidized LDL levels in patients with type 2 diabetes.
Topics: Atherosclerosis; Atorvastatin; Biomarkers; Brachial Artery; Carotid Arteries; Cholesterol, LDL; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Tunica Intima | 2008 |
Von Willebrand disease and angiodysplasia responding to atorvastatin.
Topics: Angiodysplasia; Anticholesteremic Agents; Atorvastatin; Hemophilia A; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome; von Willebrand Diseases | 2008 |
A novel membrane-based anti-diabetic action of atorvastatin.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Atorvastatin; Cell Membrane; Cholesterol; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Insulin Resistance; Mice; Picolinic Acids; Pyrroles | 2008 |
Possible involvement of advanced glycation end products in carry-over benefits of atorvastatin in ASCOT-BPLA.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Glycation End Products, Advanced; Heptanoic Acids; Humans; Pyrroles | 2008 |
The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2008 |
Does atorvastatin affect androgen levels in men in the era of very-low LDL targeting therapy?
Topics: Androgens; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles | 2009 |
Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis.
Topics: Adolescent; Adult; Atorvastatin; Cytokines; Data Interpretation, Statistical; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon Type I; Interleukin-5; Male; Middle Aged; Multiple Sclerosis; Pyrroles; Recombinant Proteins; Th1 Cells; Th2 Cells | 2008 |
CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin.
Topics: Alleles; Anticholesteremic Agents; Asian People; Atorvastatin; Cholesterol, LDL; Cytochrome P-450 CYP3A; Female; Gene Frequency; Heptanoic Acids; Humans; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Prospective Studies; Pyrroles; Simvastatin | 2008 |
Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat: role of angiotensin II type 1 receptors.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Echocardiography; Heptanoic Acids; Hypercholesterolemia; Losartan; Male; Myocardial Infarction; Pyrroles; Rats; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Up-Regulation; Ventricular Dysfunction, Left; Ventricular Remodeling | 2008 |
[Effect of atorvastatin treatment on the hemorheologic and hemostatic parameters in chronic cerebrovascular patients].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Viscosity; Cerebrovascular Disorders; Chronic Disease; Drug Administration Schedule; Endothelium, Vascular; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Fibrinogen; Hematocrit; Hemorheology; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrroles; Stroke; von Willebrand Factor | 2008 |
Hippocampal volume change in the Alzheimer Disease Cholesterol-Lowering Treatment trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Cognition; Diagnostic Techniques, Neurological; Female; Heptanoic Acids; Hippocampus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pilot Projects; Psychological Tests; Psychophysiology; Pyrroles; Risk Factors | 2008 |
Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat.
Topics: Acetylcholine; Animals; Atorvastatin; Blotting, Western; Body Weight; Caspase 3; Celecoxib; Cyclooxygenase Inhibitors; Disease Progression; Drug Combinations; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Myocardium; Nitric Oxide Synthase Type III; Pulmonary Artery; Pyrazoles; Pyrroles; Rats; Rats, Wistar; Sulfonamides; Survival Analysis; Vasodilator Agents | 2008 |
[Effect of atorvastatin on ACE2 expression in pressure overload induced cardiac hypertrophy in rats].
Topics: Angiotensin-Converting Enzyme 2; Animals; Aorta; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Ligation; Male; Peptidyl-Dipeptidase A; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2008 |
Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Databases, Factual; Drug Utilization Review; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Simvastatin; Survival Analysis; United States | 2008 |
Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.
Topics: Adult; Aged; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Muscular Diseases; Pyrroles; Risk Management; Simvastatin | 2008 |
Statins, regulatory T cells, and pediatric graft coronary artery disease.
Topics: Atorvastatin; Child; Coronary Artery Disease; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; T-Lymphocytes, Regulatory | 2009 |
[Dual cholesterol inhibition. More high risk patients achieve LDL cholesterol values below 100 mg/dl].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Ezetimibe; Germany; Heptanoic Acids; Humans; Hypercholesterolemia; Multicenter Studies as Topic; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2008 |
Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus.
Topics: Administration, Oral; Animals; Antibodies, Antinuclear; Atorvastatin; Cell Proliferation; Cholesterol; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-4; Lupus Erythematosus, Systemic; Mice; Mice, Inbred NZB; Pyrroles; T-Lymphocytes; Treatment Outcome | 2008 |
Short-term evolution (9 months) of aortic atheroma in patients with or without embolic events: a follow-up transoesophageal echocardiographic study.
Topics: Aged; Analysis of Variance; Anticoagulants; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Confidence Intervals; Echocardiography, Transesophageal; Embolism; Female; Follow-Up Studies; Heptanoic Acids; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prospective Studies; Pyrroles; Risk Assessment; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Effects of atorvastatin on progression-regression of renal injury in hyperlipidemic chickens.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Chickens; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Heptanoic Acids; Hyperlipidemias; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Lipids; Male; Pyrroles | 2008 |
Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atherosclerosis; Atorvastatin; Autoantibodies; Biomarkers; Cholesterol, LDL; Coronary Angiography; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin G; Immunoglobulin M; Lipoprotein(a); Male; Malondialdehyde; Middle Aged; Oxidative Stress; Phospholipids; Pravastatin; Prospective Studies; Pyrroles; Research Design | 2008 |
Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death.
Topics: Animals; Atorvastatin; Cell Death; Disease Models, Animal; Dose-Response Relationship, Drug; Ectodysplasins; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Inflammation; Interleukin-1beta; Kainic Acid; Male; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Sprague-Dawley; Seizures; Tumor Necrosis Factor-alpha | 2008 |
Stability indicating UPLC method for simultaneous determination of atorvastatin, fenofibrate and their degradation products in tablets.
Topics: Anticholesteremic Agents; Atorvastatin; Buffers; Chromatography, High Pressure Liquid; Drug Contamination; Drug Stability; Fenofibrate; Heptanoic Acids; Hydrogen-Ion Concentration; Molecular Structure; Pyrroles; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Tablets; Time Factors | 2008 |
Effects of atherogenic diet and atorvastatin treatment on gene expression profiles in the C57BL/6J mouse liver.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Diet, Atherogenic; Female; Gene Expression Profiling; Heptanoic Acids; Lipid Metabolism; Liver; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Pyrroles; Sterol Regulatory Element Binding Proteins | 2008 |
Involvement of heat shock factor 1 in statin-induced transcriptional upregulation of endothelial thrombomodulin.
Topics: 14-3-3 Proteins; Atorvastatin; Cells, Cultured; DNA-Binding Proteins; Endothelium, Vascular; Heat Shock Transcription Factors; Heptanoic Acids; HSP90 Heat-Shock Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kruppel-Like Transcription Factors; MAP Kinase Signaling System; Plasminogen Activator Inhibitor 1; Pyrroles; Sp1 Transcription Factor; Thrombomodulin; Tissue Plasminogen Activator; Transcription Factors; Up-Regulation | 2008 |
Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress.
Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Atorvastatin; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cell Proliferation; DNA Replication; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Membrane Potential, Mitochondrial; Necrosis; Oxidative Stress; Pyrroles; Reactive Oxygen Species; Simvastatin | 2008 |
Effect of correcting serum cholesterol levels on erectile function in patients with vasculogenic erectile dysfunction.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypercholesterolemia; Impotence, Vasculogenic; Male; Middle Aged; Penile Erection; Phosphodiesterase Inhibitors; Piperazines; Purines; Pyrroles; Sildenafil Citrate; Sulfones; Ultrasonography, Doppler, Duplex | 2008 |
Lipid management: considerations in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Risk Assessment; Risk Factors; Triglycerides | 2008 |
Simultaneous estimation of atorvastatin and ramipril by RP-HPLC and spectroscopy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Capsules; Chromatography, High Pressure Liquid; Drug Combinations; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Least-Squares Analysis; Pyrroles; Ramipril; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2008 |
Efficient tirofiban infusion resulting in resolution of intracoronary thrombus.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Electrocardiography; Fibrinolytic Agents; Heptanoic Acids; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Tirofiban; Tyrosine | 2008 |
The effect of exogenous cholesterol and lipid-modulating agents on enterocytic amyloid-beta abundance.
Topics: Amyloid beta-Peptides; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Body Weight; Cholesterol; Cholesterol, Dietary; Enterocytes; Ezetimibe; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Intestinal Absorption; Mice; Mice, Inbred C57BL; Pyrroles; Random Allocation; Triglycerides | 2009 |
Commentary on "the Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics".
Topics: Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Heptanoic Acids; Humans; Indans; Multicenter Studies as Topic; Piperidines; Pyrroles; Randomized Controlled Trials as Topic | 2008 |
Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways.
Topics: Angiotensin II; Atorvastatin; Cell Line; Cell Transdifferentiation; Connective Tissue Growth Factor; Epithelial Cells; Fibrosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Kidney Tubules, Proximal; Mitogen-Activated Protein Kinase Kinases; Phenotype; Protein Kinase Inhibitors; Pyrroles; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Simvastatin; Time Factors; Transfection | 2008 |
Effect of atorvastatin on hs-CRP in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2008 |
Does knowledge of medication prices predict physicians' support for cost effective prescribing policies.
Topics: Atorvastatin; British Columbia; Cost Control; Cost-Benefit Analysis; Drug Costs; Drug Prescriptions; Drugs, Generic; Family Practice; Health Knowledge, Attitudes, Practice; Heptanoic Acids; Humans; Practice Patterns, Physicians'; Prescription Fees; Pyrroles | 2008 |
Rhabdomyolysis with atorvastatin and fusidic acid.
Topics: Aged; Anti-Bacterial Agents; Atorvastatin; Drug Interactions; Drug Therapy, Combination; Floxacillin; Fusidic Acid; Heart Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Osteomyelitis; Pyrroles; Rhabdomyolysis | 2008 |
Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS.
Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetic Angiopathies; France; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary Prevention; Pyrroles | 2008 |
Lipophilicity and cardiovascular outcome in patients with CHF.
Topics: Aged; Atorvastatin; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Heptanoic Acids; Humans; Pyrroles; Verapamil | 2008 |
Serum uric acid level reduction, cardiovascular outcome, and mortality: comment on the article by Ioachimescu et al.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Predictive Value of Tests; Pyrroles; Treatment Outcome; Uric Acid | 2008 |
Statins activate GATA-6 and induce differentiated vascular smooth muscle cells.
Topics: Actins; Amino Acid Motifs; Atorvastatin; Cell Differentiation; Cell Proliferation; Diterpenes; DNA Replication; GATA6 Transcription Factor; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nucleic Acid Synthesis Inhibitors; Polyisoprenyl Phosphates; Pyrroles; Sesquiterpenes; Simvastatin; Transcription, Genetic | 2008 |
Intensive lipid intervention in the post-ENHANCE era.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin.
Topics: Animals; Apoptosis; Atorvastatin; Catechin; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Flavonoids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Mice; Phenols; Plant Extracts; Polyphenols; Pyrroles; Tea | 2008 |
Monocyte gene-expression profile in men with familial combined hyperlipidemia and its modification by atorvastatin treatment.
Topics: Aged; Atorvastatin; Gene Expression Profiling; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Inflammation Mediators; Male; Middle Aged; Monocytes; Pyrroles; Treatment Outcome | 2008 |
Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats.
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Atorvastatin; Dementia, Vascular; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Maze Learning; Memory; Methionine; Pyrroles; Quinolines; Rats; Rats, Wistar | 2008 |
Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; British Columbia; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2008 |
High glucose induced endothelial cell growth inhibition is associated with an increase in TGFbeta1 secretion and inhibition of Ras prenylation via suppression of the mevalonate pathway.
Topics: Animals; Atorvastatin; Cell Proliferation; Diabetes Mellitus, Experimental; Down-Regulation; Endothelial Cells; Glucose; Heptanoic Acids; Humans; Kidney; Male; Mevalonic Acid; Oncogene Protein p21(ras); Oncogene Protein v-akt; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Prenylation; Pyrroles; Rats; Signal Transduction; Transforming Growth Factor beta1; Umbilical Veins | 2009 |
Molecule of the month.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Molecular Structure; Pyrroles; Structure-Activity Relationship | 2008 |
Phosphorylation of 5-lipoxygenase at ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin a4 production.
Topics: Animals; Arachidonate 5-Lipoxygenase; Atorvastatin; Cyclic AMP-Dependent Protein Kinases; Gene Expression Regulation; Heptanoic Acids; Immunologic Factors; Isoquinolines; Leukotriene B4; Lipoxins; Male; Myocardium; Phosphorylation; Pioglitazone; Pyrroles; Rats; Rats, Sprague-Dawley; Serine; Sulfonamides; Thiazolidinediones | 2008 |
Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin.
Topics: Atorvastatin; Cytochrome P-450 CYP3A; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Microsomes, Liver; Molecular Structure; Pyrroles; Recombinant Proteins | 2008 |
Assessment of regional systolic and diastolic functions affected by atorvastatin in coronary artery disease using tissue Doppler imaging.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Diastole; Female; Heart Ventricles; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Assessment; Systole; Ultrasonography, Doppler; Ventricular Function, Left | 2008 |
Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
Topics: Aged; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Atorvastatin; Calcium Carbonate; Cardiomyopathy, Restrictive; Citalopram; Connective Tissue Diseases; Diuretics; Female; Furosemide; Glucosamine; Heptanoic Acids; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Lupus Erythematosus, Systemic; Magnesium; Metolazone; Middle Aged; Naproxen; Omeprazole; Potassium Chloride; Prednisone; Pyrroles; Selective Serotonin Reuptake Inhibitors; Spironolactone | 2008 |
Ptosis, diplopia and statins: an association?
Topics: Adult; Atorvastatin; Autoantibodies; Autoimmune Diseases of the Nervous System; Azetidines; Blepharoptosis; Diabetes Complications; Diagnostic Errors; Diplopia; Eyelid Diseases; Ezetimibe; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Myasthenia Gravis; Myocardial Infarction; Pain; Pravastatin; Pyrroles; Receptors, Cholinergic; Recurrence; Strabismus | 2008 |
CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.
Topics: Aged; Alleles; Atorvastatin; Black People; Body Mass Index; Brazil; Cholesterol, LDL; Cytochrome P-450 CYP3A; DNA; DNA Primers; Female; Gene Frequency; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Restriction Fragment Length; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
Atorvastatin-induced changes in plasma coenzyme q10 and brain natriuretic peptide in patients with coronary artery disease.
Topics: Aged; Atorvastatin; Chromatography, High Pressure Liquid; Coronary Artery Disease; Dose-Response Relationship, Drug; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoassay; Natriuretic Peptide, Brain; Oxidative Stress; Pyrroles; Treatment Outcome; Ubiquinone | 2008 |
Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cholesterol, LDL; Cross-Over Studies; Dietary Supplements; Drug Interactions; Drug Synergism; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Vitamin D | 2009 |
Impact of adherence to statins on chronic heart failure in primary prevention.
Topics: Aged; Atorvastatin; Case-Control Studies; Databases, Factual; Female; Fluorobenzenes; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Lovastatin; Male; Middle Aged; Patient Compliance; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2008 |
IFNalpha treatment generates antigen-presenting cells insensitive to atorvastatin inhibition of MHC-II expression.
Topics: Atorvastatin; Cell Differentiation; Cells, Cultured; Dendritic Cells; Granulocyte-Macrophage Colony-Stimulating Factor; Heptanoic Acids; Histocompatibility Antigens Class II; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-alpha; Interleukin-4; Monocytes; Pyrroles; T-Lymphocytes | 2008 |
Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion.
Topics: Animals; Apoptosis; Atorvastatin; Cell Line, Tumor; Cell Movement; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Kinase 4; MAP Kinase Signaling System; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Invasiveness; Osteosarcoma; Phosphorylation; Proto-Oncogene Proteins c-jun; Pyrroles; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Tissue Inhibitor of Metalloproteinase-2 | 2008 |
Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Insurance Claim Review; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors | 2008 |
[Hypertension--does it matter how blood pressure is lowered?].
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Bendroflumethiazide; Cardiovascular Diseases; Cost-Benefit Analysis; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Heptanoic Acids; Humans; Hypertension; Perindopril; Pyrroles; Treatment Outcome | 2008 |
Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Atorvastatin; Bcl-2-Like Protein 11; cdc42 GTP-Binding Protein; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; JNK Mitogen-Activated Protein Kinases; Lovastatin; Membrane Proteins; Ovarian Neoplasms; Proto-Oncogene Proteins; Pyrroles; rac1 GTP-Binding Protein | 2009 |
Atorvastatin enhances hypothermia-induced neuroprotection after stroke.
Topics: Animals; Atorvastatin; Brain Infarction; CD11b Antigen; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothermia, Induced; Magnetic Resonance Imaging; Male; Neurologic Examination; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Sprague-Dawley; Statistics, Nonparametric; Stroke | 2008 |
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Myocardial Revascularization; Pyrroles; Risk Assessment; Stroke | 2009 |
Epithelial neutrophil-activating peptide (ENA-78), acute coronary syndrome prognosis, and modulatory effect of statins.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Chemokine CXCL5; Cohort Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Male; Middle Aged; Neutrophils; Peptides; Prognosis; Prospective Studies; Pyrroles | 2008 |
Evaluation cardioprotective effects of atorvastatin in rats by real time myocardial contrast echocardiography.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cardiotonic Agents; Computer Systems; Contrast Media; Echocardiography; Heptanoic Acids; Image Enhancement; Male; Myocardial Reperfusion Injury; Pyrroles; Rats; Rats, Wistar; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Ventricular Dysfunction, Left | 2008 |
A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in diabetic patients without prior cardiovascular disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Mellitus; Health Maintenance Organizations; Heptanoic Acids; Humans; Preferred Provider Organizations; Pyrroles; Simvastatin; Treatment Outcome; United States | 2008 |
Statins alone are ineffective in cerebral malaria but potentiate artesunate.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Atorvastatin; Disease Models, Animal; Drug Synergism; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Malaria, Cerebral; Malaria, Falciparum; Mice; Neuroprotective Agents; Pravastatin; Pyrroles; Simvastatin | 2008 |
Atorvastatin efficiency after traumatic brain injury in rats.
Topics: Analysis of Variance; Animals; Atorvastatin; Brain; Brain Edema; Brain Injuries; Cerebrovascular Circulation; Craniotomy; Disease Models, Animal; Heptanoic Acids; Lipid Peroxidation; Male; Microcirculation; Microscopy, Electron, Transmission; Neuroprotective Agents; Organ Size; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley | 2009 |
Ischemic stroke: a cardiovascular risk equivalent? Lessons learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Atorvastatin; Cardiovascular Diseases; Cerebral Hemorrhage; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke | 2008 |
Amelioration of human allograft arterial injury by atorvastatin or simvastatin correlates with reduction of interferon-gamma production by infiltrating T cells.
Topics: Adult; Animals; Arteries; Atorvastatin; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Leukocytes, Mononuclear; Lymphocyte Transfusion; Mice; Mice, SCID; Pyrroles; Simvastatin; T-Lymphocytes; Transplantation, Heterologous; Transplantation, Homologous | 2008 |
Atorvastatin down-regulates the primate cellular response to porcine aortic endothelial cells in vitro.
Topics: Animals; Aorta; Atorvastatin; CD4-Positive T-Lymphocytes; Cell Division; Endothelium, Vascular; Flow Cytometry; Heptanoic Acids; Humans; Pyrroles; Swine | 2008 |
Familial dysbetalipoproteinemia: a potentially fatal disorder.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Male; Pyrroles; Risk Factors | 2008 |
Kinetic studies of the metabolism of rapidly exchangeable apolipoproteins may leave investigators and readers with exchangeable results.
Topics: Apolipoprotein C-III; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Atorvastatin; Cholesterol; Down-Regulation; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kinetics; Lipoproteins, VLDL; Male; Metabolic Syndrome; Pyrroles; Research Design; Treatment Outcome; Triglycerides | 2008 |
Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Europe; Heptanoic Acids; Humans; Markov Chains; Pyrroles; Quality-Adjusted Life Years | 2009 |
Atorvastatin inhibits renal crystal retention in a rat stone forming model.
Topics: Animals; Apoptosis; Atorvastatin; Biopsy, Needle; Disease Models, Animal; Heptanoic Acids; Immunohistochemistry; Kidney Calculi; Kidney Tubules; Male; Oxalates; Oxidative Stress; Probability; Pyrroles; Random Allocation; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Statistics, Nonparametric; Superoxide Dismutase; Urinalysis | 2008 |
Statin, the black box.
Topics: Acute Coronary Syndrome; Atorvastatin; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2008 |
Tissue-specific effects of atorvastatin on 3-hydroxy-3-methylglutarylcoenzyme A reductase expression and activity in spontaneously hypertensive rats.
Topics: Animals; Atorvastatin; Cholesterol; Chromatography, High Pressure Liquid; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Lipid Metabolism; Liver; Muscle, Smooth, Vascular; Myocardium; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 2008 |
Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats.
Topics: Animals; Antifungal Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Calibration; Cyclosporine; Cytochrome P-450 CYP3A; Drug Interactions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Injections, Intravenous; Intubation, Gastrointestinal; Itraconazole; Male; Pyrroles; Rats; Rats, Sprague-Dawley | 2008 |
The influence of simvastatin, atorvastatin and high-cholesterol diet on acetylcholinesterase activity, amyloid beta and cholesterol synthesis in rat brain.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anticholesteremic Agents; Atorvastatin; Brain; Brain Chemistry; Cholesterol; Cholesterol, Dietary; Diet; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Male; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2009 |
Bilayer tablets of atorvastatin calcium and nicotinic acid: formulation and evaluation.
Topics: Atorvastatin; Carboxymethylcellulose Sodium; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Carriers; Drug Combinations; Drug Incompatibility; Drug Stability; Drug Storage; Excipients; Hardness; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypromellose Derivatives; Methylcellulose; Niacin; Pyrroles; Solubility; Tablets | 2008 |
Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen.
Topics: Aged; Amlodipine; Atorvastatin; Calcium Channel Blockers; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Patient Compliance; Pyrroles; Retrospective Studies | 2008 |
Hemorrhagic stroke in the SPARCL study.
Topics: Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Intracranial Hemorrhages; Lipoproteins, LDL; Male; Pyrroles; Risk Factors; Stroke | 2008 |
Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin.
Topics: Amino Acid Sequence; Atorvastatin; Cell Line; Cells, Cultured; Endothelial Cells; Fibroblasts; Gene Expression Profiling; Gene Expression Regulation; Heptanoic Acids; Humans; Microarray Analysis; Muscle, Smooth; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrroles; rho-Associated Kinases | 2008 |
Characterization of low-density lipoprotein cholesterol-lowering efficacy for atorvastatin in a population-based DNA biorepository.
Topics: Algorithms; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Data Interpretation, Statistical; Databases, Genetic; DNA; Dose-Response Relationship, Drug; Female; Genetics, Population; Heptanoic Acids; Humans; Male; Medical Records; Multivariate Analysis; Pharmacogenetics; Pyrroles; Treatment Outcome | 2008 |
Effects of atorvastatin on calcium-regulating proteins: a possible mechanism to repair cardiac dysfunction in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Atorvastatin; Blood Pressure; Blotting, Western; Calcium-Binding Proteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cytokines; Enzyme-Linked Immunosorbent Assay; Gene Expression; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pyrroles; Rats; Rats, Inbred SHR; Rats, Wistar; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Ventricular Function, Left | 2009 |
A case of ANCA-associated systemic vasculitis induced by atorvastatin.
Topics: Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Anticholesteremic Agents; Atorvastatin; Azathioprine; Heptanoic Acids; Humans; Immunosuppressive Agents; Male; Methylprednisolone; Middle Aged; Pyrroles; Vasculitis | 2008 |
Statins alter neutrophil migration by modulating cellular Rho activity--a potential mechanism for statins-mediated pleotropic effects?
Topics: Atorvastatin; Cells, Cultured; Chemotactic Factors; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; N-Formylmethionine Leucyl-Phenylalanine; Neutrophil Infiltration; Neutrophils; Polyisoprenyl Phosphates; Pravastatin; Pyrroles; rhoA GTP-Binding Protein; Simvastatin | 2009 |
Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
Topics: Aged; Atorvastatin; Brain Ischemia; Carotid Stenosis; Cerebral Hemorrhage; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk; Treatment Outcome | 2008 |
Effects of atorvastatin on warfarin-induced aortic medial calcification and systolic blood pressure in rats.
Topics: Animals; Aortic Diseases; Atorvastatin; Blood Pressure; Calcinosis; Heptanoic Acids; Hypertension; Male; Pyrroles; Random Allocation; Rats; Rats, Wistar; Warfarin | 2008 |
Human CYP3A4-introduced HepG2 cells: in vitro screening system of new chemicals for the evaluation of CYP3A4-inhibiting activity.
Topics: Ammonia; Animals; Atorvastatin; Cell Line, Tumor; Cricetinae; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Evaluation, Preclinical; Enzyme Inhibitors; Glutamate-Ammonia Ligase; Heptanoic Acids; Humans; Ketoconazole; Lidocaine; Nifedipine; Pyrroles | 2008 |
ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Polymorphism, Genetic; Pyrroles | 2009 |
A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Fats; Drug Therapy, Combination; Fatty Liver; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Resistance; Lipids; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Strains | 2009 |
Advertisements for atorvastatin were misleading to women.
Topics: Advertising; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Myocardial Infarction; Pyrroles; Sex Factors | 2008 |
A possible negative effect of co-administered amlodipine and atorvastatin on semen volume and spermatozoa in men.
Topics: Amlodipine; Atorvastatin; Calcium Channel Blockers; Databases, Factual; Drug Interactions; Fertility; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Semen; Spermatozoa | 2008 |
The influence of statin medications on prostate-specific antigen levels.
Topics: Aged; Atorvastatin; Biomarkers, Tumor; Cholesterol, HDL; Cholesterol, LDL; Early Diagnosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Linear Models; Longitudinal Studies; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Risk Assessment; Simvastatin; Veterans | 2008 |
Variability of lipids in patients with Type 2 diabetes taking statin treatment: implications for target setting.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Lipid Metabolism; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2008 |
Binder wars.
Topics: Anticholesteremic Agents; Atorvastatin; Calcinosis; Chelating Agents; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Polyamines; Pyrroles; Sevelamer; Stroke | 2008 |
Drug interaction potential of 2-((3,4-dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the novel nonstatin-type cholesterol-lowering agent.
Topics: Anticholesteremic Agents; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cholesterol; Cytochrome P-450 CYP3A; Drug Interactions; Fluorobenzenes; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2009 |
Tuberculosis in a patient on temozolomide: a case report.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antibiotics, Antitubercular; Anticholesteremic Agents; Anticonvulsants; Antineoplastic Agents, Alkylating; Atorvastatin; Brain Neoplasms; Combined Modality Therapy; Cyclosporine; Dacarbazine; Dexamethasone; Female; Fluoxetine; Glioblastoma; Heptanoic Acids; Humans; Immunosuppressive Agents; Isoniazid; Middle Aged; Omeprazole; Phenobarbital; Prednisone; Pyrazinamide; Pyrroles; Radiotherapy; Red-Cell Aplasia, Pure; Rifampin; Temozolomide; Trimethoprim, Sulfamethoxazole Drug Combination; Tuberculosis, Pulmonary | 2009 |
Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Drug Evaluation; Glucose Intolerance; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Retrospective Studies | 2008 |
Atorvastatin decreases stearoyl-CoA desaturase gene expression in THP-1 macrophages incubated with oxidized LDL.
Topics: Atorvastatin; Cell Line; Fatty Acids, Unsaturated; Gene Expression; Heptanoic Acids; Humans; Lipoproteins, LDL; Macrophages; Pyrroles; Stearoyl-CoA Desaturase; Sterol Regulatory Element Binding Protein 1 | 2009 |
A mechanistic study on the phototoxicity of atorvastatin: singlet oxygen generation by a phenanthrene-like photoproduct.
Topics: Atorvastatin; Cyclization; Electron Spin Resonance Spectroscopy; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Phenanthrenes; Pyrroles; Singlet Oxygen; Tryptophan | 2009 |
[Vascular prevention after cerebral infarct or transient ischemic accident. Recommendations. March, 2008].
Topics: Anticholesteremic Agents; Atorvastatin; Brain; Cerebral Infarction; Cerebrovascular Circulation; Coronary Disease; Heptanoic Acids; Humans; Hypertension; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Pyrroles; Risk Factors; Time Factors | 2008 |
Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Deficiency Diseases; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pilot Projects; Pyrroles; Severity of Illness Index | 2008 |
Effect of the TNFalpha-308 G/A polymorphism on the changes produced by atorvastatin in bone mineral density in patients with acute coronary syndrome.
Topics: Absorptiometry, Photon; Acute Coronary Syndrome; Amino Acids; Anticholesteremic Agents; Atorvastatin; Bone Density; Calcium; Cholesterol; Dose-Response Relationship, Drug; Female; Femur Neck; Follow-Up Studies; Genotype; Heptanoic Acids; Humans; Magnesium; Male; Middle Aged; Osteocalcin; Osteoporosis; Phosphorus; Polymerase Chain Reaction; Polymorphism, Genetic; Pyrroles; Risk Factors; Triglycerides; Tumor Necrosis Factor-alpha | 2008 |
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study.
Topics: Adult; Atorvastatin; Cohort Studies; Disease-Free Survival; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2008 |
The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Drug Tolerance; Dyslipidemias; Ezetimibe; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Lipids; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Young Adult | 2008 |
Atorvastatin and BMD in coronary syndrome. Role of Lys656Asn polymorphism of leptin receptor gene.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Bone Density; Bone Remodeling; Female; Heptanoic Acids; Humans; Male; Middle Aged; Osteoporosis; Polymorphism, Genetic; Pyrroles; Receptors, Leptin | 2009 |
Anti-atherosclerotic effect of atorvastatin and clopidogrel alone and in combination in rats.
Topics: Animals; Atherosclerosis; Atorvastatin; Clopidogrel; Diet, Atherogenic; Drug Interactions; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation Inhibitors; Pyrroles; Rats; Rats, Wistar; Ticlopidine | 2008 |
Statin therapy works for patients who have type 2 diabetes.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2008 |
Modulation of clopidogrel pharmacodynamic response.
Topics: Anticholesteremic Agents; Area Under Curve; Atorvastatin; Clopidogrel; Drug Interactions; Heptanoic Acids; Humans; Metabolic Clearance Rate; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrroles; Thiophenes; Ticlopidine | 2008 |
Intensive lipid-lowering therapy for patients with aortic stenosis.
Topics: Aortic Valve Stenosis; Atorvastatin; Clinical Trials as Topic; Disease Progression; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis.
Topics: Aged; Anticholesteremic Agents; APACHE; Atorvastatin; Chromatography, High Pressure Liquid; Critical Care; Female; Heptanoic Acids; Humans; Male; Prospective Studies; Pyrroles; Sepsis | 2009 |
Pharmacoeconomic analysis of hypertriglyceridemia treatment at medical institutions.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Cohort Studies; Cost-Benefit Analysis; Economics, Pharmaceutical; Fenofibrate; Health Facilities; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Pyrroles; Triglycerides | 2008 |
Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated.
Topics: Adolescent; Adult; Atorvastatin; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Primary Prevention; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk; Simvastatin; United States | 2008 |
Modulation of human T cells signaling transduction by lovastatin.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Down-Regulation; Electrophoretic Mobility Shift Assay; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; NF-kappa B; Pyrroles; Signal Transduction; T-Lymphocytes; Transcription Factor AP-1 | 2010 |
Diabetes reduces bone marrow and circulating porcine endothelial progenitor cells, an effect ameliorated by atorvastatin and independent of cholesterol.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Antibiotics, Antineoplastic; Anticholesteremic Agents; Atorvastatin; Azetidines; Bone Marrow Cells; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Endothelial Cells; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Stem Cells; Swine; Vasodilation | 2009 |
Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A.
Topics: Animals; Atorvastatin; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Dietary Carbohydrates; Enzyme Activation; Fatty Acids, Nonesterified; Fructose; Glycerol-3-Phosphate O-Acyltransferase; Heptanoic Acids; Humans; Male; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sterol Regulatory Element Binding Protein 1 | 2009 |
Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents; Atorvastatin; Carbon Tetrachloride; Cell Proliferation; Cells, Cultured; Chemical and Drug Induced Liver Injury; Collagen Type I; Collagen Type I, alpha 1 Chain; Disease Models, Animal; Hepatic Stellate Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Infusion Pumps, Implantable; Intercellular Adhesion Molecule-1; Interleukin-6; Liver; Male; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Transforming Growth Factor beta1 | 2009 |
Quantification of atorvastatin calcium in tablets by FT-Raman spectroscopy.
Topics: Atorvastatin; Calibration; Chemistry, Pharmaceutical; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Least-Squares Analysis; Neural Networks, Computer; Pharmaceutical Preparations; Principal Component Analysis; Pyrroles; Reference Standards; Reproducibility of Results; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Tablets; Time Factors | 2009 |
Cholesterol synthesis in central nervous system of rat is affected by simvastatin as well as by atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Biomarkers; Brain Chemistry; Central Nervous System; Cholesterol; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Male; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2008 |
Regression of Achilles tendon thickness after statin treatment in patients with familial hypercholesterolemia: an ultrasonographic study.
Topics: Achilles Tendon; Adult; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk; Ultrasonography; Xanthomatosis | 2009 |
Coronary plaque stabilization followed by Color Code Plaque analysis with 64-slice multidetector row computed tomography.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Stenosis; Coronary Vasospasm; Diabetes Complications; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Middle Aged; Pyrroles; Tomography, X-Ray Computed; Ultrasonography | 2009 |
[Statins and stroke].
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Ischemic Attack, Transient; Neovascularization, Physiologic; Pyrroles; Stroke | 2008 |
DFT study on hydroxy acid-lactone interconversion of statins: the case of atorvastatin.
Topics: Atorvastatin; Carboxylic Acids; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydrogen-Ion Concentration; Hydrolysis; Hydroxy Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lactones; Pyrroles; Quantum Theory | 2008 |
Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Apoptosis; Atherosclerosis; Atorvastatin; Cells, Cultured; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Knockout; Models, Biological; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pyrroles; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Smad Proteins; Transforming Growth Factor beta | 2008 |
The cost of stroke prevention.
Topics: Atorvastatin; Clinical Trials as Topic; Cost-Benefit Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Stroke | 2009 |
On call. I am pretty healthy for a 73-year-old, but my cholesterol is 280, and my doctor wants me to take Lipitor. I'm willing to do so, but I need to know what tests I should have to be sure I'm not getting side effects. What do you suggest?
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Liver; Male; Pyrroles | 2008 |
[Intensive atorvastatin therapy in patients with acute myocardial infarction].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Treatment Outcome | 2008 |
Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
Topics: Adrenal Cortex Hormones; Aged; Atorvastatin; Cholesterol; Cyclosporine; Dyslipidemias; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Safety; Sirolimus; Treatment Outcome; Triglycerides | 2008 |
eNOS T-786C polymorphism affects atorvastatin-induced changes in erythrocyte membrane fluidity.
Topics: Adult; Atorvastatin; Cholesterol; Cysteine; Electron Spin Resonance Spectroscopy; Erythrocyte Membrane; Genotype; Hemorheology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Membrane Fluidity; Middle Aged; Nitric Oxide Synthase Type III; Polymorphism, Genetic; Pyrroles; Thiobarbiturates; Threonine; Young Adult | 2009 |
[Brain hypoperfusion revealed by an ocular ischemic syndrome].
Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Brain Ischemia; Carotid Artery Thrombosis; Ciliary Body; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Ischemia; Light Coagulation; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Middle Aged; Ophthalmic Artery; Platelet Aggregation Inhibitors; Pyrroles; Recurrence; Stroke; Ultrasonography | 2008 |
Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model.
Topics: Acetates; Animals; Atherosclerosis; Atorvastatin; Carotid Arteries; Catheterization; Chemokine CCL2; Cyclopropanes; Diet, Atherogenic; Disease Progression; Heptanoic Acids; Immunohistochemistry; Leukotriene Antagonists; Lipids; Male; Pyrroles; Quinolines; Rabbits; Random Allocation; Sulfides | 2009 |
Cholesterol-induced stimulation of postinflammatory liver fibrosis.
Topics: Animals; Atorvastatin; Calcitriol; Cholesterol Esters; Cholesterol, Dietary; Collagen; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Male; Mevalonic Acid; Mice; Mice, Inbred C57BL; Pyrroles; Transforming Growth Factor beta1; Triglycerides; Zymosan | 2008 |
Statin therapy is associated with lower total but not bioavailable or free testosterone in men with type 2 diabetes.
Topics: Adult; Aged; Atorvastatin; Biological Availability; Diabetes Mellitus, Type 2; Estradiol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Sex Hormone-Binding Globulin; Simvastatin; Testosterone | 2009 |
[High dosage stain protects heart and brain from recurrence].
Topics: Anticholesteremic Agents; Atorvastatin; Cerebral Infarction; Cholesterol, LDL; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention | 2008 |
Polycystic ovary syndrome, inflammation, and statins: do we have the right target?
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Polycystic Ovary Syndrome; Pregnancy; Pyrroles; Testosterone | 2009 |
Short-term effects of atorvastatin on hemorheologic parameters and endothelial dysfunction in patients with hypercholesterolemia. Lower is better?
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cohort Studies; Dose-Response Relationship, Drug; Endothelium, Vascular; Erythrocyte Deformability; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Platelet Aggregation; Pyrroles; von Willebrand Factor | 2008 |
AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633.
Topics: Acetyl-CoA Carboxylase; Adiponectin; Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Atorvastatin; Cattle; Cells, Cultured; Chromatography, Liquid; Endothelial Cells; Enzyme Activation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Knockout; Mutation; Nanotechnology; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrazoles; Pyrimidines; Pyrroles; Ribonucleotides; RNA Interference; RNA, Small Interfering; Serine; Signal Transduction; Stress, Mechanical; Tandem Mass Spectrometry; Time Factors; Transfection | 2009 |
Atorvastatin pleiotropic effects mediated via suppression of TNF-alpha in congestive heart failure patients with initial normal TNF-alpha levels.
Topics: Animals; Apoptosis; Atorvastatin; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Animal; Pyrroles; Reference Values; Tumor Necrosis Factor-alpha | 2009 |
[Pubalgia in athlete treated by atorvastatin].
Topics: Adult; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; France; Heptanoic Acids; Humans; Male; Muscular Diseases; Pelvic Pain; Prednisone; Pyrroles; Recurrence; Sports | 2009 |
Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects.
Topics: Adrenergic beta-Agonists; Animals; Atorvastatin; Atrial Natriuretic Factor; Cardiomegaly; Cell Membrane; Circadian Rhythm; Cytosol; GTP-Binding Protein alpha Subunits, Gs; GTP-Binding Protein gamma Subunits; Heart; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infusion Pumps, Implantable; Isoproterenol; Male; Myocardial Contraction; Myocardium; Protein Transport; Pyrroles; Rats; Rats, Wistar; RNA, Messenger | 2009 |
The TNT study, women and cancer.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Estrogens; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Neoplasms; Pyrroles; T-Lymphocytes, Regulatory | 2009 |
Targeting targets for LDL-lowering therapy: lessons from the Collaborative Atorvastatin Diabetes Study (CARDS).
Topics: Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Multicenter Studies as Topic; Pyrroles | 2009 |
Atorvastatin ameliorates cerebral vasospasm and early brain injury after subarachnoid hemorrhage and inhibits caspase-dependent apoptosis pathway.
Topics: Animals; Apoptosis; Atorvastatin; Blood-Brain Barrier; Brain; Brain Edema; Brain Injuries; Caspases; DNA Fragmentation; Heptanoic Acids; Male; Neuroprotective Agents; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Subarachnoid Hemorrhage; Vasospasm, Intracranial; Water | 2009 |
[Inhibition of CD40L induced E-selectin expression in endothelial cells through extracellular signal-regulated kinase signaling pathway].
Topics: Atorvastatin; CD40 Ligand; Cells, Cultured; E-Selectin; Endothelial Cells; Heptanoic Acids; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Pyrroles; Umbilical Veins | 2008 |
Atorvastatin attenuates post-implant tissue degeneration of cardiac prosthetic valve bovine pericardial tissue in a subcutaneous animal model.
Topics: Animals; Atorvastatin; Bioprosthesis; Cattle; Heart Valve Prosthesis Implantation; Heart Valves; Heptanoic Acids; Male; Mice; Mice, Inbred C57BL; Models, Animal; Pericardium; Postoperative Complications; Pyrroles; Random Allocation; Subcutaneous Tissue | 2010 |
Atorvastatin ameliorates sildenafil-induced penile erections in experimental diabetes by inhibiting diabetes-induced RhoA/Rho-kinase signaling hyperactivation.
Topics: Animals; Atorvastatin; Diabetes Mellitus, Experimental; Disease Models, Animal; Electric Stimulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Penile Erection; Phosphodiesterase Inhibitors; Phosphorylation; Piperazines; Purines; Pyrroles; Rabbits; rho-Associated Kinases; Signal Transduction; Sildenafil Citrate; Sulfones | 2009 |
[Atorvastatin-induced drug reaction with eosinophilia and systemic symptoms (DRESS)].
Topics: Abdominal Pain; Arthralgia; Atorvastatin; Diarrhea; Drug Eruptions; Eosinophilia; Facial Dermatoses; Female; Fever; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrroles | 2009 |
Letter to editor in response to "Prevention of pediatric graft coronary artery disease: atorvastatin", by Chin et al.
Topics: Atorvastatin; Child; Coronary Artery Disease; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Postoperative Period; Pyrroles | 2009 |
[Statin therapy and muscle disorders].
Topics: Atorvastatin; Biological Availability; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Muscular Diseases; Pravastatin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
[Comment from the cardiologic viewpoint].
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pravastatin; Primary Prevention; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Heptanoic Acids; Hypercholesterolemia; Macaca fascicularis; Male; Organophosphonates; Phenols; Prodrugs; Pyrroles; Rabbits; Thyroid Hormone Receptors beta | 2009 |
Variability in pharmacy interpretations of physician prescriptions.
Topics: Alendronate; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Bone Density Conservation Agents; Comprehension; Contraindications; Drug Information Services; Drug Labeling; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Education, Pharmacy; Educational Status; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibuprofen; Patient Education as Topic; Pharmaceutical Preparations; Pharmacies; Professional Competence; Pyrroles; Trimethoprim, Sulfamethoxazole Drug Combination; Urban Health Services; Writing | 2009 |
Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.
Topics: Alkylating Agents; Animals; Anticarcinogenic Agents; Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Atorvastatin; Bexarotene; Cell Proliferation; Diet; Disease Models, Animal; Female; Genes, erbB-2; Heptanoic Acids; Lovastatin; Mammary Neoplasms, Experimental; Methylnitrosourea; Mice; Mice, Knockout; Mice, Transgenic; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Estrogen; Retinoid X Receptors; Tamoxifen; Tetrahydronaphthalenes; Treatment Outcome; Tumor Suppressor Protein p53 | 2009 |
Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels.
Topics: Apolipoprotein B-48; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Intestinal Mucosa; Lipoproteins; Liver; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2009 |
C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin.
Topics: Atorvastatin; C-Reactive Protein; Cell Division; Cell Line, Tumor; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Monocytes; p38 Mitogen-Activated Protein Kinases; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, IgG; Receptors, Immunologic; S100 Proteins; S100A12 Protein; Up-Regulation | 2010 |
3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension.
Topics: Animals; Atorvastatin; Disease Models, Animal; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Monocrotaline; Phosphodiesterase Inhibitors; Pravastatin; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2009 |
Cardiovascular conditions in hemodialysis patients may be worsened by extensive interdialytic weight gain.
Topics: Adult; Aged; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Regression Analysis; Renal Dialysis; Weight Gain | 2009 |
In vivo confirmation of the role of statins in reducing nitric oxide and C-reactive protein levels in peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nitrites; Peripheral Vascular Diseases; Prospective Studies; Pyrroles; Triglycerides | 2009 |
Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression.
Topics: Action Potentials; Animals; Atorvastatin; Benzophenanthridines; Calcium; Cell Line; Chloride Channels; Chlorides; Dose-Response Relationship, Drug; Down-Regulation; Electromyography; Enzyme Activation; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Muscle, Skeletal; Patch-Clamp Techniques; Protein Kinase C; Protein Kinase Inhibitors; Pyrroles; Rats; Rats, Wistar; RNA, Messenger; Transfection | 2009 |
Atorvastatin restores endothelial function in offspring of protein-restricted rats in a cholesterol-independent manner.
Topics: Animals; Atorvastatin; Cholesterol; Disease Models, Animal; Endothelium, Vascular; Female; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Nitric Oxide Synthase Type III; Oxidative Stress; Pregnancy; Prenatal Exposure Delayed Effects; Protein-Energy Malnutrition; Pyrroles; Rats; Rats, Wistar; RNA, Messenger; Vasculitis; Vasoconstriction; Weight Gain | 2009 |
Last fall I began taking daily doses of 1,500 mg of niacin, in addition to the 40 mg of Lipitor I've been taking for several years. Within six months, my LDL and triglycerides were down significantly and my HDL was higher. If my next bi-annual blood test
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Drug Therapy, Combination; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrroles; Triglycerides | 2008 |
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy.
Topics: Animals; Atorvastatin; Azetidines; Brain; Capillary Permeability; Diet; Disease Models, Animal; Ezetimibe; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunohistochemistry; Maze Learning; Mice; Mice, Transgenic; Neurofibrillary Tangles; Pyrroles; Simvastatin; Spinal Cord; Tauopathies | 2009 |
Anti-atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase-1.
Topics: Animals; Aorta; Arginine; Atherosclerosis; Atorvastatin; Disease Models, Animal; Endothelium, Vascular; Enzyme Inhibitors; Heme Oxygenase-1; Hemin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Malondialdehyde; Metalloporphyrins; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Peroxynitrous Acid; Protoporphyrins; Pyrroles; Rabbits; Simvastatin; Time Factors | 2009 |
Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton's Lymphoma Ascites tumor in mice.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Mice; Models, Chemical; Neoplasms, Experimental; Pyrroles; Reactive Oxygen Species | 2008 |
Preoperative statin use and infection after cardiac surgery: a cohort study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Chemoprevention; Cohort Studies; Female; Heptanoic Acids; Hospitals, University; Humans; Immunologic Factors; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Surgical Wound Infection; Thoracic Surgery; Treatment Outcome | 2009 |
Phospholipase A2 inhibitors in atherosclerosis: the race is on.
Topics: Atorvastatin; Benzaldehydes; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Coronary Artery Disease; Coronary Disease; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oximes; Phospholipases A2, Secretory; Pyrroles | 2009 |
Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin.
Topics: Antigens, CD34; Atorvastatin; Blood Platelets; Blotting, Western; Calcium; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Mass Spectrometry; Megakaryocytes; Mevalonic Acid; Microscopy, Fluorescence; Organic Anion Transporters; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA; Subcellular Fractions | 2009 |
Statins: not just for the young or the faint of heart.
Topics: Age Factors; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Stroke | 2009 |
ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.
Topics: Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Female; Finland; Half-Life; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin | 2008 |
Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins.
Topics: Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Cell Differentiation; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Regulatory Networks; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukemia; Oligonucleotide Array Sequence Analysis; Pyrroles; Retinoids; Time Factors; Tretinoin; Tumor Cells, Cultured | 2009 |
Novel management of isotretinoin-induced hypertriglyceridemia in an adolescent with severe acne.
Topics: Acne Vulgaris; Adolescent; Anticholesteremic Agents; Atorvastatin; Dermatologic Agents; Female; Heptanoic Acids; Humans; Hypertriglyceridemia; Isotretinoin; Pyrroles | 2009 |
Effect of very low LDL-cholesterol on cortisol synthesis.
Topics: Adrenocorticotropic Hormone; Adult; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol, LDL; Dose-Response Relationship, Drug; Endocrine System Diseases; Female; Heptanoic Acids; Humans; Hydrocortisone; Hypercholesterolemia; Male; Middle Aged; Pituitary-Adrenal Function Tests; Pyrroles | 2008 |
Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Arthritis, Rheumatoid; Atorvastatin; Biomarkers; Case-Control Studies; CD4-Positive T-Lymphocytes; CD8 Antigens; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Female; Fibroblasts; Flow Cytometry; Heptanoic Acids; HLA-DR Antigens; Humans; Interleukin-6; Lectins, C-Type; Leukocytes, Mononuclear; Male; Middle Aged; Probability; Pyrroles; Reference Values; Reverse Transcriptase Polymerase Chain Reaction; Synovial Membrane; T-Lymphocyte Subsets; Young Adult | 2009 |
Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure.
Topics: Atorvastatin; Biomarkers; Case-Control Studies; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Inflammation; Interferon-gamma; Interleukin-10; Interleukin-12; Interleukin-18; Interleukin-4; Male; Middle Aged; Pyrroles; Th1 Cells; Th2 Cells | 2009 |
Statins as potential antimalarial drugs: low relative potency and lack of synergy with conventional antimalarial drugs.
Topics: Animals; Antimalarials; Atorvastatin; Chloroquine; Culture Media; Drug Resistance; Drug Synergism; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Parasitic Sensitivity Tests; Plasmodium falciparum; Pyrroles | 2009 |
Effects of atorvastatin on nuclear magnetic resonance-defined lipoprotein subclasses and inflammatory markers in patients with hypercholesterolemia.
Topics: Atorvastatin; C-Reactive Protein; Chemokine CCL2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Middle Aged; Pyrroles | 2009 |
Regression and shift in composition of coronary atherosclerotic plaques by pioglitazone: insight from an intravascular ultrasound analysis.
Topics: Aged; Atorvastatin; Calcinosis; Coronary Artery Disease; Diabetes Mellitus; Drug Therapy, Combination; Female; Fibrosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Middle Aged; Necrosis; Pilot Projects; Pioglitazone; Prospective Studies; Pyrroles; Registries; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography, Interventional; User-Computer Interface | 2009 |
Comparison of UV and charged aerosol detection approach in pharmaceutical analysis of statins.
Topics: Aerosols; Atorvastatin; Chromatography, High Pressure Liquid; Equipment and Supplies; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pyrroles; Simvastatin; Tablets | 2009 |
[Effect of atorvastatin on lipopolysaccharide-induced expression of C-reactive protein in human pulmonary epithelial cells].
Topics: Atorvastatin; C-Reactive Protein; Cell Line; Down-Regulation; Epithelial Cells; Heptanoic Acids; Humans; Lipopolysaccharides; Lung; Pyrroles; RNA, Messenger | 2009 |
Effect of lipid-lowering therapy on the progression of intracranial arterial stenosis.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cerebral Arteries; Constriction, Pathologic; Disease Progression; Female; Heptanoic Acids; Humans; Hyperlipidemias; Infarction, Middle Cerebral Artery; Intracranial Arteriosclerosis; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Secondary Prevention; Sex Distribution; Stroke; Treatment Outcome; Vertebrobasilar Insufficiency | 2009 |
An association study between catalase -262C>T gene polymorphism, sodium-lithium countertransport activity, insulin resistance, blood lipid parameters and their response to atorvastatin, in Greek dyslipidaemic patients and normolipidaemic controls.
Topics: Adult; Alleles; Antiporters; Atorvastatin; Case-Control Studies; Catalase; Dyslipidemias; Erythrocytes; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Linear Models; Lipids; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Retrospective Studies | 2009 |
Effect of atorvastatin on expression of IL-10 and TNF-alpha mRNA in myocardial ischemia-reperfusion injury in rats.
Topics: Animals; Atorvastatin; Heart Ventricles; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-10; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tumor Necrosis Factor-alpha; Ventricular Function | 2009 |
Potentiated cytotoxic effects of statins and ajoene in murine melanoma cells.
Topics: Animals; Apoptosis; Atorvastatin; Cell Line, Tumor; Disulfides; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Melanocytes; Melanoma, Experimental; Mevalonic Acid; Mice; Polyisoprenyl Phosphates; Pravastatin; Pyrroles; Sulfoxides; Terpenes | 2009 |
Drug-drug interaction studies in preclinical species: should metabolite(s) kinetics be studied?
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP3A; Drug Design; Drug Interactions; Heptanoic Acids; Kinetics; Pharmacology, Clinical; Pyrroles; Verapamil | 2009 |
Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drugs, Generic; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Models, Economic; Myocardial Revascularization; Pyrroles; Randomized Controlled Trials as Topic | 2008 |
Eugenosedin-A prevents hyperglycaemia, hyperlipidaemia and lipid peroxidation in C57BL/6J mice fed a high-fat diet.
Topics: Adipose Tissue; Animals; Atorvastatin; Blood Glucose; Body Weight; Brain; Dietary Fats; Female; Glutathione Peroxidase; Heptanoic Acids; Hyperglycemia; Hyperlipidemias; Insulin; Ketanserin; Lipid Peroxidation; Lipogenesis; Liver; Malondialdehyde; Mice; Mice, Inbred C57BL; Piperazines; PPAR gamma; Prazosin; Propranolol; Pyrroles; Superoxide Dismutase; Weight Gain | 2009 |
Metformin and atorvastatin reduce adhesion formation in a rat uterine horn model.
Topics: Animals; Atorvastatin; Female; Heptanoic Acids; Metformin; Pyrroles; Rats; Rats, Wistar; Tissue Adhesions; Uterus | 2009 |
Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity.
Topics: Adult; Aged; Aryldialkylphosphatase; Atorvastatin; Cholesterol Ester Transfer Proteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Middle Aged; Phosphatidylcholine-Sterol O-Acyltransferase; Pyrroles | 2009 |
Up-regulating PPAR-γ expression and NO concentration, and down-regulating PAI-1 concentration in a rabbit atherosclerotic model: the possible antiatherogenic and antithrombotic effects of atorvastatin.
Topics: Animals; Atherosclerosis; Atorvastatin; Disease Models, Animal; Down-Regulation; Fibrinolytic Agents; Heptanoic Acids; Male; Nitric Oxide; Plasminogen Activator Inhibitor 1; PPAR gamma; Pyrroles; Rabbits; Up-Regulation | 2010 |
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
Topics: Animals; Antimalarials; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plasmodium falciparum; Pyrroles | 2009 |
Cyclooxygenase-2 induced by zymosan in human monocyte-derived dendritic cells shows high stability, and its expression is enhanced by atorvastatin.
Topics: Antigens, CD; Arachidonic Acid; Atorvastatin; Cycloheximide; Cyclooxygenase 1; Cyclooxygenase 2; Dendritic Cells; Dinoprostone; Gene Expression; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Mevalonic Acid; Peptidoglycan; Phospholipases A2, Cytosolic; Pyrroles; Zymosan | 2009 |
Statin-induced structural changes in coronary plaques evaluated by intracoronary imaging.
Topics: Aged; Angioscopy; Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Time Factors; Ultrasonography, Interventional | 2009 |
Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholesterol; Chronic Disease; Coronary Disease; Epidemiologic Methods; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Time Factors; Treatment Outcome | 2009 |
Ezetimibe and atorvastatin both immunoregulate CD4+ T cells from cardiac transplant recipients invitro.
Topics: Adult; Aged; Atorvastatin; Azetidines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Ezetimibe; Female; Graft Rejection; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles | 2009 |
Statin-induced liver injury involves cross-talk between cholesterol and selenoprotein biosynthetic pathways.
Topics: Atorvastatin; Cell Line, Tumor; Cholesterol; Cytotoxins; Glutathione Peroxidase; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoenzymes; Lovastatin; Pyridines; Pyrroles; Reactive Oxygen Species; Selenoproteins; Signal Transduction; tert-Butylhydroperoxide; Thioredoxin-Disulfide Reductase | 2009 |
Effect of statins on fibroblasts from human nasal polyps and turbinates.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Cell Division; Depression, Chemical; Drug Evaluation, Preclinical; Fatty Acids, Monounsaturated; Fibroblasts; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Nasal Polyps; Pyrroles; Simvastatin; Turbinates | 2008 |
The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Models, Economic; Pyrroles; Scandinavian and Nordic Countries; Treatment Outcome | 2009 |
Moving from A to Z: successful implementation of a statin switch program by a large physician group.
Topics: Atorvastatin; Cost Savings; Drugs, Generic; Fee-for-Service Plans; Female; Heptanoic Acids; Hospitals, Teaching; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Michigan; Middle Aged; Patient Selection; Pyrroles; Simvastatin | 2009 |
Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis.
Topics: Angiogenesis Inhibitors; Animals; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Carbocyanines; Cyclohexanes; Disease Models, Animal; Drug Carriers; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Unsaturated; Heptanoic Acids; Heterocyclic Compounds, 1-Ring; Integrin alphaVbeta3; Liver; Magnetic Resonance Imaging; Nanoparticles; Neovascularization, Pathologic; Pyrroles; Rabbits; Sesquiterpenes; Time Factors | 2008 |
Theranostic strategy against plaque angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Atherosclerosis; Atorvastatin; Carbocyanines; Cyclohexanes; Drug Carriers; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Unsaturated; Heptanoic Acids; Heterocyclic Compounds, 1-Ring; Humans; Integrin alphaVbeta3; Magnetic Resonance Imaging; Nanoparticles; Neovascularization, Pathologic; Pyrroles; Sesquiterpenes; Time Factors | 2008 |
Comparison of atorvastatin and simvastatin in prevention of atrial fibrillation after successful cardioversion.
Topics: Aged; Anti-Arrhythmia Agents; Atorvastatin; Atrial Fibrillation; Electric Countershock; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Odds Ratio; Pyrroles; Retrospective Studies; Simvastatin; Treatment Outcome | 2009 |
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Topics: Animals; Atorvastatin; Benzenesulfonates; Cystadenoma; Disease Models, Animal; Doxycycline; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Heptanoic Acids; Immunosuppressive Agents; Interferon-gamma; Kidney Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Burden; Tumor Suppressor Proteins | 2009 |
Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.
Topics: Atorvastatin; Genotype; Heptanoic Acids; Humans; Kinetics; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Polymorphism, Genetic; Pyrroles; Rifampin; Thymidine; Young Adult | 2009 |
Glucose promotes membrane cholesterol crystalline domain formation by lipid peroxidation.
Topics: Amlodipine; Atorvastatin; Cell Membrane; Cholesterol; Glucose; Heptanoic Acids; Lipid Peroxidation; Membrane Lipids; Oxidative Stress; Phospholipids; Pyrroles; X-Ray Diffraction | 2009 |
Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids.
Topics: Analysis of Variance; Animals; Atorvastatin; Blotting, Western; Cyclooxygenase 1; Cyclooxygenase 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelium, Vascular; Heptanoic Acids; Male; Malondialdehyde; Mesenteric Arteries; Probability; Prostaglandins; Pyrroles; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Reverse Transcriptase Polymerase Chain Reaction; RNA; Sensitivity and Specificity; Vasodilation | 2009 |
Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study.
Topics: Age Factors; Aged; Atorvastatin; Causality; Cerebral Hemorrhage; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Iatrogenic Disease; Intracranial Arteriosclerosis; Male; Pyrroles; Sex Factors | 2009 |
Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Density; Bone Density Conservation Agents; Clomiphene; Estrogens; Etidronic Acid; Female; Femur; Heptanoic Acids; Osteoporosis; Ovariectomy; Pyrroles; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Risedronic Acid; Selective Estrogen Receptor Modulators; Tibia | 2009 |
Decreased ABCB1 mRNA expression induced by atorvastatin results from enhanced mRNA degradation in HepG2 cells.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cholesterol; Culture Media, Serum-Free; Down-Regulation; Electrophoretic Mobility Shift Assay; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors | 2009 |
Effect of atorvastatin on cardiac remodelling and mortality in rats following hyperglycemia and myocardial infarction.
Topics: Animals; Atorvastatin; Body Weight; Cardiac Volume; Collagen Type I; Collagen Type III; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Myocardial Infarction; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley; Ventricular Remodeling | 2010 |
Antihyperlipidemic effect of the methanolic extract from Lagenaria siceraria Stand. fruit in hyperlipidemic rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol; Cucurbitaceae; Dietary Fats; Disease Models, Animal; Feces; Fruit; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Male; Phytotherapy; Plant Extracts; Pyrroles; Rats; Rats, Wistar; Triglycerides; Weight Gain | 2009 |
Statin effects on LDL and HDL cholesterol in South Asian and white populations.
Topics: Anticholesteremic Agents; Asian People; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Disease; Female; Heptanoic Acids; Humans; Linear Models; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides; White People | 2009 |
Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors.
Topics: Animals; Atherosclerosis; Atorvastatin; Capillary Permeability; Cattle; Cells, Cultured; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Down-Regulation; Endothelial Cells; Farnesol; Female; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Protein Kinase C; Protein Kinase Inhibitors; Protein-Lysine 6-Oxidase; Pyrroles; rho-Associated Kinases; rhoA GTP-Binding Protein; Risk Factors; RNA, Messenger; Simvastatin; Swine; Transfection; Tumor Necrosis Factor-alpha | 2009 |
Additive beneficial effects of amlodipine and atorvastatin in reversing advanced cardiac hypertrophy in elderly spontaneously hypertensive rats.
Topics: Aging; Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiomegaly; Drug Synergism; Drug Therapy, Combination; Fibrosis; Heart Failure, Diastolic; Hemodynamics; Heptanoic Acids; Myocytes, Cardiac; NADPH Oxidases; Natriuretic Peptide, Brain; Oxidative Stress; Pyrroles; Random Allocation; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Superoxide Dismutase; Ventricular Dysfunction, Left | 2009 |
Facile preparation of monodisperse pharmaceutical colloidal spheres of atorvastatin calcium via self-assembly.
Topics: Area Under Curve; Atorvastatin; Calcium; Chemistry, Pharmaceutical; Colloids; Drug Delivery Systems; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Models, Chemical; Nanotechnology; Particle Size; Pyrroles; Solvents; Technology, Pharmaceutical; X-Ray Diffraction | 2009 |
[Metabolic rhabdomyolysis during statin therapy].
Topics: Atorvastatin; Carnitine O-Palmitoyltransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyridines; Pyrroles; Rhabdomyolysis | 2009 |
Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease.
Topics: Adult; Atorvastatin; C-Reactive Protein; Chemokine CXCL10; Crohn Disease; Cytokines; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Young Adult | 2009 |
Beneficial effect of atorvastatin on erythropoietin responsiveness in maintenance haemodialysis patients.
Topics: Aged; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Erythropoietin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Renal Dialysis | 2009 |
Atorvastatin prevents early apoptosis after thoracic spinal cord contusion injury and promotes locomotion recovery.
Topics: Analysis of Variance; Animals; Apoptosis; Atorvastatin; Caspase 3; Female; Heptanoic Acids; In Situ Nick-End Labeling; Motor Activity; Neuroprotective Agents; Pyrroles; Rats; Rats, Sprague-Dawley; Recovery of Function; Spinal Cord Injuries; Thoracic Vertebrae | 2009 |
Effects of atorvastatin therapy on protein oxidation and oxidative DNA damage in hypercholesterolemic rabbits.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Anticholesteremic Agents; Atorvastatin; Deoxyguanosine; DNA Damage; Glutathione; Heptanoic Acids; Hypercholesterolemia; Lipid Peroxidation; Liver; Male; Malondialdehyde; Oxidation-Reduction; Oxidative Stress; Protein Carbonylation; Pyrroles; Rabbits; Random Allocation; Sulfhydryl Compounds | 2009 |
Micronization of atorvastatin calcium by antisolvent precipitation process.
Topics: Atorvastatin; Chemical Precipitation; Chemistry, Pharmaceutical; Excipients; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypromellose Derivatives; Methylcellulose; Particle Size; Powders; Pyrroles; Solubility; Solvents; Time Factors; X-Ray Diffraction | 2009 |
Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress.
Topics: Angiotensin II; Animals; Atorvastatin; Blood Pressure; Blotting, Western; Cells, Cultured; Collagen; Elasticity; Extracellular Matrix; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Malondialdehyde; Mesenteric Arteries; Microscopy, Confocal; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Nitric Oxide Synthase Type III; Oxidative Stress; Pyrroles; Rats; Rats, Sprague-Dawley; Rats, Wistar; Superoxide Dismutase; Superoxides; Vasoconstrictor Agents | 2009 |
Protein extraction of formalin-fixed, paraffin-embedded tissue enables robust proteomic profiles by mass spectrometry.
Topics: Animals; Atorvastatin; Biomarkers; Cell Nucleus; Chromatography, Liquid; Cytoplasm; Fixatives; Formaldehyde; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Membranes; Liver; Male; Paraffin Embedding; Proteome; Pyrroles; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry | 2009 |
Selective prescribing of simvastatin and atorvastatin by patient characteristics at treatment initiation over a 7-year period in Finland.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Drug Prescriptions; Female; Finland; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Patterns, Physicians'; Pyrroles; Simvastatin | 2009 |
Mechanism of inhibitory effect of atorvastatin on resistin expression induced by tumor necrosis factor-alpha in macrophages.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Glucose; Heptanoic Acids; Humans; Macrophages; Promoter Regions, Genetic; Pyrroles; Rats; Resistin; Tumor Necrosis Factor-alpha | 2009 |
Iron oxide magnetic resonance imaging for atherosclerosis therapeutic evaluation: still "rusty?".
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; Carotid Stenosis; Ferric Compounds; Heptanoic Acids; Humans; Inflammation; Macrophages; Nanoparticles; Pyrroles | 2009 |
Atorvastatin might improve ventricular electrostability and decelerate the deterioration of renal function in patients with heart failure and diabetes mellitus.
Topics: Aged; Atorvastatin; Diabetes Mellitus; Female; Glomerular Filtration Rate; Heart Failure; Heart Ventricles; Heptanoic Acids; Hospitalization; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Pyrroles; Retrospective Studies; Ventricular Premature Complexes | 2009 |
Early atorvastatin reduces hemorrhage after acute cerebral ischemia in diabetic rats.
Topics: Acute Disease; Animals; Atorvastatin; Brain Ischemia; Cerebral Hemorrhage; Diabetes Mellitus, Type 2; Drug Administration Schedule; Heptanoic Acids; Male; Pyrroles; Rats; Rats, Wistar; Time Factors | 2009 |
Long-term statin therapy and CSF cholesterol levels: implications for Alzheimer's disease.
Topics: Adult; Aged; Alzheimer Disease; Apolipoproteins E; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Mutation; Pilot Projects; Presenilin-1; Pyrroles; Simvastatin | 2009 |
Atorvastatin reduces the expression of aldo-keto reductases in HUVEC and PTEC. A new approach to influence the polyol pathway.
Topics: Alcohol Oxidoreductases; Aldehyde Reductase; Aldo-Keto Reductases; Atorvastatin; Cells, Cultured; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Polymers; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2009 |
Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cohort Studies; Cyclosporine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heart Transplantation; Heptanoic Acids; Humans; Immunosuppressive Agents; Indoles; Male; Middle Aged; Prospective Studies; Pyrroles; Tacrolimus; Treatment Outcome; Triglycerides | 2009 |
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Topics: Anticholesteremic Agents; Atorvastatin; Central Nervous System; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Heptanoic Acids; Humans; Iatrogenic Disease; Immunologic Factors; Interferon-beta; Multiple Sclerosis; Pyrroles; Risk Assessment | 2009 |
Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Computer Simulation; Cost-Benefit Analysis; Databases, Factual; Female; Health Services; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Saskatchewan; Secondary Prevention; Stroke; Survival Analysis; United States; Young Adult | 2009 |
Regulation of steroid 5-alpha reductase type 2 (Srd5a2) by sterol regulatory element binding proteins and statin.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Animals; Atorvastatin; Azetidines; Cell Line, Tumor; Ezetimibe; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hypercholesterolemia; Liver; Lovastatin; Male; Mice; Promoter Regions, Genetic; Prostate; Prostatic Neoplasms; Pyrroles; Sterol Regulatory Element Binding Protein 2; Transfection | 2009 |
Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Topics: Aged; Apolipoproteins B; Atorvastatin; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides | 2009 |
Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts.
Topics: Alendronate; Animals; Apoptosis; Atorvastatin; Bone Density Conservation Agents; Caspases; Cell Line; Diphosphonates; DNA Fragmentation; Drug Synergism; Enzyme Activation; Etidronic Acid; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myoblasts, Skeletal; Pyrroles; Rats; Rhabdomyolysis; Risedronic Acid | 2009 |
Determination of atorvastatin and its metabolite ortho-hydroxyatorvastatin in human plasma by on-line anion-exchange solid-phase extraction and liquid chromatography tandem mass spectrometry.
Topics: Adult; Aged; Anions; Atorvastatin; Chromatography, Liquid; Female; Heptanoic Acids; Humans; Male; Middle Aged; Online Systems; Pyrroles; Solid Phase Extraction; Tandem Mass Spectrometry | 2009 |
Atorvastatin prevents hippocampal cell death due to quinolinic acid-induced seizures in mice by increasing Akt phosphorylation and glutamate uptake.
Topics: Analysis of Variance; Animals; Atorvastatin; Cell Death; Complex Mixtures; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Mice; Oncogene Protein v-akt; Phosphorylation; Pyrroles; Quinolinic Acid; Seizures; Tetrazolium Salts; Thiazoles; Tritium | 2009 |
Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Topics: Aged; Atorvastatin; Canada; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Markov Chains; Middle Aged; Pyrroles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis | 2009 |
Ultra high performance liquid chromatography tandem mass spectrometric detection in clinical analysis of simvastatin and atorvastatin.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Sensitivity and Specificity; Simvastatin; Tandem Mass Spectrometry | 2009 |
Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells.
Topics: Apoptosis; Atorvastatin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Fluorouracil; Gemcitabine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrroles; Receptors, Purinergic P2; Receptors, Purinergic P2X7; RNA, Small Interfering; Signal Transduction | 2009 |
The expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells.
Topics: Animals; Atorvastatin; Caco-2 Cells; Cell Line, Tumor; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Pyrroles; RNA, Messenger; Simvastatin | 2009 |
Atorvastatin attenuates TLR4-mediated NF-kappaB activation in a MyD88-dependent pathway.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; B-Lymphocytes; Cell Line; Dendritic Cells; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Lymphocyte Antigen 96; Macrophages; Mice; Myeloid Differentiation Factor 88; NF-kappa B; Pyrroles; Toll-Like Receptor 4; Transfection | 2009 |
Preparation, characterization and in vitro intestinal absorption of a dry emulsion formulation containing atorvastatin calcium.
Topics: Administration, Oral; Animals; Atorvastatin; Chemistry, Pharmaceutical; Dextrins; Drug Carriers; Emulsions; Glycerol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Intestinal Absorption; Male; Oleic Acids; Poloxamer; Pyrroles; Rats; Rats, Sprague-Dawley; Solubility; Surface-Active Agents; Time Factors | 2009 |
Atorvastatin Increases Endoglin, SMAD2, Phosphorylated SMAD2/3 and eNOS Expression in ApoE/LDLR Double Knockout Mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blotting, Western; Endoglin; Endothelium, Vascular; Female; Heptanoic Acids; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Mice; Mice, Knockout; Nitric Oxide Synthase Type III; Phosphorylation; Pyrroles; Receptors, LDL; Smad2 Protein; Smad3 Protein | 2009 |
Crystal forms of atorvastatin.
Topics: Atorvastatin; Calorimetry, Differential Scanning; Crystallization; Drug Stability; Heptanoic Acids; Pyrroles; Thermogravimetry; X-Ray Diffraction | 2009 |
Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; Autocrine Communication; Biological Factors; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Enzyme Activation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Melanoma; Pyridines; Pyrroles; Simvastatin; Time Factors | 2009 |
Pivotal role of inflammation in vascular endothelial dysfunction of hyperlipidemic rabbit and effects by atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blood Glucose; Dietary Fats; Disease Models, Animal; Endothelium, Vascular; Heptanoic Acids; Hyperlipidemias; Insulin; Lipids; Male; Pyrroles; Rabbits; Vasculitis | 2011 |
Hypothyroidism misdiagnosed as statin intolerance.
Topics: Anticholesteremic Agents; Atorvastatin; Diagnostic Errors; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothyroidism; Male; Middle Aged; Myositis; Pyrroles | 2009 |
Unexpected and abnormally low HDL cholesterol levels on combination hypolipidemic therapy.
Topics: Atorvastatin; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2009 |
Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Animals; Atorvastatin; Cholesterol; Cystadenoma; Disease Models, Animal; Female; Hemangioma; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoenzyme Techniques; Kidney Neoplasms; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrroles; Survival Rate; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2009 |
Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection.
Topics: Animals; Aorta; Atorvastatin; Endothelium, Vascular; Gene Expression Regulation; Heptanoic Acids; Hypertension; Male; NG-Nitroarginine Methyl Ester; Pyrroles; Rats; Rats, Inbred F344 | 2009 |
Lipid profile changes associated with changing available formulary statins: removing higher potency agents.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Fasting; Formularies, Hospital as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Managed Care Programs; Medication Adherence; Pyrroles; Retrospective Studies; Triglycerides; United States | 2009 |
Statins and gender-related difference in endothelial function in cerebral small vessel disease.
Topics: Aged; Atorvastatin; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Databases, Factual; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Risk Factors; Stroke; Treatment Outcome; Vasodilation | 2009 |
Placebo-controlled trial of high-dose atorvastatin in patients with severe cerebral small vessel disease.
Topics: Aged; Atorvastatin; Blood Pressure; Brachial Artery; C-Reactive Protein; Carotid Arteries; Cerebrovascular Circulation; Cerebrovascular Disorders; Databases, Factual; Double-Blind Method; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke; Treatment Outcome; Vasodilation | 2009 |
Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cell Count; Cell Separation; Disease Progression; E-Selectin; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; Flow Cytometry; Fluorescent Antibody Technique; Health Status; Heptanoic Acids; Humans; Immunoprecipitation; Middle Aged; Prospective Studies; Pyrroles; Raynaud Disease; Scleroderma, Systemic; Severity of Illness Index; Stem Cells; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2009 |
Fluvastatin inhibits expression of the chemokine MDC/CCL22 induced by interferon-gamma in HaCaT cells, a human keratinocyte cell line.
Topics: Atorvastatin; Cell Line; Chemokine CCL22; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interferon-gamma; Keratinocytes; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Pyrroles; Signal Transduction; Simvastatin; Th2 Cells | 2009 |
Atorvastatin induces thrombomodulin expression in the aorta of cholesterol-fed rabbits and in TNFalpha-treated human aortic endothelial cells.
Topics: Animals; Aorta, Thoracic; Atorvastatin; Case-Control Studies; Cell Line; Cell Survival; Cholesterol, Dietary; Dose-Response Relationship, Drug; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Rabbits; Random Allocation; RNA, Messenger; Thrombomodulin; Time Factors; Tumor Necrosis Factor-alpha; U937 Cells; Up-Regulation | 2009 |
Isolation and structure determination of oxidative degradation products of atorvastatin.
Topics: Acetonitriles; Atorvastatin; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Stability; Heptanoic Acids; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxides; Magnetic Resonance Spectroscopy; Mass Spectrometry; Oxygen; Phosphoric Acids; Potassium Compounds; Pyrroles; Ultraviolet Rays | 2009 |
Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cross-Sectional Studies; Eating; Female; Folic Acid; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipoprotein(a); Lovastatin; Male; Middle Aged; Pyrroles; Renal Dialysis; Risk Factors; Vitamin B 6; Vitamin B Complex; Young Adult | 2009 |
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
Topics: Age Distribution; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Stenosis; Clinical Trials as Topic; Comorbidity; Coronary Artery Disease; Heptanoic Acids; Humans; Ischemic Attack, Transient; Outcome Assessment, Health Care; Pyrroles; Stroke; Treatment Outcome | 2009 |
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
Topics: Age Distribution; Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cerebral Hemorrhage; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Iatrogenic Disease; Ischemic Attack, Transient; Pyrroles; Risk Assessment; Risk Factors; Stroke | 2009 |
Protective effect of atorvastatin in cultured osteoarthritic chondrocytes.
Topics: Aged; Aged, 80 and over; Aggrecans; Atorvastatin; Cartilage, Articular; Cells, Cultured; Chondrocytes; Collagen Type II; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Knee Joint; Male; Matrix Metalloproteinase 13; Middle Aged; Osteoarthritis, Knee; Pyrroles | 2010 |
Synergistic actions of atorvastatin with gamma-tocotrienol and celecoxib against human colon cancer HT29 and HCT116 cells.
Topics: Atorvastatin; Celecoxib; Cell Cycle; Cell Division; Cell Line, Tumor; Chromans; Colonic Neoplasms; Cyclooxygenase 2 Inhibitors; Drug Synergism; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Polyisoprenyl Phosphates; Pyrazoles; Pyrroles; Sulfonamides; Vitamin E | 2010 |
Aortic and mitral valve replacement with reconstruction of the intervalvular fibrous body in familial hypercholesterolemia.
Topics: Aortic Valve Stenosis; Atorvastatin; Blood Component Removal; Female; Heart Valve Prosthesis Implantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Mitral Valve Insufficiency; Pyrroles; Treatment Outcome; Xanthomatosis; Young Adult | 2009 |
Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment.
Topics: Adiponectin; Adult; Age Distribution; Atorvastatin; Biomarkers; Cholesterol, HDL; Family; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Phenotype; Prevalence; Pyrroles; Randomized Controlled Trials as Topic; Waist Circumference; Young Adult | 2009 |
Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats.
Topics: Animals; Atorvastatin; Cerebrovascular Circulation; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Fibrinolytic Agents; Heptanoic Acids; Immunohistochemistry; Intracranial Embolism; Male; Neuroprotective Agents; Pyrroles; Rats; Rats, Wistar; Stroke; Time Factors; Tissue Plasminogen Activator | 2009 |
Right ventricular function in ST elevation myocardial infarction: effect of reperfusion.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Female; Heptanoic Acids; Humans; Male; Metoprolol; Middle Aged; Myocardial Infarction; Myocardial Reperfusion; Pyrroles; Streptokinase; Thrombolytic Therapy; Ticlopidine; Treatment Outcome; Ventricular Function, Right | 2009 |
Atorvastatin modulates Th1/Th2 response in patients with chronic heart failure.
Topics: Atorvastatin; Chronic Disease; Heart Failure; Heptanoic Acids; Humans; Pyrroles; Signal Transduction; Th1 Cells; Th2 Cells | 2009 |
Simvastatin and atorvastatin improve neurological outcome after experimental intracerebral hemorrhage.
Topics: Animals; Apoptosis; Atorvastatin; Biomarkers; Brain; Brain Infarction; Bromodeoxyuridine; Cerebral Hemorrhage; Cytoprotection; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Doublecortin Domain Proteins; Doublecortin Protein; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microtubule-Associated Proteins; Nerve Degeneration; Neurogenesis; Neuronal Plasticity; Neuropeptides; Neuroprotective Agents; Pyrroles; Rats; Rats, Wistar; Regeneration; Simvastatin; Treatment Outcome | 2009 |
[Effect of atorvastatin on inflammatory infiltration in the lung of rabbits with hypercholesterolemia].
Topics: Animals; Atorvastatin; Bronchoalveolar Lavage; Heptanoic Acids; Hypercholesterolemia; Inflammation; Lung; Macrophages, Alveolar; Male; NF-kappa B; Pyrroles; Rabbits; Random Allocation | 2009 |
Heparin treatment for severe hypertriglyceridemia in diabetic ketoacidosis.
Topics: Atorvastatin; Cholesterol; Diabetic Ketoacidosis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Omega-3; Fenofibrate; Half-Life; Heparin; Heptanoic Acids; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Male; Middle Aged; Pancreatitis, Acute Necrotizing; Pyrroles; Triglycerides | 2009 |
Topical atorvastatin in the treatment of diabetic wounds.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Experimental; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Rats; Rats, Wistar; Wound Healing; Wounds and Injuries | 2009 |
Effects of atorvastatin on angiogenesis in hindlimb ischemia and endothelial progenitor cell formation in rats.
Topics: Angiogenesis Inducing Agents; Angiogenic Proteins; Animals; Atorvastatin; Cell Count; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Hindlimb; Ischemia; Neovascularization, Physiologic; Pyrroles; Rats; Rats, Inbred SHR; Stem Cells | 2009 |
I've heard that high-fat foods and alcohol can raise triglyceride levels. I take Lipitor for high cholesterol, don't eat high-fat foods and don't drink alcohol except for half a glass of wine a few times a month. My triglycerides are always high when chec
Topics: Anticholesteremic Agents; Atorvastatin; Exercise; Female; Heptanoic Acids; Humans; Male; Pyrroles; Triglycerides; Weight Loss | 2009 |
Atorvastatin reverses cardiac remodeling possibly through regulation of protein kinase D/myocyte enhancer factor 2D activation in spontaneously hypertensive rats.
Topics: Animals; Atorvastatin; Blood Pressure; Disease Models, Animal; Enzyme Activation; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxyproline; Hypertension; Hypertrophy, Left Ventricular; Lipids; Male; MEF2 Transcription Factors; Myocardium; Protein Kinase C; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Time Factors; Transcription Factors; Ventricular Remodeling | 2010 |
Atorvastatin ameliorates tubulointerstitial fibrosis and protects renal function in chronic partial ureteral obstruction cases.
Topics: Animals; Atorvastatin; Chronic Disease; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Tubules; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Ureteral Obstruction | 2009 |
Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha.
Topics: Animals; Apolipoprotein A-V; Apolipoproteins; Atorvastatin; Cell Line, Tumor; Drug Synergism; Fenofibrate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Liver; Male; PPAR alpha; Pyrroles; Rats; Rats, Sprague-Dawley; Triglycerides; Up-Regulation | 2009 |
Case of the month. Idiopathic dilated cardiomyopathy.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Angiography; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Clopidogrel; Diuretics; Dyspnea; Echocardiography; Electrocardiography; Furosemide; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lisinopril; Male; Mineralocorticoid Receptor Antagonists; Platelet Aggregation Inhibitors; Potassium; Propanolamines; Pyrroles; Spironolactone; Ticlopidine | 2009 |
Seasonal variation in lipids: should we consider it more?
Topics: Acute Coronary Syndrome; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Seasons | 2009 |
Levels of DKK1 in patients with acute myocardial infarction and response to atorvastatin.
Topics: Aged; Atorvastatin; Female; Follow-Up Studies; Heptanoic Acids; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Myocardial Infarction; Osteogenesis; Pyrroles; Treatment Outcome | 2010 |
Atorvastatin attenuates NF-kappaB activation in trigeminal nucleus caudalis in a rat model of migraine.
Topics: Analysis of Variance; Animals; Atorvastatin; Blotting, Western; Cell Nucleus; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorescent Antibody Technique; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Migraine Disorders; Neoplasm Proteins; Neurons; NF-kappa B; Nitroglycerin; Nucleocytoplasmic Transport Proteins; Pyrroles; Rats; Rats, Sprague-Dawley; Trigeminal Caudal Nucleus | 2009 |
Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes.
Topics: Asian People; Atorvastatin; Cell Line; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Receptor for Advanced Glycation End Products; Receptors, Immunologic | 2010 |
Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Heptanoic Acids; Humans; Ischemic Attack, Transient; Male; Pyrroles; Secondary Prevention; Stroke | 2009 |
Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Atorvastatin; Azithromycin; Databases, Factual; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pravastatin; Pyridines; Pyrroles; Rhabdomyolysis; Simvastatin | 2009 |
The results support the use of atorvastatin in elderly patients with recent stroke or TIA.
Topics: Aged; Atorvastatin; Heptanoic Acids; Humans; Ischemic Attack, Transient; Pyrroles; Stroke | 2009 |
Effect of total saponins of "panax notoginseng root" on aortic intimal hyperplasia and the expressions of cell cycle protein and extracellular matrix in rats.
Topics: Animals; Anticholesteremic Agents; Aorta; Atorvastatin; Cell Cycle Proteins; Collagen Type I; Coronary Restenosis; Cyclins; Drugs, Chinese Herbal; Extracellular Matrix; Fibronectins; Heptanoic Acids; Hyperplasia; Male; Matrix Metalloproteinase 9; Panax notoginseng; Phytotherapy; Plant Roots; Proliferating Cell Nuclear Antigen; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Saponins; Tissue Inhibitor of Metalloproteinase-1; Tunica Intima | 2010 |
Statins and fibrate target ClC-1 - from side effects to CLC pharmacology.
Topics: Action Potentials; Animals; Atorvastatin; Calcium; Chloride Channels; Chlorides; Down-Regulation; Enzyme Activation; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Muscle, Skeletal; Protein Kinase C; Pyrroles; RNA, Messenger | 2009 |
Headache as the sole presenting symptom of acute myocardial infarction.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Aspirin; Atorvastatin; Clopidogrel; Headache; Heparin, Low-Molecular-Weight; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Oxygen Inhalation Therapy; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2009 |
Effects of atorvastatin on circulating CD34+/CD133+/ CD45- progenitor cells and indices of angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic vascular disease and diabetes mellitus.
Topics: Aged; Angiopoietin-1; Angiopoietin-2; Antigens, CD; Antigens, CD34; Atherosclerosis; Atorvastatin; Diabetes Mellitus; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocyte Common Antigens; Male; Middle Aged; Neovascularization, Pathologic; Prospective Studies; Pyrroles; Stem Cells; Vascular Endothelial Growth Factor A | 2010 |
Atorvastatin restores the impaired vascular endothelium-dependent relaxations mediated by nitric oxide and endothelium-derived hyperpolarizing factors but not hypotension in sepsis.
Topics: Acetylcholine; Animals; Aorta; Atorvastatin; Biological Factors; Blood Cell Count; Blood Pressure; Calcium Channel Blockers; Cytochrome P-450 Enzyme Inhibitors; Disease Models, Animal; Endothelium, Vascular; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypotension; Indomethacin; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Nitrites; Nitroprusside; Phenylephrine; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar; Sepsis; Vasodilation | 2009 |
Angiotensin type 1 receptor expression and interleukin-8 production in polymorphonuclear leukocytes of patients with peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Endarterectomy; Female; Femoral Artery; Gene Expression; Heptanoic Acids; Humans; Interleukin-8; Male; Middle Aged; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Peripheral Vascular Diseases; Pyrroles; Receptor, Angiotensin, Type 1; Triglycerides | 2009 |
Atorvastatin attenuates homocysteine-induced apoptosis in human umbilical vein endothelial cells via inhibiting NADPH oxidase-related oxidative stress-triggered p38MAPK signaling.
Topics: Apoptosis; Atorvastatin; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Enzyme Inhibitors; Heptanoic Acids; Homocysteine; Humans; Imidazoles; NADPH Oxidases; Onium Compounds; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Pyrroles; Reactive Oxygen Species; Signal Transduction; Time Factors; Umbilical Veins | 2009 |
Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Caco-2 Cells; Case-Control Studies; Ezetimibe; Female; Genetic Variation; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Mutation; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Receptors, LDL; RNA, Messenger; Serine Endopeptidases; Young Adult | 2009 |
Immunomodulation by atorvastatin upregulates expression of gap junction proteins in coxsackievirus B3 (CVB3)-induced myocarditis.
Topics: Animals; Atorvastatin; Blotting, Western; Connexin 43; Connexins; Coxsackievirus Infections; Cytokines; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Immunohistochemistry; Immunologic Factors; Interferon-gamma; Mice; Myocarditis; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha; Up-Regulation | 2010 |
Multi-residue method for trace level determination of pharmaceuticals in solid samples using pressurized liquid extraction followed by liquid chromatography/quadrupole-linear ion trap mass spectrometry.
Topics: Acetaminophen; Atorvastatin; Chromatography, Liquid; Diclofenac; Geologic Sediments; Heptanoic Acids; Hot Temperature; Hydrochlorothiazide; Ibuprofen; Pharmaceutical Preparations; Pyrroles; Reference Standards; Reproducibility of Results; Rivers; Sewage; Solid Phase Extraction; Tandem Mass Spectrometry | 2009 |
FDG-PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis.
Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Catheterization; Cholesterol, Dietary; Diagnosis, Differential; Disease Models, Animal; Fluorodeoxyglucose F18; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Male; Positron-Emission Tomography; Predictive Value of Tests; Pyrroles; Rabbits; Radiopharmaceuticals | 2010 |
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Topics: Adjuvants, Immunologic; Atorvastatin; Disease Progression; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon beta-1a; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Pyrroles | 2009 |
Comparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2010 |
UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo.
Topics: Atorvastatin; Glucuronosyltransferase; Heptanoic Acids; Humans; Lactones; Microsomes, Liver; Polymorphism, Genetic; Pyrroles | 2010 |
Atorvastatin enhances humoral immune responses but does not alter renal injury in experimental crescentic glomerulonephritis.
Topics: Animals; Atorvastatin; CD4-Positive T-Lymphocytes; Dose-Response Relationship, Drug; Glomerulonephritis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Humoral; Kidney; Male; Mice; Mice, Inbred C57BL; Pyrroles | 2009 |
Anti-inflammatory effect of atorvastatin ameliorates insulin resistance in monosodium glutamate-treated obese mice.
Topics: Adipose Tissue, White; Animals; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Blood Glucose; Cytokines; Enzyme-Linked Immunosorbent Assay; Glucose Transporter Type 4; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; I-kappa B Kinase; Immunohistochemistry; Insulin Resistance; Lipids; Male; Mice; Obesity; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA; Sodium Glutamate | 2010 |
Influence of genetic variation in CYP3A4 and ABCB1 on dose decrease or switching during simvastatin and atorvastatin therapy.
Topics: Aged; Aged, 80 and over; Alleles; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cholesterol; Cohort Studies; Cytochrome P-450 CYP3A; Databases, Factual; Female; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Sex Factors; Simvastatin | 2010 |
The functional changes of the perivascular adipose tissue in spontaneously hypertensive rats and the effects of atorvastatin therapy.
Topics: Adipose Tissue; Animals; Aorta, Thoracic; Atorvastatin; Connective Tissue; Disease Models, Animal; Endothelium-Dependent Relaxing Factors; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Vasoconstriction; Vasodilation | 2009 |
Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1.
Topics: Administration, Oral; Animals; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Macrophages; Male; Mice; Neovascularization, Pathologic; Pyrroles; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2010 |
Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Black or African American; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Combinations; Drug Tolerance; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome | 2009 |
18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Binding, Competitive; Cells, Cultured; Contrast Media; Disease Models, Animal; Endothelium, Vascular; Feasibility Studies; Fluorodeoxyglucose F18; Graft Rejection; Half-Life; Heart Transplantation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Iopamidol; Ligands; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Peptides; Positron-Emission Tomography; Predictive Value of Tests; Pyrroles; Radiopharmaceuticals; Reproducibility of Results; RNA, Messenger; Tissue Distribution; Tomography, X-Ray Computed; Vascular Cell Adhesion Molecule-1 | 2009 |
Quantitation of atorvastatin in human plasma using directly suspended acceptor droplet in liquid-liquid-liquid microextraction and high-performance liquid chromatography-ultraviolet detection.
Topics: 1-Octanol; Administration, Oral; Anticholesteremic Agents; Atorvastatin; Chemical Fractionation; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Hydrogen-Ion Concentration; Pyrroles; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2009 |
Reporter gene PET for monitoring survival of transplanted endothelial progenitor cells in the rat heart after pretreatment with VEGF and atorvastatin.
Topics: Animals; Atorvastatin; Cell Survival; Endothelial Cells; Genes, Reporter; Heart; Heptanoic Acids; Humans; Infant, Newborn; Injections; Male; Myocardium; Positron-Emission Tomography; Pyrroles; Rats; Rats, Nude; Stem Cell Transplantation; Stem Cells; Vascular Endothelial Growth Factor A | 2009 |
Atorvastatin prevents gentamicin-induced renal damage in rats through the inhibition of p38-MAPK and NF-kappaB pathways.
Topics: Analysis of Variance; Animals; Atorvastatin; Chi-Square Distribution; Disease Models, Animal; Free Radical Scavengers; Gentamicins; Heptanoic Acids; Immunohistochemistry; Kidney Function Tests; Kidney Tubular Necrosis, Acute; Male; MAP Kinase Signaling System; NF-kappa B; Nitric Oxide; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Probability; Pyrroles; Random Allocation; Rats; Rats, Wistar | 2009 |
Effect of preoperative atorvastatin therapy on paraoxonase activity and oxidative stress after coronary artery bypass grafting.
Topics: Aged; Antioxidants; Aryldialkylphosphatase; Atorvastatin; Carboxylic Ester Hydrolases; Coronary Artery Bypass; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidants; Oxidative Stress; Preoperative Care; Pyrroles | 2009 |
[The ram and the oat bag].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Drug Prescriptions; Evidence-Based Medicine; Heptanoic Acids; Humans; Norway; Practice Patterns, Physicians'; Pyrroles; Simvastatin | 2009 |
[Atorvastatin dreduces sympathetic activity and improves baroreceptor reflex sensitivity in patients with hypercholesterolemia and hypertension].
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Baroreflex; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Pressoreceptors; Pyrroles | 2009 |
Occurrence and fate of rosuvastatin, rosuvastatin lactone, and atorvastatin in Canadian sewage and surface water samples.
Topics: Atorvastatin; Chromatography, Liquid; Fluorobenzenes; Heptanoic Acids; Lactones; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sewage; Solid Phase Extraction; Sulfonamides; Tandem Mass Spectrometry; Water Pollutants, Chemical | 2009 |
The relationship between nonalcoholic fatty liver disease and the severity of coronary artery disease in patients with metabolic syndrome.
Topics: Adult; Alanine Transaminase; Atorvastatin; Contraindications; Coronary Artery Disease; Fatty Liver; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Pyrroles | 2009 |
Reduced intimal hyperplasia in rabbits via medical therapy after carotid venous bypass.
Topics: Administration, Oral; Animals; Atorvastatin; Benzopyrans; Calcium Dobesilate; Cardiovascular Agents; Carotid Stenosis; Clopidogrel; Disease Models, Animal; Ethanolamines; Graft Occlusion, Vascular; Heptanoic Acids; Hyperplasia; Jugular Veins; Male; Nebivolol; Pyrroles; Rabbits; Ticlopidine; Tunica Intima; Vascular Surgical Procedures | 2009 |
NADPH oxidase isoforms and anti-hypertensive effects of atorvastatin demonstrated in two animal models.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Aorta, Thoracic; Apolipoproteins E; Atorvastatin; Blood Pressure; Blotting, Western; Dietary Fats; Ethidium; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Isoenzymes; Mice; Mice, Inbred C57BL; Mice, Knockout; NADPH Oxidases; Nitric Oxide Synthase; Pyrroles; rac1 GTP-Binding Protein; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Three-dimensional carotid ultrasound segmentation variability dependence on signal difference and boundary orientation.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Biometry; Carotid Arteries; Carotid Stenosis; Female; Heptanoic Acids; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Pattern Recognition, Automated; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Surface Properties; Ultrasonography | 2010 |
Impact of chronic anticholesterol therapy on development of microvascular rarefaction in the metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Arterioles; Atorvastatin; Cytokines; Gemfibrozil; Heptanoic Acids; Inflammation; Male; Metabolic Syndrome; Microcirculation; Muscle, Skeletal; Nitric Oxide; Probucol; Pyrroles; Rats; Rats, Zucker; Simvastatin; Time Factors | 2009 |
Cholestatic jaundice induced by atorvastatin: a possible association with antimitochondrial antibodies.
Topics: Aged; Atorvastatin; Autoantibodies; Chemical and Drug Induced Liver Injury; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Jaundice, Obstructive; Male; Mitochondria; Pyrroles | 2009 |
Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Korea; Male; Markov Chains; Middle Aged; Models, Economic; Pyrroles; Quality-Adjusted Life Years; Risk Factors | 2009 |
Atorvastatin increases expression of low-density lipoprotein receptor mRNA in human circulating mononuclear cells.
Topics: Adult; Atorvastatin; Cholesterol; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; LDL-Receptor Related Proteins; Leukocytes, Mononuclear; Male; Middle Aged; Pyrroles; Receptors, LDL; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Up-Regulation | 2010 |
Lack of robust neurologic benefits with simvastatin or atorvastatin treatment after acute thoracic spinal cord contusion injury.
Topics: Analysis of Variance; Animals; Atorvastatin; Benzenesulfonates; Dietary Sucrose; Disease Models, Animal; Drug Administration Routes; Ectodysplasins; Exploratory Behavior; Food, Formulated; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Motor Activity; Nervous System Diseases; Pain Measurement; Pain Threshold; Psychomotor Performance; Pyrroles; Rats; Rats, Sprague-Dawley; Sacrococcygeal Region; Simvastatin; Spinal Cord Injuries | 2010 |
Atorvastatin ameliorates inflammatory hyperalgesia in rat model of monoarticular arthritis.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Atorvastatin; Diclofenac; Female; Freund's Adjuvant; Heptanoic Acids; Hyperalgesia; Inflammation; Joints; Lower Extremity; Male; Motor Activity; Pyrroles; Rats; Rats, Wistar | 2010 |
Effect of atorvastatin and diet on non-alcoholic fatty liver disease activity score in hyperlipidemic chickens.
Topics: Animals; Atorvastatin; Chickens; Cholesterol; Disease Models, Animal; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Male; Pyrroles; Severity of Illness Index; Triglycerides | 2010 |
Atorvastatin mediates increases in intralesional BAX and BAK expression in human end-stage abdominal aortic aneurysms.
Topics: Aged; Aged, 80 and over; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Apoptosis Regulatory Proteins; Atorvastatin; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Caspase 3; Disease Progression; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2009 |
2-methoxyestradiol inhibits atorvastatin-induced rounding of human vascular smooth muscle cells.
Topics: 2-Methoxyestradiol; Actins; Atorvastatin; Cell Movement; Cell Shape; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estradiol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microtubules; Molecular Motor Proteins; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Myosins; Pyrroles; rho GTP-Binding Proteins; rho-Associated Kinases; Signal Transduction; Time Factors; Tubulin Modulators | 2010 |
Human skeletal muscle drug transporters determine local exposure and toxicity of statins.
Topics: Atorvastatin; Cell Survival; Cells, Cultured; Fluorobenzenes; Gene Expression Profiling; HeLa Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Immunohistochemistry; Multidrug Resistance-Associated Proteins; Muscle, Skeletal; Myoblasts; Organic Anion Transporters; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides | 2010 |
In vitro effects of atorvastatin on lipopolysaccharide-induced gene expression in endometriotic stromal cells.
Topics: Adolescent; Adult; Atorvastatin; Biopsy; Case-Control Studies; Cell Differentiation; Cell Proliferation; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Dose-Response Relationship, Drug; Endometriosis; Endometrium; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin-Like Growth Factor Binding Protein 1; Lipopolysaccharides; Liver X Receptors; Orphan Nuclear Receptors; PPAR gamma; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic; S100 Proteins; S100A12 Protein; Stromal Cells; Uterine Diseases; Vascular Endothelial Growth Factor A; Young Adult | 2010 |
Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability.
Topics: ADP Ribose Transferases; Angiogenesis Inhibitors; Atorvastatin; Botulinum Toxins; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Down-Regulation; Endothelial Cells; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 9; Mevalonic Acid; Neovascularization, Physiologic; Nitrobenzenes; Polyisoprenyl Phosphates; Pyrroles; rho GTP-Binding Proteins; RNA, Messenger; Simvastatin; Sulfonamides; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha | 2010 |
Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin.
Topics: Animals; Antimalarials; Artemisinins; Atorvastatin; Drug Combinations; Drug Synergism; Heptanoic Acids; Parasitic Sensitivity Tests; Plasmodium falciparum; Pyrroles | 2010 |
Is initiation of atorvastatin for employees a good buy for employers?
Topics: Atorvastatin; Comparative Effectiveness Research; Health Benefit Plans, Employee; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin; United States | 2009 |
Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.
Topics: Adolescent; Adult; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Health Benefit Plans, Employee; Health Care Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrroles; Simvastatin; United States | 2009 |
Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Heptanoic Acids; Humans; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Purines; Pyrroles; Rifampin; Verapamil | 2009 |
New translational research on novel drugs for hepatitis C virus 1b infection by using a replicon system and human induced pluripotent stem cells.
Topics: Antiviral Agents; Atorvastatin; Hepacivirus; Hepatitis C; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Induced Pluripotent Stem Cells; Pyrroles; Quinolines | 2010 |
Von Willebrand disease, angiodysplasia and atorvastatin.
Topics: Angiodysplasia; Anticholesteremic Agents; Atorvastatin; Gastrointestinal Hemorrhage; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; von Willebrand Diseases | 2010 |
Montelukast inhibits matrix metalloproteinases expression in atherosclerotic rabbits.
Topics: Acetates; Animals; Atherosclerosis; Atorvastatin; Cyclopropanes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukotriene Antagonists; Lipids; Macrophages; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Myocytes, Smooth Muscle; Pyrroles; Quinolines; Rabbits; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; Sulfides | 2009 |
Antimicrobial action of atorvastatin and rosuvastatin.
Topics: Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Bacteria; Dose-Response Relationship, Drug; Ethanol; Fluorobenzenes; Heptanoic Acids; Humans; Methanol; Microbial Sensitivity Tests; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2009 |
Atorvastatin improves the impaired baroreflex sensitivity via anti-oxidant effect in the rostral ventrolateral medulla of SHRSP.
Topics: Animals; Atorvastatin; Baroreflex; Blood Pressure; Disease Models, Animal; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Medulla Oblongata; Oxidative Stress; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY | 2009 |
Atorvastatin-induced cell toxicity in yeast is linked to disruption of protein isoprenylation.
Topics: Anticholesteremic Agents; Atorvastatin; Cell Death; Cell Survival; Heptanoic Acids; Hypolipidemic Agents; Mitochondria; Protein Prenylation; Pyrroles; Saccharomyces cerevisiae | 2010 |
The role of transcranial Doppler embolic monitoring in the management of intracranial arterial stenosis.
Topics: Angiography, Digital Subtraction; Aspirin; Atorvastatin; Blood Flow Velocity; Cerebral Angiography; Clopidogrel; Constriction, Pathologic; Diagnosis, Differential; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Embolism; Ischemic Attack, Transient; Magnetic Resonance Imaging; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Tomography, X-Ray Computed; Ultrasonography, Doppler, Transcranial; Young Adult | 2011 |
Beneficial changes of serum calcification markers and contralateral carotid plaques echogenicity after combined carotid artery stenting plus intensive lipid-lowering therapy in patients with bilateral carotid stenosis.
Topics: Aged; Angioplasty; Atorvastatin; Biomarkers; C-Reactive Protein; Calcinosis; Carotid Stenosis; Combined Modality Therapy; Down-Regulation; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Osteopontin; Osteoprotegerin; Prospective Studies; Pyrroles; Severity of Illness Index; Stents; Time Factors; Treatment Outcome; Ultrasonography, Doppler | 2010 |
Atorvastatin attenuates murine anti-glomerular basement membrane glomerulonephritis.
Topics: Animals; Atorvastatin; CD4-Positive T-Lymphocytes; Glomerular Basement Membrane; Glomerulonephritis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interleukin-10; Kidney Glomerulus; Male; Mice; Mice, Inbred C57BL; Pyrroles; T-Lymphocyte Subsets; Th1 Cells | 2010 |
Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT).
Topics: Adolescent; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Area Under Curve; Atorvastatin; Biomarkers; Cardiomyopathies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Multicenter Studies as Topic; Puberty; Pyrroles; Quinapril; Randomized Controlled Trials as Topic; Research Design; Risk; Tetrahydroisoquinolines | 2009 |
Atorvastatin inhibits homocysteine-induced oxidative stress and apoptosis in endothelial progenitor cells involving Nox4 and p38MAPK.
Topics: Apoptosis; Atorvastatin; Cells, Cultured; Endothelial Cells; Enzyme Activation; Heptanoic Acids; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; NADPH Oxidase 4; NADPH Oxidases; Onium Compounds; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Pyrroles; Reactive Oxygen Species; Stem Cells | 2010 |
Efficacy of combination drug pulse therapy in maintaining lipid levels in patients intolerant of daily statin use.
Topics: Allylamine; Analysis of Variance; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Monitoring; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pulse Therapy, Drug; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2009 |
Atorvastatin improves insulin sensitivity in mice with obesity induced by monosodium glutamate.
Topics: Adipose Tissue; Administration, Oral; Animals; Atorvastatin; Blood Glucose; Blotting, Western; Disease Models, Animal; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Lipid Metabolism; Mice; Mice, Inbred ICR; Obesity; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sodium Glutamate | 2010 |
Omega-3 fatty acids and atorvastatin affect connexin 43 expression in the aorta of hereditary hypertriglyceridemic rats.
Topics: Animals; Aorta, Thoracic; Atorvastatin; Blotting, Western; Connexin 43; Endothelium, Vascular; Fatty Acids, Omega-3; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; Microscopy, Electron, Transmission; Pyrroles; Rats; Rats, Inbred SHR; Rats, Wistar | 2009 |
Atorvastatin modulates matrix metalloproteinase expression, activity, and signaling in abdominal aortic aneurysms.
Topics: Aged; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Atorvastatin; Down-Regulation; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinases; Phosphorylation; Pyrroles; Signal Transduction; Smad2 Protein; Tissue Inhibitor of Metalloproteinases; Transforming Growth Factor beta | 2010 |
Sympathoinhibition induced by centrally administered atorvastatin is associated with alteration of NAD(P)H and Mn superoxide dismutase activity in rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
Topics: Animals; Atorvastatin; Baroreflex; Heptanoic Acids; Hypertension; Injections, Intraventricular; Male; Medulla Oblongata; NADP; Oxidative Stress; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke; Superoxide Dismutase; Sympathetic Nervous System | 2010 |
Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence.
Topics: Androgens; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Blotting, Western; Celecoxib; Cell Proliferation; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Mice; Mice, SCID; Neoplasms, Hormone-Dependent; NF-kappa B; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays | 2010 |
Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Atorvastatin; Blood; Brazil; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Gene Frequency; Genotype; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Linkage Disequilibrium; Lipid Metabolism; Lipids; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Scavenger Receptors, Class B; Triglycerides | 2010 |
Concerns about heparin therapy for hypertriglyceridemia.
Topics: Atorvastatin; Cholesterol; Chylomicrons; Diabetic Ketoacidosis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Omega-3; Fenofibrate; Half-Life; Heparin; Heptanoic Acids; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Male; Middle Aged; Pancreatitis, Acute Necrotizing; Pyrroles; Triglycerides | 2010 |
Switching to aggressive statin improves vascular endothelial function in patients with stable coronary artery disease.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Lipids; Lipoproteins; Male; Middle Aged; Pravastatin; Prognosis; Pyrroles; Risk Factors; Triglycerides | 2010 |
Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population.
Topics: Aged; Atorvastatin; Belgium; Cardiovascular Diseases; Cholesterol, HDL; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drugs, Generic; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance, Health, Reimbursement; Male; Markov Chains; Middle Aged; Models, Economic; Models, Statistical; Pyrroles; Quality-Adjusted Life Years; Triglycerides | 2010 |
Monocyte expression of adhesion molecules during low- and high-flux polysulfone hemodialysis and the effect of atorvastatin administration.
Topics: Adult; Aged; Atorvastatin; CD11b Antigen; CD18 Antigens; Cell Adhesion Molecules; Cross-Over Studies; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; L-Selectin; Male; Middle Aged; Monocytes; Polymers; Pyrroles; Renal Dialysis; Sulfones | 2010 |
Inflammatory signaling in pulmonary arterial hypertension: the controversial role of CRP, and the search for new therapies.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Atorvastatin; C-Reactive Protein; Chemokine CCL2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Inflammation Mediators; Interleukin-6; Muscle, Smooth, Vascular; NF-kappa B; Pulmonary Artery; Pyrroles | 2010 |
Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway.
Topics: Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Cells, Cultured; Chemokine CCL2; Dose-Response Relationship, Drug; Down-Regulation; Electrophoretic Mobility Shift Assay; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-6; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NF-kappa B; Pulmonary Artery; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors | 2010 |
Cardiovascular outcomes in randomized trials: should time to first event for "hard" end points remain the standard approach?
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol; Endpoint Determination; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Revascularization; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke; Time Factors | 2009 |
Enhancement of oral bioavailability of atorvastatin calcium by self-emulsifying drug delivery systems (SEDDS).
Topics: Administration, Oral; Animals; Atorvastatin; Biological Availability; Chemistry, Pharmaceutical; Drug Delivery Systems; Drug Stability; Emulsions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Particle Size; Phase Transition; Pyrroles; Rats; Solubility; Surface Properties; Viscosity | 2011 |
Inhibition of C-reactive protein induced expression of matrix metalloproteinases by atorvastatin in THP-1 cells.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cell Line; Dose-Response Relationship, Drug; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; MAP Kinase Signaling System; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mitogen-Activated Protein Kinases; Monocytes; Pyrroles; Receptors, IgG; Tissue Inhibitor of Metalloproteinase-1 | 2010 |
Atorvastatin protects rat brains against permanent focal ischemia and downregulates HMGB1, HMGB1 receptors (RAGE and TLR4), NF-kappaB expression.
Topics: Animals; Atorvastatin; Behavior, Animal; Brain; Brain Edema; Brain Infarction; Brain Ischemia; Down-Regulation; Heptanoic Acids; HMGB1 Protein; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neuroprotective Agents; NF-kappa B; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Toll-Like Receptor 4 | 2010 |
Unexplained high fever in an elderly patient treated with clonidine, duloxetine, and atorvastatin.
Topics: Aged; Antidepressive Agents; Antihypertensive Agents; Atorvastatin; Body Temperature; Clonidine; Drug Interactions; Duloxetine Hydrochloride; Female; Fever of Unknown Origin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Polypharmacy; Pyrroles; Thiophenes; Time Factors | 2009 |
Discovery of safety biomarkers for atorvastatin in rat urine using mass spectrometry based metabolomics combined with global and targeted approach.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Biomarkers; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Limit of Detection; Male; Metabolomics; Pyrroles; Rats; Rats, Sprague-Dawley; Reference Standards | 2010 |
Atorvastatin causes regression of endometriotic implants in a rat model.
Topics: Animals; Antioxidants; Atorvastatin; Disease Models, Animal; Endometriosis; Endometrium; Female; Heptanoic Acids; Pyrroles; Rats; Rats, Wistar | 2010 |
Noninferiority of pitavastatin in intravascular ultrasound findings.
Topics: Acute Coronary Syndrome; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines; Reproducibility of Results; Treatment Outcome; Ultrasonography, Interventional | 2010 |
Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; CD36 Antigens; Cells, Cultured; Diabetes Mellitus, Type 2; Down-Regulation; Female; Heptanoic Acids; Humans; Inflammation; Male; Middle Aged; Monocytes; NF-kappaB-Inducing Kinase; Protein Serine-Threonine Kinases; Pyrroles; Tumor Necrosis Factor-alpha | 2010 |
Statin-induced autophagy by inhibition of geranylgeranyl biosynthesis in prostate cancer PC3 cells.
Topics: Anticholesteremic Agents; Atorvastatin; Autophagy; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; Flow Cytometry; Fluorescent Antibody Technique; Heptanoic Acids; Humans; Male; Prenylation; Prostate; Pyrroles | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Atorvastatin-induced prolonged cholestasis with bile duct damage.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Bile Ducts; Cholagogues and Choleretics; Cholangitis; Cholestasis; Dyslipidemias; Heptanoic Acids; Humans; Male; Pyrroles; Ursodeoxycholic Acid | 2010 |
[Statin-induced dysphagia].
Topics: Anticholesteremic Agents; Atorvastatin; Deglutition Disorders; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pyrroles | 2010 |
Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-beta1 in cultured cardiac fibroblasts.
Topics: Adaptor Proteins, Signal Transducing; Analysis of Variance; Androstadienes; Animals; Antigens, CD; Apoptosis Regulatory Proteins; Atorvastatin; Cells, Cultured; Collagen Type I; Endoglin; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; MAP Kinase Signaling System; Myocardium; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta1; Wortmannin | 2010 |
Neuroprotection of early and short-time applying atorvastatin in the acute phase of cerebral ischemia: down-regulated 12/15-LOX, p38MAPK and cPLA2 expression, ameliorated BBB permeability.
Topics: Acute Disease; Animals; Arachidonate 12-Lipoxygenase; Arachidonate 15-Lipoxygenase; Atorvastatin; Blood-Brain Barrier; Brain; Brain Edema; Brain Ischemia; Capillary Permeability; Down-Regulation; Heptanoic Acids; Infarction, Middle Cerebral Artery; Male; Neuroprotective Agents; p38 Mitogen-Activated Protein Kinases; Phospholipases A2, Cytosolic; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Stroke; Time Factors | 2010 |
Identification and assessment of plasma lysozyme as a putative biomarker of atherosclerosis.
Topics: Aged; Angina Pectoris; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Coronary Angiography; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoassay; Male; Middle Aged; Muramidase; Predictive Value of Tests; Pyrroles; Sensitivity and Specificity; Severity of Illness Index; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome; Up-Regulation | 2010 |
Combined hyperlipidemia in patients with lysinuric protein intolerance.
Topics: Adolescent; Adult; Amino Acid Metabolism, Inborn Errors; Atorvastatin; Biomarkers; Child; Child, Preschool; Cholesterol; Cholesterol, HDL; Cystatin C; Disease Progression; Female; Finland; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors; Treatment Outcome; Triglycerides; Young Adult | 2010 |
Atorvastatin-induced modulation of monocyte respiratory burst in vivo in patients with IgA nephropathy: a chronic inflammatory kidney disease.
Topics: Adolescent; Adult; Aged; Atorvastatin; Biopsy; Biotransformation; Creatinine; Cytokines; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Follow-Up Studies; Glomerular Filtration Rate; Glomerulonephritis, IGA; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Monocytes; Oxidative Stress; Pyrroles; Respiratory Burst; Treatment Outcome; Young Adult | 2010 |
Atorvastatin induces apoptosis in vitro and slows growth of tumor xenografts but not polyp formation in MIN mice.
Topics: Animals; Apoptosis; Atorvastatin; Colonic Neoplasms; Colonic Polyps; Disease Models, Animal; DNA Fragmentation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Nude; Pyrroles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Clinical trial efforts in Alzheimer disease: why test statins?
Topics: Alzheimer Disease; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic | 2010 |
LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
Topics: Adult; Aged; Atorvastatin; Case-Control Studies; Cholesterol, LDL; Cohort Studies; Databases, Factual; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Multivariate Analysis; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Simvastatin | 2010 |
Letter by Superko and King regarding article, "Lipid Treatment Assessment Project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals".
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Female; Genetic Predisposition to Disease; Goals; Guideline Adherence; Health Care Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kinesins; Male; Middle Aged; Mutation, Missense; Patient Selection; Pravastatin; Pyrroles; Risk | 2010 |
Marrow-derived MSCs and atorvastatin improve cardiac function in rat model of AMI.
Topics: Animals; Atorvastatin; Bone Marrow; Combined Modality Therapy; Disease Models, Animal; Heptanoic Acids; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Myocardial Infarction; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Ventricular Function | 2011 |
Effect of atorvastatin and ezetimibe treatment on serum lipid profile and oxidative state in rats fed with a high-cholesterol diet.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Catalase; Cholesterol, Dietary; Ezetimibe; Glutathione Peroxidase; Heptanoic Acids; Lipid Metabolism; Lipid Peroxidation; Lipids; Malondialdehyde; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxide Dismutase | 2010 |
Different effects of commonly prescribed statins on abdominal aortic aneurysm wall biology.
Topics: Aged; Aorta; Aortic Aneurysm, Abdominal; Atorvastatin; Biomarkers; Cathepsin A; Cathepsin B; Chi-Square Distribution; Cohort Studies; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Interleukins; Lymphotoxin-alpha; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Netherlands; Pravastatin; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Tumor Necrosis Factor-alpha; Vascular Surgical Procedures | 2010 |
Erythromelalgia: a novel postoperative complication.
Topics: Administration, Topical; Ankle Joint; Arthrodesis; Atorvastatin; Capsaicin; Erythromelalgia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Postoperative Complications; Pyrroles; Sensory System Agents | 2010 |
Atorvastatin reduces plaque vulnerability in an atherosclerotic rabbit model by altering the 5-lipoxygenase pathway.
Topics: 5-Lipoxygenase-Activating Proteins; Animals; Anticholesteremic Agents; Arachidonate 5-Lipoxygenase; Atorvastatin; Carotid Stenosis; Carrier Proteins; Disease Models, Animal; Elastic Tissue; Enzyme-Linked Immunosorbent Assay; Gene Expression; Heptanoic Acids; Leukotriene D4; Lipids; Lipoxins; Membrane Proteins; Muscle, Smooth, Vascular; Pyrroles; Rabbits; Receptors, Leukotriene; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tunica Intima | 2010 |
Statins in acute coronary syndromes and genetic insight.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Treatment Outcome | 2010 |
High-dose atorvastatin in acute coronary and cerebrovascular syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; Cerebrovascular Disorders; Coronary Circulation; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Outcome | 2010 |
Clinical usefulness of AGEs as a biomarker for the attenuation of NASH.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; Diabetes Mellitus; Fatty Liver; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hypertension; Pyrroles | 2010 |
Atorvastatin inhibits homocysteine-induced dysfunction and apoptosis in endothelial progenitor cells.
Topics: Animals; Apoptosis; Atorvastatin; Caspase 3; Cells, Cultured; Endothelial Cells; Gene Expression Regulation; Heptanoic Acids; Homocysteine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type III; p38 Mitogen-Activated Protein Kinases; Pyrroles; Reactive Oxygen Species; RNA, Messenger; Stem Cells | 2010 |
Pretreatment with atorvastatin attenuates lung injury caused by high-stretch mechanical ventilation in an isolated rabbit lung model.
Topics: Acute Lung Injury; Animals; Apoptosis; Atorvastatin; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lung; Male; Pulmonary Edema; Pyrroles; Rabbits; Respiration, Artificial; Respiratory Function Tests | 2010 |
Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes.
Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Logistic Models; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome; United States | 2010 |
Atorvastatin reduces tissue damage in rat ovaries subjected to torsion and detorsion: biochemical and histopathologic evaluation.
Topics: Animals; Antioxidants; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glutathione; Heptanoic Acids; Ischemia; Lipid Peroxidation; Ovary; Peroxidase; Pyrroles; Rats; Rats, Wistar; Reperfusion Injury; Superoxide Dismutase | 2010 |
Pravastatin treatment before coronary artery bypass grafting for reduction of postoperative atrial fibrillation.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; Biomarkers; C-Reactive Protein; Coronary Artery Bypass; Disease-Free Survival; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Pravastatin; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2010 |
Effects of clopidogrel on vascular proliferation and apoptosis in an atherosclerotic rabbit model.
Topics: Animals; Apoptosis; Atherosclerosis; Atorvastatin; C-Reactive Protein; Catheterization; Clopidogrel; Endothelium, Vascular; Heptanoic Acids; Inflammation; Male; Platelet-Derived Growth Factor; Pyrroles; Rabbits; Random Allocation; Ticlopidine; Tunica Intima | 2010 |
Solid state characterization of commercial crystalline and amorphous atorvastatin calcium samples.
Topics: Anticholesteremic Agents; Atorvastatin; Crystallization; Drug Evaluation, Preclinical; Drug Stability; Heptanoic Acids; Molecular Conformation; Powders; Pyrroles; Solubility | 2010 |
Effect of atorvastatin on dendritic cells of tubulointerstitium in diabetic rats.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Cell Movement; Dendritic Cells; Diabetes Mellitus, Experimental; Disease Models, Animal; Heptanoic Acids; Nephritis, Interstitial; P-Selectin; Pyrroles; Rats | 2010 |
Insulin resistance is associated with increased cholesterol synthesis, decreased cholesterol absorption and enhanced lipid response to statin therapy.
Topics: Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipids; Male; Metabolic Syndrome; Middle Aged; Pyrroles | 2010 |
Role of glucagon-like peptide- 1 in vascular endothelial dysfunction.
Topics: Animals; Atorvastatin; Diabetes Mellitus, Experimental; Endothelium, Vascular; Exenatide; Female; Glucagon-Like Peptide 1; Heptanoic Acids; Hyperhomocysteinemia; In Vitro Techniques; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type III; Peptides; Pyrroles; Rats; Rats, Wistar; Venoms | 2010 |
Charting new territory by simulated modeling of a clinical trial.
Topics: Atorvastatin; Cardiovascular Diseases; Computer Simulation; Databases as Topic; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Assessment; Risk Factors; Stroke; Time Factors; Treatment Outcome | 2010 |
Atorvastatin protects renal function in the rat with acute unilateral ureteral obstruction.
Topics: Acute Disease; Albuminuria; Animals; Atorvastatin; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Ureteral Obstruction | 2010 |
The AGEs-RAGE axis and nonalcoholic steatohepatitis: the evidence mounts.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; Fatty Liver; Glycation End Products, Advanced; Heptanoic Acids; Humans; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic | 2010 |
Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Calcium Channel Blockers; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Male; Managed Care Programs; Medication Adherence; Middle Aged; Odds Ratio; Pyrroles; Retrospective Studies | 2010 |
Effects of atorvastatin on the regeneration of pancreatic {beta}-cells after streptozotocin treatment in the neonatal rodent.
Topics: Animals; Animals, Newborn; Atorvastatin; Body Weight; Diabetes Mellitus, Experimental; Female; Glucose Tolerance Test; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Insulin; Insulin-Secreting Cells; Male; Neovascularization, Physiologic; Organ Size; Pregnancy; Pyrroles; Rats; Rats, Wistar | 2010 |
Intensive statin therapy: a favorable adjunct to the improvement of small-diameter vascular grafts.
Topics: Animals; Anticholesteremic Agents; Aorta, Abdominal; Atorvastatin; Blood Vessel Prosthesis; Cell Adhesion; Cell Movement; Dogs; Endothelial Cells; Endothelium, Vascular; Graft Occlusion, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microscopy, Electron, Scanning; Nitric Oxide Synthase; Polytetrafluoroethylene; Postoperative Care; Prosthesis Design; Prosthesis Fitting; Pyrroles; Stem Cells; Vascular Endothelial Growth Factor Receptor-2; Vascular Patency | 2010 |
[Effects of atorvastatin calcium on osteopontin in renovascular hypertensive rats].
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Atorvastatin; Heptanoic Acids; Hypertension, Renovascular; Male; Osteopontin; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2010 |
Effect of atorvastatin on activities of matrix metalloproteinases and chitotriosidase in male and female mice with experimental hyperlipidemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Enzyme Activation; Female; Heptanoic Acids; Hexosaminidases; Hyperlipidemias; Male; Matrix Metalloproteinases; Mice; Mice, Inbred ICR; Pyrroles; Triglycerides | 2009 |
Atorvastatin reduces calcification in rat arteries and vascular smooth muscle cells.
Topics: Animals; Aorta, Abdominal; Atorvastatin; Calcinosis; Calcium; Cells, Cultured; Drug Combinations; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Injections, Subcutaneous; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pyrroles; Rats; Rats, Sprague-Dawley; Thoracic Arteries; Vitamin D; Warfarin | 2010 |
Atorvastatin in stroke: a review of SPARCL and subgroup analysis.
Topics: Age Factors; Aged; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Hemorrhages; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Sex Factors; Stroke; Treatment Outcome | 2010 |
Regulation of vascular smooth muscle cell proliferation by nuclear orphan receptor Nur77.
Topics: Animals; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cell Proliferation; Gene Expression Regulation; Heptanoic Acids; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nuclear Receptor Subfamily 4, Group A, Member 1; Platelet-Derived Growth Factor; Pyrroles; Rats; RNA, Messenger | 2010 |
Short-term effects of periodontal therapy as an adjunct to anti-lipemic treatment.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Chronic Periodontitis; Dental Plaque Index; Dental Scaling; Female; Follow-Up Studies; Gingival Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Oral Hygiene; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Pyrroles; Root Planing; Treatment Outcome; Triglycerides | 2010 |
[The efficasy of atorvastatin in the case of paroxismal atrial fibrillation in patients with ischemic heart disease].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atorvastatin; Atrial Fibrillation; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Treatment Outcome | 2010 |
Recent trials in critical care nephrology.
Topics: Acute Kidney Injury; Atorvastatin; Critical Care; Critical Illness; Decision Support Systems, Clinical; Evidence-Based Medicine; Female; Hemofiltration; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Length of Stay; Male; Metabolic Clearance Rate; Middle Aged; Multicenter Studies as Topic; Pyrroles; Random Allocation; Randomized Controlled Trials as Topic; Renal Circulation; Renal Dialysis; Renal Replacement Therapy; Sepsis; Severity of Illness Index; Survival Rate | 2010 |
Atorvastatin preconditioning attenuates the production of endothelin-1 and prevents experimental vasospasm in rats.
Topics: Animals; Atorvastatin; Disease Models, Animal; Endothelin-1; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Preconditioning; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Rats; Rats, Sprague-Dawley; Subarachnoid Hemorrhage; Treatment Outcome; Vasodilation; Vasospasm, Intracranial | 2010 |
Effect of atorvastatin on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with coronary artery disease: a post hoc analysis of data from a prospective, randomized, double-blind study.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Double-Blind Method; Female; Fibrinolysis; Hemostasis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Pyrroles; Randomized Controlled Trials as Topic; Thrombin | 2010 |
Texture analysis of carotid artery atherosclerosis from three-dimensional ultrasound images.
Topics: Aged; Algorithms; Atherosclerosis; Atorvastatin; Carotid Arteries; Female; Heptanoic Acids; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Models, Statistical; Pyrroles; Reproducibility of Results; Ultrasonography | 2010 |
Approach to the patient who is intolerant of statin therapy.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atorvastatin; Coronary Disease; Diltiazem; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Middle Aged; Pyrroles; Simvastatin | 2010 |
[Investigation of the in vitro antibacterial effects of statins].
Topics: Atorvastatin; Bacteria; Drug Resistance, Bacterial; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microbial Sensitivity Tests; Pyrroles; Simvastatin | 2010 |
The utility of observational studies in clinical decision making: lessons learned from statin trials.
Topics: Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Decision Making; Epidemiologic Studies; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Observation; Pyrroles; Simvastatin | 2010 |
Atorvastatin affects TLR4 clustering via lipid raft modulation.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Blocking; Atorvastatin; Cell Line; Heptanoic Acids; Humans; Hypercholesterolemia; Lipopolysaccharides; Membrane Microdomains; Mevalonic Acid; Mice; Precursor Cells, B-Lymphoid; Protein Transport; Pyrroles; Receptor Aggregation; Toll-Like Receptor 4 | 2010 |
Atorvastatin protects against angiotensin II-induced injury and dysfunction in human umbilical vein endothelial cells through bradykinin 2 receptors.
Topics: Angiotensin II; Apoptosis; Atorvastatin; Cell Line; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide Synthase Type III; Pyrroles; Receptor, Bradykinin B2; Umbilical Veins | 2010 |
[Changes in bone mass with atorvastatin. BM AND AT study].
Topics: Aged; Atorvastatin; Bone Density; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles | 2011 |
Pitavastatin: the newest HMG-CoA reductase inhibitor.
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Product Surveillance, Postmarketing; Pyrroles; Quinolines; Simvastatin | 2010 |
Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum.
Topics: Antimalarials; Atorvastatin; ATP-Binding Cassette Transporters; Drug Resistance; Drug Synergism; Gene Dosage; Genetic Variation; Genotype; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitory Concentration 50; Malaria, Falciparum; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Mutation; Parasitic Sensitivity Tests; Plasmodium falciparum; Protozoan Proteins; Pyrroles; Quinine | 2010 |
The influence of Sam-Chil-Geun (Panax notoginseng) on the serum lipid levels and inflammations of rats with hyperlipidemia induced by poloxamer-407.
Topics: Animals; Atorvastatin; Cholesterol; Cyclooxygenase 2; Drugs, Chinese Herbal; Heptanoic Acids; Hyperlipidemias; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-1; Lipids; Male; Poloxamer; Pyrroles; Rats; Rats, Wistar; Triglycerides; Tumor Necrosis Factor-alpha | 2010 |
Synergy of mefloquine activity with atorvastatin, but not chloroquine and monodesethylamodiaquine, and association with the pfmdr1 gene.
Topics: Amodiaquine; Antimalarials; Atorvastatin; Chloroquine; DNA, Protozoan; Drug Synergism; Gene Dosage; Genotype; Heptanoic Acids; Humans; Inhibitory Concentration 50; Mefloquine; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Plasmodium falciparum; Pyrroles | 2010 |
Early outcome of acute ischemic stroke in hyperlipidemic patients under atorvastatin versus simvastatin.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Medical Records; Middle Aged; Neuroprotective Agents; Pyrroles; Retrospective Studies; Severity of Illness Index; Simvastatin; Statistics as Topic; Stroke; Stroke Rehabilitation; Treatment Outcome | 2010 |
The inhibitory effect of statins on urinary 11-dehydrothromboxane levels.
Topics: Aged; Aspirin; Atorvastatin; Biomarkers; Blood Glucose; Blood Platelets; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Czech Republic; Down-Regulation; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Simvastatin; Thromboxane B2; Time Factors; Treatment Outcome; Triglycerides | 2010 |
Low density lipoprotein-cholesterol variability in patients with type 2 diabetes taking atorvastatin compared to simvastatin: justification for direct measurement?
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Half-Life; Heptanoic Acids; Humans; Hypercholesterolemia; Lipid Metabolism; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2010 |
Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin.
Topics: Atorvastatin; Cell Line; Cyclosporine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Organic Anion Transporters; Pyrroles; Tacrolimus | 2010 |
High dose atorvastatin after stroke or transient ischaemic attack (SPARCL)--does every stroke patient in Pakistan deserve a statin?
Topics: Atorvastatin; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Pakistan; Pyrroles; Randomized Controlled Trials as Topic; Stroke; Treatment Outcome | 2010 |
Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental models.
Topics: Alkaline Phosphatase; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Atorvastatin; Edema; Fluorobenzenes; Granuloma; Heptanoic Acids; L-Lactate Dehydrogenase; Liver; Mice; Pain; Pain Measurement; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Rosuvastatin Calcium; Stomach Ulcer; Sulfonamides | 2010 |
[Case of branch atheromatous disease presenting capsular warning syndrome].
Topics: Anticoagulants; Aspirin; Atherosclerosis; Atorvastatin; Dextrans; Diffusion Magnetic Resonance Imaging; Drug Therapy, Combination; Heptanoic Acids; Humans; Infusions, Intravenous; Ischemic Attack, Transient; Magnetic Resonance Angiography; Male; Middle Aged; Pyrroles; Recurrence; Syndrome; Thrombolytic Therapy; Tissue Plasminogen Activator | 2010 |
Celecoxib combined with atorvastatin prevents progression of atherosclerosis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Celecoxib; Chemokine CCL2; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Progression; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Pyrazoles; Pyrroles; Sulfonamides; Vascular Cell Adhesion Molecule-1 | 2010 |
Neuroprotective effect of atorvastatin in an experimental model of nerve crush injury.
Topics: Animals; Atorvastatin; Blotting, Western; Caspases; Cell Membrane Permeability; Collagen; Electrophoretic Mobility Shift Assay; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; In Situ Nick-End Labeling; Lipid Peroxidation; Male; Nerve Crush; Nerve Degeneration; Nerve Regeneration; Neuroprotective Agents; Peroxidase; Pyrroles; Rats; Rats, Sprague-Dawley; Recovery of Function; Reverse Transcriptase Polymerase Chain Reaction; Sciatic Nerve; Signal Transduction | 2010 |
Genotoxic effects in fish induced by pharmacological agents present in the sewage of some Italian water-treatment plants.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Comet Assay; DNA Damage; Environmental Monitoring; Gemfibrozil; Heptanoic Acids; Hypolipidemic Agents; Italy; Mutagens; Piperazines; Purines; Pyrroles; Random Amplified Polymorphic DNA Technique; Sewage; Sildenafil Citrate; Sulfones; Vasodilator Agents; Waste Disposal, Fluid; Water Pollutants, Chemical; Zebrafish | 2012 |
Atorvastatin or transgenic expression of TFPI inhibits coagulation initiated by anti-nonGal IgG binding to porcine aortic endothelial cells.
Topics: Animals; Animals, Genetically Modified; Antibodies, Anti-Idiotypic; Anticholesteremic Agents; Anticoagulants; Aorta; Atorvastatin; Blood Coagulation; Endothelium, Vascular; Galactosyltransferases; Heptanoic Acids; Lipoproteins; Membrane Cofactor Protein; Papio; Pyrroles; Swine; Transgenes | 2010 |
Effect of prostaglandin E1 on TNF-induced vascular inflammation in human umbilical vein endothelial cells.
Topics: Alprostadil; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Cell Adhesion; Cell Line; Cell Survival; E-Selectin; Endothelial Cells; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Heptanoic Acids; Humans; Intercellular Adhesion Molecule-1; Pyrroles; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2010 |
Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees.
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Heart Failure; Heptanoic Acids; Humans; Male; Managed Care Programs; Middle Aged; Myocardial Infarction; Patient Compliance; Pyrroles; Retrospective Studies; United States | 2010 |
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Bisoprolol; Bone Neoplasms; Capecitabine; Colic; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Heptanoic Acids; Humans; Hypercholesterolemia; Ileus; Leucovorin; Lymphatic Metastasis; Middle Aged; Nausea; Pyrroles; Ventricular Premature Complexes; Vomiting | 2011 |
[Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain].
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Atorvastatin; Cost-Benefit Analysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Male; Middle Aged; Models, Theoretical; Myocardial Infarction; Placebos; Pyrroles; Risk Factors; Secondary Prevention; Spain; Stroke; Treatment Outcome; Young Adult | 2010 |
Effect of combined administration of ginger (Zingiber officinale Roscoe) and atorvastatin on the liver of rats.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Antioxidants; Atorvastatin; Catalase; Chemical and Drug Induced Liver Injury; Cholesterol; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Liver; Male; Malondialdehyde; Nitric Oxide; Phytotherapy; Plant Extracts; Pyrroles; Random Allocation; Rats; Rats, Wistar; Rhizome; Superoxide Dismutase; Transaminases; Vitamin E; Zingiber officinale | 2010 |
Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Topics: Adult; Alleles; Apolipoprotein A-I; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cholesterol 7-alpha-Hydroxylase; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Polymorphism, Single Nucleotide; Pyrroles; Triglycerides | 2010 |
Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study.
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Databases, Factual; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Netherlands; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Simvastatin; Time Factors | 2010 |
Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholesterol, LDL; Cohort Studies; Coronary Artery Disease; Databases, Factual; Drug Therapy, Combination; Female; Health Records, Personal; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Prognosis; Pyrroles; Retrospective Studies; Risk; Risk Factors; Risk Reduction Behavior | 2010 |
Effect of genetic variant (rs11887534) in ABCG8 gene in coronary artery disease and response to atorvastatin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Case-Control Studies; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Genotype; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Pyrroles; Risk Factors; Treatment Outcome | 2010 |
Cytotoxicity of atorvastatin and simvastatin on primary rainbow trout (Oncorhynchus mykiss) hepatocytes.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cell Survival; Cells, Cultured; Female; Hepatocytes; Heptanoic Acids; Male; Oncorhynchus mykiss; Pyrroles; Simvastatin; Water Pollutants, Chemical | 2010 |
Physiogenomic analysis of statin-treated patients: domain-specific counter effects within the ACACB gene on low-density lipoprotein cholesterol?
Topics: Acetyl-CoA Carboxylase; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Sectional Studies; Female; Fluorobenzenes; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Purinergic receptor-mediated rapid depletion of nuclear phosphorylated Akt depends on pleckstrin homology domain leucine-rich repeat phosphatase, calcineurin, protein phosphatase 2A, and PTEN phosphatases.
Topics: Active Transport, Cell Nucleus; Adenosine Triphosphate; Animals; Atorvastatin; Calcineurin; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Egtazic Acid; Enzyme Activation; Enzyme Inhibitors; Heptanoic Acids; Humans; Kinetics; Phosphoric Monoester Hydrolases; Phosphorylation; Proliferating Cell Nuclear Antigen; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; Receptors, Purinergic P2; Receptors, Purinergic P2X7; Signal Transduction; Tacrolimus Binding Proteins; Ubiquitination | 2010 |
State generic substitution laws can lower drug outlays under Medicaid.
Topics: Anticholesteremic Agents; Atorvastatin; Attitude to Health; Cost Savings; Drug Prescriptions; Drugs, Generic; Health Policy; Heptanoic Acids; Humans; Industry; Informed Consent; Medicaid; Patient Compliance; Prescription Fees; Program Evaluation; Pyrroles; Simvastatin; State Government; United States | 2010 |
[Managing myocardial infarct in general practice].
Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Anticoagulants; Atorvastatin; Blood Chemical Analysis; Chest Pain; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Education, Medical, Continuing; Electroencephalography; Family Practice; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prognosis; Pyrroles; Risk Factors; Switzerland; Ticlopidine | 2010 |
Combined atorvastatin and ramipril mitigate radiation-induced impairment of dentate gyrus neurogenesis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anticholesteremic Agents; Atorvastatin; Cesium Radioisotopes; Cranial Irradiation; Dentate Gyrus; Heptanoic Acids; Immunoenzyme Techniques; Male; Neurogenesis; Pyrroles; Radiation Injuries, Experimental; Ramipril; Rats; Rats, Inbred F344 | 2011 |
Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzazepines; Chromatography, Liquid; Drug Stability; Heptanoic Acids; Humans; Least-Squares Analysis; Male; Nevirapine; Pyrroles; Ramipril; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2011 |
Atorvastatin and cardiac hypertrophy and function in hypertrophic cardiomyopathy: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiomegaly; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Male; Middle Aged; Pilot Projects; Pyrroles; Statistics as Topic; Treatment Outcome; Young Adult | 2010 |
Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells.
Topics: Animals; Atorvastatin; Bile Ducts; Cell Proliferation; Hepatic Stellate Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligation; Liver Cirrhosis; Male; Pyrroles; Rats; Rats, Sprague-Dawley | 2010 |
Preventing intraperitoneal adhesions with atorvastatin and sodium hyaluronate/carboxymethylcellulose: a comparative study in rats.
Topics: Animals; Atorvastatin; Combined Modality Therapy; Heptanoic Acids; Hyaluronic Acid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intraperitoneal; Laparotomy; Male; Peritoneal Diseases; Pyrroles; Rats; Rats, Wistar; Tissue Adhesions | 2010 |
[How to increase the adherence to treatment of patients with arterial hypertension and dyslipidemia: focus on fixed combination of amlodipine and atorvastatin].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Diuretics; Drug Combinations; Drug Monitoring; Drug Synergism; Dyslipidemias; Heart Diseases; Heptanoic Acids; Humans; Hypertension; Patient Compliance; Pyrroles; Risk Factors | 2010 |
Diltiazem overdose: a role for high-dose insulin.
Topics: Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Diltiazem; Fluid Therapy; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypotension; Infusions, Intravenous; Insulin; Male; Prescription Drug Misuse; Pyrroles | 2010 |
Effect of atorvastatin on 5-fluorouracil-induced experimental oral mucositis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Atorvastatin; Bacteremia; Chemical and Drug Induced Liver Injury; Cricetinae; Cytokines; Dose-Response Relationship, Drug; Fluorouracil; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukopenia; Male; Mesocricetus; Mouth Mucosa; Nitric Oxide Synthase Type II; Nitrites; Peroxidase; Pyrroles; Stomatitis; Sulfhydryl Compounds | 2011 |
Statin treatment reduces oxidative stress-associated apoptosis of sciatic nerve in diabetes mellitus.
Topics: Animals; Apoptosis; Atorvastatin; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitric Oxide Synthase; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Sciatic Nerve; Streptozocin; Transforming Growth Factor beta1 | 2011 |
Beneficial effects of atorvastatin on lung structural remodeling and function in ischemic heart failure.
Topics: Animals; Atorvastatin; Cells, Cultured; Heart Failure; Heptanoic Acids; Lung; Myocardial Infarction; Myofibroblasts; Pyrroles; Random Allocation; Rats; Respiratory Function Tests | 2010 |
Re: Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Anion Transporters; Purines; Pyrroles; Research Design; Rifampin; Verapamil | 2011 |
Atorvastatin therapy is associated with improvement of oxidized low-density lipoprotein cholesterol levels, which correlates with the degree of stenosis in patients with carotid atheromatosis with and without prior angioplasty.
Topics: Aged; Aged, 80 and over; Angioplasty; Atorvastatin; Biomarkers; Carotid Stenosis; Cross-Sectional Studies; Down-Regulation; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Lipoproteins, LDL; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Pyrroles; Recurrence; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Color; Ultrasonography, Doppler, Pulsed | 2010 |
Clinical implications of switching from intensive to moderate statin therapy after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cohort Studies; Dose-Response Relationship, Drug; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Multivariate Analysis; Primary Health Care; Proportional Hazards Models; Pyrroles; Risk Factors | 2011 |
Incomparable effectiveness--apples to apples?
Topics: Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Simvastatin | 2010 |
In vitro modulation of peroxisome proliferator-activated receptor-gamma and its genes by C-reactive protein. Role of atorvastatin.
Topics: Atherosclerosis; Atorvastatin; Base Sequence; C-Reactive Protein; Cell Line; Cell Proliferation; Cell Survival; DNA Primers; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver X Receptors; Matrix Metalloproteinase 9; Orphan Nuclear Receptors; PPAR gamma; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2010 |
Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression.
Topics: Aspirin; Atorvastatin; Case-Control Studies; Confidence Intervals; Cytokines; Depressive Disorder, Major; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Middle Aged; Models, Psychological; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors | 2010 |
Comparative neuroprotective profile of statins in quinolinic acid induced neurotoxicity in rats.
Topics: Analysis of Variance; Animals; Atorvastatin; Behavior, Animal; Body Weight; Corpus Striatum; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Peroxidation; Male; Mitochondria; Motor Activity; Neuroprotective Agents; Neurotoxicity Syndromes; Nitrites; Oxidative Stress; Pyrroles; Quinolinic Acid; Rats; Rats, Wistar; Rotarod Performance Test; Simvastatin; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2011 |
Statin attenuates experimental anti-glomerular basement membrane glomerulonephritis together with the augmentation of alternatively activated macrophages.
Topics: Animals; Anti-Glomerular Basement Membrane Disease; Atorvastatin; Cytokines; Glomerular Basement Membrane; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Macrophages; Male; Microscopy, Electron; Pyrroles; Rats; Rats, Inbred WKY; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Statistics, Nonparametric | 2010 |
Statins and altered glucose metabolism: a laboratory curiosity or a new disease?
Topics: Atorvastatin; Blood Glucose; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Male; Middle Aged; Pyrroles | 2010 |
Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway.
Topics: Animals; Atorvastatin; Catalase; Cellular Senescence; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Nitric Oxide Synthase Type III; Oxidative Stress; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; Quinolines; Sirtuin 1; Umbilical Veins | 2010 |
Impact of restricted reimbursement on the use of statins in Finland: a register-based study.
Topics: Atorvastatin; Female; Finland; Fluorobenzenes; Health Policy; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; National Health Programs; Practice Patterns, Physicians'; Pyrimidines; Pyrroles; Registries; Reimbursement Mechanisms; Rosuvastatin Calcium; Sulfonamides | 2010 |
Atorvastatin pretreatment diminishes the levels of myocardial ischemia markers early after CABG operation: an observational study.
Topics: Aged; Atorvastatin; Biomarkers; Coronary Artery Bypass; Creatine Kinase, MB Form; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Troponin I | 2010 |
Effect of atorvastatin on aldosterone production induced by glucose, LDL or angiotensin II in human renal mesangial cells.
Topics: Aldosterone; Angiotensin II; Anticholesteremic Agents; Atorvastatin; Cytochrome P-450 CYP11B2; Diabetic Nephropathies; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Mesangial Cells; Pyrroles; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2010 |
Atorvastatin restores the balance between pro-inflammatory and anti-inflammatory mediators in rats with acute myocardial infarction.
Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Electrocardiography; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-10; Male; Myocardial Infarction; Plasminogen Activator Inhibitor 1; Pyrroles; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2010 |
Statins attenuate high mobility group box-1 protein induced vascular endothelial activation : a key role for TLR4/NF-κB signaling pathway.
Topics: Animals; Atorvastatin; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; HMGB1 Protein; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; NF-kappa B; Pyrroles; Rats; Signal Transduction; Toll-Like Receptor 4 | 2010 |
Vascular recovery promoted by atorvastatin and simvastatin after experimental intracerebral hemorrhage: magnetic resonance imaging and histological study.
Topics: Animals; Atorvastatin; Blood-Brain Barrier; Brain Edema; Cerebral Hemorrhage; Cerebrovascular Circulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Magnetic Resonance Imaging; Neovascularization, Physiologic; Nerve Regeneration; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2011 |
Atorvastatin upregulates nitric oxide synthases with Rho-kinase inhibition and Akt activation in the kidney of spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Atorvastatin; Blood Pressure; Heptanoic Acids; Kidney; Male; Nitric Oxide; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Inbred SHR; rho-Associated Kinases; Up-Regulation | 2010 |
Atorvastatin attenuates Coxsackie virus B3m-induced viral myocarditis in mice.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Atorvastatin; Coxsackievirus Infections; Fas Ligand Protein; fas Receptor; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Myocarditis; Myocardium; Pyrroles; RNA, Messenger; Troponin I | 2010 |
Effects of atorvastatin and L-arginine treatments on electrical field stimulation-mediated relaxations in pulmonary arterial rings of monocrotaline-induced pulmonary hypertensive rats.
Topics: Animals; Arginine; Atorvastatin; Electric Stimulation; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; In Vitro Techniques; Male; Monocrotaline; Nitric Oxide; Nitric Oxide Synthase Type III; Pulmonary Artery; Pyrroles; Rats; Rats, Sprague-Dawley; Vasodilation | 2010 |
Antihypercholesterolaemic effect of ginger rhizome (Zingiber officinale) in rats.
Topics: Administration, Oral; Animals; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dietary Fats; Dose-Response Relationship, Drug; Heptanoic Acids; Hypercholesterolemia; Hypolipidemic Agents; Phytotherapy; Plant Preparations; Pyrroles; Rats; Rats, Sprague-Dawley; Rhizome; Triglycerides; Zingiber officinale | 2010 |
Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Clarithromycin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Heptanoic Acids; Humans; In Vitro Techniques; Ketoconazole; Microsomes, Liver; Models, Molecular; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Pyrroles; Recombinant Proteins; Simvastatin; Substrate Specificity; Ticlopidine | 2010 |
Photochemical fate of atorvastatin (lipitor) in simulated natural waters.
Topics: Atorvastatin; Heptanoic Acids; Hydroxyl Radical; Photochemistry; Photolysis; Pyrroles; Singlet Oxygen; Sunlight; Water; Water Pollutants, Chemical | 2011 |
Cholesteryl ester transfer protein antagonism by drugs--a poor choice.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Polymorphism, Genetic; Pyrroles; Quinolines; Risk | 2010 |
Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.
Topics: Absenteeism; Adult; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Cost-Benefit Analysis; Diabetes Mellitus; Drug Costs; Employment; Female; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Risk; Simvastatin | 2011 |
The influence of atorvastatin on tendon healing: an experimental study on rabbits.
Topics: Achilles Tendon; Administration, Oral; Animals; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Orthopedic Procedures; Pyrroles; Rabbits; Tendon Injuries; Treatment Outcome; Wound Healing | 2010 |
Enhanced spectrophotometric determination of two antihyperlipidemic mixtures containing ezetimibe in pharmaceutical preparations.
Topics: Atorvastatin; Azetidines; Calibration; Drug Combinations; Drug Compounding; Drug Stability; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Heptanoic Acids; Hypolipidemic Agents; Molecular Structure; Pyrroles; Reproducibility of Results; Simvastatin; Solvents; Spectrophotometry, Ultraviolet; Tablets | 2011 |
Atorvastatin for reduction of myocardial damage during angioplasty trials.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents; Atorvastatin; Clopidogrel; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardium; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Treatment Outcome | 2010 |
Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-β(1-40) administration in mice: evidence for dissociation between cognitive deficits and neuronal damage.
Topics: Amino Acid Transport System X-AG; Amyloid beta-Peptides; Analysis of Variance; Animals; Animals, Newborn; Astrocytes; Atorvastatin; Cell Death; Cyclooxygenase 2; Encephalitis; Fluoresceins; Gene Expression Regulation; Glutamic Acid; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Heptanoic Acids; Hippocampus; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Learning Disabilities; Male; Maze Learning; Memory Disorders; Mice; Nerve Tissue Proteins; Neurons; Organic Chemicals; Oxidative Stress; Peptide Fragments; Propidium; Pyrroles; Tritium | 2010 |
The effects of atorvastatin on pulmonary arterial hypertension and expression of p38, p27, and Jab1 in rats.
Topics: Animals; Atorvastatin; COP9 Signalosome Complex; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Intracellular Signaling Peptides and Proteins; Male; Monocrotaline; p38 Mitogen-Activated Protein Kinases; Pneumonectomy; Proliferating Cell Nuclear Antigen; Proteins; Pulmonary Artery; Pyrroles; Rats; Rats, Wistar | 2010 |
Development of a population pharmacokinetic model for atorvastatin acid and its lactone metabolite.
Topics: Adult; Aged; Area Under Curve; Atherosclerosis; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Middle Aged; Models, Biological; Pyrroles | 2010 |
Inhibition of tau hyperphosphorylation and beta amyloid production in rat brain by oral administration of atorvastatin.
Topics: Administration, Oral; Amyloid beta-Peptides; Animals; Antibodies, Monoclonal; Atorvastatin; Blotting, Western; Brain; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Immunohistochemistry; Male; Phosphorylation; Pyrroles; Rats; Rats, Sprague-Dawley; tau Proteins | 2010 |
Photophysical characterization of atorvastatin (Lipitor®) ortho-hydroxy metabolite: role of hydroxyl group on the drug photochemistry.
Topics: Atorvastatin; Energy Transfer; Heptanoic Acids; Hydrogen; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Methanol; Photochemical Processes; Photolysis; Pyrroles; Quantum Theory; Singlet Oxygen; Thermodynamics | 2010 |
A quadruped study on chitosan microspheres containing atorvastatin calcium: preparation, characterization, quantification and in-vivo application.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Chitosan; Heptanoic Acids; Interleukin-1beta; Interleukin-6; Lipid Peroxidation; Microspheres; Neuroprotective Agents; Pyrroles; Rats; Rats, Sprague-Dawley; Spinal Cord Injuries; Tumor Necrosis Factor-alpha; Wounds and Injuries | 2010 |
[Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia].
Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Viscosity; Data Interpretation, Statistical; Dyslipidemias; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Hematocrit; Hemorheology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrroles; Time Factors | 2010 |
Atorvastatin prevents mesenchymal stem cells from hypoxia and serum-free injury through activating AMP-activated protein kinase.
Topics: AMP-Activated Protein Kinases; Animals; Atorvastatin; Cell Hypoxia; Cells, Cultured; Culture Media, Serum-Free; Dose-Response Relationship, Drug; Enzyme Activation; Heptanoic Acids; Mesenchymal Stem Cells; Pyrroles; Swine; Swine, Miniature | 2011 |
Evaluation of cardiovascular morbidity associated with adherence to atorvastatin therapy.
Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Primary Prevention; Proportional Hazards Models; Pyrroles; Retrospective Studies; Secondary Prevention; Time Factors; Treatment Outcome | 2012 |
Statin therapy for hypertrophic cardiomyopathy: too good to be true?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Anticholesteremic Agents; Atorvastatin; Cardiomyopathy, Hypertrophic; Death, Sudden, Cardiac; Heptanoic Acids; Humans; Middle Aged; Models, Biological; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Young Adult | 2010 |
CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs.
Topics: Alleles; Animals; Asia, Eastern; Atorvastatin; Biocatalysis; Camptothecin; Carbamazepine; Cytochrome P-450 CYP3A; Docetaxel; Heptanoic Acids; Humans; Irinotecan; Midazolam; Models, Molecular; Paclitaxel; Pyrroles; Spodoptera; Substrate Specificity; Taxoids; Terfenadine | 2010 |
Changes in cognition and amyloid-β processing with long term cholesterol reduction using atorvastatin in aged dogs.
Topics: Aging; Amyloid beta-Peptides; Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cognition; Discrimination Learning; Dogs; Female; Heptanoic Acids; Male; Protein Processing, Post-Translational; Psychomotor Performance; Pyrroles; Random Allocation; Time Factors | 2010 |
Atorvastatin treatment affects atrial ion currents and their tachycardia-induced remodeling in rabbits.
Topics: Animals; Atorvastatin; Atrial Fibrillation; Female; Heart Atria; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Ion Channels; Oxidative Stress; Patch-Clamp Techniques; Pyrroles; Rabbits; Tachycardia; Time Factors | 2010 |
Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells.
Topics: Absorption; Anticholesteremic Agents; Atorvastatin; ATP-Binding Cassette Transporters; Azetidines; Biological Transport; Cholesterol; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Female; Gene Expression; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Leukocytes, Mononuclear; Lipid Metabolism; Male; Middle Aged; Orphan Nuclear Receptors; Pyrroles; RNA, Messenger; Simvastatin; Up-Regulation | 2010 |
Effects of atorvastatin on development of peritoneal fibrosis in rats on peritoneal dialysis.
Topics: Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Peritoneal Dialysis; Peritoneal Fibrosis; Peritoneum; Pyrroles; Rats; Rats, Wistar | 2010 |
Gas chromatography-mass spectrometry-based simultaneous quantitative analytical method for urinary oxysterols and bile acids in rats.
Topics: Animals; Atorvastatin; Bile; Bile Acids and Salts; Chenodeoxycholic Acid; Cholesterol; Cholic Acid; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Liver; Male; Pyrroles; Rats; Rats, Sprague-Dawley | 2011 |
Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Atorvastatin; Autophagy; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Digestive System Neoplasms; Female; HCT116 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrolides; Mice; Mice, Nude; Protein Kinases; Pyrroles; RNA, Small Interfering | 2010 |
Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial.
Topics: Aged; Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Statistics as Topic | 2011 |
Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin.
Topics: Aged; Anti-Bacterial Agents; Arthritis, Infectious; Atorvastatin; Drug Interactions; Drug Therapy, Combination; Follow-Up Studies; Fusidic Acid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Osteomyelitis; Pyrroles; Rhabdomyolysis; Severity of Illness Index | 2010 |
The effects of atorvastatin on memory deficit and seizure susceptibility in pentylentetrazole-kindled rats.
Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Atorvastatin; Avoidance Learning; Disease Susceptibility; Electroencephalography; Heptanoic Acids; Kindling, Neurologic; Male; Memory Disorders; Pentylenetetrazole; Pyrroles; Rats; Rats, Wistar; Reaction Time; Seizures | 2010 |
Matrix metalloproteinase-9 may be a potential therapeutic target in epilepsy.
Topics: Animals; Anti-Bacterial Agents; Atorvastatin; Epilepsy; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Matrix Metalloproteinase 9; Mice; Minocycline; Models, Biological; Neurons; Pyrroles; Rats; Seizures; Treatment Outcome | 2011 |
Comment and reply on: Atorvastatin: safety and tolerability. Statins and polymyositis: a neglected link?
Topics: Atorvastatin; Autoimmune Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Polymyositis; Pyrroles | 2010 |
Effect of preoperative statin therapy on postoperative atrial fibrillation in cardiac surgery.
Topics: Administration, Oral; Aged; Atorvastatin; Atrial Fibrillation; Biomarkers; C-Reactive Protein; Coronary Artery Bypass, Off-Pump; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Odds Ratio; Preoperative Care; Pyrroles; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2010 |
Protective effect of atorvastatin on radiation-induced vascular endothelial cell injury in vitro.
Topics: Atorvastatin; Cells, Cultured; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Radiation Injuries | 2010 |
Effects of statin use on total oxidant and antoxidant capacity and ceruloplasmin activity.
Topics: Aged; Antioxidants; Atorvastatin; Ceruloplasmin; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidants; Pyrroles | 2010 |
p120 catenin/αN-catenin are molecular targets in the neuroprotection and neuronal plasticity mediated by atorvastatin after focal cerebral ischemia.
Topics: alpha Catenin; Analysis of Variance; Animals; Atorvastatin; Brain Ischemia; Catenins; Cell Adhesion Molecules; Cell Death; Cerebral Cortex; Delta Catenin; Gene Expression Regulation; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Longitudinal Studies; Male; Nerve Tissue Proteins; Neuronal Plasticity; Neuroprotective Agents; Protein Isoforms; Pyrroles; Rats; Rats, Wistar; Statistics, Nonparametric; Synapses | 2010 |
Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors.
Topics: Animals; Atorvastatin; Estrone; Fluorobenzenes; Genetic Variation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Oocytes; Organic Anion Transporters; Organic Anion Transporters, Sodium-Dependent; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Symporters; Taurocholic Acid; Xenopus laevis | 2011 |
Atorvastatin acts synergistically with N-acetyl cysteine to provide therapeutic advantage against Fas-activated erythrocyte apoptosis during chronic arsenic exposure in rats.
Topics: Acetylcysteine; Animals; Anticholesteremic Agents; Apoptosis; Arsenic; Arsenic Poisoning; Atorvastatin; Cell Membrane; Drug Synergism; Environmental Pollutants; Erythrocytes; fas Receptor; Free Radical Scavengers; Glutathione; Heptanoic Acids; Male; Oxidative Stress; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction | 2011 |
Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor Atorvastatin and hepatic LRP1 expression.
Topics: Animals; Antigens, CD; Atherosclerosis; Atorvastatin; Dietary Fats; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Liver; Low Density Lipoprotein Receptor-Related Protein-1; Pyrroles; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; RNA, Small Interfering; Sterol Regulatory Element Binding Protein 2; Sterol Regulatory Element Binding Proteins; Up-Regulation | 2011 |
Involvement of the p38 pathway in the differential induction of heme oxygenase-1 by statins in Neuro-2A cells exposed to lipopolysaccharide.
Topics: Animals; Atorvastatin; Blotting, Western; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cerebral Cortex; Dose-Response Relationship, Drug; Enzyme Induction; Fluorobenzenes; Heme Oxygenase-1; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iron; Iron Chelating Agents; Lipopolysaccharides; Mice; Neurons; p38 Mitogen-Activated Protein Kinases; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; Structure-Activity Relationship; Sulfonamides | 2011 |
Statins alter intracellular calcium homeostasis in malignant hyperthermia susceptible individuals.
Topics: Animals; Atorvastatin; Biopsy; Calcium; Electric Stimulation; Female; Gemfibrozil; Genotype; Heptanoic Acids; Homeostasis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Isometric Contraction; Male; Malignant Hyperthermia; Muscle, Skeletal; Phenotype; Pyrroles; Rhabdomyolysis; Simvastatin; Swine; Time Factors | 2010 |
Effects of immunomodulatory drugs on plasma inflammatory markers in a rabbit model of atherosclerosis.
Topics: Animals; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Cyclosporine; Heptanoic Acids; Immunologic Factors; Inflammation; Interferon-gamma; Interleukin-6; Male; Plasma; Pyrroles; Rabbits; Tacrolimus; Triglycerides | 2011 |
[Liver damage in a patient treated with a vitamin K antagonist, a statin and an ACE inhibitor].
Topics: Administration, Oral; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Atorvastatin; Biopsy; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug Therapy, Combination; Hematuria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Function Tests; Male; Perindopril; Phenprocoumon; Pyrroles; Vitamin K | 2010 |
Multiple organ failure after an overdose of less than 0.4 mg/kg of colchicine: role of coingestants and drugs during intensive care management.
Topics: Adult; Atorvastatin; Colchicine; Critical Care; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Overdose; Female; Heptanoic Acids; Humans; Multiple Organ Failure; Propofol; Pyrroles; Rhabdomyolysis | 2010 |
Differential effects of statins on endogenous H2S formation in perivascular adipose tissue.
Topics: Adipose Tissue; Animals; Aorta, Thoracic; Atorvastatin; Cholesterol; Cholesterol, HDL; Dose-Response Relationship, Drug; Heptanoic Acids; Hydrogen Sulfide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; KATP Channels; Liver; Male; Mitochondria, Liver; Oxidation-Reduction; Potassium Channel Blockers; Pravastatin; Pyrroles; Quinone Reductases; Rats; Rats, Wistar; Sulfides; Triglycerides; Ubiquinone; Vasoconstrictor Agents; Vasodilation | 2011 |
Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Male; Neurons; Pyrroles; Rats; Rats, Zucker; Stroke | 2011 |
[On the current debate on lowering LDL cholesterol with ezetimibe].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Financing, Personal; Fluorobenzenes; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Myocardial Infarction; National Health Programs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides | 2010 |
Microwave induced solubility enhancement of poorly water soluble atorvastatin calcium.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Biological Availability; Calcium; Chemistry, Pharmaceutical; Crystallization; Disease Models, Animal; Dosage Forms; Heptanoic Acids; Hypercholesterolemia; Male; Microwaves; Polyethylene Glycols; Polymers; Pyrroles; Rats; Rats, Wistar; Solubility | 2010 |
Atorvastatin attenuates inflammatory infiltration and vascular remodeling in lung of hypercholesterolemia rabbits.
Topics: Animals; Atorvastatin; Body Weight; Bronchoalveolar Lavage Fluid; Cell Proliferation; Drug Evaluation, Preclinical; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipids; Lung; Lung Diseases; Macrophages, Alveolar; Male; NF-kappa B; Proliferating Cell Nuclear Antigen; Pulmonary Artery; Pyrroles; Rabbits; Random Allocation | 2010 |
Zebrafish Tie-2 shares a redundant role with Tie-1 in heart development and regulates vessel integrity.
Topics: Animals; Antigens, CD; Atorvastatin; Base Sequence; Blood Vessels; Cadherins; Codon, Terminator; Embryo, Nonmammalian; Endocardium; Gene Knockdown Techniques; Head; Heart; Hemorrhage; Heptanoic Acids; Lymphatic Vessels; Molecular Sequence Data; Mutation; Myocardium; Organogenesis; Protein Structure, Tertiary; Pyrroles; Receptor, TIE-1; Receptor, TIE-2; Zebrafish; Zebrafish Proteins | 2011 |
Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Creatine Kinase, MB Form; Creatinine; Drug Administration Schedule; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Kidney Diseases; Logistic Models; Male; Myocardial Infarction; Odds Ratio; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation | 2011 |
Effect of atorvastatin on angiogenesis in degenerated intervertebral disc in rat.
Topics: Angiogenesis Inducing Agents; Animals; Atorvastatin; Biomarkers; Disease Models, Animal; Heptanoic Acids; Immunohistochemistry; Intervertebral Disc; Intervertebral Disc Degeneration; Male; Neovascularization, Physiologic; Pyrroles; Rats; Rats, Wistar; Time Factors; von Willebrand Factor | 2011 |
Neuroprotective potentials of candesartan, atorvastatin and their combination against stroke induced motor dysfunction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Behavior, Animal; Benzimidazoles; Biphenyl Compounds; Brain; Brain Ischemia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitochondria; Motor Activity; Movement Disorders; Neurons; Organ Specificity; Oxidative Stress; Pyrroles; Random Allocation; Rats; Rats, Wistar; Reperfusion Injury; Stroke; Tetrazoles | 2011 |
Pro-inflammatory cytokine levels in association between periodontal disease and hyperlipidaemia.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Body Mass Index; Chronic Periodontitis; Cytokines; Female; Gingival Crevicular Fluid; Gingivitis; Heptanoic Acids; Humans; Hyperlipidemias; Inflammation Mediators; Interleukin-1beta; Interleukin-6; Lipid Mobilization; Lipids; Male; Middle Aged; Periodontal Index; Pyrroles; Reproducibility of Results; Statistics, Nonparametric; Tumor Necrosis Factor-alpha | 2011 |
Quantitative determination of atorvastatin and ortho-hydroxy atorvastatin in human plasma by liquid chromatography tandem mass spectrometry and pharmacokinetic evaluation.
Topics: Area Under Curve; Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Pyrroles; Reproducibility of Results; Tandem Mass Spectrometry; Time Factors | 2010 |
Beneficial effect of insulin in hyperhomocysteinemia and diabetes mellitus-induced vascular endothelium dysfunction: role of phosphoinositide dependent kinase and protein kinase B.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperhomocysteinemia; Hypoglycemic Agents; Insulin; Male; Nitrates; Nitric Oxide Synthase Type III; Nitrites; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Wistar; RNA, Messenger; Signal Transduction; Vasodilation; Vasodilator Agents | 2011 |
Atorvastatin exhibits anti-inflammatory and anti-oxidant properties in adjuvant-induced monoarthritis.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Experimental; Atorvastatin; Dose-Response Relationship, Drug; Female; Freund's Adjuvant; Glutathione; Heptanoic Acids; Hyperalgesia; Injections, Intra-Articular; Joints; Male; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2010 |
Quantification of circulating endothelial progenitor cells using the modified ISHAGE protocol.
Topics: Adult; Aged; Antigens, CD34; Atorvastatin; Biomarkers; Coronary Artery Disease; Endothelial Cells; Female; Flow Cytometry; Hematology; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocyte Common Antigens; Male; Middle Aged; Myocardial Infarction; Pyrroles; Stem Cells; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
[Pharmaco-economic optimization of cholesterol-lowering treatment with statins].
Topics: Atorvastatin; Cholesterol, LDL; Cost-Benefit Analysis; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Goals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Lovastatin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Spain; Sulfonamides | 2011 |
Use of ultra high performance liquid chromatography-tandem mass spectrometry to demonstrate decreased serum statin levels after extracorporeal LDL-cholesterol elimination.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Component Removal; Cholesterol, LDL; Chromatography, High Pressure Liquid; Female; Hemofiltration; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Statistics, Nonparametric; Tandem Mass Spectrometry | 2011 |
Statins before stents: does an ounce of prevention improve outcomes?
Topics: Atorvastatin; Biomarkers; Carotid Artery Diseases; Creatine Kinase, MB Form; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Preoperative Care; Pyrroles; Risk Assessment; Risk Factors; Stents; Stroke; Treatment Outcome; Troponin I; Troponin T | 2010 |
Prevalence of dyslipidemia in statin-treated patients in Canada: results of the DYSlipidemia International Study (DYSIS).
Topics: Aged; Atorvastatin; Canada; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Prevalence; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2010 |
Effect atorvastatin on serum tumor necrosis factor alpha and interleukin-1β following acute pulmonary embolism.
Topics: Animals; Atorvastatin; Disease Models, Animal; Female; Heptanoic Acids; Interleukin-1beta; Male; Pulmonary Embolism; Pyrroles; Rabbits; Tumor Necrosis Factor-alpha | 2011 |
Assessing the matrix effects of hemolyzed samples in bioanalysis.
Topics: Atorvastatin; Benzodiazepines; Blood; Carbazoles; Carvedilol; Chemistry Techniques, Analytical; Chromatography, Liquid; Hemolysis; Heptanoic Acids; Microfluidics; Olanzapine; Pharmaceutical Preparations; Phenylephrine; Propanolamines; Pyrroles; Solid Phase Extraction; Spectrometry, Mass, Electrospray Ionization | 2009 |
Sensitivity and proportionality assessment of metabolites from microdose to high dose in rats using LC-MS/MS.
Topics: Animals; Atorvastatin; Chromatography, Liquid; Dose-Response Relationship, Drug; Heptanoic Acids; Male; Metabolome; Ofloxacin; Omeprazole; Pharmacokinetics; Pyrroles; Rats; Rats, Sprague-Dawley; Tamoxifen; Tandem Mass Spectrometry | 2010 |
Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin.
Topics: Alanine Transaminase; Alkaline Phosphatase; Atorvastatin; Cytochrome P-450 CYP3A; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Middle Aged; Pravastatin; Pyrroles | 2010 |
Sympathoinhibitory effects of atorvastatin in hypertension.
Topics: Adolescent; Adult; Aged; Animals; Atorvastatin; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Norepinephrine; Prospective Studies; Pyrroles; Sympathetic Nervous System; Time Factors | 2010 |
Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Atorvastatin; Base Sequence; Calcium Channels, L-Type; Disease Models, Animal; DNA Primers; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Inositol 1,4,5-Trisphosphate Receptors; Losartan; Male; Monocrotaline; Pulmonary Artery; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2010 |
Statins, inflammation, oxidative stress, and atrial fibrillation.
Topics: Atorvastatin; Atrial Fibrillation; Female; Heptanoic Acids; Humans; Male; Pyrroles | 2011 |
[Statin reduced triglyceride level via activating peroxisome proliferator activated receptor α and upregulating apolipoprotein A5 in hypertriglyceridemic rats].
Topics: Animals; Apolipoprotein A-V; Apolipoproteins; Atorvastatin; Down-Regulation; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Male; PPAR alpha; Pyrroles; Rats; Rats, Sprague-Dawley; Triglycerides; Up-Regulation | 2010 |
Effects of different doses of statins on liver regeneration through angiogenesis and possible relation between these effects and acute phase responses.
Topics: Acute-Phase Reaction; Animals; Atorvastatin; Biomarkers; Cell Proliferation; Dose-Response Relationship, Drug; Hepatectomy; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Liver; Liver Regeneration; Male; Neovascularization, Physiologic; Proliferating Cell Nuclear Antigen; Pyrroles; Rats; Rats, Inbred Lew; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
[Individual pharmacotherapy safety in the assessment of cytochrome P-450 3A4 (CYP3A4) isoenzyme activity].
Topics: Atorvastatin; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Enzyme Induction; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pharmacokinetics; Platelet Aggregation Inhibitors; Precision Medicine; Pyrroles; Ticlopidine | 2010 |
Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Body Weight; Brain; Cognition Disorders; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Maze Learning; Mice; Mice, Transgenic; Neuroprotective Agents; Organ Size; Phosphorylation; Plaque, Amyloid; Protein Processing, Post-Translational; Pyrroles; Quinolines; tau Proteins | 2011 |
Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment.
Topics: Animals; Atorvastatin; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cyclic AMP-Dependent Protein Kinases; Dietary Carbohydrates; Disease Models, Animal; Down-Regulation; Fatty Acids; Fatty Liver; Fructokinases; Fructose; Gene Expression Regulation; Hepatitis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; I-kappa B Proteins; Inflammation Mediators; Lipid Metabolism; Liver; Male; Metallothionein; Necrosis; NF-kappa B; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Phosphorylation; Pyrroles; Rats; Rats, Sprague-Dawley; Triglycerides | 2011 |
Atorvastatin prevents ischemic limb loss in type 2 diabetes: role of p53.
Topics: Animals; Atorvastatin; Blotting, Western; Cells, Cultured; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Extremities; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Ischemia; Male; Mice; Myoblasts; Peripheral Arterial Disease; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Pyrroles; Tumor Suppressor Protein p53; Ubiquitin; Wound Healing | 2011 |
Rhabdomyolysis following co-prescription of fusidic acid and atorvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Interactions; Fusidic Acid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Rhabdomyolysis | 2010 |
Interactions between CYP7A1 A-204C and ABCG8 C1199A polymorphisms on lipid lowering with atorvastatin.
Topics: Adult; Alleles; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Cholesterol 7-alpha-Hydroxylase; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Prospective Studies; Pyrroles | 2011 |
Atorvastatin inhibits plaque development and adventitial neovascularization in ApoE deficient mice independent of plasma cholesterol levels.
Topics: Angiogenesis Inhibitors; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cell Line; Cell Proliferation; Cholesterol; Connective Tissue; Disease Models, Animal; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Knockout; Microvessels; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Pyrroles; Time Factors | 2011 |
Antithrombotic properties of pravastatin reducing intra-thrombus fibrin deposition under high shear blood flow conditions.
Topics: Atorvastatin; Blood Platelets; Dose-Response Relationship, Drug; Fibrin; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; P-Selectin; Perfusion; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Regional Blood Flow; Stress, Mechanical; Thrombin; Thromboplastin; Thrombosis; Time Factors; von Willebrand Factor | 2011 |
[Effects of atorvastatin on p27 protein expression and cardiomyocytes apoptosis in spontaneously hypertensive rats].
Topics: Animals; Anticholesteremic Agents; Apoptosis; Atorvastatin; Cyclin-Dependent Kinase Inhibitor p27; Heptanoic Acids; Hypertension; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; Pyrroles; Random Allocation; Rats; Rats, Inbred SHR; RNA, Messenger | 2008 |
[Atorvastatin and oxidized low density lipoprotein antibody. Relationship to age].
Topics: Adult; Age Factors; Aged; Atherosclerosis; Atorvastatin; Autoantibodies; Autoantigens; Blood Glucose; C-Reactive Protein; Creatinine; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipid Peroxidation; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Risk Factors; Waist Circumference | 2011 |
Targeting cholesterol at different levels in the mevalonate pathway protects fatty liver against ischemia-reperfusion injury.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, Dietary; Choline; Choline Deficiency; Disease Models, Animal; Disease Susceptibility; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Fatty Liver; Glutathione; Heptanoic Acids; Lipotropic Agents; Liver; Male; Mevalonic Acid; Mice; Mice, Inbred C57BL; Mitochondria; Obesity; Pyrroles; Quinuclidines; Reperfusion Injury | 2011 |
Atorvastatin improves survival in septic rats: effect on tissue inflammatory pathway and on insulin signaling.
Topics: Adipose Tissue; Animals; Atorvastatin; Glucose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Insulin; Interleukin-6; Liver; Male; Muscles; Pyrroles; Rats; Rats, Wistar; Sepsis; Signal Transduction; Tumor Necrosis Factor-alpha | 2010 |
Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process.
Topics: Angiotensin II; Animals; Aorta; Atorvastatin; Blotting, Western; Cells, Cultured; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrroles; Rats; Rats, Wistar; Signal Transduction; Simvastatin; Smad Proteins; Transforming Growth Factor beta; Vasoconstrictor Agents | 2010 |
Long term observation of thin-cap fibroatheroma by optical coherence tomography.
Topics: Atorvastatin; Coronary Artery Disease; Coronary Vessels; Fibrosis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Necrosis; Pyrroles; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2010 |
Estimation of financial burden due to oversupply of medications for chronic diseases.
Topics: Aged; Atorvastatin; Chronic Disease; Clopidogrel; Drug Costs; Female; Heptanoic Acids; Hospitals, University; Humans; Male; Middle Aged; Pharmaceutical Preparations; Phenylcarbamates; Pyrroles; Retrospective Studies; Rivastigmine; Rosiglitazone; Tetrazoles; Thailand; Thiazolidinediones; Ticlopidine; Valine; Valsartan | 2012 |
[Electrophysiological effect of atorvastatin on isolated rat hearts injured by ischemia/reperfusion].
Topics: Animals; Atorvastatin; Electrophysiological Phenomena; Heart; Heptanoic Acids; In Vitro Techniques; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide; Pyrroles; Rats; Rats, Sprague-Dawley | 2010 |
Atorvastatin prevents left ventricular remodeling in spontaneously hypertensive rats.
Topics: Animals; Atorvastatin; Connective Tissue Growth Factor; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Ventricular Remodeling | 2010 |
Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats.
Topics: Animals; Anticholesteremic Agents; Area Under Curve; Atorvastatin; Blood Glucose; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; Female; Glyburide; Half-Life; Heptanoic Acids; Hypoglycemic Agents; Male; Pyrroles; Rats; Rats, Wistar | 2011 |
Comparative Effectiveness and Toxicity of Statins Among HIV-Infected Patients.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cholesterol; Cohort Studies; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Serum; Sulfonamides | 2011 |
Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action.
Topics: Alzheimer Disease; Animals; Antioxidants; Atorvastatin; Brain; Cholesterol; Disease Models, Animal; Dogs; Female; Heptanoic Acids; Male; Nitroso Compounds; Oxidative Stress; Pyrroles; Random Allocation | 2011 |
Dysregulation of angiogenesis-related microRNAs in endothelial progenitor cells from patients with coronary artery disease.
Topics: Atorvastatin; Coronary Artery Disease; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MicroRNAs; Neovascularization, Physiologic; Pyrroles; Stem Cells | 2011 |
Effect of Atorvastatin in radiographic density on alveolar bone loss in wistar rats.
Topics: Alveolar Bone Loss; Analysis of Variance; Animals; Atorvastatin; Bone Density; Disease Models, Animal; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Maxilla; Periodontitis; Pyrroles; Radiography, Dental, Digital; Rats; Rats, Wistar; Statistics, Nonparametric | 2010 |
The effect of atorvastatin on mRNA levels of inflammatory genes expression in human peripheral blood lymphocytes by DNA microarray.
Topics: Atorvastatin; Chemokines; Cytokines; Down-Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lymphocytes; Oligonucleotide Array Sequence Analysis; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2011 |
Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; C-Reactive Protein; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Liver; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Strains; Tumor Necrosis Factor-alpha | 2011 |
Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model.
Topics: Animals; Atorvastatin; Azetidines; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Hypolipidemic Agents; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Pyrroles | 2011 |
Omega-3 fatty acids and atorvastatin suppress ventricular fibrillation inducibility in hypertriglyceridemic rat hearts: implication of intracellular coupling protein, connexin-43.
Topics: Animals; Arrhythmias, Cardiac; Atorvastatin; Blood Pressure; Connexin 43; Fatty Acids, Omega-3; Heart Rate; Heart Ventricles; Heptanoic Acids; Hypertriglyceridemia; Myocardium; Myocytes, Cardiac; Phosphorylation; Pyrroles; Rats; Rats, Wistar; Triglycerides; Up-Regulation; Ventricular Fibrillation | 2010 |
Statin wars: efficacy vs. cost.
Topics: Atorvastatin; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin | 2011 |
Use of high-intensity statin therapy with simvastatin 80 mg and atorvastatin 80 mg in primary care.
Topics: Adult; Aged; Atorvastatin; Body Mass Index; Cardiovascular Diseases; England; Family Practice; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Practice Patterns, Physicians'; Pyrroles; Quality of Health Care; Retrospective Studies; Simvastatin | 2011 |
A novel use of oxidative coupling reactions for determination of some statins (cholesterol-lowering drugs) in pharmaceutical formulations.
Topics: Atorvastatin; Chemistry, Pharmaceutical; Dosage Forms; Excipients; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Molecular Structure; Oxidation-Reduction; Oxidative Coupling; Pravastatin; Pyrroles; Spectrophotometry | 2011 |
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Topics: Adult; Aged; Atorvastatin; British Columbia; Case-Control Studies; Chi-Square Distribution; Female; Gene Frequency; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Netherlands; Odds Ratio; Organic Anion Transporters; Phenotype; Polymorphism, Single Nucleotide; Pyrroles; Risk Assessment; Risk Factors; Severity of Illness Index; Simvastatin | 2012 |
Disappearance of angina pectoris by lipid-lowering in type III hyperlipoproteinemia.
Topics: Angina Pectoris; Atorvastatin; Drug Therapy, Combination; Electrocardiography; Exercise Test; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Middle Aged; Pyrroles; Tomography, X-Ray Computed | 2011 |
Generation of a specific polyclonal antibody with high affinity to atorvastatin and its employment in the development of ELISA for determination of atorvastatin in plasma.
Topics: Animals; Antibody Formation; Antibody Specificity; Atorvastatin; Enzyme-Linked Immunosorbent Assay; Female; Haptens; Heptanoic Acids; Pyrroles; Rabbits; Reproducibility of Results | 2011 |
AMP-activated protein kinase inhibits homocysteine-induced dysfunction and apoptosis in endothelial progenitor cells.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Apoptosis; Atorvastatin; Cell Movement; Cell Proliferation; Cells, Cultured; Down-Regulation; Endothelial Cells; Heptanoic Acids; Homocysteine; Humans; NADPH Oxidase 4; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Pyrroles; Reactive Oxygen Species; Ribonucleotides; Stem Cells; Up-Regulation | 2011 |
In vivo carotid plaque MRI using quantitative T2* measurements with ultrasmall superparamagnetic iron oxide particles: a dose-response study to statin therapy.
Topics: Aged; Atorvastatin; Carotid Arteries; Dextrans; Dose-Response Relationship, Drug; Echo-Planar Imaging; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Angiography; Magnetite Nanoparticles; Male; Phantoms, Imaging; Pyrroles | 2011 |
MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase.
Topics: Animals; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Kaplan-Meier Estimate; Liver Neoplasms; Mice; Mice, SCID; Mice, Transgenic; Mutation; Phosphorylation; Proto-Oncogene Proteins c-myc; Pyrroles; rac GTP-Binding Proteins; Serine; Threonine; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats.
Topics: Animals; Atorvastatin; Combined Modality Therapy; Dietary Fats; Fatty Liver; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Lipids; Liver; Male; Non-alcoholic Fatty Liver Disease; Organ Size; PPAR alpha; Pyrroles; Rats; Rats, Sprague-Dawley; Sterol Regulatory Element Binding Protein 1; Transaminases | 2011 |
Combination of amlodipine and atorvastatin synergistically reduces leukocyte recruitment to mechanically injured mouse femoral artery.
Topics: Adoptive Transfer; Amlodipine; Animals; Atorvastatin; Calcium Channel Blockers; Cell Adhesion; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Femoral Artery; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred C57BL; NADPH Oxidases; Oxidative Stress; Pyrroles | 2011 |
Synergistic protection against vascular inflammation with a calcium channel blocker and a statin.
Topics: Amlodipine; Animals; Atorvastatin; Calcium Channel Blockers; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Femoral Artery; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes; Mice; Pyrroles; Vasculitis | 2011 |
Paradoxical decrease in serum high-density lipoprotein cholesterol and lipid-lowering drugs.
Topics: Atorvastatin; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Pyrroles; Simvastatin | 2011 |
Protection against ischemic stroke damage by synergistic treatment with amlodipine plus atorvastatin in Zucker metabolic rat.
Topics: Amlodipine; Animals; Atorvastatin; Brain Ischemia; Calcium Channel Blockers; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nerve Degeneration; Neuroprotective Agents; Pyrroles; Rats; Rats, Zucker; Stroke | 2011 |
Treat the graft to improve the regenerative ability of the host.
Topics: Atorvastatin; Cell Survival; Diazoxide; Heptanoic Acids; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Pyrroles; Regeneration; Regenerative Medicine; Transplants; Trimetazidine | 2011 |
Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.
Topics: Amino Acid Sequence; Amino Acid Substitution; Atorvastatin; Fluorobenzenes; Gene Expression; HeLa Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Molecular Sequence Data; Mutagenesis, Site-Directed; Organic Anion Transporters, Sodium-Independent; Polymorphism, Genetic; Protein Conformation; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sincalide; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Substrate Specificity; Sulfonamides | 2011 |
Effect of atorvastatin and etidronate combination therapy on regression of aortic atherosclerotic plaques evaluated by magnetic resonance imaging.
Topics: Aorta; Atorvastatin; Bone Density Conservation Agents; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Magnetic Resonance Imaging; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Treatment Outcome | 2011 |
TIAs - management in general practice.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Atorvastatin; Clopidogrel; Dipyridamole; Dopamine Antagonists; General Practitioners; Heptanoic Acids; Humans; Hypolipidemic Agents; Ischemic Attack, Transient; Perindopril; Platelet Aggregation Inhibitors; Primary Health Care; Prochlorperazine; Pyrroles; Ticlopidine; Vasodilator Agents; Warfarin | 2010 |
Simultaneous estimation of atorvastatin and its two metabolites from human plasma by ESI-LC-MS/MS.
Topics: Atorvastatin; Calibration; Chromatography, High Pressure Liquid; Drug Stability; Heptanoic Acids; Humans; Molecular Structure; Pyrroles; Reproducibility of Results; Solid Phase Extraction; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Therapeutic Equivalency | 2011 |
[Atorvastatin attenuates hypoxic pulmonary hypertension in rats by inhibiting RhoA/Rho kinase pathway].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Hemodynamics; Heptanoic Acids; Hypertension, Pulmonary; Hypoxia; Male; Pulmonary Artery; Pyrroles; Random Allocation; Rats; Rats, Wistar; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Ventricular Remodeling | 2011 |
CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis.
Topics: Animals; Apoptosis; Atorvastatin; Bone and Bones; Cell Line; Cell Movement; Cell Proliferation; Cell Survival; Cysteine-Rich Protein 61; Down-Regulation; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Osteosarcoma; Prenylation; Pyrroles | 2011 |
Atorvastatin suppresses LPS-induced rapid upregulation of Toll-like receptor 4 and its signaling pathway in endothelial cells.
Topics: Aorta; Atorvastatin; Cells, Cultured; Endothelium, Vascular; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Pyrroles; Signal Transduction; Toll-Like Receptor 4; Umbilical Veins; Up-Regulation | 2011 |
[Effect of atorvastatin on MMP-9 and TIMP-1 levels in bronchoalveolar lavage fluid and serum of rats with bleomycin-induced pulmonary fibrosis].
Topics: Animals; Atorvastatin; Bleomycin; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Female; Heptanoic Acids; Matrix Metalloproteinase 9; Pulmonary Fibrosis; Pyrroles; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-1 | 2011 |
Simultaneous determination of rosuvastatin and atorvastatin in human serum using RP-HPLC/UV detection: method development, validation and optimization of various experimental parameters.
Topics: Atorvastatin; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Stability; Fluorobenzenes; Heptanoic Acids; Humans; Hydrogen-Ion Concentration; Linear Models; Methanol; Pyrimidines; Pyrroles; Reproducibility of Results; Rosuvastatin Calcium; Sensitivity and Specificity; Sulfonamides; Water | 2011 |
Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cytochrome P-450 CYP2C9; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Losartan; Male; Middle Aged; Pyrroles; Retrospective Studies | 2011 |
Microextraction by packed sorbent as sample preparation step for atorvastatin and its metabolites in biological samples--critical evaluation.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Reproducibility of Results; Solid Phase Extraction; Tandem Mass Spectrometry; Triglycerides | 2011 |
Model-based development of anacetrapib, a novel cholesteryl ester transfer protein inhibitor.
Topics: Anticholesteremic Agents; Atorvastatin; Biological Availability; Capsules; Cholesterol Ester Transfer Proteins; Computer Simulation; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Design; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Models, Biological; Nonlinear Dynamics; Oxazolidinones; Pyrroles; Tablets | 2011 |
Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia.
Topics: Aged; Atorvastatin; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Epichlorohydrin; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Hypoglycemic Agents; Imidazoles; Lipids; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyrroles; Quinolines; Resins, Synthetic; Retrospective Studies; Treatment Outcome | 2011 |
Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents.
Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Proliferation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Ovarian Neoplasms; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Tumor Cells, Cultured | 2010 |
Atorvastatin improved scopolamine-induced impairment in memory acquisition in mice: involvement of nitric oxide.
Topics: Animals; Arginine; Atorvastatin; Cholinergic Antagonists; Disease Models, Animal; Enzyme Inhibitors; Guanidines; Heptanoic Acids; Learning Disabilities; Memory; Memory Disorders; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Pyrroles; Scopolamine | 2011 |
Effect of atorvastatin in a case of feline multicentric lymphoma - Case report.
Topics: Animals; Atorvastatin; Cat Diseases; Cats; Chemotherapy, Adjuvant; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphoma; Male; Pyrroles | 2011 |
Atorvastatin prevents Plasmodium falciparum cytoadherence and endothelial damage.
Topics: Antimalarials; Atorvastatin; Cell Adhesion; Cells, Cultured; Coculture Techniques; Endothelial Cells; Heptanoic Acids; Humans; Plasmodium falciparum; Pyrroles | 2011 |
New perspectives of 19F MAS NMR in the characterization of amorphous forms of atorvastatin in dosage formulations.
Topics: Atorvastatin; Crystallization; Factor Analysis, Statistical; Fluorine; Heptanoic Acids; Magnetic Resonance Spectroscopy; Powder Diffraction; Pyrroles; Reproducibility of Results; Spectroscopy, Fourier Transform Infrared; Time Factors | 2011 |
Effects of atorvastatin on fine particle-induced inflammatory response, oxidative stress and endothelial function in human umbilical vein endothelial cells.
Topics: Air Pollutants; Anti-Inflammatory Agents; Atorvastatin; Cell Survival; Cells, Cultured; Endothelin-1; Endothelium, Vascular; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Malondialdehyde; Nitric Oxide; Oxidative Stress; P-Selectin; Particulate Matter; Pyrroles; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2011 |
Development and validation of a sensitive, simple, and rapid method for simultaneous quantitation of atorvastatin and its acid and lactone metabolites by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Topics: Anticholesteremic Agents; Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Lactones; Limit of Detection; Pyrroles; Tandem Mass Spectrometry | 2011 |
The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease.
Topics: Animals; Antigens, Bacterial; Arteritis; Atorvastatin; Cell Wall; Coronary Aneurysm; Coronary Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Induction; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Lacticaseibacillus casei; Lymphocyte Activation; MAP Kinase Signaling System; Matrix Metalloproteinase 9; Mevalonic Acid; Mice; Mice, Inbred C57BL; Mucocutaneous Lymph Node Syndrome; Pyrroles; Specific Pathogen-Free Organisms; Superantigens; Tumor Necrosis Factor-alpha | 2011 |
[Rhabdomyolysis associated with atorvastatin combined with amiodarone and fluconazole].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticholesteremic Agents; Antifungal Agents; Atorvastatin; Coronary Artery Bypass, Off-Pump; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Fluconazole; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; Postoperative Complications; Pyrroles; Rhabdomyolysis | 2011 |
Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in LDLr-/- mice.
Topics: Adipose Tissue; Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Avena; beta-Glucans; Blood; Body Weight; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Dietary Fiber; Eating; Female; Heptanoic Acids; Intestinal Absorption; Lipids; Liver; Mice; Mice, Inbred Strains; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Receptors, LDL; Treatment Outcome; Triglycerides | 2011 |
Statins utilisation pattern: a retrospective evaluation in a tertiary care hospital in Thailand.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cohort Studies; Coronary Disease; Electronic Health Records; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Patterns, Physicians'; Pravastatin; Primary Prevention; Pyrroles; Retrospective Studies; Secondary Prevention; Simvastatin; Thailand | 2011 |
The effects of BuYang HuanWu Decoction and its effective components on proliferation-related factors and ERK1/2 signal transduction pathway in cultured vascular smooth muscle cells.
Topics: Alkaloids; Animals; Atorvastatin; Cardiovascular Agents; Cell Cycle; Cell Proliferation; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Drugs, Chinese Herbal; Dual Specificity Phosphatase 1; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Glycosides; Heptanoic Acids; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Platelet-Derived Growth Factor; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction | 2011 |
[Effects of early statin treatment on inflammatory biomarkers and clinical deterioration in patients with acute ischemic stroke].
Topics: Aged; Atorvastatin; Biomarkers; C-Reactive Protein; Cerebral Infarction; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukins; Male; Matrix Metalloproteinases; Prospective Studies; Pyrroles; Time Factors | 2011 |
Protective effect of dietary tocotrienols against infection and inflammation-induced hyperlipidemia: an in vivo and in silico study.
Topics: Administration, Oral; Animals; Atorvastatin; Cholesterol; Cricetinae; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lipid Metabolism; Lipoproteins, LDL; Male; Molecular Structure; Pyrroles; Tocotrienols | 2011 |
Not a graves' situation.
Topics: Atorvastatin; Biomarkers; Diagnosis, Differential; Drug Therapy, Combination; Eye Diseases; Fenofibrate; Graves Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Oculomotor Muscles; Pyrroles; Thyroid Gland | 2011 |
Why does atorvastatin inhibit renal crystal retention?
Topics: Animals; Atorvastatin; Calcium Oxalate; Catalase; Crystallization; Disease Models, Animal; Heptanoic Acids; Kidney; Kidney Calculi; Male; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; NADPH Oxidases; Pyrroles; rac1 GTP-Binding Protein; Rats; Rats, Sprague-Dawley; Rats, Wistar; Superoxide Dismutase; Transforming Growth Factor beta | 2011 |
Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cohort Studies; Drug Costs; Drug Substitution; Drugs, Generic; Female; Finland; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Pyrroles; Registries; Simvastatin | 2012 |
Atorvastatin prevents vascular hyporeactivity to norepinephrine in sepsis: role of nitric oxide and α₁-adrenoceptor mRNA expression.
Topics: Animals; Atorvastatin; Enzyme Inhibitors; Guanylate Cyclase; Heptanoic Acids; Mice; Nitric Oxide; Norepinephrine; Oxadiazoles; Polymerase Chain Reaction; Pyrroles; Quinoxalines; Receptors, Adrenergic, alpha-1; RNA, Messenger; Sepsis; Vasoconstrictor Agents | 2011 |
ABCA1 and ABCG1 expressions are regulated by statins and ezetimibe in Caco-2 cells.
Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Azetidines; Caco-2 Cells; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Ezetimibe; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Polymerase Chain Reaction; Pyrroles; RNA, Messenger; Simvastatin; Time Factors | 2011 |
Atorvastatin and pitavastatin protect cerebellar Purkinje cells in AD model mice and preserve the cytokines MCP-1 and TNF-α.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Chemokine CCL2; Disease Models, Animal; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Mice; Mice, Transgenic; Purkinje Cells; Pyrroles; Quinolines; Tumor Necrosis Factor-alpha | 2011 |
Reduction in coronary heart disease with atorvastatin independent of low-density lipoprotein cholesterol.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2011 |
Study of Atorvastatin in experimental allergic airway inflammation in mice.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Bronchial Hyperreactivity; Bronchoalveolar Lavage Fluid; Cholesterol; Cytokines; Dexamethasone; Drug Interactions; Heptanoic Acids; Immunoglobulin E; Inflammation; Leukocytes; Male; Mice; Ovalbumin; Pyrroles; Respiratory System | 2011 |
Ameliorative role of atorvastatin on methionine-induced hyperhomocysteinemia and hematological changes in albino rats.
Topics: Albinism; Animals; Anticholesteremic Agents; Atorvastatin; Drug Evaluation, Preclinical; Female; Hematologic Tests; Heptanoic Acids; Hyperhomocysteinemia; Male; Methionine; Pyrroles; Rats; Rats, Mutant Strains; Rats, Wistar | 2011 |
The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis.
Topics: Acute Disease; Animals; Atorvastatin; Colitis; Cytokines; Disease Models, Animal; Down-Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Factors; Mice; Mice, Inbred BALB C; Pyrroles; Th1 Cells; Th2 Cells | 2011 |
[Subclinical carotid atherosclerosis in patients with familial combined hyperlipidemia. Two years follow-up after treatment with high doses of atorvastatin].
Topics: Anticholesteremic Agents; Atorvastatin; Carotid Artery Diseases; Female; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Statistics, Nonparametric; Ultrasonography | 2012 |
Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis.
Topics: Activin Receptors, Type I; Activin Receptors, Type II; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Biomarkers, Pharmacological; Blood; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Endoglin; Female; Heptanoic Acids; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Phosphorylation; Plaque, Atherosclerotic; Pyrroles; Receptors, LDL; Sinus of Valsalva; Smad1 Protein; Vascular Endothelial Growth Factor A | 2011 |
Atorvastatin affects the tissue concentration of hydrogen sulfide in mouse kidneys and other organs.
Topics: Animals; Atorvastatin; Brain; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Hydrogen Sulfide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intraperitoneal; Kidney; Liver; Mice; Mice, Inbred CBA; Myocardium; Pyrroles; Spectrophotometry | 2011 |
Atorvastatin activates heme oxygenase-1 at the stress response elements.
Topics: Apoptosis; Atorvastatin; Breast Neoplasms; Cell Line, Tumor; Female; Heme Oxygenase-1; Heptanoic Acids; Humans; Male; Oxidative Stress; Polyisoprenyl Phosphates; Promoter Regions, Genetic; Prostatic Neoplasms; Pyrroles; Signal Transduction; Transcriptional Activation; Up-Regulation | 2012 |
Effects of statins on matrix metalloproteinases and their endogenous inhibitors in human endothelial cells.
Topics: Atorvastatin; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pravastatin; Pyrroles; Simvastatin; Tetradecanoylphorbol Acetate; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Umbilical Veins | 2011 |
Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction.
Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Coronary Angiography; Coronary Artery Disease; Creatine Kinase, MB Form; Creatinine; Drug Administration Schedule; Evidence-Based Medicine; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Myocardial Infarction; Pyrroles; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Up-Regulation | 2011 |
Atorvastatin prevents age-related and amyloid-β-induced microglial activation by blocking interferon-γ release from natural killer cells in the brain.
Topics: Aging; Amyloid beta-Peptides; Animals; Anticholesteremic Agents; Atorvastatin; Biomarkers; Brain; Heptanoic Acids; Interferon-gamma; Killer Cells, Natural; Male; Microglia; Natural Cytotoxicity Triggering Receptor 1; NK Cell Lectin-Like Receptor Subfamily B; Pyrroles; Rats; Rats, Wistar | 2011 |
Prevention of transplant coronary artery disease by prenylation inhibitors.
Topics: Animals; Atorvastatin; Bridged Bicyclo Compounds, Heterocyclic; Coronary Artery Disease; Diphosphonates; Genes, MHC Class II; Graft Survival; Heart Transplantation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Male; Mice; Mice, Inbred C57BL; Models, Biological; Muscle, Smooth; Polyenes; Polyunsaturated Alkamides; Prenylation; Pyridines; Pyrroles; Signal Transduction; Time Factors; Transplantation, Heterotopic; Tricarboxylic Acids | 2011 |
Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
Topics: Atorvastatin; Bayes Theorem; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Drug Costs; Drug Prescriptions; Drugs, Generic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Markov Chains; Medication Adherence; Models, Economic; Pyrimidines; Pyrroles; Quality Indicators, Health Care; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome | 2012 |
Statins regulate interleukin-1β-induced RANKL and osteoprotegerin production by human gingival fibroblasts.
Topics: Atorvastatin; Cell Culture Techniques; Cell Survival; Cells, Cultured; Coloring Agents; Culture Media, Serum-Free; Fibroblasts; Gingiva; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Osteoprotegerin; Pyrroles; RANK Ligand; Simvastatin; Temperature; Tetrazolium Salts; Thiazoles; Time Factors | 2011 |
Impact of high-dose atorvastatin on endothelial, platelet, and angiogenic indices: effect of ethnicity, cardiovascular disease, and diabetes.
Topics: Adult; Aged; Angiogenic Proteins; Asian People; Atorvastatin; Cardiovascular Diseases; Case-Control Studies; CD40 Ligand; Diabetes Mellitus; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; P-Selectin; Pyrroles; von Willebrand Factor; White People | 2011 |
Lifestyle changes and 14-year change in high-density lipoprotein cholesterol in a cohort of male physicians.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Risk Reduction Behavior; Stroke; Time Factors; Treatment Outcome | 2011 |
Statins exert differential effects on angiotensin II-induced atherosclerosis, but no benefit for abdominal aortic aneurysms.
Topics: Angiotensin II; Animal Feed; Animals; Anti-Inflammatory Agents; Aorta; Aortic Aneurysm, Abdominal; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blood Pressure; Fluorobenzenes; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2011 |
Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Benzimidazoles; Biomarkers; Biphenyl Compounds; C-Reactive Protein; Cholesterol; Coronary Artery Disease; Dinoprost; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Longitudinal Studies; Male; Matrix Metalloproteinase 9; Middle Aged; Pyrroles; Tetrazoles; Tomography, X-Ray Computed | 2011 |
Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD.
Topics: Aged; Atorvastatin; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Pulmonary Wedge Pressure; Pyrroles; Regression Analysis; Simvastatin | 2011 |
Statins and prostate cancer diagnosis and grade in a veterans population.
Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Biomarkers, Tumor; Cholesterol; Confounding Factors, Epidemiologic; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lipids; Lovastatin; Male; Middle Aged; Multivariate Analysis; New England; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Risk Assessment; Severity of Illness Index; Simvastatin; Veterans | 2011 |
Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Beverages; Citrus paradisi; Cohort Studies; Dose-Response Relationship, Drug; Female; Food-Drug Interactions; Heptanoic Acids; Humans; Lipid Metabolism; Lipid Metabolism Disorders; Male; Middle Aged; Pyrroles; Time Factors | 2011 |
Plaque-stabilizing effect of atorvastatin is stronger for plaques evaluated as more unstable by angioscopy and intravenous ultrasound.
Topics: Analysis of Variance; Angioscopy; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Pyrroles; Rupture, Spontaneous; Severity of Illness Index; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2011 |
PDGF-induced proliferation of smooth muscular cells is related to the regulation of CREB phosphorylation and Nur77 expression.
Topics: Animals; Atorvastatin; Cell Proliferation; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Heptanoic Acids; Male; Muscle Cells; Muscle, Smooth, Vascular; Nuclear Receptor Subfamily 4, Group A, Member 1; Phosphorylation; Platelet-Derived Growth Factor; Pyrroles; Rats; Rats, Sprague-Dawley | 2011 |
Effect of statins on cholesterol crystallization and atherosclerotic plaque stabilization.
Topics: Animals; Atorvastatin; Cholesterol; Crystallization; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Microscopy, Electron, Scanning; Plaque, Atherosclerotic; Pravastatin; Pyrroles; Rabbits; Simvastatin | 2011 |
Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load.
Topics: ADP-ribosyl Cyclase 1; Atorvastatin; CD4-Positive T-Lymphocytes; Down-Regulation; Female; Heptanoic Acids; HIV Infections; Humans; Lymphocyte Activation; Male; Membrane Glycoproteins; Pyrroles; Viral Load | 2011 |
Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Caco-2 Cells; DNA; Ezetimibe; Female; Hep G2 Cells; Heptanoic Acids; Humans; Hypercholesterolemia; Leukocytes, Mononuclear; Lipids; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; RNA, Messenger; Scavenger Receptors, Class B; Simvastatin | 2011 |
The beneficial effects of statin therapy may not apply to all forms of crescentic glomerulonephritis.
Topics: Animals; Atorvastatin; Disease Models, Animal; Glomerulonephritis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Rats; Rats, Inbred WKY; Simvastatin | 2011 |
Strong statins as the major players for dyslipidemia in high-risk patients: are they all the same or not?
Topics: Analysis of Variance; Atorvastatin; Biomarkers; Cholesterol, LDL; Evidence-Based Medicine; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Patient Selection; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2011 |
Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders.
Topics: Alzheimer Disease; Animals; Atorvastatin; Cholesterol; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Neurodegenerative Diseases; Pyrimidines; Pyrroles; Quinolines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Amlodipine and atorvastatin exert protective and additive effects via antiapoptotic and antiautophagic mechanisms after transient middle cerebral artery occlusion in Zucker metabolic syndrome rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Apoptosis; Atorvastatin; Autophagy; Brain; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Infarction, Middle Cerebral Artery; Pyrroles; Rats; Rats, Zucker | 2011 |
Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia.
Topics: Adult; Aged; Apolipoproteins B; Atorvastatin; Body Mass Index; Family Health; Female; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hyperlipidemia, Familial Combined; Insulin Resistance; Lipoproteins, VLDL; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases; Sterol Regulatory Element Binding Protein 2 | 2011 |
Statins reverse renal inflammation and endothelial dysfunction induced by chronic high salt intake.
Topics: Animals; Atorvastatin; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Pyrroles; Rats; Rats, Wistar; Sodium Chloride, Dietary; Vasodilation | 2011 |
Impact of HMG-CoA reductase inhibition on oxidant-induced injury in human retinal pigment epithelium cells.
Topics: Atorvastatin; Caspase 3; Cell Line; Cell Survival; Enzyme Activation; Epithelial Cells; Heptanoic Acids; Humans; Hydrogen Peroxide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; NADPH Oxidases; Oxidants; Oxidative Stress; Pyrroles; Retinal Pigment Epithelium; Simvastatin; Tumor Necrosis Factor-alpha | 2011 |
Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: a possible compensatory mechanism.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol; Female; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxylation; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes.
Topics: Atorvastatin; Biological Transport; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Gene Expression Regulation, Enzymologic; Glucuronosyltransferase; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Space; Lactones; Metabolic Detoxication, Phase I; Metabolic Detoxication, Phase II; Models, Biological; Pyrroles; Systems Biology | 2011 |
Lipitor kicks off onslaught of drug patent conversions.
Topics: Atorvastatin; Drugs, Generic; Economic Competition; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patents as Topic; Pyrroles; United States | 2011 |
Regulation mechanism of ABCA1 expression by statins in hepatocytes.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Gene Expression Regulation; Hep G2 Cells; Hepatocytes; Heptanoic Acids; Humans; Male; PPAR alpha; Pyrroles; Quinolines; Rats; Rats, Wistar | 2011 |
Effect of atorvastatin (Lipitor) on myocardial apoptosis and caspase-8 activation following coronary microembolization.
Topics: Animals; Apoptosis; Atorvastatin; Caspase 3; Caspase 8; Coronary Vessels; Embolization, Therapeutic; Enzyme Activation; Heart; Heptanoic Acids; Male; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Death Domain | 2011 |
Atorvastatin improving renal ischemia reperfusion injury via direct inhibition of active caspase-3 in rats.
Topics: Animals; Apoptosis; Atorvastatin; Caspase Inhibitors; Creatinine; Enzyme Inhibitors; Heptanoic Acids; Kidney Tubules; Metabolic Clearance Rate; Protective Agents; Pyrroles; Rats; Reperfusion Injury | 2011 |
Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus--an observational study from the Swedish National Diabetes Register.
Topics: Adolescent; Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Statistical; Pyrimidines; Pyrroles; Registries; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Sweden; Treatment Outcome | 2011 |
[The effects of atorvastatin on aging kidney].
Topics: Aging; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Female; Heptanoic Acids; Kidney; Kidney Diseases; Pyrroles; Rats; Rats, Wistar; Renal Artery | 2011 |
The cholesterol ester transfer protein inhibitor, anacetrapib.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Drug Therapy, Combination; Heptanoic Acids; Humans; Oxazolidinones; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Combined atorvastatin and coenzyme Q10 improve the left ventricular function in isoproterenol-induced heart failure in rat.
Topics: Animals; Atorvastatin; Body Weight; Drug Interactions; Heart Failure; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoproterenol; Male; Myocardium; Organ Size; Pyrroles; Rats; Rats, Wistar; Ubiquinone; Ventricular Dysfunction, Left | 2011 |
Influence of atorvastatin on fractional and subfractional composition of serum lipoproteins and MMP activity in mice with Triton WR 1339-induced lipaemia.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Cholesterol; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Liver; Male; Matrix Metalloproteinases; Mice; Mice, Inbred ICR; Polyethylene Glycols; Pyrroles; Scattering, Small Angle; Triglycerides; X-Ray Diffraction | 2011 |
Suppression of inflammatory response and endothelial nitric oxide synthase downregulation in hyperlipidaemic C57BL/6J mice by eugenosedin-A.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Atorvastatin; Dietary Fats; Down-Regulation; Endothelium, Vascular; Female; Heptanoic Acids; Hyperlipidemias; Inflammation; Interferon-gamma; Liver; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Nitric Oxide; Nitric Oxide Synthase Type III; Obesity; Piperazines; Pyrroles; Random Allocation; RNA, Messenger; Tumor Necrosis Factor-alpha | 2011 |
Synergism between melatonin and atorvastatin against endothelial cell damage induced by lipopolysaccharide.
Topics: Atorvastatin; Base Sequence; Blotting, Western; Cells, Cultured; DNA Primers; Drug Synergism; Endothelium, Vascular; Free Radicals; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lipopolysaccharides; Melatonin; Nitric Oxide Synthase Type III; Oxidative Stress; Pyrroles; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2011 |
Hip circumference is associated with high density lipoprotein cholesterol response following statin therapy in hypertensive subjects.
Topics: Aged; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Waist Circumference; Waist-Hip Ratio | 2011 |
[Retention behavior of statins in microemulsion liquid chromatography].
Topics: Atorvastatin; Chromatography, Liquid; Emulsions; Heptanoic Acids; Lovastatin; Models, Chemical; Pravastatin; Pyrroles; Simvastatin | 2011 |
Fabry disease and Factor V Leiden: a potent vascular risk combination.
Topics: Activated Protein C Resistance; alpha-Galactosidase; Aspirin; Atorvastatin; Coronary Stenosis; Defibrillators, Implantable; Drug Therapy, Combination; Enzyme Replacement Therapy; Fabry Disease; Factor V; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metoprolol; Middle Aged; Perindopril; Pyrroles; Quality of Life; Recurrence; Sequence Deletion; Stents; Stroke; Stroke Rehabilitation; Thrombophilia; Warfarin | 2011 |
Atorvastatin and its collateral effects on microparticles.
Topics: Atorvastatin; Blood Platelets; Cell-Derived Microparticles; Female; Heptanoic Acids; Humans; Male; Peripheral Arterial Disease; Pyrroles | 2011 |
Effect of statin therapy on plasma adiponectin concentrations in patients with the sepsis syndrome: a preliminary investigation.
Topics: Adiponectin; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Systemic Inflammatory Response Syndrome | 2011 |
Nitric oxide involvement in consolidation, but not retrieval phase of cognitive performance enhanced by atorvastatin in mice.
Topics: Animals; Arginine; Atorvastatin; Cognition; Drug Antagonism; Drug Synergism; Guanidines; Heptanoic Acids; Memory; Memory Disorders; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Pyrroles; Scopolamine; Spatial Behavior | 2011 |
[Research on the effect of statins on insulin secretion from pancreatic islet in rats and its mechanisms].
Topics: Animals; Atorvastatin; Cells, Cultured; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Insulin; Insulin Secretion; Islets of Langerhans; Male; Pyrroles; Rats; Rats, Wistar | 2011 |
Court refuses to hurry generic Lipitor decision.
Topics: Atorvastatin; Drug Industry; Drugs, Generic; Heptanoic Acids; Humans; Judicial Role; Patents as Topic; Pyrroles | 2011 |
A case of recurrent ventricular tachycardia.
Topics: Aged; Atorvastatin; Cardiovascular Agents; Digoxin; Drug Therapy, Combination; Female; Furosemide; Heptanoic Acids; Humans; Isosorbide Dinitrate; Lisinopril; Nitroglycerin; Pyrroles; Recurrence; Tachycardia, Ventricular; Warfarin | 2011 |
Impact of statins on glucose metabolism--a matter of debate.
Topics: Atorvastatin; Fluorobenzenes; Glucose; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2011 |
Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products.
Topics: Animals; Atorvastatin; Heptanoic Acids; Humans; Microscopy, Electron, Transmission; Oxidative Stress; Pyrroles; Rats; Receptor for Advanced Glycation End Products; Receptors, Immunologic | 2011 |
Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Topics: Atorvastatin; Benzylamines; beta-Cyclodextrins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholesterol; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Heptanoic Acids; Humans; Lovastatin; Membrane Microdomains; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Thiophenes | 2011 |
Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Health Status Indicators; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Longitudinal Studies; Male; Middle Aged; Pyrroles; Simvastatin; Spain; Young Adult | 2011 |
Recurrent ischemic stroke in a patient with ulcerative colitis and high levels of lipoprotein (a).
Topics: Anticholesteremic Agents; Anticoagulants; Aspirin; Atorvastatin; Blood Coagulation Tests; Carotid Stenosis; Clopidogrel; Colitis, Ulcerative; Female; Heparin, Low-Molecular-Weight; Heptanoic Acids; Humans; Lipoprotein(a); Magnetic Resonance Imaging; Middle Aged; Pyrroles; Risk Factors; Stroke; Thrombosis; Ticlopidine; Ultrasonography | 2011 |
Atorvastatin protects against ischemia-reperfusion injury in fructose-induced insulin resistant rats.
Topics: Animals; Atorvastatin; Endothelium, Vascular; Fructose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Male; Nitric Oxide Synthase; Nitrites; Oxidative Stress; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Wistar; Reperfusion Injury | 2011 |
Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells.
Topics: Apoptosis; Atorvastatin; Caspase 3; Cell Cycle; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Cholangiocarcinoma; Extracellular Signal-Regulated MAP Kinases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neoplastic Stem Cells; Pyrroles; Quinolines | 2011 |
The effects of triple vs. dual and monotherapy with rosiglitazone, glimepiride, and atorvastatin on lipid profile and glycemic control in type 2 diabetes mellitus rats.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Female; Glycated Hemoglobin; Heptanoic Acids; Hypolipidemic Agents; Lipids; Male; Pyrroles; Rats; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2012 |
Atorvastatin worsens left ventricular diastolic dysfunction and endothelial dysfunction of epicardial coronary arteries in normocholesterolemic porcine with left ventricular hypertrophy.
Topics: Angiotensin II; Animals; Aorta; Atorvastatin; Coronary Vessels; Cyclic GMP; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Echocardiography; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Male; Nitrates; Nitrites; Pyrroles; Random Allocation; Swine; Vasodilation; Ventricular Dysfunction, Left | 2011 |
Low-density lipoprotein cholesterol goal attainment among Malaysian dyslipidemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Logistic Models; Malaysia; Male; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.
Topics: Atorvastatin; Caco-2 Cells; Cell Line; Chromatography, Liquid; Estrone; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Intestinal Absorption; Organic Anion Transporters; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Tandem Mass Spectrometry | 2011 |
Bilateral carotid atherosclerosis: an inevitable consequence of homozygous familial hypercholesterolemia.
Topics: Angioplasty; Atorvastatin; Carotid Stenosis; Disease Progression; Genetic Predisposition to Disease; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Liver Transplantation; Phenotype; Pyrroles; Radiography; Severity of Illness Index; Stents; Time Factors; Treatment Outcome; Treatment Refusal | 2011 |
The war over Lipitor.
Topics: Anticholesteremic Agents; Atorvastatin; Drugs, Generic; Economic Competition; Heptanoic Acids; Humans; Pyrroles; United States | 2011 |
Effects of dexamethasone and atorvastatin on atrial sodium current and its early tachycardia-induced electrical remodeling in rabbits.
Topics: Animals; Atorvastatin; Cardiac Pacing, Artificial; Cardiotonic Agents; Dexamethasone; Disease Models, Animal; Heart Atria; Heptanoic Acids; Membrane Potentials; Patch-Clamp Techniques; Pyrroles; Rabbits; Sodium Channels; Tachycardia | 2011 |
Multifactorial treatment for improvement of renal function and cardiovascular risk: an ATTEMPT for patients with metabolic syndrome and chronic kidney disease.
Topics: Atorvastatin; Cholesterol, LDL; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Pyrroles; Uric Acid | 2011 |
Drug repurposing for vascular protection after acute ischemic stroke.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Brain Infarction; Diabetes Mellitus, Type 2; Disease Models, Animal; Enalapril; Enzyme-Linked Immunosorbent Assay; Functional Laterality; Hemoglobins; Hemorrhage; Heptanoic Acids; Male; Matrix Metalloproteinase 9; Pyrroles; Rats; Rats, Inbred SHR; Rats, Wistar; Reperfusion; Stroke; Tetrazoles; Vascular System Injuries | 2011 |
Hypolipidemic potential of flowers of Nerium oleander in high fat diet-fed Sprague Dawley rats.
Topics: Animals; Atorvastatin; Dietary Fats; Flowers; Heptanoic Acids; Hypolipidemic Agents; Lipoproteins; Nerium; Plant Extracts; Pyrroles; Rats; Rats, Sprague-Dawley; Weight Gain | 2011 |
Atorvastatin treatment during epileptogenesis in a rat model for temporal lobe epilepsy.
Topics: Animals; Anticonvulsants; Atorvastatin; Blood-Brain Barrier; Brain; Disease Models, Animal; Electroencephalography; Epilepsy, Temporal Lobe; Heptanoic Acids; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Seizures; Triglycerides | 2011 |
Effect of atorvastatin therapy on oxidant-antioxidant status and atherosclerotic plaque formation.
Topics: Animals; Antioxidants; Aorta; Aortic Diseases; Aryldialkylphosphatase; Atherosclerosis; Atorvastatin; Catalase; Disease Models, Animal; Erythrocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipid Peroxidation; Lipoproteins, LDL; Male; Oxidation-Reduction; Plaque, Atherosclerotic; Pyrroles; Rabbits; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances; Time Factors | 2011 |
Therapy and clinical trials: aggressive statin therapy versus combined and emerging approaches.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Clinical Trials as Topic; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Atorvastatin and clopidogrel interfere with photosensitization in vitro.
Topics: Animals; Anticholesteremic Agents; Aspirin; Atorvastatin; Cathepsin B; Cell Line; Clopidogrel; Heptanoic Acids; Humans; Light; Macrophages; Mice; Neoplasms; Photochemotherapy; Photosensitizing Agents; Polyethylene Glycols; Polylysine; Porphyrins; Pyrroles; Ticlopidine | 2011 |
Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes.
Topics: Aged; Apelin; Atorvastatin; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cytokines; Diabetes Mellitus, Type 2; Female; Ghrelin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Pyrroles | 2012 |
[A dyslipidemia animal model induced by poloxamer 407 in golden hamsters and pilot study on the mechanism].
Topics: Animals; Anticholesteremic Agents; Atorvastatin; CD36 Antigens; Cricetinae; Disease Models, Animal; Dyslipidemias; Fenofibrate; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Malondialdehyde; Mesocricetus; Nitric Oxide; Phosphatidylcholine-Sterol O-Acyltransferase; Poloxamer; PPAR alpha; Pyrroles; RNA, Messenger; Superoxide Dismutase | 2011 |
Inferring statin-induced gene regulatory relationships in primary human hepatocytes.
Topics: Anticholesteremic Agents; Atorvastatin; Cytochrome P-450 CYP3A; Drug Interactions; Gene Expression Profiling; Gene Expression Regulation; Genes, Regulator; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Molecular Sequence Data; Protein Binding; Pyrroles; RNA; Transcription Factors | 2011 |
Coenzyme Q10 and cognition in atorvastatin treated dogs.
Topics: Aging; Animals; Atorvastatin; Cognition Disorders; Dogs; Female; Heptanoic Acids; Male; Mitochondria; Oxidative Phosphorylation; Oxidative Stress; Parietal Lobe; Pyrroles; Ubiquinone | 2011 |
Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/β-catenin/cyclin D1 signaling pathway in rats.
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Azoxymethane; beta Catenin; Carcinogens; Colonic Neoplasms; Cyclin D1; eIF-2 Kinase; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Immunoenzyme Techniques; Interleukin-4; Male; Naproxen; Nitric Oxide Synthase Type II; Pyrroles; Rats; Rats, Inbred F344; Signal Transduction; Sulindac; Tumor Necrosis Factor-alpha | 2011 |
Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain.
Topics: Aldehydes; Alzheimer Disease; Animals; Anticholesteremic Agents; Atorvastatin; Brain; Cognition Disorders; Disease Models, Animal; Dogs; Glutathione; Heme Oxygenase-1; Heptanoic Acids; Ketocholesterols; Linear Models; Liver; Oxidative Stress; Pyrroles; Up-Regulation | 2012 |
Right hemiparesis in right carotid stenosis.
Topics: Aged; Anticholesteremic Agents; Atherectomy; Atorvastatin; Carotid Stenosis; Clopidogrel; Combined Modality Therapy; Diffusion Magnetic Resonance Imaging; Heptanoic Acids; Humans; Male; Paresis; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine; Treatment Outcome; Ultrasonography | 2011 |
Atorvastatin induces autophagy in prostate cancer PC3 cells through activation of LC3 transcription.
Topics: Atorvastatin; Autophagy; Cell Growth Processes; Diterpenes; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; MAP Kinase Signaling System; Microtubule-Associated Proteins; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Pyrroles; TOR Serine-Threonine Kinases; Transcription, Genetic; Transcriptional Activation | 2011 |
Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC-1.
Topics: Animals; Antioxidants; Atorvastatin; Heart Atria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitochondria, Heart; Mitochondria, Muscle; Muscle Fibers, Skeletal; Muscle, Skeletal; Myocytes, Cardiac; Pyrroles; Quercetin; Rats; Rats, Wistar; Reactive Oxygen Species; RNA, Messenger; Superoxide Dismutase; Transcription Factors | 2012 |
Antimalarial activity of potential inhibitors of Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies.
Topics: Animals; Antimalarials; Atorvastatin; Catalytic Domain; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; L-Lactate Dehydrogenase; Malaria; Mice; Plasmodium falciparum; Pyrroles; Triazoles | 2011 |
[Pleiotropic effects of statins in systemic sclerosis].
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cytokines; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Retrospective Studies; Scleroderma, Systemic; Treatment Outcome; Young Adult | 2011 |
Effects of atorvastatin on progression of diabetic nephropathy and local RAGE and soluble RAGE expressions in rats.
Topics: Animals; Atorvastatin; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; Streptozocin | 2011 |
Effects of simvastatin, atorvastatin, ezetimibe, and ezetimibe + simvastatin combination on the inflammatory process and on the liver metabolic changes of arthritic rats.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Leukocyte Count; Leukocytes; Liver; Liver Function Tests; Perfusion; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin | 2012 |
Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer.
Topics: Animals; Antineoplastic Agents; Atorvastatin; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Hypolipidemic Agents; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 6; Neoplasms, Experimental; NF-kappa B; Pyrroles; ras Proteins; Receptor, ErbB-2; rhoA GTP-Binding Protein; Terpenes | 2011 |
Mechanism of the inhibitory effect of atorvastatin on leptin expression induced by angiotensin II in cultured human coronary artery smooth muscle cells.
Topics: Angiotensin II; Anticholesteremic Agents; Atorvastatin; Blotting, Western; Cell Movement; Cell Proliferation; Cells, Cultured; Coronary Vessels; Heptanoic Acids; Humans; JNK Mitogen-Activated Protein Kinases; Leptin; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Pyrroles; rac1 GTP-Binding Protein; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; Signal Transduction; Transcription Factor AP-1; Vasoconstrictor Agents | 2012 |
Effects of atorvastatin on bone metabolism and bone mineral density in Wistar rats.
Topics: Alkaline Phosphatase; Animals; Atorvastatin; Biomarkers; Bone and Bones; Bone Density; Bone Development; Calcium; Creatine; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Phosphorus; Pyrroles; Rats; Rats, Wistar | 2011 |
Study on bioavailability difference between clopidogrel bisulfate form I and form II using liquid chromatography/tandem mass spectrometry.
Topics: Animals; Area Under Curve; Atorvastatin; Biological Availability; Chromatography, High Pressure Liquid; Clopidogrel; Half-Life; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation Inhibitors; Pyrroles; Rats; Rats, Sprague-Dawley; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet; Tandem Mass Spectrometry; Ticlopidine | 2011 |
[Atorvastatin induced increase in homologous angiotensin I converting enzyme (ACE2) mRNA is associated to decreased fibrosis and decreased left ventricular hypertrophy in a rat model of diabetic cardiomyopathy].
Topics: Animals; Atorvastatin; Diabetic Cardiomyopathies; Disease Models, Animal; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy, Left Ventricular; Male; Peptidyl-Dipeptidase A; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2011 |
[Asymmetric synthesis of atorvastatin intermediate by Pichia pastoris X-33].
Topics: Anticholesteremic Agents; Atorvastatin; Catalysis; Enzymes; Fermentation; Heptanoic Acids; Isoindoles; Oxidation-Reduction; Pentanoic Acids; Pichia; Pyrroles; Stereoisomerism | 2011 |
Atorvastatin reduces functional deficits caused by photodynamic therapy in rats.
Topics: Animals; Astrocytes; Atorvastatin; Brain; Cell Line, Tumor; Cell Proliferation; Dihematoporphyrin Ether; Endothelial Cells; Glioma; Heptanoic Acids; Humans; Mental Disorders; Neovascularization, Physiologic; Neuroprotective Agents; Photochemotherapy; Pyrroles; Rats; Rats, Inbred F344; Synaptophysin; Vascular Endothelial Growth Factor A; von Willebrand Factor | 2011 |
Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United States | 2011 |
Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy.
Topics: Adult; Aged; Anthracyclines; Atorvastatin; Cardiomyopathies; Cardiotonic Agents; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome | 2011 |
Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress.
Topics: Animals; Atorvastatin; Cell Respiration; Cholesterol; Creatine Kinase; Glucose Transporter Type 4; Glycogen; Heptanoic Acids; Male; Mitochondria; Muscle, Skeletal; Oxidative Stress; Physical Conditioning, Animal; Physical Endurance; Pyrroles; Rats; Rats, Wistar; Reactive Oxygen Species; RNA, Messenger | 2011 |
In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions.
Topics: Atorvastatin; Computer Simulation; Drug Interactions; Estradiol; Gene Expression; HEK293 Cells; Heptanoic Acids; Humans; Liver-Specific Organic Anion Transporter 1; Models, Biological; Organic Anion Transporters; Pyrroles | 2012 |
Enhanced bioavailability of nano-sized chitosan-atorvastatin conjugate after oral administration to rats.
Topics: Adhesiveness; Administration, Oral; Animals; Atorvastatin; Biological Availability; Chitosan; Chromatography, High Pressure Liquid; Drug Compounding; Drug Stability; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Mucosa; Intestine, Small; Microscopy, Electron, Scanning; Molecular Structure; Nanoconjugates; Particle Size; Pyrroles; Rats; Solubility; Spectroscopy, Fourier Transform Infrared; Surface Properties | 2011 |
The human primary hepatocyte transcriptome reveals novel insights into atorvastatin and rosuvastatin action.
Topics: Atorvastatin; Cells, Cultured; Cholesterol; Constitutive Androstane Receptor; Energy Metabolism; Fluorobenzenes; Gene Expression Regulation; Gene Regulatory Networks; Hepatocytes; Heptanoic Acids; Homeostasis; Humans; Membrane Transport Proteins; Metabolic Networks and Pathways; Oligonucleotide Array Sequence Analysis; Pregnane X Receptor; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Reproducibility of Results; Rosuvastatin Calcium; Sulfonamides; Transcriptome | 2011 |
Treatment of an adrenomyeloneuropathy patient with Lorenzo's oil and supplementation with docosahexaenoic acid--a case report.
Topics: Adrenoleukodystrophy; Adult; Anticholesteremic Agents; Atorvastatin; Combined Modality Therapy; Dietary Supplements; Disease Progression; Docosahexaenoic Acids; Drug Combinations; Drug Therapy, Combination; Erucic Acids; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Pyrroles; Treatment Outcome; Triolein | 2011 |
Antinociception induced by atorvastatin in different pain models.
Topics: Animals; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Heptanoic Acids; Hot Temperature; Male; Mice; Pain; Pain Measurement; Pyrroles | 2011 |
Additional data supporting the use of statins to prevent contrast induced nephropathy.
Topics: Acute Kidney Injury; Atorvastatin; Contrast Media; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment | 2011 |
Long-term results from statin trials: answers but more unresolved questions.
Topics: Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Pyrroles | 2011 |
Enhanced bioavailability of atorvastatin calcium from stabilized gastric resident formulation.
Topics: Administration, Oral; Animals; Atorvastatin; Biological Availability; Calorimetry, Differential Scanning; Carboxymethylcellulose Sodium; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dioctyl Sulfosuccinic Acid; Drug Compounding; Drug Stability; Excipients; Female; Gastric Mucosa; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypromellose Derivatives; Male; Mannitol; Methylcellulose; Polyethylene Glycols; Powder Diffraction; Pyrroles; Rabbits; Regression Analysis; Sodium Bicarbonate; Solubility; Stearic Acids; Tablets; Technology, Pharmaceutical; Viscosity; Water; X-Ray Diffraction | 2011 |
Atorvastatin inhibits homocysteine-induced endoplasmic reticulum stress through activation of AMP-activated protein kinase.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blotting, Western; Dose-Response Relationship, Drug; Endoplasmic Reticulum Stress; Heptanoic Acids; Homocysteine; Human Umbilical Vein Endothelial Cells; Humans; Lipids; Mice; Polymerase Chain Reaction; Pyrroles; Ribonucleotides; Time Factors | 2012 |
Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells.
Topics: Animals; Atorvastatin; Cattle; Cytokines; Female; Guillain-Barre Syndrome; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Interferon-gamma; Interleukin-17; Myelin Sheath; Neuritis, Autoimmune, Experimental; Pyrroles; Rats; Rats, Inbred Lew; Sciatic Nerve; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells | 2011 |
Opposite effects of pravastatin and atorvastatin on insulin sensitivity in the rat: role of vitamin D metabolites.
Topics: Adipokines; Adipose Tissue; Animals; Atorvastatin; Biomarkers; Blood Glucose; Calcifediol; Calcitriol; Cholecalciferol; Fasting; Fatty Acids, Nonesterified; Glucose Clamp Technique; Glycerol; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Insulin; Insulin Resistance; Liver; Male; Muscle, Skeletal; Pravastatin; Pyrroles; Rats; Rats, Wistar; Time Factors | 2011 |
Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Atorvastatin; Chemical and Drug Induced Liver Injury; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Simvastatin; Sweden; Time Factors | 2012 |
Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERSAL, A to Z, JUPITER, HEART PROTECTION, and ASCOT trials.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Stroke | 2012 |
Atorvastatin reduces sympathetic activity in patients with chronic kidney disease.
Topics: Adult; Amides; Arteries; Atorvastatin; Blood Pressure; Case-Control Studies; Female; Fumarates; Glomerular Filtration Rate; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Pyrroles; Sympathetic Nervous System; Sympatholytics; Time Factors | 2011 |
The role of atorvastatin in bone metabolism in male albino Wistar rats.
Topics: Absorptiometry, Photon; Alkaline Phosphatase; Animals; Atorvastatin; Biomarkers; Biomechanical Phenomena; Blotting, Western; Bone and Bones; Bone Density; Bone Morphogenetic Protein 2; Collagen Type I; Electrophoresis, Polyacrylamide Gel; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Osteocalcin; Osteoprotegerin; Peptide Fragments; Procollagen; Protein Prenylation; Pyrroles; Rats; Rats, Wistar | 2011 |
Differential effects of atorvastatin treatment and withdrawal on pentylenetetrazol-induced seizures.
Topics: Animals; Anticonvulsants; Atorvastatin; Blood-Brain Barrier; Cerebral Cortex; Cholesterol; Convulsants; Electroencephalography; Heptanoic Acids; Male; Pentylenetetrazole; Pyrroles; Rats; Rats, Wistar; Seizures; Simvastatin | 2011 |
Effect of counterions on the properties of amorphous atorvastatin salts.
Topics: Atorvastatin; Calcium; Calorimetry, Differential Scanning; Cations; Crystallization; Drug Stability; Heptanoic Acids; Magnesium; Microscopy, Polarization; Phase Transition; Powder Diffraction; Pyrroles; Salts; Sodium; Solubility; Thermodynamics; Transition Temperature; Vitrification; Water; X-Ray Diffraction | 2011 |
Three different spectrophotometric methods manipulating ratio spectra for determination of binary mixture of Amlodipine and Atorvastatin.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Heptanoic Acids; Pharmaceutical Preparations; Pyrroles; Sensitivity and Specificity; Spectrophotometry; Tablets | 2011 |
Hypernatremia due to rhabdomyolysis in a patient on statin.
Topics: Anterior Wall Myocardial Infarction; Atorvastatin; Creatine Kinase, MB Form; Creatinine; Fatal Outcome; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypernatremia; Male; Middle Aged; Peritoneal Dialysis; Pyrroles; Rhabdomyolysis | 2011 |
Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptor.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cell Line, Tumor; Co-Repressor Proteins; Constitutive Androstane Receptor; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Genes, Reporter; Hep G2 Cells; Hepatocytes; Heptanoic Acids; Humans; Ligands; Membrane Transport Proteins; Oxidoreductases, N-Demethylating; Pregnane X Receptor; Promoter Regions, Genetic; Pyrroles; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; RNA, Messenger | 2012 |
Protective effect of lemongrass oil against dexamethasone induced hyperlipidemia in rats: possible role of decreased lecithin cholesterol acetyl transferase activity.
Topics: Animals; Atorvastatin; Cholesterol; Cymbopogon; Dexamethasone; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Male; Phosphatidylcholine-Sterol O-Acyltransferase; Phytotherapy; Plant Extracts; Plant Oils; Pyrroles; Rats; Rats, Wistar; Terpenes; Triglycerides | 2011 |
MR imaging-verified plaque delipidation with lipid-lowering therapy important questions remain.
Topics: Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Angiography; Male; Pyrroles | 2011 |
[Effect of atorvastatin on advanced glycation end products induced monocyte chemoattractant protein-1 expression in cultured human endothelial cells].
Topics: Atorvastatin; Cells, Cultured; Chemokine CCL2; Glycation End Products, Advanced; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; PPAR gamma; Pyrroles; RNA, Messenger; Signal Transduction; Transcription Factor RelA | 2011 |
Atorvastatin decreases computed tomography and S100-assessed brain ischemia after subarachnoid aneurysmal hemorrhage: a comparative study.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Brain Ischemia; Case-Control Studies; Confidence Intervals; Critical Care; Critical Illness; Female; Follow-Up Studies; Glasgow Coma Scale; Heptanoic Acids; Hospitals, University; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intensive Care Units; Male; Middle Aged; Nerve Growth Factors; Predictive Value of Tests; Pyrroles; Retrospective Studies; Risk Assessment; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Severity of Illness Index; Statistics, Nonparametric; Subarachnoid Hemorrhage; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; Vasospasm, Intracranial | 2012 |
SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Brazil; Female; Genetic Diseases, Inborn; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Pyrroles | 2012 |
RLIP76, a glutathione-conjugate transporter, plays a major role in the pathogenesis of metabolic syndrome.
Topics: Animals; Antisense Elements (Genetics); Atorvastatin; Gemfibrozil; GTPase-Activating Proteins; Heptanoic Acids; Hypoglycemic Agents; Hypolipidemic Agents; Metabolic Syndrome; Metformin; Mice; Mice, Knockout; Pyrroles; Rosiglitazone; Thiazolidinediones | 2011 |
[Association of a polymorphic marker Trp719Arg of KIF6 gene with effects of atorvastatin and simvastatin in patients with early ischemic heart disease].
Topics: Age of Onset; Apolipoprotein A-I; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hypolipidemic Agents; Kinesins; Male; Middle Aged; Myocardial Ischemia; Pharmacogenetics; Polymorphism, Genetic; Pyrroles; Simvastatin; Treatment Outcome | 2011 |
Simultaneous estimation of ramipril, acetylsalicylic acid and atorvastatin calcium by chemometrics assisted UV-spectrophotometric method in capsules.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Calibration; Capsules; Chemistry, Pharmaceutical; Heptanoic Acids; Humans; Least-Squares Analysis; Models, Theoretical; Pyrroles; Ramipril; Regression Analysis; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2011 |
Sildenafil improves the beneficial hemodynamic effects exerted by atorvastatin during acute pulmonary thromboembolism.
Topics: Acute Disease; Animals; Atorvastatin; Bronchoalveolar Lavage; Drug Synergism; Enzyme Activation; Heart Ventricles; Hemodynamics; Heptanoic Acids; Lipid Peroxidation; Lung; Male; Matrix Metalloproteinases; Myocytes, Cardiac; Neutrophils; Oxidative Stress; Piperazines; Pulmonary Embolism; Purines; Pyrroles; Sildenafil Citrate; Sulfones | 2011 |
Differentially expressed genes in human peripheral blood as potential markers for statin response.
Topics: Adult; Atorvastatin; Biomarkers, Pharmacological; Cholesterol; Gene Expression; Gene Expression Profiling; Genes, MHC Class II; Genome, Human; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles | 2012 |
Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice.
Topics: Animals; Atherosclerosis; Atorvastatin; CD4-Positive T-Lymphocytes; Cholesterol; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Mice; Mice, Inbred C57BL; Mycophenolic Acid; Pyrroles | 2012 |
Progressive neurovascular disturbances in the cerebral cortex of Alzheimer's disease-model mice: protection by atorvastatin and pitavastatin.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Blotting, Western; Cerebral Cortex; Cerebrovascular Circulation; Disease Models, Animal; Endothelium, Vascular; Enzyme Activation; Female; Fluorescent Antibody Technique; Heptanoic Acids; Humans; Immunohistochemistry; Matrix Metalloproteinase 9; Mice; Mice, Transgenic; Neuroprotective Agents; Pyrroles; Quinolines | 2011 |
The value of atorvastatin over the product life cycle in the United States.
Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Utilization Review; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Economic; Pyrroles; Quality-Adjusted Life Years; Simvastatin; Time Factors; United States | 2011 |
Atorvastatin suppresses inflammatory response induced by oxLDL through inhibition of ERK phosphorylation, IκBα degradation, and COX-2 expression in murine macrophages.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Cell Line; Cell Shape; Chemokines; Cyclooxygenase 2; Gene Expression; Gene Expression Regulation, Enzymologic; Heptanoic Acids; I-kappa B Proteins; Inflammation; Lipoproteins, LDL; Macrophages; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; NF-KappaB Inhibitor alpha; Phosphorylation; Protein Processing, Post-Translational; Proteolysis; Pyrroles | 2012 |
Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response.
Topics: Animals; Apoptosis; Atorvastatin; Caspase 12; Cells, Cultured; Disease Models, Animal; Endoplasmic Reticulum Stress; Female; Heart Failure; Heat-Shock Proteins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Myocardial Infarction; Natriuretic Peptide, Brain; Pyrroles; Rats; Rats, Wistar; Transcription Factor CHOP | 2011 |
Species-dependent sensitivity to contaminants: an approach using primary hepatocyte cultures with three marine fish species.
Topics: Animals; Atorvastatin; Cells, Cultured; Copper; Female; Fishes; Hepatocytes; Heptanoic Acids; Male; Pyrroles; Simvastatin; Species Specificity; Water Pollutants, Chemical | 2011 |
Statins amplify TLR-induced responses in microglia via inhibition of cholesterol biosynthesis.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Marrow; Brain; Cells, Cultured; Cholesterol; Cytokines; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Macaca mulatta; Macrophages; Microglia; Myeloid Differentiation Factor 88; Pyrroles; RNA, Messenger; Signal Transduction; Toll-Like Receptor 2 | 2012 |
Atorvastatin ameliorates tissue damage of obstructed ureter in rats.
Topics: Animals; Apoptosis; Atorvastatin; Cytokines; Female; Fibrosis; Heptanoic Acids; Hydronephrosis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; In Situ Nick-End Labeling; Muscle, Smooth; Proliferating Cell Nuclear Antigen; Pyrroles; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta1; Ureter; Ureteral Obstruction | 2011 |
Mitohormesis: another pleiotropic effect of statins?
Topics: Animals; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitochondria, Muscle; Muscle, Skeletal; Pyrroles; Reactive Oxygen Species; Transcription Factors | 2012 |
Atorvastatin therapy during the peri-infarct period attenuates left ventricular dysfunction and remodeling after myocardial infarction.
Topics: Animals; Apoptosis; Atorvastatin; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxyproline; Muscle Contraction; Myocardial Infarction; Myocytes, Cardiac; Pyrroles; Rats; Rats, Inbred F344; Ventricular Dysfunction, Left; Ventricular Remodeling | 2011 |
Efficacy of Atorvastatin combined with adipose-derived mesenchymal stem cell transplantation on cardiac function in rats with acute myocardial infarction.
Topics: Adipose Tissue; Animals; Atorvastatin; bcl-2-Associated X Protein; Cell Differentiation; Cell Proliferation; Cells, Cultured; Coculture Techniques; Disease Models, Animal; GATA4 Transcription Factor; Heart Function Tests; Heptanoic Acids; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Myocardial Infarction; Myocytes, Cardiac; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Rats; Rats, Sprague-Dawley; Troponin I; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2011 |
Early onset of coronary heart disease in a young woman with familial hypercholesterolemia: coronary findings and effect of short term treatment with high dose atorvastatin.
Topics: Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Pyrroles; Radiography; Time Factors; Treatment Outcome; Young Adult | 2012 |
Beneficial effect of atorvastatin on renal function in patients with type 2 diabetes.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glycated Hemoglobin; Glycemic Index; Heptanoic Acids; Humans; Hypercholesterolemia; Kidney Function Tests; Male; Middle Aged; Prognosis; Prospective Studies; Pyrroles; Retrospective Studies; Risk Factors; Triglycerides | 2011 |
Pleiotropic role of atorvastatin in regulation of human retinal pigment epithelial cell behaviors in vitro.
Topics: Atorvastatin; Blotting, Western; Cell Adhesion; Cell Cycle; Cell Line; Cell Movement; Cell Proliferation; Cell Shape; Dose-Response Relationship, Drug; Epithelial Cells; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 8; Myosin Light Chains; Myosin-Light-Chain Phosphatase; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Retinal Pigment Epithelium; Signal Transduction; Time Factors; Transforming Growth Factor beta2 | 2011 |
Sympathoinhibitory effects of statins in chronic kidney disease: are they clinically relevant?
Topics: Atorvastatin; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Pyrroles; Sympathetic Nervous System | 2011 |
Small unruptured partially thrombosed aneurysms and stroke: report of three cases and review of the literature.
Topics: Aspirin; Atorvastatin; Craniotomy; Echocardiography, Transesophageal; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Intracranial Aneurysm; Intracranial Embolism; Male; Middle Aged; Neurosurgical Procedures; Paresis; Pyrroles; Stroke; Tomography, X-Ray Computed; Ultrasonography, Doppler, Color | 2012 |
Statins exhibit anticancer effects through modifications of the pAkt signaling pathway.
Topics: Antineoplastic Agents; Atorvastatin; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; DNA Damage; Etoposide; Fluorouracil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Phosphatidylinositol 3-Kinases; Phosphoprotein Phosphatases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; Receptors, Purinergic P2X; Signal Transduction | 2012 |
Gender specific influence of fish oil or atorvastatin on functional properties of renal Na,K-ATPase in healthy Wistar and hypertriglyceridemic rats.
Topics: Adenosine Triphosphate; Animals; Anticholesteremic Agents; Atorvastatin; Female; Fish Oils; Heptanoic Acids; Hypertriglyceridemia; Kidney; Male; Pyrroles; Rats; Rats, Inbred Strains; Rats, Wistar; Sex Factors; Sodium-Potassium-Exchanging ATPase | 2011 |
Pleiotropic effects of statins in distal human pulmonary artery smooth muscle cells.
Topics: Apoptosis; Atorvastatin; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Female; Genetic Pleiotropy; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pravastatin; Pulmonary Artery; Pyrroles; Simvastatin | 2011 |
Anti-inflammatory and anti-thrombotic intervention strategies using atorvastatin, clopidogrel and knock-down of CD40L do not modify radiation-induced atherosclerosis in ApoE null mice.
Topics: Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Atorvastatin; Carotid Arteries; CD40 Antigens; Clopidogrel; Disease Models, Animal; Heptanoic Acids; Immunohistochemistry; Mice; Mice, Inbred C57BL; Mice, Knockout; Platelet Aggregation Inhibitors; Pyrroles; Radiation Dosage; Radiation Injuries, Experimental; Random Allocation; Reference Values; Statistics, Nonparametric; Ticlopidine | 2011 |
Neutral effects of statins to prevent atrial fibrillation recurrences after catheter ablation of atrial fibrillation: should we bury upstream therapy for secondary prevention of atrial fibrillation?
Topics: Atorvastatin; Atrial Fibrillation; Catheter Ablation; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Postoperative Complications; Pulmonary Veins; Pyrroles | 2012 |
Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease.
Topics: Alzheimer Disease; Animals; Atorvastatin; Biomarkers; Blotting, Western; Brain; Cerebellum; Cognition; Dogs; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoprecipitation; Learning; Liver; Neuroprotective Agents; Oxidative Stress; Oxidoreductases Acting on CH-CH Group Donors; Parietal Lobe; Phosphorylation; Protein Processing, Post-Translational; Pyrroles; Up-Regulation | 2012 |
Effects of atorvastatin on pathological changes in brain tissue and plasma MMP-9 in rats with intracerebral hemorrhage.
Topics: Animals; Atorvastatin; Brain; Brain Edema; Cerebral Hemorrhage; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Neuroprotective Agents; Pyrroles; Rats; Rats, Wistar; Water | 2012 |
Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Apolipoprotein B-100; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reference Values; Regression Analysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult | 2011 |
[Side effects of the HMG-CoA reductase inhibitors (statins). Lupus erythematosus induced by Atorvastatin therapy].
Topics: Anticholesteremic Agents; Arthralgia; Atorvastatin; Autoantibodies; Collagen Diseases; Creatine Kinase; Dermatomyositis; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Middle Aged; Pyrroles; Transaminases | 2011 |
Neurotoxic effect of statins on mouse neuroblastoma NB2a cell line.
Topics: Animals; Atorvastatin; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Neurites; Neuroblastoma; Pyrroles | 2011 |
Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Atorvastatin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Esophageal Neoplasms; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; NF-kappa B; Pravastatin; Pyrroles; Simvastatin | 2011 |
Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Gene Frequency; Genotype; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Linkage Disequilibrium; Liver-Specific Organic Anion Transporter 1; Logistic Models; Male; Middle Aged; Multivariate Analysis; Organic Anion Transporters; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrroles; Treatment Outcome | 2011 |
Antioxidative strategies in cognitive impairment: a novel connection between biliverdin-reductase and statins.
Topics: Alzheimer Disease; Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neuroprotective Agents; Oxidoreductases Acting on CH-CH Group Donors; Pyrroles | 2012 |
Modelling approach to simulate reductions in LDL cholesterol levels after combined intake of statins and phytosterols/-stanols in humans.
Topics: Algorithms; Atorvastatin; Cholesterol, LDL; Computer Simulation; Dose-Response Relationship, Drug; Drug Synergism; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Models, Biological; Phytosterols; Phytotherapy; Pyrroles | 2011 |
Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Multivariate Analysis; Pyrroles; Regression Analysis; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; United States | 2011 |
Trastuzumab-related palmar plantar erythrodysaesthesia.
Topics: Aged; Amlodipine; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Antihypertensive Agents; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Foot Dermatoses; Hand Dermatoses; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Trastuzumab | 2012 |
Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction.
Topics: Aged; Atorvastatin; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Male; Pyrazines; Pyrroles; Rhabdomyolysis; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Should children and adolescents with systemic lupus erythematosus be given statin therapy to prevent early atherosclerosis?
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Female; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Male; Pyrroles | 2012 |
Differential modulation of cytochrome P450 activity and the effect of 1-aminobenzotriazole on hepatic transport in sandwich-cultured human hepatocytes.
Topics: Anti-Anxiety Agents; Anticholesteremic Agents; Atorvastatin; Bile; Biological Transport; Cell Survival; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Fluorobenzenes; Hepatocytes; Heptanoic Acids; Humans; Isoenzymes; Midazolam; Models, Biological; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors; Triazoles | 2012 |
The interactions of atorvastatin and fluvastatin with carbamazepine, phenytoin and valproate in the mouse maximal electroshock seizure model.
Topics: Animals; Anticonvulsants; Atorvastatin; Brain; Carbamazepine; Disease Models, Animal; Drug Interactions; Electroshock; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Indoles; Male; Memory; Mice; Motor Activity; Phenytoin; Pyrroles; Seizures; Valproic Acid | 2012 |
Differential effect of atorvastatin and tacrolimus on proliferation of vascular smooth muscle and endothelial cells.
Topics: Aged; Aged, 80 and over; Antigens, CD; Atorvastatin; beta Catenin; Cardiovascular Agents; Cell Proliferation; Cells, Cultured; Cyclin B; DNA Replication; Dose-Response Relationship, Drug; Drug-Eluting Stents; Endoglin; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Pyrroles; Receptors, Cell Surface; Tacrolimus; Time Factors | 2012 |
Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Case-Control Studies; Female; Gene Expression; Genetic Association Studies; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Leukocytes, Mononuclear; Lipids; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; RNA, Messenger | 2011 |
Silencing p110β prevents rapid depletion of nuclear pAkt.
Topics: Animals; Atorvastatin; Cell Line, Tumor; Cell Nucleus; Class I Phosphatidylinositol 3-Kinases; Fibroblasts; Gene Silencing; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Knockout; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; RNA, Small Interfering; Tacrolimus Binding Proteins | 2011 |
Effect of ether- and water-soluble fractions of Carica papaya ethanol extract in experimentally induced hyperlipidemia in rats.
Topics: Animals; Atorvastatin; Carica; Cholesterol, HDL; Chromatography, Thin Layer; Dose-Response Relationship, Drug; Ethanol; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Mice; Olive Oil; Plant Extracts; Plant Oils; Pyrroles; Rats; Solvents; Spectrophotometry, Ultraviolet; Water | 2011 |
Self-microemulsifying smaller molecular volume oil (Capmul MCM) using non-ionic surfactants: a delivery system for poorly water-soluble drug.
Topics: Atorvastatin; Caco-2 Cells; Caprylates; Chemistry, Pharmaceutical; Drug Delivery Systems; Emulsions; Glycerides; Heptanoic Acids; Humans; Oils; Organic Chemicals; Particle Size; Permeability; Polysorbates; Pyrroles; Solubility; Surface-Active Agents; Thermodynamics | 2012 |
[The effects of atorvastatin on C-reactive protein induced Toll-like receptor 4 expression on CD14+ monocyte].
Topics: Anti-Inflammatory Agents; Atorvastatin; C-Reactive Protein; Cells, Cultured; Heptanoic Acids; Humans; Lipopolysaccharide Receptors; Monocytes; Pyrroles; Toll-Like Receptor 4 | 2011 |
Activation of TGF-β receptors and Smad proteins by atorvastatin is related to reduced atherogenesis in ApoE/LDLR double knockout mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blotting, Western; Cholesterol; Endoglin; Female; Heptanoic Acids; Immunoenzyme Techniques; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; Protein Serine-Threonine Kinases; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptors, LDL; Receptors, Transforming Growth Factor beta; Smad1 Protein; Smad2 Protein; Vascular Endothelial Growth Factor A | 2012 |
Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Case-Control Studies; Female; Galectin 3; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pilot Projects; Pravastatin; Prognosis; Prospective Studies; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Chile; Cytochrome P-450 CYP3A; Female; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrroles; Treatment Outcome | 2012 |
Low-density lipoprotein cholesterol lowering therapy and established atherosclerosis.
Topics: Atorvastatin; Azetidines; Coronary Artery Disease; Coronary Vessels; Ezetimibe; Female; Heptanoic Acids; Humans; Male; Plaque, Atherosclerotic; Pyrroles | 2012 |
Use of atorvastatin to inhibit hypoxia-induced myocardin expression.
Topics: Animals; Animals, Newborn; Atorvastatin; Blotting, Western; Cells, Cultured; Electrophoretic Mobility Shift Assay; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertrophy; Hypoxia; Myocytes, Cardiac; Nuclear Proteins; Pyrroles; Rats; Rats, Wistar; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Trans-Activators | 2012 |
Blockbuster drug bows out.
Topics: Atorvastatin; Drug Industry; Drugs, Generic; Heptanoic Acids; Patents as Topic; Pyrroles | 2011 |
Different statins produce highly divergent changes in gene expression profiles of human hepatoma cells: a pilot study.
Topics: Atorvastatin; Carcinoma, Hepatocellular; Computational Biology; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Profiling; Gene Expression Regulation; Genome, Human; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Metabolic Networks and Pathways; Mevalonic Acid; Oligonucleotide Array Sequence Analysis; Pilot Projects; Principal Component Analysis; Pyrroles; Simvastatin | 2011 |
Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin.
Topics: Amides; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Female; Fumarates; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Transgenic; Pyrroles | 2012 |
Statins lower calcium-induced oxidative stress in isolated mitochondria.
Topics: Animals; Atorvastatin; Calcium; Cytochromes c; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lipid Peroxidation; Membrane Potential, Mitochondrial; Mitochondria, Liver; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Nitric Oxide Synthase; Oxidative Stress; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin | 2012 |
Generic atorvastatin and health care costs.
Topics: Atorvastatin; Cost Savings; Drug Costs; Drug Industry; Drugs, Generic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; United States | 2012 |
Proinflammatory cytokine levels in hyperlipidemic patients with periodontitis after periodontal treatment.
Topics: Adult; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Cytokines; Dental Scaling; Diet, Fat-Restricted; Female; Follow-Up Studies; Gingival Crevicular Fluid; Gingival Hemorrhage; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation Mediators; Interleukin-1beta; Interleukin-6; Male; Middle Aged; Periodontitis; Pyrroles; Root Planing; Triglycerides; Tumor Necrosis Factor-alpha | 2012 |
Lessons from Lipitor and the broken blockbuster drug model.
Topics: Academic Medical Centers; Advertising; Anticholesteremic Agents; Atorvastatin; Cooperative Behavior; Drug Industry; Heptanoic Acids; Humans; Models, Organizational; Patents as Topic; Pyrroles | 2011 |
Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production.
Topics: Animals; Apoptosis; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Catalase; Cell Line, Tumor; Cell Membrane; Female; Glutathione Peroxidase; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mice, Nude; NADPH Oxidases; Protein Transport; Pyrroles; rac1 GTP-Binding Protein; Reactive Oxygen Species; Vascular Endothelial Growth Factor A | 2012 |
Does the combination of a renin inhibitor with a statin have potential for improved inhibition of atherosclerosis?
Topics: Amides; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Female; Fumarates; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2012 |
Altered metabolism of low-density lipoprotein and very-low-density lipoprotein remnant in autosomal recessive hypercholesterolemia: results from stable isotope kinetic study in vivo.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hypercholesterolemia; Isotope Labeling; Kinetics; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Pedigree; Pyrroles | 2012 |
Trifluoromethylation of arenes and heteroarenes by means of photoredox catalysis.
Topics: Anticholesteremic Agents; Atorvastatin; Catalysis; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Donepezil; Drug Design; Flavones; Halogenation; Heptanoic Acids; Indans; Isomerism; Light; Methylation; Molecular Structure; Oxidation-Reduction; Pharmaceutical Preparations; Photochemical Processes; Piperidines; Pyrroles; Uracil | 2011 |
Atorvastatin inhibits collar-induced intimal thickening of rat carotid artery: effect on C-type natriuretic peptide expression.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Carotid Artery Injuries; Cyclic GMP-Dependent Protein Kinase Type I; Cyclic GMP-Dependent Protein Kinases; Gene Expression Regulation; Heptanoic Acids; Male; Natriuretic Peptide, C-Type; Neointima; Pyrroles; Rats | 2012 |
Chemoprevention of mouse lung and colon tumors by suberoylanilide hydroxamic acid and atorvastatin.
Topics: Animals; Atorvastatin; Colonic Neoplasms; Dimethylhydrazines; Female; Heptanoic Acids; Histone Deacetylase Inhibitors; Hydroxamic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lung Neoplasms; Mice; Nitrosamines; Pyrroles; RNA, Messenger; Urethane; Vorinostat | 2012 |
Effect of atorvastatin on the cortical bones of corticosteroid treated rabbits.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Compressive Strength; Drug Interactions; Equipment Failure Analysis; Femur; Glucocorticoids; Heptanoic Acids; Injections, Intramuscular; Methylprednisolone; Pyrroles; Rabbits; Stress, Mechanical; Tibia | 2012 |
Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cell Movement; Cholesterol; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice; Mice, Transgenic; Models, Biological; Monocytes; Promoter Regions, Genetic; Pyrroles; Receptors, CCR7; Response Elements; Sterol Regulatory Element Binding Proteins; Sterols | 2011 |
[The composition of blood lipoproteins of donors 2 hours later after single atorvastatin intake].
Topics: Anticholesteremic Agents; Atorvastatin; Biological Transport, Active; Female; Heptanoic Acids; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Male; Pyrroles; Sex Characteristics; Time Factors | 2011 |
Patent cliff. Billions to be saved--starting now. Lipitor led the way, and other blockbusters are following.
Topics: Anticholesteremic Agents; Atorvastatin; Cost Savings; Drugs, Generic; Heptanoic Acids; Humans; Managed Care Programs; Patents as Topic; Pyrroles; United States | 2011 |
Atorvastatin inhibits functional expression of proatherogenic TLR2 in arterial endothelial cells.
Topics: Anticholesteremic Agents; Atorvastatin; Casein Kinase II; Cell Line; Endothelial Cells; Gene Expression Regulation; Heart Atria; Heptanoic Acids; Humans; Lipopeptides; Phosphorylation; Pyrroles; Sp1 Transcription Factor; Toll-Like Receptor 2 | 2011 |
Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia.
Topics: Adipocytes; Adipokines; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cells, Cultured; Drug Therapy, Combination; Dyslipidemias; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Heptanoic Acids; Humans; In Vitro Techniques; Intra-Abdominal Fat; Male; Middle Aged; Pyrroles; Subcutaneous Fat | 2011 |
Effects of atorvastatin on heart mitochondrial function and coenzyme Q content in the experiment.
Topics: Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Mitochondria, Heart; Pyrroles; Rats; Rats, Wistar; Ubiquinone | 2011 |
Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Association Studies; Haplotypes; Heptanoic Acids; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide; Proportional Hazards Models; Pyrroles; Simvastatin | 2013 |
Long-term efficacy of upstream therapy with lipophilic or hydrophilic statins on antiarrhythmic drugs in patients with paroxysmal atrial fibrillation: comparison between atorvastatin and pravastatin.
Topics: Aged; Anti-Arrhythmia Agents; Atorvastatin; Atrial Fibrillation; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Electrocardiography; Female; Follow-Up Studies; Heart Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pravastatin; Pyrroles; Retrospective Studies; Secondary Prevention; Tachycardia, Paroxysmal; Time Factors; Treatment Outcome | 2011 |
Monitoring anti-inflammatory therapies in patients with atherosclerosis: FDG PET emerges as the method of choice.
Topics: Abdominal Fat; Anti-Inflammatory Agents; Arteritis; Atorvastatin; Female; Heptanoic Acids; Humans; Male; Pyrroles; Vascular Calcification | 2012 |
Acute effects of statins.
Topics: Atorvastatin; Cardiac Surgical Procedures; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Oxidation-Reduction; Pyrroles | 2012 |
Effect of atorvastatin with or without prednisolone on Freund's adjuvant induced-arthritis in rats.
Topics: Animals; Ankle Joint; Arthritis, Experimental; Atorvastatin; Drug Interactions; Freund's Adjuvant; Heptanoic Acids; Lipids; Male; Oxidative Stress; Prednisolone; Pyrroles; Rats | 2012 |
Statin use in COPD patients is associated with a reduction in mortality: a national cohort study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medical Record Linkage; Middle Aged; New Zealand; Pulmonary Disease, Chronic Obstructive; Pyrroles; Simvastatin; Treatment Outcome | 2012 |
Myocardial infarction in an young patient associated with oral contraceptive, smoking and elevated cholesterol level.
Topics: Abortion, Induced; Adult; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Clopidogrel; Contraceptives, Oral; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Myocardial Infarction; Pregnancy; Pyrroles; Smoking; Ticlopidine | 2012 |
Effect of low-dose atorvastatin on plasma concentrations of adipokines in patients with metabolic syndrome.
Topics: Adipokines; Adult; Atorvastatin; Biomarkers; Female; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Treatment Outcome | 2012 |
Influence of atorvastatin on the pharmacodynamic and pharmacokinetic activity of repaglinide in rats and rabbits.
Topics: Animals; Atorvastatin; Blood Glucose; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Diabetes Mellitus, Experimental; Drug Interactions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Piperidines; Pyrroles; Rabbits; Rats | 2012 |
Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acute Coronary Syndrome; Aged; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Lipoproteins; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Ischemia; Oxidation-Reduction; Phospholipases A2, Secretory; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk; Risk Factors; Survival Analysis | 2012 |
Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model.
Topics: Animals; Antimalarials; Apoptosis; Atorvastatin; Brain; Disease Models, Animal; Drug Therapy, Combination; Female; Heptanoic Acids; Histocytochemistry; Immunohistochemistry; Malaria, Cerebral; Mefloquine; Mice; Neurons; Plasmodium berghei; Pyrroles; Survival Analysis; Treatment Outcome | 2012 |
Probucol and atorvastatin in combination protect rat brains in MCAO model: upregulating Peroxiredoxin2, Foxo3a and Nrf2 expression.
Topics: Animals; Atorvastatin; Body Fluids; Brain; Disease Models, Animal; Drug Therapy, Combination; Forkhead Box Protein O3; Forkhead Transcription Factors; Heptanoic Acids; Infarction, Middle Cerebral Artery; Male; NF-E2-Related Factor 2; Peroxiredoxins; Probucol; Pyrroles; Rats; Up-Regulation; Water | 2012 |
Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population.
Topics: Age Factors; Aged; Atorvastatin; Cohort Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Databases, Factual; Drug Interactions; Enzyme Inhibitors; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Patterns, Physicians'; Primary Health Care; Pyrroles; Retrospective Studies; Simvastatin; United Kingdom | 2012 |
[Drug-induced pneumonitis due to sirolimus: an interaction with atorvastatin?].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Interactions; Female; Heptanoic Acids; Humans; Immunosuppressive Agents; Male; Middle Aged; Pneumonia; Pyrroles; Sirolimus | 2012 |
Postoperative adhesion prevention using a statin-containing cellulose film in an experimental model.
Topics: Animals; Atorvastatin; Biocompatible Materials; Carboxymethylcellulose Sodium; Fibrosis; Heptanoic Acids; Hyaluronic Acid; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Random Allocation; Rats; Rats, Wistar; Tissue Adhesions | 2012 |
Statins as neuroprotectants after subarachnoid hemorrhage.
Topics: Atorvastatin; Brain Ischemia; Female; Heptanoic Acids; Humans; Male; Nerve Growth Factors; Pyrroles; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Subarachnoid Hemorrhage | 2012 |
Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy.
Topics: Adult; Animals; Apolipoprotein A-I; Apolipoprotein A-II; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; CD36 Antigens; CHO Cells; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Cricetinae; Cricetulus; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL2; Liver; Macrophages; Male; Mice; Middle Aged; Paris; Particle Size; Postprandial Period; Pyrroles; Quinolines; Time Factors; Transfection; Treatment Outcome | 2012 |
Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
Topics: Adiponectin; Adult; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Collagen Type IV; Dyslipidemias; Fatty Liver; Female; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrroles; Regression Analysis; Severity of Illness Index; Triglycerides; Tumor Necrosis Factor-alpha | 2012 |
Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland.
Topics: Atorvastatin; Drugs, Generic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Omeprazole; Practice Patterns, Physicians'; Proton Pump Inhibitors; Pyrroles; Scotland; Simvastatin | 2012 |
Development and characterization of self-nanoemulsifying drug delivery systems (SNEDDS) of atorvastatin calcium.
Topics: Anticholesteremic Agents; Atorvastatin; Biological Availability; Chemistry, Pharmaceutical; Drug Delivery Systems; Drug Stability; Emulsifying Agents; Excipients; Heptanoic Acids; Hydrogen-Ion Concentration; Nanoparticles; Particle Size; Plant Oils; Pyrroles; Solubility; Surface-Active Agents | 2012 |
Postoperative adhesion prevention using a statin-containing cellulose film in an experimental model (Br J Surg 2012; 99: 423-429).
Topics: Animals; Atorvastatin; Carboxymethylcellulose Sodium; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Tissue Adhesions | 2012 |
Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice.
Topics: Animals; Apoptosis; Atorvastatin; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cytokines; Disease Progression; Fluorescent Antibody Technique; Heptanoic Acids; Humans; Immunoenzyme Techniques; Integrases; Interferon-Stimulated Gene Factor 3, gamma Subunit; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2012 |
No adverse effects of statins on muscle function and health-related parameters in the elderly: an exercise study.
Topics: Adipose Tissue; Aged; Atorvastatin; Body Constitution; Body Mass Index; Case-Control Studies; Diet Records; Energy Metabolism; Exercise; Exercise Test; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Maximal Voluntary Ventilation; Muscle, Skeletal; Pyrroles | 2013 |
Liver mitochondrial respiratory function and coenzyme Q content in rats on a hypercholesterolemic diet treated with atorvastatin.
Topics: Animals; Atorvastatin; Cholesterol; Diet; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Male; Micronutrients; Mitochondria, Liver; Pyrroles; Rats; Ubiquinone | 2012 |
Anti-inflammatory effect of atorvastatin on vascular reactivity and insulin resistance in fructose fed rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; Atorvastatin; Dietary Sucrose; Fructose; Heptanoic Acids; Insulin Resistance; Male; Pyrroles; Rats; Rats, Wistar; Vascular Diseases | 2012 |
Simvastatin and atorvastatin attenuate VCAM-1 and uPAR expression on human endothelial cells and platelet surface expression of CD40 ligand.
Topics: Anti-Inflammatory Agents; Atorvastatin; Biomarkers; Blood Platelets; CD40 Ligand; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Lipopolysaccharides; Matrix Metalloproteinase 14; P-Selectin; Platelet Activation; Pyrroles; Receptors, Urokinase Plasminogen Activator; Simvastatin; Thrombin; Vascular Cell Adhesion Molecule-1 | 2012 |
[Atorvastatin for secondary prevention in patients with coronary artery disease].
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Artery Disease; Heptanoic Acids; Humans; Pyrroles; Secondary Prevention | 2011 |
Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Agents; Apoptosis; Atorvastatin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Female; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mice, Nude; Proto-Oncogene Proteins c-akt; Pyrroles; Tissue Inhibitor of Metalloproteinase-1; Xenograft Model Antitumor Assays | 2012 |
Protective effect of atorvastatin on bone tissue in orchidectomised male albino Wistar rats.
Topics: Animals; Atorvastatin; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium; Compressive Strength; Disease Models, Animal; Femur; Heptanoic Acids; Male; Orchiectomy; Osteoporosis; Pyrroles; Rats; Rats, Wistar; Tibia | 2012 |
[Symptomatic coronary heart disease. Impressive plaque reduction with high dose statins].
Topics: Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Disease Progression; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Survival Rate | 2011 |
Acquired cerebellar ataxia due to statin use.
Topics: Atorvastatin; Cerebellar Ataxia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Severity of Illness Index; Time Factors | 2012 |
Usefulness of lymphocyte activation test in atorvastatin hypersensitivity.
Topics: Adult; Atorvastatin; Drug Hypersensitivity; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocyte Activation; Male; Pyrroles | 2011 |
Managing dyslipidaemia: evolving role of combination therapy.
Topics: Atorvastatin; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Niacin; Pyrroles | 2011 |
Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407.
Topics: Animals; Atorvastatin; beta-Glucans; Biomarkers; Cholesterol, LDL; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Lipoproteins, LDL; Liver; Male; Matrix Metalloproteinases; Mice; Mice, Inbred ICR; Poloxamer; Pyrroles; Scattering, Small Angle; Time Factors; Triglycerides; X-Ray Diffraction | 2012 |
[Atorvastatin protects swine bone marrow mesenchymal stem cells from apoptosis through AMPK but not PI3K/Akt pathway].
Topics: Adenylate Kinase; Animals; Apoptosis; Atorvastatin; Bone Marrow Cells; Culture Media, Serum-Free; Heptanoic Acids; Mesenchymal Stem Cells; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Swine | 2011 |
Atorvastatin may delay cardiac aging by upregulating peroxisome proliferator-activated receptors in rats.
Topics: Aging; Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cells, Cultured; Gene Expression Regulation; Heart; Heptanoic Acids; Inflammation Mediators; Myocardium; Oxidoreductases; Peroxisome Proliferator-Activated Receptors; Pyrroles; Rats; Rats, Wistar; Up-Regulation | 2012 |
Atorvastatin attenuates TNF-α-induced increase of glucose oxidation through PGC-1α upregulation in cardiomyocytes.
Topics: Animals; Atorvastatin; Carnitine O-Palmitoyltransferase; Cell Line; Down-Regulation; Glucose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocytes, Cardiac; Oxidation-Reduction; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Protein Kinases; Pyrroles; Rats; RNA-Binding Proteins; Transcription Factors; Tumor Necrosis Factor-alpha; Up-Regulation | 2012 |
Statins for COPD: a challenge to conventional beliefs?
Topics: Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pulmonary Disease, Chronic Obstructive; Pyrroles; Simvastatin | 2012 |
Statin-dependent activation of protein kinase Cδ in acute promyelocytic leukemia cells and induction of leukemic cell differentiation.
Topics: Antineoplastic Agents; Atorvastatin; Cell Differentiation; Cell Line, Tumor; Chemokine CCL3; Chemokine CCL4; Drug Synergism; Enzyme Activation; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation, Leukemic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoblotting; Indoles; Leukemia, Promyelocytic, Acute; Protein Kinase C-delta; Proteolysis; Pyrroles; RNA Interference; Signal Transduction; Tretinoin | 2012 |
Autophagy activation: a novel mechanism of atorvastatin to protect mesenchymal stem cells from hypoxia and serum deprivation via AMP-activated protein kinase/mammalian target of rapamycin pathway.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Atorvastatin; Autophagy; Blotting, Western; Cell Hypoxia; Culture Media, Serum-Free; Cytoprotection; Dose-Response Relationship, Drug; Heptanoic Acids; Male; Mesenchymal Stem Cells; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
Solid-state NMR studies of form I of atorvastatin calcium.
Topics: Atorvastatin; Carbon Isotopes; Fluorine; Heptanoic Acids; Magnetic Resonance Spectroscopy; Molecular Conformation; Pyrroles | 2012 |
Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Disease Models, Animal; Heptanoic Acids; Inflammation; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide; Pyrroles; Receptors, LDL | 2012 |
Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a).
Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Genome-Wide Association Study; Genotype; Glucosyltransferases; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Placebo Effect; Polymorphism, Single Nucleotide; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Lysophosphatidic Acid; Treatment Outcome | 2012 |
Effects of atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism.
Topics: Atorvastatin; Biomarkers; Blood Coagulation; Blood Coagulation Tests; Case-Control Studies; Dyslipidemias; Fibrin; Fibrinolytic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Poland; Pyrroles; Treatment Outcome; Ultrasonography, Doppler, Color; Venous Thromboembolism | 2012 |
[Effect of atorvastatin on cardiac function and TGF-β1 signaling pathway after acute myocardial infarction in rats].
Topics: Animals; Atorvastatin; Heart; Heptanoic Acids; Male; Myocardial Infarction; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction; Smad2 Protein; Transforming Growth Factor beta1; Ventricular Remodeling | 2012 |
[Focal myositis as a side effect of antilipidemics - 2 patients with involvement of the forearm].
Topics: Anticholesteremic Agents; Atorvastatin; Bezafibrate; Coronary Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Forearm; Heptanoic Acids; Humans; Hyperlipidemias; Image Interpretation, Computer-Assisted; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Myositis; Pyrroles | 2012 |
Ask the doctor. After a heart attack six years ago, I went on Lipitor (atorvastatin) because my doctor said it was proven to reduce the risk of a second heart attack in high-risk people like me. Three years ago, I switched to a generic (simvastatin) to sa
Topics: Atorvastatin; Drugs, Generic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Pyrroles | 2012 |
Proveblue (methylene blue) as an antimalarial agent: in vitro synergy with dihydroartemisinin and atorvastatin.
Topics: Antimalarials; Artemisinins; Atorvastatin; Drug Interactions; Heptanoic Acids; Inhibitory Concentration 50; Methylene Blue; Plasmodium falciparum; Pyrroles | 2012 |
Preparation, physicochemical characteristics and bioavailability studies of an atorvastatin hydroxypropyl-beta-cyclodextrin complex.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Algorithms; Analysis of Variance; Animals; Area Under Curve; Atorvastatin; beta-Cyclodextrins; Biological Availability; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Delayed-Action Preparations; Electrochemistry; Excipients; Hardness; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Spectroscopy; Models, Molecular; Pyrroles; Rats; Solubility; Spectroscopy, Fourier Transform Infrared; Tablets; X-Ray Diffraction | 2012 |
Inhibition of hepatic uptake transporters by flavonoids.
Topics: 1-Methyl-4-phenylpyridinium; Apigenin; Atorvastatin; Biological Transport; Flavanones; Flavonoids; Food-Drug Interactions; HEK293 Cells; Hepatocytes; Heptanoic Acids; Humans; Inhibitory Concentration 50; Kaempferols; Liver-Specific Organic Anion Transporter 1; Metformin; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Organic Cation Transporter 1; Pyrroles; Quercetin; Rutin; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfobromophthalein; Tritium | 2012 |
Chronic administration of atorvastatin induced anti-convulsant effects in mice: the role of nitric oxide.
Topics: Analysis of Variance; Animals; Anticonvulsants; Atorvastatin; Convulsants; Disease Models, Animal; Drug Administration Routes; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Guanidines; Heptanoic Acids; Male; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pentylenetetrazole; Pyrroles; Seizures; Time Factors | 2012 |
Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition.
Topics: Adult; Aspirin; Atorvastatin; Blood Platelets; Cholesterol; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Simvastatin; Young Adult | 2012 |
Simultaneous determination of atorvastatin and niacin in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.
Topics: Atorvastatin; Chromatography, High Pressure Liquid; Drug Stability; Heptanoic Acids; Humans; Linear Models; Liquid-Liquid Extraction; Male; Nevirapine; Niacin; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |
Statin therapy for subclinical atherosclerosis in primary prevention: time to prove it?
Topics: Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Primary Prevention; Pyrroles; Vascular Calcification | 2012 |
Characterization of solid polymer dispersions of active pharmaceutical ingredients by 19F MAS NMR and factor analysis.
Topics: Atorvastatin; Crystallization; Factor Analysis, Statistical; Fluorine; Heptanoic Acids; Magnetic Resonance Spectroscopy; Pharmaceutical Preparations; Povidone; Pyrroles; Time Factors | 2013 |
Proteomic analysis of endothelial lipid rafts reveals a novel role of statins in antioxidation.
Topics: Amino Acid Sequence; Antioxidants; Atorvastatin; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Glycoproteins; Membrane Microdomains; Molecular Sequence Data; NADPH Oxidase 2; NADPH Oxidases; Protein Disulfide-Isomerases; Proteins; Proteome; Pyrroles; Reactive Oxygen Species; Reproducibility of Results | 2012 |
Anticonvulsive effect of atorvastatin on pentylenetetrazole-induced seizures in mice: the role of nitric oxide pathway.
Topics: Animals; Anticonvulsants; Arginine; Atorvastatin; Heptanoic Acids; Male; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pentylenetetrazole; Pyrroles; Seizures; Signal Transduction | 2013 |
The effect of a high dose of atorvastatin on the occurrence of atrial fibrillation after coronary artery bypass grafting.
Topics: Aged; Atorvastatin; Atrial Fibrillation; Coronary Artery Bypass; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Postoperative Complications; Pyrroles; Retrospective Studies | 2012 |
Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.
Topics: Administration, Oral; Animals; Atorvastatin; Cell Adhesion Molecules; Cytokines; Cytoprotection; Disease Models, Animal; Down-Regulation; Drug Administration Schedule; Enzyme Activation; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intravenous; Liver; Male; Mice; Mice, Obese; NF-kappa B; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Reperfusion Injury; RNA, Messenger; Thromboxane B2; Time Factors; Toll-Like Receptor 4 | 2012 |
Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-pres
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Proportional Hazards Models; Pyrroles | 2012 |
Atorvastatin inhibits the inflammatory response caused by anti-M(3) peptide IgG in patients with primary Sjögren's syndrome.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Autoantibodies; Dinoprostone; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Humans; Immunoglobulin G; In Vitro Techniques; Interleukin-1beta; Male; Matrix Metalloproteinase 3; Middle Aged; Peptide Fragments; Pyrroles; Rats; Receptor, Muscarinic M3; Sjogren's Syndrome; Submandibular Gland | 2012 |
Statin use and the risk of Clostridium difficile in academic medical centres.
Topics: Academic Medical Centers; Adult; Age Distribution; Aged; Aged, 80 and over; Atorvastatin; Case-Control Studies; Clostridioides difficile; Clostridium Infections; Confidence Intervals; Cross Infection; Databases, Factual; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Logistic Models; Male; Middle Aged; Odds Ratio; Pyrroles; Reference Values; Risk Assessment; Sex Distribution; Simvastatin; United States; Young Adult | 2012 |
[Statin-ezetimibe combination in hyperlipidemia treatment].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Simvastatin | 2012 |
Daming capsule restores endothelial dysfunction induced by high-fat diet.
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Atorvastatin; Diet, High-Fat; Drugs, Chinese Herbal; Endothelium, Vascular; Enzyme Inhibitors; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Phytotherapy; Potassium Channels; Pyrroles; Rats; Rats, Wistar; Vascular Diseases; Vasoconstriction; Vasodilation | 2012 |
[Protective effect of atrovastatin against myocardial ischemia-reperfusion injury and on liver and kidney functions in aged rats].
Topics: Aging; Animals; Atorvastatin; Female; Heptanoic Acids; Kidney; Liver; Male; Multiple Organ Failure; Myocardial Ischemia; Myocardial Reperfusion Injury; Pyrroles; Rats; Rats, Wistar | 2012 |
Qualitative plaque stabilization but not quantitative plaque regression.
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2012 |
Reverse vessel remodeling but not coronary plaque regression could predict future cardiovascular events in ACS patients with intensive statin therapy--the extended JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Atorvastatin; Biomarkers; Cerebral Infarction; Cholesterol, HDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Plaque, Atherosclerotic; Predictive Value of Tests; Proportional Hazards Models; Pyrroles; Quinolines; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Improvement of arterial stiffness by reducing oxidative stress damage in elderly hypertensive patients after 6 months of atorvastatin therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Anticholesteremic Agents; Arteries; Atorvastatin; Biomarkers; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Oxidative Stress; Prospective Studies; Pyrroles; Statistics as Topic; Statistics, Nonparametric | 2012 |
Reducing residual risk in secondary prevention of cardiovascular disease.
Topics: Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles | 2012 |
PCSK9 inhibition: the next statin?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases | 2012 |
Effect of solvent type on the nanoparticle formation of atorvastatin calcium by the supercritical antisolvent process.
Topics: Acetone; Atorvastatin; Chemistry, Pharmaceutical; Dimethyl Sulfoxide; Furans; Heptanoic Acids; Nanoparticles; Particle Size; Pyrroles; Pyrrolidinones; Solvents | 2012 |
Anti-inflammatory effects of perioperative statin therapy.
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles | 2012 |
Perioperative statin therapy: understanding the evidence in a Bayesian context.
Topics: Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles | 2012 |
Reversible dysphasia and statins.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Anxiety; Aphasia; Atorvastatin; Cytochrome P-450 Enzyme System; Depression; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Indapamide; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
Periodontal status and hyperlipidemia: statin users versus non-users.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chronic Periodontitis; Cross-Sectional Studies; Dental Plaque Index; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontium; Pyrroles; Single-Blind Method; Triglycerides | 2013 |
The effect of herb-partition moxibustion on Toll-like receptor 4 in rabbit aorta during atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Antigens; Aorta; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Heptanoic Acids; Magnoliopsida; Moxibustion; Plant Preparations; Polymerase Chain Reaction; Pyrroles; Rabbits; Random Allocation; RNA, Messenger; Toll-Like Receptor 4 | 2012 |
If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis?
Topics: Anticholesteremic Agents; Atorvastatin; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Male; Non-alcoholic Fatty Liver Disease; Pyrroles; Tumor Necrosis Factor-alpha | 2012 |
Nitric oxide-donating statins: a new concept to boost the lipid-independent effects.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Atorvastatin; Heptanoic Acids; Nitric Oxide; Pyrroles | 2012 |
Atorvastatin prevents the downregulation of aquaporin-2 receptor after bilateral ureteral obstruction and protects renal function in a rat model.
Topics: Animals; Aquaporin 2; Atorvastatin; Down-Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Pyrroles; Rats; Rats, Wistar; Ureteral Obstruction | 2012 |
Statin therapy prevents expansive remodeling in venous bypass grafts.
Topics: Anastomosis, Surgical; Animals; Atorvastatin; Biomarkers; Carotid Artery, Common; Cell Proliferation; Cholesterol, Dietary; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperplasia; Immunohistochemistry; Jugular Veins; Macrophages; Matrix Metalloproteinase 12; Matrix Metalloproteinase 2; Models, Animal; Neointima; Pyrroles; Rabbits; Time Factors; Ultrasonography; Vascular Grafting | 2012 |
Statins synergize dexamethasone-induced adipocyte fatty acid binding protein expression in macrophages.
Topics: Active Transport, Cell Nucleus; Adipose Tissue; Animals; Atorvastatin; Cell Line; Cholesterol; Dexamethasone; Dose-Response Relationship, Drug; Drug Synergism; Fatty Acid-Binding Proteins; Glucocorticoids; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Male; Mevalonic Acid; Mice; Mice, Inbred C57BL; Promoter Regions, Genetic; Protein Prenylation; Pyrroles; Quinolines; Receptors, Glucocorticoid; Time Factors; Transfection; Up-Regulation | 2012 |
Acute rhabdomyolysis caused by combination therapy with atorvastatin and warfarin.
Topics: Acute Disease; Aged; Anticholesteremic Agents; Anticoagulants; Atorvastatin; Atrial Fibrillation; Drug Interactions; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles; Rhabdomyolysis; Warfarin | 2012 |
Statins and glycaemic control--a cause for concern?
Topics: Atorvastatin; Blood Glucose; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2012 |
Atorvastatin synergizes with IFN-γ in treating human non-small cell lung carcinomas via potent inhibition of RhoA activity.
Topics: Animals; Antineoplastic Agents; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Interferon-gamma; Lung Neoplasms; Mice; Organ Specificity; Pyrroles; rhoA GTP-Binding Protein | 2012 |
Cell killing and radiosensitizing effects of atorvastatin in PC3 prostate cancer cells.
Topics: Atorvastatin; Autophagy; Cell Line, Tumor; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Heptanoic Acids; Humans; Male; Prostatic Neoplasms; Pyrroles; Radiation Tolerance; Radiation-Sensitizing Agents | 2012 |
PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.
Topics: Anticholesteremic Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Data Interpretation, Statistical; Female; Gene Expression Regulation, Enzymologic; Genotype; Hepatocytes; Heptanoic Acids; Humans; Hydroxylation; Liver; Male; Microsomes, Liver; Phenotype; Polymorphism, Single Nucleotide; PPAR alpha; Pyrroles; RNA, Messenger; RNA, Small Interfering | 2012 |
Atorvastatin and pitavastatin enhance lipoprotein lipase production in L6 skeletal muscle cells through activation of adenosine monophosphate-activated protein kinase.
Topics: AMP-Activated Protein Kinases; Animals; Atorvastatin; Cells, Cultured; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Mevalonic Acid; Muscle, Skeletal; Pyrroles; Quinolines; Rats; Real-Time Polymerase Chain Reaction; RNA, Messenger | 2012 |
Lysophosphatidic acid pretreatment prevents micromolar atorvastatin-induced endothelial cell death and ensures the beneficial effects of high-concentration statin therapy on endothelial gene expression.
Topics: Apoptosis; Atorvastatin; Cell Death; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Endothelin-1; Gene Expression Regulation; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lysophospholipids; Nitric Oxide Synthase Type III; Oligonucleotide Array Sequence Analysis; Pyrroles; RNA | 2012 |
Characterization of semi-solid Self-Emulsifying Drug Delivery Systems (SEDDS) of atorvastatin calcium by Raman image spectroscopy and chemometrics.
Topics: Atorvastatin; Combinatorial Chemistry Techniques; Drug Carriers; Drug Compounding; Emulsions; Heptanoic Acids; Hydrophobic and Hydrophilic Interactions; Multivariate Analysis; Phase Transition; Polyethylene Glycols; Pyrroles; Regression Analysis; Solubility; Solvents; Spectrum Analysis, Raman; Surface Properties; Surface-Active Agents | 2013 |
Long-term outcome after statin treatment in routine clinical practice: results from a prospective PCI cohort study.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Cohort Studies; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrroles; Simvastatin; Survival Rate | 2012 |
Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
Topics: Alkynes; Angiogenesis Inhibitors; Animals; Anticholesteremic Agents; Antineoplastic Agents; Atorvastatin; Brain; Carbamates; Cell Line, Tumor; Cell Proliferation; Cricetinae; Cyclohexanes; Drug Screening Assays, Antitumor; Drug Synergism; Endothelial Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intramolecular Transferases; Microsomes, Liver; Neovascularization, Pathologic; Pyrroles; Structure-Activity Relationship | 2012 |
Fate and transport of atorvastatin and simvastatin drugs during conventional wastewater treatment.
Topics: Atorvastatin; Biomass; Biotransformation; Heptanoic Acids; Models, Statistical; Molecular Weight; Pyrroles; Reproducibility of Results; Sewage; Simvastatin; Waste Disposal, Fluid; Water Pollutants, Chemical | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice.
Topics: Animals; Atorvastatin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Epoxide Hydrolases; Heptanoic Acids; Homeodomain Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Ki-67 Antigen; Mice; Pancreas; Pancreatic Neoplasms; Phosphorylation; Prenylation; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Pyrroles; Trans-Activators; Transcriptome; Tumor Suppressor Protein p53 | 2013 |
The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers.
Topics: Adult; Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Female; Genotype; Glucuronosyltransferase; Heptanoic Acids; Humans; Lactones; Lipid Metabolism; Lipids; Male; Neoplasm Proteins; Polymorphism, Genetic; Pyrroles | 2012 |
Atorvastatin up-regulate toxicologically relevant genes in rainbow trout gills.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Gene Expression; Gills; Heptanoic Acids; Liver; Oncorhynchus mykiss; Pyrroles; Sodium-Potassium-Exchanging ATPase; Up-Regulation; Water Pollutants, Chemical | 2012 |
[In addition to atorvastatin. Innovative antibody lowers LDL around 72%].
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Clinical Trials, Phase II as Topic; Coronary Artery Disease; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Serine Endopeptidases | 2012 |
Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin.
Topics: Anti-Bacterial Agents; Atorvastatin; Drug Resistance, Multiple, Bacterial; Fluorobenzenes; Gram-Negative Bacteria; Gram-Positive Bacteria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microbial Sensitivity Tests; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Genetic predisposition to atorvastatin-induced myopathy: a case report.
Topics: Aged; Atorvastatin; Coronary Artery Disease; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Genetic; Pyrroles | 2012 |
Cholesteryl ester transfer protein and ATP-binding cassette transporter A1 genotype alter the atorvastatin and simvastatin efficacy: time for genotype-guided therapy?
Topics: Aged; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Biomarkers; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Female; Gene Frequency; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Patient Selection; Phenotype; Polymorphism, Genetic; Precision Medicine; Pyrroles; Simvastatin; Treatment Outcome | 2013 |
Pfizer Australia faces scrutiny over atorvastatin advertising campaign.
Topics: Advertising; Atorvastatin; Australia; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Marketing of Health Services; Patient Education as Topic; Pyrroles | 2012 |
Effects of atorvastatin on expression of ICAM-1 in atherosclerotic rabbits.
Topics: Animals; Atherosclerosis; Atorvastatin; Disease Models, Animal; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Intercellular Adhesion Molecule-1; Male; Pyrroles; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2013 |
Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atorvastatin; Biomarkers; Blood Pressure; Coronary Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Male; Myocardial Reperfusion Injury; Perfusion; Pyrroles; Rats; Rats, Wistar; Time Factors; Vasodilation; Vasodilator Agents | 2013 |
Protective effects of atorvastatin against oxidized LDL-induced downregulation of KLF expression in EA.hy926 cells.
Topics: Atorvastatin; Cytoprotection; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kruppel-Like Transcription Factors; Lipoproteins, LDL; Pyrroles; Reproducibility of Results; Resting Phase, Cell Cycle | 2012 |
Atorvastatin inhibits myocardin expression in vascular smooth muscle cells.
Topics: Actins; Amides; Animals; Aorta; Atorvastatin; Blotting, Western; Cell Line; Enzyme Inhibitors; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Mevalonic Acid; Mice; Mice, Inbred C57BL; Microfilament Proteins; Muscle Proteins; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nuclear Proteins; Polyisoprenyl Phosphates; Potassium Chloride; Pyridines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; rho-Associated Kinases; rhoA GTP-Binding Protein; Trans-Activators; Vasoconstriction | 2012 |
Single non-ionic surfactant based self-nanoemulsifying drug delivery systems: formulation, characterization, cytotoxicity and permeability enhancement study.
Topics: Anticholesteremic Agents; Atorvastatin; Caco-2 Cells; Chemistry, Pharmaceutical; Drug Delivery Systems; Glycerol; Heptanoic Acids; Humans; Nanoparticles; Particle Size; Permeability; Pyrroles; Solubility; Surface-Active Agents | 2013 |
Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin.
Topics: Aged; Angina, Stable; Atorvastatin; Biomarkers; C-Reactive Protein; Case-Control Studies; Chi-Square Distribution; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Down-Regulation; Female; Fibrosis; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Predictive Value of Tests; Pyrroles; Serum Amyloid P-Component; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Uric Acid | 2012 |
Polymer-directed crystallization of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cellulose; Chitosan; Crystallization; Drug Stability; Heptanoic Acids; Models, Molecular; Polyethylene Glycols; Polymers; Powder Diffraction; Pyrroles; Solubility; X-Ray Diffraction | 2012 |
Anticancer effect of atorvastatin nanostructured polymeric micelles based on stearyl-grafted chitosan.
Topics: Antineoplastic Agents; Atorvastatin; Capsules; Chitosan; Delayed-Action Preparations; Drug Carriers; HCT116 Cells; Heptanoic Acids; Humans; MCF-7 Cells; Micelles; Nanostructures; Particle Size; Polymers; Pyrroles; Stearic Acids | 2012 |
Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance.
Topics: Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactic Acid; Male; Mice; Mice, Inbred C57BL; Mitochondria, Muscle; Muscle Cells; Muscle Strength; Muscle, Skeletal; Organ Size; Oxygen Consumption; Physical Conditioning, Animal; Physical Endurance; Pravastatin; Pyrroles; Ubiquinone | 2012 |
Effects of atorvastatin in the regulation of circulating EPCs and angiogenesis in traumatic brain injury in rats.
Topics: Animals; Atorvastatin; Brain Injuries; Endothelial Cells; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Long-Term Potentiation; Male; Maze Learning; Neovascularization, Pathologic; Pyrroles; Rats; Rats, Wistar; Recovery of Function; Stem Cells | 2012 |
Do animal models of vein graft atherosclerosis predict outcomes in man?
Topics: Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Jugular Veins; Pyrroles; Vascular Grafting | 2012 |
Atorvastatin preserves the integrity of endothelial adherens junctions by inhibiting vascular endothelial cadherin tyrosine phosphorylation.
Topics: Adherens Junctions; Atorvastatin; Cadherins; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Humans; Interleukin-1beta; Lipopolysaccharides; Myosin Light Chains; Phosphorylation; Pyrroles; Structure-Activity Relationship; Tumor Necrosis Factor-alpha; Tyrosine | 2012 |
Effectiveness of lipid-lowering therapy with statins for secondary prevention of atherosclerosis--guidelines vs. reality.
Topics: Atherosclerosis; Atorvastatin; Cholesterol, LDL; Decision Making; Diet, Fat-Restricted; Diet, Reducing; Dose-Response Relationship, Drug; Female; Health Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Middle Aged; Patient Compliance; Poland; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Rural Population; Secondary Prevention; Simvastatin; Urban Population | 2012 |
Combination therapy of atorvastatin and amlodipine inhibits sympathetic nervous system activation and improves cognitive function in hypertensive rats.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Antioxidants; Atorvastatin; Cognition; Drug Therapy, Combination; Heptanoic Acids; Hippocampus; Hypertension; Male; Nerve Tissue Proteins; Pyrroles; Rats; Rats, Inbred SHR; Superoxide Dismutase; Sympathetic Nervous System | 2012 |
Immunomodulatory synergy by combining atorvastatin and rapamycin in the treatment of experimental autoimmune encephalomyelitis (EAE).
Topics: Animals; Atorvastatin; Blotting, Western; Cytokines; Drug Synergism; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Enzyme-Linked Immunosorbent Assay; Extracellular Signal-Regulated MAP Kinases; Female; Flow Cytometry; Heptanoic Acids; Immunologic Factors; Mice; Mice, Inbred C57BL; Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Sirolimus; Spinal Cord; T-Lymphocytes | 2012 |
Buerger's disease (Thromboangiitis obliterans): a diagnostic challenge.
Topics: Adult; Angiography; Aspirin; Atorvastatin; Calcium Channel Blockers; Drug Therapy, Combination; Heparin, Low-Molecular-Weight; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iloprost; Male; Nifedipine; Pentoxifylline; Platelet Aggregation Inhibitors; Pyrroles; Smoking Cessation; Thromboangiitis Obliterans | 2011 |
Acute atorvastatin treatment exerts antidepressant-like effect in mice via the L-arginine-nitric oxide-cyclic guanosine monophosphate pathway and increases BDNF levels.
Topics: Animals; Antidepressive Agents; Arginine; Atorvastatin; Brain-Derived Neurotrophic Factor; Cyclic GMP; Depression; Heptanoic Acids; Male; Mice; Nitric Oxide; Pyrroles; Signal Transduction | 2013 |
A rare case of a coronary vascular ring arising from an anomalous single coronary artery.
Topics: Aged; Aspirin; Atorvastatin; Coronary Angiography; Coronary Vessel Anomalies; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Pyrroles; Rare Diseases; Risk Assessment; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Novel approach to reduce postsurgical adhesions to a minimum: administration of losartan plus atorvastatin intraperitoneally.
Topics: Angiotensin Receptor Antagonists; Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intraperitoneal; Losartan; Male; Mice; Plasminogen Activator Inhibitor 1; Postoperative Complications; Pyrroles; RNA, Messenger; Tissue Adhesions; Tissue Plasminogen Activator; Transforming Growth Factor beta1 | 2013 |
Atorvastatin improves sodium handling and decreases blood pressure in salt-loaded rats with chronic renal insufficiency.
Topics: Animals; Atorvastatin; Blood Pressure; Creatinine; Diet; Fatty Acids, Unsaturated; Heart Ventricles; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney; Male; Nephrectomy; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Proteinuria; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Sodium; Sodium Chloride, Dietary | 2012 |
Synergistic inhibition of interleukin-6 production in adipose stem cells by tart cherry anthocyanins and atorvastatin.
Topics: Adipose Tissue; Anthocyanins; Anti-Inflammatory Agents; Atorvastatin; Cells, Cultured; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Fruit; Glucosides; Heptanoic Acids; Herb-Drug Interactions; Humans; Inflammation; Interleukin-6; Lipopolysaccharides; Phytotherapy; Plant Extracts; Prunus; Pyrroles; Stem Cells | 2012 |
Atorvastatin enhances neurite outgrowth in cortical neurons in vitro via up-regulating the Akt/mTOR and Akt/GSK-3β signaling pathways.
Topics: Animals; Atorvastatin; Cells, Cultured; Cerebral Cortex; Enzyme Activation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neurites; Neurons; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
The effects of atorvastatin therapy on rheological characteristics of erythrocyte membrane, serum lipid profile and oxidative status in patients with dyslipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Dyslipidemias; Erythrocyte Membrane; Female; Heptanoic Acids; Humans; Lipid Peroxidation; Lipids; Male; Membrane Fluidity; Middle Aged; Oxidation-Reduction; Pyrroles; Sodium-Potassium-Exchanging ATPase | 2012 |
Capsular warning syndrome caused by spontaneous middle cerebral artery dissection.
Topics: Angiography, Digital Subtraction; Aspirin; Atorvastatin; Brain Ischemia; Cerebral Angiography; Diffusion Magnetic Resonance Imaging; Echocardiography; Electrocardiography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Male; Middle Aged; Middle Cerebral Artery; Platelet Aggregation Inhibitors; Pyrroles; Smoking | 2012 |
Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cholesterol; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Metabolism; Liver Neoplasms; Lovastatin; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tumor Suppressor Protein p53 | 2012 |
Lipitor goes generic: business as usual or more big business?
Topics: Anticholesteremic Agents; Atorvastatin; Drug Industry; Drugs, Generic; Heptanoic Acids; Humans; Insurance Coverage; Medicare Part D; Prescription Fees; Pyrroles; United States | 2012 |
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Heptanoic Acids; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Losartan; Male; Obesity; Pioglitazone; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2013 |
Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model.
Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Computer Simulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides | 2012 |
Deleterious effects of high concentrations of (-)-epigallocatechin-3-gallate and atorvastatin in mice with colon inflammation.
Topics: Animals; Atorvastatin; Azoxymethane; Catechin; Colitis; Colon; Colonic Neoplasms; Dextran Sulfate; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gastrointestinal Hemorrhage; Heptanoic Acids; Leukotriene B4; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Pyrroles; Rectum; Weight Loss | 2012 |
Polymorphisms in the mitochondrial ribosome recycling factor EF-G2mt/MEF2 compromise cell respiratory function and increase atorvastatin toxicity.
Topics: Atorvastatin; Cell Death; Cell Line; Cell Respiration; Gene Expression Regulation; Heptanoic Acids; Humans; Mitochondria; Peptide Elongation Factor G; Peptide Elongation Factors; Polymorphism, Single Nucleotide; Pyrroles; Ribosomes; RNA, Small Interfering; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins | 2012 |
Effect of phosphatidylinositol 3-kinase-γ inhibitor CAY10505 in hypertension, and its associated vascular endothelium dysfunction in rats.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Atorvastatin; Blood Pressure; Desoxycorticosterone; Endothelium, Vascular; Female; Glutathione; Heptanoic Acids; Hypertension; Losartan; Male; Nitrates; Nitrites; Phosphoinositide-3 Kinase Inhibitors; Pyrroles; Rats; Rats, Wistar; Thiazolidinediones | 2012 |
Atorvastatin and pitavastatin reduce senile plaques and inflammatory responses in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Atorvastatin; Brain; Disease Models, Animal; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Inflammation; Mice; Mice, Transgenic; Plaque, Amyloid; Pyrroles; Quinolines | 2012 |
Brain targeting of Atorvastatin loaded amphiphilic PLGA-b-PEG nanoparticles.
Topics: Atorvastatin; Brain; Fluorescent Dyes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nanoparticles; Particle Size; Polyethylene Glycols; Polyglactin 910; Pyrroles; Spectroscopy, Fourier Transform Infrared | 2013 |
Invited commentary.
Topics: Atorvastatin; Atrial Fibrillation; Coronary Artery Bypass; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Postoperative Complications; Pyrroles | 2012 |
Discontinuation of statin therapy due to muscular side effects: a survey in real life.
Topics: Adult; Aged; Atorvastatin; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Motor Activity; Muscle Cramp; Muscle Weakness; Muscle, Skeletal; Musculoskeletal Diseases; Pain; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2013 |
Atorvastatin-related thrombocytopenic purpura.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Purpura, Thrombocytopenic; Pyrroles | 2010 |
Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Netherlands; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Highly upregulated expression of CD36 and MSR1 in circulating monocytes of patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Case-Control Studies; CD36 Antigens; Female; Gene Expression; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Middle Aged; Monocytes; Pyrroles; Real-Time Polymerase Chain Reaction; RNA, Messenger; Scavenger Receptors, Class A; Statistics, Nonparametric; Up-Regulation | 2012 |
What price atorvastatin?
Topics: Anticholesteremic Agents; Atorvastatin; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Pyrroles; Risk Factors | 2012 |
The molecular mechanism of the anticancer effect of atorvastatin: DNA microarray and bioinformatic analyses.
Topics: Antineoplastic Agents; Atorvastatin; Cell Cycle; Cell Line; Computational Biology; Endothelial Cells; Gene Expression Profiling; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kruppel-Like Transcription Factors; Neoplasms; Oligonucleotide Array Sequence Analysis; Pyrroles | 2012 |
The top prescription drugs of 2009 in the US: CNS therapeutics rank among highest grossing.
Topics: Analgesics, Opioid; Antipsychotic Agents; Atorvastatin; Drug Industry; Drug Prescriptions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neurotransmitter Uptake Inhibitors; Oxycodone; Prescription Drugs; Pyrroles; United States | 2010 |
Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.
Topics: Amphetamine; Analysis of Variance; Animals; Atorvastatin; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Glutathione; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Malondialdehyde; Mitochondria; Motor Activity; NADH Dehydrogenase; Nitrites; Oxidopamine; Parkinsonian Disorders; Pyrroles; Rats; Rats, Wistar; Simvastatin; Tetrazolium Salts; Thiazoles; Tumor Necrosis Factor-alpha | 2012 |
Statins have therapeutic potential for the treatment of Alzheimer's disease, likely via protection of the neurovascular unit in the AD brain.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Collagen Type IV; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glial Fibrillary Acidic Protein; Glucosamine; Heptanoic Acids; Humans; Matrix Metalloproteinase 9; Maze Learning; Methylcellulose; Mice; Mice, Transgenic; Mutation; Pyrroles; Quinolines | 2012 |
Bilateral posterior cerebral artery infarction.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Confusion; Dominance, Cerebral; Drug Therapy, Combination; Fibrinolytic Agents; Hemianopsia; Heptanoic Acids; Humans; Infarction, Posterior Cerebral Artery; Magnetic Resonance Imaging; Male; Memory Disorders; Memory, Short-Term; Perindopril; Pyrroles; Tomography, X-Ray Computed | 2010 |
[Painless myocardial ischemia in patient with extensive constrictive atherosclerosis of coronary arteries].
Topics: Angioplasty; Anticholesteremic Agents; Asymptomatic Diseases; Atorvastatin; Cardiovascular Agents; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Echocardiography; Electrophysiologic Techniques, Cardiac; Exercise Test; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Severity of Illness Index; Treatment Outcome | 2012 |
Tendinous xanthoma.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Angiography; Coronary Stenosis; Echocardiography; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Pyrroles; Stents; Tendons; Treatment Outcome; Xanthomatosis | 2012 |
Ambivalent effects of atorvastatin on angiogenesis, epidermal cell proliferation and tumorgenesis in animal models.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Atorvastatin; Cell Proliferation; Croton Oil; Epidermal Cells; Epidermis; Female; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mevalonic Acid; Mice; Neovascularization, Pathologic; Pyrroles; Rats; Rats, Wistar; Skin Neoplasms | 2012 |
Genetic variation in MDR1, LPL and eNOS genes and the response to atorvastatin treatment in ischemic stroke.
Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Case-Control Studies; Female; Follow-Up Studies; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Ischemia; Lipoprotein Lipase; Male; Middle Aged; Minisatellite Repeats; Nitric Oxide Synthase Type III; Polymorphism, Genetic; Prognosis; Pyrroles; Risk Factors; Stroke | 2012 |
Atorvastatin and simvastatin, but not pravastatin, up-regulate LPS-induced MMP-9 expression in macrophages by regulating phosphorylation of ERK and CREB.
Topics: Animals; Atorvastatin; Calcium; Cell Line; Cyclic AMP Response Element-Binding Protein; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Macrophages; Matrix Metalloproteinase 9; Mice; Microglia; Phosphorylation; Polyisoprenyl Phosphates; Pravastatin; Pyrroles; Signal Transduction; Simvastatin; Up-Regulation | 2012 |
Statins affect the presentation of endothelial chemokines by targeting to multivesicular bodies.
Topics: Atorvastatin; Cell Compartmentation; Chemokine CXCL1; Chemokines; E-Selectin; Endocytosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukin-1beta; Intracellular Space; Multivesicular Bodies; Pravastatin; Prenylation; Pyrroles; Simvastatin; Solubility; Subcellular Fractions; Tetraspanin 30 | 2012 |
Enhancing organ pool by statins: is this the future?
Topics: Animals; Atorvastatin; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Reperfusion Injury; Toll-Like Receptor 4 | 2012 |
Disproportionation of the calcium salt of atorvastatin in the presence of acidic excipients.
Topics: Acids; Acrylic Resins; Atorvastatin; Calcium; Calibration; Chemistry, Pharmaceutical; Citric Acid; Excipients; Heptanoic Acids; Humidity; Hydrogen-Ion Concentration; Powders; Pyrroles; Solutions; Temperature | 2012 |
Current statin usage for patients with acute coronary syndrome undergoing percutaneous coronary intervention: multicenter survey in Korea.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Chi-Square Distribution; Drug Utilization; Drug Utilization Review; Evidence-Based Medicine; Female; Fluorobenzenes; Guideline Adherence; Health Care Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prospective Studies; Pyrimidines; Pyrroles; Registries; Republic of Korea; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2012 |
Clinical equivalence of proprietary and generic atorvastatin in lipid clinic patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Canada; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Drugs, Generic; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Therapeutic Equivalency; Treatment Outcome; Triglycerides | 2013 |
Spectroscopic characterization and quantitative determination of atorvastatin calcium impurities by novel HPLC method.
Topics: Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Magnetic Resonance Spectroscopy; Pyrroles; Reproducibility of Results; Solutions; Spectrophotometry, Infrared | 2012 |
Effect of raloxifene and atorvastatin in atherosclerotic process in ovariectomized rats.
Topics: Animals; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Chemokine CCL2; Endothelium, Vascular; Estrogen Antagonists; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Ovariectomy; Pyrroles; Raloxifene Hydrochloride; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2013 |
Efficacy of combined atorvastatin and sildenafil in promoting recovery after ischemic stroke in mice.
Topics: Animals; Atorvastatin; Behavior, Animal; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Neuropsychological Tests; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrroles; Recovery of Function; Sildenafil Citrate; Stroke; Sulfones | 2013 |
Regulation of PUMA induced by mechanical stress in rat cardiomyocytes.
Topics: Animals; Aorta; Apoptosis; Apoptosis Regulatory Proteins; Atorvastatin; Blood Volume; Cells, Cultured; Gene Expression Regulation; Heptanoic Acids; Male; Myocytes, Cardiac; Pyrroles; Rats; Rats, Wistar; RNA, Messenger; Signal Transduction; Stress, Mechanical | 2012 |
Development and validation of stability-indicating assay method by UPLC for a fixed dose combination of atorvastatin and ezetimibe.
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Chromatography, High Pressure Liquid; Drug Combinations; Drug Stability; Ezetimibe; Heptanoic Acids; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Tablets | 2013 |
Atorvastatin accelerates both neointimal coverage and re-endothelialization after sirolimus-eluting stent implantation in a porcine model: new findings from optical coherence tomography and pathology.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Drug-Eluting Stents; Endothelium, Vascular; Heptanoic Acids; Microscopy, Electron, Scanning; Neointima; Platelet Adhesiveness; Pyrroles; Stem Cells; Swine; Tomography, Optical Coherence | 2012 |
CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin.
Topics: Aged; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; China; Cholesterol 7-alpha-Hydroxylase; Cholesterol, LDL; Cytochrome P-450 CYP3A; Female; Genetic Variation; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles | 2012 |
Combined effect of atorvastatin and probucol on plasma cystatin C levels and severity of coronary lesion in patients with borderline coronary lesion.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Coronary Disease; Cystatin C; Female; Heptanoic Acids; Humans; Male; Middle Aged; Probucol; Prospective Studies; Pyrroles | 2012 |
Atorvastatin and whisker stimulation synergistically enhance angiogenesis in the barrel cortex of rats following focal ischemia.
Topics: Animals; Atorvastatin; Brain Ischemia; Brain-Derived Neurotrophic Factor; Fluorescent Antibody Technique; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microvessels; Neovascularization, Physiologic; Pyrroles; Rats; Rats, Sprague-Dawley; Somatosensory Cortex; Vascular Endothelial Growth Factor A; Vibrissae | 2012 |
[Roles of periostin in proliferation and migration of vascular smooth muscle cells and the effect of atorvastatin on them].
Topics: Animals; Atorvastatin; Cell Adhesion Molecules; Cell Movement; Cell Proliferation; Heptanoic Acids; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Primary Cell Culture; Pyrroles; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; RNA, Messenger; Signal Transduction; Transforming Growth Factor beta1 | 2012 |
Atorvastatin prevents dehydromonocrotaline-induced pulmonary hypertension in beagles.
Topics: Alkylating Agents; Animals; Atorvastatin; Cell Proliferation; Cytokines; Dogs; Endothelium, Vascular; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Lung; Male; Monocrotaline; Muscle, Smooth, Vascular; Nitric Oxide Synthase Type III; Pyrroles | 2012 |
Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats.
Topics: Actins; Aging; Animals; Apoptosis; Atorvastatin; beta-Galactosidase; Cell Proliferation; Collagen; Connective Tissue Growth Factor; Desmin; Dose-Response Relationship, Drug; Flow Cytometry; Hepatic Stellate Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Male; Myofibroblasts; Pyrroles; Rats; Rats, Sprague-Dawley; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta1 | 2012 |
Atorvastatin suppresses oxidized LDL-induced dendritic cell-like differentiation of RAW264.7 cells regulated by the p38 MAPK pathway.
Topics: Animals; Antigens, CD1d; Atorvastatin; B7-2 Antigen; Cell Differentiation; Cell Proliferation; Dendritic Cells; Down-Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Macrophages; Mice; p38 Mitogen-Activated Protein Kinases; Pyrroles; Signal Transduction; Time Factors | 2012 |
Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin.
Topics: Animals; Apolipoproteins B; Atorvastatin; Disease Progression; Fluorodeoxyglucose F18; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Liver X Receptors; Macrophages; Multimodal Imaging; Orphan Nuclear Receptors; Plaque, Atherosclerotic; Positron-Emission Tomography; Pyrroles; Rabbits; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Atorvastatin; Cells, Cultured; Coculture Techniques; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Male; Osteoclasts; Osteogenesis; Pyrroles; RANK Ligand; Synovial Membrane | 2012 |
Mitochondria of trained skeletal muscle are protected from deleterious effects of statins.
Topics: Animals; Atorvastatin; Heptanoic Acids; Hydrogen Peroxide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitochondria, Muscle; Muscle, Skeletal; Oxygen Consumption; Physical Conditioning, Animal; Physical Endurance; Pyrroles; Rats; Rats, Wistar; Reactive Oxygen Species | 2012 |
The involvement of nitric oxide in the anti-seizure effect of acute atorvastatin treatment in mice.
Topics: Animals; Anticonvulsants; Atorvastatin; Brain; Convulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Electroshock; Enzyme Inhibitors; Epilepsy, Tonic-Clonic; Guanidines; Heptanoic Acids; Male; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pentylenetetrazole; Pyrroles | 2012 |
The evaluation of analgesic effects of simvastatin, pravastatin and atorvastatin in hot plate test.
Topics: Analgesics; Animals; Atorvastatin; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred BALB C; Naloxone; NG-Nitroarginine Methyl Ester; Pravastatin; Pyrroles; Simvastatin | 2012 |
Evaluation of ultrasmall superparamagnetic iron oxide-enhanced MRI of carotid atherosclerosis to assess risk of cerebrovascular and cardiovascular events: follow-up of the ATHEROMA trial.
Topics: Aged; Atorvastatin; Carotid Artery Diseases; Contrast Media; Dextrans; Diabetes Complications; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Macrophage Activation; Macrophages; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Middle Aged; Multicenter Studies as Topic; Proportional Hazards Models; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Stroke | 2012 |
Statin-induced rhabdomyolysis and dermatomyositis: a rare combination.
Topics: Atorvastatin; Comorbidity; Dermatomyositis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Rhabdomyolysis | 2012 |
Evaluation of transporter-mediated hepatic uptake in a non-radioactive high-throughput assay: a study of kinetics, species difference and plasma protein effect.
Topics: Animals; Atorvastatin; Biological Assay; Biological Transport; Blood Proteins; Cells, Cultured; Cryopreservation; Estrone; Female; Hepatocytes; Heptanoic Acids; High-Throughput Screening Assays; Humans; Kinetics; Liver; Male; Metformin; Organic Anion Transporters; Pravastatin; Pyrroles; Radioactivity; Reproducibility of Results; Species Specificity; Time Factors | 2013 |
A low-dose atorvastatin and losartan combination directly improves aortic ring relaxation and diminishes ischaemic-reperfusion injury in isolated rat hearts.
Topics: Analysis of Variance; Animals; Aorta; Atorvastatin; Coronary Vessels; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heptanoic Acids; Losartan; Male; Muscle Relaxation; Pyrroles; Rats; Rats, Wistar; Regional Blood Flow; Reperfusion Injury; Treatment Outcome | 2012 |
Drug-drug interaction study to assess the effects of atorvastatin co-administration on pharmacokinetics and anti-thrombotic properties of cilostazol in male Wistar rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bleeding Time; Carotid Arteries; Cilostazol; Drug Interactions; Fibrinolytic Agents; Heptanoic Acids; Intestinal Absorption; Male; Microsomes, Liver; Platelet Aggregation; Pyrroles; Rats; Rats, Wistar; Tetrazoles | 2012 |
A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Topics: Atorvastatin; Databases, Factual; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Pravastatin; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tendons; United States; United States Food and Drug Administration | 2012 |
Relationship between atorvastatin dose and the harm caused by torcetrapib.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular System; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Quinolines | 2012 |
Chemopreventive efficacy of Atorvastatin against nitrosamine-induced rat bladder cancer: antioxidant, anti-proliferative and anti-inflammatory properties.
Topics: Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Antioxidants; Atorvastatin; Biomarkers, Tumor; Butylhydroxybutylnitrosamine; Cell Proliferation; Drug Evaluation, Preclinical; Heptanoic Acids; Male; Oxidative Stress; Pyrroles; Rats, Wistar; Urinary Bladder; Urinary Bladder Neoplasms | 2012 |
[Atorvastatin inhibits the H₂O₂-induced apoptosis of human vascular endothelial cells through a down-regulation of cleaved caspase-9/caspase-3].
Topics: Apoptosis; Atorvastatin; Caspase 3; Caspase 9; Cells, Cultured; Down-Regulation; Endothelial Cells; Heptanoic Acids; Humans; Hydrogen Peroxide; Pyrroles | 2012 |
[Effects of atorvastatin and CoQ(10) on myocardial energy metabolism in rabbits with hypercholesterolemia].
Topics: Animals; Atorvastatin; Energy Metabolism; Heptanoic Acids; Hypercholesterolemia; Male; Mitochondria, Heart; Myocardium; Pyrroles; Rabbits; Ubiquinone | 2012 |
Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drugs, Generic; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Markov Chains; Middle Aged; Primary Prevention; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Spain; Sulfonamides | 2012 |
Effects of acute and chronic atorvastatin on cardioprotection of ischemic postconditioning in isolated rat hearts.
Topics: Animals; Atorvastatin; Cardiotonic Agents; Drug Administration Schedule; Hemodynamics; Heptanoic Acids; In Vitro Techniques; Ischemic Postconditioning; Male; Myocardial Contraction; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Wistar; Signal Transduction; Time Factors | 2013 |
Sudden bilateral anterior cerebral infarction: unusual stroke associated with unusual vascular anomalies.
Topics: Adult; Aspirin; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Internal; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Anterior Cerebral Artery; Magnetic Resonance Angiography; Male; Platelet Aggregation Inhibitors; Pyrroles; Stroke | 2013 |
Restoration of dietary-fat induced blood-brain barrier dysfunction by anti-inflammatory lipid-modulating agents.
Topics: Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apolipoproteins B; Atorvastatin; Blood-Brain Barrier; Brain; Diet, High-Fat; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Ibuprofen; Immunoglobulin G; Mice; Mice, Inbred C57BL; Pravastatin; Pyrroles | 2012 |
Reduced CD26 expression is associated with improved cardiac function after acute myocardial infarction: insights from the REPERATOR study.
Topics: Adult; Aged; Atorvastatin; Cell Movement; Chemokine CXCL12; Dipeptidyl Peptidase 4; Female; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes, Mononuclear; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Myocardium; Pyrroles | 2012 |
Steroid hormones specifically modify the activity of organic anion transporting polypeptides.
Topics: Atorvastatin; Biological Transport; Cell Line; Dehydroepiandrosterone Sulfate; Dexamethasone; Estrone; Glucocorticoids; Glyburide; HEK293 Cells; Heptanoic Acids; Hormones; Humans; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Progesterone; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Steroids | 2012 |
Atorvastatin preconditioning improves the forward blood flow in the no-reflow rats.
Topics: Animals; Atorvastatin; Echocardiography; Fibrinogen; Fibrosis; Hemodynamics; Heptanoic Acids; Inflammation; Male; Microcirculation; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Pyrroles; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Tumor Necrosis Factor-alpha | 2014 |
A novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) splice variant with an alternative exon 1 potentially encoding an extended N-terminus.
Topics: Alternative Splicing; Anticholesteremic Agents; Atorvastatin; Cervix Uteri; Computational Biology; Esophagus; Exons; Female; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Open Reading Frames; Promoter Regions, Genetic; Pyrroles; RNA, Messenger; Skin; Up-Regulation | 2012 |
Effects of statins on oxidative stress and primed polymorphonuclear leukocytes in hyperlipidemic patients.
Topics: Adult; Apoptosis; Atorvastatin; Biomarkers; CD11b Antigen; Cells, Cultured; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Leukocyte Count; Male; Neutrophils; Oxidative Stress; Phorbol Esters; Pyrroles; Superoxides | 2012 |
The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins.
Topics: Animals; Atorvastatin; Cell Communication; Disease Models, Animal; Endothelial Cells; Gene Expression; Hepatic Stellate Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Portal; Kruppel-Like Transcription Factors; Liver; Liver Circulation; Liver Cirrhosis, Experimental; Lovastatin; Male; Paracrine Communication; Pyrroles; Rats; Rats, Wistar; Simvastatin; Stress, Mechanical | 2013 |
[Specific features of hypolipidemic therapy in patients with abdominal ischemic disease].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Cholagogues and Choleretics; Drug Therapy, Combination; Fatty Liver; Female; Heptanoic Acids; Humans; Ischemia; Male; Middle Aged; Pyrroles; Ursodeoxycholic Acid; Young Adult | 2012 |
Atorvastatin delays murine platelet activation in vivo even in the absence of endothelial NO synthase.
Topics: Administration, Oral; Animals; Atorvastatin; Blood Platelets; Cyclic GMP; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Membrane Glycoprotein IIb; Pyrroles; Receptors, Thrombin; Signal Transduction; Thrombin; Time Factors | 2012 |
Atorvastatin increases oxidative stress and modulates angiogenesis in Ossabaw swine with the metabolic syndrome.
Topics: Angiogenesis Inducing Agents; Angiogenic Proteins; Animals; Atorvastatin; Biomarkers; Collateral Circulation; Coronary Circulation; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Metabolic Syndrome; Microvessels; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardium; Neovascularization, Physiologic; Oxidative Stress; Pyrroles; Signal Transduction; Swine; Swine, Miniature; Vasodilation; Vasodilator Agents | 2012 |
[Dynamics of microrheologic properties of erythrocytes in patients with arterial hypertension and dyslipidemia treated with atorvastatin].
Topics: Anticholesteremic Agents; Atorvastatin; Comorbidity; Dyslipidemias; Erythrocytes; Heptanoic Acids; Humans; Hypertension; Middle Aged; Pyrroles; Rheology; Severity of Illness Index | 2012 |
FOXO1 impairs whereas statin protects endothelial function in diabetes through reciprocal regulation of Kruppel-like factor 2.
Topics: Animals; Atorvastatin; Base Sequence; Binding Sites; Blood Glucose; Cells, Cultured; Chromatin Immunoprecipitation; Cytoprotection; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kruppel-Like Transcription Factors; Male; Mevalonic Acid; Molecular Sequence Data; Nerve Tissue Proteins; Nitric Oxide Synthase Type III; Phosphorylation; Promoter Regions, Genetic; Pyrroles; Rats; Rats, Inbred OLETF; RNA Interference; Time Factors; Transfection; Vasodilation; Vasodilator Agents | 2013 |
Statins reduce new-onset atrial fibrillation in a first-time myocardial infarction population: a nationwide propensity score-matched study.
Topics: Age Factors; Aged; Aged, 80 and over; Atorvastatin; Atrial Fibrillation; Chi-Square Distribution; Comorbidity; Denmark; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Myocardial Infarction; Polypharmacy; Pravastatin; Propensity Score; Proportional Hazards Models; Pyrroles; Registries; Retrospective Studies; Risk Factors; Sex Factors; Simvastatin; Time Factors; Treatment Outcome | 2014 |
Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Iceland; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reimbursement Mechanisms; Rosuvastatin Calcium; Simvastatin; Social Security; Sulfonamides; Treatment Outcome | 2012 |
Adipokines: a novel link between adiposity and carotid plaque vulnerability.
Topics: Adiposity; Aged; Anticholesteremic Agents; Apelin; Atorvastatin; Body Mass Index; Cholesterol, LDL; Cytokines; Female; Heptanoic Acids; Humans; Image Interpretation, Computer-Assisted; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Obesity; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Pyrroles; Risk Factors; Ultrasonography, Doppler, Color | 2012 |
Nitric oxide prevents atorvastatin-induced skeletal muscle dysfunction and alterations in mice.
Topics: Animals; Atorvastatin; Atrophy; Citrate (si)-Synthase; Creatine Kinase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; L-Lactate Dehydrogenase; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Myosin Heavy Chains; Nitric Oxide; Nitric Oxide Donors; Pyrroles | 2013 |
Effect of multidose cilostazol on pharmacokinetic and lipid profile of atorvastatin in male Wistar rats.
Topics: Animals; Atorvastatin; Cholesterol; Cholesterol, LDL; Chromatography, High Pressure Liquid; Cilostazol; Drug Interactions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Microsomes, Liver; Pyrroles; Rats; Rats, Wistar; Tandem Mass Spectrometry; Tetrazoles; Triglycerides; Vasodilator Agents | 2012 |
Statins: is it safe and effective to use generic "equivalents"?
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Drugs, Generic; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles | 2013 |
Atorvastatin does not impair endothelial cell wound healing in an in vitro model of vascular injury.
Topics: Atorvastatin; Cell Line; Cell Movement; Cell Proliferation; Cell Survival; Cytokines; Fibronectins; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Percutaneous Coronary Intervention; Pyrroles; Vascular System Injuries; Wound Healing | 2012 |
Effect of atorvastatin on IgA nephropathy in the rat.
Topics: Animals; Atorvastatin; Creatinine; Fluorescent Antibody Technique; Glomerulonephritis, IGA; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Pyrroles; Rats; Rats, Inbred WKY | 2013 |
Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Kidney Injury; Aged; Aryl Hydrocarbon Hydroxylases; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Pantoprazole; Polymorphism, Single Nucleotide; Proton Pump Inhibitors; Pyrroles; Renal Dialysis; Rhabdomyolysis; Risk Factors; Treatment Outcome | 2012 |
Characterization of nanochannel delivery membrane systems for the sustained release of resveratrol and atorvastatin: new perspectives on promoting heart health.
Topics: Anticholesteremic Agents; Atorvastatin; Cell Line; Cell Survival; Diffusion; Drug Delivery Systems; Drug Implants; Equipment Design; Heptanoic Acids; Humans; Membranes, Artificial; Nanostructures; Pyrroles; Resveratrol; Stilbenes; Vasodilator Agents | 2013 |
Neuroprotective effect of atorvastatin involves suppression of TNF-α and upregulation of IL-10 in a rat model of intracerebral hemorrhage.
Topics: Animals; Atorvastatin; Behavior, Animal; Brain Edema; Cerebral Hemorrhage; Disease Models, Animal; Heptanoic Acids; Interleukin-10; Male; Microglia; Neuroprotective Agents; Pyrroles; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; Up-Regulation | 2013 |
Treatment with low-dose atorvastatin, losartan, and their combination increases expression of vasoactive-related genes in rat aortas.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atorvastatin; Drug Therapy, Combination; Female; Gene Expression Regulation; Heptanoic Acids; Losartan; Male; Organ Culture Techniques; Pyrroles; Random Allocation; Rats; Rats, Wistar; Treatment Outcome; Vasodilation | 2013 |
Atorvastatin sensitises vascular smooth muscle cells, but not endothelial cells, to TNF-α-induced cell death.
Topics: Atorvastatin; Cell Death; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Activators; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; JNK Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; NF-kappa B; Protein Kinase C; Protein Kinase C beta; Protein Kinase Inhibitors; Pyrroles; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Necrosis Factor-alpha | 2012 |
Prooxidative toxicity and selenoprotein suppression by cerivastatin in muscle cells.
Topics: Animals; Atorvastatin; Cell Line; Cell Survival; Gene Expression Regulation; Heptanoic Acids; Hydrogen Peroxide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Mice; Myoblasts; Oxidative Stress; Pyridines; Pyrroles; Rats; Selenium; Selenoproteins | 2012 |
Statin pleiotropy in acute myocardial infarction--is it about timing?
Topics: Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrroles | 2012 |
Impact of variants within seven candidate genes on statin treatment efficacy.
Topics: Aged; Alleles; Anticholesteremic Agents; Apolipoproteins E; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Genetic Variation; Genome, Human; Genotype; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Treatment Outcome | 2012 |
Vasa vasorum and plaque progression, and responses to atorvastatin in a rabbit model of atherosclerosis: contrast-enhanced ultrasound imaging and intravascular ultrasound study.
Topics: Animals; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Common; Cell Proliferation; Contrast Media; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Enhancement; Male; Plaque, Atherosclerotic; Pyrroles; Rabbits; Ultrasonography, Interventional; Vasa Vasorum | 2013 |
[Rhabdomyolysis following the coprescription of atorvastatin and fusidic acid].
Topics: Aged; Anti-Bacterial Agents; Atorvastatin; Creatine Kinase; Fusidic Acid; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscle Weakness; Prosthesis-Related Infections; Pyrroles; Rhabdomyolysis; Staphylococcal Infections | 2013 |
Atorvastatin decreases Toll-like receptor 4 expression and downstream signaling in human monocytic leukemia cells.
Topics: Atorvastatin; Blotting, Western; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation, Leukemic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Interleukin-6; Leukemia; Lipopolysaccharides; Monocytes; NF-kappa B; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2012 |
Comparison of cardioprotective efficacy resulting from a combination of atorvastatin and ischaemic post-conditioning in diabetic and non-diabetic rats.
Topics: Animals; Atorvastatin; Cardiotonic Agents; Diabetes Mellitus, Experimental; Heart; Hemodynamics; Heptanoic Acids; Ischemic Postconditioning; Male; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Wistar; Signal Transduction | 2012 |
Who benefits from statins? Patient or focal plaque?
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Pyrroles; Quinolines | 2012 |
The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members.
Topics: Administration, Oral; Atorvastatin; Biological Transport; Diabetes Mellitus, Type 2; Drug Interactions; HEK293 Cells; Heptanoic Acids; Humans; Hypoglycemic Agents; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfobromophthalein | 2013 |
Atorvastatin stimulates neuroblastoma cells to induce neurite outgrowth by increasing cellular prion protein expression.
Topics: Animals; Atorvastatin; Cell Line, Tumor; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Neurites; Neuroblastoma; Prions; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
Preparation of candesartan and atorvastatin nanoparticles by solvent evaporation.
Topics: Acetone; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Carboxymethylcellulose Sodium; Desiccation; Dextrans; Excipients; Heptanoic Acids; Methylene Chloride; Nanospheres; Particle Size; Polyethylene Glycols; Polysorbates; Pyrroles; Sodium Dodecyl Sulfate; Solubility; Solvents; Surface-Active Agents; Tetrazoles | 2012 |
A novel matrix for the short-term storage of cells: utility in drug metabolism and drug transporter studies with rat, dog and human hepatocytes.
Topics: Animals; Atorvastatin; Biological Transport; Cell Separation; Cryopreservation; Cytochrome P-450 Enzyme System; Dogs; Glucuronosyltransferase; Hepatocytes; Heptanoic Acids; Humans; Organic Anion Transporters; Pharmaceutical Preparations; Pyrroles; Rats; Substrate Specificity; Suspensions; Time Factors | 2013 |
Rapid insight into heating-induced phase transformations in the solid state of the calcium salt of atorvastatin using multivariate data analysis.
Topics: Anticholesteremic Agents; Atorvastatin; Calorimetry, Differential Scanning; Freezing; Heating; Heptanoic Acids; Multivariate Analysis; Phase Transition; Powder Diffraction; Pyrroles; Spectrum Analysis, Raman; Thermogravimetry; Water; X-Ray Diffraction | 2013 |
Development, validation and testing of a human tissue engineered hypertrophic scar model.
Topics: Animal Testing Alternatives; Atorvastatin; Cell Proliferation; Cicatrix, Hypertrophic; Gene Expression Regulation; Hazardous Substances; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Interleukin-8; Mesenchymal Stem Cells; Models, Biological; Pyrroles; Reproducibility of Results; Skin; Tissue Engineering | 2012 |
Severe colchicine intoxication in a renal transplant recipient on cyclosporine.
Topics: Acute Kidney Injury; Atorvastatin; Colchicine; Cyclosporine; Drug Interactions; Gout; Gout Suppressants; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Pyrroles; Quadriplegia; Rhabdomyolysis; Treatment Outcome | 2012 |
[Pharmacological influencing of abdominal aortic aneurysm model - animal experimental study, primary results].
Topics: Animals; Aortic Aneurysm, Abdominal; Atorvastatin; Cholinergic Antagonists; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Pyrroles; Sus scrofa | 2012 |
Targeting specific traditional risk factors to improve cardiovascular outcomes: Sound or flawed?
Topics: Atorvastatin; Coronary Artery Disease; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Niacin; Pyrroles | 2013 |
Association between circulating matrix metalloproteinase levels and coronary plaque regression after acute coronary syndrome--subanalysis of the JAPAN-ACS study.
Topics: Acute Coronary Syndrome; Atorvastatin; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinases; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Quinolines; Remission Induction | 2013 |
SDF-1α upregulation by atorvastatin in rats with acute myocardial infarction via nitric oxide production confers anti-inflammatory and anti-apoptotic effects.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Atorvastatin; Benzylamines; Chemokine CXCL12; Coronary Vessels; Cyclams; Heptanoic Acids; Heterocyclic Compounds; Ligation; Male; Myocardial Infarction; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, CXCR4; STAT3 Transcription Factor; Up-Regulation | 2012 |
Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry).
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Atherectomy; Atorvastatin; Cardiovascular Agents; Clopidogrel; Combined Modality Therapy; Critical Illness; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyrroles; Recurrence; Registries; Retrospective Studies; Risk Factors; Severity of Illness Index; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Pilot Projects; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrroles; Retrospective Studies; Sex Factors; Simvastatin; Triglycerides | 2012 |
Atorvastatin modulates the DDAH1/ADMA system in high-fat diet-induced insulin-resistant rats with endothelial dysfunction.
Topics: Amidohydrolases; Animals; Arginine; Atorvastatin; Diet, High-Fat; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Insulin; Insulin Resistance; Pyrroles; Rats; Rats, Sprague-Dawley | 2012 |
Devic syndrome: can antiphospholipid antibodies be a factor?
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Antirheumatic Agents; Aspirin; Atorvastatin; Azathioprine; Complement C4; Cyclophosphamide; Female; Glucocorticoids; Heparin; Heptanoic Acids; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin G; Immunosuppressive Agents; Magnetic Resonance Imaging; Methylprednisolone; Neuromyelitis Optica; Plasmapheresis; Prednisolone; Pulse Therapy, Drug; Pyrroles; Warfarin | 2012 |
Dramatic regression of three-vessel disease under statin treatment in patients with stable angina pectoris.
Topics: Angina, Stable; Atorvastatin; Cardiovascular Agents; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrroles; Treatment Outcome | 2012 |
High-dose supplementation with natural α-tocopherol does neither alter the pharmacodynamics of atorvastatin nor its phase I metabolism in guinea pigs.
Topics: alpha-Tocopherol; Animals; Anticholesteremic Agents; Atorvastatin; Blotting, Western; Cholesterol; Cytochrome P-450 CYP3A; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Guinea Pigs; Heptanoic Acids; Liver; Pyrroles; Random Allocation | 2013 |
Leave-one-out procedure in the validation of elimination rate constant analysis.
Topics: Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Antifungal Agents; Atorvastatin; Dosage Forms; Drug Design; Female; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Male; Middle Aged; Perindopril; Pharmaceutical Preparations; Pharmacokinetics; Pyrroles; Reproducibility of Results; Therapeutic Equivalency; Trimetazidine; Vasodilator Agents; Young Adult | 2012 |
The 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) pathway regulates developmental cerebral-vascular stability via prenylation-dependent signalling pathway.
Topics: Alkyl and Aryl Transferases; Animals; Atorvastatin; cdc42 GTP-Binding Protein; Cerebral Hemorrhage; Cerebrum; Embryo, Nonmammalian; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Morpholinos; Polyisoprenyl Phosphates; Prenylation; Pyrroles; rhoA GTP-Binding Protein; Signal Transduction; Zebrafish | 2013 |
Glass particles found in generic atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Contamination; Drug Recalls; Drugs, Generic; Glass; Heptanoic Acids; Pyrroles; United States | 2012 |
Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Anticholesteremic Agents; Atorvastatin; Death, Sudden, Cardiac; Drug Synergism; Female; Heptanoic Acids; Humans; Hydrocortisone; Kaplan-Meier Estimate; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Young Adult | 2013 |
Formulation development and in vitro evaluation of solidified self-microemulsion in the form of tablet containing atorvastatin calcium.
Topics: Anticholesteremic Agents; Atorvastatin; Chemical Phenomena; Differential Thermal Analysis; Drug Compounding; Emulsions; Excipients; Heptanoic Acids; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Mechanical Phenomena; Particle Size; Powder Diffraction; Pyrroles; Quality Control; Silicon Dioxide; Solubility; Spectroscopy, Fourier Transform Infrared; Starch; Tablets | 2013 |
Surface engineering of titanium substrates with chitosan-atorvastatin conjugate for reduced inflammation responses and improved cytocompatibility.
Topics: Acid Phosphatase; Animals; Atorvastatin; Biocompatible Materials; Cells, Immobilized; Chitosan; Cytokines; Dogs; Fluorescent Antibody Technique; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; L-Lactate Dehydrogenase; Macrophages; Magnetic Resonance Spectroscopy; Microscopy, Electron, Scanning; Nitric Oxide; Proteins; Pyrroles; Reactive Oxygen Species; Surface Properties; Titanium | 2013 |
Antilipid agents may provide allergy protection.
Topics: Animals; Asthma; Atorvastatin; Bronchial Hyperreactivity; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypersensitivity; Pravastatin; Pyrroles | 2013 |
Effect of oral administration with pravastatin and atorvastatin on airway hyperresponsiveness and allergic reactions in asthmatic mice.
Topics: Administration, Oral; Animals; Asthma; Atorvastatin; Bronchial Hyperreactivity; Cytokines; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypersensitivity; Immunoglobulin G; Mice; Mice, Inbred BALB C; Ovalbumin; Pravastatin; Pyrroles; Rats, Sprague-Dawley; Th1 Cells | 2013 |
Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response.
Topics: Atherosclerosis; Atorvastatin; Dyslipidemias; Female; Genotype; Heptanoic Acids; Humans; Lipid Metabolism; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Treatment Outcome | 2013 |
Atorvastatin: an efficient step forward in mesenchymal stem cell therapy of diabetic retinopathy.
Topics: Animals; Atorvastatin; Diabetic Retinopathy; Gene Expression Regulation; Genetic Therapy; Heptanoic Acids; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Rats; Receptors, CXCR4; Vascular Endothelial Growth Factor A | 2013 |
Use of secondary preventive medications in patients with atherosclerotic disease in urban China: a cross-sectional study of 16, 860 patients.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Atorvastatin; Cerebrovascular Disorders; Coronary Artery Disease; Cross-Sectional Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Peripheral Vascular Diseases; Pyrroles; Secondary Prevention; Simvastatin | 2012 |
Critical promoter region for statin-induced human endothelial nitric oxide synthase (eNOS) transcription in EA.hy926 cells.
Topics: Atorvastatin; Cells, Cultured; Fatty Acids, Monounsaturated; Fluvastatin; Genes, Reporter; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Nitric Oxide Synthase Type III; Plasmids; Promoter Regions, Genetic; Pyrroles; Quinolines; RNA, Messenger; Transcription, Genetic | 2013 |
Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Topics: Adult; Aged; Analysis of Variance; Asian People; Atorvastatin; Biomarkers; Chi-Square Distribution; China; Cholesterol, HDL; Cholesterol, LDL; Cytochrome P-450 CYP3A; Female; Gene Frequency; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Pharmacogenetics; Phenotype; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2013 |
Association of ANRIL polymorphism (rs1333049:C>G) with myocardial infarction and its pharmacogenomic role in hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol; Drug Resistance; Female; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Pakistan; Polymorphism, Single Nucleotide; Pyrroles; Risk; RNA, Long Noncoding; Sequence Analysis, DNA; Triglycerides | 2013 |
Three different methods for determination of binary mixture of Amlodipine and Atorvastatin using dual wavelength spectrophotometry.
Topics: Absorption; Amlodipine; Atorvastatin; Heptanoic Acids; Methanol; Pyrroles; Reproducibility of Results; Spectrophotometry; Tablets | 2013 |
[Effect of atorvastatin on eNOS synthesis in organs of aging rats with myocardial ischemia-reperfusion].
Topics: Animals; Atorvastatin; Female; Heptanoic Acids; Kidney; Liver; Male; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide Synthase Type III; Pyrroles; Rats; Rats, Wistar | 2012 |
Statins reduce amyloid β-peptide production by modulating amyloid precursor protein maturation and phosphorylation through a cholesterol-independent mechanism in cultured neurons.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Cholesterol; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Neurons; Peptide Fragments; Phosphorylation; Pyrroles; Quinolines; Rats | 2013 |
Lipid-lowering pharmacotherapy in Central and Eastern European countries in cardiovascular prevention: self-reported prescription patterns of primary care physicians.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cross-Sectional Studies; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Europe; Female; Health Care Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Physicians, Primary Care; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Risk; Secondary Care; Self Report; Simvastatin | 2013 |
[Atorvastatin and oxidative stress in coronary heart disease with obesity].
Topics: Adult; Aged; Antioxidants; Atorvastatin; Case-Control Studies; Coronary Disease; Dyslipidemias; Electrocardiography, Ambulatory; Electron Spin Resonance Spectroscopy; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lipids; Middle Aged; Obesity; Oxidative Stress; Pyrroles | 2012 |
A piece of my mind: A pain in the tuches.
Topics: Anticholesteremic Agents; Atorvastatin; Buttocks; Cardiovascular Diseases; Heptanoic Acids; Humans; Medication Adherence; Mortality, Premature; Muscular Diseases; Pain; Physicians; Pyrroles; Sciatica; Self Care | 2012 |
Cocoa flavanol metabolites activate HNF-3β, Sp1, and NFY-mediated transcription of apolipoprotein AI in human cells.
Topics: Apolipoprotein A-I; Atorvastatin; Binding Sites; Cacao; Catechin; CCAAT-Binding Factor; Estrogen Receptor alpha; Flavonoids; Gene Expression Regulation; Hep G2 Cells; Hepatocyte Nuclear Factor 3-beta; Hepatocyte Nuclear Factor 4; Heptanoic Acids; Humans; Promoter Regions, Genetic; Pyrroles; Sp1 Transcription Factor; Transcription, Genetic; Up-Regulation | 2013 |
Atorvastatin-induced increase in progenitor cell levels is rather caused by enhanced receptor activator of NF-kappaB ligand (RANKL) cell proliferation than by bone marrow mobilization.
Topics: Animals; Antigens, Ly; Atorvastatin; Bone Marrow; Cell Proliferation; Fibroblast Growth Factor 2; Heptanoic Acids; Hindlimb; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Physiologic; Osteoprotegerin; Perfusion; Pyrroles; RANK Ligand; Re-Epithelialization; Stem Cells; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Atorvastatin ameliorates podocyte injury in patients with type 2 diabetes complicated with dyslipidemia.
Topics: Aged; Atorvastatin; Biomarkers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dyslipidemias; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oxidative Stress; Podocytes; Pyrroles | 2013 |
CYP3A4/5 combined genotype analysis for predicting statin dose requirement for optimal lipid control.
Topics: Aged; Atorvastatin; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Female; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pyrroles; Simvastatin | 2013 |
Soluplus-coated colloidal silica nanomatrix system for enhanced supersaturation and oral absorption of poorly water-soluble drugs.
Topics: Absorption; Administration, Oral; Animals; Atorvastatin; Colloids; Drug Carriers; Heptanoic Acids; Hydrophobic and Hydrophilic Interactions; Male; Nanomedicine; Nanoparticles; Polyethylene Glycols; Polyvinyls; Pyrroles; Rats; Rats, Sprague-Dawley; Silicon Dioxide; Solubility; Water | 2013 |
Atorvastatin and pitavastatin reduce oxidative stress and improve IR/LDL-R signals in Alzheimer's disease.
Topics: Adiponectin; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Cerebral Cortex; Endothelium, Vascular; Female; Glycation End Products, Advanced; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Mice; Neurons; Oxidative Stress; Plaque, Amyloid; Pyrroles; Quinolines; Receptor, Insulin; Receptors, LDL | 2013 |
Combination benefit of amlodipine plus atorvastatin treatment on carotid atherosclerosis in Zucker metabolic rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Common; Chemokine CCL2; Cyclin-Dependent Kinase Inhibitor p21; Drug Therapy, Combination; Endothelial Cells; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Rats; Sirtuin 1; Tumor Suppressor Protein p53 | 2013 |
Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.
Topics: Animals; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol, Dietary; Cholesterol, LDL; Drug Synergism; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mice; Mice, Transgenic; Oxidative Stress; Pyrroles; Resveratrol; Stilbenes | 2013 |
[Myopathy due to deficiency of desaminase myoadenilate induced by atorvastatine].
Topics: Aged; Amino Acid Substitution; AMP Deaminase; Atorvastatin; Biopsy; Causality; Creatine Kinase, MM Form; Exercise Tolerance; Female; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Mitochondria, Muscle; Models, Genetic; Muscle, Skeletal; Mutation, Missense; Myalgia; Organic Anion Transporters; Parkinsonian Disorders; Point Mutation; Polymorphism, Single Nucleotide; Purine-Pyrimidine Metabolism, Inborn Errors; Pyrroles; Ubiquinone | 2013 |
Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats.
Topics: Animals; Atorvastatin; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Fluorobenzenes; Hepatic Stellate Cells; Heptanoic Acids; Hypertension, Portal; In Vitro Techniques; Incidence; Injections; Liver Cirrhosis; Liver Cirrhosis, Experimental; Male; Oxidative Stress; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Thioacetamide | 2013 |
Degradation kinetics of atorvastatin under stress conditions and chemical analysis by HPLC.
Topics: Atorvastatin; Chromatography, High Pressure Liquid; Drug Stability; Heptanoic Acids; Hydrochloric Acid; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Oxidation-Reduction; Pyrroles; Reproducibility of Results; Sodium Hydroxide; Spectrophotometry, Ultraviolet; Temperature; Time Factors; Ultraviolet Rays | 2013 |
Reduction of platelet cytosolic phospholipase A2 activity by atorvastatin and simvastatin: biochemical regulatory mechanisms.
Topics: Anticholesteremic Agents; Aspirin; Atorvastatin; Blood Platelets; Calcium; Collagen; Cyclooxygenase 1; Drug Combinations; Drug Synergism; Heptanoic Acids; Humans; Mitogen-Activated Protein Kinases; Phospholipase A2 Inhibitors; Phospholipases A2; Phosphorylation; Platelet Aggregation; Pravastatin; Pyrroles; Simvastatin; Thromboxane A2; Thromboxane-A Synthase | 2013 |
The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study.
Topics: Atorvastatin; Biomarkers; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin; Treatment Outcome; Vitamin D | 2013 |
Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio.
Topics: Age Factors; Aged; Atorvastatin; Biomarkers; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Disease Progression; Dyslipidemias; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrroles; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2014 |
Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.
Topics: Adult; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Body Mass Index; Cytochrome P-450 CYP3A; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Mucosa; Liver; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Obesity; Organic Anion Transporters; Pyrroles | 2013 |
[Atorvastatin attenuates parathyroid hormone 1-34 induced cardiomyocytes hypertrophy through downregulating K-Ras-ERK1/2 pathway].
Topics: Animals; Animals, Newborn; Atorvastatin; Cardiomegaly; Cells, Cultured; Heptanoic Acids; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Myocytes, Cardiac; Parathyroid Hormone; Pyrroles; Rats; Rats, Wistar | 2012 |
Predicting metabolic clearance for drugs that are actively transported into hepatocytes: incubational binding as a consequence of in vitro hepatocyte concentration is a key factor.
Topics: Amino Acid Transport Systems, Neutral; Animals; Atorvastatin; Biological Transport, Active; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Metabolic Clearance Rate; Models, Biological; Pyrroles; Rats | 2013 |
Role of endothelial nitric oxide synthase and vagal activity in the endothelial protection of atorvastatin in ischemia/reperfusion injury.
Topics: Acetylcholine; Animals; Apoptosis; Atorvastatin; Endothelium, Vascular; Enzyme Inhibitors; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mesenteric Artery, Superior; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinase; Pyrroles; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Vagus Nerve; Vasoconstrictor Agents | 2013 |
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
Topics: Adrenergic beta-Antagonists; Amines; Ammonium Chloride; Antidepressive Agents, Tricyclic; Atorvastatin; Cell Line, Transformed; Diuretics; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imipramine; Lysosomes; Monensin; Nigericin; Propranolol; Pyrroles | 2013 |
The mitochondrial permeability transition pore as a target for cardioprotection in hypertrophic cardiomyopathy.
Topics: Atorvastatin; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cells, Cultured; Cyclosporine; Heptanoic Acids; Humans; Ion Channel Gating; Membrane Potential, Mitochondrial; Microscopy, Confocal; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocardial Reperfusion Injury; Myocytes, Cardiac; Pyrroles; Time Factors | 2013 |
Protective role of atorvastatin against doxorubicin-induced cardiotoxicity and testicular toxicity in mice.
Topics: Animals; Antioxidants; Atorvastatin; Cardiomyopathies; Comet Assay; DNA Fragmentation; Doxorubicin; Glutathione; Heart; Heptanoic Acids; Lipid Peroxidation; Male; Malondialdehyde; Mice; Micronucleus Tests; Oxidative Stress; Pyrroles; Testicular Diseases; Testis | 2013 |
Atorvastatin attenuates the production of IL-1β, IL-6, and TNF-α in the hippocampus of an amyloid β1-42-induced rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anticholesteremic Agents; Atorvastatin; Disease Models, Animal; Heptanoic Acids; Hippocampus; Inflammation Mediators; Interleukin-1beta; Interleukin-6; Male; Pyrroles; Rats; Rats, Wistar; Tumor Necrosis Factor-alpha | 2013 |
Influence of atorvastatin on angiotensin I metabolism in resting and TNF-α -activated rat vascular smooth muscle cells.
Topics: Angiotensin I; Angiotensin-Converting Enzyme 2; Animals; Atorvastatin; Heptanoic Acids; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neprilysin; Peptidyl-Dipeptidase A; Pyrroles; Rats, Wistar; Rest; Tumor Necrosis Factor-alpha | 2014 |
A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility.
Topics: Atorvastatin; Biological Transport; Carrier Proteins; Cell Line, Tumor; Coat Protein Complex I; Endoplasmic Reticulum; Epistasis, Genetic; Heptanoic Acids; Humans; Membrane Proteins; Proto-Oncogene Proteins; Pyrroles; Ribosomal Proteins; Ricin; RNA, Small Interfering; Vesicular Transport Proteins | 2013 |
Role of Krüppel-like factor 2 and protease-activated receptor-1 in vulnerable plaques of ApoE(-/-) mice and intervention with statin.
Topics: Animals; Apolipoproteins E; Atorvastatin; Blotting, Western; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Kruppel-Like Transcription Factors; Mice; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Receptor, PAR-1; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Nitric oxide-donating atorvastatin attenuates neutrophil recruitment during vascular inflammation independent of changes in plasma cholesterol.
Topics: Acute Disease; Animals; Atherosclerosis; Atorvastatin; Carotid Arteries; Cell Survival; Chemotaxis, Leukocyte; Cholesterol; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-8; Male; Molecular Structure; Monocytes; Neutrophil Infiltration; Neutrophils; Nitric Oxide Donors; Pyrroles; Rabbits | 2013 |
Asymptomatic carotid stenosis.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Aspirin; Asymptomatic Diseases; Atorvastatin; Azetidines; Carotid Stenosis; Diet, Mediterranean; Drug Therapy, Combination; Exercise Therapy; Ezetimibe; Female; Heptanoic Acids; Humans; Perindopril; Pyrroles; Risk; Stroke; Treatment Outcome; Ultrasonography; Vasodilator Agents | 2013 |
Atorvastatin protects against deleterious cardiovascular consequences induced by chronic intermittent hypoxia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Disease Models, Animal; Heptanoic Acids; Hypoxia; Oxidative Stress; Pyrroles; Rats; Treatment Outcome | 2013 |
Factors associated with statin selection among privately insured commercial and Medicare patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult | 2013 |
Protective effect of HMG CoA reductase inhibitors against running wheel activity induced fatigue, anxiety like behavior, oxidative stress and mitochondrial dysfunction in mice.
Topics: Animals; Anxiety; Atorvastatin; Behavior, Animal; Brain; Catalase; Electron Transport Chain Complex Proteins; Fatigue Syndrome, Chronic; Fatty Acids, Monounsaturated; Fluvastatin; Glutathione; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipid Peroxidation; Male; Maze Learning; Mice; Mitochondria; Motor Activity; Nitrites; Oxidative Stress; Physical Exertion; Pyrroles; Running; Swimming; Time Factors | 2012 |
In acute kidney injury, indoxyl sulfate impairs human endothelial progenitor cells: modulation by statin.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Animals; Apoptosis; Atorvastatin; Blotting, Western; Centrifugation, Density Gradient; Endothelial Cells; Female; Flow Cytometry; Gene Expression Regulation; Heptanoic Acids; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Indican; Male; Mice; Mice, Inbred C57BL; Middle Aged; Nitric Oxide Synthase Type III; Pyrroles; Reactive Oxygen Species; Stem Cells; Taiwan; Vascular Cell Adhesion Molecule-1 | 2013 |
Atorvastatin requires geranylgeranyl transferase-I and Rac1 activation to exert neuronal protection and induce plasticity.
Topics: Alkyl and Aryl Transferases; Animals; Atorvastatin; Base Sequence; DNA Primers; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neuronal Plasticity; Neurons; Pyrroles; rac1 GTP-Binding Protein; Rats; Rats, Wistar | 2013 |
Atorvastatin-induced cardioprotection of human myocardium is mediated by the inhibition of mitochondrial permeability transition pore opening via tumor necrosis factor-α and Janus kinase/signal transducers and activators of transcription pathway.
Topics: Aged; Atorvastatin; Blotting, Western; Cardiotonic Agents; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Janus Kinases; Male; Middle Aged; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocardial Reperfusion Injury; Myocardium; Pyrroles; Signal Transduction; Tumor Necrosis Factor-alpha | 2013 |
Pharmacological interactions: the next frontier?
Topics: Atorvastatin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyrroles; Ticlopidine | 2013 |
Atorvastatin withdrawal elicits oxidative/nitrosative damage in the rat cerebral cortex.
Topics: Animals; Atorvastatin; Cerebral Cortex; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitric Oxide; Oxidation-Reduction; Pyrroles; Rats; Rats, Wistar; Substance Withdrawal Syndrome; Superoxide Dismutase; Tyrosine | 2013 |
Atorvastatin suppresses aldosterone-induced neonatal rat cardiac fibroblast proliferation by inhibiting ERK1/2 in the genomic pathway.
Topics: Aldosterone; Animals; Atorvastatin; Blotting, Western; Cell Cycle; Cell Proliferation; Cells, Cultured; Chronic Disease; DNA; Fibroblasts; Flow Cytometry; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Mineralocorticoid Receptor Antagonists; Myocardium; Pyrroles; Rats; Rats, Sprague-Dawley | 2013 |
Voltammetric oxidation and determination of atorvastatin based on the enhancement effect of cetyltrimethyl ammonium bromide at a carbon paste electrode.
Topics: Adsorption; Atorvastatin; Calibration; Carbon; Cetrimonium; Cetrimonium Compounds; Electrochemical Techniques; Electrodes; Heptanoic Acids; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Limit of Detection; Oxidation-Reduction; Pyrroles | 2013 |
Streamlined catalytic asymmetric synthesis of atorvastatin.
Topics: Aldehydes; Anticholesteremic Agents; Atorvastatin; Catalysis; Heptanoic Acids; Molecular Structure; Pyrroles; Stereoisomerism | 2013 |
An improved HPLC method with the aid of a chemometric protocol: simultaneous determination of atorvastatin and its metabolites in plasma.
Topics: Algorithms; Animals; Anticholesteremic Agents; Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Metabolic Networks and Pathways; Models, Chemical; Pyrroles; Rats | 2013 |
Promising anti-leukemic activity of atorvastatin.
Topics: Aged; Aged, 80 and over; Apoptosis; Apoptosis Regulatory Proteins; Atorvastatin; bcl-2-Associated X Protein; Cell Membrane Permeability; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; DNA Fragmentation; Female; Heptanoic Acids; Humans; Lamin B Receptor; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Mitochondria; Mitochondrial Membranes; Myeloid Cell Leukemia Sequence 1 Protein; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Receptors, Cytoplasmic and Nuclear | 2013 |
Nitric oxide-donating statins upgrade the benefits of lipid-lowering in vascular inflammation by desensitizing neutrophil activation: editorial to: "Nitric oxide-donating atorvastatin attenuates neutrophil recruitment during vascular inflammation independ
Topics: Animals; Atherosclerosis; Atorvastatin; Cholesterol; Heptanoic Acids; Humans; Male; Neutrophil Infiltration; Nitric Oxide Donors; Pyrroles | 2013 |
An unusual cause of delayed puberty: Berardinelli- Seip syndrome.
Topics: Administration, Cutaneous; Adolescent; Atorvastatin; Combined Modality Therapy; Diet, Fat-Restricted; Drug Therapy, Combination; Estrogens; Exercise Therapy; Female; Fenofibrate; Fish Oils; Heptanoic Acids; Humans; Hypertension, Portal; Hypertriglyceridemia; Insulin; Insulin Resistance; Lipodystrophy, Congenital Generalized; Pioglitazone; Propranolol; Puberty, Delayed; Pyrroles; Thiazolidinediones; Treatment Outcome | 2012 |
Bioenergetic study of murine hepatic tissue treated in vitro with atorvastatin.
Topics: Adenosine Triphosphate; Animals; Atorvastatin; Caspases; Energy Metabolism; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Liver; Male; Mice; Mice, Inbred C57BL; Oxygen; Pyrroles; Urea | 2013 |
HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway.
Topics: Acetylcysteine; Acyl Coenzyme A; Animals; Antioxidants; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; DNA Fragmentation; Extracellular Signal-Regulated MAP Kinases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lymphoma; Membrane Potential, Mitochondrial; Mevalonic Acid; Mice; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Reactive Oxygen Species; Signal Transduction; Simvastatin | 2013 |
Multiple statistical methods for assessing differential gene expression in microarray data of diabetic model rats to predict the molecular mechanism of atorvastatin on anti-atherogenesis.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Data Interpretation, Statistical; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Gene Expression Profiling; Heptanoic Acids; Male; Microarray Analysis; Prognosis; Pyrroles; Rats; Rats, Sprague-Dawley; Rats, Wistar; Streptozocin; Treatment Outcome | 2013 |
Generalized erythematous-violaceous plaques in a patient with a history of dyslipidemia. Interstitial granulomatous drug reaction (IGDR).
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Eruptions; Dyslipidemias; Erythema; Female; Granuloma; Heptanoic Acids; Humans; Pyrroles | 2013 |
A novel role for receptor activator of nuclear factor (NF)-κβ ligand (RANKL) in atorvastatin-mediated mobilization of endothelial progenitor cells.
Topics: Atorvastatin; Endothelial Cells; Heptanoic Acids; Humans; Pyrroles; RANK Ligand; Stem Cells | 2013 |
Effect of atorvastatin on hematologic parameters in patients with hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Cell Count; Erythrocyte Indices; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Leukocyte Count; Male; Middle Aged; Platelet Activation; Pyrroles | 2013 |
Statins for treating stable angina: can statins improve the plaque morphology and angina?
Topics: Angina Pectoris; Angina, Stable; Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pravastatin; Pyrroles; Ultrasonography, Interventional | 2013 |
Polytetrafluorethylene film-based liquid-three phase micro extraction coupled with differential pulse voltammetry for the determination of atorvastatin calcium.
Topics: Atorvastatin; Electrochemistry; Heptanoic Acids; Humans; Hydrogen-Ion Concentration; Limit of Detection; Liquid Phase Microextraction; Osmolar Concentration; Polytetrafluoroethylene; Pyrroles; Solvents; Time Factors | 2013 |
Plaque stabilization by intensive LDL-cholesterol lowering therapy with atorvastatin is delayed in type 2 diabetic patients with coronary artery disease-Serial angioscopic and intravascular ultrasound analysis.
Topics: Aged; Angioscopy; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Risk Factors; Time Factors; Ultrasonography, Interventional | 2013 |
Ranolazine-induced myopathy in a patient on chronic statin therapy.
Topics: Acetanilides; Aged, 80 and over; Atorvastatin; Drug Interactions; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Piperazines; Pyrroles; Ranolazine | 2013 |
Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
Topics: Adiponectin; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Diabetes Complications; Drug Therapy, Combination; Ezetimibe; Fatty Liver; Female; Heptanoic Acids; Insulin; Liver; MAP Kinase Signaling System; Metabolic Syndrome; Mice; Mice, Mutant Strains; Mice, Obese; Non-alcoholic Fatty Liver Disease; Pyrroles | 2013 |
Atorvastatin prevents cell damage via modulation of oxidative stress, glutamate uptake and glutamine synthetase activity in hippocampal slices subjected to oxygen/glucose deprivation.
Topics: Animals; Atorvastatin; Cell Death; Glucose; Glutamate-Ammonia Ligase; Glutamic Acid; Heptanoic Acids; Hippocampus; Male; Mice; Neurons; Neuroprotective Agents; Oxidative Stress; Oxygen; Pyrroles; Reactive Oxygen Species | 2013 |
Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol, LDL; Cytochrome P-450 CYP3A; Drug Administration Schedule; Female; Gene Expression; Genetic Heterogeneity; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Leukocytes, Mononuclear; Male; Middle Aged; Phenotype; Pyrroles; RNA, Messenger | 2013 |
Inhibitory effect of atorvastatin on AGE-induced HCAEC apoptosis by upregulating HSF-1 protein.
Topics: Apoptosis; Atorvastatin; Cells, Cultured; DNA-Binding Proteins; Endothelial Cells; Glycation End Products, Advanced; Heat Shock Transcription Factors; Heptanoic Acids; HSP70 Heat-Shock Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Transcription Factors; Up-Regulation | 2013 |
Altered microRNA expression in the ischemic-reperfusion spinal cord with atorvastatin therapy.
Topics: Animals; Atorvastatin; Disease Models, Animal; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MicroRNAs; Neuroprotective Agents; Pyrroles; Rats; Real-Time Polymerase Chain Reaction; Reperfusion Injury; Spinal Cord; Spinal Cord Ischemia | 2013 |
Compliance and echographic carotid plaque evolution in patients with acute ischemic stroke treated with atorvastatin according to usual care.
Topics: Aged; Atorvastatin; Brain Ischemia; Carotid Arteries; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Monitoring; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Medication Adherence; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Spain; Stroke; Triglycerides; Ultrasonography | 2014 |
Piriformis muscle syndrome: an unusual adverse effect of atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Dyslipidemias; Female; Heptanoic Acids; Humans; Magnetic Resonance Imaging; Middle Aged; Piriformis Muscle Syndrome; Pyrroles | 2013 |
Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.
Topics: Adolescent; Adult; Area Under Curve; Atorvastatin; Cross-Over Studies; Drug Interactions; Female; Hepacivirus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Proline; Protease Inhibitors; Pyrroles; Treatment Outcome; Young Adult | 2013 |
Ultrasound common carotid artery segmentation based on active shape model.
Topics: Adventitia; Aged; Algorithms; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Common; Computer Simulation; Disease Progression; Female; Heptanoic Acids; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Models, Anatomic; Pattern Recognition, Automated; Placebos; Pyrroles; Software; Tunica Intima; Tunica Media; Ultrasonography | 2013 |
Statins and sepsis: potential benefit but more unanswered questions.
Topics: Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-6; Male; Pyrroles; Sepsis | 2013 |
The effect of atorvastatin on survival of rat ischemic flap.
Topics: Angiogenesis Inducing Agents; Animals; Anticholesteremic Agents; Atorvastatin; Drug Evaluation, Preclinical; Gene Expression; Heptanoic Acids; Ischemia; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Skin; Surgical Flaps; Vascular Endothelial Growth Factor A | 2013 |
Atorvastatin-modified dendritic cells in vitro ameliorate experimental autoimmune myasthenia gravis by up-regulated Treg cells and shifted Th1/Th17 to Th2 cytokines.
Topics: Animals; Atorvastatin; Cell Proliferation; Cytokines; Dendritic Cells; Female; Forkhead Transcription Factors; Heptanoic Acids; Immunotherapy; Lymph Nodes; Myasthenia Gravis, Autoimmune, Experimental; Pyrroles; Rats; Rats, Inbred Lew; Spleen; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory; Thymus Gland; Up-Regulation | 2013 |
Rhabdomyolysis developing secondary to atorvastatin therapy in a patient with liver cirrhosis.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Liver Cirrhosis; Pyrroles; Rhabdomyolysis | 2013 |
Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Analysis of Variance; Animals; Antiparkinson Agents; Atorvastatin; Brain; Cognition Disorders; Cytokines; Disease Models, Animal; Food Preferences; Heptanoic Acids; Male; Maze Learning; Mood Disorders; Motor Activity; Parkinsonian Disorders; Pyrroles; Rats; Rats, Wistar; Social Behavior; Sucrose; Sweetening Agents; Swimming; Tyrosine 3-Monooxygenase | 2013 |
Discovery of Rho-kinase inhibitors by docking-based virtual screening.
Topics: Animals; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Cell Line, Tumor; Cerebral Hemorrhage; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Female; HeLa Cells; Heptanoic Acids; Humans; Lung Neoplasms; Models, Molecular; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Multiple Myeloma; Protein Kinase Inhibitors; Pyrroles; rho-Associated Kinases; Zebrafish | 2013 |
Inhibition of Rho and Rac geranylgeranylation by atorvastatin is critical for preservation of endothelial junction integrity.
Topics: Antigens, CD; Atorvastatin; Cadherins; cdc42 GTP-Binding Protein; Guanosine Triphosphate; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Junctions; Interleukin-6; Interleukin-8; Lipopolysaccharides; Mevalonic Acid; Polyisoprenyl Phosphates; Prenylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Pyrroles; rho-Associated Kinases; Sesquiterpenes; Thrombin | 2013 |
In vivo fluorescence-mediated tomography imaging demonstrates atorvastatin-mediated reduction of lesion macrophages in ApoE-/- mice.
Topics: Animals; Apolipoproteins E; Arteries; Atorvastatin; Cell Migration Assays, Macrophage; Cells, Cultured; Diet; Fluorescence; Green Fluorescent Proteins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Lipoproteins, LDL; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Tomography | 2013 |
Usefulness of preprocedural levels of advanced glycation end products to predict restenosis in patients with controlled diabetes mellitus undergoing drug-eluting stent implantation for stable angina pectoris (from the Prospective ARMYDA-AGEs Study).
Topics: Aged; Angina, Stable; Atorvastatin; Chi-Square Distribution; Coronary Angiography; Coronary Restenosis; Diabetes Complications; Drug-Eluting Stents; Female; Glycation End Products, Advanced; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Paclitaxel; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Pyrroles; ROC Curve; Tubulin Modulators | 2013 |
Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats.
Topics: Animals; Atorvastatin; Behavior, Animal; Brain; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Heptanoic Acids; Huntington Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Malonates; Neurons; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Simvastatin; Sulfones | 2013 |
Oral absorption of atorvastatin solid dispersion based on cellulose or pyrrolidone derivative polymers.
Topics: Absorption; Administration, Oral; Animals; Atorvastatin; Heptanoic Acids; Hypromellose Derivatives; Male; Methylcellulose; Povidone; Pyrroles; Pyrrolidines; Rats; Rats, Sprague-Dawley; Solubility; Suspensions; Vinyl Compounds | 2013 |
Promising role of ferulic acid, atorvastatin and their combination in ameliorating high fat diet-induced stress in mice.
Topics: Animals; Antioxidants; Atorvastatin; Coumaric Acids; Diet, High-Fat; Drug Therapy, Combination; Free Radical Scavengers; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Interleukin-6; Lipid Peroxidation; Liver; Male; Mice; NF-kappa B; Oxidative Stress; Pyrroles; Reactive Oxygen Species; Signal Transduction; Tumor Necrosis Factor-alpha; Weight Gain | 2013 |
Atorvastatin active metabolite inhibits oxidative modification of small dense low-density lipoprotein.
Topics: Antioxidants; Atorvastatin; Chemical Phenomena; Copper Sulfate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxides; Lipoproteins, LDL; Lipoproteins, VLDL; Liposomes; Osmolar Concentration; Oxidants; Oxidation-Reduction; Oxidative Stress; Particle Size; Prodrugs; Pyrroles; Ultracentrifugation; Unilamellar Liposomes | 2013 |
Standards of statin usage in Poland in high-risk patients: 3ST-POL study results.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticholesteremic Agents; Atorvastatin; Cardiology; Cardiovascular Diseases; Cohort Studies; Comorbidity; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Utilization; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Outpatients; Patient Compliance; Poland; Population Surveillance; Primary Health Care; Pyrroles; Simvastatin; Surveys and Questionnaires; Treatment Failure | 2013 |
UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone.
Topics: Adult; Alleles; Atorvastatin; Female; Genotype; Glucuronosyltransferase; Heptanoic Acids; Humans; Lactones; Male; Middle Aged; Muscular Diseases; Polymorphism, Genetic; Pyrroles | 2013 |
Statin-associated polymyositis following omeprazole treatment.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Interactions; Esophagitis; Gemfibrozil; Heptanoic Acids; Humans; Male; Methotrexate; Middle Aged; Myocardial Infarction; Omeprazole; Polymyositis; Prednisone; Proton Pump Inhibitors; Pyrroles; Treatment Outcome; Withholding Treatment | 2013 |
Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and (18)F-FDG using a combined PET/MR scanner.
Topics: Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Contrast Media; Dextrans; Disease Models, Animal; Disease Progression; Fluorodeoxyglucose F18; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Magnetic Resonance Imaging; Magnetite Nanoparticles; Plaque, Atherosclerotic; Positron-Emission Tomography; Predictive Value of Tests; Pyrroles; Rabbits; Radiography; Radiopharmaceuticals; Time Factors | 2013 |
Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model.
Topics: Animals; Antimalarials; Atorvastatin; Disease Models, Animal; Drug Synergism; Female; Heptanoic Acids; Kaplan-Meier Estimate; Malaria, Cerebral; Methylene Blue; Mice; Mice, Inbred C57BL; Parasitemia; Pyrroles | 2013 |
Biocatalytic retrosynthesis.
Topics: Atorvastatin; Biocatalysis; Chemistry Techniques, Synthetic; Heptanoic Acids; Molecular Structure; Oligopeptides; Organic Chemicals; Pyrroles | 2013 |
Lipoprotein kinetics in male hemodialysis patients treated with atorvastatin.
Topics: Adolescent; Adult; Aged; Apolipoproteins B; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Pyrroles; Renal Dialysis | 2013 |
Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus; Drug Prescriptions; Drugs, Generic; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; France; General Practitioners; Heart Diseases; Heptanoic Acids; Humans; Indoles; Lipid Metabolism Disorders; Male; Middle Aged; Models, Statistical; Practice Patterns, Physicians'; Pravastatin; Prescription Drugs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2013 |
Regulation of multidrug resistance protein 2 (MRP2, ABCC2) expression by statins: involvement of SREBP-mediated gene regulation.
Topics: Animals; Atorvastatin; ATP-Binding Cassette Transporters; Cells, Cultured; Gene Expression Regulation; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver X Receptors; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Orphan Nuclear Receptors; Pyrroles; Quinolines; Rats; Rats, Wistar; RNA, Messenger; Sterol Regulatory Element Binding Proteins | 2013 |
Atorvastatin inhibits the 5-lipoxygenase pathway and expression of CCL3 to alleviate atherosclerotic lesions in atherosclerotic ApoE knockout mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoproteins E; Arachidonate 5-Lipoxygenase; Atherosclerosis; Atorvastatin; Chemokine CCL3; Cholesterol, Dietary; Down-Regulation; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukotrienes; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Random Allocation; Signal Transduction | 2013 |
Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice--a translational model for atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein E3; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, Dietary; Disease Models, Animal; Heptanoic Acids; Humans; Hypercholesterolemia; Mice; Mice, Transgenic; Osteoarthritis; Pyrroles | 2014 |
Pharmacologic inhibition of CXCL10 in combination with anti-malarial therapy eliminates mortality associated with murine model of cerebral malaria.
Topics: Animals; Antimalarials; Apoptosis; Artemether; Artemisinins; Atorvastatin; Blood-Brain Barrier; Caspases; Cell Count; Chemokine CXCL10; Disease Models, Animal; Drug Interactions; Endothelial Cells; Gene Expression Regulation; Heme Oxygenase-1; Heptanoic Acids; Humans; Leukocytes; Malaria, Cerebral; Membrane Proteins; Mice; Mice, Inbred C57BL; Models, Molecular; Neuroglia; Nucleic Acid Conformation; Pyrroles; Survival Analysis | 2013 |
Elucidation of the biochemical basis for a clinical drug-drug interaction between atorvastatin and 5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778875), a subtype selective agonist of the peroxisome proliferator-activated recep
Topics: Animals; Atorvastatin; Benzoates; Benzoic Acid; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dogs; Drug Interactions; HEK293 Cells; Heptanoic Acids; Humans; Hydroxylation; Madin Darby Canine Kidney Cells; Membrane Transport Proteins; Oxidation-Reduction; PPAR alpha; Pyrroles; Sulfonamides; Time Factors | 2013 |
Multitargeted low-dose GLAD combination chemoprevention: a novel and promising approach to combat colon carcinogenesis.
Topics: Adenomatous Polyps; Animals; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Carcinogenesis; Cell Proliferation; Chemoprevention; Colon; Colonic Neoplasms; Cytokines; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Eflornithine; Female; Gefitinib; Heptanoic Acids; Intestine, Small; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Pyrroles; Quinazolines | 2013 |
Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Topics: Adult; Atorvastatin; Costs and Cost Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Managed Care Programs; Models, Economic; Myocardial Infarction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; United States | 2013 |
Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies.
Topics: Aged; Anticholesteremic Agents; Asian People; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Hong Kong; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; White People | 2013 |
Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Databases, Factual; Dose-Response Relationship, Drug; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Odds Ratio; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2013 |
Assessment of vascular endothelial growth factor and matrix metalloproteinase-9 in the periodontium of rats treated with atorvastatin.
Topics: Administration, Oral; Administration, Topical; Alveolar Bone Loss; Alveolar Process; Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Male; Matrix Metalloproteinase 9; Periodontal Attachment Loss; Periodontal Ligament; Periodontitis; Protective Agents; Pyrroles; Rats; Rats, Wistar; Vascular Endothelial Growth Factor A | 2014 |
Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Cardiovascular System; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Longitudinal Studies; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk; Simvastatin; Treatment Outcome; Young Adult | 2013 |
Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis.
Topics: Animals; Atorvastatin; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Mice; Neoplasm Metastasis; Phosphorylation; Pyrroles; rho GTP-Binding Proteins; rhoC GTP-Binding Protein; STAT3 Transcription Factor | 2013 |
[Role of inflammation in etiology of atrial fibrillation--is lone arrhythmia really alone].
Topics: Atorvastatin; Atrial Fibrillation; C-Reactive Protein; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Pyrroles; Recurrence | 2012 |
Generic atorvastatin-induced thrombocytopenic purpura: a raised red flag.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drugs, Generic; Female; Glucocorticoids; Heptanoic Acids; Humans; Purpura, Thrombocytopenic; Pyrroles; Treatment Outcome; Withholding Treatment | 2013 |
[Impacts of atovastatin and tinidazole on cardiac muscle inflammation factors of tumor necrosis factor-α, interleukin-1 and metalloproteinase-2 of experimental rabbits with atherosclerosis and periodontitis].
Topics: Animals; Atherosclerosis; Atorvastatin; Heptanoic Acids; Interleukin-1; Male; Matrix Metalloproteinase 2; Periodontitis; Pyrroles; Rabbits; Tinidazole; Tumor Necrosis Factor-alpha | 2013 |
Cerebral infarction in a case of Parry-Romberg syndrome.
Topics: Adult; Aspirin; Atorvastatin; Cerebral Infarction; Diffusion Magnetic Resonance Imaging; Facial Hemiatrophy; Female; Fibrinolytic Agents; Foramen Ovale, Patent; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors; Treatment Outcome | 2014 |
Effect of atorvastatin and methotrexate on solid Ehrlich tumor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Atorvastatin; Carcinoma, Ehrlich Tumor; Catalase; Cholesterol; Glutathione Reductase; Heptanoic Acids; Immunohistochemistry; Male; Methotrexate; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
Exploratory analysis on the use of statins with or without n-3 PUFA and major events in patients discharged for acute myocardial infarction: an observational retrospective study.
Topics: Aged; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Heptanoic Acids; Humans; Kaplan-Meier Estimate; Male; Matched-Pair Analysis; Middle Aged; Myocardial Infarction; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Simvastatin; Treatment Outcome | 2013 |
Effect of minocycline on carotid atherosclerotic plaques.
Topics: Animals; Anti-Inflammatory Agents; Atherosclerosis; Atorvastatin; Basigin; Carotid Artery, Common; Cholesterol; Cholesterol, LDL; Heptanoic Acids; Male; Matrix Metalloproteinase 9; Minocycline; Plaque, Atherosclerotic; Pyrroles; Rabbits | 2013 |
Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cholesterol, HDL; Cholesterol, LDL; Egypt; Female; Genetic Variation; Heptanoic Acids; Humans; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Genetic; Pyrroles; Risk Factors; Sex Characteristics; Triglycerides | 2013 |
Effect of statins with α-tricalcium phosphate on proliferation, differentiation, and mineralization of human dental pulp cells.
Topics: Adolescent; Adult; Alkaline Phosphatase; Aluminum Compounds; Atorvastatin; Biocompatible Materials; Biomarkers; Bone Morphogenetic Protein 2; Calcification, Physiologic; Calcium Compounds; Calcium Phosphates; Cell Adhesion; Cell Differentiation; Cell Proliferation; Dental Pulp; Dentin; Drug Combinations; Extracellular Matrix Proteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Odontoblasts; Osteogenesis; Osteonectin; Oxides; Phosphoproteins; Pyrroles; Sialoglycoproteins; Silicates; Simvastatin; Young Adult | 2013 |
The activity of atorvastatin and rosiglitazone on CD38, ZAP70 and apoptosis in lymphocytes of B-cell chronic lymphocytic leukemia in vitro.
Topics: ADP-ribosyl Cyclase 1; Annexin A5; Apoptosis; Atorvastatin; Calcium; CD5 Antigens; Female; Heptanoic Acids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Lymphocytes; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Rosiglitazone; Thiazolidinediones; ZAP-70 Protein-Tyrosine Kinase | 2013 |
Differential expression of Nad(P)H oxidase isoforms and the effects of atorvastatin on cardiac remodeling in two-kidney two-clip hypertensive rats.
Topics: Animals; Atorvastatin; Atrial Natriuretic Factor; Blotting, Western; Fibrosis; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Renovascular; Isoenzymes; Male; Membrane Glycoproteins; Myocardium; Myosin Heavy Chains; NADPH Oxidase 2; NADPH Oxidase 4; NADPH Oxidases; Pyrroles; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2013 |
PPARα is involved in the multitargeted effects of a pretreatment with atorvastatin in experimental stroke.
Topics: Animals; Atorvastatin; Cerebral Cortex; Disease Models, Animal; Gene Expression; Heptanoic Acids; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Mice, Inbred C57BL; Mice, Knockout; Neuroprotective Agents; Nitric Oxide Synthase Type II; PPAR alpha; Pyrroles; Stroke; Vascular Cell Adhesion Molecule-1 | 2014 |
Risk of incident diabetes among patients treated with statins: population based study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
Atorvastatin suppresses glioma invasion and migration by reducing microglial MT1-MMP expression.
Topics: Atorvastatin; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioblastoma; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Microglia; Neoplasm Invasiveness; p38 Mitogen-Activated Protein Kinases; Pyrroles | 2013 |
Mean platelet volume measurement in patients with hypercholesterolemia: a methodological issue.
Topics: Anticholesteremic Agents; Atorvastatin; Erythrocyte Indices; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles | 2013 |
Development and validation of a liquid chromatography-tandem mass spectrometry method for simultaneous determination of amlodipine, atorvastatin and its metabolites ortho-hydroxy atorvastatin and para-hydroxy atorvastatin in human plasma and its applicati
Topics: Amlodipine; Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Liquid-Liquid Extraction; Male; Pyrroles; Spectrometry, Mass, Electrospray Ionization; Tablets; Tandem Mass Spectrometry; Therapeutic Equivalency | 2013 |
Focal histopathological progression of porcine experimental abdominal aortic aneurysm is mitigated by atorvastatin.
Topics: Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Atorvastatin; Disease Models, Animal; Disease Progression; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatic Elastase; Pyrroles; Sus scrofa; Time Factors; Ultrasonography | 2013 |
Effect of atorvastatin on expression of TLR4 and NF-κB p65 in atherosclerotic rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Disease Models, Animal; Gene Expression; Heptanoic Acids; Histocytochemistry; Male; Pyrroles; Rabbits; Random Allocation; Toll-Like Receptor 4; Transcription Factor RelA | 2013 |
Inhibitory effect of atorvastatin on the cell growth of cardiac myxomas via the PTEN and PHLPP2 phosphatase signaling pathway.
Topics: Atorvastatin; Cell Proliferation; Heart Neoplasms; Heptanoic Acids; Humans; Insulin-Like Growth Factor I; Middle Aged; Myxoma; Phosphoprotein Phosphatases; PTEN Phosphohydrolase; Pyrroles; Signal Transduction | 2013 |
Hepatitis B virus reactivation associated with atorvastatin.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Atorvastatin; Cholesterol, LDL; Hepatitis B; Hepatitis B virus; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrroles; Viral Load; Virus Activation; Virus Replication | 2013 |
In vivo evaluation of atherosclerotic plaque inflammation and of anti-inflammatory effects of statins by 18F-fluorodeoxyglucose positron emission tomography.
Topics: Aorta, Thoracic; Atherosclerosis; Atorvastatin; Carotid Arteries; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Plaque, Atherosclerotic; Pyrroles; Radionuclide Imaging | 2013 |
Atorvastatin enhance efficacy of mesenchymal stem cells treatment for swine myocardial infarction via activation of nitric oxide synthase.
Topics: Animals; Apoptosis; Atorvastatin; C-Reactive Protein; Disease Models, Animal; Enzyme Activation; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Mesenchymal Stem Cell Transplantation; Myocardial Infarction; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pyrroles; Swine; Tomography, Emission-Computed, Single-Photon; Ventricular Function, Left | 2013 |
Low-dose combination of alendronate and atorvastatin reduces ligature-induced alveolar bone loss in rats.
Topics: Acid Phosphatase; Alanine Transaminase; Alendronate; Alkaline Phosphatase; Alveolar Bone Loss; Animals; Aspartate Aminotransferases; Atorvastatin; Body Weight; Bone Density Conservation Agents; Dental Cementum; Gingiva; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infusions, Parenteral; Injections, Subcutaneous; Isoenzymes; Leukocyte Disorders; Leukocytes; Leukocytosis; Male; Monocytes; Neutrophils; Peroxidase; Pyrroles; Rats, Wistar; Root Resorption; Tartrate-Resistant Acid Phosphatase | 2014 |
Redox markers and inflammation are differentially affected by atorvastatin, pravastatin or simvastatin administered before endotoxin-induced acute lung injury.
Topics: Animals; Atorvastatin; Biomarkers; Endotoxins; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lung Injury; Male; Mice; Mice, Inbred C57BL; Oxidation-Reduction; Pravastatin; Pyrroles; Simvastatin | 2013 |
Effects of atorvastatin on the hypertension-induced oxidative stress in the rat brain.
Topics: Animals; Atorvastatin; Blood Pressure; Brain; Cardiomegaly; Catalase; Glutathione; Heptanoic Acids; Hypertension; Male; Malondialdehyde; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Superoxide Dismutase | 2013 |
Mechanisms of the statins cytotoxicity in freshly isolated rat hepatocytes.
Topics: Animals; Atorvastatin; Cell Death; Cell Survival; Glutathione; Glutathione Disulfide; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lovastatin; Male; Membrane Potential, Mitochondrial; Pyrroles; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Simvastatin | 2013 |
Atorvastatin reduces myocardial fibrosis in a rat model with post-myocardial infarction heart failure by increasing the matrix metalloproteinase-2/tissue matrix metalloproteinase inhibitor-2 ratio.
Topics: Animals; Atorvastatin; Collagen; Disease Models, Animal; Female; Fibrosis; Heart Failure; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Matrix Metalloproteinase 2; Myocardial Infarction; Myocardium; Pyrroles; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-2; Ventricular Remodeling | 2013 |
Epidemiology of CYP3A4-mediated clopidogrel drug-drug interactions and their clinical consequences.
Topics: Aged; Atorvastatin; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Ticlopidine | 2013 |
[Statins after drug discontinuation are usually well tolerated].
Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Drug Substitution; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Retreatment; Retrospective Studies; Simvastatin | 2013 |
Atorvastatin favorably modulates proinflammatory cytokine profile in patients following deep vein thrombosis.
Topics: Atorvastatin; C-Reactive Protein; Cytokines; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukins; P-Selectin; Pyrroles; Venous Thromboembolism | 2013 |
Atorvastatin in stable angina patients lowers CCL2 and ICAM1 expression: pleiotropic evidence from plasma mRNA analyses.
Topics: Aged; Angina, Stable; Anticholesteremic Agents; Atorvastatin; Chemokine CCL2; Cholesterol, LDL; Drug Administration Schedule; Female; Gene Expression; Heptanoic Acids; Humans; Intercellular Adhesion Molecule-1; Male; Middle Aged; Pyrroles; RNA, Messenger | 2013 |
Comparison of rosuvastatin versus atorvastatin for preventing postoperative atrial fibrillation.
Topics: Atorvastatin; Atrial Fibrillation; Comorbidity; Coronary Artery Bypass; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Premedication; Prevalence; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Turkey | 2013 |
Atorvastatin counteracts aberrant soft tissue mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6⁻/⁻).
Topics: Animals; Atorvastatin; ATP-Binding Cassette Transporters; Calcinosis; Calcium; Connective Tissue; Dermis; Disease Models, Animal; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Mice; Mice, Knockout; Pseudoxanthoma Elasticum; Pyrroles | 2013 |
Improved neurocognitive functions correlate with reduced inflammatory burden in atrial fibrillation patients treated with intensive cholesterol lowering therapy.
Topics: Aged; Amygdala; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Azetidines; Brain; Cognition; Electrocardiography; Executive Function; Ezetimibe; Female; Heptanoic Acids; Hippocampus; Humans; Image Processing, Computer-Assisted; Inflammation; Magnetic Resonance Imaging; Male; Memory; Neuroimaging; Neuropsychological Tests; Psychomotor Performance; Pyrroles; Reaction Time; Vocabulary | 2013 |
HMG-CoA reductase inhibitors, simvastatin and atorvastatin, downregulate ABCG1-mediated cholesterol efflux in human macrophages.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Cassette Transporters; Biotinylation; Blotting, Western; Cell Separation; Cells, Cultured; CHO Cells; Cholesterol; Cricetinae; Cricetulus; Down-Regulation; Heptanoic Acids; Humans; Hydrocarbons, Fluorinated; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indicators and Reagents; Lipoproteins, LDL; Liver X Receptors; Macrophages; Orphan Nuclear Receptors; Plasmids; Pyrroles; Real-Time Polymerase Chain Reaction; Simvastatin; Sulfonamides; Transfection | 2013 |
In vitro study of dual drug-eluting stents with locally focused sirolimus and atorvastatin release.
Topics: Atorvastatin; Calorimetry, Differential Scanning; Cell Proliferation; Cells, Cultured; Drug-Eluting Stents; Heptanoic Acids; Humans; In Vitro Techniques; Microscopy, Electron, Scanning; Molecular Weight; Pyrroles; Sirolimus | 2013 |
Atorvastatin is beneficial for muscle reinnervation after complete sciatic nerve section in rats.
Topics: Animals; Atorvastatin; Axons; Biomechanical Phenomena; Electromyography; Female; Fibrin Tissue Adhesive; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Locomotion; Microsurgery; Models, Animal; Muscle Strength; Muscle, Skeletal; Myelin Sheath; Nerve Regeneration; Pyrroles; Rats; Rats, Sprague-Dawley; Recovery of Function; Sciatic Nerve; Sutures; Tissue Adhesives | 2013 |
MicroRNA-22 downregulation by atorvastatin in a mouse model of cardiac hypertrophy: a new mechanism for antihypertrophic intervention.
Topics: Angiotensin II; Animals; Anticholesteremic Agents; Atorvastatin; Atrial Natriuretic Factor; Cardiomegaly; Cells, Cultured; Disease Models, Animal; Down-Regulation; Heptanoic Acids; Male; Mice; MicroRNAs; Myocardium; Myocytes, Cardiac; Myosin Heavy Chains; Natriuretic Peptide, Brain; Oligonucleotides, Antisense; Phosphoric Monoester Hydrolases; PTEN Phosphohydrolase; Pyrroles; Rats | 2013 |
Structural characterization of electrochemically and in vitro biologically generated oxidation products of atorvastatin using UHPLC/MS/MS.
Topics: Animals; Atorvastatin; Biological Transport; Biotransformation; Cells, Cultured; Chromatography, High Pressure Liquid; Electrolysis; Glycols; Hepatocytes; Heptanoic Acids; Hydrogen-Ion Concentration; Hydroxylation; Lactones; Male; Molecular Weight; Oxidation-Reduction; Pyrroles; Rats; Tandem Mass Spectrometry | 2013 |
Atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms.
Topics: Administration, Oral; Anthropometry; Anti-Inflammatory Agents; Atorvastatin; Canada; Child; Child Development; Cholesterol; Coronary Aneurysm; Coronary Vessels; Dose-Response Relationship, Drug; Drug Monitoring; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver Function Tests; Male; Medical Records, Problem-Oriented; Mucocutaneous Lymph Node Syndrome; Pyrroles; Retrospective Studies | 2014 |
Antihyperalgesic and anti-inflammatory effects of atorvastatin in chronic constriction injury-induced neuropathic pain in rats.
Topics: Analgesia; Animals; Anti-Inflammatory Agents; Atorvastatin; Constriction; Dinoprostone; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1beta; Male; Matrix Metalloproteinase 2; Nerve Growth Factor; Neuralgia; Pain Measurement; Pyrroles; Rats; Rats, Wistar; Sciatic Nerve; Spinal Cord; Tumor Necrosis Factor-alpha | 2013 |
Comparative protective effect of hawthorn berry hydroalcoholic extract, atorvastatin, and mesalamine on experimentally induced colitis in rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Colitis; Crataegus; Fruit; Heptanoic Acids; Humans; Lipid Peroxidation; Male; Mesalamine; Plant Extracts; Pyrroles; Rats; Rats, Wistar | 2013 |
Synergistic effect of combined treatment with gamma-tocotrienol and statin on human malignant mesothelioma cells.
Topics: Apoptosis; Atorvastatin; Caspase 3; Cell Line, Tumor; Cell Proliferation; Chromans; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Enzyme Activation; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mesothelioma; Metabolic Networks and Pathways; Mevalonic Acid; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Simvastatin; Vitamin E | 2013 |
LC-MS-MS simultaneous determination of atorvastatin and ezetimibe in human plasma.
Topics: Atorvastatin; Azetidines; Chromatography, Liquid; Ezetimibe; Heptanoic Acids; Humans; Pyrroles; Reproducibility of Results; Tandem Mass Spectrometry | 2014 |
Atorvastatin as novel treatment for neuropathic pain: a case report.
Topics: Analgesics; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neuralgia; Phantom Limb; Pyrroles; Treatment Outcome | 2013 |
Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care.
Topics: Adult; Alabama; Atorvastatin; California; CD4-Positive T-Lymphocytes; Cohort Studies; Comparative Effectiveness Research; Drug Interactions; Female; Fenofibrate; Fish Oils; Gemfibrozil; Heptanoic Acids; HIV Infections; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; North Carolina; Practice Guidelines as Topic; Pyrroles; Retrospective Studies; San Francisco; Treatment Outcome; Triglycerides; Washington | 2013 |
Mod5 protein binds to tRNA gene complexes and affects local transcriptional silencing.
Topics: Alkyl and Aryl Transferases; Arabidopsis; Atorvastatin; Blotting, Northern; Cell Nucleolus; Chromatin Immunoprecipitation; Cloning, Molecular; DNA Primers; Gene Silencing; Heptanoic Acids; Humans; Immunoprecipitation; In Situ Hybridization; Oligonucleotides; Promoter Regions, Genetic; Pyrroles; RNA Polymerase II; RNA, Transfer; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins | 2013 |
Acute vascular effects of atorvastatin in hypertensive men: a pilot study.
Topics: Angiotensin II; Atorvastatin; Endothelium, Vascular; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pilot Projects; Pyrroles; Regional Blood Flow; Vasoconstriction; Vasodilation | 2013 |
Evidence based policy decisions through a Bayesian approach: the case of a statin appraisal in The Netherlands.
Topics: Atorvastatin; Bayes Theorem; Decision Making; Drug and Narcotic Control; Evidence-Based Medicine; Heptanoic Acids; Humans; Hypolipidemic Agents; Insurance, Health, Reimbursement; Netherlands; Practice Patterns, Physicians'; Pyrroles; Simvastatin | 2013 |
Inhibition of proliferation and induction of autophagy by atorvastatin in PC3 prostate cancer cells correlate with downregulation of Bcl2 and upregulation of miR-182 and p21.
Topics: Atorvastatin; Autophagy; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Diterpenes; Down-Regulation; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Humans; Male; MicroRNAs; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Up-Regulation | 2013 |
Differential sensitivity of the species of Candida parapsilosis sensu lato complex against statins.
Topics: Anticholesteremic Agents; Antifungal Agents; Atorvastatin; Candida; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Indoles; Microbial Sensitivity Tests; Microbiological Techniques; Pyrroles; Sensitivity and Specificity | 2013 |
Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
Topics: Animals; Atorvastatin; Caspase 3; Cell Line; Cell Proliferation; Cell Shape; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; Humans; Lymphangioleiomyomatosis; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Simvastatin; Sirolimus; TOR Serine-Threonine Kinases; Transfection; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2013 |
ASK NOT what CRP can do for you.
Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cardiovascular Diseases; Female; Heptanoic Acids; Humans; Male; Pyrroles | 2013 |
Electronegative low-density lipoprotein increases C-reactive protein expression in vascular endothelial cells through the LOX-1 receptor.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cells, Cultured; Endothelial Cells; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins, LDL; Male; Middle Aged; Pyrroles; Reactive Oxygen Species; Scavenger Receptors, Class E | 2013 |
High coronary plaque load: a heavy burden.
Topics: Atorvastatin; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2013 |
Combination therapy with atorvastatin and amlodipine suppresses angiotensin II-induced aortic aneurysm formation.
Topics: Amlodipine; Angiotensin II; Animals; Aortic Aneurysm, Abdominal; Apoptosis; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Drug Therapy, Combination; Enzyme Activation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Matrix Metalloproteinases; Mice; Mice, Knockout; Pyrroles; rho-Associated Kinases | 2013 |
Effect of atorvastatin on atherosclerotic plaque formation and platelet activation in hypercholesterolemic rats.
Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Atorvastatin; Biomarkers; CD40 Antigens; CD40 Ligand; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipids; Male; P-Selectin; Plaque, Atherosclerotic; Platelet Activation; Platelet Factor 4; Pyrroles; Rats; Rats, Wistar | 2013 |
Prevalence and types of persistent dyslipidemia in patients treated with statins.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Croatia; Cross-Sectional Studies; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prevalence; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2013 |
Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model.
Topics: Animals; Anti-Inflammatory Agents; Antimalarials; Artemisinins; Atorvastatin; Biomarkers; Disease Models, Animal; Drug Therapy, Combination; Female; Heptanoic Acids; Inflammation; Malaria, Cerebral; Mice; Mice, Inbred C57BL; Pyrroles; Survival Analysis; Treatment Outcome | 2013 |
Atorvastatin improves microenvironment to enhance the beneficial effects of BMSCs therapy in a rabbit model of acute myocardial infarction.
Topics: Animals; Atorvastatin; Cells, Cultured; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Mesenchymal Stem Cell Transplantation; Myocardial Infarction; Myocytes, Cardiac; Pyrroles; Rabbits | 2013 |
The effects of atorvastatin on oxidative stress in L-NAME-treated rats.
Topics: Animals; Aryldialkylphosphatase; Atorvastatin; Drug Evaluation, Preclinical; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lipid Peroxidation; Lipids; Male; NG-Nitroarginine Methyl Ester; Oxidative Stress; Protein Carbonylation; Pyrroles; Rats; Rats, Wistar; Sulfhydryl Compounds | 2013 |
Pseudoxanthoma elasticum and statin prophylaxis.
Topics: Animals; Atorvastatin; Calcinosis; Connective Tissue; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pseudoxanthoma Elasticum; Pyrroles | 2013 |
Chronic pravastatin but not atorvastatin treatment impairs cognitive function in two rodent models of learning and memory.
Topics: Animals; Atorvastatin; Body Weight; Cholesterol; Cognition; Discrimination, Psychological; Heptanoic Acids; Male; Memory; Pravastatin; Pyrroles; Rats; Reversal Learning; Time Factors | 2013 |
Effect of P-glycoprotein on the rat intestinal permeability and metabolism of the BDDCS class 1 drug verapamil.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Digoxin; Heptanoic Acids; Intestinal Absorption; Pyrroles; Rats; Rats, Sprague-Dawley; Verapamil | 2013 |
Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3,227 patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Muscular Diseases; Observation; Prospective Studies; Pyrroles; Surveys and Questionnaires | 2013 |
Synergistic effects of atorvastatin and all-trans retinoic acid in ameliorating animal model of multiple sclerosis.
Topics: Animals; Atorvastatin; Brain; Cytokines; Disease Models, Animal; Drug Synergism; Encephalomyelitis, Autoimmune, Experimental; Female; Forkhead Transcription Factors; Heptanoic Acids; Mice; Multiple Sclerosis; Pyrroles; T-Lymphocytes, Regulatory; Tretinoin; Weight Loss | 2014 |
Effect of atorvastatin on left atrial function of patients with paroxysmal atrial fibrillation.
Topics: Adult; Atorvastatin; Atrial Fibrillation; Atrial Function, Left; Echocardiography; Female; Heart Atria; Heptanoic Acids; Humans; Hypertension; Male; Middle Aged; Pyrroles | 2013 |
How do statins work?: changing paradigms with implications for statin allocation.
Topics: Atorvastatin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Periodontal Diseases; Pyrroles | 2013 |
Characterization of partial ligation-induced carotid atherosclerosis model using dual-modality molecular imaging in ApoE knock-out mice.
Topics: Animals; Apolipoproteins E; Atorvastatin; Carotid Artery Diseases; Cell Line; Heptanoic Acids; Ligation; Lithium Chloride; Mice; Mice, Knockout; Molecular Imaging; Pyrroles | 2013 |
Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Pyrroles; Quinazolines; ras Proteins; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Atorvastatin-loaded hydrogel affects the smooth muscle cells of human veins.
Topics: Atorvastatin; Blotting, Western; Cell Movement; Cell Proliferation; DNA Primers; Dose-Response Relationship, Drug; Heptanoic Acids; Humans; Hydrogels; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Myocytes, Smooth Muscle; Primary Cell Culture; Pyrroles; Transcription, Genetic; Veins | 2013 |
Comment on atorvastatin safety in kawasaki disease patients with coronary artery aneurysms.
Topics: Atorvastatin; Child Development; Coronary Aneurysm; Coronary Vessels; Female; Heptanoic Acids; Humans; Inflammation; Male; Mucocutaneous Lymph Node Syndrome; Pyrroles | 2014 |
Long-term use of statins reduces the risk of hospitalization for dementia.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Case-Control Studies; Dementia; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Italy; Logistic Models; Male; Middle Aged; Pravastatin; Pyrroles; Risk; Simvastatin; Time Factors | 2013 |
STOMPing forward: statins, muscle complaints and CK.
Topics: Atherosclerosis; Atorvastatin; Creatine Kinase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Weakness; Muscle, Skeletal; Muscles; Muscular Diseases; Myalgia; Pyrroles; Randomized Controlled Trials as Topic | 2013 |
[Influence of CETP gene -629C/A polymorphism on the efficacy of atorvastatin treatment and clinical outcome].
Topics: Adult; Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Female; Heptanoic Acids; Humans; Male; Middle Aged; Mutation, Missense; Polymorphism, Single Nucleotide; Pyrroles; Treatment Outcome | 2013 |
Characterization of statin dose response in electronic medical records.
Topics: Algorithms; Alleles; Atorvastatin; Cholesterol, LDL; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Electronic Health Records; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Lipids; Phenotype; Polymorphism, Single Nucleotide; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2014 |
[A multi-device approach to an unusual case of left main thrombosis: when manual thrombectomy is not enough].
Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Anticoagulants; Atorvastatin; Combined Modality Therapy; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Embolic Protection Devices; Embolism; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Immunoglobulin Fab Fragments; Infusions, Intra-Arterial; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Suction; Thrombectomy; Tomography, Optical Coherence | 2013 |
Author reply to comment on "atorvastatin safety in Kawasaki disease patients with coronary artery aneurysms".
Topics: Atorvastatin; Child Development; Coronary Aneurysm; Coronary Vessels; Female; Heptanoic Acids; Humans; Inflammation; Male; Mucocutaneous Lymph Node Syndrome; Pyrroles | 2014 |
A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation.
Topics: Allografts; Animals; Atorvastatin; Biopsy; Cohort Studies; Dasatinib; Databases as Topic; Disease Models, Animal; Drug Approval; Electronic Health Records; Gene Expression Regulation; Gene Regulatory Networks; Graft Rejection; Graft Survival; Heart Transplantation; Heptanoic Acids; Humans; Kidney; Kidney Transplantation; Meta-Analysis as Topic; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Organ Specificity; Pyrimidines; Pyrroles; Reproducibility of Results; Retrospective Studies; Thiazoles; Transplantation; United States; United States Food and Drug Administration | 2013 |
Are statins 'IDEAL' for non-alcoholic fatty liver disease?
Topics: Atorvastatin; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver; Liver Neoplasms; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Triglycerides | 2014 |
The effects of statins on the mevalonic acid pathway in recombinant yeast strains expressing human HMG-CoA reductase.
Topics: Atorvastatin; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Fungal Proteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Isoenzymes; Mevalonic Acid; Organisms, Genetically Modified; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Saccharomyces cerevisiae; Simvastatin; Sterols; Sulfonamides; Terpenes | 2013 |
Atorvastatin decreases bone loss, inflammation and oxidative stress in experimental periodontitis.
Topics: Alveolar Bone Loss; Animals; Atorvastatin; Heptanoic Acids; Inflammation; Male; Oxidative Stress; Periodontitis; Pyrroles; Rats; Rats, Wistar | 2013 |
Toxoplasma gondii relies on both host and parasite isoprenoids and can be rendered sensitive to atorvastatin.
Topics: Animals; Apicoplasts; Atorvastatin; Diphosphates; Diterpenes; Farnesyltranstransferase; Female; Gene Knockdown Techniques; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred BALB C; Polyisoprenyl Phosphates; Protozoan Proteins; Pyrroles; Sesquiterpenes; Toxoplasma; Toxoplasmosis | 2013 |
RP-HPLC method development and validation for simultaneous estimation of atorvastatin calcium and pioglitazone hydrochloride in pharmaceutical dosage form.
Topics: Atorvastatin; Calibration; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Dosage Forms; Drug Combinations; Heptanoic Acids; Hydrogen-Ion Concentration; Limit of Detection; Phosphoric Acids; Pioglitazone; Pyrroles; Reproducibility of Results; Thiazolidinediones | 2014 |
Atorvastatin reduces the myocardial content of coenzyme Q10 in isoproterenol-induced heart failure in rats.
Topics: Animals; Antioxidants; Atorvastatin; Heart Failure; Heptanoic Acids; Isoproterenol; Lipid Peroxidation; Lipids; Male; Malondialdehyde; Myocardium; Pyrroles; Rats; Rats, Wistar; Ubiquinone | 2014 |
One case of eosinophilia caused by atorvastatin.
Topics: Atorvastatin; Eosinophilia; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles | 2013 |
Zinc chelation: a metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance.
Topics: Adolescent; Atorvastatin; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Survival; Chelating Agents; Child; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Heptanoic Acids; Humans; Metallothionein; Osteoblasts; Osteosarcoma; Prognosis; Protein Conformation; Pyrroles; RNA, Messenger; Tumor Suppressor Protein p53; Zinc | 2013 |
Antifibrotic effect of atorvastatin on paraquat-induced pulmonary fibrosis: role of PPARγ receptors.
Topics: Anilides; Animals; Atorvastatin; Body Weight; Heptanoic Acids; Herbicides; Hydroxyproline; Lung; Male; Organ Size; Paraquat; Pioglitazone; PPAR gamma; Protective Agents; Pulmonary Fibrosis; Pyrroles; Rats; Rats, Wistar; RNA, Messenger; Thiazolidinediones; Transforming Growth Factor beta1 | 2013 |
Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Apolipoproteins B; Atherosclerosis; Atorvastatin; Biomarkers; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemias; Lipoproteins, LDL; Male; Middle Aged; Pilot Projects; Pyrroles; Time Factors; Treatment Outcome; Triglycerides | 2014 |
Inhibitory effect of co-administration of atorvastatin and endothelin-1 receptor antagonist on the progression of atherosclerosis in rabbit.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Disease Progression; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Endothelin-1; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Inflammation Mediators; Lipids; Male; Matrix Metalloproteinase 9; NF-kappa B; Phenylpropionates; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rabbits; RNA, Messenger | 2014 |
Leveraging electronic health records to notify pediatric patients of a drug recall.
Topics: Atorvastatin; Boston; Child; Drug Contamination; Drug Recalls; Electronic Health Records; Heptanoic Acids; Humans; Patient Identification Systems; Pyrroles | 2013 |
Effect of extraction solvents and plant parts used on the antihyperlipidemic and antioxidant effects of Garcinia atroviridis: a comparative study.
Topics: Animals; Antioxidants; Atorvastatin; Flavonoids; Fruit; Garcinia; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Methanol; Phenols; Phytotherapy; Plant Extracts; Plant Leaves; Plant Stems; Pyrroles; Rats; Rats, Sprague-Dawley; Solvents; Water | 2014 |
[Effects of genetic variations of cholesteryl ester transfer protein on atorvastatin treatment efficacy and clinical outcomes in patients with coronary artery disease].
Topics: Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Coronary Artery Disease; Enzyme-Linked Immunosorbent Assay; Genetic Variation; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Promoter Regions, Genetic; Pyrroles; Treatment Outcome | 2013 |
Near-infrared fluorescence imaging of murine atherosclerosis using an oxidized low density lipoprotein-targeted fluorochrome.
Topics: Animals; Antibodies; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cell Line; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Feasibility Studies; Fluorescent Dyes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isothiocyanates; Lipoproteins, LDL; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Optical Imaging; Plaque, Atherosclerotic; Pyrroles; Time Factors | 2014 |
Atorvastatin inhibited Rho-associated kinase 1 (ROCK1) and focal adhesion kinase (FAK) mediated adhesion and differentiation of CD133+CD44+ prostate cancer stem cells.
Topics: AC133 Antigen; Aged; Antigens, CD; Antineoplastic Agents; Atorvastatin; Cell Adhesion; Cell Differentiation; Focal Adhesion Kinase 1; Glycoproteins; Heptanoic Acids; Humans; Hyaluronan Receptors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neoplastic Stem Cells; Peptides; Prostate; Prostatic Neoplasms; Pyrroles; rho-Associated Kinases; Tumor Cells, Cultured | 2013 |
Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Cell Adhesion; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dietary Fats; Endothelial Cells; Heptanoic Acids; Hypercholesterolemia; Macrophages; Male; Monocytes; Plaque, Atherosclerotic; Probucol; Pyrroles; Rabbits; Triglycerides; Tunica Intima | 2013 |
Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.
Topics: Adolescent; Adult; Aged; Animals; Atorvastatin; Biological Availability; Heptanoic Acids; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Mice; Mice, Knockout; Middle Aged; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Pravastatin; Pyrroles; Simvastatin; Solute Carrier Organic Anion Transporter Family Member 1B3; Tissue Distribution; Young Adult | 2014 |
Effect of vanillin on lipid profile in a model of hyperlipidemia, a preliminary study.
Topics: Animal Feed; Animals; Atorvastatin; Benzaldehydes; Cholesterol; Diet, High-Fat; Dietary Fats; Female; Free Radicals; Gene Expression Regulation; Heptanoic Acids; Hyperlipidemias; Lipids; Male; Oxygen; Pyrroles; Rats; Rats, Wistar; Triglycerides | 2013 |
Statins decrease mean platelet volume irrespective of cholesterol lowering effect.
Topics: Adult; Atorvastatin; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Mean Platelet Volume; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides | 2013 |
Networks of genes modulating the pleiotropic drug response in Saccharomyces cerevisiae.
Topics: Atorvastatin; ATP-Binding Cassette Transporters; DNA-Binding Proteins; Drug Resistance, Multiple; Gene Deletion; Gene Expression Regulation, Fungal; Gene Regulatory Networks; Heptanoic Acids; Pyrroles; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Signal Transduction; Transcription Factors; Transcription, Genetic | 2014 |
Coamorphous atorvastatin calcium to improve its physicochemical and pharmacokinetic properties.
Topics: Animals; Atorvastatin; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Niacinamide; Pyrroles; Rats; Rats, Wistar; Solubility | 2013 |
Metabonomics study of the therapeutic mechanism of Gynostemma pentaphyllum and atorvastatin for hyperlipidemia in rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Gynostemma; Heptanoic Acids; Hyperlipidemias; Lipid Metabolism; Liver; Magnetic Resonance Spectroscopy; Male; Metabolomics; Methylamines; Phosphatidylcholines; Phytotherapy; Plant Extracts; Pyrroles; Rats; Rats, Sprague-Dawley; Treatment Outcome; Triglycerides | 2013 |
Influence of PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms on the lipid-lowering efficacy and safety of statin therapy.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Anticholesteremic Agents; Atorvastatin; Constitutive Androstane Receptor; Dyslipidemias; Female; Genotype; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; PPAR alpha; Pregnane X Receptor; Pyrroles; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Retinoid X Receptor alpha; Risk Factors; Simvastatin; Treatment Outcome | 2013 |
Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation.
Topics: Animals; Apolipoproteins E; Atorvastatin; CD36 Antigens; Cholesterol; Cholesterol, Dietary; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance; Feedback, Physiological; Hep G2 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Inflammation Mediators; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Pyrroles; RNA Interference; Scavenger Receptors, Class A; Stress, Physiological; Time Factors; Transfection | 2014 |
Low level of inflammatory marker in hyperhomocysteinemic patients on statin therapy.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Case-Control Studies; Cells, Cultured; Chemokines; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperhomocysteinemia; Inflammation Mediators; Leukocytes, Mononuclear; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Young Adult | 2014 |
Exploring Leishmania donovani 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) as a potential drug target by biochemical, biophysical and inhibition studies.
Topics: Amino Acid Sequence; Atorvastatin; Cholesterol; Cloning, Molecular; DNA, Protozoan; Drug Delivery Systems; Ergosterol; Gene Expression Regulation, Enzymologic; Genes, Protozoan; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leishmania donovani; Molecular Sequence Data; Open Reading Frames; Protein Structure, Secondary; Pyrroles; Recombinant Proteins; Resveratrol; Sequence Analysis, DNA; Simvastatin; Stilbenes | 2014 |
The therapeutic potential of atorvastatin in a mouse model of postoperative cognitive decline.
Topics: Administration, Oral; Animals; Atorvastatin; Cognition; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Memory; Mice; Mice, Inbred C57BL; Nephrectomy; Postoperative Complications; Pyrroles; Recovery of Function; Treatment Outcome | 2014 |
Development and validation of a discriminative dissolution method for atorvastatin calcium tablets using in vivo data by LC and UV methods.
Topics: Atorvastatin; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Heptanoic Acids; Pyrroles; Quality Control; Solubility; Spectrophotometry, Ultraviolet; Tablets | 2014 |
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Cholesterol, LDL; Databases, Factual; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Managed Care Programs; Middle Aged; Multivariate Analysis; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; United States | 2013 |
10-Dehydrogingerdione raises HDL-cholesterol through a CETP inhibition and wards off oxidation and inflammation in dyslipidemic rabbits.
Topics: Animals; Atorvastatin; C-Reactive Protein; Cell Proliferation; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Diet, Atherogenic; Disease Models, Animal; Dyslipidemias; Guaiacol; Heptanoic Acids; Inflammation; Male; Mass Spectrometry; Oxygen; Pyrroles; Rabbits; Risk Factors | 2013 |
Protective mechanisms of atorvastatin against doxorubicin-induced hepato-renal toxicity.
Topics: Animals; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antioxidants; Apoptosis; Atorvastatin; Chemical and Drug Induced Liver Injury; Down-Regulation; Doxorubicin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Male; Nitric Oxide; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Up-Regulation | 2014 |
Effects of atorvastatin on chronic subdural hematoma: a preliminary report from three medical centers.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cohort Studies; Female; Follow-Up Studies; Hematoma, Subdural, Chronic; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2014 |
Endothelial relaxation mechanisms and oxidative stress are restored by atorvastatin therapy in ovariectomized rats.
Topics: Acetylcholine; Animals; Atorvastatin; Biological Factors; Blotting, Western; Body Weight; Cholesterol; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Endothelium, Vascular; Female; Heptanoic Acids; Mesenteric Arteries; NADPH Oxidases; Nitric Oxide Synthase; Organ Size; Ovariectomy; Oxidative Stress; Prostaglandins; Pyrroles; Rats, Wistar; Reactive Oxygen Species; Uterus; Vasodilation | 2013 |
HMG CoA reductase inhibitor treatment induces dysglycemia in renal allograft recipients.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Dyslipidemias; Fasting; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Immunosuppressive Agents; Incidence; Indoles; Kidney Transplantation; Male; Middle Aged; Pyrroles; Renal Insufficiency | 2014 |
Effects of HMG-CoA reductase inhibitors on learning and memory in the guinea pig.
Topics: Amnesia; Animals; Atorvastatin; Behavior, Animal; Guinea Pigs; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Long-Term Potentiation; Male; Maze Learning; Memory; Pyrroles; Simvastatin; Synaptic Transmission | 2014 |
Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Castration; Celecoxib; Cell Survival; Cyclooxygenase 2 Inhibitors; Disease Progression; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitor of Apoptosis Proteins; Interleukin-6; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Survivin; Xenograft Model Antitumor Assays | 2014 |
Polymorphisms of the farnesyl diphosphate synthase gene modulate bone changes in response to atorvastatin.
Topics: Absorptiometry, Photon; Aged; Atorvastatin; Bone Density; Coronary Disease; Female; Femur; Gene Frequency; Genotype; Geranyltranstransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Pyrroles; Time Factors; Treatment Outcome | 2014 |
Atorvastatin treatment of rats with ischemia-reperfusion injury improves adipose-derived mesenchymal stem cell migration and survival via the SDF-1α/CXCR-4 axis.
Topics: Adipose Tissue; Allografts; Animals; Atorvastatin; Cell Movement; Cell Survival; Chemokine CXCL12; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Myocardial Reperfusion Injury; Myocytes, Cardiac; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, CXCR4 | 2013 |
Effects of simvaglyzin and atorvaglyzin on the expression of 3-hydroxy-3-methyl-glutaryl-CoA reductase in rat liver.
Topics: Animals; Atorvastatin; Gene Expression; Glycyrrhizic Acid; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Microsomes, Liver; Pyrroles; Rats; Rats, Wistar; RNA, Messenger; Simvastatin | 2013 |
The thyroid receptor modulator KB3495 reduces atherosclerosis independently of total cholesterol in the circulation in ApoE deficient mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins B; Apolipoproteins E; Atherosclerosis; Atorvastatin; Bile Acids and Salts; Biological Transport; Cytokines; Disease Models, Animal; Drug Synergism; Feces; Heptanoic Acids; Male; Mice; Mice, Knockout; Molecular Mimicry; Plaque, Atherosclerotic; Pyrroles; Thyroid Hormones | 2013 |
Myopathy after switching from brand to generic atorvastatin.
Topics: Aged; Atorvastatin; Blood Chemical Analysis; Drugs, Generic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Muscular Diseases; Polypharmacy; Pyrroles | 2013 |
Continuous oral administration of atorvastatin ameliorates brain damage after transient focal ischemia in rats.
Topics: Administration, Oral; Animals; Atorvastatin; Brain; Brain Edema; Brain Ischemia; DNA Damage; Heptanoic Acids; Lipid Peroxidation; Magnetic Resonance Imaging; Male; Microglia; Neuroimaging; Neuroprotective Agents; Oxidative Stress; Pyrroles; Rats; Rats, Sprague-Dawley; Time Factors; Tumor Necrosis Factor-alpha | 2014 |
Effects of silymarin on the pharmacokinetics of atorvastatin in diabetic rats.
Topics: Animals; Atorvastatin; Cytochrome P-450 CYP3A; Diabetes Mellitus, Experimental; Drug Interactions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Pyrroles; Rats; Rats, Wistar; Silymarin; Streptozocin; Testosterone | 2014 |
Atorvastatin attenuates bleomycin-induced pulmonary fibrosis via suppressing iNOS expression and the CTGF (CCN2)/ERK signaling pathway.
Topics: Animals; Atorvastatin; Bleomycin; Body Weight; Collagen; Connective Tissue Growth Factor; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxyproline; Male; Malondialdehyde; Nitric Oxide; Nitric Oxide Synthase Type II; Phosphorylation; Pulmonary Fibrosis; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction | 2013 |
Atorvastatin and sildenafil lower blood pressure and improve endothelial dysfunction, but only atorvastatin increases vascular stores of nitric oxide in hypertension.
Topics: Animals; Aorta; Atorvastatin; Blood Pressure; Body Weight; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Hypertension, Renovascular; Male; Nitric Oxide; Piperazines; Purines; Pyrroles; Rats; Rats, Wistar; Sildenafil Citrate; Sulfonamides | 2013 |
Moving branded statins to lowest copay tier improves patient adherence.
Topics: Aged; Aged, 80 and over; Atorvastatin; Cross-Sectional Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medicare Part D; Middle Aged; Patient Compliance; Prescription Drugs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; United States | 2014 |
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Fenofibrate; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liraglutide; Male; Metabolic Syndrome; Mice, Transgenic; Niacin; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Rosiglitazone; Thiazolidinediones | 2014 |
[The effect of PPARalpha signal channel on atorvastatin inhibiting MMP-9 expression in aging myocytes].
Topics: Aging; Animals; Atorvastatin; Cells, Cultured; Heptanoic Acids; Matrix Metalloproteinase 9; Muscle Cells; Oxazoles; PPAR alpha; Pyrroles; Rats; Rats, Wistar; Signal Transduction; Tyrosine | 2013 |
Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats.
Topics: Amlodipine; Animals; Atorvastatin; Biopterins; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Fructose; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Rats; Rats, Sprague-Dawley; Superoxides; Vasoconstriction; Vasodilation | 2014 |
Comparison of effects of different statins on growth and steroidogenesis of rat ovarian theca-interstitial cells.
Topics: Animals; Atorvastatin; Cell Proliferation; Cells, Cultured; Female; Gonadal Steroid Hormones; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Metabolic Networks and Pathways; Ovary; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Theca Cells | 2014 |
Effects of atorvastatin and insulin in vascular dysfunction associated with type 2 diabetes.
Topics: Animals; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Heptanoic Acids; Hypoglycemic Agents; Insulin; Male; Pyrroles; Rats; Treatment Outcome | 2014 |
Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in salt-sensitive hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Atorvastatin; Blood Pressure; C-Reactive Protein; Calcium Channel Blockers; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy; Male; Nitric Oxide Synthase Type III; Pyrroles; Rats, Inbred Dahl; Scavenger Receptors, Class E; Sodium Chloride, Dietary; Superoxides; Time Factors; Vasodilation | 2014 |
Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Computer Simulation; Drug Substitution; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Middle Aged; Models, Biological; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2014 |
Atorvastatin treatment attenuates renal injury in an experimental model of ischemia-reperfusion in rats.
Topics: Acute Kidney Injury; Animals; Anticholesteremic Agents; Atorvastatin; Disease Models, Animal; Glomerular Filtration Rate; Heptanoic Acids; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Treatment Outcome | 2014 |
Atorvastatin prevents sepsis-induced downregulation of myocardial β1-adrenoceptors and decreased cAMP response in mice.
Topics: Animals; Atorvastatin; Blotting, Western; Catecholamines; Cyclic AMP; Heptanoic Acids; Lactic Acid; Male; Mice; Myocardium; Pyrroles; Real-Time Polymerase Chain Reaction; Receptors, Adrenergic, beta; Sepsis; Ventricular Function, Left | 2014 |
Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cohort Studies; Cytochrome P-450 CYP3A; Female; Gene Frequency; Genetic Association Studies; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; NADPH-Ferrihemoprotein Reductase; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin | 2014 |
Atorvastatin ameliorates contrast medium-induced renal tubular cell apoptosis in diabetic rats via suppression of Rho-kinase pathway.
Topics: Acute Kidney Injury; Animals; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Caspase 3; Contrast Media; Diabetes Mellitus, Experimental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iohexol; Kidney Tubules; Male; Protein Phosphatase 1; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Rats; Rats, Wistar; rho-Associated Kinases | 2014 |
Beyond greyscale IVUS assessment of progression/regression: it should be simple, but it's not.
Topics: Atorvastatin; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2014 |
Atorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cells.
Topics: Adenosine Triphosphate; Atorvastatin; Blotting, Western; Carrier Proteins; Cell Movement; Cell Nucleus; Cell Proliferation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoenzyme Techniques; Male; Neoplasm Invasiveness; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; Receptors, Purinergic P2X7; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured | 2014 |
Atorvastatin inhibits hyperglycemia-induced expression of osteopontin in the diabetic rat kidney via the p38 MAPK pathway.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Diabetic Nephropathies; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Kidney Glomerulus; Kidney Tubules; Lipids; Male; MAP Kinase Signaling System; Osteopontin; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrroles; Rats | 2014 |
Statins combined with exercise are associated with the increased renal function mediated by high-molecular-weight adiponectin in coronary artery disease patients.
Topics: Adiponectin; Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Combined Modality Therapy; Coronary Artery Disease; Exercise Therapy; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Molecular Weight; Multivariate Analysis; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Coenzyme Q10 supplementation improves metabolic parameters, liver function and mitochondrial respiration in rats with high doses of atorvastatin and a cholesterol-rich diet.
Topics: Animals; Atorvastatin; Cell Respiration; Cholesterol, Dietary; Cholesterol, HDL; Diet, High-Fat; Dietary Supplements; Drug Evaluation, Preclinical; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Male; Mitochondria, Liver; Pyrroles; Rats; Rats, Wistar; Triglycerides; Ubiquinone | 2014 |
Long-term atorvastatin improves age-related endothelial dysfunction by ameliorating oxidative stress and normalizing eNOS/iNOS imbalance in rat aorta.
Topics: Aging; Animals; Aorta, Thoracic; Atorvastatin; Body Weight; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Pyrroles; Rats, Wistar; Sirtuin 1 | 2014 |
Secondary prevention of atherothrombotic or cryptogenic stroke.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Clopidogrel; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Life Style; Platelet Aggregation Inhibitors; Pyrroles; Recurrence; Risk Factors; Secondary Prevention; Stroke; Ticlopidine | 2014 |
Mystery case: a 63-year-old man with progressive proximal pain and weakness.
Topics: Atorvastatin; Blood Sedimentation; C-Reactive Protein; Creatine Kinase; Diabetes Mellitus, Type 2; Disease Progression; Electromyography; Fatigue; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscle Weakness; Neuromuscular Junction Diseases; Pain; Pyrroles; Shoulder Pain; Tomography, X-Ray Computed | 2014 |
Hypoxia/reoxygenation stress signals an increase in organic anion transporting polypeptide 1a4 (Oatp1a4) at the blood-brain barrier: relevance to CNS drug delivery.
Topics: Animals; Atorvastatin; Biological Transport; Blood Gas Analysis; Blood-Brain Barrier; Blotting, Western; Carbon Dioxide; Drug Delivery Systems; Electrolytes; Female; Heptanoic Acids; Hypoxia, Brain; Microvessels; Neuroprotective Agents; Organic Anion Transporters; Oxygen; Pyrroles; Rats; Rats, Sprague-Dawley; Reperfusion Injury | 2014 |
Atorvastatin suppresses Toll-like receptor 4 expression and NF-κB activation in rabbit atherosclerotic plaques.
Topics: Animals; Atherosclerosis; Atorvastatin; Diet, High-Fat; Gene Expression Regulation; Heptanoic Acids; NF-kappa B; Plaque, Atherosclerotic; Pyrroles; Rabbits; RNA, Messenger; Signal Transduction; Toll-Like Receptor 4 | 2014 |
Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperuricemia; Kidney; Male; Middle Aged; Pyrimidines; Pyrroles; Renal Insufficiency, Chronic; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Uric Acid | 2014 |
Total and low-density lipoprotein cholesterol in high-risk patients treated with atorvastatin monotherapy in the United Kingdom: analysis of a primary-care database.
Topics: Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Primary Health Care; Pyrroles; Retrospective Studies | 2014 |
BSA nanoparticle loaded atorvastatin calcium--a new facet for an old drug.
Topics: Adult; Animals; Anticholesteremic Agents; Antineoplastic Agents; Atorvastatin; Cattle; Cell Line, Tumor; Cell Survival; Hemolysis; Heptanoic Acids; Humans; Kinetics; Microscopy, Confocal; Microscopy, Electron, Scanning; Molecular Docking Simulation; Nanoparticles; Pancreatic Neoplasms; Pyrroles; Reactive Oxygen Species; Serum Albumin, Bovine; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Time Factors | 2014 |
Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity.
Topics: Adenylyl Cyclases; Animals; Atorvastatin; Cell Differentiation; Cell Proliferation; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Forkhead Transcription Factors; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-4; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pyrroles; Rats; STAT6 Transcription Factor; T-Lymphocytes, Regulatory; Th2 Cells | 2014 |
Effects of serum lipoproteins on cyclosporine A cellular uptake and renal toxicity in vitro.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Cyclosporine; Hepatocytes; Heptanoic Acids; Hypolipidemic Agents; Immunosuppressive Agents; Kidney; Lipoproteins; Pyrroles; Rats; Rats, Sprague-Dawley | 2014 |
The impact of pre-intervention rate of kidney function change on the assessment of CKD progression.
Topics: Aged; Atorvastatin; Biomarkers; Creatinine; Disease Progression; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Randomized Controlled Trials as Topic; Recovery of Function; Renal Insufficiency, Chronic; Research Design; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
Atorvastatin for ovarian torsion: effects on follicle counts, AMH, and VEGF expression.
Topics: Animals; Anti-Mullerian Hormone; Atorvastatin; Drug Evaluation, Preclinical; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemia; Ovarian Diseases; Ovarian Follicle; Pyrroles; Rats, Wistar; Reperfusion Injury; Torsion Abnormality; Vascular Endothelial Growth Factor A | 2014 |
Atorvastatin attenuates neuropathic pain in rat neuropathy model by down-regulating oxidative damage at peripheral, spinal and supraspinal levels.
Topics: Animals; Antioxidants; Atorvastatin; Down-Regulation; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperalgesia; Male; Neuralgia; Oxidative Stress; Pyrroles; Rats, Wistar; Sciatic Nerve; Spinal Cord | 2014 |
The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats.
Topics: Adrenergic beta-Antagonists; Animals; Atorvastatin; Bilirubin; Carbazoles; Carvedilol; Creatinine; Droxidopa; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hemodynamics; Heptanoic Acids; Liver Cirrhosis, Experimental; Mesenteric Artery, Superior; Osmolar Concentration; Portal Pressure; Potassium; Propanolamines; Propranolol; Pyrroles; Rats; Serum Albumin; Sodium; Vascular Resistance | 2015 |
Formulation and evaluation of fixed-dose combination of bilayer gastroretentive matrix tablet containing atorvastatin as fast-release and atenolol as sustained-release.
Topics: Administration, Oral; Atenolol; Atorvastatin; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Combinations; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Pyrroles; Solubility | 2014 |
Dickkopf-1 is regulated by the mevalonate pathway in breast cancer.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Density Conservation Agents; Bone Neoplasms; cdc42 GTP-Binding Protein; Cell Line, Tumor; Diphosphonates; Female; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; L Cells; Lymphocyte Activation; MCF-7 Cells; Mevalonic Acid; Mice; Osteoblasts; Osteogenesis; Osteoprotegerin; Prenylation; Pyrroles; Rho Factor; RNA Interference; RNA, Small Interfering; Triple Negative Breast Neoplasms; Wnt3A Protein; Zoledronic Acid | 2014 |
Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Atorvastatin; Azetidines; Brazil; Cholesterol, LDL; Ezetimibe; Female; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Pyrroles; Receptors, LDL | 2014 |
Long-term follow-up on the effect of combined therapy of bile acids and statins in the treatment of cerebrotendinous xanthomatosis: a case report.
Topics: Adult; Atorvastatin; Chenodeoxycholic Acid; Cognition; Drug Therapy, Combination; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neuropsychological Tests; Pyridines; Pyrroles; Simvastatin; Treatment Outcome; Xanthomatosis, Cerebrotendinous | 2014 |
Atorvastatin prevents type 2 diabetes mellitus--an experimental study.
Topics: Animals; Atorvastatin; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose Tolerance Test; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Lipid Metabolism; Male; Pyrroles; Rats; Rats, Wistar; Triglycerides | 2014 |
Electrochemical determination of atorvastatin on nano-scaled polypyrrole film.
Topics: Atorvastatin; Carbon; Electrochemical Techniques; Electrodes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Limit of Detection; Microscopy, Electrochemical, Scanning; Molecular Structure; Nanoparticles; Polymers; Pyrroles; Reproducibility of Results; Surface Properties | 2014 |
Effects of single-dose atorvastatin on interleukin-6, interferon gamma, and myocardial no-reflow in a rabbit model of acute myocardial infarction and reperfusion.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Coronary Occlusion; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; Immunohistochemistry; Inflammation; Interferon-gamma; Interleukin-6; Ligation; Male; Multivariate Analysis; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Necrosis; No-Reflow Phenomenon; Pyrroles; Rabbits; Random Allocation | 2014 |
Daily administration of atorvastatin and simvastatin for one week improves cardiac function in type 1 diabetic rats.
Topics: Animals; Atorvastatin; Blood Glucose; Cardiac Output; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Drug Administration Schedule; Heart; Heart Rate; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Ventricular Function, Left | 2014 |
Statins for millions more?
Topics: Atorvastatin; Cardiovascular Diseases; Cost-Benefit Analysis; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Participation; Practice Guidelines as Topic; Primary Prevention; Pyrroles; Risk Assessment; Risk Factors; Risk Reduction Behavior; Secondary Prevention; United Kingdom | 2014 |
A benign tumor as the apparent trigger for myopathy.
Topics: Aged; Atorvastatin; Female; Gynecologic Surgical Procedures; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Leg; Leiomyoma; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Neoplasms; Pyrroles; Treatment Outcome; Uterine Neoplasms | 2014 |
Therapeutic potential of atorvastatin-modified dendritic cells in experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells and NKR-P1(+) cells.
Topics: Animals; Atorvastatin; Cattle; Cytokines; Dendritic Cells; Female; Heptanoic Acids; Neuritis, Autoimmune, Experimental; NK Cell Lectin-Like Receptor Subfamily B; Pyrroles; Rats; Rats, Inbred Lew; T-Lymphocytes, Regulatory; Th1 Cells; Th17 Cells; Up-Regulation | 2014 |
Population and economic impact of the 2013 ACC/AHA guidelines compared with European guidelines to prevent cardiovascular disease.
Topics: Aged; American Heart Association; Atorvastatin; Cardiovascular Diseases; Europe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Societies, Medical; United States | 2014 |
Atorvastatin attenuates involvement of RhoA/Rho-kinase pathway and NF-κB activation in hypoxic pulmonary hypertensive rats.
Topics: Animals; Atorvastatin; Blotting, Western; Heptanoic Acids; Hypertension, Pulmonary; Hypoxia; Male; NF-kappa B; Pyrroles; Random Allocation; Rats; Rats, Wistar; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction | 2014 |
Asymmetric synthesis of the HMG-CoA reductase inhibitor atorvastatin calcium: an organocatalytic anhydride desymmetrization and cyanide-free side chain elongation approach.
Topics: Anhydrides; Atorvastatin; Calcium; Cyanides; Glutarates; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2014 |
Atorvastatin attenuates myocardial remodeling induced by chronic intermittent hypoxia in rats: partly involvement of TLR-4/MYD88 pathway.
Topics: Animals; Atorvastatin; Cardiomegaly; Cytokines; Heart; Heptanoic Acids; Hypoxia; Male; Myeloid Differentiation Factor 88; Myocardium; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Reactive Oxygen Species; RNA, Messenger; Signal Transduction; Sleep Apnea, Obstructive; Toll-Like Receptor 4; Ventricular Remodeling | 2014 |
Atorvastatin inhibits CXCR7 induction to reduce macrophage migration.
Topics: Anticholesteremic Agents; Atorvastatin; Base Sequence; Cell Differentiation; Cell Line; Cell Movement; Cholesterol; DNA Primers; Heptanoic Acids; Humans; Macrophages; Pyrroles; Real-Time Polymerase Chain Reaction; Receptors, CXCR; RNA, Messenger | 2014 |
Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Disease Models, Animal; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipids; Macrophages; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Plaque, Atherosclerotic; Probucol; Pyrroles; Rabbits; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2014 |
Comparison of the effects of escitalopram and atorvastatin on diet-induced atherosclerosis in rats.
Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Body Weight; Citalopram; Diet, High-Fat; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Pyrroles; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Vascular Cell Adhesion Molecule-1 | 2014 |
Prevention of arterial stiffening by using low-dose atorvastatin in diabetes is associated with decreased malondialdehyde.
Topics: Animals; Arginine; Atorvastatin; Blood Glucose; Blood Pressure; Body Weight; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Fatty Acids; Glycation End Products, Advanced; Hemodynamics; Heptanoic Acids; Lysine; Male; Malondialdehyde; Organ Size; Pyrroles; Rats, Wistar; Streptozocin; Vascular Stiffness | 2014 |
Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling.
Topics: Alzheimer Disease; Atorvastatin; Clinical Trials, Phase III as Topic; Cognition Disorders; Databases, Factual; Heptanoic Acids; Humans; Longitudinal Studies; Models, Biological; Pyrroles; Statistics as Topic | 2014 |
Oxidative stress and inflammation are differentially affected by atorvastatin, pravastatin, rosuvastatin, and simvastatin on lungs from mice exposed to cigarette smoke.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Atorvastatin; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Inhalation Exposure; Lung; Male; Mice; Mice, Inbred C57BL; Oxidative Stress; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Smoking; Sulfonamides | 2014 |
Influence of SREBP-2 and SCAP gene polymorphisms on lipid-lowering response to atorvastatin in a cohort of Chilean subjects with Amerindian background.
Topics: Atorvastatin; Cholesterol, LDL; Female; Haplotypes; Heptanoic Acids; Humans; Hypercholesterolemia; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrroles; Sterol Regulatory Element Binding Protein 2 | 2014 |
Atorvastatin induces autophagy of mesenchymal stem cells under hypoxia and serum deprivation conditions by activating the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway.
Topics: Animals; Atorvastatin; Autophagy; Cell Hypoxia; Cells, Cultured; Flow Cytometry; Heptanoic Acids; Male; MAP Kinase Signaling System; Mesenchymal Stem Cells; Microscopy, Electron, Transmission; Pyrroles; Rats | 2014 |
In situ assessment of atorvastatin impurity using MALDI mass spectrometry imaging (MALDI-MSI).
Topics: Atorvastatin; Chemistry Techniques, Analytical; Chromatography, High Pressure Liquid; Heptanoic Acids; Pyrroles; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tablets; Temperature; Time Factors | 2014 |
Characterization of the pharmaceutical effect of drugs on atherosclerotic lesions in vivo using integrated fluorescence imaging and Raman spectral measurements.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Blood Vessels; Ezetimibe; Heptanoic Acids; Hypercholesterolemia; Lipid Metabolism; Lipids; Microscopy, Confocal; Pyrroles; Spectrum Analysis, Raman; Zebrafish | 2014 |
A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Female; Heptanoic Acids; Humans; Injections, Intraperitoneal; Mice; Mice, SCID; Neoplasms, Experimental; Pancreatic Neoplasms; Pyrazoles; Pyrroles; Quinolones; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Statin treatment is associated with reduction in serum levels of receptor activator of NF-κB ligand and neutrophil activation in patients with severe carotid stenosis.
Topics: Aged; Atherosclerosis; Atorvastatin; Carotid Stenosis; Cohort Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Matrix Metalloproteinase 9; Middle Aged; Neutrophil Activation; Neutrophils; NF-kappa B; Osteopontin; Osteoprotegerin; Pyrimidines; Pyrroles; RANK Ligand; Risk Factors; RNA, Messenger; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
Long-term atorvastatin treatment leads to alterations in behavior, cognition, and hippocampal biochemistry.
Topics: Animals; Atorvastatin; Behavior, Animal; Cognition; Disks Large Homolog 4 Protein; Exploratory Behavior; Guanylate Kinases; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Maze Learning; Membrane Proteins; Mice, Inbred C57BL; Motor Activity; Pyrroles; Reflex, Startle; Synaptophysin; Syntaxin 1; Time Factors | 2014 |
No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
Topics: Adult; Aged; Alleles; Atorvastatin; Cholesterol, LDL; Drug Administration Schedule; Female; Gene Frequency; Gene-Environment Interaction; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin | 2014 |
Synergistic therapeutic vascular cytoprotection against complement-mediated injury induced via a PKCα-, AMPK-, and CREB-dependent pathway.
Topics: AMP-Activated Protein Kinases; Animals; Atorvastatin; CD55 Antigens; Complement Activation; Complement System Proteins; Cyclic AMP Response Element-Binding Protein; Cytoprotection; Drug Synergism; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Mice; Protein Kinase C; Pyrroles; Signal Transduction; Sirolimus | 2014 |
Differential effects of Rifampin and Ketoconazole on the blood and liver concentration of atorvastatin in wild-type and Cyp3a and Oatp1a/b knockout mice.
Topics: Animals; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; HEK293 Cells; Heptanoic Acids; Humans; Ketoconazole; Liver; Mice; Mice, Knockout; Organic Anion Transport Protein 1; Pyrroles; Rifampin | 2014 |
Atorvastatin combining with probucol: a new way to reduce serum uric acid level during perioperative period of interventional procedure.
Topics: Acute Kidney Injury; Aged; Antioxidants; Atorvastatin; Biomarkers; Contrast Media; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Kidney Function Tests; Male; Middle Aged; Perioperative Period; Probucol; Prospective Studies; Pyrroles; Risk Factors; Uric Acid | 2014 |
Prediction of clinical irrelevance of PK differences in atorvastatin using PK/PD models derived from literature-based meta-analyses.
Topics: Atorvastatin; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Meta-Analysis as Topic; Models, Biological; Pyrroles; Therapeutic Equivalency | 2014 |
Comparative study of three modified numerical spectrophotometric methods: an application on pharmaceutical ternary mixture of aspirin, atorvastatin and clopedogrel.
Topics: Aspirin; Atorvastatin; Clopidogrel; Heptanoic Acids; Pyrroles; Spectrophotometry; Ticlopidine | 2014 |
Effect of atorvastatin on the angiogenic responsiveness of coronary endothelial cells in normal and streptozotocin (STZ) induced diabetic rats.
Topics: Androstadienes; Animals; Anticholesteremic Agents; Atorvastatin; Benzophenanthridines; Chick Embryo; Chorioallantoic Membrane; Coronary Vessels; Diabetes Mellitus, Experimental; Endothelial Cells; Enzyme Inhibitors; Heptanoic Acids; Male; Myocardial Reperfusion Injury; Neovascularization, Physiologic; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pyrroles; Rats; Rats, Wistar; Streptozocin; Vascular Endothelial Growth Factor A; Wortmannin | 2014 |
Suppression of memory acquisition following co-administration of lithium and atorvastatin through nitric oxide pathway in mice.
Topics: Animals; Atorvastatin; Avoidance Learning; Dose-Response Relationship, Drug; Heptanoic Acids; Lithium; Male; Memory; Memory Disorders; Mice; Nitric Oxide; Pyrroles; Signal Transduction | 2014 |
Persisting weakness after withdrawal of a statin.
Topics: Aged, 80 and over; Atorvastatin; Autoimmune Diseases; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Weakness; Myositis; Necrosis; Pyrroles | 2014 |
Frequency and evolution of thin-capped fibroatheromas in left main coronary artery as assessed by serial virtual histology intravascular ultrasound analysis.
Topics: Aged; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Phenotype; Plaque, Atherosclerotic; Pyrroles; Quinolines; Registries; Retrospective Studies; Simvastatin; Ultrasonography, Interventional | 2014 |
Statins for non-cystic fibrosis bronchiectasis.
Topics: Atorvastatin; Bronchiectasis; Female; Heptanoic Acids; Humans; Male; Pyrroles; Quality of Life | 2014 |
LDL cholesterol variability in patients with Type 2 diabetes taking atorvastatin and simvastatin: a comparison of two formulae for LDL-C estimation.
Topics: Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Drug Monitoring; Half-Life; Heptanoic Acids; Humans; Hypolipidemic Agents; Immunoassay; Prospective Studies; Pyrroles; Simvastatin; Triglycerides | 2015 |
[Atorvastatin inhibits cardiomyocyte apoptosis via down-cegulation the expression mitofusin 2 after myocardial ischemia/reperfusion injury in rats].
Topics: Animals; Apoptosis; Atorvastatin; Down-Regulation; GTP Phosphohydrolases; Heptanoic Acids; Male; Membrane Proteins; Mitochondrial Proteins; Myocardial Reperfusion Injury; Myocytes, Cardiac; Phosphoproteins; Protein Transport; Proto-Oncogene Proteins c-akt; Pyrroles; Rats; Rats, Sprague-Dawley | 2014 |
Dietary α-tocopherol and atorvastatin reduce high-fat-induced lipid accumulation and down-regulate CD36 protein in the liver of guinea pigs.
Topics: alpha-Tocopherol; Animals; Anticholesteremic Agents; Atorvastatin; CD36 Antigens; Dietary Supplements; Down-Regulation; Guinea Pigs; Heptanoic Acids; Lipid Metabolism; Liver; Oxidative Stress; Pyrroles; Receptors, LDL; Triglycerides; Ubiquitination | 2014 |
Role of calcifying nanoparticle in the development of hyperplasia and vascular calcification in an animal model.
Topics: Angioplasty, Balloon; Animals; Atorvastatin; Calcifying Nanoparticles; Carotid Arteries; Carotid Artery Injuries; Carotid Intima-Media Thickness; Cholesterol; Disease Models, Animal; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperplasia; Male; Muscle, Smooth, Vascular; Neointima; Pyrroles; Rabbits; Time Factors; Triglycerides; Vascular Calcification | 2014 |
Effects of an angiotensin II type 1 receptor blocker on aortic valve sclerosis in a preclinical model.
Topics: Angiotensin Receptor Antagonists; Animals; Aortic Valve; Atorvastatin; Bicuspid Aortic Valve Disease; Disease Progression; Heart Defects, Congenital; Heart Valve Diseases; Heptanoic Acids; Imidazoles; Immunohistochemistry; Male; Pyrroles; Rabbits; Random Allocation; Sclerosis; Tetrazoles | 2014 |
Hepatic ischemia/reperfusion injury is diminished by atorvastatin in Wistar rats.
Topics: Animals; Antithrombin III; Atorvastatin; Endothelin-1; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Liver; Male; Pyrroles; Rats, Wistar; Reperfusion Injury; Tumor Necrosis Factor-alpha | 2014 |
Interrelated cathepsin S-lowering and LDL subclass profile improvements induced by atorvastatin in the plasma of stable angina patients.
Topics: Angina, Stable; Anticholesteremic Agents; Atorvastatin; Biomarkers; Blotting, Western; Cathepsins; Cholesterol, HDL; Cholesterol, LDL; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Prognosis; Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2014 |
Summaries for patients. Treatment trials to determine whether statins are the cause of a patient's discomfort.
Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myalgia; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Sulfonamides | 2014 |
Relationship between the cholesterol ester transfer protein TaqIB polymorphism and the lipid-lowering effect of atorvastatin in patients with coronary atherosclerotic heart disease.
Topics: Adult; Aged; Alleles; Atorvastatin; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Female; Follow-Up Studies; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Polymorphism, Restriction Fragment Length; Pyrroles; Treatment Outcome | 2014 |
Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia.
Topics: Aged; Atorvastatin; Azetidines; C-Reactive Protein; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cholesterol, LDL; Drug Combinations; Ezetimibe; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles | 2014 |
Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Atorvastatin; C-Reactive Protein; Colchicine; Diet, High-Fat; Heptanoic Acids; Hyperlipidemias; Male; Nitrogen Oxides; Pyrroles; Rats; Rats, Sprague-Dawley | 2014 |
The Carotid intima-media thickness modification following atorvastatin is bound to the modification of the oxidative balance.
Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Cholesterol; Heptanoic Acids; Humans; Hypercholesterolemia; Italy; Male; Middle Aged; Oxidative Stress; Pyrroles; Registries; Treatment Outcome | 2014 |
Involvement and alteration of the Sonic Hedgehog pathway is associated with decreased cholesterol level in trisomy 18 and SLO amniocytes.
Topics: Amniotic Fluid; Atorvastatin; Bone Morphogenetic Protein 2; Cells, Cultured; Cholesterol; Chromosomes, Human, Pair 18; Collagen Type I; Collagen Type I, alpha 1 Chain; Culture Media; Estriol; Female; Gene Expression Regulation; Hedgehog Proteins; Heptanoic Acids; Humans; Pregnancy; Pyrroles; Signal Transduction; Smith-Lemli-Opitz Syndrome; Trisomy; Trisomy 18 Syndrome | 2014 |
Differential pulse adsorptive stripping voltammetric determination of nanomolar levels of atorvastatin calcium in pharmaceutical and biological samples using a vertically aligned carbon nanotube/graphene oxide electrode.
Topics: Adsorption; Atorvastatin; Electrodes; Graphite; Heptanoic Acids; Hydrogen-Ion Concentration; Kinetics; Limit of Detection; Microscopy, Electron, Scanning; Nanotubes, Carbon; Oxides; Pharmaceutical Preparations; Pyrroles | 2014 |
[Lipid-lowering therapy and patient adherence in the MULTI GAP 2013 trial].
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Databases, Factual; Drug Prescriptions; Drug Therapy, Combination; Female; Fluorobenzenes; Guideline Adherence; Heptanoic Acids; Humans; Hungary; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insurance, Health; Male; Middle Aged; Patient Compliance; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Surveys and Questionnaires; Treatment Outcome | 2014 |
Berberine combined with atorvastatin downregulates LOX‑1 expression through the ET‑1 receptor in monocyte/macrophages.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Berberine; Body Weight; Cells, Cultured; Cholesterol; Diet, High-Fat; Dietary Fats; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation; Heptanoic Acids; Macrophages; Male; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; RNA, Small Interfering; Scavenger Receptors, Class E; Signal Transduction; Triglycerides | 2014 |
Atorvastatin ameliorates cardiac fibrosis and improves left ventricular diastolic function in hypertensive diastolic heart failure model rats.
Topics: Animals; Atorvastatin; Cells, Cultured; Disease Models, Animal; Fibroblasts; Fibrosis; Heart Failure, Diastolic; Heptanoic Acids; HSP47 Heat-Shock Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Myocardium; Pyrroles; Rats; Rats, Inbred Dahl; rho-Associated Kinases; Ventricular Function, Left | 2014 |
Impact of high-dose statin pre-treatment and contrast-induced acute kidney injury on follow-up events in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Atorvastatin; Contrast Media; Disease-Free Survival; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Percutaneous Coronary Intervention; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2014 |
Atorvastatin evokes a serotonergic system-dependent antidepressant-like effect in mice.
Topics: Animals; Antidepressive Agents; Atorvastatin; Brain; Depression; Heptanoic Acids; Male; Mice; Pyrroles; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Treatment Outcome | 2014 |
Atorvastatin increases endothelial progenitor cells in balloon-injured mouse carotid artery.
Topics: Angioplasty, Balloon, Coronary; Animals; Atorvastatin; Carotid Artery Injuries; Carotid Artery, Common; Cell Differentiation; Cell Proliferation; Cells, Cultured; Endothelial Progenitor Cells; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Nitric Oxide Synthase Type III; Pyrroles | 2014 |
Effects of atorvastatin on the inflammation regulation and elimination of subdural hematoma in rats.
Topics: Analysis of Variance; Animals; Atorvastatin; Blood Cell Count; Brain; Cytokines; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Hematoma, Subdural; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Processing, Computer-Assisted; Inflammation; Lipids; Magnetic Resonance Imaging; Male; Neurologic Examination; Pyrroles; Rats; Rats, Wistar; Time Factors | 2014 |
Impact of serum high mobility group box 1 and soluble receptor for advanced glycation end-products on subclinical atherosclerosis in patients with granulomatosis with polyangiitis.
Topics: Atherosclerosis; Atorvastatin; Female; Granulomatosis with Polyangiitis; Heptanoic Acids; HMGB1 Protein; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prednisolone; Pyrroles; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Solubility | 2014 |
Statin-induced impairment of monocyte migration is gender-related.
Topics: Atherosclerosis; Atorvastatin; Cell Movement; Female; Healthy Volunteers; Heptanoic Acids; Humans; Inflammation; Lipopolysaccharides; Male; Monocytes; Pyrroles; Sex Characteristics; Simvastatin; Tumor Necrosis Factor-alpha | 2014 |
Atorvastatin prevents amyloid-β peptide oligomer-induced synaptotoxicity and memory dysfunction in rats through a p38 MAPK-dependent pathway.
Topics: Amyloid beta-Peptides; Animals; Anticholesteremic Agents; Atorvastatin; Cells, Cultured; Heptanoic Acids; Hippocampus; Male; Maze Learning; Memory Disorders; Neurons; Neuroprotective Agents; p38 Mitogen-Activated Protein Kinases; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction; Synapses | 2014 |
Olmesartan induced enterocolitis.
Topics: Aged; Amitriptyline; Anticholesteremic Agents; Antidepressive Agents, Tricyclic; Antihypertensive Agents; Atenolol; Atorvastatin; Dihydropyridines; Enterocolitis; Female; Heptanoic Acids; Humans; Imidazoles; Pyrroles; Tetrazoles | 2014 |
Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions.
Topics: Atorvastatin; Base Sequence; Cell Line; Chromatography, Liquid; DNA Primers; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Pyrroles; Tandem Mass Spectrometry | 2014 |
Combinational effects of farnesoid X receptor antagonist and statin on plasma lipid levels and low-density lipoprotein clearance in guinea pigs.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Benzoates; Cholestenones; Cholesterol; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Guinea Pigs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Male; Pyrazoles; Pyrroles; Receptors, Cytoplasmic and Nuclear; Time Factors | 2014 |
Effects of single pill-based combination therapy of amlodipine and atorvastatin on within-visit blood pressure variability and parameters of renal and vascular function in hypertensive patients with chronic kidney disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Capsules; Drug Therapy, Combination; Female; Glucose; Heptanoic Acids; Humans; Hypertension; Inflammation; Kidney; Kidney Function Tests; Lipid Metabolism; Male; Multivariate Analysis; Oxidative Stress; Pyrroles; Regression Analysis; Renal Insufficiency, Chronic | 2014 |
Add-on effect of probucol in atherosclerotic, cholesterol-fed rabbits treated with atorvastatin.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Drug Synergism; Heptanoic Acids; Probucol; Pyrroles; Rabbits | 2014 |
Effectiveness of combination therapy of atorvastatin and non lipid-modifying tanshinone IIA from Danshen in a mouse model of atherosclerosis.
Topics: Abietanes; Animals; Atherosclerosis; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drugs, Chinese Herbal; Heptanoic Acids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrroles; Salvia miltiorrhiza; Treatment Outcome | 2014 |
Inhibition of autophagy potentiates atorvastatin-induced apoptotic cell death in human bladder cancer cells in vitro.
Topics: Anticholesteremic Agents; Antineoplastic Agents; Apoptosis; Atorvastatin; Autophagy; Cell Line, Tumor; Heptanoic Acids; Humans; Pyrroles; Urinary Bladder; Urinary Bladder Neoplasms | 2014 |
Atorvastatin improves plaque stability in ApoE-knockout mice by regulating chemokines and chemokine receptors.
Topics: Animals; Apolipoproteins E; Atorvastatin; Chemokines; Collagenases; Heptanoic Acids; Macrophages; Mice; Mice, Knockout; Monocytes; Plaque, Atherosclerotic; Pyrroles; Receptors, Chemokine; Time Factors | 2014 |
Statin-associated acute interstitial nephritis and rhabdomyolysis.
Topics: Acute Kidney Injury; Atorvastatin; Glucocorticoids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Nephritis, Interstitial; Prednisolone; Pyrroles; Renal Dialysis; Rhabdomyolysis; Time Factors; Treatment Outcome | 2014 |
Micellar electrokinetic chromatographic determination of rosuvastatin in rabbit plasma and evaluation of its pharmacokinetics and interaction with niacin.
Topics: Animals; Atorvastatin; Chromatography, Micellar Electrokinetic Capillary; Drug Interactions; Fluorobenzenes; Heptanoic Acids; Hydrogen-Ion Concentration; Limit of Detection; Linear Models; Male; Niacin; Pyrimidines; Pyrroles; Rabbits; Reproducibility of Results; Rosuvastatin Calcium; Sodium Dodecyl Sulfate; Sulfonamides | 2014 |
Overview on pharmacological and nutraceutical strategies for treatment of borderline dyslipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Dietary Supplements; Fatty Acids; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Male; Pyrroles; Risk Factors; Treatment Outcome | 2014 |
Hollow-fiber-supported liquid membrane microextraction of amlodipine and atorvastatin.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Chromatography, High Pressure Liquid; Heptanoic Acids; Humans; Liquid Phase Microextraction; Pyrroles; Solid Phase Microextraction; Water Pollutants, Chemical | 2014 |
Distribution study of atorvastatin and its metabolites in rat tissues using combined information from UHPLC/MS and MALDI-Orbitrap-MS imaging.
Topics: Animals; Atorvastatin; Chromatography, High Pressure Liquid; Feces; Heptanoic Acids; Liver; Male; Pyrroles; Rats; Rats, Wistar; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry; Tissue Distribution | 2014 |
Systemic administration of atorvastatin improves locomotor functions and hyperacute-acute response after experimental spinal cord injury: an ultrastructural and biochemical analysis.
Topics: Animals; Atorvastatin; Heptanoic Acids; Interleukin-1beta; Interleukin-6; Lipid Peroxidation; Male; Motor Activity; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Spinal Cord; Spinal Cord Injuries | 2014 |
Combined administration of RG7652, a recombinant human monoclonal antibody against PCSK9, and atorvastatin does not result in reduction of immune function.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Hypersensitivity, Delayed; Macaca fascicularis; Male; Proprotein Convertase 9; Proprotein Convertases; Pyrroles; Recombinant Proteins; Serine Endopeptidases | 2014 |
Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.
Topics: Aged; Aged, 80 and over; Atorvastatin; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Down-Regulation; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Pyrroles; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; United States | 2014 |
Cranberry juice, atorvastatin and back pain.
Topics: Anticholesteremic Agents; Atorvastatin; Back Pain; Beverages; Fruit; Heptanoic Acids; Herb-Drug Interactions; Humans; Hyperlipidemias; Male; Middle Aged; Pyrroles; Vaccinium macrocarpon | 2014 |
Atorvastatin improves survival of implanted stem cells in a rat model of renal ischemia-reperfusion injury.
Topics: Acute Kidney Injury; Animals; Atorvastatin; Graft Survival; Heptanoic Acids; HMGB1 Protein; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Innate; Inflammation; Kidney; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Oxidative Stress; Pyrroles; Rats; Reperfusion Injury; Toll-Like Receptor 4 | 2014 |
Temporal trends in the use of high-dose potent statins following acute coronary syndrome in Israel.
Topics: Analysis of Variance; Angina, Unstable; Atorvastatin; Cohort Studies; Drug Prescriptions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Israel; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Patient Discharge; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Preparation and evaluation of solid dispersion of atorvastatin calcium with Soluplus® by spray drying technique.
Topics: Administration, Oral; Animals; Atorvastatin; Biological Availability; Desiccation; Heptanoic Acids; Male; Polyethylene Glycols; Polyvinyls; Pyrroles; Rats; Rats, Sprague-Dawley; Solubility; Water | 2014 |
Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site.
Topics: Atorvastatin; Benzimidazoles; Binding Sites; Cell Line, Tumor; Computer Simulation; Cyclic Nucleotide Phosphodiesterases, Type 6; Drug Design; Esters; Ethers; Heptanoic Acids; Humans; Kinetics; Models, Molecular; Protein Prenylation; Pyrroles; ras Proteins; Stereoisomerism; Structure-Activity Relationship; Thermodynamics | 2014 |
In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum.
Topics: Antimalarials; Atorvastatin; Drug Synergism; Ethanolamines; Fluorenes; Heptanoic Acids; Inhibitory Concentration 50; Lumefantrine; Parasitic Sensitivity Tests; Plasmodium falciparum; Pyrroles; Quinolines | 2014 |
Inflammatory stress reduces the effectiveness of statins in the kidney by disrupting HMGCoA reductase feedback regulation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apolipoproteins E; Atorvastatin; Blotting, Western; Caseins; CD36 Antigens; Cells, Cultured; Cholesterol; Cytokines; Drug Resistance; Feedback, Physiological; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Kidney; Lipopolysaccharides; Male; Mesangial Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sterol Regulatory Element Binding Protein 2; Stress, Physiological; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
Red yeast rice and coenzyme Q10 as safe alternatives to surmount atorvastatin-induced myopathy in hyperlipidemic rats.
Topics: Animals; Aorta; Atorvastatin; Biological Products; Combined Modality Therapy; Creatine Kinase; Diet, High-Fat; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Liver; Male; Muscular Diseases; Myocardium; Pyrroles; Rats; Ubiquinone | 2014 |
Hydrogen-bonded and reduction-responsive micelles loading atorvastatin for therapy of breast cancer metastasis.
Topics: Animals; Atorvastatin; Breast; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Female; Heptanoic Acids; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Neoplasms; Lung; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Micelles; Oxidation-Reduction; Polyethylene Glycols; Pyrroles; Vitamin E | 2014 |
The influence of elastin degradation products, glucose and atorvastatin on metalloproteinase-1, -2, -9 and tissue inhibitor of metalloproteinases-1, -2, -3 expression in human retinal pigment epithelial cells.
Topics: Atorvastatin; Cell Line; Elastin; Epithelial Cells; Gene Expression; Glucose; Heptanoic Acids; Humans; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Peptide Fragments; Proteolysis; Pyrroles; Retinal Pigment Epithelium; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinase-3 | 2014 |
Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes.
Topics: Animals; Atorvastatin; ATP-Binding Cassette Transporters; Bilirubin; Biological Transport; Cell Culture Techniques; Cells, Cultured; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Hepatocytes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Multidrug Resistance-Associated Proteins; Organic Anion Transporters; Pravastatin; Pyrimidines; Pyrroles; Rats; Rosuvastatin Calcium; Sulfonamides | 2014 |
Atorvastatin exerts anti-nociceptive activity and decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in a rat endometriosis model.
Topics: Analgesics; Animals; Atorvastatin; C-Reactive Protein; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Endometriosis; Endometrium; Female; Heptanoic Acids; Humans; Leuprolide; Nociception; Nociceptive Pain; Pyrroles; Rats; Rats, Wistar; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
Stimulatory interactions between human coronary smooth muscle cells and dendritic cells.
Topics: Animals; Atorvastatin; Cell Adhesion; Cell Adhesion Molecules; Cell Differentiation; Cell Movement; Cellular Microenvironment; Coculture Techniques; Coronary Vessels; Cytokines; Dendritic Cells; Heptanoic Acids; Humans; Immunophenotyping; Inflammation; Male; Myocytes, Smooth Muscle; Phenotype; Pyrroles; Rats, Wistar; Rosiglitazone; Solubility; Thiazolidinediones | 2014 |
The roles of nitric oxide and hydrogen sulfide in the anti-atherosclerotic effect of atorvastatin.
Topics: Alkynes; Animals; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Diet, High-Fat; Glycine; Heptanoic Acids; Hydrogen Sulfide; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pyrroles; Rats, Sprague-Dawley | 2015 |
GluN2B N-methyl-D-aspartic acid receptor subunit mediates atorvastatin-Induced neuroprotection after focal cerebral ischemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Embryo, Mammalian; Heptanoic Acids; Male; Maze Learning; Nerve Tissue Proteins; Nervous System Diseases; Piperidines; Platelet Aggregation Inhibitors; Pyrroles; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Recovery of Function; Somatosensory Cortex; Time Factors | 2014 |
Atorvastatin helps preserve pancreatic β cell function in obese C57BL/6 J mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress.
Topics: Animals; Apoptosis; Atorvastatin; Blotting, Western; Cell Survival; Endoplasmic Reticulum Stress; Fluorescent Antibody Technique; Heptanoic Acids; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Obesity; Pancreas; Pyrroles; Real-Time Polymerase Chain Reaction | 2014 |
Statins upregulate cystathionine γ-lyase transcription and H2S generation via activating Akt signaling in macrophage.
Topics: Animals; Atorvastatin; Cell Line; Cystathionine gamma-Lyase; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hydrogen Sulfide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Macrophages; Mice; Pravastatin; Proto-Oncogene Proteins c-akt; Pyrroles; RNA, Messenger; Signal Transduction; Up-Regulation | 2014 |
The effect of leptin promoter and leptin receptor gene polymorphisms on lipid profile among the diabetic population: modulations by atorvastatin treatment and environmental factors.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Gene-Environment Interaction; Genotype; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Receptors, Leptin; Sex Factors; Triglycerides | 2014 |
[Atorvastatin inhibits macrophage-derived foam cell formation by suppressing the activation of PPARγ and NF-κB pathway].
Topics: Atorvastatin; ATP Binding Cassette Transporter 1; Cell Line; Foam Cells; Heptanoic Acids; Humans; I-kappa B Proteins; Lipoproteins, LDL; Macrophages; NF-kappa B; PPAR gamma; Pyrroles; Signal Transduction; Transcriptional Activation; Up-Regulation | 2014 |
Effect of beta-3 adrenoceptor stimulation on the levels of ApoA-I, PPARα, and PPARγ in apolipoprotein E-deficient mice.
Topics: Adrenergic beta-3 Receptor Agonists; Adrenergic beta-3 Receptor Antagonists; Animals; Apolipoprotein A-I; Apolipoproteins E; Atherosclerosis; Atorvastatin; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Regulation; Heptanoic Acids; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; PPAR alpha; PPAR gamma; Pyrroles; Real-Time Polymerase Chain Reaction; Receptors, Adrenergic, beta-3; RNA, Messenger | 2014 |
Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Growth Processes; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Heptanoic Acids; Humans; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
High-dose atorvastatin ameliorates the uterine microenvironment in streptozotocin-induced diabetic rats.
Topics: Animals; Atorvastatin; Diabetes Mellitus, Experimental; Endometrium; ErbB Receptors; Female; Fibrosis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Rats; Rats, Sprague-Dawley; Uterus; Vascular Endothelial Growth Factor A | 2014 |
Contribution of homeostatic chemokines CCL19 and CCL21 and their receptor CCR7 to coronary artery disease.
Topics: Aged; Alleles; Atorvastatin; Cell Adhesion; Chemokine CCL19; Chemokine CCL21; Chemotaxis, Leukocyte; China; Coronary Artery Disease; Disease Progression; Ethnicity; Female; Genotype; Heptanoic Acids; Homeostasis; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Male; Middle Aged; Monocytes; Plaque, Atherosclerotic; Polymorphism, Single Nucleotide; Pyrroles; Receptors, CCR7; Signal Transduction | 2014 |
Solubility and bioavailability enhancement of poorly aqueous soluble atorvastatin: in vitro, ex vivo, and in vivo studies.
Topics: Atorvastatin; Biological Availability; Drug Carriers; Heptanoic Acids; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl CoA Reductases; In Vitro Techniques; Pyrroles; Solubility; Solvents; Water | 2014 |
Atorvastatin post-conditioning attenuates myocardial ischemia reperfusion injury via inhibiting endoplasmic reticulum stress-related apoptosis.
Topics: Animals; Apoptosis; Atorvastatin; Endoplasmic Reticulum Stress; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Postconditioning; Male; Myocardial Reperfusion Injury; Pyrroles; Rats; Rats, Sprague-Dawley | 2014 |
[Renoprotective efficacy of different doses of statins in experimental acute renal failure].
Topics: Acute Kidney Injury; Administration, Topical; Animals; Atorvastatin; Creatine Kinase; Diuresis; Glomerular Filtration Rate; Glycerol; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Lovastatin; Pyrroles; Rats; Rhabdomyolysis; Simvastatin; Stomach; Urodynamics | 2014 |
Renoprotective effect of atorvastatin on STZ-diabetic rats through attenuating kidney-associated dysmetabolism.
Topics: Animals; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Kidney; Lipoproteins, HDL; Lipoproteins, LDL; Male; Proteinuria; Pyrroles; Rats, Sprague-Dawley; RNA, Messenger; Streptozocin; Transforming Growth Factor beta1 | 2014 |
The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials.
Topics: Adult; Ambulatory Care; Anticholesteremic Agents; Atorvastatin; Databases, Factual; Electronic Health Records; Evaluation Studies as Topic; Feasibility Studies; Female; General Practitioners; Heptanoic Acids; Humans; Male; Middle Aged; Patient Selection; Pragmatic Clinical Trials as Topic; Pyrroles; Simvastatin | 2014 |
Modulation of dendritic cell immunobiology via inhibition of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase.
Topics: Animals; Atorvastatin; Cell Movement; Cells, Cultured; Dendritic Cells; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-10; Mice; Mice, Inbred C57BL; Phagocytosis; Pyrroles; T-Lymphocytes, Regulatory | 2014 |
Evaluation of statin therapy on endothelial function in hypercholesterolemic rabbits by automatic measurement of arterial wall movement using ultrasound images.
Topics: Algorithms; Animals; Atorvastatin; Blood Flow Velocity; Disease Models, Animal; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Image Processing, Computer-Assisted; Male; Pyrroles; Rabbits; Ultrasonography, Doppler; Vasodilator Agents | 2014 |
Molecular modeling studies of atorvastatin analogues as HMGR inhibitors using 3D-QSAR, molecular docking and molecular dynamics simulations.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Models, Molecular; Molecular Structure; Pyrroles; Quantitative Structure-Activity Relationship | 2014 |
Metformin enhances nitric oxide production and diminishes Rho kinase activity in rats with hyperlipidemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Drug Evaluation, Preclinical; Heptanoic Acids; Hypercholesterolemia; Male; Metformin; Nitric Oxide; Pyrroles; Rats, Sprague-Dawley; rho-Associated Kinases | 2014 |
A calcified left ventricular mass.
Topics: Aged, 80 and over; Aging; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Calcinosis; Diagnosis, Differential; Female; Heart Neoplasms; Heart Valve Diseases; Heptanoic Acids; Humans; Hypertension; Mitral Valve; Monitoring, Physiologic; Platelet Aggregation Inhibitors; Pyrroles; Quinapril; Radiography; Tetrahydroisoquinolines; Treatment Outcome | 2014 |
Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study.
Topics: Adult; Aged; Atorvastatin; Chemical and Drug Induced Liver Injury; Chronic Disease; Cohort Studies; Follow-Up Studies; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Liver Diseases; Male; Middle Aged; Pyrroles; Risk; Severity of Illness Index; Taiwan; Time Factors | 2015 |
Effect of lifestyle changes and atorvastatin administration on dyslipidemia in hemodialysis patients: a prospective study.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Dyslipidemias; Female; Heptanoic Acids; Humans; Life Style; Male; Middle Aged; Prospective Studies; Pyrroles; Renal Dialysis | 2014 |
Statins increase rifampin mycobactericidal effect.
Topics: Animals; Antitubercular Agents; Atorvastatin; Cell Line; Drug Synergism; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leprosy; Macrophages; Mice; Mice, Inbred BALB C; Mycobacterium leprae; Mycobacterium tuberculosis; Pyrroles; Rifampin; Simvastatin | 2014 |
Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comorbidity; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus; Drug Costs; Drug Substitution; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Style; Lipoproteins, LDL; Medicare; Models, Cardiovascular; Nuclear Magnetic Resonance, Biomolecular; Pyrroles; Quality-Adjusted Life Years; Risk; Risk Reduction Behavior; Simvastatin; Treatment Outcome; United States | 2014 |
Cholesterol synthesis inhibitor RO 48-8071 suppresses transcriptional activity of human estrogen and androgen receptor.
Topics: Atorvastatin; Benzophenones; Breast Neoplasms; Cell Line, Tumor; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intramolecular Transferases; Pyrroles; Real-Time Polymerase Chain Reaction; Receptors, Androgen; RNA, Messenger; Transcriptional Activation; Triple Negative Breast Neoplasms | 2014 |
Statins on trial. Pfizer faces clot of lawsuits that claim Lipitor caused women's diabetes.
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Drug Industry; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Sex Factors; United States | 2014 |
Atorvastatin restores arsenic-induced vascular dysfunction in rats: modulation of nitric oxide signaling and inflammatory mediators.
Topics: Animals; Aorta, Thoracic; Arsenic; Atorvastatin; Dose-Response Relationship, Drug; Endothelium, Vascular; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Male; Nitric Oxide; Organ Culture Techniques; Pyrroles; Random Allocation; Rats; Rats, Wistar; Signal Transduction | 2014 |
Effect of atorvastatin on serum oxidative stress and N-terminal brain natriuretic peptide expression in rats.
Topics: Animals; Atorvastatin; Heptanoic Acids; Male; Myocardial Reperfusion Injury; Natriuretic Peptide, Brain; Oxidative Stress; Peptide Fragments; Pyrroles; Rats; Rats, Sprague-Dawley | 2014 |
The anti-atherogenic effects of berberine on foam cell formation are mediated through the upregulation of sirtuin 1.
Topics: Adenylate Kinase; Atherosclerosis; Atorvastatin; Berberine; Cholesterol; Foam Cells; Heptanoic Acids; Humans; Lipoproteins, LDL; Macrophages; PPAR gamma; Pyrroles; Sirtuin 1; Up-Regulation | 2014 |
Demonstration of an add-on effect of probucol and cilostazol on the statin-induced anti-atherogenic effects.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cilostazol; Drug Therapy, Combination; Heptanoic Acids; Hypercholesterolemia; Immunohistochemistry; Lipids; Probucol; Pyrroles; Rabbits; Tetrazoles | 2014 |
HspB8 expression in brain tissue after cerebral ischemic reperfusion and atorvastatin intervention in Sprague-Dawley rats.
Topics: Animals; Apoptosis; Atorvastatin; Blotting, Western; Brain Ischemia; Cerebral Cortex; Disease Models, Animal; Heat-Shock Proteins; Heptanoic Acids; In Situ Nick-End Labeling; Infarction, Middle Cerebral Artery; Male; Neurons; Neuroprotective Agents; Pyrroles; Random Allocation; Rats, Sprague-Dawley; Reperfusion Injury; Severity of Illness Index; Tetrazolium Salts | 2015 |
Statins do not alter the incidence of mesothelioma in asbestos exposed mice or humans.
Topics: Adult; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Asbestos; Atorvastatin; Cohort Studies; Cyclooxygenase 2 Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lung Neoplasms; Male; Mesothelioma; Mice; Mice, Transgenic; Middle Aged; Pyrroles | 2014 |
Effect of angiotensin II and small GTPase Ras signaling pathway inhibition on early renal changes in a murine model of obstructive nephropathy.
Topics: Angiotensin II; Animals; Atorvastatin; Disease Models, Animal; Fibrosis; Heptanoic Acids; Humans; Kidney; Kidney Diseases; Mice; Monomeric GTP-Binding Proteins; Pyrroles; Receptor, Angiotensin, Type 1; Signal Transduction; Ureteral Obstruction | 2014 |
Rosuvastatin activates ATP-binding cassette transporter A1-dependent efflux ex vivo and promotes reverse cholesterol transport in macrophage cells in mice fed a high-fat diet.
Topics: Animals; Apolipoprotein A-I; Atherosclerosis; Atorvastatin; ATP Binding Cassette Transporter 1; Biological Transport; Cell Line; Cholesterol Esters; Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, VLDL; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2014 |
Geranylgeranylation signals to the Hippo pathway for breast cancer cell proliferation and migration.
Topics: Atorvastatin; Benzamides; Breast Neoplasms; Cell Movement; Cell Proliferation; Female; HEK293 Cells; Heptanoic Acids; Hippo Signaling Pathway; Humans; MCF-7 Cells; Prenylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Pyrroles; Signal Transduction; Tumor Cells, Cultured | 2015 |
Atorvastatin represses the angiotensin 2-induced oxidative stress and inflammatory response in dendritic cells via the PI3K/Akt/Nrf 2 pathway.
Topics: Angiotensin II; Animals; Anticholesteremic Agents; Atorvastatin; Bone Marrow Cells; Cell Proliferation; Cells, Cultured; Cytokines; Dendritic Cells; Heptanoic Acids; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Oxidative Stress; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Reactive Oxygen Species; Signal Transduction; Superoxide Dismutase; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2014 |
If I had resistant hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydrochlorothiazide; Hypertension; Imidazoles; Male; Middle Aged; Pyrroles; Spironolactone; Tetrazoles; Treatment Failure; Treatment Outcome | 2014 |
Inhibition of neointimal hyperplasia in rats treated with atorvastatin after carotid artery injury may be mainly associated with down-regulation of survivin and Fas expression.
Topics: Animals; Apoptosis; Atorvastatin; Carotid Artery Injuries; Disease Models, Animal; Down-Regulation; Enzyme-Linked Immunosorbent Assay; fas Receptor; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperplasia; In Situ Nick-End Labeling; Male; Microtubule-Associated Proteins; Muscle, Smooth, Vascular; Neointima; Pyrroles; Rats; Survivin | 2014 |
Evaluation of sexual dimorphism in the efficacy and safety of simvastatin/atorvastatin therapy in a southern Brazilian cohort.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Brazil; Cholesterol; Creatine Kinase; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Myalgia; Prospective Studies; Pyrroles; Sex Factors; Simvastatin | 2014 |
Atorvastatin induces T cell proliferation by a telomerase reverse transcriptase (TERT) mediated mechanism.
Topics: Animals; Atorvastatin; Cardiovascular Diseases; Catalytic Domain; CD4-Positive T-Lymphocytes; Cell Division; Cells, Cultured; Cholesterol, LDL; Dose-Response Relationship, Drug; Enzyme Induction; Genes, Reporter; Heptanoic Acids; Humans; Leukocytes, Mononuclear; Lymphocyte Activation; Mice; Mice, Knockout; Mice, Transgenic; Pyrroles; Risk; Telomerase; Telomere; Telomere Homeostasis | 2014 |
Short-term intensive atorvastatin therapy improves endothelial function partly via attenuating perivascular adipose tissue inflammation through 5-lipoxygenase pathway in hyperlipidemic rabbits.
Topics: Adipose Tissue; Animals; Arachidonate 5-Lipoxygenase; Atorvastatin; Heptanoic Acids; Hyperlipidemias; Inflammation; Lipid Metabolism; Male; Pyrroles; Rabbits | 2014 |
Pleiotropic effects of atorvastatin in experimental sepsis: preservation of β1-adrenoreceptor signaling in the heart.
Topics: Animals; Atorvastatin; Cyclic AMP; Heptanoic Acids; Male; Myocardium; Pyrroles; Receptors, Adrenergic, beta; Sepsis | 2014 |
Atorvastatin treatment improves the effects of mesenchymal stem cell transplantation on acute myocardial infarction: the role of the RhoA/ROCK/ERK pathway.
Topics: Animals; Atorvastatin; Cells, Cultured; Female; Heptanoic Acids; Male; MAP Kinase Signaling System; Mesenchymal Stem Cell Transplantation; Myocardial Infarction; Pyrroles; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; rhoA GTP-Binding Protein; Treatment Outcome; Ultrasonography | 2014 |
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Disease Progression; Drug Combinations; Female; Heptanoic Acids; Mice, Transgenic; Oxazolidinones; Pyrroles; Serum Amyloid A Protein | 2015 |
Hypolipidemic effect of fenugreek seeds and its comparison with atorvastatin on experimentally induced hyperlipidemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; India; Lipid Metabolism; Lipids; Male; Phytotherapy; Plant Extracts; Pyrroles; Rabbits; Triglycerides; Trigonella | 2014 |
RNA-sequencing analysis of HepG2 cells treated with atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Exons; Gene Expression; Hep G2 Cells; Hepatocytes; Heptanoic Acids; Humans; Pyrroles; RNA Splicing; Sequence Analysis, RNA; Transcriptome | 2014 |
99mTc-cAbVCAM1-5 imaging is a sensitive and reproducible tool for the detection of inflamed atherosclerotic lesions in mice.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Female; Heptanoic Acids; Humans; Immunoglobulin Fragments; Immunohistochemistry; Inflammation; Mice; Multimodal Imaging; Pyrroles; Reference Values; Reproducibility of Results; Technetium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Vascular Cell Adhesion Molecule-1 | 2014 |
Coronary artery calcium score.
Topics: Atorvastatin; Calcium; Cardiovascular Diseases; Coronary Vessels; Diet; Exercise; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Middle Aged; Pyrroles; Risk; Tomography, X-Ray Computed; Vascular Calcification | 2014 |
Statin use in Australian children: a retrospective audit of four pediatric hospitals.
Topics: Adolescent; Atorvastatin; Australia; Child; Child, Preschool; Drug Utilization Review; Fluorobenzenes; Heptanoic Acids; Hospitals, Pediatric; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Kidney Diseases; Organ Transplantation; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
The MYLIP p.N342S polymorphism is associated with response to lipid-lowering therapy in Brazilian patients with familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Base Sequence; Brazil; Cholesterol; DNA Primers; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Polymorphism, Genetic; Pyrroles; Ubiquitin-Protein Ligases | 2014 |
Insights into the antiatherogenic molecular mechanisms of andrographolide against Porphyromonas gingivalis-induced atherosclerosis in rabbits.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Atherosclerosis; Atorvastatin; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Heptanoic Acids; Intercellular Adhesion Molecule-1; Lipid Peroxidation; Male; Plaque, Atherosclerotic; Porphyromonas gingivalis; Pyrroles; Rabbits; Vascular Cell Adhesion Molecule-1 | 2014 |
Possible association of ABCB1:c.3435T>C polymorphism with high-density-lipoprotein-cholesterol response to statin treatment--a pilot study.
Topics: Aged; Alleles; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; Cholesterol, HDL; Female; Genotype; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Multivariate Analysis; Pilot Projects; Polymorphism, Genetic; Pyrroles; RNA, Messenger; Simvastatin; Triglycerides | 2014 |
[Impacts of atorvastatin on blood lipids and arterial media thickness in new-onset type 2 diabetes patients].
Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Pyrroles; Tunica Media | 2014 |
Atorvastatin attenuates the paraquat-induced pulmonary inflammation via PPARγ receptors: a new indication for atorvastatin.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Heptanoic Acids; Herbicides; Interleukin-6; Lung; Male; Malondialdehyde; Nitric Oxide; Paraquat; Peroxidase; Pioglitazone; Pneumonia; PPAR gamma; Pyrroles; Rats, Wistar; Thiazolidinediones; Tumor Necrosis Factor-alpha; Weight Loss | 2014 |
[Atorvastatin inhibits platelet aggregation and activation following carotid balloon injury in cholesterol-fed rabbits].
Topics: Animals; Atorvastatin; Blood Platelets; Carotid Artery Injuries; Cholesterol; Enzyme-Linked Immunosorbent Assay; Heptanoic Acids; P-Selectin; Platelet Activation; Platelet Aggregation; Pyrroles; Rabbits; Thromboxane B2 | 2014 |
[Proaterogenic metabolic disorders in patients with chronic kidney disease nondiabetic origin: possibility of statin therapy].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Cardiotonic Agents; Disease Progression; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipid Metabolism; Male; Metabolic Diseases; Middle Aged; Prognosis; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid | 2014 |
Statins enhance rotator cuff healing by stimulating the COX2/PGE2/EP4 pathway: an in vivo and in vitro study.
Topics: Animals; Atorvastatin; Biomechanical Phenomena; Celecoxib; Cell Adhesion; Cell Movement; Cell Proliferation; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Animal; Pyrazoles; Pyrroles; Random Allocation; Rats, Wistar; Receptors, Prostaglandin E, EP4 Subtype; Rotator Cuff; Sulfonamides; Tendons; Wound Healing | 2014 |
Disruption of ldlr causes increased LDL-c and vascular lipid accumulation in a zebrafish model of hypercholesterolemia.
Topics: Animals; Atorvastatin; Base Sequence; Blood Vessels; Cholesterol, LDL; Disease Models, Animal; Embryo, Nonmammalian; Gene Expression Regulation; Gene Knockdown Techniques; Hepatomegaly; Heptanoic Acids; Hypercholesterolemia; Liver; Molecular Sequence Data; Morpholinos; Oxidation-Reduction; Pyrroles; Receptors, LDL; Veins; Zebrafish | 2014 |
Legumain expression, activity and secretion are increased during monocyte-to-macrophage differentiation and inhibited by atorvastatin.
Topics: Anticholesteremic Agents; Atorvastatin; Cell Differentiation; Cysteine Endopeptidases; Heptanoic Acids; Humans; Macrophages; Monocytes; Pyrroles | 2015 |
Evaluation of the effect of andrographolide on atherosclerotic rabbits induced by Porphyromonas gingivalis.
Topics: Animals; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Bacteroidaceae Infections; C-Reactive Protein; Cytokines; Diterpenes; Female; Heptanoic Acids; Lipids; Male; Muscle, Smooth; Porphyromonas gingivalis; Pyrroles; Rabbits; Tunica Intima | 2014 |
Atorvastatin ameliorates arsenic-induced hypertension and enhancement of vascular redox signaling in rats.
Topics: Animals; Aorta, Thoracic; Arsenites; Atorvastatin; Catalase; Cholesterol; Glutathione Peroxidase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; NADPH Oxidase 4; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Pyrroles; Random Allocation; Rats, Wistar; Real-Time Polymerase Chain Reaction; RNA, Messenger; Sodium Compounds; Superoxide Dismutase; Tyrosine | 2014 |
Atorvastatin administered before myocardial infarction in rats improves contractility irrespective of metabolic changes.
Topics: Animals; Atorvastatin; Echocardiography; Glucose Transporter Type 4; Heart Ventricles; Heptanoic Acids; Male; Muscle Contraction; Myocardial Infarction; Myocardium; Pyrroles; Rats; Rats, Inbred WKY; Ventricular Remodeling | 2014 |
Is high-dose statin loading effective for acute decompensated heart failure? Insight of inflammation and acute kidney injury.
Topics: Acute Kidney Injury; Atorvastatin; Female; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Natriuretic Peptide, Brain; Peptide Fragments; Pyrroles | 2014 |
Atorvastatin reduces the proadhesive and prothrombotic endothelial cell phenotype induced by cocaine and plasma from cocaine consumers in vitro.
Topics: Anticholesteremic Agents; Atorvastatin; Caveolin 1; Cell Adhesion; Cells, Cultured; Cocaine; Cocaine-Related Disorders; Endothelium, Vascular; Heptanoic Acids; Humans; In Vitro Techniques; Nitric Oxide; Nitric Oxide Synthase Type III; Phenotype; Plasma; Pyrroles; Reactive Oxygen Species; Thrombosis; von Willebrand Factor | 2014 |
Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN.
Topics: Aged; Atorvastatin; C-Reactive Protein; Comorbidity; Coronary Artery Disease; Diabetic Angiopathies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sex Factors; Sulfonamides; Ultrasonography, Interventional | 2014 |
Differential effects of atorvastatin on autophagy in ischemic and nonischemic myocardium in Ossabaw swine with metabolic syndrome.
Topics: Animals; Atorvastatin; Autophagy; Biomarkers; Cholesterol, Dietary; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Myocardial Ischemia; Myocardium; Pyrroles; Signal Transduction; Swine | 2014 |
Pemphigus erythematosus relapse associated with atorvastatin intake.
Topics: Atorvastatin; Heptanoic Acids; Humans; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Pemphigus; Pyrroles; Recurrence | 2014 |
The low-dose atorvastatin and valsartan combination effectively protects the arterial wall from atherogenic diet-induced impairment in the guinea pig.
Topics: Animals; Aorta, Abdominal; Aorta, Thoracic; Atherosclerosis; Atorvastatin; Diet, Atherogenic; Drug Therapy, Combination; Female; Guinea Pigs; Heptanoic Acids; Interleukin-1beta; Male; Nitric Oxide Synthase Type III; Plaque, Atherosclerotic; Protective Agents; Pyrroles; Tetrazoles; Valine; Valsartan | 2014 |
[Effect of compound Danshen dripping pills combined with atorvastatin on restenosis after angioplasty in rabbits].
Topics: Angioplasty; Animals; Aorta; Atorvastatin; Cell Proliferation; Chemokine CCL2; Drugs, Chinese Herbal; Heptanoic Acids; Hyperplasia; Myocytes, Smooth Muscle; NF-kappa B; Phenanthrolines; Pyrroles; Rabbits; Salvia miltiorrhiza; Tunica Intima | 2014 |
Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cholestanetriol 26-Monooxygenase; Cholesterol 7-alpha-Hydroxylase; Cytochrome P-450 Enzyme Inducers; Enterohepatic Circulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ileum; Intestinal Mucosa; Lipoproteins; Liver; Liver-Specific Organic Anion Transporter 1; Male; Mice, Inbred C57BL; Organic Anion Transporters, Sodium-Dependent; Organic Anion Transporters, Sodium-Independent; Pyrroles; RNA-Binding Proteins; Signal Transduction; Symporters | 2014 |
Atorvastatin inhibits CD68 expression in aortic root through a GRP78-involved pathway.
Topics: Animals; Anticholesteremic Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Aorta; Atherosclerosis; Atorvastatin; Endoplasmic Reticulum Chaperone BiP; Glucose; Heat-Shock Proteins; Heptanoic Acids; Macrophages; Male; Mesocricetus; Pyrroles; Signal Transduction; Trichothecenes | 2014 |
Modulation of LXR-α and the effector genes by Ascorbic acid and Statins in psoriatic keratinocytes.
Topics: Adolescent; Adult; Antioxidants; Ascorbic Acid; Atorvastatin; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxycholesterols; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Keratinocytes; Liver X Receptors; Male; Orphan Nuclear Receptors; Psoriasis; Pyrroles | 2014 |
Upregulated expression of human alpha-defensins 1, 2 and 3 in hypercholesteremia and its relationship with serum lipid levels.
Topics: Aged; alpha-Defensins; Anticholesteremic Agents; Atorvastatin; Case-Control Studies; Cholesterol; Cholesterol, LDL; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Neutrophils; Pyrroles | 2014 |
Inhibition of protein geranylgeranylation specifically interferes with CD40-dependent B cell activation, resulting in a reduced capacity to induce T cell immunity.
Topics: Antigen Presentation; Atorvastatin; B-Lymphocytes; CD40 Antigens; Dendritic Cells; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunity, Cellular; Lymphocyte Activation; Mevalonic Acid; Primary Cell Culture; Protein Prenylation; Pyrroles; Signal Transduction; Simvastatin; T-Lymphocytes; Transcriptome | 2014 |
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Topics: Aged; Atorvastatin; Diabetes Mellitus; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Quinolines; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2015 |
Chemically induced mouse liver tumors are resistant to treatment with atorvastatin.
Topics: Animals; Antineoplastic Agents; Atorvastatin; Biological Transport; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Genes, ras; Heptanoic Acids; Liver Neoplasms, Experimental; Liver-Specific Organic Anion Transporter 1; Male; Mice; Mutation; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Proto-Oncogene Proteins B-raf; Pyrroles; Tumor Burden | 2014 |
Effect of atorvastatin on the expression of gamma-glutamyl transferase in aortic atherosclerotic plaques of apolipoprotein E-knockout mice.
Topics: Animals; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cholesterol, Dietary; Diet, High-Fat; Disease Models, Animal; Down-Regulation; gamma-Glutamyltransferase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Intercellular Adhesion Molecule-1; Male; Mice, Inbred C57BL; Mice, Knockout; Plaque, Atherosclerotic; Pyrroles; Time Factors; Vascular Cell Adhesion Molecule-1 | 2014 |
Giant cell arteritis and polymyalgia rheumatica after reexposure to a statin: a case report.
Topics: Aged; Atorvastatin; Female; Fluorobenzenes; Giant Cell Arteritis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Polymyalgia Rheumatica; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2014 |
Atorvastatin Attenuates TNF-alpha Production via Heme Oxygenase-1 Pathway in LPS-stimulated RAW264.7 Macrophages.
Topics: Adjuvants, Immunologic; Animals; Atorvastatin; Enzyme Activation; Heme Oxygenase-1; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Macrophages; Membrane Proteins; Mice; Pyrroles; Tumor Necrosis Factor-alpha | 2014 |
The effect of atorvastatin and atorvastatin-ezetimibe combination therapy on androgen production in hyperandrogenic women with elevated cholesterol levels.
Topics: Adult; Androgens; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hyperandrogenism; Hypercholesterolemia; Middle Aged; Pyrroles; Sex Hormone-Binding Globulin; Treatment Outcome; Young Adult | 2015 |
Statin adverse effects: sorting out the evidence.
Topics: Atorvastatin; Clinical Trials as Topic; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Practice; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Outcome Assessment, Health Care; Practice Guidelines as Topic; Pyrroles; Rhabdomyolysis; Risk Adjustment; Ubiquinone; Vitamins | 2014 |
Vascular injury in diabetic db/db mice is ameliorated by atorvastatin: role of Rac1/2-sensitive Nox-dependent pathways.
Topics: Acetylcholine; Animals; Arteries; Atorvastatin; Blotting, Western; Diabetes Mellitus, Type 2; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; In Vitro Techniques; Insulin; Lipids; Male; Mice, Mutant Strains; Mitogen-Activated Protein Kinases; NADPH Oxidases; Phosphorylation; Pyrroles; rac GTP-Binding Proteins; rac1 GTP-Binding Protein; RAC2 GTP-Binding Protein; Reactive Oxygen Species; Receptors, Leptin; Signal Transduction; Thiobarbituric Acid Reactive Substances; Vasodilation; Vasodilator Agents | 2015 |
Synergistic effects of atorvastatin and rosiglitazone on endothelium protection in rats with dyslipidemia.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cytoprotection; Drug Evaluation, Preclinical; Drug Synergism; Dyslipidemias; Endothelium, Vascular; Heptanoic Acids; Male; Myocardium; Oxidative Stress; Pyrroles; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2014 |
Does coenzyme-Q have a protective effect against atorvastatin induced myopathy? A histopathological and immunohistochemical study in albino rats.
Topics: Animals; Atorvastatin; bcl-2-Associated X Protein; Creatine Kinase; Cytochromes c; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Muscle, Skeletal; Muscular Diseases; Protective Agents; Pyrroles; Rats; Ubiquinone | 2015 |
Sensitive determination of atorvastatin in human plasma by dispersive liquid-liquid microextraction and solidification of floating organic drop followed by high-performance liquid chromatography.
Topics: Adult; Atorvastatin; Chromatography, High Pressure Liquid; Female; Heptanoic Acids; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Limit of Detection; Liquid Phase Microextraction; Male; Pyrroles; Sodium Chloride; Spectrophotometry, Ultraviolet; Young Adult | 2015 |
Atorvastatin-mediated protection of the retina in a model of diabetes with hyperlipidemia.
Topics: Animals; Antioxidants; Atorvastatin; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Diet, Atherogenic; Heptanoic Acids; Hyperlipidemias; Insulin Resistance; Lipid Metabolism; Male; Oxidative Stress; Proteasome Endopeptidase Complex; Pyrroles; Rats; Reactive Oxygen Species; Retina; Ubiquitin | 2014 |
Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
Topics: Aged; Aged, 80 and over; Atorvastatin; Brazil; Cardiovascular Diseases; Cost-Benefit Analysis; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Models, Economic; National Health Programs; Primary Prevention; Pyrimidines; Pyrroles; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides | 2015 |
Antidepressant-like effect of atorvastatin in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway.
Topics: Anilides; Animals; Antidepressive Agents; Atorvastatin; Depression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imipramine; Male; Mice; Motor Activity; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pioglitazone; PPAR gamma; Pyrroles; Signal Transduction; Swimming; Thiazolidinediones | 2014 |
Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism.
Topics: Antioxidants; Atorvastatin; Cholesterol, LDL; Eicosapentaenoic Acid; Fenofibrate; Gemfibrozil; Glucose; Heptanoic Acids; Lipid Peroxidation; Lipid Peroxides; Membrane Lipids; Membranes, Artificial; Niacin; Pyrroles | 2015 |
Strengthening the Achilles heel of high-risk plaques.
Topics: Atorvastatin; Coronary Vessels; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrroles; Tomography, Optical Coherence | 2014 |
Metformin enhances the anti-adipogenic effects of atorvastatin via modulation of STAT3 and TGF-β/Smad3 signaling.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Atorvastatin; Cell Differentiation; Cell Survival; Cyclin D1; Heptanoic Acids; Homeostasis; Hypoglycemic Agents; Kruppel-Like Transcription Factors; Metformin; Mice; Pyrroles; Signal Transduction; Smad3 Protein; Smad7 Protein; STAT3 Transcription Factor; Transforming Growth Factor beta; Tumor Suppressor Protein p53 | 2015 |
Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease.
Topics: Aged; Atherosclerosis; Atorvastatin; Blood Pressure; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Female; Fluorobenzenes; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Heptanoic Acids; Humans; Inflammation; Interleukin-10; Lipids; Lipoproteins, HDL; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Monocytes; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2014 |
Diffuse three-vessel coronary artery spasm.
Topics: Atorvastatin; Coronary Vasospasm; Diagnosis, Differential; Diagnostic Imaging; Diltiazem; Drug Therapy, Combination; Electrocardiography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isosorbide Dinitrate; Male; Middle Aged; Nitroglycerin; Pyrroles; Risk Factors; Vasodilator Agents | 2015 |
[Effect of atorvastatin on pro-inflammatory status (in vivo and in vitro) in patients with essential hypertension and metabolic syndrome].
Topics: Anticholesteremic Agents; Atorvastatin; Cytokines; Dose-Response Relationship, Drug; Drug Monitoring; Essential Hypertension; Female; Heptanoic Acids; Humans; Hypertension; Inflammation; Leukocytes, Mononuclear; Male; Metabolic Syndrome; Middle Aged; Patient Acuity; Prospective Studies; Pyrroles; Reactive Oxygen Species; Severity of Illness Index; Treatment Outcome | 2014 |
High levels of LDL-C combined with low levels of HDL-C further increase platelet activation in hypercholesterolemic patients.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Female; Flow Cytometry; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrroles; Statistics, Nonparametric | 2015 |
Statin use and risk of depression: a Swedish national cohort study.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Cohort Studies; Depression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Population Surveillance; Pyrroles; Risk Factors; Simvastatin; Sweden | 2014 |
Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin.
Topics: Administration, Oral; Adult; Atorvastatin; Cross-Over Studies; Drug Interactions; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Treatment Outcome | 2015 |
Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications.
Topics: Angiotensin-Converting Enzyme 2; Animals; Atherosclerosis; Atorvastatin; Disease Models, Animal; Epigenesis, Genetic; Heptanoic Acids; Histones; Male; Peptidyl-Dipeptidase A; Pyrroles; Rabbits; Tissue Distribution; Up-Regulation | 2015 |
Can atorvastatin calcium cause asymptomatic hypercalcemia?
Topics: Administration, Oral; Atorvastatin; Diagnosis, Differential; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercalcemia; Hyperlipidemias; Middle Aged; Pyrroles | 2014 |
Atorvastatin combined with poly-unsaturated fatty acid confers better improvement of dyslipidemia and endothelium function.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Drug Evaluation, Preclinical; Drug Therapy, Combination; Dyslipidemias; Endothelium, Vascular; Fatty Acids, Unsaturated; Heptanoic Acids; Male; Nitric Oxide; Pyrroles; Rabbits | 2014 |
Atorvastatin prevents development of kindling by modulating hippocampal levels of dopamine, glutamate, and GABA in mice.
Topics: Animals; Anticonvulsants; Atorvastatin; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kindling, Neurologic; Male; Mice; Pyrroles; Seizures | 2015 |
Atorvastatin regulates apoptosis in chronically ischemic myocardium.
Topics: Animals; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Caspase 3; Chronic Disease; Disease Models, Animal; Gene Expression Regulation, Developmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; MAP Kinase Signaling System; Metabolic Syndrome; Myocardial Ischemia; Myocardium; Neovascularization, Pathologic; Pyrroles; Swine; Swine, Miniature | 2015 |
Role of microRNAs 221/222 on statin induced nitric oxide release in human endothelial cells.
Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Azetidines; Cell Survival; Cells, Cultured; Down-Regulation; Endothelium, Vascular; Ezetimibe; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Luminescence; MicroRNAs; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrroles; Real-Time Polymerase Chain Reaction; Simvastatin | 2015 |
Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Heptanoic Acids; Inflammasomes; Kupffer Cells; Liver; Mice; Mice, Mutant Strains; Non-alcoholic Fatty Liver Disease; Pyrroles | 2015 |
POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia.
Topics: Adolescent; Alleles; Atorvastatin; Child; Female; Genetic Association Studies; Genotype; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipid Metabolism; Lipoproteins, LDL; Male; NADPH-Ferrihemoprotein Reductase; Polymorphism, Single Nucleotide; Pyrroles; Receptors, LDL | 2014 |
Role of inflammation in the initiation and maintenance of atrial fibrillation and the protective effect of atorvastatin in a goat model of aseptic pericarditis.
Topics: Animals; Atorvastatin; Atrial Fibrillation; Cardiac Surgical Procedures; Cytokines; Disease Models, Animal; Goats; Heart Atria; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Pericarditis; Pyrroles | 2015 |
Protection effect of atorvastatin in cerebral ischemia-reperfusion injury rats by blocking the mitochondrial permeability transition pore.
Topics: Animals; Anticholesteremic Agents; Apoptosis; Atorvastatin; Brain Ischemia; Cytochromes c; Disease Models, Animal; Heptanoic Acids; Infarction, Middle Cerebral Artery; Male; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Pyrroles; Rats, Sprague-Dawley; Reperfusion Injury | 2014 |
[Negative effects of termination statinotherapy in patients after acute coronary event with concominent non-alcoholic steatohepatitis].
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Non-alcoholic Fatty Liver Disease; Pyrimidines; Pyrroles; Recurrence; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2014 |
[Analysis of clinical use of shuxuening injection in treatment of cerebral infarction based on real world].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atorvastatin; Cerebral Infarction; Drugs, Chinese Herbal; Female; Heptanoic Acids; Humans; Male; Middle Aged; Piperazines; Pyrroles; Young Adult | 2014 |
Effect of CETP polymorphism on atorvastatin lipid-regulating effect and clinical prognosis of patients with coronary heart disease.
Topics: Atorvastatin; China; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Female; Follow-Up Studies; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Pyrroles; Survival Rate | 2014 |
Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients.
Topics: Anti-Retroviral Agents; Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; HIV Infections; HIV-1; Humans; Immunologic Factors; Interferon-gamma; Lymphocyte Activation; Pravastatin; Pyrroles; Retrospective Studies; T-Lymphocyte Subsets; T-Lymphocytes | 2014 |
Green analytical method development for statin analysis.
Topics: Acetonitriles; Atorvastatin; Chromatography, High Pressure Liquid; Ethanol; Fatty Acids, Monounsaturated; Fluvastatin; Green Chemistry Technology; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Pyrroles; Solubility; Solvents | 2015 |
Effects of atorvastatin and rosuvastatin on renal function in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Atorvastatin; China; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Taiwan | 2015 |
Possibilities of retention modeling and computer assisted method development in supercritical fluid chromatography.
Topics: Atorvastatin; Chemistry, Physical; Chromatography, Supercritical Fluid; Cytochrome P-450 Enzyme System; Heptanoic Acids; Models, Theoretical; Pharmaceutical Preparations; Pyrroles | 2015 |
Liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma.
Topics: Adult; Aged; Atorvastatin; Calibration; Chromatography, Liquid; Heptanoic Acids; Humans; Lovastatin; Middle Aged; Pyrroles; Quality Control; Reproducibility of Results; Simvastatin; Tandem Mass Spectrometry | 2015 |
Comment on Stegman et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care 2014;37:3114-3120.
Topics: Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2015 |
Response to Comment on Stegman et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care 2014;37:3114-3120.
Topics: Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides | 2015 |
Rh(II)-catalyzed [3+2] cycloaddition of 2 H-azirines with N-sulfonyl-1,2,3-triazoles.
Topics: Atorvastatin; Azirines; Benzyl Compounds; Catalysis; Cycloaddition Reaction; Pyrroles; Rhodium; Stereoisomerism; Triazoles | 2015 |
Trends in statin consumption and cardiovascular mortality in Croatia 2004-2012.
Topics: Adolescent; Adult; Atorvastatin; Cardiovascular Diseases; Child; Child, Preschool; Croatia; Drug Costs; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infant; Infant, Newborn; Middle Aged; Practice Patterns, Physicians'; Pyrroles; Simvastatin; Young Adult | 2014 |
Neuroprotective effect of atorvastatin in spinal cord ischemia-reperfusion injury.
Topics: Animals; Atorvastatin; Biopsy; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Malondialdehyde; Neuroprotective Agents; Nitric Oxide; Paraplegia; Pyrroles; Rabbits; Random Allocation; Reperfusion Injury; Reproducibility of Results; Spinal Cord Ischemia; Superoxide Dismutase; Time Factors | 2015 |
Atorvastatin prevents angiotensin II-induced high permeability of human arterial endothelial cell monolayers via ROCK signaling pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Arteries; Atorvastatin; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Humans; Lim Kinases; Permeability; Phosphorylation; Pyrroles; rho-Associated Kinases; Signal Transduction; Zonula Occludens-1 Protein | 2015 |
Recurrent ischaemic stroke unveils polycythaemia vera.
Topics: Aspirin; Atorvastatin; Bloodletting; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Polycythemia Vera; Pyrroles; Recurrence; Stroke; Treatment Outcome | 2015 |
Switching from high-efficacy lipid-lowering therapies [atorvastatin or rosuvastatin] to simvastatin and the results on low-density lipoprotein cholesterol level.
Topics: Atorvastatin; Drugs, Essential; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Thailand | 2015 |
Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats.
Topics: Angiotensin II; Animals; Atorvastatin; Benzazepines; C-Reactive Protein; Cardio-Renal Syndrome; Case-Control Studies; Drug Synergism; Heptanoic Acids; Lipids; Male; Natriuretic Peptide, Brain; Proteinuria; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2015 |
Lipid biomarkers and cardiovascular risk: which path to take at the fork in the road?
Topics: Apolipoprotein B-100; Atorvastatin; Cardiovascular Diseases; Coronary Disease; Female; Heptanoic Acids; Humans; Male; Phospholipids; Pyrroles | 2015 |
Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cohort Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Thailand; Treatment Outcome | 2015 |
Lovastatin-Mediated Changes in Human Tendon Cells.
Topics: Atorvastatin; Cholesterol; Cytoskeleton; Gap Junctions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pyrroles; Simvastatin; Tendons | 2015 |
Statin-associated myotoxicity in an incarcerated Indigenous youth - the perfect storm.
Topics: Adolescent; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Myositis; Native Hawaiian or Other Pacific Islander; Prisoners; Pyrroles; Vitamin D Deficiency | 2015 |
Atorvastatin counteracts high glucose-induced Krüppel-like factor 2 suppression in human umbilical vein endothelial cells.
Topics: Atorvastatin; Cell Culture Techniques; Glucose; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Kruppel-Like Transcription Factors; MAP Kinase Signaling System; Nitric Oxide Synthase Type III; Pyrroles; Vascular Cell Adhesion Molecule-1 | 2015 |
MicroRNA-208a Increases Myocardial Endoglin Expression and Myocardial Fibrosis in Acute Myocardial Infarction.
Topics: Animals; Atorvastatin; Blotting, Western; Cells, Cultured; Disease Models, Animal; Endoglin; Fibrosis; Gene Expression Regulation; Hemodynamics; Heptanoic Acids; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Male; MicroRNAs; Muscle Cells; Myocardial Infarction; Polymerase Chain Reaction; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sensitivity and Specificity; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2015 |
Relief of photoallergy: atorvastatin replacing simvastatin.
Topics: Atorvastatin; Dermatitis, Photoallergic; Drug Eruptions; Drug Substitution; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunologic Tests; Male; Predictive Value of Tests; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2015 |
Fixed drug eruption due to atorvastatin.
Topics: Aged, 80 and over; Atorvastatin; Drug Eruptions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Patch Tests; Predictive Value of Tests; Pyrroles; Recurrence; Risk Factors | 2015 |
The hypolipidemic effect of artesunate and ursolic acid in rats.
Topics: Animals; Artemisinins; Artesunate; Atorvastatin; Cholesterol; Disease Models, Animal; Heptanoic Acids; Hyperlipidemias; Hypolipidemic Agents; Pyrroles; Rats; Triglycerides; Triterpenes; Ursolic Acid | 2015 |
[Liver damage caused by atorvastatin and cyclosporine in patients with renal transplant].
Topics: Atorvastatin; Chemical and Drug Induced Liver Injury; Cyclosporine; Graft Rejection; Graft Survival; Heptanoic Acids; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Liver; Male; Middle Aged; Pyrroles | 2014 |
Ask the doctor. I am 61 and had been on atorvastatin for 10 years with no problems. Recently, I've had disabling muscle pain with both the generic atorvastatin and the brand-name version, Lipitor. My doctor says that I can no longer take statin drugs.
Topics: Anticholesteremic Agents; Atorvastatin; Female; Health Behavior; Heptanoic Acids; Humans; Middle Aged; Muscle, Skeletal; Pyrroles; Rhabdomyolysis; Stroke | 2014 |
The effects of atorvastatin on antioxidant/antiinflammatory properties of HDLs in hypercholesterolemics.
Topics: Adult; Anticholesteremic Agents; Arginine; Atorvastatin; Drug Monitoring; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Inflammation; Lipoproteins, HDL; Male; Malondialdehyde; Middle Aged; Nitric Oxide; Oxidative Stress; Pyrroles; Treatment Outcome | 2015 |
Effects of carbohydrate polymers in self-microemulsified tablets on the bioavailability of atorvastatin: In vitro-in vivo study.
Topics: Animals; Atorvastatin; Emulsions; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Polysaccharides; Pyrroles; Rabbits; Rats; Tablets | 2015 |
The effect of oxLDL on aortic valve calcification via the Wnt/ β-catenin signaling pathway: an important molecular mechanism.
Topics: Animals; Aortic Valve; Apoptosis; Atorvastatin; Bicuspid Aortic Valve Disease; Blotting, Western; Calcinosis; Cells, Cultured; Heart Defects, Congenital; Heart Valve Diseases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Myofibroblasts; Pyrroles; Swine; Wnt Signaling Pathway | 2015 |
Atorvastatin-induced dermatomyositis in a 47-year-old woman with Sjögren's syndrome.
Topics: Anticholesteremic Agents; Atorvastatin; Dermatomyositis; Female; Heptanoic Acids; Humans; Hyperlipidemias; Middle Aged; Pyrroles; Sjogren's Syndrome | 2015 |
AUSTRALIAN COMPETITION AND CONSUMER COMMISSION v PFIZER: EVERGREENING AND MARKET POWER AS A BLOCKBUSTER DRUG GOES OFF PATENT.
Topics: Anticholesteremic Agents; Atorvastatin; Australia; Commerce; Drug Industry; Drugs, Generic; Economic Competition; Heptanoic Acids; Patents as Topic; Pyrroles | 2015 |
Discovery of Novel ROCK1 Inhibitors via Integrated Virtual Screening Strategy and Bioassays.
Topics: Actin Depolymerizing Factors; Amides; Animals; Atorvastatin; Binding Sites; Cerebral Hemorrhage; Databases, Chemical; Databases, Protein; Disease Models, Animal; Enzyme Activation; Human Umbilical Vein Endothelial Cells; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Pyrroles; rho-Associated Kinases; Signal Transduction; Structure-Activity Relationship; Zebrafish | 2015 |
[One year persistence of atorvastatin and amlodipine fixed dose combination versus atorvastatin therapy].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Linear Models; Male; Medication Adherence; Middle Aged; Pyrroles; Retrospective Studies; Treatment Outcome | 2016 |
New pentasubstituted pyrrole hybrid atorvastatin-quinoline derivatives with antiplasmodial activity.
Topics: Antimalarials; Atorvastatin; Dose-Response Relationship, Drug; Molecular Structure; Parasitic Sensitivity Tests; Plasmodium falciparum; Pyrroles; Quinolines; Structure-Activity Relationship | 2016 |
Ask the doctor. My doctor says I should switch to generic version of Lipitor, but is it really the same as Lipitor?
Topics: Anticholesteremic Agents; Atorvastatin; Drugs, Generic; Humans; Physicians; Pyrroles | 2012 |
Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Case-Control Studies; Disease Management; Drug Administration Schedule; Drug Combinations; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Middle Aged; Patient Compliance; Pyrroles | 2016 |
Development and validation of HPLC and CE methods for simultaneous determination of amlodipine and atorvastatin in the presence of their acidic degradation products in tablets.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Calibration; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Combinations; Drug Stability; Electrophoresis, Capillary; Heptanoic Acids; Hydrochloric Acid; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Limit of Detection; Molecular Structure; Pyrroles; Reproducibility of Results; Tablets | 2016 |
[Pleotropic Effects of Atorvastatin in Patients With Chronic Ischemic Heart Disease].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Middle Aged; Myocardial Ischemia; Pyrroles | 2016 |
α-Unsubstituted Pyrroles by NHC-Catalyzed Three-Component Coupling: Direct Synthesis of a Versatile Atorvastatin Derivative.
Topics: Atorvastatin; Catalysis; Chalcone; Heterocyclic Compounds; Methane; Pyrroles | 2017 |
Pleiotropic effects and biological activities of atorvastatin: The sun never set.
Topics: Anticholesteremic Agents; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2018 |
Effects of Switching from Treatment with Amlodipine and Atorvastatin Using Two Pills to an Equal Dose of Single-Pill Therapy in Japanese Outpatients.
Topics: Age Factors; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cholesterol, LDL; Drug Combinations; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Retrospective Studies | 2020 |
[Preprocedural high - sensitivity C-reactive protein (hsCRP) decrease during intensive atorvastatin therapy: the presumable impact on atherosclerosis progression after coronary stenting].
Topics: Atherosclerosis; Atorvastatin; C-Reactive Protein; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Outcome | 2019 |
Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cerebrovascular Disorders; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Primary Prevention; Pyrroles; Quinolines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin | 2020 |
Atorvastatin and pravastatin stimulate nitric oxide and reactive oxygen species generation, affect mitochondrial network architecture and elevate nicotinamide N-methyltransferase level in endothelial cells.
Topics: Anticholesteremic Agents; Antioxidants; Atorvastatin; Cell Line; Cells, Cultured; Endothelial Cells; Histones; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mitochondria; Nicotinamide N-Methyltransferase; Nitric Oxide; Pravastatin; Pyrroles; Reactive Oxygen Species | 2021 |
Effects of mineral oil administration on the pharmacokinetics, metabolism and pharmacodynamics of atorvastatin and pravastatin in mice and dogs.
Topics: Animals; Atorvastatin; Dogs; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Inbred C57BL; Mineral Oil; Pravastatin; Pyrroles | 2021 |
Pitavastatin versus Atorvastatin: Potential Differences in their Effects on Serum Lipoprotein Lipase and Cardiovascular Disease.
Topics: Atorvastatin; Cardiovascular Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein Lipase; Pyrroles; Quinolines | 2022 |
SLCO1B1*5 Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care.
Topics: Alleles; Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Muscles; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin | 2022 |
The vascular impact of dapagliflozin, liraglutide, and atorvastatin alone or in combinations in type 2 diabetic rat model.
Topics: Animals; Atorvastatin; Benzhydryl Compounds; C-Reactive Protein; Cholesterol, LDL; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Liraglutide; Male; Pyrroles; Rats; Thyrotropin | 2022 |
Implications of Ezetimibe in Combination with Low- to Moderate-Intensity Atorvastatin Adjuvant Aspirin Therapy for Cerebrovascular Disease.
Topics: Activities of Daily Living; Anticholesteremic Agents; Aspirin; Atorvastatin; C-Reactive Protein; Carotid Intima-Media Thickness; Cerebrovascular Disorders; Cholesterol, LDL; Ezetimibe; Humans; Leptin; Pyrroles; Treatment Outcome; Triglycerides | 2022 |
Drug Eruption From Atorvastatin: With Initial Misdiagnosis of
Topics: Aged; Atorvastatin; Drug Eruptions; Drug Substitution; Exanthema; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Simvastatin; Tinea cruris | 2023 |
Short-term safety and efficacy of escalating doses of atorvastatin for dyslipidemia in children with predialysis chronic kidney disease stage 2-5.
Topics: Anticholesteremic Agents; Atorvastatin; Child; Cholesterol; Cholesterol, LDL; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome | 2023 |
In silico and in vitro assessment of anti-Trypanosoma cruzi efficacy, genotoxicity and pharmacokinetics of pentasubstituted pyrrolic Atorvastatin-aminoquinoline hybrid compounds.
Topics: Aminoquinolines; Animals; Antimalarials; Atorvastatin; Chagas Disease; DNA Damage; Mice; Pharmaceutical Preparations; Pyrroles; Trypanocidal Agents; Trypanosoma cruzi | 2023 |
Atropostatin: Design and Total Synthesis of an Atropisomeric Lactone-Atorvastatin Prodrug.
Topics: Atorvastatin; Heptanoic Acids; Lactones; Prodrugs; Pyrroles | 2023 |
Some pleiotropic effects of statins on hepatocellular carcinoma cells: Comparative study on atorvastatin, rosuvastatin and simvastatin.
Topics: Atorvastatin; Carcinoma, Hepatocellular; Fluorobenzenes; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Pyrimidines; Pyrroles; Reactive Oxygen Species; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2023 |